	sents	ner_seq	bio_preds	entities	num_entities	num_tokens	prompts	empty_prompts
0	Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant .	B I I O O O B O O O O O	O O O O B I O O O O O O	['tricuspid valve regurgitation', 'toxicity']	2	10	"Sentence: Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant .
Diseases: tricuspid valve regurgitation, toxicity"	"Sentence: Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant .
Diseases:"
1	A newborn with massive tricuspid regurgitation , atrial flutter , congestive heart failure , and a high serum lithium level is described .	O O O O B I O B I O B I I O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O	['tricuspid regurgitation', 'congestive heart failure', 'atrial flutter']	3	17	"Sentence: A newborn with massive tricuspid regurgitation , atrial flutter , congestive heart failure , and a high serum lithium level is described .
Diseases: tricuspid regurgitation, congestive heart failure, atrial flutter"	"Sentence: A newborn with massive tricuspid regurgitation , atrial flutter , congestive heart failure , and a high serum lithium level is described .
Diseases:"
2	This is the first patient to initially manifest tricuspid regurgitation and atrial flutter , and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy .	O O O O O O O O B I O B I O O O O O O O B I O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['tricuspid regurgitation', 'cardiac disease', 'atrial flutter']	3	15	"Sentence: This is the first patient to initially manifest tricuspid regurgitation and atrial flutter , and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy .
Diseases: tricuspid regurgitation, cardiac disease, atrial flutter"	"Sentence: This is the first patient to initially manifest tricuspid regurgitation and atrial flutter , and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy .
Diseases:"
3	Sixty - three percent of these infants had tricuspid valve involvement .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: Sixty - three percent of these infants had tricuspid valve involvement .
Diseases: "	"Sentence: Sixty - three percent of these infants had tricuspid valve involvement .
Diseases:"
4	Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy .	O O O O O O O O O O O B I I O O O O O O	B I O O O O O O O O O O O O O O O O O O	['congenital heart disease']	1	5	"Sentence: Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy .
Diseases: congenital heart disease"	"Sentence: Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy .
Diseases:"
5	It also causes neurologic depression , cyanosis , and cardiac arrhythmia when consumed prior to delivery .	O O O B I O B O O B I O O O O O O	O O O O O O O O O O O O O O O O O	['cardiac arrhythmia', 'cyanosis', 'neurologic depression']	3	13	"Sentence: It also causes neurologic depression , cyanosis , and cardiac arrhythmia when consumed prior to delivery .
Diseases: cardiac arrhythmia, cyanosis, neurologic depression"	"Sentence: It also causes neurologic depression , cyanosis , and cardiac arrhythmia when consumed prior to delivery .
Diseases:"
6	Phenobarbital - induced dyskinesia in a neurologically - impaired child .	O O O B O O B I I O O	B O O O O O O O O O O	['dyskinesia', 'neurologically - impaired']	2	10	"Sentence: Phenobarbital - induced dyskinesia in a neurologically - impaired child .
Diseases: dyskinesia, neurologically - impaired"	"Sentence: Phenobarbital - induced dyskinesia in a neurologically - impaired child .
Diseases:"
7	A 2 - year - old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures .	O O O O O O O O O B I O O B O O O O O O B O	O O O O O O O O O O O O O O O O O B O O O O	['dyskinesia', 'seizures', 'neurologic impairment']	3	11	"Sentence: A 2 - year - old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures .
Diseases: dyskinesia, seizures, neurologic impairment"	"Sentence: A 2 - year - old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures .
Diseases:"
8	Known causes of movement disorders were eliminated after evaluation .	O O O B I O O O O O	O O O O O O O O O O	['movement disorders']	1	3	"Sentence: Known causes of movement disorders were eliminated after evaluation .
Diseases: movement disorders"	"Sentence: Known causes of movement disorders were eliminated after evaluation .
Diseases:"
9	On repeat challenge with phenobarbital , the dyskinesia recurred .	O O O O O O O B O O	O O O O B O O O O O	['dyskinesia']	1	5	"Sentence: On repeat challenge with phenobarbital , the dyskinesia recurred .
Diseases: dyskinesia"	"Sentence: On repeat challenge with phenobarbital , the dyskinesia recurred .
Diseases:"
10	Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders .	O O O O O O O O O O O O O B I O	B O O O O O O O O O O O O O O O	['movement disorders']	1	3	"Sentence: Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders .
Diseases: movement disorders"	"Sentence: Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders .
Diseases:"
11	Acute changes of blood ammonia may predict short - term adverse effects of valproic acid .	O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O B I O	[]	0	0	"Sentence: Acute changes of blood ammonia may predict short - term adverse effects of valproic acid .
Diseases: "	"Sentence: Acute changes of blood ammonia may predict short - term adverse effects of valproic acid .
Diseases:"
12	Valproic acid ( VPA ) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs .	O O O O O O O O O B O O O O O O O O O O O	B I O B O O O O O O O O O O O O O O O O O	['epileptic']	1	3	"Sentence: Valproic acid ( VPA ) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs .
Diseases: epileptic"	"Sentence: Valproic acid ( VPA ) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs .
Diseases:"
13	A standardized loading dose of VPA was administered , and venous blood was sampled at 0 , 1 , 2 , 3 , and 4 hours .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A standardized loading dose of VPA was administered , and venous blood was sampled at 0 , 1 , 2 , 3 , and 4 hours .
Diseases: "	"Sentence: A standardized loading dose of VPA was administered , and venous blood was sampled at 0 , 1 , 2 , 3 , and 4 hours .
Diseases:"
14	Ammonia ( NH3 ) was higher in patients who , during continuous therapy , complained of drowsiness ( 7 patients ) than in those who were symptom - free ( 17 patients ) , although VPA plasma levels were similar in both groups .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['drowsiness']	1	3	"Sentence: Ammonia ( NH3 ) was higher in patients who , during continuous therapy , complained of drowsiness ( 7 patients ) than in those who were symptom - free ( 17 patients ) , although VPA plasma levels were similar in both groups .
Diseases: drowsiness"	"Sentence: Ammonia ( NH3 ) was higher in patients who , during continuous therapy , complained of drowsiness ( 7 patients ) than in those who were symptom - free ( 17 patients ) , although VPA plasma levels were similar in both groups .
Diseases:"
15	By measuring VPA - induced changes of blood NH3 content , it may be possible to identify patients at higher risk of obtundation when VPA is given chronically .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O B O O O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: By measuring VPA - induced changes of blood NH3 content , it may be possible to identify patients at higher risk of obtundation when VPA is given chronically .
Diseases: "	"Sentence: By measuring VPA - induced changes of blood NH3 content , it may be possible to identify patients at higher risk of obtundation when VPA is given chronically .
Diseases:"
16	Effects of calcitonin on rat extrapyramidal motor system : behavioral and biochemical data .	O O O O O O O O O O O O O O	O O B O O O O O O O O O O O	[]	0	0	"Sentence: Effects of calcitonin on rat extrapyramidal motor system : behavioral and biochemical data .
Diseases: "	"Sentence: Effects of calcitonin on rat extrapyramidal motor system : behavioral and biochemical data .
Diseases:"
17	The effects of i . v . c . injection of human and salmon calcitonin on biochemical and behavioral parameters related to the extrapyramidal motor system , were investigated in male rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The effects of i . v . c . injection of human and salmon calcitonin on biochemical and behavioral parameters related to the extrapyramidal motor system , were investigated in male rats .
Diseases: "	"Sentence: The effects of i . v . c . injection of human and salmon calcitonin on biochemical and behavioral parameters related to the extrapyramidal motor system , were investigated in male rats .
Diseases:"
18	Calcitonin injection resulted in a potentiation of haloperidol - induced catalepsy and a partial prevention of apomorphine - induced hyperactivity .	O O O O O O O O O O B O O O O O O O O B O	B O O O O O O B O O O O O O O O B O O O O	['catalepsy', 'hyperactivity']	2	7	"Sentence: Calcitonin injection resulted in a potentiation of haloperidol - induced catalepsy and a partial prevention of apomorphine - induced hyperactivity .
Diseases: catalepsy, hyperactivity"	"Sentence: Calcitonin injection resulted in a potentiation of haloperidol - induced catalepsy and a partial prevention of apomorphine - induced hyperactivity .
Diseases:"
19	Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity .	O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O B O B O O O O O	[]	0	0	"Sentence: Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity .
Diseases: "	"Sentence: Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity .
Diseases:"
20	The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA - related behavioral messages of striatal origin .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA - related behavioral messages of striatal origin .
Diseases: "	"Sentence: The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA - related behavioral messages of striatal origin .
Diseases:"
21	Development of isoproterenol - induced cardiac hypertrophy .	O O O O O B I O	O O B O O O O O	['cardiac hypertrophy']	1	5	"Sentence: Development of isoproterenol - induced cardiac hypertrophy .
Diseases: cardiac hypertrophy"	"Sentence: Development of isoproterenol - induced cardiac hypertrophy .
Diseases:"
22	The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol ( ISO ) ( 0 . 3 mg / kg body weight ) .	O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O	['cardiac hypertrophy']	1	5	"Sentence: The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol ( ISO ) ( 0 . 3 mg / kg body weight ) .
Diseases: cardiac hypertrophy"	"Sentence: The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol ( ISO ) ( 0 . 3 mg / kg body weight ) .
Diseases:"
23	A time course was established for the change in tissue mass , RNA and DNA content , as well as hydroxyproline content .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: A time course was established for the change in tissue mass , RNA and DNA content , as well as hydroxyproline content .
Diseases: "	"Sentence: A time course was established for the change in tissue mass , RNA and DNA content , as well as hydroxyproline content .
Diseases:"
24	Heart weight increased 44 % after 8 days of treatment with a half time of 3 . 4 days .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Heart weight increased 44 % after 8 days of treatment with a half time of 3 . 4 days .
Diseases: "	"Sentence: Heart weight increased 44 % after 8 days of treatment with a half time of 3 . 4 days .
Diseases:"
25	Ventricular RNA content was elevated 26 % after 24 h of a single injection and reached a maximal level following 8 days of therapy .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ventricular RNA content was elevated 26 % after 24 h of a single injection and reached a maximal level following 8 days of therapy .
Diseases: "	"Sentence: Ventricular RNA content was elevated 26 % after 24 h of a single injection and reached a maximal level following 8 days of therapy .
Diseases:"
26	The half time for RNA accumulation was 2 . 0 days .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: The half time for RNA accumulation was 2 . 0 days .
Diseases: "	"Sentence: The half time for RNA accumulation was 2 . 0 days .
Diseases:"
27	The total content of hydroxyproline remained stable during the first 2 days of treatment but increased 46 % after 4 days of therapy .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The total content of hydroxyproline remained stable during the first 2 days of treatment but increased 46 % after 4 days of therapy .
Diseases: "	"Sentence: The total content of hydroxyproline remained stable during the first 2 days of treatment but increased 46 % after 4 days of therapy .
Diseases:"
28	Ventricular DNA content was unchanged during the early stage ( 1 - 4 days ) of hypertrophic growth but increased to a new steady - state level 19 % above the controls after 8 days of treatment .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertrophic']	1	3	"Sentence: Ventricular DNA content was unchanged during the early stage ( 1 - 4 days ) of hypertrophic growth but increased to a new steady - state level 19 % above the controls after 8 days of treatment .
Diseases: hypertrophic"	"Sentence: Ventricular DNA content was unchanged during the early stage ( 1 - 4 days ) of hypertrophic growth but increased to a new steady - state level 19 % above the controls after 8 days of treatment .
Diseases:"
29	Intraventricular pressures and coronary flow measures were similar for control and experimental animals following 4 days of developed hypertrophy .	O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O	['hypertrophy']	1	4	"Sentence: Intraventricular pressures and coronary flow measures were similar for control and experimental animals following 4 days of developed hypertrophy .
Diseases: hypertrophy"	"Sentence: Intraventricular pressures and coronary flow measures were similar for control and experimental animals following 4 days of developed hypertrophy .
Diseases:"
30	However , dP / dt in the ISO - treated hearts was slightly but significantly ( P less than 0 . 05 ) elevated .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , dP / dt in the ISO - treated hearts was slightly but significantly ( P less than 0 . 05 ) elevated .
Diseases: "	"Sentence: However , dP / dt in the ISO - treated hearts was slightly but significantly ( P less than 0 . 05 ) elevated .
Diseases:"
31	These data indicate that the adaptive response to ISO shows an early hypertrophic phase ( 1 - 4 days ) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertrophic']	1	3	"Sentence: These data indicate that the adaptive response to ISO shows an early hypertrophic phase ( 1 - 4 days ) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA .
Diseases: hypertrophic"	"Sentence: These data indicate that the adaptive response to ISO shows an early hypertrophic phase ( 1 - 4 days ) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA .
Diseases:"
32	However , prolonged stimulation ( 8 - 12 days ) appears to represent a complex integration of both cellular hypertrophy and hyperplasia within the heart .	O O O O O O O O O O O O O O O O O O O B O B O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['hyperplasia', 'hypertrophy']	2	7	"Sentence: However , prolonged stimulation ( 8 - 12 days ) appears to represent a complex integration of both cellular hypertrophy and hyperplasia within the heart .
Diseases: hyperplasia, hypertrophy"	"Sentence: However , prolonged stimulation ( 8 - 12 days ) appears to represent a complex integration of both cellular hypertrophy and hyperplasia within the heart .
Diseases:"
33	Co - carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole .	O O B O O O O O B I O O O O O O O O O	O O O O O B I O O O O O O O O O B I O	['forestomach carcinogenesis', 'carcinogenic']	2	9	"Sentence: Co - carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole .
Diseases: forestomach carcinogenesis, carcinogenic"	"Sentence: Co - carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole .
Diseases:"
34	The potential modifying effect of retinyl acetate ( RA ) on butylated hydroxyanisole	O O O O O O O O O O O O O	O O O O O B I O B O O B I	[]	0	0	"Sentence: The potential modifying effect of retinyl acetate ( RA ) on butylated hydroxyanisole
Diseases: "	"Sentence: The potential modifying effect of retinyl acetate ( RA ) on butylated hydroxyanisole
Diseases:"
35	( BHA ) - induced rat forestomach tumorigenesis was examined .	O O O O O O B I O O O	O B O O O O O O O O O	['forestomach tumorigenesis']	1	5	"Sentence: ( BHA ) - induced rat forestomach tumorigenesis was examined .
Diseases: forestomach tumorigenesis"	"Sentence: ( BHA ) - induced rat forestomach tumorigenesis was examined .
Diseases:"
36	Male F344 rats , 5 weeks of age , were maintained on diet containing 1 % or 2 % BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations ( w / v ) for 52 weeks .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: Male F344 rats , 5 weeks of age , were maintained on diet containing 1 % or 2 % BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations ( w / v ) for 52 weeks .
Diseases: "	"Sentence: Male F344 rats , 5 weeks of age , were maintained on diet containing 1 % or 2 % BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations ( w / v ) for 52 weeks .
Diseases:"
37	In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( squamous cell papilloma and carcinoma ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given RA - free water .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O B I I O B O O O O O O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['carcinoma', 'squamous cell papilloma', 'forestomach tumors']	3	15	"Sentence: In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( squamous cell papilloma and carcinoma ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given RA - free water .
Diseases: carcinoma, squamous cell papilloma, forestomach tumors"	"Sentence: In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( squamous cell papilloma and carcinoma ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given RA - free water .
Diseases:"
38	In rats given 1 % BHA , RA co - administered at a dose of 0 . 05 , 0 . 1 , 0 . 2 or 0 . 25 % showed a dose - dependent enhancing effect on the development of the BHA - induced epithelial hyperplasia .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	['epithelial hyperplasia']	1	6	"Sentence: In rats given 1 % BHA , RA co - administered at a dose of 0 . 05 , 0 . 1 , 0 . 2 or 0 . 25 % showed a dose - dependent enhancing effect on the development of the BHA - induced epithelial hyperplasia .
Diseases: epithelial hyperplasia"	"Sentence: In rats given 1 % BHA , RA co - administered at a dose of 0 . 05 , 0 . 1 , 0 . 2 or 0 . 25 % showed a dose - dependent enhancing effect on the development of the BHA - induced epithelial hyperplasia .
Diseases:"
39	Tumors , all papillomas , were induced in 3 rats ( 17 % ) with 0 . 25 % RA and in one rat ( 10 % ) with 0 . 05 % RA co - administration .	B O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O B O O O O	['papillomas', 'tumors']	2	6	"Sentence: Tumors , all papillomas , were induced in 3 rats ( 17 % ) with 0 . 25 % RA and in one rat ( 10 % ) with 0 . 05 % RA co - administration .
Diseases: papillomas, tumors"	"Sentence: Tumors , all papillomas , were induced in 3 rats ( 17 % ) with 0 . 25 % RA and in one rat ( 10 % ) with 0 . 05 % RA co - administration .
Diseases:"
40	RA alone did not induce hyperplastic changes in the forestomach .	O O O O O O O O O O O	B O O O O O O O O O O	[]	0	0	"Sentence: RA alone did not induce hyperplastic changes in the forestomach .
Diseases: "	"Sentence: RA alone did not induce hyperplastic changes in the forestomach .
Diseases:"
41	These findings indicate that RA acted as a co - carcinogen in the BHA forestomach carcinogenesis of the rat .	O O O O O O O O O O O O O O B I O O O O	O O O O B O O O O O O O O O O O O O O O	['forestomach carcinogenesis']	1	4	"Sentence: These findings indicate that RA acted as a co - carcinogen in the BHA forestomach carcinogenesis of the rat .
Diseases: forestomach carcinogenesis"	"Sentence: These findings indicate that RA acted as a co - carcinogen in the BHA forestomach carcinogenesis of the rat .
Diseases:"
42	Ketanserin pretreatment reverses alfentanil - induced muscle rigidity .	O O O O O O B I O	B O O B O O O O O	['muscle rigidity']	1	4	"Sentence: Ketanserin pretreatment reverses alfentanil - induced muscle rigidity .
Diseases: muscle rigidity"	"Sentence: Ketanserin pretreatment reverses alfentanil - induced muscle rigidity .
Diseases:"
43	Systemic pretreatment with ketanserin , a relatively specific type - 2 serotonin receptor antagonist , significantly attenuated the muscle rigidity produced in rats by the potent short - acting opiate agonist alfentanil .	O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O	O O O B O O O O O O O B O O O O O O O O O O O O O O O O O O O B O	['muscle rigidity']	1	4	"Sentence: Systemic pretreatment with ketanserin , a relatively specific type - 2 serotonin receptor antagonist , significantly attenuated the muscle rigidity produced in rats by the potent short - acting opiate agonist alfentanil .
Diseases: muscle rigidity"	"Sentence: Systemic pretreatment with ketanserin , a relatively specific type - 2 serotonin receptor antagonist , significantly attenuated the muscle rigidity produced in rats by the potent short - acting opiate agonist alfentanil .
Diseases:"
44	Following placement of subcutaneous electrodes in each animal 's left gastrocnemius muscle , rigidity was assessed by analyzing root - mean - square electromyographic activity .	O O O O O O O O O O O O O B O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['rigidity']	1	2	"Sentence: Following placement of subcutaneous electrodes in each animal 's left gastrocnemius muscle , rigidity was assessed by analyzing root - mean - square electromyographic activity .
Diseases: rigidity"	"Sentence: Following placement of subcutaneous electrodes in each animal 's left gastrocnemius muscle , rigidity was assessed by analyzing root - mean - square electromyographic activity .
Diseases:"
45	Intraperitoneal ketanserin administration at doses of 0 . 63 and 2 . 5 mg / kg prevented the alfentanil - induced increase in electromyographic activity compared with animals pretreated with saline .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: Intraperitoneal ketanserin administration at doses of 0 . 63 and 2 . 5 mg / kg prevented the alfentanil - induced increase in electromyographic activity compared with animals pretreated with saline .
Diseases: "	"Sentence: Intraperitoneal ketanserin administration at doses of 0 . 63 and 2 . 5 mg / kg prevented the alfentanil - induced increase in electromyographic activity compared with animals pretreated with saline .
Diseases:"
46	Chlordiazepoxide at doses up to 10 mg / kg failed to significantly influence the rigidity produced by alfentanil .	O O O O O O O O O O O O O O B O O O O	B O O O O O O O O O O O O O O O O B O	['rigidity']	1	2	"Sentence: Chlordiazepoxide at doses up to 10 mg / kg failed to significantly influence the rigidity produced by alfentanil .
Diseases: rigidity"	"Sentence: Chlordiazepoxide at doses up to 10 mg / kg failed to significantly influence the rigidity produced by alfentanil .
Diseases:"
47	Despite the absence of rigidity , animals that received ketanserin ( greater than 0 . 31 mg / kg i . p . ) followed by alfentanil were motionless , flaccid , and less responsive to external stimuli than were animals receiving alfentanil alone .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O B O O	['rigidity']	1	2	"Sentence: Despite the absence of rigidity , animals that received ketanserin ( greater than 0 . 31 mg / kg i . p . ) followed by alfentanil were motionless , flaccid , and less responsive to external stimuli than were animals receiving alfentanil alone .
Diseases: rigidity"	"Sentence: Despite the absence of rigidity , animals that received ketanserin ( greater than 0 . 31 mg / kg i . p . ) followed by alfentanil were motionless , flaccid , and less responsive to external stimuli than were animals receiving alfentanil alone .
Diseases:"
48	Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60 - min recording period than did animals that received ketanserin alone .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O B O O O O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60 - min recording period than did animals that received ketanserin alone .
Diseases: "	"Sentence: Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60 - min recording period than did animals that received ketanserin alone .
Diseases:"
49	These results , in combination with previous work , suggest that muscle rigidity , a clinically relevant side - effect of parenteral narcotic administration , may be partly mediated via serotonergic pathways .	O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['muscle rigidity']	1	4	"Sentence: These results , in combination with previous work , suggest that muscle rigidity , a clinically relevant side - effect of parenteral narcotic administration , may be partly mediated via serotonergic pathways .
Diseases: muscle rigidity"	"Sentence: These results , in combination with previous work , suggest that muscle rigidity , a clinically relevant side - effect of parenteral narcotic administration , may be partly mediated via serotonergic pathways .
Diseases:"
50	Pretreatment with type - 2 serotonin antagonists may be clinically useful in attenuating opiate - induced rigidity , although further studies will be necessary to assess the interaction of possibly enhanced CNS , cardiovascular , and respiratory depression .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O B I I I I O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['rigidity', 'cardiovascular , and respiratory depression']	2	8	"Sentence: Pretreatment with type - 2 serotonin antagonists may be clinically useful in attenuating opiate - induced rigidity , although further studies will be necessary to assess the interaction of possibly enhanced CNS , cardiovascular , and respiratory depression .
Diseases: rigidity, cardiovascular , and respiratory depression"	"Sentence: Pretreatment with type - 2 serotonin antagonists may be clinically useful in attenuating opiate - induced rigidity , although further studies will be necessary to assess the interaction of possibly enhanced CNS , cardiovascular , and respiratory depression .
Diseases:"
51	Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium .	O O O O O O O O O O O O	B O O O O O O O O O B O	[]	0	0	"Sentence: Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium .
Diseases: "	"Sentence: Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium .
Diseases:"
52	We have compared , in 60 adult patients , the cardiovascular effects of glycopyrronium 5 micrograms kg - 1 and 10 micrograms kg - 1 given either simultaneously or 1 min before edrophonium 1 mg kg - 1 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O B O O O O O O	[]	0	0	"Sentence: We have compared , in 60 adult patients , the cardiovascular effects of glycopyrronium 5 micrograms kg - 1 and 10 micrograms kg - 1 given either simultaneously or 1 min before edrophonium 1 mg kg - 1 .
Diseases: "	"Sentence: We have compared , in 60 adult patients , the cardiovascular effects of glycopyrronium 5 micrograms kg - 1 and 10 micrograms kg - 1 given either simultaneously or 1 min before edrophonium 1 mg kg - 1 .
Diseases:"
53	Significant differences between the four groups were detected ( P less than 0 . 001 ) .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Significant differences between the four groups were detected ( P less than 0 . 001 ) .
Diseases: "	"Sentence: Significant differences between the four groups were detected ( P less than 0 . 001 ) .
Diseases:"
54	Both groups receiving 10 micrograms kg - 1 showed increases in heart rate of up to 30 beat min - 1 ( 95 % confidence limits 28 - 32 beat min - 1 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Both groups receiving 10 micrograms kg - 1 showed increases in heart rate of up to 30 beat min - 1 ( 95 % confidence limits 28 - 32 beat min - 1 ) .
Diseases: "	"Sentence: Both groups receiving 10 micrograms kg - 1 showed increases in heart rate of up to 30 beat min - 1 ( 95 % confidence limits 28 - 32 beat min - 1 ) .
Diseases:"
55	Use of glycopyrronium 5 micrograms kg - 1 provided greater cardiovascular stability and , given 1 min before the edrophonium , was sufficient to minimize early , edrophonium - induced bradycardias .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O B O O O O O O O O O O O O O O O O B O O O O O O O B O O O O	['bradycardias']	1	4	"Sentence: Use of glycopyrronium 5 micrograms kg - 1 provided greater cardiovascular stability and , given 1 min before the edrophonium , was sufficient to minimize early , edrophonium - induced bradycardias .
Diseases: bradycardias"	"Sentence: Use of glycopyrronium 5 micrograms kg - 1 provided greater cardiovascular stability and , given 1 min before the edrophonium , was sufficient to minimize early , edrophonium - induced bradycardias .
Diseases:"
56	This low dose of glycopyrronium provided good control of oropharyngeal secretions .	O O O O O O O O O O O O	O O O O B O O O O O O O	[]	0	0	"Sentence: This low dose of glycopyrronium provided good control of oropharyngeal secretions .
Diseases: "	"Sentence: This low dose of glycopyrronium provided good control of oropharyngeal secretions .
Diseases:"
57	Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl - induced muscular rigidity in the rat .	O O O O O O O O O O O B I O O O O	O O O O O O O O B O O O O O O O O	['muscular rigidity']	1	4	"Sentence: Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl - induced muscular rigidity in the rat .
Diseases: muscular rigidity"	"Sentence: Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl - induced muscular rigidity in the rat .
Diseases:"
58	Whereas muscular rigidity is a well - known side effect that is associated with high - dose fentanyl anesthesia , a paucity of information exists with regard to its underlying mechanism ( s ) .	O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['muscular rigidity']	1	4	"Sentence: Whereas muscular rigidity is a well - known side effect that is associated with high - dose fentanyl anesthesia , a paucity of information exists with regard to its underlying mechanism ( s ) .
Diseases: muscular rigidity"	"Sentence: Whereas muscular rigidity is a well - known side effect that is associated with high - dose fentanyl anesthesia , a paucity of information exists with regard to its underlying mechanism ( s ) .
Diseases:"
59	We investigated in this study the possible engagement of locus coeruleus of the pons in this phenomenon , using male Sprague - Dawley rats anesthetized with ketamine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: We investigated in this study the possible engagement of locus coeruleus of the pons in this phenomenon , using male Sprague - Dawley rats anesthetized with ketamine .
Diseases: "	"Sentence: We investigated in this study the possible engagement of locus coeruleus of the pons in this phenomenon , using male Sprague - Dawley rats anesthetized with ketamine .
Diseases:"
60	Under proper control of respiration , body temperature and end - tidal CO2 , intravenous administration of fentanyl ( 50 or 100 micrograms / kg ) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Under proper control of respiration , body temperature and end - tidal CO2 , intravenous administration of fentanyl ( 50 or 100 micrograms / kg ) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles .
Diseases: "	"Sentence: Under proper control of respiration , body temperature and end - tidal CO2 , intravenous administration of fentanyl ( 50 or 100 micrograms / kg ) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles .
Diseases:"
61	Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha - adrenoceptor blocker , prazosin .	O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['muscular rigidity']	1	4	"Sentence: Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha - adrenoceptor blocker , prazosin .
Diseases: muscular rigidity"	"Sentence: Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha - adrenoceptor blocker , prazosin .
Diseases:"
62	Microinjection of fentanyl ( 2 . 5 micrograms / 50 nl ) directly into this pontine nucleus , on the other hand , elicited discernible electromyographic excitation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Microinjection of fentanyl ( 2 . 5 micrograms / 50 nl ) directly into this pontine nucleus , on the other hand , elicited discernible electromyographic excitation .
Diseases: "	"Sentence: Microinjection of fentanyl ( 2 . 5 micrograms / 50 nl ) directly into this pontine nucleus , on the other hand , elicited discernible electromyographic excitation .
Diseases:"
63	It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons .	O O O O O O O B I O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O	['muscular rigidity']	1	4	"Sentence: It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons .
Diseases: muscular rigidity"	"Sentence: It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons .
Diseases:"
64	Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia .	B I I O O O O O O O O B O	O O O O O O O O O O O O O	['menorrhagia', 'cerebral sinus thrombosis']	2	15	"Sentence: Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia .
Diseases: menorrhagia, cerebral sinus thrombosis"	"Sentence: Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia .
Diseases:"
65	We describe a 42 - year - old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon - aminocaproic acid therapy for menorrhagia .	O O O O O O O O O O O O B I I I I I O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O B I I I O O O O	['sagittal and left transverse sinus thrombosis', 'menorrhagia']	2	19	"Sentence: We describe a 42 - year - old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon - aminocaproic acid therapy for menorrhagia .
Diseases: sagittal and left transverse sinus thrombosis, menorrhagia"	"Sentence: We describe a 42 - year - old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon - aminocaproic acid therapy for menorrhagia .
Diseases:"
66	This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss .	O O O O O O O O O B O O O O O B I O	O O O O O O O O O O O O O O O O O O	['menorrhagia', 'blood loss']	2	8	"Sentence: This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss .
Diseases: menorrhagia, blood loss"	"Sentence: This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss .
Diseases:"
67	Although increased risk of thromboembolic disease has been reported during treatment with epsilon - aminocaproic acid , cerebral sinus thrombosis has not been previously described .	O O O O B I O O O O O O O O O O O B I I O O O O O O	O O O O O O O O O O O O B I I I O O O O O O O O O O	['thromboembolic disease', 'cerebral sinus thrombosis']	2	14	"Sentence: Although increased risk of thromboembolic disease has been reported during treatment with epsilon - aminocaproic acid , cerebral sinus thrombosis has not been previously described .
Diseases: thromboembolic disease, cerebral sinus thrombosis"	"Sentence: Although increased risk of thromboembolic disease has been reported during treatment with epsilon - aminocaproic acid , cerebral sinus thrombosis has not been previously described .
Diseases:"
68	Careful use of epsilon - aminocaproic acid therapy is recommended .	O O O O O O O O O O O	O O O B I I I O O O O	[]	0	0	"Sentence: Careful use of epsilon - aminocaproic acid therapy is recommended .
Diseases: "	"Sentence: Careful use of epsilon - aminocaproic acid therapy is recommended .
Diseases:"
69	Hemorrhagic cystitis complicating bone marrow transplantation .	B I O O O O O	O O O O O O O	['hemorrhagic cystitis']	1	7	"Sentence: Hemorrhagic cystitis complicating bone marrow transplantation .
Diseases: hemorrhagic cystitis"	"Sentence: Hemorrhagic cystitis complicating bone marrow transplantation .
Diseases:"
70	Hemorrhagic cystitis is a potentially serious complication of high - dose cyclophosphamide therapy administered before bone marrow transplantation .	B I O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O	['hemorrhagic cystitis']	1	7	"Sentence: Hemorrhagic cystitis is a potentially serious complication of high - dose cyclophosphamide therapy administered before bone marrow transplantation .
Diseases: hemorrhagic cystitis"	"Sentence: Hemorrhagic cystitis is a potentially serious complication of high - dose cyclophosphamide therapy administered before bone marrow transplantation .
Diseases:"
71	As standard practice at our institution , patients who are scheduled to receive a bone marrow transplant are treated prophylactically with forced hydration and bladder irrigation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: As standard practice at our institution , patients who are scheduled to receive a bone marrow transplant are treated prophylactically with forced hydration and bladder irrigation .
Diseases: "	"Sentence: As standard practice at our institution , patients who are scheduled to receive a bone marrow transplant are treated prophylactically with forced hydration and bladder irrigation .
Diseases:"
72	In an attempt to obviate the inconvenience of bladder irrigation , we conducted a feasibility trial of uroprophylaxis with mesna , which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O B O O O O O O O B O O O O O	['hemorrhagic cystitis']	1	7	"Sentence: In an attempt to obviate the inconvenience of bladder irrigation , we conducted a feasibility trial of uroprophylaxis with mesna , which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis .
Diseases: hemorrhagic cystitis"	"Sentence: In an attempt to obviate the inconvenience of bladder irrigation , we conducted a feasibility trial of uroprophylaxis with mesna , which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis .
Diseases:"
73	Of 97 patients who received standard prophylaxis , 4 had symptomatic hemorrhagic cystitis .	O O O O O O O O O O O B I O	O O O O O O O O O O O O O O	['hemorrhagic cystitis']	1	7	"Sentence: Of 97 patients who received standard prophylaxis , 4 had symptomatic hemorrhagic cystitis .
Diseases: hemorrhagic cystitis"	"Sentence: Of 97 patients who received standard prophylaxis , 4 had symptomatic hemorrhagic cystitis .
Diseases:"
74	In contrast , two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks .	O O O O O O O O O O O O O O O O O O O B I O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O O O	['hemorrhagic cystitis']	1	7	"Sentence: In contrast , two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks .
Diseases: hemorrhagic cystitis"	"Sentence: In contrast , two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks .
Diseases:"
75	Because of this suboptimal result , we resumed the use of bladder irrigation and forced hydration to minimize the risk of hemorrhagic cystitis .	O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O	['hemorrhagic cystitis']	1	7	"Sentence: Because of this suboptimal result , we resumed the use of bladder irrigation and forced hydration to minimize the risk of hemorrhagic cystitis .
Diseases: hemorrhagic cystitis"	"Sentence: Because of this suboptimal result , we resumed the use of bladder irrigation and forced hydration to minimize the risk of hemorrhagic cystitis .
Diseases:"
76	Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids : report of a double - blind multicenter study .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O B O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids : report of a double - blind multicenter study .
Diseases: "	"Sentence: Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids : report of a double - blind multicenter study .
Diseases:"
77	The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II .	O O O O O O O O O O O O O	O B O O O O O B O O O O O	[]	0	0	"Sentence: The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II .
Diseases: "	"Sentence: The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II .
Diseases:"
78	The efficacy and safety of a new benzodiazepine antagonist , flumazenil , were assessed in a double - blind multicenter study .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O B O O O O O O O O O O O	[]	0	0	"Sentence: The efficacy and safety of a new benzodiazepine antagonist , flumazenil , were assessed in a double - blind multicenter study .
Diseases: "	"Sentence: The efficacy and safety of a new benzodiazepine antagonist , flumazenil , were assessed in a double - blind multicenter study .
Diseases:"
79	Flumazenil ( mean dose , 0 . 76 mg ) or placebo ( mean dose , 8 . 9 ml ) was administered intravenously to 130 and 67 patients , respectively , who had been given diazepam in conjunction with an opioid ( fentanyl , meperidine , or morphine ) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O B O B O O B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Flumazenil ( mean dose , 0 . 76 mg ) or placebo ( mean dose , 8 . 9 ml ) was administered intravenously to 130 and 67 patients , respectively , who had been given diazepam in conjunction with an opioid ( fentanyl , meperidine , or morphine ) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures .
Diseases: "	"Sentence: Flumazenil ( mean dose , 0 . 76 mg ) or placebo ( mean dose , 8 . 9 ml ) was administered intravenously to 130 and 67 patients , respectively , who had been given diazepam in conjunction with an opioid ( fentanyl , meperidine , or morphine ) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures .
Diseases:"
80	The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O	[]	0	0	"Sentence: The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo .
Diseases: "	"Sentence: The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo .
Diseases:"
81	After 5 minutes , 80 / 115 ( 70 % ) flumazenil - treated patients , compared with 21 / 63 ( 33 % ) placebo - treated patients , were completely awake and alert , as indicated by a score of 5 on the Observer 's Assessment of Alertness / Sedation Scale .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After 5 minutes , 80 / 115 ( 70 % ) flumazenil - treated patients , compared with 21 / 63 ( 33 % ) placebo - treated patients , were completely awake and alert , as indicated by a score of 5 on the Observer 's Assessment of Alertness / Sedation Scale .
Diseases: "	"Sentence: After 5 minutes , 80 / 115 ( 70 % ) flumazenil - treated patients , compared with 21 / 63 ( 33 % ) placebo - treated patients , were completely awake and alert , as indicated by a score of 5 on the Observer 's Assessment of Alertness / Sedation Scale .
Diseases:"
82	Ninety - five percent of patients in each group who attained a score of 5 at the 5 - minute assessment showed no loss of alertness throughout the 180 - minute assessment period .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ninety - five percent of patients in each group who attained a score of 5 at the 5 - minute assessment showed no loss of alertness throughout the 180 - minute assessment period .
Diseases: "	"Sentence: Ninety - five percent of patients in each group who attained a score of 5 at the 5 - minute assessment showed no loss of alertness throughout the 180 - minute assessment period .
Diseases:"
83	Flumazenil - treated patients also performed significantly better on the Finger - to - Nose Test and the recall of pictures shown at the 5 - minute assessment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Flumazenil - treated patients also performed significantly better on the Finger - to - Nose Test and the recall of pictures shown at the 5 - minute assessment .
Diseases: "	"Sentence: Flumazenil - treated patients also performed significantly better on the Finger - to - Nose Test and the recall of pictures shown at the 5 - minute assessment .
Diseases:"
84	Flumazenil was well tolerated , with no serious adverse effects reported .	O O O O O O O O O O O O	B O O O O O O O O O O O	[]	0	0	"Sentence: Flumazenil was well tolerated , with no serious adverse effects reported .
Diseases: "	"Sentence: Flumazenil was well tolerated , with no serious adverse effects reported .
Diseases:"
85	Thirty - nine ( 30 % ) of flumazenil - treated patients , compared with 17 ( 25 % ) of placebo - treated patients had one or more drug - related adverse experiences .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thirty - nine ( 30 % ) of flumazenil - treated patients , compared with 17 ( 25 % ) of placebo - treated patients had one or more drug - related adverse experiences .
Diseases: "	"Sentence: Thirty - nine ( 30 % ) of flumazenil - treated patients , compared with 17 ( 25 % ) of placebo - treated patients had one or more drug - related adverse experiences .
Diseases:"
86	The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection - site pain in the placebo group .	O O O O O O B O B O O O O O B O O O O B O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O	['nausea', 'vomiting', 'pain']	3	7	"Sentence: The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection - site pain in the placebo group .
Diseases: nausea, vomiting, pain"	"Sentence: The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection - site pain in the placebo group .
Diseases:"
87	Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids .	O O O O O O O O O O O O O O O O	B O O O O O O O O B O O O O O O	[]	0	0	"Sentence: Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids .
Diseases: "	"Sentence: Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids .
Diseases:"
88	Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives : case reports .	O B O B I I O O O O O O O O O O O O O	O O O O O O O O O O O O O B I O O O O	['adenomas', 'focal nodular hyperplasia']	2	9	"Sentence: Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives : case reports .
Diseases: adenomas, focal nodular hyperplasia"	"Sentence: Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives : case reports .
Diseases:"
89	Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives , are reported .	O O O O B O O O B I I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B I O O O O	['focal nodular hyperplasia', 'adenoma']	2	9	"Sentence: Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives , are reported .
Diseases: focal nodular hyperplasia, adenoma"	"Sentence: Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives , are reported .
Diseases:"
90	Special reference is made to their clinical presentation , which may be totally asymptomatic .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Special reference is made to their clinical presentation , which may be totally asymptomatic .
Diseases: "	"Sentence: Special reference is made to their clinical presentation , which may be totally asymptomatic .
Diseases:"
91	Liver - function tests are of little diagnostic value , but valuable information may be obtained from both liver scanning and hepatic angiography .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Liver - function tests are of little diagnostic value , but valuable information may be obtained from both liver scanning and hepatic angiography .
Diseases: "	"Sentence: Liver - function tests are of little diagnostic value , but valuable information may be obtained from both liver scanning and hepatic angiography .
Diseases:"
92	Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed .	O O O O O O O B O B I I O O O O O O	O O O O O O O O O O O O O O O O O O	['focal nodular hyperplasia', 'adenoma']	2	9	"Sentence: Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed .
Diseases: focal nodular hyperplasia, adenoma"	"Sentence: Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed .
Diseases:"
93	Arterial thromboembolism in patients receiving systemic heparin therapy : a complication associated with heparin - induced thrombocytopenia .	O B O O O O O O O O O O O O O O B O	O O O O O O B O O O O O O B O O O O	['thromboembolism', 'thrombocytopenia']	2	14	"Sentence: Arterial thromboembolism in patients receiving systemic heparin therapy : a complication associated with heparin - induced thrombocytopenia .
Diseases: thromboembolism, thrombocytopenia"	"Sentence: Arterial thromboembolism in patients receiving systemic heparin therapy : a complication associated with heparin - induced thrombocytopenia .
Diseases:"
94	Arterial thromboembolism is a recognized complication of systemic heparin therapy .	O B O O O O O O O O O	O O O O O O O O B O O	['thromboembolism']	1	6	"Sentence: Arterial thromboembolism is a recognized complication of systemic heparin therapy .
Diseases: thromboembolism"	"Sentence: Arterial thromboembolism is a recognized complication of systemic heparin therapy .
Diseases:"
95	Characteristic of the entity is arterial occlusion by platelet - fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy , preceded by profound thrombocytopenia with platelet counts in the range of 30 , 000 to 40 , 000 per cubic millimeter .	O O O O O B I O O O O B O O B O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['arterial occlusion', 'thrombocytopenia', 'ischemia', 'thrombi']	4	21	"Sentence: Characteristic of the entity is arterial occlusion by platelet - fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy , preceded by profound thrombocytopenia with platelet counts in the range of 30 , 000 to 40 , 000 per cubic millimeter .
Diseases: arterial occlusion, thrombocytopenia, ischemia, thrombi"	"Sentence: Characteristic of the entity is arterial occlusion by platelet - fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy , preceded by profound thrombocytopenia with platelet counts in the range of 30 , 000 to 40 , 000 per cubic millimeter .
Diseases:"
96	The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin , and might serve to warn the clinician of these complications .	O O O O O O O O B I I I O O O O B O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['gastrointestinal and musculoskeletal symptoms', 'ischemic']	2	15	"Sentence: The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin , and might serve to warn the clinician of these complications .
Diseases: gastrointestinal and musculoskeletal symptoms, ischemic"	"Sentence: The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin , and might serve to warn the clinician of these complications .
Diseases:"
97	Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O	[]	0	0	"Sentence: Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed .
Diseases: "	"Sentence: Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed .
Diseases:"
98	The common factor relating thromboembolism and thrombocytopenia is heparin - induced platelet aggregation .	O O O O B O B O O O O B I O	O O O O O O O O B O O O O O	['platelet aggregation', 'thromboembolism', 'thrombocytopenia']	3	18	"Sentence: The common factor relating thromboembolism and thrombocytopenia is heparin - induced platelet aggregation .
Diseases: platelet aggregation, thromboembolism, thrombocytopenia"	"Sentence: The common factor relating thromboembolism and thrombocytopenia is heparin - induced platelet aggregation .
Diseases:"
99	Appropriate treatment consists of discontinuation of heparin , and anticoagulation with sodium warfarin if necessary .	O O O O O O O O O O O O O O O O	O O O O O O B O O O O B I O O O	[]	0	0	"Sentence: Appropriate treatment consists of discontinuation of heparin , and anticoagulation with sodium warfarin if necessary .
Diseases: "	"Sentence: Appropriate treatment consists of discontinuation of heparin , and anticoagulation with sodium warfarin if necessary .
Diseases:"
100	Vascular procedures are performed as indicated .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: Vascular procedures are performed as indicated .
Diseases: "	"Sentence: Vascular procedures are performed as indicated .
Diseases:"
101	Long - term prognosis for transplant - free survivors of paracetamol - induced acute liver failure .	O O O O O O O O O O O O O B I I O	O O O O O O O O O O B O O O O O O	['acute liver failure']	1	4	"Sentence: Long - term prognosis for transplant - free survivors of paracetamol - induced acute liver failure .
Diseases: acute liver failure"	"Sentence: Long - term prognosis for transplant - free survivors of paracetamol - induced acute liver failure .
Diseases:"
102	BACKGROUND :	O O	O O	[]	0	0	"Sentence: BACKGROUND :
Diseases: "	"Sentence: BACKGROUND :
Diseases:"
103	The prognosis for transplant - free survivors of paracetamol - induced acute liver failure remains unknown .	O O O O O O O O O O O B I I O O O	O O O O O O O O B O O O O O O O O	['acute liver failure']	1	4	"Sentence: The prognosis for transplant - free survivors of paracetamol - induced acute liver failure remains unknown .
Diseases: acute liver failure"	"Sentence: The prognosis for transplant - free survivors of paracetamol - induced acute liver failure remains unknown .
Diseases:"
104	AIM : To examine whether paracetamol - induced acute liver failure increases long - term mortality .	O O O O O O O O B I I O O O O O O	O O O O O B O O O O O O O O O O O	['acute liver failure']	1	4	"Sentence: AIM : To examine whether paracetamol - induced acute liver failure increases long - term mortality .
Diseases: acute liver failure"	"Sentence: AIM : To examine whether paracetamol - induced acute liver failure increases long - term mortality .
Diseases:"
105	METHODS : We followed up all transplant - free survivors of paracetamol - induced acute liver injury , hospitalized in a Danish national referral centre during 1984 - 2004 .	O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	['acute liver injury']	1	4	"Sentence: METHODS : We followed up all transplant - free survivors of paracetamol - induced acute liver injury , hospitalized in a Danish national referral centre during 1984 - 2004 .
Diseases: acute liver injury"	"Sentence: METHODS : We followed up all transplant - free survivors of paracetamol - induced acute liver injury , hospitalized in a Danish national referral centre during 1984 - 2004 .
Diseases:"
106	We compared age - specific mortality rates from 1 year post - discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not .	O O O O O O O O O O O O O O O O O O O O B I O O O B I I O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['acute liver failure', 'liver injury']	2	7	"Sentence: We compared age - specific mortality rates from 1 year post - discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not .
Diseases: acute liver failure, liver injury"	"Sentence: We compared age - specific mortality rates from 1 year post - discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not .
Diseases:"
107	RESULTS :	O O	O O	[]	0	0	"Sentence: RESULTS :
Diseases: "	"Sentence: RESULTS :
Diseases:"
108	We included 641 patients .	O O O O O	O O O O O	[]	0	0	"Sentence: We included 641 patients .
Diseases: "	"Sentence: We included 641 patients .
Diseases:"
109	On average , age - specific mortality rates were slightly higher for the 101 patients whose paracetamol - induced liver injury had caused an acute liver failure ( adjusted mortality rate ratio = 1 . 70 , 95 % CI 1 . 02 - 2 . 85 ) , but the association was age - dependent , and no survivors of acute liver failure died of liver disease , whereas suicides were frequent in both groups .	O O O O O O O O O O O O O O O O O O O B I O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O O B I O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['acute liver failure', 'liver disease', 'liver injury']	3	10	"Sentence: On average , age - specific mortality rates were slightly higher for the 101 patients whose paracetamol - induced liver injury had caused an acute liver failure ( adjusted mortality rate ratio = 1 . 70 , 95 % CI 1 . 02 - 2 . 85 ) , but the association was age - dependent , and no survivors of acute liver failure died of liver disease , whereas suicides were frequent in both groups .
Diseases: acute liver failure, liver disease, liver injury"	"Sentence: On average , age - specific mortality rates were slightly higher for the 101 patients whose paracetamol - induced liver injury had caused an acute liver failure ( adjusted mortality rate ratio = 1 . 70 , 95 % CI 1 . 02 - 2 . 85 ) , but the association was age - dependent , and no survivors of acute liver failure died of liver disease , whereas suicides were frequent in both groups .
Diseases:"
110	These observations speak against long - term effects of acute liver failure .	O O O O O O O O O B I I O	O O O O O O O O O O O O O	['acute liver failure']	1	4	"Sentence: These observations speak against long - term effects of acute liver failure .
Diseases: acute liver failure"	"Sentence: These observations speak against long - term effects of acute liver failure .
Diseases:"
111	More likely , the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure .	O O O O O O O O O O O O O O O O O B I O O O B I I O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['substance abuse', 'acute liver failure']	2	8	"Sentence: More likely , the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure .
Diseases: substance abuse, acute liver failure"	"Sentence: More likely , the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure .
Diseases:"
112	CONCLUSIONS : Paracetamol - induced acute liver failure did not affect long - term mortality .	O O O O O B I I O O O O O O O O	O O B O O O O O O O O O O O O O	['acute liver failure']	1	4	"Sentence: CONCLUSIONS : Paracetamol - induced acute liver failure did not affect long - term mortality .
Diseases: acute liver failure"	"Sentence: CONCLUSIONS : Paracetamol - induced acute liver failure did not affect long - term mortality .
Diseases:"
113	Clinical follow - up may be justified by the cause of the liver failure , but not by the liver failure itself .	O O O O O O O O O O O O B I O O O O O B I O O	O O O O O O O O O O O O O O O O O O O O O O O	['liver failure']	1	3	"Sentence: Clinical follow - up may be justified by the cause of the liver failure , but not by the liver failure itself .
Diseases: liver failure"	"Sentence: Clinical follow - up may be justified by the cause of the liver failure , but not by the liver failure itself .
Diseases:"
114	Serotonin 6 receptor gene is associated with methamphetamine - induced psychosis in a Japanese population .	O O O O O O O O O O B O O O O O	B O O O O O O B O O O O O O O O	['psychosis']	1	2	"Sentence: Serotonin 6 receptor gene is associated with methamphetamine - induced psychosis in a Japanese population .
Diseases: psychosis"	"Sentence: Serotonin 6 receptor gene is associated with methamphetamine - induced psychosis in a Japanese population .
Diseases:"
115	Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia .	O O O O O O O O O O O O B I O O B O	O O O O O O O O O O O O O O O O O O	['schizophrenia', 'psychotic disorders']	2	6	"Sentence: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia .
Diseases: schizophrenia, psychotic disorders"	"Sentence: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia .
Diseases:"
116	The serotonin 6 ( 5 - HT6 ) receptor is therapeutically targeted by several second generation antipsychotics , such as clozapine and olanzapine , and d - amphetamine - induced hyperactivity in rats is corrected with the use of a selective 5 - HT6 receptor antagonist .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O O B O B O O B I I O O O O O O O O O O O O O O O O O O O	['hyperactivity']	1	2	"Sentence: The serotonin 6 ( 5 - HT6 ) receptor is therapeutically targeted by several second generation antipsychotics , such as clozapine and olanzapine , and d - amphetamine - induced hyperactivity in rats is corrected with the use of a selective 5 - HT6 receptor antagonist .
Diseases: hyperactivity"	"Sentence: The serotonin 6 ( 5 - HT6 ) receptor is therapeutically targeted by several second generation antipsychotics , such as clozapine and olanzapine , and d - amphetamine - induced hyperactivity in rats is corrected with the use of a selective 5 - HT6 receptor antagonist .
Diseases:"
117	In addition , the disrupted prepulse inhibition induced by d - amphetamine or phencyclidine was restored by 5 - HT6 receptor antagonist in an animal study using rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B I I O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition , the disrupted prepulse inhibition induced by d - amphetamine or phencyclidine was restored by 5 - HT6 receptor antagonist in an animal study using rats .
Diseases: "	"Sentence: In addition , the disrupted prepulse inhibition induced by d - amphetamine or phencyclidine was restored by 5 - HT6 receptor antagonist in an animal study using rats .
Diseases:"
118	These animal models were considered to reflect the positive symptoms of schizophrenia , and the above evidence suggests that altered 5 - HT6 receptors are involved in the pathophysiology of psychotic disorders .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['schizophrenia', 'psychotic disorders']	2	6	"Sentence: These animal models were considered to reflect the positive symptoms of schizophrenia , and the above evidence suggests that altered 5 - HT6 receptors are involved in the pathophysiology of psychotic disorders .
Diseases: schizophrenia, psychotic disorders"	"Sentence: These animal models were considered to reflect the positive symptoms of schizophrenia , and the above evidence suggests that altered 5 - HT6 receptors are involved in the pathophysiology of psychotic disorders .
Diseases:"
119	The symptoms of methamphetamine ( METH ) - induced psychosis are similar to those of paranoid type schizophrenia .	O O O O O O O O O B O O O O O B I I O	O O O B O B O O O O O O O O O O O O O	['psychosis', 'paranoid type schizophrenia']	2	6	"Sentence: The symptoms of methamphetamine ( METH ) - induced psychosis are similar to those of paranoid type schizophrenia .
Diseases: psychosis, paranoid type schizophrenia"	"Sentence: The symptoms of methamphetamine ( METH ) - induced psychosis are similar to those of paranoid type schizophrenia .
Diseases:"
120	Therefore , we conducted an analysis of the association of the 5 - HT6 gene ( HTR6 ) with METH - induced psychosis .	O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O B O O O O	['psychosis']	1	2	"Sentence: Therefore , we conducted an analysis of the association of the 5 - HT6 gene ( HTR6 ) with METH - induced psychosis .
Diseases: psychosis"	"Sentence: Therefore , we conducted an analysis of the association of the 5 - HT6 gene ( HTR6 ) with METH - induced psychosis .
Diseases:"
121	METHOD : Using five tagging SNPs ( rs6693503 , rs1805054 , rs4912138 , rs3790757 and rs9659997 ) , we conducted a genetic association analysis of case - control samples ( 197 METH - induced psychosis patients and 337 controls ) in the Japanese population .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	['psychosis']	1	2	"Sentence: METHOD : Using five tagging SNPs ( rs6693503 , rs1805054 , rs4912138 , rs3790757 and rs9659997 ) , we conducted a genetic association analysis of case - control samples ( 197 METH - induced psychosis patients and 337 controls ) in the Japanese population .
Diseases: psychosis"	"Sentence: METHOD : Using five tagging SNPs ( rs6693503 , rs1805054 , rs4912138 , rs3790757 and rs9659997 ) , we conducted a genetic association analysis of case - control samples ( 197 METH - induced psychosis patients and 337 controls ) in the Japanese population .
Diseases:"
122	The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O	[]	0	0	"Sentence: The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients .
Diseases: "	"Sentence: The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients .
Diseases:"
123	rs6693503 was associated with METH - induced psychosis patients in the allele / genotype - wise analysis .	O O O O O O O B O O O O O O O O O O	O O O O B O O O O O O O O O O O O O	['psychosis']	1	2	"Sentence: rs6693503 was associated with METH - induced psychosis patients in the allele / genotype - wise analysis .
Diseases: psychosis"	"Sentence: rs6693503 was associated with METH - induced psychosis patients in the allele / genotype - wise analysis .
Diseases:"
124	Moreover , this association remained significant after Bonferroni correction .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Moreover , this association remained significant after Bonferroni correction .
Diseases: "	"Sentence: Moreover , this association remained significant after Bonferroni correction .
Diseases:"
125	In the haplotype - wise analysis , we detected an association between two markers ( rs6693503 and rs1805054 ) and three markers ( rs6693503 , rs1805054 and rs4912138 ) in HTR6 and METH - induced psychosis patients , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['psychosis']	1	2	"Sentence: In the haplotype - wise analysis , we detected an association between two markers ( rs6693503 and rs1805054 ) and three markers ( rs6693503 , rs1805054 and rs4912138 ) in HTR6 and METH - induced psychosis patients , respectively .
Diseases: psychosis"	"Sentence: In the haplotype - wise analysis , we detected an association between two markers ( rs6693503 and rs1805054 ) and three markers ( rs6693503 , rs1805054 and rs4912138 ) in HTR6 and METH - induced psychosis patients , respectively .
Diseases:"
126	CONCLUSION : HTR6 may play an important role in the pathophysiology of METH - induced psychosis in the Japanese population .	O O O O O O O O O O O O O O O B O O O O O	O O O O O O O O O O O O B O O O O O O O O	['psychosis']	1	2	"Sentence: CONCLUSION : HTR6 may play an important role in the pathophysiology of METH - induced psychosis in the Japanese population .
Diseases: psychosis"	"Sentence: CONCLUSION : HTR6 may play an important role in the pathophysiology of METH - induced psychosis in the Japanese population .
Diseases:"
127	Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride - induced seizures in mice .	O O O O O O O O O O O B O O O	O O O O O O O B I O O O O O O	['seizures']	1	3	"Sentence: Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride - induced seizures in mice .
Diseases: seizures"	"Sentence: Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride - induced seizures in mice .
Diseases:"
128	It is not known if there is a relationship between input rate and incidence of bupropion - induced seizures .	O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O B O O O O	['seizures']	1	3	"Sentence: It is not known if there is a relationship between input rate and incidence of bupropion - induced seizures .
Diseases: seizures"	"Sentence: It is not known if there is a relationship between input rate and incidence of bupropion - induced seizures .
Diseases:"
129	This is important , since different controlled release formulations of bupropion release the active drug at different rates .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: This is important , since different controlled release formulations of bupropion release the active drug at different rates .
Diseases: "	"Sentence: This is important , since different controlled release formulations of bupropion release the active drug at different rates .
Diseases:"
130	METHODS : We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg / kg , a known convulsive dose 50 ( CD50 ) , on the incidence and severity of bupropion - induced convulsions in the Swiss albino mice .	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	['convulsive', 'convulsions']	2	6	"Sentence: METHODS : We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg / kg , a known convulsive dose 50 ( CD50 ) , on the incidence and severity of bupropion - induced convulsions in the Swiss albino mice .
Diseases: convulsive, convulsions"	"Sentence: METHODS : We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg / kg , a known convulsive dose 50 ( CD50 ) , on the incidence and severity of bupropion - induced convulsions in the Swiss albino mice .
Diseases:"
131	A total of 69 mice , approximately 7 weeks of age , and weighing 21 . 0 to 29 . 1 g were randomly assigned to bupropion HCl 120 mg / kg treatment by intraperitoneal ( IP ) administration in 7 groups ( 9 to 10 animals per group ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A total of 69 mice , approximately 7 weeks of age , and weighing 21 . 0 to 29 . 1 g were randomly assigned to bupropion HCl 120 mg / kg treatment by intraperitoneal ( IP ) administration in 7 groups ( 9 to 10 animals per group ) .
Diseases: "	"Sentence: A total of 69 mice , approximately 7 weeks of age , and weighing 21 . 0 to 29 . 1 g were randomly assigned to bupropion HCl 120 mg / kg treatment by intraperitoneal ( IP ) administration in 7 groups ( 9 to 10 animals per group ) .
Diseases:"
132	Bupropion HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min , 15 min , 30 min , 60 min , 90 min , 120 min , and 240 min .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Bupropion HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min , 15 min , 30 min , 60 min , 90 min , 120 min , and 240 min .
Diseases: "	"Sentence: Bupropion HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min , 15 min , 30 min , 60 min , 90 min , 120 min , and 240 min .
Diseases:"
133	The number , time of onset , duration and the intensity of the convulsions or absence of convulsions were recorded .	O O O O O O O O O O O O O B O O O B O O O	O O O O O O O O O O O O O O O O O O O O O	['convulsions']	1	3	"Sentence: The number , time of onset , duration and the intensity of the convulsions or absence of convulsions were recorded .
Diseases: convulsions"	"Sentence: The number , time of onset , duration and the intensity of the convulsions or absence of convulsions were recorded .
Diseases:"
134	The results showed that IP administration of bupropion HCl 120 mg / kg by bolus injection induced convulsions in 6 out of 10 mice ( 60 % of convulsing mice ) in group 1 .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O	['convulsions']	1	3	"Sentence: The results showed that IP administration of bupropion HCl 120 mg / kg by bolus injection induced convulsions in 6 out of 10 mice ( 60 % of convulsing mice ) in group 1 .
Diseases: convulsions"	"Sentence: The results showed that IP administration of bupropion HCl 120 mg / kg by bolus injection induced convulsions in 6 out of 10 mice ( 60 % of convulsing mice ) in group 1 .
Diseases:"
135	Logistic regression analysis revealed that infusion time was significant ( p = 0 . 0004 ; odds ratio = 0 . 974 ) and increasing the IP infusion time of bupropion HCl 120 mg / kg was associated with a 91 % reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O	['convulsions']	1	3	"Sentence: Logistic regression analysis revealed that infusion time was significant ( p = 0 . 0004 ; odds ratio = 0 . 974 ) and increasing the IP infusion time of bupropion HCl 120 mg / kg was associated with a 91 % reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection .
Diseases: convulsions"	"Sentence: Logistic regression analysis revealed that infusion time was significant ( p = 0 . 0004 ; odds ratio = 0 . 974 ) and increasing the IP infusion time of bupropion HCl 120 mg / kg was associated with a 91 % reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection .
Diseases:"
136	Further increase in infusion time resulted in further reduction in the odds of convulsions to 99 . 8 % reduction at 240 min .	O O O O O O O O O O O O O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	['convulsions']	1	3	"Sentence: Further increase in infusion time resulted in further reduction in the odds of convulsions to 99 . 8 % reduction at 240 min .
Diseases: convulsions"	"Sentence: Further increase in infusion time resulted in further reduction in the odds of convulsions to 99 . 8 % reduction at 240 min .
Diseases:"
137	CONCLUSION :	O O	O O	[]	0	0	"Sentence: CONCLUSION :
Diseases: "	"Sentence: CONCLUSION :
Diseases:"
138	In conclusion , the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel .	O O O O O O O O O O O O O O O O B O O O O O O O B O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	['convulsive', 'convulsions']	2	6	"Sentence: In conclusion , the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel .
Diseases: convulsive, convulsions"	"Sentence: In conclusion , the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel .
Diseases:"
139	Detailed spectral profile analysis of penicillin - induced epileptiform activity in anesthetized rats .	O O O O O O O O B I O O O O	O O O O O B O O O O O O O O	['epileptiform activity']	1	5	"Sentence: Detailed spectral profile analysis of penicillin - induced epileptiform activity in anesthetized rats .
Diseases: epileptiform activity"	"Sentence: Detailed spectral profile analysis of penicillin - induced epileptiform activity in anesthetized rats .
Diseases:"
140	Penicillin model is a widely used experimental model for epilepsy research .	O O O O O O O O O B O O	B O O O O O O O O O O O	['epilepsy']	1	3	"Sentence: Penicillin model is a widely used experimental model for epilepsy research .
Diseases: epilepsy"	"Sentence: Penicillin model is a widely used experimental model for epilepsy research .
Diseases:"
141	In the present study we aimed to portray a detailed spectral analysis of penicillin - induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats .	O O O O O O O O O O O O O O O O B I O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	['epileptiform activity']	1	5	"Sentence: In the present study we aimed to portray a detailed spectral analysis of penicillin - induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats .
Diseases: epileptiform activity"	"Sentence: In the present study we aimed to portray a detailed spectral analysis of penicillin - induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats .
Diseases:"
142	Male Wistar rats were anesthetized with i . p .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Male Wistar rats were anesthetized with i . p .
Diseases: "	"Sentence: Male Wistar rats were anesthetized with i . p .
Diseases:"
143	urethane and connected to an electrocorticogram setup .	O O O O O O O O	B O O O O O O O	[]	0	0	"Sentence: urethane and connected to an electrocorticogram setup .
Diseases: "	"Sentence: urethane and connected to an electrocorticogram setup .
Diseases:"
144	After a short period of basal activity recording , epileptic focus was induced by injecting 400IU / 2 microl penicillin - G potassium into the left lateral ventricle while the cortical activity was continuously recorded .	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B I O I O O O O O O O O O O O O O	['epileptic']	1	3	"Sentence: After a short period of basal activity recording , epileptic focus was induced by injecting 400IU / 2 microl penicillin - G potassium into the left lateral ventricle while the cortical activity was continuously recorded .
Diseases: epileptic"	"Sentence: After a short period of basal activity recording , epileptic focus was induced by injecting 400IU / 2 microl penicillin - G potassium into the left lateral ventricle while the cortical activity was continuously recorded .
Diseases:"
145	Basal activity , latent period and the penicillin - induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis .	O O O O O O O O O O B I O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O	['epileptiform activity']	1	5	"Sentence: Basal activity , latent period and the penicillin - induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis .
Diseases: epileptiform activity"	"Sentence: Basal activity , latent period and the penicillin - induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis .
Diseases:"
146	Spectral analyses were conducted by dividing the whole spectrum into different frequency bands including delta , theta ( slow and fast ) , alpha - sigma , beta ( 1 and 2 ) and gamma ( 1 and 2 ) bands .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Spectral analyses were conducted by dividing the whole spectrum into different frequency bands including delta , theta ( slow and fast ) , alpha - sigma , beta ( 1 and 2 ) and gamma ( 1 and 2 ) bands .
Diseases: "	"Sentence: Spectral analyses were conducted by dividing the whole spectrum into different frequency bands including delta , theta ( slow and fast ) , alpha - sigma , beta ( 1 and 2 ) and gamma ( 1 and 2 ) bands .
Diseases:"
147	Our results show that the most affected frequency bands were delta , theta , beta - 2 and gamma - 2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes ( basal activity , latent period and epileptiform activity ) .	O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O B I O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['epileptiform activity']	1	5	"Sentence: Our results show that the most affected frequency bands were delta , theta , beta - 2 and gamma - 2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes ( basal activity , latent period and epileptiform activity ) .
Diseases: epileptiform activity"	"Sentence: Our results show that the most affected frequency bands were delta , theta , beta - 2 and gamma - 2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes ( basal activity , latent period and epileptiform activity ) .
Diseases:"
148	Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental epilepsies .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['epilepsies']	1	4	"Sentence: Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental epilepsies .
Diseases: epilepsies"	"Sentence: Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental epilepsies .
Diseases:"
149	High dose dexmedetomidine as the sole sedative for pediatric MRI .	O O O O O O O O O O O	O O B O O O O O O O O	[]	0	0	"Sentence: High dose dexmedetomidine as the sole sedative for pediatric MRI .
Diseases: "	"Sentence: High dose dexmedetomidine as the sole sedative for pediatric MRI .
Diseases:"
150	OBJECTIVE :	O O	O O	[]	0	0	"Sentence: OBJECTIVE :
Diseases: "	"Sentence: OBJECTIVE :
Diseases:"
151	This large - scale retrospective review evaluates the sedation profile of dexmedetomidine .	O O O O O O O O O O O O O	O O O O O O O O O O O B O	[]	0	0	"Sentence: This large - scale retrospective review evaluates the sedation profile of dexmedetomidine .
Diseases: "	"Sentence: This large - scale retrospective review evaluates the sedation profile of dexmedetomidine .
Diseases:"
152	AIM : To determine the hemodynamic responses , efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging ( MRI ) studies .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: AIM : To determine the hemodynamic responses , efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging ( MRI ) studies .
Diseases: "	"Sentence: AIM : To determine the hemodynamic responses , efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging ( MRI ) studies .
Diseases:"
153	Dexmedetomidine has been used at our institution since 2005 to provide sedation for pediatric radiological imaging studies .	O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Dexmedetomidine has been used at our institution since 2005 to provide sedation for pediatric radiological imaging studies .
Diseases: "	"Sentence: Dexmedetomidine has been used at our institution since 2005 to provide sedation for pediatric radiological imaging studies .
Diseases:"
154	Over time , an effective protocol utilizing high dose dexmedetomidine as the sole sedative agent has evolved .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: Over time , an effective protocol utilizing high dose dexmedetomidine as the sole sedative agent has evolved .
Diseases: "	"Sentence: Over time , an effective protocol utilizing high dose dexmedetomidine as the sole sedative agent has evolved .
Diseases:"
155	METHODS / MATERIALS :	O O O O	O O O O	[]	0	0	"Sentence: METHODS / MATERIALS :
Diseases: "	"Sentence: METHODS / MATERIALS :
Diseases:"
156	As part of the ongoing Quality Assurance process , data on all sedations are reviewed monthly and protocols modified as needed .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: As part of the ongoing Quality Assurance process , data on all sedations are reviewed monthly and protocols modified as needed .
Diseases: "	"Sentence: As part of the ongoing Quality Assurance process , data on all sedations are reviewed monthly and protocols modified as needed .
Diseases:"
157	Data were analyzed from all 747 consecutive patients who received dexmedetomidine for MRI sedation from April 2005 to April 2007 .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: Data were analyzed from all 747 consecutive patients who received dexmedetomidine for MRI sedation from April 2005 to April 2007 .
Diseases: "	"Sentence: Data were analyzed from all 747 consecutive patients who received dexmedetomidine for MRI sedation from April 2005 to April 2007 .
Diseases:"
158	Since 2005 , the 10 - min loading dose of our dexmedetomidine protocol increased from 2 to 3 microg . kg ( - 1 ) , and the infusion rate increased from 1 to 1 . 5 to 2 microg . kg ( - 1 ) . h ( - 1 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Since 2005 , the 10 - min loading dose of our dexmedetomidine protocol increased from 2 to 3 microg . kg ( - 1 ) , and the infusion rate increased from 1 to 1 . 5 to 2 microg . kg ( - 1 ) . h ( - 1 ) .
Diseases: "	"Sentence: Since 2005 , the 10 - min loading dose of our dexmedetomidine protocol increased from 2 to 3 microg . kg ( - 1 ) , and the infusion rate increased from 1 to 1 . 5 to 2 microg . kg ( - 1 ) . h ( - 1 ) .
Diseases:"
159	The current sedation protocol progressively increased the rate of successful sedation ( able to complete the imaging study ) when using dexmedetomidine alone from 91 . 8 % to 97 . 6 % ( P = 0 . 009 ) , reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min ( P < 0 . 001 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O B O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The current sedation protocol progressively increased the rate of successful sedation ( able to complete the imaging study ) when using dexmedetomidine alone from 91 . 8 % to 97 . 6 % ( P = 0 . 009 ) , reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min ( P < 0 . 001 ) .
Diseases: "	"Sentence: The current sedation protocol progressively increased the rate of successful sedation ( able to complete the imaging study ) when using dexmedetomidine alone from 91 . 8 % to 97 . 6 % ( P = 0 . 009 ) , reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min ( P < 0 . 001 ) .
Diseases:"
160	Although dexmedetomidine sedation was associated with a 16 % incidence of bradycardia , all concomitant mean arterial blood pressures were within 20 % of age - adjusted normal range and oxygen saturations were 95 % or higher .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['bradycardia']	1	4	"Sentence: Although dexmedetomidine sedation was associated with a 16 % incidence of bradycardia , all concomitant mean arterial blood pressures were within 20 % of age - adjusted normal range and oxygen saturations were 95 % or higher .
Diseases: bradycardia"	"Sentence: Although dexmedetomidine sedation was associated with a 16 % incidence of bradycardia , all concomitant mean arterial blood pressures were within 20 % of age - adjusted normal range and oxygen saturations were 95 % or higher .
Diseases:"
161	CONCLUSION : Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies .	O O O O O O O O O O O O O O	O O B O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSION : Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies .
Diseases: "	"Sentence: CONCLUSION : Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies .
Diseases:"
162	While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established ' awake ' norms , this deviation is generally within 20 % of norms , and is not associated with adverse sequelae .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established ' awake ' norms , this deviation is generally within 20 % of norms , and is not associated with adverse sequelae .
Diseases: "	"Sentence: While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established ' awake ' norms , this deviation is generally within 20 % of norms , and is not associated with adverse sequelae .
Diseases:"
163	Dexmedetomidine is useful as the sole sedative for pediatric MRI .	O O O O O O O O O O O	B O O O O O O O O O O	[]	0	0	"Sentence: Dexmedetomidine is useful as the sole sedative for pediatric MRI .
Diseases: "	"Sentence: Dexmedetomidine is useful as the sole sedative for pediatric MRI .
Diseases:"
164	Methamphetamine causes alterations in the MAP kinase - related pathways in the brains of mice that display increased aggressiveness .	O O O O O O O O O O O O O O O O O O B O	B O O O O O O O O O O O O O O O O O O O	['aggressiveness']	1	3	"Sentence: Methamphetamine causes alterations in the MAP kinase - related pathways in the brains of mice that display increased aggressiveness .
Diseases: aggressiveness"	"Sentence: Methamphetamine causes alterations in the MAP kinase - related pathways in the brains of mice that display increased aggressiveness .
Diseases:"
165	Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders , and are common in methamphetamine ( METH ) abusers .	B I O O O O O O O O O B I O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O B O O O	['aggressive behaviors', 'psychiatric disorders']	2	5	"Sentence: Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders , and are common in methamphetamine ( METH ) abusers .
Diseases: aggressive behaviors, psychiatric disorders"	"Sentence: Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders , and are common in methamphetamine ( METH ) abusers .
Diseases:"
166	Herein , we report that multiple ( but not single ) injections of METH significantly increased aggressiveness in male CD - 1 mice .	O O O O O O O O O O O O O O O O B O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O	['aggressiveness']	1	3	"Sentence: Herein , we report that multiple ( but not single ) injections of METH significantly increased aggressiveness in male CD - 1 mice .
Diseases: aggressiveness"	"Sentence: Herein , we report that multiple ( but not single ) injections of METH significantly increased aggressiveness in male CD - 1 mice .
Diseases:"
167	This increase in aggressiveness was not secondary to METH - induced hyperactivity .	O O O B O O O O O O O B O	O O O O O O O O B O O O O	['hyperactivity', 'aggressiveness']	2	5	"Sentence: This increase in aggressiveness was not secondary to METH - induced hyperactivity .
Diseases: hyperactivity, aggressiveness"	"Sentence: This increase in aggressiveness was not secondary to METH - induced hyperactivity .
Diseases:"
168	Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase - related pathways after multiple and single METH injections .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase - related pathways after multiple and single METH injections .
Diseases: "	"Sentence: Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase - related pathways after multiple and single METH injections .
Diseases:"
169	There were statistically significant ( p < 0 . 05 ) decreases in MEK1 , Erk2p , GSK3alpha , 14 - 3 - 3e , and MEK7 in the striata of mice after multiple injections of METH .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: There were statistically significant ( p < 0 . 05 ) decreases in MEK1 , Erk2p , GSK3alpha , 14 - 3 - 3e , and MEK7 in the striata of mice after multiple injections of METH .
Diseases: "	"Sentence: There were statistically significant ( p < 0 . 05 ) decreases in MEK1 , Erk2p , GSK3alpha , 14 - 3 - 3e , and MEK7 in the striata of mice after multiple injections of METH .
Diseases:"
170	MEK1 was significantly decreased also after a single injection of METH , but to a much lesser degree than after multiple injections of METH .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O B O	[]	0	0	"Sentence: MEK1 was significantly decreased also after a single injection of METH , but to a much lesser degree than after multiple injections of METH .
Diseases: "	"Sentence: MEK1 was significantly decreased also after a single injection of METH , but to a much lesser degree than after multiple injections of METH .
Diseases:"
171	In the frontal cortex , there was a statistically significant decrease in GSK3alpha after multiple ( but not single ) injections of METH .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: In the frontal cortex , there was a statistically significant decrease in GSK3alpha after multiple ( but not single ) injections of METH .
Diseases: "	"Sentence: In the frontal cortex , there was a statistically significant decrease in GSK3alpha after multiple ( but not single ) injections of METH .
Diseases:"
172	These findings suggest that alterations in MAP kinase - related pathways in the prefronto - striatal circuitries might be involved in the manifestation of aggressive behaviors in mice .	O O O O O O O O O O O O O O O O O O O O O O O O B I O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['aggressive behaviors']	1	2	"Sentence: These findings suggest that alterations in MAP kinase - related pathways in the prefronto - striatal circuitries might be involved in the manifestation of aggressive behaviors in mice .
Diseases: aggressive behaviors"	"Sentence: These findings suggest that alterations in MAP kinase - related pathways in the prefronto - striatal circuitries might be involved in the manifestation of aggressive behaviors in mice .
Diseases:"
173	Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies .	O O O O O O O B O B I I O	B O O O O O O O O O O O O	['idiopathic generalized epilepsies', 'myoclonus']	2	13	"Sentence: Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies .
Diseases: idiopathic generalized epilepsies, myoclonus"	"Sentence: Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies .
Diseases:"
174	Five patients with idiopathic generalized epilepsies ( IGE ) treated with lamotrigine ( LTG ) experienced exacerbation or de novo appearance of myoclonic jerks ( MJ ) .	O O O B I I O B O O O O O O O O O O O O O O B I O B O O	O O O O O O O O O O O B O B O O O O O O O O O O O O O O	['myoclonic jerks', 'mj', 'idiopathic generalized epilepsies', 'ige']	4	20	"Sentence: Five patients with idiopathic generalized epilepsies ( IGE ) treated with lamotrigine ( LTG ) experienced exacerbation or de novo appearance of myoclonic jerks ( MJ ) .
Diseases: myoclonic jerks, mj, idiopathic generalized epilepsies, ige"	"Sentence: Five patients with idiopathic generalized epilepsies ( IGE ) treated with lamotrigine ( LTG ) experienced exacerbation or de novo appearance of myoclonic jerks ( MJ ) .
Diseases:"
175	In three patients , LTG exacerbated MJ in a dose - dependent manner with early aggravation during titration .	O O O O O O B O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O	['mj']	1	2	"Sentence: In three patients , LTG exacerbated MJ in a dose - dependent manner with early aggravation during titration .
Diseases: mj"	"Sentence: In three patients , LTG exacerbated MJ in a dose - dependent manner with early aggravation during titration .
Diseases:"
176	MJ disappeared when LTG dose was decreased by 25 to 50 % .	B O O O O O O O O O O O O	O O O B O O O O O O O O O	['mj']	1	2	"Sentence: MJ disappeared when LTG dose was decreased by 25 to 50 % .
Diseases: mj"	"Sentence: MJ disappeared when LTG dose was decreased by 25 to 50 % .
Diseases:"
177	In two patients , LTG exacerbated MJ in a delayed but more severe manner , with myoclonic status that only ceased after LTG withdrawal .	O O O O O O B O O O O O O O O O B I O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O B O O	['mj', 'myoclonic status']	2	7	"Sentence: In two patients , LTG exacerbated MJ in a delayed but more severe manner , with myoclonic status that only ceased after LTG withdrawal .
Diseases: mj, myoclonic status"	"Sentence: In two patients , LTG exacerbated MJ in a delayed but more severe manner , with myoclonic status that only ceased after LTG withdrawal .
Diseases:"
178	rTMS of supplementary motor area modulates therapy - induced dyskinesias in Parkinson disease .	O O O O O O O O O B O B I O	O O O O O O O O O O O O O O	['dyskinesias', 'parkinson disease']	2	9	"Sentence: rTMS of supplementary motor area modulates therapy - induced dyskinesias in Parkinson disease .
Diseases: dyskinesias, parkinson disease"	"Sentence: rTMS of supplementary motor area modulates therapy - induced dyskinesias in Parkinson disease .
Diseases:"
179	The neural mechanisms and circuitry involved in levodopa - induced dyskinesia are unclear .	O O O O O O O O O O B O O O	O O O O O O O B O O O O O O	['dyskinesia']	1	5	"Sentence: The neural mechanisms and circuitry involved in levodopa - induced dyskinesia are unclear .
Diseases: dyskinesia"	"Sentence: The neural mechanisms and circuitry involved in levodopa - induced dyskinesia are unclear .
Diseases:"
180	Using repetitive transcranial magnetic stimulation ( rTMS ) over the supplementary motor area ( SMA ) in a group of patients with advanced Parkinson disease , the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion .	O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O B O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['parkinson disease', 'dyskinetic']	2	7	"Sentence: Using repetitive transcranial magnetic stimulation ( rTMS ) over the supplementary motor area ( SMA ) in a group of patients with advanced Parkinson disease , the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion .
Diseases: parkinson disease, dyskinetic"	"Sentence: Using repetitive transcranial magnetic stimulation ( rTMS ) over the supplementary motor area ( SMA ) in a group of patients with advanced Parkinson disease , the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion .
Diseases:"
181	rTMS at 1 Hz was observed to markedly reduce drug - induced dyskinesias , whereas 5 - Hz rTMS induced a slight but not significant increase .	O O O O O O O O O B I I I O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['drug - induced dyskinesias']	1	7	"Sentence: rTMS at 1 Hz was observed to markedly reduce drug - induced dyskinesias , whereas 5 - Hz rTMS induced a slight but not significant increase .
Diseases: drug - induced dyskinesias"	"Sentence: rTMS at 1 Hz was observed to markedly reduce drug - induced dyskinesias , whereas 5 - Hz rTMS induced a slight but not significant increase .
Diseases:"
182	Assessment of the onset and persistence of amnesia during procedural sedation with propofol .	O O O O O O O B O O O O O O	O O O O O O O O O O O O B O	['amnesia']	1	2	"Sentence: Assessment of the onset and persistence of amnesia during procedural sedation with propofol .
Diseases: amnesia"	"Sentence: Assessment of the onset and persistence of amnesia during procedural sedation with propofol .
Diseases:"
183	OBJECTIVES :	O O	O O	[]	0	0	"Sentence: OBJECTIVES :
Diseases: "	"Sentence: OBJECTIVES :
Diseases:"
184	To assess patients ' ability to repeat and recall words presented to them while undergoing procedural sedation with propofol , and correlate their recall with their level of awareness as measured by bispectral index ( BIS ) monitoring .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: To assess patients ' ability to repeat and recall words presented to them while undergoing procedural sedation with propofol , and correlate their recall with their level of awareness as measured by bispectral index ( BIS ) monitoring .
Diseases: "	"Sentence: To assess patients ' ability to repeat and recall words presented to them while undergoing procedural sedation with propofol , and correlate their recall with their level of awareness as measured by bispectral index ( BIS ) monitoring .
Diseases:"
185	METHODS :	O O	O O	[]	0	0	"Sentence: METHODS :
Diseases: "	"Sentence: METHODS :
Diseases:"
186	This was a prospective , single - intervention study of consenting adult patients undergoing procedural sedation with propofol between December 28 , 2002 , and October 31 , 2003 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: This was a prospective , single - intervention study of consenting adult patients undergoing procedural sedation with propofol between December 28 , 2002 , and October 31 , 2003 .
Diseases: "	"Sentence: This was a prospective , single - intervention study of consenting adult patients undergoing procedural sedation with propofol between December 28 , 2002 , and October 31 , 2003 .
Diseases:"
187	BIS monitoring was initiated starting 3 minutes before the procedure and continuing until the patient had regained baseline mental status .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: BIS monitoring was initiated starting 3 minutes before the procedure and continuing until the patient had regained baseline mental status .
Diseases: "	"Sentence: BIS monitoring was initiated starting 3 minutes before the procedure and continuing until the patient had regained baseline mental status .
Diseases:"
188	At 1 - minute intervals during the procedural sedation , until the patient regained baseline mental status at the end of the procedure , a word from a standardized list was read aloud , and the patient was asked to immediately repeat the word to the investigator .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At 1 - minute intervals during the procedural sedation , until the patient regained baseline mental status at the end of the procedure , a word from a standardized list was read aloud , and the patient was asked to immediately repeat the word to the investigator .
Diseases: "	"Sentence: At 1 - minute intervals during the procedural sedation , until the patient regained baseline mental status at the end of the procedure , a word from a standardized list was read aloud , and the patient was asked to immediately repeat the word to the investigator .
Diseases:"
189	The BIS score at the time the word was read and the patient 's ability to repeat the word were recorded .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The BIS score at the time the word was read and the patient 's ability to repeat the word were recorded .
Diseases: "	"Sentence: The BIS score at the time the word was read and the patient 's ability to repeat the word were recorded .
Diseases:"
190	After the procedure , the patient was asked to state all of the words from the list that he or she could recall , and to identify the last word recalled from prior to the start of the procedure and the first word recalled from after the procedure was completed .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After the procedure , the patient was asked to state all of the words from the list that he or she could recall , and to identify the last word recalled from prior to the start of the procedure and the first word recalled from after the procedure was completed .
Diseases: "	"Sentence: After the procedure , the patient was asked to state all of the words from the list that he or she could recall , and to identify the last word recalled from prior to the start of the procedure and the first word recalled from after the procedure was completed .
Diseases:"
191	Seventy - five consenting patients were enrolled ; one patient was excluded from data analysis for a protocol violation .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Seventy - five consenting patients were enrolled ; one patient was excluded from data analysis for a protocol violation .
Diseases: "	"Sentence: Seventy - five consenting patients were enrolled ; one patient was excluded from data analysis for a protocol violation .
Diseases:"
192	No serious adverse events were noted during the procedural sedations .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: No serious adverse events were noted during the procedural sedations .
Diseases: "	"Sentence: No serious adverse events were noted during the procedural sedations .
Diseases:"
193	The mean ( + / - standard deviation ) time of data collection was 16 . 4 minutes ( + / - 7 . 1 ; range 5 to 34 minutes ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mean ( + / - standard deviation ) time of data collection was 16 . 4 minutes ( + / - 7 . 1 ; range 5 to 34 minutes ) .
Diseases: "	"Sentence: The mean ( + / - standard deviation ) time of data collection was 16 . 4 minutes ( + / - 7 . 1 ; range 5 to 34 minutes ) .
Diseases:"
194	The mean initial ( preprocedure ) BIS score was 97 . 1 ( + / - 2 . 3 ; range 92 to 99 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mean initial ( preprocedure ) BIS score was 97 . 1 ( + / - 2 . 3 ; range 92 to 99 ) .
Diseases: "	"Sentence: The mean initial ( preprocedure ) BIS score was 97 . 1 ( + / - 2 . 3 ; range 92 to 99 ) .
Diseases:"
195	The mean lowest BIS score occurring during these procedural sedations was 66 . 9 ( + / - 14 . 4 ; range 33 to 91 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mean lowest BIS score occurring during these procedural sedations was 66 . 9 ( + / - 14 . 4 ; range 33 to 91 ) .
Diseases: "	"Sentence: The mean lowest BIS score occurring during these procedural sedations was 66 . 9 ( + / - 14 . 4 ; range 33 to 91 ) .
Diseases:"
196	The mean lowest BIS score corresponding to the ability of the patient to immediately repeat words read from the list was 77 . 1 ( 95 % CI = 74 . 3 to 80 . 0 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mean lowest BIS score corresponding to the ability of the patient to immediately repeat words read from the list was 77 . 1 ( 95 % CI = 74 . 3 to 80 . 0 ) .
Diseases: "	"Sentence: The mean lowest BIS score corresponding to the ability of the patient to immediately repeat words read from the list was 77 . 1 ( 95 % CI = 74 . 3 to 80 . 0 ) .
Diseases:"
197	The mean highest BIS score corresponding to the inability to repeat words was 81 . 5 ( 95 % CI = 78 . 1 to 84 . 8 ) .	O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['inability to repeat words']	1	5	"Sentence: The mean highest BIS score corresponding to the inability to repeat words was 81 . 5 ( 95 % CI = 78 . 1 to 84 . 8 ) .
Diseases: inability to repeat words"	"Sentence: The mean highest BIS score corresponding to the inability to repeat words was 81 . 5 ( 95 % CI = 78 . 1 to 84 . 8 ) .
Diseases:"
198	The mean BIS score corresponding to the last word recalled from prior to the initiation of the sedation was 96 . 7 ( + / - 2 . 4 ; range 84 to 98 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mean BIS score corresponding to the last word recalled from prior to the initiation of the sedation was 96 . 7 ( + / - 2 . 4 ; range 84 to 98 ) .
Diseases: "	"Sentence: The mean BIS score corresponding to the last word recalled from prior to the initiation of the sedation was 96 . 7 ( + / - 2 . 4 ; range 84 to 98 ) .
Diseases:"
199	The mean BIS score corresponding to the first word recalled after the procedure was completed was 91 . 2 ( 95 % CI = 88 . 1 to 94 . 3 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mean BIS score corresponding to the first word recalled after the procedure was completed was 91 . 2 ( 95 % CI = 88 . 1 to 94 . 3 ) .
Diseases: "	"Sentence: The mean BIS score corresponding to the first word recalled after the procedure was completed was 91 . 2 ( 95 % CI = 88 . 1 to 94 . 3 ) .
Diseases:"
200	All patients recalled at least one word that had been read to them during the protocol .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All patients recalled at least one word that had been read to them during the protocol .
Diseases: "	"Sentence: All patients recalled at least one word that had been read to them during the protocol .
Diseases:"
201	The mean lowest BIS score for any recalled word was 91 . 5 ( + / - 11 . 1 ; range 79 to 98 ) , and no words were recalled when the corresponding BIS score was less than 90 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mean lowest BIS score for any recalled word was 91 . 5 ( + / - 11 . 1 ; range 79 to 98 ) , and no words were recalled when the corresponding BIS score was less than 90 .
Diseases: "	"Sentence: The mean lowest BIS score for any recalled word was 91 . 5 ( + / - 11 . 1 ; range 79 to 98 ) , and no words were recalled when the corresponding BIS score was less than 90 .
Diseases:"
202	CONCLUSIONS : There is a range of BIS scores during which sedated patients are able to repeat words read to them but are not able to subsequently recall these words .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSIONS : There is a range of BIS scores during which sedated patients are able to repeat words read to them but are not able to subsequently recall these words .
Diseases: "	"Sentence: CONCLUSIONS : There is a range of BIS scores during which sedated patients are able to repeat words read to them but are not able to subsequently recall these words .
Diseases:"
203	Furthermore , patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation , suggestive of retrograde amnesia .	O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['retrograde amnesia']	1	5	"Sentence: Furthermore , patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation , suggestive of retrograde amnesia .
Diseases: retrograde amnesia"	"Sentence: Furthermore , patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation , suggestive of retrograde amnesia .
Diseases:"
204	Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals .	O O O B I O B O O O O O O O	O O O O O O O O O O O O O O	['rubella', 'hepatitis b']	2	7	"Sentence: Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals .
Diseases: rubella, hepatitis b"	"Sentence: Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals .
Diseases:"
205	To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire .	O O O O O O O B I O B O O O O O O	O O O O O O O O O O O O O O O O O	['rubella', 'hepatitis b']	2	7	"Sentence: To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire .
Diseases: rubella, hepatitis b"	"Sentence: To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire .
Diseases:"
206	METHODS : Data were extracted from 2021 paired mother - infant records for the year 2000 birth cohort in New Hampshire 's 25 delivery hospitals .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : Data were extracted from 2021 paired mother - infant records for the year 2000 birth cohort in New Hampshire 's 25 delivery hospitals .
Diseases: "	"Sentence: METHODS : Data were extracted from 2021 paired mother - infant records for the year 2000 birth cohort in New Hampshire 's 25 delivery hospitals .
Diseases:"
207	Assessment was done on the following : prenatal screening for hepatitis B and rubella , administration of the hepatitis B vaccine birth dose to all infants , administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen - positive mothers , rubella immunity , and administration of in - hospital postpartum rubella vaccine to rubella nonimmune women .	O O O O O O O O O O B I O B O O O O B I O O O O O O O O O B I O O O O O O O O O O O O O O O O B O O O O O O O O O B O O B O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O O	['rubella', 'hepatitis b']	2	7	"Sentence: Assessment was done on the following : prenatal screening for hepatitis B and rubella , administration of the hepatitis B vaccine birth dose to all infants , administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen - positive mothers , rubella immunity , and administration of in - hospital postpartum rubella vaccine to rubella nonimmune women .
Diseases: rubella, hepatitis b"	"Sentence: Assessment was done on the following : prenatal screening for hepatitis B and rubella , administration of the hepatitis B vaccine birth dose to all infants , administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen - positive mothers , rubella immunity , and administration of in - hospital postpartum rubella vaccine to rubella nonimmune women .
Diseases:"
208	Prenatal screening rates for hepatitis B ( 98 . 8 % ) and rubella ( 99 . 4 % ) were high .	O O O O B I O O O O O O O B O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['rubella', 'hepatitis b']	2	7	"Sentence: Prenatal screening rates for hepatitis B ( 98 . 8 % ) and rubella ( 99 . 4 % ) were high .
Diseases: rubella, hepatitis b"	"Sentence: Prenatal screening rates for hepatitis B ( 98 . 8 % ) and rubella ( 99 . 4 % ) were high .
Diseases:"
209	Hepatitis B vaccine birth dose was administered to 76 . 2 % of all infants .	B I O O O O O O O O O O O O O O	B I O O O O O O O O O O O O O O	['hepatitis b']	1	4	"Sentence: Hepatitis B vaccine birth dose was administered to 76 . 2 % of all infants .
Diseases: hepatitis b"	"Sentence: Hepatitis B vaccine birth dose was administered to 76 . 2 % of all infants .
Diseases:"
210	All infants who were born to hepatitis B surface antigen - positive mothers also received hepatitis B immune globulin .	O O O O O O O O O O O O O O O B I O O O	O O O O O O B I I I O O O O O B I I I O	['hepatitis b']	1	4	"Sentence: All infants who were born to hepatitis B surface antigen - positive mothers also received hepatitis B immune globulin .
Diseases: hepatitis b"	"Sentence: All infants who were born to hepatitis B surface antigen - positive mothers also received hepatitis B immune globulin .
Diseases:"
211	Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination .	O O O O O O O O O O O O O O O O O B I O O	O O O O O O O O O O O O O O O O O O O O O	['hepatitis b']	1	4	"Sentence: Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination .
Diseases: hepatitis b"	"Sentence: Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination .
Diseases:"
212	The proportion of infants who were vaccinated in January and February 2000 ( 48 . 5 % and 67 . 5 % , respectively ) was less than any other months , whereas the proportion who were vaccinated in December 2000 ( 88 . 2 % ) was the highest .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The proportion of infants who were vaccinated in January and February 2000 ( 48 . 5 % and 67 . 5 % , respectively ) was less than any other months , whereas the proportion who were vaccinated in December 2000 ( 88 . 2 % ) was the highest .
Diseases: "	"Sentence: The proportion of infants who were vaccinated in January and February 2000 ( 48 . 5 % and 67 . 5 % , respectively ) was less than any other months , whereas the proportion who were vaccinated in December 2000 ( 88 . 2 % ) was the highest .
Diseases:"
213	Women who were born between 1971 and 1975 had the highest rate of rubella nonimmunity ( 9 . 5 % ) .	O O O O O O O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O	['rubella']	1	2	"Sentence: Women who were born between 1971 and 1975 had the highest rate of rubella nonimmunity ( 9 . 5 % ) .
Diseases: rubella"	"Sentence: Women who were born between 1971 and 1975 had the highest rate of rubella nonimmunity ( 9 . 5 % ) .
Diseases:"
214	In - hospital postpartum rubella vaccine administration was documented for 75 . 6 % of nonimmune women .	O O O O B O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O	['rubella']	1	2	"Sentence: In - hospital postpartum rubella vaccine administration was documented for 75 . 6 % of nonimmune women .
Diseases: rubella"	"Sentence: In - hospital postpartum rubella vaccine administration was documented for 75 . 6 % of nonimmune women .
Diseases:"
215	This study documents good compliance in New Hampshire 's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement .	O O O O O O O O O O O O O O O O B I O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['rubella', 'hepatitis b']	2	7	"Sentence: This study documents good compliance in New Hampshire 's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement .
Diseases: rubella, hepatitis b"	"Sentence: This study documents good compliance in New Hampshire 's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement .
Diseases:"
216	Expression of p300 protects cardiac myocytes from apoptosis in vivo .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: Expression of p300 protects cardiac myocytes from apoptosis in vivo .
Diseases: "	"Sentence: Expression of p300 protects cardiac myocytes from apoptosis in vivo .
Diseases:"
217	Doxorubicin is an anti - tumor agent that represses cardiac - specific gene expression and induces myocardial cell apoptosis .	O O O O O B O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O	['tumor']	1	3	"Sentence: Doxorubicin is an anti - tumor agent that represses cardiac - specific gene expression and induces myocardial cell apoptosis .
Diseases: tumor"	"Sentence: Doxorubicin is an anti - tumor agent that represses cardiac - specific gene expression and induces myocardial cell apoptosis .
Diseases:"
218	Doxorubicin depletes cardiac p300 , a transcriptional coactivator that is required for the maintenance of the differentiated phenotype of cardiac myocytes .	O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Doxorubicin depletes cardiac p300 , a transcriptional coactivator that is required for the maintenance of the differentiated phenotype of cardiac myocytes .
Diseases: "	"Sentence: Doxorubicin depletes cardiac p300 , a transcriptional coactivator that is required for the maintenance of the differentiated phenotype of cardiac myocytes .
Diseases:"
219	However , the role of p300 in protection against doxorubicin - induced apoptosis is unknown .	O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O	[]	0	0	"Sentence: However , the role of p300 in protection against doxorubicin - induced apoptosis is unknown .
Diseases: "	"Sentence: However , the role of p300 in protection against doxorubicin - induced apoptosis is unknown .
Diseases:"
220	Transgenic mice overexpressing p300 in the heart and wild - type mice were subjected to doxorubicin treatment .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Transgenic mice overexpressing p300 in the heart and wild - type mice were subjected to doxorubicin treatment .
Diseases: "	"Sentence: Transgenic mice overexpressing p300 in the heart and wild - type mice were subjected to doxorubicin treatment .
Diseases:"
221	Compared with wild - type mice , transgenic mice exhibited higher survival rate as well as more preserved left ventricular function and cardiac expression of alpha - sarcomeric actin .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Compared with wild - type mice , transgenic mice exhibited higher survival rate as well as more preserved left ventricular function and cardiac expression of alpha - sarcomeric actin .
Diseases: "	"Sentence: Compared with wild - type mice , transgenic mice exhibited higher survival rate as well as more preserved left ventricular function and cardiac expression of alpha - sarcomeric actin .
Diseases:"
222	Doxorubicin induced myocardial cell apoptosis in wild - type mice but not in transgenic mice .	O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Doxorubicin induced myocardial cell apoptosis in wild - type mice but not in transgenic mice .
Diseases: "	"Sentence: Doxorubicin induced myocardial cell apoptosis in wild - type mice but not in transgenic mice .
Diseases:"
223	Expression of p300 increased the cardiac level of bcl - 2 and mdm - 2 , but not that of p53 or other members of the bcl - 2 family .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Expression of p300 increased the cardiac level of bcl - 2 and mdm - 2 , but not that of p53 or other members of the bcl - 2 family .
Diseases: "	"Sentence: Expression of p300 increased the cardiac level of bcl - 2 and mdm - 2 , but not that of p53 or other members of the bcl - 2 family .
Diseases:"
224	These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin - induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo .	O O O O O O O O O O O O O O O O O O O O O B I O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['heart failure']	1	2	"Sentence: These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin - induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo .
Diseases: heart failure"	"Sentence: These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin - induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo .
Diseases:"
225	Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis .	O O O O O O O O O O O B O	O O O O O O O O O O B O O	['nephrosis']	1	3	"Sentence: Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis .
Diseases: nephrosis"	"Sentence: Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis .
Diseases:"
226	Doxorubicin induces a self - perpetuating nephropathy characterized by early glomerular and late - onset tubular lesions in rats .	O O O O O O B O O O B I I I I I I O O O	B O O O O O O O O O O O O O O O O O O O	['nephropathy', 'glomerular and late - onset tubular lesions']	2	15	"Sentence: Doxorubicin induces a self - perpetuating nephropathy characterized by early glomerular and late - onset tubular lesions in rats .
Diseases: nephropathy, glomerular and late - onset tubular lesions"	"Sentence: Doxorubicin induces a self - perpetuating nephropathy characterized by early glomerular and late - onset tubular lesions in rats .
Diseases:"
227	We investigated the potential role of mitochondrial injury in the onset of these lesions .	O O O O O O B I O O O O O O O	O O O O O O O O O O O O O O O	['mitochondrial injury']	1	4	"Sentence: We investigated the potential role of mitochondrial injury in the onset of these lesions .
Diseases: mitochondrial injury"	"Sentence: We investigated the potential role of mitochondrial injury in the onset of these lesions .
Diseases:"
228	METHODS : Rats were treated with intravenous doxorubicin ( 1 mg kg ( - 1 ) week ( - 1 ) ) for 7 weeks and were sacrificed either 1 week ( ' short - term ' ) or 30 weeks ( ' long - term ' ) following the last dose .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : Rats were treated with intravenous doxorubicin ( 1 mg kg ( - 1 ) week ( - 1 ) ) for 7 weeks and were sacrificed either 1 week ( ' short - term ' ) or 30 weeks ( ' long - term ' ) following the last dose .
Diseases: "	"Sentence: METHODS : Rats were treated with intravenous doxorubicin ( 1 mg kg ( - 1 ) week ( - 1 ) ) for 7 weeks and were sacrificed either 1 week ( ' short - term ' ) or 30 weeks ( ' long - term ' ) following the last dose .
Diseases:"
229	Additional rats received a single dose either 6 days or 2 h prior to euthanasia .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Additional rats received a single dose either 6 days or 2 h prior to euthanasia .
Diseases: "	"Sentence: Additional rats received a single dose either 6 days or 2 h prior to euthanasia .
Diseases:"
230	All rats were killed at 48 weeks of age .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: All rats were killed at 48 weeks of age .
Diseases: "	"Sentence: All rats were killed at 48 weeks of age .
Diseases:"
231	Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components .	B I I I O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	['glomerular and tubular injury']	1	6	"Sentence: Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components .
Diseases: glomerular and tubular injury"	"Sentence: Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components .
Diseases:"
232	Finally , we quantified both nuclear and mitochondrial DNA ( mtDNA ) as well as superoxide production and the 4834 base pair ' common ' mtDNA deletion .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: Finally , we quantified both nuclear and mitochondrial DNA ( mtDNA ) as well as superoxide production and the 4834 base pair ' common ' mtDNA deletion .
Diseases: "	"Sentence: Finally , we quantified both nuclear and mitochondrial DNA ( mtDNA ) as well as superoxide production and the 4834 base pair ' common ' mtDNA deletion .
Diseases:"
233	The ' long - term ' group had significant glomerular and tubular lesions , depressed activities of mtDNA - encoded NADH dehydrogenase and cytochrome - c oxidase ( COX ) and increased citrate synthase activity .	O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O B O O O	['glomerular and tubular lesions']	1	6	"Sentence: The ' long - term ' group had significant glomerular and tubular lesions , depressed activities of mtDNA - encoded NADH dehydrogenase and cytochrome - c oxidase ( COX ) and increased citrate synthase activity .
Diseases: glomerular and tubular lesions"	"Sentence: The ' long - term ' group had significant glomerular and tubular lesions , depressed activities of mtDNA - encoded NADH dehydrogenase and cytochrome - c oxidase ( COX ) and increased citrate synthase activity .
Diseases:"
234	In addition , expression of the mtDNA - encoded COX subunit I was reduced and mtDNA levels were decreased .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition , expression of the mtDNA - encoded COX subunit I was reduced and mtDNA levels were decreased .
Diseases: "	"Sentence: In addition , expression of the mtDNA - encoded COX subunit I was reduced and mtDNA levels were decreased .
Diseases:"
235	In ' short - term ' rats , there were fewer tubular lesions , but similar numbers of glomerular lesions activity .	O O O O O O O O O O O B I O O O O O B I O O	O O O O O O O O O O O O O O O O O O O O O O	['glomerular lesions', 'tubular lesions']	2	7	"Sentence: In ' short - term ' rats , there were fewer tubular lesions , but similar numbers of glomerular lesions activity .
Diseases: glomerular lesions, tubular lesions"	"Sentence: In ' short - term ' rats , there were fewer tubular lesions , but similar numbers of glomerular lesions activity .
Diseases:"
236	Among all animals , glomerular and tubular injury were inversely correlated with mtDNA levels , mtDNA - encoded respiratory chain activities and with the expression of the mtDNA - encoded respiratory chain subunit COX - I . Injury was positively correlated with superoxide production and the activities of nucleus - encoded mitochondrial or cytoplasmic enzymes .	O O O O B I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	['glomerular and tubular injury']	1	6	"Sentence: Among all animals , glomerular and tubular injury were inversely correlated with mtDNA levels , mtDNA - encoded respiratory chain activities and with the expression of the mtDNA - encoded respiratory chain subunit COX - I . Injury was positively correlated with superoxide production and the activities of nucleus - encoded mitochondrial or cytoplasmic enzymes .
Diseases: glomerular and tubular injury"	"Sentence: Among all animals , glomerular and tubular injury were inversely correlated with mtDNA levels , mtDNA - encoded respiratory chain activities and with the expression of the mtDNA - encoded respiratory chain subunit COX - I . Injury was positively correlated with superoxide production and the activities of nucleus - encoded mitochondrial or cytoplasmic enzymes .
Diseases:"
237	Kidneys from the ' long - term ' group showed more mtDNA deletions than in ' short - term ' animals and these were not observed in the other groups .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Kidneys from the ' long - term ' group showed more mtDNA deletions than in ' short - term ' animals and these were not observed in the other groups .
Diseases: "	"Sentence: Kidneys from the ' long - term ' group showed more mtDNA deletions than in ' short - term ' animals and these were not observed in the other groups .
Diseases:"
238	CONCLUSIONS : These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA - encoded respiratory chain function and induction of superoxide in doxorubicin - induced renal lesions .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O	['renal lesions']	1	3	"Sentence: CONCLUSIONS : These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA - encoded respiratory chain function and induction of superoxide in doxorubicin - induced renal lesions .
Diseases: renal lesions"	"Sentence: CONCLUSIONS : These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA - encoded respiratory chain function and induction of superoxide in doxorubicin - induced renal lesions .
Diseases:"
239	Amphotericin B - induced seizures in a patient with AIDS .	O O O O B O O O O B O	B I O O O O O O O O O	['aids', 'seizures']	2	4	"Sentence: Amphotericin B - induced seizures in a patient with AIDS .
Diseases: aids, seizures"	"Sentence: Amphotericin B - induced seizures in a patient with AIDS .
Diseases:"
240	To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion .	O O O O O O O O B O O O B O O O O O O	O O O O O O O O O O O O O O O B I O O	['aids', 'seizure']	2	4	"Sentence: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion .
Diseases: aids, seizure"	"Sentence: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion .
Diseases:"
241	CASE SUMMARY :	O O O	O O O	[]	0	0	"Sentence: CASE SUMMARY :
Diseases: "	"Sentence: CASE SUMMARY :
Diseases:"
242	A 46 - year - old African - American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B , then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time .	O O O O O O O O O O O O B I I O O O O O O O O O O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O	['grand mal seizures', 'seizures']	2	5	"Sentence: A 46 - year - old African - American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B , then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time .
Diseases: grand mal seizures, seizures"	"Sentence: A 46 - year - old African - American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B , then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time .
Diseases:"
243	The patients concurrent medications included didanosine , hydroxyzine , promethazine , hydrocortisone , and prochlorperazine .	O O O O O O O O O O O O O O O O	O O O O O B O B O B O B O O B O	[]	0	0	"Sentence: The patients concurrent medications included didanosine , hydroxyzine , promethazine , hydrocortisone , and prochlorperazine .
Diseases: "	"Sentence: The patients concurrent medications included didanosine , hydroxyzine , promethazine , hydrocortisone , and prochlorperazine .
Diseases:"
244	Despite administration of phenytoin and lorazepam , the seizures persisted and occurred only during amphotercin B administration .	O O O O O O O O B O O O O O O O O O	O O O B O B O O O O O O O O B I O O	['seizures']	1	3	"Sentence: Despite administration of phenytoin and lorazepam , the seizures persisted and occurred only during amphotercin B administration .
Diseases: seizures"	"Sentence: Despite administration of phenytoin and lorazepam , the seizures persisted and occurred only during amphotercin B administration .
Diseases:"
245	DISCUSSION : AIDS and cryptococcal meningitis , both of which the patient had , can potentially cause seizures .	O O B O B I O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O	['cryptococcal meningitis', 'aids', 'seizures']	3	10	"Sentence: DISCUSSION : AIDS and cryptococcal meningitis , both of which the patient had , can potentially cause seizures .
Diseases: cryptococcal meningitis, aids, seizures"	"Sentence: DISCUSSION : AIDS and cryptococcal meningitis , both of which the patient had , can potentially cause seizures .
Diseases:"
246	The patient had a history of alcohol abuse ; alcohol intake as well as withdrawal can also cause seizures .	O O O O O O B I O O O O O O O O O O B O	O O O O O O B O O B O O O O O O O O O O	['alcohol abuse', 'seizures']	2	4	"Sentence: The patient had a history of alcohol abuse ; alcohol intake as well as withdrawal can also cause seizures .
Diseases: alcohol abuse, seizures"	"Sentence: The patient had a history of alcohol abuse ; alcohol intake as well as withdrawal can also cause seizures .
Diseases:"
247	Didanosine also has a potential for inducing seizures .	O O O O O O O B O	B O O O O O O O O	['seizures']	1	3	"Sentence: Didanosine also has a potential for inducing seizures .
Diseases: seizures"	"Sentence: Didanosine also has a potential for inducing seizures .
Diseases:"
248	However , these other potential causes of seizure were ruled out .	O O O O O O O B O O O O	O O O O O O O O O O O O	['seizure']	1	3	"Sentence: However , these other potential causes of seizure were ruled out .
Diseases: seizure"	"Sentence: However , these other potential causes of seizure were ruled out .
Diseases:"
249	The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient .	O O O O O O O O O O O O O O B O O B O O	O O O O O O O B I O O O O O O O O O O O	['aids', 'seizures']	2	4	"Sentence: The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient .
Diseases: aids, seizures"	"Sentence: The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient .
Diseases:"
250	CONCLUSIONS : Amphotericin B seems to be the probable cause of the seizures .	O O O O O O O O O O O O B O	O O B I O O O O O O O O O O	['seizures']	1	3	"Sentence: CONCLUSIONS : Amphotericin B seems to be the probable cause of the seizures .
Diseases: seizures"	"Sentence: CONCLUSIONS : Amphotericin B seems to be the probable cause of the seizures .
Diseases:"
251	To date , only three cases of seizures associated with amphotericin B have been reported in the literature , but healthcare providers should be aware of the potential for this rare adverse effect .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O	['seizures']	1	3	"Sentence: To date , only three cases of seizures associated with amphotericin B have been reported in the literature , but healthcare providers should be aware of the potential for this rare adverse effect .
Diseases: seizures"	"Sentence: To date , only three cases of seizures associated with amphotericin B have been reported in the literature , but healthcare providers should be aware of the potential for this rare adverse effect .
Diseases:"
252	Therapeutic drug monitoring of tobramycin : once - daily versus twice - daily dosage schedules .	O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: Therapeutic drug monitoring of tobramycin : once - daily versus twice - daily dosage schedules .
Diseases: "	"Sentence: Therapeutic drug monitoring of tobramycin : once - daily versus twice - daily dosage schedules .
Diseases:"
253	To evaluate the effect of dosage regimen ( once - daily vs . twice - daily ) of tobramicyn on steady - state serum concentrations and toxicity .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O B O O O O O O O O O	['toxicity']	1	2	"Sentence: To evaluate the effect of dosage regimen ( once - daily vs . twice - daily ) of tobramicyn on steady - state serum concentrations and toxicity .
Diseases: toxicity"	"Sentence: To evaluate the effect of dosage regimen ( once - daily vs . twice - daily ) of tobramicyn on steady - state serum concentrations and toxicity .
Diseases:"
254	MATERIALS AND METHODS :	O O O O	O O O O	[]	0	0	"Sentence: MATERIALS AND METHODS :
Diseases: "	"Sentence: MATERIALS AND METHODS :
Diseases:"
255	Patients undergoing treatment with i . v .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: Patients undergoing treatment with i . v .
Diseases: "	"Sentence: Patients undergoing treatment with i . v .
Diseases:"
256	tobramycin ( 4 mg / kg / day ) were randomised to two groups .	O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O	[]	0	0	"Sentence: tobramycin ( 4 mg / kg / day ) were randomised to two groups .
Diseases: "	"Sentence: tobramycin ( 4 mg / kg / day ) were randomised to two groups .
Diseases:"
257	Group OD ( n = 22 ) received a once - daily dose of tobramycin and group TD ( n = 21 ) received the same dose divided into two doses daily .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Group OD ( n = 22 ) received a once - daily dose of tobramycin and group TD ( n = 21 ) received the same dose divided into two doses daily .
Diseases: "	"Sentence: Group OD ( n = 22 ) received a once - daily dose of tobramycin and group TD ( n = 21 ) received the same dose divided into two doses daily .
Diseases:"
258	Tobramycin serum concentrations ( peak and trough ) were measured by enzyme multiplied immunoassay .	O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O	[]	0	0	"Sentence: Tobramycin serum concentrations ( peak and trough ) were measured by enzyme multiplied immunoassay .
Diseases: "	"Sentence: Tobramycin serum concentrations ( peak and trough ) were measured by enzyme multiplied immunoassay .
Diseases:"
259	The renal and auditory functions of the patients were monitored before , during and immediately after treatment .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The renal and auditory functions of the patients were monitored before , during and immediately after treatment .
Diseases: "	"Sentence: The renal and auditory functions of the patients were monitored before , during and immediately after treatment .
Diseases:"
260	The two groups were comparable with respect to sex , age , body weight and renal function .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The two groups were comparable with respect to sex , age , body weight and renal function .
Diseases: "	"Sentence: The two groups were comparable with respect to sex , age , body weight and renal function .
Diseases:"
261	No statistically significant differences were found in mean daily dose , duration of treatment , or cumulative dose .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: No statistically significant differences were found in mean daily dose , duration of treatment , or cumulative dose .
Diseases: "	"Sentence: No statistically significant differences were found in mean daily dose , duration of treatment , or cumulative dose .
Diseases:"
262	Trough concentrations were < 2 g / ml in the two groups ( 100 % ) .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Trough concentrations were < 2 g / ml in the two groups ( 100 % ) .
Diseases: "	"Sentence: Trough concentrations were < 2 g / ml in the two groups ( 100 % ) .
Diseases:"
263	Peak concentrations were > 6 microg / ml in 100 % of the OD group and in 67 % of the TD group ( P < 0 . 01 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Peak concentrations were > 6 microg / ml in 100 % of the OD group and in 67 % of the TD group ( P < 0 . 01 ) .
Diseases: "	"Sentence: Peak concentrations were > 6 microg / ml in 100 % of the OD group and in 67 % of the TD group ( P < 0 . 01 ) .
Diseases:"
264	Mean peak concentrations were markedly different : 11 . 00 + / - 2 . 89 microg / ml in OD vs . 6 . 53 + / - 1 . 45 microg / ml in TD ( P < 0 . 01 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Mean peak concentrations were markedly different : 11 . 00 + / - 2 . 89 microg / ml in OD vs . 6 . 53 + / - 1 . 45 microg / ml in TD ( P < 0 . 01 ) .
Diseases: "	"Sentence: Mean peak concentrations were markedly different : 11 . 00 + / - 2 . 89 microg / ml in OD vs . 6 . 53 + / - 1 . 45 microg / ml in TD ( P < 0 . 01 ) .
Diseases:"
265	The pharmacokinetics parameters were : Ke , ( 0 . 15 + / - 0 . 03 / h in OD vs . 0 . 24 + / - 0 . 06 / h in TD ) , t1 / 2 , ( 4 . 95 + / - 1 . 41 h in OD vs . 3 . 07 + / - 0 . 71 h in TD ) , Vd ( 0 . 35 + / - 0 . 11 l / kg in OD vs . 0 . 33 + / - 0 . 09 l / kg in TD ) , Cl ( 0 . 86 + / - 0 . 29 ml / min / kg in OD vs . 1 . 28 + / - 0 . 33 ml / min / kg in TD ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The pharmacokinetics parameters were : Ke , ( 0 . 15 + / - 0 . 03 / h in OD vs . 0 . 24 + / - 0 . 06 / h in TD ) , t1 / 2 , ( 4 . 95 + / - 1 . 41 h in OD vs . 3 . 07 + / - 0 . 71 h in TD ) , Vd ( 0 . 35 + / - 0 . 11 l / kg in OD vs . 0 . 33 + / - 0 . 09 l / kg in TD ) , Cl ( 0 . 86 + / - 0 . 29 ml / min / kg in OD vs . 1 . 28 + / - 0 . 33 ml / min / kg in TD ) .
Diseases: "	"Sentence: The pharmacokinetics parameters were : Ke , ( 0 . 15 + / - 0 . 03 / h in OD vs . 0 . 24 + / - 0 . 06 / h in TD ) , t1 / 2 , ( 4 . 95 + / - 1 . 41 h in OD vs . 3 . 07 + / - 0 . 71 h in TD ) , Vd ( 0 . 35 + / - 0 . 11 l / kg in OD vs . 0 . 33 + / - 0 . 09 l / kg in TD ) , Cl ( 0 . 86 + / - 0 . 29 ml / min / kg in OD vs . 1 . 28 + / - 0 . 33 ml / min / kg in TD ) .
Diseases:"
266	Increased serum creatinine was observed in 73 % of patients in OD versus 57 % of patients in TD , without evidence of nephrotoxicity .	O O O O O O O O O O O O O O O O O O O O O O O B O	O O B O O O O O O O O O O O O O O O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: Increased serum creatinine was observed in 73 % of patients in OD versus 57 % of patients in TD , without evidence of nephrotoxicity .
Diseases: nephrotoxicity"	"Sentence: Increased serum creatinine was observed in 73 % of patients in OD versus 57 % of patients in TD , without evidence of nephrotoxicity .
Diseases:"
267	In TD group , three patients developed decreased auditory function , of which one presented with an auditory loss of - 30 dB , whereas in the OD group only one patient presented decreased auditory function .	O O O O O O O B I I O O O O O O O B I O O O O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['auditory loss', 'decreased auditory function']	2	7	"Sentence: In TD group , three patients developed decreased auditory function , of which one presented with an auditory loss of - 30 dB , whereas in the OD group only one patient presented decreased auditory function .
Diseases: auditory loss, decreased auditory function"	"Sentence: In TD group , three patients developed decreased auditory function , of which one presented with an auditory loss of - 30 dB , whereas in the OD group only one patient presented decreased auditory function .
Diseases:"
268	This small study suggests that a once - daily dosing regimen of tobramycin is at least as effective as and is no more and possibly less toxic than the twice - daily regimen .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This small study suggests that a once - daily dosing regimen of tobramycin is at least as effective as and is no more and possibly less toxic than the twice - daily regimen .
Diseases: "	"Sentence: This small study suggests that a once - daily dosing regimen of tobramycin is at least as effective as and is no more and possibly less toxic than the twice - daily regimen .
Diseases:"
269	Using a single - dose therapy , peak concentration determination is not necessary , only trough samples should be monitored to ensure levels below 2 microg / ml .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Using a single - dose therapy , peak concentration determination is not necessary , only trough samples should be monitored to ensure levels below 2 microg / ml .
Diseases: "	"Sentence: Using a single - dose therapy , peak concentration determination is not necessary , only trough samples should be monitored to ensure levels below 2 microg / ml .
Diseases:"
270	Chronic effects of a novel synthetic anthracycline derivative ( SM - 5887 ) on normal heart and doxorubicin - induced cardiomyopathy in beagle dogs .	O O O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O B O O B I I O O O O O B O O O O O O O	['cardiomyopathy']	1	4	"Sentence: Chronic effects of a novel synthetic anthracycline derivative ( SM - 5887 ) on normal heart and doxorubicin - induced cardiomyopathy in beagle dogs .
Diseases: cardiomyopathy"	"Sentence: Chronic effects of a novel synthetic anthracycline derivative ( SM - 5887 ) on normal heart and doxorubicin - induced cardiomyopathy in beagle dogs .
Diseases:"
271	This study was designed to investigate the chronic cardiotoxic potential of SM - 5887 and a possible deteriorating effect of SM - 5887 on low - grade cardiotoxicity pre - induced by doxorubicin in beagle dogs .	O O O O O O O O B O O O O O O O O O O O O O O O O O O B O O O O O O O O O	O O O O O O O O O O O B I I O O O O O O B I I O O O O O O O O O B O O O O	['cardiotoxicity', 'cardiotoxic']	2	7	"Sentence: This study was designed to investigate the chronic cardiotoxic potential of SM - 5887 and a possible deteriorating effect of SM - 5887 on low - grade cardiotoxicity pre - induced by doxorubicin in beagle dogs .
Diseases: cardiotoxicity, cardiotoxic"	"Sentence: This study was designed to investigate the chronic cardiotoxic potential of SM - 5887 and a possible deteriorating effect of SM - 5887 on low - grade cardiotoxicity pre - induced by doxorubicin in beagle dogs .
Diseases:"
272	In the chronic treatment , beagle dogs of each sex were given intravenously once every 3 weeks , either a sublethal dose of doxorubicin ( 1 . 5 mg / kg ) or SM - 5887 ( 2 . 5 mg / kg ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O B I I O O O O O O O O O	[]	0	0	"Sentence: In the chronic treatment , beagle dogs of each sex were given intravenously once every 3 weeks , either a sublethal dose of doxorubicin ( 1 . 5 mg / kg ) or SM - 5887 ( 2 . 5 mg / kg ) .
Diseases: "	"Sentence: In the chronic treatment , beagle dogs of each sex were given intravenously once every 3 weeks , either a sublethal dose of doxorubicin ( 1 . 5 mg / kg ) or SM - 5887 ( 2 . 5 mg / kg ) .
Diseases:"
273	The experiment was terminated 3 weeks after the ninth dosing .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: The experiment was terminated 3 weeks after the ninth dosing .
Diseases: "	"Sentence: The experiment was terminated 3 weeks after the ninth dosing .
Diseases:"
274	Animals which received over six courses of doxorubicin demonstrated the electrocardiogram ( ECG ) changes , decrease of blood pressure and high - grade histopathological cardiomyopathy , while animals which were terminally sacrificed after the SM - 5887 administration did not show any changes in ECG , blood pressure and histopathological examinations .	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O	['cardiomyopathy']	1	4	"Sentence: Animals which received over six courses of doxorubicin demonstrated the electrocardiogram ( ECG ) changes , decrease of blood pressure and high - grade histopathological cardiomyopathy , while animals which were terminally sacrificed after the SM - 5887 administration did not show any changes in ECG , blood pressure and histopathological examinations .
Diseases: cardiomyopathy"	"Sentence: Animals which received over six courses of doxorubicin demonstrated the electrocardiogram ( ECG ) changes , decrease of blood pressure and high - grade histopathological cardiomyopathy , while animals which were terminally sacrificed after the SM - 5887 administration did not show any changes in ECG , blood pressure and histopathological examinations .
Diseases:"
275	To examine a possibly deteriorating cardiotoxic effect of SM - 5887 , low - grade cardiomyopathy was induced in dogs by four courses of doxorubicin ( 1 . 5 mg / kg ) .	O O O O O B O O O O O O O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O B I I O O O O O O O O O O O O O B O O O O O O O O O	['cardiotoxic', 'cardiomyopathy']	2	8	"Sentence: To examine a possibly deteriorating cardiotoxic effect of SM - 5887 , low - grade cardiomyopathy was induced in dogs by four courses of doxorubicin ( 1 . 5 mg / kg ) .
Diseases: cardiotoxic, cardiomyopathy"	"Sentence: To examine a possibly deteriorating cardiotoxic effect of SM - 5887 , low - grade cardiomyopathy was induced in dogs by four courses of doxorubicin ( 1 . 5 mg / kg ) .
Diseases:"
276	Nine weeks after pre - treatment , dogs were given four courses of either doxorubicin ( 1 . 5 mg / kg ) or SM - 5887 ( 2 . 5 mg / kg ) once every 3 weeks .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O O O B I I O O O O O O O O O O O O O	[]	0	0	"Sentence: Nine weeks after pre - treatment , dogs were given four courses of either doxorubicin ( 1 . 5 mg / kg ) or SM - 5887 ( 2 . 5 mg / kg ) once every 3 weeks .
Diseases: "	"Sentence: Nine weeks after pre - treatment , dogs were given four courses of either doxorubicin ( 1 . 5 mg / kg ) or SM - 5887 ( 2 . 5 mg / kg ) once every 3 weeks .
Diseases:"
277	The low - grade cardiotoxic changes were enhanced by the additional doxorubicin treatment .	O O O O B O O O O O O O O O	O O O O O O O O O O O B O O	['cardiotoxic']	1	3	"Sentence: The low - grade cardiotoxic changes were enhanced by the additional doxorubicin treatment .
Diseases: cardiotoxic"	"Sentence: The low - grade cardiotoxic changes were enhanced by the additional doxorubicin treatment .
Diseases:"
278	On the contrary , the SM - 5887 treatment did not progress the grade of cardiomyopathy .	O O O O O O O O O O O O O O O B O	O O O O O B I I O O O O O O O O O	['cardiomyopathy']	1	4	"Sentence: On the contrary , the SM - 5887 treatment did not progress the grade of cardiomyopathy .
Diseases: cardiomyopathy"	"Sentence: On the contrary , the SM - 5887 treatment did not progress the grade of cardiomyopathy .
Diseases:"
279	In conclusion , SM - 5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin - induced cardiotoxicity in dogs .	O O O O O O O O O O O O O B O O O O O O O B O O O	O O O B I I O O O O O O O O O O O O B O O O O O O	['cardiotoxicity']	1	3	"Sentence: In conclusion , SM - 5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin - induced cardiotoxicity in dogs .
Diseases: cardiotoxicity"	"Sentence: In conclusion , SM - 5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin - induced cardiotoxicity in dogs .
Diseases:"
280	Posteroventral medial pallidotomy in advanced Parkinson 's disease .	O O O O O B I I O	O O O O O O O O O	"[""parkinson 's disease""]"	1	5	"Sentence: Posteroventral medial pallidotomy in advanced Parkinson 's disease .
Diseases: parkinson 's disease"	"Sentence: Posteroventral medial pallidotomy in advanced Parkinson 's disease .
Diseases:"
281	Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced Parkinson 's disease , but the studies to date have involved small numbers of patients and short - term follow - up .	O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	"[""parkinson 's disease""]"	1	5	"Sentence: Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced Parkinson 's disease , but the studies to date have involved small numbers of patients and short - term follow - up .
Diseases: parkinson 's disease"	"Sentence: Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced Parkinson 's disease , but the studies to date have involved small numbers of patients and short - term follow - up .
Diseases:"
282	"METHODS : Forty patients with Parkinson 's disease underwent serial , detailed assessments both after drug withdrawal ( "" off "" period ) and while taking their optimal medical regimens ( "" on "" period ) ."	O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	"[""parkinson 's disease""]"	1	5	"Sentence: METHODS : Forty patients with Parkinson 's disease underwent serial , detailed assessments both after drug withdrawal ( "" off "" period ) and while taking their optimal medical regimens ( "" on "" period ) .
Diseases: parkinson 's disease"	"Sentence: METHODS : Forty patients with Parkinson 's disease underwent serial , detailed assessments both after drug withdrawal ( "" off "" period ) and while taking their optimal medical regimens ( "" on "" period ) .
Diseases:"
283	All patients were examined preoperatively and 39 were examined at six months ; 27 of the patients were also examined at one year , and 11 at two years .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All patients were examined preoperatively and 39 were examined at six months ; 27 of the patients were also examined at one year , and 11 at two years .
Diseases: "	"Sentence: All patients were examined preoperatively and 39 were examined at six months ; 27 of the patients were also examined at one year , and 11 at two years .
Diseases:"
284	The percent improvements at six months were as follows : off - period score for overall motor function , 28 percent ( 95 percent confidence interval , 19 to 38 percent ) , with most of the improvement in the contralateral limbs ; off - period score for activities of daily living , 29 percent ( 95 percent confidence interval , 19 to 39 percent ) ; on - period score for contralateral dyskinesias , 82 percent ( 95 percent confidence interval , 72 to 91 percent ) ; and on - period score for ipsilateral dyskinesias , 44 percent ( 95 percent confidence interval , 29 to 59 percent ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['dyskinesias']	1	5	"Sentence: The percent improvements at six months were as follows : off - period score for overall motor function , 28 percent ( 95 percent confidence interval , 19 to 38 percent ) , with most of the improvement in the contralateral limbs ; off - period score for activities of daily living , 29 percent ( 95 percent confidence interval , 19 to 39 percent ) ; on - period score for contralateral dyskinesias , 82 percent ( 95 percent confidence interval , 72 to 91 percent ) ; and on - period score for ipsilateral dyskinesias , 44 percent ( 95 percent confidence interval , 29 to 59 percent ) .
Diseases: dyskinesias"	"Sentence: The percent improvements at six months were as follows : off - period score for overall motor function , 28 percent ( 95 percent confidence interval , 19 to 38 percent ) , with most of the improvement in the contralateral limbs ; off - period score for activities of daily living , 29 percent ( 95 percent confidence interval , 19 to 39 percent ) ; on - period score for contralateral dyskinesias , 82 percent ( 95 percent confidence interval , 72 to 91 percent ) ; and on - period score for ipsilateral dyskinesias , 44 percent ( 95 percent confidence interval , 29 to 59 percent ) .
Diseases:"
285	The improvements in dyskinesias and the total scores for off - period parkinsonism , contralateral bradykinesia , and rigidity were sustained in the 11 patients examined at two years .	O O O B O O O O O O O O B O O B O O B O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['dyskinesias', 'parkinsonism', 'bradykinesia', 'rigidity']	4	18	"Sentence: The improvements in dyskinesias and the total scores for off - period parkinsonism , contralateral bradykinesia , and rigidity were sustained in the 11 patients examined at two years .
Diseases: dyskinesias, parkinsonism, bradykinesia, rigidity"	"Sentence: The improvements in dyskinesias and the total scores for off - period parkinsonism , contralateral bradykinesia , and rigidity were sustained in the 11 patients examined at two years .
Diseases:"
286	The improvement in ipsilateral dyskinesias was lost after one year , and the improvements in postural stability and gait lasted only three to six months .	O O O O B O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['dyskinesias']	1	5	"Sentence: The improvement in ipsilateral dyskinesias was lost after one year , and the improvements in postural stability and gait lasted only three to six months .
Diseases: dyskinesias"	"Sentence: The improvement in ipsilateral dyskinesias was lost after one year , and the improvements in postural stability and gait lasted only three to six months .
Diseases:"
287	Approximately half the patients who had been dependent on assistance in activities of daily living in the off period before surgery became independent after surgery .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Approximately half the patients who had been dependent on assistance in activities of daily living in the off period before surgery became independent after surgery .
Diseases: "	"Sentence: Approximately half the patients who had been dependent on assistance in activities of daily living in the off period before surgery became independent after surgery .
Diseases:"
288	The complications of surgery were generally well tolerated , and there were no significant changes in the use of medication .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The complications of surgery were generally well tolerated , and there were no significant changes in the use of medication .
Diseases: "	"Sentence: The complications of surgery were generally well tolerated , and there were no significant changes in the use of medication .
Diseases:"
289	CONCLUSIONS :	O O	O O	[]	0	0	"Sentence: CONCLUSIONS :
Diseases: "	"Sentence: CONCLUSIONS :
Diseases:"
290	In late - stage Parkinson 's disease , pallidotomy significantly reduces levodopa - induced dyskinesias and off - period disability .	O O O O B I I O O O O O O O B O O O O O O	O O O O O O O O O O O B O O O O O O O O O	"['dyskinesias', ""parkinson 's disease""]"	2	11	"Sentence: In late - stage Parkinson 's disease , pallidotomy significantly reduces levodopa - induced dyskinesias and off - period disability .
Diseases: dyskinesias, parkinson 's disease"	"Sentence: In late - stage Parkinson 's disease , pallidotomy significantly reduces levodopa - induced dyskinesias and off - period disability .
Diseases:"
291	Much of the benefit is sustained at two years , although some improvements , such as those on the ipsilateral side and in axial symptoms , wane within the first year .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Much of the benefit is sustained at two years , although some improvements , such as those on the ipsilateral side and in axial symptoms , wane within the first year .
Diseases: "	"Sentence: Much of the benefit is sustained at two years , although some improvements , such as those on the ipsilateral side and in axial symptoms , wane within the first year .
Diseases:"
292	The on - period symptoms that are resistant to dopaminergic therapy do not respond to pallidotomy .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The on - period symptoms that are resistant to dopaminergic therapy do not respond to pallidotomy .
Diseases: "	"Sentence: The on - period symptoms that are resistant to dopaminergic therapy do not respond to pallidotomy .
Diseases:"
293	Neuropeptide - Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy .	O O O O O O O O O B I I O	B I I O O O B O O O O O O	['temporal lobe epilepsy']	1	4	"Sentence: Neuropeptide - Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy .
Diseases: temporal lobe epilepsy"	"Sentence: Neuropeptide - Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy .
Diseases:"
294	Neuropeptide - Y ( NPY ) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy ( TLE ) .	O O O O O O O O O O O O O O O O O O O O O B I I O B O O	O I I O O O O O O O O O O O O O O O O O O O O O O O O O	['temporal lobe epilepsy', 'tle']	2	7	"Sentence: Neuropeptide - Y ( NPY ) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy ( TLE ) .
Diseases: temporal lobe epilepsy, tle"	"Sentence: Neuropeptide - Y ( NPY ) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy ( TLE ) .
Diseases:"
295	This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure - like events following high - frequency stimulation in hippocampal slices .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O	['seizure']	1	3	"Sentence: This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure - like events following high - frequency stimulation in hippocampal slices .
Diseases: seizure"	"Sentence: This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure - like events following high - frequency stimulation in hippocampal slices .
Diseases:"
296	The pilocarpine ( PILO ) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage .	O O O O O O O B O O O O O O O B I O O O O B O O B I O	O B O B O O O O O O O O O O O O O O O O O O O O O O O	['brain damage', 'status epilepticus', 'epilepsy', 'seizures']	4	13	"Sentence: The pilocarpine ( PILO ) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage .
Diseases: brain damage, status epilepticus, epilepsy, seizures"	"Sentence: The pilocarpine ( PILO ) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage .
Diseases:"
297	We report peroxidase - antiperoxidase immunostaining for NPY in several brain regions in this model .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We report peroxidase - antiperoxidase immunostaining for NPY in several brain regions in this model .
Diseases: "	"Sentence: We report peroxidase - antiperoxidase immunostaining for NPY in several brain regions in this model .
Diseases:"
298	PILO - injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals , in the dentate gyrus inner molecular layer and , in a few cases , within presumed granule cells .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: PILO - injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals , in the dentate gyrus inner molecular layer and , in a few cases , within presumed granule cells .
Diseases: "	"Sentence: PILO - injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals , in the dentate gyrus inner molecular layer and , in a few cases , within presumed granule cells .
Diseases:"
299	NPY immunoreactivity was also dramatically changed in the entorhinal cortex , amygdala and sensorimotor areas .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: NPY immunoreactivity was also dramatically changed in the entorhinal cortex , amygdala and sensorimotor areas .
Diseases: "	"Sentence: NPY immunoreactivity was also dramatically changed in the entorhinal cortex , amygdala and sensorimotor areas .
Diseases:"
300	In addition , PILO injected animals exhibited a reduction in the number of NPY - immunoreactive interneurons compared with controls .	O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition , PILO injected animals exhibited a reduction in the number of NPY - immunoreactive interneurons compared with controls .
Diseases: "	"Sentence: In addition , PILO injected animals exhibited a reduction in the number of NPY - immunoreactive interneurons compared with controls .
Diseases:"
301	The results demonstrate that changes in NPY expression , including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons , are present in the PILO model of TLE .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['tle']	1	1	"Sentence: The results demonstrate that changes in NPY expression , including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons , are present in the PILO model of TLE .
Diseases: tle"	"Sentence: The results demonstrate that changes in NPY expression , including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons , are present in the PILO model of TLE .
Diseases:"
302	However , the significance of this changed synthesis of NPY remains to be determined .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , the significance of this changed synthesis of NPY remains to be determined .
Diseases: "	"Sentence: However , the significance of this changed synthesis of NPY remains to be determined .
Diseases:"
303	Effect of myopic excimer laser photorefractive keratectomy on the electrophysiologic function of the retina and optic nerve .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Effect of myopic excimer laser photorefractive keratectomy on the electrophysiologic function of the retina and optic nerve .
Diseases: "	"Sentence: Effect of myopic excimer laser photorefractive keratectomy on the electrophysiologic function of the retina and optic nerve .
Diseases:"
304	PURPOSE :	O O	O O	[]	0	0	"Sentence: PURPOSE :
Diseases: "	"Sentence: PURPOSE :
Diseases:"
305	To assess by electrophysiologic testing the effect of photorefractive keratectomy ( PRK ) on the retina and optic nerve .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: To assess by electrophysiologic testing the effect of photorefractive keratectomy ( PRK ) on the retina and optic nerve .
Diseases: "	"Sentence: To assess by electrophysiologic testing the effect of photorefractive keratectomy ( PRK ) on the retina and optic nerve .
Diseases:"
306	SETTING : Eye Clinic , S . Salvatore Hospital , L'Aquila University , Italy .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: SETTING : Eye Clinic , S . Salvatore Hospital , L'Aquila University , Italy .
Diseases: "	"Sentence: SETTING : Eye Clinic , S . Salvatore Hospital , L'Aquila University , Italy .
Diseases:"
307	METHODS : Standard pattern electroretinograms ( P - ERGs ) and standard pattern visual evoked potentials ( P - VEPs ) were done in 25 eyes of 25 patients who had myopic PRK for an attempted correction between 5 . 00 and 15 . 00 diopters ( D ) ( mean 8 . 00 D ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : Standard pattern electroretinograms ( P - ERGs ) and standard pattern visual evoked potentials ( P - VEPs ) were done in 25 eyes of 25 patients who had myopic PRK for an attempted correction between 5 . 00 and 15 . 00 diopters ( D ) ( mean 8 . 00 D ) .
Diseases: "	"Sentence: METHODS : Standard pattern electroretinograms ( P - ERGs ) and standard pattern visual evoked potentials ( P - VEPs ) were done in 25 eyes of 25 patients who had myopic PRK for an attempted correction between 5 . 00 and 15 . 00 diopters ( D ) ( mean 8 . 00 D ) .
Diseases:"
308	Testing was done preoperatively and 3 , 6 , 12 , and 18 months postoperatively .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Testing was done preoperatively and 3 , 6 , 12 , and 18 months postoperatively .
Diseases: "	"Sentence: Testing was done preoperatively and 3 , 6 , 12 , and 18 months postoperatively .
Diseases:"
309	The contralateral eyes served as controls .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: The contralateral eyes served as controls .
Diseases: "	"Sentence: The contralateral eyes served as controls .
Diseases:"
310	During the follow - up , 3 patients ( 12 % ) developed steroid - induced elevated intraocular pressure ( IOP ) that resolved after corticosteroid therapy was discontinued .	O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O B O O O O	['elevated intraocular pressure']	1	6	"Sentence: During the follow - up , 3 patients ( 12 % ) developed steroid - induced elevated intraocular pressure ( IOP ) that resolved after corticosteroid therapy was discontinued .
Diseases: elevated intraocular pressure"	"Sentence: During the follow - up , 3 patients ( 12 % ) developed steroid - induced elevated intraocular pressure ( IOP ) that resolved after corticosteroid therapy was discontinued .
Diseases:"
311	No statistically significant differences were seen between treated and control eyes nor between treated eyes preoperatively and postoperatively .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: No statistically significant differences were seen between treated and control eyes nor between treated eyes preoperatively and postoperatively .
Diseases: "	"Sentence: No statistically significant differences were seen between treated and control eyes nor between treated eyes preoperatively and postoperatively .
Diseases:"
312	CONCLUSION : Myopic excimer laser PRK did not seem to affect the posterior segment .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSION : Myopic excimer laser PRK did not seem to affect the posterior segment .
Diseases: "	"Sentence: CONCLUSION : Myopic excimer laser PRK did not seem to affect the posterior segment .
Diseases:"
313	The transient steroid - induced IOP rise did not seem to cause functional impairment .	O O O O O B I O O O O O O O O	O O B O O O O O O O O O O O O	['iop rise']	1	2	"Sentence: The transient steroid - induced IOP rise did not seem to cause functional impairment .
Diseases: iop rise"	"Sentence: The transient steroid - induced IOP rise did not seem to cause functional impairment .
Diseases:"
314	Liposomal daunorubicin in advanced Kaposi 's sarcoma : a phase II study .	O O O O B I I O O O O O O	O B O O O O O O O O O O O	"[""kaposi 's sarcoma""]"	1	8	"Sentence: Liposomal daunorubicin in advanced Kaposi 's sarcoma : a phase II study .
Diseases: kaposi 's sarcoma"	"Sentence: Liposomal daunorubicin in advanced Kaposi 's sarcoma : a phase II study .
Diseases:"
315	We report a non - randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin ( DaunoXome ) in the treatment of AIDS related Kaposi 's sarcoma .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O B I I O	O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O	"['aids', ""kaposi 's sarcoma""]"	2	11	"Sentence: We report a non - randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin ( DaunoXome ) in the treatment of AIDS related Kaposi 's sarcoma .
Diseases: aids, kaposi 's sarcoma"	"Sentence: We report a non - randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin ( DaunoXome ) in the treatment of AIDS related Kaposi 's sarcoma .
Diseases:"
316	Eleven homosexual men with advanced Kaposi 's sarcoma were entered in the trial .	O O O O O B I I O O O O O O	O O O O O O O O O O O O O O	"[""kaposi 's sarcoma""]"	1	8	"Sentence: Eleven homosexual men with advanced Kaposi 's sarcoma were entered in the trial .
Diseases: kaposi 's sarcoma"	"Sentence: Eleven homosexual men with advanced Kaposi 's sarcoma were entered in the trial .
Diseases:"
317	Changes in size , colour and associated oedema of selected ' target ' lesions were measured .	O O O O O O O B O O O O O O O O O	O O O O O O O O O O O O O O O O O	['oedema']	1	3	"Sentence: Changes in size , colour and associated oedema of selected ' target ' lesions were measured .
Diseases: oedema"	"Sentence: Changes in size , colour and associated oedema of selected ' target ' lesions were measured .
Diseases:"
318	Clinical , biochemical and haematological toxicities were assessed .	O O O O O B O O O	O O O O O O O O O	['toxicities']	1	3	"Sentence: Clinical , biochemical and haematological toxicities were assessed .
Diseases: toxicities"	"Sentence: Clinical , biochemical and haematological toxicities were assessed .
Diseases:"
319	Ten subjects were evaluated .	O O O O O	O O O O O	[]	0	0	"Sentence: Ten subjects were evaluated .
Diseases: "	"Sentence: Ten subjects were evaluated .
Diseases:"
320	A partial response was achieved in four , of whom two subsequently relapsed .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: A partial response was achieved in four , of whom two subsequently relapsed .
Diseases: "	"Sentence: A partial response was achieved in four , of whom two subsequently relapsed .
Diseases:"
321	Stabilization of Kaposi 's sarcoma occurred in the remaining six , maintained until the end of the trial period in four .	O O B I I O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	"[""kaposi 's sarcoma""]"	1	8	"Sentence: Stabilization of Kaposi 's sarcoma occurred in the remaining six , maintained until the end of the trial period in four .
Diseases: kaposi 's sarcoma"	"Sentence: Stabilization of Kaposi 's sarcoma occurred in the remaining six , maintained until the end of the trial period in four .
Diseases:"
322	The drug was generally well tolerated , with few mild symptoms of toxicity .	O O O O O O O O O O O O B O	O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: The drug was generally well tolerated , with few mild symptoms of toxicity .
Diseases: toxicity"	"Sentence: The drug was generally well tolerated , with few mild symptoms of toxicity .
Diseases:"
323	The main problem encountered was haematological toxicity , with three subjects experiencing severe neutropenia ( neutrophil count < 0 . 5 x 10 ( 9 ) / l ) .	O O O O O O B O O O O O O B O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['neutropenia', 'toxicity']	2	7	"Sentence: The main problem encountered was haematological toxicity , with three subjects experiencing severe neutropenia ( neutrophil count < 0 . 5 x 10 ( 9 ) / l ) .
Diseases: neutropenia, toxicity"	"Sentence: The main problem encountered was haematological toxicity , with three subjects experiencing severe neutropenia ( neutrophil count < 0 . 5 x 10 ( 9 ) / l ) .
Diseases:"
324	There was no evidence of cardiotoxicity .	O O O O O B O	O O O O O O O	['cardiotoxicity']	1	3	"Sentence: There was no evidence of cardiotoxicity .
Diseases: cardiotoxicity"	"Sentence: There was no evidence of cardiotoxicity .
Diseases:"
325	In this small patient sample , liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi 's sarcoma .	O O O O O O O O O O O O O O O O O O O B I I O	O O O O O O O B O O O O O O O O O O O O O O O	"[""kaposi 's sarcoma""]"	1	8	"Sentence: In this small patient sample , liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi 's sarcoma .
Diseases: kaposi 's sarcoma"	"Sentence: In this small patient sample , liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi 's sarcoma .
Diseases:"
326	Failure of ancrod in the treatment of heparin - induced arterial thrombosis .	O O O O O O O O O O O B O	O O B O O O O B O O O O O	['thrombosis']	1	4	"Sentence: Failure of ancrod in the treatment of heparin - induced arterial thrombosis .
Diseases: thrombosis"	"Sentence: Failure of ancrod in the treatment of heparin - induced arterial thrombosis .
Diseases:"
327	The morbidity and mortality associated with heparin - induced thrombosis remain high despite numerous empirical therapies .	O O O O O O O O O B O O O O O O O	O O O O O O B O O O O O O O O O O	['thrombosis']	1	4	"Sentence: The morbidity and mortality associated with heparin - induced thrombosis remain high despite numerous empirical therapies .
Diseases: thrombosis"	"Sentence: The morbidity and mortality associated with heparin - induced thrombosis remain high despite numerous empirical therapies .
Diseases:"
328	Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin , but its success in patients who have developed the thrombosis syndrome is not well defined .	O O O O O O O O O O B O O O O O B I O O O O O O O O O O O O O O O O B O O O O O O	B O O O O O O O O O O O O O B O O O O O O O O B O O O O O O O O O O O O O O O O O	['platelet aggregation', 'thrombosis']	2	8	"Sentence: Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin , but its success in patients who have developed the thrombosis syndrome is not well defined .
Diseases: platelet aggregation, thrombosis"	"Sentence: Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin , but its success in patients who have developed the thrombosis syndrome is not well defined .
Diseases:"
329	The authors present a case of failure of ancrod treatment in a patient with heparin - induced thrombosis .	O O O O O O O O O O O O O O O O O B O	O O O O O O O O B O O O O O B O O O O	['thrombosis']	1	4	"Sentence: The authors present a case of failure of ancrod treatment in a patient with heparin - induced thrombosis .
Diseases: thrombosis"	"Sentence: The authors present a case of failure of ancrod treatment in a patient with heparin - induced thrombosis .
Diseases:"
330	Seizure after flumazenil administration in a pediatric patient .	B O O O O O O O O	O O B O O O O O O	['seizure']	1	3	"Sentence: Seizure after flumazenil administration in a pediatric patient .
Diseases: seizure"	"Sentence: Seizure after flumazenil administration in a pediatric patient .
Diseases:"
331	Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines .	O O O O O O O O O O O B I O O O O	B O O B O O O O O O O O O O O B O	['respiratory depression']	1	4	"Sentence: Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines .
Diseases: respiratory depression"	"Sentence: Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines .
Diseases:"
332	Seizures and cardiac arrhythmias have complicated its use in adult patients .	B O B I O O O O O O O O	O O O O O O O O O O O O	['cardiac arrhythmias', 'seizures']	2	8	"Sentence: Seizures and cardiac arrhythmias have complicated its use in adult patients .
Diseases: cardiac arrhythmias, seizures"	"Sentence: Seizures and cardiac arrhythmias have complicated its use in adult patients .
Diseases:"
333	Overdose patients who have coingested tricyclic antidepressants have a higher risk of these complications .	B O O O O O O O O O O O O O O	O O O O O B I O O O O O O O O	['overdose']	1	2	"Sentence: Overdose patients who have coingested tricyclic antidepressants have a higher risk of these complications .
Diseases: overdose"	"Sentence: Overdose patients who have coingested tricyclic antidepressants have a higher risk of these complications .
Diseases:"
334	Little information exists concerning adverse effects of flumazenil in children .	O O O O O O O O O O O	O O O O O O O B O O O	[]	0	0	"Sentence: Little information exists concerning adverse effects of flumazenil in children .
Diseases: "	"Sentence: Little information exists concerning adverse effects of flumazenil in children .
Diseases:"
335	We report the occurrence of a generalized tonic - clonic seizure in a pediatric patient following the administration of flumazenil .	O O O O O O O B I I I O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O	['tonic - clonic seizure']	1	6	"Sentence: We report the occurrence of a generalized tonic - clonic seizure in a pediatric patient following the administration of flumazenil .
Diseases: tonic - clonic seizure"	"Sentence: We report the occurrence of a generalized tonic - clonic seizure in a pediatric patient following the administration of flumazenil .
Diseases:"
336	Remodelling of nerve structure in experimental isoniazid neuropathy in the rat .	O O O O O O O B O O O O	O O O O O O B O O O O O	['neuropathy']	1	3	"Sentence: Remodelling of nerve structure in experimental isoniazid neuropathy in the rat .
Diseases: neuropathy"	"Sentence: Remodelling of nerve structure in experimental isoniazid neuropathy in the rat .
Diseases:"
337	The neuropathy caused by a single dose of isoniazid in rats was studied with a computer - assisted morphometric method .	O B O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O	['neuropathy']	1	3	"Sentence: The neuropathy caused by a single dose of isoniazid in rats was studied with a computer - assisted morphometric method .
Diseases: neuropathy"	"Sentence: The neuropathy caused by a single dose of isoniazid in rats was studied with a computer - assisted morphometric method .
Diseases:"
338	Scatter diagrams of the g ratio ( quotient fibre diameter / axon diameter ) define regenerating fibres as a distinct population , distinguishable from the surviving fibres by reduced sheath thickness and reduced axon calibre .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Scatter diagrams of the g ratio ( quotient fibre diameter / axon diameter ) define regenerating fibres as a distinct population , distinguishable from the surviving fibres by reduced sheath thickness and reduced axon calibre .
Diseases: "	"Sentence: Scatter diagrams of the g ratio ( quotient fibre diameter / axon diameter ) define regenerating fibres as a distinct population , distinguishable from the surviving fibres by reduced sheath thickness and reduced axon calibre .
Diseases:"
339	There was also evidence of a subtle direct toxic effect on the entire fibre population , causing axon shrinkage masked by readjustment of the myelin sheath .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There was also evidence of a subtle direct toxic effect on the entire fibre population , causing axon shrinkage masked by readjustment of the myelin sheath .
Diseases: "	"Sentence: There was also evidence of a subtle direct toxic effect on the entire fibre population , causing axon shrinkage masked by readjustment of the myelin sheath .
Diseases:"
340	Selective injection of iopentol , iohexol and metrizoate into the left coronary artery of the dog .	O O O O O O O O O O O O O O O O O	O O O B O B O B O O O O O O O O O	[]	0	0	"Sentence: Selective injection of iopentol , iohexol and metrizoate into the left coronary artery of the dog .
Diseases: "	"Sentence: Selective injection of iopentol , iohexol and metrizoate into the left coronary artery of the dog .
Diseases:"
341	Induction of ventricular fibrillation and decrease of aortic pressure .	O O B I O O O O O O	O O O O O O O O O O	['ventricular fibrillation']	1	5	"Sentence: Induction of ventricular fibrillation and decrease of aortic pressure .
Diseases: ventricular fibrillation"	"Sentence: Induction of ventricular fibrillation and decrease of aortic pressure .
Diseases:"
342	In twenty beagle dogs selective injections were made into the left coronary artery with iopentol , iohexol and metrizoate in doses of 4 ml , 8 ml and 16 ml .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O B O B O O O O O O O O O O O O	[]	0	0	"Sentence: In twenty beagle dogs selective injections were made into the left coronary artery with iopentol , iohexol and metrizoate in doses of 4 ml , 8 ml and 16 ml .
Diseases: "	"Sentence: In twenty beagle dogs selective injections were made into the left coronary artery with iopentol , iohexol and metrizoate in doses of 4 ml , 8 ml and 16 ml .
Diseases:"
343	Thirty - six iopentol injections , 35 iohexol injections and 37 metrizoate injections were made .	O O O O O O O O O O O O O O O O	O O O B O O O B O O O B O O O O	[]	0	0	"Sentence: Thirty - six iopentol injections , 35 iohexol injections and 37 metrizoate injections were made .
Diseases: "	"Sentence: Thirty - six iopentol injections , 35 iohexol injections and 37 metrizoate injections were made .
Diseases:"
344	Frequencies of ventricular fibrillation were significantly lower ( p less than 0 . 05 ) after iopentol ( 0 % ) and iohexol ( 3 % ) than after metrizoate ( 22 % ) .	O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O B O O O O O O B O O O O O	['ventricular fibrillation']	1	5	"Sentence: Frequencies of ventricular fibrillation were significantly lower ( p less than 0 . 05 ) after iopentol ( 0 % ) and iohexol ( 3 % ) than after metrizoate ( 22 % ) .
Diseases: ventricular fibrillation"	"Sentence: Frequencies of ventricular fibrillation were significantly lower ( p less than 0 . 05 ) after iopentol ( 0 % ) and iohexol ( 3 % ) than after metrizoate ( 22 % ) .
Diseases:"
345	Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses .	O O O O O O O O O O O O O O O O O O O	B O B O O O O O O O O O O B O O O O O	[]	0	0	"Sentence: Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses .
Diseases: "	"Sentence: Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses .
Diseases:"
346	"Magnetic resonance imaging of cerebral venous thrombosis secondary to "" low - dose "" birth control pills ."	O O O O O B I O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	['venous thrombosis']	1	6	"Sentence: Magnetic resonance imaging of cerebral venous thrombosis secondary to "" low - dose "" birth control pills .
Diseases: venous thrombosis"	"Sentence: Magnetic resonance imaging of cerebral venous thrombosis secondary to "" low - dose "" birth control pills .
Diseases:"
347	The clinical and radiographic features of cerebral deep venous thrombosis in a 21 - year - old white woman are presented .	O O O O O O O B I I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	['deep venous thrombosis']	1	7	"Sentence: The clinical and radiographic features of cerebral deep venous thrombosis in a 21 - year - old white woman are presented .
Diseases: deep venous thrombosis"	"Sentence: The clinical and radiographic features of cerebral deep venous thrombosis in a 21 - year - old white woman are presented .
Diseases:"
348	This nulliparous patient presented with relatively mild clinical symptoms and progressing mental status changes .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This nulliparous patient presented with relatively mild clinical symptoms and progressing mental status changes .
Diseases: "	"Sentence: This nulliparous patient presented with relatively mild clinical symptoms and progressing mental status changes .
Diseases:"
349	"The only known risk factor was "" low - dose "" oral contraceptive pills ."	O O O O O O O O O O O O O O O	O O O O O O O O O O O B I O O	[]	0	0	"Sentence: The only known risk factor was "" low - dose "" oral contraceptive pills .
Diseases: "	"Sentence: The only known risk factor was "" low - dose "" oral contraceptive pills .
Diseases:"
350	The magnetic resonance image ( MRI ) showed increased signal intensity from the internal cerebral veins , vein of Galen , and straight sinus .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The magnetic resonance image ( MRI ) showed increased signal intensity from the internal cerebral veins , vein of Galen , and straight sinus .
Diseases: "	"Sentence: The magnetic resonance image ( MRI ) showed increased signal intensity from the internal cerebral veins , vein of Galen , and straight sinus .
Diseases:"
351	The diagnosis was confirmed by arterial angiography .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: The diagnosis was confirmed by arterial angiography .
Diseases: "	"Sentence: The diagnosis was confirmed by arterial angiography .
Diseases:"
352	Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis : correlation with thallium - 201 single - photon emission tomography .	O O O O O O O O O O O O O B I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O O	['coronary stenosis']	1	5	"Sentence: Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis : correlation with thallium - 201 single - photon emission tomography .
Diseases: coronary stenosis"	"Sentence: Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis : correlation with thallium - 201 single - photon emission tomography .
Diseases:"
353	It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation .	O O O O O O O O O O O O O O O O O O O O O B I O O O B I O O O O B O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hyperemic', 'coronary occlusion', 'coronary stenoses']	3	13	"Sentence: It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation .
Diseases: hyperemic, coronary occlusion, coronary stenoses"	"Sentence: It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation .
Diseases:"
354	The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['coronary stenosis']	1	5	"Sentence: The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis .
Diseases: coronary stenosis"	"Sentence: The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis .
Diseases:"
355	The perfusion defect produced in 16 open chest dogs was compared with the anatomic area at risk measured by the postmortem dual - perfusion technique and with thallium - 201 single - photon emission tomography ( SPECT ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: The perfusion defect produced in 16 open chest dogs was compared with the anatomic area at risk measured by the postmortem dual - perfusion technique and with thallium - 201 single - photon emission tomography ( SPECT ) .
Diseases: "	"Sentence: The perfusion defect produced in 16 open chest dogs was compared with the anatomic area at risk measured by the postmortem dual - perfusion technique and with thallium - 201 single - photon emission tomography ( SPECT ) .
Diseases:"
356	During a transient ( 20 - s ) coronary occlusion , a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced .	O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['coronary occlusion']	1	6	"Sentence: During a transient ( 20 - s ) coronary occlusion , a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced .
Diseases: coronary occlusion"	"Sentence: During a transient ( 20 - s ) coronary occlusion , a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced .
Diseases:"
357	The perfusion defect correlated significantly with the anatomic area at risk ( r = 0 . 74 ; p less than 0 . 002 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The perfusion defect correlated significantly with the anatomic area at risk ( r = 0 . 74 ; p less than 0 . 002 ) .
Diseases: "	"Sentence: The perfusion defect correlated significantly with the anatomic area at risk ( r = 0 . 74 ; p less than 0 . 002 ) .
Diseases:"
358	During dipyridamole - induced hyperemia , 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography .	O O O O B O O O O O O O O O B I O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O O O O O O O O	['coronary stenosis', 'hyperemia']	2	9	"Sentence: During dipyridamole - induced hyperemia , 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography .
Diseases: coronary stenosis, hyperemia"	"Sentence: During dipyridamole - induced hyperemia , 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography .
Diseases:"
359	The four dogs without a perfusion defect had a stenosis that resulted in a mild ( 0 % to 50 % ) reduction in dipyridamole - induced hyperemia .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['hyperemia']	1	4	"Sentence: The four dogs without a perfusion defect had a stenosis that resulted in a mild ( 0 % to 50 % ) reduction in dipyridamole - induced hyperemia .
Diseases: hyperemia"	"Sentence: The four dogs without a perfusion defect had a stenosis that resulted in a mild ( 0 % to 50 % ) reduction in dipyridamole - induced hyperemia .
Diseases:"
360	The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk ( r = 0 . 61 ; p = 0 . 02 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk ( r = 0 . 61 ; p = 0 . 02 ) .
Diseases: "	"Sentence: The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk ( r = 0 . 61 ; p = 0 . 02 ) .
Diseases:"
361	Thallium - 201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole - induced hyperemia ; the size of the perfusion defect correlated with the anatomic area at risk ( r = 0 . 58 ; p less than 0 . 03 ) and with the perfusion defect by contrast echocardiography ( r = 0 . 58 ; p less than 0 . 03 ) .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hyperemia']	1	4	"Sentence: Thallium - 201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole - induced hyperemia ; the size of the perfusion defect correlated with the anatomic area at risk ( r = 0 . 58 ; p less than 0 . 03 ) and with the perfusion defect by contrast echocardiography ( r = 0 . 58 ; p less than 0 . 03 ) .
Diseases: hyperemia"	"Sentence: Thallium - 201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole - induced hyperemia ; the size of the perfusion defect correlated with the anatomic area at risk ( r = 0 . 58 ; p less than 0 . 03 ) and with the perfusion defect by contrast echocardiography ( r = 0 . 58 ; p less than 0 . 03 ) .
Diseases:"
362	Thus , myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis .	O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['coronary stenosis']	1	5	"Sentence: Thus , myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis .
Diseases: coronary stenosis"	"Sentence: Thus , myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis .
Diseases:"
363	The results obtained show a correlation with the anatomic area at risk similar to that obtained with thallium - 201 SPECT .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: The results obtained show a correlation with the anatomic area at risk similar to that obtained with thallium - 201 SPECT .
Diseases: "	"Sentence: The results obtained show a correlation with the anatomic area at risk similar to that obtained with thallium - 201 SPECT .
Diseases:"
364	Potential deleterious effect of furosemide in radiocontrast nephropathy .	O O O O O O O B O	O O O O B O O O O	['nephropathy']	1	4	"Sentence: Potential deleterious effect of furosemide in radiocontrast nephropathy .
Diseases: nephropathy"	"Sentence: Potential deleterious effect of furosemide in radiocontrast nephropathy .
Diseases:"
365	The purpose of the study was to determine the efficacy of furosemide in addition to intravenous fluids in the prevention of radiocontrast nephropathy .	O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O B O O O O O O O O O O O O	['nephropathy']	1	4	"Sentence: The purpose of the study was to determine the efficacy of furosemide in addition to intravenous fluids in the prevention of radiocontrast nephropathy .
Diseases: nephropathy"	"Sentence: The purpose of the study was to determine the efficacy of furosemide in addition to intravenous fluids in the prevention of radiocontrast nephropathy .
Diseases:"
366	18 patients , referred to a radiocontrast study , considered at risk because of preexisting renal insufficiency , were enrolled in a prospective , randomized , controlled trial , performed at the secondary care center of a 1 , 100 - bed private university hospital .	O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['renal insufficiency']	1	5	"Sentence: 18 patients , referred to a radiocontrast study , considered at risk because of preexisting renal insufficiency , were enrolled in a prospective , randomized , controlled trial , performed at the secondary care center of a 1 , 100 - bed private university hospital .
Diseases: renal insufficiency"	"Sentence: 18 patients , referred to a radiocontrast study , considered at risk because of preexisting renal insufficiency , were enrolled in a prospective , randomized , controlled trial , performed at the secondary care center of a 1 , 100 - bed private university hospital .
Diseases:"
367	In addition to fluids , the treatment group received furosemide ( mean dose 110 mg ) intravenously 30 min prior to the injection of contrast material .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition to fluids , the treatment group received furosemide ( mean dose 110 mg ) intravenously 30 min prior to the injection of contrast material .
Diseases: "	"Sentence: In addition to fluids , the treatment group received furosemide ( mean dose 110 mg ) intravenously 30 min prior to the injection of contrast material .
Diseases:"
368	The control group received fluids ( mean 3 liters ) .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: The control group received fluids ( mean 3 liters ) .
Diseases: "	"Sentence: The control group received fluids ( mean 3 liters ) .
Diseases:"
369	Radiological studies were mostly angiographies performed with both ionic and non - ionic contrast material , at an average dose of 245 ml .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Radiological studies were mostly angiographies performed with both ionic and non - ionic contrast material , at an average dose of 245 ml .
Diseases: "	"Sentence: Radiological studies were mostly angiographies performed with both ionic and non - ionic contrast material , at an average dose of 245 ml .
Diseases:"
370	Renal function significantly deteriorated in the group pretreated with furosemide ( p < 0 . 005 by ANOVA ) , with a rise in serum creatinine from 145 + / - 13 to 182 + / - 16 mumol / l at 24 h , while no change occurred in the control group ( from 141 + / - 6 to 142 + / - 7 mumol / l ) .	B I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['renal function significantly deteriorated']	1	5	"Sentence: Renal function significantly deteriorated in the group pretreated with furosemide ( p < 0 . 005 by ANOVA ) , with a rise in serum creatinine from 145 + / - 13 to 182 + / - 16 mumol / l at 24 h , while no change occurred in the control group ( from 141 + / - 6 to 142 + / - 7 mumol / l ) .
Diseases: renal function significantly deteriorated"	"Sentence: Renal function significantly deteriorated in the group pretreated with furosemide ( p < 0 . 005 by ANOVA ) , with a rise in serum creatinine from 145 + / - 13 to 182 + / - 16 mumol / l at 24 h , while no change occurred in the control group ( from 141 + / - 6 to 142 + / - 7 mumol / l ) .
Diseases:"
371	Renal failure was associated with weight loss in the furosemide - treated group .	B I O O O B I O O O O O O O	O O O O O O O O O B O O O O	['weight loss', 'renal failure']	2	5	"Sentence: Renal failure was associated with weight loss in the furosemide - treated group .
Diseases: weight loss, renal failure"	"Sentence: Renal failure was associated with weight loss in the furosemide - treated group .
Diseases:"
372	Furosemide may be deleterious in the prevention of radiocontrast nephropathy .	O O O O O O O O O B O	B O O O O O O O O O O	['nephropathy']	1	4	"Sentence: Furosemide may be deleterious in the prevention of radiocontrast nephropathy .
Diseases: nephropathy"	"Sentence: Furosemide may be deleterious in the prevention of radiocontrast nephropathy .
Diseases:"
373	The renal pathology in a case of lithium - induced diabetes insipidus .	O O O O O O O O O O B I O	O O O O O O O B O O O O O	['diabetes insipidus']	1	6	"Sentence: The renal pathology in a case of lithium - induced diabetes insipidus .
Diseases: diabetes insipidus"	"Sentence: The renal pathology in a case of lithium - induced diabetes insipidus .
Diseases:"
374	A case of lithium - induced diabetes insipidus is reported .	O O O O O O B I O O O	O O O B O O O O O O O	['diabetes insipidus']	1	6	"Sentence: A case of lithium - induced diabetes insipidus is reported .
Diseases: diabetes insipidus"	"Sentence: A case of lithium - induced diabetes insipidus is reported .
Diseases:"
375	At necropsy microscopy shoed unique and extensive damage to cells lining the distal nephron .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At necropsy microscopy shoed unique and extensive damage to cells lining the distal nephron .
Diseases: "	"Sentence: At necropsy microscopy shoed unique and extensive damage to cells lining the distal nephron .
Diseases:"
376	It is suggested that these changes represent a specific toxic effect of lithium , reported here for the first time in man .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: It is suggested that these changes represent a specific toxic effect of lithium , reported here for the first time in man .
Diseases: "	"Sentence: It is suggested that these changes represent a specific toxic effect of lithium , reported here for the first time in man .
Diseases:"
377	Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives .	O O O O O O B I O O O O O	O O O O O O O O O O B I O	['liver tumors']	1	3	"Sentence: Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives .
Diseases: liver tumors"	"Sentence: Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives .
Diseases:"
378	Within the last several years , previously rare liver tumors have been seen in young women using oral contraceptive steroids .	O O O O O O O O B I O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B I I O	['liver tumors']	1	3	"Sentence: Within the last several years , previously rare liver tumors have been seen in young women using oral contraceptive steroids .
Diseases: liver tumors"	"Sentence: Within the last several years , previously rare liver tumors have been seen in young women using oral contraceptive steroids .
Diseases:"
379	The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California , Irvine , has clearly identified 27 cases .	O O O B I O O O O O O O O O O O O O O O O O O	O O O O O O O B I O O O O O O O O O O O O O O	['liver tumors']	1	3	"Sentence: The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California , Irvine , has clearly identified 27 cases .
Diseases: liver tumors"	"Sentence: The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California , Irvine , has clearly identified 27 cases .
Diseases:"
380	The recent literature contains 44 case reports .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: The recent literature contains 44 case reports .
Diseases: "	"Sentence: The recent literature contains 44 case reports .
Diseases:"
381	Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia , adenoma , hamartoma , and hepatoma .	O O O O O O O O O O O B I I O B O B O O B O	O O O O O O O O O O O O O O O O O O O O O O	['adenoma', 'hepatoma', 'hamartoma', 'focal nodular hyperplasia']	4	18	"Sentence: Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia , adenoma , hamartoma , and hepatoma .
Diseases: adenoma, hepatoma, hamartoma, focal nodular hyperplasia"	"Sentence: Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia , adenoma , hamartoma , and hepatoma .
Diseases:"
382	Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids .	O O O O O O O O O O O O O	O O O O O O O O O B I I O	[]	0	0	"Sentence: Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids .
Diseases: "	"Sentence: Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids .
Diseases:"
383	Eight deaths and liver rupture in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon .	O O O O B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	['rupture']	1	2	"Sentence: Eight deaths and liver rupture in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon .
Diseases: rupture"	"Sentence: Eight deaths and liver rupture in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon .
Diseases:"
384	Graft - versus - host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy : results of the EVTAC trial .	B I I I I I O O O O O O O O O O O O B I I O B O O O O O O O	O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O	['sinusoidal obstruction syndrome', 'microangiopathy', 'graft - versus - host disease']	3	17	"Sentence: Graft - versus - host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy : results of the EVTAC trial .
Diseases: sinusoidal obstruction syndrome, microangiopathy, graft - versus - host disease"	"Sentence: Graft - versus - host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy : results of the EVTAC trial .
Diseases:"
385	A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft - versus - host disease ( GVHD ) after allogeneic hematopoietic stem cell transplantation ( HSCT ) .	O O O O O O O O O O O B I I I I I O B O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['gvhd', 'graft - versus - host disease']	2	10	"Sentence: A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft - versus - host disease ( GVHD ) after allogeneic hematopoietic stem cell transplantation ( HSCT ) .
Diseases: gvhd, graft - versus - host disease"	"Sentence: A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft - versus - host disease ( GVHD ) after allogeneic hematopoietic stem cell transplantation ( HSCT ) .
Diseases:"
386	Everolimus , a derivative of sirolimus , seems to mediate antileukemia effects .	O O O O O O O O O O O O O	B O O O O B O O O O O O O	[]	0	0	"Sentence: Everolimus , a derivative of sirolimus , seems to mediate antileukemia effects .
Diseases: "	"Sentence: Everolimus , a derivative of sirolimus , seems to mediate antileukemia effects .
Diseases:"
387	We report on a combination of everolimus and tacrolimus in 24 patients ( median age , 62 years ) with either myelodysplastic syndrome ( MDS ; n = 17 ) or acute myeloid leukemia ( AML ; n = 7 ) undergoing intensive conditioning followed by HSCT from related ( n = 4 ) or unrelated ( n = 20 ) donors .	O O O O O O O O O O O O O O O O O O O O O B I O B O O O O O O B I I O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['mds', 'acute myeloid leukemia', 'aml', 'myelodysplastic syndrome']	4	19	"Sentence: We report on a combination of everolimus and tacrolimus in 24 patients ( median age , 62 years ) with either myelodysplastic syndrome ( MDS ; n = 17 ) or acute myeloid leukemia ( AML ; n = 7 ) undergoing intensive conditioning followed by HSCT from related ( n = 4 ) or unrelated ( n = 20 ) donors .
Diseases: mds, acute myeloid leukemia, aml, myelodysplastic syndrome"	"Sentence: We report on a combination of everolimus and tacrolimus in 24 patients ( median age , 62 years ) with either myelodysplastic syndrome ( MDS ; n = 17 ) or acute myeloid leukemia ( AML ; n = 7 ) undergoing intensive conditioning followed by HSCT from related ( n = 4 ) or unrelated ( n = 20 ) donors .
Diseases:"
388	All patients engrafted , and only 1 patient experienced grade IV mucositis .	O O O O O O O O O O O B O	O O O O O O O O O O O O O	['mucositis']	1	4	"Sentence: All patients engrafted , and only 1 patient experienced grade IV mucositis .
Diseases: mucositis"	"Sentence: All patients engrafted , and only 1 patient experienced grade IV mucositis .
Diseases:"
389	Nine patients ( 37 % ) developed acute grade II - IV GVHD , and 11 of 17 evaluable patients ( 64 % ) developed chronic extensive GVHD .	O O O O O O O O O O O O B O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['gvhd']	1	3	"Sentence: Nine patients ( 37 % ) developed acute grade II - IV GVHD , and 11 of 17 evaluable patients ( 64 % ) developed chronic extensive GVHD .
Diseases: gvhd"	"Sentence: Nine patients ( 37 % ) developed acute grade II - IV GVHD , and 11 of 17 evaluable patients ( 64 % ) developed chronic extensive GVHD .
Diseases:"
390	Transplantation - associated microangiopathy ( TMA ) occurred in 7 patients ( 29 % ) , with 2 cases of acute renal failure .	B I I I O B O O O O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O O O O O O O O O O O	['transplantation - associated microangiopathy', 'acute renal failure', 'tma']	3	16	"Sentence: Transplantation - associated microangiopathy ( TMA ) occurred in 7 patients ( 29 % ) , with 2 cases of acute renal failure .
Diseases: transplantation - associated microangiopathy, acute renal failure, tma"	"Sentence: Transplantation - associated microangiopathy ( TMA ) occurred in 7 patients ( 29 % ) , with 2 cases of acute renal failure .
Diseases:"
391	The study was terminated prematurely because an additional 6 patients ( 25 % ) developed sinusoidal obstruction syndrome ( SOS ) , which was fatal in 2 cases .	O O O O O O O O O O O O O O O B I I O B O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['sinusoidal obstruction syndrome', 'sos']	2	8	"Sentence: The study was terminated prematurely because an additional 6 patients ( 25 % ) developed sinusoidal obstruction syndrome ( SOS ) , which was fatal in 2 cases .
Diseases: sinusoidal obstruction syndrome, sos"	"Sentence: The study was terminated prematurely because an additional 6 patients ( 25 % ) developed sinusoidal obstruction syndrome ( SOS ) , which was fatal in 2 cases .
Diseases:"
392	With a median follow - up of 26 months , the 2 - year overall survival rate was 47 % .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: With a median follow - up of 26 months , the 2 - year overall survival rate was 47 % .
Diseases: "	"Sentence: With a median follow - up of 26 months , the 2 - year overall survival rate was 47 % .
Diseases:"
393	Although this new combination appears to be effective as a prophylactic regimen for acute GVHD , the incidence of TMA and SOS is considerably higher than seen with other regimens .	O O O O O O O O O O O O O O B O O O O B O B O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['gvhd', 'tma', 'sos']	3	9	"Sentence: Although this new combination appears to be effective as a prophylactic regimen for acute GVHD , the incidence of TMA and SOS is considerably higher than seen with other regimens .
Diseases: gvhd, tma, sos"	"Sentence: Although this new combination appears to be effective as a prophylactic regimen for acute GVHD , the incidence of TMA and SOS is considerably higher than seen with other regimens .
Diseases:"
394	Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala - kindled rats .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O B O B O O O O O O	[]	0	0	"Sentence: Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala - kindled rats .
Diseases: "	"Sentence: Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala - kindled rats .
Diseases:"
395	Loreclezole ( 5 mg / kg ) exerted a significant protective action in amygdala - kindled rats , reducing both seizure and afterdischarge durations .	O O O O O O O O O O O O O O O O O O O O B O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O	['seizure']	1	3	"Sentence: Loreclezole ( 5 mg / kg ) exerted a significant protective action in amygdala - kindled rats , reducing both seizure and afterdischarge durations .
Diseases: seizure"	"Sentence: Loreclezole ( 5 mg / kg ) exerted a significant protective action in amygdala - kindled rats , reducing both seizure and afterdischarge durations .
Diseases:"
396	The combinations of loreclezole ( 2 . 5 mg / kg ) with valproate , clonazepam , or carbamazepine ( applied at their subprotective doses ) also exhibited antiseizure effect in this test .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O B O B O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The combinations of loreclezole ( 2 . 5 mg / kg ) with valproate , clonazepam , or carbamazepine ( applied at their subprotective doses ) also exhibited antiseizure effect in this test .
Diseases: "	"Sentence: The combinations of loreclezole ( 2 . 5 mg / kg ) with valproate , clonazepam , or carbamazepine ( applied at their subprotective doses ) also exhibited antiseizure effect in this test .
Diseases:"
397	However , only two first combinations occurred to be of pharmacodynamic nature .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: However , only two first combinations occurred to be of pharmacodynamic nature .
Diseases: "	"Sentence: However , only two first combinations occurred to be of pharmacodynamic nature .
Diseases:"
398	Among several chemoconvulsants , bicuculline , N - methyl - D - aspartic acid and BAY k - 8644 ( the opener of L - type calcium channels ) reversed the protective activity of loreclezole alone and its combination with valproate .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O B I I I I I I I O B I I I O O O O O O O B O O O O O O O B O O O O O B O	[]	0	0	"Sentence: Among several chemoconvulsants , bicuculline , N - methyl - D - aspartic acid and BAY k - 8644 ( the opener of L - type calcium channels ) reversed the protective activity of loreclezole alone and its combination with valproate .
Diseases: "	"Sentence: Among several chemoconvulsants , bicuculline , N - methyl - D - aspartic acid and BAY k - 8644 ( the opener of L - type calcium channels ) reversed the protective activity of loreclezole alone and its combination with valproate .
Diseases:"
399	On the other hand , bicuculline , aminophylline and BAY k - 8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O B O B I I I O O O O O B O O B O	[]	0	0	"Sentence: On the other hand , bicuculline , aminophylline and BAY k - 8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam .
Diseases: "	"Sentence: On the other hand , bicuculline , aminophylline and BAY k - 8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam .
Diseases:"
400	The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L - type of calcium channels .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L - type of calcium channels .
Diseases: "	"Sentence: The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L - type of calcium channels .
Diseases:"
401	Acute liver failure with concurrent bupropion and carbimazole therapy .	B I I O O O O O O O	O O O O O B O B O O	['acute liver failure']	1	4	"Sentence: Acute liver failure with concurrent bupropion and carbimazole therapy .
Diseases: acute liver failure"	"Sentence: Acute liver failure with concurrent bupropion and carbimazole therapy .
Diseases:"
402	To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole .	O O O O O O B I O O O O O O O O O O	O O O O O O O O O O O O O O B O B O	['liver failure']	1	3	"Sentence: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole .
Diseases: liver failure"	"Sentence: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole .
Diseases:"
403	A 41 - year - old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years .	O O O O O O O O O O O O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O B O O O O O O	['hyperthyroidism']	1	4	"Sentence: A 41 - year - old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years .
Diseases: hyperthyroidism"	"Sentence: A 41 - year - old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years .
Diseases:"
404	He received a 10 - day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: He received a 10 - day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation .
Diseases: "	"Sentence: He received a 10 - day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation .
Diseases:"
405	He developed acute liver failure with rapid deterioration of renal function .	O O B I I O O O O O O O	O O O O O O O O O O O O	['acute liver failure']	1	4	"Sentence: He developed acute liver failure with rapid deterioration of renal function .
Diseases: acute liver failure"	"Sentence: He developed acute liver failure with rapid deterioration of renal function .
Diseases:"
406	Liver biopsy showed evidence of nonspecific drug - induced acute liver injury .	O O O O O O B I I I I I O	O O O O O O O O O O O O O	['drug - induced acute liver injury']	1	6	"Sentence: Liver biopsy showed evidence of nonspecific drug - induced acute liver injury .
Diseases: drug - induced acute liver injury"	"Sentence: Liver biopsy showed evidence of nonspecific drug - induced acute liver injury .
Diseases:"
407	His condition was further complicated by sepsis and coagulopathy .	O O O O O O B O B O	O O O O O O O O O O	['coagulopathy', 'sepsis']	2	8	"Sentence: His condition was further complicated by sepsis and coagulopathy .
Diseases: coagulopathy, sepsis"	"Sentence: His condition was further complicated by sepsis and coagulopathy .
Diseases:"
408	Death resulted 19 days after the onset of symptoms .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Death resulted 19 days after the onset of symptoms .
Diseases: "	"Sentence: Death resulted 19 days after the onset of symptoms .
Diseases:"
409	The likelihood that bupropion induced hepatotoxicity in our patient was possible , based on the Naranjo probability scale .	O O O O O B O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O	['hepatotoxicity']	1	4	"Sentence: The likelihood that bupropion induced hepatotoxicity in our patient was possible , based on the Naranjo probability scale .
Diseases: hepatotoxicity"	"Sentence: The likelihood that bupropion induced hepatotoxicity in our patient was possible , based on the Naranjo probability scale .
Diseases:"
410	DISCUSSION :	O O	O O	[]	0	0	"Sentence: DISCUSSION :
Diseases: "	"Sentence: DISCUSSION :
Diseases:"
411	Although there is increasing evidence of hepatotoxicity induced by bupropion , this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole .	O O O O O O B O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O B O O O O O B O	['hepatotoxicity', 'acute liver failure']	2	8	"Sentence: Although there is increasing evidence of hepatotoxicity induced by bupropion , this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole .
Diseases: hepatotoxicity, acute liver failure"	"Sentence: Although there is increasing evidence of hepatotoxicity induced by bupropion , this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole .
Diseases:"
412	CONCLUSIONS : Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs .	O O O O O O O O O O B I I O O O O O O O B O O	O O O O O O O O O O O O O O O B O O O O O O O	['acute liver insult', 'hepatotoxic']	2	8	"Sentence: CONCLUSIONS : Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs .
Diseases: acute liver insult, hepatotoxic"	"Sentence: CONCLUSIONS : Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs .
Diseases:"
413	Long term hormone therapy for perimenopausal and postmenopausal women .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Long term hormone therapy for perimenopausal and postmenopausal women .
Diseases: "	"Sentence: Long term hormone therapy for perimenopausal and postmenopausal women .
Diseases:"
414	Hormone therapy ( HT ) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease , osteoporosis and dementia in older women .	O O O O O O O O O O O O O O O O O O O O O O O B I O B O B O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cardiovascular disease', 'dementia', 'osteoporosis']	3	10	"Sentence: Hormone therapy ( HT ) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease , osteoporosis and dementia in older women .
Diseases: cardiovascular disease, dementia, osteoporosis"	"Sentence: Hormone therapy ( HT ) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease , osteoporosis and dementia in older women .
Diseases:"
415	This is an updated version of the original Cochrane review first published in 2005 .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This is an updated version of the original Cochrane review first published in 2005 .
Diseases: "	"Sentence: This is an updated version of the original Cochrane review first published in 2005 .
Diseases:"
416	To assess the effect of long - term HT on mortality , cardiovascular outcomes , cancer , gallbladder disease , cognition , fractures and quality of life .	O O O O O O O O O O O O O O O B O B I O O O B O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['fractures', 'gallbladder disease', 'cancer']	3	10	"Sentence: To assess the effect of long - term HT on mortality , cardiovascular outcomes , cancer , gallbladder disease , cognition , fractures and quality of life .
Diseases: fractures, gallbladder disease, cancer"	"Sentence: To assess the effect of long - term HT on mortality , cardiovascular outcomes , cancer , gallbladder disease , cognition , fractures and quality of life .
Diseases:"
417	SEARCH STRATEGY :	O O O	O O O	[]	0	0	"Sentence: SEARCH STRATEGY :
Diseases: "	"Sentence: SEARCH STRATEGY :
Diseases:"
418	We searched the following databases to November 2007 :	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: We searched the following databases to November 2007 :
Diseases: "	"Sentence: We searched the following databases to November 2007 :
Diseases:"
419	Trials Register of the Cochrane Menstrual Disorders and Subfertility Group , Cochrane Central Register of Controlled Trials , MEDLINE , EMBASE , Biological Abstracts .	O O O O O B I O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['menstrual disorders']	1	4	"Sentence: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group , Cochrane Central Register of Controlled Trials , MEDLINE , EMBASE , Biological Abstracts .
Diseases: menstrual disorders"	"Sentence: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group , Cochrane Central Register of Controlled Trials , MEDLINE , EMBASE , Biological Abstracts .
Diseases:"
420	Also relevant non - indexed journals and conference abstracts .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Also relevant non - indexed journals and conference abstracts .
Diseases: "	"Sentence: Also relevant non - indexed journals and conference abstracts .
Diseases:"
421	SELECTION CRITERIA :	O O O	O O O	[]	0	0	"Sentence: SELECTION CRITERIA :
Diseases: "	"Sentence: SELECTION CRITERIA :
Diseases:"
422	Randomised double - blind trials of HT versus placebo , taken for at least one year by perimenopausal or postmenopausal women .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Randomised double - blind trials of HT versus placebo , taken for at least one year by perimenopausal or postmenopausal women .
Diseases: "	"Sentence: Randomised double - blind trials of HT versus placebo , taken for at least one year by perimenopausal or postmenopausal women .
Diseases:"
423	HT included oestrogens , with or without progestogens , via oral , transdermal , subcutaneous or transnasal routes .	O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: HT included oestrogens , with or without progestogens , via oral , transdermal , subcutaneous or transnasal routes .
Diseases: "	"Sentence: HT included oestrogens , with or without progestogens , via oral , transdermal , subcutaneous or transnasal routes .
Diseases:"
424	DATA COLLECTION AND ANALYSIS :	O O O O O	O O O O O	[]	0	0	"Sentence: DATA COLLECTION AND ANALYSIS :
Diseases: "	"Sentence: DATA COLLECTION AND ANALYSIS :
Diseases:"
425	Two authors independently assessed trial quality and extracted data .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Two authors independently assessed trial quality and extracted data .
Diseases: "	"Sentence: Two authors independently assessed trial quality and extracted data .
Diseases:"
426	MAIN RESULTS :	O O O	O O O	[]	0	0	"Sentence: MAIN RESULTS :
Diseases: "	"Sentence: MAIN RESULTS :
Diseases:"
427	Nineteen trials involving 41 , 904 women were included .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Nineteen trials involving 41 , 904 women were included .
Diseases: "	"Sentence: Nineteen trials involving 41 , 904 women were included .
Diseases:"
428	In relatively healthy women , combined continuous HT significantly increased the risk of venous thrombo - embolism or coronary event ( after one year 's use ) , stroke ( after three years ) , breast cancer and gallbladder disease .	O O O O O O O O O O O O O B I I I O O O O O O O O O O O B O O O O O O B I O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['venous thrombo - embolism', 'stroke', 'gallbladder disease', 'breast cancer']	4	19	"Sentence: In relatively healthy women , combined continuous HT significantly increased the risk of venous thrombo - embolism or coronary event ( after one year 's use ) , stroke ( after three years ) , breast cancer and gallbladder disease .
Diseases: venous thrombo - embolism, stroke, gallbladder disease, breast cancer"	"Sentence: In relatively healthy women , combined continuous HT significantly increased the risk of venous thrombo - embolism or coronary event ( after one year 's use ) , stroke ( after three years ) , breast cancer and gallbladder disease .
Diseases:"
429	Long - term oestrogen - only HT significantly increased the risk of venous thrombo - embolism , stroke and gallbladder disease ( after one to two years , three years and seven years ' use respectively ) , but did not significantly increase the risk of breast cancer .	O O O O O O O O O O O O B I I I O B O B I O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['venous thrombo - embolism', 'stroke', 'gallbladder disease', 'breast cancer']	4	19	"Sentence: Long - term oestrogen - only HT significantly increased the risk of venous thrombo - embolism , stroke and gallbladder disease ( after one to two years , three years and seven years ' use respectively ) , but did not significantly increase the risk of breast cancer .
Diseases: venous thrombo - embolism, stroke, gallbladder disease, breast cancer"	"Sentence: Long - term oestrogen - only HT significantly increased the risk of venous thrombo - embolism , stroke and gallbladder disease ( after one to two years , three years and seven years ' use respectively ) , but did not significantly increase the risk of breast cancer .
Diseases:"
430	The only statistically significant benefits of HT were a decreased incidence of fractures and ( for combined HT ) colon cancer , with long - term use .	O O O O O O O O O O O O B O O O O O O B I O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['colon cancer', 'fractures']	2	5	"Sentence: The only statistically significant benefits of HT were a decreased incidence of fractures and ( for combined HT ) colon cancer , with long - term use .
Diseases: colon cancer, fractures"	"Sentence: The only statistically significant benefits of HT were a decreased incidence of fractures and ( for combined HT ) colon cancer , with long - term use .
Diseases:"
431	Among women aged over 65 who were relatively healthy ( i . e . generally fit , without overt disease ) and taking continuous combined HT , there was a statistically significant increase in the incidence of dementia .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['dementia']	1	3	"Sentence: Among women aged over 65 who were relatively healthy ( i . e . generally fit , without overt disease ) and taking continuous combined HT , there was a statistically significant increase in the incidence of dementia .
Diseases: dementia"	"Sentence: Among women aged over 65 who were relatively healthy ( i . e . generally fit , without overt disease ) and taking continuous combined HT , there was a statistically significant increase in the incidence of dementia .
Diseases:"
432	Among women with cardiovascular disease , long - term use of combined continuous HT significantly increased the risk of venous thrombo - embolism .	O O O B I O O O O O O O O O O O O O O B I I I O	O O O O O O O O O O O O O O O O O O O O O O O O	['venous thrombo - embolism', 'cardiovascular disease']	2	12	"Sentence: Among women with cardiovascular disease , long - term use of combined continuous HT significantly increased the risk of venous thrombo - embolism .
Diseases: venous thrombo - embolism, cardiovascular disease"	"Sentence: Among women with cardiovascular disease , long - term use of combined continuous HT significantly increased the risk of venous thrombo - embolism .
Diseases:"
433	One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen - only HT , versus similar - sized placebo groups .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen - only HT , versus similar - sized placebo groups .
Diseases: "	"Sentence: One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen - only HT , versus similar - sized placebo groups .
Diseases:"
434	The only significantly increased risk reported was for venous thrombo - embolism in women taking combined continuous HT : their absolute risk remained low , at less than 1 / 500 .	O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['venous thrombo - embolism']	1	9	"Sentence: The only significantly increased risk reported was for venous thrombo - embolism in women taking combined continuous HT : their absolute risk remained low , at less than 1 / 500 .
Diseases: venous thrombo - embolism"	"Sentence: The only significantly increased risk reported was for venous thrombo - embolism in women taking combined continuous HT : their absolute risk remained low , at less than 1 / 500 .
Diseases:"
435	However , this study was not powered to detect differences between groups of younger women .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , this study was not powered to detect differences between groups of younger women .
Diseases: "	"Sentence: However , this study was not powered to detect differences between groups of younger women .
Diseases:"
436	AUTHORS ' CONCLUSIONS : HT is not indicated for the routine management of chronic disease .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: AUTHORS ' CONCLUSIONS : HT is not indicated for the routine management of chronic disease .
Diseases: "	"Sentence: AUTHORS ' CONCLUSIONS : HT is not indicated for the routine management of chronic disease .
Diseases:"
437	We need more evidence on the safety of HT for menopausal symptom control , though short - term use appears to be relatively safe for healthy younger women .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We need more evidence on the safety of HT for menopausal symptom control , though short - term use appears to be relatively safe for healthy younger women .
Diseases: "	"Sentence: We need more evidence on the safety of HT for menopausal symptom control , though short - term use appears to be relatively safe for healthy younger women .
Diseases:"
438	Passage of mannitol into the brain around gliomas : a potential cause of rebound phenomenon .	O O O O O O O B O O O O O O O O	O O B O O O O O O O O O O O O O	['gliomas']	1	3	"Sentence: Passage of mannitol into the brain around gliomas : a potential cause of rebound phenomenon .
Diseases: gliomas"	"Sentence: Passage of mannitol into the brain around gliomas : a potential cause of rebound phenomenon .
Diseases:"
439	A study on 21 patients .	O O O O O O	O O O O O O	[]	0	0	"Sentence: A study on 21 patients .
Diseases: "	"Sentence: A study on 21 patients .
Diseases:"
440	AIM : Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so - called rebound phenomenon .	O O O O O O O O B I O O B I O B I O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['brain edema', 'elevated icp', 'brain tumor']	3	10	"Sentence: AIM : Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so - called rebound phenomenon .
Diseases: brain edema, elevated icp, brain tumor"	"Sentence: AIM : Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so - called rebound phenomenon .
Diseases:"
441	Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .
Diseases: "	"Sentence: Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .
Diseases:"
442	This has only been demonstrated experimentally in animals .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: This has only been demonstrated experimentally in animals .
Diseases: "	"Sentence: This has only been demonstrated experimentally in animals .
Diseases:"
443	As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients .	O O O O O O O O O O O O O O O O O O O O O O B I O O	O O O O O O O O O O O O O O B O O O O O O O O O O O	['brain tumor']	1	2	"Sentence: As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients .
Diseases: brain tumor"	"Sentence: As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients .
Diseases:"
444	Mannitol ( 18 % solution ; 1 g / kg ) was administered as a bolus to patients ( ten had malignant glioma , seven brain metastases and four meningioma ) about 30 minutes before craniotomy .	O O O O O O O O O O O O O O O O O O O O O B I O O O B O O B O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['malignant glioma', 'meningioma', 'metastases']	3	13	"Sentence: Mannitol ( 18 % solution ; 1 g / kg ) was administered as a bolus to patients ( ten had malignant glioma , seven brain metastases and four meningioma ) about 30 minutes before craniotomy .
Diseases: malignant glioma, meningioma, metastases"	"Sentence: Mannitol ( 18 % solution ; 1 g / kg ) was administered as a bolus to patients ( ten had malignant glioma , seven brain metastases and four meningioma ) about 30 minutes before craniotomy .
Diseases:"
445	During resection , a sample of the surrounding edematous white matter was taken at the same time as a 10 ml venous blood sample .	O O O O O O O O B O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['edematous']	1	4	"Sentence: During resection , a sample of the surrounding edematous white matter was taken at the same time as a 10 ml venous blood sample .
Diseases: edematous"	"Sentence: During resection , a sample of the surrounding edematous white matter was taken at the same time as a 10 ml venous blood sample .
Diseases:"
446	Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al .	O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al .
Diseases: "	"Sentence: Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al .
Diseases:"
447	In most glioma patients , mannitol concentrations in white matter were 2 to 6 times higher than in plasma ( mean 3 . 5 times ) .	O O B O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O	['glioma']	1	3	"Sentence: In most glioma patients , mannitol concentrations in white matter were 2 to 6 times higher than in plasma ( mean 3 . 5 times ) .
Diseases: glioma"	"Sentence: In most glioma patients , mannitol concentrations in white matter were 2 to 6 times higher than in plasma ( mean 3 . 5 times ) .
Diseases:"
448	In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells .	O B O B O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O	['meningioma', 'metastases']	2	7	"Sentence: In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells .
Diseases: meningioma, metastases"	"Sentence: In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells .
Diseases:"
449	The results of our study show that even after a single bolus , mannitol may leak through the altered BBB near gliomas , reversing the initial plasma - to - blood osmotic gradient , aggravating peritumoral edema and promoting rebound of ICP .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['gliomas', 'edema']	2	6	"Sentence: The results of our study show that even after a single bolus , mannitol may leak through the altered BBB near gliomas , reversing the initial plasma - to - blood osmotic gradient , aggravating peritumoral edema and promoting rebound of ICP .
Diseases: gliomas, edema"	"Sentence: The results of our study show that even after a single bolus , mannitol may leak through the altered BBB near gliomas , reversing the initial plasma - to - blood osmotic gradient , aggravating peritumoral edema and promoting rebound of ICP .
Diseases:"
450	Can lidocaine reduce succinylcholine induced postoperative myalgia ?	O O O O O B I O	O B O B O O O O	['postoperative myalgia']	1	4	"Sentence: Can lidocaine reduce succinylcholine induced postoperative myalgia ?
Diseases: postoperative myalgia"	"Sentence: Can lidocaine reduce succinylcholine induced postoperative myalgia ?
Diseases:"
451	This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine - induced myalgia in patients undergoing general anesthesia for gynecological surgery .	O O O O O O O O O O O O O O O O O B O O O O O O O O O	O O O O O O O O O B O O O O B O O O O O O O O O O O O	['myalgia']	1	2	"Sentence: This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine - induced myalgia in patients undergoing general anesthesia for gynecological surgery .
Diseases: myalgia"	"Sentence: This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine - induced myalgia in patients undergoing general anesthesia for gynecological surgery .
Diseases:"
452	One hundred and thirty - five patients were assigned to one of three groups in a prospective , double blind , randomized manner .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: One hundred and thirty - five patients were assigned to one of three groups in a prospective , double blind , randomized manner .
Diseases: "	"Sentence: One hundred and thirty - five patients were assigned to one of three groups in a prospective , double blind , randomized manner .
Diseases:"
453	Group PS , the control group , received normal saline and succinylcholine 1 . 5 mg x kg ( - 1 ) ; Group LS , lidocaine 1 . 5 mg x kg ( - 1 ) and succinylcholine 1 . 5 mg x kg ( - 1 ) ; Group PR , normal saline and rocuronium 0 . 6 mg x kg ( - 1 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O B O O O O O O O O O O O B O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: Group PS , the control group , received normal saline and succinylcholine 1 . 5 mg x kg ( - 1 ) ; Group LS , lidocaine 1 . 5 mg x kg ( - 1 ) and succinylcholine 1 . 5 mg x kg ( - 1 ) ; Group PR , normal saline and rocuronium 0 . 6 mg x kg ( - 1 ) .
Diseases: "	"Sentence: Group PS , the control group , received normal saline and succinylcholine 1 . 5 mg x kg ( - 1 ) ; Group LS , lidocaine 1 . 5 mg x kg ( - 1 ) and succinylcholine 1 . 5 mg x kg ( - 1 ) ; Group PR , normal saline and rocuronium 0 . 6 mg x kg ( - 1 ) .
Diseases:"
454	Morphine 0 . 1	O O O O	B O O O	[]	0	0	"Sentence: Morphine 0 . 1
Diseases: "	"Sentence: Morphine 0 . 1
Diseases:"
455	mg x kg ( - 1 ) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor , ECG and pulse oximetry .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: mg x kg ( - 1 ) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor , ECG and pulse oximetry .
Diseases: "	"Sentence: mg x kg ( - 1 ) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor , ECG and pulse oximetry .
Diseases:"
456	Anesthesia was induced with 5 mg . kg ( - 1 ) thiopental iv . followed by succinylcholine ( Group PS , LS ) or rocuronium ( Group PR ) for tracheal intubation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O B O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: Anesthesia was induced with 5 mg . kg ( - 1 ) thiopental iv . followed by succinylcholine ( Group PS , LS ) or rocuronium ( Group PR ) for tracheal intubation .
Diseases: "	"Sentence: Anesthesia was induced with 5 mg . kg ( - 1 ) thiopental iv . followed by succinylcholine ( Group PS , LS ) or rocuronium ( Group PR ) for tracheal intubation .
Diseases:"
457	Following administration of these agents , the presence , and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['fasciculation']	1	4	"Sentence: Following administration of these agents , the presence , and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered .
Diseases: fasciculation"	"Sentence: Following administration of these agents , the presence , and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered .
Diseases:"
458	The blood pressure and heart rate of each patient were monitored on nine occasions .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The blood pressure and heart rate of each patient were monitored on nine occasions .
Diseases: "	"Sentence: The blood pressure and heart rate of each patient were monitored on nine occasions .
Diseases:"
459	Twenty - four hours later , any myalgia experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['myalgia']	1	2	"Sentence: Twenty - four hours later , any myalgia experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management .
Diseases: myalgia"	"Sentence: Twenty - four hours later , any myalgia experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management .
Diseases:"
460	The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS ( p < 0 . 001 ) .	O O O O B I O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['muscle fasciculation']	1	5	"Sentence: The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS ( p < 0 . 001 ) .
Diseases: muscle fasciculation"	"Sentence: The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS ( p < 0 . 001 ) .
Diseases:"
461	At 24 h , the incidence of myalgia was higher in Group PS than in Group LS and PR ( p < 0 . 05 ) .	O O O O O O O B O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['myalgia']	1	2	"Sentence: At 24 h , the incidence of myalgia was higher in Group PS than in Group LS and PR ( p < 0 . 05 ) .
Diseases: myalgia"	"Sentence: At 24 h , the incidence of myalgia was higher in Group PS than in Group LS and PR ( p < 0 . 05 ) .
Diseases:"
462	A correlation was not found between the incidence of myalgia and the occurrence of muscle fasciculation .	O O O O O O O O O B O O O O B I O	O O O O O O O O O O O O O O O O O	['myalgia', 'muscle fasciculation']	2	7	"Sentence: A correlation was not found between the incidence of myalgia and the occurrence of muscle fasciculation .
Diseases: myalgia, muscle fasciculation"	"Sentence: A correlation was not found between the incidence of myalgia and the occurrence of muscle fasciculation .
Diseases:"
463	The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups .
Diseases: "	"Sentence: The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups .
Diseases:"
464	In conclusion , where succinylcholine is used , lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia .	O O O O O O O O O O O O O O O O O O O O O B I O	O O O O B O O O B O O O O O O O O O O O O O O O	['postoperative myalgia']	1	4	"Sentence: In conclusion , where succinylcholine is used , lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia .
Diseases: postoperative myalgia"	"Sentence: In conclusion , where succinylcholine is used , lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia .
Diseases:"
465	Open - label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults .	O O O O O O O O O O O O B O O O	O O O O O B O O O O O O O O O O	['sinusitis']	1	3	"Sentence: Open - label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults .
Diseases: sinusitis"	"Sentence: Open - label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults .
Diseases:"
466	To evaluate the efficacy and safety of levofloxacin ( 500 mg orally once daily for 10 to 14 days ) in treating adult outpatients with acute bacterial sinusitis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	['sinusitis']	1	3	"Sentence: To evaluate the efficacy and safety of levofloxacin ( 500 mg orally once daily for 10 to 14 days ) in treating adult outpatients with acute bacterial sinusitis .
Diseases: sinusitis"	"Sentence: To evaluate the efficacy and safety of levofloxacin ( 500 mg orally once daily for 10 to 14 days ) in treating adult outpatients with acute bacterial sinusitis .
Diseases:"
467	PATIENTS AND METHODS : A total of 329 patients enrolled in the study at 24 centers .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: PATIENTS AND METHODS : A total of 329 patients enrolled in the study at 24 centers .
Diseases: "	"Sentence: PATIENTS AND METHODS : A total of 329 patients enrolled in the study at 24 centers .
Diseases:"
468	All patients had a pre - therapy Gram 's stain and culture of sinus exudate obtained by antral puncture or nasal endoscopy .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All patients had a pre - therapy Gram 's stain and culture of sinus exudate obtained by antral puncture or nasal endoscopy .
Diseases: "	"Sentence: All patients had a pre - therapy Gram 's stain and culture of sinus exudate obtained by antral puncture or nasal endoscopy .
Diseases:"
469	Clinical response was assessed on the basis of signs and symptoms and sinus radiograph or computed tomography results .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Clinical response was assessed on the basis of signs and symptoms and sinus radiograph or computed tomography results .
Diseases: "	"Sentence: Clinical response was assessed on the basis of signs and symptoms and sinus radiograph or computed tomography results .
Diseases:"
470	Microbiologic cure rates were determined on the basis of presumed plus documented eradication of the pre - therapy pathogen ( s ) .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Microbiologic cure rates were determined on the basis of presumed plus documented eradication of the pre - therapy pathogen ( s ) .
Diseases: "	"Sentence: Microbiologic cure rates were determined on the basis of presumed plus documented eradication of the pre - therapy pathogen ( s ) .
Diseases:"
471	The most common pathogens were Haemophilus influenzae , Streptococcus pneumoniae , Staphylococcus aureus , and Moraxella catarrhalis .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The most common pathogens were Haemophilus influenzae , Streptococcus pneumoniae , Staphylococcus aureus , and Moraxella catarrhalis .
Diseases: "	"Sentence: The most common pathogens were Haemophilus influenzae , Streptococcus pneumoniae , Staphylococcus aureus , and Moraxella catarrhalis .
Diseases:"
472	Of 300 clinically evaluable patients , 175 ( 58 % ) were cured and 90 ( 30 % ) were improved at the post - therapy evaluation , resulting in a clinical success rate of 88 % .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of 300 clinically evaluable patients , 175 ( 58 % ) were cured and 90 ( 30 % ) were improved at the post - therapy evaluation , resulting in a clinical success rate of 88 % .
Diseases: "	"Sentence: Of 300 clinically evaluable patients , 175 ( 58 % ) were cured and 90 ( 30 % ) were improved at the post - therapy evaluation , resulting in a clinical success rate of 88 % .
Diseases:"
473	Thirty - five patients ( 12 % ) clinically failed treatment .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: Thirty - five patients ( 12 % ) clinically failed treatment .
Diseases: "	"Sentence: Thirty - five patients ( 12 % ) clinically failed treatment .
Diseases:"
474	The microbiologic eradication rate ( presumed plus documented ) among 138 microbiologically evaluable patients was 92 % .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The microbiologic eradication rate ( presumed plus documented ) among 138 microbiologically evaluable patients was 92 % .
Diseases: "	"Sentence: The microbiologic eradication rate ( presumed plus documented ) among 138 microbiologically evaluable patients was 92 % .
Diseases:"
475	Microbiologic eradication rates ( presumed plus documented ) of the most common pathogens ranged from 93 % ( M . catarrhalis ) to 100 % ( S . pneumoniae ) at the post - therapy visit .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Microbiologic eradication rates ( presumed plus documented ) of the most common pathogens ranged from 93 % ( M . catarrhalis ) to 100 % ( S . pneumoniae ) at the post - therapy visit .
Diseases: "	"Sentence: Microbiologic eradication rates ( presumed plus documented ) of the most common pathogens ranged from 93 % ( M . catarrhalis ) to 100 % ( S . pneumoniae ) at the post - therapy visit .
Diseases:"
476	All but one of the 265 patients who were cured or improved at post - therapy returned for a long - term follow - up visit ; 243 ( 92 % ) remained well 4 to 6 weeks after therapy ; and 21 ( 8 % ) had a relapse of symptoms .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All but one of the 265 patients who were cured or improved at post - therapy returned for a long - term follow - up visit ; 243 ( 92 % ) remained well 4 to 6 weeks after therapy ; and 21 ( 8 % ) had a relapse of symptoms .
Diseases: "	"Sentence: All but one of the 265 patients who were cured or improved at post - therapy returned for a long - term follow - up visit ; 243 ( 92 % ) remained well 4 to 6 weeks after therapy ; and 21 ( 8 % ) had a relapse of symptoms .
Diseases:"
477	Adverse events considered to be related to levofloxacin administration were reported by 29 patients ( 9 % ) .	O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: Adverse events considered to be related to levofloxacin administration were reported by 29 patients ( 9 % ) .
Diseases: "	"Sentence: Adverse events considered to be related to levofloxacin administration were reported by 29 patients ( 9 % ) .
Diseases:"
478	The most common drug - related adverse events were diarrhea , flatulence , and nausea ; most adverse events were mild to moderate in severity .	O O O O O O O O O B O B O O B O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['nausea', 'flatulence', 'diarrhea']	3	8	"Sentence: The most common drug - related adverse events were diarrhea , flatulence , and nausea ; most adverse events were mild to moderate in severity .
Diseases: nausea, flatulence, diarrhea"	"Sentence: The most common drug - related adverse events were diarrhea , flatulence , and nausea ; most adverse events were mild to moderate in severity .
Diseases:"
479	The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis .	O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O B O O O O O O O O O O O O O O O	['sinusitis']	1	3	"Sentence: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis .
Diseases: sinusitis"	"Sentence: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis .
Diseases:"
480	Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol .	O O O O O O O O O O O O O O O	O O O O O O O B O B O O O B O	[]	0	0	"Sentence: Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol .
Diseases: "	"Sentence: Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol .
Diseases:"
481	Among various oral antiplatelets , a combination of a novel prostacyclin analogue beraprost ( BPT ) and a potent phosphodiesterase inhibitor cilostazol ( CLZ ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP ( cyclic adenosine 3' , 5' - monophosphate ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O B O B O O O O O O B O B O O O O O O O O O O O O O O B O B I I I I I I O O	[]	0	0	"Sentence: Among various oral antiplatelets , a combination of a novel prostacyclin analogue beraprost ( BPT ) and a potent phosphodiesterase inhibitor cilostazol ( CLZ ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP ( cyclic adenosine 3' , 5' - monophosphate ) .
Diseases: "	"Sentence: Among various oral antiplatelets , a combination of a novel prostacyclin analogue beraprost ( BPT ) and a potent phosphodiesterase inhibitor cilostazol ( CLZ ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP ( cyclic adenosine 3' , 5' - monophosphate ) .
Diseases:"
482	Thereby , a clinical study of the combined administration of the two agents was attempted .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thereby , a clinical study of the combined administration of the two agents was attempted .
Diseases: "	"Sentence: Thereby , a clinical study of the combined administration of the two agents was attempted .
Diseases:"
483	Twelve healthy volunteers were assigned to take BPT / CLZ in the following schedule ; BPT : 40 micrograms at day 1 and 120 micrograms t . i . d .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O B O O O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Twelve healthy volunteers were assigned to take BPT / CLZ in the following schedule ; BPT : 40 micrograms at day 1 and 120 micrograms t . i . d .
Diseases: "	"Sentence: Twelve healthy volunteers were assigned to take BPT / CLZ in the following schedule ; BPT : 40 micrograms at day 1 and 120 micrograms t . i . d .
Diseases:"
484	from day 7 to 14 , CLZ : 200 mg t . i . d .	O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: from day 7 to 14 , CLZ : 200 mg t . i . d .
Diseases: "	"Sentence: from day 7 to 14 , CLZ : 200 mg t . i . d .
Diseases:"
485	from day 3 to 14 .	O O O O O O	O O O O O O	[]	0	0	"Sentence: from day 3 to 14 .
Diseases: "	"Sentence: from day 3 to 14 .
Diseases:"
486	At various time intervals , physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed .	O O O O O O O O O O O O O B I O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O	['platelet aggregation']	1	3	"Sentence: At various time intervals , physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed .
Diseases: platelet aggregation"	"Sentence: At various time intervals , physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed .
Diseases:"
487	Throughout the observation period , no significant alteration in vital signs was observed .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Throughout the observation period , no significant alteration in vital signs was observed .
Diseases: "	"Sentence: Throughout the observation period , no significant alteration in vital signs was observed .
Diseases:"
488	Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one , especially after ingestion of CLZ .	O O O O O O B O O O O O B I O O O B O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O B O	['nausea', 'facial flush', 'headache']	3	8	"Sentence: Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one , especially after ingestion of CLZ .
Diseases: nausea, facial flush, headache"	"Sentence: Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one , especially after ingestion of CLZ .
Diseases:"
489	All of these symptoms , probably caused by the vasodilating effect of the two agents , were of mild degree and no special treatment was required .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All of these symptoms , probably caused by the vasodilating effect of the two agents , were of mild degree and no special treatment was required .
Diseases: "	"Sentence: All of these symptoms , probably caused by the vasodilating effect of the two agents , were of mild degree and no special treatment was required .
Diseases:"
490	Intraplatelet cAMP content was gradually but significantly increased to 9 . 84 + / - 4 . 59 pmol per 10 ( 9 ) platelets at day 14 in comparison with the initial value ( 6 . 87 + / - 2 . 25 pmol ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Intraplatelet cAMP content was gradually but significantly increased to 9 . 84 + / - 4 . 59 pmol per 10 ( 9 ) platelets at day 14 in comparison with the initial value ( 6 . 87 + / - 2 . 25 pmol ) .
Diseases: "	"Sentence: Intraplatelet cAMP content was gradually but significantly increased to 9 . 84 + / - 4 . 59 pmol per 10 ( 9 ) platelets at day 14 in comparison with the initial value ( 6 . 87 + / - 2 . 25 pmol ) .
Diseases:"
491	The platelet aggregability was significantly suppressed at various time intervals but no additive or synergistic inhibitory effect by the combined administration was noted .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The platelet aggregability was significantly suppressed at various time intervals but no additive or synergistic inhibitory effect by the combined administration was noted .
Diseases: "	"Sentence: The platelet aggregability was significantly suppressed at various time intervals but no additive or synergistic inhibitory effect by the combined administration was noted .
Diseases:"
492	In conclusion , the combined administration of BPT / CLZ is safe at doses used in the study , though the beneficial clinical effect of the combined administration has yet to be elucidated .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In conclusion , the combined administration of BPT / CLZ is safe at doses used in the study , though the beneficial clinical effect of the combined administration has yet to be elucidated .
Diseases: "	"Sentence: In conclusion , the combined administration of BPT / CLZ is safe at doses used in the study , though the beneficial clinical effect of the combined administration has yet to be elucidated .
Diseases:"
493	Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients : results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial ( EDGE - II ) .	O O O O O B I O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O B O B I O O O O O O O O O O O	['rheumatoid arthritis']	1	5	"Sentence: Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients : results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial ( EDGE - II ) .
Diseases: rheumatoid arthritis"	"Sentence: Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients : results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial ( EDGE - II ) .
Diseases:"
494	A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis ( RA ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O B I O B O O	O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O	['ra', 'rheumatoid arthritis']	2	7	"Sentence: A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis ( RA ) .
Diseases: ra, rheumatoid arthritis"	"Sentence: A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis ( RA ) .
Diseases:"
495	PATIENTS AND METHODS : A total of 4086 patients ( mean age 60 . 8 years ) diagnosed with RA were enrolled and received etoricoxib 90 mg daily ( n = 2032 ) or diclofenac 75 mg twice daily ( n = 2054 ) .	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O B O O O O O O O O O O	['ra']	1	1	"Sentence: PATIENTS AND METHODS : A total of 4086 patients ( mean age 60 . 8 years ) diagnosed with RA were enrolled and received etoricoxib 90 mg daily ( n = 2032 ) or diclofenac 75 mg twice daily ( n = 2054 ) .
Diseases: ra"	"Sentence: PATIENTS AND METHODS : A total of 4086 patients ( mean age 60 . 8 years ) diagnosed with RA were enrolled and received etoricoxib 90 mg daily ( n = 2032 ) or diclofenac 75 mg twice daily ( n = 2054 ) .
Diseases:"
496	Use of gastroprotective agents and low - dose aspirin was allowed .	O O O O O O O O O O O O	O O O O O O O O B O O O	[]	0	0	"Sentence: Use of gastroprotective agents and low - dose aspirin was allowed .
Diseases: "	"Sentence: Use of gastroprotective agents and low - dose aspirin was allowed .
Diseases:"
497	The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences ( AEs ) .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences ( AEs ) .
Diseases: "	"Sentence: The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences ( AEs ) .
Diseases:"
498	General safety was also assessed , including adjudicated thrombotic cardiovascular event data .	O O O O O O O O B I O O O	O O O O O O O O O O O O O	['thrombotic cardiovascular']	1	5	"Sentence: General safety was also assessed , including adjudicated thrombotic cardiovascular event data .
Diseases: thrombotic cardiovascular"	"Sentence: General safety was also assessed , including adjudicated thrombotic cardiovascular event data .
Diseases:"
499	Efficacy was evaluated using the Patient Global Assessment of Disease Status ( PGADS ; 0 - 4 point scale ) .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Efficacy was evaluated using the Patient Global Assessment of Disease Status ( PGADS ; 0 - 4 point scale ) .
Diseases: "	"Sentence: Efficacy was evaluated using the Patient Global Assessment of Disease Status ( PGADS ; 0 - 4 point scale ) .
Diseases:"
500	Mean ( SD ; maximum ) duration of treatment was 19 . 3 ( 10 . 3 ; 32 . 9 ) and 19 . 1 ( 10 . 4 ; 33 . 1 ) months in the etoricoxib and diclofenac groups , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O	[]	0	0	"Sentence: Mean ( SD ; maximum ) duration of treatment was 19 . 3 ( 10 . 3 ; 32 . 9 ) and 19 . 1 ( 10 . 4 ; 33 . 1 ) months in the etoricoxib and diclofenac groups , respectively .
Diseases: "	"Sentence: Mean ( SD ; maximum ) duration of treatment was 19 . 3 ( 10 . 3 ; 32 . 9 ) and 19 . 1 ( 10 . 4 ; 33 . 1 ) months in the etoricoxib and diclofenac groups , respectively .
Diseases:"
501	The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac ( 5 . 2 vs 8 . 5 events per 100 patient - years , respectively ; hazard ratio 0 . 62 ( 95 % CI : 0 . 47 , 0 . 81 ; p < or = 0 . 001 ) ) .	O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['gi aes']	1	3	"Sentence: The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac ( 5 . 2 vs 8 . 5 events per 100 patient - years , respectively ; hazard ratio 0 . 62 ( 95 % CI : 0 . 47 , 0 . 81 ; p < or = 0 . 001 ) ) .
Diseases: gi aes"	"Sentence: The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac ( 5 . 2 vs 8 . 5 events per 100 patient - years , respectively ; hazard ratio 0 . 62 ( 95 % CI : 0 . 47 , 0 . 81 ; p < or = 0 . 001 ) ) .
Diseases:"
502	The incidence of discontinuations for hypertension - related and oedema - related AEs were significantly higher with etoricoxib ( 2 . 5 % and 1 . 1 % respectively ) compared with diclofenac ( 1 . 5 % and 0 . 4 % respectively ; p < 0 . 001 for hypertension and p < 0 . 01 for oedema ) .	O O O O O B O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O B O O	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['oedema', 'hypertension']	2	5	"Sentence: The incidence of discontinuations for hypertension - related and oedema - related AEs were significantly higher with etoricoxib ( 2 . 5 % and 1 . 1 % respectively ) compared with diclofenac ( 1 . 5 % and 0 . 4 % respectively ; p < 0 . 001 for hypertension and p < 0 . 01 for oedema ) .
Diseases: oedema, hypertension"	"Sentence: The incidence of discontinuations for hypertension - related and oedema - related AEs were significantly higher with etoricoxib ( 2 . 5 % and 1 . 1 % respectively ) compared with diclofenac ( 1 . 5 % and 0 . 4 % respectively ; p < 0 . 001 for hypertension and p < 0 . 01 for oedema ) .
Diseases:"
503	Etoricoxib and diclofenac treatment resulted in similar efficacy ( PGADS mean changes from baseline - 0 . 62 vs - 0 . 58 , respectively ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O B O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Etoricoxib and diclofenac treatment resulted in similar efficacy ( PGADS mean changes from baseline - 0 . 62 vs - 0 . 58 , respectively ) .
Diseases: "	"Sentence: Etoricoxib and diclofenac treatment resulted in similar efficacy ( PGADS mean changes from baseline - 0 . 62 vs - 0 . 58 , respectively ) .
Diseases:"
504	CONCLUSIONS : Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg .	O O O O O O O O O O O O O O O B I O O O O O O	O O B O O O O O O O O O O O O O O O O B O O O	['gi aes']	1	3	"Sentence: CONCLUSIONS : Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg .
Diseases: gi aes"	"Sentence: CONCLUSIONS : Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg .
Diseases:"
505	Discontinuations from renovascular AEs , although less common than discontinuations from GI AEs , were significantly higher with etoricoxib .	O O O O O O O O O O O B I O O O O O O O	O O O O O O O O O O O O O O O O O O B O	['gi aes']	1	3	"Sentence: Discontinuations from renovascular AEs , although less common than discontinuations from GI AEs , were significantly higher with etoricoxib .
Diseases: gi aes"	"Sentence: Discontinuations from renovascular AEs , although less common than discontinuations from GI AEs , were significantly higher with etoricoxib .
Diseases:"
506	Placebo - level incidence of extrapyramidal symptoms ( EPS ) with quetiapine in controlled studies of patients with bipolar mania .	O O O O O B I O B O O O O O O O O O B I O	O O O O O O O O O O O B O O O O O O O O O	['bipolar mania', 'eps', 'extrapyramidal symptoms']	3	13	"Sentence: Placebo - level incidence of extrapyramidal symptoms ( EPS ) with quetiapine in controlled studies of patients with bipolar mania .
Diseases: bipolar mania, eps, extrapyramidal symptoms"	"Sentence: Placebo - level incidence of extrapyramidal symptoms ( EPS ) with quetiapine in controlled studies of patients with bipolar mania .
Diseases:"
507	OBJECTIVES : To evaluate extrapyramidal symptoms ( EPS ) , including akathisia , with quetiapine in patients with bipolar mania .	O O O O B I O B O O O B O O O O O O B I O	O O O O O O O O O O O O O O B O O O O O O	['akathisia', 'bipolar mania', 'eps', 'extrapyramidal symptoms']	4	17	"Sentence: OBJECTIVES : To evaluate extrapyramidal symptoms ( EPS ) , including akathisia , with quetiapine in patients with bipolar mania .
Diseases: akathisia, bipolar mania, eps, extrapyramidal symptoms"	"Sentence: OBJECTIVES : To evaluate extrapyramidal symptoms ( EPS ) , including akathisia , with quetiapine in patients with bipolar mania .
Diseases:"
508	Data were analyzed from four similarly designed , randomized , double - blind ,	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Data were analyzed from four similarly designed , randomized , double - blind ,
Diseases: "	"Sentence: Data were analyzed from four similarly designed , randomized , double - blind ,
Diseases:"
509	3 - to 12 - week studies .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: 3 - to 12 - week studies .
Diseases: "	"Sentence: 3 - to 12 - week studies .
Diseases:"
510	Two studies evaluated quetiapine monotherapy ( up to 800 mg / day ) ( n = 209 ) versus placebo ( n = 198 ) , with lithium or haloperidol monotherapy as respective active controls .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O	[]	0	0	"Sentence: Two studies evaluated quetiapine monotherapy ( up to 800 mg / day ) ( n = 209 ) versus placebo ( n = 198 ) , with lithium or haloperidol monotherapy as respective active controls .
Diseases: "	"Sentence: Two studies evaluated quetiapine monotherapy ( up to 800 mg / day ) ( n = 209 ) versus placebo ( n = 198 ) , with lithium or haloperidol monotherapy as respective active controls .
Diseases:"
511	Two studies evaluated quetiapine ( up to 800 mg / day ) in combination with a mood stabilizer ( lithium or divalproex , QTP + Li / DVP ) ( n = 196 ) compared to placebo and mood stabilizer ( PBO + Li / DVP ) ( n = 203 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O B O B O O O B O O O O O O O O O O O O O O O B O B O O O O O O O O O	[]	0	0	"Sentence: Two studies evaluated quetiapine ( up to 800 mg / day ) in combination with a mood stabilizer ( lithium or divalproex , QTP + Li / DVP ) ( n = 196 ) compared to placebo and mood stabilizer ( PBO + Li / DVP ) ( n = 203 ) .
Diseases: "	"Sentence: Two studies evaluated quetiapine ( up to 800 mg / day ) in combination with a mood stabilizer ( lithium or divalproex , QTP + Li / DVP ) ( n = 196 ) compared to placebo and mood stabilizer ( PBO + Li / DVP ) ( n = 203 ) .
Diseases:"
512	Extrapyramidal symptoms were evaluated using the Simpson - Angus Scale ( SAS ) , the Barnes Akathisia Rating Scale ( BARS ) , adverse event reports and anticholinergic drug usage .	B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['extrapyramidal symptoms']	1	6	"Sentence: Extrapyramidal symptoms were evaluated using the Simpson - Angus Scale ( SAS ) , the Barnes Akathisia Rating Scale ( BARS ) , adverse event reports and anticholinergic drug usage .
Diseases: extrapyramidal symptoms"	"Sentence: Extrapyramidal symptoms were evaluated using the Simpson - Angus Scale ( SAS ) , the Barnes Akathisia Rating Scale ( BARS ) , adverse event reports and anticholinergic drug usage .
Diseases:"
513	The incidence of EPS - related adverse events , including akathisia , was no different with quetiapine monotherapy ( 12 . 9 % ) than with placebo ( 13 . 1 % ) .	O O O B O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['akathisia', 'eps']	2	7	"Sentence: The incidence of EPS - related adverse events , including akathisia , was no different with quetiapine monotherapy ( 12 . 9 % ) than with placebo ( 13 . 1 % ) .
Diseases: akathisia, eps"	"Sentence: The incidence of EPS - related adverse events , including akathisia , was no different with quetiapine monotherapy ( 12 . 9 % ) than with placebo ( 13 . 1 % ) .
Diseases:"
514	Similarly , EPS - related adverse events with QTP + Li / DVP ( 21 . 4 % ) were no different than with PBO + Li / DVP ( 19 . 2 % ) .	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O B O B O O O O O O O O O O O B O B O B O O O O O O O	['eps']	1	1	"Sentence: Similarly , EPS - related adverse events with QTP + Li / DVP ( 21 . 4 % ) were no different than with PBO + Li / DVP ( 19 . 2 % ) .
Diseases: eps"	"Sentence: Similarly , EPS - related adverse events with QTP + Li / DVP ( 21 . 4 % ) were no different than with PBO + Li / DVP ( 19 . 2 % ) .
Diseases:"
515	Adverse events related to EPS occurred in 59 . 6 % of patients treated with haloperidol ( n = 99 ) monotherapy , whereas 26 . 5 % of patients treated with lithium ( n = 98 ) monotherapy experienced adverse events related to EPS .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	['eps']	1	1	"Sentence: Adverse events related to EPS occurred in 59 . 6 % of patients treated with haloperidol ( n = 99 ) monotherapy , whereas 26 . 5 % of patients treated with lithium ( n = 98 ) monotherapy experienced adverse events related to EPS .
Diseases: eps"	"Sentence: Adverse events related to EPS occurred in 59 . 6 % of patients treated with haloperidol ( n = 99 ) monotherapy , whereas 26 . 5 % of patients treated with lithium ( n = 98 ) monotherapy experienced adverse events related to EPS .
Diseases:"
516	The incidence of akathisia was low and similar with quetiapine monotherapy ( 3 . 3 % ) and placebo ( 6 . 1 % ) , and with QTP + Li / DVP ( 3 . 6 % ) and PBO + Li / DVP ( 4 . 9 % ) .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O B O O O O O O O O O	['akathisia']	1	4	"Sentence: The incidence of akathisia was low and similar with quetiapine monotherapy ( 3 . 3 % ) and placebo ( 6 . 1 % ) , and with QTP + Li / DVP ( 3 . 6 % ) and PBO + Li / DVP ( 4 . 9 % ) .
Diseases: akathisia"	"Sentence: The incidence of akathisia was low and similar with quetiapine monotherapy ( 3 . 3 % ) and placebo ( 6 . 1 % ) , and with QTP + Li / DVP ( 3 . 6 % ) and PBO + Li / DVP ( 4 . 9 % ) .
Diseases:"
517	Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of tremor ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar tremor , which is a known adverse effect of lithium , may have contributed to the elevated rate of tremor in patients receiving lithium therapy .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O B O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O B O O	['tremor']	1	3	"Sentence: Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of tremor ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar tremor , which is a known adverse effect of lithium , may have contributed to the elevated rate of tremor in patients receiving lithium therapy .
Diseases: tremor"	"Sentence: Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of tremor ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar tremor , which is a known adverse effect of lithium , may have contributed to the elevated rate of tremor in patients receiving lithium therapy .
Diseases:"
518	Haloperidol induced a significantly higher incidence ( p < 0 . 001 ) of akathisia ( 33 . 3 % versus 5 . 9 % ) , tremor ( 30 . 3 % versus 7 . 8 % ) , and extrapyramidal syndrome ( 35 . 4 % versus 5 . 9 % ) than quetiapine .	O O O O O O O O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O O B I O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['extrapyramidal syndrome', 'akathisia', 'tremor']	3	14	"Sentence: Haloperidol induced a significantly higher incidence ( p < 0 . 001 ) of akathisia ( 33 . 3 % versus 5 . 9 % ) , tremor ( 30 . 3 % versus 7 . 8 % ) , and extrapyramidal syndrome ( 35 . 4 % versus 5 . 9 % ) than quetiapine .
Diseases: extrapyramidal syndrome, akathisia, tremor"	"Sentence: Haloperidol induced a significantly higher incidence ( p < 0 . 001 ) of akathisia ( 33 . 3 % versus 5 . 9 % ) , tremor ( 30 . 3 % versus 7 . 8 % ) , and extrapyramidal syndrome ( 35 . 4 % versus 5 . 9 % ) than quetiapine .
Diseases:"
519	No significant differences were observed between quetiapine and placebo on SAS and BARS scores .	O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O	[]	0	0	"Sentence: No significant differences were observed between quetiapine and placebo on SAS and BARS scores .
Diseases: "	"Sentence: No significant differences were observed between quetiapine and placebo on SAS and BARS scores .
Diseases:"
520	Anticholinergic use was low and similar with quetiapine or placebo .	O O O O O O O O O O O	O O O O O O O B O O O	[]	0	0	"Sentence: Anticholinergic use was low and similar with quetiapine or placebo .
Diseases: "	"Sentence: Anticholinergic use was low and similar with quetiapine or placebo .
Diseases:"
521	In bipolar mania , the incidence of EPS , including akathisia , with quetiapine therapy is similar to that with placebo .	O B I O O O O B O O B O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O	['akathisia', 'eps', 'bipolar mania']	3	11	"Sentence: In bipolar mania , the incidence of EPS , including akathisia , with quetiapine therapy is similar to that with placebo .
Diseases: akathisia, eps, bipolar mania"	"Sentence: In bipolar mania , the incidence of EPS , including akathisia , with quetiapine therapy is similar to that with placebo .
Diseases:"
522	Contribution of the sympathetic nervous system to salt - sensitivity in lifetime captopril - treated spontaneously hypertensive rats .	O O O O O O O O O O O O O O O O B O O	O O O O O O O B O O O O B O O O O O O	['hypertensive']	1	3	"Sentence: Contribution of the sympathetic nervous system to salt - sensitivity in lifetime captopril - treated spontaneously hypertensive rats .
Diseases: hypertensive"	"Sentence: Contribution of the sympathetic nervous system to salt - sensitivity in lifetime captopril - treated spontaneously hypertensive rats .
Diseases:"
523	To test the hypothesis that , in lifetime captopril - treated spontaneously hypertensive rats ( SHR ) , the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation .	O O O O O O O O O O O O B O O O O O O O O O O O O O B O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O B I O O	['hypertensive']	1	3	"Sentence: To test the hypothesis that , in lifetime captopril - treated spontaneously hypertensive rats ( SHR ) , the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation .
Diseases: hypertensive"	"Sentence: To test the hypothesis that , in lifetime captopril - treated spontaneously hypertensive rats ( SHR ) , the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation .
Diseases:"
524	Male SHR ( aged 6 weeks ) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O B I O O O O O O B I O O	[]	0	0	"Sentence: Male SHR ( aged 6 weeks ) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet .
Diseases: "	"Sentence: Male SHR ( aged 6 weeks ) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet .
Diseases:"
525	After 2 weeks , the rats were subjected to ganglionic blockade and 2 days later , an infusion of clonidine .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: After 2 weeks , the rats were subjected to ganglionic blockade and 2 days later , an infusion of clonidine .
Diseases: "	"Sentence: After 2 weeks , the rats were subjected to ganglionic blockade and 2 days later , an infusion of clonidine .
Diseases:"
526	Lifetime captopril treatment significantly lowered mean arterial pressure in both groups .	O O O O O O O O O O O O	O B O O O O O O O O O O	[]	0	0	"Sentence: Lifetime captopril treatment significantly lowered mean arterial pressure in both groups .
Diseases: "	"Sentence: Lifetime captopril treatment significantly lowered mean arterial pressure in both groups .
Diseases:"
527	Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride - induced increase in MAP in both groups .	O O O O O O O O O O O O O O O O O O O O O O B I I O O O O	O O O O O O B O O O O O O O O O O O B I O O O O O O O O O	['increase in map']	1	4	"Sentence: Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride - induced increase in MAP in both groups .
Diseases: increase in map"	"Sentence: Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride - induced increase in MAP in both groups .
Diseases:"
528	Infusion of the central nervous system alpha2 - adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high ( compared with the basal ) sodium chloride diet .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O B I O O	[]	0	0	"Sentence: Infusion of the central nervous system alpha2 - adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high ( compared with the basal ) sodium chloride diet .
Diseases: "	"Sentence: Infusion of the central nervous system alpha2 - adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high ( compared with the basal ) sodium chloride diet .
Diseases:"
529	In both lifetime captopril - treated and control SHR , the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O B I O O	[]	0	0	"Sentence: In both lifetime captopril - treated and control SHR , the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet .
Diseases: "	"Sentence: In both lifetime captopril - treated and control SHR , the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet .
Diseases:"
530	Dose - related beneficial and adverse effects of dietary corticosterone on organophosphorus - induced delayed neuropathy in chickens .	O O O O O O O O O O O O O O O B O O O	O O O O O O O O O B O B O O O O O O O	['neuropathy']	1	3	"Sentence: Dose - related beneficial and adverse effects of dietary corticosterone on organophosphorus - induced delayed neuropathy in chickens .
Diseases: neuropathy"	"Sentence: Dose - related beneficial and adverse effects of dietary corticosterone on organophosphorus - induced delayed neuropathy in chickens .
Diseases:"
531	Tri - ortho - tolyl phosphate ( TOTP ) , 360 mg / kg , po , and 0 , 0' - diisopropyl phosphorofluoridate ( DFP ) , 1 mg / kg sc , were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B I I I I I O B O O O O O O O O O O B I I I I I O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: Tri - ortho - tolyl phosphate ( TOTP ) , 360 mg / kg , po , and 0 , 0' - diisopropyl phosphorofluoridate ( DFP ) , 1 mg / kg sc , were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone .
Diseases: "	"Sentence: Tri - ortho - tolyl phosphate ( TOTP ) , 360 mg / kg , po , and 0 , 0' - diisopropyl phosphorofluoridate ( DFP ) , 1 mg / kg sc , were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone .
Diseases:"
532	Supplemented diets were continued until clinical signs and lesions of delayed neuropathy appeared .	O O O O O O O O O O O B O O	O O O O O O O O O O O O O O	['neuropathy']	1	3	"Sentence: Supplemented diets were continued until clinical signs and lesions of delayed neuropathy appeared .
Diseases: neuropathy"	"Sentence: Supplemented diets were continued until clinical signs and lesions of delayed neuropathy appeared .
Diseases:"
533	Although low concentrations ( less than or equal to 50 ppm ) of corticosterone had beneficial effects on TOTP - induced neuropathy , greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O B O O O O O O O O O O O O O O O O O O B O B O	['neuropathy']	1	3	"Sentence: Although low concentrations ( less than or equal to 50 ppm ) of corticosterone had beneficial effects on TOTP - induced neuropathy , greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP .
Diseases: neuropathy"	"Sentence: Although low concentrations ( less than or equal to 50 ppm ) of corticosterone had beneficial effects on TOTP - induced neuropathy , greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP .
Diseases:"
534	Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20 % of values measured in chickens not given organophosphorous compounds .	B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O B O O O O O O O O O O O O B O O	['neurotoxic']	1	4	"Sentence: Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20 % of values measured in chickens not given organophosphorous compounds .
Diseases: neurotoxic"	"Sentence: Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20 % of values measured in chickens not given organophosphorous compounds .
Diseases:"
535	Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O B O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase .
Diseases: "	"Sentence: Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase .
Diseases:"
536	Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP .	B I I O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O B O	['degenerating myelinated fibers']	1	7	"Sentence: Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP .
Diseases: degenerating myelinated fibers"	"Sentence: Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP .
Diseases:"
537	In vivo characterization of a dual adenosine A2A / A1 receptor antagonist in animal models of Parkinson 's disease .	O O O O O O O O O O O O O O O O B I I O	O O O O O O B O O O O O O O O O O O O O	"[""parkinson 's disease""]"	1	5	"Sentence: In vivo characterization of a dual adenosine A2A / A1 receptor antagonist in animal models of Parkinson 's disease .
Diseases: parkinson 's disease"	"Sentence: In vivo characterization of a dual adenosine A2A / A1 receptor antagonist in animal models of Parkinson 's disease .
Diseases:"
538	The in vivo characterization of a dual adenosine A ( 2A ) / A ( 1 ) receptor antagonist in several animal models of Parkinson 's disease is described .	O O O O O O O O O O O O O O O O O O O O O O O O B I I O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	"[""parkinson 's disease""]"	1	5	"Sentence: The in vivo characterization of a dual adenosine A ( 2A ) / A ( 1 ) receptor antagonist in several animal models of Parkinson 's disease is described .
Diseases: parkinson 's disease"	"Sentence: The in vivo characterization of a dual adenosine A ( 2A ) / A ( 1 ) receptor antagonist in several animal models of Parkinson 's disease is described .
Diseases:"
539	Discovery and scale - up syntheses of compound 1 are described in detail , highlighting optimization steps that increased the overall yield of 1 from 10 . 0 % to 30 . 5 % .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Discovery and scale - up syntheses of compound 1 are described in detail , highlighting optimization steps that increased the overall yield of 1 from 10 . 0 % to 30 . 5 % .
Diseases: "	"Sentence: Discovery and scale - up syntheses of compound 1 are described in detail , highlighting optimization steps that increased the overall yield of 1 from 10 . 0 % to 30 . 5 % .
Diseases:"
540	Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ;	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ;
Diseases: "	"Sentence: Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ;
Diseases:"
541	A ( 1 ) K ( i )	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: A ( 1 ) K ( i )
Diseases: "	"Sentence: A ( 1 ) K ( i )
Diseases:"
542	= 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson 's disease including mouse and rat models of haloperidol - induced catalepsy , mouse model of reserpine - induced akinesia , rat 6 - hydroxydopamine ( 6 - OHDA ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .	O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O B O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O B O O O O O B I I O B I I O O O O O O O O O O B O O O O O O O O	"['catalepsy', 'akinesia', ""parkinson 's disease""]"	3	14	"Sentence: = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson 's disease including mouse and rat models of haloperidol - induced catalepsy , mouse model of reserpine - induced akinesia , rat 6 - hydroxydopamine ( 6 - OHDA ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .
Diseases: catalepsy, akinesia, parkinson 's disease"	"Sentence: = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson 's disease including mouse and rat models of haloperidol - induced catalepsy , mouse model of reserpine - induced akinesia , rat 6 - hydroxydopamine ( 6 - OHDA ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .
Diseases:"
543	An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha - 2b and ribavirin treatment .	O O O O O B I O O B I I O O O O O O O O O O O	O O O O O O O O O O O O O O B I I I I O B O O	['delusional parasitosis', 'chronic hepatitis c']	2	9	"Sentence: An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha - 2b and ribavirin treatment .
Diseases: delusional parasitosis, chronic hepatitis c"	"Sentence: An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha - 2b and ribavirin treatment .
Diseases:"
544	During treatment of chronic hepatitis C patients with interferon and ribavirin , a lot of side effects are described .	O O O B I I O O O O O O O O O O O O O O	O O O O O O O O B O B O O O O O O O O O	['chronic hepatitis c']	1	4	"Sentence: During treatment of chronic hepatitis C patients with interferon and ribavirin , a lot of side effects are described .
Diseases: chronic hepatitis c"	"Sentence: During treatment of chronic hepatitis C patients with interferon and ribavirin , a lot of side effects are described .
Diseases:"
545	Twenty - three percent to 44 % of patients develop depression .	O O O O O O O O O O B O	O O O O O O O O O O O O	['depression']	1	2	"Sentence: Twenty - three percent to 44 % of patients develop depression .
Diseases: depression"	"Sentence: Twenty - three percent to 44 % of patients develop depression .
Diseases:"
546	A minority of patients evolve to psychosis .	O O O O O O B O	O O O O O O O O	['psychosis']	1	2	"Sentence: A minority of patients evolve to psychosis .
Diseases: psychosis"	"Sentence: A minority of patients evolve to psychosis .
Diseases:"
547	To the best of our knowledge , no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature .	O O O O O O O O O O B I O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O O	['psychogenic parasitosis']	1	5	"Sentence: To the best of our knowledge , no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature .
Diseases: psychogenic parasitosis"	"Sentence: To the best of our knowledge , no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature .
Diseases:"
548	We present a 49 - year - old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha - 2b weekly and ribavirin .	O O O O O O O O O O O O B I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B I I I I O O B O	['delusional parasitosis']	1	5	"Sentence: We present a 49 - year - old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha - 2b weekly and ribavirin .
Diseases: delusional parasitosis"	"Sentence: We present a 49 - year - old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha - 2b weekly and ribavirin .
Diseases:"
549	She complained of seeing parasites and the larvae of fleas in her stools .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: She complained of seeing parasites and the larvae of fleas in her stools .
Diseases: "	"Sentence: She complained of seeing parasites and the larvae of fleas in her stools .
Diseases:"
550	This could not be confirmed by any technical examination .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: This could not be confirmed by any technical examination .
Diseases: "	"Sentence: This could not be confirmed by any technical examination .
Diseases:"
551	All the complaints disappeared after stopping pegylated interferon alpha - 2b and reappeared after restarting it .	O O O O O O O O O O O O O O O O O	O O O O O O B I I I I O O O O O O	[]	0	0	"Sentence: All the complaints disappeared after stopping pegylated interferon alpha - 2b and reappeared after restarting it .
Diseases: "	"Sentence: All the complaints disappeared after stopping pegylated interferon alpha - 2b and reappeared after restarting it .
Diseases:"
552	She had a complete sustained viral response .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: She had a complete sustained viral response .
Diseases: "	"Sentence: She had a complete sustained viral response .
Diseases:"
553	Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam .	O B I I O O O O O O O O O	O O O O O O O O O B O B O	['neuroleptic malignant syndrome']	1	7	"Sentence: Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam .
Diseases: neuroleptic malignant syndrome"	"Sentence: Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam .
Diseases:"
554	A 74 - year - old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia , loss of appetite , exhaustion , and agitation .	O O O O O O O O B I O O O O B O O O B O B I I O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['depressive symptoms', 'insomnia', 'agitation', 'psychiatric', 'loss of appetite']	5	13	"Sentence: A 74 - year - old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia , loss of appetite , exhaustion , and agitation .
Diseases: depressive symptoms, insomnia, agitation, psychiatric, loss of appetite"	"Sentence: A 74 - year - old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia , loss of appetite , exhaustion , and agitation .
Diseases:"
555	Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1 . 2 mg alprazolam .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O B O	[]	0	0	"Sentence: Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1 . 2 mg alprazolam .
Diseases: "	"Sentence: Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1 . 2 mg alprazolam .
Diseases:"
556	On the 10th day of paroxetine and alprazolam treatment , the patient exhibited marked psychomotor retardation , disorientation , and severe muscle rigidity with tremors .	O O O O O O O O O O O O O O B I O O O O O B I O B O	O O O O O B O B O O O O O O O O O O O O O O O O O O	['muscle rigidity', 'psychomotor retardation', 'tremors']	3	13	"Sentence: On the 10th day of paroxetine and alprazolam treatment , the patient exhibited marked psychomotor retardation , disorientation , and severe muscle rigidity with tremors .
Diseases: muscle rigidity, psychomotor retardation, tremors"	"Sentence: On the 10th day of paroxetine and alprazolam treatment , the patient exhibited marked psychomotor retardation , disorientation , and severe muscle rigidity with tremors .
Diseases:"
557	The patient had a fever ( 38 . 2 degrees C ) , fluctuating blood pressure ( between 165 / 90 and 130 / 70	O O O O B O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['fever']	1	2	"Sentence: The patient had a fever ( 38 . 2 degrees C ) , fluctuating blood pressure ( between 165 / 90 and 130 / 70
Diseases: fever"	"Sentence: The patient had a fever ( 38 . 2 degrees C ) , fluctuating blood pressure ( between 165 / 90 and 130 / 70
Diseases:"
558	mg	O	O	[]	0	0	"Sentence: mg
Diseases: "	"Sentence: mg
Diseases:"
559	mm Hg ) , and severe extrapyramidal symptoms .	O O O O O O B I O	O O O O O O O O O	['extrapyramidal symptoms']	1	6	"Sentence: mm Hg ) , and severe extrapyramidal symptoms .
Diseases: extrapyramidal symptoms"	"Sentence: mm Hg ) , and severe extrapyramidal symptoms .
Diseases:"
560	Laboratory tests showed an elevation of creatine phosphokinase ( 2218 IU / L ) , aspartate aminotransferase ( 134 IU / L ) , alanine aminotransferase ( 78 IU / L ) , and BUN ( 27 . 9 mg / ml ) levels .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O B O O O O O O O O B O O O O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: Laboratory tests showed an elevation of creatine phosphokinase ( 2218 IU / L ) , aspartate aminotransferase ( 134 IU / L ) , alanine aminotransferase ( 78 IU / L ) , and BUN ( 27 . 9 mg / ml ) levels .
Diseases: "	"Sentence: Laboratory tests showed an elevation of creatine phosphokinase ( 2218 IU / L ) , aspartate aminotransferase ( 134 IU / L ) , alanine aminotransferase ( 78 IU / L ) , and BUN ( 27 . 9 mg / ml ) levels .
Diseases:"
561	The patient received bromocriptine and diazepam to treat his symptoms .	O O O O O O O O O O O	O O O B O B O O O O O	[]	0	0	"Sentence: The patient received bromocriptine and diazepam to treat his symptoms .
Diseases: "	"Sentence: The patient received bromocriptine and diazepam to treat his symptoms .
Diseases:"
562	7 days later , the fever disappeared and the patient 's serum CPK levels were normalized ( 175 IU / L ) .	O O O O O B O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['fever']	1	2	"Sentence: 7 days later , the fever disappeared and the patient 's serum CPK levels were normalized ( 175 IU / L ) .
Diseases: fever"	"Sentence: 7 days later , the fever disappeared and the patient 's serum CPK levels were normalized ( 175 IU / L ) .
Diseases:"
563	This patient presented with symptoms of neuroleptic malignant syndrome ( NMS ) , thus demonstrating that NMS - like symptoms can occur after combined paroxetine and alprazolam treatment .	O O O O O O B I I O B O O O O O B O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B O B O O	['neuroleptic malignant syndrome', 'nms']	2	10	"Sentence: This patient presented with symptoms of neuroleptic malignant syndrome ( NMS ) , thus demonstrating that NMS - like symptoms can occur after combined paroxetine and alprazolam treatment .
Diseases: neuroleptic malignant syndrome, nms"	"Sentence: This patient presented with symptoms of neuroleptic malignant syndrome ( NMS ) , thus demonstrating that NMS - like symptoms can occur after combined paroxetine and alprazolam treatment .
Diseases:"
564	The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case , indicating a probable relationship between the patient 's NMS - like adverse symptoms and the combined treatment used in this case .	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nms']	1	2	"Sentence: The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case , indicating a probable relationship between the patient 's NMS - like adverse symptoms and the combined treatment used in this case .
Diseases: nms"	"Sentence: The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case , indicating a probable relationship between the patient 's NMS - like adverse symptoms and the combined treatment used in this case .
Diseases:"
565	The involvement of physiologic and environmental aspects specific to this patient was suspected .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: The involvement of physiologic and environmental aspects specific to this patient was suspected .
Diseases: "	"Sentence: The involvement of physiologic and environmental aspects specific to this patient was suspected .
Diseases:"
566	Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration , agitation , malnutrition , and exhaustion .	O O O O B O O O O O B O O O O O B O B O B O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['nms', 'depressive', 'dehydration', 'agitation', 'malnutrition']	5	10	"Sentence: Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration , agitation , malnutrition , and exhaustion .
Diseases: nms, depressive, dehydration, agitation, malnutrition"	"Sentence: Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration , agitation , malnutrition , and exhaustion .
Diseases:"
567	Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from depression .	O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O	['depression']	1	2	"Sentence: Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from depression .
Diseases: depression"	"Sentence: Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from depression .
Diseases:"
568	Pilocarpine seizures cause age - dependent impairment in auditory location discrimination .	O B O O O O B I I I I O	B O O O O O O O O O O O	['seizures', 'impairment in auditory location discrimination']	2	9	"Sentence: Pilocarpine seizures cause age - dependent impairment in auditory location discrimination .
Diseases: seizures, impairment in auditory location discrimination"	"Sentence: Pilocarpine seizures cause age - dependent impairment in auditory location discrimination .
Diseases:"
569	Children who have status epilepticus have continuous or rapidly repeating seizures that may be life - threatening and may cause life - long changes in brain and behavior .	O O O B I O O O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['status epilepticus', 'seizures']	2	6	"Sentence: Children who have status epilepticus have continuous or rapidly repeating seizures that may be life - threatening and may cause life - long changes in brain and behavior .
Diseases: status epilepticus, seizures"	"Sentence: Children who have status epilepticus have continuous or rapidly repeating seizures that may be life - threatening and may cause life - long changes in brain and behavior .
Diseases:"
570	The extent to which status epilepticus causes deficits in auditory discrimination is unknown .	O O O O B I O B I I I O O O	O O O O O O O O O O O O O O	['status epilepticus', 'deficits in auditory discrimination']	2	9	"Sentence: The extent to which status epilepticus causes deficits in auditory discrimination is unknown .
Diseases: status epilepticus, deficits in auditory discrimination"	"Sentence: The extent to which status epilepticus causes deficits in auditory discrimination is unknown .
Diseases:"
571	A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of status epilepticus .	O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O	['status epilepticus']	1	4	"Sentence: A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of status epilepticus .
Diseases: status epilepticus"	"Sentence: A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of status epilepticus .
Diseases:"
572	Male Sprague - Dawley rats were injected with saline on postnatal day ( P ) 20 , or a convulsant dose of pilocarpine on P20 or P45 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O B O O O O O	[]	0	0	"Sentence: Male Sprague - Dawley rats were injected with saline on postnatal day ( P ) 20 , or a convulsant dose of pilocarpine on P20 or P45 .
Diseases: "	"Sentence: Male Sprague - Dawley rats were injected with saline on postnatal day ( P ) 20 , or a convulsant dose of pilocarpine on P20 or P45 .
Diseases:"
573	Pilocarpine on either day induced status epilepticus ; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures , whereas P20 rats had no cell loss or spontaneous seizures .	O O O O O B I O B I O O O O O O O O O B O O O O O O O O O O B O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['status epilepticus', 'seizures']	2	6	"Sentence: Pilocarpine on either day induced status epilepticus ; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures , whereas P20 rats had no cell loss or spontaneous seizures .
Diseases: status epilepticus, seizures"	"Sentence: Pilocarpine on either day induced status epilepticus ; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures , whereas P20 rats had no cell loss or spontaneous seizures .
Diseases:"
574	Mature rats were trained with sound - source location and sound - silence discriminations .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Mature rats were trained with sound - source location and sound - silence discriminations .
Diseases: "	"Sentence: Mature rats were trained with sound - source location and sound - silence discriminations .
Diseases:"
575	Control ( saline P20 ) rats acquired both discriminations immediately .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: Control ( saline P20 ) rats acquired both discriminations immediately .
Diseases: "	"Sentence: Control ( saline P20 ) rats acquired both discriminations immediately .
Diseases:"
576	In status epilepticus ( P20 ) rats , acquisition of the sound - source location discrimination was moderately impaired .	O B I O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	['status epilepticus']	1	4	"Sentence: In status epilepticus ( P20 ) rats , acquisition of the sound - source location discrimination was moderately impaired .
Diseases: status epilepticus"	"Sentence: In status epilepticus ( P20 ) rats , acquisition of the sound - source location discrimination was moderately impaired .
Diseases:"
577	Status epilepticus ( P45 ) rats failed to acquire either sound - source location or sound - silence discriminations .	B I O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	['status epilepticus']	1	4	"Sentence: Status epilepticus ( P45 ) rats failed to acquire either sound - source location or sound - silence discriminations .
Diseases: status epilepticus"	"Sentence: Status epilepticus ( P45 ) rats failed to acquire either sound - source location or sound - silence discriminations .
Diseases:"
578	Status epilepticus in rat causes an age - dependent , long - term impairment in auditory discrimination .	B I O O O O O O O O O O O B I I I O	O O O O O O O O O O O O O O O O O O	['impairment in auditory discrimination', 'status epilepticus']	2	11	"Sentence: Status epilepticus in rat causes an age - dependent , long - term impairment in auditory discrimination .
Diseases: impairment in auditory discrimination, status epilepticus"	"Sentence: Status epilepticus in rat causes an age - dependent , long - term impairment in auditory discrimination .
Diseases:"
579	This impairment may explain one cause of impaired auditory location discrimination in humans .	O O O O O O O B I I I O O O	O O O O O O O O O O O O O O	['impaired auditory location discrimination']	1	6	"Sentence: This impairment may explain one cause of impaired auditory location discrimination in humans .
Diseases: impaired auditory location discrimination"	"Sentence: This impairment may explain one cause of impaired auditory location discrimination in humans .
Diseases:"
580	Cardiovascular risk with cyclooxygenase inhibitors : general problem with substance specific differences ?	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Cardiovascular risk with cyclooxygenase inhibitors : general problem with substance specific differences ?
Diseases: "	"Sentence: Cardiovascular risk with cyclooxygenase inhibitors : general problem with substance specific differences ?
Diseases:"
581	Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction , stroke , hypertension and heart failure during treatment with cyclooxygenase inhibitors .	O O O O O O O O O O O O B I O B O B O B I O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['stroke', 'heart failure', 'hypertension', 'myocardial infarction']	4	13	"Sentence: Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction , stroke , hypertension and heart failure during treatment with cyclooxygenase inhibitors .
Diseases: stroke, heart failure, hypertension, myocardial infarction"	"Sentence: Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction , stroke , hypertension and heart failure during treatment with cyclooxygenase inhibitors .
Diseases:"
582	Adverse cardiovascular effects occurred mainly , but not exclusively , in patients with concomitant risk factors .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Adverse cardiovascular effects occurred mainly , but not exclusively , in patients with concomitant risk factors .
Diseases: "	"Sentence: Adverse cardiovascular effects occurred mainly , but not exclusively , in patients with concomitant risk factors .
Diseases:"
583	Cyclooxygenase inhibitors cause complex changes in renal , vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cyclooxygenase inhibitors cause complex changes in renal , vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention .
Diseases: "	"Sentence: Cyclooxygenase inhibitors cause complex changes in renal , vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention .
Diseases:"
584	The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time .
Diseases: "	"Sentence: The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time .
Diseases:"
585	A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance - specific differences , which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin - independent effects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance - specific differences , which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin - independent effects .
Diseases: "	"Sentence: A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance - specific differences , which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin - independent effects .
Diseases:"
586	Diagnostic markers such as N - terminal pro brain natriuretic peptide ( NT - proBNP ) or high - sensitive C - reactive protein might help in the early identification of patients at risk , thus avoiding the occurrence of serious cardiovascular toxicity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cardiovascular toxicity']	1	3	"Sentence: Diagnostic markers such as N - terminal pro brain natriuretic peptide ( NT - proBNP ) or high - sensitive C - reactive protein might help in the early identification of patients at risk , thus avoiding the occurrence of serious cardiovascular toxicity .
Diseases: cardiovascular toxicity"	"Sentence: Diagnostic markers such as N - terminal pro brain natriuretic peptide ( NT - proBNP ) or high - sensitive C - reactive protein might help in the early identification of patients at risk , thus avoiding the occurrence of serious cardiovascular toxicity .
Diseases:"
587	Predictors of decreased renal function in patients with heart failure during angiotensin - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD ) BACKGROUND :	O O B I I O O O B I O O O O O O O O O O O O O B I I O O O O O	O O O O O O O O O O O B I I I I O O O O O O O O O O O O O O O	['heart failure', 'left ventricular dysfunction', 'decreased renal function']	3	11	"Sentence: Predictors of decreased renal function in patients with heart failure during angiotensin - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD ) BACKGROUND :
Diseases: heart failure, left ventricular dysfunction, decreased renal function"	"Sentence: Predictors of decreased renal function in patients with heart failure during angiotensin - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD ) BACKGROUND :
Diseases:"
588	Although angiotensin - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( CHF ) , it may also cause decreased renal function .	O O O O O O O O O O O O O B I I O B O O O O O O B I I O	O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['chf', 'congestive heart failure', 'decreased renal function']	3	11	"Sentence: Although angiotensin - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( CHF ) , it may also cause decreased renal function .
Diseases: chf, congestive heart failure, decreased renal function"	"Sentence: Although angiotensin - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( CHF ) , it may also cause decreased renal function .
Diseases:"
589	Little information is available to predict which patients are at highest risk for this complication .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Little information is available to predict which patients are at highest risk for this complication .
Diseases: "	"Sentence: Little information is available to predict which patients are at highest risk for this complication .
Diseases:"
590	To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin - converting enzyme inhibitor therapy .	O O O O O O B I I I O O O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O B I O O I O O	['chf', 'reduction in renal function']	2	7	"Sentence: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin - converting enzyme inhibitor therapy .
Diseases: chf, reduction in renal function"	"Sentence: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin - converting enzyme inhibitor therapy .
Diseases:"
591	METHOD :	O O	O O	[]	0	0	"Sentence: METHOD :
Diseases: "	"Sentence: METHOD :
Diseases:"
592	We analyzed data from the Studies of Left Ventricular Dysfunction ( SOLVD ) , a randomized , double - blind , placebo - controlled trial of enalapril for the treatment of CHF .	O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O	['chf', 'left ventricular dysfunction']	2	7	"Sentence: We analyzed data from the Studies of Left Ventricular Dysfunction ( SOLVD ) , a randomized , double - blind , placebo - controlled trial of enalapril for the treatment of CHF .
Diseases: chf, left ventricular dysfunction"	"Sentence: We analyzed data from the Studies of Left Ventricular Dysfunction ( SOLVD ) , a randomized , double - blind , placebo - controlled trial of enalapril for the treatment of CHF .
Diseases:"
593	There were 3379 patients randomly assigned to enalapril with a median follow - up of 974 days and 3379 patients randomly assigned to placebo with a mean follow - up of 967 days .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There were 3379 patients randomly assigned to enalapril with a median follow - up of 974 days and 3379 patients randomly assigned to placebo with a mean follow - up of 967 days .
Diseases: "	"Sentence: There were 3379 patients randomly assigned to enalapril with a median follow - up of 974 days and 3379 patients randomly assigned to placebo with a mean follow - up of 967 days .
Diseases:"
594	Decreased renal function was defined as a rise in serum creatinine > / = 0 . 5	B I I O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O	['decreased renal function']	1	5	"Sentence: Decreased renal function was defined as a rise in serum creatinine > / = 0 . 5
Diseases: decreased renal function"	"Sentence: Decreased renal function was defined as a rise in serum creatinine > / = 0 . 5
Diseases:"
595	mg / dL ( 44 micromol / L ) from baseline .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: mg / dL ( 44 micromol / L ) from baseline .
Diseases: "	"Sentence: mg / dL ( 44 micromol / L ) from baseline .
Diseases:"
596	We used time - to - event analysis to identify potential predictors of decrease in renal function including age , baseline ejection fraction , baseline creatinine , low systolic blood pressure ( < 100 mm Hg ) , history of hypertension , diabetes , and use of antiplatelet , diuretic , and beta - blocker therapy .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['diabetes', 'hypertension']	2	4	"Sentence: We used time - to - event analysis to identify potential predictors of decrease in renal function including age , baseline ejection fraction , baseline creatinine , low systolic blood pressure ( < 100 mm Hg ) , history of hypertension , diabetes , and use of antiplatelet , diuretic , and beta - blocker therapy .
Diseases: diabetes, hypertension"	"Sentence: We used time - to - event analysis to identify potential predictors of decrease in renal function including age , baseline ejection fraction , baseline creatinine , low systolic blood pressure ( < 100 mm Hg ) , history of hypertension , diabetes , and use of antiplatelet , diuretic , and beta - blocker therapy .
Diseases:"
597	Patients randomly assigned to enalapril had a 33 % greater likelihood of decreased renal function than controls ( P = . 003 ) .	O O O O O O O O O O O O B I I O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O	['decreased renal function']	1	5	"Sentence: Patients randomly assigned to enalapril had a 33 % greater likelihood of decreased renal function than controls ( P = . 003 ) .
Diseases: decreased renal function"	"Sentence: Patients randomly assigned to enalapril had a 33 % greater likelihood of decreased renal function than controls ( P = . 003 ) .
Diseases:"
598	By multivariate analysis , in both the placebo and enalapril groups older age , diuretic therapy , and diabetes were associated with decreased renal function , whereas beta - blocker therapy and higher ejection fraction were renoprotective .	O O O O O O O O O O O O O O O O O O B O O O B I I O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['decreased renal function', 'diabetes']	2	7	"Sentence: By multivariate analysis , in both the placebo and enalapril groups older age , diuretic therapy , and diabetes were associated with decreased renal function , whereas beta - blocker therapy and higher ejection fraction were renoprotective .
Diseases: decreased renal function, diabetes"	"Sentence: By multivariate analysis , in both the placebo and enalapril groups older age , diuretic therapy , and diabetes were associated with decreased renal function , whereas beta - blocker therapy and higher ejection fraction were renoprotective .
Diseases:"
599	Older age was associated with a greater risk of developing decreased renal function in both groups , but significantly more so in the enalapril group ( enalapril : risk ratio [ RR ] 1 . 42 per 10 years , 95 % confidence interval [ CI ] 1 . 32 - 1 . 52 with enalapril ; placebo : RR 1 . 18 , 95 % CI 1 . 12 - 1 . 25 ) .	O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['decreased renal function']	1	5	"Sentence: Older age was associated with a greater risk of developing decreased renal function in both groups , but significantly more so in the enalapril group ( enalapril : risk ratio [ RR ] 1 . 42 per 10 years , 95 % confidence interval [ CI ] 1 . 32 - 1 . 52 with enalapril ; placebo : RR 1 . 18 , 95 % CI 1 . 12 - 1 . 25 ) .
Diseases: decreased renal function"	"Sentence: Older age was associated with a greater risk of developing decreased renal function in both groups , but significantly more so in the enalapril group ( enalapril : risk ratio [ RR ] 1 . 42 per 10 years , 95 % confidence interval [ CI ] 1 . 32 - 1 . 52 with enalapril ; placebo : RR 1 . 18 , 95 % CI 1 . 12 - 1 . 25 ) .
Diseases:"
600	Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group ( RR 1 . 89 , 95 % CI 1 . 70 - 2 . 08 ) than in the placebo group ( RR 1 . 35 , 95 % CI 1 . 09 - 1 . 66 ) .	O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['decreased renal function']	1	5	"Sentence: Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group ( RR 1 . 89 , 95 % CI 1 . 70 - 2 . 08 ) than in the placebo group ( RR 1 . 35 , 95 % CI 1 . 09 - 1 . 66 ) .
Diseases: decreased renal function"	"Sentence: Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group ( RR 1 . 89 , 95 % CI 1 . 70 - 2 . 08 ) than in the placebo group ( RR 1 . 35 , 95 % CI 1 . 09 - 1 . 66 ) .
Diseases:"
601	Conversely , enalapril had a relative renoprotective effect ( RR 1 . 33 , 95 % CI 1 . 13 - 1 . 53 ) compared with placebo ( RR 1 . 96 , 95 % CI 1 . 57 - 2 . 44 ) in patients with diabetes .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['diabetes']	1	2	"Sentence: Conversely , enalapril had a relative renoprotective effect ( RR 1 . 33 , 95 % CI 1 . 13 - 1 . 53 ) compared with placebo ( RR 1 . 96 , 95 % CI 1 . 57 - 2 . 44 ) in patients with diabetes .
Diseases: diabetes"	"Sentence: Conversely , enalapril had a relative renoprotective effect ( RR 1 . 33 , 95 % CI 1 . 13 - 1 . 53 ) compared with placebo ( RR 1 . 96 , 95 % CI 1 . 57 - 2 . 44 ) in patients with diabetes .
Diseases:"
602	A lower risk of renal impairment was seen in both groups with beta - blocker therapy ( RR 0 . 70 , 95 % CI 0 . 57 - 0 . 85 ) and higher baseline ejection fraction ( RR 0 . 93 per 5 % increment , 95 % CI 0 . 91 - 0 .	O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['renal impairment']	1	3	"Sentence: A lower risk of renal impairment was seen in both groups with beta - blocker therapy ( RR 0 . 70 , 95 % CI 0 . 57 - 0 . 85 ) and higher baseline ejection fraction ( RR 0 . 93 per 5 % increment , 95 % CI 0 . 91 - 0 .
Diseases: renal impairment"	"Sentence: A lower risk of renal impairment was seen in both groups with beta - blocker therapy ( RR 0 . 70 , 95 % CI 0 . 57 - 0 . 85 ) and higher baseline ejection fraction ( RR 0 . 93 per 5 % increment , 95 % CI 0 . 91 - 0 .
Diseases:"
603	96 ) .	O O O	O O O	[]	0	0	"Sentence: 96 ) .
Diseases: "	"Sentence: 96 ) .
Diseases:"
604	CONCLUSIONS : Enalapril use caused a 33 % increase in the risk of decreased renal function in patients with CHF .	O O O O O O O O O O O O O B I I O O O B O	O O B O O O O O O O O O O O O O O O O O O	['chf', 'decreased renal function']	2	6	"Sentence: CONCLUSIONS : Enalapril use caused a 33 % increase in the risk of decreased renal function in patients with CHF .
Diseases: chf, decreased renal function"	"Sentence: CONCLUSIONS : Enalapril use caused a 33 % increase in the risk of decreased renal function in patients with CHF .
Diseases:"
605	Diuretic use and advanced age increased this risk .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Diuretic use and advanced age increased this risk .
Diseases: "	"Sentence: Diuretic use and advanced age increased this risk .
Diseases:"
606	Diabetes was associated with an increased risk of renal impairment in all patients with CHF , but this risk was reduced in the enalapril group compared with the placebo group .	B O O O O O O O B I O O O O B O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['chf', 'renal impairment', 'diabetes']	3	7	"Sentence: Diabetes was associated with an increased risk of renal impairment in all patients with CHF , but this risk was reduced in the enalapril group compared with the placebo group .
Diseases: chf, renal impairment, diabetes"	"Sentence: Diabetes was associated with an increased risk of renal impairment in all patients with CHF , but this risk was reduced in the enalapril group compared with the placebo group .
Diseases:"
607	beta - Blocker therapy and higher ejection fraction were renoprotective in all patients regardless of therapy .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: beta - Blocker therapy and higher ejection fraction were renoprotective in all patients regardless of therapy .
Diseases: "	"Sentence: beta - Blocker therapy and higher ejection fraction were renoprotective in all patients regardless of therapy .
Diseases:"
608	Pemoline induced acute choreoathetosis : case report and review of the literature .	O O O B O O O O O O O O O	B O O O O O O O O O O O O	['choreoathetosis']	1	5	"Sentence: Pemoline induced acute choreoathetosis : case report and review of the literature .
Diseases: choreoathetosis"	"Sentence: Pemoline induced acute choreoathetosis : case report and review of the literature .
Diseases:"
609	Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder .	O O O O O O O O O O O O O O O O O B I I O	B O O B O O O O O O B O O O O O O O O O O	['attention deficit disorder']	1	4	"Sentence: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder .
Diseases: attention deficit disorder"	"Sentence: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder .
Diseases:"
610	Pemoline has not been commonly associated in the literature as a cause of acute movement disorders .	O O O O O O O O O O O O O O B I O	B O O O O O O O O O O O O O O O O	['movement disorders']	1	3	"Sentence: Pemoline has not been commonly associated in the literature as a cause of acute movement disorders .
Diseases: movement disorders"	"Sentence: Pemoline has not been commonly associated in the literature as a cause of acute movement disorders .
Diseases:"
611	The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis .	O O O O O O O O O O O O O B O	O O O O O O O O O B O O O O O	['choreoathetosis']	1	5	"Sentence: The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis .
Diseases: choreoathetosis"	"Sentence: The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis .
Diseases:"
612	CASE REPORT :	O O O	O O O	[]	0	0	"Sentence: CASE REPORT :
Diseases: "	"Sentence: CASE REPORT :
Diseases:"
613	Two , 3 - year - old male , identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	[]	0	0	"Sentence: Two , 3 - year - old male , identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets .
Diseases: "	"Sentence: Two , 3 - year - old male , identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets .
Diseases:"
614	The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success .	O O O O O O O O B I I O O O O O O O	O O O O O O O O O O O O O O B O O O	['attention deficit disorder']	1	4	"Sentence: The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success .
Diseases: attention deficit disorder"	"Sentence: The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success .
Diseases:"
615	This was their first day of pemoline therapy .	O O O O O O O O O	O O O O O O B O O	[]	0	0	"Sentence: This was their first day of pemoline therapy .
Diseases: "	"Sentence: This was their first day of pemoline therapy .
Diseases:"
616	The choreoathetoid movements began 45 min to 1 h after ingestion .	O B O O O O O O O O O O	O O O O O O O O O O O O	['choreoathetoid']	1	6	"Sentence: The choreoathetoid movements began 45 min to 1 h after ingestion .
Diseases: choreoathetoid"	"Sentence: The choreoathetoid movements began 45 min to 1 h after ingestion .
Diseases:"
617	The children gave no history of prior movement disorders and there was no family history of movement disorders .	O O O O O O O B I O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O	['movement disorders']	1	3	"Sentence: The children gave no history of prior movement disorders and there was no family history of movement disorders .
Diseases: movement disorders"	"Sentence: The children gave no history of prior movement disorders and there was no family history of movement disorders .
Diseases:"
618	The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements .	O O O O O O O O O O O O O O O O O B O O	O O O O O O O O O O B O O O O O O O O O	['choreoathetoid']	1	6	"Sentence: The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements .
Diseases: choreoathetoid"	"Sentence: The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements .
Diseases:"
619	Despite treatment , the children continued to have choreoathetosis for approximately 24 hours .	O O O O O O O O B O O O O O	O O O O O O O O O O O O O O	['choreoathetosis']	1	5	"Sentence: Despite treatment , the children continued to have choreoathetosis for approximately 24 hours .
Diseases: choreoathetosis"	"Sentence: Despite treatment , the children continued to have choreoathetosis for approximately 24 hours .
Diseases:"
620	Forty - eight hours after admission , the children appeared to be at their baseline and were discharged home .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Forty - eight hours after admission , the children appeared to be at their baseline and were discharged home .
Diseases: "	"Sentence: Forty - eight hours after admission , the children appeared to be at their baseline and were discharged home .
Diseases:"
621	Pemoline associated movement disorder has been rarely reported in the acute toxicology literature .	O O B I O O O O O O O O O O	B O O O O O O O O O O O O O	['movement disorder']	1	3	"Sentence: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature .
Diseases: movement disorder"	"Sentence: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature .
Diseases:"
622	The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose .	O O O B O O O O O O O O O B O	O O O O O O O O O O O O B O O	['choreoathetoid', 'overdose']	2	8	"Sentence: The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose .
Diseases: choreoathetoid, overdose"	"Sentence: The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose .
Diseases:"
623	Continuous subcutaneous administration of mesna to prevent ifosfamide - induced hemorrhagic cystitis .	O O O O O O O O O O B I O	O O O O B O O B O O O O O	['hemorrhagic cystitis']	1	7	"Sentence: Continuous subcutaneous administration of mesna to prevent ifosfamide - induced hemorrhagic cystitis .
Diseases: hemorrhagic cystitis"	"Sentence: Continuous subcutaneous administration of mesna to prevent ifosfamide - induced hemorrhagic cystitis .
Diseases:"
624	Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent .	B I O O O O B O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O B O O O O O O	['hemorrhagic cystitis', 'toxicity']	2	9	"Sentence: Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent .
Diseases: hemorrhagic cystitis, toxicity"	"Sentence: Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent .
Diseases:"
625	Mesna is generally administered by the intravenous route , although experience with oral delivery of the drug has increased .	O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Mesna is generally administered by the intravenous route , although experience with oral delivery of the drug has increased .
Diseases: "	"Sentence: Mesna is generally administered by the intravenous route , although experience with oral delivery of the drug has increased .
Diseases:"
626	The continuous subcutaneous administration of mesna has the advantage of not requiring intravenous access .	O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O	[]	0	0	"Sentence: The continuous subcutaneous administration of mesna has the advantage of not requiring intravenous access .
Diseases: "	"Sentence: The continuous subcutaneous administration of mesna has the advantage of not requiring intravenous access .
Diseases:"
627	In addition , subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations , such as in a patient taking oral mesna who experiences severe ifosfamide - induced emesis and is unable to absorb the drug .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O B O O O B O O O O O O O O O O O	['emesis']	1	2	"Sentence: In addition , subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations , such as in a patient taking oral mesna who experiences severe ifosfamide - induced emesis and is unable to absorb the drug .
Diseases: emesis"	"Sentence: In addition , subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations , such as in a patient taking oral mesna who experiences severe ifosfamide - induced emesis and is unable to absorb the drug .
Diseases:"
628	Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe , practical , and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe , practical , and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting .
Diseases: "	"Sentence: Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe , practical , and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting .
Diseases:"
629	Modification of drug action by hyperammonemia .	O O O O O B O	O O O O O O O	['hyperammonemia']	1	4	"Sentence: Modification of drug action by hyperammonemia .
Diseases: hyperammonemia"	"Sentence: Modification of drug action by hyperammonemia .
Diseases:"
630	Pretreatment with ammonium acetate ( NH4Ac ) ( 6 mmol / kg s . c . ) approximately doubled the time morphine - treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam , but NH4Ac treatment alone had no effect .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	O O B I O B O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O B O O B O O O O O O	['incoordination']	1	3	"Sentence: Pretreatment with ammonium acetate ( NH4Ac ) ( 6 mmol / kg s . c . ) approximately doubled the time morphine - treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam , but NH4Ac treatment alone had no effect .
Diseases: incoordination"	"Sentence: Pretreatment with ammonium acetate ( NH4Ac ) ( 6 mmol / kg s . c . ) approximately doubled the time morphine - treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam , but NH4Ac treatment alone had no effect .
Diseases:"
631	Thus , hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease .	O O B O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hyperammonemia', 'liver disease']	2	7	"Sentence: Thus , hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease .
Diseases: hyperammonemia, liver disease"	"Sentence: Thus , hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease .
Diseases:"
632	Experiments in vitro showed that acetylcholine - induced catecholamine release from bovine adrenal medulla is depressed as much as 50 % by 0 . 3 mM	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Experiments in vitro showed that acetylcholine - induced catecholamine release from bovine adrenal medulla is depressed as much as 50 % by 0 . 3 mM
Diseases: "	"Sentence: Experiments in vitro showed that acetylcholine - induced catecholamine release from bovine adrenal medulla is depressed as much as 50 % by 0 . 3 mM
Diseases:"
633	NH4Ac and KCl - induced contractions of guinea - pig ileum were inhibited 20 % by 5 mM NH4Ac .	O O O O O O O O O O O O O O O O O O O O	B O B O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: NH4Ac and KCl - induced contractions of guinea - pig ileum were inhibited 20 % by 5 mM NH4Ac .
Diseases: "	"Sentence: NH4Ac and KCl - induced contractions of guinea - pig ileum were inhibited 20 % by 5 mM NH4Ac .
Diseases:"
634	Addition of excess calcium reversed the depression in both tissues , but calcium - independent catecholamine release by acetaldehyde was not blocked by NH4Ac .	O O O O O O B O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O B O O B O O B O O O O B O	['depression']	1	2	"Sentence: Addition of excess calcium reversed the depression in both tissues , but calcium - independent catecholamine release by acetaldehyde was not blocked by NH4Ac .
Diseases: depression"	"Sentence: Addition of excess calcium reversed the depression in both tissues , but calcium - independent catecholamine release by acetaldehyde was not blocked by NH4Ac .
Diseases:"
635	These results suggested that ammonia blocks calcium channels .	O O O O O O O O O	O O O O B O B O O	[]	0	0	"Sentence: These results suggested that ammonia blocks calcium channels .
Diseases: "	"Sentence: These results suggested that ammonia blocks calcium channels .
Diseases:"
636	Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept .	O O O O O O O O O O O O O O O O	O O O O O B O O B O O B O O O O	[]	0	0	"Sentence: Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept .
Diseases: "	"Sentence: Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept .
Diseases:"
637	Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine analgesia - and diazepam - induced muscular incoordination and antagonized amphetamine - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of metrazol .	O O O O O O O O O O O O O O O O O B O O O O O O B O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O B O O B O O O B O O O O O O B O O O O O O O B O B O O O O O B O	['incoordination', 'analgesia']	2	6	"Sentence: Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine analgesia - and diazepam - induced muscular incoordination and antagonized amphetamine - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of metrazol .
Diseases: incoordination, analgesia"	"Sentence: Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine analgesia - and diazepam - induced muscular incoordination and antagonized amphetamine - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of metrazol .
Diseases:"
638	The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics .	O O O O B O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O	['hyperammonemia']	1	4	"Sentence: The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics .
Diseases: hyperammonemia"	"Sentence: The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics .
Diseases:"
639	Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography : a prospective study .	O O B O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	['nephropathy']	1	4	"Sentence: Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography : a prospective study .
Diseases: nephropathy"	"Sentence: Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography : a prospective study .
Diseases:"
640	Despite increasing reports on nonionic contrast media - induced nephropathy ( CIN ) in hospitalized adult patients during cardiac procedures , the studies in pediatrics are limited , with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography .	O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cin', 'nephropathy']	2	6	"Sentence: Despite increasing reports on nonionic contrast media - induced nephropathy ( CIN ) in hospitalized adult patients during cardiac procedures , the studies in pediatrics are limited , with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography .
Diseases: cin, nephropathy"	"Sentence: Despite increasing reports on nonionic contrast media - induced nephropathy ( CIN ) in hospitalized adult patients during cardiac procedures , the studies in pediatrics are limited , with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography .
Diseases:"
641	This prospective study determined the incidence of CIN for two nonionic contrast media ( CM ) , iopromide and iohexol , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cin', 'cyanosis']	2	4	"Sentence: This prospective study determined the incidence of CIN for two nonionic contrast media ( CM ) , iopromide and iohexol , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis .
Diseases: cin, cyanosis"	"Sentence: This prospective study determined the incidence of CIN for two nonionic contrast media ( CM ) , iopromide and iohexol , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis .
Diseases:"
642	The 80 patients in the study consecutively received either iopromide ( group A , n = 40 ) or iohexol ( group B , n = 40 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: The 80 patients in the study consecutively received either iopromide ( group A , n = 40 ) or iohexol ( group B , n = 40 ) .
Diseases: "	"Sentence: The 80 patients in the study consecutively received either iopromide ( group A , n = 40 ) or iohexol ( group B , n = 40 ) .
Diseases:"
643	Serum sodium ( Na ) , potassium ( K ) , and creatinine ( Cr ) were measured 24 h before angiography as baseline values , then measured again at 12 - , 24 - , and 48 - h intervals after CM use .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O B O O B O B O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Serum sodium ( Na ) , potassium ( K ) , and creatinine ( Cr ) were measured 24 h before angiography as baseline values , then measured again at 12 - , 24 - , and 48 - h intervals after CM use .
Diseases: "	"Sentence: Serum sodium ( Na ) , potassium ( K ) , and creatinine ( Cr ) were measured 24 h before angiography as baseline values , then measured again at 12 - , 24 - , and 48 - h intervals after CM use .
Diseases:"
644	Urine samples for Na and Cr also were checked at the same intervals .	O O O O O O O O O O O O O O	O O O B O B O O O O O O O O	[]	0	0	"Sentence: Urine samples for Na and Cr also were checked at the same intervals .
Diseases: "	"Sentence: Urine samples for Na and Cr also were checked at the same intervals .
Diseases:"
645	Risk of renal failure , Injury to the kidney , Failure of kidney function , Loss of kidney function , and End - stage renal damage ( RIFLE criteria ) were used to define CIN and its incidence in the study population .	O O B I O B I I I O B I I I O B I I I O O O O O B I O O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['renal damage', 'cin', 'failure of kidney function', 'injury to the kidney', 'loss of kidney function', 'renal failure']	6	24	"Sentence: Risk of renal failure , Injury to the kidney , Failure of kidney function , Loss of kidney function , and End - stage renal damage ( RIFLE criteria ) were used to define CIN and its incidence in the study population .
Diseases: renal damage, cin, failure of kidney function, injury to the kidney, loss of kidney function, renal failure"	"Sentence: Risk of renal failure , Injury to the kidney , Failure of kidney function , Loss of kidney function , and End - stage renal damage ( RIFLE criteria ) were used to define CIN and its incidence in the study population .
Diseases:"
646	Accordingly , among the 15 CIN patients ( 18 . 75 % ) , 7 . 5 % of the patients in group A had increased risk and 3 . 75 % had renal injury , whereas 5 % of group B had increased risk and 2 . 5 % had renal injury .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['renal injury', 'cin']	2	6	"Sentence: Accordingly , among the 15 CIN patients ( 18 . 75 % ) , 7 . 5 % of the patients in group A had increased risk and 3 . 75 % had renal injury , whereas 5 % of group B had increased risk and 2 . 5 % had renal injury .
Diseases: renal injury, cin"	"Sentence: Accordingly , among the 15 CIN patients ( 18 . 75 % ) , 7 . 5 % of the patients in group A had increased risk and 3 . 75 % had renal injury , whereas 5 % of group B had increased risk and 2 . 5 % had renal injury .
Diseases:"
647	Whereas 33 . 3 % of the patients with CIN were among those who received the proper dosage of CM , the percentage increased to 66 . 6 % among those who received larger doses , with a significant difference in the incidence of CIN related to the different dosages of CM ( p = 0 . 014 ) .	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['cin']	1	1	"Sentence: Whereas 33 . 3 % of the patients with CIN were among those who received the proper dosage of CM , the percentage increased to 66 . 6 % among those who received larger doses , with a significant difference in the incidence of CIN related to the different dosages of CM ( p = 0 . 014 ) .
Diseases: cin"	"Sentence: Whereas 33 . 3 % of the patients with CIN were among those who received the proper dosage of CM , the percentage increased to 66 . 6 % among those who received larger doses , with a significant difference in the incidence of CIN related to the different dosages of CM ( p = 0 . 014 ) .
Diseases:"
648	Among the 15 patients with CIN , 6 had cyanotic congenital heart diseases , but the incidence did not differ significantly from that for the noncyanotic patients ( p = 0 . 243 ) .	O O O O O B O O O O B I I O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['congenital heart diseases', 'cin']	2	8	"Sentence: Among the 15 patients with CIN , 6 had cyanotic congenital heart diseases , but the incidence did not differ significantly from that for the noncyanotic patients ( p = 0 . 243 ) .
Diseases: congenital heart diseases, cin"	"Sentence: Among the 15 patients with CIN , 6 had cyanotic congenital heart diseases , but the incidence did not differ significantly from that for the noncyanotic patients ( p = 0 . 243 ) .
Diseases:"
649	Although clinically silent , CIN is not rare in pediatrics .	O O O O B O O O O O O	O O O O O O O O O O O	['cin']	1	1	"Sentence: Although clinically silent , CIN is not rare in pediatrics .
Diseases: cin"	"Sentence: Although clinically silent , CIN is not rare in pediatrics .
Diseases:"
650	The incidence depends on dosage but not on the type of consumed nonionic CM , nor on the presence of cyanosis , and although CIN usually is reversible , more concern is needed for the prevention of such a complication in children .	O O O O O O O O O O O O O O O O O O O O B O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cin', 'cyanosis']	2	4	"Sentence: The incidence depends on dosage but not on the type of consumed nonionic CM , nor on the presence of cyanosis , and although CIN usually is reversible , more concern is needed for the prevention of such a complication in children .
Diseases: cin, cyanosis"	"Sentence: The incidence depends on dosage but not on the type of consumed nonionic CM , nor on the presence of cyanosis , and although CIN usually is reversible , more concern is needed for the prevention of such a complication in children .
Diseases:"
651	A case of ventricular tachycardia related to caffeine pretreatment .	O O O B I O O O O O	O O O O O O O B O O	['ventricular tachycardia']	1	6	"Sentence: A case of ventricular tachycardia related to caffeine pretreatment .
Diseases: ventricular tachycardia"	"Sentence: A case of ventricular tachycardia related to caffeine pretreatment .
Diseases:"
652	Suboptimal seizure duration is commonly encountered in electroconvulsive therapy practice , especially in older patients with higher seizure thresholds .	O B O O O O O O O O O O O O O O O B O O	O O O O O O O O O O O O O O O O O O O O	['seizure']	1	3	"Sentence: Suboptimal seizure duration is commonly encountered in electroconvulsive therapy practice , especially in older patients with higher seizure thresholds .
Diseases: seizure"	"Sentence: Suboptimal seizure duration is commonly encountered in electroconvulsive therapy practice , especially in older patients with higher seizure thresholds .
Diseases:"
653	Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy .	O O O O O O O B O O O O O O O O O O O O O O O O O O B I O	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ventricular ectopy', 'seizure']	2	6	"Sentence: Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy .
Diseases: ventricular ectopy, seizure"	"Sentence: Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy .
Diseases:"
654	We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration .	O O O O O O O O O B I O B O O O O O O O O O B I O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['cardiac disease', 'ventricular tachycardia', 'arrhythmia']	3	15	"Sentence: We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration .
Diseases: cardiac disease, ventricular tachycardia, arrhythmia"	"Sentence: We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration .
Diseases:"
655	Although intravenous caffeine is generally well tolerated , the clinician should be aware of the potential for unpredictable and serious ventricular arrhythmias .	O O O O O O O O O O O O O O O O O O O O B I O	O O B O O O O O O O O O O O O O O O O O O O O	['ventricular arrhythmias']	1	6	"Sentence: Although intravenous caffeine is generally well tolerated , the clinician should be aware of the potential for unpredictable and serious ventricular arrhythmias .
Diseases: ventricular arrhythmias"	"Sentence: Although intravenous caffeine is generally well tolerated , the clinician should be aware of the potential for unpredictable and serious ventricular arrhythmias .
Diseases:"
656	Optical coherence tomography can measure axonal loss in patients with ethambutol - induced optic neuropathy .	O O O O O O O O O O O O O B I O	O O O O O O O O O O B O O O O O	['optic neuropathy']	1	4	"Sentence: Optical coherence tomography can measure axonal loss in patients with ethambutol - induced optic neuropathy .
Diseases: optic neuropathy"	"Sentence: Optical coherence tomography can measure axonal loss in patients with ethambutol - induced optic neuropathy .
Diseases:"
657	To map and identify the pattern , in vivo , of axonal degeneration in ethambutol - induced optic neuropathy using optical coherence tomography ( OCT ) .	O O O O O O O O O O O B I O O O O B I O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O O O O O O	['axonal degeneration', 'optic neuropathy']	2	8	"Sentence: To map and identify the pattern , in vivo , of axonal degeneration in ethambutol - induced optic neuropathy using optical coherence tomography ( OCT ) .
Diseases: axonal degeneration, optic neuropathy"	"Sentence: To map and identify the pattern , in vivo , of axonal degeneration in ethambutol - induced optic neuropathy using optical coherence tomography ( OCT ) .
Diseases:"
658	Ethambutol is an antimycobacterial agent often used to treat tuberculosis .	O O O O O O O O O B O	B O O O O O O O O O O	['tuberculosis']	1	3	"Sentence: Ethambutol is an antimycobacterial agent often used to treat tuberculosis .
Diseases: tuberculosis"	"Sentence: Ethambutol is an antimycobacterial agent often used to treat tuberculosis .
Diseases:"
659	A serious complication of ethambutol is an optic neuropathy that impairs visual acuity , contrast sensitivity , and color vision .	O O O O O O O B I O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O	['optic neuropathy']	1	4	"Sentence: A serious complication of ethambutol is an optic neuropathy that impairs visual acuity , contrast sensitivity , and color vision .
Diseases: optic neuropathy"	"Sentence: A serious complication of ethambutol is an optic neuropathy that impairs visual acuity , contrast sensitivity , and color vision .
Diseases:"
660	However , early on , when the toxic optic neuropathy is mild and partly reversible , the funduscopic findings are often subtle and easy to miss .	O O O O O O O O B I O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['optic neuropathy']	1	4	"Sentence: However , early on , when the toxic optic neuropathy is mild and partly reversible , the funduscopic findings are often subtle and easy to miss .
Diseases: optic neuropathy"	"Sentence: However , early on , when the toxic optic neuropathy is mild and partly reversible , the funduscopic findings are often subtle and easy to miss .
Diseases:"
661	METHODS : Three subjects with a history of ethambutol ( EMB ) - induced optic neuropathy of short - , intermediate - , and long - term visual deficits were administered a full neuro - ophthalmologic examination including visual acuity , color vision , contrast sensitivity , and fundus examination .	O O O O O O O O O O O O O O B I O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['visual deficits', 'optic neuropathy']	2	6	"Sentence: METHODS : Three subjects with a history of ethambutol ( EMB ) - induced optic neuropathy of short - , intermediate - , and long - term visual deficits were administered a full neuro - ophthalmologic examination including visual acuity , color vision , contrast sensitivity , and fundus examination .
Diseases: visual deficits, optic neuropathy"	"Sentence: METHODS : Three subjects with a history of ethambutol ( EMB ) - induced optic neuropathy of short - , intermediate - , and long - term visual deficits were administered a full neuro - ophthalmologic examination including visual acuity , color vision , contrast sensitivity , and fundus examination .
Diseases:"
662	In addition , OCT ( OCT 3000 , Humphrey - Zeiss , Dublin , CA ) was performed on both eyes of each subject using the retinal nerve fiber layer ( RNFL ) analysis protocol .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition , OCT ( OCT 3000 , Humphrey - Zeiss , Dublin , CA ) was performed on both eyes of each subject using the retinal nerve fiber layer ( RNFL ) analysis protocol .
Diseases: "	"Sentence: In addition , OCT ( OCT 3000 , Humphrey - Zeiss , Dublin , CA ) was performed on both eyes of each subject using the retinal nerve fiber layer ( RNFL ) analysis protocol .
Diseases:"
663	OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL .
Diseases: "	"Sentence: OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL .
Diseases:"
664	The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT , n = 661 .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT , n = 661 .
Diseases: "	"Sentence: The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT , n = 661 .
Diseases:"
665	In all subjects with history of EMB - induced optic neuropathy , there was a mean loss of 72 % nerve fiber layer thickness in the temporal quadrant ( patient A , with eventual recovery of visual acuity and fields , 58 % loss ; patient B , with intermediate visual deficits , 68 % loss ; patient C , with chronic visual deficits , 90 % loss ) , with an average mean optic nerve thickness of 26 + / - 16 microm .	O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['visual deficits', 'optic neuropathy']	2	6	"Sentence: In all subjects with history of EMB - induced optic neuropathy , there was a mean loss of 72 % nerve fiber layer thickness in the temporal quadrant ( patient A , with eventual recovery of visual acuity and fields , 58 % loss ; patient B , with intermediate visual deficits , 68 % loss ; patient C , with chronic visual deficits , 90 % loss ) , with an average mean optic nerve thickness of 26 + / - 16 microm .
Diseases: visual deficits, optic neuropathy"	"Sentence: In all subjects with history of EMB - induced optic neuropathy , there was a mean loss of 72 % nerve fiber layer thickness in the temporal quadrant ( patient A , with eventual recovery of visual acuity and fields , 58 % loss ; patient B , with intermediate visual deficits , 68 % loss ; patient C , with chronic visual deficits , 90 % loss ) , with an average mean optic nerve thickness of 26 + / - 16 microm .
Diseases:"
666	There was a combined mean loss of 46 % of fibers from the superior , inferior , and nasal quadrants in the ( six ) eyes of all three subjects ( mean average thickness of 55 + / - 29 microm ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There was a combined mean loss of 46 % of fibers from the superior , inferior , and nasal quadrants in the ( six ) eyes of all three subjects ( mean average thickness of 55 + / - 29 microm ) .
Diseases: "	"Sentence: There was a combined mean loss of 46 % of fibers from the superior , inferior , and nasal quadrants in the ( six ) eyes of all three subjects ( mean average thickness of 55 + / - 29 microm ) .
Diseases:"
667	In both sets ( four ) of eyes of the subjects with persistent visual deficits ( patients B and C ) , there was an average loss of 79 % of nerve fiber thickness in the temporal quadrant .	O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['visual deficits']	1	2	"Sentence: In both sets ( four ) of eyes of the subjects with persistent visual deficits ( patients B and C ) , there was an average loss of 79 % of nerve fiber thickness in the temporal quadrant .
Diseases: visual deficits"	"Sentence: In both sets ( four ) of eyes of the subjects with persistent visual deficits ( patients B and C ) , there was an average loss of 79 % of nerve fiber thickness in the temporal quadrant .
Diseases:"
668	CONCLUSIONS : The OCT results in these patients with EMB - induced optic neuropathy show considerable loss especially of the temporal fibers .	O O O O O O O O O O O O B I O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O	['optic neuropathy']	1	4	"Sentence: CONCLUSIONS : The OCT results in these patients with EMB - induced optic neuropathy show considerable loss especially of the temporal fibers .
Diseases: optic neuropathy"	"Sentence: CONCLUSIONS : The OCT results in these patients with EMB - induced optic neuropathy show considerable loss especially of the temporal fibers .
Diseases:"
669	This is consistent with prior histopathological studies that show predominant loss of parvo - cellular axons ( or small - caliber axons ) within the papillo - macular bundle in toxic or hereditary optic neuropathies .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['optic neuropathies']	1	5	"Sentence: This is consistent with prior histopathological studies that show predominant loss of parvo - cellular axons ( or small - caliber axons ) within the papillo - macular bundle in toxic or hereditary optic neuropathies .
Diseases: optic neuropathies"	"Sentence: This is consistent with prior histopathological studies that show predominant loss of parvo - cellular axons ( or small - caliber axons ) within the papillo - macular bundle in toxic or hereditary optic neuropathies .
Diseases:"
670	OCT can be a valuable tool in the quantitative analysis of optic neuropathies .	O O O O O O O O O O O B I O	O O O O O O O O O O O O O O	['optic neuropathies']	1	5	"Sentence: OCT can be a valuable tool in the quantitative analysis of optic neuropathies .
Diseases: optic neuropathies"	"Sentence: OCT can be a valuable tool in the quantitative analysis of optic neuropathies .
Diseases:"
671	Additionally , in terms of management of EMB - induced optic neuropathy , it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached .	O O O O O O O O O O B I O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['optic neuropathy', 'renal impairment']	2	7	"Sentence: Additionally , in terms of management of EMB - induced optic neuropathy , it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached .
Diseases: optic neuropathy, renal impairment"	"Sentence: Additionally , in terms of management of EMB - induced optic neuropathy , it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached .
Diseases:"
672	Effects of the cyclooxygenase - 2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis .	O O O O O O O O O O O O O O O O O B O O O O B O	O O O O O O O O B O O O O O O O O O O O O O O O	['thrombotic', 'arthritis']	2	6	"Sentence: Effects of the cyclooxygenase - 2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis .
Diseases: thrombotic, arthritis"	"Sentence: Effects of the cyclooxygenase - 2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis .
Diseases:"
673	There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase ( COX ) - 2 - specific inhibitors than nonselective nonsteroidal antiinflammatory drugs ( NSAIDs ) .	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['thrombotic']	1	4	"Sentence: There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase ( COX ) - 2 - specific inhibitors than nonselective nonsteroidal antiinflammatory drugs ( NSAIDs ) .
Diseases: thrombotic"	"Sentence: There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase ( COX ) - 2 - specific inhibitors than nonselective nonsteroidal antiinflammatory drugs ( NSAIDs ) .
Diseases:"
674	We evaluated cardiovascular event data for valdecoxib , a new COX - 2 - specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials .	O O O O O O O O O O O O O O O O O O O O O B O B I O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	['osteoarthritis', 'rheumatoid arthritis']	2	11	"Sentence: We evaluated cardiovascular event data for valdecoxib , a new COX - 2 - specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials .
Diseases: osteoarthritis, rheumatoid arthritis"	"Sentence: We evaluated cardiovascular event data for valdecoxib , a new COX - 2 - specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials .
Diseases:"
675	The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , ibuprofen 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6 - 52 weeks in duration .	O O O O B O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B I O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O B O O O O B O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['osteoarthritis', 'rheumatoid arthritis', 'thrombotic']	3	16	"Sentence: The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , ibuprofen 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6 - 52 weeks in duration .
Diseases: osteoarthritis, rheumatoid arthritis, thrombotic"	"Sentence: The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , ibuprofen 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6 - 52 weeks in duration .
Diseases:"
676	The incidence rates of events were determined in all patients ( n = 7934 ) and in users of low - dose ( < or = 325 mg daily ) aspirin ( n = 1051 ) and nonusers of aspirin ( n = 6883 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O B O O O O O O	[]	0	0	"Sentence: The incidence rates of events were determined in all patients ( n = 7934 ) and in users of low - dose ( < or = 325 mg daily ) aspirin ( n = 1051 ) and nonusers of aspirin ( n = 6883 ) .
Diseases: "	"Sentence: The incidence rates of events were determined in all patients ( n = 7934 ) and in users of low - dose ( < or = 325 mg daily ) aspirin ( n = 1051 ) and nonusers of aspirin ( n = 6883 ) .
Diseases:"
677	Crude and exposure - adjusted incidences of thrombotic events were similar for valdecoxib , NSAIDs , and placebo .	O O O O O O O B O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O	['thrombotic']	1	4	"Sentence: Crude and exposure - adjusted incidences of thrombotic events were similar for valdecoxib , NSAIDs , and placebo .
Diseases: thrombotic"	"Sentence: Crude and exposure - adjusted incidences of thrombotic events were similar for valdecoxib , NSAIDs , and placebo .
Diseases:"
678	The risk of serious thrombotic events was also similar for each valdecoxib dose .	O O O O B O O O O O O O O O	O O O O O O O O O O O B O O	['thrombotic']	1	4	"Sentence: The risk of serious thrombotic events was also similar for each valdecoxib dose .
Diseases: thrombotic"	"Sentence: The risk of serious thrombotic events was also similar for each valdecoxib dose .
Diseases:"
679	Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin ( placebo , 1 . 4 % vs . 0 % ; valdecoxib , 1 . 7 % vs . 0 . 2 % ; NSAIDs , 1 . 9 % vs . 0 . 5 % ) .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O O	['thrombotic']	1	4	"Sentence: Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin ( placebo , 1 . 4 % vs . 0 % ; valdecoxib , 1 . 7 % vs . 0 . 2 % ; NSAIDs , 1 . 9 % vs . 0 . 5 % ) .
Diseases: thrombotic"	"Sentence: Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin ( placebo , 1 . 4 % vs . 0 % ; valdecoxib , 1 . 7 % vs . 0 . 2 % ; NSAIDs , 1 . 9 % vs . 0 . 5 % ) .
Diseases:"
680	The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O B O O	[]	0	0	"Sentence: The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses .
Diseases: "	"Sentence: The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses .
Diseases:"
681	Short - and intermediate - term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O B O B I O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['osteoarthritis', 'rheumatoid arthritis', 'thrombotic']	3	16	"Sentence: Short - and intermediate - term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials .
Diseases: osteoarthritis, rheumatoid arthritis, thrombotic"	"Sentence: Short - and intermediate - term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials .
Diseases:"
682	A randomized , placebo - controlled , crossover study of ephedrine for SSRI - induced female sexual dysfunction .	O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O B O B O O O O O O	['sexual dysfunction']	1	2	"Sentence: A randomized , placebo - controlled , crossover study of ephedrine for SSRI - induced female sexual dysfunction .
Diseases: sexual dysfunction"	"Sentence: A randomized , placebo - controlled , crossover study of ephedrine for SSRI - induced female sexual dysfunction .
Diseases:"
683	The objective of this study was to determine whether ephedrine , an alpha - and beta - adrenergic agonist previously shown to enhance genital blood flow in women , has beneficial effects in reversing antidepressant - induced sexual dysfunction .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	['sexual dysfunction']	1	2	"Sentence: The objective of this study was to determine whether ephedrine , an alpha - and beta - adrenergic agonist previously shown to enhance genital blood flow in women , has beneficial effects in reversing antidepressant - induced sexual dysfunction .
Diseases: sexual dysfunction"	"Sentence: The objective of this study was to determine whether ephedrine , an alpha - and beta - adrenergic agonist previously shown to enhance genital blood flow in women , has beneficial effects in reversing antidepressant - induced sexual dysfunction .
Diseases:"
684	Nineteen sexually dysfunctional women receiving either fluoxetine , sertraline , or paroxetine participated in an eight - week , double - blind , placebo - controlled , cross - over study of the effects of ephedrine ( 50 mg ) on self - report measures of sexual desire , arousal , orgasm , and sexual satisfaction .	O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O B O O B O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	['sexually dysfunctional']	1	3	"Sentence: Nineteen sexually dysfunctional women receiving either fluoxetine , sertraline , or paroxetine participated in an eight - week , double - blind , placebo - controlled , cross - over study of the effects of ephedrine ( 50 mg ) on self - report measures of sexual desire , arousal , orgasm , and sexual satisfaction .
Diseases: sexually dysfunctional"	"Sentence: Nineteen sexually dysfunctional women receiving either fluoxetine , sertraline , or paroxetine participated in an eight - week , double - blind , placebo - controlled , cross - over study of the effects of ephedrine ( 50 mg ) on self - report measures of sexual desire , arousal , orgasm , and sexual satisfaction .
Diseases:"
685	Although there were significant improvements relative to baseline in sexual desire and orgasm intensity / pleasure on 50 mg ephedrine 1 - hr prior to sexual activity , significant improvements in these measures , as well as in sexual arousal and orgasmic ability also were noted with placebo .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Although there were significant improvements relative to baseline in sexual desire and orgasm intensity / pleasure on 50 mg ephedrine 1 - hr prior to sexual activity , significant improvements in these measures , as well as in sexual arousal and orgasmic ability also were noted with placebo .
Diseases: "	"Sentence: Although there were significant improvements relative to baseline in sexual desire and orgasm intensity / pleasure on 50 mg ephedrine 1 - hr prior to sexual activity , significant improvements in these measures , as well as in sexual arousal and orgasmic ability also were noted with placebo .
Diseases:"
686	These findings highlight the importance of conducting placebo - controlled trials for this condition .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These findings highlight the importance of conducting placebo - controlled trials for this condition .
Diseases: "	"Sentence: These findings highlight the importance of conducting placebo - controlled trials for this condition .
Diseases:"
687	Erectile dysfunction occurs following substantia nigra lesions in the rat .	B I O O O O O O O O O	O O O O O O O O O O O	['erectile dysfunction']	1	4	"Sentence: Erectile dysfunction occurs following substantia nigra lesions in the rat .
Diseases: erectile dysfunction"	"Sentence: Erectile dysfunction occurs following substantia nigra lesions in the rat .
Diseases:"
688	Erectile function was assessed 6 weeks following uni - and bilateral injections of 6 - hydroxydopamine in the substantia nigra nucleus of the brain .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B I I O O O O O O O O O	[]	0	0	"Sentence: Erectile function was assessed 6 weeks following uni - and bilateral injections of 6 - hydroxydopamine in the substantia nigra nucleus of the brain .
Diseases: "	"Sentence: Erectile function was assessed 6 weeks following uni - and bilateral injections of 6 - hydroxydopamine in the substantia nigra nucleus of the brain .
Diseases:"
689	Behavioral apomorphine - induced penile erections were reduced ( 5 / 8 ) and increased ( 3 / 8 ) in uni - and bilateral lesioned animals .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Behavioral apomorphine - induced penile erections were reduced ( 5 / 8 ) and increased ( 3 / 8 ) in uni - and bilateral lesioned animals .
Diseases: "	"Sentence: Behavioral apomorphine - induced penile erections were reduced ( 5 / 8 ) and increased ( 3 / 8 ) in uni - and bilateral lesioned animals .
Diseases:"
690	Intracavernous pressures , following electrical stimulation of the cavernous nerve , decreased in lesioned animals .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Intracavernous pressures , following electrical stimulation of the cavernous nerve , decreased in lesioned animals .
Diseases: "	"Sentence: Intracavernous pressures , following electrical stimulation of the cavernous nerve , decreased in lesioned animals .
Diseases:"
691	Lesions of the substantia nigra were confirmed by histology .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Lesions of the substantia nigra were confirmed by histology .
Diseases: "	"Sentence: Lesions of the substantia nigra were confirmed by histology .
Diseases:"
692	Concentration of dopamine and its metabolites were decreased in the striatum of substantia nigra lesioned rats .	O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: Concentration of dopamine and its metabolites were decreased in the striatum of substantia nigra lesioned rats .
Diseases: "	"Sentence: Concentration of dopamine and its metabolites were decreased in the striatum of substantia nigra lesioned rats .
Diseases:"
693	Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson 's disease .	O O O O O O O O O B I O O O O O O O O O O B I O B I I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	"['erectile dysfunction', ""parkinson 's disease""]"	2	10	"Sentence: Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson 's disease .
Diseases: erectile dysfunction, parkinson 's disease"	"Sentence: Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson 's disease .
Diseases:"
694	Potential therapeutic use of the selective dopamine D1 receptor agonist , A - 86929 : an acute study in parkinsonian levodopa - primed monkeys .	O O O O O O O O O O O O O O O O O O O B O O O O O	O O O O O O B O O O O B I I O O O O O O B O O O O	['parkinsonian']	1	3	"Sentence: Potential therapeutic use of the selective dopamine D1 receptor agonist , A - 86929 : an acute study in parkinsonian levodopa - primed monkeys .
Diseases: parkinsonian"	"Sentence: Potential therapeutic use of the selective dopamine D1 receptor agonist , A - 86929 : an acute study in parkinsonian levodopa - primed monkeys .
Diseases:"
695	The clinical utility of dopamine ( DA ) D1 receptor agonists in the treatment of Parkinson 's disease ( PD ) is still unclear .	O O O O O O O O O O O O O O O B I I O B O O O O O	O O O O B O B O O O O O O O O O O O O O O O O O O	"['pd', ""parkinson 's disease""]"	2	7	"Sentence: The clinical utility of dopamine ( DA ) D1 receptor agonists in the treatment of Parkinson 's disease ( PD ) is still unclear .
Diseases: pd, parkinson 's disease"	"Sentence: The clinical utility of dopamine ( DA ) D1 receptor agonists in the treatment of Parkinson 's disease ( PD ) is still unclear .
Diseases:"
696	The therapeutic use of selective DA D1 receptor agonists such as SKF - 82958 ( 6 - chloro - 7 , 8 - dihydroxy - 3 - allyl - 1 - phenyl - 2 , 3 , 4 , 5 - tetrahydro - 1H - 3 - benzaze pine hydrobromide ) and A - 77636 ( [ 1R , 3S ] 3 - [ 1' - admantyl ] - 1 - aminomethyl - 3 , 4 - dihydro - 5 , 6 - dihydroxy - 1H - 2 - benzo pyran hydrochloride ) seems limited because of their duration of action , which is too short for SKF - 82958 ( < 1 hr ) and too long for A - 77636 ( > 20 hr , leading to behavioral tolerance ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O B I I O B I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I O O B I I O B I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I O O O O O O O O O O O O O O O B I I O O O O O O O O O B I I O O O O O O O O O O O	[]	0	0	"Sentence: The therapeutic use of selective DA D1 receptor agonists such as SKF - 82958 ( 6 - chloro - 7 , 8 - dihydroxy - 3 - allyl - 1 - phenyl - 2 , 3 , 4 , 5 - tetrahydro - 1H - 3 - benzaze pine hydrobromide ) and A - 77636 ( [ 1R , 3S ] 3 - [ 1' - admantyl ] - 1 - aminomethyl - 3 , 4 - dihydro - 5 , 6 - dihydroxy - 1H - 2 - benzo pyran hydrochloride ) seems limited because of their duration of action , which is too short for SKF - 82958 ( < 1 hr ) and too long for A - 77636 ( > 20 hr , leading to behavioral tolerance ) .
Diseases: "	"Sentence: The therapeutic use of selective DA D1 receptor agonists such as SKF - 82958 ( 6 - chloro - 7 , 8 - dihydroxy - 3 - allyl - 1 - phenyl - 2 , 3 , 4 , 5 - tetrahydro - 1H - 3 - benzaze pine hydrobromide ) and A - 77636 ( [ 1R , 3S ] 3 - [ 1' - admantyl ] - 1 - aminomethyl - 3 , 4 - dihydro - 5 , 6 - dihydroxy - 1H - 2 - benzo pyran hydrochloride ) seems limited because of their duration of action , which is too short for SKF - 82958 ( < 1 hr ) and too long for A - 77636 ( > 20 hr , leading to behavioral tolerance ) .
Diseases:"
697	We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B I I I I I I I I I I I I I I I I O B O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O B I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I O O O I I I I I I I I I I I I I I I O O O O O O B O O O O O O O O O O O O	['dyskinesias', 'dyskinetic']	2	9	"Sentence: We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .
Diseases: dyskinesias, dyskinetic"	"Sentence: We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .
Diseases:"
698	Levodopa and the DA D2 - like receptor agonist , LY - 171555 ( [ 4aR - trans ] - 4 , 4a , 5 , 6 , 7 , 8 , 8a , 9 - o - dihydro - 5n - propyl - 2H - pyrazo lo - 3 - 4 - quinoline hydrochloride ) were also used for comparison .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O B O O O O O O B I I O B I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I O O O O O O O	[]	0	0	"Sentence: Levodopa and the DA D2 - like receptor agonist , LY - 171555 ( [ 4aR - trans ] - 4 , 4a , 5 , 6 , 7 , 8 , 8a , 9 - o - dihydro - 5n - propyl - 2H - pyrazo lo - 3 - 4 - quinoline hydrochloride ) were also used for comparison .
Diseases: "	"Sentence: Levodopa and the DA D2 - like receptor agonist , LY - 171555 ( [ 4aR - trans ] - 4 , 4a , 5 , 6 , 7 , 8 , 8a , 9 - o - dihydro - 5n - propyl - 2H - pyrazo lo - 3 - 4 - quinoline hydrochloride ) were also used for comparison .
Diseases:"
699	Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced parkinsonism as levodopa and LY - 171555 , but was less likely to reproduce the levodopa - induced dyskinesias in these animals than with either LY - 171555 or subsequent challenge of levodopa .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	O O O B I I O O O O O B O O O O B O B I I O O O O O O O O B O O O O O O O O O B I I O O O O B O	['dyskinesias', 'parkinsonism']	2	9	"Sentence: Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced parkinsonism as levodopa and LY - 171555 , but was less likely to reproduce the levodopa - induced dyskinesias in these animals than with either LY - 171555 or subsequent challenge of levodopa .
Diseases: dyskinesias, parkinsonism"	"Sentence: Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced parkinsonism as levodopa and LY - 171555 , but was less likely to reproduce the levodopa - induced dyskinesias in these animals than with either LY - 171555 or subsequent challenge of levodopa .
Diseases:"
700	Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus ( referred to as the basal ganglia output ) compared with levodopa and selective DA D2 receptor agonist .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O B O O O O	[]	0	0	"Sentence: Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus ( referred to as the basal ganglia output ) compared with levodopa and selective DA D2 receptor agonist .
Diseases: "	"Sentence: Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus ( referred to as the basal ganglia output ) compared with levodopa and selective DA D2 receptor agonist .
Diseases:"
701	Potent DA D1 receptor agents with an intermediate duration of efficacy such as A - 86929 ( approximately 4 hr at higher doses tested ) are potential therapeutic tools in PD and merit further attention .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	O B O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O	['pd']	1	1	"Sentence: Potent DA D1 receptor agents with an intermediate duration of efficacy such as A - 86929 ( approximately 4 hr at higher doses tested ) are potential therapeutic tools in PD and merit further attention .
Diseases: pd"	"Sentence: Potent DA D1 receptor agents with an intermediate duration of efficacy such as A - 86929 ( approximately 4 hr at higher doses tested ) are potential therapeutic tools in PD and merit further attention .
Diseases:"
702	Deaths from local anesthetic - induced convulsions in mice .	O O O O O O B O O O	O O O O O O O O O O	['convulsions']	1	3	"Sentence: Deaths from local anesthetic - induced convulsions in mice .
Diseases: convulsions"	"Sentence: Deaths from local anesthetic - induced convulsions in mice .
Diseases:"
703	Median convulsant ( CD50 ) and median lethal ( LD50 ) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic - induced convulsions .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['convulsions']	1	3	"Sentence: Median convulsant ( CD50 ) and median lethal ( LD50 ) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic - induced convulsions .
Diseases: convulsions"	"Sentence: Median convulsant ( CD50 ) and median lethal ( LD50 ) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic - induced convulsions .
Diseases:"
704	The CD50 and LD50 , respectively , were 57 . 7 and 58 . 7 mg / kg for bupivacaine , 111 . 0 and 133 . 1 mg / kg for lidocaine , and 243 . 4 and 266 . 5 mg / kg for chloroprocaine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O O B O	[]	0	0	"Sentence: The CD50 and LD50 , respectively , were 57 . 7 and 58 . 7 mg / kg for bupivacaine , 111 . 0 and 133 . 1 mg / kg for lidocaine , and 243 . 4 and 266 . 5 mg / kg for chloroprocaine .
Diseases: "	"Sentence: The CD50 and LD50 , respectively , were 57 . 7 and 58 . 7 mg / kg for bupivacaine , 111 . 0 and 133 . 1 mg / kg for lidocaine , and 243 . 4 and 266 . 5 mg / kg for chloroprocaine .
Diseases:"
705	When given intraperitoneally , bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine .	O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O B O O O O O O B O	[]	0	0	"Sentence: When given intraperitoneally , bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine .
Diseases: "	"Sentence: When given intraperitoneally , bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine .
Diseases:"
706	Convulsions always preceded death , except after precipitous cardiopulmonary arrest from extreme doses .	B O O O O O O O B I O O O O	O O O O O O O O O O O O O O	['cardiopulmonary arrest', 'convulsions']	2	9	"Sentence: Convulsions always preceded death , except after precipitous cardiopulmonary arrest from extreme doses .
Diseases: cardiopulmonary arrest, convulsions"	"Sentence: Convulsions always preceded death , except after precipitous cardiopulmonary arrest from extreme doses .
Diseases:"
707	A CD50 dose of local anesthetic ( causing convulsions in 50 % of mice ) was fatal in 90 % of bupivacaine - induced seizures , in 57 % of the chloroprocaine group , and in 6 % of the lidocaine group .	O O O O O O O O B O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O B O O O O O O O O B O O	['seizures', 'convulsions']	2	7	"Sentence: A CD50 dose of local anesthetic ( causing convulsions in 50 % of mice ) was fatal in 90 % of bupivacaine - induced seizures , in 57 % of the chloroprocaine group , and in 6 % of the lidocaine group .
Diseases: seizures, convulsions"	"Sentence: A CD50 dose of local anesthetic ( causing convulsions in 50 % of mice ) was fatal in 90 % of bupivacaine - induced seizures , in 57 % of the chloroprocaine group , and in 6 % of the lidocaine group .
Diseases:"
708	The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated convulsions present much more of a threat to life than heretofore appreciated .	O O O O O O O O O O O O O O B O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['convulsions']	1	3	"Sentence: The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated convulsions present much more of a threat to life than heretofore appreciated .
Diseases: convulsions"	"Sentence: The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated convulsions present much more of a threat to life than heretofore appreciated .
Diseases:"
709	Myoclonic , atonic , and absence seizures following institution of carbamazepine therapy in children .	B I I I I I I O O O O O O O O	O O O O O O O O O O B O O O O	['myoclonic , atonic , and absence seizures']	1	10	"Sentence: Myoclonic , atonic , and absence seizures following institution of carbamazepine therapy in children .
Diseases: myoclonic , atonic , and absence seizures"	"Sentence: Myoclonic , atonic , and absence seizures following institution of carbamazepine therapy in children .
Diseases:"
710	Five children , aged 3 to 11 years , treated with carbamazepine for epilepsy , had an acute aberrant reaction characterized by the onset of myoclonic , atypical absence and / or atonic ( minor motor ) seizures within a few days .	O O O O O O O O O O O O O B O O O O O O O O O O O B I I I I I I I I I I I I O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['epilepsy', 'myoclonic , atypical absence and / or atonic ( minor motor ) seizures']	2	22	"Sentence: Five children , aged 3 to 11 years , treated with carbamazepine for epilepsy , had an acute aberrant reaction characterized by the onset of myoclonic , atypical absence and / or atonic ( minor motor ) seizures within a few days .
Diseases: epilepsy, myoclonic , atypical absence and / or atonic ( minor motor ) seizures"	"Sentence: Five children , aged 3 to 11 years , treated with carbamazepine for epilepsy , had an acute aberrant reaction characterized by the onset of myoclonic , atypical absence and / or atonic ( minor motor ) seizures within a few days .
Diseases:"
711	When the carbamazepine was discontinued , two of the children returned to their former state very quickly , two had the minor motor seizures resolve in 3 and 6 months , and one had the seizures persist .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O B O O	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['seizures']	1	3	"Sentence: When the carbamazepine was discontinued , two of the children returned to their former state very quickly , two had the minor motor seizures resolve in 3 and 6 months , and one had the seizures persist .
Diseases: seizures"	"Sentence: When the carbamazepine was discontinued , two of the children returned to their former state very quickly , two had the minor motor seizures resolve in 3 and 6 months , and one had the seizures persist .
Diseases:"
712	The child in whom the seizures persisted was later found to have ceroid lipofuscinosis .	O O O O O B O O O O O O B I O	O O O O O O O O O O O O O O O	['ceroid lipofuscinosis', 'seizures']	2	9	"Sentence: The child in whom the seizures persisted was later found to have ceroid lipofuscinosis .
Diseases: ceroid lipofuscinosis, seizures"	"Sentence: The child in whom the seizures persisted was later found to have ceroid lipofuscinosis .
Diseases:"
713	The other children are doing well on other anticonvulsants .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: The other children are doing well on other anticonvulsants .
Diseases: "	"Sentence: The other children are doing well on other anticonvulsants .
Diseases:"
714	Naloxone reversal of hypotension due to captopril overdose .	O O O B O O O B O	B O O O O O B O O	['overdose', 'hypotension']	2	5	"Sentence: Naloxone reversal of hypotension due to captopril overdose .
Diseases: overdose, hypotension"	"Sentence: Naloxone reversal of hypotension due to captopril overdose .
Diseases:"
715	The hemodynamic effects of captopril and other angiotensin - converting enzyme inhibitors may be mediated by the endogenous opioid system .	O O O O O O O O O O O O O O O O O O O O O	O O O O B O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: The hemodynamic effects of captopril and other angiotensin - converting enzyme inhibitors may be mediated by the endogenous opioid system .
Diseases: "	"Sentence: The hemodynamic effects of captopril and other angiotensin - converting enzyme inhibitors may be mediated by the endogenous opioid system .
Diseases:"
716	The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril .	O O O O O O O O O O O O B O O O O	O O O B O O O O O O O O O O O B O	['hypotensive']	1	3	"Sentence: The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril .
Diseases: hypotensive"	"Sentence: The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril .
Diseases:"
717	We report a case of an intentional captopril overdose , manifested by marked hypotension , that resolved promptly with the administration of naloxone .	O O O O O O O O B O O O O B O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O B O	['overdose', 'hypotension']	2	5	"Sentence: We report a case of an intentional captopril overdose , manifested by marked hypotension , that resolved promptly with the administration of naloxone .
Diseases: overdose, hypotension"	"Sentence: We report a case of an intentional captopril overdose , manifested by marked hypotension , that resolved promptly with the administration of naloxone .
Diseases:"
718	To our knowledge , this is the first reported case of captopril - induced hypotension treated with naloxone .	O O O O O O O O O O O O O O B O O O O	O O O O O O O O O O O B O O O O O B O	['hypotension']	1	3	"Sentence: To our knowledge , this is the first reported case of captopril - induced hypotension treated with naloxone .
Diseases: hypotension"	"Sentence: To our knowledge , this is the first reported case of captopril - induced hypotension treated with naloxone .
Diseases:"
719	Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril .	O O O O O O O O O O O O B O O O O	O O O O O O O B O O O O O O O B O	['hypotension']	1	3	"Sentence: Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril .
Diseases: hypotension"	"Sentence: Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril .
Diseases:"
720	Carbamazepine - induced cardiac dysfunction .	O O O B I O	B O O O O O	['cardiac dysfunction']	1	3	"Sentence: Carbamazepine - induced cardiac dysfunction .
Diseases: cardiac dysfunction"	"Sentence: Carbamazepine - induced cardiac dysfunction .
Diseases:"
721	Characterization of two distinct clinical syndromes .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: Characterization of two distinct clinical syndromes .
Diseases: "	"Sentence: Characterization of two distinct clinical syndromes .
Diseases:"
722	A patient with sinus bradycardia and atrioventricular block , induced by carbamazepine , prompted an extensive literature review of all previously reported cases .	O O O O B O B I O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O	['atrioventricular block', 'bradycardia']	2	10	"Sentence: A patient with sinus bradycardia and atrioventricular block , induced by carbamazepine , prompted an extensive literature review of all previously reported cases .
Diseases: atrioventricular block, bradycardia"	"Sentence: A patient with sinus bradycardia and atrioventricular block , induced by carbamazepine , prompted an extensive literature review of all previously reported cases .
Diseases:"
723	From the analysis of these cases , two distinct forms of carbamazepine - associated cardiac dysfunction emerged .	O O O O O O O O O O O O O O B I O O	O O O O O O O O O O O B O O O O O O	['cardiac dysfunction']	1	3	"Sentence: From the analysis of these cases , two distinct forms of carbamazepine - associated cardiac dysfunction emerged .
Diseases: cardiac dysfunction"	"Sentence: From the analysis of these cases , two distinct forms of carbamazepine - associated cardiac dysfunction emerged .
Diseases:"
724	One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose .	O O O O B I O O O O O O O B O	O O O O O O O O O O O O B O O	['overdose', 'sinus tachycardias']	2	9	"Sentence: One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose .
Diseases: overdose, sinus tachycardias"	"Sentence: One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose .
Diseases:"
725	The second group consisted almost exclusively of elderly women who developed potentially life - threatening bradyarrhythmias or atrioventricular conduction delay , associated with either therapeutic or modestly elevated carbamazepine serum levels .	O O O O O O O O O O O O O O O B O B I I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O	['atrioventricular conduction delay', 'bradyarrhythmias']	2	14	"Sentence: The second group consisted almost exclusively of elderly women who developed potentially life - threatening bradyarrhythmias or atrioventricular conduction delay , associated with either therapeutic or modestly elevated carbamazepine serum levels .
Diseases: atrioventricular conduction delay, bradyarrhythmias"	"Sentence: The second group consisted almost exclusively of elderly women who developed potentially life - threatening bradyarrhythmias or atrioventricular conduction delay , associated with either therapeutic or modestly elevated carbamazepine serum levels .
Diseases:"
726	Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions , the recognition of the latter syndrome has important implications for the use of this drug in elderly patients .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['psychiatric']	1	2	"Sentence: Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions , the recognition of the latter syndrome has important implications for the use of this drug in elderly patients .
Diseases: psychiatric"	"Sentence: Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions , the recognition of the latter syndrome has important implications for the use of this drug in elderly patients .
Diseases:"
727	Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol - induced catalepsy .	O O O O O O O O O O O O O O O B O	O O O O B O O O O O O O B O O O O	['catalepsy']	1	4	"Sentence: Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol - induced catalepsy .
Diseases: catalepsy"	"Sentence: Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol - induced catalepsy .
Diseases:"
728	The inferior colliculus ( IC ) is primarily involved in the processing of auditory information , but it is distinguished from other auditory nuclei in the brainstem by its connections with structures of the motor system .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The inferior colliculus ( IC ) is primarily involved in the processing of auditory information , but it is distinguished from other auditory nuclei in the brainstem by its connections with structures of the motor system .
Diseases: "	"Sentence: The inferior colliculus ( IC ) is primarily involved in the processing of auditory information , but it is distinguished from other auditory nuclei in the brainstem by its connections with structures of the motor system .
Diseases:"
729	Functional evidence relating the IC to motor behavior derives from experiments showing that activation of the IC by electrical stimulation or excitatory amino acid microinjection causes freezing , escape - like behavior , and immobility .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B B I O O O O O O O O O O O O	[]	0	0	"Sentence: Functional evidence relating the IC to motor behavior derives from experiments showing that activation of the IC by electrical stimulation or excitatory amino acid microinjection causes freezing , escape - like behavior , and immobility .
Diseases: "	"Sentence: Functional evidence relating the IC to motor behavior derives from experiments showing that activation of the IC by electrical stimulation or excitatory amino acid microinjection causes freezing , escape - like behavior , and immobility .
Diseases:"
730	However , the nature of this immobility is still unclear .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: However , the nature of this immobility is still unclear .
Diseases: "	"Sentence: However , the nature of this immobility is still unclear .
Diseases:"
731	The present study examined the influence of excitatory amino acid - mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically ( 1 or 0 . 5 mg / kg ) in rats .	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B I O O O O O O O O O O O O B O O B O O O O O O O O O O O O O O O	['catalepsy']	1	4	"Sentence: The present study examined the influence of excitatory amino acid - mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically ( 1 or 0 . 5 mg / kg ) in rats .
Diseases: catalepsy"	"Sentence: The present study examined the influence of excitatory amino acid - mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically ( 1 or 0 . 5 mg / kg ) in rats .
Diseases:"
732	Haloperidol - induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists , MK - 801 ( 15 or 30 mmol / 0 . 5 microl ) and AP7 ( 10 or 20 nmol / 0 . 5 microl ) , or of the NMDA receptor agonist N - methyl - d - aspartate ( NMDA , 20 or 30 nmol / 0 . 5 microl ) .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O B B O O O B I I O O O O O O O O O O O O B O O O O O O O O O O O O O O O B O O B I I I I I I O B O O O O O O O O O O O O	['catalepsy']	1	4	"Sentence: Haloperidol - induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists , MK - 801 ( 15 or 30 mmol / 0 . 5 microl ) and AP7 ( 10 or 20 nmol / 0 . 5 microl ) , or of the NMDA receptor agonist N - methyl - d - aspartate ( NMDA , 20 or 30 nmol / 0 . 5 microl ) .
Diseases: catalepsy"	"Sentence: Haloperidol - induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists , MK - 801 ( 15 or 30 mmol / 0 . 5 microl ) and AP7 ( 10 or 20 nmol / 0 . 5 microl ) , or of the NMDA receptor agonist N - methyl - d - aspartate ( NMDA , 20 or 30 nmol / 0 . 5 microl ) .
Diseases:"
733	The results showed that intracollicular microinjection of MK - 801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy , as indicated by a reduced latency to step down from a horizontal bar .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	O O O O O O O B I I O B O O O O O B O O O O O O O O O O O O O O O O O O O	['catalepsy']	1	4	"Sentence: The results showed that intracollicular microinjection of MK - 801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy , as indicated by a reduced latency to step down from a horizontal bar .
Diseases: catalepsy"	"Sentence: The results showed that intracollicular microinjection of MK - 801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy , as indicated by a reduced latency to step down from a horizontal bar .
Diseases:"
734	Accordingly , intracollicular microinjection of NMDA increased the latency to step down the bar .	O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O	[]	0	0	"Sentence: Accordingly , intracollicular microinjection of NMDA increased the latency to step down the bar .
Diseases: "	"Sentence: Accordingly , intracollicular microinjection of NMDA increased the latency to step down the bar .
Diseases:"
735	These findings suggest that glutamate - mediated mechanisms in the neural circuits at the IC level influence haloperidol - induced catalepsy and participate in the regulation of motor activity .	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O	['catalepsy']	1	4	"Sentence: These findings suggest that glutamate - mediated mechanisms in the neural circuits at the IC level influence haloperidol - induced catalepsy and participate in the regulation of motor activity .
Diseases: catalepsy"	"Sentence: These findings suggest that glutamate - mediated mechanisms in the neural circuits at the IC level influence haloperidol - induced catalepsy and participate in the regulation of motor activity .
Diseases:"
736	Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson 's disease .	O O O O O O O O O O O O B I I O	O B O O O O O O O O O O O O O O	"[""parkinson 's disease""]"	1	5	"Sentence: Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson 's disease .
Diseases: parkinson 's disease"	"Sentence: Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson 's disease .
Diseases:"
737	Metabotropic glutamate ( mGlu ) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson 's disease ( PD ) .	O O O O O O O O O O O O O O O O O O O O O O O B I I O B O O	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	"['pd', ""parkinson 's disease""]"	2	7	"Sentence: Metabotropic glutamate ( mGlu ) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson 's disease ( PD ) .
Diseases: pd, parkinson 's disease"	"Sentence: Metabotropic glutamate ( mGlu ) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson 's disease ( PD ) .
Diseases:"
738	Among the eight mGlu receptor subtypes , mGlu7 receptor is prominently expressed in the basal ganglia , but its role in restoring motor function in animal models of PD is not known .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pd']	1	1	"Sentence: Among the eight mGlu receptor subtypes , mGlu7 receptor is prominently expressed in the basal ganglia , but its role in restoring motor function in animal models of PD is not known .
Diseases: pd"	"Sentence: Among the eight mGlu receptor subtypes , mGlu7 receptor is prominently expressed in the basal ganglia , but its role in restoring motor function in animal models of PD is not known .
Diseases:"
739	The effects of N , N' - dibenzhydrylethane - 1 , 2 - diamine dihydrochloride ( AMN082 ) , the first selective allosteric activator of mGlu7 receptors , were thus tested in different rodent models of PD .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O B I I I I I I I I I I I O B O O O O O O O O O O O O O O O O O O O O O	['pd']	1	1	"Sentence: The effects of N , N' - dibenzhydrylethane - 1 , 2 - diamine dihydrochloride ( AMN082 ) , the first selective allosteric activator of mGlu7 receptors , were thus tested in different rodent models of PD .
Diseases: pd"	"Sentence: The effects of N , N' - dibenzhydrylethane - 1 , 2 - diamine dihydrochloride ( AMN082 ) , the first selective allosteric activator of mGlu7 receptors , were thus tested in different rodent models of PD .
Diseases:"
740	Here , we show that oral ( 5 mg / kg ) or intrastriatal administration ( 0 . 1 and 0 . 5 nmol ) of AMN082 reverses haloperidol - induced catalepsy in rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O	['catalepsy']	1	4	"Sentence: Here , we show that oral ( 5 mg / kg ) or intrastriatal administration ( 0 . 1 and 0 . 5 nmol ) of AMN082 reverses haloperidol - induced catalepsy in rats .
Diseases: catalepsy"	"Sentence: Here , we show that oral ( 5 mg / kg ) or intrastriatal administration ( 0 . 1 and 0 . 5 nmol ) of AMN082 reverses haloperidol - induced catalepsy in rats .
Diseases:"
741	AMN082 ( 2 . 5 and 5 mg / kg ) reduces apomorphine - induced rotations in unilateral 6 - hydroxydopamine ( 6 - OHDA ) - lesioned rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O B O O O O O B I I O B I I O O O O O	[]	0	0	"Sentence: AMN082 ( 2 . 5 and 5 mg / kg ) reduces apomorphine - induced rotations in unilateral 6 - hydroxydopamine ( 6 - OHDA ) - lesioned rats .
Diseases: "	"Sentence: AMN082 ( 2 . 5 and 5 mg / kg ) reduces apomorphine - induced rotations in unilateral 6 - hydroxydopamine ( 6 - OHDA ) - lesioned rats .
Diseases:"
742	In a more complex task commonly used to evaluate major akinetic symptoms of PD patients , 5 mg / kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6 - OHDA - lesioned rats .	O O O O O O O O O O B O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O B I I O O O O	['akinetic', 'pd']	2	5	"Sentence: In a more complex task commonly used to evaluate major akinetic symptoms of PD patients , 5 mg / kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6 - OHDA - lesioned rats .
Diseases: akinetic, pd"	"Sentence: In a more complex task commonly used to evaluate major akinetic symptoms of PD patients , 5 mg / kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6 - OHDA - lesioned rats .
Diseases:"
743	In addition , AMN082 reduces the duration of haloperidol - induced catalepsy in a mGlu7 receptor - dependent manner in wild - type but not mGlu7 receptor knockout mice .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	O O O B O O O O B O O O O O O O O O O O O O O O O O O O O O	['catalepsy']	1	4	"Sentence: In addition , AMN082 reduces the duration of haloperidol - induced catalepsy in a mGlu7 receptor - dependent manner in wild - type but not mGlu7 receptor knockout mice .
Diseases: catalepsy"	"Sentence: In addition , AMN082 reduces the duration of haloperidol - induced catalepsy in a mGlu7 receptor - dependent manner in wild - type but not mGlu7 receptor knockout mice .
Diseases:"
744	Higher doses of AMN082 ( 10 and 20 mg / kg p . o . ) have no effect on the same models of PD .	O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O B O O O O O O O O O O O O O O O O O O O O O O	['pd']	1	1	"Sentence: Higher doses of AMN082 ( 10 and 20 mg / kg p . o . ) have no effect on the same models of PD .
Diseases: pd"	"Sentence: Higher doses of AMN082 ( 10 and 20 mg / kg p . o . ) have no effect on the same models of PD .
Diseases:"
745	Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity .
Diseases: "	"Sentence: Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity .
Diseases:"
746	Selective ligands of mGlu7 receptor subtypes may thus be considered as promising compounds for the development of antiparkinsonian therapeutic strategies .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Selective ligands of mGlu7 receptor subtypes may thus be considered as promising compounds for the development of antiparkinsonian therapeutic strategies .
Diseases: "	"Sentence: Selective ligands of mGlu7 receptor subtypes may thus be considered as promising compounds for the development of antiparkinsonian therapeutic strategies .
Diseases:"
747	Nimodipine prevents memory impairment caused by nitroglycerin - induced hypotension in adult mice .	O O B I O O O O O B O O O O	B O O O O O B O O O O O O O	['hypotension', 'memory impairment']	2	6	"Sentence: Nimodipine prevents memory impairment caused by nitroglycerin - induced hypotension in adult mice .
Diseases: hypotension, memory impairment"	"Sentence: Nimodipine prevents memory impairment caused by nitroglycerin - induced hypotension in adult mice .
Diseases:"
748	BACKGROUND : Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction .	O O B O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O	['hypotension', 'cognitive dysfunction']	2	6	"Sentence: BACKGROUND : Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction .
Diseases: hypotension, cognitive dysfunction"	"Sentence: BACKGROUND : Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction .
Diseases:"
749	We tested the hypothesis that nimodipine ( NIMO ) administered at the onset of nitroglycerin ( NTG ) - induced hypotension would preserve long - term associative memory .	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	O O O O O B O B O O O O O O B O B O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: We tested the hypothesis that nimodipine ( NIMO ) administered at the onset of nitroglycerin ( NTG ) - induced hypotension would preserve long - term associative memory .
Diseases: hypotension"	"Sentence: We tested the hypothesis that nimodipine ( NIMO ) administered at the onset of nitroglycerin ( NTG ) - induced hypotension would preserve long - term associative memory .
Diseases:"
750	The passive avoidance ( PA ) paradigm was used to assess memory retention .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: The passive avoidance ( PA ) paradigm was used to assess memory retention .
Diseases: "	"Sentence: The passive avoidance ( PA ) paradigm was used to assess memory retention .
Diseases:"
751	For PA training , latencies ( seconds ) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: For PA training , latencies ( seconds ) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered .
Diseases: "	"Sentence: For PA training , latencies ( seconds ) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered .
Diseases:"
752	Latencies were recorded 48 h later for a testing trial .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: Latencies were recorded 48 h later for a testing trial .
Diseases: "	"Sentence: Latencies were recorded 48 h later for a testing trial .
Diseases:"
753	Ninety - six Swiss - Webster mice ( 30 - 35 g , 6 - 8 wk ) , were randomized into 6 groups 1 ) saline ( control ) , 2 ) NTG immediately after learning , 3 ) NTG 3 h after learning , 4 ) NTG and NIMO , 5 ) vehicle , and 6 ) NIMO alone .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O B O O O O O O O B O B O O O O O O O O B O O	[]	0	0	"Sentence: Ninety - six Swiss - Webster mice ( 30 - 35 g , 6 - 8 wk ) , were randomized into 6 groups 1 ) saline ( control ) , 2 ) NTG immediately after learning , 3 ) NTG 3 h after learning , 4 ) NTG and NIMO , 5 ) vehicle , and 6 ) NIMO alone .
Diseases: "	"Sentence: Ninety - six Swiss - Webster mice ( 30 - 35 g , 6 - 8 wk ) , were randomized into 6 groups 1 ) saline ( control ) , 2 ) NTG immediately after learning , 3 ) NTG 3 h after learning , 4 ) NTG and NIMO , 5 ) vehicle , and 6 ) NIMO alone .
Diseases:"
754	The extent of hypotension and changes in brain tissue oxygenation ( PbtO ( 2 ) ) and in cerebral blood flow were studied in a separate group of animals .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: The extent of hypotension and changes in brain tissue oxygenation ( PbtO ( 2 ) ) and in cerebral blood flow were studied in a separate group of animals .
Diseases: hypotension"	"Sentence: The extent of hypotension and changes in brain tissue oxygenation ( PbtO ( 2 ) ) and in cerebral blood flow were studied in a separate group of animals .
Diseases:"
755	RESULTS : All groups exhibited similar training latencies ( 17 . 0 + / - 4 . 6 s ) .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: RESULTS : All groups exhibited similar training latencies ( 17 . 0 + / - 4 . 6 s ) .
Diseases: "	"Sentence: RESULTS : All groups exhibited similar training latencies ( 17 . 0 + / - 4 . 6 s ) .
Diseases:"
756	Mice subjected to hypotensive episodes showed a significant decrease in latency time ( 178 + / -	O O O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	['hypotensive']	1	3	"Sentence: Mice subjected to hypotensive episodes showed a significant decrease in latency time ( 178 + / -
Diseases: hypotensive"	"Sentence: Mice subjected to hypotensive episodes showed a significant decrease in latency time ( 178 + / -
Diseases:"
757	156 s ) compared with those injected with saline , NTG + NIMO , or delayed NTG ( 580 + / -	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O B O O O B O O O O O	[]	0	0	"Sentence: 156 s ) compared with those injected with saline , NTG + NIMO , or delayed NTG ( 580 + / -
Diseases: "	"Sentence: 156 s ) compared with those injected with saline , NTG + NIMO , or delayed NTG ( 580 + / -
Diseases:"
758	81 s , 557 + / -	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: 81 s , 557 + / -
Diseases: "	"Sentence: 81 s , 557 + / -
Diseases:"
759	67 s , and 493 + / -	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: 67 s , and 493 + / -
Diseases: "	"Sentence: 67 s , and 493 + / -
Diseases:"
760	146 s , respectively ) .	O O O O O O	O O O O O O	[]	0	0	"Sentence: 146 s , respectively ) .
Diseases: "	"Sentence: 146 s , respectively ) .
Diseases:"
761	A Kruskal - Wallis 1 - way analysis of variance indicated a significant difference among the 4 treatment groups ( H = 15 . 34 ; P < 0 . 001 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A Kruskal - Wallis 1 - way analysis of variance indicated a significant difference among the 4 treatment groups ( H = 15 . 34 ; P < 0 . 001 ) .
Diseases: "	"Sentence: A Kruskal - Wallis 1 - way analysis of variance indicated a significant difference among the 4 treatment groups ( H = 15 . 34 ; P < 0 . 001 ) .
Diseases:"
762	In a separate group of mice not subjected to behavioral studies , the same dose of NTG ( n = 3 ) and NTG + NIMO ( n = 3 ) caused mean arterial blood pressure to decrease from 85 . 9 + / -	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O B O B O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In a separate group of mice not subjected to behavioral studies , the same dose of NTG ( n = 3 ) and NTG + NIMO ( n = 3 ) caused mean arterial blood pressure to decrease from 85 . 9 + / -
Diseases: "	"Sentence: In a separate group of mice not subjected to behavioral studies , the same dose of NTG ( n = 3 ) and NTG + NIMO ( n = 3 ) caused mean arterial blood pressure to decrease from 85 . 9 + / -
Diseases:"
763	3 . 8 mm	O O O O	O O O O	[]	0	0	"Sentence: 3 . 8 mm
Diseases: "	"Sentence: 3 . 8 mm
Diseases:"
764	Hg sem to 31 . 6 + / - 0 . 8 mm	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Hg sem to 31 . 6 + / - 0 . 8 mm
Diseases: "	"Sentence: Hg sem to 31 . 6 + / - 0 . 8 mm
Diseases:"
765	Hg sem and from 86 . 2 + / -	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Hg sem and from 86 . 2 + / -
Diseases: "	"Sentence: Hg sem and from 86 . 2 + / -
Diseases:"
766	3 . 7 mm	O O O O	O O O O	[]	0	0	"Sentence: 3 . 7 mm
Diseases: "	"Sentence: 3 . 7 mm
Diseases:"
767	Hg sem to 32 . 6 + / -	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Hg sem to 32 . 6 + / -
Diseases: "	"Sentence: Hg sem to 32 . 6 + / -
Diseases:"
768	0 . 2 mm	O O O O	O O O O	[]	0	0	"Sentence: 0 . 2 mm
Diseases: "	"Sentence: 0 . 2 mm
Diseases:"
769	Hg sem , respectively .	O O O O O	O O O O O	[]	0	0	"Sentence: Hg sem , respectively .
Diseases: "	"Sentence: Hg sem , respectively .
Diseases:"
770	Mean arterial blood pressure in mice treated with NIMO alone decreased from 88 . 1 + / - 3 . 8 mm	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: Mean arterial blood pressure in mice treated with NIMO alone decreased from 88 . 1 + / - 3 . 8 mm
Diseases: "	"Sentence: Mean arterial blood pressure in mice treated with NIMO alone decreased from 88 . 1 + / - 3 . 8 mm
Diseases:"
771	Hg to 80 . 0 + / - 2 . 9 mm	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: Hg to 80 . 0 + / - 2 . 9 mm
Diseases: "	"Sentence: Hg to 80 . 0 + / - 2 . 9 mm
Diseases:"
772	Hg .	O O	O O	[]	0	0	"Sentence: Hg .
Diseases: "	"Sentence: Hg .
Diseases:"
773	The intergroup difference was statistically significant ( P < 0 . 05 ) .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: The intergroup difference was statistically significant ( P < 0 . 05 ) .
Diseases: "	"Sentence: The intergroup difference was statistically significant ( P < 0 . 05 ) .
Diseases:"
774	PbtO ( 2 ) decreased from 51 . 7 + / -	O O O O O O O O O O O O	B O O O O O O O O O O O	[]	0	0	"Sentence: PbtO ( 2 ) decreased from 51 . 7 + / -
Diseases: "	"Sentence: PbtO ( 2 ) decreased from 51 . 7 + / -
Diseases:"
775	4 . 5 mm	O O O O	O O O O	[]	0	0	"Sentence: 4 . 5 mm
Diseases: "	"Sentence: 4 . 5 mm
Diseases:"
776	Hg sem to 33 . 8 + / -	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Hg sem to 33 . 8 + / -
Diseases: "	"Sentence: Hg sem to 33 . 8 + / -
Diseases:"
777	5 . 2 mm	O O O O	O O O O	[]	0	0	"Sentence: 5 . 2 mm
Diseases: "	"Sentence: 5 . 2 mm
Diseases:"
778	Hg sem in the NTG group and from 38 . 6 + / -	O O O O O O O O O O O O O O	O O O O B O O O O O O O O O	[]	0	0	"Sentence: Hg sem in the NTG group and from 38 . 6 + / -
Diseases: "	"Sentence: Hg sem in the NTG group and from 38 . 6 + / -
Diseases:"
779	6 . 1 mm	O O O O	O O O O	[]	0	0	"Sentence: 6 . 1 mm
Diseases: "	"Sentence: 6 . 1 mm
Diseases:"
780	Hg sem to 25 . 4 + / - 2 . 0 mm	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Hg sem to 25 . 4 + / - 2 . 0 mm
Diseases: "	"Sentence: Hg sem to 25 . 4 + / - 2 . 0 mm
Diseases:"
781	Hg sem in the NTG + NIMO groups , respectively .	O O O O O O O O O O O	O O O O B O B O O O O	[]	0	0	"Sentence: Hg sem in the NTG + NIMO groups , respectively .
Diseases: "	"Sentence: Hg sem in the NTG + NIMO groups , respectively .
Diseases:"
782	There were no significant differences among groups .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: There were no significant differences among groups .
Diseases: "	"Sentence: There were no significant differences among groups .
Diseases:"
783	In a PA retention paradigm , the injection of NTG immediately after learning produced a significant impairment of long - term associative memory in mice , whereas delayed induced hypotension had no effect .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: In a PA retention paradigm , the injection of NTG immediately after learning produced a significant impairment of long - term associative memory in mice , whereas delayed induced hypotension had no effect .
Diseases: hypotension"	"Sentence: In a PA retention paradigm , the injection of NTG immediately after learning produced a significant impairment of long - term associative memory in mice , whereas delayed induced hypotension had no effect .
Diseases:"
784	NIMO attenuated the disruption in consolidation of long - term memory caused by NTG but did not improve latency in the absence of hypotension .	O O O O O O O O O O O O O O O O O O O O O O O B O	B O O O O O O O O O O O O B O O O O O O O O O O O	['hypotension']	1	3	"Sentence: NIMO attenuated the disruption in consolidation of long - term memory caused by NTG but did not improve latency in the absence of hypotension .
Diseases: hypotension"	"Sentence: NIMO attenuated the disruption in consolidation of long - term memory caused by NTG but did not improve latency in the absence of hypotension .
Diseases:"
785	The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension , because there were no differences in the PbtO ( 2 ) indices among groups .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension , because there were no differences in the PbtO ( 2 ) indices among groups .
Diseases: hypotension"	"Sentence: The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension , because there were no differences in the PbtO ( 2 ) indices among groups .
Diseases:"
786	Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin .	O B O B I O O O O O O O O O O	O O O O O O O O O O B O O B O	['gastrointestinal haemorrhage', 'haemopericardium']	2	16	"Sentence: Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin .
Diseases: gastrointestinal haemorrhage, haemopericardium"	"Sentence: Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin .
Diseases:"
787	We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O O O O O O O O B O	['haemorrhage']	1	5	"Sentence: We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin .
Diseases: haemorrhage"	"Sentence: We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin .
Diseases:"
788	We propose that naturally occurring compounds such as flavonoids , which are present in fruit juices , may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O B O O O O O O O O B O	[]	0	0	"Sentence: We propose that naturally occurring compounds such as flavonoids , which are present in fruit juices , may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin .
Diseases: "	"Sentence: We propose that naturally occurring compounds such as flavonoids , which are present in fruit juices , may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin .
Diseases:"
789	While traditionally regarded as foodstuffs , consumption of fruit juices should be considered when patients develop adverse drug reactions .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: While traditionally regarded as foodstuffs , consumption of fruit juices should be considered when patients develop adverse drug reactions .
Diseases: "	"Sentence: While traditionally regarded as foodstuffs , consumption of fruit juices should be considered when patients develop adverse drug reactions .
Diseases:"
790	Isoproterenol induces primary loss of dystrophin in rat hearts : correlation with myocardial injury .	O O O O O O O O O O O O B I O	B O O O O O O O O O O O O O O	['myocardial injury']	1	4	"Sentence: Isoproterenol induces primary loss of dystrophin in rat hearts : correlation with myocardial injury .
Diseases: myocardial injury"	"Sentence: Isoproterenol induces primary loss of dystrophin in rat hearts : correlation with myocardial injury .
Diseases:"
791	The mechanism of isoproterenol - induced myocardial damage is unknown , but a mismatch of oxygen supply vs . demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed .	O O O O O O B I O O O O O O O O O O O O O O B O B I O O O O O O O O O O O	O O O B O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	['myocardial hyperactivity', 'myocardial damage', 'hypotension']	3	13	"Sentence: The mechanism of isoproterenol - induced myocardial damage is unknown , but a mismatch of oxygen supply vs . demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed .
Diseases: myocardial hyperactivity, myocardial damage, hypotension"	"Sentence: The mechanism of isoproterenol - induced myocardial damage is unknown , but a mismatch of oxygen supply vs . demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed .
Diseases:"
792	Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by isoproterenol .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by isoproterenol .
Diseases: "	"Sentence: Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by isoproterenol .
Diseases:"
793	Taking into account that the sarcolemmal integrity is stabilized by the dystrophin - glycoprotein complex ( DGC ) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins , this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: Taking into account that the sarcolemmal integrity is stabilized by the dystrophin - glycoprotein complex ( DGC ) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins , this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins .
Diseases: "	"Sentence: Taking into account that the sarcolemmal integrity is stabilized by the dystrophin - glycoprotein complex ( DGC ) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins , this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins .
Diseases:"
794	We found different sensitivity of the DGC and integrin to isoproterenol subcutaneous administration .	O O O O O O O O O O O O O O	O O O O O O O O O O B O O O	[]	0	0	"Sentence: We found different sensitivity of the DGC and integrin to isoproterenol subcutaneous administration .
Diseases: "	"Sentence: We found different sensitivity of the DGC and integrin to isoproterenol subcutaneous administration .
Diseases:"
795	Immunofluorescent staining revealed that dystrophin is the most sensitive among the structures connecting the actin in the cardiomyocyte cytoskeleton and the extracellular matrix .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Immunofluorescent staining revealed that dystrophin is the most sensitive among the structures connecting the actin in the cardiomyocyte cytoskeleton and the extracellular matrix .
Diseases: "	"Sentence: Immunofluorescent staining revealed that dystrophin is the most sensitive among the structures connecting the actin in the cardiomyocyte cytoskeleton and the extracellular matrix .
Diseases:"
796	The sarcomeric actin dissolution occurred after the reduction or loss of dystrophin .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: The sarcomeric actin dissolution occurred after the reduction or loss of dystrophin .
Diseases: "	"Sentence: The sarcomeric actin dissolution occurred after the reduction or loss of dystrophin .
Diseases:"
797	Subsequently , after lysis of myofilaments , gamma - sarcoglycan , beta - dystroglycan , beta1 - integrin , and laminin alpha - 2 expressions were reduced followed by their breakdown , as epiphenomena of the myocytolytic process .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Subsequently , after lysis of myofilaments , gamma - sarcoglycan , beta - dystroglycan , beta1 - integrin , and laminin alpha - 2 expressions were reduced followed by their breakdown , as epiphenomena of the myocytolytic process .
Diseases: "	"Sentence: Subsequently , after lysis of myofilaments , gamma - sarcoglycan , beta - dystroglycan , beta1 - integrin , and laminin alpha - 2 expressions were reduced followed by their breakdown , as epiphenomena of the myocytolytic process .
Diseases:"
798	In conclusion , administration of isoproterenol to rats results in primary loss of dystrophin , the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In conclusion , administration of isoproterenol to rats results in primary loss of dystrophin , the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte .
Diseases: "	"Sentence: In conclusion , administration of isoproterenol to rats results in primary loss of dystrophin , the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte .
Diseases:"
799	These changes , related to ischaemic injury , explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol .	O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['ischaemic injury']	1	4	"Sentence: These changes , related to ischaemic injury , explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol .
Diseases: ischaemic injury"	"Sentence: These changes , related to ischaemic injury , explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol .
Diseases:"
800	High fat diet - fed obese rats are highly sensitive to doxorubicin - induced cardiotoxicity .	O O O O O B O O O O O O O O B O	O O O O O O O O O O O B O O O O	['cardiotoxicity', 'obese']	2	5	"Sentence: High fat diet - fed obese rats are highly sensitive to doxorubicin - induced cardiotoxicity .
Diseases: cardiotoxicity, obese"	"Sentence: High fat diet - fed obese rats are highly sensitive to doxorubicin - induced cardiotoxicity .
Diseases:"
801	Often , chemotherapy by doxorubicin ( Adriamycin ) is limited due to life threatening cardiotoxicity in patients during and posttherapy .	O O O O O O O O O O O O O O B O O O O O O	O O O O B O B O O O O O O O O O O O O O O	['cardiotoxicity']	1	3	"Sentence: Often , chemotherapy by doxorubicin ( Adriamycin ) is limited due to life threatening cardiotoxicity in patients during and posttherapy .
Diseases: cardiotoxicity"	"Sentence: Often , chemotherapy by doxorubicin ( Adriamycin ) is limited due to life threatening cardiotoxicity in patients during and posttherapy .
Diseases:"
802	Recently , we have shown that moderate diet restriction remarkably protects against doxorubicin - induced cardiotoxicity .	O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O B O O O O	['cardiotoxicity']	1	3	"Sentence: Recently , we have shown that moderate diet restriction remarkably protects against doxorubicin - induced cardiotoxicity .
Diseases: cardiotoxicity"	"Sentence: Recently , we have shown that moderate diet restriction remarkably protects against doxorubicin - induced cardiotoxicity .
Diseases:"
803	This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty - acid oxidation , ATP synthesis , and upregulated JAK / STAT3 pathway .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O I O O B O O O O O O O O O	[]	0	0	"Sentence: This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty - acid oxidation , ATP synthesis , and upregulated JAK / STAT3 pathway .
Diseases: "	"Sentence: This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty - acid oxidation , ATP synthesis , and upregulated JAK / STAT3 pathway .
Diseases:"
804	In the current study , we investigated whether a physiological intervention by feeding 40 % high fat diet ( HFD ) , which induces obesity in male Sprague - Dawley rats ( 250 - 275 g ) , sensitizes to doxorubicin - induced cardiotoxicity .	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['cardiotoxicity', 'obesity']	2	5	"Sentence: In the current study , we investigated whether a physiological intervention by feeding 40 % high fat diet ( HFD ) , which induces obesity in male Sprague - Dawley rats ( 250 - 275 g ) , sensitizes to doxorubicin - induced cardiotoxicity .
Diseases: cardiotoxicity, obesity"	"Sentence: In the current study , we investigated whether a physiological intervention by feeding 40 % high fat diet ( HFD ) , which induces obesity in male Sprague - Dawley rats ( 250 - 275 g ) , sensitizes to doxorubicin - induced cardiotoxicity .
Diseases:"
805	A LD ( 10 ) dose ( 8 mg doxorubicin / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity , cardiac dysfunction , lipid peroxidation , and 80 % mortality in the obese ( OB ) rats in the absence of any significant renal or hepatic toxicity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B I O O O O O O O O O O B O B O O O O O O O O B I I I O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cardiotoxicity', 'ob', 'obese', 'cardiac dysfunction', 'renal or hepatic toxicity']	5	16	"Sentence: A LD ( 10 ) dose ( 8 mg doxorubicin / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity , cardiac dysfunction , lipid peroxidation , and 80 % mortality in the obese ( OB ) rats in the absence of any significant renal or hepatic toxicity .
Diseases: cardiotoxicity, ob, obese, cardiac dysfunction, renal or hepatic toxicity"	"Sentence: A LD ( 10 ) dose ( 8 mg doxorubicin / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity , cardiac dysfunction , lipid peroxidation , and 80 % mortality in the obese ( OB ) rats in the absence of any significant renal or hepatic toxicity .
Diseases:"
806	Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol ( toxic metabolite ) in the normal diet - fed ( ND ) and OB hearts .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	B O O O O O O O O B O B O O O O O O O O O O O O O O O O O	['ob']	1	1	"Sentence: Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol ( toxic metabolite ) in the normal diet - fed ( ND ) and OB hearts .
Diseases: ob"	"Sentence: Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol ( toxic metabolite ) in the normal diet - fed ( ND ) and OB hearts .
Diseases:"
807	Mechanistic studies revealed that OB rats are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3 , ( 2 ) downregulation of cardiac peroxisome proliferators activated receptor - alpha , ( 3 ) decreased plasma adiponectin levels , ( 4 ) decreased cardiac fatty - acid oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in OB ) , ( 5 ) decreased mitochondrial AMP - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac ATP levels accompanied by decreased ATP / ADP ratio after doxorubicin administration .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O B O I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O B O O O O B O B O O B O O	['ob']	1	1	"Sentence: Mechanistic studies revealed that OB rats are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3 , ( 2 ) downregulation of cardiac peroxisome proliferators activated receptor - alpha , ( 3 ) decreased plasma adiponectin levels , ( 4 ) decreased cardiac fatty - acid oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in OB ) , ( 5 ) decreased mitochondrial AMP - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac ATP levels accompanied by decreased ATP / ADP ratio after doxorubicin administration .
Diseases: ob"	"Sentence: Mechanistic studies revealed that OB rats are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3 , ( 2 ) downregulation of cardiac peroxisome proliferators activated receptor - alpha , ( 3 ) decreased plasma adiponectin levels , ( 4 ) decreased cardiac fatty - acid oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in OB ) , ( 5 ) decreased mitochondrial AMP - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac ATP levels accompanied by decreased ATP / ADP ratio after doxorubicin administration .
Diseases:"
808	Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK / STAT3 pathway .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK / STAT3 pathway .
Diseases: "	"Sentence: Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK / STAT3 pathway .
Diseases:"
809	In conclusion , HFD - induced obese rats are highly sensitized to doxorubicin - induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation , increasing oxidative stress and downregulating the JAK / STAT3 pathway .	O O O O O O B O O O O O O O O B O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O B O O O O O O O O O O O O O	['cardiotoxicity', 'obese']	2	5	"Sentence: In conclusion , HFD - induced obese rats are highly sensitized to doxorubicin - induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation , increasing oxidative stress and downregulating the JAK / STAT3 pathway .
Diseases: cardiotoxicity, obese"	"Sentence: In conclusion , HFD - induced obese rats are highly sensitized to doxorubicin - induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation , increasing oxidative stress and downregulating the JAK / STAT3 pathway .
Diseases:"
810	Complete atrioventricular block secondary to lithium therapy .	O B I O O O O O	O O O O O B O O	['atrioventricular block']	1	5	"Sentence: Complete atrioventricular block secondary to lithium therapy .
Diseases: atrioventricular block"	"Sentence: Complete atrioventricular block secondary to lithium therapy .
Diseases:"
811	Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium .	B I I O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O	['sinus node dysfunction']	1	4	"Sentence: Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium .
Diseases: sinus node dysfunction"	"Sentence: Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium .
Diseases:"
812	In the present case , complete atrioventricular ( AV ) block with syncopal attacks developed secondary to lithium therapy , necessitating permanent pacemaker implantation .	O O O O O O B I I I I O B I O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O O	['atrioventricular ( av ) block', 'syncopal attacks']	2	12	"Sentence: In the present case , complete atrioventricular ( AV ) block with syncopal attacks developed secondary to lithium therapy , necessitating permanent pacemaker implantation .
Diseases: atrioventricular ( av ) block, syncopal attacks"	"Sentence: In the present case , complete atrioventricular ( AV ) block with syncopal attacks developed secondary to lithium therapy , necessitating permanent pacemaker implantation .
Diseases:"
813	Serum lithium levels remained under or within the therapeutic range during the syncopal attacks .	O O O O O O O O O O O O B I O	O B O O O O O O O O O O O O O	['syncopal attacks']	1	3	"Sentence: Serum lithium levels remained under or within the therapeutic range during the syncopal attacks .
Diseases: syncopal attacks"	"Sentence: Serum lithium levels remained under or within the therapeutic range during the syncopal attacks .
Diseases:"
814	Lithium should be used with extreme caution , especially in patients with mild disturbance of AV conduction .	O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Lithium should be used with extreme caution , especially in patients with mild disturbance of AV conduction .
Diseases: "	"Sentence: Lithium should be used with extreme caution , especially in patients with mild disturbance of AV conduction .
Diseases:"
815	Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment .	B I I O O O O O O O O O O	O O O O O B O O O O O O O	['neuroleptic malignant syndrome']	1	7	"Sentence: Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment .
Diseases: neuroleptic malignant syndrome"	"Sentence: Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment .
Diseases:"
816	Neuroleptic malignant syndrome ( NMS ) is the rarest and most serious of the neuroleptic - induced movement disorders .	B I I O B O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O	['neuroleptic malignant syndrome', 'movement disorders', 'nms']	3	13	"Sentence: Neuroleptic malignant syndrome ( NMS ) is the rarest and most serious of the neuroleptic - induced movement disorders .
Diseases: neuroleptic malignant syndrome, movement disorders, nms"	"Sentence: Neuroleptic malignant syndrome ( NMS ) is the rarest and most serious of the neuroleptic - induced movement disorders .
Diseases:"
817	We describe a case of neuroleptic malignant syndrome ( NMS ) associated with the use of ziprasidone .	O O O O O B I I O B O O O O O O O O	O O O O O O O O O O O O O O O O B O	['neuroleptic malignant syndrome', 'nms']	2	10	"Sentence: We describe a case of neuroleptic malignant syndrome ( NMS ) associated with the use of ziprasidone .
Diseases: neuroleptic malignant syndrome, nms"	"Sentence: We describe a case of neuroleptic malignant syndrome ( NMS ) associated with the use of ziprasidone .
Diseases:"
818	Although conventional neuroleptics are more frequently associated with NMS , atypical antipsychotic drugs like ziprasidone may also be a cause .	O O O O O O O O B O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O	['nms']	1	2	"Sentence: Although conventional neuroleptics are more frequently associated with NMS , atypical antipsychotic drugs like ziprasidone may also be a cause .
Diseases: nms"	"Sentence: Although conventional neuroleptics are more frequently associated with NMS , atypical antipsychotic drugs like ziprasidone may also be a cause .
Diseases:"
819	The patient is a 24 - year - old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80 - mg / day dose of orally administrated ziprasidone .	O O O O O O O O O O O O O O B O O O O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['schizophrenia', 'nms']	2	6	"Sentence: The patient is a 24 - year - old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80 - mg / day dose of orally administrated ziprasidone .
Diseases: schizophrenia, nms"	"Sentence: The patient is a 24 - year - old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80 - mg / day dose of orally administrated ziprasidone .
Diseases:"
820	This case is the earliest ( second day of treatment )	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: This case is the earliest ( second day of treatment )
Diseases: "	"Sentence: This case is the earliest ( second day of treatment )
Diseases:"
821	NMS due to ziprasidone reported in the literature .	B O O O O O O O O	O O O B O O O O O	['nms']	1	2	"Sentence: NMS due to ziprasidone reported in the literature .
Diseases: nms"	"Sentence: NMS due to ziprasidone reported in the literature .
Diseases:"
822	Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol - induced myocardial infarction in rats .	O O O O O O O O O O O O O B I O O O	O O B O O O O O O O B O O O O O O O	['myocardial infarction']	1	6	"Sentence: Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol - induced myocardial infarction in rats .
Diseases: myocardial infarction"	"Sentence: Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol - induced myocardial infarction in rats .
Diseases:"
823	The current study dealt with the protective role of mangiferin , a polyphenol from Mangifera indica Linn .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O B I O O	[]	0	0	"Sentence: The current study dealt with the protective role of mangiferin , a polyphenol from Mangifera indica Linn .
Diseases: "	"Sentence: The current study dealt with the protective role of mangiferin , a polyphenol from Mangifera indica Linn .
Diseases:"
824	( Anacardiaceae ) , on isoproterenol ( ISPH ) - induced myocardial infarction ( MI ) in rats through its antioxidative mechanism .	O O O O O O O O O O O B I O B O O O O O O O O	O O O O O B O B O O O O O O O O O O O O O O O	['mi', 'myocardial infarction']	2	8	"Sentence: ( Anacardiaceae ) , on isoproterenol ( ISPH ) - induced myocardial infarction ( MI ) in rats through its antioxidative mechanism .
Diseases: mi, myocardial infarction"	"Sentence: ( Anacardiaceae ) , on isoproterenol ( ISPH ) - induced myocardial infarction ( MI ) in rats through its antioxidative mechanism .
Diseases:"
825	Subcutaneous injection of ISPH ( 200 mg / kg body weight in 1 ml saline ) to rats for 2 consecutive days caused myocardial damage in rat heart , which was determined by the increased activity of serum lactate dehydrogenase ( LDH ) and creatine phosphokinase isoenzymes ( CK - MB ) , increased uric acid level and reduced plasma iron binding capacity .	O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O B O O O O O O O O O B I O O O O B O O O	['myocardial damage']	1	4	"Sentence: Subcutaneous injection of ISPH ( 200 mg / kg body weight in 1 ml saline ) to rats for 2 consecutive days caused myocardial damage in rat heart , which was determined by the increased activity of serum lactate dehydrogenase ( LDH ) and creatine phosphokinase isoenzymes ( CK - MB ) , increased uric acid level and reduced plasma iron binding capacity .
Diseases: myocardial damage"	"Sentence: Subcutaneous injection of ISPH ( 200 mg / kg body weight in 1 ml saline ) to rats for 2 consecutive days caused myocardial damage in rat heart , which was determined by the increased activity of serum lactate dehydrogenase ( LDH ) and creatine phosphokinase isoenzymes ( CK - MB ) , increased uric acid level and reduced plasma iron binding capacity .
Diseases:"
826	The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride ( TTC ) test used for macroscopic enzyme mapping assay of the ischemic myocardium .	O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O B O O O B I I O B O O O O O O O O O O O O O	['ischemic myocardium']	1	6	"Sentence: The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride ( TTC ) test used for macroscopic enzyme mapping assay of the ischemic myocardium .
Diseases: ischemic myocardium"	"Sentence: The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride ( TTC ) test used for macroscopic enzyme mapping assay of the ischemic myocardium .
Diseases:"
827	The heart tissue antioxidant enzymes such as superoxide dismutase , catalase , glutathione peroxidase , glutathione transferase and glutathione reductase activities , non - enzymic antioxidants such as cerruloplasmin , Vitamin C , Vitamin E and glutathione levels were altered in MI rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	O O O O O O O B O O O O B O O B O O B O O O O O O O O O B O B I O B I O B O O O O O O O	['mi']	1	1	"Sentence: The heart tissue antioxidant enzymes such as superoxide dismutase , catalase , glutathione peroxidase , glutathione transferase and glutathione reductase activities , non - enzymic antioxidants such as cerruloplasmin , Vitamin C , Vitamin E and glutathione levels were altered in MI rats .
Diseases: mi"	"Sentence: The heart tissue antioxidant enzymes such as superoxide dismutase , catalase , glutathione peroxidase , glutathione transferase and glutathione reductase activities , non - enzymic antioxidants such as cerruloplasmin , Vitamin C , Vitamin E and glutathione levels were altered in MI rats .
Diseases:"
828	Upon pretreatment with mangiferin ( 100 mg / kg body weight suspended in 2 ml of dimethyl sulphoxide ) given intraperitoneally for 28 days to MI rats protected the above - mentioned parameters to fall from the normal levels .	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O	['mi']	1	1	"Sentence: Upon pretreatment with mangiferin ( 100 mg / kg body weight suspended in 2 ml of dimethyl sulphoxide ) given intraperitoneally for 28 days to MI rats protected the above - mentioned parameters to fall from the normal levels .
Diseases: mi"	"Sentence: Upon pretreatment with mangiferin ( 100 mg / kg body weight suspended in 2 ml of dimethyl sulphoxide ) given intraperitoneally for 28 days to MI rats protected the above - mentioned parameters to fall from the normal levels .
Diseases:"
829	Activities of heart tissue enzymic antioxidants and serum non - enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH - induced MI rats .	O O O O O O O O O O O O O O O O O O O O O O O O B O O	O O O O O O O O O O O O O O O O B O O O O B O O O O O	['mi']	1	1	"Sentence: Activities of heart tissue enzymic antioxidants and serum non - enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH - induced MI rats .
Diseases: mi"	"Sentence: Activities of heart tissue enzymic antioxidants and serum non - enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH - induced MI rats .
Diseases:"
830	From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH - induced MI due to its antioxidant potential , which regulated the tissues defense system against cardiac damage .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O B I O	O O O O O O O O B O O O O O B O O O O O O O O O O O O O O O O O O O	['mi', 'cardiac damage']	2	4	"Sentence: From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH - induced MI due to its antioxidant potential , which regulated the tissues defense system against cardiac damage .
Diseases: mi, cardiac damage"	"Sentence: From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH - induced MI due to its antioxidant potential , which regulated the tissues defense system against cardiac damage .
Diseases:"
831	Remifentanil pretreatment reduces myoclonus after etomidate .	O O O B O O O	B O O O O B O	['myoclonus']	1	4	"Sentence: Remifentanil pretreatment reduces myoclonus after etomidate .
Diseases: myoclonus"	"Sentence: Remifentanil pretreatment reduces myoclonus after etomidate .
Diseases:"
832	STUDY OBJECTIVE :	O O O	O O O	[]	0	0	"Sentence: STUDY OBJECTIVE :
Diseases: "	"Sentence: STUDY OBJECTIVE :
Diseases:"
833	The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg / kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O B O	['myoclonus']	1	4	"Sentence: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg / kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate .
Diseases: myoclonus"	"Sentence: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg / kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate .
Diseases:"
834	DESIGN :	O O	O O	[]	0	0	"Sentence: DESIGN :
Diseases: "	"Sentence: DESIGN :
Diseases:"
835	This was a randomized , double - blind study .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: This was a randomized , double - blind study .
Diseases: "	"Sentence: This was a randomized , double - blind study .
Diseases:"
836	SETTING :	O O	O O	[]	0	0	"Sentence: SETTING :
Diseases: "	"Sentence: SETTING :
Diseases:"
837	The study was conducted at a university hospital .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: The study was conducted at a university hospital .
Diseases: "	"Sentence: The study was conducted at a university hospital .
Diseases:"
838	PATIENTS :	O O	O O	[]	0	0	"Sentence: PATIENTS :
Diseases: "	"Sentence: PATIENTS :
Diseases:"
839	Sixty patients were pretreated in a randomized double - blinded fashion with remifentanil 1 microg / kg or placebo .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: Sixty patients were pretreated in a randomized double - blinded fashion with remifentanil 1 microg / kg or placebo .
Diseases: "	"Sentence: Sixty patients were pretreated in a randomized double - blinded fashion with remifentanil 1 microg / kg or placebo .
Diseases:"
840	Two minutes after remifentanil or placebo injection , etomidate 0 . 3 mg / kg was given .	O O O O O O O O O O O O O O O O O O	O O O B O O O O B O O O O O O O O O	[]	0	0	"Sentence: Two minutes after remifentanil or placebo injection , etomidate 0 . 3 mg / kg was given .
Diseases: "	"Sentence: Two minutes after remifentanil or placebo injection , etomidate 0 . 3 mg / kg was given .
Diseases:"
841	MEASUREMENTS : Myoclonus was recorded with a scale of 0 to 3 .	O O B O O O O O O O O O O	O O O O O O O O O O O O O	['myoclonus']	1	4	"Sentence: MEASUREMENTS : Myoclonus was recorded with a scale of 0 to 3 .
Diseases: myoclonus"	"Sentence: MEASUREMENTS : Myoclonus was recorded with a scale of 0 to 3 .
Diseases:"
842	The grade of sedation ( none , mild , moderate , severe ) , nausea , pruritus , and apnea were recorded after injection of both drugs .	O O O O O O O O O O O O O O B O B O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nausea', 'pruritus', 'apnea']	3	10	"Sentence: The grade of sedation ( none , mild , moderate , severe ) , nausea , pruritus , and apnea were recorded after injection of both drugs .
Diseases: nausea, pruritus, apnea"	"Sentence: The grade of sedation ( none , mild , moderate , severe ) , nausea , pruritus , and apnea were recorded after injection of both drugs .
Diseases:"
843	The incidence of myoclonus was significantly lower in the remifentanil group ( 6 . 7 % ) than in the placebo group ( 70 % ) ( P < 0 . 001 ) .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['myoclonus']	1	4	"Sentence: The incidence of myoclonus was significantly lower in the remifentanil group ( 6 . 7 % ) than in the placebo group ( 70 % ) ( P < 0 . 001 ) .
Diseases: myoclonus"	"Sentence: The incidence of myoclonus was significantly lower in the remifentanil group ( 6 . 7 % ) than in the placebo group ( 70 % ) ( P < 0 . 001 ) .
Diseases:"
844	None of the patients experienced sedation , apnea , nausea , or pruritus after injection of both drugs .	O O O O O O O B O B O O B O O O O O O	O O O O O O O O O O O O O O O O O O O	['apnea', 'nausea', 'pruritus']	3	8	"Sentence: None of the patients experienced sedation , apnea , nausea , or pruritus after injection of both drugs .
Diseases: apnea, nausea, pruritus"	"Sentence: None of the patients experienced sedation , apnea , nausea , or pruritus after injection of both drugs .
Diseases:"
845	In the placebo group , male patients were associated with significantly increased incidence of myoclonus after etomidate administration .	O O O O O O O O O O O O O O B O O O O	O O O O O O O O O O O O O O O O B O O	['myoclonus']	1	4	"Sentence: In the placebo group , male patients were associated with significantly increased incidence of myoclonus after etomidate administration .
Diseases: myoclonus"	"Sentence: In the placebo group , male patients were associated with significantly increased incidence of myoclonus after etomidate administration .
Diseases:"
846	Pretreatment with remifentanil 1 microg / kg reduced myoclonus after etomidate induction without side effects such as sedation , apnea , nausea , or pruritus .	O O O O O O O O B O O O O O O O O O O B O B O O B O	O O B O O O O O O O B O O O O O O O O O O O O O O O	['apnea', 'nausea', 'pruritus', 'myoclonus']	4	13	"Sentence: Pretreatment with remifentanil 1 microg / kg reduced myoclonus after etomidate induction without side effects such as sedation , apnea , nausea , or pruritus .
Diseases: apnea, nausea, pruritus, myoclonus"	"Sentence: Pretreatment with remifentanil 1 microg / kg reduced myoclonus after etomidate induction without side effects such as sedation , apnea , nausea , or pruritus .
Diseases:"
847	Men experience increased incidence of myoclonus than women after etomidate administration .	O O O O O B O O O O O O	O O O O O O O O O B O O	['myoclonus']	1	4	"Sentence: Men experience increased incidence of myoclonus than women after etomidate administration .
Diseases: myoclonus"	"Sentence: Men experience increased incidence of myoclonus than women after etomidate administration .
Diseases:"
848	Daidzein activates choline acetyltransferase from MC - IXC cells and improves drug - induced amnesia .	O O O O O O O O O O O O O O B O	B O B O O O O O O O O O O O O O	['amnesia']	1	2	"Sentence: Daidzein activates choline acetyltransferase from MC - IXC cells and improves drug - induced amnesia .
Diseases: amnesia"	"Sentence: Daidzein activates choline acetyltransferase from MC - IXC cells and improves drug - induced amnesia .
Diseases:"
849	The choline acetyltransferase ( ChAT ) activator , which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine ( ACh ) , is an important factor in the treatment of Alzheimer 's disease ( AD ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O B O O	O B O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O	"[""alzheimer 's disease"", 'ad']"	2	8	"Sentence: The choline acetyltransferase ( ChAT ) activator , which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine ( ACh ) , is an important factor in the treatment of Alzheimer 's disease ( AD ) .
Diseases: alzheimer 's disease, ad"	"Sentence: The choline acetyltransferase ( ChAT ) activator , which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine ( ACh ) , is an important factor in the treatment of Alzheimer 's disease ( AD ) .
Diseases:"
850	Methanolic extracts from Pueraria thunbergiana exhibited an activation effect ( 46 % ) on ChAT in vitro .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Methanolic extracts from Pueraria thunbergiana exhibited an activation effect ( 46 % ) on ChAT in vitro .
Diseases: "	"Sentence: Methanolic extracts from Pueraria thunbergiana exhibited an activation effect ( 46 % ) on ChAT in vitro .
Diseases:"
851	Via the sequential isolation of Pueraria thunbergiana , the active component was ultimately identified as daidzein ( 4' , 7 - dihydroxy - isoflavone ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O B I I I I I I O O	[]	0	0	"Sentence: Via the sequential isolation of Pueraria thunbergiana , the active component was ultimately identified as daidzein ( 4' , 7 - dihydroxy - isoflavone ) .
Diseases: "	"Sentence: Via the sequential isolation of Pueraria thunbergiana , the active component was ultimately identified as daidzein ( 4' , 7 - dihydroxy - isoflavone ) .
Diseases:"
852	In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine - induced impairments of learning and memory , we conducted a series of in vivo tests .	O O O O O O O O O O O O O O O B I I I I O O O O O O O O O O	O O O O O O O B O O O O B O O O O O O O O O O O O O O O O O	['impairments of learning and memory']	1	7	"Sentence: In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine - induced impairments of learning and memory , we conducted a series of in vivo tests .
Diseases: impairments of learning and memory"	"Sentence: In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine - induced impairments of learning and memory , we conducted a series of in vivo tests .
Diseases:"
853	Administration of daidzein ( 4 . 5 mg / kg body weight ) to mice was shown significantly to reverse scopolamine - induced amnesia , according to the results of a Y - maze test .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	['amnesia']	1	2	"Sentence: Administration of daidzein ( 4 . 5 mg / kg body weight ) to mice was shown significantly to reverse scopolamine - induced amnesia , according to the results of a Y - maze test .
Diseases: amnesia"	"Sentence: Administration of daidzein ( 4 . 5 mg / kg body weight ) to mice was shown significantly to reverse scopolamine - induced amnesia , according to the results of a Y - maze test .
Diseases:"
854	Injections of scopolamine into mice resulted in impaired performance on Y - maze tests ( a 37 % decreases in alternation behavior ) .	O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Injections of scopolamine into mice resulted in impaired performance on Y - maze tests ( a 37 % decreases in alternation behavior ) .
Diseases: "	"Sentence: Injections of scopolamine into mice resulted in impaired performance on Y - maze tests ( a 37 % decreases in alternation behavior ) .
Diseases:"
855	By way of contrast , mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment ( an approximately 12 % - 21 % decrease in alternation behavior ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O B O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: By way of contrast , mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment ( an approximately 12 % - 21 % decrease in alternation behavior ) .
Diseases: "	"Sentence: By way of contrast , mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment ( an approximately 12 % - 21 % decrease in alternation behavior ) .
Diseases:"
856	These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator , and that it also ameliorates scopolamine - induced amnesia .	O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O B O O O O O B O O O O O O O O O O O B O O O O	['amnesia']	1	2	"Sentence: These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator , and that it also ameliorates scopolamine - induced amnesia .
Diseases: amnesia"	"Sentence: These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator , and that it also ameliorates scopolamine - induced amnesia .
Diseases:"
857	Possible azithromycin - associated hiccups .	O O O O B O	O B O O O O	['hiccups']	1	3	"Sentence: Possible azithromycin - associated hiccups .
Diseases: hiccups"	"Sentence: Possible azithromycin - associated hiccups .
Diseases:"
858	To report a case of persistent hiccups associated by azithromycin therapy .	O O O O O O B O O O O O	O O O O O O O O O B O O	['hiccups']	1	3	"Sentence: To report a case of persistent hiccups associated by azithromycin therapy .
Diseases: hiccups"	"Sentence: To report a case of persistent hiccups associated by azithromycin therapy .
Diseases:"
859	A 76 - year - old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis .	O O O O O O O O O O B O O O O O O O B O	O O O O O O O O O O O O O B O O O O O O	['pharyngitis', 'hiccups']	2	8	"Sentence: A 76 - year - old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis .
Diseases: pharyngitis, hiccups"	"Sentence: A 76 - year - old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis .
Diseases:"
860	Hiccups were persistent and exhausting .	B O O O O O	O O O O O O	['hiccups']	1	3	"Sentence: Hiccups were persistent and exhausting .
Diseases: hiccups"	"Sentence: Hiccups were persistent and exhausting .
Diseases:"
861	Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups .	O O O O O O O O O B O	O O B O O O B O O O O	['hiccups']	1	3	"Sentence: Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups .
Diseases: hiccups"	"Sentence: Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups .
Diseases:"
862	No organic cause of hiccups was identified despite extensive investigation .	O O O O B O O O O O O	O O O O O O O O O O O	['hiccups']	1	3	"Sentence: No organic cause of hiccups was identified despite extensive investigation .
Diseases: hiccups"	"Sentence: No organic cause of hiccups was identified despite extensive investigation .
Diseases:"
863	Pharmacotherapeutic agents have been uncommonly associated with hiccups .	O O O O O O O B O	O O O O O O O O O	['hiccups']	1	3	"Sentence: Pharmacotherapeutic agents have been uncommonly associated with hiccups .
Diseases: hiccups"	"Sentence: Pharmacotherapeutic agents have been uncommonly associated with hiccups .
Diseases:"
864	Corticosteroids ( dexamethasone and methylprednisolone ) , benzodiazepines ( midazolam ) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	B O B O B O O B O B O O O O O O O O O O O O O O O O O O O O O O O O	['hiccups']	1	3	"Sentence: Corticosteroids ( dexamethasone and methylprednisolone ) , benzodiazepines ( midazolam ) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups .
Diseases: hiccups"	"Sentence: Corticosteroids ( dexamethasone and methylprednisolone ) , benzodiazepines ( midazolam ) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups .
Diseases:"
865	Few cases of drug - induced hiccups have been reported related to macrolide antimicrobials .	O O O O O O B O O O O O O O O	O O O O O O O O O O O O B O O	['hiccups']	1	3	"Sentence: Few cases of drug - induced hiccups have been reported related to macrolide antimicrobials .
Diseases: hiccups"	"Sentence: Few cases of drug - induced hiccups have been reported related to macrolide antimicrobials .
Diseases:"
866	Using the Naranjo adverse effect reaction probability scale this event could be classified as possible ( score 5 points ) , mostly because of the close temporal sequence , previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	['hiccups']	1	3	"Sentence: Using the Naranjo adverse effect reaction probability scale this event could be classified as possible ( score 5 points ) , mostly because of the close temporal sequence , previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups .
Diseases: hiccups"	"Sentence: Using the Naranjo adverse effect reaction probability scale this event could be classified as possible ( score 5 points ) , mostly because of the close temporal sequence , previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups .
Diseases:"
867	Our hypothesis is that a vagal mechanism mediated by azithromycin could be the pathogenesis of hiccups in our patient .	O O O O O O O O O O O O O O O B O O O O	O O O O O O O O O B O O O O O O O O O O	['hiccups']	1	3	"Sentence: Our hypothesis is that a vagal mechanism mediated by azithromycin could be the pathogenesis of hiccups in our patient .
Diseases: hiccups"	"Sentence: Our hypothesis is that a vagal mechanism mediated by azithromycin could be the pathogenesis of hiccups in our patient .
Diseases:"
868	CONCLUSIONS : Diagnosis of drug - induced hiccups is difficult and often achieved only by a process of elimination .	O O O O O O O B O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	['hiccups']	1	3	"Sentence: CONCLUSIONS : Diagnosis of drug - induced hiccups is difficult and often achieved only by a process of elimination .
Diseases: hiccups"	"Sentence: CONCLUSIONS : Diagnosis of drug - induced hiccups is difficult and often achieved only by a process of elimination .
Diseases:"
869	However , macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side - effect .	O O O O O O O O O O O B O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O	['hiccups']	1	3	"Sentence: However , macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side - effect .
Diseases: hiccups"	"Sentence: However , macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side - effect .
Diseases:"
870	Time trends in warfarin - associated hemorrhage .	O O O O O O B O	O O O B O O O O	['hemorrhage']	1	4	"Sentence: Time trends in warfarin - associated hemorrhage .
Diseases: hemorrhage"	"Sentence: Time trends in warfarin - associated hemorrhage .
Diseases:"
871	The annual incidence of warfarin - related bleeding at Brigham and Women 's Hospital increased from 0 . 97 / 1 , 000 patient admissions in the first time period ( January 1995 to October 1998 ) to 1 . 19 / 1 , 000 patient admissions in the second time period ( November 1998 to August 2002 ) of this study .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['bleeding']	1	2	"Sentence: The annual incidence of warfarin - related bleeding at Brigham and Women 's Hospital increased from 0 . 97 / 1 , 000 patient admissions in the first time period ( January 1995 to October 1998 ) to 1 . 19 / 1 , 000 patient admissions in the second time period ( November 1998 to August 2002 ) of this study .
Diseases: bleeding"	"Sentence: The annual incidence of warfarin - related bleeding at Brigham and Women 's Hospital increased from 0 . 97 / 1 , 000 patient admissions in the first time period ( January 1995 to October 1998 ) to 1 . 19 / 1 , 000 patient admissions in the second time period ( November 1998 to August 2002 ) of this study .
Diseases:"
872	The proportion of patients with major and intracranial bleeding increased from 20 . 2 % and 1 . 9 % , respectively , in the first time period , to 33 . 3 % and 7 . 8 % , respectively , in the second .	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['intracranial bleeding']	1	5	"Sentence: The proportion of patients with major and intracranial bleeding increased from 20 . 2 % and 1 . 9 % , respectively , in the first time period , to 33 . 3 % and 7 . 8 % , respectively , in the second .
Diseases: intracranial bleeding"	"Sentence: The proportion of patients with major and intracranial bleeding increased from 20 . 2 % and 1 . 9 % , respectively , in the first time period , to 33 . 3 % and 7 . 8 % , respectively , in the second .
Diseases:"
873	Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy .	O B I O O O O O	O O O O O B O O	['haemorrhagic myocarditis']	1	8	"Sentence: Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy .
Diseases: haemorrhagic myocarditis"	"Sentence: Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy .
Diseases:"
874	Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy .	B I O O O O O O O O O O	O O O O O O O O O B O O	['haemorrhagic myocarditis']	1	8	"Sentence: Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy .
Diseases: haemorrhagic myocarditis"	"Sentence: Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy .
Diseases:"
875	Echocardiographic identification of the disorder can be made .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Echocardiographic identification of the disorder can be made .
Diseases: "	"Sentence: Echocardiographic identification of the disorder can be made .
Diseases:"
876	We believe that the ultrasound features of this disorder have not been previously reported .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We believe that the ultrasound features of this disorder have not been previously reported .
Diseases: "	"Sentence: We believe that the ultrasound features of this disorder have not been previously reported .
Diseases:"
877	Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura .	O O O O O B I I O O O B I I O	B I O O O O O O O O O O O O O	['migraine with aura', 'migraine without aura']	2	9	"Sentence: Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura .
Diseases: migraine with aura, migraine without aura"	"Sentence: Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura .
Diseases:"
878	Migraine with aura and migraine without aura have the same pain phase , thus indicating that migraine with aura and migraine without aura share a common pathway of nociception .	B I I O B I I O O O B O O O O O B I I O B I I O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['migraine with aura', 'pain', 'migraine without aura']	3	11	"Sentence: Migraine with aura and migraine without aura have the same pain phase , thus indicating that migraine with aura and migraine without aura share a common pathway of nociception .
Diseases: migraine with aura, pain, migraine without aura"	"Sentence: Migraine with aura and migraine without aura have the same pain phase , thus indicating that migraine with aura and migraine without aura share a common pathway of nociception .
Diseases:"
879	In recent years , increasing evidence has suggested that the messenger molecule nitric oxide ( NO ) is involved in pain mechanisms of migraine without aura .	O O O O O O O O O O O O O O O O O O O O B O O B I I O	O O O O O O O O O O O O B I O B O O O O O O O O O O O	['pain', 'migraine without aura']	2	5	"Sentence: In recent years , increasing evidence has suggested that the messenger molecule nitric oxide ( NO ) is involved in pain mechanisms of migraine without aura .
Diseases: pain, migraine without aura"	"Sentence: In recent years , increasing evidence has suggested that the messenger molecule nitric oxide ( NO ) is involved in pain mechanisms of migraine without aura .
Diseases:"
880	In order to clarify whether the same is true for migraine with aura , in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate ( GTN ) ( 0 . 5 microg / kg / min for 20 min ) in 12 sufferers of migraine with aura .	O O O O O O O O O O B I I O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O B O O O O O O O O O O O O O O O O O O O O O O	['migraine with aura', 'headache']	2	7	"Sentence: In order to clarify whether the same is true for migraine with aura , in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate ( GTN ) ( 0 . 5 microg / kg / min for 20 min ) in 12 sufferers of migraine with aura .
Diseases: migraine with aura, headache"	"Sentence: In order to clarify whether the same is true for migraine with aura , in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate ( GTN ) ( 0 . 5 microg / kg / min for 20 min ) in 12 sufferers of migraine with aura .
Diseases:"
881	The specific aim was to elucidate whether an aura and / or an attack of migraine without aura could be induced .	O O O O O O O O O O O O O O O B I I O O O O	O O O O O O O O O O O O O O O O O O O O O O	['migraine without aura']	1	5	"Sentence: The specific aim was to elucidate whether an aura and / or an attack of migraine without aura could be induced .
Diseases: migraine without aura"	"Sentence: The specific aim was to elucidate whether an aura and / or an attack of migraine without aura could be induced .
Diseases:"
882	Fourteen healthy subjects served as controls .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: Fourteen healthy subjects served as controls .
Diseases: "	"Sentence: Fourteen healthy subjects served as controls .
Diseases:"
883	Aura symptoms were not elicited in any subject .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Aura symptoms were not elicited in any subject .
Diseases: "	"Sentence: Aura symptoms were not elicited in any subject .
Diseases:"
884	Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion ( p = 0 . 037 ) as well as during the following 11 h ( p = 0 . 008 ) .	B O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['headache', 'migraineurs']	2	5	"Sentence: Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion ( p = 0 . 037 ) as well as during the following 11 h ( p = 0 . 008 ) .
Diseases: headache, migraineurs"	"Sentence: Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion ( p = 0 . 037 ) as well as during the following 11 h ( p = 0 . 008 ) .
Diseases:"
885	In the controls , the GTN - induced headache gradually disappeared , whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post - infusion .	O O O O O O O O B O O O O O B O B O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['headache', 'migraineurs']	2	5	"Sentence: In the controls , the GTN - induced headache gradually disappeared , whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post - infusion .
Diseases: headache, migraineurs"	"Sentence: In the controls , the GTN - induced headache gradually disappeared , whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post - infusion .
Diseases:"
886	At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society .	O O O O O B O O O O B O O O O O B I I O O O B O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['headache', 'migraine without aura', 'migraineurs']	3	9	"Sentence: At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society .
Diseases: headache, migraine without aura, migraineurs"	"Sentence: At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society .
Diseases:"
887	The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura .	O O O O O O O O O O B O O B I I O	O O O O O B O O O O O O O O O O O	['migraine with aura', 'pain']	2	7	"Sentence: The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura .
Diseases: migraine with aura, pain"	"Sentence: The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura .
Diseases:"
888	Since cortical spreading depression has been shown to liberate NO in animals , this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura .	O O O B O O O O O O O O O O O O O O O O O O O O O B O B O B I I O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['migraine with aura', 'depression', 'headache']	3	9	"Sentence: Since cortical spreading depression has been shown to liberate NO in animals , this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura .
Diseases: migraine with aura, depression, headache"	"Sentence: Since cortical spreading depression has been shown to liberate NO in animals , this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura .
Diseases:"
889	Stroke and cocaine or amphetamine use .	B O O O O O O	O O B O B O O	['stroke']	1	1	"Sentence: Stroke and cocaine or amphetamine use .
Diseases: stroke"	"Sentence: Stroke and cocaine or amphetamine use .
Diseases:"
890	The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series .	O O O O O O O O O O B B O O O O O O O O O O	O O O B O B O O O O O O O O O O O O O O O O	['stroke', 'ischemic']	2	5	"Sentence: The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series .
Diseases: stroke, ischemic"	"Sentence: The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series .
Diseases:"
891	The limited number of epidemiologic studies of stroke and use of cocaine and / or amphetamine have been done in settings that serve mostly the poor and / or minorities .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O B O O O O O O O O O O O O O O O	['stroke']	1	1	"Sentence: The limited number of epidemiologic studies of stroke and use of cocaine and / or amphetamine have been done in settings that serve mostly the poor and / or minorities .
Diseases: stroke"	"Sentence: The limited number of epidemiologic studies of stroke and use of cocaine and / or amphetamine have been done in settings that serve mostly the poor and / or minorities .
Diseases:"
892	This case - control study was conducted in the defined population comprising members of Kaiser Permanente of Northern and Southern California .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This case - control study was conducted in the defined population comprising members of Kaiser Permanente of Northern and Southern California .
Diseases: "	"Sentence: This case - control study was conducted in the defined population comprising members of Kaiser Permanente of Northern and Southern California .
Diseases:"
893	We attempted to identify all incident strokes in women ages 15 - 44 years during a 3 - year period using hospital admission and discharge records , emergency department logs , and payment requests for out - of - plan hospitalizations .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['strokes']	1	2	"Sentence: We attempted to identify all incident strokes in women ages 15 - 44 years during a 3 - year period using hospital admission and discharge records , emergency department logs , and payment requests for out - of - plan hospitalizations .
Diseases: strokes"	"Sentence: We attempted to identify all incident strokes in women ages 15 - 44 years during a 3 - year period using hospital admission and discharge records , emergency department logs , and payment requests for out - of - plan hospitalizations .
Diseases:"
894	We selected controls , matched on age and facility of usual care , at random from healthy members of the health plan .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We selected controls , matched on age and facility of usual care , at random from healthy members of the health plan .
Diseases: "	"Sentence: We selected controls , matched on age and facility of usual care , at random from healthy members of the health plan .
Diseases:"
895	We obtained information in face - to - face interviews .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: We obtained information in face - to - face interviews .
Diseases: "	"Sentence: We obtained information in face - to - face interviews .
Diseases:"
896	There were 347 confirmed stroke cases and 1 , 021 controls .	O O O O B O O O O O O O	O O O O O O O O O O O O	['stroke']	1	1	"Sentence: There were 347 confirmed stroke cases and 1 , 021 controls .
Diseases: stroke"	"Sentence: There were 347 confirmed stroke cases and 1 , 021 controls .
Diseases:"
897	The univariate matched odds ratio for stroke in women who admitted to using cocaine and / or amphetamine was 8 . 5 ( 95 % confidence interval = 3 . 6 - 20 . 0 ) .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O B O O O O O O O O O O O O O O O O O O O	['stroke']	1	1	"Sentence: The univariate matched odds ratio for stroke in women who admitted to using cocaine and / or amphetamine was 8 . 5 ( 95 % confidence interval = 3 . 6 - 20 . 0 ) .
Diseases: stroke"	"Sentence: The univariate matched odds ratio for stroke in women who admitted to using cocaine and / or amphetamine was 8 . 5 ( 95 % confidence interval = 3 . 6 - 20 . 0 ) .
Diseases:"
898	After further adjustment for potential confounders , the odds ratio in women who reported using cocaine and / or amphetamine was 7 . 0 ( 95 % confidence interval = 2 . 8 - 17 . 9 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O B O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After further adjustment for potential confounders , the odds ratio in women who reported using cocaine and / or amphetamine was 7 . 0 ( 95 % confidence interval = 2 . 8 - 17 . 9 ) .
Diseases: "	"Sentence: After further adjustment for potential confounders , the odds ratio in women who reported using cocaine and / or amphetamine was 7 . 0 ( 95 % confidence interval = 2 . 8 - 17 . 9 ) .
Diseases:"
899	The use of cocaine and / or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous , insured urban population .	O O O O O O O O O O O O O O B O O O O O O O O O	O O O B O O O B O O O O O O O O O O O O O O O O	['stroke']	1	1	"Sentence: The use of cocaine and / or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous , insured urban population .
Diseases: stroke"	"Sentence: The use of cocaine and / or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous , insured urban population .
Diseases:"
900	Prevention of breast cancer with tamoxifen : preliminary findings from the Italian randomised trial among hysterectomised women .	O O B I O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O	['breast cancer']	1	3	"Sentence: Prevention of breast cancer with tamoxifen : preliminary findings from the Italian randomised trial among hysterectomised women .
Diseases: breast cancer"	"Sentence: Prevention of breast cancer with tamoxifen : preliminary findings from the Italian randomised trial among hysterectomised women .
Diseases:"
901	Italian Tamoxifen Prevention Study .	O O O O O	O B O O O	[]	0	0	"Sentence: Italian Tamoxifen Prevention Study .
Diseases: "	"Sentence: Italian Tamoxifen Prevention Study .
Diseases:"
902	Tamoxifen is a candidate chemopreventive agent in breast cancer , although the drug may be associated with the development of endometrial cancer .	O O O O O O O B I O O O O O O O O O O O B I O	B O O O O O O O O O O O O O O O O O O O O O O	['endometrial cancer', 'breast cancer']	2	7	"Sentence: Tamoxifen is a candidate chemopreventive agent in breast cancer , although the drug may be associated with the development of endometrial cancer .
Diseases: endometrial cancer, breast cancer"	"Sentence: Tamoxifen is a candidate chemopreventive agent in breast cancer , although the drug may be associated with the development of endometrial cancer .
Diseases:"
903	Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive .	O O O O O O O O O O O O O O	O O O O O O O O O B O O O O	[]	0	0	"Sentence: Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive .
Diseases: "	"Sentence: Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive .
Diseases:"
904	In October , 1992 , we started a double - blind placebo - controlled , randomised trial of tamoxifen in women ( mainly in Italy ) who did not have breast cancer and who had had a hysterectomy .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['breast cancer']	1	3	"Sentence: In October , 1992 , we started a double - blind placebo - controlled , randomised trial of tamoxifen in women ( mainly in Italy ) who did not have breast cancer and who had had a hysterectomy .
Diseases: breast cancer"	"Sentence: In October , 1992 , we started a double - blind placebo - controlled , randomised trial of tamoxifen in women ( mainly in Italy ) who did not have breast cancer and who had had a hysterectomy .
Diseases:"
905	Women were randomised to receive tamoxifen 20 mg per day or placebo , both orally for 5 years .	O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: Women were randomised to receive tamoxifen 20 mg per day or placebo , both orally for 5 years .
Diseases: "	"Sentence: Women were randomised to receive tamoxifen 20 mg per day or placebo , both orally for 5 years .
Diseases:"
906	The original plan was to follow the intervention phase by 5 years ' follow - up .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The original plan was to follow the intervention phase by 5 years ' follow - up .
Diseases: "	"Sentence: The original plan was to follow the intervention phase by 5 years ' follow - up .
Diseases:"
907	In June , 1997 , the trialists and the data - monitoring committee decided to end recruitment primarily because of the number of women dropping out of the study .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In June , 1997 , the trialists and the data - monitoring committee decided to end recruitment primarily because of the number of women dropping out of the study .
Diseases: "	"Sentence: In June , 1997 , the trialists and the data - monitoring committee decided to end recruitment primarily because of the number of women dropping out of the study .
Diseases:"
908	Recruitment ended on July 11 , 1997 , and the study will continue as planned .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Recruitment ended on July 11 , 1997 , and the study will continue as planned .
Diseases: "	"Sentence: Recruitment ended on July 11 , 1997 , and the study will continue as planned .
Diseases:"
909	The primary endpoints are the occurrence of and deaths from breast cancer .	O O O O O O O O O O B I O	O O O O O O O O O O O O O	['breast cancer']	1	3	"Sentence: The primary endpoints are the occurrence of and deaths from breast cancer .
Diseases: breast cancer"	"Sentence: The primary endpoints are the occurrence of and deaths from breast cancer .
Diseases:"
910	This preliminary interim analysis is based on intention - to - treat .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: This preliminary interim analysis is based on intention - to - treat .
Diseases: "	"Sentence: This preliminary interim analysis is based on intention - to - treat .
Diseases:"
911	FINDINGS : 5408 women were randomised ; participating women have a median follow - up of 46 months for major endpoints .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: FINDINGS : 5408 women were randomised ; participating women have a median follow - up of 46 months for major endpoints .
Diseases: "	"Sentence: FINDINGS : 5408 women were randomised ; participating women have a median follow - up of 46 months for major endpoints .
Diseases:"
912	41 cases of breast cancer occurred so far ; there have been no deaths from breast cancer .	O O O B I O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O	['breast cancer']	1	3	"Sentence: 41 cases of breast cancer occurred so far ; there have been no deaths from breast cancer .
Diseases: breast cancer"	"Sentence: 41 cases of breast cancer occurred so far ; there have been no deaths from breast cancer .
Diseases:"
913	There is no difference in breast - cancer frequency between the placebo ( 22 cases ) and tamoxifen ( 19 ) arms .	O O O O O B I I O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O	['breast - cancer']	1	4	"Sentence: There is no difference in breast - cancer frequency between the placebo ( 22 cases ) and tamoxifen ( 19 ) arms .
Diseases: breast - cancer"	"Sentence: There is no difference in breast - cancer frequency between the placebo ( 22 cases ) and tamoxifen ( 19 ) arms .
Diseases:"
914	There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone - replacement therapy during the trial : among 390 women on such therapy and allocated to placebo , we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen .	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['breast cancer']	1	3	"Sentence: There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone - replacement therapy during the trial : among 390 women on such therapy and allocated to placebo , we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen .
Diseases: breast cancer"	"Sentence: There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone - replacement therapy during the trial : among 390 women on such therapy and allocated to placebo , we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen .
Diseases:"
915	Compared with the placebo group , there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen .	O O O O O O O O O O O O O B I O B O O O O O	O O O O O O O O O O O O O O O O O O O O B O	['hypertriglyceridaemia', 'vascular events']	2	9	"Sentence: Compared with the placebo group , there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen .
Diseases: hypertriglyceridaemia, vascular events"	"Sentence: Compared with the placebo group , there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen .
Diseases:"
916	INTERPRETATION :	O O	O O	[]	0	0	"Sentence: INTERPRETATION :
Diseases: "	"Sentence: INTERPRETATION :
Diseases:"
917	Although this preliminary analysis has low power , in this cohort of women at low - to - normal risk of breast cancer , the postulated protective effects of tamoxifen are not yet apparent .	O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	['breast cancer']	1	3	"Sentence: Although this preliminary analysis has low power , in this cohort of women at low - to - normal risk of breast cancer , the postulated protective effects of tamoxifen are not yet apparent .
Diseases: breast cancer"	"Sentence: Although this preliminary analysis has low power , in this cohort of women at low - to - normal risk of breast cancer , the postulated protective effects of tamoxifen are not yet apparent .
Diseases:"
918	Women using hormone - replacement therapy appear to have benefited from use of tamoxifen .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O	[]	0	0	"Sentence: Women using hormone - replacement therapy appear to have benefited from use of tamoxifen .
Diseases: "	"Sentence: Women using hormone - replacement therapy appear to have benefited from use of tamoxifen .
Diseases:"
919	There were no deaths from breast cancer recorded in women in the study .	O O O O O B I O O O O O O O	O O O O O O O O O O O O O O	['breast cancer']	1	3	"Sentence: There were no deaths from breast cancer recorded in women in the study .
Diseases: breast cancer"	"Sentence: There were no deaths from breast cancer recorded in women in the study .
Diseases:"
920	It is essential to continue follow - up to quantify the long - term risks and benefits of tamoxifen therapy .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: It is essential to continue follow - up to quantify the long - term risks and benefits of tamoxifen therapy .
Diseases: "	"Sentence: It is essential to continue follow - up to quantify the long - term risks and benefits of tamoxifen therapy .
Diseases:"
921	A measure of pupillary oscillation as a marker of cocaine - induced paranoia .	O O O B I O O O O O O O B O	O O O O O O O O O B O O O O	['paranoia', 'pupillary oscillation']	2	7	"Sentence: A measure of pupillary oscillation as a marker of cocaine - induced paranoia .
Diseases: paranoia, pupillary oscillation"	"Sentence: A measure of pupillary oscillation as a marker of cocaine - induced paranoia .
Diseases:"
922	Cocaine - induced paranoia ( CIP ) remains an important drug - induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged .	O O O B O B O O O O O O O O O O B O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O	['paranoia', 'cip']	2	5	"Sentence: Cocaine - induced paranoia ( CIP ) remains an important drug - induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged .
Diseases: paranoia, cip"	"Sentence: Cocaine - induced paranoia ( CIP ) remains an important drug - induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged .
Diseases:"
923	Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP ( n = 32 ) from another group of crack addicts who denied past CIP ( n = 29 ) .	O O B I O O O O O O O O O O O O O O B O O O O O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O O I O O O O O O O O O O O O O O O O O O O O O O O O O	['pupillary oscillation', 'cip']	2	8	"Sentence: Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP ( n = 32 ) from another group of crack addicts who denied past CIP ( n = 29 ) .
Diseases: pupillary oscillation, cip"	"Sentence: Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP ( n = 32 ) from another group of crack addicts who denied past CIP ( n = 29 ) .
Diseases:"
924	Seizures induced by combined levomepromazine - fluvoxamine treatment .	B O O O O O O O O	O O O O B I B O O	['seizures']	1	3	"Sentence: Seizures induced by combined levomepromazine - fluvoxamine treatment .
Diseases: seizures"	"Sentence: Seizures induced by combined levomepromazine - fluvoxamine treatment .
Diseases:"
925	We report a case of combined levomepromazine - fluvoxamine treatment - induced seizures .	O O O O O O O O O O O O B O	O O O O O O B I B O O O O O	['seizures']	1	3	"Sentence: We report a case of combined levomepromazine - fluvoxamine treatment - induced seizures .
Diseases: seizures"	"Sentence: We report a case of combined levomepromazine - fluvoxamine treatment - induced seizures .
Diseases:"
926	It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity .	O O O O O O O O O O O O O O	O O O O O O B O B O O O O O	[]	0	0	"Sentence: It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity .
Diseases: "	"Sentence: It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity .
Diseases:"
927	Why may epsilon - aminocaproic acid ( EACA ) induce myopathy in man ?	O O O O O O O O O O B O O O	O O B I I I O B O O O O O O	['myopathy']	1	2	"Sentence: Why may epsilon - aminocaproic acid ( EACA ) induce myopathy in man ?
Diseases: myopathy"	"Sentence: Why may epsilon - aminocaproic acid ( EACA ) induce myopathy in man ?
Diseases:"
928	Report of a case and literature review .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: Report of a case and literature review .
Diseases: "	"Sentence: Report of a case and literature review .
Diseases:"
929	A case of necrotizing myopathy due to a short epsilon - aminocaproic acid ( EACA ) treatment in a 72 year - old patient with subarachnoid haemorrhage ( SAH ) is described .	O O O B I O O O O O O O O O O O O O O O O O O O O B I O B O O O O	O O O O O O O O O B I I I O B O O O O O O O O O O O O O O O O O O	['sah', 'necrotizing myopathy', 'subarachnoid haemorrhage']	3	19	"Sentence: A case of necrotizing myopathy due to a short epsilon - aminocaproic acid ( EACA ) treatment in a 72 year - old patient with subarachnoid haemorrhage ( SAH ) is described .
Diseases: sah, necrotizing myopathy, subarachnoid haemorrhage"	"Sentence: A case of necrotizing myopathy due to a short epsilon - aminocaproic acid ( EACA ) treatment in a 72 year - old patient with subarachnoid haemorrhage ( SAH ) is described .
Diseases:"
930	Pathogenetic hypotheses are discussed .	O O O O O	O O O O O	[]	0	0	"Sentence: Pathogenetic hypotheses are discussed .
Diseases: "	"Sentence: Pathogenetic hypotheses are discussed .
Diseases:"
931	Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states .	O O O O O O O O O O O O O O O O O O O	O O O O O B O B O O O O O O O O O O O	[]	0	0	"Sentence: Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states .
Diseases: "	"Sentence: Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states .
Diseases:"
932	The H2 - histamine receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short - and long - term basis in 22 patients with gastric acid hypersecretory states .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The H2 - histamine receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short - and long - term basis in 22 patients with gastric acid hypersecretory states .
Diseases: "	"Sentence: The H2 - histamine receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short - and long - term basis in 22 patients with gastric acid hypersecretory states .
Diseases:"
933	Nineteen patients had Zollinger - Ellison syndrome , one patient had systemic mastocytosis , and two patients had idiopathic hypersecretion .	O O O B I I I O O O O B I O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	['zollinger - ellison syndrome', 'systemic mastocytosis']	2	13	"Sentence: Nineteen patients had Zollinger - Ellison syndrome , one patient had systemic mastocytosis , and two patients had idiopathic hypersecretion .
Diseases: zollinger - ellison syndrome, systemic mastocytosis"	"Sentence: Nineteen patients had Zollinger - Ellison syndrome , one patient had systemic mastocytosis , and two patients had idiopathic hypersecretion .
Diseases:"
934	The rates of onset of the action of cimetidine and ranitidine were the same .	O O O O O O O O O O O O O O O	O O O O O O O O B O B O O O O	[]	0	0	"Sentence: The rates of onset of the action of cimetidine and ranitidine were the same .
Diseases: "	"Sentence: The rates of onset of the action of cimetidine and ranitidine were the same .
Diseases:"
935	The actions of both drugs were increased by anticholinergic agents , and there was a close correlation between the daily maintenance dose of each drug needed to control acid secretion .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The actions of both drugs were increased by anticholinergic agents , and there was a close correlation between the daily maintenance dose of each drug needed to control acid secretion .
Diseases: "	"Sentence: The actions of both drugs were increased by anticholinergic agents , and there was a close correlation between the daily maintenance dose of each drug needed to control acid secretion .
Diseases:"
936	However , ranitidine was threefold more potent than cimetidine both in acute inhibition studies and in the median maintenance dose needed ( 1 . 2 g per day for ranitidine and 3 . 6 g per day for cimetidine ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O O O B O O	[]	0	0	"Sentence: However , ranitidine was threefold more potent than cimetidine both in acute inhibition studies and in the median maintenance dose needed ( 1 . 2 g per day for ranitidine and 3 . 6 g per day for cimetidine ) .
Diseases: "	"Sentence: However , ranitidine was threefold more potent than cimetidine both in acute inhibition studies and in the median maintenance dose needed ( 1 . 2 g per day for ranitidine and 3 . 6 g per day for cimetidine ) .
Diseases:"
937	Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine .	O O O O O O O O O B O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O B O O O B O	['impotence']	1	3	"Sentence: Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine .
Diseases: impotence"	"Sentence: Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine .
Diseases:"
938	Treatment with high doses of cimetidine ( one to 60 months ; median , 11 months ) or ranitidine ( two to 31 months ; median , 14 months ) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations , but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O B O O O B O O O O O O O O B O O O O B O O	['hepatic or hematologic toxicity']	1	8	"Sentence: Treatment with high doses of cimetidine ( one to 60 months ; median , 11 months ) or ranitidine ( two to 31 months ; median , 14 months ) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations , but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy .
Diseases: hepatic or hematologic toxicity"	"Sentence: Treatment with high doses of cimetidine ( one to 60 months ; median , 11 months ) or ranitidine ( two to 31 months ; median , 14 months ) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations , but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy .
Diseases:"
939	The results show that both drugs can adequately inhibit acid secretion in patients with gastric hypersecretory states .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results show that both drugs can adequately inhibit acid secretion in patients with gastric hypersecretory states .
Diseases: "	"Sentence: The results show that both drugs can adequately inhibit acid secretion in patients with gastric hypersecretory states .
Diseases:"
940	Both are safe at high doses , but ranitidine is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of cimetidine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: Both are safe at high doses , but ranitidine is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of cimetidine .
Diseases: "	"Sentence: Both are safe at high doses , but ranitidine is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of cimetidine .
Diseases:"
941	A catch in the Reye .	O O O O B O	O O O O O O	['reye']	1	2	"Sentence: A catch in the Reye .
Diseases: reye"	"Sentence: A catch in the Reye .
Diseases:"
942	Twenty - six cases of Reye syndrome from The Children 's Hospital , Camperdown , Australia , occurring between 1973 and 1982 were reviewed .	O O O O O B I O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['reye syndrome']	1	3	"Sentence: Twenty - six cases of Reye syndrome from The Children 's Hospital , Camperdown , Australia , occurring between 1973 and 1982 were reviewed .
Diseases: reye syndrome"	"Sentence: Twenty - six cases of Reye syndrome from The Children 's Hospital , Camperdown , Australia , occurring between 1973 and 1982 were reviewed .
Diseases:"
943	Of these , 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of Reye syndrome .	O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O	['reye syndrome']	1	3	"Sentence: Of these , 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of Reye syndrome .
Diseases: reye syndrome"	"Sentence: Of these , 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of Reye syndrome .
Diseases:"
944	Aspirin or salicylate ingestion had occurred in only one of the 20 cases ( 5 % ) , and paracetamol ( acetaminophen ) had been administered in only six of the cases ( 30 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O B O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Aspirin or salicylate ingestion had occurred in only one of the 20 cases ( 5 % ) , and paracetamol ( acetaminophen ) had been administered in only six of the cases ( 30 % ) .
Diseases: "	"Sentence: Aspirin or salicylate ingestion had occurred in only one of the 20 cases ( 5 % ) , and paracetamol ( acetaminophen ) had been administered in only six of the cases ( 30 % ) .
Diseases:"
945	Pathologic confirmation of the diagnosis of Reye syndrome was accomplished in 90 % of the cases .	O O O O O O B I O O O O O O O O O	O O O O O O O O O O O O O O O O O	['reye syndrome']	1	3	"Sentence: Pathologic confirmation of the diagnosis of Reye syndrome was accomplished in 90 % of the cases .
Diseases: reye syndrome"	"Sentence: Pathologic confirmation of the diagnosis of Reye syndrome was accomplished in 90 % of the cases .
Diseases:"
946	The incidence of Reye syndrome in New South Wales , Australia , is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain .	O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['reye syndrome']	1	3	"Sentence: The incidence of Reye syndrome in New South Wales , Australia , is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain .
Diseases: reye syndrome"	"Sentence: The incidence of Reye syndrome in New South Wales , Australia , is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain .
Diseases:"
947	The mortality for these Reye syndrome cases in Australia was 45 % as compared with a 32 % case - fatality rate in the United States .	O O O O B I O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['reye syndrome']	1	3	"Sentence: The mortality for these Reye syndrome cases in Australia was 45 % as compared with a 32 % case - fatality rate in the United States .
Diseases: reye syndrome"	"Sentence: The mortality for these Reye syndrome cases in Australia was 45 % as compared with a 32 % case - fatality rate in the United States .
Diseases:"
948	In Australia , the pediatric usage of aspirin has been extremely low for the past 25 years ( less than 1 % of total dosage units sold ) , with paracetamol ( acetaminophen ) dominating the pediatric analgesic and antipyretic market .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O	[]	0	0	"Sentence: In Australia , the pediatric usage of aspirin has been extremely low for the past 25 years ( less than 1 % of total dosage units sold ) , with paracetamol ( acetaminophen ) dominating the pediatric analgesic and antipyretic market .
Diseases: "	"Sentence: In Australia , the pediatric usage of aspirin has been extremely low for the past 25 years ( less than 1 % of total dosage units sold ) , with paracetamol ( acetaminophen ) dominating the pediatric analgesic and antipyretic market .
Diseases:"
949	Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion , since there were no cases found at The Children 's Hospital in 1983 , 1984 , or 1985 .	B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O	['reye syndrome']	1	3	"Sentence: Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion , since there were no cases found at The Children 's Hospital in 1983 , 1984 , or 1985 .
Diseases: reye syndrome"	"Sentence: Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion , since there were no cases found at The Children 's Hospital in 1983 , 1984 , or 1985 .
Diseases:"
950	St . Anthony 's fire , then and now : a case report and historical review .	B I I I I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	"[""st . anthony 's fire""]"	1	7	"Sentence: St . Anthony 's fire , then and now : a case report and historical review .
Diseases: st . anthony 's fire"	"Sentence: St . Anthony 's fire , then and now : a case report and historical review .
Diseases:"
951	A rare case of morbid vasospasm , together with striking angiographic findings , is described secondary to the ingestion of methysergide by a 48 - year - old woman .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	['vasospasm']	1	3	"Sentence: A rare case of morbid vasospasm , together with striking angiographic findings , is described secondary to the ingestion of methysergide by a 48 - year - old woman .
Diseases: vasospasm"	"Sentence: A rare case of morbid vasospasm , together with striking angiographic findings , is described secondary to the ingestion of methysergide by a 48 - year - old woman .
Diseases:"
952	A brief review of the literature on similar cases is presented .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: A brief review of the literature on similar cases is presented .
Diseases: "	"Sentence: A brief review of the literature on similar cases is presented .
Diseases:"
953	A discussion of the history of ergot includes its original discovery , the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O B I O	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['migraine headache', 'gangrene']	2	7	"Sentence: A discussion of the history of ergot includes its original discovery , the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache .
Diseases: migraine headache, gangrene"	"Sentence: A discussion of the history of ergot includes its original discovery , the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache .
Diseases:"
954	Despite the advent of calcium channel blockers and beta - adrenergic antagonists , ergot preparations continue to play a major role in migraine therapy , so that the danger of St . Anthony 's fire persists .	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O B I I I I O O	O O O O B O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	"['migraine', ""st . anthony 's fire""]"	2	11	"Sentence: Despite the advent of calcium channel blockers and beta - adrenergic antagonists , ergot preparations continue to play a major role in migraine therapy , so that the danger of St . Anthony 's fire persists .
Diseases: migraine, st . anthony 's fire"	"Sentence: Despite the advent of calcium channel blockers and beta - adrenergic antagonists , ergot preparations continue to play a major role in migraine therapy , so that the danger of St . Anthony 's fire persists .
Diseases:"
955	Beta - 2 - adrenoceptor - mediated hypokalemia and its abolishment by oxprenolol .	O O O O O O O B O O O O O O	O O O O O O O O O O O O B O	['hypokalemia']	1	4	"Sentence: Beta - 2 - adrenoceptor - mediated hypokalemia and its abolishment by oxprenolol .
Diseases: hypokalemia"	"Sentence: Beta - 2 - adrenoceptor - mediated hypokalemia and its abolishment by oxprenolol .
Diseases:"
956	The time course and concentration - effect relationship of terbutaline - induced hypokalemia was studied , using computer - aided pharmacokinetic - dynamic modeling .	O O O O O O O O O O O O B O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O	['hypokalemia']	1	4	"Sentence: The time course and concentration - effect relationship of terbutaline - induced hypokalemia was studied , using computer - aided pharmacokinetic - dynamic modeling .
Diseases: hypokalemia"	"Sentence: The time course and concentration - effect relationship of terbutaline - induced hypokalemia was studied , using computer - aided pharmacokinetic - dynamic modeling .
Diseases:"
957	Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia , together with the pharmacokinetic interaction between both drugs .	O O O O O O O O O O B O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O	['hypokalemia']	1	4	"Sentence: Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia , together with the pharmacokinetic interaction between both drugs .
Diseases: hypokalemia"	"Sentence: Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia , together with the pharmacokinetic interaction between both drugs .
Diseases:"
958	Six healthy subjects were given a 0 . 5 mg subcutaneous dose of terbutaline on two occasions : 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Six healthy subjects were given a 0 . 5 mg subcutaneous dose of terbutaline on two occasions : 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally .
Diseases: "	"Sentence: Six healthy subjects were given a 0 . 5 mg subcutaneous dose of terbutaline on two occasions : 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally .
Diseases:"
959	In the 7 - hour period after terbutaline administration , plasma samples were taken for determination of plasma potassium levels and drug concentrations .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O B O O O O O	[]	0	0	"Sentence: In the 7 - hour period after terbutaline administration , plasma samples were taken for determination of plasma potassium levels and drug concentrations .
Diseases: "	"Sentence: In the 7 - hour period after terbutaline administration , plasma samples were taken for determination of plasma potassium levels and drug concentrations .
Diseases:"
960	The sigmoid Emax model offered a good description of the relation between terbutaline concentrations and potassium effects .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O B O O	[]	0	0	"Sentence: The sigmoid Emax model offered a good description of the relation between terbutaline concentrations and potassium effects .
Diseases: "	"Sentence: The sigmoid Emax model offered a good description of the relation between terbutaline concentrations and potassium effects .
Diseases:"
961	Oxprenolol caused decreases of 65 % and 56 % of terbutaline volume of distribution and clearance , respectively , and an increase of 130 % of its AUC .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O B O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Oxprenolol caused decreases of 65 % and 56 % of terbutaline volume of distribution and clearance , respectively , and an increase of 130 % of its AUC .
Diseases: "	"Sentence: Oxprenolol caused decreases of 65 % and 56 % of terbutaline volume of distribution and clearance , respectively , and an increase of 130 % of its AUC .
Diseases:"
962	In spite of higher terbutaline concentrations after oxprenolol pretreatment , the hypokalemia was almost completely antagonized by the beta 2 - blocking action .	O O O O O O O O O O O B O O O O O O O O O O O O	O O O O B O O B O O O O O O O O O O O O O O O O	['hypokalemia']	1	4	"Sentence: In spite of higher terbutaline concentrations after oxprenolol pretreatment , the hypokalemia was almost completely antagonized by the beta 2 - blocking action .
Diseases: hypokalemia"	"Sentence: In spite of higher terbutaline concentrations after oxprenolol pretreatment , the hypokalemia was almost completely antagonized by the beta 2 - blocking action .
Diseases:"
963	Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa .	O O O O O O O O O O B O O O O	O O B O O O O O O O O O O B O	['hypotensive']	1	3	"Sentence: Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa .
Diseases: hypotensive"	"Sentence: Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa .
Diseases:"
964	Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord .	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O B O O O O O O O O O O O O O O O O O O	['hypotensive']	1	3	"Sentence: Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord .
Diseases: hypotensive"	"Sentence: Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord .
Diseases:"
965	The present experiments were designed to investigate the role of the midline cells of the B3 serotonin neurons in the medulla , coinciding with the raphe magnus .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: The present experiments were designed to investigate the role of the midline cells of the B3 serotonin neurons in the medulla , coinciding with the raphe magnus .
Diseases: "	"Sentence: The present experiments were designed to investigate the role of the midline cells of the B3 serotonin neurons in the medulla , coinciding with the raphe magnus .
Diseases:"
966	In spontaneously hypertensive , stroke - prone rats , microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin 5 , 7 - dihydroxytryptamine ( 5 , 7 - DHT ) injected intracerebroventricularly .	O O B O B O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B I I I I O B I I I I O O O O	['stroke', 'hypertensive', 'hypotension']	3	7	"Sentence: In spontaneously hypertensive , stroke - prone rats , microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin 5 , 7 - dihydroxytryptamine ( 5 , 7 - DHT ) injected intracerebroventricularly .
Diseases: stroke, hypertensive, hypotension"	"Sentence: In spontaneously hypertensive , stroke - prone rats , microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin 5 , 7 - dihydroxytryptamine ( 5 , 7 - DHT ) injected intracerebroventricularly .
Diseases:"
967	However , intraspinal injection of 5 , 7 - DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O B I I I I O O O O O O O O O B O O O O O O O O O O O	['hypotension']	1	3	"Sentence: However , intraspinal injection of 5 , 7 - DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension .
Diseases: hypotension"	"Sentence: However , intraspinal injection of 5 , 7 - DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension .
Diseases:"
968	Further , 5 , 7 - DHT lesion of serotonin nerves travelling in the median forebrain bundle , one of the main ascending pathways from the B3 serotonin cells , did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B I I I I O O B O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O B I O O	[]	0	0	"Sentence: Further , 5 , 7 - DHT lesion of serotonin nerves travelling in the median forebrain bundle , one of the main ascending pathways from the B3 serotonin cells , did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection .
Diseases: "	"Sentence: Further , 5 , 7 - DHT lesion of serotonin nerves travelling in the median forebrain bundle , one of the main ascending pathways from the B3 serotonin cells , did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection .
Diseases:"
969	It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a methyldopa - induced hypotension via descending projections , the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O O O B O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypotensive', 'hypotension']	2	6	"Sentence: It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a methyldopa - induced hypotension via descending projections , the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem .
Diseases: hypotensive, hypotension"	"Sentence: It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a methyldopa - induced hypotension via descending projections , the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem .
Diseases:"
970	Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers .	O O O B I I O O O O O O	B O O O O O O O B O O O	['sexual side effects']	1	3	"Sentence: Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers .
Diseases: sexual side effects"	"Sentence: Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers .
Diseases:"
971	BACKGROUND : Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence .	O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O B O O O O O O O O O O O O O O	['male impotence']	1	4	"Sentence: BACKGROUND : Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence .
Diseases: male impotence"	"Sentence: BACKGROUND : Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence .
Diseases:"
972	A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine .	O O O O O O O O O O O O O B I I O O O	O O O O O O B O O O O O O O O O O B O	['sexual side effects']	1	3	"Sentence: A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine .
Diseases: sexual side effects"	"Sentence: A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine .
Diseases:"
973	This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers .	O O O O O O O O O B I I O O O O O O	O O O B O O O O O O O O O O B O O O	['sexual side effects']	1	3	"Sentence: This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers .
Diseases: sexual side effects"	"Sentence: This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers .
Diseases:"
974	Six patients with either obsessive compulsive disorder , trichotillomania , anxiety , or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p . r . n . basis in an open clinical trial .	O O O O B I I O B O B O O B I O O B I I O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O O O O B O O O O O O O O O O O O O O O	['obsessive compulsive disorder', 'sexual side effects', 'anxiety', 'trichotillomania', 'affective disorders']	5	23	"Sentence: Six patients with either obsessive compulsive disorder , trichotillomania , anxiety , or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p . r . n . basis in an open clinical trial .
Diseases: obsessive compulsive disorder, sexual side effects, anxiety, trichotillomania, affective disorders"	"Sentence: Six patients with either obsessive compulsive disorder , trichotillomania , anxiety , or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p . r . n . basis in an open clinical trial .
Diseases:"
975	Various doses of yohimbine were used to determine the ideal dose for each patient .	O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O	[]	0	0	"Sentence: Various doses of yohimbine were used to determine the ideal dose for each patient .
Diseases: "	"Sentence: Various doses of yohimbine were used to determine the ideal dose for each patient .
Diseases:"
976	Five of the six patients experienced improved sexual functioning after taking yohimbine .	O O O O O O O O O O O O O	O O O O O O O O O O O B O	[]	0	0	"Sentence: Five of the six patients experienced improved sexual functioning after taking yohimbine .
Diseases: "	"Sentence: Five of the six patients experienced improved sexual functioning after taking yohimbine .
Diseases:"
977	One patient who failed to comply with yohimbine treatment had no therapeutic effects .	O O O O O O O O O O O O O O	O O O O O O O B O O O O O O	[]	0	0	"Sentence: One patient who failed to comply with yohimbine treatment had no therapeutic effects .
Diseases: "	"Sentence: One patient who failed to comply with yohimbine treatment had no therapeutic effects .
Diseases:"
978	Side effects of yohimbine included excessive sweating , increased anxiety , and a wound - up feeling in some patients .	O O O O O O O O O B O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O	['anxiety']	1	2	"Sentence: Side effects of yohimbine included excessive sweating , increased anxiety , and a wound - up feeling in some patients .
Diseases: anxiety"	"Sentence: Side effects of yohimbine included excessive sweating , increased anxiety , and a wound - up feeling in some patients .
Diseases:"
979	The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers .	O O O O O O O O O O O O O O O B I I O O O O O O	O O O O O O O B O O O O O O O O O O O O B O O O	['sexual side effects']	1	3	"Sentence: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers .
Diseases: sexual side effects"	"Sentence: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers .
Diseases:"
980	Future controlled studies are needed to further investigate the effectiveness and safety of yohimbine for this indication .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: Future controlled studies are needed to further investigate the effectiveness and safety of yohimbine for this indication .
Diseases: "	"Sentence: Future controlled studies are needed to further investigate the effectiveness and safety of yohimbine for this indication .
Diseases:"
981	Hypersensitivity immune reaction as a mechanism for dilevalol - associated hepatitis .	B O O O O O O O O O B O	O O O O O O O B O O O O	['hypersensitivity', 'hepatitis']	2	5	"Sentence: Hypersensitivity immune reaction as a mechanism for dilevalol - associated hepatitis .
Diseases: hypersensitivity, hepatitis"	"Sentence: Hypersensitivity immune reaction as a mechanism for dilevalol - associated hepatitis .
Diseases:"
982	To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol - induced liver injury .	O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O B O O O O O O O B O O O O O O O B O O O O O	['liver injury']	1	3	"Sentence: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol - induced liver injury .
Diseases: liver injury"	"Sentence: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol - induced liver injury .
Diseases:"
983	PATIENT :	O O	O O	[]	0	0	"Sentence: PATIENT :
Diseases: "	"Sentence: PATIENT :
Diseases:"
984	A 58 - year - old woman with a clinical diagnosis of dilevalol - induced liver injury .	O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O B O O O O O	['liver injury']	1	3	"Sentence: A 58 - year - old woman with a clinical diagnosis of dilevalol - induced liver injury .
Diseases: liver injury"	"Sentence: A 58 - year - old woman with a clinical diagnosis of dilevalol - induced liver injury .
Diseases:"
985	Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O B O O	[]	0	0	"Sentence: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake .
Diseases: "	"Sentence: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake .
Diseases:"
986	A similar protocol was performed with lymphocytes from a healthy subject .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: A similar protocol was performed with lymphocytes from a healthy subject .
Diseases: "	"Sentence: A similar protocol was performed with lymphocytes from a healthy subject .
Diseases:"
987	No lymphocyte proliferation was observed either in the patient or in the healthy volunteer in the presence of dilevalol solutions .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: No lymphocyte proliferation was observed either in the patient or in the healthy volunteer in the presence of dilevalol solutions .
Diseases: "	"Sentence: No lymphocyte proliferation was observed either in the patient or in the healthy volunteer in the presence of dilevalol solutions .
Diseases:"
988	A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake .
Diseases: "	"Sentence: A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake .
Diseases:"
989	No reactivity was found when lymphocytes from the healthy subject were tested under similar conditions .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: No reactivity was found when lymphocytes from the healthy subject were tested under similar conditions .
Diseases: "	"Sentence: No reactivity was found when lymphocytes from the healthy subject were tested under similar conditions .
Diseases:"
990	The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo - prepared dilevalol antigens , suggesting the involvement of an immunologic mechanism in dilevalol - induced liver injury .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O B O O O O O O O O O O B O O O O O	['liver injury']	1	3	"Sentence: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo - prepared dilevalol antigens , suggesting the involvement of an immunologic mechanism in dilevalol - induced liver injury .
Diseases: liver injury"	"Sentence: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo - prepared dilevalol antigens , suggesting the involvement of an immunologic mechanism in dilevalol - induced liver injury .
Diseases:"
991	Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient : case report .	O B I O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O	['myocardial hypertrophy']	1	6	"Sentence: Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient : case report .
Diseases: myocardial hypertrophy"	"Sentence: Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient : case report .
Diseases:"
992	Tacrolimus is a potent immunosuppressant that is frequently used in organ transplantation .	O O O O O O O O O O O O O	B O O O O O O O O O O O O	[]	0	0	"Sentence: Tacrolimus is a potent immunosuppressant that is frequently used in organ transplantation .
Diseases: "	"Sentence: Tacrolimus is a potent immunosuppressant that is frequently used in organ transplantation .
Diseases:"
993	However , adverse effects include cardiac toxicity .	O O O O O B I O	O O O O O O O O	['cardiac toxicity']	1	3	"Sentence: However , adverse effects include cardiac toxicity .
Diseases: cardiac toxicity"	"Sentence: However , adverse effects include cardiac toxicity .
Diseases:"
994	Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation .	O O O O B I O O O O O O O	O O O O O O O O B O O O O	['myocardial hypertrophy']	1	6	"Sentence: Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation .
Diseases: myocardial hypertrophy"	"Sentence: Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation .
Diseases:"
995	The hypertrophy caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography .	O B O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['hypertrophy']	1	4	"Sentence: The hypertrophy caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography .
Diseases: hypertrophy"	"Sentence: The hypertrophy caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography .
Diseases:"
996	Initially , allograft rejection was feared ; however , myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy ; neither cellular nor humoral rejection was detected .	O O O O O O O O O O O O O O O B O O B I O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['myocardial hypertrophy', 'edema']	2	9	"Sentence: Initially , allograft rejection was feared ; however , myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy ; neither cellular nor humoral rejection was detected .
Diseases: myocardial hypertrophy, edema"	"Sentence: Initially , allograft rejection was feared ; however , myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy ; neither cellular nor humoral rejection was detected .
Diseases:"
997	The blood tacrolimus concentration was higher than usual at that time ; thus , tacrolimus dosage was reduced .	O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: The blood tacrolimus concentration was higher than usual at that time ; thus , tacrolimus dosage was reduced .
Diseases: "	"Sentence: The blood tacrolimus concentration was higher than usual at that time ; thus , tacrolimus dosage was reduced .
Diseases:"
998	Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur , as confirmed at echocardiography and myocardial biopsy .	B I O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O	['myocardial hypertrophy']	1	6	"Sentence: Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur , as confirmed at echocardiography and myocardial biopsy .
Diseases: myocardial hypertrophy"	"Sentence: Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur , as confirmed at echocardiography and myocardial biopsy .
Diseases:"
999	Thus , we conclude that tacrolimus induces reversible myocardial hypertrophy .	O O O O O O O O B I O	O O O O O B O O O O O	['myocardial hypertrophy']	1	6	"Sentence: Thus , we conclude that tacrolimus induces reversible myocardial hypertrophy .
Diseases: myocardial hypertrophy"	"Sentence: Thus , we conclude that tacrolimus induces reversible myocardial hypertrophy .
Diseases:"
1000	In patients receiving tacrolimus therapy , blood concentration should be carefully controlled and extreme attention paid to cardiac involvement .	O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In patients receiving tacrolimus therapy , blood concentration should be carefully controlled and extreme attention paid to cardiac involvement .
Diseases: "	"Sentence: In patients receiving tacrolimus therapy , blood concentration should be carefully controlled and extreme attention paid to cardiac involvement .
Diseases:"
1001	Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson 's disease .	O O O O O O O O O B I I I O	O O O O O O O O O O O O O O	"[""idiopathic parkinson 's disease""]"	1	9	"Sentence: Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson 's disease .
Diseases: idiopathic parkinson 's disease"	"Sentence: Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson 's disease .
Diseases:"
1002	A prospective , randomized , double - blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson 's disease ( PD ) refractory to medical treatment was designed .	O O O O O O O O O O O O O O O O O O O O O O B I I I O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	"['pd', ""idiopathic parkinson 's disease""]"	2	11	"Sentence: A prospective , randomized , double - blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson 's disease ( PD ) refractory to medical treatment was designed .
Diseases: pd, idiopathic parkinson 's disease"	"Sentence: A prospective , randomized , double - blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson 's disease ( PD ) refractory to medical treatment was designed .
Diseases:"
1003	Ten consecutive patients ( mean age , 58 . 4 + / - 6 . 8 years ; 7 men , 3 women ) with similar characteristics at the duration of disease ( mean disease time , 8 . 4 + / - 3 . 5 years ) , disabling motor fluctuations ( Hoehn _ Yahr stage 3 - 5 in off - drug phases ) and levodopa - induced dyskinesias were selected .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O	['dyskinesias']	1	5	"Sentence: Ten consecutive patients ( mean age , 58 . 4 + / - 6 . 8 years ; 7 men , 3 women ) with similar characteristics at the duration of disease ( mean disease time , 8 . 4 + / - 3 . 5 years ) , disabling motor fluctuations ( Hoehn _ Yahr stage 3 - 5 in off - drug phases ) and levodopa - induced dyskinesias were selected .
Diseases: dyskinesias"	"Sentence: Ten consecutive patients ( mean age , 58 . 4 + / - 6 . 8 years ; 7 men , 3 women ) with similar characteristics at the duration of disease ( mean disease time , 8 . 4 + / - 3 . 5 years ) , disabling motor fluctuations ( Hoehn _ Yahr stage 3 - 5 in off - drug phases ) and levodopa - induced dyskinesias were selected .
Diseases:"
1004	All patients had bilateral symptoms and their levodopa equivalent dosing were analysed .	O O O O O O O O O O O O O	O O O O O O O B O O O O O	[]	0	0	"Sentence: All patients had bilateral symptoms and their levodopa equivalent dosing were analysed .
Diseases: "	"Sentence: All patients had bilateral symptoms and their levodopa equivalent dosing were analysed .
Diseases:"
1005	Six patients were operated on in the globus pallidus interna ( GPi ) and four in the subthalamic nucleus ( STN ) .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Six patients were operated on in the globus pallidus interna ( GPi ) and four in the subthalamic nucleus ( STN ) .
Diseases: "	"Sentence: Six patients were operated on in the globus pallidus interna ( GPi ) and four in the subthalamic nucleus ( STN ) .
Diseases:"
1006	Clinical evaluation included the use of the Unified Parkinson 's Disease Rating Scale ( UPDRS ) , Hoehn_Yahr score and Schwab England activities of daily living ( ADL ) score in ' on' - and ' off' - drug conditions before surgery and 6 months after surgery .	O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	"[""parkinson 's disease""]"	1	5	"Sentence: Clinical evaluation included the use of the Unified Parkinson 's Disease Rating Scale ( UPDRS ) , Hoehn_Yahr score and Schwab England activities of daily living ( ADL ) score in ' on' - and ' off' - drug conditions before surgery and 6 months after surgery .
Diseases: parkinson 's disease"	"Sentence: Clinical evaluation included the use of the Unified Parkinson 's Disease Rating Scale ( UPDRS ) , Hoehn_Yahr score and Schwab England activities of daily living ( ADL ) score in ' on' - and ' off' - drug conditions before surgery and 6 months after surgery .
Diseases:"
1007	There was statistically significant improvement in all contralateral major parkinsonian motor signs in all patients followed for 6 months .	O O O O O O O O O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	['parkinsonian']	1	3	"Sentence: There was statistically significant improvement in all contralateral major parkinsonian motor signs in all patients followed for 6 months .
Diseases: parkinsonian"	"Sentence: There was statistically significant improvement in all contralateral major parkinsonian motor signs in all patients followed for 6 months .
Diseases:"
1008	Levodopa equivalent daily intake was significantly reduced in the STN group .	O O O O O O O O O O O O	B O O O O O O O O O O O	[]	0	0	"Sentence: Levodopa equivalent daily intake was significantly reduced in the STN group .
Diseases: "	"Sentence: Levodopa equivalent daily intake was significantly reduced in the STN group .
Diseases:"
1009	Changes in UPDRS , Hoehn _ Yahr and Schwab England ADL scores were similar in both groups .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Changes in UPDRS , Hoehn _ Yahr and Schwab England ADL scores were similar in both groups .
Diseases: "	"Sentence: Changes in UPDRS , Hoehn _ Yahr and Schwab England ADL scores were similar in both groups .
Diseases:"
1010	Cognitive functions were unchanged in both groups .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: Cognitive functions were unchanged in both groups .
Diseases: "	"Sentence: Cognitive functions were unchanged in both groups .
Diseases:"
1011	Complications were observed in two patients : one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg / day .	O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	['homonymous hemianopsia']	1	6	"Sentence: Complications were observed in two patients : one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg / day .
Diseases: homonymous hemianopsia"	"Sentence: Complications were observed in two patients : one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg / day .
Diseases:"
1012	The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment .	O O O O O O O O O O O O O O O O O O O O O O B O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pd']	1	1	"Sentence: The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment .
Diseases: pd"	"Sentence: The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment .
Diseases:"
1013	Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats .	O O O O O O O B O O O	O O O B O B I O O O O	['nephrosis']	1	3	"Sentence: Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats .
Diseases: nephrosis"	"Sentence: Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats .
Diseases:"
1014	We investigated the effects of antithrombin , a plasma inhibitor of coagulation factors , in rats with puromycin aminonucleoside - induced nephrosis , which is an experimental model of human nephrotic syndrome .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O B I O	O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O	['nephrotic syndrome', 'nephrosis']	2	9	"Sentence: We investigated the effects of antithrombin , a plasma inhibitor of coagulation factors , in rats with puromycin aminonucleoside - induced nephrosis , which is an experimental model of human nephrotic syndrome .
Diseases: nephrotic syndrome, nephrosis"	"Sentence: We investigated the effects of antithrombin , a plasma inhibitor of coagulation factors , in rats with puromycin aminonucleoside - induced nephrosis , which is an experimental model of human nephrotic syndrome .
Diseases:"
1015	Antithrombin ( 50 or 500 IU / kg / i . v . ) was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside ( 50 mg / kg / i . v . ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O	[]	0	0	"Sentence: Antithrombin ( 50 or 500 IU / kg / i . v . ) was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside ( 50 mg / kg / i . v . ) .
Diseases: "	"Sentence: Antithrombin ( 50 or 500 IU / kg / i . v . ) was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside ( 50 mg / kg / i . v . ) .
Diseases:"
1016	Treatment with antithrombin attenuated the puromycin aminonucleoside - induced hematological abnormalities .	O O O O O O O O O B I O	O O O O O B I O O O O O	['hematological abnormalities']	1	3	"Sentence: Treatment with antithrombin attenuated the puromycin aminonucleoside - induced hematological abnormalities .
Diseases: hematological abnormalities"	"Sentence: Treatment with antithrombin attenuated the puromycin aminonucleoside - induced hematological abnormalities .
Diseases:"
1017	Puromycin aminonucleoside - induced renal dysfunction and hyperlipidemia were also suppressed .	O O O O B I O B O O O O	B I O O O O O O O O O O	['hyperlipidemia', 'renal dysfunction']	2	7	"Sentence: Puromycin aminonucleoside - induced renal dysfunction and hyperlipidemia were also suppressed .
Diseases: hyperlipidemia, renal dysfunction"	"Sentence: Puromycin aminonucleoside - induced renal dysfunction and hyperlipidemia were also suppressed .
Diseases:"
1018	Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats , while an improvement of the damage was seen in antithrombin - treated rats .	O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['renal damage']	1	3	"Sentence: Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats , while an improvement of the damage was seen in antithrombin - treated rats .
Diseases: renal damage"	"Sentence: Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats , while an improvement of the damage was seen in antithrombin - treated rats .
Diseases:"
1019	In addition , antithrombin treatment markedly suppressed puromycin aminonucleoside - induced apoptosis of renal tubular epithelial cells .	O O O O O O O O O O O O O O O O O O	O O O B O O O B I O O O O O O O O O	[]	0	0	"Sentence: In addition , antithrombin treatment markedly suppressed puromycin aminonucleoside - induced apoptosis of renal tubular epithelial cells .
Diseases: "	"Sentence: In addition , antithrombin treatment markedly suppressed puromycin aminonucleoside - induced apoptosis of renal tubular epithelial cells .
Diseases:"
1020	Furthermore , puromycin aminonucleoside - induced increases in renal cytokine content were also decreased .	O O O O O O O O O O O O O O O	O O B I O O O O O O O O O O O	[]	0	0	"Sentence: Furthermore , puromycin aminonucleoside - induced increases in renal cytokine content were also decreased .
Diseases: "	"Sentence: Furthermore , puromycin aminonucleoside - induced increases in renal cytokine content were also decreased .
Diseases:"
1021	These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside - induced nephrotic syndrome .	O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O B I O O O O O	['nephrotic syndrome']	1	5	"Sentence: These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside - induced nephrotic syndrome .
Diseases: nephrotic syndrome"	"Sentence: These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside - induced nephrotic syndrome .
Diseases:"
1022	Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome .	O O O O O O O O O O B I O	O O O O O O O O O O O O O	['nephrotic syndrome']	1	5	"Sentence: Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome .
Diseases: nephrotic syndrome"	"Sentence: Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome .
Diseases:"
1023	Reverse or inverted left ventricular apical ballooning syndrome ( reverse Takotsubo cardiomyopathy ) in a young woman in the setting of amphetamine use .	O O O B I I I I O O B I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B O O	['left ventricular apical ballooning syndrome', 'takotsubo cardiomyopathy']	2	18	"Sentence: Reverse or inverted left ventricular apical ballooning syndrome ( reverse Takotsubo cardiomyopathy ) in a young woman in the setting of amphetamine use .
Diseases: left ventricular apical ballooning syndrome, takotsubo cardiomyopathy"	"Sentence: Reverse or inverted left ventricular apical ballooning syndrome ( reverse Takotsubo cardiomyopathy ) in a young woman in the setting of amphetamine use .
Diseases:"
1024	"Transient left ventricular apical ballooning syndrome was first described in Japan as "" Takotsubo cardiomyopathy ."	O B I I I I O O O O O O O B I O	O O O O O O O O O O O O O O O O	['left ventricular apical ballooning syndrome', 'takotsubo cardiomyopathy']	2	18	"Sentence: Transient left ventricular apical ballooning syndrome was first described in Japan as "" Takotsubo cardiomyopathy .
Diseases: left ventricular apical ballooning syndrome, takotsubo cardiomyopathy"	"Sentence: Transient left ventricular apical ballooning syndrome was first described in Japan as "" Takotsubo cardiomyopathy .
Diseases:"
1025	""" This syndrome has been identified in many other countries ."	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: "" This syndrome has been identified in many other countries .
Diseases: "	"Sentence: "" This syndrome has been identified in many other countries .
Diseases:"
1026	Many variations of this syndrome have been recently described in the literature .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Many variations of this syndrome have been recently described in the literature .
Diseases: "	"Sentence: Many variations of this syndrome have been recently described in the literature .
Diseases:"
1027	One of the rarest is the reverse type of this syndrome , with hyperdynamic apex and complete akinesia of the base ( as opposed to the classic apical ballooning ) .	O O O O O O O O O O O O O O O O O B O O O O O O O O O B I O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['akinesia', 'apical ballooning']	2	8	"Sentence: One of the rarest is the reverse type of this syndrome , with hyperdynamic apex and complete akinesia of the base ( as opposed to the classic apical ballooning ) .
Diseases: akinesia, apical ballooning"	"Sentence: One of the rarest is the reverse type of this syndrome , with hyperdynamic apex and complete akinesia of the base ( as opposed to the classic apical ballooning ) .
Diseases:"
1028	In this article , we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after amphetamine use .	O O O O O O O O O O O O O O O O O O O O O B I I O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['apical ballooning syndrome']	1	5	"Sentence: In this article , we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after amphetamine use .
Diseases: apical ballooning syndrome"	"Sentence: In this article , we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after amphetamine use .
Diseases:"
1029	This report is followed by review of the literature .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: This report is followed by review of the literature .
Diseases: "	"Sentence: This report is followed by review of the literature .
Diseases:"
1030	Attenuated disruption of prepulse inhibition by dopaminergic stimulation after maternal deprivation and adolescent corticosterone treatment in rats .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: Attenuated disruption of prepulse inhibition by dopaminergic stimulation after maternal deprivation and adolescent corticosterone treatment in rats .
Diseases: "	"Sentence: Attenuated disruption of prepulse inhibition by dopaminergic stimulation after maternal deprivation and adolescent corticosterone treatment in rats .
Diseases:"
1031	The development of schizophrenia may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events , in combination leading to overt disease .	O O O B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['schizophrenia']	1	3	"Sentence: The development of schizophrenia may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events , in combination leading to overt disease .
Diseases: schizophrenia"	"Sentence: The development of schizophrenia may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events , in combination leading to overt disease .
Diseases:"
1032	We investigated the effect of an early stress , in the form of maternal deprivation , combined with a later stress , simulated by chronic periadolescent corticosterone treatment , on behaviour in rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: We investigated the effect of an early stress , in the form of maternal deprivation , combined with a later stress , simulated by chronic periadolescent corticosterone treatment , on behaviour in rats .
Diseases: "	"Sentence: We investigated the effect of an early stress , in the form of maternal deprivation , combined with a later stress , simulated by chronic periadolescent corticosterone treatment , on behaviour in rats .
Diseases:"
1033	Acute treatment with apomorphine caused disruption of prepulse inhibition ( PPI ) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment , but was surprisingly absent in rats that had undergone the combined early and late stress .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Acute treatment with apomorphine caused disruption of prepulse inhibition ( PPI ) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment , but was surprisingly absent in rats that had undergone the combined early and late stress .
Diseases: "	"Sentence: Acute treatment with apomorphine caused disruption of prepulse inhibition ( PPI ) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment , but was surprisingly absent in rats that had undergone the combined early and late stress .
Diseases:"
1034	Amphetamine treatment significantly disrupted PPI in both non - deprived groups , but was absent in both maternally deprived groups .	O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Amphetamine treatment significantly disrupted PPI in both non - deprived groups , but was absent in both maternally deprived groups .
Diseases: "	"Sentence: Amphetamine treatment significantly disrupted PPI in both non - deprived groups , but was absent in both maternally deprived groups .
Diseases:"
1035	The serotonin - 1A receptor agonist , 8 - OH - DPAT , induced a significant disruption of PPI in all groups .	O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O B I I I I O O O O O O O O O O O	[]	0	0	"Sentence: The serotonin - 1A receptor agonist , 8 - OH - DPAT , induced a significant disruption of PPI in all groups .
Diseases: "	"Sentence: The serotonin - 1A receptor agonist , 8 - OH - DPAT , induced a significant disruption of PPI in all groups .
Diseases:"
1036	Amphetamine - induced locomotor hyperactivity was similar in all groups .	O O O B I O O O O O O	B O O O O O O O O O O	['locomotor hyperactivity']	1	5	"Sentence: Amphetamine - induced locomotor hyperactivity was similar in all groups .
Diseases: locomotor hyperactivity"	"Sentence: Amphetamine - induced locomotor hyperactivity was similar in all groups .
Diseases:"
1037	These results show an inhibitory interaction of early stress , caused by maternal deprivation , combined with ' adolescent ' stress , simulated by corticosterone treatment , on dopaminergic regulation of PPI .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: These results show an inhibitory interaction of early stress , caused by maternal deprivation , combined with ' adolescent ' stress , simulated by corticosterone treatment , on dopaminergic regulation of PPI .
Diseases: "	"Sentence: These results show an inhibitory interaction of early stress , caused by maternal deprivation , combined with ' adolescent ' stress , simulated by corticosterone treatment , on dopaminergic regulation of PPI .
Diseases:"
1038	The altered effects of apomorphine and amphetamine could indicate differential changes in dopamine receptor signalling leading to functional desensitisation , or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O B O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The altered effects of apomorphine and amphetamine could indicate differential changes in dopamine receptor signalling leading to functional desensitisation , or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus .
Diseases: "	"Sentence: The altered effects of apomorphine and amphetamine could indicate differential changes in dopamine receptor signalling leading to functional desensitisation , or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus .
Diseases:"
1039	Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra .	O O O O B I I I O O O O O	O B I O O O O O O O O O O	['degeneration of dopaminergic neurons']	1	8	"Sentence: Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra .
Diseases: degeneration of dopaminergic neurons"	"Sentence: Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra .
Diseases:"
1040	Iron accumulation is considered to be involved in the pathogenesis of Parkinson 's disease .	O O O O O O O O O O O B I I O	B O O O O O O O O O O O O O O	"[""parkinson 's disease""]"	1	5	"Sentence: Iron accumulation is considered to be involved in the pathogenesis of Parkinson 's disease .
Diseases: parkinson 's disease"	"Sentence: Iron accumulation is considered to be involved in the pathogenesis of Parkinson 's disease .
Diseases:"
1041	To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra ( SN ) , in the present study we used fast cyclic voltammetry , tyrosine hydroxylase ( TH ) immunohistochemistry , Perls ' iron staining , and high performance liquid chromatography - electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O B O O O O O O O O O O O O O O O O O O O B O O O O O B O O O O	['degeneration of dopaminergic neurons']	1	8	"Sentence: To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra ( SN ) , in the present study we used fast cyclic voltammetry , tyrosine hydroxylase ( TH ) immunohistochemistry , Perls ' iron staining , and high performance liquid chromatography - electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals .
Diseases: degeneration of dopaminergic neurons"	"Sentence: To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra ( SN ) , in the present study we used fast cyclic voltammetry , tyrosine hydroxylase ( TH ) immunohistochemistry , Perls ' iron staining , and high performance liquid chromatography - electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals .
Diseases:"
1042	The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH - immunoreactive neurons in the SN .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH - immunoreactive neurons in the SN .
Diseases: "	"Sentence: The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH - immunoreactive neurons in the SN .
Diseases:"
1043	As a result , dopamine release and content , as well as its metabolites contents were decreased in caudate putamen .	O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: As a result , dopamine release and content , as well as its metabolites contents were decreased in caudate putamen .
Diseases: "	"Sentence: As a result , dopamine release and content , as well as its metabolites contents were decreased in caudate putamen .
Diseases:"
1044	Even more dramatic changes were found in chronic overload group .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: Even more dramatic changes were found in chronic overload group .
Diseases: "	"Sentence: Even more dramatic changes were found in chronic overload group .
Diseases:"
1045	These results suggest that peripheral iron dextran can increase the iron level in the SN , where excessive iron causes the degeneration of dopaminergic neurons .	O O O O O O O O O O O O O O O O O O O O O B I I I O	O O O O O B O O O O B O O O O O O O B O O O O O O O	['degeneration of dopaminergic neurons']	1	8	"Sentence: These results suggest that peripheral iron dextran can increase the iron level in the SN , where excessive iron causes the degeneration of dopaminergic neurons .
Diseases: degeneration of dopaminergic neurons"	"Sentence: These results suggest that peripheral iron dextran can increase the iron level in the SN , where excessive iron causes the degeneration of dopaminergic neurons .
Diseases:"
1046	The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload .	O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O B O O	[]	0	0	"Sentence: The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload .
Diseases: "	"Sentence: The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload .
Diseases:"
1047	Warfarin - induced leukocytoclastic vasculitis .	O O O B I O	B O O O O O	['leukocytoclastic vasculitis']	1	9	"Sentence: Warfarin - induced leukocytoclastic vasculitis .
Diseases: leukocytoclastic vasculitis"	"Sentence: Warfarin - induced leukocytoclastic vasculitis .
Diseases:"
1048	Skin reactions associated with oral coumarin - derived anticoagulants are an uncommon occurrence .	O O O O O O O O O O O O O O	O O O O O B O O O O O O O O	[]	0	0	"Sentence: Skin reactions associated with oral coumarin - derived anticoagulants are an uncommon occurrence .
Diseases: "	"Sentence: Skin reactions associated with oral coumarin - derived anticoagulants are an uncommon occurrence .
Diseases:"
1049	Leukocytoclastic vasculitis ( LV ) is primarily a cutaneous small vessel vasculitis , though systemic involvement may be encountered .	B I O B O O O O B I I I O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	['leukocytoclastic vasculitis', 'cutaneous small vessel vasculitis', 'lv']	3	20	"Sentence: Leukocytoclastic vasculitis ( LV ) is primarily a cutaneous small vessel vasculitis , though systemic involvement may be encountered .
Diseases: leukocytoclastic vasculitis, cutaneous small vessel vasculitis, lv"	"Sentence: Leukocytoclastic vasculitis ( LV ) is primarily a cutaneous small vessel vasculitis , though systemic involvement may be encountered .
Diseases:"
1050	We report 4 patients with late - onset LV probably due to warfarin .	O O O O O O O O B O O O O O	O O O O O O O O O O O O B O	['lv']	1	1	"Sentence: We report 4 patients with late - onset LV probably due to warfarin .
Diseases: lv"	"Sentence: We report 4 patients with late - onset LV probably due to warfarin .
Diseases:"
1051	All 4 patients presented with skin eruptions that developed after receiving warfarin for several years .	O O O O O B I O O O O O O O O O	O O O O O O O O O O O B O O O O	['skin eruptions']	1	3	"Sentence: All 4 patients presented with skin eruptions that developed after receiving warfarin for several years .
Diseases: skin eruptions"	"Sentence: All 4 patients presented with skin eruptions that developed after receiving warfarin for several years .
Diseases:"
1052	The results of skin lesion biopsies were available in 3 patients , confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued .	O O O B I O O O O O O O O B I I O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B O O O	['lv cutaneous lesions', 'skin lesion']	2	8	"Sentence: The results of skin lesion biopsies were available in 3 patients , confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued .
Diseases: lv cutaneous lesions, skin lesion"	"Sentence: The results of skin lesion biopsies were available in 3 patients , confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued .
Diseases:"
1053	In 2 of the 4 patients , rechallenge with warfarin led to recurrence of the lesions .	O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: In 2 of the 4 patients , rechallenge with warfarin led to recurrence of the lesions .
Diseases: "	"Sentence: In 2 of the 4 patients , rechallenge with warfarin led to recurrence of the lesions .
Diseases:"
1054	LV may be a late - onset adverse reaction associated with warfarin therapy .	B O O O O O O O O O O O O O	B O O O O O O O O O O B O O	['lv']	1	1	"Sentence: LV may be a late - onset adverse reaction associated with warfarin therapy .
Diseases: lv"	"Sentence: LV may be a late - onset adverse reaction associated with warfarin therapy .
Diseases:"
1055	The activation of spinal N - methyl - D - aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O	O O O O B I I I I I I O O O O O O O O O O O O B O O O O O O O O O	['spinal cord ischemia']	1	6	"Sentence: The activation of spinal N - methyl - D - aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia .
Diseases: spinal cord ischemia"	"Sentence: The activation of spinal N - methyl - D - aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia .
Diseases:"
1056	We investigated the relationship between the degeneration of spinal motor neurons and activation of N - methyl - d - aspartate ( NMDA ) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O	O O O O O O O O O O O O O O B I I I I I I O B O O O O B O O O O O O O O O O	['aortic occlusion']	1	6	"Sentence: We investigated the relationship between the degeneration of spinal motor neurons and activation of N - methyl - d - aspartate ( NMDA ) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats .
Diseases: aortic occlusion"	"Sentence: We investigated the relationship between the degeneration of spinal motor neurons and activation of N - methyl - d - aspartate ( NMDA ) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats .
Diseases:"
1057	Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter .	B I I O O O B I O O O O O O O O	O O O O O O O O O O O O O O O O	['aortic occlusion', 'spinal cord ischemia']	2	12	"Sentence: Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter .
Diseases: aortic occlusion, spinal cord ischemia"	"Sentence: Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter .
Diseases:"
1058	In a microdialysis study , 10 muL of saline ( group C ; n = 8 ) or 30 mug of morphine ( group M ; n = 8 ) was injected intrathecally ( IT ) 0 . 5 h after reflow , and 30 mug of morphine ( group SM ; n = 8 ) or 10 muL of saline ( group SC ; n = 8 ) was injected IT 0 . 5 h after sham operation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In a microdialysis study , 10 muL of saline ( group C ; n = 8 ) or 30 mug of morphine ( group M ; n = 8 ) was injected intrathecally ( IT ) 0 . 5 h after reflow , and 30 mug of morphine ( group SM ; n = 8 ) or 10 muL of saline ( group SC ; n = 8 ) was injected IT 0 . 5 h after sham operation .
Diseases: "	"Sentence: In a microdialysis study , 10 muL of saline ( group C ; n = 8 ) or 30 mug of morphine ( group M ; n = 8 ) was injected intrathecally ( IT ) 0 . 5 h after reflow , and 30 mug of morphine ( group SM ; n = 8 ) or 10 muL of saline ( group SC ; n = 8 ) was injected IT 0 . 5 h after sham operation .
Diseases:"
1059	Microdialysis samples were collected preischemia , before IT injection , and at 2 , 4 , 8 , 24 , and 48 h of reperfusion ( after IT injection ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Microdialysis samples were collected preischemia , before IT injection , and at 2 , 4 , 8 , 24 , and 48 h of reperfusion ( after IT injection ) .
Diseases: "	"Sentence: Microdialysis samples were collected preischemia , before IT injection , and at 2 , 4 , 8 , 24 , and 48 h of reperfusion ( after IT injection ) .
Diseases:"
1060	Second , we investigated the effect of IT MK - 801 ( 30 mug ) on the histopathologic changes in the spinal cord after morphine - induced spastic paraparesis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O B I I O O O O O O O O O O O O O B O O O O O	['spastic paraparesis']	1	5	"Sentence: Second , we investigated the effect of IT MK - 801 ( 30 mug ) on the histopathologic changes in the spinal cord after morphine - induced spastic paraparesis .
Diseases: spastic paraparesis"	"Sentence: Second , we investigated the effect of IT MK - 801 ( 30 mug ) on the histopathologic changes in the spinal cord after morphine - induced spastic paraparesis .
Diseases:"
1061	After IT morphine , the cerebrospinal fluid ( CSF ) glutamate concentration was increased in group M relative to both baseline and group C ( P < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After IT morphine , the cerebrospinal fluid ( CSF ) glutamate concentration was increased in group M relative to both baseline and group C ( P < 0 . 05 ) .
Diseases: "	"Sentence: After IT morphine , the cerebrospinal fluid ( CSF ) glutamate concentration was increased in group M relative to both baseline and group C ( P < 0 . 05 ) .
Diseases:"
1062	This increase persisted for 8 hrs .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: This increase persisted for 8 hrs .
Diseases: "	"Sentence: This increase persisted for 8 hrs .
Diseases:"
1063	IT MK - 801 significantly reduced the number of dark - stained alpha - motoneurons after morphine - induced spastic paraparesis compared with the saline group .	O O O O O O O O O O O O O O O O O O O B I O O O O O O	O B I I O O O O O O O O O O O O B O O O O O O O O O O	['spastic paraparesis']	1	5	"Sentence: IT MK - 801 significantly reduced the number of dark - stained alpha - motoneurons after morphine - induced spastic paraparesis compared with the saline group .
Diseases: spastic paraparesis"	"Sentence: IT MK - 801 significantly reduced the number of dark - stained alpha - motoneurons after morphine - induced spastic paraparesis compared with the saline group .
Diseases:"
1064	These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate , which is involved in NMDA receptor activation .	O O O O O O O B I O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O B O O O O O B O O O	['spastic paraparesis']	1	5	"Sentence: These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate , which is involved in NMDA receptor activation .
Diseases: spastic paraparesis"	"Sentence: These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate , which is involved in NMDA receptor activation .
Diseases:"
1065	We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation .	O O O O O O B O O O O B I I O O O O O	O O O O O O O O O O O O O O O B O O O	['spinal cord ischemia', 'neurotoxic']	2	9	"Sentence: We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation .
Diseases: spinal cord ischemia, neurotoxic"	"Sentence: We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation .
Diseases:"
1066	Reduced sodium channel density , altered voltage dependence of inactivation , and increased susceptibility to seizures in mice lacking sodium channel beta 2 - subunits .	O O O O O O O O O O O O O O O B O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O B O O O O O O	['seizures']	1	3	"Sentence: Reduced sodium channel density , altered voltage dependence of inactivation , and increased susceptibility to seizures in mice lacking sodium channel beta 2 - subunits .
Diseases: seizures"	"Sentence: Reduced sodium channel density , altered voltage dependence of inactivation , and increased susceptibility to seizures in mice lacking sodium channel beta 2 - subunits .
Diseases:"
1067	Sodium channel beta - subunits modulate channel gating , assembly , and cell surface expression in heterologous cell systems .	O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Sodium channel beta - subunits modulate channel gating , assembly , and cell surface expression in heterologous cell systems .
Diseases: "	"Sentence: Sodium channel beta - subunits modulate channel gating , assembly , and cell surface expression in heterologous cell systems .
Diseases:"
1068	We generated beta2 ( - / - ) mice to investigate the role of beta2 in control of sodium channel density , localization , and function in neurons in vivo .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: We generated beta2 ( - / - ) mice to investigate the role of beta2 in control of sodium channel density , localization , and function in neurons in vivo .
Diseases: "	"Sentence: We generated beta2 ( - / - ) mice to investigate the role of beta2 in control of sodium channel density , localization , and function in neurons in vivo .
Diseases:"
1069	Measurements of [ ( 3 ) H ] saxitoxin ( STX ) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2 ( - / - ) neurons .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O I O B O B O O O O O O O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: Measurements of [ ( 3 ) H ] saxitoxin ( STX ) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2 ( - / - ) neurons .
Diseases: "	"Sentence: Measurements of [ ( 3 ) H ] saxitoxin ( STX ) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2 ( - / - ) neurons .
Diseases:"
1070	The loss of beta2 resulted in negative shifts in the voltage dependence of inactivation as well as significant decreases in sodium current density in acutely dissociated hippocampal neurons .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: The loss of beta2 resulted in negative shifts in the voltage dependence of inactivation as well as significant decreases in sodium current density in acutely dissociated hippocampal neurons .
Diseases: "	"Sentence: The loss of beta2 resulted in negative shifts in the voltage dependence of inactivation as well as significant decreases in sodium current density in acutely dissociated hippocampal neurons .
Diseases:"
1071	The integral of the compound action potential in optic nerve was significantly reduced , and the threshold for action potential generation was increased , indicating a reduction in the level of functional plasma membrane sodium channels .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: The integral of the compound action potential in optic nerve was significantly reduced , and the threshold for action potential generation was increased , indicating a reduction in the level of functional plasma membrane sodium channels .
Diseases: "	"Sentence: The integral of the compound action potential in optic nerve was significantly reduced , and the threshold for action potential generation was increased , indicating a reduction in the level of functional plasma membrane sodium channels .
Diseases:"
1072	In contrast , the conduction velocity , the number and size of axons in the optic nerve , and the specific localization of Na ( v ) 1 . 6 channels in the nodes of Ranvier were unchanged .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast , the conduction velocity , the number and size of axons in the optic nerve , and the specific localization of Na ( v ) 1 . 6 channels in the nodes of Ranvier were unchanged .
Diseases: "	"Sentence: In contrast , the conduction velocity , the number and size of axons in the optic nerve , and the specific localization of Na ( v ) 1 . 6 channels in the nodes of Ranvier were unchanged .
Diseases:"
1073	beta2 ( - / - ) mice displayed increased susceptibility to seizures , as indicated by reduced latency and threshold for pilocarpine - induced seizures , but seemed normal in other neurological tests .	O O O O O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	['seizures']	1	3	"Sentence: beta2 ( - / - ) mice displayed increased susceptibility to seizures , as indicated by reduced latency and threshold for pilocarpine - induced seizures , but seemed normal in other neurological tests .
Diseases: seizures"	"Sentence: beta2 ( - / - ) mice displayed increased susceptibility to seizures , as indicated by reduced latency and threshold for pilocarpine - induced seizures , but seemed normal in other neurological tests .
Diseases:"
1074	Our observations show that beta2 - subunits play an important role in the regulation of sodium channel density and function in neurons in vivo and are required for normal action potential generation and control of excitability .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Our observations show that beta2 - subunits play an important role in the regulation of sodium channel density and function in neurons in vivo and are required for normal action potential generation and control of excitability .
Diseases: "	"Sentence: Our observations show that beta2 - subunits play an important role in the regulation of sodium channel density and function in neurons in vivo and are required for normal action potential generation and control of excitability .
Diseases:"
1075	Screening for stimulant use in adult emergency department seizure patients .	O O O O O O O O B O O	O O O O O O O O O O O	['seizure']	1	3	"Sentence: Screening for stimulant use in adult emergency department seizure patients .
Diseases: seizure"	"Sentence: Screening for stimulant use in adult emergency department seizure patients .
Diseases:"
1076	The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients .	O O O O O O O O O O O O O O O O O O O O O O O B O O	O O O O O O O O O O O O O O O O B O B O O O O O O O	['seizure']	1	3	"Sentence: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients .
Diseases: seizure"	"Sentence: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients .
Diseases:"
1077	This prospective study evaluated consecutive eligible seizure patients who had a plasma sample collected as part of their clinical evaluation .	O O O O O O B O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	['seizure']	1	3	"Sentence: This prospective study evaluated consecutive eligible seizure patients who had a plasma sample collected as part of their clinical evaluation .
Diseases: seizure"	"Sentence: This prospective study evaluated consecutive eligible seizure patients who had a plasma sample collected as part of their clinical evaluation .
Diseases:"
1078	Plasma was tested for amphetamine and the cocaine metabolite benzoylecgonine using enzyme - mediated immunoassay methodology .	O O O O O O O O O O O O O O O O O	O O O O B O O B O B O O O O O O O	[]	0	0	"Sentence: Plasma was tested for amphetamine and the cocaine metabolite benzoylecgonine using enzyme - mediated immunoassay methodology .
Diseases: "	"Sentence: Plasma was tested for amphetamine and the cocaine metabolite benzoylecgonine using enzyme - mediated immunoassay methodology .
Diseases:"
1079	Plasma samples with benzoylecgonine greater than 150 ng / mL or an amphetamine greater than 500 ng / mL were defined as positive .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: Plasma samples with benzoylecgonine greater than 150 ng / mL or an amphetamine greater than 500 ng / mL were defined as positive .
Diseases: "	"Sentence: Plasma samples with benzoylecgonine greater than 150 ng / mL or an amphetamine greater than 500 ng / mL were defined as positive .
Diseases:"
1080	Patient demographics , history of underlying drug or alcohol - related seizure disorder , estimated time from seizure to sample collection , history or suspicion of cocaine or amphetamine abuse , results of clinical urine testing for drugs of abuse , and assay results were recorded without patient identifiers .	O O O O O O O O O O O B O O O O O B O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O	['cocaine or amphetamine abuse', 'seizure']	2	9	"Sentence: Patient demographics , history of underlying drug or alcohol - related seizure disorder , estimated time from seizure to sample collection , history or suspicion of cocaine or amphetamine abuse , results of clinical urine testing for drugs of abuse , and assay results were recorded without patient identifiers .
Diseases: cocaine or amphetamine abuse, seizure"	"Sentence: Patient demographics , history of underlying drug or alcohol - related seizure disorder , estimated time from seizure to sample collection , history or suspicion of cocaine or amphetamine abuse , results of clinical urine testing for drugs of abuse , and assay results were recorded without patient identifiers .
Diseases:"
1081	Fourteen of 248 ( 5 . 6 % , 95 % CI 2 . 7 % - 8 . 5 % ) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples ( 0 % , 95 % CI 0 - 1 . 2 % ) were positive for amphetamine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: Fourteen of 248 ( 5 . 6 % , 95 % CI 2 . 7 % - 8 . 5 % ) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples ( 0 % , 95 % CI 0 - 1 . 2 % ) were positive for amphetamine .
Diseases: "	"Sentence: Fourteen of 248 ( 5 . 6 % , 95 % CI 2 . 7 % - 8 . 5 % ) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples ( 0 % , 95 % CI 0 - 1 . 2 % ) were positive for amphetamine .
Diseases:"
1082	Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse ( p < 0 . 0005 ) .	O O O O O O O O O O O O O O O O O B I I I O O O O O O O O	O O O O O O O O O O O O O O O O O B O B O O O O O O O O O	['cocaine or amphetamine abuse']	1	7	"Sentence: Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse ( p < 0 . 0005 ) .
Diseases: cocaine or amphetamine abuse"	"Sentence: Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse ( p < 0 . 0005 ) .
Diseases:"
1083	During this study period , routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield .	O O O O O O O O O O O O O O B O O O O O O	O O O O O O O O O B O B O O O O O O O O O	['seizure']	1	3	"Sentence: During this study period , routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield .
Diseases: seizure"	"Sentence: During this study period , routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield .
Diseases:"
1084	As a result , routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of drug abuse in this population .	O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['drug abuse']	1	2	"Sentence: As a result , routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of drug abuse in this population .
Diseases: drug abuse"	"Sentence: As a result , routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of drug abuse in this population .
Diseases:"
1085	Evidence of functional somatotopy in GPi from results of pallidotomy .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: Evidence of functional somatotopy in GPi from results of pallidotomy .
Diseases: "	"Sentence: Evidence of functional somatotopy in GPi from results of pallidotomy .
Diseases:"
1086	The objective of this study was to explore the functional anatomy of the globus pallidus internus ( GPi ) by studying the effects of unilateral pallidotomy on parkinsonian ' off ' signs and levodopa - induced dyskinesias ( LID ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O B O B O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['dyskinesias', 'parkinsonian', 'lid']	3	11	"Sentence: The objective of this study was to explore the functional anatomy of the globus pallidus internus ( GPi ) by studying the effects of unilateral pallidotomy on parkinsonian ' off ' signs and levodopa - induced dyskinesias ( LID ) .
Diseases: dyskinesias, parkinsonian, lid"	"Sentence: The objective of this study was to explore the functional anatomy of the globus pallidus internus ( GPi ) by studying the effects of unilateral pallidotomy on parkinsonian ' off ' signs and levodopa - induced dyskinesias ( LID ) .
Diseases:"
1087	We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests ( Core Assessment Program for Intracerebral Transplantations ) in the contralateral limbs and the improvement in these scores after surgery , whereas there was no correlation with the improvement in LID .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O B O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['lid']	1	2	"Sentence: We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests ( Core Assessment Program for Intracerebral Transplantations ) in the contralateral limbs and the improvement in these scores after surgery , whereas there was no correlation with the improvement in LID .
Diseases: lid"	"Sentence: We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests ( Core Assessment Program for Intracerebral Transplantations ) in the contralateral limbs and the improvement in these scores after surgery , whereas there was no correlation with the improvement in LID .
Diseases:"
1088	We also found a highly significant correlation ( P : < 0 . 0001 , r = 0 . 8 ) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs , whereas there was no correlation between the ventral volume and the improvement in parkinsonian ' off ' signs .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O B O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['parkinsonian', 'lid']	2	5	"Sentence: We also found a highly significant correlation ( P : < 0 . 0001 , r = 0 . 8 ) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs , whereas there was no correlation between the ventral volume and the improvement in parkinsonian ' off ' signs .
Diseases: parkinsonian, lid"	"Sentence: We also found a highly significant correlation ( P : < 0 . 0001 , r = 0 . 8 ) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs , whereas there was no correlation between the ventral volume and the improvement in parkinsonian ' off ' signs .
Diseases:"
1089	The volumes of the total lesion cylinder and the dorsal lesion did not correlate with the outcome of either dyskinesias or parkinsonian ' off ' signs .	O O O O O O O O O O O O O O O O O O O B O B O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['dyskinesias', 'parkinsonian']	2	9	"Sentence: The volumes of the total lesion cylinder and the dorsal lesion did not correlate with the outcome of either dyskinesias or parkinsonian ' off ' signs .
Diseases: dyskinesias, parkinsonian"	"Sentence: The volumes of the total lesion cylinder and the dorsal lesion did not correlate with the outcome of either dyskinesias or parkinsonian ' off ' signs .
Diseases:"
1090	The differential predictive value of levodopa responsiveness for the outcome of parkinsonian ' off ' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian ' off ' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian ' off ' signs and dyskinesias .	O O O O O O O O O O O B O O O O O B O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O B O O O O O B O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['dyskinesias', 'parkinsonian', 'lid']	3	11	"Sentence: The differential predictive value of levodopa responsiveness for the outcome of parkinsonian ' off ' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian ' off ' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian ' off ' signs and dyskinesias .
Diseases: dyskinesias, parkinsonian, lid"	"Sentence: The differential predictive value of levodopa responsiveness for the outcome of parkinsonian ' off ' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian ' off ' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian ' off ' signs and dyskinesias .
Diseases:"
1091	Whereas cells in a wider area of the GPi may be implicated in parkinsonism , the ventral GPi seems to be crucial for the manifestation of LID .	O O O O O O O O O O O O O B O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['parkinsonism', 'lid']	2	5	"Sentence: Whereas cells in a wider area of the GPi may be implicated in parkinsonism , the ventral GPi seems to be crucial for the manifestation of LID .
Diseases: parkinsonism, lid"	"Sentence: Whereas cells in a wider area of the GPi may be implicated in parkinsonism , the ventral GPi seems to be crucial for the manifestation of LID .
Diseases:"
1092	We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate parkinsonism and dyskinesias , especially along the dorsoventral trajectory used in pallidotomy .	O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['dyskinesias', 'parkinsonism']	2	9	"Sentence: We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate parkinsonism and dyskinesias , especially along the dorsoventral trajectory used in pallidotomy .
Diseases: dyskinesias, parkinsonism"	"Sentence: We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate parkinsonism and dyskinesias , especially along the dorsoventral trajectory used in pallidotomy .
Diseases:"
1093	The outcome of pallidotomy in which the lesion involves the ventral and dorsal GPi could be the net effect of alteration in the activity of pathways which mediate different symptoms , and hence could be variable .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The outcome of pallidotomy in which the lesion involves the ventral and dorsal GPi could be the net effect of alteration in the activity of pathways which mediate different symptoms , and hence could be variable .
Diseases: "	"Sentence: The outcome of pallidotomy in which the lesion involves the ventral and dorsal GPi could be the net effect of alteration in the activity of pathways which mediate different symptoms , and hence could be variable .
Diseases:"
1094	Pain responses in methadone - maintained opioid abusers .	B O O O O O O O O	O O O B O O O O O	['pain']	1	1	"Sentence: Pain responses in methadone - maintained opioid abusers .
Diseases: pain"	"Sentence: Pain responses in methadone - maintained opioid abusers .
Diseases:"
1095	Providing pain management for known opioid abusers is a challenging clinical task , in part because little is known about their pain experience and analgesic requirements .	O B O O O O O O O O O O O O O O O O O O O B O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: Providing pain management for known opioid abusers is a challenging clinical task , in part because little is known about their pain experience and analgesic requirements .
Diseases: pain"	"Sentence: Providing pain management for known opioid abusers is a challenging clinical task , in part because little is known about their pain experience and analgesic requirements .
Diseases:"
1096	This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone - maintenance ( MM ) treatment ( n = 60 ) in comparison to matched nondependent control subjects ( n = 60 ) .	O O O O O O B O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['opioid addicts', 'pain']	2	6	"Sentence: This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone - maintenance ( MM ) treatment ( n = 60 ) in comparison to matched nondependent control subjects ( n = 60 ) .
Diseases: opioid addicts, pain"	"Sentence: This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone - maintenance ( MM ) treatment ( n = 60 ) in comparison to matched nondependent control subjects ( n = 60 ) .
Diseases:"
1097	By using a placebo - controlled , two - way factorial design , tolerance to cold - pressor ( CP ) pain was examined , both before and after oral administration of therapeutic doses of common opioid ( hydromorphone 2 mg ) and nonsteroidal anti - inflammatory ( ketorolac 10 mg ) analgesic agents .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O B O O O O O O	['pain']	1	1	"Sentence: By using a placebo - controlled , two - way factorial design , tolerance to cold - pressor ( CP ) pain was examined , both before and after oral administration of therapeutic doses of common opioid ( hydromorphone 2 mg ) and nonsteroidal anti - inflammatory ( ketorolac 10 mg ) analgesic agents .
Diseases: pain"	"Sentence: By using a placebo - controlled , two - way factorial design , tolerance to cold - pressor ( CP ) pain was examined , both before and after oral administration of therapeutic doses of common opioid ( hydromorphone 2 mg ) and nonsteroidal anti - inflammatory ( ketorolac 10 mg ) analgesic agents .
Diseases:"
1098	Results showed that MM individuals were significantly less tolerant of CP pain than control subjects , replicating previous work .	O O O O O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: Results showed that MM individuals were significantly less tolerant of CP pain than control subjects , replicating previous work .
Diseases: pain"	"Sentence: Results showed that MM individuals were significantly less tolerant of CP pain than control subjects , replicating previous work .
Diseases:"
1099	Analgesic effects were significant neither for medication nor group .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Analgesic effects were significant neither for medication nor group .
Diseases: "	"Sentence: Analgesic effects were significant neither for medication nor group .
Diseases:"
1100	These data indicate that MM opioid abusers represent a pain - intolerant subset of clinical patients .	O O O O O O O O O B I I O O O O O	O O O O O O O O O O O O O O O O O	['pain - intolerant']	1	4	"Sentence: These data indicate that MM opioid abusers represent a pain - intolerant subset of clinical patients .
Diseases: pain - intolerant"	"Sentence: These data indicate that MM opioid abusers represent a pain - intolerant subset of clinical patients .
Diseases:"
1101	Their complaints of pain should be evaluated seriously and managed aggressively .	O O O B O O O O O O O O	O O O O O O O O O O O O	['pain']	1	1	"Sentence: Their complaints of pain should be evaluated seriously and managed aggressively .
Diseases: pain"	"Sentence: Their complaints of pain should be evaluated seriously and managed aggressively .
Diseases:"
1102	Urine N - acetyl - beta - D - glucosaminidase - - a marker of tubular damage ?	O O O O O O O O O O O O O O O O O O	O B I I I I I I I O O O O O O O O O	[]	0	0	"Sentence: Urine N - acetyl - beta - D - glucosaminidase - - a marker of tubular damage ?
Diseases: "	"Sentence: Urine N - acetyl - beta - D - glucosaminidase - - a marker of tubular damage ?
Diseases:"
1103	Although an indicator of renal tubular dysfunction , an increased urinary N - acetyl - beta - D - glucosaminidase ( NAG ) activity might reflect increased lysosomal activity in renal tubular cells .	O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B I I I I I I I I O O O O O O O O O O O O O O	['renal tubular dysfunction']	1	5	"Sentence: Although an indicator of renal tubular dysfunction , an increased urinary N - acetyl - beta - D - glucosaminidase ( NAG ) activity might reflect increased lysosomal activity in renal tubular cells .
Diseases: renal tubular dysfunction"	"Sentence: Although an indicator of renal tubular dysfunction , an increased urinary N - acetyl - beta - D - glucosaminidase ( NAG ) activity might reflect increased lysosomal activity in renal tubular cells .
Diseases:"
1104	METHODS : Puromycin aminonucleoside ( PAN ) was administered to Sprague Dawley rats to induce proteinuria .	O O O O O O O O O O O O O O O B O	O O B I O B O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: METHODS : Puromycin aminonucleoside ( PAN ) was administered to Sprague Dawley rats to induce proteinuria .
Diseases: proteinuria"	"Sentence: METHODS : Puromycin aminonucleoside ( PAN ) was administered to Sprague Dawley rats to induce proteinuria .
Diseases:"
1105	Total protein , albumin , NAG activity and protein electrophoretic pattern were assessed in daily urine samples for 33 days .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Total protein , albumin , NAG activity and protein electrophoretic pattern were assessed in daily urine samples for 33 days .
Diseases: "	"Sentence: Total protein , albumin , NAG activity and protein electrophoretic pattern were assessed in daily urine samples for 33 days .
Diseases:"
1106	The morphological appearance of the kidneys was examined on days three , four , six , eight and thirty three and the NAG isoenzyme patterns on days zero , four , eight and thirty three .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The morphological appearance of the kidneys was examined on days three , four , six , eight and thirty three and the NAG isoenzyme patterns on days zero , four , eight and thirty three .
Diseases: "	"Sentence: The morphological appearance of the kidneys was examined on days three , four , six , eight and thirty three and the NAG isoenzyme patterns on days zero , four , eight and thirty three .
Diseases:"
1107	Following intravenous PAN urine volume and urine NAG activity increased significantly by day two , but returned to normal by day four .	O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Following intravenous PAN urine volume and urine NAG activity increased significantly by day two , but returned to normal by day four .
Diseases: "	"Sentence: Following intravenous PAN urine volume and urine NAG activity increased significantly by day two , but returned to normal by day four .
Diseases:"
1108	After day four all treated animals exhibited a marked rise in urine albumin , total protein excretion and NAG activity .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After day four all treated animals exhibited a marked rise in urine albumin , total protein excretion and NAG activity .
Diseases: "	"Sentence: After day four all treated animals exhibited a marked rise in urine albumin , total protein excretion and NAG activity .
Diseases:"
1109	Electrophoresis showed a generalised increase in middle and high molecular weight urine proteins from day four onwards .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Electrophoresis showed a generalised increase in middle and high molecular weight urine proteins from day four onwards .
Diseases: "	"Sentence: Electrophoresis showed a generalised increase in middle and high molecular weight urine proteins from day four onwards .
Diseases:"
1110	Protein droplets first appeared prominent in tubular cells on day four .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: Protein droplets first appeared prominent in tubular cells on day four .
Diseases: "	"Sentence: Protein droplets first appeared prominent in tubular cells on day four .
Diseases:"
1111	Peak urine NAG activity and a change in NAG isoenzyme pattern coincided with both the peak proteinuria and the reduction in intracellular protein and NAG droplets ( day six onwards ) .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: Peak urine NAG activity and a change in NAG isoenzyme pattern coincided with both the peak proteinuria and the reduction in intracellular protein and NAG droplets ( day six onwards ) .
Diseases: proteinuria"	"Sentence: Peak urine NAG activity and a change in NAG isoenzyme pattern coincided with both the peak proteinuria and the reduction in intracellular protein and NAG droplets ( day six onwards ) .
Diseases:"
1112	CONCLUSIONS : This animal model demonstrates that an increase in lysosomal turnover and hence urine NAG activity , occurs when increased protein is presented to the tubular cells .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSIONS : This animal model demonstrates that an increase in lysosomal turnover and hence urine NAG activity , occurs when increased protein is presented to the tubular cells .
Diseases: "	"Sentence: CONCLUSIONS : This animal model demonstrates that an increase in lysosomal turnover and hence urine NAG activity , occurs when increased protein is presented to the tubular cells .
Diseases:"
1113	Urine NAG activity is thus a measure of altered function in the renal tubules and not simply an indicator of damage .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Urine NAG activity is thus a measure of altered function in the renal tubules and not simply an indicator of damage .
Diseases: "	"Sentence: Urine NAG activity is thus a measure of altered function in the renal tubules and not simply an indicator of damage .
Diseases:"
1114	Over expression of vascular endothelial growth factor and its receptor during the development of estrogen - induced rat pituitary tumors may mediate estrogen - initiated tumor angiogenesis .	O O O O O O O O O O O O O O O O O O B I O O O O O B O O	O O O O O O O O O O O O O O B O O O O O O O B O O O O O	['tumor', 'pituitary tumors']	2	8	"Sentence: Over expression of vascular endothelial growth factor and its receptor during the development of estrogen - induced rat pituitary tumors may mediate estrogen - initiated tumor angiogenesis .
Diseases: tumor, pituitary tumors"	"Sentence: Over expression of vascular endothelial growth factor and its receptor during the development of estrogen - induced rat pituitary tumors may mediate estrogen - initiated tumor angiogenesis .
Diseases:"
1115	Estrogens , which have been associated with several types of human and animal cancers , can induce tumor angiogenesis in the pituitary of Fischer 344 rats .	O O O O O O O O O O O O O B O O O B O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O	['tumor', 'cancers']	2	5	"Sentence: Estrogens , which have been associated with several types of human and animal cancers , can induce tumor angiogenesis in the pituitary of Fischer 344 rats .
Diseases: tumor, cancers"	"Sentence: Estrogens , which have been associated with several types of human and animal cancers , can induce tumor angiogenesis in the pituitary of Fischer 344 rats .
Diseases:"
1116	The mechanistic details of tumor angiogenesis induction , during estrogen carcinogenesis , are still unknown .	O O O O B O O O O O B O O O O O	O O O O O O O O O B O O O O O O	['tumor', 'carcinogenesis']	2	6	"Sentence: The mechanistic details of tumor angiogenesis induction , during estrogen carcinogenesis , are still unknown .
Diseases: tumor, carcinogenesis"	"Sentence: The mechanistic details of tumor angiogenesis induction , during estrogen carcinogenesis , are still unknown .
Diseases:"
1117	To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats , the density of blood vessels was analysed using factor VIII related antigen ( FVIIIRAg ) immunohistochemistry and the expression of vascular endothelial growth factor / vascular permeability factor ( VEGF / VPF ) was examined by Western blot and immunohistochemical analysis .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['tumor']	1	3	"Sentence: To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats , the density of blood vessels was analysed using factor VIII related antigen ( FVIIIRAg ) immunohistochemistry and the expression of vascular endothelial growth factor / vascular permeability factor ( VEGF / VPF ) was examined by Western blot and immunohistochemical analysis .
Diseases: tumor"	"Sentence: To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats , the density of blood vessels was analysed using factor VIII related antigen ( FVIIIRAg ) immunohistochemistry and the expression of vascular endothelial growth factor / vascular permeability factor ( VEGF / VPF ) was examined by Western blot and immunohistochemical analysis .
Diseases:"
1118	The expression of VEGF receptor ( VEGFR - 2 / Flk - 1 / KDR ) was also examined by immunohistochemistry .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The expression of VEGF receptor ( VEGFR - 2 / Flk - 1 / KDR ) was also examined by immunohistochemistry .
Diseases: "	"Sentence: The expression of VEGF receptor ( VEGFR - 2 / Flk - 1 / KDR ) was also examined by immunohistochemistry .
Diseases:"
1119	The results demonstrated that 17beta - estradiol ( E2 ) induces neovascularization , as well as the growth and enlargement of blood vessels after 7 days of exposure .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B I I O B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results demonstrated that 17beta - estradiol ( E2 ) induces neovascularization , as well as the growth and enlargement of blood vessels after 7 days of exposure .
Diseases: "	"Sentence: The results demonstrated that 17beta - estradiol ( E2 ) induces neovascularization , as well as the growth and enlargement of blood vessels after 7 days of exposure .
Diseases:"
1120	The high tumor angiogenic potential was associated with an elevated VEGF / VPF protein expression in the E2 exposed pituitary of ovariectomized ( OVEX ) rats .	O O B O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O O O O	['tumor']	1	3	"Sentence: The high tumor angiogenic potential was associated with an elevated VEGF / VPF protein expression in the E2 exposed pituitary of ovariectomized ( OVEX ) rats .
Diseases: tumor"	"Sentence: The high tumor angiogenic potential was associated with an elevated VEGF / VPF protein expression in the E2 exposed pituitary of ovariectomized ( OVEX ) rats .
Diseases:"
1121	VEGF / VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin ( UEA1 ) binding studies , indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non - endothelial cells .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: VEGF / VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin ( UEA1 ) binding studies , indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non - endothelial cells .
Diseases: "	"Sentence: VEGF / VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin ( UEA1 ) binding studies , indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non - endothelial cells .
Diseases:"
1122	After 15 days of E2 exposure , VEGF / VPF protein expression , in the non - endothelial cell population , sharply declined and was restricted to the blood vessels .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After 15 days of E2 exposure , VEGF / VPF protein expression , in the non - endothelial cell population , sharply declined and was restricted to the blood vessels .
Diseases: "	"Sentence: After 15 days of E2 exposure , VEGF / VPF protein expression , in the non - endothelial cell population , sharply declined and was restricted to the blood vessels .
Diseases:"
1123	The function of non - endothelial - derived VEGF is not clear .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: The function of non - endothelial - derived VEGF is not clear .
Diseases: "	"Sentence: The function of non - endothelial - derived VEGF is not clear .
Diseases:"
1124	Furthermore , immunohistochemical studies demonstrated that VEGFR - 2 ( flk - 1 / KDR ) , expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Furthermore , immunohistochemical studies demonstrated that VEGFR - 2 ( flk - 1 / KDR ) , expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure .
Diseases: "	"Sentence: Furthermore , immunohistochemical studies demonstrated that VEGFR - 2 ( flk - 1 / KDR ) , expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure .
Diseases:"
1125	These findings suggest that over expression of VEGF and its receptor ( VEGFR - 2 ) may play an important role in the initial step of the regulation of estrogen induced tumor angiogenesis in the rat pituitary .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['tumor']	1	3	"Sentence: These findings suggest that over expression of VEGF and its receptor ( VEGFR - 2 ) may play an important role in the initial step of the regulation of estrogen induced tumor angiogenesis in the rat pituitary .
Diseases: tumor"	"Sentence: These findings suggest that over expression of VEGF and its receptor ( VEGFR - 2 ) may play an important role in the initial step of the regulation of estrogen induced tumor angiogenesis in the rat pituitary .
Diseases:"
1126	Pravastatin - associated myopathy .	O O O B O	B O O O O	['myopathy']	1	2	"Sentence: Pravastatin - associated myopathy .
Diseases: myopathy"	"Sentence: Pravastatin - associated myopathy .
Diseases:"
1127	Report of a case .	O O O O O	O O O O O	[]	0	0	"Sentence: Report of a case .
Diseases: "	"Sentence: Report of a case .
Diseases:"
1128	A case of acute inflammatory myopathy associated with the use of pravastatin , a new hydrophilic 3 - hydroxy - 3 methylglutaril coenzyme A reductase inhibitor , is reported .	O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O B I I O O I O I O O O O O O	['inflammatory myopathy']	1	3	"Sentence: A case of acute inflammatory myopathy associated with the use of pravastatin , a new hydrophilic 3 - hydroxy - 3 methylglutaril coenzyme A reductase inhibitor , is reported .
Diseases: inflammatory myopathy"	"Sentence: A case of acute inflammatory myopathy associated with the use of pravastatin , a new hydrophilic 3 - hydroxy - 3 methylglutaril coenzyme A reductase inhibitor , is reported .
Diseases:"
1129	The patient , a 69 - year - old man was affected by non - insulin - dependent diabetes mellitus and hypertension .	O O O O O O O O O O O O O B I I I I I I O B O	O O O O O O O O O O O O O O O O O O O O O O O	['non - insulin - dependent diabetes mellitus', 'hypertension']	2	10	"Sentence: The patient , a 69 - year - old man was affected by non - insulin - dependent diabetes mellitus and hypertension .
Diseases: non - insulin - dependent diabetes mellitus, hypertension"	"Sentence: The patient , a 69 - year - old man was affected by non - insulin - dependent diabetes mellitus and hypertension .
Diseases:"
1130	He assumed pravastatin ( 20 mg / day ) because of hypercholesterolemia .	O O O O O O O O O O O B O	O O B O O O O O O O O O O	['hypercholesterolemia']	1	5	"Sentence: He assumed pravastatin ( 20 mg / day ) because of hypercholesterolemia .
Diseases: hypercholesterolemia"	"Sentence: He assumed pravastatin ( 20 mg / day ) because of hypercholesterolemia .
Diseases:"
1131	He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation .	O O O O O B O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O	['myopathy']	1	2	"Sentence: He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation .
Diseases: myopathy"	"Sentence: He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation .
Diseases:"
1132	A previously unknown hypothyroidism , probably due to chronic autoimmune thyroiditis , was evidenced .	O O O B O O O O O B I O O O O	O O O O O O O O O O O O O O O	['hypothyroidism', 'autoimmune thyroiditis']	2	8	"Sentence: A previously unknown hypothyroidism , probably due to chronic autoimmune thyroiditis , was evidenced .
Diseases: hypothyroidism, autoimmune thyroiditis"	"Sentence: A previously unknown hypothyroidism , probably due to chronic autoimmune thyroiditis , was evidenced .
Diseases:"
1133	Muscle biopsy ( left gastrocnemius ) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4 + lymphocytes .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Muscle biopsy ( left gastrocnemius ) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4 + lymphocytes .
Diseases: "	"Sentence: Muscle biopsy ( left gastrocnemius ) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4 + lymphocytes .
Diseases:"
1134	While lovastatin and simvastatin have been associated with toxic myopathy , pravastatin - associated myopathy could represent a distinct , inflammatory entity .	O O O O O O O O O B O O O O B O O O O O O O O	O B O B O O O O O O O B O O O O O O O O O O O	['myopathy']	1	2	"Sentence: While lovastatin and simvastatin have been associated with toxic myopathy , pravastatin - associated myopathy could represent a distinct , inflammatory entity .
Diseases: myopathy"	"Sentence: While lovastatin and simvastatin have been associated with toxic myopathy , pravastatin - associated myopathy could represent a distinct , inflammatory entity .
Diseases:"
1135	Dose - effect and structure - function relationships in doxorubicin cardiomyopathy .	O O O O O O O O O O B O	O O O O O O O O O B O O	['cardiomyopathy']	1	4	"Sentence: Dose - effect and structure - function relationships in doxorubicin cardiomyopathy .
Diseases: cardiomyopathy"	"Sentence: Dose - effect and structure - function relationships in doxorubicin cardiomyopathy .
Diseases:"
1136	The cardiomyopathy ( CM ) produced by the anticancer drug doxorubicin ( DXR ) ( Adriamycin ) provides a unique opportunity to analyze dose - effect and structure - function relationships during development of myocardial disease .	O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O B O B O O B O O O O O O O O O O O O O O O O O O O O O	['cardiomyopathy', 'cm', 'myocardial disease']	3	11	"Sentence: The cardiomyopathy ( CM ) produced by the anticancer drug doxorubicin ( DXR ) ( Adriamycin ) provides a unique opportunity to analyze dose - effect and structure - function relationships during development of myocardial disease .
Diseases: cardiomyopathy, cm, myocardial disease"	"Sentence: The cardiomyopathy ( CM ) produced by the anticancer drug doxorubicin ( DXR ) ( Adriamycin ) provides a unique opportunity to analyze dose - effect and structure - function relationships during development of myocardial disease .
Diseases:"
1137	We measured the degree of morphologic damage by ultrastructural examination of endomyocardial biopsy and the degree of performance abnormally by right heart catheterization in patients receiving DXR .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: We measured the degree of morphologic damage by ultrastructural examination of endomyocardial biopsy and the degree of performance abnormally by right heart catheterization in patients receiving DXR .
Diseases: "	"Sentence: We measured the degree of morphologic damage by ultrastructural examination of endomyocardial biopsy and the degree of performance abnormally by right heart catheterization in patients receiving DXR .
Diseases:"
1138	Morphologic damage was variable but was proportional to the total cumulative DXR dose between 100 and 600 mg / m2 .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: Morphologic damage was variable but was proportional to the total cumulative DXR dose between 100 and 600 mg / m2 .
Diseases: "	"Sentence: Morphologic damage was variable but was proportional to the total cumulative DXR dose between 100 and 600 mg / m2 .
Diseases:"
1139	"Performance abnormalities correlated weakly with dose , exhibited a curvilinear relationship , and had a "" threshold "" for expression ."	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Performance abnormalities correlated weakly with dose , exhibited a curvilinear relationship , and had a "" threshold "" for expression .
Diseases: "	"Sentence: Performance abnormalities correlated weakly with dose , exhibited a curvilinear relationship , and had a "" threshold "" for expression .
Diseases:"
1140	Catheterization abnormalities correlated well with morphologic damage ( r = 0 . 57 to 0 . 78 ) in a subgroup of patients in whom exercise hemodynamics were measured , and this relationship also exhibited a curvilinear , threshold configuration .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Catheterization abnormalities correlated well with morphologic damage ( r = 0 . 57 to 0 . 78 ) in a subgroup of patients in whom exercise hemodynamics were measured , and this relationship also exhibited a curvilinear , threshold configuration .
Diseases: "	"Sentence: Catheterization abnormalities correlated well with morphologic damage ( r = 0 . 57 to 0 . 78 ) in a subgroup of patients in whom exercise hemodynamics were measured , and this relationship also exhibited a curvilinear , threshold configuration .
Diseases:"
1141	In DXR - CM myocardial damage is proportional to the degree of cytotoxic insult ( DXR dose ) while myocardial function is preserved until a critical dose or degree of damage is reached , after which myocardial performance deteriorates rapidly .	O O O B B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['myocardial damage', 'cm']	2	6	"Sentence: In DXR - CM myocardial damage is proportional to the degree of cytotoxic insult ( DXR dose ) while myocardial function is preserved until a critical dose or degree of damage is reached , after which myocardial performance deteriorates rapidly .
Diseases: myocardial damage, cm"	"Sentence: In DXR - CM myocardial damage is proportional to the degree of cytotoxic insult ( DXR dose ) while myocardial function is preserved until a critical dose or degree of damage is reached , after which myocardial performance deteriorates rapidly .
Diseases:"
1142	Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol .	O B I O O O O O O O	O O O O O O O O B O	['aplastic anemia']	1	5	"Sentence: Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol .
Diseases: aplastic anemia"	"Sentence: Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol .
Diseases:"
1143	A 73 - year - old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol .	O O O O O O O O O B I O O O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B O	['cataract', 'aplastic anemia']	2	9	"Sentence: A 73 - year - old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol .
Diseases: cataract, aplastic anemia"	"Sentence: A 73 - year - old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol .
Diseases:"
1144	The first signs of pancytopenia began within one month of the surgery .	O O O O B O O O O O O O O	O O O O O O O O O O O O O	['pancytopenia']	1	5	"Sentence: The first signs of pancytopenia began within one month of the surgery .
Diseases: pancytopenia"	"Sentence: The first signs of pancytopenia began within one month of the surgery .
Diseases:"
1145	The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol .	O O O O B I O O O O O O O O O	O O O O O O O O O O O O O B O	['aplastic anemia']	1	5	"Sentence: The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol .
Diseases: aplastic anemia"	"Sentence: The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol .
Diseases:"
1146	This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions , although two cases of reversible bone marrow hypoplasia have also been reported .	O O O O O O O B I O O O O O O O O O O O O O O B I I O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['aplastic anemia', 'bone marrow hypoplasia']	2	11	"Sentence: This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions , although two cases of reversible bone marrow hypoplasia have also been reported .
Diseases: aplastic anemia, bone marrow hypoplasia"	"Sentence: This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions , although two cases of reversible bone marrow hypoplasia have also been reported .
Diseases:"
1147	Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug - Induced Ocular Side Effects , Oregon Health Sciences University , Portland , OR 97201 .	O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['ocular toxicity']	1	2	"Sentence: Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug - Induced Ocular Side Effects , Oregon Health Sciences University , Portland , OR 97201 .
Diseases: ocular toxicity"	"Sentence: Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug - Induced Ocular Side Effects , Oregon Health Sciences University , Portland , OR 97201 .
Diseases:"
1148	Bradycardia due to trihexyphenidyl hydrochloride .	B O O O O O	O O O B I O	['bradycardia']	1	4	"Sentence: Bradycardia due to trihexyphenidyl hydrochloride .
Diseases: bradycardia"	"Sentence: Bradycardia due to trihexyphenidyl hydrochloride .
Diseases:"
1149	A chronic schizophrenic patient was treated with an anticholinergic drug , trihexyphenidyl hydrochloride .	O O B O O O O O O O O O O O	O O O O O O O O O O O B I O	['schizophrenic']	1	3	"Sentence: A chronic schizophrenic patient was treated with an anticholinergic drug , trihexyphenidyl hydrochloride .
Diseases: schizophrenic"	"Sentence: A chronic schizophrenic patient was treated with an anticholinergic drug , trihexyphenidyl hydrochloride .
Diseases:"
1150	The patient developed , paradoxically , sinus bradycardia .	O O O O O O O B O	O O O O O O O O O	['bradycardia']	1	4	"Sentence: The patient developed , paradoxically , sinus bradycardia .
Diseases: bradycardia"	"Sentence: The patient developed , paradoxically , sinus bradycardia .
Diseases:"
1151	The reaction was specific to trihexyphenidyl and not to other anticholinergic drugs .	O O O O O O O O O O O O O	O O O O O B O O O O O O O	[]	0	0	"Sentence: The reaction was specific to trihexyphenidyl and not to other anticholinergic drugs .
Diseases: "	"Sentence: The reaction was specific to trihexyphenidyl and not to other anticholinergic drugs .
Diseases:"
1152	This antidyskinetic drug is widely used in clinical psychiatric practice and physicians should be aware of this side effect .	O O O O O O O O B O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	['psychiatric']	1	2	"Sentence: This antidyskinetic drug is widely used in clinical psychiatric practice and physicians should be aware of this side effect .
Diseases: psychiatric"	"Sentence: This antidyskinetic drug is widely used in clinical psychiatric practice and physicians should be aware of this side effect .
Diseases:"
1153	Experimental cyclosporine nephrotoxicity : risk of concomitant chemotherapy .	O O B O O O O O O	O B O O O O O O O	['nephrotoxicity']	1	4	"Sentence: Experimental cyclosporine nephrotoxicity : risk of concomitant chemotherapy .
Diseases: nephrotoxicity"	"Sentence: Experimental cyclosporine nephrotoxicity : risk of concomitant chemotherapy .
Diseases:"
1154	The role of cyclosporine ( CSA ) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats .	O O O O O O O O O O O O O O O O O O B I O O O O O	O O O B O B O O O O O O O O O O O O O O O O O O O	['renal toxicity']	1	3	"Sentence: The role of cyclosporine ( CSA ) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats .
Diseases: renal toxicity"	"Sentence: The role of cyclosporine ( CSA ) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats .
Diseases:"
1155	Administration of 20 mg / kg / day CSA for 4 weeks caused renal functional and structural changes similar to those reported in man .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Administration of 20 mg / kg / day CSA for 4 weeks caused renal functional and structural changes similar to those reported in man .
Diseases: "	"Sentence: Administration of 20 mg / kg / day CSA for 4 weeks caused renal functional and structural changes similar to those reported in man .
Diseases:"
1156	The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential , such as gentamicin ( at therapeutic doses ) , amphothericin B and ketoconazole , which are frequently used in immunosuppressed patients , did not aggravate the CSA induced toxicity in the rat model .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	O O O O B O O O O O O O O O O O B O O O O O O B I O B O O O O O O O O O O O O O B O O O O O O O	['nephrotoxic', 'toxicity']	2	6	"Sentence: The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential , such as gentamicin ( at therapeutic doses ) , amphothericin B and ketoconazole , which are frequently used in immunosuppressed patients , did not aggravate the CSA induced toxicity in the rat model .
Diseases: nephrotoxic, toxicity"	"Sentence: The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential , such as gentamicin ( at therapeutic doses ) , amphothericin B and ketoconazole , which are frequently used in immunosuppressed patients , did not aggravate the CSA induced toxicity in the rat model .
Diseases:"
1157	Gentamicin at toxic doses , however , increased CSA nephrotoxicity .	O O O O O O O O O B O	B O O O O O O O B O O	['nephrotoxicity']	1	4	"Sentence: Gentamicin at toxic doses , however , increased CSA nephrotoxicity .
Diseases: nephrotoxicity"	"Sentence: Gentamicin at toxic doses , however , increased CSA nephrotoxicity .
Diseases:"
1158	Thus , the nephrotoxicity induced by CSA has a different pathogenetic mechanism .	O O O B O O O O O O O O O	O O O O O O B O O O O O O	['nephrotoxicity']	1	4	"Sentence: Thus , the nephrotoxicity induced by CSA has a different pathogenetic mechanism .
Diseases: nephrotoxicity"	"Sentence: Thus , the nephrotoxicity induced by CSA has a different pathogenetic mechanism .
Diseases:"
1159	Receptor mechanisms of nicotine - induced locomotor hyperactivity in chronic nicotine - treated rats .	O O O O O O B I O O O O O O O	O O O B O O O O O O B O O O O	['locomotor hyperactivity']	1	5	"Sentence: Receptor mechanisms of nicotine - induced locomotor hyperactivity in chronic nicotine - treated rats .
Diseases: locomotor hyperactivity"	"Sentence: Receptor mechanisms of nicotine - induced locomotor hyperactivity in chronic nicotine - treated rats .
Diseases:"
1160	Rats were pretreated with saline or nicotine ( 1 . 5 mg / kg per day ) by subcutaneously implanting each animal with an Alzet osmotic mini - pump which continuously released saline or nicotine for 1 , 5 and 14 days .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: Rats were pretreated with saline or nicotine ( 1 . 5 mg / kg per day ) by subcutaneously implanting each animal with an Alzet osmotic mini - pump which continuously released saline or nicotine for 1 , 5 and 14 days .
Diseases: "	"Sentence: Rats were pretreated with saline or nicotine ( 1 . 5 mg / kg per day ) by subcutaneously implanting each animal with an Alzet osmotic mini - pump which continuously released saline or nicotine for 1 , 5 and 14 days .
Diseases:"
1161	At the end of each pretreatment period , animals were used for ( i ) determining their locomotor response to acutely injected nicotine ( 0 . 2 mg / kg , s . c . ) and ( ii ) measuring the density of L - [ 3H ] nicotine and [ 3H ] spiperone binding sites in the striatum .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O B I I I I I O B I I I O O O O O O	[]	0	0	"Sentence: At the end of each pretreatment period , animals were used for ( i ) determining their locomotor response to acutely injected nicotine ( 0 . 2 mg / kg , s . c . ) and ( ii ) measuring the density of L - [ 3H ] nicotine and [ 3H ] spiperone binding sites in the striatum .
Diseases: "	"Sentence: At the end of each pretreatment period , animals were used for ( i ) determining their locomotor response to acutely injected nicotine ( 0 . 2 mg / kg , s . c . ) and ( ii ) measuring the density of L - [ 3H ] nicotine and [ 3H ] spiperone binding sites in the striatum .
Diseases:"
1162	We observed no changes in nicotine - induced locomotor response , striatal L - [ 3H ] nicotine and [ 3H ] spiperone binding in the animals pretreated with nicotine for 1 day .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O B I I I I I O B I I I O O O O O O B O O O O	[]	0	0	"Sentence: We observed no changes in nicotine - induced locomotor response , striatal L - [ 3H ] nicotine and [ 3H ] spiperone binding in the animals pretreated with nicotine for 1 day .
Diseases: "	"Sentence: We observed no changes in nicotine - induced locomotor response , striatal L - [ 3H ] nicotine and [ 3H ] spiperone binding in the animals pretreated with nicotine for 1 day .
Diseases:"
1163	In rats which were pretreated with nicotine for 5 days , there was a significant increase in the nicotine - stimulated locomotor response which was associated with an increase in the number of L - [ 3H ] nicotine binding sites and also with an elevated dopamine ( DA ) level in the striatum .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O B O O O O O O O O O O O O O O B I I I I I O O O O O O O B O B O O O O O O	[]	0	0	"Sentence: In rats which were pretreated with nicotine for 5 days , there was a significant increase in the nicotine - stimulated locomotor response which was associated with an increase in the number of L - [ 3H ] nicotine binding sites and also with an elevated dopamine ( DA ) level in the striatum .
Diseases: "	"Sentence: In rats which were pretreated with nicotine for 5 days , there was a significant increase in the nicotine - stimulated locomotor response which was associated with an increase in the number of L - [ 3H ] nicotine binding sites and also with an elevated dopamine ( DA ) level in the striatum .
Diseases:"
1164	The number of striatal [ 3H ] spiperone binding sites was not affected .	O O O O O O O O O O O O O O	O O O O B I I I O O O O O O	[]	0	0	"Sentence: The number of striatal [ 3H ] spiperone binding sites was not affected .
Diseases: "	"Sentence: The number of striatal [ 3H ] spiperone binding sites was not affected .
Diseases:"
1165	In animals pretreated with nicotine for 14 days , the nicotine - induced locomotor response remained to be potentiated .	O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O B O O O O O O O O O	[]	0	0	"Sentence: In animals pretreated with nicotine for 14 days , the nicotine - induced locomotor response remained to be potentiated .
Diseases: "	"Sentence: In animals pretreated with nicotine for 14 days , the nicotine - induced locomotor response remained to be potentiated .
Diseases:"
1166	However , this response was correlated with an elevated number of striatal [ 3H ] spiperone binding sites , whereas the number of striatal L - [ 3H ] nicotine binding sites and the striatal DA level were normal .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B I I I O O O O O O O O B I I I I I O O O O O B O O O O	[]	0	0	"Sentence: However , this response was correlated with an elevated number of striatal [ 3H ] spiperone binding sites , whereas the number of striatal L - [ 3H ] nicotine binding sites and the striatal DA level were normal .
Diseases: "	"Sentence: However , this response was correlated with an elevated number of striatal [ 3H ] spiperone binding sites , whereas the number of striatal L - [ 3H ] nicotine binding sites and the striatal DA level were normal .
Diseases:"
1167	These results suggest that chronic nicotine - treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration , followed by inducing DA receptor supersensitivity in the striatum .	O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O B O O O O O O O O O O O O B O O O O O B O O O O O O	['locomotor hyperactivity']	1	5	"Sentence: These results suggest that chronic nicotine - treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration , followed by inducing DA receptor supersensitivity in the striatum .
Diseases: locomotor hyperactivity"	"Sentence: These results suggest that chronic nicotine - treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration , followed by inducing DA receptor supersensitivity in the striatum .
Diseases:"
1168	Hydrocortisone - induced hypertension in humans : pressor responsiveness and sympathetic function .	O O O B O O O O O O O O O	B O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: Hydrocortisone - induced hypertension in humans : pressor responsiveness and sympathetic function .
Diseases: hypertension"	"Sentence: Hydrocortisone - induced hypertension in humans : pressor responsiveness and sympathetic function .
Diseases:"
1169	Oral hydrocortisone increases blood pressure and enhances pressor responsiveness in normal human subjects .	O O O O O O O O O O O O O O	O B O O O O O O O O O O O O	[]	0	0	"Sentence: Oral hydrocortisone increases blood pressure and enhances pressor responsiveness in normal human subjects .
Diseases: "	"Sentence: Oral hydrocortisone increases blood pressure and enhances pressor responsiveness in normal human subjects .
Diseases:"
1170	We studied the effects of 1 week of oral hydrocortisone ( 200 mg / day ) on blood pressure , cardiac output , total peripheral resistance , forearm vascular resistance , and norepinephrine spillover to plasma in eight healthy male volunteers .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: We studied the effects of 1 week of oral hydrocortisone ( 200 mg / day ) on blood pressure , cardiac output , total peripheral resistance , forearm vascular resistance , and norepinephrine spillover to plasma in eight healthy male volunteers .
Diseases: "	"Sentence: We studied the effects of 1 week of oral hydrocortisone ( 200 mg / day ) on blood pressure , cardiac output , total peripheral resistance , forearm vascular resistance , and norepinephrine spillover to plasma in eight healthy male volunteers .
Diseases:"
1171	Although diastolic blood pressure remained unchanged , systolic blood pressure increased from 119 to 135 mm Hg ( SED + / - 3 . 4 , p less than 0 . 01 ) , associated with an increased cardiac output ( 5 . 85 - 7 . 73 l / min , SED + / - 0 . 46 , p less than 0 . 01 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['increased cardiac output']	1	4	"Sentence: Although diastolic blood pressure remained unchanged , systolic blood pressure increased from 119 to 135 mm Hg ( SED + / - 3 . 4 , p less than 0 . 01 ) , associated with an increased cardiac output ( 5 . 85 - 7 . 73 l / min , SED + / - 0 . 46 , p less than 0 . 01 ) .
Diseases: increased cardiac output"	"Sentence: Although diastolic blood pressure remained unchanged , systolic blood pressure increased from 119 to 135 mm Hg ( SED + / - 3 . 4 , p less than 0 . 01 ) , associated with an increased cardiac output ( 5 . 85 - 7 . 73 l / min , SED + / - 0 . 46 , p less than 0 . 01 ) .
Diseases:"
1172	Total peripheral vascular resistance fell from 15 . 1 to 12 . 2 mm Hg / l / min ( SED + / - 1 . 03 , p less than 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Total peripheral vascular resistance fell from 15 . 1 to 12 . 2 mm Hg / l / min ( SED + / - 1 . 03 , p less than 0 . 05 ) .
Diseases: "	"Sentence: Total peripheral vascular resistance fell from 15 . 1 to 12 . 2 mm Hg / l / min ( SED + / - 1 . 03 , p less than 0 . 05 ) .
Diseases:"
1173	Resting forearm vascular resistance remained unchanged , but the reflex response to the cold pressor test was accentuated ,	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Resting forearm vascular resistance remained unchanged , but the reflex response to the cold pressor test was accentuated ,
Diseases: "	"Sentence: Resting forearm vascular resistance remained unchanged , but the reflex response to the cold pressor test was accentuated ,
Diseases:"
1174	the rise in resistance increasing from 10 . 5 mm Hg / ml / 100 ml / min ( R units ) before treatment to 32 . 6 R units after treatment ( SED + / - 6 . 4 , p less than 0 . 025 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: the rise in resistance increasing from 10 . 5 mm Hg / ml / 100 ml / min ( R units ) before treatment to 32 . 6 R units after treatment ( SED + / - 6 . 4 , p less than 0 . 025 ) .
Diseases: "	"Sentence: the rise in resistance increasing from 10 . 5 mm Hg / ml / 100 ml / min ( R units ) before treatment to 32 . 6 R units after treatment ( SED + / - 6 . 4 , p less than 0 . 025 ) .
Diseases:"
1175	The rise in forearm vascular resistance accompanying intra - arterial norepinephrine ( 25 , 50 , and 100 ng / min ) was also significantly greater after hydrocortisone , increasing from an average of 14 . 9 + / - 2 . 4 R units before treatment to 35 . 1 + / - 5 . 5 R units after hydrocortisone ( SED + / - 6 . 0 , p less than 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The rise in forearm vascular resistance accompanying intra - arterial norepinephrine ( 25 , 50 , and 100 ng / min ) was also significantly greater after hydrocortisone , increasing from an average of 14 . 9 + / - 2 . 4 R units before treatment to 35 . 1 + / - 5 . 5 R units after hydrocortisone ( SED + / - 6 . 0 , p less than 0 . 05 ) .
Diseases: "	"Sentence: The rise in forearm vascular resistance accompanying intra - arterial norepinephrine ( 25 , 50 , and 100 ng / min ) was also significantly greater after hydrocortisone , increasing from an average of 14 . 9 + / - 2 . 4 R units before treatment to 35 . 1 + / - 5 . 5 R units after hydrocortisone ( SED + / - 6 . 0 , p less than 0 . 05 ) .
Diseases:"
1176	A shift to the left in the dose - response relation and fall in threshold suggested increased sensitivity to norepinephrine after treatment .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O	[]	0	0	"Sentence: A shift to the left in the dose - response relation and fall in threshold suggested increased sensitivity to norepinephrine after treatment .
Diseases: "	"Sentence: A shift to the left in the dose - response relation and fall in threshold suggested increased sensitivity to norepinephrine after treatment .
Diseases:"
1177	Measurement of resting norepinephrine spillover rate to plasma and norepinephrine uptake indicated that overall resting sympathetic nervous system activity was not increased .	O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: Measurement of resting norepinephrine spillover rate to plasma and norepinephrine uptake indicated that overall resting sympathetic nervous system activity was not increased .
Diseases: "	"Sentence: Measurement of resting norepinephrine spillover rate to plasma and norepinephrine uptake indicated that overall resting sympathetic nervous system activity was not increased .
Diseases:"
1178	The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output ( presumably due to increased blood volume ) . ( ABSTRACT TRUNCATED AT 250 WORDS )	O B I I I I O O O O O O B I I O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['increased cardiac output', 'rise in resting blood pressure']	2	10	"Sentence: The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output ( presumably due to increased blood volume ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases: increased cardiac output, rise in resting blood pressure"	"Sentence: The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output ( presumably due to increased blood volume ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases:"
1179	Effects of suprofen on the isolated perfused rat kidney .	O O O O O O O O O O	O O B O O O O O O O	[]	0	0	"Sentence: Effects of suprofen on the isolated perfused rat kidney .
Diseases: "	"Sentence: Effects of suprofen on the isolated perfused rat kidney .
Diseases:"
1180	Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects , the mechanism of damage remains unclear .	O O O O O O O O O B I I O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O O O O O O O	['acute renal failure']	1	4	"Sentence: Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects , the mechanism of damage remains unclear .
Diseases: acute renal failure"	"Sentence: Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects , the mechanism of damage remains unclear .
Diseases:"
1181	The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell - free buffer with or without the addition of 5 mg / dL of uric acid .	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['nephrotoxic']	1	4	"Sentence: The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell - free buffer with or without the addition of 5 mg / dL of uric acid .
Diseases: nephrotoxic"	"Sentence: The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell - free buffer with or without the addition of 5 mg / dL of uric acid .
Diseases:"
1182	There were no significant differences in renal sodium excretion , oxygen consumption , or urinary flow rates in kidneys perfused with suprofen compared with the drug - free control groups .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O B O O O O O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: There were no significant differences in renal sodium excretion , oxygen consumption , or urinary flow rates in kidneys perfused with suprofen compared with the drug - free control groups .
Diseases: "	"Sentence: There were no significant differences in renal sodium excretion , oxygen consumption , or urinary flow rates in kidneys perfused with suprofen compared with the drug - free control groups .
Diseases:"
1183	In contrast , a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid ; no changes were found with suprofen in the absence of uric acid .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O B I O O O O O O B O O O O B I O	[]	0	0	"Sentence: In contrast , a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid ; no changes were found with suprofen in the absence of uric acid .
Diseases: "	"Sentence: In contrast , a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid ; no changes were found with suprofen in the absence of uric acid .
Diseases:"
1184	A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen , compared with drug - free controls .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B I O O O O O B O O O O O O O O	[]	0	0	"Sentence: A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen , compared with drug - free controls .
Diseases: "	"Sentence: A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen , compared with drug - free controls .
Diseases:"
1185	However , the fractional excretion of uric acid was unchanged between the groups over the experimental period .	O O O O O O O O O O O O O O O O O O	O O O O O O B I O O O O O O O O O O	[]	0	0	"Sentence: However , the fractional excretion of uric acid was unchanged between the groups over the experimental period .
Diseases: "	"Sentence: However , the fractional excretion of uric acid was unchanged between the groups over the experimental period .
Diseases:"
1186	In summary , suprofen causes acute declines in renal function , most likely by directly altering the intrarenal distribution of uric acid .	O O O O O B I I I I O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O B I O	['acute declines in renal function']	1	6	"Sentence: In summary , suprofen causes acute declines in renal function , most likely by directly altering the intrarenal distribution of uric acid .
Diseases: acute declines in renal function"	"Sentence: In summary , suprofen causes acute declines in renal function , most likely by directly altering the intrarenal distribution of uric acid .
Diseases:"
1187	Cocaine - induced brainstem seizures and behavior .	O O O O B O O O	B O O O O O O O	['seizures']	1	3	"Sentence: Cocaine - induced brainstem seizures and behavior .
Diseases: seizures"	"Sentence: Cocaine - induced brainstem seizures and behavior .
Diseases:"
1188	A variety of abnormal sensory / motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical ( electrode implants ) and DC electrical current stimulations and by acute and chronic administration of cocaine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: A variety of abnormal sensory / motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical ( electrode implants ) and DC electrical current stimulations and by acute and chronic administration of cocaine .
Diseases: "	"Sentence: A variety of abnormal sensory / motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical ( electrode implants ) and DC electrical current stimulations and by acute and chronic administration of cocaine .
Diseases:"
1189	The electrode implant implicated one side or the other of the reticular system of the brainstem but subjects were not incapacitated by the stimulations .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The electrode implant implicated one side or the other of the reticular system of the brainstem but subjects were not incapacitated by the stimulations .
Diseases: "	"Sentence: The electrode implant implicated one side or the other of the reticular system of the brainstem but subjects were not incapacitated by the stimulations .
Diseases:"
1190	Cocaine ( 40 mg / kg ) was injected subcutaneously for an acute experiment and subsequent 20 mg / kg doses twice daily for 3 days in a chronic study .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cocaine ( 40 mg / kg ) was injected subcutaneously for an acute experiment and subsequent 20 mg / kg doses twice daily for 3 days in a chronic study .
Diseases: "	"Sentence: Cocaine ( 40 mg / kg ) was injected subcutaneously for an acute experiment and subsequent 20 mg / kg doses twice daily for 3 days in a chronic study .
Diseases:"
1191	Cocaine generated more abnormal behaviors in the brainstem perturbation group , especially the electrically perturbated subjects .	O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cocaine generated more abnormal behaviors in the brainstem perturbation group , especially the electrically perturbated subjects .
Diseases: "	"Sentence: Cocaine generated more abnormal behaviors in the brainstem perturbation group , especially the electrically perturbated subjects .
Diseases:"
1192	"The abnormal behaviors were yawning , retrocollis , hyperactivity , hypersensitivity , "" beating drum "" behavior , squealing , head bobbing , circling , sniffing , abnormal posturing , and facial twitching ."	O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypersensitivity', 'hyperactivity']	2	6	"Sentence: The abnormal behaviors were yawning , retrocollis , hyperactivity , hypersensitivity , "" beating drum "" behavior , squealing , head bobbing , circling , sniffing , abnormal posturing , and facial twitching .
Diseases: hypersensitivity, hyperactivity"	"Sentence: The abnormal behaviors were yawning , retrocollis , hyperactivity , hypersensitivity , "" beating drum "" behavior , squealing , head bobbing , circling , sniffing , abnormal posturing , and facial twitching .
Diseases:"
1193	Shifts in the power frequency spectra of the discharge patterns were noted between quiet and pacing behavioral states .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Shifts in the power frequency spectra of the discharge patterns were noted between quiet and pacing behavioral states .
Diseases: "	"Sentence: Shifts in the power frequency spectra of the discharge patterns were noted between quiet and pacing behavioral states .
Diseases:"
1194	Hypersensitivity to various auditory , tactile , and visual stimulation was present and shifts in the brainstem ambient power spectral frequency occurred in response to tactile stimulation .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypersensitivity']	1	3	"Sentence: Hypersensitivity to various auditory , tactile , and visual stimulation was present and shifts in the brainstem ambient power spectral frequency occurred in response to tactile stimulation .
Diseases: hypersensitivity"	"Sentence: Hypersensitivity to various auditory , tactile , and visual stimulation was present and shifts in the brainstem ambient power spectral frequency occurred in response to tactile stimulation .
Diseases:"
1195	These findings suggest that the brainstem generates and propagates pathological discharges that can be elicited by mechanical and DC electrical perturbation .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These findings suggest that the brainstem generates and propagates pathological discharges that can be elicited by mechanical and DC electrical perturbation .
Diseases: "	"Sentence: These findings suggest that the brainstem generates and propagates pathological discharges that can be elicited by mechanical and DC electrical perturbation .
Diseases:"
1196	Cocaine was found to activate the discharge system and thus induce abnormal behaviors that are generated at the discharge site and at distant sites to which the discharge propagates .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cocaine was found to activate the discharge system and thus induce abnormal behaviors that are generated at the discharge site and at distant sites to which the discharge propagates .
Diseases: "	"Sentence: Cocaine was found to activate the discharge system and thus induce abnormal behaviors that are generated at the discharge site and at distant sites to which the discharge propagates .
Diseases:"
1197	Cognitive functions may also be involved since dopaminergic and serotonergic cellular elements at the brainstem level are also implicated .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cognitive functions may also be involved since dopaminergic and serotonergic cellular elements at the brainstem level are also implicated .
Diseases: "	"Sentence: Cognitive functions may also be involved since dopaminergic and serotonergic cellular elements at the brainstem level are also implicated .
Diseases:"
1198	Increased sulfation and decreased 7alpha - hydroxylation of deoxycholic acid in ethinyl estradiol - induced cholestasis in rats .	O O O O O O O O O O O O O O O B O O O	O O O O O O O O B I O B I O O O O O O	['cholestasis']	1	4	"Sentence: Increased sulfation and decreased 7alpha - hydroxylation of deoxycholic acid in ethinyl estradiol - induced cholestasis in rats .
Diseases: cholestasis"	"Sentence: Increased sulfation and decreased 7alpha - hydroxylation of deoxycholic acid in ethinyl estradiol - induced cholestasis in rats .
Diseases:"
1199	Deoxycholic acid conjugation , transport capacity , and metabolism were compared in control and ethinyl estradiol - treated rats .	O O O O O O O O O O O O O O O O O O O O	B I O O O O O O O O O O O O B I O O O O	[]	0	0	"Sentence: Deoxycholic acid conjugation , transport capacity , and metabolism were compared in control and ethinyl estradiol - treated rats .
Diseases: "	"Sentence: Deoxycholic acid conjugation , transport capacity , and metabolism were compared in control and ethinyl estradiol - treated rats .
Diseases:"
1200	Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid , and both were decreased by ethinyl estradiol treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B I O B I O O O O O O B I O O	[]	0	0	"Sentence: Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid , and both were decreased by ethinyl estradiol treatment .
Diseases: "	"Sentence: Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid , and both were decreased by ethinyl estradiol treatment .
Diseases:"
1201	During [ 24 - 14C ] sodium deoxycholate infusion , [ 14C ] biliary bile acid secretion increased , but bile flow did not change significantly in either control or ethinyl estradiol - treated rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O B I I I I I I O O B I O O B I O O O O O O O O O O O O O O B I O O O O	[]	0	0	"Sentence: During [ 24 - 14C ] sodium deoxycholate infusion , [ 14C ] biliary bile acid secretion increased , but bile flow did not change significantly in either control or ethinyl estradiol - treated rats .
Diseases: "	"Sentence: During [ 24 - 14C ] sodium deoxycholate infusion , [ 14C ] biliary bile acid secretion increased , but bile flow did not change significantly in either control or ethinyl estradiol - treated rats .
Diseases:"
1202	Ethinyl estradiol - treated animals excreted significantly less 14C as taurocholic acid than did control animals , consistent with an impairment of 7alpha - hydroxylation of taurodeoxycholic acid .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B I O O O O O O B O B I O O O O O O O O O O O O O O B I O	[]	0	0	"Sentence: Ethinyl estradiol - treated animals excreted significantly less 14C as taurocholic acid than did control animals , consistent with an impairment of 7alpha - hydroxylation of taurodeoxycholic acid .
Diseases: "	"Sentence: Ethinyl estradiol - treated animals excreted significantly less 14C as taurocholic acid than did control animals , consistent with an impairment of 7alpha - hydroxylation of taurodeoxycholic acid .
Diseases:"
1203	Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid , but did result in an increase in sulfation of taurodeoxycholic acid from 1 . 5 % in controls to nearly 4 . 0 % ( P less than 0 . 01 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B I O O O O O O B I O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid , but did result in an increase in sulfation of taurodeoxycholic acid from 1 . 5 % in controls to nearly 4 . 0 % ( P less than 0 . 01 ) .
Diseases: "	"Sentence: Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid , but did result in an increase in sulfation of taurodeoxycholic acid from 1 . 5 % in controls to nearly 4 . 0 % ( P less than 0 . 01 ) .
Diseases:"
1204	These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B I O O O O O O	[]	0	0	"Sentence: These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species .
Diseases: "	"Sentence: These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species .
Diseases:"
1205	Furthermore , the rat converts deoxycholic acid , a poor choleretic , to taurocholic acid , a good choleretic .	O O O O O O O O O O O O O O O O O O O O	O O O O O B I O O O O O O B I O O O O O	[]	0	0	"Sentence: Furthermore , the rat converts deoxycholic acid , a poor choleretic , to taurocholic acid , a good choleretic .
Diseases: "	"Sentence: Furthermore , the rat converts deoxycholic acid , a poor choleretic , to taurocholic acid , a good choleretic .
Diseases:"
1206	When this conversion is impaired with ethinyl estradiol treatment , sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B I O O O O O O O O O O O O O O O B I O	[]	0	0	"Sentence: When this conversion is impaired with ethinyl estradiol treatment , sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid .
Diseases: "	"Sentence: When this conversion is impaired with ethinyl estradiol treatment , sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid .
Diseases:"
1207	Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease .	O O O O O O O O O O O O O B I I O	O O B O O B O O O O O O O O O O O	['coronary artery disease']	1	5	"Sentence: Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease .
Diseases: coronary artery disease"	"Sentence: Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease .
Diseases:"
1208	A hemodynamic , volumetric , and metabolic study in patients without heart failure .	O O O O O O O O O O O B I O	O O O O O O O O O O O O O O	['heart failure']	1	2	"Sentence: A hemodynamic , volumetric , and metabolic study in patients without heart failure .
Diseases: heart failure"	"Sentence: A hemodynamic , volumetric , and metabolic study in patients without heart failure .
Diseases:"
1209	The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease , but have not been measured previously in man .	O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O	O O O B O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['coronary artery disease']	1	5	"Sentence: The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease , but have not been measured previously in man .
Diseases: coronary artery disease"	"Sentence: The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease , but have not been measured previously in man .
Diseases:"
1210	We assessed the effects of ouabain ( 0 . 015 mg / kg body weight ) on hemodynamic , volumetric , and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O O B I I O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['congestive heart failure', 'coronary artery disease']	2	10	"Sentence: We assessed the effects of ouabain ( 0 . 015 mg / kg body weight ) on hemodynamic , volumetric , and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure .
Diseases: congestive heart failure, coronary artery disease"	"Sentence: We assessed the effects of ouabain ( 0 . 015 mg / kg body weight ) on hemodynamic , volumetric , and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure .
Diseases:"
1211	Because the protocol was long and involved interventions which might affect the determinations , we also studied in nine patients using an identical protocol except that ouabain administration was omitted .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: Because the protocol was long and involved interventions which might affect the determinations , we also studied in nine patients using an identical protocol except that ouabain administration was omitted .
Diseases: "	"Sentence: Because the protocol was long and involved interventions which might affect the determinations , we also studied in nine patients using an identical protocol except that ouabain administration was omitted .
Diseases:"
1212	Left ventricular end - diastolic pressure and left ventricular end - diastolic volume fell in each patient given ouabain , even though they were initially elevated in only two patients .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: Left ventricular end - diastolic pressure and left ventricular end - diastolic volume fell in each patient given ouabain , even though they were initially elevated in only two patients .
Diseases: "	"Sentence: Left ventricular end - diastolic pressure and left ventricular end - diastolic volume fell in each patient given ouabain , even though they were initially elevated in only two patients .
Diseases:"
1213	Left ventricular end - diastolic pressure fell from 11 . 5 + / - 1 . 4 ( mean + / - SE ) to 5 . 6 + / - 0 . 9 mm	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Left ventricular end - diastolic pressure fell from 11 . 5 + / - 1 . 4 ( mean + / - SE ) to 5 . 6 + / - 0 . 9 mm
Diseases: "	"Sentence: Left ventricular end - diastolic pressure fell from 11 . 5 + / - 1 . 4 ( mean + / - SE ) to 5 . 6 + / - 0 . 9 mm
Diseases:"
1214	Hg ( P less than 0 . 001 ) and left ventricular end - diastolic volume fell from 100 + / - 17 to 82 + / - 12 ml / m2 ( P less than 0 . 01 ) 1 h after ouabain infusion was completed .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: Hg ( P less than 0 . 001 ) and left ventricular end - diastolic volume fell from 100 + / - 17 to 82 + / - 12 ml / m2 ( P less than 0 . 01 ) 1 h after ouabain infusion was completed .
Diseases: "	"Sentence: Hg ( P less than 0 . 001 ) and left ventricular end - diastolic volume fell from 100 + / - 17 to 82 + / - 12 ml / m2 ( P less than 0 . 01 ) 1 h after ouabain infusion was completed .
Diseases:"
1215	The maximum velocity of contractile element shortening increased from 1 . 68 + / - 0 . 11 ml / s to 2 . 18 + / - 0 . 21 muscle - lengths / s	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The maximum velocity of contractile element shortening increased from 1 . 68 + / - 0 . 11 ml / s to 2 . 18 + / - 0 . 21 muscle - lengths / s
Diseases: "	"Sentence: The maximum velocity of contractile element shortening increased from 1 . 68 + / - 0 . 11 ml / s to 2 . 18 + / - 0 . 21 muscle - lengths / s
Diseases:"
1216	( P less than 0 . 05 ) and is consistent with an increase in contractility .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: ( P less than 0 . 05 ) and is consistent with an increase in contractility .
Diseases: "	"Sentence: ( P less than 0 . 05 ) and is consistent with an increase in contractility .
Diseases:"
1217	No significant change in these parameters occurred in the control patients .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: No significant change in these parameters occurred in the control patients .
Diseases: "	"Sentence: No significant change in these parameters occurred in the control patients .
Diseases:"
1218	No significant change in myocardial oxygen consumption occurred after ouabain administration	O O O O O O O O O O O	O O O O O B O O O B O	[]	0	0	"Sentence: No significant change in myocardial oxygen consumption occurred after ouabain administration
Diseases: "	"Sentence: No significant change in myocardial oxygen consumption occurred after ouabain administration
Diseases:"
1219	but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients .
Diseases: "	"Sentence: but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients .
Diseases:"
1220	We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end - diastolic volume falls after ouabain administration even when it is initially normal .	O O O O O O O B I I O O O O O B I I B I I I I I I O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['congestive heart failure', 'coronary artery disease', 'left ventricular end - diastolic volume falls']	3	21	"Sentence: We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end - diastolic volume falls after ouabain administration even when it is initially normal .
Diseases: congestive heart failure, coronary artery disease, left ventricular end - diastolic volume falls"	"Sentence: We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end - diastolic volume falls after ouabain administration even when it is initially normal .
Diseases:"
1221	Though this fall would be associated with a decrease in wall tension , and , therefore , of myocardial oxygen consumption , it may not be of sufficient magnitude to prevent a net increase in myocardial oxygen consumption .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Though this fall would be associated with a decrease in wall tension , and , therefore , of myocardial oxygen consumption , it may not be of sufficient magnitude to prevent a net increase in myocardial oxygen consumption .
Diseases: "	"Sentence: Though this fall would be associated with a decrease in wall tension , and , therefore , of myocardial oxygen consumption , it may not be of sufficient magnitude to prevent a net increase in myocardial oxygen consumption .
Diseases:"
1222	Nevertheless , compensatory mechanisms prevent a deterioration of resting myocardial metabolism .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: Nevertheless , compensatory mechanisms prevent a deterioration of resting myocardial metabolism .
Diseases: "	"Sentence: Nevertheless , compensatory mechanisms prevent a deterioration of resting myocardial metabolism .
Diseases:"
1223	Prolongation of the QT interval related to cisapride - diltiazem interaction .	B I I I I O O O O O O O	O O O O O O O B O B O O	['prolongation of the qt interval']	1	8	"Sentence: Prolongation of the QT interval related to cisapride - diltiazem interaction .
Diseases: prolongation of the qt interval"	"Sentence: Prolongation of the QT interval related to cisapride - diltiazem interaction .
Diseases:"
1224	Cisapride , a cytochrome P450 3A4 ( CYP3A4 ) substrate , is widely prescribed for the treatment of gastrointestinal motility disorders .	O O O O O O O O O O O O O O O O O O B I I O	B O O O O O O O O O O O O O O O O O O O O O	['gastrointestinal motility disorders']	1	7	"Sentence: Cisapride , a cytochrome P450 3A4 ( CYP3A4 ) substrate , is widely prescribed for the treatment of gastrointestinal motility disorders .
Diseases: gastrointestinal motility disorders"	"Sentence: Cisapride , a cytochrome P450 3A4 ( CYP3A4 ) substrate , is widely prescribed for the treatment of gastrointestinal motility disorders .
Diseases:"
1225	Prolongation of QT interval , torsades de pointes , and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents , but not with other CYP3A4 inhibitors .	B I I I O B I I O O B I I O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O	['prolongation of qt interval', 'sudden cardiac death', 'torsades de pointes']	3	18	"Sentence: Prolongation of QT interval , torsades de pointes , and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents , but not with other CYP3A4 inhibitors .
Diseases: prolongation of qt interval, sudden cardiac death, torsades de pointes"	"Sentence: Prolongation of QT interval , torsades de pointes , and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents , but not with other CYP3A4 inhibitors .
Diseases:"
1226	A possible drug interaction occurred in a 45 - year - old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem , an agent that has inhibitory effect on CYP3A4 , for hypertension .	O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O B O O O O O B O O O O O O O O O O O O O	['gastroesophageal reflux disorder', 'hypertension']	2	12	"Sentence: A possible drug interaction occurred in a 45 - year - old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem , an agent that has inhibitory effect on CYP3A4 , for hypertension .
Diseases: gastroesophageal reflux disorder, hypertension"	"Sentence: A possible drug interaction occurred in a 45 - year - old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem , an agent that has inhibitory effect on CYP3A4 , for hypertension .
Diseases:"
1227	The patient was in near syncope and had QT - interval prolongation .	O O O O O B O O B I I I O	O O O O O O O O O O O O O	['syncope', 'qt - interval prolongation']	2	9	"Sentence: The patient was in near syncope and had QT - interval prolongation .
Diseases: syncope, qt - interval prolongation"	"Sentence: The patient was in near syncope and had QT - interval prolongation .
Diseases:"
1228	After discontinuing cisapride , the QT interval returned to normal and symptoms did not recur .	O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: After discontinuing cisapride , the QT interval returned to normal and symptoms did not recur .
Diseases: "	"Sentence: After discontinuing cisapride , the QT interval returned to normal and symptoms did not recur .
Diseases:"
1229	We suggest that caution be taken when cisapride is prescribed with any potent inhibitor of CYP3A4 , including diltiazem .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O B O	[]	0	0	"Sentence: We suggest that caution be taken when cisapride is prescribed with any potent inhibitor of CYP3A4 , including diltiazem .
Diseases: "	"Sentence: We suggest that caution be taken when cisapride is prescribed with any potent inhibitor of CYP3A4 , including diltiazem .
Diseases:"
1230	Paclitaxel combined with carboplatin in the first - line treatment of advanced ovarian cancer .	O O O O O O O O O O O O B I O	B O O B O O O O O O O O O O O	['ovarian cancer']	1	3	"Sentence: Paclitaxel combined with carboplatin in the first - line treatment of advanced ovarian cancer .
Diseases: ovarian cancer"	"Sentence: Paclitaxel combined with carboplatin in the first - line treatment of advanced ovarian cancer .
Diseases:"
1231	In a phase I study to determine the maximum tolerated dose of paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) given as a 3 - hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer , paclitaxel doses were escalated as follows : level 1 , 135 mg / m2 ; level 2 , 160 mg / m2 ; level 3 , 185 mg / m2 ; and level 4 , 210 mg / m2 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ovarian cancer']	1	3	"Sentence: In a phase I study to determine the maximum tolerated dose of paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) given as a 3 - hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer , paclitaxel doses were escalated as follows : level 1 , 135 mg / m2 ; level 2 , 160 mg / m2 ; level 3 , 185 mg / m2 ; and level 4 , 210 mg / m2 .
Diseases: ovarian cancer"	"Sentence: In a phase I study to determine the maximum tolerated dose of paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) given as a 3 - hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer , paclitaxel doses were escalated as follows : level 1 , 135 mg / m2 ; level 2 , 160 mg / m2 ; level 3 , 185 mg / m2 ; and level 4 , 210 mg / m2 .
Diseases:"
1232	The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration - time curve ( AUC ) of 5 using the Calvert formula .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration - time curve ( AUC ) of 5 using the Calvert formula .
Diseases: "	"Sentence: The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration - time curve ( AUC ) of 5 using the Calvert formula .
Diseases:"
1233	In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7 . 5 , respectively , combined with a fixed paclitaxel dose of 185 mg / m2 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7 . 5 , respectively , combined with a fixed paclitaxel dose of 185 mg / m2 .
Diseases: "	"Sentence: In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7 . 5 , respectively , combined with a fixed paclitaxel dose of 185 mg / m2 .
Diseases:"
1234	To date , 30 previously untreated patients , all with a good performance status ( Eastern Cooperative Oncology Group 0 to 2 ) have been entered into this ongoing study .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: To date , 30 previously untreated patients , all with a good performance status ( Eastern Cooperative Oncology Group 0 to 2 ) have been entered into this ongoing study .
Diseases: "	"Sentence: To date , 30 previously untreated patients , all with a good performance status ( Eastern Cooperative Oncology Group 0 to 2 ) have been entered into this ongoing study .
Diseases:"
1235	The dose - limiting toxicity of the combination was myelosuppression ( leukopenia , granulocytopenia , and thrombocytopenia ) .	O O O O B O O O O B O B O B O O B O O	O O O O O O O O O O O O O O O O O O O	['myelosuppression', 'granulocytopenia', 'thrombocytopenia', 'leukopenia', 'toxicity']	5	27	"Sentence: The dose - limiting toxicity of the combination was myelosuppression ( leukopenia , granulocytopenia , and thrombocytopenia ) .
Diseases: myelosuppression, granulocytopenia, thrombocytopenia, leukopenia, toxicity"	"Sentence: The dose - limiting toxicity of the combination was myelosuppression ( leukopenia , granulocytopenia , and thrombocytopenia ) .
Diseases:"
1236	Neurotoxicity was largely moderate .	B O O O O	O O O O O	['neurotoxicity']	1	4	"Sentence: Neurotoxicity was largely moderate .
Diseases: neurotoxicity"	"Sentence: Neurotoxicity was largely moderate .
Diseases:"
1237	So far , 14 patients are evaluable for response ; of these , eight ( 57 % ) showed objective ( complete or partial ) response and disease stabilized in six patients .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: So far , 14 patients are evaluable for response ; of these , eight ( 57 % ) showed objective ( complete or partial ) response and disease stabilized in six patients .
Diseases: "	"Sentence: So far , 14 patients are evaluable for response ; of these , eight ( 57 % ) showed objective ( complete or partial ) response and disease stabilized in six patients .
Diseases:"
1238	No patient had disease progression .	O O O O O O	O O O O O O	[]	0	0	"Sentence: No patient had disease progression .
Diseases: "	"Sentence: No patient had disease progression .
Diseases:"
1239	We conclude that the combination of paclitaxel 185 mg / m2 administered as a 3 - hour infusion followed immediately by a 1 - hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21 - day schedule in the outpatient setting .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We conclude that the combination of paclitaxel 185 mg / m2 administered as a 3 - hour infusion followed immediately by a 1 - hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21 - day schedule in the outpatient setting .
Diseases: "	"Sentence: We conclude that the combination of paclitaxel 185 mg / m2 administered as a 3 - hour infusion followed immediately by a 1 - hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21 - day schedule in the outpatient setting .
Diseases:"
1240	The recommended dose for phase III studies is paclitaxel 185 mg / m2 and carboplatin AUC 6 .	O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O B O O O	[]	0	0	"Sentence: The recommended dose for phase III studies is paclitaxel 185 mg / m2 and carboplatin AUC 6 .
Diseases: "	"Sentence: The recommended dose for phase III studies is paclitaxel 185 mg / m2 and carboplatin AUC 6 .
Diseases:"
1241	Treatment of tacrolimus - related adverse effects by conversion to cyclosporine in liver transplant recipients .	O O O O O O O O O O O O O O O O	O O B O O O O O O O B O O O O O	[]	0	0	"Sentence: Treatment of tacrolimus - related adverse effects by conversion to cyclosporine in liver transplant recipients .
Diseases: "	"Sentence: Treatment of tacrolimus - related adverse effects by conversion to cyclosporine in liver transplant recipients .
Diseases:"
1242	When tacrolimus side effects persist despite dose reduction , conversion to cyclosporine - based immunosuppression ( CyA ) is necessary .	O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O B O O O O B O O O O	[]	0	0	"Sentence: When tacrolimus side effects persist despite dose reduction , conversion to cyclosporine - based immunosuppression ( CyA ) is necessary .
Diseases: "	"Sentence: When tacrolimus side effects persist despite dose reduction , conversion to cyclosporine - based immunosuppression ( CyA ) is necessary .
Diseases:"
1243	We characterized tacrolimus side effects that warranted discontinuation of the drug , and outcomes after conversion .	O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: We characterized tacrolimus side effects that warranted discontinuation of the drug , and outcomes after conversion .
Diseases: "	"Sentence: We characterized tacrolimus side effects that warranted discontinuation of the drug , and outcomes after conversion .
Diseases:"
1244	Of 388 liver recipients who received tacrolimus as primary immunosuppression , 70 required conversion to CyA . We recorded indication for conversion , whether conversion was early or late after transplantation , tacrolimus dose and trough blood level at conversion , and incidence of rejection after conversion .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O B O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of 388 liver recipients who received tacrolimus as primary immunosuppression , 70 required conversion to CyA . We recorded indication for conversion , whether conversion was early or late after transplantation , tacrolimus dose and trough blood level at conversion , and incidence of rejection after conversion .
Diseases: "	"Sentence: Of 388 liver recipients who received tacrolimus as primary immunosuppression , 70 required conversion to CyA . We recorded indication for conversion , whether conversion was early or late after transplantation , tacrolimus dose and trough blood level at conversion , and incidence of rejection after conversion .
Diseases:"
1245	Conversion was early in 29 patients ( 41 . 4 % ) and late in 41 ( 58 . 6 % ) .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Conversion was early in 29 patients ( 41 . 4 % ) and late in 41 ( 58 . 6 % ) .
Diseases: "	"Sentence: Conversion was early in 29 patients ( 41 . 4 % ) and late in 41 ( 58 . 6 % ) .
Diseases:"
1246	Indications for early conversion were neurotoxicity ( 20 ) , ( insulin - dependent ) diabetes mellitus ( IDDM ) ( 5 ) , nephrotoxicity ( 3 ) , gastrointestinal ( GI ) toxicity ( 6 ) , and cardiomyopathy ( 1 ) , and for late conversion were neurotoxicity ( 15 ) , IDDM ( 12 ) , nephrotoxicity ( 3 ) , GI toxicity ( 5 ) , hepatotoxicity ( 6 ) , post - transplant lmphoproliferate disease ( PTLD )	O O O O O B O O O O B I I I I I I O B O O O O O B O O O O B I I I I O O O O O B O O O O O O O O O B O O O O B O O O O B O O O O B I O O O O B O O O O B I I I I O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ptld', '( insulin - dependent ) diabetes mellitus', 'neurotoxicity', 'post - transplant lmphoproliferate disease', 'hepatotoxicity', 'iddm', 'nephrotoxicity', 'cardiomyopathy', 'gi toxicity', 'gastrointestinal ( gi ) toxicity']	10	54	"Sentence: Indications for early conversion were neurotoxicity ( 20 ) , ( insulin - dependent ) diabetes mellitus ( IDDM ) ( 5 ) , nephrotoxicity ( 3 ) , gastrointestinal ( GI ) toxicity ( 6 ) , and cardiomyopathy ( 1 ) , and for late conversion were neurotoxicity ( 15 ) , IDDM ( 12 ) , nephrotoxicity ( 3 ) , GI toxicity ( 5 ) , hepatotoxicity ( 6 ) , post - transplant lmphoproliferate disease ( PTLD )
Diseases: ptld, ( insulin - dependent ) diabetes mellitus, neurotoxicity, post - transplant lmphoproliferate disease, hepatotoxicity, iddm, nephrotoxicity, cardiomyopathy, gi toxicity, gastrointestinal ( gi ) toxicity"	"Sentence: Indications for early conversion were neurotoxicity ( 20 ) , ( insulin - dependent ) diabetes mellitus ( IDDM ) ( 5 ) , nephrotoxicity ( 3 ) , gastrointestinal ( GI ) toxicity ( 6 ) , and cardiomyopathy ( 1 ) , and for late conversion were neurotoxicity ( 15 ) , IDDM ( 12 ) , nephrotoxicity ( 3 ) , GI toxicity ( 5 ) , hepatotoxicity ( 6 ) , post - transplant lmphoproliferate disease ( PTLD )
Diseases:"
1247	( 2 ) , cardiomyopathy ( 1 ) , hemolytic anemia ( 1 ) , and pruritus ( 1 ) .	O O O O B O O O O B I O O O O O B O O O O	O O O O O O O O O O O O O O O O O O O O O	['cardiomyopathy', 'pruritus', 'hemolytic anemia']	3	14	"Sentence: ( 2 ) , cardiomyopathy ( 1 ) , hemolytic anemia ( 1 ) , and pruritus ( 1 ) .
Diseases: cardiomyopathy, pruritus, hemolytic anemia"	"Sentence: ( 2 ) , cardiomyopathy ( 1 ) , hemolytic anemia ( 1 ) , and pruritus ( 1 ) .
Diseases:"
1248	All early - conversion patients showed improvement / resolution of symptoms .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: All early - conversion patients showed improvement / resolution of symptoms .
Diseases: "	"Sentence: All early - conversion patients showed improvement / resolution of symptoms .
Diseases:"
1249	Among late - conversion patients , 37 ( 90 . 2 % ) had improvement / resolution ; in 4 ( 9 . 8 % ) , adverse effects persisted .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Among late - conversion patients , 37 ( 90 . 2 % ) had improvement / resolution ; in 4 ( 9 . 8 % ) , adverse effects persisted .
Diseases: "	"Sentence: Among late - conversion patients , 37 ( 90 . 2 % ) had improvement / resolution ; in 4 ( 9 . 8 % ) , adverse effects persisted .
Diseases:"
1250	The overall rejection rate was 30 % .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: The overall rejection rate was 30 % .
Diseases: "	"Sentence: The overall rejection rate was 30 % .
Diseases:"
1251	Sixty - two patients ( 88 . 6 % ) are alive with functioning grafts 686 + / - 362 days ( range , 154 - 1433 days ) after conversion .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Sixty - two patients ( 88 . 6 % ) are alive with functioning grafts 686 + / - 362 days ( range , 154 - 1433 days ) after conversion .
Diseases: "	"Sentence: Sixty - two patients ( 88 . 6 % ) are alive with functioning grafts 686 + / - 362 days ( range , 154 - 1433 days ) after conversion .
Diseases:"
1252	When tacrolimus side effects are unresponsive to dose reduction , conversion to CyA can be accomplished safely , with no increased risk of rejection and excellent long - term outcome .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: When tacrolimus side effects are unresponsive to dose reduction , conversion to CyA can be accomplished safely , with no increased risk of rejection and excellent long - term outcome .
Diseases: "	"Sentence: When tacrolimus side effects are unresponsive to dose reduction , conversion to CyA can be accomplished safely , with no increased risk of rejection and excellent long - term outcome .
Diseases:"
1253	Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients .	O O O B O O O O O O O O	O O O O O B O B O O O O	['toxicity']	1	2	"Sentence: Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients .
Diseases: toxicity"	"Sentence: Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients .
Diseases:"
1254	We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections .	O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O B I O B I O O O B I O O O O O O O O O	['infections']	1	2	"Sentence: We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections .
Diseases: infections"	"Sentence: We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections .
Diseases:"
1255	The two treatment regimens were equally efficacious .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: The two treatment regimens were equally efficacious .
Diseases: "	"Sentence: The two treatment regimens were equally efficacious .
Diseases:"
1256	Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin ( 17 % vs 11 % ) .	B O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O B O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin ( 17 % vs 11 % ) .
Diseases: nephrotoxicity"	"Sentence: Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin ( 17 % vs 11 % ) .
Diseases:"
1257	Ototoxicity occurred in four ( 9 . 5 % ) of 42 netilmicin and piperacillin and in 12 ( 22 % ) of 54 tobramycin and piperacillin - treated patients .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O B O O O O O O O O O B O B O O O O	['ototoxicity']	1	3	"Sentence: Ototoxicity occurred in four ( 9 . 5 % ) of 42 netilmicin and piperacillin and in 12 ( 22 % ) of 54 tobramycin and piperacillin - treated patients .
Diseases: ototoxicity"	"Sentence: Ototoxicity occurred in four ( 9 . 5 % ) of 42 netilmicin and piperacillin and in 12 ( 22 % ) of 54 tobramycin and piperacillin - treated patients .
Diseases:"
1258	Of those evaluated with posttherapy audiograms , three of four netilmicin and piperacillin - treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin - treated patients .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O B O O O O O O O O O O O O O O B O B O O O O	[]	0	0	"Sentence: Of those evaluated with posttherapy audiograms , three of four netilmicin and piperacillin - treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin - treated patients .
Diseases: "	"Sentence: Of those evaluated with posttherapy audiograms , three of four netilmicin and piperacillin - treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin - treated patients .
Diseases:"
1259	The number of greater than or equal to 15 - dB increases in auditory threshold as a proportion of total greater than or equal to 15 - dB changes ( increases and decreases ) was significantly lower in netilmicin and piperacillin - vs tobramycin and piperacillin - treated patients ( 18 of 78 vs 67 of 115 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O B O B O O O O O O O O O O O O O	[]	0	0	"Sentence: The number of greater than or equal to 15 - dB increases in auditory threshold as a proportion of total greater than or equal to 15 - dB changes ( increases and decreases ) was significantly lower in netilmicin and piperacillin - vs tobramycin and piperacillin - treated patients ( 18 of 78 vs 67 of 115 ) .
Diseases: "	"Sentence: The number of greater than or equal to 15 - dB increases in auditory threshold as a proportion of total greater than or equal to 15 - dB changes ( increases and decreases ) was significantly lower in netilmicin and piperacillin - vs tobramycin and piperacillin - treated patients ( 18 of 78 vs 67 of 115 ) .
Diseases:"
1260	We conclude that aminoglycoside - associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin .	O O O O O O B O O O O O O O O O O O O O	O O O B O O O O O O O O O O O B O O B O	['ototoxicity']	1	3	"Sentence: We conclude that aminoglycoside - associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin .
Diseases: ototoxicity"	"Sentence: We conclude that aminoglycoside - associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin .
Diseases:"
1261	Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats .	O O O O O O O O B O O O	O O B O O O O O O O O O	['convulsions']	1	3	"Sentence: Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats .
Diseases: convulsions"	"Sentence: Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats .
Diseases:"
1262	To investigate the relationship of prostaglandins ( PGs ) to seizure induction , the effects of six PG synthetase inhibitors on convulsions induced by flurothyl , picrotoxin , pentetrazol ( PTZ ) , electroshock or bicuculline were evaluated .	O O O O O O O O O O B O O O O O O O O O O B O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O B O B O B O B O O O O B O O O	['seizure', 'convulsions']	2	7	"Sentence: To investigate the relationship of prostaglandins ( PGs ) to seizure induction , the effects of six PG synthetase inhibitors on convulsions induced by flurothyl , picrotoxin , pentetrazol ( PTZ ) , electroshock or bicuculline were evaluated .
Diseases: seizure, convulsions"	"Sentence: To investigate the relationship of prostaglandins ( PGs ) to seizure induction , the effects of six PG synthetase inhibitors on convulsions induced by flurothyl , picrotoxin , pentetrazol ( PTZ ) , electroshock or bicuculline were evaluated .
Diseases:"
1263	Ibuprofen , sulindac , mefenamic acid , and low dose meclofenamic acid increased the latency - to - onset in the flurothyl and / or PTZ models ; the electroshock , picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O B O B I O O O O B I O O O O O O O O O B O O O B O O O O O B O B O O O O O O O O O O O O	[]	0	0	"Sentence: Ibuprofen , sulindac , mefenamic acid , and low dose meclofenamic acid increased the latency - to - onset in the flurothyl and / or PTZ models ; the electroshock , picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents .
Diseases: "	"Sentence: Ibuprofen , sulindac , mefenamic acid , and low dose meclofenamic acid increased the latency - to - onset in the flurothyl and / or PTZ models ; the electroshock , picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents .
Diseases:"
1264	These results suggest that PGs are involved in the mechanism ( s ) underlying fluorthyl - and PTZ - induced convulsions , but not picrotoxin - , electroshock - , or bicuculline - induced convulsions .	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O B O O B O O O O O O B O O O O O O B O O O O	['convulsions']	1	3	"Sentence: These results suggest that PGs are involved in the mechanism ( s ) underlying fluorthyl - and PTZ - induced convulsions , but not picrotoxin - , electroshock - , or bicuculline - induced convulsions .
Diseases: convulsions"	"Sentence: These results suggest that PGs are involved in the mechanism ( s ) underlying fluorthyl - and PTZ - induced convulsions , but not picrotoxin - , electroshock - , or bicuculline - induced convulsions .
Diseases:"
1265	Angiotensin - converting enzyme ( ACE ) inhibitor - associated angioedema of the stomach and small intestine : a case report .	O O O O O O O O O O B O O O O O O O O O O O	B I I I I B I I O O O O O O O O O O O O O O	['angioedema']	1	4	"Sentence: Angiotensin - converting enzyme ( ACE ) inhibitor - associated angioedema of the stomach and small intestine : a case report .
Diseases: angioedema"	"Sentence: Angiotensin - converting enzyme ( ACE ) inhibitor - associated angioedema of the stomach and small intestine : a case report .
Diseases:"
1266	This is a case report on a 45 - year old African - American female with newly diagnosed hypertension , who was started on a combination pill of amlodipine / benazapril 10 / 5 mg .	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O	['hypertension']	1	3	"Sentence: This is a case report on a 45 - year old African - American female with newly diagnosed hypertension , who was started on a combination pill of amlodipine / benazapril 10 / 5 mg .
Diseases: hypertension"	"Sentence: This is a case report on a 45 - year old African - American female with newly diagnosed hypertension , who was started on a combination pill of amlodipine / benazapril 10 / 5 mg .
Diseases:"
1267	The very next day , she presented at the emergency room ( ER ) with abdominal pain , nausea and vomiting .	O O O O O O O O O O O O O O O B I O B O B O	O O O O O O O O O O O O O O O O O O O O O O	['nausea', 'vomiting', 'abdominal pain']	3	8	"Sentence: The very next day , she presented at the emergency room ( ER ) with abdominal pain , nausea and vomiting .
Diseases: nausea, vomiting, abdominal pain"	"Sentence: The very next day , she presented at the emergency room ( ER ) with abdominal pain , nausea and vomiting .
Diseases:"
1268	Physical exam , complete metabolic panel , and hemogram were in the normal range .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Physical exam , complete metabolic panel , and hemogram were in the normal range .
Diseases: "	"Sentence: Physical exam , complete metabolic panel , and hemogram were in the normal range .
Diseases:"
1269	She was discharged from the ER after a few hours of treatment with fluid and analgesics .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: She was discharged from the ER after a few hours of treatment with fluid and analgesics .
Diseases: "	"Sentence: She was discharged from the ER after a few hours of treatment with fluid and analgesics .
Diseases:"
1270	However , she returned to the ER the next day with the same complaints .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , she returned to the ER the next day with the same complaints .
Diseases: "	"Sentence: However , she returned to the ER the next day with the same complaints .
Diseases:"
1271	This time the physical exam was significant for a distended abdomen with dullness to percussion .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This time the physical exam was significant for a distended abdomen with dullness to percussion .
Diseases: "	"Sentence: This time the physical exam was significant for a distended abdomen with dullness to percussion .
Diseases:"
1272	CT scan of the abdomen revealed markedly thickened antrum of the stomach , duodenum and jejunum , along with fluid in the abdominal and pelvic cavity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CT scan of the abdomen revealed markedly thickened antrum of the stomach , duodenum and jejunum , along with fluid in the abdominal and pelvic cavity .
Diseases: "	"Sentence: CT scan of the abdomen revealed markedly thickened antrum of the stomach , duodenum and jejunum , along with fluid in the abdominal and pelvic cavity .
Diseases:"
1273	Angiotensin - converting enzyme inhibitor ( ACEI ) - induced angioedema was suspected , and anti - hypertensive medications were discontinued .	O O O O O O O O O O B O O O O O O B O O O O	B I I I I O B O O O O O O O O O O O O O O O	['angioedema', 'hypertensive']	2	7	"Sentence: Angiotensin - converting enzyme inhibitor ( ACEI ) - induced angioedema was suspected , and anti - hypertensive medications were discontinued .
Diseases: angioedema, hypertensive"	"Sentence: Angiotensin - converting enzyme inhibitor ( ACEI ) - induced angioedema was suspected , and anti - hypertensive medications were discontinued .
Diseases:"
1274	Her symptoms improved within the next 24 hours , and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ascites .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ascites']	1	2	"Sentence: Her symptoms improved within the next 24 hours , and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ascites .
Diseases: ascites"	"Sentence: Her symptoms improved within the next 24 hours , and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ascites .
Diseases:"
1275	The recognition of angiotensin - converting enzyme ( ACE ) and angiotensin receptor blocker ( ARB ) intestinal angioedema constitutes a challenge to primary care physicians , internists , emergency room personal and surgeons .	O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O	O O O B O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O	['intestinal angioedema']	1	5	"Sentence: The recognition of angiotensin - converting enzyme ( ACE ) and angiotensin receptor blocker ( ARB ) intestinal angioedema constitutes a challenge to primary care physicians , internists , emergency room personal and surgeons .
Diseases: intestinal angioedema"	"Sentence: The recognition of angiotensin - converting enzyme ( ACE ) and angiotensin receptor blocker ( ARB ) intestinal angioedema constitutes a challenge to primary care physicians , internists , emergency room personal and surgeons .
Diseases:"
1276	Valproic acid I : time course of lipid peroxidation biomarkers , liver toxicity , and valproic acid metabolite levels in rats .	O O O O O O O O O O O B I O O O O O O O O O	B I O O O O O O O O O O O O O B I O O O O O	['liver toxicity']	1	3	"Sentence: Valproic acid I : time course of lipid peroxidation biomarkers , liver toxicity , and valproic acid metabolite levels in rats .
Diseases: liver toxicity"	"Sentence: Valproic acid I : time course of lipid peroxidation biomarkers , liver toxicity , and valproic acid metabolite levels in rats .
Diseases:"
1277	A single dose of valproic acid ( VPA ) , which is a widely used antiepileptic drug , is associated with oxidative stress in rats , as recently demonstrated by elevated levels of 15 - F ( 2t ) - isoprostane ( 15 - F ( 2t ) - IsoP ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B I O B O O O O O O O O O O O O O O O O O O O O O O O O O B I I I I I I I O B I I I I I I I O O	[]	0	0	"Sentence: A single dose of valproic acid ( VPA ) , which is a widely used antiepileptic drug , is associated with oxidative stress in rats , as recently demonstrated by elevated levels of 15 - F ( 2t ) - isoprostane ( 15 - F ( 2t ) - IsoP ) .
Diseases: "	"Sentence: A single dose of valproic acid ( VPA ) , which is a widely used antiepileptic drug , is associated with oxidative stress in rats , as recently demonstrated by elevated levels of 15 - F ( 2t ) - isoprostane ( 15 - F ( 2t ) - IsoP ) .
Diseases:"
1278	To determine whether there was a temporal relationship between VPA - associated oxidative stress and hepatotoxicity , adult male Sprague - Dawley rats were treated ip with VPA ( 500 mg / kg ) or 0 . 9 % saline ( vehicle ) once daily for 2 , 4 , 7 , 10 , or 14 days .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hepatotoxicity']	1	4	"Sentence: To determine whether there was a temporal relationship between VPA - associated oxidative stress and hepatotoxicity , adult male Sprague - Dawley rats were treated ip with VPA ( 500 mg / kg ) or 0 . 9 % saline ( vehicle ) once daily for 2 , 4 , 7 , 10 , or 14 days .
Diseases: hepatotoxicity"	"Sentence: To determine whether there was a temporal relationship between VPA - associated oxidative stress and hepatotoxicity , adult male Sprague - Dawley rats were treated ip with VPA ( 500 mg / kg ) or 0 . 9 % saline ( vehicle ) once daily for 2 , 4 , 7 , 10 , or 14 days .
Diseases:"
1279	Oxidative stress was assessed by determining plasma and liver levels of 15 - F ( 2t ) - IsoP , lipid hydroperoxides ( LPO ) , and thiobarbituric acid reactive substances ( TBARs ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B I I I I I I I O O O O O O O O O I O O O O O O	[]	0	0	"Sentence: Oxidative stress was assessed by determining plasma and liver levels of 15 - F ( 2t ) - IsoP , lipid hydroperoxides ( LPO ) , and thiobarbituric acid reactive substances ( TBARs ) .
Diseases: "	"Sentence: Oxidative stress was assessed by determining plasma and liver levels of 15 - F ( 2t ) - IsoP , lipid hydroperoxides ( LPO ) , and thiobarbituric acid reactive substances ( TBARs ) .
Diseases:"
1280	Plasma and liver 15 - F ( 2t ) - IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B I I I I I I I O O O O O O O O O O B O O O O O	[]	0	0	"Sentence: Plasma and liver 15 - F ( 2t ) - IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control .
Diseases: "	"Sentence: Plasma and liver 15 - F ( 2t ) - IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control .
Diseases:"
1281	Liver LPO levels were not elevated until day 7 of treatment ( 1 . 8 - fold versus control , p < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Liver LPO levels were not elevated until day 7 of treatment ( 1 . 8 - fold versus control , p < 0 . 05 ) .
Diseases: "	"Sentence: Liver LPO levels were not elevated until day 7 of treatment ( 1 . 8 - fold versus control , p < 0 . 05 ) .
Diseases:"
1282	Liver and plasma TBARs were not increased until 14 days ( 2 - fold vs . control , p < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Liver and plasma TBARs were not increased until 14 days ( 2 - fold vs . control , p < 0 . 05 ) .
Diseases: "	"Sentence: Liver and plasma TBARs were not increased until 14 days ( 2 - fold vs . control , p < 0 . 05 ) .
Diseases:"
1283	Liver toxicity was evaluated based on serum levels of alpha - glutathione S - transferase ( alpha - GST ) and by histology .	B I O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O	['liver toxicity']	1	3	"Sentence: Liver toxicity was evaluated based on serum levels of alpha - glutathione S - transferase ( alpha - GST ) and by histology .
Diseases: liver toxicity"	"Sentence: Liver toxicity was evaluated based on serum levels of alpha - glutathione S - transferase ( alpha - GST ) and by histology .
Diseases:"
1284	Serum alpha - GST levels were significantly elevated by day 4 , which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule , necrosis , and steatosis throughout the study .	O O O O O O O O O O O O O O O B O O O O O O O B O O O O O B O O B O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hepatotoxicity', 'steatosis', 'inflammation', 'necrosis']	4	13	"Sentence: Serum alpha - GST levels were significantly elevated by day 4 , which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule , necrosis , and steatosis throughout the study .
Diseases: hepatotoxicity, steatosis, inflammation, necrosis"	"Sentence: Serum alpha - GST levels were significantly elevated by day 4 , which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule , necrosis , and steatosis throughout the study .
Diseases:"
1285	The liver levels of beta - oxidation metabolites of VPA were decreased by day 14 , while the levels of 4 - ene - VPA and ( E ) - 2 , 4 - diene - VPA were not elevated throughout the study .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O B I I I I O B I I I I I I I I I B O O O O O O O	[]	0	0	"Sentence: The liver levels of beta - oxidation metabolites of VPA were decreased by day 14 , while the levels of 4 - ene - VPA and ( E ) - 2 , 4 - diene - VPA were not elevated throughout the study .
Diseases: "	"Sentence: The liver levels of beta - oxidation metabolites of VPA were decreased by day 14 , while the levels of 4 - ene - VPA and ( E ) - 2 , 4 - diene - VPA were not elevated throughout the study .
Diseases:"
1286	Overall , these findings indicate that VPA treatment results in oxidative stress , as measured by levels of 15 - F ( 2t ) - IsoP , which precedes the onset of necrosis , steatosis , and elevated levels of serum alpha - GST .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O	O O O O O O B O O O O O O O O O O O B I I I I I I I O O O O O O O O O O O O O O O O O O O	['steatosis', 'necrosis']	2	6	"Sentence: Overall , these findings indicate that VPA treatment results in oxidative stress , as measured by levels of 15 - F ( 2t ) - IsoP , which precedes the onset of necrosis , steatosis , and elevated levels of serum alpha - GST .
Diseases: steatosis, necrosis"	"Sentence: Overall , these findings indicate that VPA treatment results in oxidative stress , as measured by levels of 15 - F ( 2t ) - IsoP , which precedes the onset of necrosis , steatosis , and elevated levels of serum alpha - GST .
Diseases:"
1287	Pheochromocytoma unmasked by amisulpride and tiapride .	B O O O O O O	O O O B O B O	['pheochromocytoma']	1	6	"Sentence: Pheochromocytoma unmasked by amisulpride and tiapride .
Diseases: pheochromocytoma"	"Sentence: Pheochromocytoma unmasked by amisulpride and tiapride .
Diseases:"
1288	To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride .	O O O O O B O O O O O O O O O	O O O O O O O O O O O B O B O	['pheochromocytoma']	1	6	"Sentence: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride .
Diseases: pheochromocytoma"	"Sentence: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride .
Diseases:"
1289	A 42 - year - old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg .	O O O O O O O O O O B O O B O B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O O O B O O O	['vomiting', 'headache', 'hypertension']	3	7	"Sentence: A 42 - year - old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg .
Diseases: vomiting, headache, hypertension"	"Sentence: A 42 - year - old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg .
Diseases:"
1290	Both drugs were immediately discontinued , and the patient recovered after subsequent nicardipine and verapamil treatment .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O B O O	[]	0	0	"Sentence: Both drugs were immediately discontinued , and the patient recovered after subsequent nicardipine and verapamil treatment .
Diseases: "	"Sentence: Both drugs were immediately discontinued , and the patient recovered after subsequent nicardipine and verapamil treatment .
Diseases:"
1291	Abdominal ultrasound showed an adrenal mass , and postoperative histologic examination confirmed the diagnosis of pheochromocytoma .	O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O	['pheochromocytoma']	1	6	"Sentence: Abdominal ultrasound showed an adrenal mass , and postoperative histologic examination confirmed the diagnosis of pheochromocytoma .
Diseases: pheochromocytoma"	"Sentence: Abdominal ultrasound showed an adrenal mass , and postoperative histologic examination confirmed the diagnosis of pheochromocytoma .
Diseases:"
1292	DISCUSSION : Drug - induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs , but the underlying mechanism is unknown .	O O O O O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B I O O O O O O O O O	['pheochromocytoma']	1	6	"Sentence: DISCUSSION : Drug - induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs , but the underlying mechanism is unknown .
Diseases: pheochromocytoma"	"Sentence: DISCUSSION : Drug - induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs , but the underlying mechanism is unknown .
Diseases:"
1293	In our case , use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy .	O O O O O O O O O O O O O O O O B O O O O O O O	O O O O O O O O O O O O O O O O O O O B O B O O	['hypertensive']	1	3	"Sentence: In our case , use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy .
Diseases: hypertensive"	"Sentence: In our case , use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy .
Diseases:"
1294	CONCLUSIONS : As of March 24 , 2005 , this is the first reported case of amisulpride - and tiapride - induced hypertensive crisis in a patient with pheochromocytoma .	O O O O O O O O O O O O O O O O O O O O O O B O O O O O B O	O O O O O O O O O O O O O O O O B O O B O O O O O O O O O O	['hypertensive', 'pheochromocytoma']	2	11	"Sentence: CONCLUSIONS : As of March 24 , 2005 , this is the first reported case of amisulpride - and tiapride - induced hypertensive crisis in a patient with pheochromocytoma .
Diseases: hypertensive, pheochromocytoma"	"Sentence: CONCLUSIONS : As of March 24 , 2005 , this is the first reported case of amisulpride - and tiapride - induced hypertensive crisis in a patient with pheochromocytoma .
Diseases:"
1295	Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O B O	[]	0	0	"Sentence: Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride .
Diseases: "	"Sentence: Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride .
Diseases:"
1296	Quantitative drug levels in stimulant psychosis : relationship to symptom severity , catecholamines and hyperkinesia .	O O O O O B O O O O O O O O B O	O O O O O O O O O O O O O O O O	['psychosis', 'hyperkinesia']	2	7	"Sentence: Quantitative drug levels in stimulant psychosis : relationship to symptom severity , catecholamines and hyperkinesia .
Diseases: psychosis, hyperkinesia"	"Sentence: Quantitative drug levels in stimulant psychosis : relationship to symptom severity , catecholamines and hyperkinesia .
Diseases:"
1297	To examine the relationship between quantitative stimulant drug levels , catecholamines , and psychotic symptoms , nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine - or cocaine - induced psychosis were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels .	O O O O O O O O O O O O O B I O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O O O B O O B O O O O O O O O O O O O O O O O O O O B O O O	['psychosis', 'psychotic symptoms', 'psychiatric']	3	7	"Sentence: To examine the relationship between quantitative stimulant drug levels , catecholamines , and psychotic symptoms , nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine - or cocaine - induced psychosis were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels .
Diseases: psychosis, psychotic symptoms, psychiatric"	"Sentence: To examine the relationship between quantitative stimulant drug levels , catecholamines , and psychotic symptoms , nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine - or cocaine - induced psychosis were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels .
Diseases:"
1298	Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating .	O O O O O O O O O O O O O B O O	B O B O O O O O O O O O O O O O	['hyperkinesia']	1	4	"Sentence: Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating .
Diseases: hyperkinesia"	"Sentence: Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating .
Diseases:"
1299	HVA levels were related to global hyperkinesia but not to psychopathology ratings .	O O O O O O B O O O O O O	B O O O O O O O O O O O O	['hyperkinesia']	1	4	"Sentence: HVA levels were related to global hyperkinesia but not to psychopathology ratings .
Diseases: hyperkinesia"	"Sentence: HVA levels were related to global hyperkinesia but not to psychopathology ratings .
Diseases:"
1300	Although many other factors such as sensitization may play a role , intensity of stimulant - induced psychotic symptoms and stereotypies appears to be at least in part dose - related .	O O O O O O O O O O O O O O O O O B I O B O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['psychotic symptoms', 'stereotypies']	2	6	"Sentence: Although many other factors such as sensitization may play a role , intensity of stimulant - induced psychotic symptoms and stereotypies appears to be at least in part dose - related .
Diseases: psychotic symptoms, stereotypies"	"Sentence: Although many other factors such as sensitization may play a role , intensity of stimulant - induced psychotic symptoms and stereotypies appears to be at least in part dose - related .
Diseases:"
1301	Delayed asystolic cardiac arrest after diltiazem overdose ; resuscitation with high dose intravenous calcium .	O B B I O O B O O O O O O O O	O O O O O B O O O O O O O B O	['overdose', 'asystolic', 'cardiac arrest']	3	10	"Sentence: Delayed asystolic cardiac arrest after diltiazem overdose ; resuscitation with high dose intravenous calcium .
Diseases: overdose, asystolic, cardiac arrest"	"Sentence: Delayed asystolic cardiac arrest after diltiazem overdose ; resuscitation with high dose intravenous calcium .
Diseases:"
1302	A 51 year old man took a mixed overdose including 1 . 8 - 3 . 6 g of diltiazem , paracetamol , aspirin , isosorbide nitrate , and alcohol .	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O B O B O B I O O B O	['overdose']	1	2	"Sentence: A 51 year old man took a mixed overdose including 1 . 8 - 3 . 6 g of diltiazem , paracetamol , aspirin , isosorbide nitrate , and alcohol .
Diseases: overdose"	"Sentence: A 51 year old man took a mixed overdose including 1 . 8 - 3 . 6 g of diltiazem , paracetamol , aspirin , isosorbide nitrate , and alcohol .
Diseases:"
1303	He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids .	O O O O O O O O O O B O O O O O O O O O O	O O O O O O O O O O O O O O O B I O O O O	['hypotension']	1	3	"Sentence: He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids .
Diseases: hypotension"	"Sentence: He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids .
Diseases:"
1304	Eighteen hours after the overdose he had two generalised tonic - clonic seizures .	O O O O B O O O O B I I I O	O O O O O O O O O O O O O O	['overdose', 'tonic - clonic seizures']	2	9	"Sentence: Eighteen hours after the overdose he had two generalised tonic - clonic seizures .
Diseases: overdose, tonic - clonic seizures"	"Sentence: Eighteen hours after the overdose he had two generalised tonic - clonic seizures .
Diseases:"
1305	The patient remained unresponsive with junctional bradycardia , unrecordable blood pressure , and then became asystolic .	O O O O O O B O O O O O O O O B O	O O O O O O O O O O O O O O O O O	['bradycardia', 'asystolic']	2	9	"Sentence: The patient remained unresponsive with junctional bradycardia , unrecordable blood pressure , and then became asystolic .
Diseases: bradycardia, asystolic"	"Sentence: The patient remained unresponsive with junctional bradycardia , unrecordable blood pressure , and then became asystolic .
Diseases:"
1306	He was resuscitated with high dose ( 13 . 5 g ) intravenous calcium and adrenaline ( epinephrine ) .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O B O B O O	[]	0	0	"Sentence: He was resuscitated with high dose ( 13 . 5 g ) intravenous calcium and adrenaline ( epinephrine ) .
Diseases: "	"Sentence: He was resuscitated with high dose ( 13 . 5 g ) intravenous calcium and adrenaline ( epinephrine ) .
Diseases:"
1307	He required inotropic support and temporary pacing over the next 48 hours .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: He required inotropic support and temporary pacing over the next 48 hours .
Diseases: "	"Sentence: He required inotropic support and temporary pacing over the next 48 hours .
Diseases:"
1308	This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose , particularly with the onset of asystole .	O O O O O O O O O O O O O O O O O B O O O O O O B O	O O O O O O O O O O O O B O O O B O O O O O O O O O	['overdose', 'asystole']	2	7	"Sentence: This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose , particularly with the onset of asystole .
Diseases: overdose, asystole"	"Sentence: This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose , particularly with the onset of asystole .
Diseases:"
1309	It should be considered early in cases of cardiac arrest after diltiazem overdose .	O O O O O O O O B I O O B O	O O O O O O O O O O O B O O	['overdose', 'cardiac arrest']	2	5	"Sentence: It should be considered early in cases of cardiac arrest after diltiazem overdose .
Diseases: overdose, cardiac arrest"	"Sentence: It should be considered early in cases of cardiac arrest after diltiazem overdose .
Diseases:"
1310	The case also highlights the problems with delayed toxicity when whole bowel irrigation is not administered .	O O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: The case also highlights the problems with delayed toxicity when whole bowel irrigation is not administered .
Diseases: toxicity"	"Sentence: The case also highlights the problems with delayed toxicity when whole bowel irrigation is not administered .
Diseases:"
1311	Renal papillary necrosis due to naproxen .	B I I O O O O	O O O O O B O	['renal papillary necrosis']	1	6	"Sentence: Renal papillary necrosis due to naproxen .
Diseases: renal papillary necrosis"	"Sentence: Renal papillary necrosis due to naproxen .
Diseases:"
1312	A 31 - year - old man with rheumatoid arthritis , who had previously been treated with sulindac , fenoprofen calcium , high dose salicylates and gold salts , developed renal papillary necrosis ( RPN ) 4 months after institution of naproxen therapy .	O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O B I I O B O O O O O O O O O	O O O O O O O O O O O O O O O O O B O B I O O O B O B O O O O O O O O O O O O O O B O O	['rheumatoid arthritis', 'rpn', 'renal papillary necrosis']	3	15	"Sentence: A 31 - year - old man with rheumatoid arthritis , who had previously been treated with sulindac , fenoprofen calcium , high dose salicylates and gold salts , developed renal papillary necrosis ( RPN ) 4 months after institution of naproxen therapy .
Diseases: rheumatoid arthritis, rpn, renal papillary necrosis"	"Sentence: A 31 - year - old man with rheumatoid arthritis , who had previously been treated with sulindac , fenoprofen calcium , high dose salicylates and gold salts , developed renal papillary necrosis ( RPN ) 4 months after institution of naproxen therapy .
Diseases:"
1313	No other factor predisposing to RPN could be discovered .	O O O O O B O O O O	O O O O O O O O O O	['rpn']	1	2	"Sentence: No other factor predisposing to RPN could be discovered .
Diseases: rpn"	"Sentence: No other factor predisposing to RPN could be discovered .
Diseases:"
1314	Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months .	O O O O O O O O O O O O O O O O O O	B O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months .
Diseases: "	"Sentence: Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months .
Diseases:"
1315	We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents .	O O O O O B O O O O O O O O O O O O O O O B I O O O O O	O O O O O B O O O O O O O O O B O O O O O O O O O O O O	['renal toxicity', 'rpn']	2	6	"Sentence: We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents .
Diseases: renal toxicity, rpn"	"Sentence: We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents .
Diseases:"
1316	Adverse interaction between beta - adrenergic blocking drugs and verapamil - - report of three cases .	O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: Adverse interaction between beta - adrenergic blocking drugs and verapamil - - report of three cases .
Diseases: "	"Sentence: Adverse interaction between beta - adrenergic blocking drugs and verapamil - - report of three cases .
Diseases:"
1317	Three patients with ischaemic heart disease developed profound cardiac failure , hypotension and bradycardia during combined therapy with verapamil and beta - adrenergic blocking drugs .	O O O B I I O O B I O B O B O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O	['bradycardia', 'cardiac failure', 'hypotension', 'ischaemic heart disease']	4	17	"Sentence: Three patients with ischaemic heart disease developed profound cardiac failure , hypotension and bradycardia during combined therapy with verapamil and beta - adrenergic blocking drugs .
Diseases: bradycardia, cardiac failure, hypotension, ischaemic heart disease"	"Sentence: Three patients with ischaemic heart disease developed profound cardiac failure , hypotension and bradycardia during combined therapy with verapamil and beta - adrenergic blocking drugs .
Diseases:"
1318	This clinical picture resolved completely with cessation of the combined therapy .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: This clinical picture resolved completely with cessation of the combined therapy .
Diseases: "	"Sentence: This clinical picture resolved completely with cessation of the combined therapy .
Diseases:"
1319	Baseline left ventricular function , assessed by cardiac catheterisation or nuclear angiography , was normal in two patients and only mildly reduced in the other .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Baseline left ventricular function , assessed by cardiac catheterisation or nuclear angiography , was normal in two patients and only mildly reduced in the other .
Diseases: "	"Sentence: Baseline left ventricular function , assessed by cardiac catheterisation or nuclear angiography , was normal in two patients and only mildly reduced in the other .
Diseases:"
1320	Simultaneously administration of beta - adrenergic blocking drugs and verapamil may result in profound adverse interactions and should only be administered with great caution .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Simultaneously administration of beta - adrenergic blocking drugs and verapamil may result in profound adverse interactions and should only be administered with great caution .
Diseases: "	"Sentence: Simultaneously administration of beta - adrenergic blocking drugs and verapamil may result in profound adverse interactions and should only be administered with great caution .
Diseases:"
1321	Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension .	O O O O O O O O O O O B O	O O O B O B O O O O O O O	['hypertension']	1	3	"Sentence: Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension .
Diseases: hypertension"	"Sentence: Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension .
Diseases:"
1322	Report of Medical Research Council Working Party on Mild to Moderate Hypertension .	O O O O O O O O O O O B O	O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: Report of Medical Research Council Working Party on Mild to Moderate Hypertension .
Diseases: hypertension"	"Sentence: Report of Medical Research Council Working Party on Mild to Moderate Hypertension .
Diseases:"
1323	Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups : bendrofluazide , propranolol , or a placebo for either of these drugs .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O	['hypertension']	1	3	"Sentence: Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups : bendrofluazide , propranolol , or a placebo for either of these drugs .
Diseases: hypertension"	"Sentence: Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups : bendrofluazide , propranolol , or a placebo for either of these drugs .
Diseases:"
1324	The trial is single - blind .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: The trial is single - blind .
Diseases: "	"Sentence: The trial is single - blind .
Diseases:"
1325	23 582 patient - years of observation have been completed so far , 10 684 on active drugs and 12 898 on placebos .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 23 582 patient - years of observation have been completed so far , 10 684 on active drugs and 12 898 on placebos .
Diseases: "	"Sentence: 23 582 patient - years of observation have been completed so far , 10 684 on active drugs and 12 898 on placebos .
Diseases:"
1326	The results show an association between bendrofluazide treatment and impotence , and impotence also occurred more frequently in patients taking propranolol than in those taking placebos .	O O O O O O O O O B O O B O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O B O O O O O O	['impotence']	1	3	"Sentence: The results show an association between bendrofluazide treatment and impotence , and impotence also occurred more frequently in patients taking propranolol than in those taking placebos .
Diseases: impotence"	"Sentence: The results show an association between bendrofluazide treatment and impotence , and impotence also occurred more frequently in patients taking propranolol than in those taking placebos .
Diseases:"
1327	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men , associated with bendrofluazide treatment , and Raynaud 's phenomenon and dyspnoea in men and women taking propranolol .	O O O O O O O O O B I I O O O O O B O O O O O O O O O B I I O B O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O B O	"['impaired glucose tolerance', ""raynaud 's phenomenon"", 'gout', 'dyspnoea']"	4	20	"Sentence: Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men , associated with bendrofluazide treatment , and Raynaud 's phenomenon and dyspnoea in men and women taking propranolol .
Diseases: impaired glucose tolerance, raynaud 's phenomenon, gout, dyspnoea"	"Sentence: Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men , associated with bendrofluazide treatment , and Raynaud 's phenomenon and dyspnoea in men and women taking propranolol .
Diseases:"
1328	No corneal disease is known to have occurred in the propranolol group .	O B I O O O O O O O O O O	O O O O O O O O O O B O O	['corneal disease']	1	4	"Sentence: No corneal disease is known to have occurred in the propranolol group .
Diseases: corneal disease"	"Sentence: No corneal disease is known to have occurred in the propranolol group .
Diseases:"
1329	Mean serum potassium level fell , and urea and uric acid levels rose , in men and women taking bendrofluazide .	O O O O O O O O O O O O O O O O O O O O O	O O B O O O O B O B I O O O O O O O O B O	[]	0	0	"Sentence: Mean serum potassium level fell , and urea and uric acid levels rose , in men and women taking bendrofluazide .
Diseases: "	"Sentence: Mean serum potassium level fell , and urea and uric acid levels rose , in men and women taking bendrofluazide .
Diseases:"
1330	In the propranolol group , serum potassium and uric acid levels rose in both sexes , but the urea level rose significantly in women only .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O B O B I O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: In the propranolol group , serum potassium and uric acid levels rose in both sexes , but the urea level rose significantly in women only .
Diseases: "	"Sentence: In the propranolol group , serum potassium and uric acid levels rose in both sexes , but the urea level rose significantly in women only .
Diseases:"
1331	Dexmedetomidine and cardiac protection for non - cardiac surgery : a meta - analysis of randomised controlled trials .	O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Dexmedetomidine and cardiac protection for non - cardiac surgery : a meta - analysis of randomised controlled trials .
Diseases: "	"Sentence: Dexmedetomidine and cardiac protection for non - cardiac surgery : a meta - analysis of randomised controlled trials .
Diseases:"
1332	We conducted a systematic review of the effects of dexmedetomidine on cardiac outcomes following non - cardiac surgery .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: We conducted a systematic review of the effects of dexmedetomidine on cardiac outcomes following non - cardiac surgery .
Diseases: "	"Sentence: We conducted a systematic review of the effects of dexmedetomidine on cardiac outcomes following non - cardiac surgery .
Diseases:"
1333	We included prospective , randomised peri - operative studies of dexmedetomidine that reported mortality , cardiac morbidity or adverse drug events .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: We included prospective , randomised peri - operative studies of dexmedetomidine that reported mortality , cardiac morbidity or adverse drug events .
Diseases: "	"Sentence: We included prospective , randomised peri - operative studies of dexmedetomidine that reported mortality , cardiac morbidity or adverse drug events .
Diseases:"
1334	A PubMed Central and EMBASE search was conducted up to July 2007 .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: A PubMed Central and EMBASE search was conducted up to July 2007 .
Diseases: "	"Sentence: A PubMed Central and EMBASE search was conducted up to July 2007 .
Diseases:"
1335	The reference lists of identified papers were examined for further trials .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: The reference lists of identified papers were examined for further trials .
Diseases: "	"Sentence: The reference lists of identified papers were examined for further trials .
Diseases:"
1336	Of 425 studies identified , 20 were included in the meta - analysis ( 840 patients ) .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of 425 studies identified , 20 were included in the meta - analysis ( 840 patients ) .
Diseases: "	"Sentence: Of 425 studies identified , 20 were included in the meta - analysis ( 840 patients ) .
Diseases:"
1337	Dexmedetomidine was associated with a trend towards improved cardiac outcomes ; all - cause mortality ( OR 0 . 27 , 95 % CI 0 . 01 - 7 . 13 , p = 0 . 44 ) , non - fatal myocardial infarction ( OR 0 . 26 , 95 % CI 0 . 04 - 1 . 60 , p = 0 . 14 ) , and myocardial ischaemia ( OR 0 . 65 , 95 % CI 0 . 26 - 1 . 63 , p = 0 . 36 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['myocardial ischaemia', 'myocardial infarction']	2	13	"Sentence: Dexmedetomidine was associated with a trend towards improved cardiac outcomes ; all - cause mortality ( OR 0 . 27 , 95 % CI 0 . 01 - 7 . 13 , p = 0 . 44 ) , non - fatal myocardial infarction ( OR 0 . 26 , 95 % CI 0 . 04 - 1 . 60 , p = 0 . 14 ) , and myocardial ischaemia ( OR 0 . 65 , 95 % CI 0 . 26 - 1 . 63 , p = 0 . 36 ) .
Diseases: myocardial ischaemia, myocardial infarction"	"Sentence: Dexmedetomidine was associated with a trend towards improved cardiac outcomes ; all - cause mortality ( OR 0 . 27 , 95 % CI 0 . 01 - 7 . 13 , p = 0 . 44 ) , non - fatal myocardial infarction ( OR 0 . 26 , 95 % CI 0 . 04 - 1 . 60 , p = 0 . 14 ) , and myocardial ischaemia ( OR 0 . 65 , 95 % CI 0 . 26 - 1 . 63 , p = 0 . 36 ) .
Diseases:"
1338	Peri - operative hypotension ( 26 % , OR 3 . 80 , 95 % CI 1 . 91 - 7 . 54 , p = 0 . 0001 ) and bradycardia ( 17 % , OR 5 . 45 , 95 % CI 2 . 98 - 9 . 95 , p < 0 . 00001 ) were significantly increased .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['bradycardia', 'hypotension']	2	7	"Sentence: Peri - operative hypotension ( 26 % , OR 3 . 80 , 95 % CI 1 . 91 - 7 . 54 , p = 0 . 0001 ) and bradycardia ( 17 % , OR 5 . 45 , 95 % CI 2 . 98 - 9 . 95 , p < 0 . 00001 ) were significantly increased .
Diseases: bradycardia, hypotension"	"Sentence: Peri - operative hypotension ( 26 % , OR 3 . 80 , 95 % CI 1 . 91 - 7 . 54 , p = 0 . 0001 ) and bradycardia ( 17 % , OR 5 . 45 , 95 % CI 2 . 98 - 9 . 95 , p < 0 . 00001 ) were significantly increased .
Diseases:"
1339	An anticholinergic did not reduce the incidence of bradycardia ( p = 0 . 43 ) .	O O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O	['bradycardia']	1	4	"Sentence: An anticholinergic did not reduce the incidence of bradycardia ( p = 0 . 43 ) .
Diseases: bradycardia"	"Sentence: An anticholinergic did not reduce the incidence of bradycardia ( p = 0 . 43 ) .
Diseases:"
1340	A randomised placebo - controlled trial of dexmedetomidine is warranted .	O O O O O O O O O O O	O O O O O O O B O O O	[]	0	0	"Sentence: A randomised placebo - controlled trial of dexmedetomidine is warranted .
Diseases: "	"Sentence: A randomised placebo - controlled trial of dexmedetomidine is warranted .
Diseases:"
1341	Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus .	O O O O O O O O O B I I O	O O O O O B O O O O O O O	['systemic lupus erythematosus']	1	11	"Sentence: Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus .
Diseases: systemic lupus erythematosus"	"Sentence: Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus .
Diseases:"
1342	We report the clinical and bioptic findings for a 57 - year - old woman with severe chloroquine - induced myopathy .	O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O B O O O O	['myopathy']	1	2	"Sentence: We report the clinical and bioptic findings for a 57 - year - old woman with severe chloroquine - induced myopathy .
Diseases: myopathy"	"Sentence: We report the clinical and bioptic findings for a 57 - year - old woman with severe chloroquine - induced myopathy .
Diseases:"
1343	Since 1989 , she had been suffering from systemic lupus erythematosus ( SLE ) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide .	O O O O O O O O B I I O B O O B I O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O B O	['renal involvement', 'systemic lupus erythematosus', 'sle']	3	16	"Sentence: Since 1989 , she had been suffering from systemic lupus erythematosus ( SLE ) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide .
Diseases: renal involvement, systemic lupus erythematosus, sle"	"Sentence: Since 1989 , she had been suffering from systemic lupus erythematosus ( SLE ) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide .
Diseases:"
1344	Additional therapy with chloroquine ( CQ ) was started because of arthralgia .	O O O O O O O O O O O B O	O O O B O B O O O O O O O	['arthralgia']	1	4	"Sentence: Additional therapy with chloroquine ( CQ ) was started because of arthralgia .
Diseases: arthralgia"	"Sentence: Additional therapy with chloroquine ( CQ ) was started because of arthralgia .
Diseases:"
1345	At the same time , slightly increased creatine kinase ( CK ) levels were noted .	O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: At the same time , slightly increased creatine kinase ( CK ) levels were noted .
Diseases: "	"Sentence: At the same time , slightly increased creatine kinase ( CK ) levels were noted .
Diseases:"
1346	Myositis was suspected , and the patient was treated with steroids .	B O O O O O O O O O O O	O O O O O O O O O O B O	['myositis']	1	3	"Sentence: Myositis was suspected , and the patient was treated with steroids .
Diseases: myositis"	"Sentence: Myositis was suspected , and the patient was treated with steroids .
Diseases:"
1347	The CK increase persisted , however , and she developed progressive muscular weakness and muscular atrophy .	O O O O O O O O O O O B I O B I O	O O O O O O O O O O O O O O O O O	['muscular weakness', 'muscular atrophy']	2	7	"Sentence: The CK increase persisted , however , and she developed progressive muscular weakness and muscular atrophy .
Diseases: muscular weakness, muscular atrophy"	"Sentence: The CK increase persisted , however , and she developed progressive muscular weakness and muscular atrophy .
Diseases:"
1348	Routine controls revealed markedly elevated CK levels of 1 , 700 U / l .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Routine controls revealed markedly elevated CK levels of 1 , 700 U / l .
Diseases: "	"Sentence: Routine controls revealed markedly elevated CK levels of 1 , 700 U / l .
Diseases:"
1349	The neurological and electrophysiological findings were not typical of myositis .	O O O O O O O O O B O	O O O O O O O O O O O	['myositis']	1	3	"Sentence: The neurological and electrophysiological findings were not typical of myositis .
Diseases: myositis"	"Sentence: The neurological and electrophysiological findings were not typical of myositis .
Diseases:"
1350	Thus , muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy .	O O O O O O O O O O O O O O B O O B O	O O O O O O O O O O O O O O O O O O O	['myopathy', 'polymyositis']	2	7	"Sentence: Thus , muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy .
Diseases: myopathy, polymyositis"	"Sentence: Thus , muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy .
Diseases:"
1351	As it revealed chloroquine - induced myopathy , medication was stopped .	O O O O O O B O O O O O	O O O B O O O O O O O O	['myopathy']	1	2	"Sentence: As it revealed chloroquine - induced myopathy , medication was stopped .
Diseases: myopathy"	"Sentence: As it revealed chloroquine - induced myopathy , medication was stopped .
Diseases:"
1352	Discriminating between primary SLE - induced affection of the musculoskeletal system and drug - induced side effects is important for appropriate treatment of SLE patients .	O O O B O O B I I I I O O O O O O O O O O O O B O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['affection of the musculoskeletal system', 'sle']	2	12	"Sentence: Discriminating between primary SLE - induced affection of the musculoskeletal system and drug - induced side effects is important for appropriate treatment of SLE patients .
Diseases: affection of the musculoskeletal system, sle"	"Sentence: Discriminating between primary SLE - induced affection of the musculoskeletal system and drug - induced side effects is important for appropriate treatment of SLE patients .
Diseases:"
1353	Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children .	O O O O O B I O O O O	O B O O O O O O O O O	['adenovirus disease']	1	4	"Sentence: Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children .
Diseases: adenovirus disease"	"Sentence: Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children .
Diseases:"
1354	Adenovirus is an important cause of morbidity and mortality in the immunocompromised host .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Adenovirus is an important cause of morbidity and mortality in the immunocompromised host .
Diseases: "	"Sentence: Adenovirus is an important cause of morbidity and mortality in the immunocompromised host .
Diseases:"
1355	The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children , where case fatality rates as high as 50 % to 80 % have been reported .	O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['adenovirus disease']	1	4	"Sentence: The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children , where case fatality rates as high as 50 % to 80 % have been reported .
Diseases: adenovirus disease"	"Sentence: The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children , where case fatality rates as high as 50 % to 80 % have been reported .
Diseases:"
1356	There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease , nor are there any prospective randomized , controlled trials of potentially useful anti - adenovirus therapies .	O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['adenovirus disease']	1	4	"Sentence: There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease , nor are there any prospective randomized , controlled trials of potentially useful anti - adenovirus therapies .
Diseases: adenovirus disease"	"Sentence: There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease , nor are there any prospective randomized , controlled trials of potentially useful anti - adenovirus therapies .
Diseases:"
1357	Apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports and small series .	O O O O O O O O B I O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	['adenovirus disease']	1	4	"Sentence: Apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports and small series .
Diseases: adenovirus disease"	"Sentence: Apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports and small series .
Diseases:"
1358	Experience is greatest with intravenous ribavirin and cidofovir .	O O O O O O O O O	O O O O O B O B O	[]	0	0	"Sentence: Experience is greatest with intravenous ribavirin and cidofovir .
Diseases: "	"Sentence: Experience is greatest with intravenous ribavirin and cidofovir .
Diseases:"
1359	Ribavirin , a guanosine analogue , has broad antiviral activity against both RNA and DNA viruses , including documented activity against adenovirus in vitro .	O O O O O O O O O O O O O O O O O O O O O O O O O	B O O B O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ribavirin , a guanosine analogue , has broad antiviral activity against both RNA and DNA viruses , including documented activity against adenovirus in vitro .
Diseases: "	"Sentence: Ribavirin , a guanosine analogue , has broad antiviral activity against both RNA and DNA viruses , including documented activity against adenovirus in vitro .
Diseases:"
1360	Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection , and orally in combination with interferon to treat hepatitis C . Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses .	O O O O O O O O O O B I I I O O O O O O O O O B I O O O O O O O O O B I I I I O	B O O O O O O O O O O O O O O O O O O O B O O O O O O B O O O O O O O O O O O O	['respiratory syncytial virus infection', 'hepatitis c', 'infection with hemorrhagic fever viruses']	3	19	"Sentence: Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection , and orally in combination with interferon to treat hepatitis C . Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses .
Diseases: respiratory syncytial virus infection, hepatitis c, infection with hemorrhagic fever viruses"	"Sentence: Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection , and orally in combination with interferon to treat hepatitis C . Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses .
Diseases:"
1361	The most common adverse effect of intravenous ribavirin is reversible mild anemia .	O O O O O O O O O O O B O	O O O O O O O B O O O O O	['anemia']	1	2	"Sentence: The most common adverse effect of intravenous ribavirin is reversible mild anemia .
Diseases: anemia"	"Sentence: The most common adverse effect of intravenous ribavirin is reversible mild anemia .
Diseases:"
1362	The use of cidofovir in severe adenovirus infection has been limited by adverse effects , the most significant of which is nephrotoxicity .	O O O O O O B I O O O O O O O O O O O O O B O	O O O B O O O O O O O O O O O O O O O O O O O	['nephrotoxicity', 'adenovirus infection']	2	10	"Sentence: The use of cidofovir in severe adenovirus infection has been limited by adverse effects , the most significant of which is nephrotoxicity .
Diseases: nephrotoxicity, adenovirus infection"	"Sentence: The use of cidofovir in severe adenovirus infection has been limited by adverse effects , the most significant of which is nephrotoxicity .
Diseases:"
1363	We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature .	O O O O O O O O O O B I O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O	['adenovirus disease']	1	4	"Sentence: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature .
Diseases: adenovirus disease"	"Sentence: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature .
Diseases:"
1364	DESIGN / METHODS : We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease .	O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O B O O O O O O	['adenovirus disease']	1	4	"Sentence: DESIGN / METHODS : We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease .
Diseases: adenovirus disease"	"Sentence: DESIGN / METHODS : We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease .
Diseases:"
1365	Two patients developed adenovirus hemorrhagic cystitis after cardiac and bone marrow transplants , respectively .	O O O O B I O O O O O O O O O	O O O O O O O O O O O O O O O	['hemorrhagic cystitis']	1	7	"Sentence: Two patients developed adenovirus hemorrhagic cystitis after cardiac and bone marrow transplants , respectively .
Diseases: hemorrhagic cystitis"	"Sentence: Two patients developed adenovirus hemorrhagic cystitis after cardiac and bone marrow transplants , respectively .
Diseases:"
1366	The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease .	O O O O O O O O O O O O O O	O O O O O O O O B O O O O O	[]	0	0	"Sentence: The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease .
Diseases: "	"Sentence: The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease .
Diseases:"
1367	An additional 3 children developed adenovirus pneumonia ; 2 were neonates , 1 of whom had partial DiGeorge syndrome .	O O O O O B I O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O	['adenovirus pneumonia', 'digeorge syndrome']	2	9	"Sentence: An additional 3 children developed adenovirus pneumonia ; 2 were neonates , 1 of whom had partial DiGeorge syndrome .
Diseases: adenovirus pneumonia, digeorge syndrome"	"Sentence: An additional 3 children developed adenovirus pneumonia ; 2 were neonates , 1 of whom had partial DiGeorge syndrome .
Diseases:"
1368	The remaining infant had recently undergone a cardiac transplant .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: The remaining infant had recently undergone a cardiac transplant .
Diseases: "	"Sentence: The remaining infant had recently undergone a cardiac transplant .
Diseases:"
1369	Intravenous ribavirin was administered on a compassionate - use protocol .	O O O O O O O O O O O	O B O O O O O O O O O	[]	0	0	"Sentence: Intravenous ribavirin was administered on a compassionate - use protocol .
Diseases: "	"Sentence: Intravenous ribavirin was administered on a compassionate - use protocol .
Diseases:"
1370	Complete clinical recovery followed later by viral clearance was observed in 2 children : the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia .	O O O O O O O O O O O O O O O O O O O O B I O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['adenovirus pneumonia', 'hemorrhagic cystitis']	2	10	"Sentence: Complete clinical recovery followed later by viral clearance was observed in 2 children : the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia .
Diseases: adenovirus pneumonia, hemorrhagic cystitis"	"Sentence: Complete clinical recovery followed later by viral clearance was observed in 2 children : the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia .
Diseases:"
1371	The remaining 3 children died of adenovirus disease .	O O O O O O B I O	O O O O O O O O O	['adenovirus disease']	1	4	"Sentence: The remaining 3 children died of adenovirus disease .
Diseases: adenovirus disease"	"Sentence: The remaining 3 children died of adenovirus disease .
Diseases:"
1372	Intravenous ribavirin therapy was well tolerated .	O O O O O O O	O B O O O O O	[]	0	0	"Sentence: Intravenous ribavirin therapy was well tolerated .
Diseases: "	"Sentence: Intravenous ribavirin therapy was well tolerated .
Diseases:"
1373	Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia .	O O O O O O O O O B I I O B O	O O B O O O O O O O O O O O O	['progressive renal failure', 'neutropenia']	2	9	"Sentence: Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia .
Diseases: progressive renal failure, neutropenia"	"Sentence: Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia .
Diseases:"
1374	Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease , namely solid - organ and bone marrow transplant recipients , neonates , and children with immunodeficiency .	O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['immunodeficiency', 'adenovirus disease']	2	11	"Sentence: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease , namely solid - organ and bone marrow transplant recipients , neonates , and children with immunodeficiency .
Diseases: immunodeficiency, adenovirus disease"	"Sentence: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease , namely solid - organ and bone marrow transplant recipients , neonates , and children with immunodeficiency .
Diseases:"
1375	Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature , therapy is unlikely to be of benefit if begun late in the course of the infection .	O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O B O	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['infection', 'adenovirus disease']	2	6	"Sentence: Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature , therapy is unlikely to be of benefit if begun late in the course of the infection .
Diseases: infection, adenovirus disease"	"Sentence: Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature , therapy is unlikely to be of benefit if begun late in the course of the infection .
Diseases:"
1376	Early identification , eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response .	O O O O O O O O O O O O O O O B I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['adenovirus disease']	1	4	"Sentence: Early identification , eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response .
Diseases: adenovirus disease"	"Sentence: Early identification , eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response .
Diseases:"
1377	CONCLUSIONS : Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered .	O O O O O O O O B I O O O O O O	O O O O O O O O O O O O O B O O	['adenovirus disease']	1	4	"Sentence: CONCLUSIONS : Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered .
Diseases: adenovirus disease"	"Sentence: CONCLUSIONS : Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered .
Diseases:"
1378	The availability of newer rapid diagnostic techniques , such as polymerase chain reaction , may make earlier , more effective treatment of adenovirus infection possible .	O O O O O O O O O O O O O O O O O O O O O O B I O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['adenovirus infection']	1	4	"Sentence: The availability of newer rapid diagnostic techniques , such as polymerase chain reaction , may make earlier , more effective treatment of adenovirus infection possible .
Diseases: adenovirus infection"	"Sentence: The availability of newer rapid diagnostic techniques , such as polymerase chain reaction , may make earlier , more effective treatment of adenovirus infection possible .
Diseases:"
1379	Given the seriousness and increasing prevalence of adenovirus disease in certain hosts , especially children , a large , multicenter clinical trial of potentially useful anti - adenoviral therapies , such as intravenous ribavirin , is clearly required to demonstrate the most effective and least toxic therapy .	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	['adenovirus disease']	1	4	"Sentence: Given the seriousness and increasing prevalence of adenovirus disease in certain hosts , especially children , a large , multicenter clinical trial of potentially useful anti - adenoviral therapies , such as intravenous ribavirin , is clearly required to demonstrate the most effective and least toxic therapy .
Diseases: adenovirus disease"	"Sentence: Given the seriousness and increasing prevalence of adenovirus disease in certain hosts , especially children , a large , multicenter clinical trial of potentially useful anti - adenoviral therapies , such as intravenous ribavirin , is clearly required to demonstrate the most effective and least toxic therapy .
Diseases:"
1380	Hepatotoxicity of amiodarone .	B O O O	O O B O	['hepatotoxicity']	1	4	"Sentence: Hepatotoxicity of amiodarone .
Diseases: hepatotoxicity"	"Sentence: Hepatotoxicity of amiodarone .
Diseases:"
1381	Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias .	O O O O O O O O O O O O B O	B O O O O O O O O O O O O O	['tachyarrhythmias']	1	6	"Sentence: Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias .
Diseases: tachyarrhythmias"	"Sentence: Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias .
Diseases:"
1382	The use of amiodarone has , however , been limited due to its serious side - effects .	O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: The use of amiodarone has , however , been limited due to its serious side - effects .
Diseases: "	"Sentence: The use of amiodarone has , however , been limited due to its serious side - effects .
Diseases:"
1383	A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given .	O O O B I O O O O O O O O O O O O B O O O O O	O O O O O O O B O O O O O O O O O O O B O O O	['hepatotoxicity', 'cholestatic hepatitis']	2	10	"Sentence: A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given .
Diseases: hepatotoxicity, cholestatic hepatitis"	"Sentence: A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given .
Diseases:"
1384	It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment , including steatosis , alterations resembling alcoholic hepatitis , cholestatic hepatitis and micronodular cirrhosis of the liver .	O O O O O O O O B I O O O O O O B O O O B I O B I O O B I I I O	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['steatosis', 'cirrhosis of the liver', 'cholestatic hepatitis', 'alcoholic hepatitis', 'hepatic injury']	5	23	"Sentence: It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment , including steatosis , alterations resembling alcoholic hepatitis , cholestatic hepatitis and micronodular cirrhosis of the liver .
Diseases: steatosis, cirrhosis of the liver, cholestatic hepatitis, alcoholic hepatitis, hepatic injury"	"Sentence: It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment , including steatosis , alterations resembling alcoholic hepatitis , cholestatic hepatitis and micronodular cirrhosis of the liver .
Diseases:"
1385	Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels .	O O O O O O O O O O O O O O	O O B O O O O O O O O O O O	[]	0	0	"Sentence: Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels .
Diseases: "	"Sentence: Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels .
Diseases:"
1386	Therapy should be discontinued on the suspicion of cholestatic injury or hepatomegaly .	O O O O O O O O B I O B O	O O O O O O O O O O O O O	['cholestatic injury', 'hepatomegaly']	2	10	"Sentence: Therapy should be discontinued on the suspicion of cholestatic injury or hepatomegaly .
Diseases: cholestatic injury, hepatomegaly"	"Sentence: Therapy should be discontinued on the suspicion of cholestatic injury or hepatomegaly .
Diseases:"
1387	Catalepsy induced by combinations of ketamine and morphine : potentiation , antagonism , tolerance and cross - tolerance in the rat .	B O O O O O O O O O O O O O O O O O O O O O	O O O O O B O B O O O O O O O O O O O O O O	['catalepsy']	1	4	"Sentence: Catalepsy induced by combinations of ketamine and morphine : potentiation , antagonism , tolerance and cross - tolerance in the rat .
Diseases: catalepsy"	"Sentence: Catalepsy induced by combinations of ketamine and morphine : potentiation , antagonism , tolerance and cross - tolerance in the rat .
Diseases:"
1388	Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat .	O O O O O O O O O B O B O O O O	O O O O O B O B O O O O O O O O	['catalepsy', 'analgesia']	2	7	"Sentence: Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat .
Diseases: catalepsy, analgesia"	"Sentence: Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat .
Diseases:"
1389	Pre - treatment with ketamine produced cross - tolerance to morphine , whereas pretreatment with morphine did not induce cross - tolerance to ketamine but rather augmented the cataleptic response ; this augmentation was attributed to residual morphine in the brain .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	O O O O B O O O O O B O O O O B O O O O O O O B O O O O O O O O O O O O O B O O O O	['cataleptic']	1	3	"Sentence: Pre - treatment with ketamine produced cross - tolerance to morphine , whereas pretreatment with morphine did not induce cross - tolerance to ketamine but rather augmented the cataleptic response ; this augmentation was attributed to residual morphine in the brain .
Diseases: cataleptic"	"Sentence: Pre - treatment with ketamine produced cross - tolerance to morphine , whereas pretreatment with morphine did not induce cross - tolerance to ketamine but rather augmented the cataleptic response ; this augmentation was attributed to residual morphine in the brain .
Diseases:"
1390	The present studies explored the duration of the loss of righting reflex induced by sub - effective doses of ketamine and morphine , administered simultaneously .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O B O O O O	[]	0	0	"Sentence: The present studies explored the duration of the loss of righting reflex induced by sub - effective doses of ketamine and morphine , administered simultaneously .
Diseases: "	"Sentence: The present studies explored the duration of the loss of righting reflex induced by sub - effective doses of ketamine and morphine , administered simultaneously .
Diseases:"
1391	There was mutual potentiation between sub - effective doses of ketamine and morphine , but sub - effective doses of ketamine partly antagonized fully - effective doses of morphine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O B O O O O O O O B O O O O O O O B O	[]	0	0	"Sentence: There was mutual potentiation between sub - effective doses of ketamine and morphine , but sub - effective doses of ketamine partly antagonized fully - effective doses of morphine .
Diseases: "	"Sentence: There was mutual potentiation between sub - effective doses of ketamine and morphine , but sub - effective doses of ketamine partly antagonized fully - effective doses of morphine .
Diseases:"
1392	Latency to the loss of righting reflex , rigidity and behavior on recovery , reflected the relative predominance of ketamine or morphine in each combination .	O O O O O O O O B O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O B O O O O	['rigidity']	1	2	"Sentence: Latency to the loss of righting reflex , rigidity and behavior on recovery , reflected the relative predominance of ketamine or morphine in each combination .
Diseases: rigidity"	"Sentence: Latency to the loss of righting reflex , rigidity and behavior on recovery , reflected the relative predominance of ketamine or morphine in each combination .
Diseases:"
1393	Naloxone inhibited the induced cataleptic effects .	O O O O B O O	B O O O O O O	['cataleptic']	1	3	"Sentence: Naloxone inhibited the induced cataleptic effects .
Diseases: cataleptic"	"Sentence: Naloxone inhibited the induced cataleptic effects .
Diseases:"
1394	The degree and time course of development of tolerance to daily administration of sub - effective dose combinations of ketamine and morphine were similar .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O B O O O	[]	0	0	"Sentence: The degree and time course of development of tolerance to daily administration of sub - effective dose combinations of ketamine and morphine were similar .
Diseases: "	"Sentence: The degree and time course of development of tolerance to daily administration of sub - effective dose combinations of ketamine and morphine were similar .
Diseases:"
1395	Rats , tolerant to ketamine - dominant combinations , were cross - tolerant to both drugs , while those tolerant to morphine - dominant combinations were cross - tolerant to morphine but showed either no cross - tolerance or an augmented response to ketamine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O B O O O O O O O O B O O O O O O O O O O O O B O	[]	0	0	"Sentence: Rats , tolerant to ketamine - dominant combinations , were cross - tolerant to both drugs , while those tolerant to morphine - dominant combinations were cross - tolerant to morphine but showed either no cross - tolerance or an augmented response to ketamine .
Diseases: "	"Sentence: Rats , tolerant to ketamine - dominant combinations , were cross - tolerant to both drugs , while those tolerant to morphine - dominant combinations were cross - tolerant to morphine but showed either no cross - tolerance or an augmented response to ketamine .
Diseases:"
1396	While the mutual potentiation , antagonism and tolerance suggest common mechanisms for the induced catalepsy , differences in latency , rigidity and behavior , asymmetry of cross - tolerance and a widely - different ID50 for naloxone would argue against an action at a single opioid site .	O O O O O O O O O O O O O O B O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	['rigidity', 'catalepsy']	2	7	"Sentence: While the mutual potentiation , antagonism and tolerance suggest common mechanisms for the induced catalepsy , differences in latency , rigidity and behavior , asymmetry of cross - tolerance and a widely - different ID50 for naloxone would argue against an action at a single opioid site .
Diseases: rigidity, catalepsy"	"Sentence: While the mutual potentiation , antagonism and tolerance suggest common mechanisms for the induced catalepsy , differences in latency , rigidity and behavior , asymmetry of cross - tolerance and a widely - different ID50 for naloxone would argue against an action at a single opioid site .
Diseases:"
1397	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis .	B I I O O O B O O O O O O O O B O	O O O O O O O O B O O O B O O O O	['acute renal failure', 'osteomyelitis', 'aids']	3	11	"Sentence: Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis .
Diseases: acute renal failure, osteomyelitis, aids"	"Sentence: Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis .
Diseases:"
1398	Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen .	B I O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O B I I O O O O O O O	['renal failure']	1	3	"Sentence: Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen .
Diseases: renal failure"	"Sentence: Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen .
Diseases:"
1399	Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule .	O O O O O O O O B I O B I O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O	['renal insufficiency', 'fanconi syndrome']	2	9	"Sentence: Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule .
Diseases: renal insufficiency, fanconi syndrome"	"Sentence: Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule .
Diseases:"
1400	Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent .	O B O O O O O O O O O B O O	B O O O O O O O O O O O O O	['nephrotoxicity', 'nephrotoxic']	2	9	"Sentence: Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent .
Diseases: nephrotoxicity, nephrotoxic"	"Sentence: Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent .
Diseases:"
1401	Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin .	O O O O O O O O O O O B I O O O O O O	O O O O O B O O O O O O O O O O O B O	['renal failure']	1	3	"Sentence: Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin .
Diseases: renal failure"	"Sentence: Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin .
Diseases:"
1402	Delayed leukoencephalopathy with stroke - like presentation in chemotherapy recipients .	O B O B O O O O O O O	O O O O O O O O O O O	['stroke', 'leukoencephalopathy']	2	7	"Sentence: Delayed leukoencephalopathy with stroke - like presentation in chemotherapy recipients .
Diseases: stroke, leukoencephalopathy"	"Sentence: Delayed leukoencephalopathy with stroke - like presentation in chemotherapy recipients .
Diseases:"
1403	A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy , most commonly in recipients of intrathecal methotrexate for childhood leukaemia .	O O B O B I O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O B O O O O	['leukaemia', 'leukoencephalopathy', 'cerebrovascular accident']	3	16	"Sentence: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy , most commonly in recipients of intrathecal methotrexate for childhood leukaemia .
Diseases: leukaemia, leukoencephalopathy, cerebrovascular accident"	"Sentence: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy , most commonly in recipients of intrathecal methotrexate for childhood leukaemia .
Diseases:"
1404	Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration .
Diseases: "	"Sentence: Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration .
Diseases:"
1405	METHODS : We reviewed the medical literature for single reports and case series of patients presenting with stroke - like episodes while receiving systemic or intrathecal chemotherapy .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['stroke']	1	1	"Sentence: METHODS : We reviewed the medical literature for single reports and case series of patients presenting with stroke - like episodes while receiving systemic or intrathecal chemotherapy .
Diseases: stroke"	"Sentence: METHODS : We reviewed the medical literature for single reports and case series of patients presenting with stroke - like episodes while receiving systemic or intrathecal chemotherapy .
Diseases:"
1406	We only included studies providing detailed neuroimaging data .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: We only included studies providing detailed neuroimaging data .
Diseases: "	"Sentence: We only included studies providing detailed neuroimaging data .
Diseases:"
1407	Patients with cerebrovascular accidents were excluded .	O O B I O O O	O O O O O O O	['cerebrovascular accidents']	1	6	"Sentence: Patients with cerebrovascular accidents were excluded .
Diseases: cerebrovascular accidents"	"Sentence: Patients with cerebrovascular accidents were excluded .
Diseases:"
1408	We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate ( intrathecal , systemic ) , 5 - fluorouracil and its derivative carmofur , and capecitabine .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O B I I O O O B O O B O	['leukoencephalopathy']	1	5	"Sentence: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate ( intrathecal , systemic ) , 5 - fluorouracil and its derivative carmofur , and capecitabine .
Diseases: leukoencephalopathy"	"Sentence: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate ( intrathecal , systemic ) , 5 - fluorouracil and its derivative carmofur , and capecitabine .
Diseases:"
1409	Diffusion weighted imaging ( DWI ) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum , corresponding to areas of decreased proton diffusion on apparent diffusion coefficient ( ADC ) maps ( available in 21 / 27 patients ) .	O O O O O O O O O O O O O B I I I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	['lesions within the subcortical white matter']	1	10	"Sentence: Diffusion weighted imaging ( DWI ) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum , corresponding to areas of decreased proton diffusion on apparent diffusion coefficient ( ADC ) maps ( available in 21 / 27 patients ) .
Diseases: lesions within the subcortical white matter"	"Sentence: Diffusion weighted imaging ( DWI ) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum , corresponding to areas of decreased proton diffusion on apparent diffusion coefficient ( ADC ) maps ( available in 21 / 27 patients ) .
Diseases:"
1410	Lesions exceeded the confines of adjacent vascular territories .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Lesions exceeded the confines of adjacent vascular territories .
Diseases: "	"Sentence: Lesions exceeded the confines of adjacent vascular territories .
Diseases:"
1411	Complete resolution of symptoms within 1 - 4 days was accompanied by normalisation of ADC abnormalities .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Complete resolution of symptoms within 1 - 4 days was accompanied by normalisation of ADC abnormalities .
Diseases: "	"Sentence: Complete resolution of symptoms within 1 - 4 days was accompanied by normalisation of ADC abnormalities .
Diseases:"
1412	However , fluid attenuated inversion recovery ( FLAIR ) sequences frequently revealed persistent white matter abnormalities .	O O O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O O O O	['white matter abnormalities']	1	3	"Sentence: However , fluid attenuated inversion recovery ( FLAIR ) sequences frequently revealed persistent white matter abnormalities .
Diseases: white matter abnormalities"	"Sentence: However , fluid attenuated inversion recovery ( FLAIR ) sequences frequently revealed persistent white matter abnormalities .
Diseases:"
1413	CONCLUSIONS : Several pathophysiological models of delayed leukoencephalopathy after exposure to intrathecal or systemic chemotherapy have been proposed .	O O O O O O O B O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	['leukoencephalopathy']	1	5	"Sentence: CONCLUSIONS : Several pathophysiological models of delayed leukoencephalopathy after exposure to intrathecal or systemic chemotherapy have been proposed .
Diseases: leukoencephalopathy"	"Sentence: CONCLUSIONS : Several pathophysiological models of delayed leukoencephalopathy after exposure to intrathecal or systemic chemotherapy have been proposed .
Diseases:"
1414	DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome .	O O O O O O O O B I I I I I O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cytotoxic oedema within cerebral white matter']	1	11	"Sentence: DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome .
Diseases: cytotoxic oedema within cerebral white matter"	"Sentence: DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome .
Diseases:"
1415	Down - regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local - anesthetics - induced convulsions and the counteraction by co - administration with local anesthetics .	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	O O O O B O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['convulsions']	1	3	"Sentence: Down - regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local - anesthetics - induced convulsions and the counteraction by co - administration with local anesthetics .
Diseases: convulsions"	"Sentence: Down - regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local - anesthetics - induced convulsions and the counteraction by co - administration with local anesthetics .
Diseases:"
1416	Alterations of norepinephrine transporter ( NET ) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice .	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O B O O O O O O O O	['seizures']	1	3	"Sentence: Alterations of norepinephrine transporter ( NET ) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice .
Diseases: seizures"	"Sentence: Alterations of norepinephrine transporter ( NET ) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice .
Diseases:"
1417	Daily administration of desipramine , an inhibitor of the NET , for 5 days decreased [ ( 3 ) H ] norepinephrine uptake in the P2 fractions of hippocampus but not cortex , striatum or amygdalae .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O B O O O I O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Daily administration of desipramine , an inhibitor of the NET , for 5 days decreased [ ( 3 ) H ] norepinephrine uptake in the P2 fractions of hippocampus but not cortex , striatum or amygdalae .
Diseases: "	"Sentence: Daily administration of desipramine , an inhibitor of the NET , for 5 days decreased [ ( 3 ) H ] norepinephrine uptake in the P2 fractions of hippocampus but not cortex , striatum or amygdalae .
Diseases:"
1418	Co - administration of lidocaine , bupivacaine or tricaine with desipramine reversed this effect .	O O O O O O O O O O O O O O O	O O O O B O B O B O B O O O O	[]	0	0	"Sentence: Co - administration of lidocaine , bupivacaine or tricaine with desipramine reversed this effect .
Diseases: "	"Sentence: Co - administration of lidocaine , bupivacaine or tricaine with desipramine reversed this effect .
Diseases:"
1419	Daily treatment of cocaine increased [ ( 3 ) H ] norepinephrine uptake into the hippocampus .	O O O O O O O O O O O O O O O O O	O O O B O O O O O I O B O O O O O	[]	0	0	"Sentence: Daily treatment of cocaine increased [ ( 3 ) H ] norepinephrine uptake into the hippocampus .
Diseases: "	"Sentence: Daily treatment of cocaine increased [ ( 3 ) H ] norepinephrine uptake into the hippocampus .
Diseases:"
1420	Daily administration of desipramine increased the incidence of appearance of lidocaine - induced convulsions and decreased that of cocaine - induced convulsions .	O O O O O O O O O O O O O B O O O O O O O B O	O O O B O O O O O O B O O O O O O O B O O O O	['convulsions']	1	3	"Sentence: Daily administration of desipramine increased the incidence of appearance of lidocaine - induced convulsions and decreased that of cocaine - induced convulsions .
Diseases: convulsions"	"Sentence: Daily administration of desipramine increased the incidence of appearance of lidocaine - induced convulsions and decreased that of cocaine - induced convulsions .
Diseases:"
1421	Co - administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine .	O O O O O O O O O O O B O O O O O O O O O O O O	O O O O B O B O O O O O O O B O B O O O O O B O	['convulsive']	1	2	"Sentence: Co - administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine .
Diseases: convulsive"	"Sentence: Co - administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine .
Diseases:"
1422	These results suggest that down - regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine - induced sensitization of lidocaine convulsions .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O B O O O O B O O O O B O O	['convulsions']	1	3	"Sentence: These results suggest that down - regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine - induced sensitization of lidocaine convulsions .
Diseases: convulsions"	"Sentence: These results suggest that down - regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine - induced sensitization of lidocaine convulsions .
Diseases:"
1423	Inhibition of Na ( + ) channels by local anesthetics may regulate desipramine - induced down - regulation of NET function .	O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: Inhibition of Na ( + ) channels by local anesthetics may regulate desipramine - induced down - regulation of NET function .
Diseases: "	"Sentence: Inhibition of Na ( + ) channels by local anesthetics may regulate desipramine - induced down - regulation of NET function .
Diseases:"
1424	Repeated administration of cocaine induces up - regulation of hippocampal NET function .	O O O O O O O O O O O O O	O O O B O O O O O O O O O	[]	0	0	"Sentence: Repeated administration of cocaine induces up - regulation of hippocampal NET function .
Diseases: "	"Sentence: Repeated administration of cocaine induces up - regulation of hippocampal NET function .
Diseases:"
1425	Desipramine - induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine .	O O O O O O B O O O O O O O O O O O O O O	B O O O O B O O O O O O O O O O O O O B O	['seizures']	1	3	"Sentence: Desipramine - induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine .
Diseases: seizures"	"Sentence: Desipramine - induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine .
Diseases:"
1426	Definition and management of anemia in patients infected with hepatitis C virus .	O O O O B O O B I I I I O	O O O O O O O O O O O O O	['anemia', 'infected with hepatitis c virus']	2	8	"Sentence: Definition and management of anemia in patients infected with hepatitis C virus .
Diseases: anemia, infected with hepatitis c virus"	"Sentence: Definition and management of anemia in patients infected with hepatitis C virus .
Diseases:"
1427	Chronic infection with hepatitis C virus ( HCV ) can progress to cirrhosis , hepatocellular carcinoma , and end - stage liver disease .	B I I I I I O O O O O O B O B I O O B I I I I O	O O O O O O O O O O O O O O O O O O O O O O O O	['cirrhosis', 'chronic infection with hepatitis c virus', 'hepatocellular carcinoma', 'end - stage liver disease']	4	24	"Sentence: Chronic infection with hepatitis C virus ( HCV ) can progress to cirrhosis , hepatocellular carcinoma , and end - stage liver disease .
Diseases: cirrhosis, chronic infection with hepatitis c virus, hepatocellular carcinoma, end - stage liver disease"	"Sentence: Chronic infection with hepatitis C virus ( HCV ) can progress to cirrhosis , hepatocellular carcinoma , and end - stage liver disease .
Diseases:"
1428	The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin .	O O O O O B I O O O O O O O O O	O O O O O O O O O O O B I O B O	['hcv infection']	1	3	"Sentence: The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin .
Diseases: hcv infection"	"Sentence: The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin .
Diseases:"
1429	Although this regimen produces sustained virologic responses ( SVRs ) in approximately 50 % of patients , it can be associated with a potentially dose - limiting hemolytic anemia .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hemolytic anemia']	1	5	"Sentence: Although this regimen produces sustained virologic responses ( SVRs ) in approximately 50 % of patients , it can be associated with a potentially dose - limiting hemolytic anemia .
Diseases: hemolytic anemia"	"Sentence: Although this regimen produces sustained virologic responses ( SVRs ) in approximately 50 % of patients , it can be associated with a potentially dose - limiting hemolytic anemia .
Diseases:"
1430	Hemoglobin concentrations decrease mainly as a result of ribavirin - induced hemolysis , and this anemia can be problematic in patients with HCV infection , especially those who have comorbid renal or cardiovascular disorders .	O O O O O O O O O O O B O O O B O O O O O O B I O O O O O O B I I I O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['renal or cardiovascular disorders', 'hemolysis', 'anemia', 'hcv infection']	4	16	"Sentence: Hemoglobin concentrations decrease mainly as a result of ribavirin - induced hemolysis , and this anemia can be problematic in patients with HCV infection , especially those who have comorbid renal or cardiovascular disorders .
Diseases: renal or cardiovascular disorders, hemolysis, anemia, hcv infection"	"Sentence: Hemoglobin concentrations decrease mainly as a result of ribavirin - induced hemolysis , and this anemia can be problematic in patients with HCV infection , especially those who have comorbid renal or cardiovascular disorders .
Diseases:"
1431	In general , anemia can increase the risk of morbidity and mortality , and may have negative effects on cerebral function and quality of life .	O O O B O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['anemia']	1	2	"Sentence: In general , anemia can increase the risk of morbidity and mortality , and may have negative effects on cerebral function and quality of life .
Diseases: anemia"	"Sentence: In general , anemia can increase the risk of morbidity and mortality , and may have negative effects on cerebral function and quality of life .
Diseases:"
1432	Although ribavirin - associated anemia can be reversed by dose reduction or discontinuation , this approach compromises outcomes by significantly decreasing SVR rates .	O O O O B O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O O O O O O	['anemia']	1	2	"Sentence: Although ribavirin - associated anemia can be reversed by dose reduction or discontinuation , this approach compromises outcomes by significantly decreasing SVR rates .
Diseases: anemia"	"Sentence: Although ribavirin - associated anemia can be reversed by dose reduction or discontinuation , this approach compromises outcomes by significantly decreasing SVR rates .
Diseases:"
1433	Recombinant human erythropoietin has been used to manage ribavirin - associated anemia but has other potential disadvantages .	O O O O O O O O O O O B O O O O O O	O O O O O O O O B O O O O O O O O O	['anemia']	1	2	"Sentence: Recombinant human erythropoietin has been used to manage ribavirin - associated anemia but has other potential disadvantages .
Diseases: anemia"	"Sentence: Recombinant human erythropoietin has been used to manage ribavirin - associated anemia but has other potential disadvantages .
Diseases:"
1434	Viramidine , a liver - targeting prodrug of ribavirin , has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C .	O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O B I I O	B O O O O O O O B O O O O O O O O O O B O O O O O O O O O O O O O O	['chronic hepatitis c', 'hemolytic anemia']	2	10	"Sentence: Viramidine , a liver - targeting prodrug of ribavirin , has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C .
Diseases: chronic hepatitis c, hemolytic anemia"	"Sentence: Viramidine , a liver - targeting prodrug of ribavirin , has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C .
Diseases:"
1435	Calcium carbonate toxicity : the updated milk - alkali syndrome ; report of 3 cases and review of the literature .	O O B O O O B I I I O O O O O O O O O O O	B I O O O O O O O O O O O O O O O O O O O	['milk - alkali syndrome', 'toxicity']	2	8	"Sentence: Calcium carbonate toxicity : the updated milk - alkali syndrome ; report of 3 cases and review of the literature .
Diseases: milk - alkali syndrome, toxicity"	"Sentence: Calcium carbonate toxicity : the updated milk - alkali syndrome ; report of 3 cases and review of the literature .
Diseases:"
1436	To describe 3 patients with calcium carbonate - induced hypercalcemia and gain insights into the cause and management of the milk - alkali syndrome .	O O O O O O O O O B O O O O O O O O O O B I I I O	O O O O O B I O O O O O O O O O O O O O O O O O O	['milk - alkali syndrome', 'hypercalcemia']	2	11	"Sentence: To describe 3 patients with calcium carbonate - induced hypercalcemia and gain insights into the cause and management of the milk - alkali syndrome .
Diseases: milk - alkali syndrome, hypercalcemia"	"Sentence: To describe 3 patients with calcium carbonate - induced hypercalcemia and gain insights into the cause and management of the milk - alkali syndrome .
Diseases:"
1437	We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia ( corrected serum calcium > or = 14 mg / dL ) and review the pertinent literature on milk - alkali syndrome .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O B I I I O	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['milk - alkali syndrome', 'hypercalcemia']	2	11	"Sentence: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia ( corrected serum calcium > or = 14 mg / dL ) and review the pertinent literature on milk - alkali syndrome .
Diseases: milk - alkali syndrome, hypercalcemia"	"Sentence: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia ( corrected serum calcium > or = 14 mg / dL ) and review the pertinent literature on milk - alkali syndrome .
Diseases:"
1438	The 3 patients had acute renal insufficiency , relative metabolic alkalosis , and low parathyroid hormone ( PTH ) , PTH - related peptide , and 1 , 25 - dihydroxyvitamin D concentrations .	O O O O B I I O O B I O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I I I O O	['metabolic alkalosis', 'acute renal insufficiency']	2	11	"Sentence: The 3 patients had acute renal insufficiency , relative metabolic alkalosis , and low parathyroid hormone ( PTH ) , PTH - related peptide , and 1 , 25 - dihydroxyvitamin D concentrations .
Diseases: metabolic alkalosis, acute renal insufficiency"	"Sentence: The 3 patients had acute renal insufficiency , relative metabolic alkalosis , and low parathyroid hormone ( PTH ) , PTH - related peptide , and 1 , 25 - dihydroxyvitamin D concentrations .
Diseases:"
1439	No malignant lesion was found .	O O O O O O	O O O O O O	[]	0	0	"Sentence: No malignant lesion was found .
Diseases: "	"Sentence: No malignant lesion was found .
Diseases:"
1440	Treatment included aggressive hydration and varied amounts of furosemide .	O O O O O O O O O O	O O O O O O O O B O	[]	0	0	"Sentence: Treatment included aggressive hydration and varied amounts of furosemide .
Diseases: "	"Sentence: Treatment included aggressive hydration and varied amounts of furosemide .
Diseases:"
1441	The 2 patients with the higher serum calcium concentrations received pamidronate intravenously ( 60 and 30 mg , respectively ) , which caused severe hypocalcemia .	O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O B O O B O O O O O O O O O O O O O O O	['hypocalcemia']	1	4	"Sentence: The 2 patients with the higher serum calcium concentrations received pamidronate intravenously ( 60 and 30 mg , respectively ) , which caused severe hypocalcemia .
Diseases: hypocalcemia"	"Sentence: The 2 patients with the higher serum calcium concentrations received pamidronate intravenously ( 60 and 30 mg , respectively ) , which caused severe hypocalcemia .
Diseases:"
1442	Of the 3 patients , 2 were ingesting acceptable doses of elemental calcium ( 1 g and 2 g daily , respectively ) in the form of calcium carbonate .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O O O B I O	[]	0	0	"Sentence: Of the 3 patients , 2 were ingesting acceptable doses of elemental calcium ( 1 g and 2 g daily , respectively ) in the form of calcium carbonate .
Diseases: "	"Sentence: Of the 3 patients , 2 were ingesting acceptable doses of elemental calcium ( 1 g and 2 g daily , respectively ) in the form of calcium carbonate .
Diseases:"
1443	In addition to our highlighted cases , we review the history , classification , pathophysiologic features , and treatment of milk - alkali syndrome and summarize the cases reported from early 1995 to November 2003 .	O O O O O O O O O O O O O O O O O O O O B I I I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['milk - alkali syndrome']	1	6	"Sentence: In addition to our highlighted cases , we review the history , classification , pathophysiologic features , and treatment of milk - alkali syndrome and summarize the cases reported from early 1995 to November 2003 .
Diseases: milk - alkali syndrome"	"Sentence: In addition to our highlighted cases , we review the history , classification , pathophysiologic features , and treatment of milk - alkali syndrome and summarize the cases reported from early 1995 to November 2003 .
Diseases:"
1444	CONCLUSION : Milk - alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons .	O O B I I I O O O O O O O B O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O	['milk - alkali syndrome', 'hypercalcemia']	2	11	"Sentence: CONCLUSION : Milk - alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons .
Diseases: milk - alkali syndrome, hypercalcemia"	"Sentence: CONCLUSION : Milk - alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons .
Diseases:"
1445	Treatment with hydration , furosemide , and discontinuation of the calcium and vitamin D source is adequate .	O O O O O O O O O O O O O O O O O O	O O O O B O O O O O B O B I O O O O	[]	0	0	"Sentence: Treatment with hydration , furosemide , and discontinuation of the calcium and vitamin D source is adequate .
Diseases: "	"Sentence: Treatment with hydration , furosemide , and discontinuation of the calcium and vitamin D source is adequate .
Diseases:"
1446	Pamidronate treatment is associated with considerable risk for hypocalcemia , even in cases of initially severe hypercalcemia .	O O O O O O O O B O O O O O O O B O	B O O O O O O O O O O O O O O O O O	['hypocalcemia', 'hypercalcemia']	2	9	"Sentence: Pamidronate treatment is associated with considerable risk for hypocalcemia , even in cases of initially severe hypercalcemia .
Diseases: hypocalcemia, hypercalcemia"	"Sentence: Pamidronate treatment is associated with considerable risk for hypocalcemia , even in cases of initially severe hypercalcemia .
Diseases:"
1447	Management strategies for ribavirin - induced hemolytic anemia in the treatment of hepatitis C : clinical and economic implications .	O O O O O O B I O O O O B I O O O O O O	O O O B O O O O O O O O O O O O O O O O	['hepatitis c', 'hemolytic anemia']	2	10	"Sentence: Management strategies for ribavirin - induced hemolytic anemia in the treatment of hepatitis C : clinical and economic implications .
Diseases: hepatitis c, hemolytic anemia"	"Sentence: Management strategies for ribavirin - induced hemolytic anemia in the treatment of hepatitis C : clinical and economic implications .
Diseases:"
1448	Recently published studies have demonstrated increased efficacy and cost - effectiveness of combination therapy with interferon and alpha - 2b / ribavirin compared with interferon - alpha monotherapy in the treatment of chronic hepatitis C ( CHC ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O B O O	O O O O O O O O O O O O O O O B I I I I O B O O B I I O O O O O O O O O O O O	['chc', 'chronic hepatitis c']	2	6	"Sentence: Recently published studies have demonstrated increased efficacy and cost - effectiveness of combination therapy with interferon and alpha - 2b / ribavirin compared with interferon - alpha monotherapy in the treatment of chronic hepatitis C ( CHC ) .
Diseases: chc, chronic hepatitis c"	"Sentence: Recently published studies have demonstrated increased efficacy and cost - effectiveness of combination therapy with interferon and alpha - 2b / ribavirin compared with interferon - alpha monotherapy in the treatment of chronic hepatitis C ( CHC ) .
Diseases:"
1449	Combination therapy is associated with a clinically important adverse effect : ribavirin - induced hemolytic anemia ( RIHA ) .	O O O O O O O O O O O O O O B I O B O O	O O O O O O O O O O O B O O O O O O O O	['hemolytic anemia', 'riha']	2	9	"Sentence: Combination therapy is associated with a clinically important adverse effect : ribavirin - induced hemolytic anemia ( RIHA ) .
Diseases: hemolytic anemia, riha"	"Sentence: Combination therapy is associated with a clinically important adverse effect : ribavirin - induced hemolytic anemia ( RIHA ) .
Diseases:"
1450	The objective of this study was to evaluate the direct health - care costs and management of RIHA during treatment of CHC in a clinical trial setting .	O O O O O O O O O O O O O O O O O B O O O B O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['chc', 'riha']	2	6	"Sentence: The objective of this study was to evaluate the direct health - care costs and management of RIHA during treatment of CHC in a clinical trial setting .
Diseases: chc, riha"	"Sentence: The objective of this study was to evaluate the direct health - care costs and management of RIHA during treatment of CHC in a clinical trial setting .
Diseases:"
1451	METHODS : A systematic literature review was conducted to synthesize information on the incidence and management of RIHA .	O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O	['riha']	1	2	"Sentence: METHODS : A systematic literature review was conducted to synthesize information on the incidence and management of RIHA .
Diseases: riha"	"Sentence: METHODS : A systematic literature review was conducted to synthesize information on the incidence and management of RIHA .
Diseases:"
1452	Decision - analytic techniques were used to estimate the cost of treating RIHA .	O O O O O O O O O O O O B O	O O O O O O O O O O O O O O	['riha']	1	2	"Sentence: Decision - analytic techniques were used to estimate the cost of treating RIHA .
Diseases: riha"	"Sentence: Decision - analytic techniques were used to estimate the cost of treating RIHA .
Diseases:"
1453	Uncertainty was evaluated using sensitivity analyses .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: Uncertainty was evaluated using sensitivity analyses .
Diseases: "	"Sentence: Uncertainty was evaluated using sensitivity analyses .
Diseases:"
1454	RESULTS : RIHA , defined as a reduction in hemoglobin to less than 100 g / L , occurs in approximately 7 % to 9 % of patients treated with combination therapy .	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['riha']	1	2	"Sentence: RESULTS : RIHA , defined as a reduction in hemoglobin to less than 100 g / L , occurs in approximately 7 % to 9 % of patients treated with combination therapy .
Diseases: riha"	"Sentence: RESULTS : RIHA , defined as a reduction in hemoglobin to less than 100 g / L , occurs in approximately 7 % to 9 % of patients treated with combination therapy .
Diseases:"
1455	The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage .	O O O O O O O B O O O O O O O O O	O O O O O O O O O O O O O O B O O	['riha']	1	2	"Sentence: The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage .
Diseases: riha"	"Sentence: The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage .
Diseases:"
1456	We estimated the direct cost of treating clinically significant RIHA to be 170 per patient receiving combination therapy per 48 - week treatment course ( range	O O O O O O O O O B O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['riha']	1	2	"Sentence: We estimated the direct cost of treating clinically significant RIHA to be 170 per patient receiving combination therapy per 48 - week treatment course ( range
Diseases: riha"	"Sentence: We estimated the direct cost of treating clinically significant RIHA to be 170 per patient receiving combination therapy per 48 - week treatment course ( range
Diseases:"
1457	68 - 692 ) .	O O O O O	O O O O O	[]	0	0	"Sentence: 68 - 692 ) .
Diseases: "	"Sentence: 68 - 692 ) .
Diseases:"
1458	The results of the one - way sensitivity analyses ranged from 57 to 317 .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results of the one - way sensitivity analyses ranged from 57 to 317 .
Diseases: "	"Sentence: The results of the one - way sensitivity analyses ranged from 57 to 317 .
Diseases:"
1459	In comparison , the cost of 48 weeks of combination therapy is 16 , 459 .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In comparison , the cost of 48 weeks of combination therapy is 16 , 459 .
Diseases: "	"Sentence: In comparison , the cost of 48 weeks of combination therapy is 16 , 459 .
Diseases:"
1460	The direct cost of treating clinically significant RIHA is 1 % ( 170 / 16 , 459 ) of drug treatment costs .	O O O O O O O B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['riha']	1	2	"Sentence: The direct cost of treating clinically significant RIHA is 1 % ( 170 / 16 , 459 ) of drug treatment costs .
Diseases: riha"	"Sentence: The direct cost of treating clinically significant RIHA is 1 % ( 170 / 16 , 459 ) of drug treatment costs .
Diseases:"
1461	Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real - world population .	O O O O O O O O O O O O B O O O O O O O	O O O O O O O B O O O O O O O O O O O O	['riha']	1	2	"Sentence: Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real - world population .
Diseases: riha"	"Sentence: Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real - world population .
Diseases:"
1462	Despite these uncertainties , this initial evaluation of the direct cost of treating RIHA provides an estimate of the cost and management implications of this clinically important adverse effect .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['riha']	1	2	"Sentence: Despite these uncertainties , this initial evaluation of the direct cost of treating RIHA provides an estimate of the cost and management implications of this clinically important adverse effect .
Diseases: riha"	"Sentence: Despite these uncertainties , this initial evaluation of the direct cost of treating RIHA provides an estimate of the cost and management implications of this clinically important adverse effect .
Diseases:"
1463	Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals .	O O O O O O B O O O O O O	O O B O O B O O O O O O O	['catatonia']	1	3	"Sentence: Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals .
Diseases: catatonia"	"Sentence: Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals .
Diseases:"
1464	The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine - induced catatonia in the intact , pinealectomized or hypophysectomized chick and rat .	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	O O O O O O O O O O B O O B O B O O O O O O O O O O O O O O	['catatonia']	1	3	"Sentence: The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine - induced catatonia in the intact , pinealectomized or hypophysectomized chick and rat .
Diseases: catatonia"	"Sentence: The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine - induced catatonia in the intact , pinealectomized or hypophysectomized chick and rat .
Diseases:"
1465	In the pinealectomized chick , pretreatment with dopamine increased the duration of catatonia ( DOC ) after ketamine , but pretreatment with norepinephrine did not .	O O O O O O O O O O O O B O O O O O O O O O O O O O	O O O O O O O B O O O O O O B O O B O O O O B O O O	['catatonia']	1	3	"Sentence: In the pinealectomized chick , pretreatment with dopamine increased the duration of catatonia ( DOC ) after ketamine , but pretreatment with norepinephrine did not .
Diseases: catatonia"	"Sentence: In the pinealectomized chick , pretreatment with dopamine increased the duration of catatonia ( DOC ) after ketamine , but pretreatment with norepinephrine did not .
Diseases:"
1466	The pineal indolamines exhibited mixed actions .	O O O O O O O	O O B O O O O	[]	0	0	"Sentence: The pineal indolamines exhibited mixed actions .
Diseases: "	"Sentence: The pineal indolamines exhibited mixed actions .
Diseases:"
1467	Serotonin and N - acetyl serotonin which augmented ketamine DOC , did not do so in the absence of the pineal gland , whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O B I I I O O B O O O O O O O O O O O O O O O B O O B O O O O O O O O O	[]	0	0	"Sentence: Serotonin and N - acetyl serotonin which augmented ketamine DOC , did not do so in the absence of the pineal gland , whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick .
Diseases: "	"Sentence: Serotonin and N - acetyl serotonin which augmented ketamine DOC , did not do so in the absence of the pineal gland , whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick .
Diseases:"
1468	Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent ; furthermore , melatonin did not augment the ketamine DOC whereas dopamine continued to do so .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O B O O O O B O O B O O O O O	[]	0	0	"Sentence: Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent ; furthermore , melatonin did not augment the ketamine DOC whereas dopamine continued to do so .
Diseases: "	"Sentence: Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent ; furthermore , melatonin did not augment the ketamine DOC whereas dopamine continued to do so .
Diseases:"
1469	This study did not demonstrate a species difference regarding the role of the amines on the pineal in spite of the immature blood - brain barrier in the young chick and the intact barrier in the rat .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This study did not demonstrate a species difference regarding the role of the amines on the pineal in spite of the immature blood - brain barrier in the young chick and the intact barrier in the rat .
Diseases: "	"Sentence: This study did not demonstrate a species difference regarding the role of the amines on the pineal in spite of the immature blood - brain barrier in the young chick and the intact barrier in the rat .
Diseases:"
1470	In addition , these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by melatonin .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O B O	[]	0	0	"Sentence: In addition , these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by melatonin .
Diseases: "	"Sentence: In addition , these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by melatonin .
Diseases:"
1471	Furthermore , dopamine appeared to act on systems more closely involved with the induction of ketamine catatonia rather than directly on the pituitary .	O O O O O O O O O O O O O O O O B O O O O O O O	O O B O O O O O O O O O O O O B O O O O O O O O	['catatonia']	1	3	"Sentence: Furthermore , dopamine appeared to act on systems more closely involved with the induction of ketamine catatonia rather than directly on the pituitary .
Diseases: catatonia"	"Sentence: Furthermore , dopamine appeared to act on systems more closely involved with the induction of ketamine catatonia rather than directly on the pituitary .
Diseases:"
1472	Multicenter , double - blind , multiple - dose , parallel - groups efficacy and safety trial of azelastine , chlorpheniramine , and placebo in the treatment of spring allergic rhinitis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O	['spring allergic rhinitis']	1	5	"Sentence: Multicenter , double - blind , multiple - dose , parallel - groups efficacy and safety trial of azelastine , chlorpheniramine , and placebo in the treatment of spring allergic rhinitis .
Diseases: spring allergic rhinitis"	"Sentence: Multicenter , double - blind , multiple - dose , parallel - groups efficacy and safety trial of azelastine , chlorpheniramine , and placebo in the treatment of spring allergic rhinitis .
Diseases:"
1473	Azelastine , a novel antiallergic medication , was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter , double - blind , multiple - dose , parallel - groups study .	O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O	B O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['spring allergic rhinitis']	1	5	"Sentence: Azelastine , a novel antiallergic medication , was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter , double - blind , multiple - dose , parallel - groups study .
Diseases: spring allergic rhinitis"	"Sentence: Azelastine , a novel antiallergic medication , was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter , double - blind , multiple - dose , parallel - groups study .
Diseases:"
1474	One hundred fifty - five subjects participated .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: One hundred fifty - five subjects participated .
Diseases: "	"Sentence: One hundred fifty - five subjects participated .
Diseases:"
1475	Subjects ranged in age from 18 to 60 years of age and had at least a 2 - year history of spring allergic rhinitis , confirmed by positive skin test to spring aeroallergens .	O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['spring allergic rhinitis']	1	5	"Sentence: Subjects ranged in age from 18 to 60 years of age and had at least a 2 - year history of spring allergic rhinitis , confirmed by positive skin test to spring aeroallergens .
Diseases: spring allergic rhinitis"	"Sentence: Subjects ranged in age from 18 to 60 years of age and had at least a 2 - year history of spring allergic rhinitis , confirmed by positive skin test to spring aeroallergens .
Diseases:"
1476	Medications were given four times daily ; the azelastine groups received 0 . 5 , 1 . 0 , or 2 . 0 mg in the morning and evening with placebo in the early and late afternoon ; the chlorpheniramine group received 4 . 0 mg four times daily .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: Medications were given four times daily ; the azelastine groups received 0 . 5 , 1 . 0 , or 2 . 0 mg in the morning and evening with placebo in the early and late afternoon ; the chlorpheniramine group received 4 . 0 mg four times daily .
Diseases: "	"Sentence: Medications were given four times daily ; the azelastine groups received 0 . 5 , 1 . 0 , or 2 . 0 mg in the morning and evening with placebo in the early and late afternoon ; the chlorpheniramine group received 4 . 0 mg four times daily .
Diseases:"
1477	Daily subject symptom cards were completed during a screening period to assess pretreatment symptoms and during a 4 - week treatment period while subjects received study medications .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Daily subject symptom cards were completed during a screening period to assess pretreatment symptoms and during a 4 - week treatment period while subjects received study medications .
Diseases: "	"Sentence: Daily subject symptom cards were completed during a screening period to assess pretreatment symptoms and during a 4 - week treatment period while subjects received study medications .
Diseases:"
1478	Individual symptoms , total symptoms , and major symptoms were compared to determine efficacy of medication .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Individual symptoms , total symptoms , and major symptoms were compared to determine efficacy of medication .
Diseases: "	"Sentence: Individual symptoms , total symptoms , and major symptoms were compared to determine efficacy of medication .
Diseases:"
1479	Elicited , volunteered , and observed adverse experiences were recorded for each subject and compared among groups .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Elicited , volunteered , and observed adverse experiences were recorded for each subject and compared among groups .
Diseases: "	"Sentence: Elicited , volunteered , and observed adverse experiences were recorded for each subject and compared among groups .
Diseases:"
1480	Vital signs , body weights , serum chemistry values , complete blood cell counts , urine studies , and electrocardiograms were obtained for each subject and compared among groups .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Vital signs , body weights , serum chemistry values , complete blood cell counts , urine studies , and electrocardiograms were obtained for each subject and compared among groups .
Diseases: "	"Sentence: Vital signs , body weights , serum chemistry values , complete blood cell counts , urine studies , and electrocardiograms were obtained for each subject and compared among groups .
Diseases:"
1481	Symptoms relief in the group receiving the highest concentration of azelastine ( 2 . 0 mg twice daily ) was statistically greater than in the placebo group during all weeks of the study .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Symptoms relief in the group receiving the highest concentration of azelastine ( 2 . 0 mg twice daily ) was statistically greater than in the placebo group during all weeks of the study .
Diseases: "	"Sentence: Symptoms relief in the group receiving the highest concentration of azelastine ( 2 . 0 mg twice daily ) was statistically greater than in the placebo group during all weeks of the study .
Diseases:"
1482	Lower doses of azelastine were statistically more effective than placebo only during portions of the first 3 weeks of the study .	O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Lower doses of azelastine were statistically more effective than placebo only during portions of the first 3 weeks of the study .
Diseases: "	"Sentence: Lower doses of azelastine were statistically more effective than placebo only during portions of the first 3 weeks of the study .
Diseases:"
1483	In contrast , although the chlorpheniramine group did have fewer symptoms than the placebo group during the study , the difference never reached statistical significance during any week of the study .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast , although the chlorpheniramine group did have fewer symptoms than the placebo group during the study , the difference never reached statistical significance during any week of the study .
Diseases: "	"Sentence: In contrast , although the chlorpheniramine group did have fewer symptoms than the placebo group during the study , the difference never reached statistical significance during any week of the study .
Diseases:"
1484	There were no serious side effects in any of the treatment groups .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: There were no serious side effects in any of the treatment groups .
Diseases: "	"Sentence: There were no serious side effects in any of the treatment groups .
Diseases:"
1485	Drowsiness and altered taste perception were increased significantly over placebo only in the high - dose azelastine group .	B O B I I O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O	['drowsiness', 'altered taste perception']	2	7	"Sentence: Drowsiness and altered taste perception were increased significantly over placebo only in the high - dose azelastine group .
Diseases: drowsiness, altered taste perception"	"Sentence: Drowsiness and altered taste perception were increased significantly over placebo only in the high - dose azelastine group .
Diseases:"
1486	Azelastine appears to be a safe , efficacious medication for seasonal allergic rhinitis .	O O O O O O O O O O B I I O	B O O O O O O O O O O O O O	['seasonal allergic rhinitis']	1	6	"Sentence: Azelastine appears to be a safe , efficacious medication for seasonal allergic rhinitis .
Diseases: seasonal allergic rhinitis"	"Sentence: Azelastine appears to be a safe , efficacious medication for seasonal allergic rhinitis .
Diseases:"
1487	Obsolete but dangerous antacid preparations .	O O O O O O	O O O O O O	[]	0	0	"Sentence: Obsolete but dangerous antacid preparations .
Diseases: "	"Sentence: Obsolete but dangerous antacid preparations .
Diseases:"
1488	One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon - ate - sodium bicarbonate powders for more than 20 years .	O O O O B O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B I I I O B I O O O O O O O	['nephrolithiasis', 'hypercalcaemia']	2	10	"Sentence: One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon - ate - sodium bicarbonate powders for more than 20 years .
Diseases: nephrolithiasis, hypercalcaemia"	"Sentence: One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon - ate - sodium bicarbonate powders for more than 20 years .
Diseases:"
1489	The powders had been obtained from pharmacists unknown to the patients ' medical practitioners .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The powders had been obtained from pharmacists unknown to the patients ' medical practitioners .
Diseases: "	"Sentence: The powders had been obtained from pharmacists unknown to the patients ' medical practitioners .
Diseases:"
1490	It is suggested that these preparations were responsible for the patient 's problems , and that such powders should no longer be freely obtainable .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It is suggested that these preparations were responsible for the patient 's problems , and that such powders should no longer be freely obtainable .
Diseases: "	"Sentence: It is suggested that these preparations were responsible for the patient 's problems , and that such powders should no longer be freely obtainable .
Diseases:"
1491	Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids .	O B O O O O O O O O O	O O O O O O O O O B O	['paralysis']	1	2	"Sentence: Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids .
Diseases: paralysis"	"Sentence: Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids .
Diseases:"
1492	The long - term use of nondepolarizing neuromuscular blocking agents ( ND - NMBA ) has recently been implicated as a cause of prolonged muscle weakness , although the site of the lesion and the predisposing factors have been unclear .	O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O	O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O	['muscle weakness']	1	3	"Sentence: The long - term use of nondepolarizing neuromuscular blocking agents ( ND - NMBA ) has recently been implicated as a cause of prolonged muscle weakness , although the site of the lesion and the predisposing factors have been unclear .
Diseases: muscle weakness"	"Sentence: The long - term use of nondepolarizing neuromuscular blocking agents ( ND - NMBA ) has recently been implicated as a cause of prolonged muscle weakness , although the site of the lesion and the predisposing factors have been unclear .
Diseases:"
1493	We report 3 patients ( age 37 - 52 years ) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND - NMBAs .	O O O O O O O O O O O O O B I O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B I I O	['weakness', 'respiratory insufficiency']	2	7	"Sentence: We report 3 patients ( age 37 - 52 years ) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND - NMBAs .
Diseases: weakness, respiratory insufficiency"	"Sentence: We report 3 patients ( age 37 - 52 years ) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND - NMBAs .
Diseases:"
1494	Two patients also received intravenous corticosteroids .	O O O O O O O	O O O O O B O	[]	0	0	"Sentence: Two patients also received intravenous corticosteroids .
Diseases: "	"Sentence: Two patients also received intravenous corticosteroids .
Diseases:"
1495	Renal function was normal but hepatic function	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: Renal function was normal but hepatic function
Diseases: "	"Sentence: Renal function was normal but hepatic function
Diseases:"
1496	was impaired in all patients , and all had acidosis .	O O O O O O O O O B O	O O O O O O O O O O O	['acidosis']	1	2	"Sentence: was impaired in all patients , and all had acidosis .
Diseases: acidosis"	"Sentence: was impaired in all patients , and all had acidosis .
Diseases:"
1497	Electrophysiologic studies revealed low amplitude compound motor action potentials , normal sensory studies , and fibrillations .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Electrophysiologic studies revealed low amplitude compound motor action potentials , normal sensory studies , and fibrillations .
Diseases: "	"Sentence: Electrophysiologic studies revealed low amplitude compound motor action potentials , normal sensory studies , and fibrillations .
Diseases:"
1498	Repetitive stimulation at 2 Hz showed a decremental response in 2 patients .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Repetitive stimulation at 2 Hz showed a decremental response in 2 patients .
Diseases: "	"Sentence: Repetitive stimulation at 2 Hz showed a decremental response in 2 patients .
Diseases:"
1499	The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng / mL . A muscle biopsy in this patient showed loss of thick , myosin filaments .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I I I O	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['loss of thick , myosin filaments']	1	9	"Sentence: The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng / mL . A muscle biopsy in this patient showed loss of thick , myosin filaments .
Diseases: loss of thick , myosin filaments"	"Sentence: The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng / mL . A muscle biopsy in this patient showed loss of thick , myosin filaments .
Diseases:"
1500	The weakness in these patients is due to pathology at both the neuromuscular junction ( most likely due to ND - NMBA ) and muscle ( most likely due to corticosteroids ) .	O B O O O O O O B I I I I I O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O	['pathology at both the neuromuscular junction', 'weakness']	2	12	"Sentence: The weakness in these patients is due to pathology at both the neuromuscular junction ( most likely due to ND - NMBA ) and muscle ( most likely due to corticosteroids ) .
Diseases: pathology at both the neuromuscular junction, weakness"	"Sentence: The weakness in these patients is due to pathology at both the neuromuscular junction ( most likely due to ND - NMBA ) and muscle ( most likely due to corticosteroids ) .
Diseases:"
1501	Hepatic dysfunction and acidosis are contributing risk factors .	B I O B O O O O O	O O O O O O O O O	['hepatic dysfunction', 'acidosis']	2	7	"Sentence: Hepatic dysfunction and acidosis are contributing risk factors .
Diseases: hepatic dysfunction, acidosis"	"Sentence: Hepatic dysfunction and acidosis are contributing risk factors .
Diseases:"
1502	Prostaglandin E2 - induced bladder hyperactivity in normal , conscious rats : involvement of tachykinins ?	O O O O B I O O O O O O O O O O	B I O O O O O O O O O O O O O O	['bladder hyperactivity']	1	4	"Sentence: Prostaglandin E2 - induced bladder hyperactivity in normal , conscious rats : involvement of tachykinins ?
Diseases: bladder hyperactivity"	"Sentence: Prostaglandin E2 - induced bladder hyperactivity in normal , conscious rats : involvement of tachykinins ?
Diseases:"
1503	In normal conscious rats investigated by continuous cystometry , intravesically instilled prostaglandin ( PG ) E2 facilitated micturition and increased basal intravesical pressure .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B I B I I O O O O O O O O	[]	0	0	"Sentence: In normal conscious rats investigated by continuous cystometry , intravesically instilled prostaglandin ( PG ) E2 facilitated micturition and increased basal intravesical pressure .
Diseases: "	"Sentence: In normal conscious rats investigated by continuous cystometry , intravesically instilled prostaglandin ( PG ) E2 facilitated micturition and increased basal intravesical pressure .
Diseases:"
1504	The effect was attenuated by both the NK1 receptor selective antagonist RP 67 , 580 and the NK2 receptor selective antagonist SR 48 , 968 , given intra - arterially , suggesting that it was mediated by stimulation of both NK1 and NK2 receptors .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B I I I O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The effect was attenuated by both the NK1 receptor selective antagonist RP 67 , 580 and the NK2 receptor selective antagonist SR 48 , 968 , given intra - arterially , suggesting that it was mediated by stimulation of both NK1 and NK2 receptors .
Diseases: "	"Sentence: The effect was attenuated by both the NK1 receptor selective antagonist RP 67 , 580 and the NK2 receptor selective antagonist SR 48 , 968 , given intra - arterially , suggesting that it was mediated by stimulation of both NK1 and NK2 receptors .
Diseases:"
1505	Intra - arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex , indicating that the PG had a direct contractant effect on the detrusor smooth muscle .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: Intra - arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex , indicating that the PG had a direct contractant effect on the detrusor smooth muscle .
Diseases: "	"Sentence: Intra - arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex , indicating that the PG had a direct contractant effect on the detrusor smooth muscle .
Diseases:"
1506	The effect of intra - arterial PGE2 could not be blocked by intra - arterial RP 67 , 580 or SR 48 , 968 , which opens the possibility that the micturition reflex elicited by intra - arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O B I I I O B I I I O O O O O O O O O O O O O O B O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: The effect of intra - arterial PGE2 could not be blocked by intra - arterial RP 67 , 580 or SR 48 , 968 , which opens the possibility that the micturition reflex elicited by intra - arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically .
Diseases: "	"Sentence: The effect of intra - arterial PGE2 could not be blocked by intra - arterial RP 67 , 580 or SR 48 , 968 , which opens the possibility that the micturition reflex elicited by intra - arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically .
Diseases:"
1507	The present results thus suggest that intra - arterial PGE2 , given near the bladder , may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The present results thus suggest that intra - arterial PGE2 , given near the bladder , may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor .
Diseases: "	"Sentence: The present results thus suggest that intra - arterial PGE2 , given near the bladder , may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor .
Diseases:"
1508	However , when given intravesically , PGE2 may stimulate micturition by releasing tachykinins from nerves in and / or immediately below the urothelium .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , when given intravesically , PGE2 may stimulate micturition by releasing tachykinins from nerves in and / or immediately below the urothelium .
Diseases: "	"Sentence: However , when given intravesically , PGE2 may stimulate micturition by releasing tachykinins from nerves in and / or immediately below the urothelium .
Diseases:"
1509	These tachykinins , in turn , initiate a micturition reflex by stimulating NK1 and NK2 receptors .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These tachykinins , in turn , initiate a micturition reflex by stimulating NK1 and NK2 receptors .
Diseases: "	"Sentence: These tachykinins , in turn , initiate a micturition reflex by stimulating NK1 and NK2 receptors .
Diseases:"
1510	Prostanoids may , via release of tachykinins , contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract .	O O O O O O O O O O O O O B I O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['bladder hyperactivity']	1	4	"Sentence: Prostanoids may , via release of tachykinins , contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract .
Diseases: bladder hyperactivity"	"Sentence: Prostanoids may , via release of tachykinins , contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract .
Diseases:"
1511	Thiazide diuretics , hypokalemia and cardiac arrhythmias .	O O O B O B I O	B O O O O O O O	['cardiac arrhythmias', 'hypokalemia']	2	11	"Sentence: Thiazide diuretics , hypokalemia and cardiac arrhythmias .
Diseases: cardiac arrhythmias, hypokalemia"	"Sentence: Thiazide diuretics , hypokalemia and cardiac arrhythmias .
Diseases:"
1512	Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs .	O O O O O O O O O O O O O	B O O O O O O O O O O O O	[]	0	0	"Sentence: Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs .
Diseases: "	"Sentence: Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs .
Diseases:"
1513	Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy .	B O O O O O O O O O O O	O O O O O O O O O B O O	['hypokalemia']	1	4	"Sentence: Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy .
Diseases: hypokalemia"	"Sentence: Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy .
Diseases:"
1514	We treated 38 patients ( 22 low renin , 16 normal renin ) with moderate diastolic hypertension with hydrochlorothiazide ( HCTC ) administered on a twice daily schedule .	O O O O O O O O O O O O O O O B I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O B O O O O O O O O	['diastolic hypertension']	1	4	"Sentence: We treated 38 patients ( 22 low renin , 16 normal renin ) with moderate diastolic hypertension with hydrochlorothiazide ( HCTC ) administered on a twice daily schedule .
Diseases: diastolic hypertension"	"Sentence: We treated 38 patients ( 22 low renin , 16 normal renin ) with moderate diastolic hypertension with hydrochlorothiazide ( HCTC ) administered on a twice daily schedule .
Diseases:"
1515	Initial dose was 50 mg	O O O O O	O O O O O	[]	0	0	"Sentence: Initial dose was 50 mg
Diseases: "	"Sentence: Initial dose was 50 mg
Diseases:"
1516	and the dose was increased at monthly intervals to 100 mg , 150 mg and 200 mg daily until blood pressure normalized .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: and the dose was increased at monthly intervals to 100 mg , 150 mg and 200 mg daily until blood pressure normalized .
Diseases: "	"Sentence: and the dose was increased at monthly intervals to 100 mg , 150 mg and 200 mg daily until blood pressure normalized .
Diseases:"
1517	The serum K during the control period was 4 . 5 + / - 0 . 2 mEq / l an on 50 , 100 , 150 and 200 mg HCTZ daily 3 . 9 + / - 0 . 3 , 3 . 4 + / - 0 . 2 , 2 . 9 + / - 0 . 2 , and 2 . 4 + / - 0 . 3 mEq / l , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The serum K during the control period was 4 . 5 + / - 0 . 2 mEq / l an on 50 , 100 , 150 and 200 mg HCTZ daily 3 . 9 + / - 0 . 3 , 3 . 4 + / - 0 . 2 , 2 . 9 + / - 0 . 2 , and 2 . 4 + / - 0 . 3 mEq / l , respectively .
Diseases: "	"Sentence: The serum K during the control period was 4 . 5 + / - 0 . 2 mEq / l an on 50 , 100 , 150 and 200 mg HCTZ daily 3 . 9 + / - 0 . 3 , 3 . 4 + / - 0 . 2 , 2 . 9 + / - 0 . 2 , and 2 . 4 + / - 0 . 3 mEq / l , respectively .
Diseases:"
1518	Corresponding figures for whole body K were 4107 + / - 208 , 3722 + / - 319 , 3628 + / - 257 , 3551 + / - 336 , and 3269 + / - 380 mEq , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Corresponding figures for whole body K were 4107 + / - 208 , 3722 + / - 319 , 3628 + / - 257 , 3551 + / - 336 , and 3269 + / - 380 mEq , respectively .
Diseases: "	"Sentence: Corresponding figures for whole body K were 4107 + / - 208 , 3722 + / - 319 , 3628 + / - 257 , 3551 + / - 336 , and 3269 + / - 380 mEq , respectively .
Diseases:"
1519	In 13 patients we observed the effects of HCTZ therapy ( 100 mg daily ) on the occurrence of PVC 's during rest as well as during static and dynamic exercise .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In 13 patients we observed the effects of HCTZ therapy ( 100 mg daily ) on the occurrence of PVC 's during rest as well as during static and dynamic exercise .
Diseases: "	"Sentence: In 13 patients we observed the effects of HCTZ therapy ( 100 mg daily ) on the occurrence of PVC 's during rest as well as during static and dynamic exercise .
Diseases:"
1520	During rest we observed 0 . 6 + / - 0 . 08 PVC beats / min + / -	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: During rest we observed 0 . 6 + / - 0 . 08 PVC beats / min + / -
Diseases: "	"Sentence: During rest we observed 0 . 6 + / - 0 . 08 PVC beats / min + / -
Diseases:"
1521	SEM and during static and dynamic exercise 0 . 6 + / - 0 . 06 and 0 . 8 + / - 0 . 15 , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: SEM and during static and dynamic exercise 0 . 6 + / - 0 . 06 and 0 . 8 + / - 0 . 15 , respectively .
Diseases: "	"Sentence: SEM and during static and dynamic exercise 0 . 6 + / - 0 . 06 and 0 . 8 + / - 0 . 15 , respectively .
Diseases:"
1522	Corresponding figures during HCTZ therapy 100 mg daily were 1 . 4 + / - 0 . 1 , 3 . 6 + / - 0 . 7 and 5 . 7 4 / - 0 . 8 , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Corresponding figures during HCTZ therapy 100 mg daily were 1 . 4 + / - 0 . 1 , 3 . 6 + / - 0 . 7 and 5 . 7 4 / - 0 . 8 , respectively .
Diseases: "	"Sentence: Corresponding figures during HCTZ therapy 100 mg daily were 1 . 4 + / - 0 . 1 , 3 . 6 + / - 0 . 7 and 5 . 7 4 / - 0 . 8 , respectively .
Diseases:"
1523	The occurrence of PVC 's correlated significantly with the fall in serum K + observed r = 0 . 72 , p less than 0 . 001 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The occurrence of PVC 's correlated significantly with the fall in serum K + observed r = 0 . 72 , p less than 0 . 001 .
Diseases: "	"Sentence: The occurrence of PVC 's correlated significantly with the fall in serum K + observed r = 0 . 72 , p less than 0 . 001 .
Diseases:"
1524	In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium .	O O O O O O O O B O O O O O O	O O O O O B O O O O O O O B O	['hypokalemia']	1	4	"Sentence: In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium .
Diseases: hypokalemia"	"Sentence: In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium .
Diseases:"
1525	The more profound hypokalemia , the greater the propensity for the occurrence of PVC 's .	O O O B O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	['hypokalemia']	1	4	"Sentence: The more profound hypokalemia , the greater the propensity for the occurrence of PVC 's .
Diseases: hypokalemia"	"Sentence: The more profound hypokalemia , the greater the propensity for the occurrence of PVC 's .
Diseases:"
1526	Diuretics , potassium and arrhythmias in hypertensive coronary disease .	O O O O B O B B I O	O O B O O O O O O O	['arrhythmias', 'hypertensive', 'coronary disease']	3	10	"Sentence: Diuretics , potassium and arrhythmias in hypertensive coronary disease .
Diseases: arrhythmias, hypertensive, coronary disease"	"Sentence: Diuretics , potassium and arrhythmias in hypertensive coronary disease .
Diseases:"
1527	It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias .	O O O O O O O O O O O O O O O B I O	O O O O O O O O O B O O O O O O O O	['cardiac arrhythmias']	1	6	"Sentence: It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias .
Diseases: cardiac arrhythmias"	"Sentence: It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias .
Diseases:"
1528	If this were so , patients with coronary artery disease might be especially susceptible .	O O O O O O O B I I O O O O O	O O O O O O O O O O O O O O O	['coronary artery disease']	1	5	"Sentence: If this were so , patients with coronary artery disease might be especially susceptible .
Diseases: coronary artery disease"	"Sentence: If this were so , patients with coronary artery disease might be especially susceptible .
Diseases:"
1529	Thus , myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium - conserving diuretic ( amiloride ) and a similar period on a potassium - losing diuretic ( chlorthalidone ) in a randomised study .	O O O O O O O O O O O O B O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O B O O O O O O O B O O O O B O O O O O O	['coronary artery disease', 'hypertension']	2	7	"Sentence: Thus , myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium - conserving diuretic ( amiloride ) and a similar period on a potassium - losing diuretic ( chlorthalidone ) in a randomised study .
Diseases: coronary artery disease, hypertension"	"Sentence: Thus , myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium - conserving diuretic ( amiloride ) and a similar period on a potassium - losing diuretic ( chlorthalidone ) in a randomised study .
Diseases:"
1530	Plasma potassium concentrations were on average 1 mmol /	O O O O O O O O O	O B O O O O O O O	[]	0	0	"Sentence: Plasma potassium concentrations were on average 1 mmol /
Diseases: "	"Sentence: Plasma potassium concentrations were on average 1 mmol /
Diseases:"
1531	L lower during the chlorthalidone phase compared to amiloride therapy .	O O O O O O O O O O O	O O O O B O O O B O O	[]	0	0	"Sentence: L lower during the chlorthalidone phase compared to amiloride therapy .
Diseases: "	"Sentence: L lower during the chlorthalidone phase compared to amiloride therapy .
Diseases:"
1532	Blood pressure and volume states as assessed by bodyweight , plasma renin and noradrenaline ( norepinephrine ) concentrations were similar on the 2 regimens .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O B O O O O O O O O O	[]	0	0	"Sentence: Blood pressure and volume states as assessed by bodyweight , plasma renin and noradrenaline ( norepinephrine ) concentrations were similar on the 2 regimens .
Diseases: "	"Sentence: Blood pressure and volume states as assessed by bodyweight , plasma renin and noradrenaline ( norepinephrine ) concentrations were similar on the 2 regimens .
Diseases:"
1533	Compared to amiloride treatment , the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats ( 24 - hour Holter monitoring ) and a higher Lown grading , increased upslope and duration of the monophasic action potential , prolonged ventricular effective refractory period , and increased electrical instability during programmed ventricular stimulation .	O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ventricular ectopic beats']	1	5	"Sentence: Compared to amiloride treatment , the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats ( 24 - hour Holter monitoring ) and a higher Lown grading , increased upslope and duration of the monophasic action potential , prolonged ventricular effective refractory period , and increased electrical instability during programmed ventricular stimulation .
Diseases: ventricular ectopic beats"	"Sentence: Compared to amiloride treatment , the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats ( 24 - hour Holter monitoring ) and a higher Lown grading , increased upslope and duration of the monophasic action potential , prolonged ventricular effective refractory period , and increased electrical instability during programmed ventricular stimulation .
Diseases:"
1534	The above results indicate that because potassium - losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease , even minor falls in plasma potassium concentrations are probably best avoided in such patients .	O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	['ischaemic heart disease']	1	5	"Sentence: The above results indicate that because potassium - losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease , even minor falls in plasma potassium concentrations are probably best avoided in such patients .
Diseases: ischaemic heart disease"	"Sentence: The above results indicate that because potassium - losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease , even minor falls in plasma potassium concentrations are probably best avoided in such patients .
Diseases:"
1535	GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental .	O O O O O O O B I O O O O	B O O B O O O O O O O B O	['respiratory paralysis']	1	4	"Sentence: GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental .
Diseases: respiratory paralysis"	"Sentence: GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental .
Diseases:"
1536	No agent is yet available to reverse respiratory paralysis produced by CNS depressants , such as general anesthetics .	O O O O O O O B I O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	['respiratory paralysis']	1	4	"Sentence: No agent is yet available to reverse respiratory paralysis produced by CNS depressants , such as general anesthetics .
Diseases: respiratory paralysis"	"Sentence: No agent is yet available to reverse respiratory paralysis produced by CNS depressants , such as general anesthetics .
Diseases:"
1537	In this study naloxone reversed respiratory paralysis induced by thiopental in rats .	O O O O O B I O O O O O O	O O O B O O O O O B O O O	['respiratory paralysis']	1	4	"Sentence: In this study naloxone reversed respiratory paralysis induced by thiopental in rats .
Diseases: respiratory paralysis"	"Sentence: In this study naloxone reversed respiratory paralysis induced by thiopental in rats .
Diseases:"
1538	25 mg / kg , i . v .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: 25 mg / kg , i . v .
Diseases: "	"Sentence: 25 mg / kg , i . v .
Diseases:"
1539	thiopental produced anesthesia without altering respiratory rate , increased GABA , decreased glutamate , and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O B O O B O O O O O O B O B O O O O O O O O O O O	[]	0	0	"Sentence: thiopental produced anesthesia without altering respiratory rate , increased GABA , decreased glutamate , and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem .
Diseases: "	"Sentence: thiopental produced anesthesia without altering respiratory rate , increased GABA , decreased glutamate , and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem .
Diseases:"
1540	Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental .	O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental .
Diseases: "	"Sentence: Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental .
Diseases:"
1541	50 mg / kg , i . v .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: 50 mg / kg , i . v .
Diseases: "	"Sentence: 50 mg / kg , i . v .
Diseases:"
1542	thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain .	O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O B O O O B O O O O O O O O O O O B I O O O O O O O O	['respiratory arrest']	1	4	"Sentence: thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain .
Diseases: respiratory arrest"	"Sentence: thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain .
Diseases:"
1543	Naloxone ( 2 . 5 mg / kg , i . v . ) reversed respiratory paralysis , glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum .	O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O	['respiratory paralysis']	1	4	"Sentence: Naloxone ( 2 . 5 mg / kg , i . v . ) reversed respiratory paralysis , glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum .
Diseases: respiratory paralysis"	"Sentence: Naloxone ( 2 . 5 mg / kg , i . v . ) reversed respiratory paralysis , glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum .
Diseases:"
1544	These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action .	O O O O O B I O O O O O O O O O O	O O O B O O O O O B O O B O O O O	['respiratory paralysis']	1	4	"Sentence: These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action .
Diseases: respiratory paralysis"	"Sentence: These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action .
Diseases:"
1545	National project on the prevention of mother - to - infant infection by hepatitis B virus in Japan .	O O O O O O O O O O O B I I I I O O O	O O O O O O O O O O O O O O O O O O O	['infection by hepatitis b virus']	1	6	"Sentence: National project on the prevention of mother - to - infant infection by hepatitis B virus in Japan .
Diseases: infection by hepatitis b virus"	"Sentence: National project on the prevention of mother - to - infant infection by hepatitis B virus in Japan .
Diseases:"
1546	In Japan , a nationwide prevention program against mother - to - infant infection by hepatitis B virus ( HBV ) started in 1985 .	O O O O O O O O O O O O O B I I I I O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['infection by hepatitis b virus']	1	6	"Sentence: In Japan , a nationwide prevention program against mother - to - infant infection by hepatitis B virus ( HBV ) started in 1985 .
Diseases: infection by hepatitis b virus"	"Sentence: In Japan , a nationwide prevention program against mother - to - infant infection by hepatitis B virus ( HBV ) started in 1985 .
Diseases:"
1547	This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen ( HBsAg ) and hepatitis B e antigen ( HBeAg ) positive mothers .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B I I I O B O O B I I I O B O O O O	[]	0	0	"Sentence: This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen ( HBsAg ) and hepatitis B e antigen ( HBeAg ) positive mothers .
Diseases: "	"Sentence: This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen ( HBsAg ) and hepatitis B e antigen ( HBeAg ) positive mothers .
Diseases:"
1548	These infants are treated with two injections of hepatitis B immune globulin ( HBIG ) and at least three injections of plasma derived hepatitis B vaccine .	O O O O O O O O B I O O O O O O O O O O O O O O O O O	O O O O O O O O O O O I O B O O O O O O O O O O O O O	['hepatitis b']	1	4	"Sentence: These infants are treated with two injections of hepatitis B immune globulin ( HBIG ) and at least three injections of plasma derived hepatitis B vaccine .
Diseases: hepatitis b"	"Sentence: These infants are treated with two injections of hepatitis B immune globulin ( HBIG ) and at least three injections of plasma derived hepatitis B vaccine .
Diseases:"
1549	We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987 .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987 .
Diseases: "	"Sentence: We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987 .
Diseases:"
1550	93 . 4 % pregnant women had the chance to be examined for HBsAg , and the positive rate was 1 . 4 to 1 . 5 % .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 93 . 4 % pregnant women had the chance to be examined for HBsAg , and the positive rate was 1 . 4 to 1 . 5 % .
Diseases: "	"Sentence: 93 . 4 % pregnant women had the chance to be examined for HBsAg , and the positive rate was 1 . 4 to 1 . 5 % .
Diseases:"
1551	The HBeAg positive rate in HBsAg positive was 23 to 26 % .	O O O O O O O O O O O O O	O B O O O B O O O O O O O	[]	0	0	"Sentence: The HBeAg positive rate in HBsAg positive was 23 to 26 % .
Diseases: "	"Sentence: The HBeAg positive rate in HBsAg positive was 23 to 26 % .
Diseases:"
1552	The HBsAg positive rate in neonates and in infants before two months were 3 % and 2 % respectively .	O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The HBsAg positive rate in neonates and in infants before two months were 3 % and 2 % respectively .
Diseases: "	"Sentence: The HBsAg positive rate in neonates and in infants before two months were 3 % and 2 % respectively .
Diseases:"
1553	Some problems may arise , because 27 to 30 % of infants need the fourth vaccination in some restricted areas .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Some problems may arise , because 27 to 30 % of infants need the fourth vaccination in some restricted areas .
Diseases: "	"Sentence: Some problems may arise , because 27 to 30 % of infants need the fourth vaccination in some restricted areas .
Diseases:"
1554	Nociceptive effects induced by intrathecal administration of prostaglandin D2 , E2 , or F2 alpha to conscious mice .	O O O O O O O O O O O O O O O O O O O	O O O O O O O B I O I O O I I O O O O	[]	0	0	"Sentence: Nociceptive effects induced by intrathecal administration of prostaglandin D2 , E2 , or F2 alpha to conscious mice .
Diseases: "	"Sentence: Nociceptive effects induced by intrathecal administration of prostaglandin D2 , E2 , or F2 alpha to conscious mice .
Diseases:"
1555	The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests .	O O O O O O O O B O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O B I O O O	['pain']	1	1	"Sentence: The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests .
Diseases: pain"	"Sentence: The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests .
Diseases:"
1556	Prostaglandin D2 ( 0 . 5 - 3 ng / mouse ) had a hyperalgesic action on the response to a hot plate during a 3 - 60 min period after injection .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hyperalgesic']	1	4	"Sentence: Prostaglandin D2 ( 0 . 5 - 3 ng / mouse ) had a hyperalgesic action on the response to a hot plate during a 3 - 60 min period after injection .
Diseases: hyperalgesic"	"Sentence: Prostaglandin D2 ( 0 . 5 - 3 ng / mouse ) had a hyperalgesic action on the response to a hot plate during a 3 - 60 min period after injection .
Diseases:"
1557	Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng / mouse , but the effect lasted shorter ( 3 - 30 min ) than that of prostaglandin D2 .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['hyperalgesic']	1	4	"Sentence: Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng / mouse , but the effect lasted shorter ( 3 - 30 min ) than that of prostaglandin D2 .
Diseases: hyperalgesic"	"Sentence: Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng / mouse , but the effect lasted shorter ( 3 - 30 min ) than that of prostaglandin D2 .
Diseases:"
1558	Similar results were obtained by acetic acid writhing tests .	O O O O O O O O O O	O O O O O B I O O O	[]	0	0	"Sentence: Similar results were obtained by acetic acid writhing tests .
Diseases: "	"Sentence: Similar results were obtained by acetic acid writhing tests .
Diseases:"
1559	The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist ( greater than or equal to 100 ng ) but not by AH6809 , a prostanoid EP1 - receptor antagonist .	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B I O O O O O O O B I O O O O O O O O O O O O O B O O O O O O O O	['hyperalgesic']	1	4	"Sentence: The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist ( greater than or equal to 100 ng ) but not by AH6809 , a prostanoid EP1 - receptor antagonist .
Diseases: hyperalgesic"	"Sentence: The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist ( greater than or equal to 100 ng ) but not by AH6809 , a prostanoid EP1 - receptor antagonist .
Diseases:"
1560	Conversely , prostaglandin E2 - induced hyperalgesia was blocked by AH6809 ( greater than or equal to 500 ng ) but not by the substance P antagonist .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O	O O B I O O O O O O B O O O O O O O O O O O O O O I O O	['hyperalgesia']	1	4	"Sentence: Conversely , prostaglandin E2 - induced hyperalgesia was blocked by AH6809 ( greater than or equal to 500 ng ) but not by the substance P antagonist .
Diseases: hyperalgesia"	"Sentence: Conversely , prostaglandin E2 - induced hyperalgesia was blocked by AH6809 ( greater than or equal to 500 ng ) but not by the substance P antagonist .
Diseases:"
1561	Prostaglandin F2 alpha had little effect on pain responses .	O O O O O O O B O O	B I I O O O O O O O	['pain']	1	1	"Sentence: Prostaglandin F2 alpha had little effect on pain responses .
Diseases: pain"	"Sentence: Prostaglandin F2 alpha had little effect on pain responses .
Diseases:"
1562	These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord , but in different ways .	O O O O O O O O O O O B O O O O O O O O O O	O O O O O B I O B I O O O O O O O O O O O O	['hyperalgesia']	1	4	"Sentence: These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord , but in different ways .
Diseases: hyperalgesia"	"Sentence: These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord , but in different ways .
Diseases:"
1563	Swallowing - induced atrial tachyarrhythmia triggered by salbutamol : case report and review of the literature .	O O O B I O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O	['atrial tachyarrhythmia']	1	8	"Sentence: Swallowing - induced atrial tachyarrhythmia triggered by salbutamol : case report and review of the literature .
Diseases: atrial tachyarrhythmia"	"Sentence: Swallowing - induced atrial tachyarrhythmia triggered by salbutamol : case report and review of the literature .
Diseases:"
1564	CASE : A 49 - year - old patient experienced chest discomfort while swallowing .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CASE : A 49 - year - old patient experienced chest discomfort while swallowing .
Diseases: "	"Sentence: CASE : A 49 - year - old patient experienced chest discomfort while swallowing .
Diseases:"
1565	On electrocardiogram , episodes of atrial tachyarrhythmia were recorded immediately after swallowing ; 24 - hour Holter monitoring recorded several events .	O O O O O B I O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	['atrial tachyarrhythmia']	1	8	"Sentence: On electrocardiogram , episodes of atrial tachyarrhythmia were recorded immediately after swallowing ; 24 - hour Holter monitoring recorded several events .
Diseases: atrial tachyarrhythmia"	"Sentence: On electrocardiogram , episodes of atrial tachyarrhythmia were recorded immediately after swallowing ; 24 - hour Holter monitoring recorded several events .
Diseases:"
1566	The arrhythmia resolved after therapy with atenolol , but recurred a year later .	O B O O O O O O O O O O O O	O O O O O O B O O O O O O O	['arrhythmia']	1	4	"Sentence: The arrhythmia resolved after therapy with atenolol , but recurred a year later .
Diseases: arrhythmia"	"Sentence: The arrhythmia resolved after therapy with atenolol , but recurred a year later .
Diseases:"
1567	The patient noticed that before these episodes he had been using an inhalator of salbutamol .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: The patient noticed that before these episodes he had been using an inhalator of salbutamol .
Diseases: "	"Sentence: The patient noticed that before these episodes he had been using an inhalator of salbutamol .
Diseases:"
1568	After stopping the beta - agonist , and after a week with the atenolol , the arrhythmia disappeared .	O O O O O O O O O O O O O O O O B O O	O O O O O O O O O O O O O B O O O O O	['arrhythmia']	1	4	"Sentence: After stopping the beta - agonist , and after a week with the atenolol , the arrhythmia disappeared .
Diseases: arrhythmia"	"Sentence: After stopping the beta - agonist , and after a week with the atenolol , the arrhythmia disappeared .
Diseases:"
1569	Swallowing - induced atrial tachyarrhythmia ( SIAT ) is a rare phenomenon .	O O O B I O B O O O O O O	O O O O O O O O O O O O O	['siat', 'atrial tachyarrhythmia']	2	11	"Sentence: Swallowing - induced atrial tachyarrhythmia ( SIAT ) is a rare phenomenon .
Diseases: siat, atrial tachyarrhythmia"	"Sentence: Swallowing - induced atrial tachyarrhythmia ( SIAT ) is a rare phenomenon .
Diseases:"
1570	Fewer than 50 cases of SIAT have been described in the literature .	O O O O O B O O O O O O O	O O O O O O O O O O O O O	['siat']	1	2	"Sentence: Fewer than 50 cases of SIAT have been described in the literature .
Diseases: siat"	"Sentence: Fewer than 50 cases of SIAT have been described in the literature .
Diseases:"
1571	This article summarizes all the cases published , creating a comprehensive review of the current knowledge and approach to SIAT .	O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O	['siat']	1	2	"Sentence: This article summarizes all the cases published , creating a comprehensive review of the current knowledge and approach to SIAT .
Diseases: siat"	"Sentence: This article summarizes all the cases published , creating a comprehensive review of the current knowledge and approach to SIAT .
Diseases:"
1572	It discusses demographics , clinical characteristics and types of arrhythmia , postulated mechanisms of SIAT , and different treatment possibilities such as medications , surgery , and radiofrequency catheter ablation ( RFCA ) .	O O O O O O O O O B O O O O B O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['siat', 'arrhythmia']	2	7	"Sentence: It discusses demographics , clinical characteristics and types of arrhythmia , postulated mechanisms of SIAT , and different treatment possibilities such as medications , surgery , and radiofrequency catheter ablation ( RFCA ) .
Diseases: siat, arrhythmia"	"Sentence: It discusses demographics , clinical characteristics and types of arrhythmia , postulated mechanisms of SIAT , and different treatment possibilities such as medications , surgery , and radiofrequency catheter ablation ( RFCA ) .
Diseases:"
1573	Salbutamol is presented here as a possible trigger for SIAT .	O O O O O O O O O B O	B O O O O O O O O O O	['siat']	1	2	"Sentence: Salbutamol is presented here as a possible trigger for SIAT .
Diseases: siat"	"Sentence: Salbutamol is presented here as a possible trigger for SIAT .
Diseases:"
1574	Although it is difficult to define causality in a case report , it is logical to think that a beta - agonist like salbutamol ( known to induce tachycardia ) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta - blocker such as atenolol ( that blocks the adrenergic activity ) may relieve it .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	['tachycardia']	1	4	"Sentence: Although it is difficult to define causality in a case report , it is logical to think that a beta - agonist like salbutamol ( known to induce tachycardia ) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta - blocker such as atenolol ( that blocks the adrenergic activity ) may relieve it .
Diseases: tachycardia"	"Sentence: Although it is difficult to define causality in a case report , it is logical to think that a beta - agonist like salbutamol ( known to induce tachycardia ) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta - blocker such as atenolol ( that blocks the adrenergic activity ) may relieve it .
Diseases:"
1575	Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice .	O O O O O O B O O O	B I O O O B O O O O	['nephrotoxicity']	1	4	"Sentence: Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice .
Diseases: nephrotoxicity"	"Sentence: Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice .
Diseases:"
1576	The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i . p . injection of cisplatin ( 5 mg / kg ) .	O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O	O O O O B I O O O O O O O O O O O O O O O O O O B O O O O O O O	['acute renal injury']	1	4	"Sentence: The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i . p . injection of cisplatin ( 5 mg / kg ) .
Diseases: acute renal injury"	"Sentence: The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i . p . injection of cisplatin ( 5 mg / kg ) .
Diseases:"
1577	Coenzyme Q10 treatment ( 10 mg / kg / day , i . p . ) was applied for 6 consecutive days , starting 1 day before cisplatin administration .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B I O O O O O O O O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Coenzyme Q10 treatment ( 10 mg / kg / day , i . p . ) was applied for 6 consecutive days , starting 1 day before cisplatin administration .
Diseases: "	"Sentence: Coenzyme Q10 treatment ( 10 mg / kg / day , i . p . ) was applied for 6 consecutive days , starting 1 day before cisplatin administration .
Diseases:"
1578	Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin .	O O O O O O O O O O O O O O O O O	B I O O O B I O O B O O O O O B O	[]	0	0	"Sentence: Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin .
Diseases: "	"Sentence: Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin .
Diseases:"
1579	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of tumor necrosis factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B I O O O O O O O O O O B O O B O O O O O O O O O O O O O O O O O O B I O B O O O O O O O O B O B O O O O O O B O O	['tumor', 'necrosis']	2	6	"Sentence: Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of tumor necrosis factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .
Diseases: tumor, necrosis"	"Sentence: Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of tumor necrosis factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .
Diseases:"
1580	Also , histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment .	O O O B I I O O O O O O O O O O	O O O O O O O O B O O O B I O O	['renal tissue damage']	1	4	"Sentence: Also , histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment .
Diseases: renal tissue damage"	"Sentence: Also , histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment .
Diseases:"
1581	Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin - induced overexpression of inducible nitric oxide synthase , nuclear factor - kappaB , caspase - 3 and p53 in renal tissue .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B I O O O B O O O O O B I O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin - induced overexpression of inducible nitric oxide synthase , nuclear factor - kappaB , caspase - 3 and p53 in renal tissue .
Diseases: "	"Sentence: Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin - induced overexpression of inducible nitric oxide synthase , nuclear factor - kappaB , caspase - 3 and p53 in renal tissue .
Diseases:"
1582	It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice .	O O O O O O O O O O O O O O O O B O O O O O O	O O O O B I O O O O O O O O O B O O O O O O O	['nephrotoxicity']	1	4	"Sentence: It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice .
Diseases: nephrotoxicity"	"Sentence: It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice .
Diseases:"
1583	Metformin prevents experimental gentamicin - induced nephropathy by a mitochondria - dependent pathway .	O O O O O O B O O O O O O O	B O O B O O O O O O O O O O	['nephropathy']	1	4	"Sentence: Metformin prevents experimental gentamicin - induced nephropathy by a mitochondria - dependent pathway .
Diseases: nephropathy"	"Sentence: Metformin prevents experimental gentamicin - induced nephropathy by a mitochondria - dependent pathway .
Diseases:"
1584	The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients .	O O O O O O O O O O O O O O O O B I O O O O O	O O O B O O O O O O O O O O O O O O O O O O O	['vascular dysfunction']	1	3	"Sentence: The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients .
Diseases: vascular dysfunction"	"Sentence: The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients .
Diseases:"
1585	Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity .	O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O B O O	['toxicity']	1	2	"Sentence: Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity .
Diseases: toxicity"	"Sentence: Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity .
Diseases:"
1586	Mitochondrial analysis , respiration intensity , levels of reactive oxygen species , permeability transition , and cytochrome c release were assessed 3 and 6 days after gentamicin administration .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Mitochondrial analysis , respiration intensity , levels of reactive oxygen species , permeability transition , and cytochrome c release were assessed 3 and 6 days after gentamicin administration .
Diseases: "	"Sentence: Mitochondrial analysis , respiration intensity , levels of reactive oxygen species , permeability transition , and cytochrome c release were assessed 3 and 6 days after gentamicin administration .
Diseases:"
1587	Metformin treatment fully blocked gentamicin - mediated acute renal failure .	O O O O O O O B I I O	B O O O B O O O O O O	['acute renal failure']	1	4	"Sentence: Metformin treatment fully blocked gentamicin - mediated acute renal failure .
Diseases: acute renal failure"	"Sentence: Metformin treatment fully blocked gentamicin - mediated acute renal failure .
Diseases:"
1588	This was accompanied by a lower activity of N - acetyl - beta - D - glucosaminidase , together with a decrease of lipid peroxidation and increase of antioxidant systems .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B I I I I I I I O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This was accompanied by a lower activity of N - acetyl - beta - D - glucosaminidase , together with a decrease of lipid peroxidation and increase of antioxidant systems .
Diseases: "	"Sentence: This was accompanied by a lower activity of N - acetyl - beta - D - glucosaminidase , together with a decrease of lipid peroxidation and increase of antioxidant systems .
Diseases:"
1589	Metformin also protected the kidney from histological damage 6 days after gentamicin administration .	O O O O O O O O O O O O O O	B O O O O O O O O O O B O O	[]	0	0	"Sentence: Metformin also protected the kidney from histological damage 6 days after gentamicin administration .
Diseases: "	"Sentence: Metformin also protected the kidney from histological damage 6 days after gentamicin administration .
Diseases:"
1590	These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function .	O O O O O B I O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O	['kidney dysfunction']	1	3	"Sentence: These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function .
Diseases: kidney dysfunction"	"Sentence: These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function .
Diseases:"
1591	We found that gentamicin treatment depleted respiratory components ( cytochrome c , NADH ) , probably due to the opening of mitochondrial transition pores .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: We found that gentamicin treatment depleted respiratory components ( cytochrome c , NADH ) , probably due to the opening of mitochondrial transition pores .
Diseases: "	"Sentence: We found that gentamicin treatment depleted respiratory components ( cytochrome c , NADH ) , probably due to the opening of mitochondrial transition pores .
Diseases:"
1592	These injuries , partly mediated by a rise in reactive oxygen species from the electron transfer chain , were significantly decreased by metformin .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O B O	[]	0	0	"Sentence: These injuries , partly mediated by a rise in reactive oxygen species from the electron transfer chain , were significantly decreased by metformin .
Diseases: "	"Sentence: These injuries , partly mediated by a rise in reactive oxygen species from the electron transfer chain , were significantly decreased by metformin .
Diseases:"
1593	Thus , our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis .	O O O O O O O O O O O O O B O O O O O	O O O O O O O O O B O O B O O O O O O	['nephrotoxicity']	1	4	"Sentence: Thus , our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis .
Diseases: nephrotoxicity"	"Sentence: Thus , our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis .
Diseases:"
1594	Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair .	O O O O O O O O O B I O O O O B I O O	O O O O O O O O O O O O O O O O O O O	['hip fracture', 'postoperative delirium']	2	8	"Sentence: Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair .
Diseases: hip fracture, postoperative delirium"	"Sentence: Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair .
Diseases:"
1595	To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium .	O O O O O O O O O O O B I O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O	['postoperative delirium', 'hip fracture']	2	8	"Sentence: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium .
Diseases: postoperative delirium, hip fracture"	"Sentence: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium .
Diseases:"
1596	PATIENTS AND METHODS : We performed a double - blind , randomized controlled trial at an academic medical center of elderly patients ( > or = 65 years ) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O B O O B I O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['delirium', 'dementia', 'hip fracture']	3	8	"Sentence: PATIENTS AND METHODS : We performed a double - blind , randomized controlled trial at an academic medical center of elderly patients ( > or = 65 years ) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation .
Diseases: delirium, dementia, hip fracture"	"Sentence: PATIENTS AND METHODS : We performed a double - blind , randomized controlled trial at an academic medical center of elderly patients ( > or = 65 years ) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation .
Diseases:"
1597	Sedation depth was titrated using processed electroencephalography with the bispectral index ( BIS ) , and patients were randomized to receive either deep ( BIS , approximately 50 ) or light ( BIS , > or = 80 ) sedation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Sedation depth was titrated using processed electroencephalography with the bispectral index ( BIS ) , and patients were randomized to receive either deep ( BIS , approximately 50 ) or light ( BIS , > or = 80 ) sedation .
Diseases: "	"Sentence: Sedation depth was titrated using processed electroencephalography with the bispectral index ( BIS ) , and patients were randomized to receive either deep ( BIS , approximately 50 ) or light ( BIS , > or = 80 ) sedation .
Diseases:"
1598	Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders ( Third Edition Revised ) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery .	B I O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['mental disorders', 'postoperative delirium']	2	8	"Sentence: Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders ( Third Edition Revised ) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery .
Diseases: mental disorders, postoperative delirium"	"Sentence: Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders ( Third Edition Revised ) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery .
Diseases:"
1599	From April 2 , 2005 , through October 30 , 2008 , a total of 114 patients were randomized .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: From April 2 , 2005 , through October 30 , 2008 , a total of 114 patients were randomized .
Diseases: "	"Sentence: From April 2 , 2005 , through October 30 , 2008 , a total of 114 patients were randomized .
Diseases:"
1600	The prevalence of postoperative delirium was significantly lower in the light sedation group ( 11 / 57 [ 19 % ] vs 23 / 57	O O O B I O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['postoperative delirium']	1	5	"Sentence: The prevalence of postoperative delirium was significantly lower in the light sedation group ( 11 / 57 [ 19 % ] vs 23 / 57
Diseases: postoperative delirium"	"Sentence: The prevalence of postoperative delirium was significantly lower in the light sedation group ( 11 / 57 [ 19 % ] vs 23 / 57
Diseases:"
1601	[ 40 % ] in the deep sedation group ; P = . 02 ) , indicating that 1 incident of delirium will be prevented for every 4 . 7 patients treated with light sedation .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['delirium']	1	3	"Sentence: [ 40 % ] in the deep sedation group ; P = . 02 ) , indicating that 1 incident of delirium will be prevented for every 4 . 7 patients treated with light sedation .
Diseases: delirium"	"Sentence: [ 40 % ] in the deep sedation group ; P = . 02 ) , indicating that 1 incident of delirium will be prevented for every 4 . 7 patients treated with light sedation .
Diseases:"
1602	The mean + / - SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group ( 0 . 5 + / - 1 . 5 days vs 1 . 4 + / - 4 . 0 days ; P = . 01 ) .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['delirium']	1	3	"Sentence: The mean + / - SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group ( 0 . 5 + / - 1 . 5 days vs 1 . 4 + / - 4 . 0 days ; P = . 01 ) .
Diseases: delirium"	"Sentence: The mean + / - SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group ( 0 . 5 + / - 1 . 5 days vs 1 . 4 + / - 4 . 0 days ; P = . 01 ) .
Diseases:"
1603	The use of light propofol sedation decreased the prevalence of postoperative delirium by 50 % compared with deep sedation .	O O O O O O O O O O B I O O O O O O O O	O O O O B O O O O O O O O O O O O O O O	['postoperative delirium']	1	5	"Sentence: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50 % compared with deep sedation .
Diseases: postoperative delirium"	"Sentence: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50 % compared with deep sedation .
Diseases:"
1604	Limiting depth of sedation during spinal anesthesia is a simple , safe , and cost - effective intervention for preventing postoperative delirium in elderly patients that could be widely and readily adopted .	O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['postoperative delirium']	1	5	"Sentence: Limiting depth of sedation during spinal anesthesia is a simple , safe , and cost - effective intervention for preventing postoperative delirium in elderly patients that could be widely and readily adopted .
Diseases: postoperative delirium"	"Sentence: Limiting depth of sedation during spinal anesthesia is a simple , safe , and cost - effective intervention for preventing postoperative delirium in elderly patients that could be widely and readily adopted .
Diseases:"
1605	Sorafenib - induced acute myocardial infarction due to coronary artery spasm .	O O O O B I O O B I I O	B O O O O O O O O O O O	['coronary artery spasm', 'myocardial infarction']	2	11	"Sentence: Sorafenib - induced acute myocardial infarction due to coronary artery spasm .
Diseases: coronary artery spasm, myocardial infarction"	"Sentence: Sorafenib - induced acute myocardial infarction due to coronary artery spasm .
Diseases:"
1606	A 65 - year - old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest .	O O O O O O O O O B I I O O O O O B I O O O	O O O O O O O O O O O O O O O O O O O O O O	['chest pain', 'renal cell carcinoma']	2	8	"Sentence: A 65 - year - old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest .
Diseases: chest pain, renal cell carcinoma"	"Sentence: A 65 - year - old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest .
Diseases:"
1607	Two weeks before his admission , sorafenib had been started .	O O O O O O O O O O O	O O O O O O B O O O O	[]	0	0	"Sentence: Two weeks before his admission , sorafenib had been started .
Diseases: "	"Sentence: Two weeks before his admission , sorafenib had been started .
Diseases:"
1608	He was diagnosed with non - ST - elevation myocardial infarction by laboratory data and electrocardiogram .	O O O O O O O O O B I O O O O O O	O O O O O O O O O O O O O O O O O	['myocardial infarction']	1	6	"Sentence: He was diagnosed with non - ST - elevation myocardial infarction by laboratory data and electrocardiogram .
Diseases: myocardial infarction"	"Sentence: He was diagnosed with non - ST - elevation myocardial infarction by laboratory data and electrocardiogram .
Diseases:"
1609	Enhanced heart magnetic resonance imaging also showed subendocardial infarction .	O O O O O O O B I O	O O O O O O O O O O	['subendocardial infarction']	1	7	"Sentence: Enhanced heart magnetic resonance imaging also showed subendocardial infarction .
Diseases: subendocardial infarction"	"Sentence: Enhanced heart magnetic resonance imaging also showed subendocardial infarction .
Diseases:"
1610	However , there was no stenosis in coronary arteries on angiography .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: However , there was no stenosis in coronary arteries on angiography .
Diseases: "	"Sentence: However , there was no stenosis in coronary arteries on angiography .
Diseases:"
1611	Coronary artery spasm was induced by a provocative test .	B I I O O O O O O O	O O O O O O O O O O	['coronary artery spasm']	1	6	"Sentence: Coronary artery spasm was induced by a provocative test .
Diseases: coronary artery spasm"	"Sentence: Coronary artery spasm was induced by a provocative test .
Diseases:"
1612	Cessation of sorafenib and administration of Ca - channel blocker and nitrates ameliorated his symptoms , but relapse occurred after resumption of sorafenib .	O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O B O O O O B O O O O O O O O O O B O	[]	0	0	"Sentence: Cessation of sorafenib and administration of Ca - channel blocker and nitrates ameliorated his symptoms , but relapse occurred after resumption of sorafenib .
Diseases: "	"Sentence: Cessation of sorafenib and administration of Ca - channel blocker and nitrates ameliorated his symptoms , but relapse occurred after resumption of sorafenib .
Diseases:"
1613	Addition of oral nicorandil reduced his symptoms and maintained stable angina status .	O O O O O O O O O B I O O	O O O B O O O O O O O O O	['stable angina']	1	3	"Sentence: Addition of oral nicorandil reduced his symptoms and maintained stable angina status .
Diseases: stable angina"	"Sentence: Addition of oral nicorandil reduced his symptoms and maintained stable angina status .
Diseases:"
1614	We report the first case of sorafenib - induced coronary artery spasm .	O O O O O O O O O B I I O	O O O O O O B O O O O O O	['coronary artery spasm']	1	6	"Sentence: We report the first case of sorafenib - induced coronary artery spasm .
Diseases: coronary artery spasm"	"Sentence: We report the first case of sorafenib - induced coronary artery spasm .
Diseases:"
1615	Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival .	O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival .
Diseases: "	"Sentence: Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival .
Diseases:"
1616	On the other hand , the Rho / ROCK pathway has an important role in the pathogenesis of coronary artery spasm .	O O O O O O O O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O O O O O O O O O	['coronary artery spasm']	1	6	"Sentence: On the other hand , the Rho / ROCK pathway has an important role in the pathogenesis of coronary artery spasm .
Diseases: coronary artery spasm"	"Sentence: On the other hand , the Rho / ROCK pathway has an important role in the pathogenesis of coronary artery spasm .
Diseases:"
1617	Our report may show an adverse effect on the Rho / ROCK pathway by sorafenib use .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Our report may show an adverse effect on the Rho / ROCK pathway by sorafenib use .
Diseases: "	"Sentence: Our report may show an adverse effect on the Rho / ROCK pathway by sorafenib use .
Diseases:"
1618	Anxiogenic potential of ciprofloxacin and norfloxacin in rats .	O O O O O O O O O	O O O B O B O O O	[]	0	0	"Sentence: Anxiogenic potential of ciprofloxacin and norfloxacin in rats .
Diseases: "	"Sentence: Anxiogenic potential of ciprofloxacin and norfloxacin in rats .
Diseases:"
1619	INTRODUCTION :	O O	O O	[]	0	0	"Sentence: INTRODUCTION :
Diseases: "	"Sentence: INTRODUCTION :
Diseases:"
1620	The possible anxiogenic effects of fluoroquinolones , namely ciprofloxacin and norfloxacin , were investigated in adult Charles Foster albino rats of either sex , weighing 150 - 200 g . METHODS : The drugs were given orally , in doses of 50 mg / kg for five consecutive days and the experiments were performed on the fifth day .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The possible anxiogenic effects of fluoroquinolones , namely ciprofloxacin and norfloxacin , were investigated in adult Charles Foster albino rats of either sex , weighing 150 - 200 g . METHODS : The drugs were given orally , in doses of 50 mg / kg for five consecutive days and the experiments were performed on the fifth day .
Diseases: "	"Sentence: The possible anxiogenic effects of fluoroquinolones , namely ciprofloxacin and norfloxacin , were investigated in adult Charles Foster albino rats of either sex , weighing 150 - 200 g . METHODS : The drugs were given orally , in doses of 50 mg / kg for five consecutive days and the experiments were performed on the fifth day .
Diseases:"
1621	The tests included open - field exploratory behaviour , elevated plus maze and elevated zero maze , social interaction and novelty - suppressed feeding latency behaviour .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The tests included open - field exploratory behaviour , elevated plus maze and elevated zero maze , social interaction and novelty - suppressed feeding latency behaviour .
Diseases: "	"Sentence: The tests included open - field exploratory behaviour , elevated plus maze and elevated zero maze , social interaction and novelty - suppressed feeding latency behaviour .
Diseases:"
1622	The results indicate that ciprofloxacin - and norfloxacin - treated rats showed anxious behaviour in comparison to control rats in all the parameters studied .	O O O O O O O O O O O O B I O O O O O O O O O O O	O O O O B O O B O O O O O O O O O O O O O O O O O	['anxious behaviour']	1	3	"Sentence: The results indicate that ciprofloxacin - and norfloxacin - treated rats showed anxious behaviour in comparison to control rats in all the parameters studied .
Diseases: anxious behaviour"	"Sentence: The results indicate that ciprofloxacin - and norfloxacin - treated rats showed anxious behaviour in comparison to control rats in all the parameters studied .
Diseases:"
1623	However , ciprofloxacin - and norfloxacin - treated rats did not differ significantly from each other in various behavioural parameters .	O O O O O O O O O O O O O O O O O O O O O	O O B O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , ciprofloxacin - and norfloxacin - treated rats did not differ significantly from each other in various behavioural parameters .
Diseases: "	"Sentence: However , ciprofloxacin - and norfloxacin - treated rats did not differ significantly from each other in various behavioural parameters .
Diseases:"
1624	The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin .	O O O O O O O O O O O O O O O	O O O O O O O O O O O B O B O	[]	0	0	"Sentence: The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin .
Diseases: "	"Sentence: The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin .
Diseases:"
1625	Myocardial Fas ligand expression increases susceptibility to AZT - induced cardiomyopathy .	O O O O O O O O O O B O	O O O O O O O B O O O O	['cardiomyopathy']	1	4	"Sentence: Myocardial Fas ligand expression increases susceptibility to AZT - induced cardiomyopathy .
Diseases: cardiomyopathy"	"Sentence: Myocardial Fas ligand expression increases susceptibility to AZT - induced cardiomyopathy .
Diseases:"
1626	Dilated cardiomyopathy ( DCM ) and myocarditis occur in many HIV - infected individuals , resulting in symptomatic heart failure in up to 5 % of patients .	B I O B O O B O O O B I I O O O O O B I O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hiv - infected', 'heart failure', 'dcm', 'dilated cardiomyopathy', 'myocarditis']	5	21	"Sentence: Dilated cardiomyopathy ( DCM ) and myocarditis occur in many HIV - infected individuals , resulting in symptomatic heart failure in up to 5 % of patients .
Diseases: hiv - infected, heart failure, dcm, dilated cardiomyopathy, myocarditis"	"Sentence: Dilated cardiomyopathy ( DCM ) and myocarditis occur in many HIV - infected individuals , resulting in symptomatic heart failure in up to 5 % of patients .
Diseases:"
1627	Highly active antiretroviral therapy ( HAART ) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome ( AIDS ) , but has resulted in an increase in cardiac and skeletal myopathies .	O O O O O O O O O O O O O O B I I O B O O O O O O O O O B I I I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['acquired immunodeficiency syndrome', 'aids', 'cardiac and skeletal myopathies']	3	16	"Sentence: Highly active antiretroviral therapy ( HAART ) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome ( AIDS ) , but has resulted in an increase in cardiac and skeletal myopathies .
Diseases: acquired immunodeficiency syndrome, aids, cardiac and skeletal myopathies"	"Sentence: Highly active antiretroviral therapy ( HAART ) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome ( AIDS ) , but has resulted in an increase in cardiac and skeletal myopathies .
Diseases:"
1628	METHODS AND RESULTS :	O O O O	O O O O	[]	0	0	"Sentence: METHODS AND RESULTS :
Diseases: "	"Sentence: METHODS AND RESULTS :
Diseases:"
1629	In order to investigate whether the HAART component zidovudine ( 3' - azido - 2' , 3' - deoxythymidine ; AZT ) triggers the Fas - dependent cell - death pathway and cause cytoskeletal disruption in a murine model of DCM , 8 - week - old transgenic ( expressing Fas ligand in the myocardium : FasL Tg ) and non - transgenic ( NTg ) mice received water ad libitum containing different concentrations of AZT ( 0 , 0 . 07 , 0 . 2 , and 0 . 7 mg / ml ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O B I I I I I I I I O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['dcm']	1	2	"Sentence: In order to investigate whether the HAART component zidovudine ( 3' - azido - 2' , 3' - deoxythymidine ; AZT ) triggers the Fas - dependent cell - death pathway and cause cytoskeletal disruption in a murine model of DCM , 8 - week - old transgenic ( expressing Fas ligand in the myocardium : FasL Tg ) and non - transgenic ( NTg ) mice received water ad libitum containing different concentrations of AZT ( 0 , 0 . 07 , 0 . 2 , and 0 . 7 mg / ml ) .
Diseases: dcm"	"Sentence: In order to investigate whether the HAART component zidovudine ( 3' - azido - 2' , 3' - deoxythymidine ; AZT ) triggers the Fas - dependent cell - death pathway and cause cytoskeletal disruption in a murine model of DCM , 8 - week - old transgenic ( expressing Fas ligand in the myocardium : FasL Tg ) and non - transgenic ( NTg ) mice received water ad libitum containing different concentrations of AZT ( 0 , 0 . 07 , 0 . 2 , and 0 . 7 mg / ml ) .
Diseases:"
1630	After 6 weeks , cardiac function was assessed by echocardiography and morphology was assessed by histopathologic and immunohistochemical methods .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After 6 weeks , cardiac function was assessed by echocardiography and morphology was assessed by histopathologic and immunohistochemical methods .
Diseases: "	"Sentence: After 6 weeks , cardiac function was assessed by echocardiography and morphology was assessed by histopathologic and immunohistochemical methods .
Diseases:"
1631	NTg and untreated FasL	O O O O	B O O O	[]	0	0	"Sentence: NTg and untreated FasL
Diseases: "	"Sentence: NTg and untreated FasL
Diseases:"
1632	Tg mice showed little or no change in cardiac structure or function .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Tg mice showed little or no change in cardiac structure or function .
Diseases: "	"Sentence: Tg mice showed little or no change in cardiac structure or function .
Diseases:"
1633	In contrast , AZT - treated FasL	O O O O O O O	O O O B O O O	[]	0	0	"Sentence: In contrast , AZT - treated FasL
Diseases: "	"Sentence: In contrast , AZT - treated FasL
Diseases:"
1634	Tg mice developed cardiac dilation and depressed cardiac function in a dose - dependent manner , with concomitant inflammatory infiltration of both ventricles .	O O O B I O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	['cardiac dilation']	1	4	"Sentence: Tg mice developed cardiac dilation and depressed cardiac function in a dose - dependent manner , with concomitant inflammatory infiltration of both ventricles .
Diseases: cardiac dilation"	"Sentence: Tg mice developed cardiac dilation and depressed cardiac function in a dose - dependent manner , with concomitant inflammatory infiltration of both ventricles .
Diseases:"
1635	These changes were associated with an increased sarcolemmal expression of Fas and FasL , as well as increased activation of caspase 3 , translocation of calpain 1 to the sarcolemma and sarcomere , and increased numbers of cells undergoing apoptosis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These changes were associated with an increased sarcolemmal expression of Fas and FasL , as well as increased activation of caspase 3 , translocation of calpain 1 to the sarcolemma and sarcomere , and increased numbers of cells undergoing apoptosis .
Diseases: "	"Sentence: These changes were associated with an increased sarcolemmal expression of Fas and FasL , as well as increased activation of caspase 3 , translocation of calpain 1 to the sarcolemma and sarcomere , and increased numbers of cells undergoing apoptosis .
Diseases:"
1636	These were associated with changes in dystrophin and cardiac troponin I localization , as well as loss of sarcolemmal integrity .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These were associated with changes in dystrophin and cardiac troponin I localization , as well as loss of sarcolemmal integrity .
Diseases: "	"Sentence: These were associated with changes in dystrophin and cardiac troponin I localization , as well as loss of sarcolemmal integrity .
Diseases:"
1637	CONCLUSIONS : The expression of Fas ligand in the myocardium , as identified in HIV - positive patients , might increase the susceptibility to HAART - induced cardiomyopathy due to activation of apoptotic pathways , resulting in cardiac dilation and dysfunction .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O B I I I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cardiomyopathy', 'cardiac dilation and dysfunction']	2	10	"Sentence: CONCLUSIONS : The expression of Fas ligand in the myocardium , as identified in HIV - positive patients , might increase the susceptibility to HAART - induced cardiomyopathy due to activation of apoptotic pathways , resulting in cardiac dilation and dysfunction .
Diseases: cardiomyopathy, cardiac dilation and dysfunction"	"Sentence: CONCLUSIONS : The expression of Fas ligand in the myocardium , as identified in HIV - positive patients , might increase the susceptibility to HAART - induced cardiomyopathy due to activation of apoptotic pathways , resulting in cardiac dilation and dysfunction .
Diseases:"
1638	Valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia .	O O O B O B O O B I O	B O O O O O O O O O O	['encephalopathy', 'nonketotic hyperglycinemia', 'chorea']	3	15	"Sentence: Valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia .
Diseases: encephalopathy, nonketotic hyperglycinemia, chorea"	"Sentence: Valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia .
Diseases:"
1639	Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments .	B I O O B I I I I O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B I O O O O O O O B O O O O O O O B O O O O O O O O	['nonketotic hyperglycinemia', 'disorder of amino acid metabolism']	2	14	"Sentence: Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments .
Diseases: nonketotic hyperglycinemia, disorder of amino acid metabolism"	"Sentence: Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments .
Diseases:"
1640	In the classical form it presents as neonatal apnea , intractable seizures , and hypotonia , followed by significant psychomotor retardation .	O O O O O O O O B O O B O O B O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O	['apnea', 'psychomotor retardation', 'seizures', 'hypotonia']	4	13	"Sentence: In the classical form it presents as neonatal apnea , intractable seizures , and hypotonia , followed by significant psychomotor retardation .
Diseases: apnea, psychomotor retardation, seizures, hypotonia"	"Sentence: In the classical form it presents as neonatal apnea , intractable seizures , and hypotonia , followed by significant psychomotor retardation .
Diseases:"
1641	An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner .	O O O O O O B I O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	['nonketotic hyperglycinemia']	1	8	"Sentence: An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner .
Diseases: nonketotic hyperglycinemia"	"Sentence: An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner .
Diseases:"
1642	This report describes a patient with mild language delay and mental retardation , who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy .	O O O O O O O B I O B I O O O O O O B I O O O O O B O B O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['mental retardation', 'encephalopathy', 'nonketotic hyperglycinemia', 'language delay', 'chorea']	5	22	"Sentence: This report describes a patient with mild language delay and mental retardation , who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy .
Diseases: mental retardation, encephalopathy, nonketotic hyperglycinemia, language delay, chorea"	"Sentence: This report describes a patient with mild language delay and mental retardation , who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy .
Diseases:"
1643	Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine - induced amnesia in adult male rats .	O O O O O O O O O O O O O B O O O O O	O O B O O O O O O O B O O O O O O O O	['amnesia']	1	2	"Sentence: Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine - induced amnesia in adult male rats .
Diseases: amnesia"	"Sentence: Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine - induced amnesia in adult male rats .
Diseases:"
1644	The effect of ritanserin ( 5 - HT2 antagonist ) on scopolamine ( muscarinic cholinergic antagonist ) - induced amnesia in Morris water maze ( MWM ) was investigated .	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	O O O B O B I I O O O B O O O O O O O O O O O O O O O O O O	['amnesia']	1	2	"Sentence: The effect of ritanserin ( 5 - HT2 antagonist ) on scopolamine ( muscarinic cholinergic antagonist ) - induced amnesia in Morris water maze ( MWM ) was investigated .
Diseases: amnesia"	"Sentence: The effect of ritanserin ( 5 - HT2 antagonist ) on scopolamine ( muscarinic cholinergic antagonist ) - induced amnesia in Morris water maze ( MWM ) was investigated .
Diseases:"
1645	Rats were divided into eight groups and bilaterally cannulated into CA1 region of the hippocampus .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Rats were divided into eight groups and bilaterally cannulated into CA1 region of the hippocampus .
Diseases: "	"Sentence: Rats were divided into eight groups and bilaterally cannulated into CA1 region of the hippocampus .
Diseases:"
1646	One week later , they received repeatedly vehicles ( saline , DMSO , saline + DMSO ) , scopolamine ( 2 microg / 0 . 5 microl saline / side ;	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O B O O B O O O O O O O O O O O O	[]	0	0	"Sentence: One week later , they received repeatedly vehicles ( saline , DMSO , saline + DMSO ) , scopolamine ( 2 microg / 0 . 5 microl saline / side ;
Diseases: "	"Sentence: One week later , they received repeatedly vehicles ( saline , DMSO , saline + DMSO ) , scopolamine ( 2 microg / 0 . 5 microl saline / side ;
Diseases:"
1647	30 min before training ) , ritanserin ( 2 , 4 and 8 microg / 0 . 5 microl DMSO / side ; 20 min before training ) and scopolamine ( 2 microg / 0 . 5 microl ; 30 min before ritanserin injection ) + ritanserin ( 4 microg / 0 . 5 microl DMSO ) through cannulae each day .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O B O O O O O O O O O B O O O O O O O O O O O O B O O O B O O O O O O O O B O O O O O O	[]	0	0	"Sentence: 30 min before training ) , ritanserin ( 2 , 4 and 8 microg / 0 . 5 microl DMSO / side ; 20 min before training ) and scopolamine ( 2 microg / 0 . 5 microl ; 30 min before ritanserin injection ) + ritanserin ( 4 microg / 0 . 5 microl DMSO ) through cannulae each day .
Diseases: "	"Sentence: 30 min before training ) , ritanserin ( 2 , 4 and 8 microg / 0 . 5 microl DMSO / side ; 20 min before training ) and scopolamine ( 2 microg / 0 . 5 microl ; 30 min before ritanserin injection ) + ritanserin ( 4 microg / 0 . 5 microl DMSO ) through cannulae each day .
Diseases:"
1648	Animals were tested for four consecutive days ( 4 trial / day ) in MWM during which the position of hidden platform was unchanged .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Animals were tested for four consecutive days ( 4 trial / day ) in MWM during which the position of hidden platform was unchanged .
Diseases: "	"Sentence: Animals were tested for four consecutive days ( 4 trial / day ) in MWM during which the position of hidden platform was unchanged .
Diseases:"
1649	In the fifth day , the platform was elevated above the water surface in another position to evaluate the function of motor , motivational and visual systems .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the fifth day , the platform was elevated above the water surface in another position to evaluate the function of motor , motivational and visual systems .
Diseases: "	"Sentence: In the fifth day , the platform was elevated above the water surface in another position to evaluate the function of motor , motivational and visual systems .
Diseases:"
1650	The results showed a significant increase in escape latencies and traveled distances to find platform in scopolamine - treated group as compared to saline group .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: The results showed a significant increase in escape latencies and traveled distances to find platform in scopolamine - treated group as compared to saline group .
Diseases: "	"Sentence: The results showed a significant increase in escape latencies and traveled distances to find platform in scopolamine - treated group as compared to saline group .
Diseases:"
1651	Ritanserin - treated rats ( 4 microg / 0 . 5 microl / side ) showed a significant decrease in the mentioned parameters as compared to DMSO - treated group .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: Ritanserin - treated rats ( 4 microg / 0 . 5 microl / side ) showed a significant decrease in the mentioned parameters as compared to DMSO - treated group .
Diseases: "	"Sentence: Ritanserin - treated rats ( 4 microg / 0 . 5 microl / side ) showed a significant decrease in the mentioned parameters as compared to DMSO - treated group .
Diseases:"
1652	However , scopolamine and ritanserin co - administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine - treated rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O B O O O O O O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: However , scopolamine and ritanserin co - administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine - treated rats .
Diseases: "	"Sentence: However , scopolamine and ritanserin co - administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine - treated rats .
Diseases:"
1653	Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine - induced amnesia .	O O O O O O O O O O O O O O O O O O O B O	O O O O O O B O O O O O O O O O B O O O O	['amnesia']	1	2	"Sentence: Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine - induced amnesia .
Diseases: amnesia"	"Sentence: Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine - induced amnesia .
Diseases:"
1654	Hypoxia in renal disease with proteinuria and / or glomerular hypertension .	B O B I O B O O O O B O	O O O O O O O O O O O O	['renal disease', 'proteinuria', 'hypertension', 'hypoxia']	4	11	"Sentence: Hypoxia in renal disease with proteinuria and / or glomerular hypertension .
Diseases: renal disease, proteinuria, hypertension, hypoxia"	"Sentence: Hypoxia in renal disease with proteinuria and / or glomerular hypertension .
Diseases:"
1655	Despite the increasing need to identify and quantify tissue oxygenation at the cellular level , relatively few methods have been available .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Despite the increasing need to identify and quantify tissue oxygenation at the cellular level , relatively few methods have been available .
Diseases: "	"Sentence: Despite the increasing need to identify and quantify tissue oxygenation at the cellular level , relatively few methods have been available .
Diseases:"
1656	In this study , we developed a new hypoxia - responsive reporter vector using a hypoxia - responsive element of the 5 ' vascular endothelial growth factor untranslated region and generated a novel hypoxia - sensing transgenic rat .	O O O O O O O O B O O O O O O B O O O O O O O O O O O O O O O O O B O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypoxia']	1	3	"Sentence: In this study , we developed a new hypoxia - responsive reporter vector using a hypoxia - responsive element of the 5 ' vascular endothelial growth factor untranslated region and generated a novel hypoxia - sensing transgenic rat .
Diseases: hypoxia"	"Sentence: In this study , we developed a new hypoxia - responsive reporter vector using a hypoxia - responsive element of the 5 ' vascular endothelial growth factor untranslated region and generated a novel hypoxia - sensing transgenic rat .
Diseases:"
1657	We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney .	O O O O O O O O O O O B O O B I O	O O O O O O O O O O O O O O O O O	['diseased kidney', 'hypoxia']	2	8	"Sentence: We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney .
Diseases: diseased kidney, hypoxia"	"Sentence: We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney .
Diseases:"
1658	With this model , we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside - induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model .	O O O O O O O O O O O B O O O O O O B I O O O O B O O O O O O	O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O	['nephrotic syndrome', 'hypoxia']	2	9	"Sentence: With this model , we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside - induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model .
Diseases: nephrotic syndrome, hypoxia"	"Sentence: With this model , we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside - induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model .
Diseases:"
1659	Expression of the hypoxia - responsive transgene increased throughout the observation period , reaching 2 . 2 - fold at 2 weeks in the puromycin aminonucleoside model and 2 . 6 - fold at 4 weeks in the remnant kidney model , whereas that of vascular endothelial growth factor showed a mild decrease , reflecting distinct behaviors of the two genes .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypoxia']	1	3	"Sentence: Expression of the hypoxia - responsive transgene increased throughout the observation period , reaching 2 . 2 - fold at 2 weeks in the puromycin aminonucleoside model and 2 . 6 - fold at 4 weeks in the remnant kidney model , whereas that of vascular endothelial growth factor showed a mild decrease , reflecting distinct behaviors of the two genes .
Diseases: hypoxia"	"Sentence: Expression of the hypoxia - responsive transgene increased throughout the observation period , reaching 2 . 2 - fold at 2 weeks in the puromycin aminonucleoside model and 2 . 6 - fold at 4 weeks in the remnant kidney model , whereas that of vascular endothelial growth factor showed a mild decrease , reflecting distinct behaviors of the two genes .
Diseases:"
1660	The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models .	O O O B O O O O O O B I O O O O	O O O O O O O O O O O O O O O O	['tubulointerstitial injury', 'hypoxia']	2	8	"Sentence: The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models .
Diseases: tubulointerstitial injury, hypoxia"	"Sentence: The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models .
Diseases:"
1661	Finally , we identified the localization of proliferating cell nuclear antigen - positive , ED - 1 - positive , and terminal dUTP nick - end labeled - positive cells in the hypoxic cortical area in the remnant kidney model .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O I O O O O O O O O O O O O O O O O O O	['hypoxic']	1	2	"Sentence: Finally , we identified the localization of proliferating cell nuclear antigen - positive , ED - 1 - positive , and terminal dUTP nick - end labeled - positive cells in the hypoxic cortical area in the remnant kidney model .
Diseases: hypoxic"	"Sentence: Finally , we identified the localization of proliferating cell nuclear antigen - positive , ED - 1 - positive , and terminal dUTP nick - end labeled - positive cells in the hypoxic cortical area in the remnant kidney model .
Diseases:"
1662	We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases .	O O O O O O O O O O B O O B I O	O O O O O O O O O O O O O O O O	['glomerular diseases', 'hypoxia']	2	7	"Sentence: We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases .
Diseases: glomerular diseases, hypoxia"	"Sentence: We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases .
Diseases:"
1663	Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases , with special reference to systemic sclerosis and multiple sclerosis .	O O O B O O O O O O O O O O B I O O O O O B I O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cardiotoxicity', 'multiple sclerosis', 'autoimmune diseases', 'systemic sclerosis']	4	12	"Sentence: Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases , with special reference to systemic sclerosis and multiple sclerosis .
Diseases: cardiotoxicity, multiple sclerosis, autoimmune diseases, systemic sclerosis"	"Sentence: Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases , with special reference to systemic sclerosis and multiple sclerosis .
Diseases:"
1664	Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases .	O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O	['autoimmune diseases']	1	3	"Sentence: Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases .
Diseases: autoimmune diseases"	"Sentence: Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases .
Diseases:"
1665	Worldwide , over 650 patients have been transplanted in the context of phase I and II clinical trials .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Worldwide , over 650 patients have been transplanted in the context of phase I and II clinical trials .
Diseases: "	"Sentence: Worldwide , over 650 patients have been transplanted in the context of phase I and II clinical trials .
Diseases:"
1666	The results are encouraging enough to begin randomised phase III trials .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: The results are encouraging enough to begin randomised phase III trials .
Diseases: "	"Sentence: The results are encouraging enough to begin randomised phase III trials .
Diseases:"
1667	However , as predicted , significant transplant - related morbidity and mortality have been observed .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , as predicted , significant transplant - related morbidity and mortality have been observed .
Diseases: "	"Sentence: However , as predicted , significant transplant - related morbidity and mortality have been observed .
Diseases:"
1668	This is primarily due to complications related to either the stage of the disease at transplant or due to infections .	O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O	['infections']	1	2	"Sentence: This is primarily due to complications related to either the stage of the disease at transplant or due to infections .
Diseases: infections"	"Sentence: This is primarily due to complications related to either the stage of the disease at transplant or due to infections .
Diseases:"
1669	The number of deaths related to cardiac toxicity is low .	O O O O O O B I O O O	O O O O O O O O O O O	['cardiac toxicity']	1	3	"Sentence: The number of deaths related to cardiac toxicity is low .
Diseases: cardiac toxicity"	"Sentence: The number of deaths related to cardiac toxicity is low .
Diseases:"
1670	However , caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage , for example , systemic sclerosis patients .	O O O O O O O O O O O O O O O O O O O O B I O O O O B I O O	O O O O O O B O B O O B O O O O O O O O O O O O O O O O O O	['systemic sclerosis', 'heart damage']	2	6	"Sentence: However , caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage , for example , systemic sclerosis patients .
Diseases: systemic sclerosis, heart damage"	"Sentence: However , caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage , for example , systemic sclerosis patients .
Diseases:"
1671	In November 2002 , a meeting was held in Florence , bringing together a number of experts in various fields , including rheumatology , cardiology , neurology , pharmacology and transplantation medicine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In November 2002 , a meeting was held in Florence , bringing together a number of experts in various fields , including rheumatology , cardiology , neurology , pharmacology and transplantation medicine .
Diseases: "	"Sentence: In November 2002 , a meeting was held in Florence , bringing together a number of experts in various fields , including rheumatology , cardiology , neurology , pharmacology and transplantation medicine .
Diseases:"
1672	The object of the meeting was to analyse existing data , both published or available , in the European Group for Blood and Marrow Transplantation autoimmune disease database , and to propose a safe approach to such patients .	O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['autoimmune disease']	1	3	"Sentence: The object of the meeting was to analyse existing data , both published or available , in the European Group for Blood and Marrow Transplantation autoimmune disease database , and to propose a safe approach to such patients .
Diseases: autoimmune disease"	"Sentence: The object of the meeting was to analyse existing data , both published or available , in the European Group for Blood and Marrow Transplantation autoimmune disease database , and to propose a safe approach to such patients .
Diseases:"
1673	A full cardiological assessment before and during the transplant emerged as the major recommendation .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A full cardiological assessment before and during the transplant emerged as the major recommendation .
Diseases: "	"Sentence: A full cardiological assessment before and during the transplant emerged as the major recommendation .
Diseases:"
1674	Immunohistochemical study on inducible type of nitric oxide ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) in arteritis induced in rats by fenoldopam and theophylline , vasodilators .	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O B O O O O O O O O O O	O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O O	['tumor', 'arteritis']	2	6	"Sentence: Immunohistochemical study on inducible type of nitric oxide ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) in arteritis induced in rats by fenoldopam and theophylline , vasodilators .
Diseases: tumor, arteritis"	"Sentence: Immunohistochemical study on inducible type of nitric oxide ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) in arteritis induced in rats by fenoldopam and theophylline , vasodilators .
Diseases:"
1675	Arteritis induced in rats by vasodilators , fenoldopam and theophylline , was examined immunohistochemically for expressions of inducible type of nitric oxide synthase ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	O O O O O O O B O B O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O	['tumor', 'arteritis']	2	6	"Sentence: Arteritis induced in rats by vasodilators , fenoldopam and theophylline , was examined immunohistochemically for expressions of inducible type of nitric oxide synthase ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) .
Diseases: tumor, arteritis"	"Sentence: Arteritis induced in rats by vasodilators , fenoldopam and theophylline , was examined immunohistochemically for expressions of inducible type of nitric oxide synthase ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) .
Diseases:"
1676	Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline .	O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline .
Diseases: "	"Sentence: Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline .
Diseases:"
1677	Irrespective of theophylline administration , iNOS antigens were remarkably abundant in ED - 1 - positive cells on day 5 and 8 post - fenoldopam - infusion ( DPI ) ; bFGF antigens were remarkably abundant in ED - 1 - positive cells on 1 and 3 DPI ; TGF - beta1 antigens were observed in ED - 1 - positive cells on and after 5 DPI .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Irrespective of theophylline administration , iNOS antigens were remarkably abundant in ED - 1 - positive cells on day 5 and 8 post - fenoldopam - infusion ( DPI ) ; bFGF antigens were remarkably abundant in ED - 1 - positive cells on 1 and 3 DPI ; TGF - beta1 antigens were observed in ED - 1 - positive cells on and after 5 DPI .
Diseases: "	"Sentence: Irrespective of theophylline administration , iNOS antigens were remarkably abundant in ED - 1 - positive cells on day 5 and 8 post - fenoldopam - infusion ( DPI ) ; bFGF antigens were remarkably abundant in ED - 1 - positive cells on 1 and 3 DPI ; TGF - beta1 antigens were observed in ED - 1 - positive cells on and after 5 DPI .
Diseases:"
1678	These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen , and bFGF may have a suppressive effect on iNOS expression in these rat arteritis models .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	['arteritis']	1	2	"Sentence: These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen , and bFGF may have a suppressive effect on iNOS expression in these rat arteritis models .
Diseases: arteritis"	"Sentence: These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen , and bFGF may have a suppressive effect on iNOS expression in these rat arteritis models .
Diseases:"
1679	On the other hand , TGF - beta1 was not considered to have a suppressive effect on iNOS expression in these models .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: On the other hand , TGF - beta1 was not considered to have a suppressive effect on iNOS expression in these models .
Diseases: "	"Sentence: On the other hand , TGF - beta1 was not considered to have a suppressive effect on iNOS expression in these models .
Diseases:"
1680	Low - molecular - weight heparin for the treatment of patients with mechanical heart valves .	O O O O O O O O O O O O O O O O	O O O O I B O O O O O O O O O O	[]	0	0	"Sentence: Low - molecular - weight heparin for the treatment of patients with mechanical heart valves .
Diseases: "	"Sentence: Low - molecular - weight heparin for the treatment of patients with mechanical heart valves .
Diseases:"
1681	The interruption of oral anticoagulant ( OAC ) administration is sometimes indicated in patients with mechanical heart valves , mainly before noncardiac surgery , non - surgical interventions , and pregnancy .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O B O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The interruption of oral anticoagulant ( OAC ) administration is sometimes indicated in patients with mechanical heart valves , mainly before noncardiac surgery , non - surgical interventions , and pregnancy .
Diseases: "	"Sentence: The interruption of oral anticoagulant ( OAC ) administration is sometimes indicated in patients with mechanical heart valves , mainly before noncardiac surgery , non - surgical interventions , and pregnancy .
Diseases:"
1682	Unfractionated heparin ( UH ) is currently the substitute for selected patients .	O O O O O O O O O O O O O	B B O B O O O O O O O O O	[]	0	0	"Sentence: Unfractionated heparin ( UH ) is currently the substitute for selected patients .
Diseases: "	"Sentence: Unfractionated heparin ( UH ) is currently the substitute for selected patients .
Diseases:"
1683	Low - molecular - weight heparin ( LMWH ) offers theoretical advantages over UH , but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Low - molecular - weight heparin ( LMWH ) offers theoretical advantages over UH , but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves .
Diseases: "	"Sentence: Low - molecular - weight heparin ( LMWH ) offers theoretical advantages over UH , but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves .
Diseases:"
1684	HYPOTHESIS :	O O	O O	[]	0	0	"Sentence: HYPOTHESIS :
Diseases: "	"Sentence: HYPOTHESIS :
Diseases:"
1685	The aim of the present study was to review the data accumulated so far on the use of LMWH in this patient population and to discuss its applicability in common practice .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: The aim of the present study was to review the data accumulated so far on the use of LMWH in this patient population and to discuss its applicability in common practice .
Diseases: "	"Sentence: The aim of the present study was to review the data accumulated so far on the use of LMWH in this patient population and to discuss its applicability in common practice .
Diseases:"
1686	For this paper , the current medical literature on LMWH in patients with mechanical heart valves was extensively reviewed .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: For this paper , the current medical literature on LMWH in patients with mechanical heart valves was extensively reviewed .
Diseases: "	"Sentence: For this paper , the current medical literature on LMWH in patients with mechanical heart valves was extensively reviewed .
Diseases:"
1687	There were eight series and six case reports .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: There were eight series and six case reports .
Diseases: "	"Sentence: There were eight series and six case reports .
Diseases:"
1688	None of the studies was randomized , and only one was prospective .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: None of the studies was randomized , and only one was prospective .
Diseases: "	"Sentence: None of the studies was randomized , and only one was prospective .
Diseases:"
1689	Data to establish the thromboembolic risk were incomplete .	O O O O B O O O O	O O O O O O O O O	['thromboembolic']	1	5	"Sentence: Data to establish the thromboembolic risk were incomplete .
Diseases: thromboembolic"	"Sentence: Data to establish the thromboembolic risk were incomplete .
Diseases:"
1690	After excluding case reports , the following groups were constructed : ( a ) short - term administration , after valve insertion ( n = 212 ) ; ( b ) short - term , perioperative ( noncardiac ) / periprocedural ( n = 114 ) ; ( c ) long - term , due to intolerance to OAC ( n = 16 ) ; ( d ) long - term , in pregnancy ( n = 10 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After excluding case reports , the following groups were constructed : ( a ) short - term administration , after valve insertion ( n = 212 ) ; ( b ) short - term , perioperative ( noncardiac ) / periprocedural ( n = 114 ) ; ( c ) long - term , due to intolerance to OAC ( n = 16 ) ; ( d ) long - term , in pregnancy ( n = 10 ) .
Diseases: "	"Sentence: After excluding case reports , the following groups were constructed : ( a ) short - term administration , after valve insertion ( n = 212 ) ; ( b ) short - term , perioperative ( noncardiac ) / periprocedural ( n = 114 ) ; ( c ) long - term , due to intolerance to OAC ( n = 16 ) ; ( d ) long - term , in pregnancy ( n = 10 ) .
Diseases:"
1691	The incidence rate of thromboembolism was 0 . 9 % for all the studies and 0 . 5 , 0 , 20 , and 0 % in groups a , b , c , and d , respectively ; for hemorrhage , the overall rate was 3 . 4 % ( 3 . 8 , 2 . 6 , 10 , and 0 % for the respective groups ) .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hemorrhage', 'thromboembolism']	2	11	"Sentence: The incidence rate of thromboembolism was 0 . 9 % for all the studies and 0 . 5 , 0 , 20 , and 0 % in groups a , b , c , and d , respectively ; for hemorrhage , the overall rate was 3 . 4 % ( 3 . 8 , 2 . 6 , 10 , and 0 % for the respective groups ) .
Diseases: hemorrhage, thromboembolism"	"Sentence: The incidence rate of thromboembolism was 0 . 9 % for all the studies and 0 . 5 , 0 , 20 , and 0 % in groups a , b , c , and d , respectively ; for hemorrhage , the overall rate was 3 . 4 % ( 3 . 8 , 2 . 6 , 10 , and 0 % for the respective groups ) .
Diseases:"
1692	In patients with mechanical heart valves , short - term LMWH therapy compares favorably with UH .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O B O	[]	0	0	"Sentence: In patients with mechanical heart valves , short - term LMWH therapy compares favorably with UH .
Diseases: "	"Sentence: In patients with mechanical heart valves , short - term LMWH therapy compares favorably with UH .
Diseases:"
1693	Data on mid - and long - term LMWH administration in these patients are sparse .	O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: Data on mid - and long - term LMWH administration in these patients are sparse .
Diseases: "	"Sentence: Data on mid - and long - term LMWH administration in these patients are sparse .
Diseases:"
1694	Further randomized studies are needed to confirm the safety and precise indications for the use of LMWH in patients with mechanical heart valves .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: Further randomized studies are needed to confirm the safety and precise indications for the use of LMWH in patients with mechanical heart valves .
Diseases: "	"Sentence: Further randomized studies are needed to confirm the safety and precise indications for the use of LMWH in patients with mechanical heart valves .
Diseases:"
1695	Topiramate - induced nephrolithiasis .	O O O B O	B O O O O	['nephrolithiasis']	1	5	"Sentence: Topiramate - induced nephrolithiasis .
Diseases: nephrolithiasis"	"Sentence: Topiramate - induced nephrolithiasis .
Diseases:"
1696	Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures .	O O O O O O O O O O O O O O O O O O O B I O	B O O O O O O O O O O O O O O O O O O O O O	['refractory seizures']	1	4	"Sentence: Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures .
Diseases: refractory seizures"	"Sentence: Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures .
Diseases:"
1697	Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase .	O O O O O O O O O B I O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	['metabolic acidosis']	1	4	"Sentence: Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase .
Diseases: metabolic acidosis"	"Sentence: Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase .
Diseases:"
1698	In addition , a distal tubular acidification defect may result , thus impairing the normal compensatory drop in urine pH . These factors can lead to the development of calcium phosphate nephrolithiasis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O	['nephrolithiasis']	1	5	"Sentence: In addition , a distal tubular acidification defect may result , thus impairing the normal compensatory drop in urine pH . These factors can lead to the development of calcium phosphate nephrolithiasis .
Diseases: nephrolithiasis"	"Sentence: In addition , a distal tubular acidification defect may result , thus impairing the normal compensatory drop in urine pH . These factors can lead to the development of calcium phosphate nephrolithiasis .
Diseases:"
1699	We report the first two cases of topiramate - induced nephrolithiasis in the urologic literature .	O O O O O O O O O O B O O O O O	O O O O O O O B O O O O O O O O	['nephrolithiasis']	1	5	"Sentence: We report the first two cases of topiramate - induced nephrolithiasis in the urologic literature .
Diseases: nephrolithiasis"	"Sentence: We report the first two cases of topiramate - induced nephrolithiasis in the urologic literature .
Diseases:"
1700	Spironolactone : is it a novel drug for the prevention of amphotericin B - related hypokalemia in cancer patients ?	O O O O O O O O O O O O O O O B O B O O	B O O O O O O O O O O B I O O O O O O O	['cancer', 'hypokalemia']	2	6	"Sentence: Spironolactone : is it a novel drug for the prevention of amphotericin B - related hypokalemia in cancer patients ?
Diseases: cancer, hypokalemia"	"Sentence: Spironolactone : is it a novel drug for the prevention of amphotericin B - related hypokalemia in cancer patients ?
Diseases:"
1701	Nephrotoxicity is the major adverse effect of amphotericin B ( AmB ) , often limiting administration of full dosage .	B O O O O O O O O O O O O O O O O O O O	O O O O O O O B I O B O O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: Nephrotoxicity is the major adverse effect of amphotericin B ( AmB ) , often limiting administration of full dosage .
Diseases: nephrotoxicity"	"Sentence: Nephrotoxicity is the major adverse effect of amphotericin B ( AmB ) , often limiting administration of full dosage .
Diseases:"
1702	Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB . Potassium depletion also potentiates the tubular toxicity of AmB .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O	O O O O O O O O O O O O B O O O O O O O O O O O B O B O O O O O O O B O	['toxicity']	1	2	"Sentence: Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB . Potassium depletion also potentiates the tubular toxicity of AmB .
Diseases: toxicity"	"Sentence: Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB . Potassium depletion also potentiates the tubular toxicity of AmB .
Diseases:"
1703	This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment .	O O O O O O O O O O O O O O O O O B O B O O O O O	O O O O O O O O O B O O B O O O O O O O O O B O O	['hypokalemia', 'neutropenic']	2	8	"Sentence: This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment .
Diseases: hypokalemia, neutropenic"	"Sentence: This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment .
Diseases:"
1704	In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection .	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O B O O B O O B O O O O O O O O O O O O O	['fungal infection', 'hematological disorders']	2	9	"Sentence: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection .
Diseases: fungal infection, hematological disorders"	"Sentence: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection .
Diseases:"
1705	Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone ( P = 0 . 0027 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O B O O O O B O O O O B O O O O O O O O O	[]	0	0	"Sentence: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone ( P = 0 . 0027 ) .
Diseases: "	"Sentence: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone ( P = 0 . 0027 ) .
Diseases:"
1706	Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range ( P = 0 . 022 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O B O O O B O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range ( P = 0 . 022 ) .
Diseases: "	"Sentence: Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range ( P = 0 . 022 ) .
Diseases:"
1707	Moreover , urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone ( P = 0 . 040 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O B O B O O O B O O O O O O O O O	[]	0	0	"Sentence: Moreover , urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone ( P = 0 . 040 ) .
Diseases: "	"Sentence: Moreover , urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone ( P = 0 . 040 ) .
Diseases:"
1708	This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment .	O O O O O O O O O O O B O O O O O O B O O O O O	O O O O B O O B O O O O O O O B O O O O O B O O	['hypokalemia', 'neutropenic']	2	8	"Sentence: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment .
Diseases: hypokalemia, neutropenic"	"Sentence: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment .
Diseases:"
1709	Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs .	O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O	[]	0	0	"Sentence: Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs .
Diseases: "	"Sentence: Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs .
Diseases:"
1710	Dopamine ( DA ) , through D1 / D2 receptor - mediated signaling , plays a major role in the control of epileptic seizures arising in the limbic system .	O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O	B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	['epileptic seizures']	1	4	"Sentence: Dopamine ( DA ) , through D1 / D2 receptor - mediated signaling , plays a major role in the control of epileptic seizures arising in the limbic system .
Diseases: epileptic seizures"	"Sentence: Dopamine ( DA ) , through D1 / D2 receptor - mediated signaling , plays a major role in the control of epileptic seizures arising in the limbic system .
Diseases:"
1711	Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level .	B O O O O O O O O O O O O O O B O O O O O	O O O O O O O O O O O O O O O O O O O O O	['excitotoxicity', 'seizures']	2	6	"Sentence: Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level .
Diseases: excitotoxicity, seizures"	"Sentence: Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level .
Diseases:"
1712	In this respect , little is known about the role of DA receptors in the occurrence of epilepsy - induced neuronal cell death .	O O O O O O O O O O O O O O O O O B O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O	['epilepsy']	1	3	"Sentence: In this respect , little is known about the role of DA receptors in the occurrence of epilepsy - induced neuronal cell death .
Diseases: epilepsy"	"Sentence: In this respect , little is known about the role of DA receptors in the occurrence of epilepsy - induced neuronal cell death .
Diseases:"
1713	Here we analyze the occurrence of seizures and neurotoxicity in D2R - / - mice treated with the cholinergic agonist pilocarpine .	O O O O O O B O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O B O	['neurotoxicity', 'seizures']	2	6	"Sentence: Here we analyze the occurrence of seizures and neurotoxicity in D2R - / - mice treated with the cholinergic agonist pilocarpine .
Diseases: neurotoxicity, seizures"	"Sentence: Here we analyze the occurrence of seizures and neurotoxicity in D2R - / - mice treated with the cholinergic agonist pilocarpine .
Diseases:"
1714	We compared these results with those previously obtained with kainic acid ( KA ) , a potent glutamate agonist .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B I O B O O O O B O O	[]	0	0	"Sentence: We compared these results with those previously obtained with kainic acid ( KA ) , a potent glutamate agonist .
Diseases: "	"Sentence: We compared these results with those previously obtained with kainic acid ( KA ) , a potent glutamate agonist .
Diseases:"
1715	Importantly , D2R - / - mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity .	O O O O O O O O B O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['neurotoxicity', 'seizures']	2	6	"Sentence: Importantly , D2R - / - mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity .
Diseases: neurotoxicity, seizures"	"Sentence: Importantly , D2R - / - mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity .
Diseases:"
1716	However , pilocarpine - induced seizures result in a more widespread neuronal death in both WT and D2R - / - brains in comparison to KA .	O O O O O B O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O B O	['seizures']	1	3	"Sentence: However , pilocarpine - induced seizures result in a more widespread neuronal death in both WT and D2R - / - brains in comparison to KA .
Diseases: seizures"	"Sentence: However , pilocarpine - induced seizures result in a more widespread neuronal death in both WT and D2R - / - brains in comparison to KA .
Diseases:"
1717	Thus , the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine .	O O O O O O O O O O B O O O O O O O	O O O O O O O O O O O O O O B O B O	['seizures']	1	3	"Sentence: Thus , the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine .
Diseases: seizures"	"Sentence: Thus , the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine .
Diseases:"
1718	Moreover , the dopaminergic control of epilepsy - induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters .	O O O O O O B O O B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['neurodegeneration', 'epilepsy']	2	7	"Sentence: Moreover , the dopaminergic control of epilepsy - induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters .
Diseases: neurodegeneration, epilepsy"	"Sentence: Moreover , the dopaminergic control of epilepsy - induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters .
Diseases:"
1719	Treatment of risperidone - induced hyperprolactinemia with a dopamine agonist in children .	O O O O O B O O O O O O O	O O B O O O O O B O O O O	['hyperprolactinemia']	1	6	"Sentence: Treatment of risperidone - induced hyperprolactinemia with a dopamine agonist in children .
Diseases: hyperprolactinemia"	"Sentence: Treatment of risperidone - induced hyperprolactinemia with a dopamine agonist in children .
Diseases:"
1720	Risperidone , a potent antagonist of both serotonergic ( 5HT2A ) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children .	O O O O O O O O O O O O O O O O O O B O O O O O	B O O O O O O O O B O O O O O O O O O O O O O O	['hyperprolactinemia']	1	6	"Sentence: Risperidone , a potent antagonist of both serotonergic ( 5HT2A ) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children .
Diseases: hyperprolactinemia"	"Sentence: Risperidone , a potent antagonist of both serotonergic ( 5HT2A ) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children .
Diseases:"
1721	Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature .	O O O O O O O B O O O O O O O O O O O B I O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['delayed puberty', 'prolactinomas']	2	8	"Sentence: Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature .
Diseases: delayed puberty, prolactinomas"	"Sentence: Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature .
Diseases:"
1722	These possibilities stress the importance of developing a safe and effective approach to drug - induced hyperprolactinemia in youth .	O O O O O O O O O O O O O O O O B O O O	O O O O O O O O O O O O O O O O O O O O	['hyperprolactinemia']	1	6	"Sentence: These possibilities stress the importance of developing a safe and effective approach to drug - induced hyperprolactinemia in youth .
Diseases: hyperprolactinemia"	"Sentence: These possibilities stress the importance of developing a safe and effective approach to drug - induced hyperprolactinemia in youth .
Diseases:"
1723	We report the successful treatment of risperidone - induced hyperprolactinemia with cabergoline in youth .	O O O O O O O O O B O O O O O	O O O O O O B O O O O B O O O	['hyperprolactinemia']	1	6	"Sentence: We report the successful treatment of risperidone - induced hyperprolactinemia with cabergoline in youth .
Diseases: hyperprolactinemia"	"Sentence: We report the successful treatment of risperidone - induced hyperprolactinemia with cabergoline in youth .
Diseases:"
1724	We undertook a retrospective case review of four children with risperidone - induced hyperprolactinemia treated with cabergoline .	O O O O O O O O O O O O O B O O O O	O O O O O O O O O O B O O O O O B O	['hyperprolactinemia']	1	6	"Sentence: We undertook a retrospective case review of four children with risperidone - induced hyperprolactinemia treated with cabergoline .
Diseases: hyperprolactinemia"	"Sentence: We undertook a retrospective case review of four children with risperidone - induced hyperprolactinemia treated with cabergoline .
Diseases:"
1725	Four males ( age 6 - 11 years ) with Diagnostic and Statistical Manual of Mental Disorders ( fourth edition ) bipolar disorder or psychoses , with risperidone - induced elevations in serum prolactin levels ( 57 . 5 - 129 ng / mL , normal 5 - 15 ng / mL ) , were treated with cabergoline ( mean dose 2 . 13 + / - 0 . 09 mg / week ) .	O O O O O O O O O O O O O O O B I O O O O B I O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['bipolar disorder', 'mental disorders', 'psychoses']	3	9	"Sentence: Four males ( age 6 - 11 years ) with Diagnostic and Statistical Manual of Mental Disorders ( fourth edition ) bipolar disorder or psychoses , with risperidone - induced elevations in serum prolactin levels ( 57 . 5 - 129 ng / mL , normal 5 - 15 ng / mL ) , were treated with cabergoline ( mean dose 2 . 13 + / - 0 . 09 mg / week ) .
Diseases: bipolar disorder, mental disorders, psychoses"	"Sentence: Four males ( age 6 - 11 years ) with Diagnostic and Statistical Manual of Mental Disorders ( fourth edition ) bipolar disorder or psychoses , with risperidone - induced elevations in serum prolactin levels ( 57 . 5 - 129 ng / mL , normal 5 - 15 ng / mL ) , were treated with cabergoline ( mean dose 2 . 13 + / - 0 . 09 mg / week ) .
Diseases:"
1726	When serum prolactin levels normalized in all four subjects ( mean 11 . 2 + / - 10 . 9 ng / mL ) , the cabergoline dose was reduced to 1 mg / week in three of four subjects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: When serum prolactin levels normalized in all four subjects ( mean 11 . 2 + / - 10 . 9 ng / mL ) , the cabergoline dose was reduced to 1 mg / week in three of four subjects .
Diseases: "	"Sentence: When serum prolactin levels normalized in all four subjects ( mean 11 . 2 + / - 10 . 9 ng / mL ) , the cabergoline dose was reduced to 1 mg / week in three of four subjects .
Diseases:"
1727	The mean duration of therapy with cabergoline was 523 . 5 + / - 129 . 7 days , and the mean duration of therapy with risperidone was 788 . 5 + / - 162 . 5 days .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: The mean duration of therapy with cabergoline was 523 . 5 + / - 129 . 7 days , and the mean duration of therapy with risperidone was 788 . 5 + / - 162 . 5 days .
Diseases: "	"Sentence: The mean duration of therapy with cabergoline was 523 . 5 + / - 129 . 7 days , and the mean duration of therapy with risperidone was 788 . 5 + / - 162 . 5 days .
Diseases:"
1728	Cabergoline was well tolerated without adverse effects .	O O O O O O O O	B O O O O O O O	[]	0	0	"Sentence: Cabergoline was well tolerated without adverse effects .
Diseases: "	"Sentence: Cabergoline was well tolerated without adverse effects .
Diseases:"
1729	CONCLUSIONS : Cabergoline may be useful for the treatment of risperidone - induced hyperprolactinemia in youth ; however , further research is needed .	O O O O O O O O O O O O O B O O O O O O O O O O	O O B O O O O O O O B O O O O O O O O O O O O O	['hyperprolactinemia']	1	6	"Sentence: CONCLUSIONS : Cabergoline may be useful for the treatment of risperidone - induced hyperprolactinemia in youth ; however , further research is needed .
Diseases: hyperprolactinemia"	"Sentence: CONCLUSIONS : Cabergoline may be useful for the treatment of risperidone - induced hyperprolactinemia in youth ; however , further research is needed .
Diseases:"
1730	Cholestatic jaundice associated with the use of metformin .	B I O O O O O O O	O O O O O O O B O	['cholestatic jaundice']	1	7	"Sentence: Cholestatic jaundice associated with the use of metformin .
Diseases: cholestatic jaundice"	"Sentence: Cholestatic jaundice associated with the use of metformin .
Diseases:"
1731	We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride .	O O O O O O B I O O O O O O O O O	O O O O O O O O O O O O O O B I O	['cholestatic jaundice']	1	7	"Sentence: We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride .
Diseases: cholestatic jaundice"	"Sentence: We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride .
Diseases:"
1732	Ultrasound of the liver and abdominal CT were normal .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Ultrasound of the liver and abdominal CT were normal .
Diseases: "	"Sentence: Ultrasound of the liver and abdominal CT were normal .
Diseases:"
1733	An ERCP showed normal biliary anatomy .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: An ERCP showed normal biliary anatomy .
Diseases: "	"Sentence: An ERCP showed normal biliary anatomy .
Diseases:"
1734	A percutaneous liver biopsy was obtained showing marked cholestasis , with portal edema , ductular proliferation , and acute inflammation .	O O O O O O O O B O O O B O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O	['cholestasis', 'inflammation', 'edema']	3	9	"Sentence: A percutaneous liver biopsy was obtained showing marked cholestasis , with portal edema , ductular proliferation , and acute inflammation .
Diseases: cholestasis, inflammation, edema"	"Sentence: A percutaneous liver biopsy was obtained showing marked cholestasis , with portal edema , ductular proliferation , and acute inflammation .
Diseases:"
1735	Metformin hydrochloride was discontinued , and the patient 's jaundice resolved slowly over a period of several months .	O O O O O O O O O B O O O O O O O O O	B I O O O O O O O O O O O O O O O O O	['jaundice']	1	3	"Sentence: Metformin hydrochloride was discontinued , and the patient 's jaundice resolved slowly over a period of several months .
Diseases: jaundice"	"Sentence: Metformin hydrochloride was discontinued , and the patient 's jaundice resolved slowly over a period of several months .
Diseases:"
1736	Given the onset of his jaundice 2 wk after the initiation of metformin , we believe that this case represents an example of metformin - associated hepatotoxicity , the first such case reported .	O O O O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O B O O O O O O O O O O	['hepatotoxicity', 'jaundice']	2	8	"Sentence: Given the onset of his jaundice 2 wk after the initiation of metformin , we believe that this case represents an example of metformin - associated hepatotoxicity , the first such case reported .
Diseases: hepatotoxicity, jaundice"	"Sentence: Given the onset of his jaundice 2 wk after the initiation of metformin , we believe that this case represents an example of metformin - associated hepatotoxicity , the first such case reported .
Diseases:"
1737	Electro - oculography , electroretinography , visual evoked potentials , and multifocal electroretinography in patients with vigabatrin - attributed visual field constriction .	O O O O O O O O O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O O O B O O O O O O	['visual field constriction']	1	4	"Sentence: Electro - oculography , electroretinography , visual evoked potentials , and multifocal electroretinography in patients with vigabatrin - attributed visual field constriction .
Diseases: visual field constriction"	"Sentence: Electro - oculography , electroretinography , visual evoked potentials , and multifocal electroretinography in patients with vigabatrin - attributed visual field constriction .
Diseases:"
1738	Symptomatic visual field constriction thought to be associated with vigabatrin has been reported .	O B I I O O O O O O O O O O	O O O O O O O O O B O O O O	['visual field constriction']	1	4	"Sentence: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported .
Diseases: visual field constriction"	"Sentence: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported .
Diseases:"
1739	The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin - attributed visual field loss , three of whom were reported previously .	O O O O O O O O O O O O O O O O O O B I I O O O O O O O O	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	['visual field loss']	1	3	"Sentence: The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin - attributed visual field loss , three of whom were reported previously .
Diseases: visual field loss"	"Sentence: The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin - attributed visual field loss , three of whom were reported previously .
Diseases:"
1740	Six of the patients were no longer receiving vigabatrin .	O O O O O O O O O O	O O O O O O O O B O	[]	0	0	"Sentence: Six of the patients were no longer receiving vigabatrin .
Diseases: "	"Sentence: Six of the patients were no longer receiving vigabatrin .
Diseases:"
1741	The central and peripheral fields were examined with the Humphrey Visual Field Analyzer .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: The central and peripheral fields were examined with the Humphrey Visual Field Analyzer .
Diseases: "	"Sentence: The central and peripheral fields were examined with the Humphrey Visual Field Analyzer .
Diseases:"
1742	Full visual electrophysiology , including flash electroretinography ( ERG ) , pattern electroretinography , multifocal ERG using the VERIS system , electro - oculography , and flash and pattern visual evoked potentials , was undertaken .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Full visual electrophysiology , including flash electroretinography ( ERG ) , pattern electroretinography , multifocal ERG using the VERIS system , electro - oculography , and flash and pattern visual evoked potentials , was undertaken .
Diseases: "	"Sentence: Full visual electrophysiology , including flash electroretinography ( ERG ) , pattern electroretinography , multifocal ERG using the VERIS system , electro - oculography , and flash and pattern visual evoked potentials , was undertaken .
Diseases:"
1743	Seven patients showed marked visual field constriction with some sparing of the temporal visual field .	O O O O B I I O O O O O O O O O	O O O O O O O O O O O O O O O O	['visual field constriction']	1	4	"Sentence: Seven patients showed marked visual field constriction with some sparing of the temporal visual field .
Diseases: visual field constriction"	"Sentence: Seven patients showed marked visual field constriction with some sparing of the temporal visual field .
Diseases:"
1744	The eighth exhibited concentric constriction .	O O O O O O	O O O O O O	[]	0	0	"Sentence: The eighth exhibited concentric constriction .
Diseases: "	"Sentence: The eighth exhibited concentric constriction .
Diseases:"
1745	Most electrophysiological responses were usually just within normal limits ; two patients had subnormal Arden electro - oculography indices ; and one patient showed an abnormally delayed photopic b wave .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Most electrophysiological responses were usually just within normal limits ; two patients had subnormal Arden electro - oculography indices ; and one patient showed an abnormally delayed photopic b wave .
Diseases: "	"Sentence: Most electrophysiological responses were usually just within normal limits ; two patients had subnormal Arden electro - oculography indices ; and one patient showed an abnormally delayed photopic b wave .
Diseases:"
1746	However , five patients showed delayed 30 - Hz flicker b waves , and seven patients showed delayed oscillatory potentials .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , five patients showed delayed 30 - Hz flicker b waves , and seven patients showed delayed oscillatory potentials .
Diseases: "	"Sentence: However , five patients showed delayed 30 - Hz flicker b waves , and seven patients showed delayed oscillatory potentials .
Diseases:"
1747	Multifocal ERG showed abnormalities that sometimes correlated with the visual field appearance and confirmed that the deficit occurs at the retinal level .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Multifocal ERG showed abnormalities that sometimes correlated with the visual field appearance and confirmed that the deficit occurs at the retinal level .
Diseases: "	"Sentence: Multifocal ERG showed abnormalities that sometimes correlated with the visual field appearance and confirmed that the deficit occurs at the retinal level .
Diseases:"
1748	Marked visual field constriction appears to be associated with vigabatrin therapy .	O B I I O O O O O O O O	O O O O O O O O O B O O	['visual field constriction']	1	4	"Sentence: Marked visual field constriction appears to be associated with vigabatrin therapy .
Diseases: visual field constriction"	"Sentence: Marked visual field constriction appears to be associated with vigabatrin therapy .
Diseases:"
1749	The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn .	O O O O O O O O O O O O O O	O O O O O O O O O B O O O O	[]	0	0	"Sentence: The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn .
Diseases: "	"Sentence: The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn .
Diseases:"
1750	Conversion to rapamycin immunosuppression in renal transplant recipients : report of an initial experience .	O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O	[]	0	0	"Sentence: Conversion to rapamycin immunosuppression in renal transplant recipients : report of an initial experience .
Diseases: "	"Sentence: Conversion to rapamycin immunosuppression in renal transplant recipients : report of an initial experience .
Diseases:"
1751	The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine ( CsA ) or tacrolimus ( Tac ) toxicity .	O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O B O O O O B O B O O B O B O O O	['toxicity']	1	2	"Sentence: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine ( CsA ) or tacrolimus ( Tac ) toxicity .
Diseases: toxicity"	"Sentence: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine ( CsA ) or tacrolimus ( Tac ) toxicity .
Diseases:"
1752	METHODS : Twenty renal transplant recipients were switched to fixed dose rapamycin ( RAPA ) ( 5 mg / day ) 0 to 204 months posttransplant .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O B O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : Twenty renal transplant recipients were switched to fixed dose rapamycin ( RAPA ) ( 5 mg / day ) 0 to 204 months posttransplant .
Diseases: "	"Sentence: METHODS : Twenty renal transplant recipients were switched to fixed dose rapamycin ( RAPA ) ( 5 mg / day ) 0 to 204 months posttransplant .
Diseases:"
1753	Drug monitoring was not initially used to adjust doses .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Drug monitoring was not initially used to adjust doses .
Diseases: "	"Sentence: Drug monitoring was not initially used to adjust doses .
Diseases:"
1754	The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .	O O O O O O O O O B O O O O O O O O B O O O O O B I O O O O B I I O B O O O O O O O O B O O O	O O O O O O B O B O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['facial dysmorphism', 'ptld', 'posttransplant lymphoproliferative disorder', 'hepatotoxicity', 'nephrotoxicity', 'toxicity']	6	29	"Sentence: The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
Diseases: facial dysmorphism, ptld, posttransplant lymphoproliferative disorder, hepatotoxicity, nephrotoxicity, toxicity"	"Sentence: The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
Diseases:"
1755	Follow - up is 7 to 24 months .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Follow - up is 7 to 24 months .
Diseases: "	"Sentence: Follow - up is 7 to 24 months .
Diseases:"
1756	In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [ 233 + / - 34 to 210 + / - 56 micromol / liter ( P < 0 . 05 ) at 6 months ] .	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [ 233 + / - 34 to 210 + / - 56 micromol / liter ( P < 0 . 05 ) at 6 months ] .
Diseases: nephrotoxicity"	"Sentence: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [ 233 + / - 34 to 210 + / - 56 micromol / liter ( P < 0 . 05 ) at 6 months ] .
Diseases:"
1757	Facial dysmorphism improved in two patients .	B I O O O O O	O O O O O O O	['facial dysmorphism']	1	5	"Sentence: Facial dysmorphism improved in two patients .
Diseases: facial dysmorphism"	"Sentence: Facial dysmorphism improved in two patients .
Diseases:"
1758	No relapse of PTLD was observed .	O O O B O O O	O O O O O O O	['ptld']	1	2	"Sentence: No relapse of PTLD was observed .
Diseases: ptld"	"Sentence: No relapse of PTLD was observed .
Diseases:"
1759	Five patients developed pneumonia ( two Pneumocystis carinii pneumonia , one infectious mononucleosis with polyclonal PTLD lung infiltrate ) and two had bronchiolitis obliterans .	O O O B O O B I I O O B I O O B O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O	['pneumonia', 'ptld', 'bronchiolitis obliterans', 'infectious mononucleosis', 'pneumocystis carinii pneumonia']	5	28	"Sentence: Five patients developed pneumonia ( two Pneumocystis carinii pneumonia , one infectious mononucleosis with polyclonal PTLD lung infiltrate ) and two had bronchiolitis obliterans .
Diseases: pneumonia, ptld, bronchiolitis obliterans, infectious mononucleosis, pneumocystis carinii pneumonia"	"Sentence: Five patients developed pneumonia ( two Pneumocystis carinii pneumonia , one infectious mononucleosis with polyclonal PTLD lung infiltrate ) and two had bronchiolitis obliterans .
Diseases:"
1760	There were no deaths .	O O O O O	O O O O O	[]	0	0	"Sentence: There were no deaths .
Diseases: "	"Sentence: There were no deaths .
Diseases:"
1761	RAPA was discontinued in four patients , because of pneumonia in two , PTLD in one , and oral aphtous ulcers in one .	O O O O O O O O O B O O O B O O O O O B I O O O	B O O O O O O O O O O O O O O O O O O O O O O O	['pneumonia', 'ptld', 'aphtous ulcers']	3	12	"Sentence: RAPA was discontinued in four patients , because of pneumonia in two , PTLD in one , and oral aphtous ulcers in one .
Diseases: pneumonia, ptld, aphtous ulcers"	"Sentence: RAPA was discontinued in four patients , because of pneumonia in two , PTLD in one , and oral aphtous ulcers in one .
Diseases:"
1762	RAPA levels were high ( > 15 ng / ml ) in 7 of 13 ( 54 % ) patients .	O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: RAPA levels were high ( > 15 ng / ml ) in 7 of 13 ( 54 % ) patients .
Diseases: "	"Sentence: RAPA levels were high ( > 15 ng / ml ) in 7 of 13 ( 54 % ) patients .
Diseases:"
1763	CONCLUSIONS : RAPA conversion provides adequate immunosuppression to enable CsA withdrawal .	O O O O O O O O O O O O	O O B O O O O O O B O O	[]	0	0	"Sentence: CONCLUSIONS : RAPA conversion provides adequate immunosuppression to enable CsA withdrawal .
Diseases: "	"Sentence: CONCLUSIONS : RAPA conversion provides adequate immunosuppression to enable CsA withdrawal .
Diseases:"
1764	However , when converting patients to RAPA drug levels should be monitored to avoid over - immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given .	O O O O O O O O O O O O O O O O O O O O O B I I O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	['pneumocystis carinii pneumonia']	1	9	"Sentence: However , when converting patients to RAPA drug levels should be monitored to avoid over - immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given .
Diseases: pneumocystis carinii pneumonia"	"Sentence: However , when converting patients to RAPA drug levels should be monitored to avoid over - immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given .
Diseases:"
1765	Worsening of levodopa - induced dyskinesias by motor and mental tasks .	O O O O O B O O O O O O	O O B O O O O O O O O O	['dyskinesias']	1	5	"Sentence: Worsening of levodopa - induced dyskinesias by motor and mental tasks .
Diseases: dyskinesias"	"Sentence: Worsening of levodopa - induced dyskinesias by motor and mental tasks .
Diseases:"
1766	Ten patients who had Parkinson 's disease with disabling dyskinesia were included in this study to evaluate the role of mental ( mental calculation ) and motor ( flexion / extension of right fingers , flexion / extension of left fingers , flexion / extension of the neck , speaking aloud ) tasks on the worsening of peak - dose dyskinesia following administration of an effective single dose of apomorphine .	O O O O B I I O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	"['dyskinesia', ""parkinson 's disease""]"	2	11	"Sentence: Ten patients who had Parkinson 's disease with disabling dyskinesia were included in this study to evaluate the role of mental ( mental calculation ) and motor ( flexion / extension of right fingers , flexion / extension of left fingers , flexion / extension of the neck , speaking aloud ) tasks on the worsening of peak - dose dyskinesia following administration of an effective single dose of apomorphine .
Diseases: dyskinesia, parkinson 's disease"	"Sentence: Ten patients who had Parkinson 's disease with disabling dyskinesia were included in this study to evaluate the role of mental ( mental calculation ) and motor ( flexion / extension of right fingers , flexion / extension of left fingers , flexion / extension of the neck , speaking aloud ) tasks on the worsening of peak - dose dyskinesia following administration of an effective single dose of apomorphine .
Diseases:"
1767	Compared with the score at rest ( 1 . 3 + / - 0 . 3 ) , a significant aggravation of the dyskinesia score was observed during speaking aloud ( 5 . 2 + / - 1 . 1 , p < 0 . 05 ) , movements of right ( 4 . 5 + / - 1 . 0 , p < 0 . 05 ) and left ( 3 . 7 + / - 0 . 8 , p < 0 . 05 ) fingers , movements of the neck ( 5 . 1 + / - 1 . 0 , p < 0 . 05 ) , and mental calculation ( 3 . 1 + / - 1 . 0 , p < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['dyskinesia']	1	5	"Sentence: Compared with the score at rest ( 1 . 3 + / - 0 . 3 ) , a significant aggravation of the dyskinesia score was observed during speaking aloud ( 5 . 2 + / - 1 . 1 , p < 0 . 05 ) , movements of right ( 4 . 5 + / - 1 . 0 , p < 0 . 05 ) and left ( 3 . 7 + / - 0 . 8 , p < 0 . 05 ) fingers , movements of the neck ( 5 . 1 + / - 1 . 0 , p < 0 . 05 ) , and mental calculation ( 3 . 1 + / - 1 . 0 , p < 0 . 05 ) .
Diseases: dyskinesia"	"Sentence: Compared with the score at rest ( 1 . 3 + / - 0 . 3 ) , a significant aggravation of the dyskinesia score was observed during speaking aloud ( 5 . 2 + / - 1 . 1 , p < 0 . 05 ) , movements of right ( 4 . 5 + / - 1 . 0 , p < 0 . 05 ) and left ( 3 . 7 + / - 0 . 8 , p < 0 . 05 ) fingers , movements of the neck ( 5 . 1 + / - 1 . 0 , p < 0 . 05 ) , and mental calculation ( 3 . 1 + / - 1 . 0 , p < 0 . 05 ) .
Diseases:"
1768	"These results suggest that activation tasks such as "" speaking aloud "" could be used for objective assessment of dyskinesia severity ."	O O O O O O O O O O O O O O O O O O O B O O	O O O O O O O O O O O O O O O O O O O O O O	['dyskinesia']	1	5	"Sentence: These results suggest that activation tasks such as "" speaking aloud "" could be used for objective assessment of dyskinesia severity .
Diseases: dyskinesia"	"Sentence: These results suggest that activation tasks such as "" speaking aloud "" could be used for objective assessment of dyskinesia severity .
Diseases:"
1769	Structural and functional impairment of mitochondria in adriamycin - induced cardiomyopathy in mice : suppression of cytochrome	B I I I I I O O O O B O O O O O O	O O O O O O O B O O O O O O O O O	['cardiomyopathy', 'structural and functional impairment of mitochondria']	2	12	"Sentence: Structural and functional impairment of mitochondria in adriamycin - induced cardiomyopathy in mice : suppression of cytochrome
Diseases: cardiomyopathy, structural and functional impairment of mitochondria"	"Sentence: Structural and functional impairment of mitochondria in adriamycin - induced cardiomyopathy in mice : suppression of cytochrome
Diseases:"
1770	c oxidase II gene expression .	O O O O O O	O O O O O O	[]	0	0	"Sentence: c oxidase II gene expression .
Diseases: "	"Sentence: c oxidase II gene expression .
Diseases:"
1771	The use of adriamycin ( ADR ) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity .	O O O O O O O O B O O O O O O O O B I O	O O O B O B O O O O O O O O O O O O O O	['cardiovascular toxicity', 'cancer']	2	5	"Sentence: The use of adriamycin ( ADR ) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity .
Diseases: cardiovascular toxicity, cancer"	"Sentence: The use of adriamycin ( ADR ) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity .
Diseases:"
1772	Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase ( COX ) and suppresses its enzyme activity led us to investigate ADR 's action on the cardiovascular functions and heart mitochondrial morphology in Balb - c mice i . p .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase ( COX ) and suppresses its enzyme activity led us to investigate ADR 's action on the cardiovascular functions and heart mitochondrial morphology in Balb - c mice i . p .
Diseases: "	"Sentence: Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase ( COX ) and suppresses its enzyme activity led us to investigate ADR 's action on the cardiovascular functions and heart mitochondrial morphology in Balb - c mice i . p .
Diseases:"
1773	treated with ADR for several weeks .	O O O O O O O	O O B O O O O	[]	0	0	"Sentence: treated with ADR for several weeks .
Diseases: "	"Sentence: treated with ADR for several weeks .
Diseases:"
1774	At various times during treatment , the animals were assessed for cardiovascular functions by electrocardiography and for heart tissue damage by electron microscopy .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At various times during treatment , the animals were assessed for cardiovascular functions by electrocardiography and for heart tissue damage by electron microscopy .
Diseases: "	"Sentence: At various times during treatment , the animals were assessed for cardiovascular functions by electrocardiography and for heart tissue damage by electron microscopy .
Diseases:"
1775	In parallel , total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady - state level of three RNA transcripts encoded by the COXII , COXIII , and COXIV genes .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In parallel , total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady - state level of three RNA transcripts encoded by the COXII , COXIII , and COXIV genes .
Diseases: "	"Sentence: In parallel , total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady - state level of three RNA transcripts encoded by the COXII , COXIII , and COXIV genes .
Diseases:"
1776	Similarly , samples obtained from the liver of the same animals were analyzed for comparative studies .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Similarly , samples obtained from the liver of the same animals were analyzed for comparative studies .
Diseases: "	"Sentence: Similarly , samples obtained from the liver of the same animals were analyzed for comparative studies .
Diseases:"
1777	Our results indicated that 1 ) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia , extension of ventricular depolarization time ( tQRS ) , and failure of QRS at high concentrations ( 10 - 14 mg / kg body weight cumulative dose ) ; 2 ) the heart mitochondria underwent swelling , fusion , dissolution , and / or disruption of mitochondrial cristae after several weeks of treatment .	O O O O O O O O O O O O B I O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['swelling', 'cardiovascular arrhythmias', 'bradycardia']	3	13	"Sentence: Our results indicated that 1 ) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia , extension of ventricular depolarization time ( tQRS ) , and failure of QRS at high concentrations ( 10 - 14 mg / kg body weight cumulative dose ) ; 2 ) the heart mitochondria underwent swelling , fusion , dissolution , and / or disruption of mitochondrial cristae after several weeks of treatment .
Diseases: swelling, cardiovascular arrhythmias, bradycardia"	"Sentence: Our results indicated that 1 ) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia , extension of ventricular depolarization time ( tQRS ) , and failure of QRS at high concentrations ( 10 - 14 mg / kg body weight cumulative dose ) ; 2 ) the heart mitochondria underwent swelling , fusion , dissolution , and / or disruption of mitochondrial cristae after several weeks of treatment .
Diseases:"
1778	Such abnormalities were not observed in the mitochondria of liver tissue ; and 3 ) among the three genes of COX enzyme examined , only COXII gene expression was suppressed by ADR treatment , mainly after 8 weeks in both heart and liver .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: Such abnormalities were not observed in the mitochondria of liver tissue ; and 3 ) among the three genes of COX enzyme examined , only COXII gene expression was suppressed by ADR treatment , mainly after 8 weeks in both heart and liver .
Diseases: "	"Sentence: Such abnormalities were not observed in the mitochondria of liver tissue ; and 3 ) among the three genes of COX enzyme examined , only COXII gene expression was suppressed by ADR treatment , mainly after 8 weeks in both heart and liver .
Diseases:"
1779	Knowing that heart mitochondria represent almost 40 % of heart muscle by weight , we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment .	O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I I O	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	['mitochondrial structural and functional impairment']	1	7	"Sentence: Knowing that heart mitochondria represent almost 40 % of heart muscle by weight , we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment .
Diseases: mitochondrial structural and functional impairment"	"Sentence: Knowing that heart mitochondria represent almost 40 % of heart muscle by weight , we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment .
Diseases:"
1780	Enhanced bradycardia induced by beta - adrenoceptor antagonists in rats pretreated with isoniazid .	O B O O O O O O O O O O O O	O O O O O O O O O O O O B O	['bradycardia']	1	4	"Sentence: Enhanced bradycardia induced by beta - adrenoceptor antagonists in rats pretreated with isoniazid .
Diseases: bradycardia"	"Sentence: Enhanced bradycardia induced by beta - adrenoceptor antagonists in rats pretreated with isoniazid .
Diseases:"
1781	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia , an interaction attributed to decreased synthesis of brain gamma - aminobutyric acid ( GABA ) .	O O O O O B O O O O O O O O B O B O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O O B I I I O B O O	['bradycardia', 'tachycardia', 'hypotension']	3	12	"Sentence: High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia , an interaction attributed to decreased synthesis of brain gamma - aminobutyric acid ( GABA ) .
Diseases: bradycardia, tachycardia, hypotension"	"Sentence: High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia , an interaction attributed to decreased synthesis of brain gamma - aminobutyric acid ( GABA ) .
Diseases:"
1782	In the present study , the possible enhancement by isoniazid of bradycardia induced by beta - adrenoceptor antagonists was determined in rats anaesthetised with chloralose - urethane .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O B O B O	['bradycardia']	1	4	"Sentence: In the present study , the possible enhancement by isoniazid of bradycardia induced by beta - adrenoceptor antagonists was determined in rats anaesthetised with chloralose - urethane .
Diseases: bradycardia"	"Sentence: In the present study , the possible enhancement by isoniazid of bradycardia induced by beta - adrenoceptor antagonists was determined in rats anaesthetised with chloralose - urethane .
Diseases:"
1783	Isoniazid significantly increased bradycardia after propranolol , pindolol , labetalol and atenolol , as well as after clonidine , but not after hexamethonium or carbachol .	O O O B O O O O O O O O O O O O O O O O O O O O O O	B O O O O B O B O B O B O O O O O B O O O O B O B O	['bradycardia']	1	4	"Sentence: Isoniazid significantly increased bradycardia after propranolol , pindolol , labetalol and atenolol , as well as after clonidine , but not after hexamethonium or carbachol .
Diseases: bradycardia"	"Sentence: Isoniazid significantly increased bradycardia after propranolol , pindolol , labetalol and atenolol , as well as after clonidine , but not after hexamethonium or carbachol .
Diseases:"
1784	Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised .	O O O O O O O O O O O O O	O O O O O O O O B O O O O	[]	0	0	"Sentence: Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised .
Diseases: "	"Sentence: Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised .
Diseases:"
1785	These results are compatible with interference by isoniazid with GABAergic inhibition of cardiac parasympathetic tone .	O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: These results are compatible with interference by isoniazid with GABAergic inhibition of cardiac parasympathetic tone .
Diseases: "	"Sentence: These results are compatible with interference by isoniazid with GABAergic inhibition of cardiac parasympathetic tone .
Diseases:"
1786	Such interference could be exerted centrally , possibly at the nucleus ambiguus , or peripherally at the sinus node .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Such interference could be exerted centrally , possibly at the nucleus ambiguus , or peripherally at the sinus node .
Diseases: "	"Sentence: Such interference could be exerted centrally , possibly at the nucleus ambiguus , or peripherally at the sinus node .
Diseases:"
1787	Epileptogenic activity of folic acid after drug induces SLE ( folic acid and epilepsy )	O O O O O O O O B O O O O B O	O O O B I O O O O O B I O O O	['epilepsy', 'sle']	2	5	"Sentence: Epileptogenic activity of folic acid after drug induces SLE ( folic acid and epilepsy )
Diseases: epilepsy, sle"	"Sentence: Epileptogenic activity of folic acid after drug induces SLE ( folic acid and epilepsy )
Diseases:"
1788	To study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects .	O O O O O O O O O O O O B O O O O O O O O O O O O O B I O B O O O O O	O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['epileptic', 'birth defects', 'epilepsy']	3	8	"Sentence: To study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects .
Diseases: epileptic, birth defects, epilepsy"	"Sentence: To study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects .
Diseases:"
1789	STUDY DESIGN :	O O O	O O O	[]	0	0	"Sentence: STUDY DESIGN :
Diseases: "	"Sentence: STUDY DESIGN :
Diseases:"
1790	First a randomised trial , later periconception care including in total 12225 females .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: First a randomised trial , later periconception care including in total 12225 females .
Diseases: "	"Sentence: First a randomised trial , later periconception care including in total 12225 females .
Diseases:"
1791	RESULTS : Of 60 epileptic women with periconceptional folic acid ( 0 . 8 mg ) - containing multivitamin supplementation , no one developed epilepsy - related side effects during the periconception period .	O O O O B O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O	['epileptic', 'epilepsy']	2	5	"Sentence: RESULTS : Of 60 epileptic women with periconceptional folic acid ( 0 . 8 mg ) - containing multivitamin supplementation , no one developed epilepsy - related side effects during the periconception period .
Diseases: epileptic, epilepsy"	"Sentence: RESULTS : Of 60 epileptic women with periconceptional folic acid ( 0 . 8 mg ) - containing multivitamin supplementation , no one developed epilepsy - related side effects during the periconception period .
Diseases:"
1792	One epileptic woman delivered a newborn with cleft lip and palate .	O B O O O O O B I I I O	O O O O O O O O O O O O	['epileptic', 'cleft lip and palate']	2	9	"Sentence: One epileptic woman delivered a newborn with cleft lip and palate .
Diseases: epileptic, cleft lip and palate"	"Sentence: One epileptic woman delivered a newborn with cleft lip and palate .
Diseases:"
1793	Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin .	O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O	['seizures']	1	3	"Sentence: Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin .
Diseases: seizures"	"Sentence: Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin .
Diseases:"
1794	This 22 - year - old epileptic woman was treated continuously by carbamazepine and a folic acid ( 1 mg ) - containing multivitamin from the 20th week of gestation .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O B I O O O O O O O O O O O O O O	['epileptic']	1	3	"Sentence: This 22 - year - old epileptic woman was treated continuously by carbamazepine and a folic acid ( 1 mg ) - containing multivitamin from the 20th week of gestation .
Diseases: epileptic"	"Sentence: This 22 - year - old epileptic woman was treated continuously by carbamazepine and a folic acid ( 1 mg ) - containing multivitamin from the 20th week of gestation .
Diseases:"
1795	She developed status epilepticus and later symptoms of systemic lupus erythematodes .	O O B I O O O O B I I O	O O O O O O O O O O O O	['status epilepticus', 'systemic lupus erythematodes']	2	14	"Sentence: She developed status epilepticus and later symptoms of systemic lupus erythematodes .
Diseases: status epilepticus, systemic lupus erythematodes"	"Sentence: She developed status epilepticus and later symptoms of systemic lupus erythematodes .
Diseases:"
1796	Her pregnancy ended with stillbirth .	O O O O B O	O O O O O O	['stillbirth']	1	2	"Sentence: Her pregnancy ended with stillbirth .
Diseases: stillbirth"	"Sentence: Her pregnancy ended with stillbirth .
Diseases:"
1797	CONCLUSIONS : The epileptic pregnant patient 's autoimmune disease ( probably drug - induced lupus ) could damage the blood - brain barrier , therefore the therapeutic dose ( > or = 1 mg ) of folic acid triggered a cluster of seizures .	O O O B O O O B I O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O	['lupus', 'epileptic', 'seizures', 'autoimmune disease']	4	11	"Sentence: CONCLUSIONS : The epileptic pregnant patient 's autoimmune disease ( probably drug - induced lupus ) could damage the blood - brain barrier , therefore the therapeutic dose ( > or = 1 mg ) of folic acid triggered a cluster of seizures .
Diseases: lupus, epileptic, seizures, autoimmune disease"	"Sentence: CONCLUSIONS : The epileptic pregnant patient 's autoimmune disease ( probably drug - induced lupus ) could damage the blood - brain barrier , therefore the therapeutic dose ( > or = 1 mg ) of folic acid triggered a cluster of seizures .
Diseases:"
1798	Physiological dose ( < 1 mg ) of folic acid both in healthy and 60 epileptic women , all without any autoimmune disease , did not increase the risk for epileptic seizures .	O O O O O O O O O O O O O O O B O O O O O B I O O O O O O O B I O	O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O	['epileptic', 'autoimmune disease', 'epileptic seizures']	3	10	"Sentence: Physiological dose ( < 1 mg ) of folic acid both in healthy and 60 epileptic women , all without any autoimmune disease , did not increase the risk for epileptic seizures .
Diseases: epileptic, autoimmune disease, epileptic seizures"	"Sentence: Physiological dose ( < 1 mg ) of folic acid both in healthy and 60 epileptic women , all without any autoimmune disease , did not increase the risk for epileptic seizures .
Diseases:"
1799	Effects of cisapride on symptoms and postcibal small - bowel motor function in patients with irritable bowel syndrome .	O O O O O O O O O O O O O O O B I I O	O O B O O O O O O O O O O O O O O O O	['irritable bowel syndrome']	1	5	"Sentence: Effects of cisapride on symptoms and postcibal small - bowel motor function in patients with irritable bowel syndrome .
Diseases: irritable bowel syndrome"	"Sentence: Effects of cisapride on symptoms and postcibal small - bowel motor function in patients with irritable bowel syndrome .
Diseases:"
1800	Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility .	B I I O O O O O B I O O O O O O O B I I O	O O O O O O O O O O O O O O O O O O O O O	['irritable bowel syndrome', 'abdominal pain', 'disordered gastrointestinal motility']	3	14	"Sentence: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility .
Diseases: irritable bowel syndrome, abdominal pain, disordered gastrointestinal motility"	"Sentence: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility .
Diseases:"
1801	Our aim was to assess the effects of long - term treatment with a prokinetic agent , cisapride , on postprandial jejunal motility and symptoms in the irritable bowel syndrome ( IBS ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O B O O	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	['ibs', 'irritable bowel syndrome']	2	7	"Sentence: Our aim was to assess the effects of long - term treatment with a prokinetic agent , cisapride , on postprandial jejunal motility and symptoms in the irritable bowel syndrome ( IBS ) .
Diseases: ibs, irritable bowel syndrome"	"Sentence: Our aim was to assess the effects of long - term treatment with a prokinetic agent , cisapride , on postprandial jejunal motility and symptoms in the irritable bowel syndrome ( IBS ) .
Diseases:"
1802	Thirty - eight patients with IBS ( constipation - predominant , n = 17 ; diarrhoea - predominant , n = 21 ) underwent 24 - h ambulatory jejunal manometry before and after 12 week 's treatment [ cisapride , 5 mg three times daily ( n = 19 ) or placebo ( n = 19 ) ] .	O O O O O B O B O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['ibs', 'constipation', 'diarrhoea']	3	9	"Sentence: Thirty - eight patients with IBS ( constipation - predominant , n = 17 ; diarrhoea - predominant , n = 21 ) underwent 24 - h ambulatory jejunal manometry before and after 12 week 's treatment [ cisapride , 5 mg three times daily ( n = 19 ) or placebo ( n = 19 ) ] .
Diseases: ibs, constipation, diarrhoea"	"Sentence: Thirty - eight patients with IBS ( constipation - predominant , n = 17 ; diarrhoea - predominant , n = 21 ) underwent 24 - h ambulatory jejunal manometry before and after 12 week 's treatment [ cisapride , 5 mg three times daily ( n = 19 ) or placebo ( n = 19 ) ] .
Diseases:"
1803	In diarrhoea - predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups .	O B O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O	['diarrhoea']	1	4	"Sentence: In diarrhoea - predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups .
Diseases: diarrhoea"	"Sentence: In diarrhoea - predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups .
Diseases:"
1804	In cisapride - treated diarrhoea - predominant patients the mean contraction amplitude was higher ( 29 . 3 + / - 3 . 2 versus 24 . 9 + / -	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['diarrhoea']	1	4	"Sentence: In cisapride - treated diarrhoea - predominant patients the mean contraction amplitude was higher ( 29 . 3 + / - 3 . 2 versus 24 . 9 + / -
Diseases: diarrhoea"	"Sentence: In cisapride - treated diarrhoea - predominant patients the mean contraction amplitude was higher ( 29 . 3 + / - 3 . 2 versus 24 . 9 + / -
Diseases:"
1805	2 . 6 mm	O O O O	O O O O	[]	0	0	"Sentence: 2 . 6 mm
Diseases: "	"Sentence: 2 . 6 mm
Diseases:"
1806	Hg , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 25 . 7 + / - 6 . 0 mm Hg ) , the mean contraction duration longer ( 3 . 4 + / - 0 . 2 versus 3 . 0 + / - 0 . 2 sec , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 3 . 1 + / - 0 . 5 sec ) , and the mean contraction frequency lower ( 2 . 0 + / - 0 . 2 versus 2 . 5 + / - 0 . 4 cont . / min , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 2 . 5 + / - 1 . 1 cont . / min ] than patients treated with placebo .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Hg , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 25 . 7 + / - 6 . 0 mm Hg ) , the mean contraction duration longer ( 3 . 4 + / - 0 . 2 versus 3 . 0 + / - 0 . 2 sec , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 3 . 1 + / - 0 . 5 sec ) , and the mean contraction frequency lower ( 2 . 0 + / - 0 . 2 versus 2 . 5 + / - 0 . 4 cont . / min , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 2 . 5 + / - 1 . 1 cont . / min ] than patients treated with placebo .
Diseases: "	"Sentence: Hg , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 25 . 7 + / - 6 . 0 mm Hg ) , the mean contraction duration longer ( 3 . 4 + / - 0 . 2 versus 3 . 0 + / - 0 . 2 sec , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 3 . 1 + / - 0 . 5 sec ) , and the mean contraction frequency lower ( 2 . 0 + / - 0 . 2 versus 2 . 5 + / - 0 . 4 cont . / min , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 2 . 5 + / - 1 . 1 cont . / min ] than patients treated with placebo .
Diseases:"
1807	No significant differences in jejunal motility were found in the constipation - predominant IBS group .	O O O O O O O O O O B O O B O O	O O O O O O O O O O O O O O O O	['ibs', 'constipation']	2	5	"Sentence: No significant differences in jejunal motility were found in the constipation - predominant IBS group .
Diseases: ibs, constipation"	"Sentence: No significant differences in jejunal motility were found in the constipation - predominant IBS group .
Diseases:"
1808	Symptoms were assessed by using a visual analogue scale before and after treatment .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Symptoms were assessed by using a visual analogue scale before and after treatment .
Diseases: "	"Sentence: Symptoms were assessed by using a visual analogue scale before and after treatment .
Diseases:"
1809	Symptom scores relating to the severity of constipation were lower in cisapride - treated constipation - predominant IBS patients [ score , 54 + / - 5 versus 67 + / -	O O O O O O O B O O O O O O B O O B O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['ibs', 'constipation']	2	5	"Sentence: Symptom scores relating to the severity of constipation were lower in cisapride - treated constipation - predominant IBS patients [ score , 54 + / - 5 versus 67 + / -
Diseases: ibs, constipation"	"Sentence: Symptom scores relating to the severity of constipation were lower in cisapride - treated constipation - predominant IBS patients [ score , 54 + / - 5 versus 67 + / -
Diseases:"
1810	14 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 62 + / -	O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 14 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 62 + / -
Diseases: "	"Sentence: 14 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 62 + / -
Diseases:"
1811	19 mm ] .	O O O O	O O O O	[]	0	0	"Sentence: 19 mm ] .
Diseases: "	"Sentence: 19 mm ] .
Diseases:"
1812	Diarrhoea - predominant IBS patients had a higher pain score after cisapride therapy [ score , 55 + / - 15 versus 34 + / - 12 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 67 + / -	B O O B O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	['ibs', 'pain', 'diarrhoea']	3	8	"Sentence: Diarrhoea - predominant IBS patients had a higher pain score after cisapride therapy [ score , 55 + / - 15 versus 34 + / - 12 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 67 + / -
Diseases: ibs, pain, diarrhoea"	"Sentence: Diarrhoea - predominant IBS patients had a higher pain score after cisapride therapy [ score , 55 + / - 15 versus 34 + / - 12 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 67 + / -
Diseases:"
1813	Cisapride affects jejunal contraction characteristics and some symptoms in IBS .	O O O O O O O O O B O	B O O O O O O O O O O	['ibs']	1	2	"Sentence: Cisapride affects jejunal contraction characteristics and some symptoms in IBS .
Diseases: ibs"	"Sentence: Cisapride affects jejunal contraction characteristics and some symptoms in IBS .
Diseases:"
1814	Clarithromycin - induced ventricular tachycardia .	O O O B I O	B O O O O O	['ventricular tachycardia']	1	6	"Sentence: Clarithromycin - induced ventricular tachycardia .
Diseases: ventricular tachycardia"	"Sentence: Clarithromycin - induced ventricular tachycardia .
Diseases:"
1815	Clarithromycin is a relatively new macrolide antibiotic that offers twice - daily dosing .	O O O O O O O O O O O O O O	B O O O O B O O O O O O O O	[]	0	0	"Sentence: Clarithromycin is a relatively new macrolide antibiotic that offers twice - daily dosing .
Diseases: "	"Sentence: Clarithromycin is a relatively new macrolide antibiotic that offers twice - daily dosing .
Diseases:"
1816	It differs from erythromycin only in the methylation of the hydroxyl group at position 6 .	O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: It differs from erythromycin only in the methylation of the hydroxyl group at position 6 .
Diseases: "	"Sentence: It differs from erythromycin only in the methylation of the hydroxyl group at position 6 .
Diseases:"
1817	Although the side - effect profile of erythromycin is established , including gastroenteritis and interactions with other drugs subject to hepatic mixed - function oxidase metabolism , experience with the newer macrolides is still being recorded .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	['gastroenteritis']	1	5	"Sentence: Although the side - effect profile of erythromycin is established , including gastroenteritis and interactions with other drugs subject to hepatic mixed - function oxidase metabolism , experience with the newer macrolides is still being recorded .
Diseases: gastroenteritis"	"Sentence: Although the side - effect profile of erythromycin is established , including gastroenteritis and interactions with other drugs subject to hepatic mixed - function oxidase metabolism , experience with the newer macrolides is still being recorded .
Diseases:"
1818	Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides .	B O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O B O	['cardiotoxicity']	1	3	"Sentence: Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides .
Diseases: cardiotoxicity"	"Sentence: Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides .
Diseases:"
1819	We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin .	O O O O O B I O O O O O O O O O	O O O O O O O O O O O O O O B O	['ventricular dysrhythmias']	1	6	"Sentence: We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin .
Diseases: ventricular dysrhythmias"	"Sentence: We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin .
Diseases:"
1820	The dysrhythmias resolved after discontinuation of the drug .	O B O O O O O O O	O O O O O O O O O	['dysrhythmias']	1	5	"Sentence: The dysrhythmias resolved after discontinuation of the drug .
Diseases: dysrhythmias"	"Sentence: The dysrhythmias resolved after discontinuation of the drug .
Diseases:"
1821	Persistent nephrogenic diabetes insipidus following lithium therapy .	O B I I O O O O	O O O O O B O O	['nephrogenic diabetes insipidus']	1	9	"Sentence: Persistent nephrogenic diabetes insipidus following lithium therapy .
Diseases: nephrogenic diabetes insipidus"	"Sentence: Persistent nephrogenic diabetes insipidus following lithium therapy .
Diseases:"
1822	We report the case of a patient who developed severe hypernatraemic dehydration following a head injury .	O O O O O O O O O O O B O O B I O	O O O O O O O O O O O O O O O O O	['head injury', 'dehydration']	2	4	"Sentence: We report the case of a patient who developed severe hypernatraemic dehydration following a head injury .
Diseases: head injury, dehydration"	"Sentence: We report the case of a patient who developed severe hypernatraemic dehydration following a head injury .
Diseases:"
1823	Ten years previously he had been diagnosed to have lithium - induced nephrogenic diabetes insipidus , and lithium therapy had been discontinued .	O O O O O O O O O O O O B I I O O O O O O O O	O O O O O O O O O B O O O O O O O B O O O O O	['nephrogenic diabetes insipidus']	1	9	"Sentence: Ten years previously he had been diagnosed to have lithium - induced nephrogenic diabetes insipidus , and lithium therapy had been discontinued .
Diseases: nephrogenic diabetes insipidus"	"Sentence: Ten years previously he had been diagnosed to have lithium - induced nephrogenic diabetes insipidus , and lithium therapy had been discontinued .
Diseases:"
1824	He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion , with clear evidence of nephrogenic diabetes insipidus .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O B I I O	O O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O	['nephrogenic diabetes insipidus', 'polyuric']	2	13	"Sentence: He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion , with clear evidence of nephrogenic diabetes insipidus .
Diseases: nephrogenic diabetes insipidus, polyuric"	"Sentence: He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion , with clear evidence of nephrogenic diabetes insipidus .
Diseases:"
1825	Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped .	O O B I I O O O O O O O O O O B O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O B O O O	['polyuria', 'nephrogenic diabetes insipidus']	2	12	"Sentence: Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped .
Diseases: polyuria, nephrogenic diabetes insipidus"	"Sentence: Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped .
Diseases:"
1826	We discuss the possible renal mechanisms and the implications for management of patients with lithium - induced nephrogenic diabetes insipidus .	O O O O O O O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O B O O O O O O	['nephrogenic diabetes insipidus']	1	9	"Sentence: We discuss the possible renal mechanisms and the implications for management of patients with lithium - induced nephrogenic diabetes insipidus .
Diseases: nephrogenic diabetes insipidus"	"Sentence: We discuss the possible renal mechanisms and the implications for management of patients with lithium - induced nephrogenic diabetes insipidus .
Diseases:"
1827	Late cardiotoxicity after treatment for a malignant bone tumor .	O B O O O O O B I O	O O O O O O O O O O	['cardiotoxicity', 'bone tumor']	2	6	"Sentence: Late cardiotoxicity after treatment for a malignant bone tumor .
Diseases: cardiotoxicity, bone tumor"	"Sentence: Late cardiotoxicity after treatment for a malignant bone tumor .
Diseases:"
1828	Cardiac function was assessed in long - term survivors of malignant bone tumors who were treated according to Rosen 's T5 or T10 protocol , both including doxorubicin .	O O O O O O O O O O O B I O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['bone tumors']	1	2	"Sentence: Cardiac function was assessed in long - term survivors of malignant bone tumors who were treated according to Rosen 's T5 or T10 protocol , both including doxorubicin .
Diseases: bone tumors"	"Sentence: Cardiac function was assessed in long - term survivors of malignant bone tumors who were treated according to Rosen 's T5 or T10 protocol , both including doxorubicin .
Diseases:"
1829	Thirty - one patients , age 10 - 45 years ( median age 17 . 8 years ) were evaluated 2 . 3 - 14 . 1 years ( median 8 . 9 years ) following completion of treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thirty - one patients , age 10 - 45 years ( median age 17 . 8 years ) were evaluated 2 . 3 - 14 . 1 years ( median 8 . 9 years ) following completion of treatment .
Diseases: "	"Sentence: Thirty - one patients , age 10 - 45 years ( median age 17 . 8 years ) were evaluated 2 . 3 - 14 . 1 years ( median 8 . 9 years ) following completion of treatment .
Diseases:"
1830	Cumulative doses of doxorubicin were 225 - 550 mg / m2 ( median dose 360 ) .	O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: Cumulative doses of doxorubicin were 225 - 550 mg / m2 ( median dose 360 ) .
Diseases: "	"Sentence: Cumulative doses of doxorubicin were 225 - 550 mg / m2 ( median dose 360 ) .
Diseases:"
1831	The evaluation consisted of a history , physical examination , electrocardiogram ( ECG ) , signal averaged ECG , 24 - hour ambulatory ECG , echocardiography and radionuclide angiography .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The evaluation consisted of a history , physical examination , electrocardiogram ( ECG ) , signal averaged ECG , 24 - hour ambulatory ECG , echocardiography and radionuclide angiography .
Diseases: "	"Sentence: The evaluation consisted of a history , physical examination , electrocardiogram ( ECG ) , signal averaged ECG , 24 - hour ambulatory ECG , echocardiography and radionuclide angiography .
Diseases:"
1832	Eighteen of 31 ( 58 % ) patients showed cardiac toxicity , defined as having one or more of the following abnormalities : late potentials , complex ventricular arrhythmias , left ventricular dilation , decreased shortening fraction , or decreased ejection fraction .	O O O O O O O O O B I O O O O O O O O O O O O O O O O B I O O B I O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ventricular dilation', 'cardiac toxicity', 'ventricular arrhythmias']	3	14	"Sentence: Eighteen of 31 ( 58 % ) patients showed cardiac toxicity , defined as having one or more of the following abnormalities : late potentials , complex ventricular arrhythmias , left ventricular dilation , decreased shortening fraction , or decreased ejection fraction .
Diseases: ventricular dilation, cardiac toxicity, ventricular arrhythmias"	"Sentence: Eighteen of 31 ( 58 % ) patients showed cardiac toxicity , defined as having one or more of the following abnormalities : late potentials , complex ventricular arrhythmias , left ventricular dilation , decreased shortening fraction , or decreased ejection fraction .
Diseases:"
1833	The incidence of cardiac abnormalities increased with length of follow - up ( P < or = . 05 ) .	O O O B I O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	['cardiac abnormalities']	1	3	"Sentence: The incidence of cardiac abnormalities increased with length of follow - up ( P < or = . 05 ) .
Diseases: cardiac abnormalities"	"Sentence: The incidence of cardiac abnormalities increased with length of follow - up ( P < or = . 05 ) .
Diseases:"
1834	No correlation could be demonstrated between cumulative dose of doxorubicin and cardiac status , except for heart rate variability .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: No correlation could be demonstrated between cumulative dose of doxorubicin and cardiac status , except for heart rate variability .
Diseases: "	"Sentence: No correlation could be demonstrated between cumulative dose of doxorubicin and cardiac status , except for heart rate variability .
Diseases:"
1835	When adjusted to body surface area , the left ventricular posterior wall thickness ( LVPW index ) was decreased in all patients .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: When adjusted to body surface area , the left ventricular posterior wall thickness ( LVPW index ) was decreased in all patients .
Diseases: "	"Sentence: When adjusted to body surface area , the left ventricular posterior wall thickness ( LVPW index ) was decreased in all patients .
Diseases:"
1836	The incidence of doxorubicin - induced cardiotoxicity is high and increases with follow - up , irrespective of cumulative dose .	O O O O O O B O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O	['cardiotoxicity']	1	3	"Sentence: The incidence of doxorubicin - induced cardiotoxicity is high and increases with follow - up , irrespective of cumulative dose .
Diseases: cardiotoxicity"	"Sentence: The incidence of doxorubicin - induced cardiotoxicity is high and increases with follow - up , irrespective of cumulative dose .
Diseases:"
1837	Life - long cardiac follow - up in these patients is warranted .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Life - long cardiac follow - up in these patients is warranted .
Diseases: "	"Sentence: Life - long cardiac follow - up in these patients is warranted .
Diseases:"
1838	The results of our study suggest that heart rate variability and LVPW index could be sensitive indicators for cardiotoxicity .	O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O	['cardiotoxicity']	1	3	"Sentence: The results of our study suggest that heart rate variability and LVPW index could be sensitive indicators for cardiotoxicity .
Diseases: cardiotoxicity"	"Sentence: The results of our study suggest that heart rate variability and LVPW index could be sensitive indicators for cardiotoxicity .
Diseases:"
1839	Venous complications of midazolam versus diazepam .	B I O O O O O	O O O B O B O	['venous complications']	1	3	"Sentence: Venous complications of midazolam versus diazepam .
Diseases: venous complications"	"Sentence: Venous complications of midazolam versus diazepam .
Diseases:"
1840	Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures , this variable has not been well documented .	O O O O O O B I O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O B O O O O O O O O O O O O	['venous complications']	1	3	"Sentence: Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures , this variable has not been well documented .
Diseases: venous complications"	"Sentence: Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures , this variable has not been well documented .
Diseases:"
1841	We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy .	O O O O O O B I O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O B O O O O O O O O O	['venous complications']	1	3	"Sentence: We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy .
Diseases: venous complications"	"Sentence: We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy .
Diseases:"
1842	Overall , venous complications were more frequent with diazepam ( 22 of 62 patients ) than with midazolam ( 4 of 60 patients ) ( p < 0 . 001 ) .	O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O B O O O O O O O O O O O O O O	['venous complications']	1	3	"Sentence: Overall , venous complications were more frequent with diazepam ( 22 of 62 patients ) than with midazolam ( 4 of 60 patients ) ( p < 0 . 001 ) .
Diseases: venous complications"	"Sentence: Overall , venous complications were more frequent with diazepam ( 22 of 62 patients ) than with midazolam ( 4 of 60 patients ) ( p < 0 . 001 ) .
Diseases:"
1843	A palpable venous cord was present in 23 % ( 14 of 62 ) of patients in the diazepam group , compared with 2 % ( 1 of 60 patients ) in the midazolam group ( p < 0 . 002 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: A palpable venous cord was present in 23 % ( 14 of 62 ) of patients in the diazepam group , compared with 2 % ( 1 of 60 patients ) in the midazolam group ( p < 0 . 002 ) .
Diseases: "	"Sentence: A palpable venous cord was present in 23 % ( 14 of 62 ) of patients in the diazepam group , compared with 2 % ( 1 of 60 patients ) in the midazolam group ( p < 0 . 002 ) .
Diseases:"
1844	Pain at the injection site occurred in 35 % ( 22 of 62 ) of patients in the diazepam group compared with 7 % ( 4 of 60 patients ) in the midazolam group ( p < 0 . 001 ) .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O B O O O O O O O O O	['pain']	1	1	"Sentence: Pain at the injection site occurred in 35 % ( 22 of 62 ) of patients in the diazepam group compared with 7 % ( 4 of 60 patients ) in the midazolam group ( p < 0 . 001 ) .
Diseases: pain"	"Sentence: Pain at the injection site occurred in 35 % ( 22 of 62 ) of patients in the diazepam group compared with 7 % ( 4 of 60 patients ) in the midazolam group ( p < 0 . 001 ) .
Diseases:"
1845	Swelling and warmth at the injection site were not significantly different between the two groups .	B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	['swelling']	1	2	"Sentence: Swelling and warmth at the injection site were not significantly different between the two groups .
Diseases: swelling"	"Sentence: Swelling and warmth at the injection site were not significantly different between the two groups .
Diseases:"
1846	Smoking , nonsteroidal anti - inflammatory drug use , intravenous catheter site , dwell time of the needle , alcohol use , and pain during the injection had no effect on the incidence of venous complications .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['pain', 'venous complications']	2	5	"Sentence: Smoking , nonsteroidal anti - inflammatory drug use , intravenous catheter site , dwell time of the needle , alcohol use , and pain during the injection had no effect on the incidence of venous complications .
Diseases: pain, venous complications"	"Sentence: Smoking , nonsteroidal anti - inflammatory drug use , intravenous catheter site , dwell time of the needle , alcohol use , and pain during the injection had no effect on the incidence of venous complications .
Diseases:"
1847	Tetany and rhabdomyolysis due to surreptitious furosemide - - importance of magnesium supplementation .	B O B O O O O O O O O O O O	O O O O O O B O O O O B O O	['rhabdomyolysis', 'tetany']	2	9	"Sentence: Tetany and rhabdomyolysis due to surreptitious furosemide - - importance of magnesium supplementation .
Diseases: rhabdomyolysis, tetany"	"Sentence: Tetany and rhabdomyolysis due to surreptitious furosemide - - importance of magnesium supplementation .
Diseases:"
1848	Diuretics may induce hypokalemia , hypocalcemia and hypomagnesemia .	O O O B O B O B O	O O O O O O O O O	['hypomagnesemia', 'hypocalcemia', 'hypokalemia']	3	15	"Sentence: Diuretics may induce hypokalemia , hypocalcemia and hypomagnesemia .
Diseases: hypomagnesemia, hypocalcemia, hypokalemia"	"Sentence: Diuretics may induce hypokalemia , hypocalcemia and hypomagnesemia .
Diseases:"
1849	While severe hypokalemia may cause muscle weakness , severe hypomagnesemia is associated with muscle spasms and tetany which can not be corrected by potassium and calcium supplementation alone ( 1 , 2 ) .	O O B O O B I O O B O O O B I O B O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O	['muscle spasms', 'muscle weakness', 'hypokalemia', 'hypomagnesemia', 'tetany']	5	21	"Sentence: While severe hypokalemia may cause muscle weakness , severe hypomagnesemia is associated with muscle spasms and tetany which can not be corrected by potassium and calcium supplementation alone ( 1 , 2 ) .
Diseases: muscle spasms, muscle weakness, hypokalemia, hypomagnesemia, tetany"	"Sentence: While severe hypokalemia may cause muscle weakness , severe hypomagnesemia is associated with muscle spasms and tetany which can not be corrected by potassium and calcium supplementation alone ( 1 , 2 ) .
Diseases:"
1850	Surreptitious diuretic ingestion has been described , mainly in women who are concerned that they are obese or edematous .	O O O O O O O O O O O O O O O O B O B O	O O O O O O O O O O O O O O O O O O O O	['edematous', 'obese']	2	6	"Sentence: Surreptitious diuretic ingestion has been described , mainly in women who are concerned that they are obese or edematous .
Diseases: edematous, obese"	"Sentence: Surreptitious diuretic ingestion has been described , mainly in women who are concerned that they are obese or edematous .
Diseases:"
1851	Symptomatic hypokalemia has been reported in such patients ( 3 - 7 ) and in one case hypocalcemia was observed ( 8 ) , but the effects of magnesium depletion were not noted in these patients .	O B O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['hypocalcemia', 'hypokalemia']	2	9	"Sentence: Symptomatic hypokalemia has been reported in such patients ( 3 - 7 ) and in one case hypocalcemia was observed ( 8 ) , but the effects of magnesium depletion were not noted in these patients .
Diseases: hypocalcemia, hypokalemia"	"Sentence: Symptomatic hypokalemia has been reported in such patients ( 3 - 7 ) and in one case hypocalcemia was observed ( 8 ) , but the effects of magnesium depletion were not noted in these patients .
Diseases:"
1852	Loss of glutamate decarboxylase mRNA - containing neurons in the rat dentate gyrus following pilocarpine - induced seizures .	O O O O O O O O O O O O O O O O O B O	O O B O O O O O O O O O O O B O O O O	['seizures']	1	3	"Sentence: Loss of glutamate decarboxylase mRNA - containing neurons in the rat dentate gyrus following pilocarpine - induced seizures .
Diseases: seizures"	"Sentence: Loss of glutamate decarboxylase mRNA - containing neurons in the rat dentate gyrus following pilocarpine - induced seizures .
Diseases:"
1853	In situ hybridization methods were used to determine if glutamic acid decarboxylase ( GAD ) mRNA - containing neurons within the hilus of the dentate gyrus are vulnerable to seizure - induced damage in a model of chronic seizures .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O B O	O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['seizures', 'seizure']	2	5	"Sentence: In situ hybridization methods were used to determine if glutamic acid decarboxylase ( GAD ) mRNA - containing neurons within the hilus of the dentate gyrus are vulnerable to seizure - induced damage in a model of chronic seizures .
Diseases: seizures, seizure"	"Sentence: In situ hybridization methods were used to determine if glutamic acid decarboxylase ( GAD ) mRNA - containing neurons within the hilus of the dentate gyrus are vulnerable to seizure - induced damage in a model of chronic seizures .
Diseases:"
1854	Sprague - Dawley rats were injected intraperitoneally with pilocarpine , and the hippocampal formation was studied histologically at 1 , 2 , 4 , and 8 week intervals after pilocarpine - induced seizures .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O B O O O O	['seizures']	1	3	"Sentence: Sprague - Dawley rats were injected intraperitoneally with pilocarpine , and the hippocampal formation was studied histologically at 1 , 2 , 4 , and 8 week intervals after pilocarpine - induced seizures .
Diseases: seizures"	"Sentence: Sprague - Dawley rats were injected intraperitoneally with pilocarpine , and the hippocampal formation was studied histologically at 1 , 2 , 4 , and 8 week intervals after pilocarpine - induced seizures .
Diseases:"
1855	In situ hybridization histochemistry , using a digoxigenin - labeled GAD cRNA probe , demonstrated a substantial decrease in the number of GAD mRNA - containing neurons in the hilus of the dentate gyrus in the pilocarpine - treated rats as compared to controls at all time intervals .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: In situ hybridization histochemistry , using a digoxigenin - labeled GAD cRNA probe , demonstrated a substantial decrease in the number of GAD mRNA - containing neurons in the hilus of the dentate gyrus in the pilocarpine - treated rats as compared to controls at all time intervals .
Diseases: "	"Sentence: In situ hybridization histochemistry , using a digoxigenin - labeled GAD cRNA probe , demonstrated a substantial decrease in the number of GAD mRNA - containing neurons in the hilus of the dentate gyrus in the pilocarpine - treated rats as compared to controls at all time intervals .
Diseases:"
1856	Additional neuronanatomical studies , including cresyl violet staining , neuronal degeneration methods , and histochemical localization of glial fibrillary acidic protein , suggested that the decrease in the number of GAD mRNA - containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels .	O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O	O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['neuronal degeneration', 'neuronal loss']	2	8	"Sentence: Additional neuronanatomical studies , including cresyl violet staining , neuronal degeneration methods , and histochemical localization of glial fibrillary acidic protein , suggested that the decrease in the number of GAD mRNA - containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels .
Diseases: neuronal degeneration, neuronal loss"	"Sentence: Additional neuronanatomical studies , including cresyl violet staining , neuronal degeneration methods , and histochemical localization of glial fibrillary acidic protein , suggested that the decrease in the number of GAD mRNA - containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels .
Diseases:"
1857	The loss of GAD mRNA - containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The loss of GAD mRNA - containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer .
Diseases: "	"Sentence: The loss of GAD mRNA - containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer .
Diseases:"
1858	Quantitative analyses of labeled neurons in three regions of the dentate gyrus in the 1 and 2 week groups showed statistically significant decreases in the mean number of GAD mRNA - containing neurons in the hilus of both groups of experimental animals .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Quantitative analyses of labeled neurons in three regions of the dentate gyrus in the 1 and 2 week groups showed statistically significant decreases in the mean number of GAD mRNA - containing neurons in the hilus of both groups of experimental animals .
Diseases: "	"Sentence: Quantitative analyses of labeled neurons in three regions of the dentate gyrus in the 1 and 2 week groups showed statistically significant decreases in the mean number of GAD mRNA - containing neurons in the hilus of both groups of experimental animals .
Diseases:"
1859	No significant differences were found in the molecular layer or the granule cell layer , which included labeled neurons along the lower margin of the granule cell layer .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: No significant differences were found in the molecular layer or the granule cell layer , which included labeled neurons along the lower margin of the granule cell layer .
Diseases: "	"Sentence: No significant differences were found in the molecular layer or the granule cell layer , which included labeled neurons along the lower margin of the granule cell layer .
Diseases:"
1860	The results indicate that , in this model , a subpopulation of GAD mRNA - containing neurons within the dentate gyrus is selectively vulnerable to seizure - induced damage .	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['seizure']	1	3	"Sentence: The results indicate that , in this model , a subpopulation of GAD mRNA - containing neurons within the dentate gyrus is selectively vulnerable to seizure - induced damage .
Diseases: seizure"	"Sentence: The results indicate that , in this model , a subpopulation of GAD mRNA - containing neurons within the dentate gyrus is selectively vulnerable to seizure - induced damage .
Diseases:"
1861	Such differential vulnerability appears to be another indication of the heterogeneity of GABA neurons .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Such differential vulnerability appears to be another indication of the heterogeneity of GABA neurons .
Diseases: "	"Sentence: Such differential vulnerability appears to be another indication of the heterogeneity of GABA neurons .
Diseases:"
1862	Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients .	O O O O O O O B I O O O O	O O O B O B O O O O O O O	['renal dysfunction']	1	3	"Sentence: Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients .
Diseases: renal dysfunction"	"Sentence: Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients .
Diseases:"
1863	To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin .	O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O B O	[]	0	0	"Sentence: To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin .
Diseases: "	"Sentence: To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin .
Diseases:"
1864	METHODS : Forty - five hospitalized elderly patients ( > 65 years old ) who required therapy with nonsteroidal antiinflammatory drugs ( NSAID ) were randomly assigned to receive either indomethacin , 150 mg / day ( Group A ) , or indomethacin 150 mg / day plus misoprostol at 0 . 6 mg / day ( Group B ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O B O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : Forty - five hospitalized elderly patients ( > 65 years old ) who required therapy with nonsteroidal antiinflammatory drugs ( NSAID ) were randomly assigned to receive either indomethacin , 150 mg / day ( Group A ) , or indomethacin 150 mg / day plus misoprostol at 0 . 6 mg / day ( Group B ) .
Diseases: "	"Sentence: METHODS : Forty - five hospitalized elderly patients ( > 65 years old ) who required therapy with nonsteroidal antiinflammatory drugs ( NSAID ) were randomly assigned to receive either indomethacin , 150 mg / day ( Group A ) , or indomethacin 150 mg / day plus misoprostol at 0 . 6 mg / day ( Group B ) .
Diseases:"
1865	Laboratory variables of renal function [ serum creatinine , blood urea nitrogen ( BUN ) and electrolytes ] were evaluated before initiation of therapy and every 2 days , until termination of the study ( a period of at least 6 days ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Laboratory variables of renal function [ serum creatinine , blood urea nitrogen ( BUN ) and electrolytes ] were evaluated before initiation of therapy and every 2 days , until termination of the study ( a period of at least 6 days ) .
Diseases: "	"Sentence: Laboratory variables of renal function [ serum creatinine , blood urea nitrogen ( BUN ) and electrolytes ] were evaluated before initiation of therapy and every 2 days , until termination of the study ( a period of at least 6 days ) .
Diseases:"
1866	Response to treatment was estimated by the visual analog scale for severity of pain .	O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: Response to treatment was estimated by the visual analog scale for severity of pain .
Diseases: pain"	"Sentence: Response to treatment was estimated by the visual analog scale for severity of pain .
Diseases:"
1867	Forty - two patients completed the study , 22 in Group A and 20 in Group B . BUN and creatinine increased by > 50 % of baseline levels in 54 and 45 % of Group A patients , respectively , compared to only 20 and 10 % of Group B patients ( p < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Forty - two patients completed the study , 22 in Group A and 20 in Group B . BUN and creatinine increased by > 50 % of baseline levels in 54 and 45 % of Group A patients , respectively , compared to only 20 and 10 % of Group B patients ( p < 0 . 05 ) .
Diseases: "	"Sentence: Forty - two patients completed the study , 22 in Group A and 20 in Group B . BUN and creatinine increased by > 50 % of baseline levels in 54 and 45 % of Group A patients , respectively , compared to only 20 and 10 % of Group B patients ( p < 0 . 05 ) .
Diseases:"
1868	Potassium ( K ) increment of 0 . 6 mEq / l or more was observed in 50 % of Group A , but in only 15 % of Group B patients ( p < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Potassium ( K ) increment of 0 . 6 mEq / l or more was observed in 50 % of Group A , but in only 15 % of Group B patients ( p < 0 . 05 ) .
Diseases: "	"Sentence: Potassium ( K ) increment of 0 . 6 mEq / l or more was observed in 50 % of Group A , but in only 15 % of Group B patients ( p < 0 . 05 ) .
Diseases:"
1869	The mean increments in BUN , creatinine , and K were reduced by 63 , 80 , and 42 % , respectively , in Group B patients compared to Group A . Response to treatment did not differ significantly between the 2 groups .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mean increments in BUN , creatinine , and K were reduced by 63 , 80 , and 42 % , respectively , in Group B patients compared to Group A . Response to treatment did not differ significantly between the 2 groups .
Diseases: "	"Sentence: The mean increments in BUN , creatinine , and K were reduced by 63 , 80 , and 42 % , respectively , in Group B patients compared to Group A . Response to treatment did not differ significantly between the 2 groups .
Diseases:"
1870	CONCLUSION : Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction .	O O O O O O O O O O O O B I O	O O O O O O O O O O B O O O O	['renal dysfunction']	1	3	"Sentence: CONCLUSION : Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction .
Diseases: renal dysfunction"	"Sentence: CONCLUSION : Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction .
Diseases:"
1871	Addition of misoprostol can minimize this renal impairment without affecting pain control .	O O O O O O B I O O B O O	O O B O O O O O O O O O O	['pain', 'renal impairment']	2	4	"Sentence: Addition of misoprostol can minimize this renal impairment without affecting pain control .
Diseases: pain, renal impairment"	"Sentence: Addition of misoprostol can minimize this renal impairment without affecting pain control .
Diseases:"
1872	Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation .	B O O O O O O O O O O O	O O O B O O O O O O O O	['nephrotoxic']	1	4	"Sentence: Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation .
Diseases: nephrotoxic"	"Sentence: Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation .
Diseases:"
1873	To quantify the effects of gentamicin , kanamycin and netilmicin on renal protein reabsorption and accumulation , these drugs were administered to rats intraperitoneally ( 30 mg / kg / day ) for 7 , 14 or 21 days .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: To quantify the effects of gentamicin , kanamycin and netilmicin on renal protein reabsorption and accumulation , these drugs were administered to rats intraperitoneally ( 30 mg / kg / day ) for 7 , 14 or 21 days .
Diseases: "	"Sentence: To quantify the effects of gentamicin , kanamycin and netilmicin on renal protein reabsorption and accumulation , these drugs were administered to rats intraperitoneally ( 30 mg / kg / day ) for 7 , 14 or 21 days .
Diseases:"
1874	Scanning electron microscopy of the glomerular endothelia , urinary measurements of sodium , potassium , endogenous lysozyme , N - acetyl - beta - D - glucosaminidase ( NAG ) as well as clearance and accumulation experiments after i . v .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O B O O O O B I I I I I I I I O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Scanning electron microscopy of the glomerular endothelia , urinary measurements of sodium , potassium , endogenous lysozyme , N - acetyl - beta - D - glucosaminidase ( NAG ) as well as clearance and accumulation experiments after i . v .
Diseases: "	"Sentence: Scanning electron microscopy of the glomerular endothelia , urinary measurements of sodium , potassium , endogenous lysozyme , N - acetyl - beta - D - glucosaminidase ( NAG ) as well as clearance and accumulation experiments after i . v .
Diseases:"
1875	administration of egg - white lysozyme and measurements of inulin clearance ( GFR ) were done in each treatment group .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: administration of egg - white lysozyme and measurements of inulin clearance ( GFR ) were done in each treatment group .
Diseases: "	"Sentence: administration of egg - white lysozyme and measurements of inulin clearance ( GFR ) were done in each treatment group .
Diseases:"
1876	Gentamicin administration decreased diameter , density and shape of endothelial fenestrae .	O O O O O O O O O O O O	B O O O O O O O O O O O	[]	0	0	"Sentence: Gentamicin administration decreased diameter , density and shape of endothelial fenestrae .
Diseases: "	"Sentence: Gentamicin administration decreased diameter , density and shape of endothelial fenestrae .
Diseases:"
1877	Kanamycin and netilmicin appeared to have no effect at the dose used .	O O O O O O O O O O O O O	B O B O O O O O O O O O O	[]	0	0	"Sentence: Kanamycin and netilmicin appeared to have no effect at the dose used .
Diseases: "	"Sentence: Kanamycin and netilmicin appeared to have no effect at the dose used .
Diseases:"
1878	All three aminoglycosides decreased GFR and increased urinary excretion of sodium and potassium .	O O O O O O O O O O O O O O	O O B O O O O O O O B O B O	[]	0	0	"Sentence: All three aminoglycosides decreased GFR and increased urinary excretion of sodium and potassium .
Diseases: "	"Sentence: All three aminoglycosides decreased GFR and increased urinary excretion of sodium and potassium .
Diseases:"
1879	While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i . v .	O O O O O O O O O O O O O O O O O	O B O B O O O O O O O O O O O O O	[]	0	0	"Sentence: While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i . v .
Diseases: "	"Sentence: While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i . v .
Diseases:"
1880	administration of egg - white lysozyme netilmicin had no effect .	O O O O O O O O O O O	O O O O O O B O O O O	[]	0	0	"Sentence: administration of egg - white lysozyme netilmicin had no effect .
Diseases: "	"Sentence: administration of egg - white lysozyme netilmicin had no effect .
Diseases:"
1881	Daily excretion of total protein , endogenous lysozyme and NAG increased only after treatment with kanamycin and gentamicin .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O B O	[]	0	0	"Sentence: Daily excretion of total protein , endogenous lysozyme and NAG increased only after treatment with kanamycin and gentamicin .
Diseases: "	"Sentence: Daily excretion of total protein , endogenous lysozyme and NAG increased only after treatment with kanamycin and gentamicin .
Diseases:"
1882	Thus , aminoglycosides may act as nephrotoxicants at glomerular and / or tubular level inducing impairment of renal reabsorption and accumulation of proteins .	O O O O O O O O O O O O O O O B I I I O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O	['impairment of renal reabsorption']	1	8	"Sentence: Thus , aminoglycosides may act as nephrotoxicants at glomerular and / or tubular level inducing impairment of renal reabsorption and accumulation of proteins .
Diseases: impairment of renal reabsorption"	"Sentence: Thus , aminoglycosides may act as nephrotoxicants at glomerular and / or tubular level inducing impairment of renal reabsorption and accumulation of proteins .
Diseases:"
1883	Pharmacology of GYKI - 41 099 ( chlorpropanol , Tobanum ) a new potent beta - adrenergic antagonist .	O O O O O O O O O O O O O O O O O O O	O O B I I I O B O B O O O O O O O O O	[]	0	0	"Sentence: Pharmacology of GYKI - 41 099 ( chlorpropanol , Tobanum ) a new potent beta - adrenergic antagonist .
Diseases: "	"Sentence: Pharmacology of GYKI - 41 099 ( chlorpropanol , Tobanum ) a new potent beta - adrenergic antagonist .
Diseases:"
1884	The compound GYKI - 41 099 , as a beta - adrenergic antagonist , is 3 - 8 times more potent than propranolol in vitro and in vivo .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B I I I O O O O O O O O O O O O O O O O B O O O O O O	[]	0	0	"Sentence: The compound GYKI - 41 099 , as a beta - adrenergic antagonist , is 3 - 8 times more potent than propranolol in vitro and in vivo .
Diseases: "	"Sentence: The compound GYKI - 41 099 , as a beta - adrenergic antagonist , is 3 - 8 times more potent than propranolol in vitro and in vivo .
Diseases:"
1885	Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats .	O O O O O O O O O O O O B O O O O O	O O O O O O B O B O O B O O O O O O	['arrhythmia']	1	4	"Sentence: Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats .
Diseases: arrhythmia"	"Sentence: Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats .
Diseases:"
1886	GYKI - 41 900 has a negligible cardiodepressant activity ; it is not cardioselective .	O O O O O O O O O O O O O O O	B I I I O O O O O O O O O O O	[]	0	0	"Sentence: GYKI - 41 900 has a negligible cardiodepressant activity ; it is not cardioselective .
Diseases: "	"Sentence: GYKI - 41 900 has a negligible cardiodepressant activity ; it is not cardioselective .
Diseases:"
1887	The compound shows a rapid and long lasting effect .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: The compound shows a rapid and long lasting effect .
Diseases: "	"Sentence: The compound shows a rapid and long lasting effect .
Diseases:"
1888	There was a prolonged elimination of the radioactivity after the injection of 14C - 41 099 to rats and dogs .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B I I I O O O O O	[]	0	0	"Sentence: There was a prolonged elimination of the radioactivity after the injection of 14C - 41 099 to rats and dogs .
Diseases: "	"Sentence: There was a prolonged elimination of the radioactivity after the injection of 14C - 41 099 to rats and dogs .
Diseases:"
1889	The half life of the unlabeled substance in humans was more than 10 hours .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The half life of the unlabeled substance in humans was more than 10 hours .
Diseases: "	"Sentence: The half life of the unlabeled substance in humans was more than 10 hours .
Diseases:"
1890	Chorea associated with oral contraception .	B O O O O O	O O O B I O	['chorea']	1	2	"Sentence: Chorea associated with oral contraception .
Diseases: chorea"	"Sentence: Chorea associated with oral contraception .
Diseases:"
1891	Three patients developed chorea while receiving oral contraceptives .	O O O B O O O O O	O O O O O O B I O	['chorea']	1	2	"Sentence: Three patients developed chorea while receiving oral contraceptives .
Diseases: chorea"	"Sentence: Three patients developed chorea while receiving oral contraceptives .
Diseases:"
1892	Two were young patients whose chorea developed long after treatment had been started and disappeared soon after it had been discontinued .	O O O O O B O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	['chorea']	1	2	"Sentence: Two were young patients whose chorea developed long after treatment had been started and disappeared soon after it had been discontinued .
Diseases: chorea"	"Sentence: Two were young patients whose chorea developed long after treatment had been started and disappeared soon after it had been discontinued .
Diseases:"
1893	The third patient had acute amphetamine - induced chorea after prolonged oral contraception .	O O O O O O O O B O O O O O	O O O O O B O O O O O O O O	['chorea']	1	2	"Sentence: The third patient had acute amphetamine - induced chorea after prolonged oral contraception .
Diseases: chorea"	"Sentence: The third patient had acute amphetamine - induced chorea after prolonged oral contraception .
Diseases:"
1894	Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever .	O O O O O O O O O O O B O O O O O O O B O B I O	O O O O O O O O O O O O O O O O O O O O O O O O	['rheumatic fever', 'chorea']	2	7	"Sentence: Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever .
Diseases: rheumatic fever, chorea"	"Sentence: Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever .
Diseases:"
1895	Reversal of ammonia coma in rats by L - dopa : a peripheral effect .	O O O B O O O O O O O O O O O	O O B O O O O B I I O O O O O	['coma']	1	2	"Sentence: Reversal of ammonia coma in rats by L - dopa : a peripheral effect .
Diseases: coma"	"Sentence: Reversal of ammonia coma in rats by L - dopa : a peripheral effect .
Diseases:"
1896	Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1 . 7 mmol NH4CL .	O B O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O B O	['coma']	1	2	"Sentence: Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1 . 7 mmol NH4CL .
Diseases: coma"	"Sentence: Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1 . 7 mmol NH4CL .
Diseases:"
1897	This coma was prevented with 1 . 68 mmol L - dopa given by gastric intubation 15 minutes before the ammonium salt injection .	O B O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B I I O O O O O O O O B O O O	['coma']	1	2	"Sentence: This coma was prevented with 1 . 68 mmol L - dopa given by gastric intubation 15 minutes before the ammonium salt injection .
Diseases: coma"	"Sentence: This coma was prevented with 1 . 68 mmol L - dopa given by gastric intubation 15 minutes before the ammonium salt injection .
Diseases:"
1898	The effect of L - dopa was correlated with a decrease in blood and brain ammonia , an increase in brain dopamine , and an increase in renal excretion of ammonia and urea .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B I I O O O O O O O O O B O O O O O B O O O O O O O O B O B O	[]	0	0	"Sentence: The effect of L - dopa was correlated with a decrease in blood and brain ammonia , an increase in brain dopamine , and an increase in renal excretion of ammonia and urea .
Diseases: "	"Sentence: The effect of L - dopa was correlated with a decrease in blood and brain ammonia , an increase in brain dopamine , and an increase in renal excretion of ammonia and urea .
Diseases:"
1899	Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations .	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	O O O B O O O O O B O O O O O O O O B O O O O O O O B O O	['coma']	1	2	"Sentence: Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations .
Diseases: coma"	"Sentence: Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations .
Diseases:"
1900	Bilateral nephrectomy eliminated the beneficial effect of L - dopa on blood and brain ammonia and the ammonia coma was not prevented .	O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O O B I I O O O O B O O B O O O O O	['coma']	1	2	"Sentence: Bilateral nephrectomy eliminated the beneficial effect of L - dopa on blood and brain ammonia and the ammonia coma was not prevented .
Diseases: coma"	"Sentence: Bilateral nephrectomy eliminated the beneficial effect of L - dopa on blood and brain ammonia and the ammonia coma was not prevented .
Diseases:"
1901	Thus , the reduction in blood and brain ammonia and the prevention of ammonia coma after L - dopa , can be accounted for by the peripheral effect of dopamine on renal function rather than its central action .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O B O O B I I O O O O O O O O O O B O O O O O O O O O	['coma']	1	2	"Sentence: Thus , the reduction in blood and brain ammonia and the prevention of ammonia coma after L - dopa , can be accounted for by the peripheral effect of dopamine on renal function rather than its central action .
Diseases: coma"	"Sentence: Thus , the reduction in blood and brain ammonia and the prevention of ammonia coma after L - dopa , can be accounted for by the peripheral effect of dopamine on renal function rather than its central action .
Diseases:"
1902	These results provide a reasonable explanation for the beneficial effects observed in some encephalopathic patients receiving L - dopa .	O O O O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O O O O B I I O	['encephalopathic']	1	3	"Sentence: These results provide a reasonable explanation for the beneficial effects observed in some encephalopathic patients receiving L - dopa .
Diseases: encephalopathic"	"Sentence: These results provide a reasonable explanation for the beneficial effects observed in some encephalopathic patients receiving L - dopa .
Diseases:"
1903	Heparin - induced thrombocytopenia after liver transplantation .	O O O B O O O O	B O O O O O O O	['thrombocytopenia']	1	7	"Sentence: Heparin - induced thrombocytopenia after liver transplantation .
Diseases: thrombocytopenia"	"Sentence: Heparin - induced thrombocytopenia after liver transplantation .
Diseases:"
1904	Unfractionated heparin sodium ( UFH ) or low - molecular weight heparin ( LMWH ) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation .	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	B B I O B O O O O O O B O B O O O O O O O O O O O O O O O O	['thrombosis']	1	4	"Sentence: Unfractionated heparin sodium ( UFH ) or low - molecular weight heparin ( LMWH ) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation .
Diseases: thrombosis"	"Sentence: Unfractionated heparin sodium ( UFH ) or low - molecular weight heparin ( LMWH ) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation .
Diseases:"
1905	Heparin - induced thrombocytopenia ( HIT ) is an adverse immune - mediated reaction to heparin , resulting in platelet count decreases of more than 50 % .	O O O B O B O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O B O O O O O O O O O O O O	['hit', 'thrombocytopenia']	2	9	"Sentence: Heparin - induced thrombocytopenia ( HIT ) is an adverse immune - mediated reaction to heparin , resulting in platelet count decreases of more than 50 % .
Diseases: hit, thrombocytopenia"	"Sentence: Heparin - induced thrombocytopenia ( HIT ) is an adverse immune - mediated reaction to heparin , resulting in platelet count decreases of more than 50 % .
Diseases:"
1906	The frequencies of HIT after liver transplantation and platelet factor 4 / heparin - reactive antibody ( HIT antibody ) positivity in liver transplantation patients , however , are unknown .	O O O B O O O O O O O O O O O O O B O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	['hit']	1	1	"Sentence: The frequencies of HIT after liver transplantation and platelet factor 4 / heparin - reactive antibody ( HIT antibody ) positivity in liver transplantation patients , however , are unknown .
Diseases: hit"	"Sentence: The frequencies of HIT after liver transplantation and platelet factor 4 / heparin - reactive antibody ( HIT antibody ) positivity in liver transplantation patients , however , are unknown .
Diseases:"
1907	PATIENTS AND METHODS : The 32 men and 20 women underwent living donor liver transplantation .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: PATIENTS AND METHODS : The 32 men and 20 women underwent living donor liver transplantation .
Diseases: "	"Sentence: PATIENTS AND METHODS : The 32 men and 20 women underwent living donor liver transplantation .
Diseases:"
1908	We started LMWH ( 25 IU / kg / h ) on postoperative day ( POD ) 1 , switching to UFH ( 5000 U / d ) on POD 2 or 3 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: We started LMWH ( 25 IU / kg / h ) on postoperative day ( POD ) 1 , switching to UFH ( 5000 U / d ) on POD 2 or 3 .
Diseases: "	"Sentence: We started LMWH ( 25 IU / kg / h ) on postoperative day ( POD ) 1 , switching to UFH ( 5000 U / d ) on POD 2 or 3 .
Diseases:"
1909	The dose of UFH was changed according to the activated clotting time level .	O O O O O O O O O O O O O O	O O O B O O O O O O O O O O	[]	0	0	"Sentence: The dose of UFH was changed according to the activated clotting time level .
Diseases: "	"Sentence: The dose of UFH was changed according to the activated clotting time level .
Diseases:"
1910	HIT antibody levels were measured the day before surgery and on POD 7 and 14 .	B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	['hit']	1	1	"Sentence: HIT antibody levels were measured the day before surgery and on POD 7 and 14 .
Diseases: hit"	"Sentence: HIT antibody levels were measured the day before surgery and on POD 7 and 14 .
Diseases:"
1911	Platelet count was measured daily for 3 weeks .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Platelet count was measured daily for 3 weeks .
Diseases: "	"Sentence: Platelet count was measured daily for 3 weeks .
Diseases:"
1912	The average platelet counts preoperatively , and on POD 7 , 14 , and 21 were 65 , 88 , 149 , and 169 x 10 ( 9 ) / L , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The average platelet counts preoperatively , and on POD 7 , 14 , and 21 were 65 , 88 , 149 , and 169 x 10 ( 9 ) / L , respectively .
Diseases: "	"Sentence: The average platelet counts preoperatively , and on POD 7 , 14 , and 21 were 65 , 88 , 149 , and 169 x 10 ( 9 ) / L , respectively .
Diseases:"
1913	Two patients developed hepatic artery thrombosis on POD 11 and 19 , respectively , although they were HIT antibody - negative and their platelet counts were stable .	O O O O O B O O O O O O O O O O O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hit', 'thrombosis']	2	6	"Sentence: Two patients developed hepatic artery thrombosis on POD 11 and 19 , respectively , although they were HIT antibody - negative and their platelet counts were stable .
Diseases: hit, thrombosis"	"Sentence: Two patients developed hepatic artery thrombosis on POD 11 and 19 , respectively , although they were HIT antibody - negative and their platelet counts were stable .
Diseases:"
1914	In 2 other patients , the platelet count decreased suddenly from 107 x 10 ( 9 ) / L on POD 4 to 65 x 10 ( 9 ) / L on POD 6 and from 76 x 10 ( 9 ) / L on POD 7 to 33 x 10 ( 9 ) / L on POD 9 , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In 2 other patients , the platelet count decreased suddenly from 107 x 10 ( 9 ) / L on POD 4 to 65 x 10 ( 9 ) / L on POD 6 and from 76 x 10 ( 9 ) / L on POD 7 to 33 x 10 ( 9 ) / L on POD 9 , respectively .
Diseases: "	"Sentence: In 2 other patients , the platelet count decreased suddenly from 107 x 10 ( 9 ) / L on POD 4 to 65 x 10 ( 9 ) / L on POD 6 and from 76 x 10 ( 9 ) / L on POD 7 to 33 x 10 ( 9 ) / L on POD 9 , respectively .
Diseases:"
1915	The heparin - induced platelet aggregation test was negative in these patients .	O O O O B I O O O O O O O	O B O O O O O O O O O O O	['platelet aggregation']	1	3	"Sentence: The heparin - induced platelet aggregation test was negative in these patients .
Diseases: platelet aggregation"	"Sentence: The heparin - induced platelet aggregation test was negative in these patients .
Diseases:"
1916	The percentage of HIT antibody - positive patients was 0 . 5 % preoperatively , 5 . 6 % on POD 7 , and 5 . 6 % on POD 14 .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hit']	1	1	"Sentence: The percentage of HIT antibody - positive patients was 0 . 5 % preoperatively , 5 . 6 % on POD 7 , and 5 . 6 % on POD 14 .
Diseases: hit"	"Sentence: The percentage of HIT antibody - positive patients was 0 . 5 % preoperatively , 5 . 6 % on POD 7 , and 5 . 6 % on POD 14 .
Diseases:"
1917	None of the subjects / patients developed UFH - related HIT .	O O O O O O O O O O B O	O O O O O O O B O O O O	['hit']	1	1	"Sentence: None of the subjects / patients developed UFH - related HIT .
Diseases: hit"	"Sentence: None of the subjects / patients developed UFH - related HIT .
Diseases:"
1918	In our series , the occurrence of HIT after liver transplantation was uncommon .	O O O O O O O B O O O O O O	O O O O O O O O O O O O O O	['hit']	1	1	"Sentence: In our series , the occurrence of HIT after liver transplantation was uncommon .
Diseases: hit"	"Sentence: In our series , the occurrence of HIT after liver transplantation was uncommon .
Diseases:"
1919	PTU - associated vasculitis in a girl with Turner Syndrome and Graves ' disease .	O O O B O O O O B I O B I I O	B O O O O O O O O O O O O O O	"['vasculitis', 'turner syndrome', ""graves ' disease""]"	3	11	"Sentence: PTU - associated vasculitis in a girl with Turner Syndrome and Graves ' disease .
Diseases: vasculitis, turner syndrome, graves ' disease"	"Sentence: PTU - associated vasculitis in a girl with Turner Syndrome and Graves ' disease .
Diseases:"
1920	Palpable purpura is a concerning clinical finding in pediatric patients and can have many causes , including infectious and autoimmune processes .	O B O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	['purpura']	1	3	"Sentence: Palpable purpura is a concerning clinical finding in pediatric patients and can have many causes , including infectious and autoimmune processes .
Diseases: purpura"	"Sentence: Palpable purpura is a concerning clinical finding in pediatric patients and can have many causes , including infectious and autoimmune processes .
Diseases:"
1921	A rare cause , drug - induced vasculitis , may result from the production of antineutrophil cytoplasmic antibodies ( ANCAs ) in response to a medication .	O O O O O O O B O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['vasculitis']	1	3	"Sentence: A rare cause , drug - induced vasculitis , may result from the production of antineutrophil cytoplasmic antibodies ( ANCAs ) in response to a medication .
Diseases: vasculitis"	"Sentence: A rare cause , drug - induced vasculitis , may result from the production of antineutrophil cytoplasmic antibodies ( ANCAs ) in response to a medication .
Diseases:"
1922	We report a girl with Turner syndrome and Graves ' disease who presented with palpable purpuric lesions .	O O O O O B I O B I I O O O O B I O	O O O O O O O O O O O O O O O O O O	"['purpuric lesions', 'turner syndrome', ""graves ' disease""]"	3	12	"Sentence: We report a girl with Turner syndrome and Graves ' disease who presented with palpable purpuric lesions .
Diseases: purpuric lesions, turner syndrome, graves ' disease"	"Sentence: We report a girl with Turner syndrome and Graves ' disease who presented with palpable purpuric lesions .
Diseases:"
1923	The diagnosis of propylthiouracil ( PTU ) - associated vasculitis was made by observation of consistent clinical features , the detection of elevated ANA and ANCA in the blood , and the observed clinical resolution of symptoms following withdrawal of PTU .	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['vasculitis']	1	3	"Sentence: The diagnosis of propylthiouracil ( PTU ) - associated vasculitis was made by observation of consistent clinical features , the detection of elevated ANA and ANCA in the blood , and the observed clinical resolution of symptoms following withdrawal of PTU .
Diseases: vasculitis"	"Sentence: The diagnosis of propylthiouracil ( PTU ) - associated vasculitis was made by observation of consistent clinical features , the detection of elevated ANA and ANCA in the blood , and the observed clinical resolution of symptoms following withdrawal of PTU .
Diseases:"
1924	Subsequent treatment of persistent hyperthyroidism with radioablation did not result in an exacerbation of the vasculitis , a complication described in prior case reports .	O O O O B O O O O O O O O O O B O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['vasculitis', 'hyperthyroidism']	2	8	"Sentence: Subsequent treatment of persistent hyperthyroidism with radioablation did not result in an exacerbation of the vasculitis , a complication described in prior case reports .
Diseases: vasculitis, hyperthyroidism"	"Sentence: Subsequent treatment of persistent hyperthyroidism with radioablation did not result in an exacerbation of the vasculitis , a complication described in prior case reports .
Diseases:"
1925	Succinylcholine - induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body .	O O O B I I O O O O O O O O O	B O O O O O O O O O O O O O O	['masseter muscle rigidity']	1	5	"Sentence: Succinylcholine - induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body .
Diseases: masseter muscle rigidity"	"Sentence: Succinylcholine - induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body .
Diseases:"
1926	Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia .	B I I O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O	['malignant hyperthermia', 'masseter muscle rigidity']	2	11	"Sentence: Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia .
Diseases: malignant hyperthermia, masseter muscle rigidity"	"Sentence: Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia .
Diseases:"
1927	The decision whether to continue or discontinue the procedure depends on the urgency of the surgery and severity of masseter muscle rigidity .	O O O O O O O O O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O O O O O O O O O O	['masseter muscle rigidity']	1	5	"Sentence: The decision whether to continue or discontinue the procedure depends on the urgency of the surgery and severity of masseter muscle rigidity .
Diseases: masseter muscle rigidity"	"Sentence: The decision whether to continue or discontinue the procedure depends on the urgency of the surgery and severity of masseter muscle rigidity .
Diseases:"
1928	Here , we describe a case of severe masseter muscle rigidity ( jaw of steel ) after succinylcholine ( Sch ) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body .	O O O O O O O O B I I O B I I O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O	['jaw of steel', 'masseter muscle rigidity']	2	10	"Sentence: Here , we describe a case of severe masseter muscle rigidity ( jaw of steel ) after succinylcholine ( Sch ) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body .
Diseases: jaw of steel, masseter muscle rigidity"	"Sentence: Here , we describe a case of severe masseter muscle rigidity ( jaw of steel ) after succinylcholine ( Sch ) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body .
Diseases:"
1929	Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia .	O O O O O O O O O O O O O O O O B I O	O O O O O B O O O O O O O O O O O O O	['malignant hyperthermia']	1	5	"Sentence: Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia .
Diseases: malignant hyperthermia"	"Sentence: Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia .
Diseases:"
1930	Minor neurological dysfunction , cognitive development , and somatic development at the age of 3 to 7 years after dexamethasone treatment in very - low birth - weight infants .	O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	['neurological dysfunction']	1	5	"Sentence: Minor neurological dysfunction , cognitive development , and somatic development at the age of 3 to 7 years after dexamethasone treatment in very - low birth - weight infants .
Diseases: neurological dysfunction"	"Sentence: Minor neurological dysfunction , cognitive development , and somatic development at the age of 3 to 7 years after dexamethasone treatment in very - low birth - weight infants .
Diseases:"
1931	The objective of this study was to assess minor neurological dysfunction , cognitive development , and somatic development after dexamethasone therapy in very - low - birthweight infants .	O O O O O O O O O B I O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	['neurological dysfunction']	1	5	"Sentence: The objective of this study was to assess minor neurological dysfunction , cognitive development , and somatic development after dexamethasone therapy in very - low - birthweight infants .
Diseases: neurological dysfunction"	"Sentence: The objective of this study was to assess minor neurological dysfunction , cognitive development , and somatic development after dexamethasone therapy in very - low - birthweight infants .
Diseases:"
1932	Thirty - three children after dexamethasone treatment were matched to 33 children without dexamethasone treatment .	O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O B O O	[]	0	0	"Sentence: Thirty - three children after dexamethasone treatment were matched to 33 children without dexamethasone treatment .
Diseases: "	"Sentence: Thirty - three children after dexamethasone treatment were matched to 33 children without dexamethasone treatment .
Diseases:"
1933	Data were assessed at the age of 3 - 7 years .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: Data were assessed at the age of 3 - 7 years .
Diseases: "	"Sentence: Data were assessed at the age of 3 - 7 years .
Diseases:"
1934	Dexamethasone was started between the 7th and the 28th day of life over 7 days with a total dose of 2 . 35 mg / kg / day .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Dexamethasone was started between the 7th and the 28th day of life over 7 days with a total dose of 2 . 35 mg / kg / day .
Diseases: "	"Sentence: Dexamethasone was started between the 7th and the 28th day of life over 7 days with a total dose of 2 . 35 mg / kg / day .
Diseases:"
1935	Exclusion criteria were asphyxia , malformations , major surgical interventions , small for gestational age , intraventricular haemorrhage grades III and IV , periventricular leukomalacia , and severe psychomotor retardation .	O O O B O B O O O O O O O O O O O B O O O O O B I O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['asphyxia', 'haemorrhage', 'malformations', 'psychomotor retardation', 'periventricular leukomalacia']	5	28	"Sentence: Exclusion criteria were asphyxia , malformations , major surgical interventions , small for gestational age , intraventricular haemorrhage grades III and IV , periventricular leukomalacia , and severe psychomotor retardation .
Diseases: asphyxia, haemorrhage, malformations, psychomotor retardation, periventricular leukomalacia"	"Sentence: Exclusion criteria were asphyxia , malformations , major surgical interventions , small for gestational age , intraventricular haemorrhage grades III and IV , periventricular leukomalacia , and severe psychomotor retardation .
Diseases:"
1936	Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw - a - Man Test .	O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['neurological dysfunctions']	1	7	"Sentence: Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw - a - Man Test .
Diseases: neurological dysfunctions"	"Sentence: Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw - a - Man Test .
Diseases:"
1937	There were no differences in demographic data , growth , and socio - economic status between the two groups .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There were no differences in demographic data , growth , and socio - economic status between the two groups .
Diseases: "	"Sentence: There were no differences in demographic data , growth , and socio - economic status between the two groups .
Diseases:"
1938	Fine motor skills and gross motor function were significantly better in the control group ( p < 0 . 01 ) .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Fine motor skills and gross motor function were significantly better in the control group ( p < 0 . 01 ) .
Diseases: "	"Sentence: Fine motor skills and gross motor function were significantly better in the control group ( p < 0 . 01 ) .
Diseases:"
1939	In the Draw - a - Man Test , the control group showed better results ( p < 0 . 001 ) .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the Draw - a - Man Test , the control group showed better results ( p < 0 . 001 ) .
Diseases: "	"Sentence: In the Draw - a - Man Test , the control group showed better results ( p < 0 . 001 ) .
Diseases:"
1940	There were no differences in development of speech , social development , and the Kaufman Assessment Battery for Children .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There were no differences in development of speech , social development , and the Kaufman Assessment Battery for Children .
Diseases: "	"Sentence: There were no differences in development of speech , social development , and the Kaufman Assessment Battery for Children .
Diseases:"
1941	After dexamethasone treatment , children showed a higher rate of minor neurological dysfunctions .	O O O O O O O O O O O B I O	O B O O O O O O O O O O O O	['neurological dysfunctions']	1	7	"Sentence: After dexamethasone treatment , children showed a higher rate of minor neurological dysfunctions .
Diseases: neurological dysfunctions"	"Sentence: After dexamethasone treatment , children showed a higher rate of minor neurological dysfunctions .
Diseases:"
1942	Neurological development was affected even without neurological diagnosis .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Neurological development was affected even without neurological diagnosis .
Diseases: "	"Sentence: Neurological development was affected even without neurological diagnosis .
Diseases:"
1943	Further long - term follow - up studies will be necessary to fully evaluate the impact of dexamethasone on neurological and cognitive development .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O	[]	0	0	"Sentence: Further long - term follow - up studies will be necessary to fully evaluate the impact of dexamethasone on neurological and cognitive development .
Diseases: "	"Sentence: Further long - term follow - up studies will be necessary to fully evaluate the impact of dexamethasone on neurological and cognitive development .
Diseases:"
1944	Force overflow and levodopa - induced dyskinesias in Parkinson 's disease .	O O O O O O B O B I I O	O O O B O O O O O O O O	"['dyskinesias', ""parkinson 's disease""]"	2	11	"Sentence: Force overflow and levodopa - induced dyskinesias in Parkinson 's disease .
Diseases: dyskinesias, parkinson 's disease"	"Sentence: Force overflow and levodopa - induced dyskinesias in Parkinson 's disease .
Diseases:"
1945	We assessed force coordination of the hand in Parkinson 's disease and its relationship to motor complications of levodopa therapy , particularly to levodopa - induced dyskinesias ( LID ) .	O O O O O O O O B I I O O O O O O O O O O O O O O O B O B O O	O O O O O O O O O O O O O O O O O O B O O O O B O O O O O O O	"['dyskinesias', 'lid', ""parkinson 's disease""]"	3	13	"Sentence: We assessed force coordination of the hand in Parkinson 's disease and its relationship to motor complications of levodopa therapy , particularly to levodopa - induced dyskinesias ( LID ) .
Diseases: dyskinesias, lid, parkinson 's disease"	"Sentence: We assessed force coordination of the hand in Parkinson 's disease and its relationship to motor complications of levodopa therapy , particularly to levodopa - induced dyskinesias ( LID ) .
Diseases:"
1946	We studied two groups of Parkinson 's disease patients with ( Parkinson 's disease + LID , n = 23 ) and without levodopa - induced dyskinesias ( Parkinson 's disease - LID , n = 10 ) , and age - matched healthy controls .	O O O O O B I I O O O B I I O B O O O O O O O O O O B O B I I O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	"['dyskinesias', 'lid', ""parkinson 's disease""]"	3	13	"Sentence: We studied two groups of Parkinson 's disease patients with ( Parkinson 's disease + LID , n = 23 ) and without levodopa - induced dyskinesias ( Parkinson 's disease - LID , n = 10 ) , and age - matched healthy controls .
Diseases: dyskinesias, lid, parkinson 's disease"	"Sentence: We studied two groups of Parkinson 's disease patients with ( Parkinson 's disease + LID , n = 23 ) and without levodopa - induced dyskinesias ( Parkinson 's disease - LID , n = 10 ) , and age - matched healthy controls .
Diseases:"
1947	The motor score of the Unified Parkinson 's Disease Rating Scale , a dyskinesia score and force in a grip - lift paradigm were assessed ON and OFF levodopa .	O O O O O O B I I O O O O B O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	"['dyskinesia', ""parkinson 's disease""]"	2	11	"Sentence: The motor score of the Unified Parkinson 's Disease Rating Scale , a dyskinesia score and force in a grip - lift paradigm were assessed ON and OFF levodopa .
Diseases: dyskinesia, parkinson 's disease"	"Sentence: The motor score of the Unified Parkinson 's Disease Rating Scale , a dyskinesia score and force in a grip - lift paradigm were assessed ON and OFF levodopa .
Diseases:"
1948	A pathological increase of forces was seen in ON - state in Parkinson 's disease + LID only .	O O O O O O O O O O O O B I I O B O O	O O O O O O O O O O O O O O O O O O O	"['lid', ""parkinson 's disease""]"	2	7	"Sentence: A pathological increase of forces was seen in ON - state in Parkinson 's disease + LID only .
Diseases: lid, parkinson 's disease"	"Sentence: A pathological increase of forces was seen in ON - state in Parkinson 's disease + LID only .
Diseases:"
1949	In Parkinson 's disease + LID , the force involved in pressing down the object before lifting was significantly increased by levodopa ( by 61 % , P < 0 . 05 ) .	O B I I O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	"['lid', ""parkinson 's disease""]"	2	7	"Sentence: In Parkinson 's disease + LID , the force involved in pressing down the object before lifting was significantly increased by levodopa ( by 61 % , P < 0 . 05 ) .
Diseases: lid, parkinson 's disease"	"Sentence: In Parkinson 's disease + LID , the force involved in pressing down the object before lifting was significantly increased by levodopa ( by 61 % , P < 0 . 05 ) .
Diseases:"
1950	An overshooting of peak grip force by 51 % ( P < 0 . 05 ) and of static grip force by 45 % ( P < 0 . 01 ) was observed in the ON - compared with the OFF - drug condition .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: An overshooting of peak grip force by 51 % ( P < 0 . 05 ) and of static grip force by 45 % ( P < 0 . 01 ) was observed in the ON - compared with the OFF - drug condition .
Diseases: "	"Sentence: An overshooting of peak grip force by 51 % ( P < 0 . 05 ) and of static grip force by 45 % ( P < 0 . 01 ) was observed in the ON - compared with the OFF - drug condition .
Diseases:"
1951	In contrast , no excessive force was found in Parkinson 's disease - LID .	O O O O O O O O O B I I O B O	O O O O O O O O O O O O O O O	"['lid', ""parkinson 's disease""]"	2	7	"Sentence: In contrast , no excessive force was found in Parkinson 's disease - LID .
Diseases: lid, parkinson 's disease"	"Sentence: In contrast , no excessive force was found in Parkinson 's disease - LID .
Diseases:"
1952	Peak grip force in ON - state was 140 % ( P < 0 . 05 ) higher in Parkinson 's disease + LID than in Parkinson 's disease - LID , while static grip force was increased by 138 % ( P < 0 . 01 ) between groups .	O O O O O O O O O O O O O O O O O O O B I I O B O O B I I O B O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	"['lid', ""parkinson 's disease""]"	2	7	"Sentence: Peak grip force in ON - state was 140 % ( P < 0 . 05 ) higher in Parkinson 's disease + LID than in Parkinson 's disease - LID , while static grip force was increased by 138 % ( P < 0 . 01 ) between groups .
Diseases: lid, parkinson 's disease"	"Sentence: Peak grip force in ON - state was 140 % ( P < 0 . 05 ) higher in Parkinson 's disease + LID than in Parkinson 's disease - LID , while static grip force was increased by 138 % ( P < 0 . 01 ) between groups .
Diseases:"
1953	Severity of peak - dose dyskinesias was strongly correlated with grip force in ON - state ( r = 0 . 79 with peak force , P < 0 . 01 ) .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['dyskinesias']	1	5	"Sentence: Severity of peak - dose dyskinesias was strongly correlated with grip force in ON - state ( r = 0 . 79 with peak force , P < 0 . 01 ) .
Diseases: dyskinesias"	"Sentence: Severity of peak - dose dyskinesias was strongly correlated with grip force in ON - state ( r = 0 . 79 with peak force , P < 0 . 01 ) .
Diseases:"
1954	No correlation was observed between forces and the motor score as well as with the daily dose of dopaminergic medication .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: No correlation was observed between forces and the motor score as well as with the daily dose of dopaminergic medication .
Diseases: "	"Sentence: No correlation was observed between forces and the motor score as well as with the daily dose of dopaminergic medication .
Diseases:"
1955	Force excess was only observed in patients with LID and motor fluctuations .	O O O O O O O O B O O O O	O O O O O O O O O O O O O	['lid']	1	2	"Sentence: Force excess was only observed in patients with LID and motor fluctuations .
Diseases: lid"	"Sentence: Force excess was only observed in patients with LID and motor fluctuations .
Diseases:"
1956	A close relationship was seen between the overshooting of forces and dyskinesias in the ON - drug condition .	O O O O O O O O O O O B O O O O O O O	O O O O O O O O O O O O O O O O O O O	['dyskinesias']	1	5	"Sentence: A close relationship was seen between the overshooting of forces and dyskinesias in the ON - drug condition .
Diseases: dyskinesias"	"Sentence: A close relationship was seen between the overshooting of forces and dyskinesias in the ON - drug condition .
Diseases:"
1957	We postulate that both LID and grip force excess share common pathophysiological mechanisms related to motor fluctuations .	O O O O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	['lid']	1	2	"Sentence: We postulate that both LID and grip force excess share common pathophysiological mechanisms related to motor fluctuations .
Diseases: lid"	"Sentence: We postulate that both LID and grip force excess share common pathophysiological mechanisms related to motor fluctuations .
Diseases:"
1958	Postinfarction ventricular septal defect associated with long - term steroid therapy .	O B I I O O O O O O O O	O O O O O O O O O B O O	['ventricular septal defect']	1	6	"Sentence: Postinfarction ventricular septal defect associated with long - term steroid therapy .
Diseases: ventricular septal defect"	"Sentence: Postinfarction ventricular septal defect associated with long - term steroid therapy .
Diseases:"
1959	Two cases of postinfarction ventricular septal rupture in patients on long - term steroid therapy are presented and the favourable outcome in both cases described .	O O O O B I I O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O	['ventricular septal rupture']	1	6	"Sentence: Two cases of postinfarction ventricular septal rupture in patients on long - term steroid therapy are presented and the favourable outcome in both cases described .
Diseases: ventricular septal rupture"	"Sentence: Two cases of postinfarction ventricular septal rupture in patients on long - term steroid therapy are presented and the favourable outcome in both cases described .
Diseases:"
1960	A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed .	O O O O O O O O O B I O O O	O O O O B O O O O O O O O O	['septal rupture']	1	4	"Sentence: A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed .
Diseases: septal rupture"	"Sentence: A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed .
Diseases:"
1961	Angioedema associated with droperidol administration .	B O O O O O	O O O B O O	['angioedema']	1	4	"Sentence: Angioedema associated with droperidol administration .
Diseases: angioedema"	"Sentence: Angioedema associated with droperidol administration .
Diseases:"
1962	Angioedema , also known as angioneurotic edema or Quincke 's disease , is a well - demarcated , localized edema involving the subcutaneous tissues that may cause upper - airway obstruction .	B O O O O B I O B I I O O O O O O O O B O O O O O O O B I I I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	"['upper - airway obstruction', 'angioedema', 'edema', 'angioneurotic edema', ""quincke 's disease""]"	5	27	"Sentence: Angioedema , also known as angioneurotic edema or Quincke 's disease , is a well - demarcated , localized edema involving the subcutaneous tissues that may cause upper - airway obstruction .
Diseases: upper - airway obstruction, angioedema, edema, angioneurotic edema, quincke 's disease"	"Sentence: Angioedema , also known as angioneurotic edema or Quincke 's disease , is a well - demarcated , localized edema involving the subcutaneous tissues that may cause upper - airway obstruction .
Diseases:"
1963	We report the case of a previously healthy 19 - year - old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol .	O O O O O O O O O O O O O O O O O B I O O B O O B I O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['tongue swelling', 'angioedema', 'drug allergies']	3	12	"Sentence: We report the case of a previously healthy 19 - year - old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol .
Diseases: tongue swelling, angioedema, drug allergies"	"Sentence: We report the case of a previously healthy 19 - year - old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol .
Diseases:"
1964	Clarithromycin - associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis .	O O O B I O O O O B I I O O O O O O	B O O O O O O O O O O O O O O O O O	['visual hallucinations', 'chronic renal failure']	2	6	"Sentence: Clarithromycin - associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis .
Diseases: visual hallucinations, chronic renal failure"	"Sentence: Clarithromycin - associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis .
Diseases:"
1965	Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se .	B I O O O O O B I I O O O O B O O O	O O O O O O O O O O O O O O O O O O	['uremia', 'visual hallucinations', 'chronic renal failure']	3	9	"Sentence: Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se .
Diseases: uremia, visual hallucinations, chronic renal failure"	"Sentence: Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se .
Diseases:"
1966	Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic , clarithromycin .	O O O O O B I O O O O O O O O O O O	O O O O O O O O O O O O O B O O B O	['visual hallucinations']	1	2	"Sentence: Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic , clarithromycin .
Diseases: visual hallucinations"	"Sentence: Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic , clarithromycin .
Diseases:"
1967	We describe such a case in a patient with end - stage renal disease ( ESRD ) maintained on continuous ambulatory peritoneal dialysis ( CAPD ) .	O O O O O O O O O B I I I I O B O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['esrd', 'end - stage renal disease']	2	8	"Sentence: We describe such a case in a patient with end - stage renal disease ( ESRD ) maintained on continuous ambulatory peritoneal dialysis ( CAPD ) .
Diseases: esrd, end - stage renal disease"	"Sentence: We describe such a case in a patient with end - stage renal disease ( ESRD ) maintained on continuous ambulatory peritoneal dialysis ( CAPD ) .
Diseases:"
1968	The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient , with underlying aluminum intoxication , may have facilitated the appearance of this neurotoxic side effect .	O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O B O O O	O O O O O O O O B O O O O O O O O O O O O O O B O O O O O O O O O O O O O	['chronic renal failure', 'neurotoxic']	2	7	"Sentence: The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient , with underlying aluminum intoxication , may have facilitated the appearance of this neurotoxic side effect .
Diseases: chronic renal failure, neurotoxic"	"Sentence: The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient , with underlying aluminum intoxication , may have facilitated the appearance of this neurotoxic side effect .
Diseases:"
1969	It is important to understand the pharmacokinetics of medications in face of chronic renal failure , the possibility of drug interactions , and how these factors should help guide medication therapy in the ESRD patient .	O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O B O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['esrd', 'chronic renal failure']	2	6	"Sentence: It is important to understand the pharmacokinetics of medications in face of chronic renal failure , the possibility of drug interactions , and how these factors should help guide medication therapy in the ESRD patient .
Diseases: esrd, chronic renal failure"	"Sentence: It is important to understand the pharmacokinetics of medications in face of chronic renal failure , the possibility of drug interactions , and how these factors should help guide medication therapy in the ESRD patient .
Diseases:"
1970	Acute renal toxicity of doxorubicin ( adriamycin ) - loaded cyanoacrylate nanoparticles .	O B I O O O O O O O O O O	O O O O B O B O O O B O O	['renal toxicity']	1	3	"Sentence: Acute renal toxicity of doxorubicin ( adriamycin ) - loaded cyanoacrylate nanoparticles .
Diseases: renal toxicity"	"Sentence: Acute renal toxicity of doxorubicin ( adriamycin ) - loaded cyanoacrylate nanoparticles .
Diseases:"
1971	Acute doxorubicin - loaded nanoparticle ( DXNP ) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis .	O O O O O O O O B I O O O O O O O O O O B O	O B O O O O B O O O O O O O O O O O O O O O	['renal toxicity', 'glomerulonephritis']	2	10	"Sentence: Acute doxorubicin - loaded nanoparticle ( DXNP ) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis .
Diseases: renal toxicity, glomerulonephritis"	"Sentence: Acute doxorubicin - loaded nanoparticle ( DXNP ) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis .
Diseases:"
1972	In normal rats , 2 / 6 rats given free doxorubicin ( DX ) ( 5 mg / kg ) died within one week , whereas all control animals and all rats having received free NP or DXNP survived .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O B O B O O	[]	0	0	"Sentence: In normal rats , 2 / 6 rats given free doxorubicin ( DX ) ( 5 mg / kg ) died within one week , whereas all control animals and all rats having received free NP or DXNP survived .
Diseases: "	"Sentence: In normal rats , 2 / 6 rats given free doxorubicin ( DX ) ( 5 mg / kg ) died within one week , whereas all control animals and all rats having received free NP or DXNP survived .
Diseases:"
1973	A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX .	O O O O B O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O B O	['proteinuria']	1	2	"Sentence: A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX .
Diseases: proteinuria"	"Sentence: A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX .
Diseases:"
1974	Free NP did not provoke any proteinuria .	O O O O O O B O	O B O O O O O O	['proteinuria']	1	2	"Sentence: Free NP did not provoke any proteinuria .
Diseases: proteinuria"	"Sentence: Free NP did not provoke any proteinuria .
Diseases:"
1975	Two hr post - injection , DXNP was 2 . 7 times more concentrated in kidneys than free DX ( p < 0 . 025 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: Two hr post - injection , DXNP was 2 . 7 times more concentrated in kidneys than free DX ( p < 0 . 025 ) .
Diseases: "	"Sentence: Two hr post - injection , DXNP was 2 . 7 times more concentrated in kidneys than free DX ( p < 0 . 025 ) .
Diseases:"
1976	In rats with immune experimental glomerulonephritis , 5 / 6 rats given DX died within 7 days , in contrast to animals treated by DXNP , NP , or untreated , which all survived .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O B O B O O O O O O O O	['glomerulonephritis']	1	5	"Sentence: In rats with immune experimental glomerulonephritis , 5 / 6 rats given DX died within 7 days , in contrast to animals treated by DXNP , NP , or untreated , which all survived .
Diseases: glomerulonephritis"	"Sentence: In rats with immune experimental glomerulonephritis , 5 / 6 rats given DX died within 7 days , in contrast to animals treated by DXNP , NP , or untreated , which all survived .
Diseases:"
1977	Proteinuria appeared in all series , but was 2 - 5 times more intense ( p > 0 . 001 ) and prolonged after doxorubicin treatment ( 400 - 700 mg / day ) , without significant difference between DXNP and DX .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O B O B O	['proteinuria']	1	2	"Sentence: Proteinuria appeared in all series , but was 2 - 5 times more intense ( p > 0 . 001 ) and prolonged after doxorubicin treatment ( 400 - 700 mg / day ) , without significant difference between DXNP and DX .
Diseases: proteinuria"	"Sentence: Proteinuria appeared in all series , but was 2 - 5 times more intense ( p > 0 . 001 ) and prolonged after doxorubicin treatment ( 400 - 700 mg / day ) , without significant difference between DXNP and DX .
Diseases:"
1978	Rats treated by unloaded NP behaved as controls .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Rats treated by unloaded NP behaved as controls .
Diseases: "	"Sentence: Rats treated by unloaded NP behaved as controls .
Diseases:"
1979	These results demonstrate that , in these experimental conditions , DXNP killed less animals than free DX , despite of an enhanced renal toxicity of the former .	O O O O O O O O O O O O O O O O O O O O O O B I O O O O	O O O O O O O O O O B O O O O O B O O O O O O O O O O O	['renal toxicity']	1	3	"Sentence: These results demonstrate that , in these experimental conditions , DXNP killed less animals than free DX , despite of an enhanced renal toxicity of the former .
Diseases: renal toxicity"	"Sentence: These results demonstrate that , in these experimental conditions , DXNP killed less animals than free DX , despite of an enhanced renal toxicity of the former .
Diseases:"
1980	Both effects ( better survival and nephrosis ) are most probably related to an enhanced capture of DXNP by cells of the mononuclear phagocyte system , including mesangial cells .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	['nephrosis']	1	3	"Sentence: Both effects ( better survival and nephrosis ) are most probably related to an enhanced capture of DXNP by cells of the mononuclear phagocyte system , including mesangial cells .
Diseases: nephrosis"	"Sentence: Both effects ( better survival and nephrosis ) are most probably related to an enhanced capture of DXNP by cells of the mononuclear phagocyte system , including mesangial cells .
Diseases:"
1981	Etoposide - related myocardial infarction .	O O O B I O	B O O O O O	['myocardial infarction']	1	6	"Sentence: Etoposide - related myocardial infarction .
Diseases: myocardial infarction"	"Sentence: Etoposide - related myocardial infarction .
Diseases:"
1982	The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide , in a man with no risk factors for coronary heart disease .	O O O O B I O O O O O O O O O O O O O O O B I I O	O O O O O O O O O O O B O O O O O O O O O O O O O	['coronary heart disease', 'myocardial infarction']	2	10	"Sentence: The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide , in a man with no risk factors for coronary heart disease .
Diseases: coronary heart disease, myocardial infarction"	"Sentence: The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide , in a man with no risk factors for coronary heart disease .
Diseases:"
1983	Possible causal mechanisms are discussed .	O O O O O O	O O O O O O	[]	0	0	"Sentence: Possible causal mechanisms are discussed .
Diseases: "	"Sentence: Possible causal mechanisms are discussed .
Diseases:"
1984	Subjective assessment of sexual dysfunction of patients on long - term administration of digoxin .	O O O B I O O O O O O O O O O	O O O O O O O O O O O O O B O	['sexual dysfunction']	1	2	"Sentence: Subjective assessment of sexual dysfunction of patients on long - term administration of digoxin .
Diseases: sexual dysfunction"	"Sentence: Subjective assessment of sexual dysfunction of patients on long - term administration of digoxin .
Diseases:"
1985	Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone ( LH ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O B O O O O O B O O O O O O O	[]	0	0	"Sentence: Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone ( LH ) .
Diseases: "	"Sentence: Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone ( LH ) .
Diseases:"
1986	This study was undertaken to investigate the links between the long - term administration of digoxin therapy and sexual behavior , and the effect of digoxin on plasma levels of estradiol , testosterone , and LH .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O O O O O O O B O O O O B O B O O O O	[]	0	0	"Sentence: This study was undertaken to investigate the links between the long - term administration of digoxin therapy and sexual behavior , and the effect of digoxin on plasma levels of estradiol , testosterone , and LH .
Diseases: "	"Sentence: This study was undertaken to investigate the links between the long - term administration of digoxin therapy and sexual behavior , and the effect of digoxin on plasma levels of estradiol , testosterone , and LH .
Diseases:"
1987	The patients of the study and control group ( without digoxin ) were of similar cardiac functional capacity and age ( 25 - 40 years ) and were randomly selected from the rheumatic heart disease patients .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O O	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['rheumatic heart disease']	1	5	"Sentence: The patients of the study and control group ( without digoxin ) were of similar cardiac functional capacity and age ( 25 - 40 years ) and were randomly selected from the rheumatic heart disease patients .
Diseases: rheumatic heart disease"	"Sentence: The patients of the study and control group ( without digoxin ) were of similar cardiac functional capacity and age ( 25 - 40 years ) and were randomly selected from the rheumatic heart disease patients .
Diseases:"
1988	A subjective assessment of sexual behavior in the study and control groups was carried out , using parameters such as sexual desire , sexual excitement , and frequency of sexual relations .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A subjective assessment of sexual behavior in the study and control groups was carried out , using parameters such as sexual desire , sexual excitement , and frequency of sexual relations .
Diseases: "	"Sentence: A subjective assessment of sexual behavior in the study and control groups was carried out , using parameters such as sexual desire , sexual excitement , and frequency of sexual relations .
Diseases:"
1989	Personal interviews and a questionnaire were also used for the evaluation of sexual behavior .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Personal interviews and a questionnaire were also used for the evaluation of sexual behavior .
Diseases: "	"Sentence: Personal interviews and a questionnaire were also used for the evaluation of sexual behavior .
Diseases:"
1990	The findings support the reports concerning digoxin effect on plasma estradiol , testosterone , and LH .	O O O O O O O O O O O O O O O O O	O O O O O O B O O O B O B O O O O	[]	0	0	"Sentence: The findings support the reports concerning digoxin effect on plasma estradiol , testosterone , and LH .
Diseases: "	"Sentence: The findings support the reports concerning digoxin effect on plasma estradiol , testosterone , and LH .
Diseases:"
1991	The differences in the means were significant .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: The differences in the means were significant .
Diseases: "	"Sentence: The differences in the means were significant .
Diseases:"
1992	Tests used to evaluate the changes in sexual behavior showed a significant decrease in sexual desire , sexual excitement phase ( erection ) , and frequency of sexual relations in the study group .	O O O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['decrease in sexual desire']	1	6	"Sentence: Tests used to evaluate the changes in sexual behavior showed a significant decrease in sexual desire , sexual excitement phase ( erection ) , and frequency of sexual relations in the study group .
Diseases: decrease in sexual desire"	"Sentence: Tests used to evaluate the changes in sexual behavior showed a significant decrease in sexual desire , sexual excitement phase ( erection ) , and frequency of sexual relations in the study group .
Diseases:"
1993	Fatal aplastic anemia due to indomethacin - - lymphocyte transformation tests in vitro .	O B I O O O O O O O O O O O	O O O O O B O O O O O O O O	['aplastic anemia']	1	5	"Sentence: Fatal aplastic anemia due to indomethacin - - lymphocyte transformation tests in vitro .
Diseases: aplastic anemia"	"Sentence: Fatal aplastic anemia due to indomethacin - - lymphocyte transformation tests in vitro .
Diseases:"
1994	Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations , its role has not been definitely established .	O O O O O O O O O O B I O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	['aplastic anemia']	1	5	"Sentence: Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations , its role has not been definitely established .
Diseases: aplastic anemia"	"Sentence: Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations , its role has not been definitely established .
Diseases:"
1995	A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given .	O O O O B I O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O B O O O	['aplastic anemia']	1	5	"Sentence: A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given .
Diseases: aplastic anemia"	"Sentence: A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given .
Diseases:"
1996	Indomethacin was first given four weeks prior to the onset of symptoms .	O O O O O O O O O O O O O	B O O O O O O O O O O O O	[]	0	0	"Sentence: Indomethacin was first given four weeks prior to the onset of symptoms .
Diseases: "	"Sentence: Indomethacin was first given four weeks prior to the onset of symptoms .
Diseases:"
1997	A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient .	O O O O O O O O O O O O O O O O O O O B I O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O	['aplastic anemia']	1	5	"Sentence: A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient .
Diseases: aplastic anemia"	"Sentence: A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient .
Diseases:"
1998	Fortunately , this seems to be a very rare complication .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: Fortunately , this seems to be a very rare complication .
Diseases: "	"Sentence: Fortunately , this seems to be a very rare complication .
Diseases:"
1999	Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside .	O O O O O O O O O O B I O O O O O O O O	O O O O O O O O O O O O O O O O O B I O	['nephrotic syndrome']	1	5	"Sentence: Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside .
Diseases: nephrotic syndrome"	"Sentence: Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside .
Diseases:"
2000	This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se , or , at least in part , to the aminonucleoside .	O O O O O O O O O O O O O O B I O O O O O O O B I O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O B O	['nephrotic syndrome']	1	5	"Sentence: This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se , or , at least in part , to the aminonucleoside .
Diseases: nephrotic syndrome"	"Sentence: This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se , or , at least in part , to the aminonucleoside .
Diseases:"
2001	The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside ( 20 mg / kg for 7 days ) and the subsequent development of nephrotic syndrome .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O	['nephrotic syndrome']	1	5	"Sentence: The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside ( 20 mg / kg for 7 days ) and the subsequent development of nephrotic syndrome .
Diseases: nephrotic syndrome"	"Sentence: The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside ( 20 mg / kg for 7 days ) and the subsequent development of nephrotic syndrome .
Diseases:"
2002	Since massive albuminuria occurred after 6 days of treatment , the time - course study was divided into two stages : pre - nephrotic stage ( day 1 - 5 ) and nephrotic stage ( day 6 - 11 ) .	O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['albuminuria', 'nephrotic']	2	8	"Sentence: Since massive albuminuria occurred after 6 days of treatment , the time - course study was divided into two stages : pre - nephrotic stage ( day 1 - 5 ) and nephrotic stage ( day 6 - 11 ) .
Diseases: albuminuria, nephrotic"	"Sentence: Since massive albuminuria occurred after 6 days of treatment , the time - course study was divided into two stages : pre - nephrotic stage ( day 1 - 5 ) and nephrotic stage ( day 6 - 11 ) .
Diseases:"
2003	In pre - nephrotic stage the plasma level of fatty acids , triacylglycerol and VLDL decreased while that of phospholipid , cholesteryl esters and HDL remained constant .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O I O O O O O O O O O O B I O O O O O	['nephrotic']	1	4	"Sentence: In pre - nephrotic stage the plasma level of fatty acids , triacylglycerol and VLDL decreased while that of phospholipid , cholesteryl esters and HDL remained constant .
Diseases: nephrotic"	"Sentence: In pre - nephrotic stage the plasma level of fatty acids , triacylglycerol and VLDL decreased while that of phospholipid , cholesteryl esters and HDL remained constant .
Diseases:"
2004	Plasma apolipoprotein A - I tended to increase ( 40 % increase at day 5 ) .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Plasma apolipoprotein A - I tended to increase ( 40 % increase at day 5 ) .
Diseases: "	"Sentence: Plasma apolipoprotein A - I tended to increase ( 40 % increase at day 5 ) .
Diseases:"
2005	At the beginning of nephrotic stage ( day 6 ) the concentration of plasma albumin dropped to a very low level , while that of apolipoprotein A - I increased abruptly ( 4 - fold increase ) and continued to rise , although less steeply , in the following days .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nephrotic']	1	4	"Sentence: At the beginning of nephrotic stage ( day 6 ) the concentration of plasma albumin dropped to a very low level , while that of apolipoprotein A - I increased abruptly ( 4 - fold increase ) and continued to rise , although less steeply , in the following days .
Diseases: nephrotic"	"Sentence: At the beginning of nephrotic stage ( day 6 ) the concentration of plasma albumin dropped to a very low level , while that of apolipoprotein A - I increased abruptly ( 4 - fold increase ) and continued to rise , although less steeply , in the following days .
Diseases:"
2006	The plasma concentration of HDL followed the same pattern .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: The plasma concentration of HDL followed the same pattern .
Diseases: "	"Sentence: The plasma concentration of HDL followed the same pattern .
Diseases:"
2007	Plasma VLDL and LDL increased at a later stage ( day 9 ) .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Plasma VLDL and LDL increased at a later stage ( day 9 ) .
Diseases: "	"Sentence: Plasma VLDL and LDL increased at a later stage ( day 9 ) .
Diseases:"
2008	Plasma apolipoprotein A - I was found not only in HDL ( 1 . 063 - 1 . 210 g / ml ) but also in the LDL density class ( 1 . 025 - 1 . 050 g / ml ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Plasma apolipoprotein A - I was found not only in HDL ( 1 . 063 - 1 . 210 g / ml ) but also in the LDL density class ( 1 . 025 - 1 . 050 g / ml ) .
Diseases: "	"Sentence: Plasma apolipoprotein A - I was found not only in HDL ( 1 . 063 - 1 . 210 g / ml ) but also in the LDL density class ( 1 . 025 - 1 . 050 g / ml ) .
Diseases:"
2009	In the pre - nephrotic stage lipoproteinuria was negligible , while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL .	O O O O B O O O O O O O O O B O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nephrotic']	1	4	"Sentence: In the pre - nephrotic stage lipoproteinuria was negligible , while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL .
Diseases: nephrotic"	"Sentence: In the pre - nephrotic stage lipoproteinuria was negligible , while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL .
Diseases:"
2010	These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL .	O O O O O O O O O O O O O O O O	O O O O B I O O O O O O O O O O	[]	0	0	"Sentence: These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL .
Diseases: "	"Sentence: These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL .
Diseases:"
2011	It is likely that the early and striking increase of plasma HDL found in nephrotic rats is related to a direct effect of the drug on HDL metabolism .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nephrotic']	1	4	"Sentence: It is likely that the early and striking increase of plasma HDL found in nephrotic rats is related to a direct effect of the drug on HDL metabolism .
Diseases: nephrotic"	"Sentence: It is likely that the early and striking increase of plasma HDL found in nephrotic rats is related to a direct effect of the drug on HDL metabolism .
Diseases:"
2012	Circulating lysosomal enzymes and acute hepatic necrosis .	O O O O B I I O	O O O O O O O O	['acute hepatic necrosis']	1	6	"Sentence: Circulating lysosomal enzymes and acute hepatic necrosis .
Diseases: acute hepatic necrosis"	"Sentence: Circulating lysosomal enzymes and acute hepatic necrosis .
Diseases:"
2013	The activities of the lysosomal enzymes acid and neutral protease , N - acetylglucosaminidase , and acid phosphatase were measured in the serum of patients with fulminant hepatic failure .	O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['fulminant hepatic failure']	1	6	"Sentence: The activities of the lysosomal enzymes acid and neutral protease , N - acetylglucosaminidase , and acid phosphatase were measured in the serum of patients with fulminant hepatic failure .
Diseases: fulminant hepatic failure"	"Sentence: The activities of the lysosomal enzymes acid and neutral protease , N - acetylglucosaminidase , and acid phosphatase were measured in the serum of patients with fulminant hepatic failure .
Diseases:"
2014	Acid protease ( cathepsin D ) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose , whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived .	O O O O O O O O O O O O O O O O O O O O O O B I I O O B O O O O O O O O O B I I O O B I O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['overdose', 'viral hepatitis', 'fulminant hepatic failure']	3	12	"Sentence: Acid protease ( cathepsin D ) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose , whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived .
Diseases: overdose, viral hepatitis, fulminant hepatic failure"	"Sentence: Acid protease ( cathepsin D ) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose , whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived .
Diseases:"
2015	A correlation was found between serum acid protease activity and prothrombin time , and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase , which showed a sharp early peak and then a fall .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: A correlation was found between serum acid protease activity and prothrombin time , and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase , which showed a sharp early peak and then a fall .
Diseases: "	"Sentence: A correlation was found between serum acid protease activity and prothrombin time , and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase , which showed a sharp early peak and then a fall .
Diseases:"
2016	Circulating lysosomal proteases can damage other organs , and measurement of their activity may therefore be of added value in assessing prognosis in this condition .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Circulating lysosomal proteases can damage other organs , and measurement of their activity may therefore be of added value in assessing prognosis in this condition .
Diseases: "	"Sentence: Circulating lysosomal proteases can damage other organs , and measurement of their activity may therefore be of added value in assessing prognosis in this condition .
Diseases:"
2017	Transketolase abnormality in tolazamide - induced Wernicke 's encephalopathy .	O O O O O O B I I O	O O O B O O O O O O	"[""wernicke 's encephalopathy""]"	1	9	"Sentence: Transketolase abnormality in tolazamide - induced Wernicke 's encephalopathy .
Diseases: wernicke 's encephalopathy"	"Sentence: Transketolase abnormality in tolazamide - induced Wernicke 's encephalopathy .
Diseases:"
2018	We studied a thiamine - dependent enzyme , transketolase , from fibroblasts of a diabetic patient who developed Wernicke 's encephalopathy when treated with tolazamide , in order to delineate if this patient also had transketolase abnormality [ high Km for thiamine pyrophosphate ( TPP ) ] , as previously reported in postalcoholic Wernicke - Korsakoff syndrome .	O O O O O O O O O O O O O O B O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I O	O O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O B I O B O O O O O O O O O O O O O	"[""wernicke 's encephalopathy"", 'wernicke - korsakoff syndrome', 'diabetic']"	3	22	"Sentence: We studied a thiamine - dependent enzyme , transketolase , from fibroblasts of a diabetic patient who developed Wernicke 's encephalopathy when treated with tolazamide , in order to delineate if this patient also had transketolase abnormality [ high Km for thiamine pyrophosphate ( TPP ) ] , as previously reported in postalcoholic Wernicke - Korsakoff syndrome .
Diseases: wernicke 's encephalopathy, wernicke - korsakoff syndrome, diabetic"	"Sentence: We studied a thiamine - dependent enzyme , transketolase , from fibroblasts of a diabetic patient who developed Wernicke 's encephalopathy when treated with tolazamide , in order to delineate if this patient also had transketolase abnormality [ high Km for thiamine pyrophosphate ( TPP ) ] , as previously reported in postalcoholic Wernicke - Korsakoff syndrome .
Diseases:"
2019	In addition to this patient , we also studied this enzyme from three diabetic kindreds without any history of Wernicke 's encephalopathy and from four normal controls .	O O O O O O O O O O O O O B O O O O O B I I O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	"[""wernicke 's encephalopathy"", 'diabetic']"	2	11	"Sentence: In addition to this patient , we also studied this enzyme from three diabetic kindreds without any history of Wernicke 's encephalopathy and from four normal controls .
Diseases: wernicke 's encephalopathy, diabetic"	"Sentence: In addition to this patient , we also studied this enzyme from three diabetic kindreds without any history of Wernicke 's encephalopathy and from four normal controls .
Diseases:"
2020	We found that the above - mentioned patient and one of the diabetic kindreds with no history of Wernicke 's encephalopathy had abnormal transketolase as determined by its Km for TPP .	O O O O O O O O O O O O B O O O O O B I I O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	"[""wernicke 's encephalopathy"", 'diabetic']"	2	11	"Sentence: We found that the above - mentioned patient and one of the diabetic kindreds with no history of Wernicke 's encephalopathy had abnormal transketolase as determined by its Km for TPP .
Diseases: wernicke 's encephalopathy, diabetic"	"Sentence: We found that the above - mentioned patient and one of the diabetic kindreds with no history of Wernicke 's encephalopathy had abnormal transketolase as determined by its Km for TPP .
Diseases:"
2021	These data suggest a similarity between postalcoholic Wernicke - Korsakoff syndrome and the patient with tolazamide - induced Wernicke 's encephalopathy from the standpoint of transketolase abnormality .	O O O O O O O B I I I O O O O O O O B I I O O O O O O O	O O O O O O O O O O O O O O O B O O O O O O O O O O O O	"[""wernicke 's encephalopathy"", 'wernicke - korsakoff syndrome']"	2	20	"Sentence: These data suggest a similarity between postalcoholic Wernicke - Korsakoff syndrome and the patient with tolazamide - induced Wernicke 's encephalopathy from the standpoint of transketolase abnormality .
Diseases: wernicke 's encephalopathy, wernicke - korsakoff syndrome"	"Sentence: These data suggest a similarity between postalcoholic Wernicke - Korsakoff syndrome and the patient with tolazamide - induced Wernicke 's encephalopathy from the standpoint of transketolase abnormality .
Diseases:"
2022	Mechanisms of myocardial ischemia induced by epinephrine : comparison with exercise - induced ischemia .	O O B I O O O O O O O O O B O	O O O O O O B O O O O O O O O	['myocardial ischemia', 'ischemia']	2	10	"Sentence: Mechanisms of myocardial ischemia induced by epinephrine : comparison with exercise - induced ischemia .
Diseases: myocardial ischemia, ischemia"	"Sentence: Mechanisms of myocardial ischemia induced by epinephrine : comparison with exercise - induced ischemia .
Diseases:"
2023	The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease .	O O O O O O B I O O O O O B I I O	O O O B O O O O O O O O O O O O O	['coronary artery disease', 'myocardial ischemia']	2	10	"Sentence: The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease .
Diseases: coronary artery disease, myocardial ischemia"	"Sentence: The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease .
Diseases:"
2024	Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise .	O O O B O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O B O O O O O O	['ischemia']	1	3	"Sentence: Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise .
Diseases: ischemia"	"Sentence: Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise .
Diseases:"
2025	Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina .	O O O O O B I O O O O O B O B O	O B O O O O O O O O O O O O O O	['depression', 'myocardial ischemia', 'angina']	3	12	"Sentence: Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina .
Diseases: depression, myocardial ischemia, angina"	"Sentence: Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina .
Diseases:"
2026	However , the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise .	O O O O O B I O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O	['myocardial ischemia']	1	6	"Sentence: However , the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise .
Diseases: myocardial ischemia"	"Sentence: However , the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise .
Diseases:"
2027	Exercise - induced myocardial ischemia was marked predominantly by increased heart rate and rate - pressure product with a minor contribution of end - diastolic volume , while epinephrine - induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate - pressure product .	O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['myocardial ischemia', 'ischemia']	2	10	"Sentence: Exercise - induced myocardial ischemia was marked predominantly by increased heart rate and rate - pressure product with a minor contribution of end - diastolic volume , while epinephrine - induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate - pressure product .
Diseases: myocardial ischemia, ischemia"	"Sentence: Exercise - induced myocardial ischemia was marked predominantly by increased heart rate and rate - pressure product with a minor contribution of end - diastolic volume , while epinephrine - induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate - pressure product .
Diseases:"
2028	These findings indicate that ischemia produced by epinephrine , as may occur during states of emotional distress , has a mechanism distinct from that due to physical exertion .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	['ischemia']	1	3	"Sentence: These findings indicate that ischemia produced by epinephrine , as may occur during states of emotional distress , has a mechanism distinct from that due to physical exertion .
Diseases: ischemia"	"Sentence: These findings indicate that ischemia produced by epinephrine , as may occur during states of emotional distress , has a mechanism distinct from that due to physical exertion .
Diseases:"
2029	Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine .	O B I O O B I I O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O	['substantia nigra lesion', 'contralateral rotation']	2	12	"Sentence: Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine .
Diseases: substantia nigra lesion, contralateral rotation"	"Sentence: Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine .
Diseases:"
2030	Following unilateral 6 - OHDA induced SN lesion , a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling .	O O O O O O B I O O O O O B I O O O O O O O B I O	O O B I I O O O O O O O O O O O O O O O O O O O O	['ipsilateral circling', 'contralateral rotation', 'sn lesion']	3	12	"Sentence: Following unilateral 6 - OHDA induced SN lesion , a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling .
Diseases: ipsilateral circling, contralateral rotation, sn lesion"	"Sentence: Following unilateral 6 - OHDA induced SN lesion , a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling .
Diseases:"
2031	In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion , on amphetamine - induced rotational behavior .	O O O O O O O O O B I O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	['rotational behavior', 'contralateral rotation']	2	8	"Sentence: In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion , on amphetamine - induced rotational behavior .
Diseases: rotational behavior, contralateral rotation"	"Sentence: In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion , on amphetamine - induced rotational behavior .
Diseases:"
2032	Three days post lesion , most rats circled predominantly contralaterally to the lesion .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Three days post lesion , most rats circled predominantly contralaterally to the lesion .
Diseases: "	"Sentence: Three days post lesion , most rats circled predominantly contralaterally to the lesion .
Diseases:"
2033	Such contralateral rotation may result from either degeneration - induced breakdown of the DA pool , or lesion - induced increase of DA turnover in the spared neurons .	O B I O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O B O O O O O O	['contralateral rotation']	1	4	"Sentence: Such contralateral rotation may result from either degeneration - induced breakdown of the DA pool , or lesion - induced increase of DA turnover in the spared neurons .
Diseases: contralateral rotation"	"Sentence: Such contralateral rotation may result from either degeneration - induced breakdown of the DA pool , or lesion - induced increase of DA turnover in the spared neurons .
Diseases:"
2034	A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning , indicating involvement of spared cells in the contralateral rotation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	['contralateral rotation']	1	4	"Sentence: A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning , indicating involvement of spared cells in the contralateral rotation .
Diseases: contralateral rotation"	"Sentence: A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning , indicating involvement of spared cells in the contralateral rotation .
Diseases:"
2035	However , regardless of the duration of recovery ( and irrespective of either lesion volume , amphetamine dose , or post - lesion motor exercise ) , amphetamine - induced rotation tended to become gradually more ipsilateral as the observation session progressed , and all rats circled ipsilaterally to the lesion in response to further amphetamine injections .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['rotation']	1	2	"Sentence: However , regardless of the duration of recovery ( and irrespective of either lesion volume , amphetamine dose , or post - lesion motor exercise ) , amphetamine - induced rotation tended to become gradually more ipsilateral as the observation session progressed , and all rats circled ipsilaterally to the lesion in response to further amphetamine injections .
Diseases: rotation"	"Sentence: However , regardless of the duration of recovery ( and irrespective of either lesion volume , amphetamine dose , or post - lesion motor exercise ) , amphetamine - induced rotation tended to become gradually more ipsilateral as the observation session progressed , and all rats circled ipsilaterally to the lesion in response to further amphetamine injections .
Diseases:"
2036	These findings suggest that amphetamine has an irreversible effect on the post - lesion DA pool contributing to contralateral rotation .	O O O O O O O O O O O O O O O O O O B I O	O O O O B O O O O O O O O O B O O O O O O	['contralateral rotation']	1	4	"Sentence: These findings suggest that amphetamine has an irreversible effect on the post - lesion DA pool contributing to contralateral rotation .
Diseases: contralateral rotation"	"Sentence: These findings suggest that amphetamine has an irreversible effect on the post - lesion DA pool contributing to contralateral rotation .
Diseases:"
2037	Thyroid function and urine - concentrating ability during lithium treatment .	O O O O O O O O O O O	O O O O O O O O B O O	[]	0	0	"Sentence: Thyroid function and urine - concentrating ability during lithium treatment .
Diseases: "	"Sentence: Thyroid function and urine - concentrating ability during lithium treatment .
Diseases:"
2038	It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment .	O O O O O O O O O O O O O O O O B I I O B O O O O	O O O O O O O O O O O O O O O O O O O O O O B O O	['hypothyroidism', 'nephrogenic diabetes insipidus']	2	14	"Sentence: It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment .
Diseases: hypothyroidism, nephrogenic diabetes insipidus"	"Sentence: It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment .
Diseases:"
2039	We measured serum thyroxine and urine - concentrating ability ( Umax ) in response to desmopressin ( DDAVP ) in 85 patients receiving lithium .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O B O B O O O O O B O	[]	0	0	"Sentence: We measured serum thyroxine and urine - concentrating ability ( Umax ) in response to desmopressin ( DDAVP ) in 85 patients receiving lithium .
Diseases: "	"Sentence: We measured serum thyroxine and urine - concentrating ability ( Umax ) in response to desmopressin ( DDAVP ) in 85 patients receiving lithium .
Diseases:"
2040	Hypothyroidism developed in eight patients while they were taking lithium .	B O O O O O O O O O O	O O O O O O O O O B O	['hypothyroidism']	1	4	"Sentence: Hypothyroidism developed in eight patients while they were taking lithium .
Diseases: hypothyroidism"	"Sentence: Hypothyroidism developed in eight patients while they were taking lithium .
Diseases:"
2041	Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well .	O O O O O O O O B O O O B O O O O O O	O O O O O O O O O O O O O O O O O O O	['hypothyroid']	1	3	"Sentence: Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well .
Diseases: hypothyroid"	"Sentence: Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well .
Diseases:"
2042	It is concluded that the dominant mechanisms by which lithium exerts these two effects are different .	O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: It is concluded that the dominant mechanisms by which lithium exerts these two effects are different .
Diseases: "	"Sentence: It is concluded that the dominant mechanisms by which lithium exerts these two effects are different .
Diseases:"
2043	Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice .	O O O O O O O O O O B O O	O O O O O O O O B O O O O	['immunodeficient']	1	5	"Sentence: Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice .
Diseases: immunodeficient"	"Sentence: Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice .
Diseases:"
2044	The anaemia induced by 3' - azido - 3'dideoxythymidine ( AZT ) is poorly understood .	O B O O O O O O O O O O O O O O	O O O O B I I I I O B O O O O O	['anaemia']	1	2	"Sentence: The anaemia induced by 3' - azido - 3'dideoxythymidine ( AZT ) is poorly understood .
Diseases: anaemia"	"Sentence: The anaemia induced by 3' - azido - 3'dideoxythymidine ( AZT ) is poorly understood .
Diseases:"
2045	We have used a murine model of AIDS , infection of female C57BL / 6 mice with LP - BM5 murine leukaemia ( MuLV ) virus , to determine if AZT - induced anaemia is due , in part , to decreased responsiveness of erythropoietic precursors ( BFU - e ) to erythropoietin ( EPO ) .	O O O O O O O B O B O O O O O O O O O O O B O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['aids', 'anaemia', 'leukaemia', 'infection']	4	11	"Sentence: We have used a murine model of AIDS , infection of female C57BL / 6 mice with LP - BM5 murine leukaemia ( MuLV ) virus , to determine if AZT - induced anaemia is due , in part , to decreased responsiveness of erythropoietic precursors ( BFU - e ) to erythropoietin ( EPO ) .
Diseases: aids, anaemia, leukaemia, infection"	"Sentence: We have used a murine model of AIDS , infection of female C57BL / 6 mice with LP - BM5 murine leukaemia ( MuLV ) virus , to determine if AZT - induced anaemia is due , in part , to decreased responsiveness of erythropoietic precursors ( BFU - e ) to erythropoietin ( EPO ) .
Diseases:"
2046	Mice in the early stage of LP - BM5 MuLV disease were given AZT in their drinking water at 1 . 0 and 2 . 5 mg / ml .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Mice in the early stage of LP - BM5 MuLV disease were given AZT in their drinking water at 1 . 0 and 2 . 5 mg / ml .
Diseases: "	"Sentence: Mice in the early stage of LP - BM5 MuLV disease were given AZT in their drinking water at 1 . 0 and 2 . 5 mg / ml .
Diseases:"
2047	AZT produced anaemia in both groups , in a dose - dependent fashion .	O O B O O O O O O O O O O O	B O O O O O O O O O O O O O	['anaemia']	1	2	"Sentence: AZT produced anaemia in both groups , in a dose - dependent fashion .
Diseases: anaemia"	"Sentence: AZT produced anaemia in both groups , in a dose - dependent fashion .
Diseases:"
2048	Despite the anaemia , the number of splenic and bone marrow BFU - e in AZT treated mice increased up to five - fold over levels observed in infected untreated animals after 15 d of treatment .	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	['anaemia']	1	2	"Sentence: Despite the anaemia , the number of splenic and bone marrow BFU - e in AZT treated mice increased up to five - fold over levels observed in infected untreated animals after 15 d of treatment .
Diseases: anaemia"	"Sentence: Despite the anaemia , the number of splenic and bone marrow BFU - e in AZT treated mice increased up to five - fold over levels observed in infected untreated animals after 15 d of treatment .
Diseases:"
2049	Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected , untreated mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected , untreated mice .
Diseases: "	"Sentence: Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected , untreated mice .
Diseases:"
2050	By day 30 , sensitivity of both splenic and bone marrow BFU - e of treated animals returned to that observed from cells of infected untreated animals .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: By day 30 , sensitivity of both splenic and bone marrow BFU - e of treated animals returned to that observed from cells of infected untreated animals .
Diseases: "	"Sentence: By day 30 , sensitivity of both splenic and bone marrow BFU - e of treated animals returned to that observed from cells of infected untreated animals .
Diseases:"
2051	The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of anaemia observed when compared with phenylhydrazine ( PHZ ) treated mice .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O B O B O O O O	['anaemia']	1	2	"Sentence: The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of anaemia observed when compared with phenylhydrazine ( PHZ ) treated mice .
Diseases: anaemia"	"Sentence: The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of anaemia observed when compared with phenylhydrazine ( PHZ ) treated mice .
Diseases:"
2052	The numbers of BFU - e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O B O B O O O O O O O O	['anaemia']	1	2	"Sentence: The numbers of BFU - e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia .
Diseases: anaemia"	"Sentence: The numbers of BFU - e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia .
Diseases:"
2053	However , reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice .	O O B O O O O O O B O O O O O O O	O O O O O O O O O O O O B O O O O	['reticulocytosis', 'anaemia']	2	9	"Sentence: However , reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice .
Diseases: reticulocytosis, anaemia"	"Sentence: However , reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice .
Diseases:"
2054	AZT - induced peripheral anaemia in the face of increased numbers of BFU - e and increased levels of plasma EPO suggest a lesion in terminal differentiation .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O	['anaemia']	1	2	"Sentence: AZT - induced peripheral anaemia in the face of increased numbers of BFU - e and increased levels of plasma EPO suggest a lesion in terminal differentiation .
Diseases: anaemia"	"Sentence: AZT - induced peripheral anaemia in the face of increased numbers of BFU - e and increased levels of plasma EPO suggest a lesion in terminal differentiation .
Diseases:"
2055	Detection of abnormal cardiac adrenergic neuron activity in adriamycin - induced cardiomyopathy with iodine - 125 - metaiodobenzylguanidine .	O O O O O O O O O O O B O O O O O O O	O O O O O O O O B O O O O B I I I I O	['cardiomyopathy']	1	4	"Sentence: Detection of abnormal cardiac adrenergic neuron activity in adriamycin - induced cardiomyopathy with iodine - 125 - metaiodobenzylguanidine .
Diseases: cardiomyopathy"	"Sentence: Detection of abnormal cardiac adrenergic neuron activity in adriamycin - induced cardiomyopathy with iodine - 125 - metaiodobenzylguanidine .
Diseases:"
2056	Radiolabeled metaiodobenzylguanidine ( MIBG ) , an analog of norepinephrine ( NE ) , serves as an index of adrenergic neuron integrity and function .	O O O O O O O O O O O O O O O O O O O O O O O O O	O B O B O O O O O B O B O O O O O O O O O O O O O	[]	0	0	"Sentence: Radiolabeled metaiodobenzylguanidine ( MIBG ) , an analog of norepinephrine ( NE ) , serves as an index of adrenergic neuron integrity and function .
Diseases: "	"Sentence: Radiolabeled metaiodobenzylguanidine ( MIBG ) , an analog of norepinephrine ( NE ) , serves as an index of adrenergic neuron integrity and function .
Diseases:"
2057	Using a rat model of adriamycin - induced cardiomyopathy , we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose - dependently in adriamycin cardiomyopathy .	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O B O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O B O O	['cardiomyopathy']	1	4	"Sentence: Using a rat model of adriamycin - induced cardiomyopathy , we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose - dependently in adriamycin cardiomyopathy .
Diseases: cardiomyopathy"	"Sentence: Using a rat model of adriamycin - induced cardiomyopathy , we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose - dependently in adriamycin cardiomyopathy .
Diseases:"
2058	The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment ( 2 mg / kg , once a week ) .	O O O B I I I I O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	['vacuolar degeneration of myocardial cells']	1	11	"Sentence: The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment ( 2 mg / kg , once a week ) .
Diseases: vacuolar degeneration of myocardial cells"	"Sentence: The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment ( 2 mg / kg , once a week ) .
Diseases:"
2059	There were no abnormalities or only isolated degeneration in the 1 - or 2 - wk treatment groups , isolated or scattered degeneration in half of the 3 - wk group , frequent scattered degeneration in the 4 - wk group , scattered or focal degeneration in the 5 - wk group , and extensive degeneration in the 8 - wk group .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There were no abnormalities or only isolated degeneration in the 1 - or 2 - wk treatment groups , isolated or scattered degeneration in half of the 3 - wk group , frequent scattered degeneration in the 4 - wk group , scattered or focal degeneration in the 5 - wk group , and extensive degeneration in the 8 - wk group .
Diseases: "	"Sentence: There were no abnormalities or only isolated degeneration in the 1 - or 2 - wk treatment groups , isolated or scattered degeneration in half of the 3 - wk group , frequent scattered degeneration in the 4 - wk group , scattered or focal degeneration in the 5 - wk group , and extensive degeneration in the 8 - wk group .
Diseases:"
2060	Myocardial accumulation of [ 125I ] MIBG 4 hr after intravenous injection did not differ between the controls and the groups treated 3 wk or less .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B I I B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Myocardial accumulation of [ 125I ] MIBG 4 hr after intravenous injection did not differ between the controls and the groups treated 3 wk or less .
Diseases: "	"Sentence: Myocardial accumulation of [ 125I ] MIBG 4 hr after intravenous injection did not differ between the controls and the groups treated 3 wk or less .
Diseases:"
2061	However , the 4 - wk group had a slightly lower accumulation in the right ventricular wall ( 82 % of the control ) and significantly lower accumulation in the left ventricular wall ( about 66 % of the control : p less than 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , the 4 - wk group had a slightly lower accumulation in the right ventricular wall ( 82 % of the control ) and significantly lower accumulation in the left ventricular wall ( about 66 % of the control : p less than 0 . 05 ) .
Diseases: "	"Sentence: However , the 4 - wk group had a slightly lower accumulation in the right ventricular wall ( 82 % of the control ) and significantly lower accumulation in the left ventricular wall ( about 66 % of the control : p less than 0 . 05 ) .
Diseases:"
2062	In the 5 - wk group , MIBG accumulation in the right and left ventricular wall was 35 % and 27 % of that in controls , respectively ( p less than 0 . 001 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the 5 - wk group , MIBG accumulation in the right and left ventricular wall was 35 % and 27 % of that in controls , respectively ( p less than 0 . 001 ) .
Diseases: "	"Sentence: In the 5 - wk group , MIBG accumulation in the right and left ventricular wall was 35 % and 27 % of that in controls , respectively ( p less than 0 . 001 ) .
Diseases:"
2063	In the 8 - wk group , MIBG accumulation in the right and left ventricular wall was 18 % and 14 % of that in controls , respectively ( p less than 0 . 001 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the 8 - wk group , MIBG accumulation in the right and left ventricular wall was 18 % and 14 % of that in controls , respectively ( p less than 0 . 001 ) .
Diseases: "	"Sentence: In the 8 - wk group , MIBG accumulation in the right and left ventricular wall was 18 % and 14 % of that in controls , respectively ( p less than 0 . 001 ) .
Diseases:"
2064	Thus , MIBG accumulation in the myocardium decreased in an adriamycin dose - dependent manner .	O O O O O O O O O O O O O O O O	O O B O O O O O O O B O O O O O	[]	0	0	"Sentence: Thus , MIBG accumulation in the myocardium decreased in an adriamycin dose - dependent manner .
Diseases: "	"Sentence: Thus , MIBG accumulation in the myocardium decreased in an adriamycin dose - dependent manner .
Diseases:"
2065	The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment ( scattered or focal vacuolar degeneration ) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin - induced cardiomyopathy .	O O O O O O O O O O O O O B I O O O O B I O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O B O O O O	['vacuolar degeneration', 'cardiomyopathy', 'myocardial impairment']	3	16	"Sentence: The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment ( scattered or focal vacuolar degeneration ) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin - induced cardiomyopathy .
Diseases: vacuolar degeneration, cardiomyopathy, myocardial impairment"	"Sentence: The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment ( scattered or focal vacuolar degeneration ) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin - induced cardiomyopathy .
Diseases:"
2066	Amnestic syndrome associated with propranolol toxicity : a case report .	B I O O O B O O O O O	O O O O B O O O O O O	['amnestic syndrome', 'toxicity']	2	5	"Sentence: Amnestic syndrome associated with propranolol toxicity : a case report .
Diseases: amnestic syndrome, toxicity"	"Sentence: Amnestic syndrome associated with propranolol toxicity : a case report .
Diseases:"
2067	An elderly woman developed an Alzheimer - like subacute dementia as a result of propranolol toxicity .	O O O O O B O O O B O O O O O B O	O O O O O O O O O O O O O O B O O	['alzheimer', 'dementia', 'toxicity']	3	7	"Sentence: An elderly woman developed an Alzheimer - like subacute dementia as a result of propranolol toxicity .
Diseases: alzheimer, dementia, toxicity"	"Sentence: An elderly woman developed an Alzheimer - like subacute dementia as a result of propranolol toxicity .
Diseases:"
2068	Analysis of the manifestations showed that severe impairment of memory accounted for virtually all of the abnormalities .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Analysis of the manifestations showed that severe impairment of memory accounted for virtually all of the abnormalities .
Diseases: "	"Sentence: Analysis of the manifestations showed that severe impairment of memory accounted for virtually all of the abnormalities .
Diseases:"
2069	There is evidence that cerebral reactions to drug toxicity can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain .	O O O O O O O O B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: There is evidence that cerebral reactions to drug toxicity can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain .
Diseases: toxicity"	"Sentence: There is evidence that cerebral reactions to drug toxicity can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain .
Diseases:"
2070	Biphasic response of the SA node of the dog heart in vivo to selective administration of ketamine .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: Biphasic response of the SA node of the dog heart in vivo to selective administration of ketamine .
Diseases: "	"Sentence: Biphasic response of the SA node of the dog heart in vivo to selective administration of ketamine .
Diseases:"
2071	Effect of ketamine on the SA node of the dog heart was studied in vivo using a selective perfusion technique of the SA node artery .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Effect of ketamine on the SA node of the dog heart was studied in vivo using a selective perfusion technique of the SA node artery .
Diseases: "	"Sentence: Effect of ketamine on the SA node of the dog heart was studied in vivo using a selective perfusion technique of the SA node artery .
Diseases:"
2072	Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action .	O O O O O O O O O O O O O O O O B O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O O O	['depression']	1	2	"Sentence: Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action .
Diseases: depression"	"Sentence: Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action .
Diseases:"
2073	This depression was followed by the sudden appearance of a stimulatory phase .	O B O O O O O O O O O O O	O O O O O O O O O O O O O	['depression']	1	2	"Sentence: This depression was followed by the sudden appearance of a stimulatory phase .
Diseases: depression"	"Sentence: This depression was followed by the sudden appearance of a stimulatory phase .
Diseases:"
2074	Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine - induced tachycardia , while it was completely abolished in the reserpinized dogs or by a prior injection of a beta - blocking agent into the SA node artery .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['tachycardia']	1	4	"Sentence: Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine - induced tachycardia , while it was completely abolished in the reserpinized dogs or by a prior injection of a beta - blocking agent into the SA node artery .
Diseases: tachycardia"	"Sentence: Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine - induced tachycardia , while it was completely abolished in the reserpinized dogs or by a prior injection of a beta - blocking agent into the SA node artery .
Diseases:"
2075	This may indicate that an activation of the peripheral adrenergic mechanism plays an important role in the induction of the excitatory effect of ketamine injected in the SA node artery .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: This may indicate that an activation of the peripheral adrenergic mechanism plays an important role in the induction of the excitatory effect of ketamine injected in the SA node artery .
Diseases: "	"Sentence: This may indicate that an activation of the peripheral adrenergic mechanism plays an important role in the induction of the excitatory effect of ketamine injected in the SA node artery .
Diseases:"
2076	The use of serum cholinesterase in succinylcholine apnoea .	O O O O O O O B O	O O O O O O B O O	['apnoea']	1	4	"Sentence: The use of serum cholinesterase in succinylcholine apnoea .
Diseases: apnoea"	"Sentence: The use of serum cholinesterase in succinylcholine apnoea .
Diseases:"
2077	Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase .	O O O O O B O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O	['apnoea']	1	4	"Sentence: Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase .
Diseases: apnoea"	"Sentence: Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase .
Diseases:"
2078	Adequate spontaneous respiration was re - established in an average period of ten minutes after the injection .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Adequate spontaneous respiration was re - established in an average period of ten minutes after the injection .
Diseases: "	"Sentence: Adequate spontaneous respiration was re - established in an average period of ten minutes after the injection .
Diseases:"
2079	In 12 patients biochemical genetic examinations confirmed the presence of an atypical serum cholinesterase .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In 12 patients biochemical genetic examinations confirmed the presence of an atypical serum cholinesterase .
Diseases: "	"Sentence: In 12 patients biochemical genetic examinations confirmed the presence of an atypical serum cholinesterase .
Diseases:"
2080	In three patients none of the usual variants were found .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: In three patients none of the usual variants were found .
Diseases: "	"Sentence: In three patients none of the usual variants were found .
Diseases:"
2081	It is therefore supposed that other unknown variants of serum cholinesterase exist which can not hydrolyze succinylcholine .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: It is therefore supposed that other unknown variants of serum cholinesterase exist which can not hydrolyze succinylcholine .
Diseases: "	"Sentence: It is therefore supposed that other unknown variants of serum cholinesterase exist which can not hydrolyze succinylcholine .
Diseases:"
2082	The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist .	O O O O O O O B O O O O O O O O O	O O O O O O B O O O O O O O O O O	['apnoea']	1	4	"Sentence: The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist .
Diseases: apnoea"	"Sentence: The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist .
Diseases:"
2083	Orthostatic hypotension occurs following alpha 2 - adrenoceptor blockade in chronic prazosin - pretreated conscious spontaneously hypertensive rats .	B I O O O O O O O O O O O O O O B O O	O O O O O O O O O O O B O O O O O O O	['orthostatic hypotension', 'hypertensive']	2	8	"Sentence: Orthostatic hypotension occurs following alpha 2 - adrenoceptor blockade in chronic prazosin - pretreated conscious spontaneously hypertensive rats .
Diseases: orthostatic hypotension, hypertensive"	"Sentence: Orthostatic hypotension occurs following alpha 2 - adrenoceptor blockade in chronic prazosin - pretreated conscious spontaneously hypertensive rats .
Diseases:"
2084	1 .	O O	O O	[]	0	0	"Sentence: 1 .
Diseases: "	"Sentence: 1 .
Diseases:"
2085	Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2 - adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously hypertensive rats ( SHR ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['hypertensive']	1	3	"Sentence: Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2 - adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously hypertensive rats ( SHR ) .
Diseases: hypertensive"	"Sentence: Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2 - adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously hypertensive rats ( SHR ) .
Diseases:"
2086	2 .	O O	O O	[]	0	0	"Sentence: 2 .
Diseases: "	"Sentence: 2 .
Diseases:"
2087	Conscious SHR ( male 300 - 350 g ) were subjected to 90 degrees head - up tilts for 60 s following acute administration of prazosin ( 0 . 1 mg kg - 1 i . p . ) or rauwolscine ( 3 mg kg - 1 i . v . ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: Conscious SHR ( male 300 - 350 g ) were subjected to 90 degrees head - up tilts for 60 s following acute administration of prazosin ( 0 . 1 mg kg - 1 i . p . ) or rauwolscine ( 3 mg kg - 1 i . v . ) .
Diseases: "	"Sentence: Conscious SHR ( male 300 - 350 g ) were subjected to 90 degrees head - up tilts for 60 s following acute administration of prazosin ( 0 . 1 mg kg - 1 i . p . ) or rauwolscine ( 3 mg kg - 1 i . v . ) .
Diseases:"
2088	Orthostatic hypotension was determined by the average decrease ( % ) in mean arterial pressure ( MAP femoral ) over the 60 - s tilt period .	B I O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['orthostatic hypotension']	1	5	"Sentence: Orthostatic hypotension was determined by the average decrease ( % ) in mean arterial pressure ( MAP femoral ) over the 60 - s tilt period .
Diseases: orthostatic hypotension"	"Sentence: Orthostatic hypotension was determined by the average decrease ( % ) in mean arterial pressure ( MAP femoral ) over the 60 - s tilt period .
Diseases:"
2089	The basal MAP of conscious SHR was reduced to a similar extent by prazosin ( - 23 % ( - ) - 26 % MAP ) and rauwolscine ( - 16 % ( - ) - 33 % MAP ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: The basal MAP of conscious SHR was reduced to a similar extent by prazosin ( - 23 % ( - ) - 26 % MAP ) and rauwolscine ( - 16 % ( - ) - 33 % MAP ) .
Diseases: "	"Sentence: The basal MAP of conscious SHR was reduced to a similar extent by prazosin ( - 23 % ( - ) - 26 % MAP ) and rauwolscine ( - 16 % ( - ) - 33 % MAP ) .
Diseases:"
2090	However , the head - up tilt induced orthostatic hypotension in the SHR treated with prazosin ( - 16 % MAP , n = 6 ) , but not in the SHR treated with rauwolscine ( less than + 2 % MAP , n = 6 ) .	O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	['orthostatic hypotension']	1	5	"Sentence: However , the head - up tilt induced orthostatic hypotension in the SHR treated with prazosin ( - 16 % MAP , n = 6 ) , but not in the SHR treated with rauwolscine ( less than + 2 % MAP , n = 6 ) .
Diseases: orthostatic hypotension"	"Sentence: However , the head - up tilt induced orthostatic hypotension in the SHR treated with prazosin ( - 16 % MAP , n = 6 ) , but not in the SHR treated with rauwolscine ( less than + 2 % MAP , n = 6 ) .
Diseases:"
2091	3 .	O O	O O	[]	0	0	"Sentence: 3 .
Diseases: "	"Sentence: 3 .
Diseases:"
2092	Conscious SHR were treated for 4 days with prazosin at 2 mg kg - 1 day - 1 i . p .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: Conscious SHR were treated for 4 days with prazosin at 2 mg kg - 1 day - 1 i . p .
Diseases: "	"Sentence: Conscious SHR were treated for 4 days with prazosin at 2 mg kg - 1 day - 1 i . p .
Diseases:"
2093	for chronic alpha 1 - adrenoceptor blockade .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: for chronic alpha 1 - adrenoceptor blockade .
Diseases: "	"Sentence: for chronic alpha 1 - adrenoceptor blockade .
Diseases:"
2094	MAP in conscious SHR after chronic prazosin treatment was 14 % lower than in the untreated SHR ( n = 8 ) .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: MAP in conscious SHR after chronic prazosin treatment was 14 % lower than in the untreated SHR ( n = 8 ) .
Diseases: "	"Sentence: MAP in conscious SHR after chronic prazosin treatment was 14 % lower than in the untreated SHR ( n = 8 ) .
Diseases:"
2095	Head - up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin ( 0 . 1 mg kg - 1 i . p . ) .	O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	['orthostatic hypotension']	1	5	"Sentence: Head - up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin ( 0 . 1 mg kg - 1 i . p . ) .
Diseases: orthostatic hypotension"	"Sentence: Head - up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin ( 0 . 1 mg kg - 1 i . p . ) .
Diseases:"
2096	Conversely , administration of rauwolscine ( 3 mg kg - 1 i . v . )	O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: Conversely , administration of rauwolscine ( 3 mg kg - 1 i . v . )
Diseases: "	"Sentence: Conversely , administration of rauwolscine ( 3 mg kg - 1 i . v . )
Diseases:"
2097	in chronic prazosin treated SHR decreased the basal MAP by 12 - 31 % ( n = 4 ) , and subsequent tilts induced further drops of MAP by 19 - 23 % in these rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: in chronic prazosin treated SHR decreased the basal MAP by 12 - 31 % ( n = 4 ) , and subsequent tilts induced further drops of MAP by 19 - 23 % in these rats .
Diseases: "	"Sentence: in chronic prazosin treated SHR decreased the basal MAP by 12 - 31 % ( n = 4 ) , and subsequent tilts induced further drops of MAP by 19 - 23 % in these rats .
Diseases:"
2098	4 .	O O	O O	[]	0	0	"Sentence: 4 .
Diseases: "	"Sentence: 4 .
Diseases:"
2099	The pressor responses and bradycardia to the alpha 1 - agonist cirazoline ( 0 . 6 and 2 micrograms kg - 1 i . v . ) , the alpha 2 - agonist Abbott - 53693 ( 1 and 3 micrograms kg - 1 i . v . ) , and noradrenaline ( 0 . 1 and 1 . 0 micrograms kg - 1 i . v . ) were determined in conscious SHR with and without chronic prazosin pretreatment .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['bradycardia']	1	4	"Sentence: The pressor responses and bradycardia to the alpha 1 - agonist cirazoline ( 0 . 6 and 2 micrograms kg - 1 i . v . ) , the alpha 2 - agonist Abbott - 53693 ( 1 and 3 micrograms kg - 1 i . v . ) , and noradrenaline ( 0 . 1 and 1 . 0 micrograms kg - 1 i . v . ) were determined in conscious SHR with and without chronic prazosin pretreatment .
Diseases: bradycardia"	"Sentence: The pressor responses and bradycardia to the alpha 1 - agonist cirazoline ( 0 . 6 and 2 micrograms kg - 1 i . v . ) , the alpha 2 - agonist Abbott - 53693 ( 1 and 3 micrograms kg - 1 i . v . ) , and noradrenaline ( 0 . 1 and 1 . 0 micrograms kg - 1 i . v . ) were determined in conscious SHR with and without chronic prazosin pretreatment .
Diseases:"
2100	Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR ( n = 4 ) as compared to the untreated SHR ( n = 4 ) .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O B O O O O O O O O O O O O O O O O O O O	['bradycardia']	1	4	"Sentence: Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR ( n = 4 ) as compared to the untreated SHR ( n = 4 ) .
Diseases: bradycardia"	"Sentence: Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR ( n = 4 ) as compared to the untreated SHR ( n = 4 ) .
Diseases:"
2101	On the other hand , the pressor effects of Abbott - 53693 were similar in both groups of SHR , but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O B O O O O O O	['bradycardia']	1	4	"Sentence: On the other hand , the pressor effects of Abbott - 53693 were similar in both groups of SHR , but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment .
Diseases: bradycardia"	"Sentence: On the other hand , the pressor effects of Abbott - 53693 were similar in both groups of SHR , but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment .
Diseases:"
2102	Furthermore , the bradycardia that accompanied the noradrenaline - induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47 - 71 % reduction of the pressor effect in chronic alpha 1 - receptor blocked SHR . ( ABSTRACT TRUNCATED AT 400 WORDS )	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['bradycardia']	1	4	"Sentence: Furthermore , the bradycardia that accompanied the noradrenaline - induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47 - 71 % reduction of the pressor effect in chronic alpha 1 - receptor blocked SHR . ( ABSTRACT TRUNCATED AT 400 WORDS )
Diseases: bradycardia"	"Sentence: Furthermore , the bradycardia that accompanied the noradrenaline - induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47 - 71 % reduction of the pressor effect in chronic alpha 1 - receptor blocked SHR . ( ABSTRACT TRUNCATED AT 400 WORDS )
Diseases:"
2103	Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones .	O O B I I I I I I I O O O O O O	O O O O O O O O O O O O O O O O	['cerebral venous sinus and internal carotid artery thrombosis']	1	17	"Sentence: Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones .
Diseases: cerebral venous sinus and internal carotid artery thrombosis"	"Sentence: Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones .
Diseases:"
2104	A case report .	O O O O	O O O O	[]	0	0	"Sentence: A case report .
Diseases: "	"Sentence: A case report .
Diseases:"
2105	A forty - six year - old premenopausal woman developed headache , nausea and vomiting , left hemiparesis and seizure two days after parenteral use of progesterone and estradiol .	O O O O O O O O O O B O B O B O O B O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O	['seizure', 'nausea', 'headache', 'vomiting', 'hemiparesis']	5	14	"Sentence: A forty - six year - old premenopausal woman developed headache , nausea and vomiting , left hemiparesis and seizure two days after parenteral use of progesterone and estradiol .
Diseases: seizure, nausea, headache, vomiting, hemiparesis"	"Sentence: A forty - six year - old premenopausal woman developed headache , nausea and vomiting , left hemiparesis and seizure two days after parenteral use of progesterone and estradiol .
Diseases:"
2106	Diabetes mellitus ( DM ) was found during admission .	B I O B O O O O O O	O O O O O O O O O O	['dm', 'diabetes mellitus']	2	5	"Sentence: Diabetes mellitus ( DM ) was found during admission .
Diseases: dm, diabetes mellitus"	"Sentence: Diabetes mellitus ( DM ) was found during admission .
Diseases:"
2107	Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus ( SSS ) .	O O O O B I O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['hemorrhagic infarct']	1	7	"Sentence: Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus ( SSS ) .
Diseases: hemorrhagic infarct"	"Sentence: Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus ( SSS ) .
Diseases:"
2108	Left carotid angiography found occlusion of the left internal carotid artery ( ICA ) .	O O O O B I I I I I I O O O O	O O O O O O O O O O O O O O O	['occlusion of the left internal carotid artery']	1	10	"Sentence: Left carotid angiography found occlusion of the left internal carotid artery ( ICA ) .
Diseases: occlusion of the left internal carotid artery"	"Sentence: Left carotid angiography found occlusion of the left internal carotid artery ( ICA ) .
Diseases:"
2109	Right carotid angiograms failed to show the SSS and inferior sagittal sinus , suggestive of venous sinus thrombosis .	O O O O O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O O O O O O	['venous sinus thrombosis']	1	8	"Sentence: Right carotid angiograms failed to show the SSS and inferior sagittal sinus , suggestive of venous sinus thrombosis .
Diseases: venous sinus thrombosis"	"Sentence: Right carotid angiograms failed to show the SSS and inferior sagittal sinus , suggestive of venous sinus thrombosis .
Diseases:"
2110	Coexistence of the cerebral artery and the venous sinus occlusion has been described infrequently .	O O O B I I I I I I O O O O O	O O O O O O O O O O O O O O O	['cerebral artery and the venous sinus occlusion']	1	13	"Sentence: Coexistence of the cerebral artery and the venous sinus occlusion has been described infrequently .
Diseases: cerebral artery and the venous sinus occlusion"	"Sentence: Coexistence of the cerebral artery and the venous sinus occlusion has been described infrequently .
Diseases:"
2111	In this case , the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity , which provided a common denominator for thrombosis of both the ICA and the venous sinus .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O B I I I I I I I I O	O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O	['thrombosis of both the ica and the venous sinus', 'dm']	2	17	"Sentence: In this case , the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity , which provided a common denominator for thrombosis of both the ICA and the venous sinus .
Diseases: thrombosis of both the ica and the venous sinus, dm"	"Sentence: In this case , the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity , which provided a common denominator for thrombosis of both the ICA and the venous sinus .
Diseases:"
2112	Chloroquine related complete heart block with blindness : case report .	O O O B I O B O O O O	B O O O O O O O O O O	['heart block', 'blindness']	2	4	"Sentence: Chloroquine related complete heart block with blindness : case report .
Diseases: heart block, blindness"	"Sentence: Chloroquine related complete heart block with blindness : case report .
Diseases:"
2113	A 27 - year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision , easy fatiguability , dyspnoea , dizziness progressing to syncopal attacks .	O O O O O O O O O O O O O O O O B I I O O B O B O B O O B I O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['syncopal attacks', 'fatiguability', 'dyspnoea', 'deterioration of vision', 'dizziness']	5	19	"Sentence: A 27 - year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision , easy fatiguability , dyspnoea , dizziness progressing to syncopal attacks .
Diseases: syncopal attacks, fatiguability, dyspnoea, deterioration of vision, dizziness"	"Sentence: A 27 - year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision , easy fatiguability , dyspnoea , dizziness progressing to syncopal attacks .
Diseases:"
2114	Ophthalmological assessment revealed features of chloroquine retinopathy , cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern .	O O O O O O B O O O O O O B I O O O B I O B I I I O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O	['retinopathy', 'heart failure', 'heart block', 'right bundle branch block']	4	14	"Sentence: Ophthalmological assessment revealed features of chloroquine retinopathy , cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern .
Diseases: retinopathy, heart failure, heart block, right bundle branch block"	"Sentence: Ophthalmological assessment revealed features of chloroquine retinopathy , cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern .
Diseases:"
2115	The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation .	O B I O O O O O O O B I O O O O O O	O O O O O O O O O O O O O O O B O O	['heart block', 'heart failure']	2	5	"Sentence: The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation .
Diseases: heart block, heart failure"	"Sentence: The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation .
Diseases:"
2116	She however remains blind .	O O O B O	O O O O O	['blind']	1	1	"Sentence: She however remains blind .
Diseases: blind"	"Sentence: She however remains blind .
Diseases:"
2117	Systemic toxicity and resuscitation in bupivacaine - , levobupivacaine - , or ropivacaine - infused rats .	O B O O O O O O O O O O O O O O O	O O O O O B O O B O O O B O O O O	['toxicity']	1	2	"Sentence: Systemic toxicity and resuscitation in bupivacaine - , levobupivacaine - , or ropivacaine - infused rats .
Diseases: toxicity"	"Sentence: Systemic toxicity and resuscitation in bupivacaine - , levobupivacaine - , or ropivacaine - infused rats .
Diseases:"
2118	We compared the systemic toxicity of bupivacaine , levobupivacaine , and ropivacaine in anesthetized rats .	O O O O B O O O O O O O O O O O	O O O O O O B O B O O B O O O O	['toxicity']	1	2	"Sentence: We compared the systemic toxicity of bupivacaine , levobupivacaine , and ropivacaine in anesthetized rats .
Diseases: toxicity"	"Sentence: We compared the systemic toxicity of bupivacaine , levobupivacaine , and ropivacaine in anesthetized rats .
Diseases:"
2119	We also compared the ability to resuscitate rats after lethal doses of these local anesthetics .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We also compared the ability to resuscitate rats after lethal doses of these local anesthetics .
Diseases: "	"Sentence: We also compared the ability to resuscitate rats after lethal doses of these local anesthetics .
Diseases:"
2120	Bupivacaine , levobupivacaine , or ropivacaine was infused at a rate of 2 mg . kg ( - 1 ) .	O O O O O O O O O O O O O O O O O O O O O	B O B O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Bupivacaine , levobupivacaine , or ropivacaine was infused at a rate of 2 mg . kg ( - 1 ) .
Diseases: "	"Sentence: Bupivacaine , levobupivacaine , or ropivacaine was infused at a rate of 2 mg . kg ( - 1 ) .
Diseases:"
2121	min ( - 1 ) while electrocardiogram , electroencephalogram , and arterial pressure were continuously monitored .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: min ( - 1 ) while electrocardiogram , electroencephalogram , and arterial pressure were continuously monitored .
Diseases: "	"Sentence: min ( - 1 ) while electrocardiogram , electroencephalogram , and arterial pressure were continuously monitored .
Diseases:"
2122	When asystole was recorded , drug infusion was stopped and a resuscitation sequence was begun .	O B O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	['asystole']	1	3	"Sentence: When asystole was recorded , drug infusion was stopped and a resuscitation sequence was begun .
Diseases: asystole"	"Sentence: When asystole was recorded , drug infusion was stopped and a resuscitation sequence was begun .
Diseases:"
2123	Epinephrine 0 . 01 mg / kg was administered at 1 - min intervals while external cardiac compressions were applied .	O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Epinephrine 0 . 01 mg / kg was administered at 1 - min intervals while external cardiac compressions were applied .
Diseases: "	"Sentence: Epinephrine 0 . 01 mg / kg was administered at 1 - min intervals while external cardiac compressions were applied .
Diseases:"
2124	Resuscitation was considered successful when a systolic arterial pressure > or = 100	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Resuscitation was considered successful when a systolic arterial pressure > or = 100
Diseases: "	"Sentence: Resuscitation was considered successful when a systolic arterial pressure > or = 100
Diseases:"
2125	mm Hg was achieved within 5 min .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: mm Hg was achieved within 5 min .
Diseases: "	"Sentence: mm Hg was achieved within 5 min .
Diseases:"
2126	The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine .	O O O O O O O O O B O O O O O O O O O O	O O O O B O B O O O O O O O O O O O B O	['seizures']	1	3	"Sentence: The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine .
Diseases: seizures"	"Sentence: The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine .
Diseases:"
2127	The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine , but they were larger than those of bupivacaine .	O O O O O O O B O B O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O B O O O O O O O O B O	['dysrhythmias', 'asystole']	2	10	"Sentence: The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine , but they were larger than those of bupivacaine .
Diseases: dysrhythmias, asystole"	"Sentence: The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine , but they were larger than those of bupivacaine .
Diseases:"
2128	The number of successful resuscitations did not differ among groups .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: The number of successful resuscitations did not differ among groups .
Diseases: "	"Sentence: The number of successful resuscitations did not differ among groups .
Diseases:"
2129	However , a smaller dose of epinephrine was required in the Ropivacaine group than in the other groups .	O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O B O O O O O O O	[]	0	0	"Sentence: However , a smaller dose of epinephrine was required in the Ropivacaine group than in the other groups .
Diseases: "	"Sentence: However , a smaller dose of epinephrine was required in the Ropivacaine group than in the other groups .
Diseases:"
2130	We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine - induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .	O O O O O B O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O	O O O O O O O B O O O O O B O B O O O O O O O O B O O O O O O O O O O O O O O O B O B O	['cardiac arrest', 'toxicity']	2	5	"Sentence: We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine - induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .
Diseases: cardiac arrest, toxicity"	"Sentence: We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine - induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .
Diseases:"
2131	22 - oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure .	O O O O B I O O B I I O O O B I O	B I I O O O O O O O O O O O O O O	['low bone turnover', 'secondary hyperparathyroidism', 'renal failure']	3	13	"Sentence: 22 - oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure .
Diseases: low bone turnover, secondary hyperparathyroidism, renal failure"	"Sentence: 22 - oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure .
Diseases:"
2132	Calcitriol therapy suppresses serum levels of parathyroid hormone ( PTH ) in patients with renal failure but has several drawbacks , including hypercalcemia and / or marked suppression of bone turnover , which may lead to adynamic bone disease .	O O O O O O O O O O O O O O B I O O O O O O B O O O O B I I I O O O O O B I I O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['adynamic bone disease', 'renal failure', 'suppression of bone turnover', 'hypercalcemia']	4	17	"Sentence: Calcitriol therapy suppresses serum levels of parathyroid hormone ( PTH ) in patients with renal failure but has several drawbacks , including hypercalcemia and / or marked suppression of bone turnover , which may lead to adynamic bone disease .
Diseases: adynamic bone disease, renal failure, suppression of bone turnover, hypercalcemia"	"Sentence: Calcitriol therapy suppresses serum levels of parathyroid hormone ( PTH ) in patients with renal failure but has several drawbacks , including hypercalcemia and / or marked suppression of bone turnover , which may lead to adynamic bone disease .
Diseases:"
2133	A new vitamin D analogue , 22 - oxacalcitriol ( OCT ) , has been shown to have promising characteristics .	O O O O O O O O O O O O O O O O O O O O O	O O B I O O B I I O B O O O O O O O O O O	[]	0	0	"Sentence: A new vitamin D analogue , 22 - oxacalcitriol ( OCT ) , has been shown to have promising characteristics .
Diseases: "	"Sentence: A new vitamin D analogue , 22 - oxacalcitriol ( OCT ) , has been shown to have promising characteristics .
Diseases:"
2134	This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function .	O O O O O O O O O O O O O O O O O O O O O O B I I O	O O O O O O O O O B O O O O O O O O O O O O O O O O	['impaired renal function']	1	5	"Sentence: This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function .
Diseases: impaired renal function"	"Sentence: This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function .
Diseases:"
2135	Sixty dogs were either nephrectomized ( Nx , N = 38 ) or sham - operated ( Sham , N = 22 ) .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Sixty dogs were either nephrectomized ( Nx , N = 38 ) or sham - operated ( Sham , N = 22 ) .
Diseases: "	"Sentence: Sixty dogs were either nephrectomized ( Nx , N = 38 ) or sham - operated ( Sham , N = 22 ) .
Diseases:"
2136	The animals received supplemental phosphate to enhance PTH secretion .	O O O O O O O O O O	O O O O B O O O O O	[]	0	0	"Sentence: The animals received supplemental phosphate to enhance PTH secretion .
Diseases: "	"Sentence: The animals received supplemental phosphate to enhance PTH secretion .
Diseases:"
2137	Fourteen weeks after the start of phosphate supplementation , half of the Nx and Sham dogs received doses of OCT ( three times per week ) ; the other half were given vehicle for 60 weeks .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Fourteen weeks after the start of phosphate supplementation , half of the Nx and Sham dogs received doses of OCT ( three times per week ) ; the other half were given vehicle for 60 weeks .
Diseases: "	"Sentence: Fourteen weeks after the start of phosphate supplementation , half of the Nx and Sham dogs received doses of OCT ( three times per week ) ; the other half were given vehicle for 60 weeks .
Diseases:"
2138	Thereafter , the treatment modalities for a subset of animals were crossed over for an additional eight months .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thereafter , the treatment modalities for a subset of animals were crossed over for an additional eight months .
Diseases: "	"Sentence: Thereafter , the treatment modalities for a subset of animals were crossed over for an additional eight months .
Diseases:"
2139	Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study , and bone biopsies were done at baseline , 60 weeks after OCT or vehicle treatment , and at the end of the crossover period .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study , and bone biopsies were done at baseline , 60 weeks after OCT or vehicle treatment , and at the end of the crossover period .
Diseases: "	"Sentence: Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study , and bone biopsies were done at baseline , 60 weeks after OCT or vehicle treatment , and at the end of the crossover period .
Diseases:"
2140	In Nx dogs , OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency .	O O O O O O O O O O O O O O O B I O	O O O O B O O O O O O O O O O O O O	['renal insufficiency']	1	5	"Sentence: In Nx dogs , OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency .
Diseases: renal insufficiency"	"Sentence: In Nx dogs , OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency .
Diseases:"
2141	In long - standing secondary hyperparathyroidism , OCT ( 0 . 03 microg / kg ) stabilized serum PTH levels during the first months .	O O O O B I O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O	['secondary hyperparathyroidism']	1	6	"Sentence: In long - standing secondary hyperparathyroidism , OCT ( 0 . 03 microg / kg ) stabilized serum PTH levels during the first months .
Diseases: secondary hyperparathyroidism"	"Sentence: In long - standing secondary hyperparathyroidism , OCT ( 0 . 03 microg / kg ) stabilized serum PTH levels during the first months .
Diseases:"
2142	Serum PTH levels rose thereafter , but the rise was less pronounced compared with baseline than the rise seen in Nx control .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Serum PTH levels rose thereafter , but the rise was less pronounced compared with baseline than the rise seen in Nx control .
Diseases: "	"Sentence: Serum PTH levels rose thereafter , but the rise was less pronounced compared with baseline than the rise seen in Nx control .
Diseases:"
2143	These effects were accompanied by episodes of hypercalcemia and hyperphosphatemia .	O O O O O O O B O B O	O O O O O O O O O O O	['hyperphosphatemia', 'hypercalcemia']	2	10	"Sentence: These effects were accompanied by episodes of hypercalcemia and hyperphosphatemia .
Diseases: hyperphosphatemia, hypercalcemia"	"Sentence: These effects were accompanied by episodes of hypercalcemia and hyperphosphatemia .
Diseases:"
2144	In animals with normal renal function , OCT induced a transient decrease in serum PTH levels at a dose of 0 . 1 microg / kg , which was not sustained with lowering of the doses .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In animals with normal renal function , OCT induced a transient decrease in serum PTH levels at a dose of 0 . 1 microg / kg , which was not sustained with lowering of the doses .
Diseases: "	"Sentence: In animals with normal renal function , OCT induced a transient decrease in serum PTH levels at a dose of 0 . 1 microg / kg , which was not sustained with lowering of the doses .
Diseases:"
2145	In Nx dogs , OCT reversed abnormal bone formation , such as woven osteoid and fibrosis , but did not significantly alter the level of bone turnover .	O O O O O O O O O O O O B I O B O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['woven osteoid', 'fibrosis']	2	7	"Sentence: In Nx dogs , OCT reversed abnormal bone formation , such as woven osteoid and fibrosis , but did not significantly alter the level of bone turnover .
Diseases: woven osteoid, fibrosis"	"Sentence: In Nx dogs , OCT reversed abnormal bone formation , such as woven osteoid and fibrosis , but did not significantly alter the level of bone turnover .
Diseases:"
2146	In addition , OCT improved mineralization lag time , ( that is , the rate at which osteoid mineralizes ) in both Nx and Sham dogs .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition , OCT improved mineralization lag time , ( that is , the rate at which osteoid mineralizes ) in both Nx and Sham dogs .
Diseases: "	"Sentence: In addition , OCT improved mineralization lag time , ( that is , the rate at which osteoid mineralizes ) in both Nx and Sham dogs .
Diseases:"
2147	CONCLUSIONS : These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency , it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and , therefore , does not increase the risk of adynamic bone disease .	O O O O O O O O O O O O O O O O B O O O O B I O O O O O O O O O O B I O O O O O B I I O O O O O O O O O O B I I O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypercalcemia', 'renal insufficiency', 'low bone turnover', 'adynamic bone disease', 'secondary hyperparathyroidism']	5	25	"Sentence: CONCLUSIONS : These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency , it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and , therefore , does not increase the risk of adynamic bone disease .
Diseases: hypercalcemia, renal insufficiency, low bone turnover, adynamic bone disease, secondary hyperparathyroidism"	"Sentence: CONCLUSIONS : These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency , it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and , therefore , does not increase the risk of adynamic bone disease .
Diseases:"
2148	Chemotherapy of advanced inoperable non - small cell lung cancer with paclitaxel : a phase II trial .	O O O O B I I I I I O O O O O O O O	O O O O O O O O O O O B O O O O O O	['non - small cell lung cancer']	1	6	"Sentence: Chemotherapy of advanced inoperable non - small cell lung cancer with paclitaxel : a phase II trial .
Diseases: non - small cell lung cancer"	"Sentence: Chemotherapy of advanced inoperable non - small cell lung cancer with paclitaxel : a phase II trial .
Diseases:"
2149	Paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) has demonstrated significant antineoplastic activity against different tumor types , notably ovarian and breast carcinoma .	O O O O O O O O O O O O O O O O O O O O O B O O O B I I I O	B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ovarian and breast carcinoma', 'tumor']	2	8	"Sentence: Paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) has demonstrated significant antineoplastic activity against different tumor types , notably ovarian and breast carcinoma .
Diseases: ovarian and breast carcinoma, tumor"	"Sentence: Paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) has demonstrated significant antineoplastic activity against different tumor types , notably ovarian and breast carcinoma .
Diseases:"
2150	Two phase II trials of 24 - hour paclitaxel infusions in chemotherapy - naive patients with stage IIIB or IV non - small cell lung cancer ( NSCLC ) reported response rates of 21 % and 24 % .	O O O O O O O O O O O O O O O O O O O O B I I I I I O B O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nsclc', 'non - small cell lung cancer']	2	10	"Sentence: Two phase II trials of 24 - hour paclitaxel infusions in chemotherapy - naive patients with stage IIIB or IV non - small cell lung cancer ( NSCLC ) reported response rates of 21 % and 24 % .
Diseases: nsclc, non - small cell lung cancer"	"Sentence: Two phase II trials of 24 - hour paclitaxel infusions in chemotherapy - naive patients with stage IIIB or IV non - small cell lung cancer ( NSCLC ) reported response rates of 21 % and 24 % .
Diseases:"
2151	Leukopenia was dose limiting : as many as 62 . 5 % of patients experienced grade 4 leukopenia .	B O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O	['leukopenia']	1	4	"Sentence: Leukopenia was dose limiting : as many as 62 . 5 % of patients experienced grade 4 leukopenia .
Diseases: leukopenia"	"Sentence: Leukopenia was dose limiting : as many as 62 . 5 % of patients experienced grade 4 leukopenia .
Diseases:"
2152	We investigated the efficacy and toxicity of a 3 - hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC .	O O O O O B O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O	['nsclc', 'toxicity']	2	5	"Sentence: We investigated the efficacy and toxicity of a 3 - hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC .
Diseases: nsclc, toxicity"	"Sentence: We investigated the efficacy and toxicity of a 3 - hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC .
Diseases:"
2153	The 58 patients treated ( 41 men and 17 women ) had a median age of 59 years ( age range , 25 to 75 ) and a performance status of 0 through 2 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The 58 patients treated ( 41 men and 17 women ) had a median age of 59 years ( age range , 25 to 75 ) and a performance status of 0 through 2 .
Diseases: "	"Sentence: The 58 patients treated ( 41 men and 17 women ) had a median age of 59 years ( age range , 25 to 75 ) and a performance status of 0 through 2 .
Diseases:"
2154	Most patients ( 72 . 4 % ) had stage IV NSCLC .	O O O O O O O O O O O B O	O O O O O O O O O O O O O	['nsclc']	1	3	"Sentence: Most patients ( 72 . 4 % ) had stage IV NSCLC .
Diseases: nsclc"	"Sentence: Most patients ( 72 . 4 % ) had stage IV NSCLC .
Diseases:"
2155	Paclitaxel 225 mg / m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication .	O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Paclitaxel 225 mg / m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication .
Diseases: "	"Sentence: Paclitaxel 225 mg / m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication .
Diseases:"
2156	Of 50 patients evaluable for response , 12 ( 24 % ) had partial remission , 26 ( 52 % ) had no change , and 12 had disease progression ( 24 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of 50 patients evaluable for response , 12 ( 24 % ) had partial remission , 26 ( 52 % ) had no change , and 12 had disease progression ( 24 % ) .
Diseases: "	"Sentence: Of 50 patients evaluable for response , 12 ( 24 % ) had partial remission , 26 ( 52 % ) had no change , and 12 had disease progression ( 24 % ) .
Diseases:"
2157	Hematologic toxicities were mild : only one patient ( 2 % ) developed grade 3 or 4 neutropenia , while 29 % had grade 1 or 2 .	O B O O O O O O O O O O O O O O O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['toxicities', 'neutropenia']	2	8	"Sentence: Hematologic toxicities were mild : only one patient ( 2 % ) developed grade 3 or 4 neutropenia , while 29 % had grade 1 or 2 .
Diseases: toxicities, neutropenia"	"Sentence: Hematologic toxicities were mild : only one patient ( 2 % ) developed grade 3 or 4 neutropenia , while 29 % had grade 1 or 2 .
Diseases:"
2158	Grade 1 or 2 polyneuropathy affected 56 % of patients while only one ( 2 % ) experienced severe polyneuropathy .	O O O O B O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O	['polyneuropathy']	1	4	"Sentence: Grade 1 or 2 polyneuropathy affected 56 % of patients while only one ( 2 % ) experienced severe polyneuropathy .
Diseases: polyneuropathy"	"Sentence: Grade 1 or 2 polyneuropathy affected 56 % of patients while only one ( 2 % ) experienced severe polyneuropathy .
Diseases:"
2159	Similarly , grade 1 or 2 myalgia / arthralgia was observed in 63 . 2 % of patients , but only 14 . 3 % experienced grade 3 or 4 .	O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['myalgia', 'arthralgia']	2	8	"Sentence: Similarly , grade 1 or 2 myalgia / arthralgia was observed in 63 . 2 % of patients , but only 14 . 3 % experienced grade 3 or 4 .
Diseases: myalgia, arthralgia"	"Sentence: Similarly , grade 1 or 2 myalgia / arthralgia was observed in 63 . 2 % of patients , but only 14 . 3 % experienced grade 3 or 4 .
Diseases:"
2160	Nausea and vomiting were infrequent , with 14 % of patients experiencing grade 1 or 2 and only 2 % experiencing grade 3 or 4 .	B O B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['nausea', 'vomiting']	2	5	"Sentence: Nausea and vomiting were infrequent , with 14 % of patients experiencing grade 1 or 2 and only 2 % experiencing grade 3 or 4 .
Diseases: nausea, vomiting"	"Sentence: Nausea and vomiting were infrequent , with 14 % of patients experiencing grade 1 or 2 and only 2 % experiencing grade 3 or 4 .
Diseases:"
2161	Paclitaxel is thus an active single agent in this patient population , with a 3 - hour infusion proving comparably effective to a 24 - hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: Paclitaxel is thus an active single agent in this patient population , with a 3 - hour infusion proving comparably effective to a 24 - hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity .
Diseases: toxicity"	"Sentence: Paclitaxel is thus an active single agent in this patient population , with a 3 - hour infusion proving comparably effective to a 24 - hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity .
Diseases:"
2162	Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated , and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O B O O O O O O O O	['nsclc']	1	3	"Sentence: Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated , and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed .
Diseases: nsclc"	"Sentence: Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated , and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed .
Diseases:"
2163	Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine .	B I O O O O O O O O	O O O O B O O O B O	['cerebral hemorrhage']	1	5	"Sentence: Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine .
Diseases: cerebral hemorrhage"	"Sentence: Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine .
Diseases:"
2164	Phenylpropanolamine ( PPA ) is a drug that has been associated with serious side effects including stroke .	O O O O O O O O O O O O O O O O B O	B O B O O O O O O O O O O O O O O O	['stroke']	1	1	"Sentence: Phenylpropanolamine ( PPA ) is a drug that has been associated with serious side effects including stroke .
Diseases: stroke"	"Sentence: Phenylpropanolamine ( PPA ) is a drug that has been associated with serious side effects including stroke .
Diseases:"
2165	"It is often combined with caffeine in diet preparations and "" look - alike "" pills ."	O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: It is often combined with caffeine in diet preparations and "" look - alike "" pills .
Diseases: "	"Sentence: It is often combined with caffeine in diet preparations and "" look - alike "" pills .
Diseases:"
2166	In order to determine if PPA / caffeine can lead to stroke in normotensive and / or hypertensive rats , we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days .	O O O O O O O O O O O B O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['stroke', 'hypertensive']	2	4	"Sentence: In order to determine if PPA / caffeine can lead to stroke in normotensive and / or hypertensive rats , we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days .
Diseases: stroke, hypertensive"	"Sentence: In order to determine if PPA / caffeine can lead to stroke in normotensive and / or hypertensive rats , we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days .
Diseases:"
2167	Subarachnoid and cerebral hemorrhage was noted in 18 % of the hypertensive rats .	B I I I O O O O O O O B O O	O O O O O O O O O O O O O O	['hypertensive', 'subarachnoid and cerebral hemorrhage']	2	13	"Sentence: Subarachnoid and cerebral hemorrhage was noted in 18 % of the hypertensive rats .
Diseases: hypertensive, subarachnoid and cerebral hemorrhage"	"Sentence: Subarachnoid and cerebral hemorrhage was noted in 18 % of the hypertensive rats .
Diseases:"
2168	A single PPA / caffeine administration ( same dose ) lead to acute hypertension in both the normotensive and hypertensive animals .	O O O O O O O O O O O O O B O O O O O B O O	O O B O B O O O O O O O O O O O O O O O O O	['hypertensive', 'hypertension']	2	5	"Sentence: A single PPA / caffeine administration ( same dose ) lead to acute hypertension in both the normotensive and hypertensive animals .
Diseases: hypertensive, hypertension"	"Sentence: A single PPA / caffeine administration ( same dose ) lead to acute hypertension in both the normotensive and hypertensive animals .
Diseases:"
2169	These results suggest that PPA / caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage .	O O O O O O O O O O B I O O B O O O O O O O O O O	O O O O B O B O O O O O O O O O O O O O O O O O O	['hypertensive', 'cerebral hemorrhage']	2	7	"Sentence: These results suggest that PPA / caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage .
Diseases: hypertensive, cerebral hemorrhage"	"Sentence: These results suggest that PPA / caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage .
Diseases:"
2170	An acute elevation in blood pressure may be a contributing factor .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: An acute elevation in blood pressure may be a contributing factor .
Diseases: "	"Sentence: An acute elevation in blood pressure may be a contributing factor .
Diseases:"
2171	Long - term efficacy and toxicity of high - dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation .	O O O O O B O O O O O O O B I O B I O	O O O O O O O O O O B O O O O O O O O	['ventricular fibrillation', 'ventricular tachycardia', 'toxicity']	3	14	"Sentence: Long - term efficacy and toxicity of high - dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation .
Diseases: ventricular fibrillation, ventricular tachycardia, toxicity"	"Sentence: Long - term efficacy and toxicity of high - dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation .
Diseases:"
2172	Amiodarone was administered to 154 patients who had sustained , symptomatic ventricular tachycardia ( VT ) ( n = 118 ) or a cardiac arrest ( n = 36 ) and who were refractory to conventional antiarrhythmic drugs .	O O O O O O O O O O O B I O B O O O O O O O O B I O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ventricular tachycardia', 'cardiac arrest', 'vt']	3	12	"Sentence: Amiodarone was administered to 154 patients who had sustained , symptomatic ventricular tachycardia ( VT ) ( n = 118 ) or a cardiac arrest ( n = 36 ) and who were refractory to conventional antiarrhythmic drugs .
Diseases: ventricular tachycardia, cardiac arrest, vt"	"Sentence: Amiodarone was administered to 154 patients who had sustained , symptomatic ventricular tachycardia ( VT ) ( n = 118 ) or a cardiac arrest ( n = 36 ) and who were refractory to conventional antiarrhythmic drugs .
Diseases:"
2173	The loading dose was 800 mg / day for 6 weeks and the maintenance dose was 600 mg / day .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The loading dose was 800 mg / day for 6 weeks and the maintenance dose was 600 mg / day .
Diseases: "	"Sentence: The loading dose was 800 mg / day for 6 weeks and the maintenance dose was 600 mg / day .
Diseases:"
2174	Sixty - nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation ( VF ) over a follow - up of 6 to 52 months ( mean + / - standard deviation 14 . 2 + / - 8 . 2 ) .	O O O O O O O O O O O O O O O O B O B I O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ventricular fibrillation', 'vf', 'vt']	3	11	"Sentence: Sixty - nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation ( VF ) over a follow - up of 6 to 52 months ( mean + / - standard deviation 14 . 2 + / - 8 . 2 ) .
Diseases: ventricular fibrillation, vf, vt"	"Sentence: Sixty - nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation ( VF ) over a follow - up of 6 to 52 months ( mean + / - standard deviation 14 . 2 + / - 8 . 2 ) .
Diseases:"
2175	Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	['vt']	1	1	"Sentence: Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug .
Diseases: vt"	"Sentence: Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug .
Diseases:"
2176	One or more adverse drug reactions occurred in 51 % of patients .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: One or more adverse drug reactions occurred in 51 % of patients .
Diseases: "	"Sentence: One or more adverse drug reactions occurred in 51 % of patients .
Diseases:"
2177	Adverse effects forced a reduction in the dose of amiodarone in 41 % and discontinuation of amiodarone in 10 % of patients .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O B O O O O O O	[]	0	0	"Sentence: Adverse effects forced a reduction in the dose of amiodarone in 41 % and discontinuation of amiodarone in 10 % of patients .
Diseases: "	"Sentence: Adverse effects forced a reduction in the dose of amiodarone in 41 % and discontinuation of amiodarone in 10 % of patients .
Diseases:"
2178	The most common symptomatic adverse reactions were tremor or ataxia ( 35 % ) , nausea and anorexia ( 8 % ) , visual halos or blurring ( 6 % ) , thyroid function abnormalities ( 6 % ) and pulmonary interstitial infiltrates ( 5 % ) .	O O O O O O O B O B O O O O O B O B O O O O O B I I I O O O O O B I I O O O O O B I I O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pulmonary interstitial infiltrates', 'tremor', 'visual halos or blurring', 'ataxia', 'nausea', 'anorexia', 'thyroid function abnormalities']	7	30	"Sentence: The most common symptomatic adverse reactions were tremor or ataxia ( 35 % ) , nausea and anorexia ( 8 % ) , visual halos or blurring ( 6 % ) , thyroid function abnormalities ( 6 % ) and pulmonary interstitial infiltrates ( 5 % ) .
Diseases: pulmonary interstitial infiltrates, tremor, visual halos or blurring, ataxia, nausea, anorexia, thyroid function abnormalities"	"Sentence: The most common symptomatic adverse reactions were tremor or ataxia ( 35 % ) , nausea and anorexia ( 8 % ) , visual halos or blurring ( 6 % ) , thyroid function abnormalities ( 6 % ) and pulmonary interstitial infiltrates ( 5 % ) .
Diseases:"
2179	Although large - dose amiodarone is highly effective in the long - term treatment of VT or VF refractory to conventional antiarrhythmic drugs , it causes significant toxicity in approximately 50 % of patients .	O O O O O O O O O O O O O O O B O B O O O O O O O O O B O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['vf', 'vt', 'toxicity']	3	7	"Sentence: Although large - dose amiodarone is highly effective in the long - term treatment of VT or VF refractory to conventional antiarrhythmic drugs , it causes significant toxicity in approximately 50 % of patients .
Diseases: vf, vt, toxicity"	"Sentence: Although large - dose amiodarone is highly effective in the long - term treatment of VT or VF refractory to conventional antiarrhythmic drugs , it causes significant toxicity in approximately 50 % of patients .
Diseases:"
2180	However , when the dose is adjusted based on clinical response or the development of adverse effects , 75 % of patients with VT or VF can be successfully managed with amiodarone .	O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['vf', 'vt']	2	5	"Sentence: However , when the dose is adjusted based on clinical response or the development of adverse effects , 75 % of patients with VT or VF can be successfully managed with amiodarone .
Diseases: vf, vt"	"Sentence: However , when the dose is adjusted based on clinical response or the development of adverse effects , 75 % of patients with VT or VF can be successfully managed with amiodarone .
Diseases:"
2181	Effect of calcium chloride and 4 - aminopyridine therapy on desipramine toxicity in rats .	O O O O O O O O O O O B O O O	O O B I O B I I O O B O O O O	['toxicity']	1	2	"Sentence: Effect of calcium chloride and 4 - aminopyridine therapy on desipramine toxicity in rats .
Diseases: toxicity"	"Sentence: Effect of calcium chloride and 4 - aminopyridine therapy on desipramine toxicity in rats .
Diseases:"
2182	Hypotension is a major contributor to mortality in tricyclic antidepressant overdose .	B O O O O O O O O O B O	O O O O O O O O B B O O	['overdose', 'hypotension']	2	5	"Sentence: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose .
Diseases: overdose, hypotension"	"Sentence: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose .
Diseases:"
2183	Recent data suggest that tricyclic antidepressants inhibit calcium influx in some tissues .	O O O O O O O O O O O O O	O O O O O B O B O O O O O	[]	0	0	"Sentence: Recent data suggest that tricyclic antidepressants inhibit calcium influx in some tissues .
Diseases: "	"Sentence: Recent data suggest that tricyclic antidepressants inhibit calcium influx in some tissues .
Diseases:"
2184	This study addressed the potential role of calcium channel blockade in tricyclic antidepressant - induced hypotension .	O O O O O O O O O O O O O O O B O	O O O O O O O B O O O B B O O O O	['hypotension']	1	3	"Sentence: This study addressed the potential role of calcium channel blockade in tricyclic antidepressant - induced hypotension .
Diseases: hypotension"	"Sentence: This study addressed the potential role of calcium channel blockade in tricyclic antidepressant - induced hypotension .
Diseases:"
2185	METHODS : Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker overdose .	O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O B O O O O	['overdose']	1	2	"Sentence: METHODS : Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker overdose .
Diseases: overdose"	"Sentence: METHODS : Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker overdose .
Diseases:"
2186	CaCl2 and 4 - aminopyridine .	O O O O O O	B O B I I O	[]	0	0	"Sentence: CaCl2 and 4 - aminopyridine .
Diseases: "	"Sentence: CaCl2 and 4 - aminopyridine .
Diseases:"
2187	Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension , QRS prolongation , and bradycardia .	O O O O O O O O O O B O O O O O B O	O O O O O B B O O O O O O O O O O O	['bradycardia', 'hypotension']	2	7	"Sentence: Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension , QRS prolongation , and bradycardia .
Diseases: bradycardia, hypotension"	"Sentence: Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension , QRS prolongation , and bradycardia .
Diseases:"
2188	Fifteen min later , animals received CaCl2 , NaHCO3 , or saline .	O O O O O O O O O O O O O	O O O O O O B O B O O O O	[]	0	0	"Sentence: Fifteen min later , animals received CaCl2 , NaHCO3 , or saline .
Diseases: "	"Sentence: Fifteen min later , animals received CaCl2 , NaHCO3 , or saline .
Diseases:"
2189	In a second experiment , rats received tricyclic antidepressant desipramine IP followed in 15 min by 4 - aminopyridine or saline .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B B O O O O O O B I I O O O	[]	0	0	"Sentence: In a second experiment , rats received tricyclic antidepressant desipramine IP followed in 15 min by 4 - aminopyridine or saline .
Diseases: "	"Sentence: In a second experiment , rats received tricyclic antidepressant desipramine IP followed in 15 min by 4 - aminopyridine or saline .
Diseases:"
2190	NaHCO3 briefly ( 5 min ) reversed hypotension and QRS prolongation .	O O O O O O O B O O O O	B O O O O O O O O O O O	['hypotension']	1	3	"Sentence: NaHCO3 briefly ( 5 min ) reversed hypotension and QRS prolongation .
Diseases: hypotension"	"Sentence: NaHCO3 briefly ( 5 min ) reversed hypotension and QRS prolongation .
Diseases:"
2191	CaCl2 and 4 - aminopyridine failed to improve blood pressure .	O O O O O O O O O O O	B O B I I O O O O O O	[]	0	0	"Sentence: CaCl2 and 4 - aminopyridine failed to improve blood pressure .
Diseases: "	"Sentence: CaCl2 and 4 - aminopyridine failed to improve blood pressure .
Diseases:"
2192	The incidence of ventricular arrhythmias ( p = 0 . 004 ) and seizures ( p = 0 . 03 ) in the CaCl2 group was higher than the other groups .	O O O B I O O O O O O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['seizures', 'ventricular arrhythmias']	2	10	"Sentence: The incidence of ventricular arrhythmias ( p = 0 . 004 ) and seizures ( p = 0 . 03 ) in the CaCl2 group was higher than the other groups .
Diseases: seizures, ventricular arrhythmias"	"Sentence: The incidence of ventricular arrhythmias ( p = 0 . 004 ) and seizures ( p = 0 . 03 ) in the CaCl2 group was higher than the other groups .
Diseases:"
2193	The administration of CaCl2 or 4 - aminopyridine did not reverse tricyclic antidepressant - induced hypotension in rats .	O O O O O O O O O O O O O O O B O O O	O O O B O B I I O O O O B O O O O O O	['hypotension']	1	3	"Sentence: The administration of CaCl2 or 4 - aminopyridine did not reverse tricyclic antidepressant - induced hypotension in rats .
Diseases: hypotension"	"Sentence: The administration of CaCl2 or 4 - aminopyridine did not reverse tricyclic antidepressant - induced hypotension in rats .
Diseases:"
2194	CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity .	O O O O O O B I I I I I O	B O O O O O O O O O O O O	['cardiovascular and central nervous system toxicity']	1	7	"Sentence: CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity .
Diseases: cardiovascular and central nervous system toxicity"	"Sentence: CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity .
Diseases:"
2195	These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant - induced hypotension .	O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O B O O O O O O B B O O O O	['hypotension']	1	3	"Sentence: These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant - induced hypotension .
Diseases: hypotension"	"Sentence: These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant - induced hypotension .
Diseases:"
2196	Phase I trial of 13 - cis - retinoic acid in children with neuroblastoma following bone marrow transplantation .	O O O O O O O O O O O O O B O O O O O	O O O O B I I I I I O O O O O O O O O	['neuroblastoma']	1	4	"Sentence: Phase I trial of 13 - cis - retinoic acid in children with neuroblastoma following bone marrow transplantation .
Diseases: neuroblastoma"	"Sentence: Phase I trial of 13 - cis - retinoic acid in children with neuroblastoma following bone marrow transplantation .
Diseases:"
2197	Treatment of neuroblastoma cell lines with 13 - cis - retinoic acid ( cis - RA ) can cause sustained inhibition of proliferation .	O O B O O O O O O O O O O O O O O O O O O O O O	O O O O O O B I I I I I O B I I O O O O O O O O	['neuroblastoma']	1	4	"Sentence: Treatment of neuroblastoma cell lines with 13 - cis - retinoic acid ( cis - RA ) can cause sustained inhibition of proliferation .
Diseases: neuroblastoma"	"Sentence: Treatment of neuroblastoma cell lines with 13 - cis - retinoic acid ( cis - RA ) can cause sustained inhibition of proliferation .
Diseases:"
2198	Since cis - RA has demonstrated clinical responses in neuroblastoma patients , it may be effective in preventing relapse after cytotoxic therapy .	O O O O O O O O O B O O O O O O O O O O O O O	O B I I O O O O O O O O O O O O O O O O O O O	['neuroblastoma']	1	4	"Sentence: Since cis - RA has demonstrated clinical responses in neuroblastoma patients , it may be effective in preventing relapse after cytotoxic therapy .
Diseases: neuroblastoma"	"Sentence: Since cis - RA has demonstrated clinical responses in neuroblastoma patients , it may be effective in preventing relapse after cytotoxic therapy .
Diseases:"
2199	This phase I trial was designed to determine the maximal - tolerated dosage ( MTD ) , toxicities , and pharmacokinetics of cis - RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation ( BMT ) .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O	['toxicities', 'neuroblastoma']	2	7	"Sentence: This phase I trial was designed to determine the maximal - tolerated dosage ( MTD ) , toxicities , and pharmacokinetics of cis - RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation ( BMT ) .
Diseases: toxicities, neuroblastoma"	"Sentence: This phase I trial was designed to determine the maximal - tolerated dosage ( MTD ) , toxicities , and pharmacokinetics of cis - RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation ( BMT ) .
Diseases:"
2200	PATIENTS AND METHODS : Fifty - one assessable patients , 2 to 12 years of age , were treated with oral cis - RA administered in two equally divided doses daily for 2 weeks , followed by a 2 - week rest period , for up to 12 courses .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: PATIENTS AND METHODS : Fifty - one assessable patients , 2 to 12 years of age , were treated with oral cis - RA administered in two equally divided doses daily for 2 weeks , followed by a 2 - week rest period , for up to 12 courses .
Diseases: "	"Sentence: PATIENTS AND METHODS : Fifty - one assessable patients , 2 to 12 years of age , were treated with oral cis - RA administered in two equally divided doses daily for 2 weeks , followed by a 2 - week rest period , for up to 12 courses .
Diseases:"
2201	The dose was escalated from 100 to 200 mg / m2 / d until dose - limiting toxicity ( DLT ) was observed .	O O O O O O O O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: The dose was escalated from 100 to 200 mg / m2 / d until dose - limiting toxicity ( DLT ) was observed .
Diseases: toxicity"	"Sentence: The dose was escalated from 100 to 200 mg / m2 / d until dose - limiting toxicity ( DLT ) was observed .
Diseases:"
2202	A single intrapatient dose escalation was permitted .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: A single intrapatient dose escalation was permitted .
Diseases: "	"Sentence: A single intrapatient dose escalation was permitted .
Diseases:"
2203	The MTD of cis - RA was 160 mg / m2 / d . Dose - limiting toxicities in six of nine patients at 200 mg / m2 / d included hypercalcemia ( n = 3 ) , rash ( n = 2 ) , and anemia / thrombocytopenia / emesis / rash ( n = 1 ) .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O B O O O O O O B O O O O O O O B O B O B O B O O O O O O	O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypercalcemia', 'anemia', 'emesis', 'thrombocytopenia', 'rash', 'toxicities']	6	23	"Sentence: The MTD of cis - RA was 160 mg / m2 / d . Dose - limiting toxicities in six of nine patients at 200 mg / m2 / d included hypercalcemia ( n = 3 ) , rash ( n = 2 ) , and anemia / thrombocytopenia / emesis / rash ( n = 1 ) .
Diseases: hypercalcemia, anemia, emesis, thrombocytopenia, rash, toxicities"	"Sentence: The MTD of cis - RA was 160 mg / m2 / d . Dose - limiting toxicities in six of nine patients at 200 mg / m2 / d included hypercalcemia ( n = 3 ) , rash ( n = 2 ) , and anemia / thrombocytopenia / emesis / rash ( n = 1 ) .
Diseases:"
2204	All toxicities resolved after cis - RA was discontinued .	O B O O O O O O O O	O O O O B I I O O O	['toxicities']	1	3	"Sentence: All toxicities resolved after cis - RA was discontinued .
Diseases: toxicities"	"Sentence: All toxicities resolved after cis - RA was discontinued .
Diseases:"
2205	Three complete responses were observed in marrow metastases .	O O O O O O O B O	O O O O O O O O O	['metastases']	1	3	"Sentence: Three complete responses were observed in marrow metastases .
Diseases: metastases"	"Sentence: Three complete responses were observed in marrow metastases .
Diseases:"
2206	Serum levels of 7 . 4 + / - 3 . 0 mumol / L ( peak ) and 4 . 0 + / - 2 . 8 mumol / L ( trough ) at the MTD were maintained during 14 days of therapy .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Serum levels of 7 . 4 + / - 3 . 0 mumol / L ( peak ) and 4 . 0 + / - 2 . 8 mumol / L ( trough ) at the MTD were maintained during 14 days of therapy .
Diseases: "	"Sentence: Serum levels of 7 . 4 + / - 3 . 0 mumol / L ( peak ) and 4 . 0 + / - 2 . 8 mumol / L ( trough ) at the MTD were maintained during 14 days of therapy .
Diseases:"
2207	The DLT correlated with serum levels > or = 10 mumol / L . CONCLUSION :	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The DLT correlated with serum levels > or = 10 mumol / L . CONCLUSION :
Diseases: "	"Sentence: The DLT correlated with serum levels > or = 10 mumol / L . CONCLUSION :
Diseases:"
2208	The MTD of cis - RA given on this intermittent schedule was 160 mg / m2 / d . Serum levels known to be effective against neuroblastoma in vitro were achieved at this dose .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['neuroblastoma']	1	4	"Sentence: The MTD of cis - RA given on this intermittent schedule was 160 mg / m2 / d . Serum levels known to be effective against neuroblastoma in vitro were achieved at this dose .
Diseases: neuroblastoma"	"Sentence: The MTD of cis - RA given on this intermittent schedule was 160 mg / m2 / d . Serum levels known to be effective against neuroblastoma in vitro were achieved at this dose .
Diseases:"
2209	The DLT included hypercalcemia , and may be predicted by serum cis - RA levels .	O O O B O O O O O O O O O O O O	O O O O O O O O O O O B I I O O	['hypercalcemia']	1	4	"Sentence: The DLT included hypercalcemia , and may be predicted by serum cis - RA levels .
Diseases: hypercalcemia"	"Sentence: The DLT included hypercalcemia , and may be predicted by serum cis - RA levels .
Diseases:"
2210	Monitoring of serum calcium and cis - RA levels is indicated in future trials .	O O O O O O O O O O O O O O O	O O O B O B I I O O O O O O O	[]	0	0	"Sentence: Monitoring of serum calcium and cis - RA levels is indicated in future trials .
Diseases: "	"Sentence: Monitoring of serum calcium and cis - RA levels is indicated in future trials .
Diseases:"
2211	Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats .	O O O O O O O O O O O O O O O O	O O B I O O O O O O B O B O O O	[]	0	0	"Sentence: Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats .
Diseases: "	"Sentence: Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats .
Diseases:"
2212	The effect of calcium chloride injected into the cerebral ventricles of group - housed unanaesthetized cats upon vocalization ( rage , hissing and snarling ) , fighting ( attack with paws and claws , defense with paws and claws and biting ) , mydriasis , tremor and clonic - tonic convulsions produced by carbachol and eserine injected similarly was investigated .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O B I I I O O O O O O O O O O	O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O	['tremor', 'mydriasis', 'clonic - tonic convulsions']	3	16	"Sentence: The effect of calcium chloride injected into the cerebral ventricles of group - housed unanaesthetized cats upon vocalization ( rage , hissing and snarling ) , fighting ( attack with paws and claws , defense with paws and claws and biting ) , mydriasis , tremor and clonic - tonic convulsions produced by carbachol and eserine injected similarly was investigated .
Diseases: tremor, mydriasis, clonic - tonic convulsions"	"Sentence: The effect of calcium chloride injected into the cerebral ventricles of group - housed unanaesthetized cats upon vocalization ( rage , hissing and snarling ) , fighting ( attack with paws and claws , defense with paws and claws and biting ) , mydriasis , tremor and clonic - tonic convulsions produced by carbachol and eserine injected similarly was investigated .
Diseases:"
2213	Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine .	O O O O O O O O O O O O O O O O O	B I O O O O O O O O O O O B O B O	[]	0	0	"Sentence: Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine .
Diseases: "	"Sentence: Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine .
Diseases:"
2214	On the other hand , mydriasis , tremor and clonic - tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride .	O O O O O B O B O B I I I O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O B O O O O O B I O	['tremor', 'mydriasis', 'clonic - tonic convulsions']	3	16	"Sentence: On the other hand , mydriasis , tremor and clonic - tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride .
Diseases: tremor, mydriasis, clonic - tonic convulsions"	"Sentence: On the other hand , mydriasis , tremor and clonic - tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride .
Diseases:"
2215	"It is apparent that calcium chloride can "" dissociate "" vocalization and fighting from autonomic and motor phenomena such as mydriasis , tremor and clonic - tonic convulsions caused by carbachol and eserine ."	O O O O O O O O O O O O O O O O O O O O B O B O B I I I O O O O O O	O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O B O B O	['tremor', 'mydriasis', 'clonic - tonic convulsions']	3	16	"Sentence: It is apparent that calcium chloride can "" dissociate "" vocalization and fighting from autonomic and motor phenomena such as mydriasis , tremor and clonic - tonic convulsions caused by carbachol and eserine .
Diseases: tremor, mydriasis, clonic - tonic convulsions"	"Sentence: It is apparent that calcium chloride can "" dissociate "" vocalization and fighting from autonomic and motor phenomena such as mydriasis , tremor and clonic - tonic convulsions caused by carbachol and eserine .
Diseases:"
2216	Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites .	O O O O O O O O O O O O O O O O O O O O O O O O O	B I O O O O O O O B O B O O O O O O O O O O O O O	[]	0	0	"Sentence: Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites .
Diseases: "	"Sentence: Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites .
Diseases:"
2217	These results further support the view that calcium ions in excess have an atropine - like action also in the central nervous system .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: These results further support the view that calcium ions in excess have an atropine - like action also in the central nervous system .
Diseases: "	"Sentence: These results further support the view that calcium ions in excess have an atropine - like action also in the central nervous system .
Diseases:"
2218	Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis .	O O O O O O O O O O B I O	O O O O B O O O O O O O O	['rheumatoid arthritis']	1	5	"Sentence: Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis .
Diseases: rheumatoid arthritis"	"Sentence: Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis .
Diseases:"
2219	Skin rashes , proteinuria , systemic lupus erythematosus , polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis .	B I O B O B I I O B O B I O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['proteinuria', 'skin rashes', 'polymyositis', 'rheumatoid arthritis', 'systemic lupus erythematosus', 'myasthenia gravis']	6	35	"Sentence: Skin rashes , proteinuria , systemic lupus erythematosus , polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis .
Diseases: proteinuria, skin rashes, polymyositis, rheumatoid arthritis, systemic lupus erythematosus, myasthenia gravis"	"Sentence: Skin rashes , proteinuria , systemic lupus erythematosus , polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis .
Diseases:"
2220	A patient who had developed all 5 is now described .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: A patient who had developed all 5 is now described .
Diseases: "	"Sentence: A patient who had developed all 5 is now described .
Diseases:"
2221	The skin lesion resembled elastosis perforans serpiginosa , which has been reported as a rare side effect in patients with Wilson 's disease but not in patients with rheumatoid arthritis treated with penicillamine .	O B I O B I I O O O O O O O O O O O O O B I I O O O O O B I O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	"['rheumatoid arthritis', 'skin lesion', 'elastosis perforans serpiginosa', ""wilson 's disease""]"	4	27	"Sentence: The skin lesion resembled elastosis perforans serpiginosa , which has been reported as a rare side effect in patients with Wilson 's disease but not in patients with rheumatoid arthritis treated with penicillamine .
Diseases: rheumatoid arthritis, skin lesion, elastosis perforans serpiginosa, wilson 's disease"	"Sentence: The skin lesion resembled elastosis perforans serpiginosa , which has been reported as a rare side effect in patients with Wilson 's disease but not in patients with rheumatoid arthritis treated with penicillamine .
Diseases:"
2222	Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs .	O O O B I O O O O O O	O O O O O O O O O O O	['cardiac arrhythmias']	1	6	"Sentence: Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs .
Diseases: cardiac arrhythmias"	"Sentence: Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs .
Diseases:"
2223	Eight patients had cardiac manifestations that were life - threatening in five while taking psychotropic drugs , either phenothiazines or tricyclic antidepressants .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O B O	[]	0	0	"Sentence: Eight patients had cardiac manifestations that were life - threatening in five while taking psychotropic drugs , either phenothiazines or tricyclic antidepressants .
Diseases: "	"Sentence: Eight patients had cardiac manifestations that were life - threatening in five while taking psychotropic drugs , either phenothiazines or tricyclic antidepressants .
Diseases:"
2224	Although most patients were receiving several drugs , Mellaril ( thioridazine ) appeared to be responsible for five cases of ventricular tachycardia , one of which was fatal in a 35 year old woman .	O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O	O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O	['ventricular tachycardia']	1	6	"Sentence: Although most patients were receiving several drugs , Mellaril ( thioridazine ) appeared to be responsible for five cases of ventricular tachycardia , one of which was fatal in a 35 year old woman .
Diseases: ventricular tachycardia"	"Sentence: Although most patients were receiving several drugs , Mellaril ( thioridazine ) appeared to be responsible for five cases of ventricular tachycardia , one of which was fatal in a 35 year old woman .
Diseases:"
2225	Supraventricular tachycardia developed in one patient receiving Thorazine ( chlorpromazine ) .	B I O O O O O O O O O O	O O O O O O O B O B O O	['supraventricular tachycardia']	1	8	"Sentence: Supraventricular tachycardia developed in one patient receiving Thorazine ( chlorpromazine ) .
Diseases: supraventricular tachycardia"	"Sentence: Supraventricular tachycardia developed in one patient receiving Thorazine ( chlorpromazine ) .
Diseases:"
2226	Aventyl ( nortriptyline ) and Elavil ( amitriptyline ) each produced left bundle branch block in a 73 year old woman .	O O O O O O O O O O O B I I I O O O O O O O	B O B O O B O B O O O O O O O O O O O O O O	['left bundle branch block']	1	4	"Sentence: Aventyl ( nortriptyline ) and Elavil ( amitriptyline ) each produced left bundle branch block in a 73 year old woman .
Diseases: left bundle branch block"	"Sentence: Aventyl ( nortriptyline ) and Elavil ( amitriptyline ) each produced left bundle branch block in a 73 year old woman .
Diseases:"
2227	Electrocardiographic T and U wave abnormalities were present in most patients .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: Electrocardiographic T and U wave abnormalities were present in most patients .
Diseases: "	"Sentence: Electrocardiographic T and U wave abnormalities were present in most patients .
Diseases:"
2228	The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock ; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one .	O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O B O O O O O O O	['ventricular arrhythmias']	1	6	"Sentence: The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock ; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one .
Diseases: ventricular arrhythmias"	"Sentence: The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock ; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one .
Diseases:"
2229	The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped .	O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	['tachyarrhythmias']	1	6	"Sentence: The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped .
Diseases: tachyarrhythmias"	"Sentence: The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped .
Diseases:"
2230	Five of the eight patients were 50 years of age or younger ; only one clearly had antecedent heart disease .	O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O	['heart disease']	1	2	"Sentence: Five of the eight patients were 50 years of age or younger ; only one clearly had antecedent heart disease .
Diseases: heart disease"	"Sentence: Five of the eight patients were 50 years of age or younger ; only one clearly had antecedent heart disease .
Diseases:"
2231	Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs .	O B I O O O O O O O B I O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	['heart disease', 'cardiac arrhythmias']	2	8	"Sentence: Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs .
Diseases: heart disease, cardiac arrhythmias"	"Sentence: Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs .
Diseases:"
2232	A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs .	O O O O O O O O O O O B I O O O O O O O O O	O O O O O O O O O O O O O O O O B O B B O O	['cardiac complications']	1	3	"Sentence: A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs .
Diseases: cardiac complications"	"Sentence: A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs .
Diseases:"
2233	Serotonergic drugs , benzodiazepines and baclofen block muscimol - induced myoclonic jerks in a strain of mice .	O O O O O O O O O O B I O O O O O O	B O O B O B O B O O O O O O O O O O	['myoclonic jerks']	1	5	"Sentence: Serotonergic drugs , benzodiazepines and baclofen block muscimol - induced myoclonic jerks in a strain of mice .
Diseases: myoclonic jerks"	"Sentence: Serotonergic drugs , benzodiazepines and baclofen block muscimol - induced myoclonic jerks in a strain of mice .
Diseases:"
2234	In male Swiss mice , muscimol produced myoclonic jerks .	O O O O O O O B I O	O O O O O B O O O O	['myoclonic jerks']	1	5	"Sentence: In male Swiss mice , muscimol produced myoclonic jerks .
Diseases: myoclonic jerks"	"Sentence: In male Swiss mice , muscimol produced myoclonic jerks .
Diseases:"
2235	A 3 mg / kg ( i . p . )	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: A 3 mg / kg ( i . p . )
Diseases: "	"Sentence: A 3 mg / kg ( i . p . )
Diseases:"
2236	dose induced this response in all of the mice tested and the peak response of 73 jerks per min was observed between 27 and 45 min .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: dose induced this response in all of the mice tested and the peak response of 73 jerks per min was observed between 27 and 45 min .
Diseases: "	"Sentence: dose induced this response in all of the mice tested and the peak response of 73 jerks per min was observed between 27 and 45 min .
Diseases:"
2237	Increasing the brain serotonin levels by the administration of 5 - hydroxytryptophan ( 80 - 160 mg / kg ) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O B I I O O O O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Increasing the brain serotonin levels by the administration of 5 - hydroxytryptophan ( 80 - 160 mg / kg ) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect .
Diseases: "	"Sentence: Increasing the brain serotonin levels by the administration of 5 - hydroxytryptophan ( 80 - 160 mg / kg ) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect .
Diseases:"
2238	However , in a similar experiment l - dopa ( 80 - 160 mg / kg ) was without effect .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O B I I O O O O O O O O O O O O	[]	0	0	"Sentence: However , in a similar experiment l - dopa ( 80 - 160 mg / kg ) was without effect .
Diseases: "	"Sentence: However , in a similar experiment l - dopa ( 80 - 160 mg / kg ) was without effect .
Diseases:"
2239	In doses of 3 - 10 mg / kg , the serotonin receptor agonist MK - 212 caused a dose - dependent blockade of the response of muscimol .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O B I I O O O O O O O O O O B O	[]	0	0	"Sentence: In doses of 3 - 10 mg / kg , the serotonin receptor agonist MK - 212 caused a dose - dependent blockade of the response of muscimol .
Diseases: "	"Sentence: In doses of 3 - 10 mg / kg , the serotonin receptor agonist MK - 212 caused a dose - dependent blockade of the response of muscimol .
Diseases:"
2240	Of the benzodiazepines , clonazepam ( 0 . 1 - 0 . 3 mg / kg ) was found to be several fold more potent than diazepam ( 0 . 3 - 3 mg / kg ) in blocking the myoclonic jerks .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O B O B O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	['myoclonic jerks']	1	5	"Sentence: Of the benzodiazepines , clonazepam ( 0 . 1 - 0 . 3 mg / kg ) was found to be several fold more potent than diazepam ( 0 . 3 - 3 mg / kg ) in blocking the myoclonic jerks .
Diseases: myoclonic jerks"	"Sentence: Of the benzodiazepines , clonazepam ( 0 . 1 - 0 . 3 mg / kg ) was found to be several fold more potent than diazepam ( 0 . 3 - 3 mg / kg ) in blocking the myoclonic jerks .
Diseases:"
2241	While ( - ) - baclofen ( 1 - 3 mg / kg ) proved to be an effective antagonist of muscimol , its ( + ) - isomer	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: While ( - ) - baclofen ( 1 - 3 mg / kg ) proved to be an effective antagonist of muscimol , its ( + ) - isomer
Diseases: "	"Sentence: While ( - ) - baclofen ( 1 - 3 mg / kg ) proved to be an effective antagonist of muscimol , its ( + ) - isomer
Diseases:"
2242	( 5 - 20 mg / kg ) lacked this property .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: ( 5 - 20 mg / kg ) lacked this property .
Diseases: "	"Sentence: ( 5 - 20 mg / kg ) lacked this property .
Diseases:"
2243	Considering the fact that 5 - HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus , the muscimol - induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition .	O O O O O O O O O O O O O O O O O O O O O B O O O O O B O O O O O O O O O O O O O O O O O O O O O O	O O O O B I I O O B O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['myoclonus']	1	4	"Sentence: Considering the fact that 5 - HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus , the muscimol - induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition .
Diseases: myoclonus"	"Sentence: Considering the fact that 5 - HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus , the muscimol - induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition .
Diseases:"
2244	Our present study indicated the possible value of MK - 212 and ( - ) - baclofen in the management of clinical myoclonus .	O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O B I I O O O O O B O O O O O O O	['myoclonus']	1	4	"Sentence: Our present study indicated the possible value of MK - 212 and ( - ) - baclofen in the management of clinical myoclonus .
Diseases: myoclonus"	"Sentence: Our present study indicated the possible value of MK - 212 and ( - ) - baclofen in the management of clinical myoclonus .
Diseases:"
2245	Hyperglycemic acidotic coma and death in Kearns - Sayre syndrome .	B I I O O O B I I I O	O O O O O O O O O O O	['hyperglycemic acidotic coma', 'kearns - sayre syndrome']	2	14	"Sentence: Hyperglycemic acidotic coma and death in Kearns - Sayre syndrome .
Diseases: hyperglycemic acidotic coma, kearns - sayre syndrome"	"Sentence: Hyperglycemic acidotic coma and death in Kearns - Sayre syndrome .
Diseases:"
2246	This paper presents the clinical and metabolic findings in two young boys with long - standing Kearns - Sayre syndrome .	O O O O O O O O O O O O O O O O B I I I O	O O O O O O O O O O O O O O O O O O O O O	['kearns - sayre syndrome']	1	7	"Sentence: This paper presents the clinical and metabolic findings in two young boys with long - standing Kearns - Sayre syndrome .
Diseases: kearns - sayre syndrome"	"Sentence: This paper presents the clinical and metabolic findings in two young boys with long - standing Kearns - Sayre syndrome .
Diseases:"
2247	Following short exposure to oral prednisone , both boys developed lethargy , increasing somnolence , polydipsia , polyphagia , and polyuria .	O O O O O O O O O O B O O B O B O B O O B O	O O O O O B O O O O O O O O O O O O O O O O	['somnolence', 'polydipsia', 'polyphagia', 'polyuria', 'lethargy']	5	22	"Sentence: Following short exposure to oral prednisone , both boys developed lethargy , increasing somnolence , polydipsia , polyphagia , and polyuria .
Diseases: somnolence, polydipsia, polyphagia, polyuria, lethargy"	"Sentence: Following short exposure to oral prednisone , both boys developed lethargy , increasing somnolence , polydipsia , polyphagia , and polyuria .
Diseases:"
2248	Both presented in the emergency room with profound coma , hypotension , severe hyperglycemia , and acidosis .	O O O O O O O O B O B O O B O O B O	O O O O O O O O O O O O O O O O O O	['hyperglycemia', 'acidosis', 'hypotension', 'coma']	4	12	"Sentence: Both presented in the emergency room with profound coma , hypotension , severe hyperglycemia , and acidosis .
Diseases: hyperglycemia, acidosis, hypotension, coma"	"Sentence: Both presented in the emergency room with profound coma , hypotension , severe hyperglycemia , and acidosis .
Diseases:"
2249	Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other .	O B I O O O O O B O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O	['lactic acidosis', 'ketosis']	2	7	"Sentence: Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other .
Diseases: lactic acidosis, ketosis"	"Sentence: Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other .
Diseases:"
2250	Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation .	B I O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	['respiratory failure']	1	4	"Sentence: Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation .
Diseases: respiratory failure"	"Sentence: Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation .
Diseases:"
2251	We believe these two cases represent a newly described and catastrophic metabolic - endocrine failure in the Kearns - Sayre syndrome .	O O O O O O O O O O O B I I I O O B I I I O	O O O O O O O O O O O O O O O O O O O O O O	['metabolic - endocrine failure', 'kearns - sayre syndrome']	2	14	"Sentence: We believe these two cases represent a newly described and catastrophic metabolic - endocrine failure in the Kearns - Sayre syndrome .
Diseases: metabolic - endocrine failure, kearns - sayre syndrome"	"Sentence: We believe these two cases represent a newly described and catastrophic metabolic - endocrine failure in the Kearns - Sayre syndrome .
Diseases:"
2252	Effects of active constituents of Crocus sativus L . , crocin on streptozocin - induced model of sporadic Alzheimer 's disease in male rats .	O O O O O O O O O O O O O O O O O O B I I O O O O	O O O O O O I O O O B O B O O O O O O O O O O O O	"[""alzheimer 's disease""]"	1	6	"Sentence: Effects of active constituents of Crocus sativus L . , crocin on streptozocin - induced model of sporadic Alzheimer 's disease in male rats .
Diseases: alzheimer 's disease"	"Sentence: Effects of active constituents of Crocus sativus L . , crocin on streptozocin - induced model of sporadic Alzheimer 's disease in male rats .
Diseases:"
2253	The involvement of water - soluble carotenoids , crocins , as the main and active components of Crocus sativus	O O O O O O O O O O O O O O O O O O O	O O O O O O B O B O O O O O O O O O O	[]	0	0	"Sentence: The involvement of water - soluble carotenoids , crocins , as the main and active components of Crocus sativus
Diseases: "	"Sentence: The involvement of water - soluble carotenoids , crocins , as the main and active components of Crocus sativus
Diseases:"
2254	L . extract in learning and memory processes has been proposed .	O O O O O O O O O O O O	O O I O O O O O O O O O	[]	0	0	"Sentence: L . extract in learning and memory processes has been proposed .
Diseases: "	"Sentence: L . extract in learning and memory processes has been proposed .
Diseases:"
2255	In the present study , the effect of crocins on sporadic Alzheimer 's disease induced by intracerebroventricular ( icv ) streptozocin ( STZ ) in male rats was investigated .	O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O B O B O O O O O O O	"[""alzheimer 's disease""]"	1	6	"Sentence: In the present study , the effect of crocins on sporadic Alzheimer 's disease induced by intracerebroventricular ( icv ) streptozocin ( STZ ) in male rats was investigated .
Diseases: alzheimer 's disease"	"Sentence: In the present study , the effect of crocins on sporadic Alzheimer 's disease induced by intracerebroventricular ( icv ) streptozocin ( STZ ) in male rats was investigated .
Diseases:"
2256	Male adult Wistar rats ( n = 90 and 260 - 290 g ) were divided into 1 , control ; 2 and 3 , crocins ( 15 and 30 mg / kg ) ; 4 , STZ ; 5 and 6 , STZ + crocins ( 15 and 30 mg / kg ) groups .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O B O O O O O B O B O O O O O O O O O O	[]	0	0	"Sentence: Male adult Wistar rats ( n = 90 and 260 - 290 g ) were divided into 1 , control ; 2 and 3 , crocins ( 15 and 30 mg / kg ) ; 4 , STZ ; 5 and 6 , STZ + crocins ( 15 and 30 mg / kg ) groups .
Diseases: "	"Sentence: Male adult Wistar rats ( n = 90 and 260 - 290 g ) were divided into 1 , control ; 2 and 3 , crocins ( 15 and 30 mg / kg ) ; 4 , STZ ; 5 and 6 , STZ + crocins ( 15 and 30 mg / kg ) groups .
Diseases:"
2257	In Alzheimer 's disease groups , rats were injected with STZ - icv bilaterally ( 3 mg / kg ) in first day and 3 days later , a similar STZ - icv application was repeated .	O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O B O O O O O O	"[""alzheimer 's disease""]"	1	6	"Sentence: In Alzheimer 's disease groups , rats were injected with STZ - icv bilaterally ( 3 mg / kg ) in first day and 3 days later , a similar STZ - icv application was repeated .
Diseases: alzheimer 's disease"	"Sentence: In Alzheimer 's disease groups , rats were injected with STZ - icv bilaterally ( 3 mg / kg ) in first day and 3 days later , a similar STZ - icv application was repeated .
Diseases:"
2258	In STZ + crocin animal groups , crocin was applied in doses of 15 and 30 mg / kg , i . p .	O O O O O O O O O O O O O O O O O O O O O O O O	O B O B O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In STZ + crocin animal groups , crocin was applied in doses of 15 and 30 mg / kg , i . p .
Diseases: "	"Sentence: In STZ + crocin animal groups , crocin was applied in doses of 15 and 30 mg / kg , i . p .
Diseases:"
2259	, one day pre - surgery and continued for three weeks .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: , one day pre - surgery and continued for three weeks .
Diseases: "	"Sentence: , one day pre - surgery and continued for three weeks .
Diseases:"
2260	Prescription of crocin in each dose was repeated once for two days .	O O O O O O O O O O O O O	O O B O O O O O O O O O O	[]	0	0	"Sentence: Prescription of crocin in each dose was repeated once for two days .
Diseases: "	"Sentence: Prescription of crocin in each dose was repeated once for two days .
Diseases:"
2261	However , the learning and memory performance was assessed using passive avoidance paradigm , and for spatial cognition evaluation , Y - maze task was used .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , the learning and memory performance was assessed using passive avoidance paradigm , and for spatial cognition evaluation , Y - maze task was used .
Diseases: "	"Sentence: However , the learning and memory performance was assessed using passive avoidance paradigm , and for spatial cognition evaluation , Y - maze task was used .
Diseases:"
2262	It was found out that crocin ( 30 mg / kg ) - treated STZ - injected rats show higher correct choices and lower errors in Y - maze than vehicle - treated STZ - injected rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O B O O O O O O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: It was found out that crocin ( 30 mg / kg ) - treated STZ - injected rats show higher correct choices and lower errors in Y - maze than vehicle - treated STZ - injected rats .
Diseases: "	"Sentence: It was found out that crocin ( 30 mg / kg ) - treated STZ - injected rats show higher correct choices and lower errors in Y - maze than vehicle - treated STZ - injected rats .
Diseases:"
2263	In addition , crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ - injected group in passive avoidance test .	O O O O O O O O O O O B I I I O O O O O O O O O O O	O O O B O O O O O O O O O O O O O B O O O O O O O O	['learning and memory impairment']	1	4	"Sentence: In addition , crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ - injected group in passive avoidance test .
Diseases: learning and memory impairment"	"Sentence: In addition , crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ - injected group in passive avoidance test .
Diseases:"
2264	Therefore , these results demonstrate the effectiveness of crocin ( 30 mg / kg ) in antagonizing the cognitive deficits caused by STZ - icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer 's disease .	O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O B I O O B I I O	O O O O O O O O B O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	"['cognitive deficits', ""alzheimer 's disease"", 'neurodegenerative diseases']"	3	16	"Sentence: Therefore , these results demonstrate the effectiveness of crocin ( 30 mg / kg ) in antagonizing the cognitive deficits caused by STZ - icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer 's disease .
Diseases: cognitive deficits, alzheimer 's disease, neurodegenerative diseases"	"Sentence: Therefore , these results demonstrate the effectiveness of crocin ( 30 mg / kg ) in antagonizing the cognitive deficits caused by STZ - icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer 's disease .
Diseases:"
2265	Rosaceiform dermatitis associated with topical tacrolimus treatment .	O B O O O O O O	O O O O O B O O	['dermatitis']	1	3	"Sentence: Rosaceiform dermatitis associated with topical tacrolimus treatment .
Diseases: dermatitis"	"Sentence: Rosaceiform dermatitis associated with topical tacrolimus treatment .
Diseases:"
2266	We describe herein 3 patients who developed rosacea - like dermatitis eruptions while using 0 . 03 % or 0 . 1 % tacrolimus ointment for facial dermatitis .	O O O O O O O B O O B B O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	['eruptions', 'facial dermatitis', 'dermatitis', 'rosacea']	4	14	"Sentence: We describe herein 3 patients who developed rosacea - like dermatitis eruptions while using 0 . 03 % or 0 . 1 % tacrolimus ointment for facial dermatitis .
Diseases: eruptions, facial dermatitis, dermatitis, rosacea"	"Sentence: We describe herein 3 patients who developed rosacea - like dermatitis eruptions while using 0 . 03 % or 0 . 1 % tacrolimus ointment for facial dermatitis .
Diseases:"
2267	Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis .	O O O O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	['telangiectasia']	1	5	"Sentence: Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis .
Diseases: telangiectasia"	"Sentence: Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis .
Diseases:"
2268	Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis , although many cases have not been reported .	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	O O O O O O O B O B O O O O O O O O O O O O O O O O O O O	['dermatitis']	1	3	"Sentence: Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis , although many cases have not been reported .
Diseases: dermatitis"	"Sentence: Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis , although many cases have not been reported .
Diseases:"
2269	A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB .
Diseases: "	"Sentence: A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB .
Diseases:"
2270	The purpose of this investigation was to explore the potentiality of a novel animal model to be used for the in vivo evaluation of the ability of a drug delivery system to promote the passage through the blood - brain barrier ( BBB ) and / or to improve the brain localization of a bioactive compound .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The purpose of this investigation was to explore the potentiality of a novel animal model to be used for the in vivo evaluation of the ability of a drug delivery system to promote the passage through the blood - brain barrier ( BBB ) and / or to improve the brain localization of a bioactive compound .
Diseases: "	"Sentence: The purpose of this investigation was to explore the potentiality of a novel animal model to be used for the in vivo evaluation of the ability of a drug delivery system to promote the passage through the blood - brain barrier ( BBB ) and / or to improve the brain localization of a bioactive compound .
Diseases:"
2271	A Tween 80 - coated poly - L - lactid acid nanoparticles was used as a model of colloidal drug delivery system , able to trespass the BBB .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O B I O O B I I I I I O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A Tween 80 - coated poly - L - lactid acid nanoparticles was used as a model of colloidal drug delivery system , able to trespass the BBB .
Diseases: "	"Sentence: A Tween 80 - coated poly - L - lactid acid nanoparticles was used as a model of colloidal drug delivery system , able to trespass the BBB .
Diseases:"
2272	Tacrine , administered in LiCl pre - treated rats , induces electrocorticographic seizures and delayed hippocampal damage .	O O O O O O O O O O O O B O O B I O	B O O O B O O O O O O O O O O O O O	['hippocampal damage', 'seizures']	2	7	"Sentence: Tacrine , administered in LiCl pre - treated rats , induces electrocorticographic seizures and delayed hippocampal damage .
Diseases: hippocampal damage, seizures"	"Sentence: Tacrine , administered in LiCl pre - treated rats , induces electrocorticographic seizures and delayed hippocampal damage .
Diseases:"
2273	The toxic effects of tacrine - loaded poly - L - lactid acid nanoparticles ( 5mg / kg ) , a saline solution of tacrine ( 5mg / kg ) and an empty colloidal nanoparticle suspension were compared following i . p .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O B I I I I I O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The toxic effects of tacrine - loaded poly - L - lactid acid nanoparticles ( 5mg / kg ) , a saline solution of tacrine ( 5mg / kg ) and an empty colloidal nanoparticle suspension were compared following i . p .
Diseases: "	"Sentence: The toxic effects of tacrine - loaded poly - L - lactid acid nanoparticles ( 5mg / kg ) , a saline solution of tacrine ( 5mg / kg ) and an empty colloidal nanoparticle suspension were compared following i . p .
Diseases:"
2274	administration in LiCl - pre - treated Wistar rats .	O O O O O O O O O O	O O B O O O O O O O	[]	0	0	"Sentence: administration in LiCl - pre - treated Wistar rats .
Diseases: "	"Sentence: administration in LiCl - pre - treated Wistar rats .
Diseases:"
2275	All the animals treated with tacrine - loaded nanoparticles showed an earlier outcome of CNS adverse symptoms , i . e . epileptic onset , with respect to those animals treated with the free compound ( 10 min vs . 22 min respectively ) .	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['epileptic']	1	3	"Sentence: All the animals treated with tacrine - loaded nanoparticles showed an earlier outcome of CNS adverse symptoms , i . e . epileptic onset , with respect to those animals treated with the free compound ( 10 min vs . 22 min respectively ) .
Diseases: epileptic"	"Sentence: All the animals treated with tacrine - loaded nanoparticles showed an earlier outcome of CNS adverse symptoms , i . e . epileptic onset , with respect to those animals treated with the free compound ( 10 min vs . 22 min respectively ) .
Diseases:"
2276	In addition , tacrine - loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals , while the saline solution of tacrine only in 60 % of animals .	O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['damage of neuronal cells']	1	4	"Sentence: In addition , tacrine - loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals , while the saline solution of tacrine only in 60 % of animals .
Diseases: damage of neuronal cells"	"Sentence: In addition , tacrine - loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals , while the saline solution of tacrine only in 60 % of animals .
Diseases:"
2277	Empty nanoparticles provided similar results to control ( saline - treated ) group of animals .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Empty nanoparticles provided similar results to control ( saline - treated ) group of animals .
Diseases: "	"Sentence: Empty nanoparticles provided similar results to control ( saline - treated ) group of animals .
Diseases:"
2278	In conclusion , the evaluation of time - to - onset of symptoms and the severity of neurodegenerative processes induced by the tacrine - lithium model of epilepsy in the rat , could be used to evaluate preliminarily the capability of a drug delivery system to trespass ( or not ) the BBB in vivo .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['epilepsy']	1	3	"Sentence: In conclusion , the evaluation of time - to - onset of symptoms and the severity of neurodegenerative processes induced by the tacrine - lithium model of epilepsy in the rat , could be used to evaluate preliminarily the capability of a drug delivery system to trespass ( or not ) the BBB in vivo .
Diseases: epilepsy"	"Sentence: In conclusion , the evaluation of time - to - onset of symptoms and the severity of neurodegenerative processes induced by the tacrine - lithium model of epilepsy in the rat , could be used to evaluate preliminarily the capability of a drug delivery system to trespass ( or not ) the BBB in vivo .
Diseases:"
2279	The antiarrhythmic effect and possible ionic mechanisms of pilocarpine on animal models .	O O O O O O O O O O O O O	O O O O O O O O B O O O O	[]	0	0	"Sentence: The antiarrhythmic effect and possible ionic mechanisms of pilocarpine on animal models .
Diseases: "	"Sentence: The antiarrhythmic effect and possible ionic mechanisms of pilocarpine on animal models .
Diseases:"
2280	This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism , using both aconitine - induced rat and ouabain - induced guinea pig arrhythmia models .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	O O O O O O O O O B O O O O O O O O O B O O O O B O O O O O O O	['arrhythmia']	1	4	"Sentence: This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism , using both aconitine - induced rat and ouabain - induced guinea pig arrhythmia models .
Diseases: arrhythmia"	"Sentence: This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism , using both aconitine - induced rat and ouabain - induced guinea pig arrhythmia models .
Diseases:"
2281	Confocal microscopy was used to measure intracellular free - calcium concentrations ( [ Ca ( 2 + ) ] ( i ) ) in isolated myocytes .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: Confocal microscopy was used to measure intracellular free - calcium concentrations ( [ Ca ( 2 + ) ] ( i ) ) in isolated myocytes .
Diseases: "	"Sentence: Confocal microscopy was used to measure intracellular free - calcium concentrations ( [ Ca ( 2 + ) ] ( i ) ) in isolated myocytes .
Diseases:"
2282	The current data showed that pilocarpine significantly delayed onset of arrhythmias , decreased the time course of ventricular tachycardia and fibrillation , reduced arrhythmia score , and increased the survival time of arrhythmic rats and guinea pigs .	O O O O O O O O O O B O O O O O O B I I I O O B O O O O O O O O B O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['arrhythmic', 'arrhythmias', 'ventricular tachycardia and fibrillation', 'arrhythmia']	4	25	"Sentence: The current data showed that pilocarpine significantly delayed onset of arrhythmias , decreased the time course of ventricular tachycardia and fibrillation , reduced arrhythmia score , and increased the survival time of arrhythmic rats and guinea pigs .
Diseases: arrhythmic, arrhythmias, ventricular tachycardia and fibrillation, arrhythmia"	"Sentence: The current data showed that pilocarpine significantly delayed onset of arrhythmias , decreased the time course of ventricular tachycardia and fibrillation , reduced arrhythmia score , and increased the survival time of arrhythmic rats and guinea pigs .
Diseases:"
2283	[ Ca ( 2 + ) ] ( i ) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine .	O O O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O B O B O O O O O O O B O	[]	0	0	"Sentence: [ Ca ( 2 + ) ] ( i ) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine .
Diseases: "	"Sentence: [ Ca ( 2 + ) ] ( i ) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine .
Diseases:"
2284	Moreover , M ( 3 ) - muscarinic acetylcholine receptor ( mAChR ) antagonist 4 - DAMP ( 4 - diphenylacetoxy - N - methylpiperidine - methiodide ) partially abolished the beneficial effects of pilocarpine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O B I I O B I I I I I I I I O O O O O O O B O	[]	0	0	"Sentence: Moreover , M ( 3 ) - muscarinic acetylcholine receptor ( mAChR ) antagonist 4 - DAMP ( 4 - diphenylacetoxy - N - methylpiperidine - methiodide ) partially abolished the beneficial effects of pilocarpine .
Diseases: "	"Sentence: Moreover , M ( 3 ) - muscarinic acetylcholine receptor ( mAChR ) antagonist 4 - DAMP ( 4 - diphenylacetoxy - N - methylpiperidine - methiodide ) partially abolished the beneficial effects of pilocarpine .
Diseases:"
2285	These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M ( 3 ) - mAChR .	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O B O B O O O O O O O O O O O	['arrhythmic']	1	4	"Sentence: These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M ( 3 ) - mAChR .
Diseases: arrhythmic"	"Sentence: These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M ( 3 ) - mAChR .
Diseases:"
2286	The mechanism may be related to the improvement of Ca ( 2 + ) handling .	O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O	[]	0	0	"Sentence: The mechanism may be related to the improvement of Ca ( 2 + ) handling .
Diseases: "	"Sentence: The mechanism may be related to the improvement of Ca ( 2 + ) handling .
Diseases:"
2287	Disulfiram - induced transient optic and peripheral neuropathy : a case report .	O O O O B I I I O O O O O	B O O O O O O O O O O O O	['optic and peripheral neuropathy']	1	6	"Sentence: Disulfiram - induced transient optic and peripheral neuropathy : a case report .
Diseases: optic and peripheral neuropathy"	"Sentence: Disulfiram - induced transient optic and peripheral neuropathy : a case report .
Diseases:"
2288	AIM : To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management .	O O O O O O O B I I I O O O O O O B I O O	O O O O O O O O O O O O O O O B O B O O O	['optic and peripheral neuropathy', 'alcohol dependence']	2	9	"Sentence: AIM : To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management .
Diseases: optic and peripheral neuropathy, alcohol dependence"	"Sentence: AIM : To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management .
Diseases:"
2289	MATERIALS AND METHODS : A case report .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: MATERIALS AND METHODS : A case report .
Diseases: "	"Sentence: MATERIALS AND METHODS : A case report .
Diseases:"
2290	A 57 - year - old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months .	O O O O O O O O O O B I I O O O O O B O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['loss of vision', 'headaches']	2	5	"Sentence: A 57 - year - old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months .
Diseases: loss of vision, headaches"	"Sentence: A 57 - year - old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months .
Diseases:"
2291	He also complained of paraesthesia with numbness in both feet .	O O O O B O B O O O O	O O O O O O O O O O O	['numbness', 'paraesthesia']	2	6	"Sentence: He also complained of paraesthesia with numbness in both feet .
Diseases: numbness, paraesthesia"	"Sentence: He also complained of paraesthesia with numbness in both feet .
Diseases:"
2292	His vision was 6 / 15 and 2 / 60 in the right and left eyes , respectively .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: His vision was 6 / 15 and 2 / 60 in the right and left eyes , respectively .
Diseases: "	"Sentence: His vision was 6 / 15 and 2 / 60 in the right and left eyes , respectively .
Diseases:"
2293	Fundoscopy revealed bilaterally swollen optic nerve heads .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: Fundoscopy revealed bilaterally swollen optic nerve heads .
Diseases: "	"Sentence: Fundoscopy revealed bilaterally swollen optic nerve heads .
Diseases:"
2294	Visual field testing confirmed bilateral central - caecal scotomata .	O O O O O O O O B O	O O O O O O O O O O	['scotomata']	1	3	"Sentence: Visual field testing confirmed bilateral central - caecal scotomata .
Diseases: scotomata"	"Sentence: Visual field testing confirmed bilateral central - caecal scotomata .
Diseases:"
2295	He had been taking disulfiram for alcohol dependence for the preceding 3 years .	O O O O O O B I O O O O O O	O O O O B O B O O O O O O O	['alcohol dependence']	1	2	"Sentence: He had been taking disulfiram for alcohol dependence for the preceding 3 years .
Diseases: alcohol dependence"	"Sentence: He had been taking disulfiram for alcohol dependence for the preceding 3 years .
Diseases:"
2296	Disulfiram discontinuation lead to an immediate symptomatic improvement .	O O O O O O O O O	B O O O O O O O O	[]	0	0	"Sentence: Disulfiram discontinuation lead to an immediate symptomatic improvement .
Diseases: "	"Sentence: Disulfiram discontinuation lead to an immediate symptomatic improvement .
Diseases:"
2297	CONCLUSION : Physicians initiating long - term disulfiram therapy should be aware of these adverse effects .	O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: CONCLUSION : Physicians initiating long - term disulfiram therapy should be aware of these adverse effects .
Diseases: "	"Sentence: CONCLUSION : Physicians initiating long - term disulfiram therapy should be aware of these adverse effects .
Diseases:"
2298	They should recommend annual ophthalmic reviews with visual field testing .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: They should recommend annual ophthalmic reviews with visual field testing .
Diseases: "	"Sentence: They should recommend annual ophthalmic reviews with visual field testing .
Diseases:"
2299	Patients should be reassured with respect to the reversibility of these adverse effects .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients should be reassured with respect to the reversibility of these adverse effects .
Diseases: "	"Sentence: Patients should be reassured with respect to the reversibility of these adverse effects .
Diseases:"
2300	Sustained clinical improvement of a patient with decompensated hepatitis B virus - related cirrhosis after treatment with lamivudine monotherapy .	O O O O O O O O B I O O O B O O O O O O	O O O O O O O O O O O O O O O O O B O O	['cirrhosis', 'hepatitis b']	2	7	"Sentence: Sustained clinical improvement of a patient with decompensated hepatitis B virus - related cirrhosis after treatment with lamivudine monotherapy .
Diseases: cirrhosis, hepatitis b"	"Sentence: Sustained clinical improvement of a patient with decompensated hepatitis B virus - related cirrhosis after treatment with lamivudine monotherapy .
Diseases:"
2301	Hepatitis B virus ( HBV ) infection , which causes liver cirrhosis and hepatocellular carcinoma , remains a major health problem in Asian countries .	B I I I I I I O O O B I O B I O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['liver cirrhosis', 'hepatitis b virus ( hbv ) infection', 'hepatocellular carcinoma']	3	22	"Sentence: Hepatitis B virus ( HBV ) infection , which causes liver cirrhosis and hepatocellular carcinoma , remains a major health problem in Asian countries .
Diseases: liver cirrhosis, hepatitis b virus ( hbv ) infection, hepatocellular carcinoma"	"Sentence: Hepatitis B virus ( HBV ) infection , which causes liver cirrhosis and hepatocellular carcinoma , remains a major health problem in Asian countries .
Diseases:"
2302	Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers , although the standard medical therapies have not been established up to now .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers , although the standard medical therapies have not been established up to now .
Diseases: "	"Sentence: Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers , although the standard medical therapies have not been established up to now .
Diseases:"
2303	In this report , we encountered a patient with decompensated HBV - related cirrhosis who exhibited the dramatic improvements after antiviral therapy .	O O O O O O O O O O O O O B O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['cirrhosis']	1	4	"Sentence: In this report , we encountered a patient with decompensated HBV - related cirrhosis who exhibited the dramatic improvements after antiviral therapy .
Diseases: cirrhosis"	"Sentence: In this report , we encountered a patient with decompensated HBV - related cirrhosis who exhibited the dramatic improvements after antiviral therapy .
Diseases:"
2304	The patient was a 50 - year - old woman .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: The patient was a 50 - year - old woman .
Diseases: "	"Sentence: The patient was a 50 - year - old woman .
Diseases:"
2305	Previous conventional medical treatments were not effective for this patient , thus this patient had been referred to our hospital .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Previous conventional medical treatments were not effective for this patient , thus this patient had been referred to our hospital .
Diseases: "	"Sentence: Previous conventional medical treatments were not effective for this patient , thus this patient had been referred to our hospital .
Diseases:"
2306	However , the administration of lamivudine , a reverse transcriptase inhibitor , for 23 months dramatically improved her liver severity .	O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , the administration of lamivudine , a reverse transcriptase inhibitor , for 23 months dramatically improved her liver severity .
Diseases: "	"Sentence: However , the administration of lamivudine , a reverse transcriptase inhibitor , for 23 months dramatically improved her liver severity .
Diseases:"
2307	During this period , no drug resistant mutant HBV emerged , and the serum HBV - DNA level was continuously suppressed .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: During this period , no drug resistant mutant HBV emerged , and the serum HBV - DNA level was continuously suppressed .
Diseases: "	"Sentence: During this period , no drug resistant mutant HBV emerged , and the serum HBV - DNA level was continuously suppressed .
Diseases:"
2308	These virological responses were also maintained even after the antiviral therapy was discontinued .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: These virological responses were also maintained even after the antiviral therapy was discontinued .
Diseases: "	"Sentence: These virological responses were also maintained even after the antiviral therapy was discontinued .
Diseases:"
2309	Moreover , both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Moreover , both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient .
Diseases: "	"Sentence: Moreover , both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient .
Diseases:"
2310	The administration of lamivudine to patients with HBV - related cirrhosis , like our present case , should be considered as an initial medical therapeutic option , especially in countries where liver transplantation is not reliably available .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cirrhosis']	1	4	"Sentence: The administration of lamivudine to patients with HBV - related cirrhosis , like our present case , should be considered as an initial medical therapeutic option , especially in countries where liver transplantation is not reliably available .
Diseases: cirrhosis"	"Sentence: The administration of lamivudine to patients with HBV - related cirrhosis , like our present case , should be considered as an initial medical therapeutic option , especially in countries where liver transplantation is not reliably available .
Diseases:"
2311	Dual effects of melatonin on barbiturate - induced narcosis in rats .	O O O O O O O O B O O O	O O O B O B O O O O O O	['narcosis']	1	3	"Sentence: Dual effects of melatonin on barbiturate - induced narcosis in rats .
Diseases: narcosis"	"Sentence: Dual effects of melatonin on barbiturate - induced narcosis in rats .
Diseases:"
2312	Melatonin affects the circadian sleep / wake cycle , but it is not clear whether it may influence drug - induced narcosis .	O O O O O O O O O O O O O O O O O O O O O B O	B O O O O O O O O O O O O O O O O O O O O O O	['narcosis']	1	3	"Sentence: Melatonin affects the circadian sleep / wake cycle , but it is not clear whether it may influence drug - induced narcosis .
Diseases: narcosis"	"Sentence: Melatonin affects the circadian sleep / wake cycle , but it is not clear whether it may influence drug - induced narcosis .
Diseases:"
2313	Sodium thiopenthal was administered intraperitoneally into male rats pre - treated with melatonin ( 0 . 05 , 0 . 5 , 5 and 50 mg / kg ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B I O O O O O O O O O O B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Sodium thiopenthal was administered intraperitoneally into male rats pre - treated with melatonin ( 0 . 05 , 0 . 5 , 5 and 50 mg / kg ) .
Diseases: "	"Sentence: Sodium thiopenthal was administered intraperitoneally into male rats pre - treated with melatonin ( 0 . 05 , 0 . 5 , 5 and 50 mg / kg ) .
Diseases:"
2314	Melatonin pre - treatment affected in a dual manner barbiturate narcosis , however , no dose - effect correlation was found .	O O O O O O O O O O B O O O O O O O O O O O	B O O O O O O O O B O O O O O O O O O O O O	['narcosis']	1	3	"Sentence: Melatonin pre - treatment affected in a dual manner barbiturate narcosis , however , no dose - effect correlation was found .
Diseases: narcosis"	"Sentence: Melatonin pre - treatment affected in a dual manner barbiturate narcosis , however , no dose - effect correlation was found .
Diseases:"
2315	In particular , low doses reduced the latency to and prolonged the duration of barbiturate narcosis .	O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O B O O	['narcosis']	1	3	"Sentence: In particular , low doses reduced the latency to and prolonged the duration of barbiturate narcosis .
Diseases: narcosis"	"Sentence: In particular , low doses reduced the latency to and prolonged the duration of barbiturate narcosis .
Diseases:"
2316	In contrast , the highest dose of melatonin ( 50 mg / kg ) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis , and a reduction in mortality rate .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['narcosis']	1	3	"Sentence: In contrast , the highest dose of melatonin ( 50 mg / kg ) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis , and a reduction in mortality rate .
Diseases: narcosis"	"Sentence: In contrast , the highest dose of melatonin ( 50 mg / kg ) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis , and a reduction in mortality rate .
Diseases:"
2317	Melatonin 0 . 5 and 5 mg / kg influenced the duration but not the latency of ketamine - or diazepam - induced narcosis .	O O O O O O O O O O O O O O O O O O O O O O O B O	B O O O O O O O O O O O O O O O O B O O B O O O O	['narcosis']	1	3	"Sentence: Melatonin 0 . 5 and 5 mg / kg influenced the duration but not the latency of ketamine - or diazepam - induced narcosis .
Diseases: narcosis"	"Sentence: Melatonin 0 . 5 and 5 mg / kg influenced the duration but not the latency of ketamine - or diazepam - induced narcosis .
Diseases:"
2318	Thus , the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action .	O O O O O O O O O B O O O O O O O O O O O	O O O O O O B O O O O O O O O O B O O O O	['narcosis']	1	3	"Sentence: Thus , the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action .
Diseases: narcosis"	"Sentence: Thus , the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action .
Diseases:"
2319	Effects of NIK - 247 on cholinesterase and scopolamine - induced amnesia .	O O O O O O O O O O O B O	O O B I I O O O B O O O O	['amnesia']	1	2	"Sentence: Effects of NIK - 247 on cholinesterase and scopolamine - induced amnesia .
Diseases: amnesia"	"Sentence: Effects of NIK - 247 on cholinesterase and scopolamine - induced amnesia .
Diseases:"
2320	The effects of NIK - 247 on cholinesterase , scopolamine - induced amnesia and spontaneous movement were examined and compared with those of the well - known cholinesterase inhibitors tacrine and E - 2020 .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	O O O B I I O O O B O O O O O O O O O O O O O O O O O O O B O B I I O	['amnesia']	1	2	"Sentence: The effects of NIK - 247 on cholinesterase , scopolamine - induced amnesia and spontaneous movement were examined and compared with those of the well - known cholinesterase inhibitors tacrine and E - 2020 .
Diseases: amnesia"	"Sentence: The effects of NIK - 247 on cholinesterase , scopolamine - induced amnesia and spontaneous movement were examined and compared with those of the well - known cholinesterase inhibitors tacrine and E - 2020 .
Diseases:"
2321	NIK - 247 , tacrine and E - 2020 all strongly inhibited acetylcholinesterase ( AChE ) in human red blood cells ( IC50s = 1 . 0 x 10 ( - 6 ) , 2 . 9 x 10 ( - 7 ) and 3 . 7 x 10 ( - 8 ) M , respectively ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B I I O B O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: NIK - 247 , tacrine and E - 2020 all strongly inhibited acetylcholinesterase ( AChE ) in human red blood cells ( IC50s = 1 . 0 x 10 ( - 6 ) , 2 . 9 x 10 ( - 7 ) and 3 . 7 x 10 ( - 8 ) M , respectively ) .
Diseases: "	"Sentence: NIK - 247 , tacrine and E - 2020 all strongly inhibited acetylcholinesterase ( AChE ) in human red blood cells ( IC50s = 1 . 0 x 10 ( - 6 ) , 2 . 9 x 10 ( - 7 ) and 3 . 7 x 10 ( - 8 ) M , respectively ) .
Diseases:"
2322	In addition , NIK - 247 and tacrine , but not E - 2020 , strongly inhibited butyrylcholinestrase ( BuChE ) in human serum .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B I I O B O O O B I I O O O O O O O O O O O	[]	0	0	"Sentence: In addition , NIK - 247 and tacrine , but not E - 2020 , strongly inhibited butyrylcholinestrase ( BuChE ) in human serum .
Diseases: "	"Sentence: In addition , NIK - 247 and tacrine , but not E - 2020 , strongly inhibited butyrylcholinestrase ( BuChE ) in human serum .
Diseases:"
2323	All three drugs produced mixed inhibition of AChE activity .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: All three drugs produced mixed inhibition of AChE activity .
Diseases: "	"Sentence: All three drugs produced mixed inhibition of AChE activity .
Diseases:"
2324	Moreover , the inhibitory effect of NIK - 247 on AChE was reversible .	O O O O O O O O O O O O O O	O O O O O O B I I O O O O O	[]	0	0	"Sentence: Moreover , the inhibitory effect of NIK - 247 on AChE was reversible .
Diseases: "	"Sentence: Moreover , the inhibitory effect of NIK - 247 on AChE was reversible .
Diseases:"
2325	All compounds at 0 . 1 - 1 mg / kg p . o .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All compounds at 0 . 1 - 1 mg / kg p . o .
Diseases: "	"Sentence: All compounds at 0 . 1 - 1 mg / kg p . o .
Diseases:"
2326	significantly improved the amnesia induced by scopolamine ( 0 . 5 mg / kg s . c . )	O O O B O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O	['amnesia']	1	2	"Sentence: significantly improved the amnesia induced by scopolamine ( 0 . 5 mg / kg s . c . )
Diseases: amnesia"	"Sentence: significantly improved the amnesia induced by scopolamine ( 0 . 5 mg / kg s . c . )
Diseases:"
2327	in rats performing a passive avoidance task .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: in rats performing a passive avoidance task .
Diseases: "	"Sentence: in rats performing a passive avoidance task .
Diseases:"
2328	The three compounds at 1 and 3 mg / kg	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: The three compounds at 1 and 3 mg / kg
Diseases: "	"Sentence: The three compounds at 1 and 3 mg / kg
Diseases:"
2329	p . o .	O O O O	O O O O	[]	0	0	"Sentence: p . o .
Diseases: "	"Sentence: p . o .
Diseases:"
2330	did not significantly decrease spontaneous movement by rats .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: did not significantly decrease spontaneous movement by rats .
Diseases: "	"Sentence: did not significantly decrease spontaneous movement by rats .
Diseases:"
2331	These findings suggest that NIK - 247 at a low dose ( 0 . 1 - 1 mg / kg p . o . ) improves scopolamine - induced amnesia but does not affect spontaneous movement .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	O O O O B I I O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	['amnesia']	1	2	"Sentence: These findings suggest that NIK - 247 at a low dose ( 0 . 1 - 1 mg / kg p . o . ) improves scopolamine - induced amnesia but does not affect spontaneous movement .
Diseases: amnesia"	"Sentence: These findings suggest that NIK - 247 at a low dose ( 0 . 1 - 1 mg / kg p . o . ) improves scopolamine - induced amnesia but does not affect spontaneous movement .
Diseases:"
2332	The findings suggest that NIK - 247 may be a useful drug for the treatment of Alzheimer 's disease .	O O O O O O O O O O O O O O O O B I I O	O O O O B I I O O O O O O O O O O O O O	"[""alzheimer 's disease""]"	1	6	"Sentence: The findings suggest that NIK - 247 may be a useful drug for the treatment of Alzheimer 's disease .
Diseases: alzheimer 's disease"	"Sentence: The findings suggest that NIK - 247 may be a useful drug for the treatment of Alzheimer 's disease .
Diseases:"
2333	Nightmares and hallucinations after long - term intake of tramadol combined with antidepressants .	O O B O O O O O O O O O O O	O O O O O O O O O B O O B O	['hallucinations']	1	3	"Sentence: Nightmares and hallucinations after long - term intake of tramadol combined with antidepressants .
Diseases: hallucinations"	"Sentence: Nightmares and hallucinations after long - term intake of tramadol combined with antidepressants .
Diseases:"
2334	Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain .	O O O O O O O O O O O O O O O O O B B O O O O B O	B O O O O O O O O O O O O O O O O O O O O O O O O	['pain', 'cancer']	2	3	"Sentence: Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain .
Diseases: pain, cancer"	"Sentence: Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain .
Diseases:"
2335	This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain .	O O O O O O O O O O O O O B O O B I O	O O O O O O O B O B I O O O O O O O O	['tetraparetic', 'chronic pain']	2	8	"Sentence: This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain .
Diseases: tetraparetic, chronic pain"	"Sentence: This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain .
Diseases:"
2336	Fifty - six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho - active drugs and tramadol .	O O O O O O O O O O O O B O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O B O	['hallucinations']	1	3	"Sentence: Fifty - six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho - active drugs and tramadol .
Diseases: hallucinations"	"Sentence: Fifty - six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho - active drugs and tramadol .
Diseases:"
2337	The case report questions the long term use of pain killers combined with psycho - active drugs in chronic non malignant pain , especially if pain is under control .	O O O O O O O O O B O O O O O O O O O O O B O O O B O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: The case report questions the long term use of pain killers combined with psycho - active drugs in chronic non malignant pain , especially if pain is under control .
Diseases: pain"	"Sentence: The case report questions the long term use of pain killers combined with psycho - active drugs in chronic non malignant pain , especially if pain is under control .
Diseases:"
2338	Apparent cure of rheumatoid arthritis by bone marrow transplantation .	O O O B I O O O O O	O O O O O O O O O O	['rheumatoid arthritis']	1	5	"Sentence: Apparent cure of rheumatoid arthritis by bone marrow transplantation .
Diseases: rheumatoid arthritis"	"Sentence: Apparent cure of rheumatoid arthritis by bone marrow transplantation .
Diseases:"
2339	We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis ( RA ) by bone marrow transplantation ( BMT ) in 2 patients .	O O O O O O O O O O O O O B I O B O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ra', 'rheumatoid arthritis']	2	7	"Sentence: We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis ( RA ) by bone marrow transplantation ( BMT ) in 2 patients .
Diseases: ra, rheumatoid arthritis"	"Sentence: We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis ( RA ) by bone marrow transplantation ( BMT ) in 2 patients .
Diseases:"
2340	BMT was used to treat severe aplastic anemia which was caused by gold in one case and D - penicillamine in the other .	O O O O O O B I O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O B I I O O O O	['aplastic anemia']	1	5	"Sentence: BMT was used to treat severe aplastic anemia which was caused by gold in one case and D - penicillamine in the other .
Diseases: aplastic anemia"	"Sentence: BMT was used to treat severe aplastic anemia which was caused by gold in one case and D - penicillamine in the other .
Diseases:"
2341	In the 8 and 6 years since the transplants ( representing 8 and 4 years since cessation of all immunosuppressive therapy , respectively ) , the RA in each case has been completely quiescent .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ra']	1	1	"Sentence: In the 8 and 6 years since the transplants ( representing 8 and 4 years since cessation of all immunosuppressive therapy , respectively ) , the RA in each case has been completely quiescent .
Diseases: ra"	"Sentence: In the 8 and 6 years since the transplants ( representing 8 and 4 years since cessation of all immunosuppressive therapy , respectively ) , the RA in each case has been completely quiescent .
Diseases:"
2342	Although short term remission of severe RA following BMT has been reported , these are the first cases for which prolonged followup has been available .	O O O O O O B O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['ra']	1	1	"Sentence: Although short term remission of severe RA following BMT has been reported , these are the first cases for which prolonged followup has been available .
Diseases: ra"	"Sentence: Although short term remission of severe RA following BMT has been reported , these are the first cases for which prolonged followup has been available .
Diseases:"
2343	This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive synovitis .	O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O	['synovitis']	1	3	"Sentence: This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive synovitis .
Diseases: synovitis"	"Sentence: This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive synovitis .
Diseases:"
2344	Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney .	O O O O O O O O B I I I I I I O	O O O O O O O O O O O O O O O O	['injury to different regions of the kidney']	1	8	"Sentence: Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney .
Diseases: injury to different regions of the kidney"	"Sentence: Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney .
Diseases:"
2345	Acute experimental models of renal damage to the proximal tubular , glomerular , and papillary regions of the rat were produced by administration of hexachloro - 1 : 3 - butadiene ( HCBD ) , puromycin aminonucleoside ( PAN ) , and 2 - bromoethylamine ( BEA ) , respectively .	B I I I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B I I I I I I O B O O B I O B O O O B I I O B O O O O	['acute experimental models of renal damage']	1	7	"Sentence: Acute experimental models of renal damage to the proximal tubular , glomerular , and papillary regions of the rat were produced by administration of hexachloro - 1 : 3 - butadiene ( HCBD ) , puromycin aminonucleoside ( PAN ) , and 2 - bromoethylamine ( BEA ) , respectively .
Diseases: acute experimental models of renal damage"	"Sentence: Acute experimental models of renal damage to the proximal tubular , glomerular , and papillary regions of the rat were produced by administration of hexachloro - 1 : 3 - butadiene ( HCBD ) , puromycin aminonucleoside ( PAN ) , and 2 - bromoethylamine ( BEA ) , respectively .
Diseases:"
2346	Several routine indicators of nephrotoxicity , the enzymes alkaline phosphatase and N - acetyl - beta - glucosaminidase , and the molecular weight of protein excretion were determined on urine samples .	O O O O B O O O O O O O O O O O O O O O O O O O B I O O O O O O	O O O O O O O O O O O O O I O O O O O O O O O O O O O O O O O O	['nephrotoxicity', 'protein excretion']	2	8	"Sentence: Several routine indicators of nephrotoxicity , the enzymes alkaline phosphatase and N - acetyl - beta - glucosaminidase , and the molecular weight of protein excretion were determined on urine samples .
Diseases: nephrotoxicity, protein excretion"	"Sentence: Several routine indicators of nephrotoxicity , the enzymes alkaline phosphatase and N - acetyl - beta - glucosaminidase , and the molecular weight of protein excretion were determined on urine samples .
Diseases:"
2347	Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN .	O O O O O O O O O O O O O O B I O O O O	O O O O B O B O O O O O O O O O O O B O	['glomerular damage']	1	3	"Sentence: Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN .
Diseases: glomerular damage"	"Sentence: Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN .
Diseases:"
2348	The latter was characterized by a pronounced increase in protein excretion , especially proteins with molecular weight greater than 40 , 000 Da .	O O O O O O O O O B I O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	['protein excretion']	1	3	"Sentence: The latter was characterized by a pronounced increase in protein excretion , especially proteins with molecular weight greater than 40 , 000 Da .
Diseases: protein excretion"	"Sentence: The latter was characterized by a pronounced increase in protein excretion , especially proteins with molecular weight greater than 40 , 000 Da .
Diseases:"
2349	In contrast , protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights .	O O O B I O O O O O O O O O O B I I O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['protein excretion', 'excretion of proteins']	2	8	"Sentence: In contrast , protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights .
Diseases: protein excretion, excretion of proteins"	"Sentence: In contrast , protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights .
Diseases:"
2350	Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis ( volume and specific gravity ) and by measurement of the two urinary enzymes .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O B O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis ( volume and specific gravity ) and by measurement of the two urinary enzymes .
Diseases: "	"Sentence: Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis ( volume and specific gravity ) and by measurement of the two urinary enzymes .
Diseases:"
2351	Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N - acetyl - beta - glucosaminidase showed a sustained elevation in papillary damage .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O B I I I O O O O O O O O O O O	[]	0	0	"Sentence: Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N - acetyl - beta - glucosaminidase showed a sustained elevation in papillary damage .
Diseases: "	"Sentence: Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N - acetyl - beta - glucosaminidase showed a sustained elevation in papillary damage .
Diseases:"
2352	It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of renal damage .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['renal damage']	1	3	"Sentence: It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of renal damage .
Diseases: renal damage"	"Sentence: It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of renal damage .
Diseases:"
2353	Neuromuscular blockade with magnesium sulfate and nifedipine .	B I O O O O O O	O O O B I O B O	['neuromuscular blockade']	1	6	"Sentence: Neuromuscular blockade with magnesium sulfate and nifedipine .
Diseases: neuromuscular blockade"	"Sentence: Neuromuscular blockade with magnesium sulfate and nifedipine .
Diseases:"
2354	A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered .	O O O O O O O O B I O O O O O O O O O	O O O O O O B O O O O O O O B I O O O	['neuromuscular blockade']	1	6	"Sentence: A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered .
Diseases: neuromuscular blockade"	"Sentence: A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered .
Diseases:"
2355	This reaction demonstrates that nifedipine can seriously potentiate the toxicity of magnesium .	O O O O O O O O O B O O O	O O O O B O O O O O O B O	['toxicity']	1	2	"Sentence: This reaction demonstrates that nifedipine can seriously potentiate the toxicity of magnesium .
Diseases: toxicity"	"Sentence: This reaction demonstrates that nifedipine can seriously potentiate the toxicity of magnesium .
Diseases:"
2356	Caution should be exercised when these two tocolytics are combined .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: Caution should be exercised when these two tocolytics are combined .
Diseases: "	"Sentence: Caution should be exercised when these two tocolytics are combined .
Diseases:"
2357	Ifosfamide continuous infusion without mesna .	O O O O O O	B O O O B O	[]	0	0	"Sentence: Ifosfamide continuous infusion without mesna .
Diseases: "	"Sentence: Ifosfamide continuous infusion without mesna .
Diseases:"
2358	A phase I trial of a 14 - day cycle .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: A phase I trial of a 14 - day cycle .
Diseases: "	"Sentence: A phase I trial of a 14 - day cycle .
Diseases:"
2359	Twenty patients received 27 courses of ifosfamide administered as a 24 - hour continuous infusion for 14 days without Mesna .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O B O	[]	0	0	"Sentence: Twenty patients received 27 courses of ifosfamide administered as a 24 - hour continuous infusion for 14 days without Mesna .
Diseases: "	"Sentence: Twenty patients received 27 courses of ifosfamide administered as a 24 - hour continuous infusion for 14 days without Mesna .
Diseases:"
2360	The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short - term infusions administered with Mesna .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short - term infusions administered with Mesna .
Diseases: "	"Sentence: The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short - term infusions administered with Mesna .
Diseases:"
2361	Dose escalations proceeded from 200 to 300 , 400 , 450 , 500 , and 550 mg / m2 / d .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Dose escalations proceeded from 200 to 300 , 400 , 450 , 500 , and 550 mg / m2 / d .
Diseases: "	"Sentence: Dose escalations proceeded from 200 to 300 , 400 , 450 , 500 , and 550 mg / m2 / d .
Diseases:"
2362	Four patients developed transient microscopic hematuria at 400 , 450 , and 500 mg / m2 / d .	O O O O O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	['hematuria']	1	3	"Sentence: Four patients developed transient microscopic hematuria at 400 , 450 , and 500 mg / m2 / d .
Diseases: hematuria"	"Sentence: Four patients developed transient microscopic hematuria at 400 , 450 , and 500 mg / m2 / d .
Diseases:"
2363	There were no instances of macroscopic hematuria .	O O O O O O B O	O O O O O O O O	['hematuria']	1	3	"Sentence: There were no instances of macroscopic hematuria .
Diseases: hematuria"	"Sentence: There were no instances of macroscopic hematuria .
Diseases:"
2364	At 550 mg / m2 / d , three patients experienced nonurologic toxicity ; confusion ( 1 ) , nausea ( 1 ) , and Grade 2 leukopenia ( 1 ) .	O O O O O O O O O O O O B O B O O O O B O O O O O O O B O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nausea', 'leukopenia', 'confusion', 'toxicity']	4	12	"Sentence: At 550 mg / m2 / d , three patients experienced nonurologic toxicity ; confusion ( 1 ) , nausea ( 1 ) , and Grade 2 leukopenia ( 1 ) .
Diseases: nausea, leukopenia, confusion, toxicity"	"Sentence: At 550 mg / m2 / d , three patients experienced nonurologic toxicity ; confusion ( 1 ) , nausea ( 1 ) , and Grade 2 leukopenia ( 1 ) .
Diseases:"
2365	The recommended dose of 500 mg / m2 / d delivers a total dose of 7 g / m2 per cycle , which is comparable to that delivered in clinical practice for bolus or short - term infusion .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The recommended dose of 500 mg / m2 / d delivers a total dose of 7 g / m2 per cycle , which is comparable to that delivered in clinical practice for bolus or short - term infusion .
Diseases: "	"Sentence: The recommended dose of 500 mg / m2 / d delivers a total dose of 7 g / m2 per cycle , which is comparable to that delivered in clinical practice for bolus or short - term infusion .
Diseases:"
2366	Because few patients received multiple courses over time , the cumulative effects are indeterminate in the present trial .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Because few patients received multiple courses over time , the cumulative effects are indeterminate in the present trial .
Diseases: "	"Sentence: Because few patients received multiple courses over time , the cumulative effects are indeterminate in the present trial .
Diseases:"
2367	The frequency and predictability of hematuria are not precise , and at least daily monitoring by urine Hematest is essential , adding Mesna to the infusate in patients with persistent hematuria .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	['hematuria']	1	3	"Sentence: The frequency and predictability of hematuria are not precise , and at least daily monitoring by urine Hematest is essential , adding Mesna to the infusate in patients with persistent hematuria .
Diseases: hematuria"	"Sentence: The frequency and predictability of hematuria are not precise , and at least daily monitoring by urine Hematest is essential , adding Mesna to the infusate in patients with persistent hematuria .
Diseases:"
2368	The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to 890 per cycle .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O B O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to 890 per cycle .
Diseases: "	"Sentence: The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to 890 per cycle .
Diseases:"
2369	Clinical activity was demonstrated in a single patient , but a comparative trial of standard bolus schedules with the protracted infusion schedule will be necessary to determine if the clinical effectiveness of the drug is maintained .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Clinical activity was demonstrated in a single patient , but a comparative trial of standard bolus schedules with the protracted infusion schedule will be necessary to determine if the clinical effectiveness of the drug is maintained .
Diseases: "	"Sentence: Clinical activity was demonstrated in a single patient , but a comparative trial of standard bolus schedules with the protracted infusion schedule will be necessary to determine if the clinical effectiveness of the drug is maintained .
Diseases:"
2370	Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction : a case report .	B I O O O O O O O O O O O O O O	O O O O O O B I O O O O O O O O	['myocardial infarction']	1	6	"Sentence: Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction : a case report .
Diseases: myocardial infarction"	"Sentence: Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction : a case report .
Diseases:"
2371	Clomiphene citrate ( CC ) is commonly prescribed for ovulation induction .	O O O O O O O O O O O O	B I O B O O O O O O O O	[]	0	0	"Sentence: Clomiphene citrate ( CC ) is commonly prescribed for ovulation induction .
Diseases: "	"Sentence: Clomiphene citrate ( CC ) is commonly prescribed for ovulation induction .
Diseases:"
2372	It is considered safe , with minimal side effects .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: It is considered safe , with minimal side effects .
Diseases: "	"Sentence: It is considered safe , with minimal side effects .
Diseases:"
2373	Thromboembolism is a rare but life - threatening complication that has been reported after ovulation induction with CC .	B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O	['thromboembolism']	1	6	"Sentence: Thromboembolism is a rare but life - threatening complication that has been reported after ovulation induction with CC .
Diseases: thromboembolism"	"Sentence: Thromboembolism is a rare but life - threatening complication that has been reported after ovulation induction with CC .
Diseases:"
2374	Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction ( MI ) during pregnancy , with a subsequently normal coronary angiogram .	O B I O B O O O O O O O O O O O O O O O B I O B O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['mi', 'coronary thrombosis', 'thromboembolism', 'myocardial infarction']	4	21	"Sentence: Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction ( MI ) during pregnancy , with a subsequently normal coronary angiogram .
Diseases: mi, coronary thrombosis, thromboembolism, myocardial infarction"	"Sentence: Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction ( MI ) during pregnancy , with a subsequently normal coronary angiogram .
Diseases:"
2375	CASE :	O O	O O	[]	0	0	"Sentence: CASE :
Diseases: "	"Sentence: CASE :
Diseases:"
2376	A 33 - year - old woman with a 5 - week gestation had recently received CC for ovulation induction and presented with chest pain .	O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O B O O O O O O O O O	['chest pain']	1	2	"Sentence: A 33 - year - old woman with a 5 - week gestation had recently received CC for ovulation induction and presented with chest pain .
Diseases: chest pain"	"Sentence: A 33 - year - old woman with a 5 - week gestation had recently received CC for ovulation induction and presented with chest pain .
Diseases:"
2377	An electrocardiogram showed a lateral and anterior wall myocardial infarction .	O O O O O O O O B I O	O O O O O O O O O O O	['myocardial infarction']	1	6	"Sentence: An electrocardiogram showed a lateral and anterior wall myocardial infarction .
Diseases: myocardial infarction"	"Sentence: An electrocardiogram showed a lateral and anterior wall myocardial infarction .
Diseases:"
2378	Cardiac enzymes showed a peak rise in troponin I to 9 . 10 ng / mL . An initial exercise stress test was normal .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cardiac enzymes showed a peak rise in troponin I to 9 . 10 ng / mL . An initial exercise stress test was normal .
Diseases: "	"Sentence: Cardiac enzymes showed a peak rise in troponin I to 9 . 10 ng / mL . An initial exercise stress test was normal .
Diseases:"
2379	At the time of admission , the patient was at high risk of radiation injury to the fetus , so a coronary angiogram was postponed until the second trimester .	O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['radiation injury']	1	3	"Sentence: At the time of admission , the patient was at high risk of radiation injury to the fetus , so a coronary angiogram was postponed until the second trimester .
Diseases: radiation injury"	"Sentence: At the time of admission , the patient was at high risk of radiation injury to the fetus , so a coronary angiogram was postponed until the second trimester .
Diseases:"
2380	It showed normal coronary vessels .	O O O O O O	O O O O O O	[]	0	0	"Sentence: It showed normal coronary vessels .
Diseases: "	"Sentence: It showed normal coronary vessels .
Diseases:"
2381	This appears to be the first reported case documenting a possible association between CC and myocardial infarction .	O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O B O O O O	['myocardial infarction']	1	6	"Sentence: This appears to be the first reported case documenting a possible association between CC and myocardial infarction .
Diseases: myocardial infarction"	"Sentence: This appears to be the first reported case documenting a possible association between CC and myocardial infarction .
Diseases:"
2382	Thrombosis might be a rare but hazardous complication of CC .	B O O O O O O O O O O	O O O O O O O O O B O	['thrombosis']	1	4	"Sentence: Thrombosis might be a rare but hazardous complication of CC .
Diseases: thrombosis"	"Sentence: Thrombosis might be a rare but hazardous complication of CC .
Diseases:"
2383	Given this life - threatening complication , appropriate prophylactic measures should be used in high - risk woman undergoing ovarian stimulation .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Given this life - threatening complication , appropriate prophylactic measures should be used in high - risk woman undergoing ovarian stimulation .
Diseases: "	"Sentence: Given this life - threatening complication , appropriate prophylactic measures should be used in high - risk woman undergoing ovarian stimulation .
Diseases:"
2384	Hepatonecrosis and cholangitis related to long - term phenobarbital therapy : an autopsy report of two patients .	B O B O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O	['cholangitis', 'hepatonecrosis']	2	10	"Sentence: Hepatonecrosis and cholangitis related to long - term phenobarbital therapy : an autopsy report of two patients .
Diseases: cholangitis, hepatonecrosis"	"Sentence: Hepatonecrosis and cholangitis related to long - term phenobarbital therapy : an autopsy report of two patients .
Diseases:"
2385	Phenobarbital ( PB ) has a reputation for safety , and it is commonly believed that PB - related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	B O B O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['liver disease']	1	3	"Sentence: Phenobarbital ( PB ) has a reputation for safety , and it is commonly believed that PB - related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease .
Diseases: liver disease"	"Sentence: Phenobarbital ( PB ) has a reputation for safety , and it is commonly believed that PB - related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease .
Diseases:"
2386	Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly : one as consequence of cardiac arrest , the other of acute bronchopneumonia .	O O O O O O O O O O O O B O O O O O O O O O O O B I O O O O O B O	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['bronchopneumonia', 'cardiac arrest', 'epilepsy']	3	11	"Sentence: Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly : one as consequence of cardiac arrest , the other of acute bronchopneumonia .
Diseases: bronchopneumonia, cardiac arrest, epilepsy"	"Sentence: Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly : one as consequence of cardiac arrest , the other of acute bronchopneumonia .
Diseases:"
2387	At autopsy , analysis of liver parenchyma revealed rich portal inflammatory infiltrate , which consisted of mixed eosinophil and monocyte cells , associated with several foci of necrosis surrounded by a hard ring of non - specific granulomatous tissue .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['necrosis']	1	2	"Sentence: At autopsy , analysis of liver parenchyma revealed rich portal inflammatory infiltrate , which consisted of mixed eosinophil and monocyte cells , associated with several foci of necrosis surrounded by a hard ring of non - specific granulomatous tissue .
Diseases: necrosis"	"Sentence: At autopsy , analysis of liver parenchyma revealed rich portal inflammatory infiltrate , which consisted of mixed eosinophil and monocyte cells , associated with several foci of necrosis surrounded by a hard ring of non - specific granulomatous tissue .
Diseases:"
2388	Inflammatory reactions of internal and external hepatic biliary ducts were also seen .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Inflammatory reactions of internal and external hepatic biliary ducts were also seen .
Diseases: "	"Sentence: Inflammatory reactions of internal and external hepatic biliary ducts were also seen .
Diseases:"
2389	Our findings illustrate that PB may be associated with chronic liver damage , which may lead to more serious and deleterious consequences .	O O O O O O O O O O B I O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O	['liver damage']	1	3	"Sentence: Our findings illustrate that PB may be associated with chronic liver damage , which may lead to more serious and deleterious consequences .
Diseases: liver damage"	"Sentence: Our findings illustrate that PB may be associated with chronic liver damage , which may lead to more serious and deleterious consequences .
Diseases:"
2390	For this reason , each clinician should recognize this entity in the differential diagnosis of PB - related asymptomatic chronic hepatic enzyme dysfunction .	O O O O O O O O O O O O O O O O O O O B I I I O	O O O O O O O O O O O O O O O B O O O O O O O O	['chronic hepatic enzyme dysfunction']	1	6	"Sentence: For this reason , each clinician should recognize this entity in the differential diagnosis of PB - related asymptomatic chronic hepatic enzyme dysfunction .
Diseases: chronic hepatic enzyme dysfunction"	"Sentence: For this reason , each clinician should recognize this entity in the differential diagnosis of PB - related asymptomatic chronic hepatic enzyme dysfunction .
Diseases:"
2391	Ethambutol - associated optic neuropathy .	O O O B I O	B O O O O O	['optic neuropathy']	1	4	"Sentence: Ethambutol - associated optic neuropathy .
Diseases: optic neuropathy"	"Sentence: Ethambutol - associated optic neuropathy .
Diseases:"
2392	Ethambutol is used in the treatment of tuberculosis , which is still prevalent in Southeast Asia , and can be associated with permanent visual loss .	O O O O O O O B O O O O O O O O O O O O O O O B I O	B O O O O O O O O O O O O O O O O O O O O O O O O O	['tuberculosis', 'visual loss']	2	6	"Sentence: Ethambutol is used in the treatment of tuberculosis , which is still prevalent in Southeast Asia , and can be associated with permanent visual loss .
Diseases: tuberculosis, visual loss"	"Sentence: Ethambutol is used in the treatment of tuberculosis , which is still prevalent in Southeast Asia , and can be associated with permanent visual loss .
Diseases:"
2393	We report 3 cases which presented with bitemporal hemianopia .	O O O O O O O B I O	O O O O O O O O O O	['bitemporal hemianopia']	1	6	"Sentence: We report 3 cases which presented with bitemporal hemianopia .
Diseases: bitemporal hemianopia"	"Sentence: We report 3 cases which presented with bitemporal hemianopia .
Diseases:"
2394	CLINICAL PICTURE :	O O O	O O O	[]	0	0	"Sentence: CLINICAL PICTURE :
Diseases: "	"Sentence: CLINICAL PICTURE :
Diseases:"
2395	Three patients with ethambutol - associated toxic optic neuropathy are described .	O O O O O O O B I O O O	O O O B O O O O O O O O	['optic neuropathy']	1	4	"Sentence: Three patients with ethambutol - associated toxic optic neuropathy are described .
Diseases: optic neuropathy"	"Sentence: Three patients with ethambutol - associated toxic optic neuropathy are described .
Diseases:"
2396	All 3 patients had loss of central visual acuity , colour vision ( Ishihara ) and visual field .	O O O O B I I I I I I I I I I I I I O	O O O O O O O O O O O O O O O O O O O	['loss of central visual acuity , colour vision ( ishihara ) and visual field']	1	17	"Sentence: All 3 patients had loss of central visual acuity , colour vision ( Ishihara ) and visual field .
Diseases: loss of central visual acuity , colour vision ( ishihara ) and visual field"	"Sentence: All 3 patients had loss of central visual acuity , colour vision ( Ishihara ) and visual field .
Diseases:"
2397	The visual field loss had a bitemporal flavour , suggesting involvement of the optic chiasm .	O B I I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	['visual field loss']	1	3	"Sentence: The visual field loss had a bitemporal flavour , suggesting involvement of the optic chiasm .
Diseases: visual field loss"	"Sentence: The visual field loss had a bitemporal flavour , suggesting involvement of the optic chiasm .
Diseases:"
2398	TREATMENT :	O O	O O	[]	0	0	"Sentence: TREATMENT :
Diseases: "	"Sentence: TREATMENT :
Diseases:"
2399	Despite stopping ethambutol on diagnosis , visual function continued to deteriorate for a few months .	O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: Despite stopping ethambutol on diagnosis , visual function continued to deteriorate for a few months .
Diseases: "	"Sentence: Despite stopping ethambutol on diagnosis , visual function continued to deteriorate for a few months .
Diseases:"
2400	Subsequent improvement was mild in 2 cases .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: Subsequent improvement was mild in 2 cases .
Diseases: "	"Sentence: Subsequent improvement was mild in 2 cases .
Diseases:"
2401	In the third case , visual acuity and colour vision normalised but the optic discs were pale .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the third case , visual acuity and colour vision normalised but the optic discs were pale .
Diseases: "	"Sentence: In the third case , visual acuity and colour vision normalised but the optic discs were pale .
Diseases:"
2402	OUTCOME :	O O	O O	[]	0	0	"Sentence: OUTCOME :
Diseases: "	"Sentence: OUTCOME :
Diseases:"
2403	All 3 patients had some permanent loss of visual function .	O O O O O O B I I I O	O O O O O O O O O O O	['loss of visual function']	1	4	"Sentence: All 3 patients had some permanent loss of visual function .
Diseases: loss of visual function"	"Sentence: All 3 patients had some permanent loss of visual function .
Diseases:"
2404	CONCLUSIONS : Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow - up .	O O O O O O O O B I O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O O O	['visual loss']	1	2	"Sentence: CONCLUSIONS : Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow - up .
Diseases: visual loss"	"Sentence: CONCLUSIONS : Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow - up .
Diseases:"
2405	The author postulates that in cases of ethambutol associated chiasmopathy , ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The author postulates that in cases of ethambutol associated chiasmopathy , ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm .
Diseases: "	"Sentence: The author postulates that in cases of ethambutol associated chiasmopathy , ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm .
Diseases:"
2406	Tolerability of nimesulide and paracetamol in patients with NSAID - induced urticaria / angioedema .	O O O O O O O O O O O B O B O	O O B O B O O O O O O O O O O	['urticaria', 'angioedema']	2	8	"Sentence: Tolerability of nimesulide and paracetamol in patients with NSAID - induced urticaria / angioedema .
Diseases: urticaria, angioedema"	"Sentence: Tolerability of nimesulide and paracetamol in patients with NSAID - induced urticaria / angioedema .
Diseases:"
2407	Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous , respiratory and anaphylactoid reactions induced by nonsteroidal anti - inflammatory drugs ( NSAIDs ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O B O O O O O O O O O O O B I I O O O O O O	[]	0	0	"Sentence: Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous , respiratory and anaphylactoid reactions induced by nonsteroidal anti - inflammatory drugs ( NSAIDs ) .
Diseases: "	"Sentence: Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous , respiratory and anaphylactoid reactions induced by nonsteroidal anti - inflammatory drugs ( NSAIDs ) .
Diseases:"
2408	In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well - documented history of NSAID - induced urticaria / angioedema .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O	O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O	['urticaria', 'angioedema']	2	8	"Sentence: In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well - documented history of NSAID - induced urticaria / angioedema .
Diseases: urticaria, angioedema"	"Sentence: In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well - documented history of NSAID - induced urticaria / angioedema .
Diseases:"
2409	Furthermore , we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O B O	[]	0	0	"Sentence: Furthermore , we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide .
Diseases: "	"Sentence: Furthermore , we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide .
Diseases:"
2410	A single - placebo - controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID - induced urticaria / angioedema .	O O O O O O O O O O O O O O O O O O O O O O O O O B O B O	O O O O O O O O O O B O B O O O O O O O O O O O O O O O O	['urticaria', 'angioedema']	2	8	"Sentence: A single - placebo - controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID - induced urticaria / angioedema .
Diseases: urticaria, angioedema"	"Sentence: A single - placebo - controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID - induced urticaria / angioedema .
Diseases:"
2411	A total of 75 / 829 ( 9 . 4 % ) patients experienced reactions to nimesulide or paracetamol .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O B O	[]	0	0	"Sentence: A total of 75 / 829 ( 9 . 4 % ) patients experienced reactions to nimesulide or paracetamol .
Diseases: "	"Sentence: A total of 75 / 829 ( 9 . 4 % ) patients experienced reactions to nimesulide or paracetamol .
Diseases:"
2412	Of the 715 patients tested with nimesulide 62 ( 8 . 6 % ) showed a positive test , while of 114 subjects submitted to the challenge with paracetamol , 13 ( 9 . 6 % ) did not tolerate this drug .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of the 715 patients tested with nimesulide 62 ( 8 . 6 % ) showed a positive test , while of 114 subjects submitted to the challenge with paracetamol , 13 ( 9 . 6 % ) did not tolerate this drug .
Diseases: "	"Sentence: Of the 715 patients tested with nimesulide 62 ( 8 . 6 % ) showed a positive test , while of 114 subjects submitted to the challenge with paracetamol , 13 ( 9 . 6 % ) did not tolerate this drug .
Diseases:"
2413	Furthermore , 18 . 28 % of patients with a history of chronic urticaria and 11 . 8 % of subjects with an history of NSAID - induced urticaria / angioedema or angioedema alone ( with or without chronic urticaria ) resulted to be intolerant to alternative drugs .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O B O B O B O O O O O O B O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['urticaria', 'angioedema']	2	8	"Sentence: Furthermore , 18 . 28 % of patients with a history of chronic urticaria and 11 . 8 % of subjects with an history of NSAID - induced urticaria / angioedema or angioedema alone ( with or without chronic urticaria ) resulted to be intolerant to alternative drugs .
Diseases: urticaria, angioedema"	"Sentence: Furthermore , 18 . 28 % of patients with a history of chronic urticaria and 11 . 8 % of subjects with an history of NSAID - induced urticaria / angioedema or angioedema alone ( with or without chronic urticaria ) resulted to be intolerant to alternative drugs .
Diseases:"
2414	Taken together , our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria / angioedema caused by NSAIDs .	O O O O O O O O O O O O O O O O O B O B O O O O	O O O O O O O O O O B O B O O O O O O O O O B O	['urticaria', 'angioedema']	2	8	"Sentence: Taken together , our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria / angioedema caused by NSAIDs .
Diseases: urticaria, angioedema"	"Sentence: Taken together , our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria / angioedema caused by NSAIDs .
Diseases:"
2415	However , the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and , above all , by a history of NSAID - induced angioedema .	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['urticaria', 'angioedema']	2	8	"Sentence: However , the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and , above all , by a history of NSAID - induced angioedema .
Diseases: urticaria, angioedema"	"Sentence: However , the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and , above all , by a history of NSAID - induced angioedema .
Diseases:"
2416	Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs .	O O O O B I O O O O O O O	O O B O O O O O O O O O O	['atrial fibrillation']	1	5	"Sentence: Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs .
Diseases: atrial fibrillation"	"Sentence: Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs .
Diseases:"
2417	Atrial tachycardia - induced remodeling promotes the occurrence and maintenance of atrial fibrillation ( AF ) and decreases L - type Ca ( 2 + ) current .	B I O O O O O O O O O B I O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B O O O O O O	['af', 'atrial fibrillation', 'atrial tachycardia']	3	14	"Sentence: Atrial tachycardia - induced remodeling promotes the occurrence and maintenance of atrial fibrillation ( AF ) and decreases L - type Ca ( 2 + ) current .
Diseases: af, atrial fibrillation, atrial tachycardia"	"Sentence: Atrial tachycardia - induced remodeling promotes the occurrence and maintenance of atrial fibrillation ( AF ) and decreases L - type Ca ( 2 + ) current .
Diseases:"
2418	There is also a clinical suggestion that acute L - type Ca ( 2 ) channel blockade can promote AF , consistent with an AF promoting effect of Ca ( 2 + ) channel inhibition .	O O O O O O O O O O O O O O O O O O O B O O O O B O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O B O O O O O O O	['af']	1	1	"Sentence: There is also a clinical suggestion that acute L - type Ca ( 2 ) channel blockade can promote AF , consistent with an AF promoting effect of Ca ( 2 + ) channel inhibition .
Diseases: af"	"Sentence: There is also a clinical suggestion that acute L - type Ca ( 2 ) channel blockade can promote AF , consistent with an AF promoting effect of Ca ( 2 + ) channel inhibition .
Diseases:"
2419	METHODS : To evaluate the potential mechanisms of AF promotion by Ca ( 2 + ) channel blockers , we administered verapamil to morphine - chloralose anesthetized dogs .	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O B O B O O O O O	['af']	1	1	"Sentence: METHODS : To evaluate the potential mechanisms of AF promotion by Ca ( 2 + ) channel blockers , we administered verapamil to morphine - chloralose anesthetized dogs .
Diseases: af"	"Sentence: METHODS : To evaluate the potential mechanisms of AF promotion by Ca ( 2 + ) channel blockers , we administered verapamil to morphine - chloralose anesthetized dogs .
Diseases:"
2420	Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments .	O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O B O B O O O O O O	[]	0	0	"Sentence: Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments .
Diseases: "	"Sentence: Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments .
Diseases:"
2421	Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF .	O O O O O O O O O O O O B O	O O O O O O O O O O O O O O	['af']	1	1	"Sentence: Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF .
Diseases: af"	"Sentence: Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF .
Diseases:"
2422	RESULTS : Verapamil caused AF promotion in six dogs , increasing mean duration of AF induced by burst pacing , from 8 + / - 4 s ( mean + / - S . E . ) to 95 + / - 39 s ( P < 0 . 01 vs . control ) at a loading dose of 0 . 1 mg / kg and 228 + / - 101 s ( P < 0 . 0005 vs . control ) at a dose of 0 . 2 mg / kg .	O O O O B O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['af']	1	1	"Sentence: RESULTS : Verapamil caused AF promotion in six dogs , increasing mean duration of AF induced by burst pacing , from 8 + / - 4 s ( mean + / - S . E . ) to 95 + / - 39 s ( P < 0 . 01 vs . control ) at a loading dose of 0 . 1 mg / kg and 228 + / - 101 s ( P < 0 . 0005 vs . control ) at a dose of 0 . 2 mg / kg .
Diseases: af"	"Sentence: RESULTS : Verapamil caused AF promotion in six dogs , increasing mean duration of AF induced by burst pacing , from 8 + / - 4 s ( mean + / - S . E . ) to 95 + / - 39 s ( P < 0 . 01 vs . control ) at a loading dose of 0 . 1 mg / kg and 228 + / - 101 s ( P < 0 . 0005 vs . control ) at a dose of 0 . 2 mg / kg .
Diseases:"
2423	Underlying electrophysiological mechanisms were studied in detail in five additional dogs under control conditions and in the presence of the higher dose of verapamil .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: Underlying electrophysiological mechanisms were studied in detail in five additional dogs under control conditions and in the presence of the higher dose of verapamil .
Diseases: "	"Sentence: Underlying electrophysiological mechanisms were studied in detail in five additional dogs under control conditions and in the presence of the higher dose of verapamil .
Diseases:"
2424	In these experiments , verapamil shortened mean effective refractory period ( ERP ) from 122 + / - 5 to 114 + / - 4 ms ( P < 0 . 02 ) at a cycle length of 300 ms , decreased ERP heterogeneity ( from 15 + / - 1 to 10 + / - 1 % , P < 0 . 05 ) , heterogeneously accelerated atrial conduction and decreased the cycle length of AF ( 94 + / - 4 to 84 + / - 3 ms , P < 0 . 005 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['af']	1	1	"Sentence: In these experiments , verapamil shortened mean effective refractory period ( ERP ) from 122 + / - 5 to 114 + / - 4 ms ( P < 0 . 02 ) at a cycle length of 300 ms , decreased ERP heterogeneity ( from 15 + / - 1 to 10 + / - 1 % , P < 0 . 05 ) , heterogeneously accelerated atrial conduction and decreased the cycle length of AF ( 94 + / - 4 to 84 + / - 3 ms , P < 0 . 005 ) .
Diseases: af"	"Sentence: In these experiments , verapamil shortened mean effective refractory period ( ERP ) from 122 + / - 5 to 114 + / - 4 ms ( P < 0 . 02 ) at a cycle length of 300 ms , decreased ERP heterogeneity ( from 15 + / - 1 to 10 + / - 1 % , P < 0 . 05 ) , heterogeneously accelerated atrial conduction and decreased the cycle length of AF ( 94 + / - 4 to 84 + / - 3 ms , P < 0 . 005 ) .
Diseases:"
2425	Diltiazem did not affect ERP , AF cycle length or AF duration , but produced conduction acceleration similar to that caused by verapamil ( n = 5 ) .	O O O O O O B O O O B O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O B O O O O O O	['af']	1	1	"Sentence: Diltiazem did not affect ERP , AF cycle length or AF duration , but produced conduction acceleration similar to that caused by verapamil ( n = 5 ) .
Diseases: af"	"Sentence: Diltiazem did not affect ERP , AF cycle length or AF duration , but produced conduction acceleration similar to that caused by verapamil ( n = 5 ) .
Diseases:"
2426	In the presence of autonomic blockade , verapamil failed to promote AF and increased , rather than decreasing , refractoriness .	O O O O O O O O O O O B O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O	['af']	1	1	"Sentence: In the presence of autonomic blockade , verapamil failed to promote AF and increased , rather than decreasing , refractoriness .
Diseases: af"	"Sentence: In the presence of autonomic blockade , verapamil failed to promote AF and increased , rather than decreasing , refractoriness .
Diseases:"
2427	Neither verapamil nor diltiazem affected atrial conduction in the presence of autonomic blockade .	O O O O O O O O O O O O O O	O B O B O O O O O O O O O O	[]	0	0	"Sentence: Neither verapamil nor diltiazem affected atrial conduction in the presence of autonomic blockade .
Diseases: "	"Sentence: Neither verapamil nor diltiazem affected atrial conduction in the presence of autonomic blockade .
Diseases:"
2428	Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle .	O O O O O O B O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O	['af']	1	1	"Sentence: Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle .
Diseases: af"	"Sentence: Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle .
Diseases:"
2429	CONCLUSIONS : Verapamil promotes AF in normal dogs by promoting multiple circuit reentry , an effect dependent on intact autonomic tone and not shared by diltiazem .	O O O O B O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O B O	['af']	1	1	"Sentence: CONCLUSIONS : Verapamil promotes AF in normal dogs by promoting multiple circuit reentry , an effect dependent on intact autonomic tone and not shared by diltiazem .
Diseases: af"	"Sentence: CONCLUSIONS : Verapamil promotes AF in normal dogs by promoting multiple circuit reentry , an effect dependent on intact autonomic tone and not shared by diltiazem .
Diseases:"
2430	Hypotension , bradycardia , and asystole after high - dose intravenous methylprednisolone in a monitored patient .	B O B O O B O O O O O O O O O O O	O O O O O O O O O O O B O O O O O	['bradycardia', 'hypotension', 'asystole']	3	12	"Sentence: Hypotension , bradycardia , and asystole after high - dose intravenous methylprednisolone in a monitored patient .
Diseases: bradycardia, hypotension, asystole"	"Sentence: Hypotension , bradycardia , and asystole after high - dose intravenous methylprednisolone in a monitored patient .
Diseases:"
2431	We report a case of hypotension , bradycardia , and asystole after intravenous administration of high - dose methylprednisolone in a 73 - year - old patient who underwent electrocardiographic ( ECG ) monitoring throughout the episode .	O O O O O B O B O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['bradycardia', 'hypotension', 'asystole']	3	12	"Sentence: We report a case of hypotension , bradycardia , and asystole after intravenous administration of high - dose methylprednisolone in a 73 - year - old patient who underwent electrocardiographic ( ECG ) monitoring throughout the episode .
Diseases: bradycardia, hypotension, asystole"	"Sentence: We report a case of hypotension , bradycardia , and asystole after intravenous administration of high - dose methylprednisolone in a 73 - year - old patient who underwent electrocardiographic ( ECG ) monitoring throughout the episode .
Diseases:"
2432	There was a history of ischemic cardiac disease 9 years earlier .	O O O O O B B I O O O O	O O O O O O O O O O O O	['cardiac disease', 'ischemic']	2	7	"Sentence: There was a history of ischemic cardiac disease 9 years earlier .
Diseases: cardiac disease, ischemic"	"Sentence: There was a history of ischemic cardiac disease 9 years earlier .
Diseases:"
2433	The patient was admitted with a pulmonary - renal syndrome with hemoptysis , rapidly progressive renal failure , and hypoxemia that required mechanical ventilation in the intensive care unit .	O O O O O O B I I I O B O O O B I O O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypoxemia', 'hemoptysis', 'pulmonary - renal syndrome', 'renal failure']	4	18	"Sentence: The patient was admitted with a pulmonary - renal syndrome with hemoptysis , rapidly progressive renal failure , and hypoxemia that required mechanical ventilation in the intensive care unit .
Diseases: hypoxemia, hemoptysis, pulmonary - renal syndrome, renal failure"	"Sentence: The patient was admitted with a pulmonary - renal syndrome with hemoptysis , rapidly progressive renal failure , and hypoxemia that required mechanical ventilation in the intensive care unit .
Diseases:"
2434	After receiving advanced cardiopulmonary resuscitation , the patient recovered cardiac rhythm .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: After receiving advanced cardiopulmonary resuscitation , the patient recovered cardiac rhythm .
Diseases: "	"Sentence: After receiving advanced cardiopulmonary resuscitation , the patient recovered cardiac rhythm .
Diseases:"
2435	The ECG showed a junctional rhythm without ventricular arrhythmia .	O O O O O O O B I O	O O O O O O O O O O	['ventricular arrhythmia']	1	6	"Sentence: The ECG showed a junctional rhythm without ventricular arrhythmia .
Diseases: ventricular arrhythmia"	"Sentence: The ECG showed a junctional rhythm without ventricular arrhythmia .
Diseases:"
2436	This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone ( IVMP ) .	O O O O O O O O B I O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O B O O	['sudden death']	1	3	"Sentence: This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone ( IVMP ) .
Diseases: sudden death"	"Sentence: This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone ( IVMP ) .
Diseases:"
2437	These mechanisms are not well understood because , in most cases , the patients were not monitored at the moment of the event .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These mechanisms are not well understood because , in most cases , the patients were not monitored at the moment of the event .
Diseases: "	"Sentence: These mechanisms are not well understood because , in most cases , the patients were not monitored at the moment of the event .
Diseases:"
2438	Rapid infusion and underlying cardiac disease were important risk factors in the case reported here , and the authors discount ventricular arrhythmia as the main mechanism .	O O O O B I O O O O O O O O O O O O O O B I O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cardiac disease', 'ventricular arrhythmia']	2	10	"Sentence: Rapid infusion and underlying cardiac disease were important risk factors in the case reported here , and the authors discount ventricular arrhythmia as the main mechanism .
Diseases: cardiac disease, ventricular arrhythmia"	"Sentence: Rapid infusion and underlying cardiac disease were important risk factors in the case reported here , and the authors discount ventricular arrhythmia as the main mechanism .
Diseases:"
2439	Lifetime treatment of mice with azidothymidine ( AZT ) produces myelodysplasia .	O O O O O O O O O O B O	O O O O O B O B O O O O	['myelodysplasia']	1	6	"Sentence: Lifetime treatment of mice with azidothymidine ( AZT ) produces myelodysplasia .
Diseases: myelodysplasia"	"Sentence: Lifetime treatment of mice with azidothymidine ( AZT ) produces myelodysplasia .
Diseases:"
2440	AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy .	O O O O B I O B O O O O O O O	B O O O O O O O O O O O B O O	['aids', 'macrocytic anemia']	2	8	"Sentence: AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy .
Diseases: aids, macrocytic anemia"	"Sentence: AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy .
Diseases:"
2441	It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O B O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation .
Diseases: "	"Sentence: It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation .
Diseases:"
2442	CBA / Ca male mice started on AZT 0 . 75 mg / ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0 . 5 mg / ml H2O for a group , another group removed from AZT to see recovery , and third group remained on 0 . 75 mg .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: CBA / Ca male mice started on AZT 0 . 75 mg / ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0 . 5 mg / ml H2O for a group , another group removed from AZT to see recovery , and third group remained on 0 . 75 mg .
Diseases: "	"Sentence: CBA / Ca male mice started on AZT 0 . 75 mg / ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0 . 5 mg / ml H2O for a group , another group removed from AZT to see recovery , and third group remained on 0 . 75 mg .
Diseases:"
2443	At 687 days mice that had been on 0 . 75 mg had average platelet counts of 2 . 5 x 10 ( 6 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At 687 days mice that had been on 0 . 75 mg had average platelet counts of 2 . 5 x 10 ( 6 ) .
Diseases: "	"Sentence: At 687 days mice that had been on 0 . 75 mg had average platelet counts of 2 . 5 x 10 ( 6 ) .
Diseases:"
2444	Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome ( MDS ) .	O O O O O O O O O B O O O O B I O B O O	O O O O O O O O O O O O O O O O O O O O	['mds', 'myelodysplastic syndrome', 'thrombocytopenia']	3	18	"Sentence: Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome ( MDS ) .
Diseases: mds, myelodysplastic syndrome, thrombocytopenia"	"Sentence: Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome ( MDS ) .
Diseases:"
2445	A variety of histological patterns was observed .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: A variety of histological patterns was observed .
Diseases: "	"Sentence: A variety of histological patterns was observed .
Diseases:"
2446	There were two cases of hypocellular myelodysplasia , two cases of hypersegmented myelodysplastic granulocytosis , two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei , one case of megakaryocytic myelosis associated with a hyperplastic marrow , dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis , hemosiderosis and a hypocellular marrow .	O O O O O O B O O O O O B O O O O O O O O O O O O O O O O O O O O O O B I O B O O B I O O O O B O B O B O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['myelodysplasia', 'hemosiderosis', 'hypocellular marrow', 'hyperplastic marrow', 'dyserythropoiesis', 'myelodysplastic', 'dysmyelopoiesis']	7	44	"Sentence: There were two cases of hypocellular myelodysplasia , two cases of hypersegmented myelodysplastic granulocytosis , two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei , one case of megakaryocytic myelosis associated with a hyperplastic marrow , dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis , hemosiderosis and a hypocellular marrow .
Diseases: myelodysplasia, hemosiderosis, hypocellular marrow, hyperplastic marrow, dyserythropoiesis, myelodysplastic, dysmyelopoiesis"	"Sentence: There were two cases of hypocellular myelodysplasia , two cases of hypersegmented myelodysplastic granulocytosis , two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei , one case of megakaryocytic myelosis associated with a hyperplastic marrow , dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis , hemosiderosis and a hypocellular marrow .
Diseases:"
2447	Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells , which is known to be seen commonly in the myelodysplastic syndrome .	O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['myelodysplastic syndrome']	1	7	"Sentence: Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells , which is known to be seen commonly in the myelodysplastic syndrome .
Diseases: myelodysplastic syndrome"	"Sentence: Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells , which is known to be seen commonly in the myelodysplastic syndrome .
Diseases:"
2448	Influence of diet free of NAD - precursors on acetaminophen hepatotoxicity in mice .	O O O O O O O O O O B O O O	O O O O O B O O O B O O O O	['hepatotoxicity']	1	4	"Sentence: Influence of diet free of NAD - precursors on acetaminophen hepatotoxicity in mice .
Diseases: hepatotoxicity"	"Sentence: Influence of diet free of NAD - precursors on acetaminophen hepatotoxicity in mice .
Diseases:"
2449	Recently , we demonstrated the hepatoprotective effects of nicotinic acid amide , a selective inhibitor of poly ( ADP - ribose ) polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from acetaminophen ( AAP ) - hepatitis , suggesting that the AAP - induced liver injury involves a step which depends on adenoribosylation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O B I O O O O O O O O	O O O O O O O O B I I O O O O O B I I I I I O O O O O O O O O O O O O O O O O B O B O O O O O O O B O O O O O O O O O O O O	['hepatitis', 'liver injury']	2	6	"Sentence: Recently , we demonstrated the hepatoprotective effects of nicotinic acid amide , a selective inhibitor of poly ( ADP - ribose ) polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from acetaminophen ( AAP ) - hepatitis , suggesting that the AAP - induced liver injury involves a step which depends on adenoribosylation .
Diseases: hepatitis, liver injury"	"Sentence: Recently , we demonstrated the hepatoprotective effects of nicotinic acid amide , a selective inhibitor of poly ( ADP - ribose ) polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from acetaminophen ( AAP ) - hepatitis , suggesting that the AAP - induced liver injury involves a step which depends on adenoribosylation .
Diseases:"
2450	The present study investigates the effects of a diet free of precursors of NAD , the substrate on which PARP acts , in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O B O O O O O O O B O O O O O	['hepatitis']	1	3	"Sentence: The present study investigates the effects of a diet free of precursors of NAD , the substrate on which PARP acts , in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals .
Diseases: hepatitis"	"Sentence: The present study investigates the effects of a diet free of precursors of NAD , the substrate on which PARP acts , in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals .
Diseases:"
2451	Liver injuries were quantified as serum activities of glutamate - oxaloacetate transaminase ( GOT ) and glutamate - pyruvate transaminase ( GPT ) .	B I O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O B O O O O O B O B O O O O O	['liver injuries']	1	3	"Sentence: Liver injuries were quantified as serum activities of glutamate - oxaloacetate transaminase ( GOT ) and glutamate - pyruvate transaminase ( GPT ) .
Diseases: liver injuries"	"Sentence: Liver injuries were quantified as serum activities of glutamate - oxaloacetate transaminase ( GOT ) and glutamate - pyruvate transaminase ( GPT ) .
Diseases:"
2452	While AAP caused a 117 - fold elevation of serum transaminase activities in mice kept on a standard laboratory diet , which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide ( NAA ) , adverse effects were noted in animals fed a diet free of precursors of NAD .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O O O O O O O O B O O O B I I O B O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: While AAP caused a 117 - fold elevation of serum transaminase activities in mice kept on a standard laboratory diet , which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide ( NAA ) , adverse effects were noted in animals fed a diet free of precursors of NAD .
Diseases: "	"Sentence: While AAP caused a 117 - fold elevation of serum transaminase activities in mice kept on a standard laboratory diet , which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide ( NAA ) , adverse effects were noted in animals fed a diet free of precursors of NAD .
Diseases:"
2453	In these animals , only minor increases of serum transaminase activities were measured in the presence of AAP , and unlike the exacerbation caused by ethanol in mice on a standard diet , the liver damage was inhibited by 50 % by ethanol .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O O B O O O O O O O O O O O O O O O O B O	['liver damage']	1	3	"Sentence: In these animals , only minor increases of serum transaminase activities were measured in the presence of AAP , and unlike the exacerbation caused by ethanol in mice on a standard diet , the liver damage was inhibited by 50 % by ethanol .
Diseases: liver damage"	"Sentence: In these animals , only minor increases of serum transaminase activities were measured in the presence of AAP , and unlike the exacerbation caused by ethanol in mice on a standard diet , the liver damage was inhibited by 50 % by ethanol .
Diseases:"
2454	A further 64 % reduction of hepatitis was observed , when NAA was given to ethanol / AAP - mice .	O O O O O O B O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O B O B O O O	['hepatitis']	1	3	"Sentence: A further 64 % reduction of hepatitis was observed , when NAA was given to ethanol / AAP - mice .
Diseases: hepatitis"	"Sentence: A further 64 % reduction of hepatitis was observed , when NAA was given to ethanol / AAP - mice .
Diseases:"
2455	Our results provide evidence that the AAP - induced hepatitis and its exacerbation by ethanol can either be reduced by end - product inhibition of PARP by NAA or by dietary depletion of the enzyme 's substrate NAD .	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O B O	['hepatitis']	1	3	"Sentence: Our results provide evidence that the AAP - induced hepatitis and its exacerbation by ethanol can either be reduced by end - product inhibition of PARP by NAA or by dietary depletion of the enzyme 's substrate NAD .
Diseases: hepatitis"	"Sentence: Our results provide evidence that the AAP - induced hepatitis and its exacerbation by ethanol can either be reduced by end - product inhibition of PARP by NAA or by dietary depletion of the enzyme 's substrate NAD .
Diseases:"
2456	We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic .	O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O	O O O O O O B O O O O O O O O O B O O O O O O O O O O O O O O O	['hepatic damage']	1	4	"Sentence: We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic .
Diseases: hepatic damage"	"Sentence: We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic .
Diseases:"
2457	Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias .	O O O O O O O B I O	O O O O B O O O O O	['ventricular arrhythmias']	1	6	"Sentence: Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias .
Diseases: ventricular arrhythmias"	"Sentence: Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias .
Diseases:"
2458	Using two - stage coronary ligation - , digitalis - , and adrenaline - induced canine ventricular arrhythmias , antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined .	O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O B O O O O	O O O O O O O O B O O O B O O O O O O O O O B O O O O O O O O O O O O O O O	['ventricular arrhythmias', 'arrhythmia']	2	11	"Sentence: Using two - stage coronary ligation - , digitalis - , and adrenaline - induced canine ventricular arrhythmias , antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined .
Diseases: ventricular arrhythmias, arrhythmia"	"Sentence: Using two - stage coronary ligation - , digitalis - , and adrenaline - induced canine ventricular arrhythmias , antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined .
Diseases:"
2459	Cibenzoline suppressed all the arrhythmias , and the minimum effective plasma concentrations for arrhythmias induced by 24 - h coronary ligation , 48 - h coronary ligation , digitalis , and adrenaline were 1 . 9 + / - 0 . 9	O O O O B O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O B O O O O O O O O O O	['arrhythmias']	1	4	"Sentence: Cibenzoline suppressed all the arrhythmias , and the minimum effective plasma concentrations for arrhythmias induced by 24 - h coronary ligation , 48 - h coronary ligation , digitalis , and adrenaline were 1 . 9 + / - 0 . 9
Diseases: arrhythmias"	"Sentence: Cibenzoline suppressed all the arrhythmias , and the minimum effective plasma concentrations for arrhythmias induced by 24 - h coronary ligation , 48 - h coronary ligation , digitalis , and adrenaline were 1 . 9 + / - 0 . 9
Diseases:"
2460	( by 8 mg / kg i . v . )	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: ( by 8 mg / kg i . v . )
Diseases: "	"Sentence: ( by 8 mg / kg i . v . )
Diseases:"
2461	, 1 . 6 + / - 0 . 5 ( by 8 mg / kg i . v . ) , 0 . 6 + / - 0 . 2 ( by 2 mg / kg i . v . ) , and 3 . 5 + / -	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: , 1 . 6 + / - 0 . 5 ( by 8 mg / kg i . v . ) , 0 . 6 + / - 0 . 2 ( by 2 mg / kg i . v . ) , and 3 . 5 + / -
Diseases: "	"Sentence: , 1 . 6 + / - 0 . 5 ( by 8 mg / kg i . v . ) , 0 . 6 + / - 0 . 2 ( by 2 mg / kg i . v . ) , and 3 . 5 + / -
Diseases:"
2462	1 . 3 ( by 5 mg / kg i . v . )	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: 1 . 3 ( by 5 mg / kg i . v . )
Diseases: "	"Sentence: 1 . 3 ( by 5 mg / kg i . v . )
Diseases:"
2463	micrograms / ml , respectively ( mean + / - SDM , n = 6 - 7 ) .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: micrograms / ml , respectively ( mean + / - SDM , n = 6 - 7 ) .
Diseases: "	"Sentence: micrograms / ml , respectively ( mean + / - SDM , n = 6 - 7 ) .
Diseases:"
2464	The concentration for adrenaline - induced arrhythmia was significantly higher than those for the other types of arrhythmias .	O O O O O O B O O O O O O O O O O B O	O O O B O O O O O O O O O O O O O O O	['arrhythmias', 'arrhythmia']	2	9	"Sentence: The concentration for adrenaline - induced arrhythmia was significantly higher than those for the other types of arrhythmias .
Diseases: arrhythmias, arrhythmia"	"Sentence: The concentration for adrenaline - induced arrhythmia was significantly higher than those for the other types of arrhythmias .
Diseases:"
2465	This pharmacological profile is similar to those of mexiletine and tocainide , and all three drugs have central nervous system ( CNS ) stimulant action .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This pharmacological profile is similar to those of mexiletine and tocainide , and all three drugs have central nervous system ( CNS ) stimulant action .
Diseases: "	"Sentence: This pharmacological profile is similar to those of mexiletine and tocainide , and all three drugs have central nervous system ( CNS ) stimulant action .
Diseases:"
2466	Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs , its clinical usefulness is expected .	O O O O O B O O O B O O O O O O O O O O O O O B O O O O O O O O	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['depressive', 'hypotensive', 'arrhythmia']	3	10	"Sentence: Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs , its clinical usefulness is expected .
Diseases: depressive, hypotensive, arrhythmia"	"Sentence: Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs , its clinical usefulness is expected .
Diseases:"
2467	Immunopathology of penicillamine - induced glomerular disease .	O O O O O B I O	O O B O O O O O	['glomerular disease']	1	3	"Sentence: Immunopathology of penicillamine - induced glomerular disease .
Diseases: glomerular disease"	"Sentence: Immunopathology of penicillamine - induced glomerular disease .
Diseases:"
2468	Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D - penicillamine .	O O O B I O O B O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B I I O	['rheumatoid arthritis', 'proteinuria']	2	8	"Sentence: Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D - penicillamine .
Diseases: rheumatoid arthritis, proteinuria"	"Sentence: Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D - penicillamine .
Diseases:"
2469	Light microscopy of renal biopsy samples showed minimal glomerular capillary wall thickening and mesangial matrix increase , or no departure from normal .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Light microscopy of renal biopsy samples showed minimal glomerular capillary wall thickening and mesangial matrix increase , or no departure from normal .
Diseases: "	"Sentence: Light microscopy of renal biopsy samples showed minimal glomerular capillary wall thickening and mesangial matrix increase , or no departure from normal .
Diseases:"
2470	Electron microscopy , however , revealed subepithelial electron - dense deposits , fusion of epithelial cell foot processes , and evidence of mesangial cell hyperactivity .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Electron microscopy , however , revealed subepithelial electron - dense deposits , fusion of epithelial cell foot processes , and evidence of mesangial cell hyperactivity .
Diseases: "	"Sentence: Electron microscopy , however , revealed subepithelial electron - dense deposits , fusion of epithelial cell foot processes , and evidence of mesangial cell hyperactivity .
Diseases:"
2471	Immunofluorescence microscopy demonstrated granular capillary wall deposits of IgG and C3 .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: Immunofluorescence microscopy demonstrated granular capillary wall deposits of IgG and C3 .
Diseases: "	"Sentence: Immunofluorescence microscopy demonstrated granular capillary wall deposits of IgG and C3 .
Diseases:"
2472	The findings were similar to those in early membranous glomerulonephritis , differences being observed however in the results of staining for the early - acting complement components C1q and C4 .	O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['membranous glomerulonephritis']	1	10	"Sentence: The findings were similar to those in early membranous glomerulonephritis , differences being observed however in the results of staining for the early - acting complement components C1q and C4 .
Diseases: membranous glomerulonephritis"	"Sentence: The findings were similar to those in early membranous glomerulonephritis , differences being observed however in the results of staining for the early - acting complement components C1q and C4 .
Diseases:"
2473	It is tentatively concluded that complement was activated by the classical pathway .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: It is tentatively concluded that complement was activated by the classical pathway .
Diseases: "	"Sentence: It is tentatively concluded that complement was activated by the classical pathway .
Diseases:"
2474	Ventricular fibrillation from diatrizoate with and without chelating agents .	B I O O O O O O O O	O O O B O O O O O O	['ventricular fibrillation']	1	5	"Sentence: Ventricular fibrillation from diatrizoate with and without chelating agents .
Diseases: ventricular fibrillation"	"Sentence: Ventricular fibrillation from diatrizoate with and without chelating agents .
Diseases:"
2475	The toxicity of Renografin 76 % was compared with that of Hypaque 76 % by selective injection of each into the right coronary artery of dogs .	O B O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O B O O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: The toxicity of Renografin 76 % was compared with that of Hypaque 76 % by selective injection of each into the right coronary artery of dogs .
Diseases: toxicity"	"Sentence: The toxicity of Renografin 76 % was compared with that of Hypaque 76 % by selective injection of each into the right coronary artery of dogs .
Diseases:"
2476	Renografin contains the chelating agents sodium citrate and disodium edetate , while Hypaque contains calcium disodium edetate and no sodium citrate .	O O O O O O O O O O O O O O O O O O O O O O	B O O O O B I O B I O O B O B I I O O B I O	[]	0	0	"Sentence: Renografin contains the chelating agents sodium citrate and disodium edetate , while Hypaque contains calcium disodium edetate and no sodium citrate .
Diseases: "	"Sentence: Renografin contains the chelating agents sodium citrate and disodium edetate , while Hypaque contains calcium disodium edetate and no sodium citrate .
Diseases:"
2477	Ventricular fibrillation occurred significantly more often with Renografin , suggesting that chelating agents contribute to toxicity in coronary angiography .	B I O O O O O O O O O O O O O B O O O O	O O O O O O O B O O O O O O O O O O O O	['ventricular fibrillation', 'toxicity']	2	7	"Sentence: Ventricular fibrillation occurred significantly more often with Renografin , suggesting that chelating agents contribute to toxicity in coronary angiography .
Diseases: ventricular fibrillation, toxicity"	"Sentence: Ventricular fibrillation occurred significantly more often with Renografin , suggesting that chelating agents contribute to toxicity in coronary angiography .
Diseases:"
2478	Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin - associated intracerebral hemorrhage .	O O O O O B O O O O O O O O O B I O	O O O O O O O O O O O O B O O O O O	['hemorrhage', 'intracerebral hemorrhage']	2	11	"Sentence: Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin - associated intracerebral hemorrhage .
Diseases: hemorrhage, intracerebral hemorrhage"	"Sentence: Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin - associated intracerebral hemorrhage .
Diseases:"
2479	Warfarin - associated intracerebral hemorrhage ( W - ICH ) is a severe type of stroke .	O O O B I O O O B O O O O O O B O	B O O O O O O O O O O O O O O O O	['stroke', 'ich', 'intracerebral hemorrhage']	3	11	"Sentence: Warfarin - associated intracerebral hemorrhage ( W - ICH ) is a severe type of stroke .
Diseases: stroke, ich, intracerebral hemorrhage"	"Sentence: Warfarin - associated intracerebral hemorrhage ( W - ICH ) is a severe type of stroke .
Diseases:"
2480	There is no consensus on the optimal treatment for W - ICH .	O O O O O O O O O O O B O	O O O O O O O O O O O O O	['ich']	1	1	"Sentence: There is no consensus on the optimal treatment for W - ICH .
Diseases: ich"	"Sentence: There is no consensus on the optimal treatment for W - ICH .
Diseases:"
2481	Using a mouse model , we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate ( PCC ) can reduce hemorrhagic blood volume .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Using a mouse model , we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate ( PCC ) can reduce hemorrhagic blood volume .
Diseases: "	"Sentence: Using a mouse model , we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate ( PCC ) can reduce hemorrhagic blood volume .
Diseases:"
2482	Male CD - 1 mice were treated with warfarin ( 2 mg / kg over 24 h ) , resulting in a mean ( + / - s . d . )	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Male CD - 1 mice were treated with warfarin ( 2 mg / kg over 24 h ) , resulting in a mean ( + / - s . d . )
Diseases: "	"Sentence: Male CD - 1 mice were treated with warfarin ( 2 mg / kg over 24 h ) , resulting in a mean ( + / - s . d . )
Diseases:"
2483	International Normalized Ratio of 3 . 5 + / - 0 . 9 .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: International Normalized Ratio of 3 . 5 + / - 0 . 9 .
Diseases: "	"Sentence: International Normalized Ratio of 3 . 5 + / - 0 . 9 .
Diseases:"
2484	First , we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: First , we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice .
Diseases: "	"Sentence: First , we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice .
Diseases:"
2485	Second , a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum .	O O O O O O O O O O O B O O O O O	O O O O O O O O O O O O O O O O O	['hemorrhage']	1	4	"Sentence: Second , a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum .
Diseases: hemorrhage"	"Sentence: Second , a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum .
Diseases:"
2486	Forty - five minutes later , the animals were randomly treated with PCC ( 100 U / kg ) or saline i . v .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: Forty - five minutes later , the animals were randomly treated with PCC ( 100 U / kg ) or saline i . v .
Diseases: "	"Sentence: Forty - five minutes later , the animals were randomly treated with PCC ( 100 U / kg ) or saline i . v .
Diseases:"
2487	( n = 12 per group ) .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: ( n = 12 per group ) .
Diseases: "	"Sentence: ( n = 12 per group ) .
Diseases:"
2488	Twenty - four hours after hemorrhage induction , hemorrhagic blood volume was quantified using a photometric hemoglobin assay .	O O O O O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	['hemorrhage']	1	4	"Sentence: Twenty - four hours after hemorrhage induction , hemorrhagic blood volume was quantified using a photometric hemoglobin assay .
Diseases: hemorrhage"	"Sentence: Twenty - four hours after hemorrhage induction , hemorrhagic blood volume was quantified using a photometric hemoglobin assay .
Diseases:"
2489	The mean hemorrhagic blood volume was reduced in PCC - treated animals ( 6 . 5 + / - 3 . 1 microL ) compared with saline controls ( 15 . 3 + / - 11 . 2 microL , P = 0 . 015 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mean hemorrhagic blood volume was reduced in PCC - treated animals ( 6 . 5 + / - 3 . 1 microL ) compared with saline controls ( 15 . 3 + / - 11 . 2 microL , P = 0 . 015 ) .
Diseases: "	"Sentence: The mean hemorrhagic blood volume was reduced in PCC - treated animals ( 6 . 5 + / - 3 . 1 microL ) compared with saline controls ( 15 . 3 + / - 11 . 2 microL , P = 0 . 015 ) .
Diseases:"
2490	In the saline group , 45 % of the mice developed large hematomas ( i . e . , > 15 microL ) .	O O O O O O O O O O O O B O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	['hematomas']	1	2	"Sentence: In the saline group , 45 % of the mice developed large hematomas ( i . e . , > 15 microL ) .
Diseases: hematomas"	"Sentence: In the saline group , 45 % of the mice developed large hematomas ( i . e . , > 15 microL ) .
Diseases:"
2491	In contrast , such extensive lesions were never found in the PCC group .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast , such extensive lesions were never found in the PCC group .
Diseases: "	"Sentence: In contrast , such extensive lesions were never found in the PCC group .
Diseases:"
2492	We provide experimental data suggesting PCC to be an effective acute treatment for W - ICH in terms of reducing hemorrhagic blood volume .	O O O O O O O O O O O O O O O B O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O	['ich']	1	1	"Sentence: We provide experimental data suggesting PCC to be an effective acute treatment for W - ICH in terms of reducing hemorrhagic blood volume .
Diseases: ich"	"Sentence: We provide experimental data suggesting PCC to be an effective acute treatment for W - ICH in terms of reducing hemorrhagic blood volume .
Diseases:"
2493	Future studies are needed to assess the therapeutic potential emerging from our finding for human W - ICH .	O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O	['ich']	1	1	"Sentence: Future studies are needed to assess the therapeutic potential emerging from our finding for human W - ICH .
Diseases: ich"	"Sentence: Future studies are needed to assess the therapeutic potential emerging from our finding for human W - ICH .
Diseases:"
2494	Impact of alcohol exposure after pregnancy recognition on ultrasonographic fetal growth measures .	O O O O O O O O O O O O O	O O B O O O O O O O O O O	[]	0	0	"Sentence: Impact of alcohol exposure after pregnancy recognition on ultrasonographic fetal growth measures .
Diseases: "	"Sentence: Impact of alcohol exposure after pregnancy recognition on ultrasonographic fetal growth measures .
Diseases:"
2495	More than 3 decades after Jones and Smith ( 1973 ) reported on the devastation caused by alcohol exposure on fetal development , the rates of heavy drinking during pregnancy remain relatively unchanged .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: More than 3 decades after Jones and Smith ( 1973 ) reported on the devastation caused by alcohol exposure on fetal development , the rates of heavy drinking during pregnancy remain relatively unchanged .
Diseases: "	"Sentence: More than 3 decades after Jones and Smith ( 1973 ) reported on the devastation caused by alcohol exposure on fetal development , the rates of heavy drinking during pregnancy remain relatively unchanged .
Diseases:"
2496	Early identification of fetal alcohol exposure and maternal abstinence led to better infant outcomes .	O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O	[]	0	0	"Sentence: Early identification of fetal alcohol exposure and maternal abstinence led to better infant outcomes .
Diseases: "	"Sentence: Early identification of fetal alcohol exposure and maternal abstinence led to better infant outcomes .
Diseases:"
2497	This study examined the utility of biometry for detecting alcohol - related fetal growth impairment .	O O O O O O O O O O O O O B I O	O O O O O O O O O B O O O O O O	['growth impairment']	1	2	"Sentence: This study examined the utility of biometry for detecting alcohol - related fetal growth impairment .
Diseases: growth impairment"	"Sentence: This study examined the utility of biometry for detecting alcohol - related fetal growth impairment .
Diseases:"
2498	METHODS : We obtained fetal ultrasound measures from routine ultrasound examinations for 167 pregnant hazardous drinkers who were enrolled in a brief alcohol intervention study .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O B O O O	[]	0	0	"Sentence: METHODS : We obtained fetal ultrasound measures from routine ultrasound examinations for 167 pregnant hazardous drinkers who were enrolled in a brief alcohol intervention study .
Diseases: "	"Sentence: METHODS : We obtained fetal ultrasound measures from routine ultrasound examinations for 167 pregnant hazardous drinkers who were enrolled in a brief alcohol intervention study .
Diseases:"
2499	The fetal measures for women who quit after learning of their pregnancies were compared with measures for women who continued some drinking throughout the course of their pregnancies .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The fetal measures for women who quit after learning of their pregnancies were compared with measures for women who continued some drinking throughout the course of their pregnancies .
Diseases: "	"Sentence: The fetal measures for women who quit after learning of their pregnancies were compared with measures for women who continued some drinking throughout the course of their pregnancies .
Diseases:"
2500	Because intensity of alcohol consumption is associated with poorer fetal outcomes , separate analyses were conducted for the heavy ( average of > or = 5 drinks per drinking day )	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Because intensity of alcohol consumption is associated with poorer fetal outcomes , separate analyses were conducted for the heavy ( average of > or = 5 drinks per drinking day )
Diseases: "	"Sentence: Because intensity of alcohol consumption is associated with poorer fetal outcomes , separate analyses were conducted for the heavy ( average of > or = 5 drinks per drinking day )
Diseases:"
2501	alcohol consumers .	O O O	B O O	[]	0	0	"Sentence: alcohol consumers .
Diseases: "	"Sentence: alcohol consumers .
Diseases:"
2502	Fetal measures from the heavy - exposed fetuses were also compared with measures from a nondrinking group that was representative of normal , uncomplicated pregnancies from our clinics .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Fetal measures from the heavy - exposed fetuses were also compared with measures from a nondrinking group that was representative of normal , uncomplicated pregnancies from our clinics .
Diseases: "	"Sentence: Fetal measures from the heavy - exposed fetuses were also compared with measures from a nondrinking group that was representative of normal , uncomplicated pregnancies from our clinics .
Diseases:"
2503	Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and drug abuse .	O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O	['drug abuse']	1	2	"Sentence: Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and drug abuse .
Diseases: drug abuse"	"Sentence: Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and drug abuse .
Diseases:"
2504	Nearly half of the pregnant drinkers abstained after learning of their pregnancies .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Nearly half of the pregnant drinkers abstained after learning of their pregnancies .
Diseases: "	"Sentence: Nearly half of the pregnant drinkers abstained after learning of their pregnancies .
Diseases:"
2505	When women reportedly quit drinking early in their pregnancies , fetal growth measures were not significantly different from a non - alcohol - exposed group , regardless of prior drinking patterns .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: When women reportedly quit drinking early in their pregnancies , fetal growth measures were not significantly different from a non - alcohol - exposed group , regardless of prior drinking patterns .
Diseases: "	"Sentence: When women reportedly quit drinking early in their pregnancies , fetal growth measures were not significantly different from a non - alcohol - exposed group , regardless of prior drinking patterns .
Diseases:"
2506	Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers .	O O O O O O O O O O O B I I O O O B I I I I O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['decreased cranial to body growth', 'reduced cerebellar growth']	2	14	"Sentence: Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers .
Diseases: decreased cranial to body growth, reduced cerebellar growth"	"Sentence: Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers .
Diseases:"
2507	Amphetamine abuse was predictive of larger cranial to body growth ratios .	O O O O O O O O O O O O	B O O O O O O O O O O O	[]	0	0	"Sentence: Amphetamine abuse was predictive of larger cranial to body growth ratios .
Diseases: "	"Sentence: Amphetamine abuse was predictive of larger cranial to body growth ratios .
Diseases:"
2508	CONCLUSIONS : Alterations in fetal biometric measurements were observed among the heavy drinkers only when they continued drinking after becoming aware of their pregnancies .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSIONS : Alterations in fetal biometric measurements were observed among the heavy drinkers only when they continued drinking after becoming aware of their pregnancies .
Diseases: "	"Sentence: CONCLUSIONS : Alterations in fetal biometric measurements were observed among the heavy drinkers only when they continued drinking after becoming aware of their pregnancies .
Diseases:"
2509	Although the reliance on self - reported drinking is a limitation in this study , these findings support the benefits of early abstinence and the potential for ultrasound examinations in the detection of fetal alcohol effects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Although the reliance on self - reported drinking is a limitation in this study , these findings support the benefits of early abstinence and the potential for ultrasound examinations in the detection of fetal alcohol effects .
Diseases: "	"Sentence: Although the reliance on self - reported drinking is a limitation in this study , these findings support the benefits of early abstinence and the potential for ultrasound examinations in the detection of fetal alcohol effects .
Diseases:"
2510	Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment .	O O O O O O O O O O O B I O O O O	O O O O O O O O O O O O O O B O O	['overactive bladder']	1	3	"Sentence: Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment .
Diseases: overactive bladder"	"Sentence: Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment .
Diseases:"
2511	To study the urinary symptoms and quality of life changes in Thai women with overactive bladder ( OAB ) after tolterodine treatment .	O O O O O O O O O O O O O O B I O B O O O O O	O O O O O O O O O O O O O O O O O O O O B O O	['oab', 'overactive bladder']	2	6	"Sentence: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder ( OAB ) after tolterodine treatment .
Diseases: oab, overactive bladder"	"Sentence: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder ( OAB ) after tolterodine treatment .
Diseases:"
2512	MATERIAL AND METHOD :	O O O O	O O O O	[]	0	0	"Sentence: MATERIAL AND METHOD :
Diseases: "	"Sentence: MATERIAL AND METHOD :
Diseases:"
2513	Thirty women ( aged 30 - 77 years ) diagnosed as having OAB at the Gynecology Clinic , King Chulalongkorn Memorial Hospital from January to April 2004 were included in the present study .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['oab']	1	2	"Sentence: Thirty women ( aged 30 - 77 years ) diagnosed as having OAB at the Gynecology Clinic , King Chulalongkorn Memorial Hospital from January to April 2004 were included in the present study .
Diseases: oab"	"Sentence: Thirty women ( aged 30 - 77 years ) diagnosed as having OAB at the Gynecology Clinic , King Chulalongkorn Memorial Hospital from January to April 2004 were included in the present study .
Diseases:"
2514	Tolterodine 2 mg , twice daily was given .	O O O O O O O O O	B O O O O O O O O	[]	0	0	"Sentence: Tolterodine 2 mg , twice daily was given .
Diseases: "	"Sentence: Tolterodine 2 mg , twice daily was given .
Diseases:"
2515	After 8 weeks treatment , changes in micturition diary variables and tolerability were determined .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After 8 weeks treatment , changes in micturition diary variables and tolerability were determined .
Diseases: "	"Sentence: After 8 weeks treatment , changes in micturition diary variables and tolerability were determined .
Diseases:"
2516	Short form 36 ( SF36 ) questionaires ( Thai version ) were given before and after 8 weeks of treatment .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Short form 36 ( SF36 ) questionaires ( Thai version ) were given before and after 8 weeks of treatment .
Diseases: "	"Sentence: Short form 36 ( SF36 ) questionaires ( Thai version ) were given before and after 8 weeks of treatment .
Diseases:"
2517	At 8 weeks , all micturition per day decreased from 16 .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: At 8 weeks , all micturition per day decreased from 16 .
Diseases: "	"Sentence: At 8 weeks , all micturition per day decreased from 16 .
Diseases:"
2518	7 + / - 5 .	O O O O O O	O O O O O O	[]	0	0	"Sentence: 7 + / - 5 .
Diseases: "	"Sentence: 7 + / - 5 .
Diseases:"
2519	3 to 6 .	O O O O	O O O O	[]	0	0	"Sentence: 3 to 6 .
Diseases: "	"Sentence: 3 to 6 .
Diseases:"
2520	7 + / -	O O O O	O O O O	[]	0	0	"Sentence: 7 + / -
Diseases: "	"Sentence: 7 + / -
Diseases:"
2521	2 . 4 times per day .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: 2 . 4 times per day .
Diseases: "	"Sentence: 2 . 4 times per day .
Diseases:"
2522	The number of nocturia episodes decreased from 5 . 4 + / - 4 . 2 to 1 . 1 + / -	O O O B O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['nocturia']	1	3	"Sentence: The number of nocturia episodes decreased from 5 . 4 + / - 4 . 2 to 1 . 1 + / -
Diseases: nocturia"	"Sentence: The number of nocturia episodes decreased from 5 . 4 + / - 4 . 2 to 1 . 1 + / -
Diseases:"
2523	1 . 0 times per night .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: 1 . 0 times per night .
Diseases: "	"Sentence: 1 . 0 times per night .
Diseases:"
2524	The most common side effect was dry month in 5 cases ( 16 . 7 % ) with 2 cases reporting a moderate degree and 1 case with severe degree .	O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['dry month']	1	2	"Sentence: The most common side effect was dry month in 5 cases ( 16 . 7 % ) with 2 cases reporting a moderate degree and 1 case with severe degree .
Diseases: dry month"	"Sentence: The most common side effect was dry month in 5 cases ( 16 . 7 % ) with 2 cases reporting a moderate degree and 1 case with severe degree .
Diseases:"
2525	Only one case ( 3 . 3 % ) withdrew from the present study due to a severe dry mouth .	O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O	['dry mouth']	1	2	"Sentence: Only one case ( 3 . 3 % ) withdrew from the present study due to a severe dry mouth .
Diseases: dry mouth"	"Sentence: Only one case ( 3 . 3 % ) withdrew from the present study due to a severe dry mouth .
Diseases:"
2526	The SF - 36 scores changed significantly in the domains of physical functioning , role function emotional , social function and mental heath .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The SF - 36 scores changed significantly in the domains of physical functioning , role function emotional , social function and mental heath .
Diseases: "	"Sentence: The SF - 36 scores changed significantly in the domains of physical functioning , role function emotional , social function and mental heath .
Diseases:"
2527	Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB .	O O O O O O O O O O O O O O O O B O	B O O O O O O O O O O O O O O O O O	['oab']	1	2	"Sentence: Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB .
Diseases: oab"	"Sentence: Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB .
Diseases:"
2528	Absence of acute cerebral vasoconstriction after cocaine - associated subarachnoid hemorrhage .	O O O O O O O O O B I O	O O O O O O B O O O O O	['subarachnoid hemorrhage']	1	7	"Sentence: Absence of acute cerebral vasoconstriction after cocaine - associated subarachnoid hemorrhage .
Diseases: subarachnoid hemorrhage"	"Sentence: Absence of acute cerebral vasoconstriction after cocaine - associated subarachnoid hemorrhage .
Diseases:"
2529	Cocaine use has been associated with neurovascular complications , including arterial vasoconstriction and vasculitis .	O O O O O O B I O O O O O B O	B O O O O O O O O O O O O O O	['vasculitis', 'neurovascular complications']	2	8	"Sentence: Cocaine use has been associated with neurovascular complications , including arterial vasoconstriction and vasculitis .
Diseases: vasculitis, neurovascular complications"	"Sentence: Cocaine use has been associated with neurovascular complications , including arterial vasoconstriction and vasculitis .
Diseases:"
2530	However , there are few studies of angiographic effects of cocaine on human cerebral arteries .	O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O	[]	0	0	"Sentence: However , there are few studies of angiographic effects of cocaine on human cerebral arteries .
Diseases: "	"Sentence: However , there are few studies of angiographic effects of cocaine on human cerebral arteries .
Diseases:"
2531	Information on these effects could be obtained from angiograms of patients with cocaine - associated subarachnoid hemorrhage ( SAH ) who underwent angiography shortly after cocaine use .	O O O O O O O O O O O O O O O B I O B O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O B O O	['subarachnoid hemorrhage', 'sah']	2	10	"Sentence: Information on these effects could be obtained from angiograms of patients with cocaine - associated subarachnoid hemorrhage ( SAH ) who underwent angiography shortly after cocaine use .
Diseases: subarachnoid hemorrhage, sah"	"Sentence: Information on these effects could be obtained from angiograms of patients with cocaine - associated subarachnoid hemorrhage ( SAH ) who underwent angiography shortly after cocaine use .
Diseases:"
2532	METHODS : We screened patients with SAH retrospectively and identified those with positive urine toxicology for cocaine or its metabolites .	O O O O O O B O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O	['sah']	1	2	"Sentence: METHODS : We screened patients with SAH retrospectively and identified those with positive urine toxicology for cocaine or its metabolites .
Diseases: sah"	"Sentence: METHODS : We screened patients with SAH retrospectively and identified those with positive urine toxicology for cocaine or its metabolites .
Diseases:"
2533	Quantitative arterial diameter measurements from angiograms of these patients were compared to measurements from control patients with SAH who were matched for factors known to influence arterial diameter .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['sah']	1	2	"Sentence: Quantitative arterial diameter measurements from angiograms of these patients were compared to measurements from control patients with SAH who were matched for factors known to influence arterial diameter .
Diseases: sah"	"Sentence: Quantitative arterial diameter measurements from angiograms of these patients were compared to measurements from control patients with SAH who were matched for factors known to influence arterial diameter .
Diseases:"
2534	Qualitative comparisons of small artery changes also were made .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Qualitative comparisons of small artery changes also were made .
Diseases: "	"Sentence: Qualitative comparisons of small artery changes also were made .
Diseases:"
2535	Thirteen patients with positive cocaine toxicology were compared to 26 controls .	O O O O O O O O O O O O	O O O O B O O O O O O O	[]	0	0	"Sentence: Thirteen patients with positive cocaine toxicology were compared to 26 controls .
Diseases: "	"Sentence: Thirteen patients with positive cocaine toxicology were compared to 26 controls .
Diseases:"
2536	There were no significant differences between groups in the mean diameters of the intradural internal carotid , sphenoidal segment of the middle cerebral , precommunicating segment of the anterior cerebral , or basilar arteries ( p greater than 0 . 05 for all comparisons , unpaired t - tests ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There were no significant differences between groups in the mean diameters of the intradural internal carotid , sphenoidal segment of the middle cerebral , precommunicating segment of the anterior cerebral , or basilar arteries ( p greater than 0 . 05 for all comparisons , unpaired t - tests ) .
Diseases: "	"Sentence: There were no significant differences between groups in the mean diameters of the intradural internal carotid , sphenoidal segment of the middle cerebral , precommunicating segment of the anterior cerebral , or basilar arteries ( p greater than 0 . 05 for all comparisons , unpaired t - tests ) .
Diseases:"
2537	There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery ( p greater than 0 . 05 , unpaired t - tests ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery ( p greater than 0 . 05 , unpaired t - tests ) .
Diseases: "	"Sentence: There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery ( p greater than 0 . 05 , unpaired t - tests ) .
Diseases:"
2538	Qualitative assessments showed two arterial irregularities in the distal vasculature in each group .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Qualitative assessments showed two arterial irregularities in the distal vasculature in each group .
Diseases: "	"Sentence: Qualitative assessments showed two arterial irregularities in the distal vasculature in each group .
Diseases:"
2539	No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use .	O O O O O O O O O O O O O O O O O B O O O O O O O O O B B O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['vasculitis', 'sah', 'aneurysmal']	3	11	"Sentence: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use .
Diseases: vasculitis, sah, aneurysmal"	"Sentence: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use .
Diseases:"
2540	Atrial fibrillation following chemotherapy for stage IIIE diffuse large B - cell gastric lymphoma in a patient with myotonic dystrophy ( Steinert 's disease ) .	B I O O O O O O O O O O B I O O O O B I O B I I O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	"['gastric lymphoma', ""steinert 's disease"", 'atrial fibrillation', 'myotonic dystrophy']"	4	25	"Sentence: Atrial fibrillation following chemotherapy for stage IIIE diffuse large B - cell gastric lymphoma in a patient with myotonic dystrophy ( Steinert 's disease ) .
Diseases: gastric lymphoma, steinert 's disease, atrial fibrillation, myotonic dystrophy"	"Sentence: Atrial fibrillation following chemotherapy for stage IIIE diffuse large B - cell gastric lymphoma in a patient with myotonic dystrophy ( Steinert 's disease ) .
Diseases:"
2541	The authors describe the unusual association between diffuse B - cell gastric lymphoma and myotonic dystrophy , the most common form of adult muscular dystrophy , and sudden atrial fibrillation following one cycle of doxorubicin - based chemotherapy in the same patient .	O O O O O O O O O O O B I O B I O O O O O O O B I O O O B I O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['gastric lymphoma', 'muscular dystrophy', 'atrial fibrillation', 'myotonic dystrophy']	4	23	"Sentence: The authors describe the unusual association between diffuse B - cell gastric lymphoma and myotonic dystrophy , the most common form of adult muscular dystrophy , and sudden atrial fibrillation following one cycle of doxorubicin - based chemotherapy in the same patient .
Diseases: gastric lymphoma, muscular dystrophy, atrial fibrillation, myotonic dystrophy"	"Sentence: The authors describe the unusual association between diffuse B - cell gastric lymphoma and myotonic dystrophy , the most common form of adult muscular dystrophy , and sudden atrial fibrillation following one cycle of doxorubicin - based chemotherapy in the same patient .
Diseases:"
2542	Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy .	B I O O B I O O O O O O O O O	O O O O O O O O O O O O O O O	['atrial fibrillation', 'cardiac arrhythmias']	2	11	"Sentence: Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy .
Diseases: atrial fibrillation, cardiac arrhythmias"	"Sentence: Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy .
Diseases:"
2543	The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient .	O B I O O O O O O O O O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cardiac toxicity', 'arrhythmia']	2	8	"Sentence: The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient .
Diseases: cardiac toxicity, arrhythmia"	"Sentence: The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient .
Diseases:"
2544	A phase II study of thalidomide in advanced metastatic renal cell carcinoma .	O O O O O O O O O B I I O	O O O O O B O O O O O O O	['renal cell carcinoma']	1	5	"Sentence: A phase II study of thalidomide in advanced metastatic renal cell carcinoma .
Diseases: renal cell carcinoma"	"Sentence: A phase II study of thalidomide in advanced metastatic renal cell carcinoma .
Diseases:"
2545	To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor , vascular endothelial growth factor ( VEGF ) 165 , with therapy .	O O O B O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['renal cell cancer', 'toxicity']	2	6	"Sentence: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor , vascular endothelial growth factor ( VEGF ) 165 , with therapy .
Diseases: renal cell cancer, toxicity"	"Sentence: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor , vascular endothelial growth factor ( VEGF ) 165 , with therapy .
Diseases:"
2546	PATIENTS AND METHODS : 29 patients were enrolled on a study of thalidomide using an intra - patient dose escalation schedule .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: PATIENTS AND METHODS : 29 patients were enrolled on a study of thalidomide using an intra - patient dose escalation schedule .
Diseases: "	"Sentence: PATIENTS AND METHODS : 29 patients were enrolled on a study of thalidomide using an intra - patient dose escalation schedule .
Diseases:"
2547	Patients began thalidomide at 400 mg / d and escalated as tolerated to 1200 mg / d by day 54 .	O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients began thalidomide at 400 mg / d and escalated as tolerated to 1200 mg / d by day 54 .
Diseases: "	"Sentence: Patients began thalidomide at 400 mg / d and escalated as tolerated to 1200 mg / d by day 54 .
Diseases:"
2548	Fifty - nine per cent of patients had had previous therapy with IL - 2 and 52 % were performance status 2 or 3 .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Fifty - nine per cent of patients had had previous therapy with IL - 2 and 52 % were performance status 2 or 3 .
Diseases: "	"Sentence: Fifty - nine per cent of patients had had previous therapy with IL - 2 and 52 % were performance status 2 or 3 .
Diseases:"
2549	Systemic plasma VEGF165 levels were measured by dual monoclonal ELISA in 8 patients .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Systemic plasma VEGF165 levels were measured by dual monoclonal ELISA in 8 patients .
Diseases: "	"Sentence: Systemic plasma VEGF165 levels were measured by dual monoclonal ELISA in 8 patients .
Diseases:"
2550	RESULTS : 24 patients were evaluable for response with one partial response of 11 months duration of a patient with hepatic and pulmonary metastases ( 4 % ) , one minor response , and 2 patients stable for over 6 months .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['metastases']	1	3	"Sentence: RESULTS : 24 patients were evaluable for response with one partial response of 11 months duration of a patient with hepatic and pulmonary metastases ( 4 % ) , one minor response , and 2 patients stable for over 6 months .
Diseases: metastases"	"Sentence: RESULTS : 24 patients were evaluable for response with one partial response of 11 months duration of a patient with hepatic and pulmonary metastases ( 4 % ) , one minor response , and 2 patients stable for over 6 months .
Diseases:"
2551	Somnolence and constipation were prominent toxicities and most patients could not tolerate the 1200 mg / day dose level .	B O B O O B O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	['somnolence', 'toxicities', 'constipation']	3	11	"Sentence: Somnolence and constipation were prominent toxicities and most patients could not tolerate the 1200 mg / day dose level .
Diseases: somnolence, toxicities, constipation"	"Sentence: Somnolence and constipation were prominent toxicities and most patients could not tolerate the 1200 mg / day dose level .
Diseases:"
2552	Systemic plasma VEGF165 levels did not change with therapy .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Systemic plasma VEGF165 levels did not change with therapy .
Diseases: "	"Sentence: Systemic plasma VEGF165 levels did not change with therapy .
Diseases:"
2553	These results are consistent with a low level of activity of thalidomide in renal cell carcinoma .	O O O O O O O O O O O O O B I I O	O O O O O O O O O O O B O O O O O	['renal cell carcinoma']	1	5	"Sentence: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma .
Diseases: renal cell carcinoma"	"Sentence: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma .
Diseases:"
2554	Administration of doses over 800 mg / day was difficult to achieve in this patient population , however lower doses were practical .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Administration of doses over 800 mg / day was difficult to achieve in this patient population , however lower doses were practical .
Diseases: "	"Sentence: Administration of doses over 800 mg / day was difficult to achieve in this patient population , however lower doses were practical .
Diseases:"
2555	The dose - response relationship , if any , of thalidomide for renal cell carcinoma is unclear .	O O O O O O O O O O O O B I I O O O	O O O O O O O O O O B O O O O O O O	['renal cell carcinoma']	1	5	"Sentence: The dose - response relationship , if any , of thalidomide for renal cell carcinoma is unclear .
Diseases: renal cell carcinoma"	"Sentence: The dose - response relationship , if any , of thalidomide for renal cell carcinoma is unclear .
Diseases:"
2556	The striatum as a target for anti - rigor effects of an antagonist of mGluR1 , but not an agonist of group II metabotropic glutamate receptors .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: The striatum as a target for anti - rigor effects of an antagonist of mGluR1 , but not an agonist of group II metabotropic glutamate receptors .
Diseases: "	"Sentence: The striatum as a target for anti - rigor effects of an antagonist of mGluR1 , but not an agonist of group II metabotropic glutamate receptors .
Diseases:"
2557	The aim of the present study was to find out whether the metabotropic receptor 1 ( mGluR1 ) and group II mGluRs , localized in the striatum , are involved in antiparkinsonian - like effects in rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The aim of the present study was to find out whether the metabotropic receptor 1 ( mGluR1 ) and group II mGluRs , localized in the striatum , are involved in antiparkinsonian - like effects in rats .
Diseases: "	"Sentence: The aim of the present study was to find out whether the metabotropic receptor 1 ( mGluR1 ) and group II mGluRs , localized in the striatum , are involved in antiparkinsonian - like effects in rats .
Diseases:"
2558	Haloperidol ( 1 mg / kg ip ) induced parkinsonian - like muscle rigidity , measured as an increased resistance of a rat 's hind foot to passive flexion and extension at the ankle joint .	O O O O O O O O O B O O B I O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['muscle rigidity', 'parkinsonian']	2	8	"Sentence: Haloperidol ( 1 mg / kg ip ) induced parkinsonian - like muscle rigidity , measured as an increased resistance of a rat 's hind foot to passive flexion and extension at the ankle joint .
Diseases: muscle rigidity, parkinsonian"	"Sentence: Haloperidol ( 1 mg / kg ip ) induced parkinsonian - like muscle rigidity , measured as an increased resistance of a rat 's hind foot to passive flexion and extension at the ankle joint .
Diseases:"
2559	( RS ) - 1 - aminoindan - 1 , 5 - dicarboxylic acid ( AIDA ; 0 . 5 - 15 microg / 0 . 5 microl ) , a potent and selective mGluR1 antagonist , or ( 2R , 4R ) - 4 - aminopyrrolidine - 2 , 4 - dicarboxylate ( 2R , 4R - APDC ; 7 . 5 - 15 microg / 0 . 5 microl ) , a selective group II agonist , was injected bilaterally into the striatum of haloperidol - treated animals .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B I I I I I I I I I I I I I O B O O O O O O O O O O O O O O O O O O O O O O B I I I I I I I I I I I I I I O B I I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: ( RS ) - 1 - aminoindan - 1 , 5 - dicarboxylic acid ( AIDA ; 0 . 5 - 15 microg / 0 . 5 microl ) , a potent and selective mGluR1 antagonist , or ( 2R , 4R ) - 4 - aminopyrrolidine - 2 , 4 - dicarboxylate ( 2R , 4R - APDC ; 7 . 5 - 15 microg / 0 . 5 microl ) , a selective group II agonist , was injected bilaterally into the striatum of haloperidol - treated animals .
Diseases: "	"Sentence: ( RS ) - 1 - aminoindan - 1 , 5 - dicarboxylic acid ( AIDA ; 0 . 5 - 15 microg / 0 . 5 microl ) , a potent and selective mGluR1 antagonist , or ( 2R , 4R ) - 4 - aminopyrrolidine - 2 , 4 - dicarboxylate ( 2R , 4R - APDC ; 7 . 5 - 15 microg / 0 . 5 microl ) , a selective group II agonist , was injected bilaterally into the striatum of haloperidol - treated animals .
Diseases:"
2560	AIDA in doses of 7 . 5 - 15 microg / 0 . 5 microl diminished the haloperidol - induced muscle rigidity .	O O O O O O O O O O O O O O O O O O O O B I O	B O O O O O O O O O O O O O O O O B O O O O O	['muscle rigidity']	1	4	"Sentence: AIDA in doses of 7 . 5 - 15 microg / 0 . 5 microl diminished the haloperidol - induced muscle rigidity .
Diseases: muscle rigidity"	"Sentence: AIDA in doses of 7 . 5 - 15 microg / 0 . 5 microl diminished the haloperidol - induced muscle rigidity .
Diseases:"
2561	In contrast , 2R , 4R - APDC injections were ineffective .	O O O O O O O O O O O O	O O O B I I I I O O O O	[]	0	0	"Sentence: In contrast , 2R , 4R - APDC injections were ineffective .
Diseases: "	"Sentence: In contrast , 2R , 4R - APDC injections were ineffective .
Diseases:"
2562	The present results may suggest that the blockade of striatal mGluR1 , but not the stimulation of group II mGluRs , may ameliorate parkinsonian muscle rigidity .	O O O O O O O O O O O O O O O O O O O O O O O B B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['muscle rigidity', 'parkinsonian']	2	8	"Sentence: The present results may suggest that the blockade of striatal mGluR1 , but not the stimulation of group II mGluRs , may ameliorate parkinsonian muscle rigidity .
Diseases: muscle rigidity, parkinsonian"	"Sentence: The present results may suggest that the blockade of striatal mGluR1 , but not the stimulation of group II mGluRs , may ameliorate parkinsonian muscle rigidity .
Diseases:"
2563	Acute cholestatic hepatitis after exposure to isoflurane .	O B I O O O O O	O O O O O O B O	['cholestatic hepatitis']	1	5	"Sentence: Acute cholestatic hepatitis after exposure to isoflurane .
Diseases: cholestatic hepatitis"	"Sentence: Acute cholestatic hepatitis after exposure to isoflurane .
Diseases:"
2564	To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane .	O O O O O O B I O O O O O O O O	O O O O O O O O O O O O O O B O	['cholestatic hepatitis']	1	5	"Sentence: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane .
Diseases: cholestatic hepatitis"	"Sentence: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane .
Diseases:"
2565	A 70 - year - old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia .	O O O O O O O O O O O O B I O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cholestatic hepatitis']	1	5	"Sentence: A 70 - year - old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia .
Diseases: cholestatic hepatitis"	"Sentence: A 70 - year - old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia .
Diseases:"
2566	There was no evidence for viral , autoimmune , or metabolic causes of hepatitis .	O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O	['hepatitis']	1	3	"Sentence: There was no evidence for viral , autoimmune , or metabolic causes of hepatitis .
Diseases: hepatitis"	"Sentence: There was no evidence for viral , autoimmune , or metabolic causes of hepatitis .
Diseases:"
2567	No other medications were involved except for dipyrone for analgesia .	O O O O O O O O O B O	O O O O O O O B O O O	['analgesia']	1	4	"Sentence: No other medications were involved except for dipyrone for analgesia .
Diseases: analgesia"	"Sentence: No other medications were involved except for dipyrone for analgesia .
Diseases:"
2568	The alanine aminotransferase was elevated to a peak concentration of 1533 U / L and the serum bilirubin reached a peak of 17 . 0 mg / dL . There was slow improvement over 4 months .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The alanine aminotransferase was elevated to a peak concentration of 1533 U / L and the serum bilirubin reached a peak of 17 . 0 mg / dL . There was slow improvement over 4 months .
Diseases: "	"Sentence: The alanine aminotransferase was elevated to a peak concentration of 1533 U / L and the serum bilirubin reached a peak of 17 . 0 mg / dL . There was slow improvement over 4 months .
Diseases:"
2569	Accidental reexposure by the patient to dipyrone was uneventful .	O O O O O O O O O O	O O O O O O B O O O	[]	0	0	"Sentence: Accidental reexposure by the patient to dipyrone was uneventful .
Diseases: "	"Sentence: Accidental reexposure by the patient to dipyrone was uneventful .
Diseases:"
2570	The clinical and histologic picture of this case resembles halothane hepatitis , which has a significant mortality rate .	O O O O O O O O O B I O O O O O O O O	O O O O O O O O O B O O O O O O O O O	['halothane hepatitis']	1	4	"Sentence: The clinical and histologic picture of this case resembles halothane hepatitis , which has a significant mortality rate .
Diseases: halothane hepatitis"	"Sentence: The clinical and histologic picture of this case resembles halothane hepatitis , which has a significant mortality rate .
Diseases:"
2571	Isoflurane , a common anesthetic agent , can cause severe cholestatic hepatitis .	O O O O O O O O O O B I O	B O O O O O O O O O O O O	['cholestatic hepatitis']	1	5	"Sentence: Isoflurane , a common anesthetic agent , can cause severe cholestatic hepatitis .
Diseases: cholestatic hepatitis"	"Sentence: Isoflurane , a common anesthetic agent , can cause severe cholestatic hepatitis .
Diseases:"
2572	Calcitonin gene - related peptide levels during nitric oxide - induced headache in patients with chronic tension - type headache .	O O O O O O O O O O O B O O O O B I I I O	B I I I O O O B I O O O O O O O O O O O O	['headache', 'tension - type headache']	2	7	"Sentence: Calcitonin gene - related peptide levels during nitric oxide - induced headache in patients with chronic tension - type headache .
Diseases: headache, tension - type headache"	"Sentence: Calcitonin gene - related peptide levels during nitric oxide - induced headache in patients with chronic tension - type headache .
Diseases:"
2573	It has been proposed that nitric oxide ( NO ) induced headache in primary headaches may be associated with release of calcitonin gene - related peptide ( CGRP ) .	O O O O O O O O O O O B O B I O O O O O O O O O O O O O O O	O O O O O B I O B O O O O O O O O O O O O B I I I I O B O O	['primary headaches', 'headache']	2	4	"Sentence: It has been proposed that nitric oxide ( NO ) induced headache in primary headaches may be associated with release of calcitonin gene - related peptide ( CGRP ) .
Diseases: primary headaches, headache"	"Sentence: It has been proposed that nitric oxide ( NO ) induced headache in primary headaches may be associated with release of calcitonin gene - related peptide ( CGRP ) .
Diseases:"
2574	In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate ( GTN ) in 16 patients with chronic tension - type headache and 16 healthy controls .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O B I I I O O O O O	O O O O O O O O O O O B O O O O O B O B I O B O O O O O O O O O O O O O O O	['headache', 'tension - type headache']	2	7	"Sentence: In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate ( GTN ) in 16 patients with chronic tension - type headache and 16 healthy controls .
Diseases: headache, tension - type headache"	"Sentence: In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate ( GTN ) in 16 patients with chronic tension - type headache and 16 healthy controls .
Diseases:"
2575	The subjects were randomly allocated to receive 0 . 5 microg / kg / min GTN or placebo over 20 min on two headache - free days .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O O O O O O O O O O B O O O O O O O O O O O O	['headache']	1	2	"Sentence: The subjects were randomly allocated to receive 0 . 5 microg / kg / min GTN or placebo over 20 min on two headache - free days .
Diseases: headache"	"Sentence: The subjects were randomly allocated to receive 0 . 5 microg / kg / min GTN or placebo over 20 min on two headache - free days .
Diseases:"
2576	Blood samples were collected at baseline , 10 , 20 and 60 min after start of infusion .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Blood samples were collected at baseline , 10 , 20 and 60 min after start of infusion .
Diseases: "	"Sentence: Blood samples were collected at baseline , 10 , 20 and 60 min after start of infusion .
Diseases:"
2577	Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls .	O O O O O O O O B O O O O O O O O O O O B O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['headache']	1	2	"Sentence: Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls .
Diseases: headache"	"Sentence: Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls .
Diseases:"
2578	There was no difference between the area under the CGRP curve ( AUCCGRP ) on GTN vs . placebo day in either patients ( P = 0 . 65 ) or controls ( P = 0 . 48 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There was no difference between the area under the CGRP curve ( AUCCGRP ) on GTN vs . placebo day in either patients ( P = 0 . 65 ) or controls ( P = 0 . 48 ) .
Diseases: "	"Sentence: There was no difference between the area under the CGRP curve ( AUCCGRP ) on GTN vs . placebo day in either patients ( P = 0 . 65 ) or controls ( P = 0 . 48 ) .
Diseases:"
2579	The AUCCGRP recorded on the GTN day did not differ between patients and controls ( P = 0 . 36 ) .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The AUCCGRP recorded on the GTN day did not differ between patients and controls ( P = 0 . 36 ) .
Diseases: "	"Sentence: The AUCCGRP recorded on the GTN day did not differ between patients and controls ( P = 0 . 36 ) .
Diseases:"
2580	Both in patients and controls , CGRP levels changed significantly over time , on both the GTN and placebo days ( P < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: Both in patients and controls , CGRP levels changed significantly over time , on both the GTN and placebo days ( P < 0 . 05 ) .
Diseases: "	"Sentence: Both in patients and controls , CGRP levels changed significantly over time , on both the GTN and placebo days ( P < 0 . 05 ) .
Diseases:"
2581	The present study indicates that NO - induced immediate headache is not associated with release of CGRP .	O O O O O O O O O B O O O O O O O O	O O O O O B O O O O O O O O O O B O	['headache']	1	2	"Sentence: The present study indicates that NO - induced immediate headache is not associated with release of CGRP .
Diseases: headache"	"Sentence: The present study indicates that NO - induced immediate headache is not associated with release of CGRP .
Diseases:"
2582	Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography .	B I O O B I I O O O O O	O O O O O O O O B O O O	['myocardial ischemia', 'coronary artery spasm']	2	11	"Sentence: Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography .
Diseases: myocardial ischemia, coronary artery spasm"	"Sentence: Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography .
Diseases:"
2583	Dobutamine stress echocardiography ( DSE ) is a useful and safe provocation test for myocardial ischemia .	O O O O O O O O O O O O O O B I O	B O O O O O O O O O O O O O O O O	['myocardial ischemia']	1	6	"Sentence: Dobutamine stress echocardiography ( DSE ) is a useful and safe provocation test for myocardial ischemia .
Diseases: myocardial ischemia"	"Sentence: Dobutamine stress echocardiography ( DSE ) is a useful and safe provocation test for myocardial ischemia .
Diseases:"
2584	Until now , the test has been focused only on the organic lesion in the coronary artery , and positive DSE has indicated the presence of significant fixed coronary artery stenosis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['coronary artery stenosis']	1	6	"Sentence: Until now , the test has been focused only on the organic lesion in the coronary artery , and positive DSE has indicated the presence of significant fixed coronary artery stenosis .
Diseases: coronary artery stenosis"	"Sentence: Until now , the test has been focused only on the organic lesion in the coronary artery , and positive DSE has indicated the presence of significant fixed coronary artery stenosis .
Diseases:"
2585	The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine .	O O O O O O O O O O B I O O B I O O O O O	O O O O O O O O O O O O O O O O O O O B O	['coronary spasm', 'myocardial ischemia']	2	12	"Sentence: The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine .
Diseases: coronary spasm, myocardial ischemia"	"Sentence: The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine .
Diseases:"
2586	We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis .	O O O O O O O B I I O O O O B I I O	O O O O O O O O O O O O O O O O O O	['coronary artery stenosis', 'coronary spastic angina']	2	12	"Sentence: We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis .
Diseases: coronary artery stenosis, coronary spastic angina"	"Sentence: We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis .
Diseases:"
2587	All patients had anginal attacks at rest with ST elevation on the electrocardiogram ( variant angina ) .	O O O B O O O O O O O O O O B I O O	O O O O O O O O O O O O O O O O O O	['variant angina', 'anginal']	2	7	"Sentence: All patients had anginal attacks at rest with ST elevation on the electrocardiogram ( variant angina ) .
Diseases: variant angina, anginal"	"Sentence: All patients had anginal attacks at rest with ST elevation on the electrocardiogram ( variant angina ) .
Diseases:"
2588	Coronary spasm was induced by intracoronary injection of acetylcholine , and no fixed coronary artery stenosis was documented on angiograms in all patients .	O O O O O O O O O O O O O B I I O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O	['coronary artery stenosis']	1	6	"Sentence: Coronary spasm was induced by intracoronary injection of acetylcholine , and no fixed coronary artery stenosis was documented on angiograms in all patients .
Diseases: coronary artery stenosis"	"Sentence: Coronary spasm was induced by intracoronary injection of acetylcholine , and no fixed coronary artery stenosis was documented on angiograms in all patients .
Diseases:"
2589	DSE was performed with intravenous dobutamine infusion with an incremental doses of 5 , 10 , 20 , 30 , and 40 microg / kg / min every 5 minutes .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: DSE was performed with intravenous dobutamine infusion with an incremental doses of 5 , 10 , 20 , 30 , and 40 microg / kg / min every 5 minutes .
Diseases: "	"Sentence: DSE was performed with intravenous dobutamine infusion with an incremental doses of 5 , 10 , 20 , 30 , and 40 microg / kg / min every 5 minutes .
Diseases:"
2590	Of the 51 patients , 7 patients showed asynergy with ST elevation .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Of the 51 patients , 7 patients showed asynergy with ST elevation .
Diseases: "	"Sentence: Of the 51 patients , 7 patients showed asynergy with ST elevation .
Diseases:"
2591	All 7 patients ( 13 . 7 % ) had chest pain during asynergy , and both chest pain and electrocardiographic changes were preceded by asynergy .	O O O O O O O O O O B I O O O O O B I O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['chest pain']	1	2	"Sentence: All 7 patients ( 13 . 7 % ) had chest pain during asynergy , and both chest pain and electrocardiographic changes were preceded by asynergy .
Diseases: chest pain"	"Sentence: All 7 patients ( 13 . 7 % ) had chest pain during asynergy , and both chest pain and electrocardiographic changes were preceded by asynergy .
Diseases:"
2592	These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina .	O O O O O O O B I O O O O B I I O	O O O O B O O O O O O O O O O O O	['coronary spasm', 'coronary spastic angina']	2	11	"Sentence: These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina .
Diseases: coronary spasm, coronary spastic angina"	"Sentence: These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina .
Diseases:"
2593	When DSE is performed to evaluate coronary artery disease , not only fixed coronary stenosis , but also coronary spasm should be considered as a genesis of asynergy .	O O O O O O B I I O O O O B I O O O B I O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['coronary spasm', 'coronary artery disease', 'coronary stenosis']	3	13	"Sentence: When DSE is performed to evaluate coronary artery disease , not only fixed coronary stenosis , but also coronary spasm should be considered as a genesis of asynergy .
Diseases: coronary spasm, coronary artery disease, coronary stenosis"	"Sentence: When DSE is performed to evaluate coronary artery disease , not only fixed coronary stenosis , but also coronary spasm should be considered as a genesis of asynergy .
Diseases:"
2594	Nitric oxide synthase expression in the course of lead - induced hypertension .	O O O O O O O O O O O B O	B I O O O O O O B O O O O	['hypertension']	1	3	"Sentence: Nitric oxide synthase expression in the course of lead - induced hypertension .
Diseases: hypertension"	"Sentence: Nitric oxide synthase expression in the course of lead - induced hypertension .
Diseases:"
2595	We recently showed elevated reactive oxygen species ( ROS ) , reduced urinary excretion of NO metabolites ( NOx ) , and increased NO sequestration as nitrotyrosine in various tissues in rats with lead - induced hypertension .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O B O O O O O O O O O B O O O O O O O B O O B O O O O O O B O O O O	['hypertension']	1	3	"Sentence: We recently showed elevated reactive oxygen species ( ROS ) , reduced urinary excretion of NO metabolites ( NOx ) , and increased NO sequestration as nitrotyrosine in various tissues in rats with lead - induced hypertension .
Diseases: hypertension"	"Sentence: We recently showed elevated reactive oxygen species ( ROS ) , reduced urinary excretion of NO metabolites ( NOx ) , and increased NO sequestration as nitrotyrosine in various tissues in rats with lead - induced hypertension .
Diseases:"
2596	This study was designed to discern whether the reduction in urinary NOx in lead - induced hypertension is , in part , due to depressed NO synthase ( NOS ) expression .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O B O O O O O O	['hypertension']	1	3	"Sentence: This study was designed to discern whether the reduction in urinary NOx in lead - induced hypertension is , in part , due to depressed NO synthase ( NOS ) expression .
Diseases: hypertension"	"Sentence: This study was designed to discern whether the reduction in urinary NOx in lead - induced hypertension is , in part , due to depressed NO synthase ( NOS ) expression .
Diseases:"
2597	Male Sprague - Dawley rats were randomly assigned to a lead - treated group ( given lead acetate , 100 ppm , in drinking water and regular rat chow ) , a group given lead and vitamin E - fortified chow , or a normal control group given either regular food and water or vitamin E - fortified food for 12 weeks .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O B I O O O O O O O O O O O O O O O O B O B I O O O O O O O O O O O O O O O O B I O O O O O O O	[]	0	0	"Sentence: Male Sprague - Dawley rats were randomly assigned to a lead - treated group ( given lead acetate , 100 ppm , in drinking water and regular rat chow ) , a group given lead and vitamin E - fortified chow , or a normal control group given either regular food and water or vitamin E - fortified food for 12 weeks .
Diseases: "	"Sentence: Male Sprague - Dawley rats were randomly assigned to a lead - treated group ( given lead acetate , 100 ppm , in drinking water and regular rat chow ) , a group given lead and vitamin E - fortified chow , or a normal control group given either regular food and water or vitamin E - fortified food for 12 weeks .
Diseases:"
2598	Tail blood pressure , urinary NOx excretion , plasma malondialdehyde ( MDA ) , and endothelial and inducible NOS ( eNOS and iNOS ) isotypes in the aorta and kidney were measured .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O B O B O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Tail blood pressure , urinary NOx excretion , plasma malondialdehyde ( MDA ) , and endothelial and inducible NOS ( eNOS and iNOS ) isotypes in the aorta and kidney were measured .
Diseases: "	"Sentence: Tail blood pressure , urinary NOx excretion , plasma malondialdehyde ( MDA ) , and endothelial and inducible NOS ( eNOS and iNOS ) isotypes in the aorta and kidney were measured .
Diseases:"
2599	The lead - treated group exhibited a rise in blood pressure and plasma MDA concentration , a fall in urinary NOx excretion , and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O B O O O O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The lead - treated group exhibited a rise in blood pressure and plasma MDA concentration , a fall in urinary NOx excretion , and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression .
Diseases: "	"Sentence: The lead - treated group exhibited a rise in blood pressure and plasma MDA concentration , a fall in urinary NOx excretion , and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression .
Diseases:"
2600	Vitamin E supplementation ameliorated hypertension , lowered plasma MDA concentration , and raised urinary NOx excretion while significantly lowering vascular , but not renal , tissue eNOS and iNOS expression .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	B I O O O O O O B O O O O O B O O O O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: Vitamin E supplementation ameliorated hypertension , lowered plasma MDA concentration , and raised urinary NOx excretion while significantly lowering vascular , but not renal , tissue eNOS and iNOS expression .
Diseases: hypertension"	"Sentence: Vitamin E supplementation ameliorated hypertension , lowered plasma MDA concentration , and raised urinary NOx excretion while significantly lowering vascular , but not renal , tissue eNOS and iNOS expression .
Diseases:"
2601	Vitamin E supplementation had no effect on either blood pressure , plasma MDA , or NOS expression in the control group .	O O O O O O O O O O O O O O O O O O O O O O	B I O O O O O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: Vitamin E supplementation had no effect on either blood pressure , plasma MDA , or NOS expression in the control group .
Diseases: "	"Sentence: Vitamin E supplementation had no effect on either blood pressure , plasma MDA , or NOS expression in the control group .
Diseases:"
2602	The study also revealed significant inhibition of NOS enzymatic activity by lead in cell - free preparations .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O	[]	0	0	"Sentence: The study also revealed significant inhibition of NOS enzymatic activity by lead in cell - free preparations .
Diseases: "	"Sentence: The study also revealed significant inhibition of NOS enzymatic activity by lead in cell - free preparations .
Diseases:"
2603	In conclusion , lead - induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression .	O O O O O O B O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: In conclusion , lead - induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression .
Diseases: hypertension"	"Sentence: In conclusion , lead - induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression .
Diseases:"
2604	This is , in part , due to ROS - mediated NO inactivation , lead - associated inhibition of NOS activity , and perhaps stimulatory actions of increased shear stress associated with hypertension .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O B O O B O O B O O O O O O O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: This is , in part , due to ROS - mediated NO inactivation , lead - associated inhibition of NOS activity , and perhaps stimulatory actions of increased shear stress associated with hypertension .
Diseases: hypertension"	"Sentence: This is , in part , due to ROS - mediated NO inactivation , lead - associated inhibition of NOS activity , and perhaps stimulatory actions of increased shear stress associated with hypertension .
Diseases:"
2605	Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication .	O O B I I O O O O O O O O O O O O O O	O O O O O O O O B O B O O O O O O O O	['valvular heart disease']	1	5	"Sentence: Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication .
Diseases: valvular heart disease"	"Sentence: Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication .
Diseases:"
2606	BACKGROUND : Because uncontrolled echocardiographic surveys suggested that up to 30 % to 38 % of users of fenfluramine and dexfenfluramine had valvular disease , these drugs were withdrawn from the market .	O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O	['valvular disease']	1	4	"Sentence: BACKGROUND : Because uncontrolled echocardiographic surveys suggested that up to 30 % to 38 % of users of fenfluramine and dexfenfluramine had valvular disease , these drugs were withdrawn from the market .
Diseases: valvular disease"	"Sentence: BACKGROUND : Because uncontrolled echocardiographic surveys suggested that up to 30 % to 38 % of users of fenfluramine and dexfenfluramine had valvular disease , these drugs were withdrawn from the market .
Diseases:"
2607	To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications .	O O O O O O O O B I O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O B O O O O O O O O O O O	['valvular abnormalities']	1	4	"Sentence: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications .
Diseases: valvular abnormalities"	"Sentence: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications .
Diseases:"
2608	DESIGN : Cohort study .	O O O O O	O O O O O	[]	0	0	"Sentence: DESIGN : Cohort study .
Diseases: "	"Sentence: DESIGN : Cohort study .
Diseases:"
2609	SETTING : Academic primary care practices .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: SETTING : Academic primary care practices .
Diseases: "	"Sentence: SETTING : Academic primary care practices .
Diseases:"
2610	PATIENTS : 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O B O O O O O O O O O O O O	[]	0	0	"Sentence: PATIENTS : 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy .
Diseases: "	"Sentence: PATIENTS : 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy .
Diseases:"
2611	MEASUREMENTS : Follow - up echocardiography .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: MEASUREMENTS : Follow - up echocardiography .
Diseases: "	"Sentence: MEASUREMENTS : Follow - up echocardiography .
Diseases:"
2612	The primary outcome was new or worsening valvulopathy , defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U . S . Food and Drug Administration criteria ( at least mild aortic regurgitation or moderate mitral regurgitation ) .	O O O O O O O B O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O O O O O B I O O B I O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['aortic or mitral regurgitation', 'valvulopathy', 'mitral regurgitation', 'aortic regurgitation']	4	27	"Sentence: The primary outcome was new or worsening valvulopathy , defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U . S . Food and Drug Administration criteria ( at least mild aortic regurgitation or moderate mitral regurgitation ) .
Diseases: aortic or mitral regurgitation, valvulopathy, mitral regurgitation, aortic regurgitation"	"Sentence: The primary outcome was new or worsening valvulopathy , defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U . S . Food and Drug Administration criteria ( at least mild aortic regurgitation or moderate mitral regurgitation ) .
Diseases:"
2613	Two patients ( 4 . 3 % [ 95 % CI , 0 . 6 % to 14 . 8 % ] ) receiving fenfluramine - phentermine developed valvular heart disease .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O	['valvular heart disease']	1	5	"Sentence: Two patients ( 4 . 3 % [ 95 % CI , 0 . 6 % to 14 . 8 % ] ) receiving fenfluramine - phentermine developed valvular heart disease .
Diseases: valvular heart disease"	"Sentence: Two patients ( 4 . 3 % [ 95 % CI , 0 . 6 % to 14 . 8 % ] ) receiving fenfluramine - phentermine developed valvular heart disease .
Diseases:"
2614	One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation .	O O O B I I O O B I O O O O O O	O O O O O O O O O O O O O O O O	['bicuspid aortic valve', 'aortic regurgitation']	2	15	"Sentence: One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation .
Diseases: bicuspid aortic valve, aortic regurgitation"	"Sentence: One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation .
Diseases:"
2615	The second patient developed new moderate aortic insufficiency .	O O O O O O B I O	O O O O O O O O O	['aortic insufficiency']	1	6	"Sentence: The second patient developed new moderate aortic insufficiency .
Diseases: aortic insufficiency"	"Sentence: The second patient developed new moderate aortic insufficiency .
Diseases:"
2616	Users of diet medications are at risk for valvular heart disease .	O O O O O O O O B I I O	O O O O O O O O O O O O	['valvular heart disease']	1	5	"Sentence: Users of diet medications are at risk for valvular heart disease .
Diseases: valvular heart disease"	"Sentence: Users of diet medications are at risk for valvular heart disease .
Diseases:"
2617	However , the incidence may be lower than that reported previously .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: However , the incidence may be lower than that reported previously .
Diseases: "	"Sentence: However , the incidence may be lower than that reported previously .
Diseases:"
2618	Carboplatin toxic effects on the peripheral nervous system of the rat .	O O O O O O O O O O O O	B O O O O O O O O O O O	[]	0	0	"Sentence: Carboplatin toxic effects on the peripheral nervous system of the rat .
Diseases: "	"Sentence: Carboplatin toxic effects on the peripheral nervous system of the rat .
Diseases:"
2619	The most striking of carboplatin 's advantages ( CBDCA ) over cisplatin ( CDDP ) is its markedly reduced rate of neurotoxic effects .	O O O O O O O O O O O O O O O O O O O O O B O O	O O O O B O O O B O O B O B O O O O O O O O O O	['neurotoxic']	1	4	"Sentence: The most striking of carboplatin 's advantages ( CBDCA ) over cisplatin ( CDDP ) is its markedly reduced rate of neurotoxic effects .
Diseases: neurotoxic"	"Sentence: The most striking of carboplatin 's advantages ( CBDCA ) over cisplatin ( CDDP ) is its markedly reduced rate of neurotoxic effects .
Diseases:"
2620	However , the use of CBDCA higher - intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O B I I I O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['neurotoxic', 'peripheral nervous system damage']	2	9	"Sentence: However , the use of CBDCA higher - intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage .
Diseases: neurotoxic, peripheral nervous system damage"	"Sentence: However , the use of CBDCA higher - intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage .
Diseases:"
2621	MATERIALS AND METHODS : Two different schedules of CBDCA administration ( 10 mg / kg and 15 mg / kg i . p .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: MATERIALS AND METHODS : Two different schedules of CBDCA administration ( 10 mg / kg and 15 mg / kg i . p .
Diseases: "	"Sentence: MATERIALS AND METHODS : Two different schedules of CBDCA administration ( 10 mg / kg and 15 mg / kg i . p .
Diseases:"
2622	twice a week for nine times ) were evaluated in Wistar rats .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: twice a week for nine times ) were evaluated in Wistar rats .
Diseases: "	"Sentence: twice a week for nine times ) were evaluated in Wistar rats .
Diseases:"
2623	Neurotoxicity was assessed for behavioral ( tail - flick test ) , neurophysiological ( nerve conduction velocity in the tail nerve ) , morphological , morphometrical and analytical effects .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['neurotoxicity']	1	4	"Sentence: Neurotoxicity was assessed for behavioral ( tail - flick test ) , neurophysiological ( nerve conduction velocity in the tail nerve ) , morphological , morphometrical and analytical effects .
Diseases: neurotoxicity"	"Sentence: Neurotoxicity was assessed for behavioral ( tail - flick test ) , neurophysiological ( nerve conduction velocity in the tail nerve ) , morphological , morphometrical and analytical effects .
Diseases:"
2624	RESULTS : CBDCA administration induced dose - dependent peripheral neurotoxicity .	O O O O O O O O B I O	O O B O O O O O O O O	['peripheral neurotoxicity']	1	5	"Sentence: RESULTS : CBDCA administration induced dose - dependent peripheral neurotoxicity .
Diseases: peripheral neurotoxicity"	"Sentence: RESULTS : CBDCA administration induced dose - dependent peripheral neurotoxicity .
Diseases:"
2625	Pain perception and nerve conduction velocity in the tail were significantly impaired , particularly after the high - dose treatment .	B O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: Pain perception and nerve conduction velocity in the tail were significantly impaired , particularly after the high - dose treatment .
Diseases: pain"	"Sentence: Pain perception and nerve conduction velocity in the tail were significantly impaired , particularly after the high - dose treatment .
Diseases:"
2626	The dorsal root ganglia sensory neurons and , to a lesser extent , satellite cells showed the same changes as those induced by CDDP , mainly affecting the nucleus and nucleolus of ganglionic sensory neurons .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: The dorsal root ganglia sensory neurons and , to a lesser extent , satellite cells showed the same changes as those induced by CDDP , mainly affecting the nucleus and nucleolus of ganglionic sensory neurons .
Diseases: "	"Sentence: The dorsal root ganglia sensory neurons and , to a lesser extent , satellite cells showed the same changes as those induced by CDDP , mainly affecting the nucleus and nucleolus of ganglionic sensory neurons .
Diseases:"
2627	Moreover , significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment .	O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O B O O	[]	0	0	"Sentence: Moreover , significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment .
Diseases: "	"Sentence: Moreover , significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment .
Diseases:"
2628	CONCLUSIONS : CBDCA is neurotoxic in our model , and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['neurotoxicity', 'neurotoxic']	2	7	"Sentence: CONCLUSIONS : CBDCA is neurotoxic in our model , and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism .
Diseases: neurotoxicity, neurotoxic"	"Sentence: CONCLUSIONS : CBDCA is neurotoxic in our model , and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism .
Diseases:"
2629	This model can be used alone or in combination with other drugs to explore the effect of CBDCA on the peripheral nervous system .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O	[]	0	0	"Sentence: This model can be used alone or in combination with other drugs to explore the effect of CBDCA on the peripheral nervous system .
Diseases: "	"Sentence: This model can be used alone or in combination with other drugs to explore the effect of CBDCA on the peripheral nervous system .
Diseases:"
2630	Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case - control study .	O O O B I O O O B I O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	['endometrial carcinoma', 'breast cancer']	2	8	"Sentence: Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case - control study .
Diseases: endometrial carcinoma, breast cancer"	"Sentence: Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case - control study .
Diseases:"
2631	F d ration Nationale des Centres de Lutte Contre le Cancer ( FNCLCC ) .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: F d ration Nationale des Centres de Lutte Contre le Cancer ( FNCLCC ) .
Diseases: "	"Sentence: F d ration Nationale des Centres de Lutte Contre le Cancer ( FNCLCC ) .
Diseases:"
2632	Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer , its endometrial iatrogenic effects must be carefully examined .	O O O O O O B I O O O O O O O O O B I O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	['breast cancer']	1	3	"Sentence: Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer , its endometrial iatrogenic effects must be carefully examined .
Diseases: breast cancer"	"Sentence: Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer , its endometrial iatrogenic effects must be carefully examined .
Diseases:"
2633	We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case - control study .	O O O O O O B I O O O O O O O O O O B I O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O	['endometrial cancer', 'breast cancer']	2	7	"Sentence: We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case - control study .
Diseases: endometrial cancer, breast cancer"	"Sentence: We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case - control study .
Diseases:"
2634	Cases of endometrial cancer diagnosed after breast cancer ( n = 135 ) and 467 controls matched for age , year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included .	O O B I O O B I O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['endometrial cancer', 'breast cancer']	2	7	"Sentence: Cases of endometrial cancer diagnosed after breast cancer ( n = 135 ) and 467 controls matched for age , year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included .
Diseases: endometrial cancer, breast cancer"	"Sentence: Cases of endometrial cancer diagnosed after breast cancer ( n = 135 ) and 467 controls matched for age , year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included .
Diseases:"
2635	Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not ( crude relative risk = 4 . 9 , p = 0 . 0001 ) .	O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['endometrial cancer']	1	4	"Sentence: Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not ( crude relative risk = 4 . 9 , p = 0 . 0001 ) .
Diseases: endometrial cancer"	"Sentence: Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not ( crude relative risk = 4 . 9 , p = 0 . 0001 ) .
Diseases:"
2636	Univariate and adjusted analyses showed that the risk increased with the length of treatment ( p = 0 . 0001 ) or the cumulative dose of tamoxifen received ( p = 0 . 0001 ) , irrespective of the daily dose .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Univariate and adjusted analyses showed that the risk increased with the length of treatment ( p = 0 . 0001 ) or the cumulative dose of tamoxifen received ( p = 0 . 0001 ) , irrespective of the daily dose .
Diseases: "	"Sentence: Univariate and adjusted analyses showed that the risk increased with the length of treatment ( p = 0 . 0001 ) or the cumulative dose of tamoxifen received ( p = 0 . 0001 ) , irrespective of the daily dose .
Diseases:"
2637	Women who had undergone pelvic radiotherapy also had a higher risk ( crude relative risk = 7 . 8 , p = 0 . 0001 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Women who had undergone pelvic radiotherapy also had a higher risk ( crude relative risk = 7 . 8 , p = 0 . 0001 ) .
Diseases: "	"Sentence: Women who had undergone pelvic radiotherapy also had a higher risk ( crude relative risk = 7 . 8 , p = 0 . 0001 ) .
Diseases:"
2638	After adjusting for confounding factors , the risk was higher for tamoxifen users ( p = 0 . 0012 ) , treatment for more than 3 years ( all p < 0 . 03 ) and pelvic radiotherapy ( p = 0 . 012 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After adjusting for confounding factors , the risk was higher for tamoxifen users ( p = 0 . 0012 ) , treatment for more than 3 years ( all p < 0 . 03 ) and pelvic radiotherapy ( p = 0 . 012 ) .
Diseases: "	"Sentence: After adjusting for confounding factors , the risk was higher for tamoxifen users ( p = 0 . 0012 ) , treatment for more than 3 years ( all p < 0 . 03 ) and pelvic radiotherapy ( p = 0 . 012 ) .
Diseases:"
2639	Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment .	O O O B I O O O O O O B I O O O O O O B I O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['advanced disease', 'endometrial cancer']	2	8	"Sentence: Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment .
Diseases: advanced disease, endometrial cancer"	"Sentence: Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment .
Diseases:"
2640	Our results suggest a causal role of tamoxifen in endometrial cancer , particularly when used as currently proposed for breast cancer prevention .	O O O O O O O O O B I O O O O O O O O B I O O	O O O O O O O B O O O O O O O O O O O O O O O	['endometrial cancer', 'breast cancer']	2	7	"Sentence: Our results suggest a causal role of tamoxifen in endometrial cancer , particularly when used as currently proposed for breast cancer prevention .
Diseases: endometrial cancer, breast cancer"	"Sentence: Our results suggest a causal role of tamoxifen in endometrial cancer , particularly when used as currently proposed for breast cancer prevention .
Diseases:"
2641	Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer .	O O O O O O O O O O O B I O	O O O O O O O O O O O O O O	['breast cancer']	1	3	"Sentence: Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer .
Diseases: breast cancer"	"Sentence: Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer .
Diseases:"
2642	Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis .	B I O O O O O O O O O O	O O O O O O O B O O O O	['endometrial cancers']	1	4	"Sentence: Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis .
Diseases: endometrial cancers"	"Sentence: Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis .
Diseases:"
2643	Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment .	O O O O O B I O O O O O O O O O O	O O O B O O O O O O O O O O O O O	['breast cancer']	1	3	"Sentence: Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment .
Diseases: breast cancer"	"Sentence: Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment .
Diseases:"
2644	A long - term evaluation of the risk - benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted .	O O O O O O O O O O O O O O O O O O B I O O O O	O O O O O O O O O O O O B O O O O O O O O O O O	['breast cancer']	1	3	"Sentence: A long - term evaluation of the risk - benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted .
Diseases: breast cancer"	"Sentence: A long - term evaluation of the risk - benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted .
Diseases:"
2645	Granulosa cell tumor of the ovary associated with antecedent tamoxifen use .	B I I I I I O O O O O O	O O O O O O O O O B O O	['granulosa cell tumor of the ovary']	1	9	"Sentence: Granulosa cell tumor of the ovary associated with antecedent tamoxifen use .
Diseases: granulosa cell tumor of the ovary"	"Sentence: Granulosa cell tumor of the ovary associated with antecedent tamoxifen use .
Diseases:"
2646	BACKGROUND : Increased attention has been focused recently on the estrogenic effects of tamoxifen .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O	[]	0	0	"Sentence: BACKGROUND : Increased attention has been focused recently on the estrogenic effects of tamoxifen .
Diseases: "	"Sentence: BACKGROUND : Increased attention has been focused recently on the estrogenic effects of tamoxifen .
Diseases:"
2647	Review of the literature reveals an association between tamoxifen use and gynecologic tumors .	O O O O O O O O O O O O B O	O O O O O O O O B O O O O O	['tumors']	1	3	"Sentence: Review of the literature reveals an association between tamoxifen use and gynecologic tumors .
Diseases: tumors"	"Sentence: Review of the literature reveals an association between tamoxifen use and gynecologic tumors .
Diseases:"
2648	CASE : A 52 - year - old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor - positive breast carcinoma .	O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O B O O O B O O O O O O	['breast carcinoma']	1	4	"Sentence: CASE : A 52 - year - old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor - positive breast carcinoma .
Diseases: breast carcinoma"	"Sentence: CASE : A 52 - year - old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor - positive breast carcinoma .
Diseases:"
2649	Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use .	O O O O O O O O O O O O O O O O	O B O O B O O O O O O O O B O O	[]	0	0	"Sentence: Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use .
Diseases: "	"Sentence: Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use .
Diseases:"
2650	After an additional 17 months of elevated serum transaminases , the patient was found to have a stage Ic granulosa cell tumor of the ovary .	O O O O O O O O O O O O O O O O O O O B I I I I I O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['granulosa cell tumor of the ovary']	1	9	"Sentence: After an additional 17 months of elevated serum transaminases , the patient was found to have a stage Ic granulosa cell tumor of the ovary .
Diseases: granulosa cell tumor of the ovary"	"Sentence: After an additional 17 months of elevated serum transaminases , the patient was found to have a stage Ic granulosa cell tumor of the ovary .
Diseases:"
2651	Patients with tamoxifen - induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism .	O O O O O B I O O O O O O B I I O O O O O O O	O O B O O O O O O O O O O O O O O O O O B O O	['granulosa cell tumors', 'liver dysfunction']	2	8	"Sentence: Patients with tamoxifen - induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism .
Diseases: granulosa cell tumors, liver dysfunction"	"Sentence: Patients with tamoxifen - induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism .
Diseases:"
2652	A murine model of adenomyosis : the effects of hyperprolactinemia induced by fluoxetine hydrochloride , a selective serotonin reuptake inhibitor , on adenomyosis induction in Wistar albino rats .	O O O O B O O O O B O O O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O B I O O B B I O O O O O O O O O O	['adenomyosis', 'hyperprolactinemia']	2	10	"Sentence: A murine model of adenomyosis : the effects of hyperprolactinemia induced by fluoxetine hydrochloride , a selective serotonin reuptake inhibitor , on adenomyosis induction in Wistar albino rats .
Diseases: adenomyosis, hyperprolactinemia"	"Sentence: A murine model of adenomyosis : the effects of hyperprolactinemia induced by fluoxetine hydrochloride , a selective serotonin reuptake inhibitor , on adenomyosis induction in Wistar albino rats .
Diseases:"
2653	The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis .	O O O O O O O O O O O O O O O O O B O O O O O O B O	O O O O O O O O O B O O O O O O O O O O O O O O O O	['adenomyosis', 'hyperprolactinemia']	2	10	"Sentence: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis .
Diseases: adenomyosis, hyperprolactinemia"	"Sentence: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis .
Diseases:"
2654	DESIGN : Fluoxetine , a serotonin reuptake inhibitor , was given to Wistar Albino rats for 98 days to produce hyperprolactinemia .	O O O O O O O O O O O O O O O O O O O O B O	O O B O O B O O O O O O O O O O O O O O O O	['hyperprolactinemia']	1	6	"Sentence: DESIGN : Fluoxetine , a serotonin reuptake inhibitor , was given to Wistar Albino rats for 98 days to produce hyperprolactinemia .
Diseases: hyperprolactinemia"	"Sentence: DESIGN : Fluoxetine , a serotonin reuptake inhibitor , was given to Wistar Albino rats for 98 days to produce hyperprolactinemia .
Diseases:"
2655	The drug was given to two groups consisting of castrated and noncastrated rats and compared to two groups of castrated and noncastrated controls .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The drug was given to two groups consisting of castrated and noncastrated rats and compared to two groups of castrated and noncastrated controls .
Diseases: "	"Sentence: The drug was given to two groups consisting of castrated and noncastrated rats and compared to two groups of castrated and noncastrated controls .
Diseases:"
2656	Prolactin levels were measured and the uteri of the rats were removed for histopathological analysis at the end of 98 days .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Prolactin levels were measured and the uteri of the rats were removed for histopathological analysis at the end of 98 days .
Diseases: "	"Sentence: Prolactin levels were measured and the uteri of the rats were removed for histopathological analysis at the end of 98 days .
Diseases:"
2657	SETTING : Marmara University School of Medicine , Department of Histology and Embryology , Zeynep Kamil Women and Children 's Hospital .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: SETTING : Marmara University School of Medicine , Department of Histology and Embryology , Zeynep Kamil Women and Children 's Hospital .
Diseases: "	"Sentence: SETTING : Marmara University School of Medicine , Department of Histology and Embryology , Zeynep Kamil Women and Children 's Hospital .
Diseases:"
2658	MAIN OUTCOME MEASURES :	O O O O	O O O O	[]	0	0	"Sentence: MAIN OUTCOME MEASURES :
Diseases: "	"Sentence: MAIN OUTCOME MEASURES :
Diseases:"
2659	Serum prolactin levels , uterine histopathology .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: Serum prolactin levels , uterine histopathology .
Diseases: "	"Sentence: Serum prolactin levels , uterine histopathology .
Diseases:"
2660	The prolactin levels of castrated and noncastrated groups treated with fluoxetine were statistically significantly higher when compared to their respective control groups .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: The prolactin levels of castrated and noncastrated groups treated with fluoxetine were statistically significantly higher when compared to their respective control groups .
Diseases: "	"Sentence: The prolactin levels of castrated and noncastrated groups treated with fluoxetine were statistically significantly higher when compared to their respective control groups .
Diseases:"
2661	Histological studies revealed 11 cases of adenomyosis , all within the noncastrated group receiving fluoxetine .	O O O O O O B O O O O O O O O O	O O O O O O O O O O O O O O B O	['adenomyosis']	1	3	"Sentence: Histological studies revealed 11 cases of adenomyosis , all within the noncastrated group receiving fluoxetine .
Diseases: adenomyosis"	"Sentence: Histological studies revealed 11 cases of adenomyosis , all within the noncastrated group receiving fluoxetine .
Diseases:"
2662	It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian steroids that results in a myometrial invasion by endometrial stroma .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian steroids that results in a myometrial invasion by endometrial stroma .
Diseases: "	"Sentence: It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian steroids that results in a myometrial invasion by endometrial stroma .
Diseases:"
2663	This invasion eventually progresses to adenomyosis .	O O O O O B O	O O O O O O O	['adenomyosis']	1	3	"Sentence: This invasion eventually progresses to adenomyosis .
Diseases: adenomyosis"	"Sentence: This invasion eventually progresses to adenomyosis .
Diseases:"
2664	Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function .	O O O B O O O O O O O O O	O O O O O O B O B O O O O	['hypotension']	1	3	"Sentence: Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function .
Diseases: hypotension"	"Sentence: Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function .
Diseases:"
2665	The effect of deliberate hypotension on brain function measured by neuropsychological tests was studied in 41 adult patients .	O O O O B O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: The effect of deliberate hypotension on brain function measured by neuropsychological tests was studied in 41 adult patients .
Diseases: hypotension"	"Sentence: The effect of deliberate hypotension on brain function measured by neuropsychological tests was studied in 41 adult patients .
Diseases:"
2666	Twenty - four patients were anaesthetized for middle - ear surgery with deliberate hypotension induced by labetalol with isoflurane ( hypotensive group ) .	O O O O O O O O O O O O O B O O O O O O B O O O	O O O O O O O O O O O O O O O O B O B O O O O O	['hypotensive', 'hypotension']	2	6	"Sentence: Twenty - four patients were anaesthetized for middle - ear surgery with deliberate hypotension induced by labetalol with isoflurane ( hypotensive group ) .
Diseases: hypotensive, hypotension"	"Sentence: Twenty - four patients were anaesthetized for middle - ear surgery with deliberate hypotension induced by labetalol with isoflurane ( hypotensive group ) .
Diseases:"
2667	Seventeen patients without hypotension served as a control group .	O O O B O O O O O O	O O O O O O O O O O	['hypotension']	1	3	"Sentence: Seventeen patients without hypotension served as a control group .
Diseases: hypotension"	"Sentence: Seventeen patients without hypotension served as a control group .
Diseases:"
2668	The mean arterial pressure was 77 + / - 2 mmHg ( 10 . 3 + / - 0 . 3 kPa ) before hypotension and 50 + / - 0	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: The mean arterial pressure was 77 + / - 2 mmHg ( 10 . 3 + / - 0 . 3 kPa ) before hypotension and 50 + / - 0
Diseases: hypotension"	"Sentence: The mean arterial pressure was 77 + / - 2 mmHg ( 10 . 3 + / - 0 . 3 kPa ) before hypotension and 50 + / - 0
Diseases:"
2669	mmHg ( 6 . 7 + / - 0 . 0 kPa ) during hypotension in the hypotensive group , and 86 + / -	O O O O O O O O O O O O O O B O O B O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['hypotensive', 'hypotension']	2	6	"Sentence: mmHg ( 6 . 7 + / - 0 . 0 kPa ) during hypotension in the hypotensive group , and 86 + / -
Diseases: hypotensive, hypotension"	"Sentence: mmHg ( 6 . 7 + / - 0 . 0 kPa ) during hypotension in the hypotensive group , and 86 + / -
Diseases:"
2670	2 mmHg ( 11 . 5 + / - 0 . 3 kPa ) during anaesthesia in the control group .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 2 mmHg ( 11 . 5 + / - 0 . 3 kPa ) during anaesthesia in the control group .
Diseases: "	"Sentence: 2 mmHg ( 11 . 5 + / - 0 . 3 kPa ) during anaesthesia in the control group .
Diseases:"
2671	The following psychological tests were performed : four subtests of the Wechsler Adult Intelligence Scale ( similarities , digit span , vocabulary and digit symbol ) , Trail - Making tests A and B , Zung tests ( self - rating anxiety scale and self - rating depression scale ) and two - part memory test battery with immediate and delayed recall .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['depression', 'anxiety']	2	4	"Sentence: The following psychological tests were performed : four subtests of the Wechsler Adult Intelligence Scale ( similarities , digit span , vocabulary and digit symbol ) , Trail - Making tests A and B , Zung tests ( self - rating anxiety scale and self - rating depression scale ) and two - part memory test battery with immediate and delayed recall .
Diseases: depression, anxiety"	"Sentence: The following psychological tests were performed : four subtests of the Wechsler Adult Intelligence Scale ( similarities , digit span , vocabulary and digit symbol ) , Trail - Making tests A and B , Zung tests ( self - rating anxiety scale and self - rating depression scale ) and two - part memory test battery with immediate and delayed recall .
Diseases:"
2672	The tests were performed preoperatively and 2 days postoperatively .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: The tests were performed preoperatively and 2 days postoperatively .
Diseases: "	"Sentence: The tests were performed preoperatively and 2 days postoperatively .
Diseases:"
2673	There were no statistically significant differences between the groups in any of the tests in the changes from preoperative value to postoperative value .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There were no statistically significant differences between the groups in any of the tests in the changes from preoperative value to postoperative value .
Diseases: "	"Sentence: There were no statistically significant differences between the groups in any of the tests in the changes from preoperative value to postoperative value .
Diseases:"
2674	The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia .	O O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O B O B O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia .
Diseases: hypotension"	"Sentence: The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia .
Diseases:"
2675	Auditory disturbance associated with interscalene brachial plexus block .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Auditory disturbance associated with interscalene brachial plexus block .
Diseases: "	"Sentence: Auditory disturbance associated with interscalene brachial plexus block .
Diseases:"
2676	We performed an audiometric study in 20 patients who underwent surgery of the shoulder region under an interscalene brachial plexus block ( IBPB ) .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We performed an audiometric study in 20 patients who underwent surgery of the shoulder region under an interscalene brachial plexus block ( IBPB ) .
Diseases: "	"Sentence: We performed an audiometric study in 20 patients who underwent surgery of the shoulder region under an interscalene brachial plexus block ( IBPB ) .
Diseases:"
2677	Bupivacaine 0 . 75 % with adrenaline was given followed by a 24 - hr continuous infusion of 0 . 25 % bupivacaine .	O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O B O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: Bupivacaine 0 . 75 % with adrenaline was given followed by a 24 - hr continuous infusion of 0 . 25 % bupivacaine .
Diseases: "	"Sentence: Bupivacaine 0 . 75 % with adrenaline was given followed by a 24 - hr continuous infusion of 0 . 25 % bupivacaine .
Diseases:"
2678	Three audiometric threshold measurements ( 0 . 25 - 18 kHz ) were made : the first before IBPB , the second 2 - 6 h after surgery and the third on the first day after operation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Three audiometric threshold measurements ( 0 . 25 - 18 kHz ) were made : the first before IBPB , the second 2 - 6 h after surgery and the third on the first day after operation .
Diseases: "	"Sentence: Three audiometric threshold measurements ( 0 . 25 - 18 kHz ) were made : the first before IBPB , the second 2 - 6 h after surgery and the third on the first day after operation .
Diseases:"
2679	In four patients hearing impairment on the side of the block was demonstrated after operation , in three measurements on the day of surgery and in one on the following day .	O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hearing impairment']	1	3	"Sentence: In four patients hearing impairment on the side of the block was demonstrated after operation , in three measurements on the day of surgery and in one on the following day .
Diseases: hearing impairment"	"Sentence: In four patients hearing impairment on the side of the block was demonstrated after operation , in three measurements on the day of surgery and in one on the following day .
Diseases:"
2680	The frequencies at which the impairment occurred varied between patients ; in one only low frequencies ( 0 . 25 - 0 . 5 kHz ) were involved .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The frequencies at which the impairment occurred varied between patients ; in one only low frequencies ( 0 . 25 - 0 . 5 kHz ) were involved .
Diseases: "	"Sentence: The frequencies at which the impairment occurred varied between patients ; in one only low frequencies ( 0 . 25 - 0 . 5 kHz ) were involved .
Diseases:"
2681	The maximum change in threshold was 35 dB at 6 kHz measured at the end of the continuous infusion of bupivacaine .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: The maximum change in threshold was 35 dB at 6 kHz measured at the end of the continuous infusion of bupivacaine .
Diseases: "	"Sentence: The maximum change in threshold was 35 dB at 6 kHz measured at the end of the continuous infusion of bupivacaine .
Diseases:"
2682	This patient had hearing threshold changes ( 15 - 20 dB ) at 6 - 10 kHz on the opposite side also .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This patient had hearing threshold changes ( 15 - 20 dB ) at 6 - 10 kHz on the opposite side also .
Diseases: "	"Sentence: This patient had hearing threshold changes ( 15 - 20 dB ) at 6 - 10 kHz on the opposite side also .
Diseases:"
2683	IBPB may cause transient auditory dysfunction in the ipsilateral ear , possibly via an effect on sympathetic innervation .	O O O O B I O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O	['auditory dysfunction']	1	3	"Sentence: IBPB may cause transient auditory dysfunction in the ipsilateral ear , possibly via an effect on sympathetic innervation .
Diseases: auditory dysfunction"	"Sentence: IBPB may cause transient auditory dysfunction in the ipsilateral ear , possibly via an effect on sympathetic innervation .
Diseases:"
2684	Midazolam compared with thiopentone as an induction agent .	O O O O O O O O O	B O O B O O O O O	[]	0	0	"Sentence: Midazolam compared with thiopentone as an induction agent .
Diseases: "	"Sentence: Midazolam compared with thiopentone as an induction agent .
Diseases:"
2685	In patients premedicated with scopolamine + morphine ( + 5 mg nitrazepam the evening before surgery ) , the sleep - inducing effect of midazolam 0 . 15 mg / kg i . v . was clearly slower in onset than that of thiopentone 4 . 67 mg / kg i . v .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O B O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: In patients premedicated with scopolamine + morphine ( + 5 mg nitrazepam the evening before surgery ) , the sleep - inducing effect of midazolam 0 . 15 mg / kg i . v . was clearly slower in onset than that of thiopentone 4 . 67 mg / kg i . v .
Diseases: "	"Sentence: In patients premedicated with scopolamine + morphine ( + 5 mg nitrazepam the evening before surgery ) , the sleep - inducing effect of midazolam 0 . 15 mg / kg i . v . was clearly slower in onset than that of thiopentone 4 . 67 mg / kg i . v .
Diseases:"
2686	Somewhat fewer cardiovascular and local sequelae were found in the midazolam group , but , although apnoea occurred less often in the midazolam group it lasted longer .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O B O O O O O	['apnoea']	1	4	"Sentence: Somewhat fewer cardiovascular and local sequelae were found in the midazolam group , but , although apnoea occurred less often in the midazolam group it lasted longer .
Diseases: apnoea"	"Sentence: Somewhat fewer cardiovascular and local sequelae were found in the midazolam group , but , although apnoea occurred less often in the midazolam group it lasted longer .
Diseases:"
2687	On the whole , the differences between midazolam and thiopentone had no apparent clinical consequences .	O O O O O O O O O O O O O O O O	O O O O O O O B O B O O O O O O	[]	0	0	"Sentence: On the whole , the differences between midazolam and thiopentone had no apparent clinical consequences .
Diseases: "	"Sentence: On the whole , the differences between midazolam and thiopentone had no apparent clinical consequences .
Diseases:"
2688	Midazolam is a new alternative agent for induction in combination anaesthesia .	O O O O O O O O O O O O	B O O O O O O O O O O O	[]	0	0	"Sentence: Midazolam is a new alternative agent for induction in combination anaesthesia .
Diseases: "	"Sentence: Midazolam is a new alternative agent for induction in combination anaesthesia .
Diseases:"
2689	Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates .	B O O O O O O O O O O	O O O O O O B O O O O	['cardiotoxic']	1	3	"Sentence: Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates .
Diseases: cardiotoxic"	"Sentence: Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates .
Diseases:"
2690	10 monkeys ( macaques ) received adriamycin by monthly intravenous injections at 12 mg / m2 ( 1 mg / kg ) .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 10 monkeys ( macaques ) received adriamycin by monthly intravenous injections at 12 mg / m2 ( 1 mg / kg ) .
Diseases: "	"Sentence: 10 monkeys ( macaques ) received adriamycin by monthly intravenous injections at 12 mg / m2 ( 1 mg / kg ) .
Diseases:"
2691	8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose ( 310 mg / m2 ) well below that considered the safe upper limit ( 550 mg / m2 ) in man .	O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['congestive heart failure']	1	5	"Sentence: 8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose ( 310 mg / m2 ) well below that considered the safe upper limit ( 550 mg / m2 ) in man .
Diseases: congestive heart failure"	"Sentence: 8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose ( 310 mg / m2 ) well below that considered the safe upper limit ( 550 mg / m2 ) in man .
Diseases:"
2692	Histologically , the myocardial lesions resembled those found in human anthracycline - induced cardiomyopathy .	O O O B I O O O O O O O O B O	O O O O O O O O O O B O O O O	['cardiomyopathy', 'myocardial lesions']	2	9	"Sentence: Histologically , the myocardial lesions resembled those found in human anthracycline - induced cardiomyopathy .
Diseases: cardiomyopathy, myocardial lesions"	"Sentence: Histologically , the myocardial lesions resembled those found in human anthracycline - induced cardiomyopathy .
Diseases:"
2693	1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg / m2 of adriamycin ; the 10th monkey is alive and well 26 months after the last dose of drug .	O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['acute myeloblastic leukemia']	1	7	"Sentence: 1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg / m2 of adriamycin ; the 10th monkey is alive and well 26 months after the last dose of drug .
Diseases: acute myeloblastic leukemia"	"Sentence: 1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg / m2 of adriamycin ; the 10th monkey is alive and well 26 months after the last dose of drug .
Diseases:"
2694	Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man , and that leukemia may be a consequence of prolonged treatment with this drug .	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['leukemia']	1	2	"Sentence: Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man , and that leukemia may be a consequence of prolonged treatment with this drug .
Diseases: leukemia"	"Sentence: Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man , and that leukemia may be a consequence of prolonged treatment with this drug .
Diseases:"
2695	Doxorubicin cardiomyopathy in children with left - sided Wilms tumor .	O B O O O O O O B I O	B O O O O O O O O O O	['cardiomyopathy', 'wilms tumor']	2	8	"Sentence: Doxorubicin cardiomyopathy in children with left - sided Wilms tumor .
Diseases: cardiomyopathy, wilms tumor"	"Sentence: Doxorubicin cardiomyopathy in children with left - sided Wilms tumor .
Diseases:"
2696	Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin .	O O O B I O O O O O O O B O O O O B O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O B O	['cardiomyopathy', 'tumor', 'wilms tumor']	3	10	"Sentence: Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin .
Diseases: cardiomyopathy, tumor, wilms tumor"	"Sentence: Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin .
Diseases:"
2697	The cardiomyopathy is attributed 1 ) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2 ) to the interaction of doxorubicin and irradiation on cardiac muscle .	O B O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O	['cardiomyopathy', 'wilms tumor']	2	8	"Sentence: The cardiomyopathy is attributed 1 ) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2 ) to the interaction of doxorubicin and irradiation on cardiac muscle .
Diseases: cardiomyopathy, wilms tumor"	"Sentence: The cardiomyopathy is attributed 1 ) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2 ) to the interaction of doxorubicin and irradiation on cardiac muscle .
Diseases:"
2698	It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation .	O O O O O O O O O O O O B I O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O	['wilms tumor']	1	4	"Sentence: It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation .
Diseases: wilms tumor"	"Sentence: It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation .
Diseases:"
2699	Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats .	O O O O O O O O O B O O O O O	O O O B O O B O O O O O O O O	['carcinogenesis']	1	4	"Sentence: Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats .
Diseases: carcinogenesis"	"Sentence: Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats .
Diseases:"
2700	Germfree ( GF )	O O O O	O O O O	[]	0	0	"Sentence: Germfree ( GF )
Diseases: "	"Sentence: Germfree ( GF )
Diseases:"
2701	Lobund strain Wistar ( LW ) rats , fed vegetable diet L - 485 , have developed prostate adenocarcinomas spontaneously ( 10 % incidence ) at average age 34 months .	O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O	O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O	['prostate adenocarcinomas']	1	8	"Sentence: Lobund strain Wistar ( LW ) rats , fed vegetable diet L - 485 , have developed prostate adenocarcinomas spontaneously ( 10 % incidence ) at average age 34 months .
Diseases: prostate adenocarcinomas"	"Sentence: Lobund strain Wistar ( LW ) rats , fed vegetable diet L - 485 , have developed prostate adenocarcinomas spontaneously ( 10 % incidence ) at average age 34 months .
Diseases:"
2702	Conventional LW rats , implanted with testosterone at age 4 months , developed a higher incidence of prostate cancer after an average interval of 14 months : 24 % had developed gross tumors , and 40 % when it included microscopic tumors .	O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O B O O O O O O O O B O	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['prostate cancer', 'tumors']	2	5	"Sentence: Conventional LW rats , implanted with testosterone at age 4 months , developed a higher incidence of prostate cancer after an average interval of 14 months : 24 % had developed gross tumors , and 40 % when it included microscopic tumors .
Diseases: prostate cancer, tumors"	"Sentence: Conventional LW rats , implanted with testosterone at age 4 months , developed a higher incidence of prostate cancer after an average interval of 14 months : 24 % had developed gross tumors , and 40 % when it included microscopic tumors .
Diseases:"
2703	Preliminary results indicate that testosterone - treated LW rats that were fed the same diet , which was supplemented with corn oil up to 20 % fat , developed prostate cancer after intervals of 6 - 12 months .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['prostate cancer']	1	3	"Sentence: Preliminary results indicate that testosterone - treated LW rats that were fed the same diet , which was supplemented with corn oil up to 20 % fat , developed prostate cancer after intervals of 6 - 12 months .
Diseases: prostate cancer"	"Sentence: Preliminary results indicate that testosterone - treated LW rats that were fed the same diet , which was supplemented with corn oil up to 20 % fat , developed prostate cancer after intervals of 6 - 12 months .
Diseases:"
2704	Aged GF Sprague - Dawley ( SD ) rats have not developed prostate cancer spontaneously .	O O O O O O O O O O O O B I O O	O O O O O O O O O O O O O O O O	['prostate cancer']	1	3	"Sentence: Aged GF Sprague - Dawley ( SD ) rats have not developed prostate cancer spontaneously .
Diseases: prostate cancer"	"Sentence: Aged GF Sprague - Dawley ( SD ) rats have not developed prostate cancer spontaneously .
Diseases:"
2705	Conventional SD rats fed diet L - 485 and treated with testosterone developed only prostatitis .	O O O O O O O O O O O O O O B O	O O O O O B I I O O O B O O O O	['prostatitis']	1	3	"Sentence: Conventional SD rats fed diet L - 485 and treated with testosterone developed only prostatitis .
Diseases: prostatitis"	"Sentence: Conventional SD rats fed diet L - 485 and treated with testosterone developed only prostatitis .
Diseases:"
2706	Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental prostate cancer .	O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O	['prostate cancer']	1	3	"Sentence: Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental prostate cancer .
Diseases: prostate cancer"	"Sentence: Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental prostate cancer .
Diseases:"
2707	Mitomycin C associated hemolytic uremic syndrome .	O O O B I I O	B I O O O O O	['hemolytic uremic syndrome']	1	7	"Sentence: Mitomycin C associated hemolytic uremic syndrome .
Diseases: hemolytic uremic syndrome"	"Sentence: Mitomycin C associated hemolytic uremic syndrome .
Diseases:"
2708	Mitomycin C associated Hemolytic Uremic Syndrome ( HUS ) is a potentially fatal but uncommon condition that is not yet widely recognised .	O O O B I I O B O O O O O O O O O O O O O O O	B I O O O O O O O O O O O O O O O O O O O O O	['hemolytic uremic syndrome', 'hus']	2	9	"Sentence: Mitomycin C associated Hemolytic Uremic Syndrome ( HUS ) is a potentially fatal but uncommon condition that is not yet widely recognised .
Diseases: hemolytic uremic syndrome, hus"	"Sentence: Mitomycin C associated Hemolytic Uremic Syndrome ( HUS ) is a potentially fatal but uncommon condition that is not yet widely recognised .
Diseases:"
2709	It consists of microangiopathic hemolytic anemia , thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10 % of patients treated with this agent .	O O O O B I O B O O B I O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B I O O O O O O O O O O O O O	['thrombocytopenia', 'hemolytic anemia', 'renal failure']	3	16	"Sentence: It consists of microangiopathic hemolytic anemia , thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10 % of patients treated with this agent .
Diseases: thrombocytopenia, hemolytic anemia, renal failure"	"Sentence: It consists of microangiopathic hemolytic anemia , thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10 % of patients treated with this agent .
Diseases:"
2710	The renal failure usually develops about 8 - 10 mth after start of mitomycin C treatment and the mortality is approximately 60 % from renal failure or pulmonary edema .	O B I O O O O O O O O O O O O O O O O O O O O O B I O B I O	O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O	['pulmonary edema', 'renal failure']	2	8	"Sentence: The renal failure usually develops about 8 - 10 mth after start of mitomycin C treatment and the mortality is approximately 60 % from renal failure or pulmonary edema .
Diseases: pulmonary edema, renal failure"	"Sentence: The renal failure usually develops about 8 - 10 mth after start of mitomycin C treatment and the mortality is approximately 60 % from renal failure or pulmonary edema .
Diseases:"
2711	Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi , expanded subendothelial zones in glomerular capillary walls , ischemic wrinkling of glomerular basement membranes and mesangiolysis .	B I O O O O O O O B O O O O B O O O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['renal lesions', 'hus', 'ischemic', 'thrombi']	4	13	"Sentence: Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi , expanded subendothelial zones in glomerular capillary walls , ischemic wrinkling of glomerular basement membranes and mesangiolysis .
Diseases: renal lesions, hus, ischemic, thrombi"	"Sentence: Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi , expanded subendothelial zones in glomerular capillary walls , ischemic wrinkling of glomerular basement membranes and mesangiolysis .
Diseases:"
2712	The mechanism of action is postulated as mitomycin C - induced endothelial cell damage .	O O O O O O O O O O O O O O O	O O O O O O O B I O O O O O O	[]	0	0	"Sentence: The mechanism of action is postulated as mitomycin C - induced endothelial cell damage .
Diseases: "	"Sentence: The mechanism of action is postulated as mitomycin C - induced endothelial cell damage .
Diseases:"
2713	We describe the clinical course and pathological findings in a 65 yr - old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema .	O O O O O O O O O O O O O O O O B I O O B I O B O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O	['pulmonary edema', 'thrombocytopenia', 'gastric adenocarcinoma', 'renal failure']	4	25	"Sentence: We describe the clinical course and pathological findings in a 65 yr - old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema .
Diseases: pulmonary edema, thrombocytopenia, gastric adenocarcinoma, renal failure"	"Sentence: We describe the clinical course and pathological findings in a 65 yr - old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema .
Diseases:"
2714	Continuous ambulatory ECG monitoring during fluorouracil therapy : a prospective study .	O O O O O O O O O O O O	O O O O O B O O O O O O	[]	0	0	"Sentence: Continuous ambulatory ECG monitoring during fluorouracil therapy : a prospective study .
Diseases: "	"Sentence: Continuous ambulatory ECG monitoring during fluorouracil therapy : a prospective study .
Diseases:"
2715	Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil ( 5 - FU ) therapy , this phenomenon has not been studied in a systematic fashion .	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O B I I O O O O O O O O O O O O O O	['cardiac toxicity']	1	3	"Sentence: Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil ( 5 - FU ) therapy , this phenomenon has not been studied in a systematic fashion .
Diseases: cardiac toxicity"	"Sentence: Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil ( 5 - FU ) therapy , this phenomenon has not been studied in a systematic fashion .
Diseases:"
2716	We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5 - FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes .	O O O O O O O O O O O O O O O O O O O B O O O O O O O B O O O	O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O	['ischemic', 'tumors']	2	5	"Sentence: We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5 - FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes .
Diseases: ischemic, tumors"	"Sentence: We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5 - FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes .
Diseases:"
2717	Patients were monitored for 23 + / - 4 hours before 5 - FU infusion , and 98 + / - 9 hours during 5 - FU infusion .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B I I O O O O O O O O O O B I I O O	[]	0	0	"Sentence: Patients were monitored for 23 + / - 4 hours before 5 - FU infusion , and 98 + / - 9 hours during 5 - FU infusion .
Diseases: "	"Sentence: Patients were monitored for 23 + / - 4 hours before 5 - FU infusion , and 98 + / - 9 hours during 5 - FU infusion .
Diseases:"
2718	Anginal episodes were rare : only one patient had angina	B O O O O O O O O B	O O O O O O O O O O	['angina', 'anginal']	2	5	"Sentence: Anginal episodes were rare : only one patient had angina
Diseases: angina, anginal"	"Sentence: Anginal episodes were rare : only one patient had angina
Diseases:"
2719	( during 5 - FU infusion ) .	O O O O O O O O	O O B I I O O O	[]	0	0	"Sentence: ( during 5 - FU infusion ) .
Diseases: "	"Sentence: ( during 5 - FU infusion ) .
Diseases:"
2720	However , asymptomatic ST changes ( greater than or equal to 1 mm ST deviation ) were common : six of 25 patients ( 24 % ) had ST changes before 5 - FU infusion v 17 ( 68 % ) during 5 - FU infusion ( P less than . 002 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O B I I O O O O O O O O O	[]	0	0	"Sentence: However , asymptomatic ST changes ( greater than or equal to 1 mm ST deviation ) were common : six of 25 patients ( 24 % ) had ST changes before 5 - FU infusion v 17 ( 68 % ) during 5 - FU infusion ( P less than . 002 ) .
Diseases: "	"Sentence: However , asymptomatic ST changes ( greater than or equal to 1 mm ST deviation ) were common : six of 25 patients ( 24 % ) had ST changes before 5 - FU infusion v 17 ( 68 % ) during 5 - FU infusion ( P less than . 002 ) .
Diseases:"
2721	The incidence of ischemic episodes per patient per hour was 0 . 05 + / - 0 . 02 prior to 5 - FU infusion v 0 . 13 + / - 0 . 03 during 5 - FU infusion ( P less than . 001 ) ; the duration of ECG changes was 0 . 6 + / - 0 . 3 minutes per patient per hour before 5 - FU v 1 . 9 + / - 0 . 5 minutes per patient per hour during 5 - FU ( P less than . 01 ) .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O B I I O O O O O O O O	['ischemic']	1	3	"Sentence: The incidence of ischemic episodes per patient per hour was 0 . 05 + / - 0 . 02 prior to 5 - FU infusion v 0 . 13 + / - 0 . 03 during 5 - FU infusion ( P less than . 001 ) ; the duration of ECG changes was 0 . 6 + / - 0 . 3 minutes per patient per hour before 5 - FU v 1 . 9 + / - 0 . 5 minutes per patient per hour during 5 - FU ( P less than . 01 ) .
Diseases: ischemic"	"Sentence: The incidence of ischemic episodes per patient per hour was 0 . 05 + / - 0 . 02 prior to 5 - FU infusion v 0 . 13 + / - 0 . 03 during 5 - FU infusion ( P less than . 001 ) ; the duration of ECG changes was 0 . 6 + / - 0 . 3 minutes per patient per hour before 5 - FU v 1 . 9 + / - 0 . 5 minutes per patient per hour during 5 - FU ( P less than . 01 ) .
Diseases:"
2722	ECG changes were more common among patients with known coronary artery disease .	O O O O O O O O O B I I O	O O O O O O O O O O O O O	['coronary artery disease']	1	5	"Sentence: ECG changes were more common among patients with known coronary artery disease .
Diseases: coronary artery disease"	"Sentence: ECG changes were more common among patients with known coronary artery disease .
Diseases:"
2723	There were two cases of sudden death , both of which occurred at the end of the chemotherapy course .	O O O O O B I O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	['sudden death']	1	3	"Sentence: There were two cases of sudden death , both of which occurred at the end of the chemotherapy course .
Diseases: sudden death"	"Sentence: There were two cases of sudden death , both of which occurred at the end of the chemotherapy course .
Diseases:"
2724	We conclude that 5 - FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia , particularly among patients with coronary artery disease .	O O O O O O O O O O O O O O O O O O O O B O O O O O B I I O	O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O	['coronary artery disease', 'ischemia']	2	9	"Sentence: We conclude that 5 - FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia , particularly among patients with coronary artery disease .
Diseases: coronary artery disease, ischemia"	"Sentence: We conclude that 5 - FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia , particularly among patients with coronary artery disease .
Diseases:"
2725	The mechanism and clinical significance of these ECG changes remain to be determined .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mechanism and clinical significance of these ECG changes remain to be determined .
Diseases: "	"Sentence: The mechanism and clinical significance of these ECG changes remain to be determined .
Diseases:"
2726	Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function .	O B O O O O O O O B I O O O B I I O	O O O O O B O O O O O O O O O O O O	['impaired renal function', 'anuria', 'breast cancer']	3	10	"Sentence: Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function .
Diseases: impaired renal function, anuria, breast cancer"	"Sentence: Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function .
Diseases:"
2727	A sixty - year - old woman with advanced breast cancer , previously treated with cisplatin , developed an irreversible lethal renal failure with anuria , the day after 5 g / m2 bolus ifosfamide .	O O O O O O O O O B I O O O O O O O O O O B I O B O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O B O	['anuria', 'renal failure', 'breast cancer']	3	8	"Sentence: A sixty - year - old woman with advanced breast cancer , previously treated with cisplatin , developed an irreversible lethal renal failure with anuria , the day after 5 g / m2 bolus ifosfamide .
Diseases: anuria, renal failure, breast cancer"	"Sentence: A sixty - year - old woman with advanced breast cancer , previously treated with cisplatin , developed an irreversible lethal renal failure with anuria , the day after 5 g / m2 bolus ifosfamide .
Diseases:"
2728	Postrenal failure was excluded by echography .	B I O O O O O	O O O O O O O	['postrenal failure']	1	4	"Sentence: Postrenal failure was excluded by echography .
Diseases: postrenal failure"	"Sentence: Postrenal failure was excluded by echography .
Diseases:"
2729	A prerenal component could have contributed to renal failure because of a transient hypotension , due to an increasing ascitis , occurring just before anuria .	O O O O O O O B I O O O O B O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['anuria', 'hypotension', 'renal failure']	3	8	"Sentence: A prerenal component could have contributed to renal failure because of a transient hypotension , due to an increasing ascitis , occurring just before anuria .
Diseases: anuria, hypotension, renal failure"	"Sentence: A prerenal component could have contributed to renal failure because of a transient hypotension , due to an increasing ascitis , occurring just before anuria .
Diseases:"
2730	However , correction of the hemodynamic parameters did not improve renal function .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: However , correction of the hemodynamic parameters did not improve renal function .
Diseases: "	"Sentence: However , correction of the hemodynamic parameters did not improve renal function .
Diseases:"
2731	Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies .	O O O O B O O O B O	B O O O O O O O O O	['nephrotoxic', 'tubulopathies']	2	9	"Sentence: Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies .
Diseases: nephrotoxic, tubulopathies"	"Sentence: Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies .
Diseases:"
2732	We strongly suspect that this lethal anuria was mainly due to ifosfamide , occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O B O O O O O O O O B O O O O O O O O O O O	['anuria', 'hypotension']	2	5	"Sentence: We strongly suspect that this lethal anuria was mainly due to ifosfamide , occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension .
Diseases: anuria, hypotension"	"Sentence: We strongly suspect that this lethal anuria was mainly due to ifosfamide , occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension .
Diseases:"
2733	We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion .	O O O O O O O O O O B O O O O O O	O O O O O B O O O O O O O O O O O	['nephrotoxic']	1	4	"Sentence: We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion .
Diseases: nephrotoxic"	"Sentence: We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion .
Diseases:"
2734	Central vein thrombosis and topical dipivalyl epinephrine .	O B I O O O O O	O O O O O B I O	['vein thrombosis']	1	6	"Sentence: Central vein thrombosis and topical dipivalyl epinephrine .
Diseases: vein thrombosis"	"Sentence: Central vein thrombosis and topical dipivalyl epinephrine .
Diseases:"
2735	A report is given on an 83 - year - old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye .	O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O	['glaucoma', 'vein thrombosis']	2	10	"Sentence: A report is given on an 83 - year - old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye .
Diseases: glaucoma, vein thrombosis"	"Sentence: A report is given on an 83 - year - old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye .
Diseases:"
2736	From present knowledge about the effects of adrenergic eye drops on ocular blood circulation , it is difficult to suggest an association between the two events , which may be coincidental only .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: From present knowledge about the effects of adrenergic eye drops on ocular blood circulation , it is difficult to suggest an association between the two events , which may be coincidental only .
Diseases: "	"Sentence: From present knowledge about the effects of adrenergic eye drops on ocular blood circulation , it is difficult to suggest an association between the two events , which may be coincidental only .
Diseases:"
2737	Amelioration of bendrofluazide - induced hypokalemia by timolol .	O O O O O B O O O	O O B O O O O B O	['hypokalemia']	1	4	"Sentence: Amelioration of bendrofluazide - induced hypokalemia by timolol .
Diseases: hypokalemia"	"Sentence: Amelioration of bendrofluazide - induced hypokalemia by timolol .
Diseases:"
2738	The beta adrenergic blocking drug , timolol , tended to correct the hypokalemia of short - term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O B O O O O O O O O O O O O O O O O	['hypokalemia']	1	4	"Sentence: The beta adrenergic blocking drug , timolol , tended to correct the hypokalemia of short - term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant .
Diseases: hypokalemia"	"Sentence: The beta adrenergic blocking drug , timolol , tended to correct the hypokalemia of short - term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant .
Diseases:"
2739	Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium / potassium ratio .	O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O B O O B O O B O O O O B O B O O	[]	0	0	"Sentence: Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium / potassium ratio .
Diseases: "	"Sentence: Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium / potassium ratio .
Diseases:"
2740	There was no evidence of a shift of potassium from the intracellular to the extracellular space .	O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: There was no evidence of a shift of potassium from the intracellular to the extracellular space .
Diseases: "	"Sentence: There was no evidence of a shift of potassium from the intracellular to the extracellular space .
Diseases:"
2741	A cross - sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O B I I I O O O O O O O	[]	0	0	"Sentence: A cross - sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys .
Diseases: "	"Sentence: A cross - sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys .
Diseases:"
2742	The aim of the present study was to investigate the effect of risperidone - induced hyperprolactinemia on trabecular bone mineral density ( BMD ) in children and adolescents .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	['hyperprolactinemia']	1	6	"Sentence: The aim of the present study was to investigate the effect of risperidone - induced hyperprolactinemia on trabecular bone mineral density ( BMD ) in children and adolescents .
Diseases: hyperprolactinemia"	"Sentence: The aim of the present study was to investigate the effect of risperidone - induced hyperprolactinemia on trabecular bone mineral density ( BMD ) in children and adolescents .
Diseases:"
2743	METHOD : Medically healthy	O O O O	O O O O	[]	0	0	"Sentence: METHOD : Medically healthy
Diseases: "	"Sentence: METHOD : Medically healthy
Diseases:"
2744	7 - to 17 - year - old males chronically treated , in a naturalistic setting , with risperidone were recruited for this cross - sectional study through child psychiatry outpatient clinics between November 2005 and June 2007 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: 7 - to 17 - year - old males chronically treated , in a naturalistic setting , with risperidone were recruited for this cross - sectional study through child psychiatry outpatient clinics between November 2005 and June 2007 .
Diseases: "	"Sentence: 7 - to 17 - year - old males chronically treated , in a naturalistic setting , with risperidone were recruited for this cross - sectional study through child psychiatry outpatient clinics between November 2005 and June 2007 .
Diseases:"
2745	Anthropometric measurements and laboratory testing were conducted .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: Anthropometric measurements and laboratory testing were conducted .
Diseases: "	"Sentence: Anthropometric measurements and laboratory testing were conducted .
Diseases:"
2746	The clinical diagnoses were based on chart review , and developmental and treatment history was obtained from the medical record .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The clinical diagnoses were based on chart review , and developmental and treatment history was obtained from the medical record .
Diseases: "	"Sentence: The clinical diagnoses were based on chart review , and developmental and treatment history was obtained from the medical record .
Diseases:"
2747	Volumetric BMD of the ultradistal radius was measured using peripheral quantitative computed tomography , and areal BMD of the lumbar spine was estimated using dual - energy x - ray absorptiometry .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Volumetric BMD of the ultradistal radius was measured using peripheral quantitative computed tomography , and areal BMD of the lumbar spine was estimated using dual - energy x - ray absorptiometry .
Diseases: "	"Sentence: Volumetric BMD of the ultradistal radius was measured using peripheral quantitative computed tomography , and areal BMD of the lumbar spine was estimated using dual - energy x - ray absorptiometry .
Diseases:"
2748	Hyperprolactinemia was present in 49 % of 83 boys ( n = 41 ) treated with risperidone for a mean of 2 . 9 years .	B O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O O O O	['hyperprolactinemia']	1	6	"Sentence: Hyperprolactinemia was present in 49 % of 83 boys ( n = 41 ) treated with risperidone for a mean of 2 . 9 years .
Diseases: hyperprolactinemia"	"Sentence: Hyperprolactinemia was present in 49 % of 83 boys ( n = 41 ) treated with risperidone for a mean of 2 . 9 years .
Diseases:"
2749	Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia .	O O O O O O O O O O O O B O	O B O O O O O O O O O O O O	['hyperprolactinemia']	1	6	"Sentence: Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia .
Diseases: hyperprolactinemia"	"Sentence: Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia .
Diseases:"
2750	As expected , bone mineral content and BMD increased with sexual maturity .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: As expected , bone mineral content and BMD increased with sexual maturity .
Diseases: "	"Sentence: As expected , bone mineral content and BMD increased with sexual maturity .
Diseases:"
2751	After adjusting for the stage of sexual development and height and BMI z scores , serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius ( P < . 03 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After adjusting for the stage of sexual development and height and BMI z scores , serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius ( P < . 03 ) .
Diseases: "	"Sentence: After adjusting for the stage of sexual development and height and BMI z scores , serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius ( P < . 03 ) .
Diseases:"
2752	Controlling for relevant covariates , we also found treatment with selective serotonin reuptake inhibitors ( SSRIs ) to be associated with lower trabecular BMD at the radius ( P = . 03 ) and BMD z score at the lumbar spine ( P < . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B I I I O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Controlling for relevant covariates , we also found treatment with selective serotonin reuptake inhibitors ( SSRIs ) to be associated with lower trabecular BMD at the radius ( P = . 03 ) and BMD z score at the lumbar spine ( P < . 05 ) .
Diseases: "	"Sentence: Controlling for relevant covariates , we also found treatment with selective serotonin reuptake inhibitors ( SSRIs ) to be associated with lower trabecular BMD at the radius ( P = . 03 ) and BMD z score at the lumbar spine ( P < . 05 ) .
Diseases:"
2753	These findings became more marked when the analysis was restricted to non - Hispanic white patients .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These findings became more marked when the analysis was restricted to non - Hispanic white patients .
Diseases: "	"Sentence: These findings became more marked when the analysis was restricted to non - Hispanic white patients .
Diseases:"
2754	Of 13 documented fractures , 3 occurred after risperidone and SSRIs were started , and none occurred in patients with hyperprolactinemia .	O O O B O O O O O O O O O O O O O O O O B O	O O O O O O O O B O B O O O O O O O O O O O	['fractures', 'hyperprolactinemia']	2	10	"Sentence: Of 13 documented fractures , 3 occurred after risperidone and SSRIs were started , and none occurred in patients with hyperprolactinemia .
Diseases: fractures, hyperprolactinemia"	"Sentence: Of 13 documented fractures , 3 occurred after risperidone and SSRIs were started , and none occurred in patients with hyperprolactinemia .
Diseases:"
2755	This is the first study to link risperidone - induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents .	O O O O O O O O O O B O O O O O O O O O O O	O O O O O O O B O O O O B O O O O O O O O O	['hyperprolactinemia']	1	6	"Sentence: This is the first study to link risperidone - induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents .
Diseases: hyperprolactinemia"	"Sentence: This is the first study to link risperidone - induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents .
Diseases:"
2756	Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues .
Diseases: "	"Sentence: Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues .
Diseases:"
2757	Seizures associated with levofloxacin : case presentation and literature review .	B O O O O O O O O O O	O O O B O O O O O O O	['seizures']	1	3	"Sentence: Seizures associated with levofloxacin : case presentation and literature review .
Diseases: seizures"	"Sentence: Seizures associated with levofloxacin : case presentation and literature review .
Diseases:"
2758	We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug - drug interactions related to the inhibition of cytochrome P450 ( CYP ) 1A2 in this case , as well as in other cases , of levofloxacin - induced seizures .	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['seizures']	1	3	"Sentence: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug - drug interactions related to the inhibition of cytochrome P450 ( CYP ) 1A2 in this case , as well as in other cases , of levofloxacin - induced seizures .
Diseases: seizures"	"Sentence: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug - drug interactions related to the inhibition of cytochrome P450 ( CYP ) 1A2 in this case , as well as in other cases , of levofloxacin - induced seizures .
Diseases:"
2759	Several biomedical databases were searched including MEDLINE , Cochrane and Ovid .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: Several biomedical databases were searched including MEDLINE , Cochrane and Ovid .
Diseases: "	"Sentence: Several biomedical databases were searched including MEDLINE , Cochrane and Ovid .
Diseases:"
2760	The main search terms utilized were case report and levofloxacin .	O O O O O O O O O O O	O O O O O O O O O B O	[]	0	0	"Sentence: The main search terms utilized were case report and levofloxacin .
Diseases: "	"Sentence: The main search terms utilized were case report and levofloxacin .
Diseases:"
2761	The search was limited to studies published in English .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: The search was limited to studies published in English .
Diseases: "	"Sentence: The search was limited to studies published in English .
Diseases:"
2762	Six cases of levofloxacin - induced seizures have been reported in the literature .	O O O O O O B O O O O O O O	O O O B O O O O O O O O O O	['seizures']	1	3	"Sentence: Six cases of levofloxacin - induced seizures have been reported in the literature .
Diseases: seizures"	"Sentence: Six cases of levofloxacin - induced seizures have been reported in the literature .
Diseases:"
2763	Drug - drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: Drug - drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases .
Diseases: "	"Sentence: Drug - drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases .
Diseases:"
2764	CONCLUSIONS : Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSIONS : Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates .
Diseases: "	"Sentence: CONCLUSIONS : Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates .
Diseases:"
2765	Mice lacking mPGES - 1 are resistant to lithium - induced polyuria .	O O O O O O O O O O O B O	O O O O O O O O B O O O O	['polyuria']	1	2	"Sentence: Mice lacking mPGES - 1 are resistant to lithium - induced polyuria .
Diseases: polyuria"	"Sentence: Mice lacking mPGES - 1 are resistant to lithium - induced polyuria .
Diseases:"
2766	Cyclooxygenase - 2 activity is required for the development of lithium - induced polyuria .	O O O O O O O O O O O O O B O	O O O O O O O O O O B O O O O	['polyuria']	1	2	"Sentence: Cyclooxygenase - 2 activity is required for the development of lithium - induced polyuria .
Diseases: polyuria"	"Sentence: Cyclooxygenase - 2 activity is required for the development of lithium - induced polyuria .
Diseases:"
2767	However , the involvement of a specific , terminal prostaglandin ( PG ) isomerase has not been evaluated .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O B O O O O O O O	[]	0	0	"Sentence: However , the involvement of a specific , terminal prostaglandin ( PG ) isomerase has not been evaluated .
Diseases: "	"Sentence: However , the involvement of a specific , terminal prostaglandin ( PG ) isomerase has not been evaluated .
Diseases:"
2768	The present study was undertaken to assess lithium - induced polyuria in mice deficient in microsomal prostaglandin E synthase - 1 ( mPGES - 1 ) .	O O O O O O O O O O B O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O B I O O O O O O O O O	['polyuria']	1	2	"Sentence: The present study was undertaken to assess lithium - induced polyuria in mice deficient in microsomal prostaglandin E synthase - 1 ( mPGES - 1 ) .
Diseases: polyuria"	"Sentence: The present study was undertaken to assess lithium - induced polyuria in mice deficient in microsomal prostaglandin E synthase - 1 ( mPGES - 1 ) .
Diseases:"
2769	A 2 - wk administration of LiCl ( 4 mmol . kg ( - 1 ) . day ( - 1 ) ip ) in mPGES - 1 + / + mice led to a marked polyuria with hyposmotic urine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['polyuria']	1	2	"Sentence: A 2 - wk administration of LiCl ( 4 mmol . kg ( - 1 ) . day ( - 1 ) ip ) in mPGES - 1 + / + mice led to a marked polyuria with hyposmotic urine .
Diseases: polyuria"	"Sentence: A 2 - wk administration of LiCl ( 4 mmol . kg ( - 1 ) . day ( - 1 ) ip ) in mPGES - 1 + / + mice led to a marked polyuria with hyposmotic urine .
Diseases:"
2770	This was associated with elevated renal mPGES - 1 protein expression and increased urine PGE ( 2 ) excretion .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B I I I O O	[]	0	0	"Sentence: This was associated with elevated renal mPGES - 1 protein expression and increased urine PGE ( 2 ) excretion .
Diseases: "	"Sentence: This was associated with elevated renal mPGES - 1 protein expression and increased urine PGE ( 2 ) excretion .
Diseases:"
2771	In contrast , mPGES - 1 - / - mice were largely resistant to lithium - induced polyuria and a urine concentrating defect , accompanied by nearly complete blockade of high urine PGE ( 2 ) and cAMP output .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O B O O O O B O O	['polyuria']	1	2	"Sentence: In contrast , mPGES - 1 - / - mice were largely resistant to lithium - induced polyuria and a urine concentrating defect , accompanied by nearly complete blockade of high urine PGE ( 2 ) and cAMP output .
Diseases: polyuria"	"Sentence: In contrast , mPGES - 1 - / - mice were largely resistant to lithium - induced polyuria and a urine concentrating defect , accompanied by nearly complete blockade of high urine PGE ( 2 ) and cAMP output .
Diseases:"
2772	Immunoblotting , immunohistochemistry , and quantitative ( q ) RT - PCR consistently detected a significant decrease in aquaporin - 2 ( AQP2 ) protein expression in both the renal cortex and medulla of lithium - treated + / + mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: Immunoblotting , immunohistochemistry , and quantitative ( q ) RT - PCR consistently detected a significant decrease in aquaporin - 2 ( AQP2 ) protein expression in both the renal cortex and medulla of lithium - treated + / + mice .
Diseases: "	"Sentence: Immunoblotting , immunohistochemistry , and quantitative ( q ) RT - PCR consistently detected a significant decrease in aquaporin - 2 ( AQP2 ) protein expression in both the renal cortex and medulla of lithium - treated + / + mice .
Diseases:"
2773	This decrease was significantly attenuated in the - / - mice .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: This decrease was significantly attenuated in the - / - mice .
Diseases: "	"Sentence: This decrease was significantly attenuated in the - / - mice .
Diseases:"
2774	qRT - PCR detected similar patterns of changes in AQP2 mRNA in the medulla but not in the cortex .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: qRT - PCR detected similar patterns of changes in AQP2 mRNA in the medulla but not in the cortex .
Diseases: "	"Sentence: qRT - PCR detected similar patterns of changes in AQP2 mRNA in the medulla but not in the cortex .
Diseases:"
2775	Similarly , the total protein abundance of the Na - K - 2Cl cotransporter ( NKCC2 ) in the medulla but not in the cortex of the + / + mice was significantly reduced by lithium treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Similarly , the total protein abundance of the Na - K - 2Cl cotransporter ( NKCC2 ) in the medulla but not in the cortex of the + / + mice was significantly reduced by lithium treatment .
Diseases: "	"Sentence: Similarly , the total protein abundance of the Na - K - 2Cl cotransporter ( NKCC2 ) in the medulla but not in the cortex of the + / + mice was significantly reduced by lithium treatment .
Diseases:"
2776	In contrast , the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the - / - mice .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast , the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the - / - mice .
Diseases: "	"Sentence: In contrast , the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the - / - mice .
Diseases:"
2777	We conclude that mPGES - 1 - derived PGE ( 2 ) mediates lithium - induced polyuria likely via inhibition of AQP2 and NKCC2 expression .	O O O O O O O O O O O O O O O O B O O O O O O O O O	O O O O O O O O B O I O O B O O O O O O O O O O O O	['polyuria']	1	2	"Sentence: We conclude that mPGES - 1 - derived PGE ( 2 ) mediates lithium - induced polyuria likely via inhibition of AQP2 and NKCC2 expression .
Diseases: polyuria"	"Sentence: We conclude that mPGES - 1 - derived PGE ( 2 ) mediates lithium - induced polyuria likely via inhibition of AQP2 and NKCC2 expression .
Diseases:"
2778	Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B I O B O O	[]	0	0	"Sentence: Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products .
Diseases: "	"Sentence: Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products .
Diseases:"
2779	Heparin is a commonly implemented anticoagulant used to treat critically ill patients .	O O O O O O O O O O O O O	B O O O O O O O O O O O O	[]	0	0	"Sentence: Heparin is a commonly implemented anticoagulant used to treat critically ill patients .
Diseases: "	"Sentence: Heparin is a commonly implemented anticoagulant used to treat critically ill patients .
Diseases:"
2780	Recently , a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate ( OSCS ) derivative that could elicit a hypotensive response in pigs following a single high - dose infusion .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	O O O O O O O O B O O O O O O O O B B I O B O O O O O O O O O O O O O O O O O O	['hypotensive']	1	3	"Sentence: Recently , a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate ( OSCS ) derivative that could elicit a hypotensive response in pigs following a single high - dose infusion .
Diseases: hypotensive"	"Sentence: Recently , a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate ( OSCS ) derivative that could elicit a hypotensive response in pigs following a single high - dose infusion .
Diseases:"
2781	Using both contaminated heparin products and the synthetically produced derivative , we showed that the OSCS produces dose - dependent hypotension in pigs .	O O O O O O O O O O O O O O O O O O O O B O O O	O O O B O O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: Using both contaminated heparin products and the synthetically produced derivative , we showed that the OSCS produces dose - dependent hypotension in pigs .
Diseases: hypotension"	"Sentence: Using both contaminated heparin products and the synthetically produced derivative , we showed that the OSCS produces dose - dependent hypotension in pigs .
Diseases:"
2782	The no observed effect level ( NOEL ) for this contaminant appears to be approximately 1mg / kg , corresponding to a contamination level of approximately 3 % .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The no observed effect level ( NOEL ) for this contaminant appears to be approximately 1mg / kg , corresponding to a contamination level of approximately 3 % .
Diseases: "	"Sentence: The no observed effect level ( NOEL ) for this contaminant appears to be approximately 1mg / kg , corresponding to a contamination level of approximately 3 % .
Diseases:"
2783	We also demonstrated that OSCS can be identified in heparin products using a simple , inexpensive , commercially available heparin enzyme immunoassay ( EIA ) kit that has a limit of detection of approximately 0 . 1 % , well below the NOEL .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We also demonstrated that OSCS can be identified in heparin products using a simple , inexpensive , commercially available heparin enzyme immunoassay ( EIA ) kit that has a limit of detection of approximately 0 . 1 % , well below the NOEL .
Diseases: "	"Sentence: We also demonstrated that OSCS can be identified in heparin products using a simple , inexpensive , commercially available heparin enzyme immunoassay ( EIA ) kit that has a limit of detection of approximately 0 . 1 % , well below the NOEL .
Diseases:"
2784	This kit may provide a useful method to test heparin products for contamination with oversulfated GAG derivatives .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O B O O	[]	0	0	"Sentence: This kit may provide a useful method to test heparin products for contamination with oversulfated GAG derivatives .
Diseases: "	"Sentence: This kit may provide a useful method to test heparin products for contamination with oversulfated GAG derivatives .
Diseases:"
2785	Doxorubicin cardiomyopathy - induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor .	O B O O B O O O O O O O O O O O O O	B O O O O O O O O O O O O O B O O O	['cardiomyopathy', 'inflammation']	2	6	"Sentence: Doxorubicin cardiomyopathy - induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor .
Diseases: cardiomyopathy, inflammation"	"Sentence: Doxorubicin cardiomyopathy - induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor .
Diseases:"
2786	Clinical use of the anthracycline doxorubicin ( DOX ) is limited by its cardiotoxic effects , which are attributed to the induction of apoptosis .	O O O O O O O O O O O O O B O O O O O O O O O O O	O O O O B B O B O O O O O O O O O O O O O O O O O	['cardiotoxic']	1	3	"Sentence: Clinical use of the anthracycline doxorubicin ( DOX ) is limited by its cardiotoxic effects , which are attributed to the induction of apoptosis .
Diseases: cardiotoxic"	"Sentence: Clinical use of the anthracycline doxorubicin ( DOX ) is limited by its cardiotoxic effects , which are attributed to the induction of apoptosis .
Diseases:"
2787	To elucidate the possible role of the kinin B1 receptor ( B1R ) during the development of DOX cardiomyopathy , we studied B1R knockout mice ( B1R ( - / - ) ) by investigating cardiac inflammation and apoptosis after induction of DOX - induced cardiomyopathy .	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O B O O O O O O O O B O	O O O O O O O B O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['cardiomyopathy', 'inflammation']	2	6	"Sentence: To elucidate the possible role of the kinin B1 receptor ( B1R ) during the development of DOX cardiomyopathy , we studied B1R knockout mice ( B1R ( - / - ) ) by investigating cardiac inflammation and apoptosis after induction of DOX - induced cardiomyopathy .
Diseases: cardiomyopathy, inflammation"	"Sentence: To elucidate the possible role of the kinin B1 receptor ( B1R ) during the development of DOX cardiomyopathy , we studied B1R knockout mice ( B1R ( - / - ) ) by investigating cardiac inflammation and apoptosis after induction of DOX - induced cardiomyopathy .
Diseases:"
2788	DOX control mice showed cardiac dysfunction measured by pressure - volume loops in vivo .	O O O O B I O O O O O O O O O	B O O O O O O O O O O O O O O	['cardiac dysfunction']	1	3	"Sentence: DOX control mice showed cardiac dysfunction measured by pressure - volume loops in vivo .
Diseases: cardiac dysfunction"	"Sentence: DOX control mice showed cardiac dysfunction measured by pressure - volume loops in vivo .
Diseases:"
2789	This was associated with a reduced activation state of AKT , as well as an increased bax / bcl2 ratio in Western blots , indicating cardiac apoptosis .	O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cardiac apoptosis']	1	4	"Sentence: This was associated with a reduced activation state of AKT , as well as an increased bax / bcl2 ratio in Western blots , indicating cardiac apoptosis .
Diseases: cardiac apoptosis"	"Sentence: This was associated with a reduced activation state of AKT , as well as an increased bax / bcl2 ratio in Western blots , indicating cardiac apoptosis .
Diseases:"
2790	Furthermore , mRNA levels of the proinflammatory cytokine interleukin 6 were increased in the cardiac tissue .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Furthermore , mRNA levels of the proinflammatory cytokine interleukin 6 were increased in the cardiac tissue .
Diseases: "	"Sentence: Furthermore , mRNA levels of the proinflammatory cytokine interleukin 6 were increased in the cardiac tissue .
Diseases:"
2791	In DOX B1R ( - / - ) mice , cardiac dysfunction was improved compared to DOX control mice , which was associated with normalization of the bax / bcl - 2 ratio and interleukin 6 , as well as AKT activation state .	O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cardiac dysfunction']	1	3	"Sentence: In DOX B1R ( - / - ) mice , cardiac dysfunction was improved compared to DOX control mice , which was associated with normalization of the bax / bcl - 2 ratio and interleukin 6 , as well as AKT activation state .
Diseases: cardiac dysfunction"	"Sentence: In DOX B1R ( - / - ) mice , cardiac dysfunction was improved compared to DOX control mice , which was associated with normalization of the bax / bcl - 2 ratio and interleukin 6 , as well as AKT activation state .
Diseases:"
2792	These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis .	O O O O O O O O O B O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O	['cardiomyopathy']	1	4	"Sentence: These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis .
Diseases: cardiomyopathy"	"Sentence: These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis .
Diseases:"
2793	These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy .	O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O B O O	['cardiomyopathy']	1	4	"Sentence: These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy .
Diseases: cardiomyopathy"	"Sentence: These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy .
Diseases:"
2794	Hepatotoxicity associated with sulfasalazine in inflammatory arthritis : A case series from a local surveillance of serious adverse events .	B O O O O O B O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O	['hepatotoxicity', 'arthritis']	2	6	"Sentence: Hepatotoxicity associated with sulfasalazine in inflammatory arthritis : A case series from a local surveillance of serious adverse events .
Diseases: hepatotoxicity, arthritis"	"Sentence: Hepatotoxicity associated with sulfasalazine in inflammatory arthritis : A case series from a local surveillance of serious adverse events .
Diseases:"
2795	Spontaneous reporting systems for adverse drug reactions ( ADRs ) are handicapped by under - reporting and limited detail on individual cases .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Spontaneous reporting systems for adverse drug reactions ( ADRs ) are handicapped by under - reporting and limited detail on individual cases .
Diseases: "	"Sentence: Spontaneous reporting systems for adverse drug reactions ( ADRs ) are handicapped by under - reporting and limited detail on individual cases .
Diseases:"
2796	We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti - rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['liver failure']	1	3	"Sentence: We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti - rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients .
Diseases: liver failure"	"Sentence: We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti - rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients .
Diseases:"
2797	Serious ADR reports have been solicited from local clinicians by regular postcards over the past seven years .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Serious ADR reports have been solicited from local clinicians by regular postcards over the past seven years .
Diseases: "	"Sentence: Serious ADR reports have been solicited from local clinicians by regular postcards over the past seven years .
Diseases:"
2798	Patients ' , who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR , were identified .	O O O O O B O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O	['hepatotoxicity']	1	4	"Sentence: Patients ' , who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR , were identified .
Diseases: hepatotoxicity"	"Sentence: Patients ' , who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR , were identified .
Diseases:"
2799	Two clinicians reviewed structured case reports and assessed causality by consensus and by using a causality assessment instrument .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Two clinicians reviewed structured case reports and assessed causality by consensus and by using a causality assessment instrument .
Diseases: "	"Sentence: Two clinicians reviewed structured case reports and assessed causality by consensus and by using a causality assessment instrument .
Diseases:"
2800	The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions .	O O O O B O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O	['hepatotoxicity']	1	4	"Sentence: The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions .
Diseases: hepatotoxicity"	"Sentence: The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions .
Diseases:"
2801	Ten cases were identified : eight occurred during surveillance .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Ten cases were identified : eight occurred during surveillance .
Diseases: "	"Sentence: Ten cases were identified : eight occurred during surveillance .
Diseases:"
2802	Eight patients were hospitalised , two in hepatic failure - one died after a liver transplant .	O O O O O O O B I O O O O O O O O	O O O O O O O O O O O O O O O O O	['hepatic failure']	1	4	"Sentence: Eight patients were hospitalised , two in hepatic failure - one died after a liver transplant .
Diseases: hepatic failure"	"Sentence: Eight patients were hospitalised , two in hepatic failure - one died after a liver transplant .
Diseases:"
2803	All but one event occurred within 6 weeks of treatment .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: All but one event occurred within 6 weeks of treatment .
Diseases: "	"Sentence: All but one event occurred within 6 weeks of treatment .
Diseases:"
2804	Seven patients had a skin rash , three eosinophilia and one interstitial nephritis .	O O O O B I O O B O O B I O	O O O O O O O O O O O O O O	['eosinophilia', 'skin rash', 'interstitial nephritis']	3	14	"Sentence: Seven patients had a skin rash , three eosinophilia and one interstitial nephritis .
Diseases: eosinophilia, skin rash, interstitial nephritis"	"Sentence: Seven patients had a skin rash , three eosinophilia and one interstitial nephritis .
Diseases:"
2805	Five patients were of Black British of African or Caribbean descent .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: Five patients were of Black British of African or Caribbean descent .
Diseases: "	"Sentence: Five patients were of Black British of African or Caribbean descent .
Diseases:"
2806	Liver enzymes showed a hepatocellular pattern in four cases and a mixed pattern in six .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Liver enzymes showed a hepatocellular pattern in four cases and a mixed pattern in six .
Diseases: "	"Sentence: Liver enzymes showed a hepatocellular pattern in four cases and a mixed pattern in six .
Diseases:"
2807	Drug - related hepatotoxicity was judged probable or highly probable in 8 patients .	O O O B O O O O O O O O O O	O O O O O O O O O O O O O O	['hepatotoxicity']	1	4	"Sentence: Drug - related hepatotoxicity was judged probable or highly probable in 8 patients .
Diseases: hepatotoxicity"	"Sentence: Drug - related hepatotoxicity was judged probable or highly probable in 8 patients .
Diseases:"
2808	The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0 . 4 % of treated patients .	O O O O O B O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O	['hepatotoxicity']	1	4	"Sentence: The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0 . 4 % of treated patients .
Diseases: hepatotoxicity"	"Sentence: The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0 . 4 % of treated patients .
Diseases:"
2809	Serious hepatotoxicity associated with sulfasalazine appears to be under - appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important .	O B O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O	['hepatotoxicity']	1	4	"Sentence: Serious hepatotoxicity associated with sulfasalazine appears to be under - appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important .
Diseases: hepatotoxicity"	"Sentence: Serious hepatotoxicity associated with sulfasalazine appears to be under - appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important .
Diseases:"
2810	An evaluation of amikacin nephrotoxicity in the hematology / oncology population .	O O O O B O O O O O O O	O O O B O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: An evaluation of amikacin nephrotoxicity in the hematology / oncology population .
Diseases: nephrotoxicity"	"Sentence: An evaluation of amikacin nephrotoxicity in the hematology / oncology population .
Diseases:"
2811	Amikacin is an aminoglycoside commonly used to provide empirical double gram - negative treatment for febrile neutropenia and other suspected infections .	O O O O O O O O O O O O O O O B I O O O B O	B O O B O O O O O O O O O O O O O O O O O O	['infections', 'febrile neutropenia']	2	11	"Sentence: Amikacin is an aminoglycoside commonly used to provide empirical double gram - negative treatment for febrile neutropenia and other suspected infections .
Diseases: infections, febrile neutropenia"	"Sentence: Amikacin is an aminoglycoside commonly used to provide empirical double gram - negative treatment for febrile neutropenia and other suspected infections .
Diseases:"
2812	Strategies of extended - interval and conventional dosing have been utilized extensively in the general medical population ; however , data are lacking to support a dosing strategy in the hematology / oncology population .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Strategies of extended - interval and conventional dosing have been utilized extensively in the general medical population ; however , data are lacking to support a dosing strategy in the hematology / oncology population .
Diseases: "	"Sentence: Strategies of extended - interval and conventional dosing have been utilized extensively in the general medical population ; however , data are lacking to support a dosing strategy in the hematology / oncology population .
Diseases:"
2813	To evaluate amikacin - associated nephrotoxicity in an adult hematology / oncology population , a prospective , randomized , open - label trial was conducted at a university - affiliated medical center .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: To evaluate amikacin - associated nephrotoxicity in an adult hematology / oncology population , a prospective , randomized , open - label trial was conducted at a university - affiliated medical center .
Diseases: nephrotoxicity"	"Sentence: To evaluate amikacin - associated nephrotoxicity in an adult hematology / oncology population , a prospective , randomized , open - label trial was conducted at a university - affiliated medical center .
Diseases:"
2814	Forty patients with a diagnosis consistent with a hematologic / oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended - interval amikacin .	O O O O O O O O B I I I O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O O O O B O	['hematologic / oncologic disorder']	1	7	"Sentence: Forty patients with a diagnosis consistent with a hematologic / oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended - interval amikacin .
Diseases: hematologic / oncologic disorder"	"Sentence: Forty patients with a diagnosis consistent with a hematologic / oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended - interval amikacin .
Diseases:"
2815	The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed .	O O O B O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O B O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed .
Diseases: nephrotoxicity"	"Sentence: The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed .
Diseases:"
2816	The occurrence of nephrotoxicity was similar between the conventional and extended - interval groups , at 10 % and 5 % , respectively ( P = 1 . 00 ) .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: The occurrence of nephrotoxicity was similar between the conventional and extended - interval groups , at 10 % and 5 % , respectively ( P = 1 . 00 ) .
Diseases: nephrotoxicity"	"Sentence: The occurrence of nephrotoxicity was similar between the conventional and extended - interval groups , at 10 % and 5 % , respectively ( P = 1 . 00 ) .
Diseases:"
2817	Six patients in the conventional group had a positive culture , compared with none in the extended - interval group ( P = 0 . 002 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Six patients in the conventional group had a positive culture , compared with none in the extended - interval group ( P = 0 . 002 ) .
Diseases: "	"Sentence: Six patients in the conventional group had a positive culture , compared with none in the extended - interval group ( P = 0 . 002 ) .
Diseases:"
2818	The occurrence of nephrotoxicity was similar between the two dosing regimens , but the distribution of risk factors was variable between the two groups .	O O O B O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: The occurrence of nephrotoxicity was similar between the two dosing regimens , but the distribution of risk factors was variable between the two groups .
Diseases: nephrotoxicity"	"Sentence: The occurrence of nephrotoxicity was similar between the two dosing regimens , but the distribution of risk factors was variable between the two groups .
Diseases:"
2819	Efficacy could not be assessed .	O O O O O O	O O O O O O	[]	0	0	"Sentence: Efficacy could not be assessed .
Diseases: "	"Sentence: Efficacy could not be assessed .
Diseases:"
2820	Memory function and serotonin transporter promoter gene polymorphism in ecstasy ( MDMA ) users .	O O O O O O O O O O O O O O O	O O O B O O O O O B O B O O O	[]	0	0	"Sentence: Memory function and serotonin transporter promoter gene polymorphism in ecstasy ( MDMA ) users .
Diseases: "	"Sentence: Memory function and serotonin transporter promoter gene polymorphism in ecstasy ( MDMA ) users .
Diseases:"
2821	Although 3 , 4 - methylenedioxymethamphetamine ( MDMA or ecstasy ) has been shown to damage brain serotonin ( 5 - HT ) neurons in animals and possibly humans , little is known about the long - term consequences of MDMA - induced 5 - HT neurotoxic lesions on functions in which 5 - HT is involved , such as cognitive function .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O	O B I I I I O B O B O O O O O O O B O B I I O O O O O O O O O O O O O O O O O O B O O B I I O O O O O O B I I O O O O O O O O	['neurotoxic lesions']	1	5	"Sentence: Although 3 , 4 - methylenedioxymethamphetamine ( MDMA or ecstasy ) has been shown to damage brain serotonin ( 5 - HT ) neurons in animals and possibly humans , little is known about the long - term consequences of MDMA - induced 5 - HT neurotoxic lesions on functions in which 5 - HT is involved , such as cognitive function .
Diseases: neurotoxic lesions"	"Sentence: Although 3 , 4 - methylenedioxymethamphetamine ( MDMA or ecstasy ) has been shown to damage brain serotonin ( 5 - HT ) neurons in animals and possibly humans , little is known about the long - term consequences of MDMA - induced 5 - HT neurotoxic lesions on functions in which 5 - HT is involved , such as cognitive function .
Diseases:"
2822	Because 5 - HT transporters play a key element in the regulation of synaptic 5 - HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5 - HT transporter promoter gene region ( 5 - HTTLPR ) when studying the effects of MDMA as well as cognitive functioning .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O B I I O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O B O O O O O O	[]	0	0	"Sentence: Because 5 - HT transporters play a key element in the regulation of synaptic 5 - HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5 - HT transporter promoter gene region ( 5 - HTTLPR ) when studying the effects of MDMA as well as cognitive functioning .
Diseases: "	"Sentence: Because 5 - HT transporters play a key element in the regulation of synaptic 5 - HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5 - HT transporter promoter gene region ( 5 - HTTLPR ) when studying the effects of MDMA as well as cognitive functioning .
Diseases:"
2823	The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function , as well as the effects of long - term abstention from MDMA , in subjects genotyped for 5 - HTTLPR .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function , as well as the effects of long - term abstention from MDMA , in subjects genotyped for 5 - HTTLPR .
Diseases: "	"Sentence: The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function , as well as the effects of long - term abstention from MDMA , in subjects genotyped for 5 - HTTLPR .
Diseases:"
2824	A second aim of the study was to determine whether these effects differ for females and males .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A second aim of the study was to determine whether these effects differ for females and males .
Diseases: "	"Sentence: A second aim of the study was to determine whether these effects differ for females and males .
Diseases:"
2825	Fifteen moderate MDMA users ( < 55 lifetime tablets ) , 22 heavy MDMA + users ( > 55 lifetime tablets ) , 16 ex - MDMA + users ( last tablet > 1 year ago ) and 13 controls were compared on a battery of neuropsychological tests .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Fifteen moderate MDMA users ( < 55 lifetime tablets ) , 22 heavy MDMA + users ( > 55 lifetime tablets ) , 16 ex - MDMA + users ( last tablet > 1 year ago ) and 13 controls were compared on a battery of neuropsychological tests .
Diseases: "	"Sentence: Fifteen moderate MDMA users ( < 55 lifetime tablets ) , 22 heavy MDMA + users ( > 55 lifetime tablets ) , 16 ex - MDMA + users ( last tablet > 1 year ago ) and 13 controls were compared on a battery of neuropsychological tests .
Diseases:"
2826	DNA from peripheral nuclear blood cells was genotyped for 5 - HTTLPR using standard polymerase chain reaction methods .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: DNA from peripheral nuclear blood cells was genotyped for 5 - HTTLPR using standard polymerase chain reaction methods .
Diseases: "	"Sentence: DNA from peripheral nuclear blood cells was genotyped for 5 - HTTLPR using standard polymerase chain reaction methods .
Diseases:"
2827	A significant group effect was observed only on memory function tasks ( p = 0 . 04 ) but not on reaction times ( p = 0 . 61 ) or attention / executive functioning ( p = 0 . 59 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A significant group effect was observed only on memory function tasks ( p = 0 . 04 ) but not on reaction times ( p = 0 . 61 ) or attention / executive functioning ( p = 0 . 59 ) .
Diseases: "	"Sentence: A significant group effect was observed only on memory function tasks ( p = 0 . 04 ) but not on reaction times ( p = 0 . 61 ) or attention / executive functioning ( p = 0 . 59 ) .
Diseases:"
2828	Heavy and ex - MDMA + users performed significantly poorer on memory tasks than controls .	O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: Heavy and ex - MDMA + users performed significantly poorer on memory tasks than controls .
Diseases: "	"Sentence: Heavy and ex - MDMA + users performed significantly poorer on memory tasks than controls .
Diseases:"
2829	In contrast , no evidence of memory impairment was observed in moderate MDMA users .	O O O O O O B I O O O O O O O	O O O O O O O O O O O O B O O	['memory impairment']	1	2	"Sentence: In contrast , no evidence of memory impairment was observed in moderate MDMA users .
Diseases: memory impairment"	"Sentence: In contrast , no evidence of memory impairment was observed in moderate MDMA users .
Diseases:"
2830	No significant effect of 5 - HTTLPR or gender was observed .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: No significant effect of 5 - HTTLPR or gender was observed .
Diseases: "	"Sentence: No significant effect of 5 - HTTLPR or gender was observed .
Diseases:"
2831	"While the use of MDMA in quantities that may be considered "" moderate "" is not associated with impaired memory functioning , heavy use of MDMA use may lead to long lasting memory impairments ."	O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O B I O	O O O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	['impaired memory functioning', 'memory impairments']	2	9	"Sentence: While the use of MDMA in quantities that may be considered "" moderate "" is not associated with impaired memory functioning , heavy use of MDMA use may lead to long lasting memory impairments .
Diseases: impaired memory functioning, memory impairments"	"Sentence: While the use of MDMA in quantities that may be considered "" moderate "" is not associated with impaired memory functioning , heavy use of MDMA use may lead to long lasting memory impairments .
Diseases:"
2832	No effect of 5 - HTTLPR or gender on memory function or MDMA use was observed .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: No effect of 5 - HTTLPR or gender on memory function or MDMA use was observed .
Diseases: "	"Sentence: No effect of 5 - HTTLPR or gender on memory function or MDMA use was observed .
Diseases:"
2833	Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol .	O O O O O O O O O O O O O B O O O O	O O O O O O O O O O O O O O O O B O	['hyperprolactinemia']	1	6	"Sentence: Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol .
Diseases: hyperprolactinemia"	"Sentence: Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol .
Diseases:"
2834	The aim of the study was to examine the influence of hyperprolactinemia , induced by haloperidol ( HAL ) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O	['hyperprolactinemia']	1	6	"Sentence: The aim of the study was to examine the influence of hyperprolactinemia , induced by haloperidol ( HAL ) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe .
Diseases: hyperprolactinemia"	"Sentence: The aim of the study was to examine the influence of hyperprolactinemia , induced by haloperidol ( HAL ) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe .
Diseases:"
2835	The study was performed on sexually mature male rats .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: The study was performed on sexually mature male rats .
Diseases: "	"Sentence: The study was performed on sexually mature male rats .
Diseases:"
2836	Serum concentrations of prolactin ( PRL ) and testosterone ( T ) were measured .	O O O O O O O O O O O O O O O	O O O O O O O O B O B O O O O	[]	0	0	"Sentence: Serum concentrations of prolactin ( PRL ) and testosterone ( T ) were measured .
Diseases: "	"Sentence: Serum concentrations of prolactin ( PRL ) and testosterone ( T ) were measured .
Diseases:"
2837	Tissue sections were evaluated with light and electron microscopy .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Tissue sections were evaluated with light and electron microscopy .
Diseases: "	"Sentence: Tissue sections were evaluated with light and electron microscopy .
Diseases:"
2838	Immunohistochemical reactions for Anti - Proliferating Cell Nuclear Antigen ( PCNA ) were performed .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Immunohistochemical reactions for Anti - Proliferating Cell Nuclear Antigen ( PCNA ) were performed .
Diseases: "	"Sentence: Immunohistochemical reactions for Anti - Proliferating Cell Nuclear Antigen ( PCNA ) were performed .
Diseases:"
2839	In rats of the experimental group , the mean concentration of : PRL was more than twice higher , whereas T concentration was almost twice lower than that in the control group .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In rats of the experimental group , the mean concentration of : PRL was more than twice higher , whereas T concentration was almost twice lower than that in the control group .
Diseases: "	"Sentence: In rats of the experimental group , the mean concentration of : PRL was more than twice higher , whereas T concentration was almost twice lower than that in the control group .
Diseases:"
2840	Light microscopy visualized the following : hypertrophy and epithelium hyperplasia of the glandular ducts , associated with increased PCNA expression .	O O O O O O B O O B O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	['hyperplasia', 'hypertrophy']	2	7	"Sentence: Light microscopy visualized the following : hypertrophy and epithelium hyperplasia of the glandular ducts , associated with increased PCNA expression .
Diseases: hyperplasia, hypertrophy"	"Sentence: Light microscopy visualized the following : hypertrophy and epithelium hyperplasia of the glandular ducts , associated with increased PCNA expression .
Diseases:"
2841	Electron microscopy revealed changes in columnar epithelial cells , concerning organelles , engaged in protein synthesis and secretion .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Electron microscopy revealed changes in columnar epithelial cells , concerning organelles , engaged in protein synthesis and secretion .
Diseases: "	"Sentence: Electron microscopy revealed changes in columnar epithelial cells , concerning organelles , engaged in protein synthesis and secretion .
Diseases:"
2842	Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes ?	O O O O O B I O O O O B O	O O B I O O O O O O O O O	['cardiovascular disease', 'diabetes']	2	5	"Sentence: Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes ?
Diseases: cardiovascular disease, diabetes"	"Sentence: Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes ?
Diseases:"
2843	Vitamin C acts as a potent antioxidant ; however , it can also be a prooxidant and glycate protein under certain circumstances in vitro .	O O O O O O O O O O O O O O O O O O O O O O O O O	B I O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Vitamin C acts as a potent antioxidant ; however , it can also be a prooxidant and glycate protein under certain circumstances in vitro .
Diseases: "	"Sentence: Vitamin C acts as a potent antioxidant ; however , it can also be a prooxidant and glycate protein under certain circumstances in vitro .
Diseases:"
2844	These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis .	O O O O O O O O O O O O O O B O O O B O	O O O O O O O O O O O B I O O O O O O O	['atherosclerosis', 'diabetic']	2	5	"Sentence: These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis .
Diseases: atherosclerosis, diabetic"	"Sentence: These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis .
Diseases:"
2845	The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease .	O O O O O O O O O O O O O O B I O	O O O O O O O O B I O O O O O O O	['cardiovascular disease']	1	3	"Sentence: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease .
Diseases: cardiovascular disease"	"Sentence: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease .
Diseases:"
2846	DESIGN : We studied the relation between vitamin C intake and mortality from total cardiovascular disease ( n = 281 ) , coronary artery disease ( n = 175 ) , and stroke ( n = 57 ) in 1923 postmenopausal women who reported being diabetic at baseline .	O O O O O O O O O O O O O O B I O O O O O O B I I O O O O O O O B O O O O O O O O O O O O B O O O	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['stroke', 'cardiovascular disease', 'coronary artery disease', 'diabetic']	4	10	"Sentence: DESIGN : We studied the relation between vitamin C intake and mortality from total cardiovascular disease ( n = 281 ) , coronary artery disease ( n = 175 ) , and stroke ( n = 57 ) in 1923 postmenopausal women who reported being diabetic at baseline .
Diseases: stroke, cardiovascular disease, coronary artery disease, diabetic"	"Sentence: DESIGN : We studied the relation between vitamin C intake and mortality from total cardiovascular disease ( n = 281 ) , coronary artery disease ( n = 175 ) , and stroke ( n = 57 ) in 1923 postmenopausal women who reported being diabetic at baseline .
Diseases:"
2847	Diet was assessed with a food - frequency questionnaire at baseline , and subjects initially free of coronary artery disease were prospectively followed for 15 y . RESULTS : After adjustment for cardiovascular disease risk factors , type of diabetes medication used , duration of diabetes , and intakes of folate , vitamin E , and beta - carotene , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .	O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O B I O O O O O B O O O O O B O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B I O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O	['cardiovascular disease', 'coronary artery disease', 'diabetes']	3	9	"Sentence: Diet was assessed with a food - frequency questionnaire at baseline , and subjects initially free of coronary artery disease were prospectively followed for 15 y . RESULTS : After adjustment for cardiovascular disease risk factors , type of diabetes medication used , duration of diabetes , and intakes of folate , vitamin E , and beta - carotene , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .
Diseases: cardiovascular disease, coronary artery disease, diabetes"	"Sentence: Diet was assessed with a food - frequency questionnaire at baseline , and subjects initially free of coronary artery disease were prospectively followed for 15 y . RESULTS : After adjustment for cardiovascular disease risk factors , type of diabetes medication used , duration of diabetes , and intakes of folate , vitamin E , and beta - carotene , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .
Diseases:"
2848	Adjusted relative risks of coronary artery disease were 1 . 0 , 0 . 81 , 0 . 99 , 1 . 26 , and 1 . 91 ( P for trend = 0 . 01 ) and of stroke were 1 . 0 , 0 . 52 , 1 . 23 , 2 . 22 , and 2 . 57 ( P for trend < 0 . 01 ) .	O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['stroke', 'coronary artery disease']	2	5	"Sentence: Adjusted relative risks of coronary artery disease were 1 . 0 , 0 . 81 , 0 . 99 , 1 . 26 , and 1 . 91 ( P for trend = 0 . 01 ) and of stroke were 1 . 0 , 0 . 52 , 1 . 23 , 2 . 22 , and 2 . 57 ( P for trend < 0 . 01 ) .
Diseases: stroke, coronary artery disease"	"Sentence: Adjusted relative risks of coronary artery disease were 1 . 0 , 0 . 81 , 0 . 99 , 1 . 26 , and 1 . 91 ( P for trend = 0 . 01 ) and of stroke were 1 . 0 , 0 . 52 , 1 . 23 , 2 . 22 , and 2 . 57 ( P for trend < 0 . 01 ) .
Diseases:"
2849	When dietary and supplemental vitamin C were analyzed separately , only supplemental vitamin C showed a positive association with mortality endpoints .	O O O O O O O O O O O O O O O O O O O O O O	O O O O B I O O O O O O B I O O O O O O O O	[]	0	0	"Sentence: When dietary and supplemental vitamin C were analyzed separately , only supplemental vitamin C showed a positive association with mortality endpoints .
Diseases: "	"Sentence: When dietary and supplemental vitamin C were analyzed separately , only supplemental vitamin C showed a positive association with mortality endpoints .
Diseases:"
2850	Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline .	O O O O O O O O B I O O O O O O O	B I O O O O O O O O O O O O O O O	['cardiovascular disease']	1	3	"Sentence: Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline .
Diseases: cardiovascular disease"	"Sentence: Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline .
Diseases:"
2851	A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes .	O O O O O O O O O O O O O O B I O O O O O B O	O O B I O O O O O O O O O O O O O O O O O O O	['cardiovascular disease', 'diabetes']	2	5	"Sentence: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes .
Diseases: cardiovascular disease, diabetes"	"Sentence: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes .
Diseases:"
2852	Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol .	O O O O O B I O O O O O O O O O	O O O O O O O O O O O B I O B O	['venous thromboembolism']	1	8	"Sentence: Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol .
Diseases: venous thromboembolism"	"Sentence: Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol .
Diseases:"
2853	To achieve absolute risk estimates of venous thromboembolism ( VTE ) among women on cyproterone acetate plus ethinylestradiol ( CPA / EE ) , and among women on combined oral contraceptives ( COCs ) .	O O O O O O B I O B O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B I O B O B O B O O O O O O O B I O O O O	['vte', 'venous thromboembolism']	2	11	"Sentence: To achieve absolute risk estimates of venous thromboembolism ( VTE ) among women on cyproterone acetate plus ethinylestradiol ( CPA / EE ) , and among women on combined oral contraceptives ( COCs ) .
Diseases: vte, venous thromboembolism"	"Sentence: To achieve absolute risk estimates of venous thromboembolism ( VTE ) among women on cyproterone acetate plus ethinylestradiol ( CPA / EE ) , and among women on combined oral contraceptives ( COCs ) .
Diseases:"
2854	METHODS : From the Danish National Register of Patients ( NRP ) , 1996 to 1998 , the records of 1 . 1 million Danish women , ages 15 to 44 years , were searched for evidence of VTE .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['vte']	1	2	"Sentence: METHODS : From the Danish National Register of Patients ( NRP ) , 1996 to 1998 , the records of 1 . 1 million Danish women , ages 15 to 44 years , were searched for evidence of VTE .
Diseases: vte"	"Sentence: METHODS : From the Danish National Register of Patients ( NRP ) , 1996 to 1998 , the records of 1 . 1 million Danish women , ages 15 to 44 years , were searched for evidence of VTE .
Diseases:"
2855	COC use was ascertained through mailed questionnaires .	O O O O O O O O	B O O O O O O O	[]	0	0	"Sentence: COC use was ascertained through mailed questionnaires .
Diseases: "	"Sentence: COC use was ascertained through mailed questionnaires .
Diseases:"
2856	Sales statistics of COCs and CPA / EE were provided through Danish Drug Statistics .	O O O O O O O O O O O O O O O	O O O O O B O B O O O O O O O	[]	0	0	"Sentence: Sales statistics of COCs and CPA / EE were provided through Danish Drug Statistics .
Diseases: "	"Sentence: Sales statistics of COCs and CPA / EE were provided through Danish Drug Statistics .
Diseases:"
2857	During the time frame of the study , 330 women were found to have had VTE while on COCs .	O O O O O O O O O O O O O O O B O O O O	O O O O O O O O O O O O O O O O O O O O	['vte']	1	2	"Sentence: During the time frame of the study , 330 women were found to have had VTE while on COCs .
Diseases: vte"	"Sentence: During the time frame of the study , 330 women were found to have had VTE while on COCs .
Diseases:"
2858	Of these women , 67 were on levonorgestrel - containing COCs .	O O O O O O O O O O O O	O O O O O O O B O O O O	[]	0	0	"Sentence: Of these women , 67 were on levonorgestrel - containing COCs .
Diseases: "	"Sentence: Of these women , 67 were on levonorgestrel - containing COCs .
Diseases:"
2859	Eleven were on CPA / EE .	O O O O O O O	O O O B O B O	[]	0	0	"Sentence: Eleven were on CPA / EE .
Diseases: "	"Sentence: Eleven were on CPA / EE .
Diseases:"
2860	The corresponding absolute risk of VTE was 3 . 4 ( range , 3 . 1 - 3 . 8 ) per 10 000 women years among the women on COCs , 4 . 2 ( range , 3 . 2 - 5 . 2 ) per 10 000 women years among women on levonorgestrel - containing COCs , and 3 . 1 ( range , 1 . 3 - 4 . 9 ) per 10 000 women years among the women on CPA / EE .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O	['vte']	1	2	"Sentence: The corresponding absolute risk of VTE was 3 . 4 ( range , 3 . 1 - 3 . 8 ) per 10 000 women years among the women on COCs , 4 . 2 ( range , 3 . 2 - 5 . 2 ) per 10 000 women years among women on levonorgestrel - containing COCs , and 3 . 1 ( range , 1 . 3 - 4 . 9 ) per 10 000 women years among the women on CPA / EE .
Diseases: vte"	"Sentence: The corresponding absolute risk of VTE was 3 . 4 ( range , 3 . 1 - 3 . 8 ) per 10 000 women years among the women on COCs , 4 . 2 ( range , 3 . 2 - 5 . 2 ) per 10 000 women years among women on levonorgestrel - containing COCs , and 3 . 1 ( range , 1 . 3 - 4 . 9 ) per 10 000 women years among the women on CPA / EE .
Diseases:"
2861	Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA / EE .	O O O O O O O B O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O B O B O	['vte']	1	2	"Sentence: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA / EE .
Diseases: vte"	"Sentence: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA / EE .
Diseases:"
2862	Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity .	O O O O O O O O O O O O O O O O O B O	O O B O O O O O O O O O O O O B O O O	['neurotoxicity']	1	4	"Sentence: Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity .
Diseases: neurotoxicity"	"Sentence: Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity .
Diseases:"
2863	Oral administration of lindane ( 2 . 5 , 5 , 10 and 15 mg / kg , body weight ) for 5 days was found to produce a dose - dependent increase in the activity of P450 dependent 7 - ethoxyresorufin - O - deethylase ( EROD ) , 7 - pentoxyresorufin - O - dealkylase ( PROD ) and N - nitrosodimethylamine demethylase ( NDMA - d ) in rat brain and liver .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O B I I O O O O O O O O B I I O O B O O O O O O O O O	[]	0	0	"Sentence: Oral administration of lindane ( 2 . 5 , 5 , 10 and 15 mg / kg , body weight ) for 5 days was found to produce a dose - dependent increase in the activity of P450 dependent 7 - ethoxyresorufin - O - deethylase ( EROD ) , 7 - pentoxyresorufin - O - dealkylase ( PROD ) and N - nitrosodimethylamine demethylase ( NDMA - d ) in rat brain and liver .
Diseases: "	"Sentence: Oral administration of lindane ( 2 . 5 , 5 , 10 and 15 mg / kg , body weight ) for 5 days was found to produce a dose - dependent increase in the activity of P450 dependent 7 - ethoxyresorufin - O - deethylase ( EROD ) , 7 - pentoxyresorufin - O - dealkylase ( PROD ) and N - nitrosodimethylamine demethylase ( NDMA - d ) in rat brain and liver .
Diseases:"
2864	A significant increase in the hepatic and brain P450 monooxygenases was also observed when the duration of exposure of low dose ( 2 . 5 mg / kg ) of lindane was increased from 5 days to 15 or 21 days .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: A significant increase in the hepatic and brain P450 monooxygenases was also observed when the duration of exposure of low dose ( 2 . 5 mg / kg ) of lindane was increased from 5 days to 15 or 21 days .
Diseases: "	"Sentence: A significant increase in the hepatic and brain P450 monooxygenases was also observed when the duration of exposure of low dose ( 2 . 5 mg / kg ) of lindane was increased from 5 days to 15 or 21 days .
Diseases:"
2865	As observed with different doses , the magnitude of induction in the activity of P450 monooxygenases was several fold higher in liver microsomes when compared with the brain .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: As observed with different doses , the magnitude of induction in the activity of P450 monooxygenases was several fold higher in liver microsomes when compared with the brain .
Diseases: "	"Sentence: As observed with different doses , the magnitude of induction in the activity of P450 monooxygenases was several fold higher in liver microsomes when compared with the brain .
Diseases:"
2866	Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1 / 1A2 , 2B1 / 2B2 and 2E1 isoenzymes .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1 / 1A2 , 2B1 / 2B2 and 2E1 isoenzymes .
Diseases: "	"Sentence: Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1 / 1A2 , 2B1 / 2B2 and 2E1 isoenzymes .
Diseases:"
2867	In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD , EROD and NDMA - d are due to the increase in the levels of P450 2B1 / 2B2 , 1A1 / 1A2 and 2E1 isoenzymes , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD , EROD and NDMA - d are due to the increase in the levels of P450 2B1 / 2B2 , 1A1 / 1A2 and 2E1 isoenzymes , respectively .
Diseases: "	"Sentence: In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD , EROD and NDMA - d are due to the increase in the levels of P450 2B1 / 2B2 , 1A1 / 1A2 and 2E1 isoenzymes , respectively .
Diseases:"
2868	Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced convulsions , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced convulsions .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O B I I O B O O O O O O O O O O O O O O O O O O O B O O O O O B O B O O O O O O O O O O B O O O O O O O O O O O O O O B O O O	['convulsions']	1	3	"Sentence: Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced convulsions , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced convulsions .
Diseases: convulsions"	"Sentence: Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced convulsions , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced convulsions .
Diseases:"
2869	Similarly , when the P450 - mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O B O O O B I O O O O O O O O O B O O B O O O O O O O B O B O O O O O O O O O O	['toxicity', 'convulsions']	2	5	"Sentence: Similarly , when the P450 - mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity .
Diseases: toxicity, convulsions"	"Sentence: Similarly , when the P450 - mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity .
Diseases:"
2870	Seizure associated with sleep deprivation and sustained - release bupropion .	B O O B I O O O O O O	O O O O O O O O O B O	['sleep deprivation', 'seizure']	2	4	"Sentence: Seizure associated with sleep deprivation and sustained - release bupropion .
Diseases: sleep deprivation, seizure"	"Sentence: Seizure associated with sleep deprivation and sustained - release bupropion .
Diseases:"
2871	This case report describes a generalized seizure associated with sustained - release bupropion use and sleep deprivation .	O O O O O O B O O O O O O O O B I O	O O O O O O O O O O O O B O O O O O	['sleep deprivation', 'seizure']	2	4	"Sentence: This case report describes a generalized seizure associated with sustained - release bupropion use and sleep deprivation .
Diseases: sleep deprivation, seizure"	"Sentence: This case report describes a generalized seizure associated with sustained - release bupropion use and sleep deprivation .
Diseases:"
2872	The subject , a 31 - year - old female smoker , was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained - release bupropion as an active control .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	[]	0	0	"Sentence: The subject , a 31 - year - old female smoker , was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained - release bupropion as an active control .
Diseases: "	"Sentence: The subject , a 31 - year - old female smoker , was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained - release bupropion as an active control .
Diseases:"
2873	After 5 weeks of bupropion use , the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['seizure']	1	3	"Sentence: After 5 weeks of bupropion use , the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence .
Diseases: seizure"	"Sentence: After 5 weeks of bupropion use , the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence .
Diseases:"
2874	The patient had no other risk factors for seizures .	O O O O O O O O B O	O O O O O O O O O O	['seizures']	1	3	"Sentence: The patient had no other risk factors for seizures .
Diseases: seizures"	"Sentence: The patient had no other risk factors for seizures .
Diseases:"
2875	We suggest that sleep deprivation may add to the risk of bupropion - associated seizures .	O O O B I O O O O O O O O O B O	O O O O O O O O O O O B O O O O	['sleep deprivation', 'seizures']	2	4	"Sentence: We suggest that sleep deprivation may add to the risk of bupropion - associated seizures .
Diseases: sleep deprivation, seizures"	"Sentence: We suggest that sleep deprivation may add to the risk of bupropion - associated seizures .
Diseases:"
2876	Nephrotoxic effects in high - risk patients undergoing angiography .	B O O O O O O O O O	O O O O O O O O O O	['nephrotoxic']	1	4	"Sentence: Nephrotoxic effects in high - risk patients undergoing angiography .
Diseases: nephrotoxic"	"Sentence: Nephrotoxic effects in high - risk patients undergoing angiography .
Diseases:"
2877	The use of iodinated contrast medium can result in nephropathy .	O O O O O O O O O B O	O O O O O O O O O O O	['nephropathy']	1	4	"Sentence: The use of iodinated contrast medium can result in nephropathy .
Diseases: nephropathy"	"Sentence: The use of iodinated contrast medium can result in nephropathy .
Diseases:"
2878	Whether iso - osmolar contrast medium is less nephrotoxic than low - osmolar contrast medium in high - risk patients is uncertain .	O O O O O O O O B O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['nephrotoxic']	1	4	"Sentence: Whether iso - osmolar contrast medium is less nephrotoxic than low - osmolar contrast medium in high - risk patients is uncertain .
Diseases: nephrotoxic"	"Sentence: Whether iso - osmolar contrast medium is less nephrotoxic than low - osmolar contrast medium in high - risk patients is uncertain .
Diseases:"
2879	METHODS : We conducted a randomized , double - blind , prospective , multicenter study comparing the nephrotoxic effects of an iso - osmolar , dimeric , nonionic contrast medium , iodixanol , with those of a low - osmolar , nonionic , monomeric contrast medium , iohexol .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O B O	['nephrotoxic']	1	4	"Sentence: METHODS : We conducted a randomized , double - blind , prospective , multicenter study comparing the nephrotoxic effects of an iso - osmolar , dimeric , nonionic contrast medium , iodixanol , with those of a low - osmolar , nonionic , monomeric contrast medium , iohexol .
Diseases: nephrotoxic"	"Sentence: METHODS : We conducted a randomized , double - blind , prospective , multicenter study comparing the nephrotoxic effects of an iso - osmolar , dimeric , nonionic contrast medium , iodixanol , with those of a low - osmolar , nonionic , monomeric contrast medium , iohexol .
Diseases:"
2880	The study involved 129 patients with diabetes with serum creatinine concentrations of 1 . 5 to 3 . 5 mg per deciliter who underwent coronary or aortofemoral angiography .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['diabetes']	1	2	"Sentence: The study involved 129 patients with diabetes with serum creatinine concentrations of 1 . 5 to 3 . 5 mg per deciliter who underwent coronary or aortofemoral angiography .
Diseases: diabetes"	"Sentence: The study involved 129 patients with diabetes with serum creatinine concentrations of 1 . 5 to 3 . 5 mg per deciliter who underwent coronary or aortofemoral angiography .
Diseases:"
2881	The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography .
Diseases: "	"Sentence: The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography .
Diseases:"
2882	Other end points were an increase in the creatinine concentration of 0 . 5 mg per deciliter or more , an increase of 1 . 0 mg per deciliter or more , and a change in the creatinine concentration from day 0 to day 7 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: Other end points were an increase in the creatinine concentration of 0 . 5 mg per deciliter or more , an increase of 1 . 0 mg per deciliter or more , and a change in the creatinine concentration from day 0 to day 7 .
Diseases: "	"Sentence: Other end points were an increase in the creatinine concentration of 0 . 5 mg per deciliter or more , an increase of 1 . 0 mg per deciliter or more , and a change in the creatinine concentration from day 0 to day 7 .
Diseases:"
2883	The creatinine concentration increased significantly less in patients who received iodixanol .	O O O O O O O O O O O O	O B O O O O O O O O B O	[]	0	0	"Sentence: The creatinine concentration increased significantly less in patients who received iodixanol .
Diseases: "	"Sentence: The creatinine concentration increased significantly less in patients who received iodixanol .
Diseases:"
2884	From day 0 to day 3 , the mean peak increase in creatinine was 0 . 13 mg per deciliter in the iodixanol group and 0 . 55 mg per deciliter in the iohexol group ( P = 0 . 001 ; the increase with iodixanol minus the increase with iohexol , - 0 . 42 mg per deciliter [ 95 percent confidence interval , - 0 . 73 to - 0 . 22 ] ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O B O O O O O O O O O O B O O O O O O O O O O O B O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: From day 0 to day 3 , the mean peak increase in creatinine was 0 . 13 mg per deciliter in the iodixanol group and 0 . 55 mg per deciliter in the iohexol group ( P = 0 . 001 ; the increase with iodixanol minus the increase with iohexol , - 0 . 42 mg per deciliter [ 95 percent confidence interval , - 0 . 73 to - 0 . 22 ] ) .
Diseases: "	"Sentence: From day 0 to day 3 , the mean peak increase in creatinine was 0 . 13 mg per deciliter in the iodixanol group and 0 . 55 mg per deciliter in the iohexol group ( P = 0 . 001 ; the increase with iodixanol minus the increase with iohexol , - 0 . 42 mg per deciliter [ 95 percent confidence interval , - 0 . 73 to - 0 . 22 ] ) .
Diseases:"
2885	Two of the 64 patients in the iodixanol group ( 3 percent ) had an increase in the creatinine concentration of 0 . 5 mg per deciliter or more , as compared with 17 of the 65 patients in the iohexol group ( 26 percent ) ( P = 0 . 002 ; odds ratio for such an increase in the iodixanol group , 0 . 09 [ 95 percent confidence interval , 0 . 02 to 0 . 41 ] ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Two of the 64 patients in the iodixanol group ( 3 percent ) had an increase in the creatinine concentration of 0 . 5 mg per deciliter or more , as compared with 17 of the 65 patients in the iohexol group ( 26 percent ) ( P = 0 . 002 ; odds ratio for such an increase in the iodixanol group , 0 . 09 [ 95 percent confidence interval , 0 . 02 to 0 . 41 ] ) .
Diseases: "	"Sentence: Two of the 64 patients in the iodixanol group ( 3 percent ) had an increase in the creatinine concentration of 0 . 5 mg per deciliter or more , as compared with 17 of the 65 patients in the iohexol group ( 26 percent ) ( P = 0 . 002 ; odds ratio for such an increase in the iodixanol group , 0 . 09 [ 95 percent confidence interval , 0 . 02 to 0 . 41 ] ) .
Diseases:"
2886	No patient receiving iodixanol had an increase of 1 . 0 mg per deciliter or more , but 10 patients in the iohexol group ( 15 percent ) did .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: No patient receiving iodixanol had an increase of 1 . 0 mg per deciliter or more , but 10 patients in the iohexol group ( 15 percent ) did .
Diseases: "	"Sentence: No patient receiving iodixanol had an increase of 1 . 0 mg per deciliter or more , but 10 patients in the iohexol group ( 15 percent ) did .
Diseases:"
2887	The mean change in the creatinine concentration from day 0 to day 7 was 0 . 07 mg per deciliter in the iodixanol group and 0 . 24 mg per deciliter in the iohexol group ( P = 0 . 003 ; value in the iodixanol group minus the value in the iohexol group , - 0 . 17 mg per deciliter [ 95 percent confidence interval , - 0 . 34 to - 0 . 07 ] ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O B O O O O O O O O O O B O O O O O O O O O O O B O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mean change in the creatinine concentration from day 0 to day 7 was 0 . 07 mg per deciliter in the iodixanol group and 0 . 24 mg per deciliter in the iohexol group ( P = 0 . 003 ; value in the iodixanol group minus the value in the iohexol group , - 0 . 17 mg per deciliter [ 95 percent confidence interval , - 0 . 34 to - 0 . 07 ] ) .
Diseases: "	"Sentence: The mean change in the creatinine concentration from day 0 to day 7 was 0 . 07 mg per deciliter in the iodixanol group and 0 . 24 mg per deciliter in the iohexol group ( P = 0 . 003 ; value in the iodixanol group minus the value in the iohexol group , - 0 . 17 mg per deciliter [ 95 percent confidence interval , - 0 . 34 to - 0 . 07 ] ) .
Diseases:"
2888	CONCLUSIONS : Nephropathy induced by contrast medium may be less likely to develop in high - risk patients when iodixanol is used rather than a low - osmolar , nonionic contrast medium .	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	['nephropathy']	1	4	"Sentence: CONCLUSIONS : Nephropathy induced by contrast medium may be less likely to develop in high - risk patients when iodixanol is used rather than a low - osmolar , nonionic contrast medium .
Diseases: nephropathy"	"Sentence: CONCLUSIONS : Nephropathy induced by contrast medium may be less likely to develop in high - risk patients when iodixanol is used rather than a low - osmolar , nonionic contrast medium .
Diseases:"
2889	Experimental cranial pain elicited by capsaicin : a PET study .	O O B O O O O O O O O	O O O O O B O O O O O	['pain']	1	1	"Sentence: Experimental cranial pain elicited by capsaicin : a PET study .
Diseases: pain"	"Sentence: Experimental cranial pain elicited by capsaicin : a PET study .
Diseases:"
2890	Using a positron emission tomography ( PET ) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the headache state , but not in the headache free interval .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O B O O O O O O B O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['migraine', 'headache']	2	5	"Sentence: Using a positron emission tomography ( PET ) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the headache state , but not in the headache free interval .
Diseases: migraine, headache"	"Sentence: Using a positron emission tomography ( PET ) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the headache state , but not in the headache free interval .
Diseases:"
2891	It was suggested that this brain stem activation is inherent to the migraine attack itself and represents the so called ' migraine generator ' .	O O O O O O O O O O O O B O O O O O O O O B O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['migraine']	1	3	"Sentence: It was suggested that this brain stem activation is inherent to the migraine attack itself and represents the so called ' migraine generator ' .
Diseases: migraine"	"Sentence: It was suggested that this brain stem activation is inherent to the migraine attack itself and represents the so called ' migraine generator ' .
Diseases:"
2892	To test this hypothesis we performed an experimental pain study in seven healthy volunteers , using the same positioning in the PET scanner as in the migraine patients .	O O O O O O O O B O O O O O O O O O O O O O O O O O B O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pain', 'migraine']	2	3	"Sentence: To test this hypothesis we performed an experimental pain study in seven healthy volunteers , using the same positioning in the PET scanner as in the migraine patients .
Diseases: pain, migraine"	"Sentence: To test this hypothesis we performed an experimental pain study in seven healthy volunteers , using the same positioning in the PET scanner as in the migraine patients .
Diseases:"
2893	A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve .	O O O O O O O O O O O O O O O O B O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O	['painful']	1	2	"Sentence: A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve .
Diseases: painful"	"Sentence: A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve .
Diseases:"
2894	Increases of regional cerebral blood flow ( rCBF ) were found bilaterally in the insula , in the anterior cingulate cortex , the cavernous sinus and the cerebellum .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Increases of regional cerebral blood flow ( rCBF ) were found bilaterally in the insula , in the anterior cingulate cortex , the cavernous sinus and the cerebellum .
Diseases: "	"Sentence: Increases of regional cerebral blood flow ( rCBF ) were found bilaterally in the insula , in the anterior cingulate cortex , the cavernous sinus and the cerebellum .
Diseases:"
2895	Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state .	O O O O O O O O O O O B O O O O O O O O O O B O O O O B O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['migraine', 'pain']	2	5	"Sentence: Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state .
Diseases: migraine, pain"	"Sentence: Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state .
Diseases:"
2896	The increase of activation in the region of the cavernous sinus however , suggests that this structure is more likely to be involved in trigeminal transmitted pain as such , rather than in a specific type of headache as was suggested for cluster headache .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O B O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pain', 'headache', 'cluster headache']	3	6	"Sentence: The increase of activation in the region of the cavernous sinus however , suggests that this structure is more likely to be involved in trigeminal transmitted pain as such , rather than in a specific type of headache as was suggested for cluster headache .
Diseases: pain, headache, cluster headache"	"Sentence: The increase of activation in the region of the cavernous sinus however , suggests that this structure is more likely to be involved in trigeminal transmitted pain as such , rather than in a specific type of headache as was suggested for cluster headache .
Diseases:"
2897	Neuroleptic malignant syndrome with risperidone .	B I I O O O	O O O O B O	['neuroleptic malignant syndrome']	1	7	"Sentence: Neuroleptic malignant syndrome with risperidone .
Diseases: neuroleptic malignant syndrome"	"Sentence: Neuroleptic malignant syndrome with risperidone .
Diseases:"
2898	Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia .	B I I O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O	['neuroleptic malignant syndrome']	1	7	"Sentence: Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia .
Diseases: neuroleptic malignant syndrome"	"Sentence: Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia .
Diseases:"
2899	Risperidone , a benzisoxazole derivative antipsychotic , has high serotonin 5 - HT2 receptor blockade and dose - related D2 receptor blockade .	O O O O O O O O O O O O O O O O O O O O O O O	B O O B O O O O O B B I I O O O O O O O O O O	[]	0	0	"Sentence: Risperidone , a benzisoxazole derivative antipsychotic , has high serotonin 5 - HT2 receptor blockade and dose - related D2 receptor blockade .
Diseases: "	"Sentence: Risperidone , a benzisoxazole derivative antipsychotic , has high serotonin 5 - HT2 receptor blockade and dose - related D2 receptor blockade .
Diseases:"
2900	The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages .	O O O O O O O O O O O B I O O O O O O	O O O O O O O O O O O O O O B O O O O	['extrapyramidal symptoms']	1	6	"Sentence: The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages .
Diseases: extrapyramidal symptoms"	"Sentence: The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages .
Diseases:"
2901	With this low frequency of extrapyramidal symptoms , it was thought the frequency of neuroleptic malignant syndrome might also be lowered .	O O O O O B I O O O O O O O B I I O O O O O	O O O O O O O O O O O O O O O O O O O O O O	['neuroleptic malignant syndrome', 'extrapyramidal symptoms']	2	13	"Sentence: With this low frequency of extrapyramidal symptoms , it was thought the frequency of neuroleptic malignant syndrome might also be lowered .
Diseases: neuroleptic malignant syndrome, extrapyramidal symptoms"	"Sentence: With this low frequency of extrapyramidal symptoms , it was thought the frequency of neuroleptic malignant syndrome might also be lowered .
Diseases:"
2902	A 73 - year - old woman developed neuroleptic malignant syndrome after monotherapy with risperidone .	O O O O O O O O B I I O O O O O	O O O O O O O O O O O O O O B O	['neuroleptic malignant syndrome']	1	7	"Sentence: A 73 - year - old woman developed neuroleptic malignant syndrome after monotherapy with risperidone .
Diseases: neuroleptic malignant syndrome"	"Sentence: A 73 - year - old woman developed neuroleptic malignant syndrome after monotherapy with risperidone .
Diseases:"
2903	The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine .	O O O O O O O O O O O O O O	O O O O O B O O O O B O B O	[]	0	0	"Sentence: The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine .
Diseases: "	"Sentence: The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine .
Diseases:"
2904	It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome .	O O O O O O O O O O O O O O O O O B I I O	O O O O O O O O O O O B O O O O O O O O O	['neuroleptic malignant syndrome']	1	7	"Sentence: It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome .
Diseases: neuroleptic malignant syndrome"	"Sentence: It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome .
Diseases:"
2905	Hepatic and extrahepatic angiotensinogen gene expression in rats with acute nephrotic syndrome .	O O O O O O O O O O B I O	O O O O O O O O O O O O O	['nephrotic syndrome']	1	5	"Sentence: Hepatic and extrahepatic angiotensinogen gene expression in rats with acute nephrotic syndrome .
Diseases: nephrotic syndrome"	"Sentence: Hepatic and extrahepatic angiotensinogen gene expression in rats with acute nephrotic syndrome .
Diseases:"
2906	Plasma concentration and urine excretion of the renin - angiotensin system proteins are altered in rats with nephrotic syndrome ( NS ) .	O O O O O O O O O O O O O O O O O B I O B O O	O O O O O O O O O B O O O O O O O O O O O O O	['nephrotic syndrome', 'ns']	2	7	"Sentence: Plasma concentration and urine excretion of the renin - angiotensin system proteins are altered in rats with nephrotic syndrome ( NS ) .
Diseases: nephrotic syndrome, ns"	"Sentence: Plasma concentration and urine excretion of the renin - angiotensin system proteins are altered in rats with nephrotic syndrome ( NS ) .
Diseases:"
2907	In this work the messenger ribonucleic acid ( mRNA ) levels of angiotensinogen ( Ao ) were analyzed with the slot - blot hybridization technique in liver and other extrahepatic tissues : kidney , heart , brain , and adrenal gland from control , nephrotic , and pair - fed ( PF ) rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	O O O O O O I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nephrotic']	1	4	"Sentence: In this work the messenger ribonucleic acid ( mRNA ) levels of angiotensinogen ( Ao ) were analyzed with the slot - blot hybridization technique in liver and other extrahepatic tissues : kidney , heart , brain , and adrenal gland from control , nephrotic , and pair - fed ( PF ) rats .
Diseases: nephrotic"	"Sentence: In this work the messenger ribonucleic acid ( mRNA ) levels of angiotensinogen ( Ao ) were analyzed with the slot - blot hybridization technique in liver and other extrahepatic tissues : kidney , heart , brain , and adrenal gland from control , nephrotic , and pair - fed ( PF ) rats .
Diseases:"
2908	NS was induced by a single injection of puromycin amino - nucleoside ( PAN ) .	B O O O O O O O O O O O O O O O	O O O O O O O O B I I I O B O O	['ns']	1	1	"Sentence: NS was induced by a single injection of puromycin amino - nucleoside ( PAN ) .
Diseases: ns"	"Sentence: NS was induced by a single injection of puromycin amino - nucleoside ( PAN ) .
Diseases:"
2909	Although a great urinary excretion and half - normal plasma levels of Ao were observed on day 6 after PAN injection , when NS was clearly established , hepatic Ao mRNA levels did not change .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	['ns']	1	1	"Sentence: Although a great urinary excretion and half - normal plasma levels of Ao were observed on day 6 after PAN injection , when NS was clearly established , hepatic Ao mRNA levels did not change .
Diseases: ns"	"Sentence: Although a great urinary excretion and half - normal plasma levels of Ao were observed on day 6 after PAN injection , when NS was clearly established , hepatic Ao mRNA levels did not change .
Diseases:"
2910	Furthermore , the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6 , nor did its hepatic levels at days 1 , 3 , 5 , or 7 after PAN injection .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Furthermore , the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6 , nor did its hepatic levels at days 1 , 3 , 5 , or 7 after PAN injection .
Diseases: "	"Sentence: Furthermore , the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6 , nor did its hepatic levels at days 1 , 3 , 5 , or 7 after PAN injection .
Diseases:"
2911	These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN .	O O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O O O O O O O O O O O O O O O O O B O	['ns']	1	1	"Sentence: These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN .
Diseases: ns"	"Sentence: These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN .
Diseases:"
2912	Cyclophosphamide associated bladder cancer - - a highly aggressive disease : analysis of 12 cases .	O O B I O O O O O O O O O O O O	B O O O O O O O O O O O O O O O	['bladder cancer']	1	3	"Sentence: Cyclophosphamide associated bladder cancer - - a highly aggressive disease : analysis of 12 cases .
Diseases: bladder cancer"	"Sentence: Cyclophosphamide associated bladder cancer - - a highly aggressive disease : analysis of 12 cases .
Diseases:"
2913	We gained knowledge of the etiology , treatment and prevention of cyclophosphamide associated urothelial cancer .	O O O O O O O O O O O O O B I O	O O O O O O O O O O O B O O O O	['urothelial cancer']	1	4	"Sentence: We gained knowledge of the etiology , treatment and prevention of cyclophosphamide associated urothelial cancer .
Diseases: urothelial cancer"	"Sentence: We gained knowledge of the etiology , treatment and prevention of cyclophosphamide associated urothelial cancer .
Diseases:"
2914	The medical records of 6 men and 6 women ( mean age 55 years ) with cyclophosphamide associated bladder cancer were reviewed .	O O O O O O O O O O O O O O O O O O B I O O O	O O O O O O O O O O O O O O O O B O O O O O O	['bladder cancer']	1	3	"Sentence: The medical records of 6 men and 6 women ( mean age 55 years ) with cyclophosphamide associated bladder cancer were reviewed .
Diseases: bladder cancer"	"Sentence: The medical records of 6 men and 6 women ( mean age 55 years ) with cyclophosphamide associated bladder cancer were reviewed .
Diseases:"
2915	RESULTS : All tumors were grade 3 or 4 transitional cell carcinoma .	O O O B O O O O O O O B O	O O O O O O O O O O O O O	['carcinoma', 'tumors']	2	6	"Sentence: RESULTS : All tumors were grade 3 or 4 transitional cell carcinoma .
Diseases: carcinoma, tumors"	"Sentence: RESULTS : All tumors were grade 3 or 4 transitional cell carcinoma .
Diseases:"
2916	Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease .
Diseases: "	"Sentence: Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease .
Diseases:"
2917	Of the 6 patients who underwent early cystectomy 4 were alive at 24 to 111 months .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of the 6 patients who underwent early cystectomy 4 were alive at 24 to 111 months .
Diseases: "	"Sentence: Of the 6 patients who underwent early cystectomy 4 were alive at 24 to 111 months .
Diseases:"
2918	The remaining patient with extensive cancer underwent partial cystectomy for palliation and died 3 months later .	O O O O O B O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	['cancer']	1	1	"Sentence: The remaining patient with extensive cancer underwent partial cystectomy for palliation and died 3 months later .
Diseases: cancer"	"Sentence: The remaining patient with extensive cancer underwent partial cystectomy for palliation and died 3 months later .
Diseases:"
2919	CONCLUSIONS : Cyclophosphamide associated bladder tumor is an aggressive disease .	O O O O B I O O O O O	O O B O O O O O O O O	['bladder tumor']	1	3	"Sentence: CONCLUSIONS : Cyclophosphamide associated bladder tumor is an aggressive disease .
Diseases: bladder tumor"	"Sentence: CONCLUSIONS : Cyclophosphamide associated bladder tumor is an aggressive disease .
Diseases:"
2920	However , long - term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease , even when noninvasive .	O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['bladder tumors']	1	3	"Sentence: However , long - term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease , even when noninvasive .
Diseases: bladder tumors"	"Sentence: However , long - term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease , even when noninvasive .
Diseases:"
2921	Leg and back pain after spinal anaesthesia involving hyperbaric 5 % lignocaine .	B I I I O O O O O O O O O	O O O O O O O O O O O B O	['leg and back pain']	1	4	"Sentence: Leg and back pain after spinal anaesthesia involving hyperbaric 5 % lignocaine .
Diseases: leg and back pain"	"Sentence: Leg and back pain after spinal anaesthesia involving hyperbaric 5 % lignocaine .
Diseases:"
2922	Fifty - four patients , aged 27 - 90 years , who were given lignocaine 5 % in 6 . 8 % glucose solution for spinal anaesthesia were studied .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O B O O O O O O O	[]	0	0	"Sentence: Fifty - four patients , aged 27 - 90 years , who were given lignocaine 5 % in 6 . 8 % glucose solution for spinal anaesthesia were studied .
Diseases: "	"Sentence: Fifty - four patients , aged 27 - 90 years , who were given lignocaine 5 % in 6 . 8 % glucose solution for spinal anaesthesia were studied .
Diseases:"
2923	Thirteen of these patients experienced pain in the legs and / or back after recovery from anaesthesia .	O O O O O B I I I I I I I O O O O O	O O O O O O O O O O O O O O O O O O	['pain in the legs and / or back']	1	8	"Sentence: Thirteen of these patients experienced pain in the legs and / or back after recovery from anaesthesia .
Diseases: pain in the legs and / or back"	"Sentence: Thirteen of these patients experienced pain in the legs and / or back after recovery from anaesthesia .
Diseases:"
2924	The patients affected were younger ( p < 0 . 05 ) and the site of the dural puncture was higher ( p < 0 . 01 ) than those individuals without pain .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: The patients affected were younger ( p < 0 . 05 ) and the site of the dural puncture was higher ( p < 0 . 01 ) than those individuals without pain .
Diseases: pain"	"Sentence: The patients affected were younger ( p < 0 . 05 ) and the site of the dural puncture was higher ( p < 0 . 01 ) than those individuals without pain .
Diseases:"
2925	Five of the 13 patients ( 38 % ) with pain and seven of the 41 patients ( 17 % ) without pain admitted to a high alcohol intake , which might be a contributing factor .	O O O O O O O O O O B O O O O O O O O O O O B O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	['pain']	1	1	"Sentence: Five of the 13 patients ( 38 % ) with pain and seven of the 41 patients ( 17 % ) without pain admitted to a high alcohol intake , which might be a contributing factor .
Diseases: pain"	"Sentence: Five of the 13 patients ( 38 % ) with pain and seven of the 41 patients ( 17 % ) without pain admitted to a high alcohol intake , which might be a contributing factor .
Diseases:"
2926	Leg and / or back pain is associated with the intrathecal use of hyperbaric 5 % lignocaine .	B I I I I I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O	['leg and / or back pain']	1	6	"Sentence: Leg and / or back pain is associated with the intrathecal use of hyperbaric 5 % lignocaine .
Diseases: leg and / or back pain"	"Sentence: Leg and / or back pain is associated with the intrathecal use of hyperbaric 5 % lignocaine .
Diseases:"
2927	Acute blood pressure elevations with caffeine in men with borderline systemic hypertension .	O O O O O O O O O O O B O	O O O O O B O O O O O O O	['hypertension']	1	3	"Sentence: Acute blood pressure elevations with caffeine in men with borderline systemic hypertension .
Diseases: hypertension"	"Sentence: Acute blood pressure elevations with caffeine in men with borderline systemic hypertension .
Diseases:"
2928	Whether the vasoconstrictive actions of caffeine are enhanced in hypertensive persons has not been demonstrated .	O O O O O O O O O B O O O O O O	O O O O O B O O O O O O O O O O	['hypertensive']	1	3	"Sentence: Whether the vasoconstrictive actions of caffeine are enhanced in hypertensive persons has not been demonstrated .
Diseases: hypertensive"	"Sentence: Whether the vasoconstrictive actions of caffeine are enhanced in hypertensive persons has not been demonstrated .
Diseases:"
2929	Thus , caffeine ( 3 . 3 mg / kg ) versus placebo was tested in 48 healthy men ( aged 20 to 35 years ) selected after screening on 2 separate occasions .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thus , caffeine ( 3 . 3 mg / kg ) versus placebo was tested in 48 healthy men ( aged 20 to 35 years ) selected after screening on 2 separate occasions .
Diseases: "	"Sentence: Thus , caffeine ( 3 . 3 mg / kg ) versus placebo was tested in 48 healthy men ( aged 20 to 35 years ) selected after screening on 2 separate occasions .
Diseases:"
2930	Borderline hypertensive men ( n = 24 ) were selected with screening systolic blood pressure ( BP ) of 140 to 160 mm Hg and / or diastolic BP 90 to 99 mm	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertensive']	1	3	"Sentence: Borderline hypertensive men ( n = 24 ) were selected with screening systolic blood pressure ( BP ) of 140 to 160 mm Hg and / or diastolic BP 90 to 99 mm
Diseases: hypertensive"	"Sentence: Borderline hypertensive men ( n = 24 ) were selected with screening systolic blood pressure ( BP ) of 140 to 160 mm Hg and / or diastolic BP 90 to 99 mm
Diseases:"
2931	Low - risk controls ( n = 24 ) reported no parental history of hypertension and had screening BP < 130 / 85 mm	O O O O O O O O O O O O O O B O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: Low - risk controls ( n = 24 ) reported no parental history of hypertension and had screening BP < 130 / 85 mm
Diseases: hypertension"	"Sentence: Low - risk controls ( n = 24 ) reported no parental history of hypertension and had screening BP < 130 / 85 mm
Diseases:"
2932	Participants were then tested on 2 occasions after 12 - hour abstinence from caffeine in each of 2 protocols ; this required a total of 4 laboratory visits .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Participants were then tested on 2 occasions after 12 - hour abstinence from caffeine in each of 2 protocols ; this required a total of 4 laboratory visits .
Diseases: "	"Sentence: Participants were then tested on 2 occasions after 12 - hour abstinence from caffeine in each of 2 protocols ; this required a total of 4 laboratory visits .
Diseases:"
2933	Caffeine - induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls ( + 8 . 4 vs + 3 . 8	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Caffeine - induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls ( + 8 . 4 vs + 3 . 8
Diseases: "	"Sentence: Caffeine - induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls ( + 8 . 4 vs + 3 . 8
Diseases:"
2934	mm Hg , p < 0 . 0001 ) , and were attributable to larger changes in impedance - derived measures of systemic vascular resistance ( + 135 vs + 45 dynes . s . cm - 5 , p < 0 . 004 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: mm Hg , p < 0 . 0001 ) , and were attributable to larger changes in impedance - derived measures of systemic vascular resistance ( + 135 vs + 45 dynes . s . cm - 5 , p < 0 . 004 ) .
Diseases: "	"Sentence: mm Hg , p < 0 . 0001 ) , and were attributable to larger changes in impedance - derived measures of systemic vascular resistance ( + 135 vs + 45 dynes . s . cm - 5 , p < 0 . 004 ) .
Diseases:"
2935	These findings were consistent and reached significance in both protocols .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: These findings were consistent and reached significance in both protocols .
Diseases: "	"Sentence: These findings were consistent and reached significance in both protocols .
Diseases:"
2936	The percentage of borderline subjects in whom diastolic BP changes exceeded the median control response was 96 % .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The percentage of borderline subjects in whom diastolic BP changes exceeded the median control response was 96 % .
Diseases: "	"Sentence: The percentage of borderline subjects in whom diastolic BP changes exceeded the median control response was 96 % .
Diseases:"
2937	Consequently , whereas all participants exhibited normotensive levels during the resting predrug baseline , 33 % of borderline subjects achieved hypertensive BP levels after caffeine ingestion .	O O O O O O O O O O O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B O O	['hypertensive']	1	3	"Sentence: Consequently , whereas all participants exhibited normotensive levels during the resting predrug baseline , 33 % of borderline subjects achieved hypertensive BP levels after caffeine ingestion .
Diseases: hypertensive"	"Sentence: Consequently , whereas all participants exhibited normotensive levels during the resting predrug baseline , 33 % of borderline subjects achieved hypertensive BP levels after caffeine ingestion .
Diseases:"
2938	Thus , in borderline hypertensive men , exaggerated responses to caffeine were : selective for diastolic BP , consistent with greater vasoconstriction , replicated in 2 protocols , and representative of nearly all borderline hypertensives .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertensives', 'hypertensive']	2	7	"Sentence: Thus , in borderline hypertensive men , exaggerated responses to caffeine were : selective for diastolic BP , consistent with greater vasoconstriction , replicated in 2 protocols , and representative of nearly all borderline hypertensives .
Diseases: hypertensives, hypertensive"	"Sentence: Thus , in borderline hypertensive men , exaggerated responses to caffeine were : selective for diastolic BP , consistent with greater vasoconstriction , replicated in 2 protocols , and representative of nearly all borderline hypertensives .
Diseases:"
2939	We suspect that the potential for caffeine to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression , as well as hinder accurate diagnosis and treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We suspect that the potential for caffeine to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression , as well as hinder accurate diagnosis and treatment .
Diseases: "	"Sentence: We suspect that the potential for caffeine to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression , as well as hinder accurate diagnosis and treatment .
Diseases:"
2940	Hallucinations and ifosfamide - induced neurotoxicity .	B O O O O B O	O O B O O O O	['hallucinations', 'neurotoxicity']	2	6	"Sentence: Hallucinations and ifosfamide - induced neurotoxicity .
Diseases: hallucinations, neurotoxicity"	"Sentence: Hallucinations and ifosfamide - induced neurotoxicity .
Diseases:"
2941	Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide .	B O O O O O B O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O	['hallucinations', 'neurotoxicity']	2	6	"Sentence: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide .
Diseases: hallucinations, neurotoxicity"	"Sentence: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide .
Diseases:"
2942	Most cases of ifosfamide - induced hallucinations have been reported with other mental status changes .	O O O O O O B O O O O O O O O O	O O O B O O O O O O O O O O O O	['hallucinations']	1	3	"Sentence: Most cases of ifosfamide - induced hallucinations have been reported with other mental status changes .
Diseases: hallucinations"	"Sentence: Most cases of ifosfamide - induced hallucinations have been reported with other mental status changes .
Diseases:"
2943	The authors interviewed six persons with ifosfamide - induced hallucinations in the presence of a clear sensorium .	O O O O O O O O O B O O O O O O O O	O O O O O O B O O O O O O O O O O O	['hallucinations']	1	3	"Sentence: The authors interviewed six persons with ifosfamide - induced hallucinations in the presence of a clear sensorium .
Diseases: hallucinations"	"Sentence: The authors interviewed six persons with ifosfamide - induced hallucinations in the presence of a clear sensorium .
Diseases:"
2944	All patients were receiving high - dose ifosfamide as part of their bone marrow transplant procedure .	O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: All patients were receiving high - dose ifosfamide as part of their bone marrow transplant procedure .
Diseases: "	"Sentence: All patients were receiving high - dose ifosfamide as part of their bone marrow transplant procedure .
Diseases:"
2945	Hallucinations occurred only when the patient 's eyes were closed and , in all but one case , were reported as disturbing or frightening .	B O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['hallucinations']	1	3	"Sentence: Hallucinations occurred only when the patient 's eyes were closed and , in all but one case , were reported as disturbing or frightening .
Diseases: hallucinations"	"Sentence: Hallucinations occurred only when the patient 's eyes were closed and , in all but one case , were reported as disturbing or frightening .
Diseases:"
2946	Underreporting of these hallucinations by patients is likely .	O O O B O O O O O	O O O O O O O O O	['hallucinations']	1	3	"Sentence: Underreporting of these hallucinations by patients is likely .
Diseases: hallucinations"	"Sentence: Underreporting of these hallucinations by patients is likely .
Diseases:"
2947	CONCLUSIONS : Hallucinations may be the sole or first manifestation of neurotoxicity .	O O B O O O O O O O O B O	O O O O O O O O O O O O O	['hallucinations', 'neurotoxicity']	2	6	"Sentence: CONCLUSIONS : Hallucinations may be the sole or first manifestation of neurotoxicity .
Diseases: hallucinations, neurotoxicity"	"Sentence: CONCLUSIONS : Hallucinations may be the sole or first manifestation of neurotoxicity .
Diseases:"
2948	The incidence may be dose and infusion - time related .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: The incidence may be dose and infusion - time related .
Diseases: "	"Sentence: The incidence may be dose and infusion - time related .
Diseases:"
2949	The clinician should be alerted for possible ifosfamide - induced hallucinations , which may occur without other signs of neurotoxicity .	O O O O O O O O O O B O O O O O O O O B O	O O O O O O O B O O O O O O O O O O O O O	['hallucinations', 'neurotoxicity']	2	6	"Sentence: The clinician should be alerted for possible ifosfamide - induced hallucinations , which may occur without other signs of neurotoxicity .
Diseases: hallucinations, neurotoxicity"	"Sentence: The clinician should be alerted for possible ifosfamide - induced hallucinations , which may occur without other signs of neurotoxicity .
Diseases:"
2950	""" Eyes - closed "" hallucinatory experiences appear to be an unusual feature of this presentation ."	O O O O O B O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	['hallucinatory']	1	3	"Sentence: "" Eyes - closed "" hallucinatory experiences appear to be an unusual feature of this presentation .
Diseases: hallucinatory"	"Sentence: "" Eyes - closed "" hallucinatory experiences appear to be an unusual feature of this presentation .
Diseases:"
2951	Patients anxious about this experience respond well to support and education about this occurrence .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients anxious about this experience respond well to support and education about this occurrence .
Diseases: "	"Sentence: Patients anxious about this experience respond well to support and education about this occurrence .
Diseases:"
2952	Optimal pharmacologic management of disturbed patients is unclear .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Optimal pharmacologic management of disturbed patients is unclear .
Diseases: "	"Sentence: Optimal pharmacologic management of disturbed patients is unclear .
Diseases:"
2953	If agitation becomes marked , high - potency neuroleptics ( i . e . , haloperidol ) may be effective .	O B O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O O O	['agitation']	1	2	"Sentence: If agitation becomes marked , high - potency neuroleptics ( i . e . , haloperidol ) may be effective .
Diseases: agitation"	"Sentence: If agitation becomes marked , high - potency neuroleptics ( i . e . , haloperidol ) may be effective .
Diseases:"
2954	Chlorpropamide - induced optic neuropathy .	O O O B I O	B O O O O O	['optic neuropathy']	1	4	"Sentence: Chlorpropamide - induced optic neuropathy .
Diseases: optic neuropathy"	"Sentence: Chlorpropamide - induced optic neuropathy .
Diseases:"
2955	A 65 - year - old woman with adult - onset diabetes treated with chlorpropamide ( Diabenese ) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy .	O O O O O O O O B I I I O O O O O O O O B I I O O O O O O O O	O O O O O O O O O O O O O O B O B O O O O O O O O O O O B O O	['adult - onset diabetes', 'toxic optic neuropathy']	2	9	"Sentence: A 65 - year - old woman with adult - onset diabetes treated with chlorpropamide ( Diabenese ) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy .
Diseases: adult - onset diabetes, toxic optic neuropathy"	"Sentence: A 65 - year - old woman with adult - onset diabetes treated with chlorpropamide ( Diabenese ) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy .
Diseases:"
2956	Visual loss occurs in diabetics for a variety of reasons , and accurate diagnosis is necessary to institute appropriate therapy .	B I O O B O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	['visual loss', 'diabetics']	2	6	"Sentence: Visual loss occurs in diabetics for a variety of reasons , and accurate diagnosis is necessary to institute appropriate therapy .
Diseases: visual loss, diabetics"	"Sentence: Visual loss occurs in diabetics for a variety of reasons , and accurate diagnosis is necessary to institute appropriate therapy .
Diseases:"
2957	The possibility of a drug - induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics .	O O O O O O O B I O O O O O O O O B I O B O	O O O O O O O O O O O O O O O O O O O O O O	['optic neuropathy', 'visual loss', 'diabetics']	3	11	"Sentence: The possibility of a drug - induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics .
Diseases: optic neuropathy, visual loss, diabetics"	"Sentence: The possibility of a drug - induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics .
Diseases:"
2958	Levodopa - induced dyskinesia and thalamotomy .	O O O B O O O	B O O O O O O	['dyskinesia']	1	5	"Sentence: Levodopa - induced dyskinesia and thalamotomy .
Diseases: dyskinesia"	"Sentence: Levodopa - induced dyskinesia and thalamotomy .
Diseases:"
2959	Levodopa - induced dyskinesia of the limbs in thirteen cases of Parkinsonism , which was choreic , ballistic or dystonic in type , was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus , but much less by the ventralis intermedius nucleus .	O O O B O O O O O O O B O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['dystonic', 'parkinsonism', 'dyskinesia']	3	12	"Sentence: Levodopa - induced dyskinesia of the limbs in thirteen cases of Parkinsonism , which was choreic , ballistic or dystonic in type , was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus , but much less by the ventralis intermedius nucleus .
Diseases: dystonic, parkinsonism, dyskinesia"	"Sentence: Levodopa - induced dyskinesia of the limbs in thirteen cases of Parkinsonism , which was choreic , ballistic or dystonic in type , was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus , but much less by the ventralis intermedius nucleus .
Diseases:"
2960	Control of levodopa - induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed .	O O O O O B O B I O O O O O O O B O O O	O O B O O O O O O O O O O O O O O O O O	['dyskinesias', 'parkinsonism', 'thalamic lesions']	3	14	"Sentence: Control of levodopa - induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed .
Diseases: dyskinesias, parkinsonism, thalamic lesions"	"Sentence: Control of levodopa - induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed .
Diseases:"
2961	Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin .	O O O B O O O O O O O O	O O O O O O O O O O B O	['nephrotoxicity']	1	4	"Sentence: Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin .
Diseases: nephrotoxicity"	"Sentence: Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin .
Diseases:"
2962	Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity .	O O O O O O O O O O O O O B O	O O O O O O B O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity .
Diseases: nephrotoxicity"	"Sentence: Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity .
Diseases:"
2963	In 42 of these patients , data were examined for factors associated with clinical outcome .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In 42 of these patients , data were examined for factors associated with clinical outcome .
Diseases: "	"Sentence: In 42 of these patients , data were examined for factors associated with clinical outcome .
Diseases:"
2964	Variables evaluated included patient weight , age , sex , serum creatinine level , creatinine clearance , duration of therapy , total dose , mean daily dose , organism minimum inhibitory concentration ( MIC ) , mean peak levels , mean trough levels , mean area under the serum concentration - time curve ( AUC ) , total AUC , mean AUC greater than MIC , total AUC greater than MIC , mean Schumacher 's intensity factor ( IF ) , total IF ,	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Variables evaluated included patient weight , age , sex , serum creatinine level , creatinine clearance , duration of therapy , total dose , mean daily dose , organism minimum inhibitory concentration ( MIC ) , mean peak levels , mean trough levels , mean area under the serum concentration - time curve ( AUC ) , total AUC , mean AUC greater than MIC , total AUC greater than MIC , mean Schumacher 's intensity factor ( IF ) , total IF ,
Diseases: "	"Sentence: Variables evaluated included patient weight , age , sex , serum creatinine level , creatinine clearance , duration of therapy , total dose , mean daily dose , organism minimum inhibitory concentration ( MIC ) , mean peak levels , mean trough levels , mean area under the serum concentration - time curve ( AUC ) , total AUC , mean AUC greater than MIC , total AUC greater than MIC , mean Schumacher 's intensity factor ( IF ) , total IF ,
Diseases:"
2965	In ( mean maximum concentration [ Cmax ] / MIC ) .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: In ( mean maximum concentration [ Cmax ] / MIC ) .
Diseases: "	"Sentence: In ( mean maximum concentration [ Cmax ] / MIC ) .
Diseases:"
2966	Model - dependent pharmacokinetic parameters were calculated by computer based on a one - compartment model .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Model - dependent pharmacokinetic parameters were calculated by computer based on a one - compartment model .
Diseases: "	"Sentence: Model - dependent pharmacokinetic parameters were calculated by computer based on a one - compartment model .
Diseases:"
2967	When the parameters were examined individually , duration of therapy and total AUC correlated significantly ( P less than . 05 ) with nephrotoxicity .	O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: When the parameters were examined individually , duration of therapy and total AUC correlated significantly ( P less than . 05 ) with nephrotoxicity .
Diseases: nephrotoxicity"	"Sentence: When the parameters were examined individually , duration of therapy and total AUC correlated significantly ( P less than . 05 ) with nephrotoxicity .
Diseases:"
2968	In contrast , a stepwise discriminant function analysis identified only duration of therapy ( P less than . 001 ) as an important factor .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast , a stepwise discriminant function analysis identified only duration of therapy ( P less than . 001 ) as an important factor .
Diseases: "	"Sentence: In contrast , a stepwise discriminant function analysis identified only duration of therapy ( P less than . 001 ) as an important factor .
Diseases:"
2969	"Based on this model and on Bayes ' theorem , the predictive accuracy of identifying "" nephrotoxic "" patients increased from 0 . 17 to 0 . 39 ."	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nephrotoxic']	1	4	"Sentence: Based on this model and on Bayes ' theorem , the predictive accuracy of identifying "" nephrotoxic "" patients increased from 0 . 17 to 0 . 39 .
Diseases: nephrotoxic"	"Sentence: Based on this model and on Bayes ' theorem , the predictive accuracy of identifying "" nephrotoxic "" patients increased from 0 . 17 to 0 . 39 .
Diseases:"
2970	When examined individually , mean IF , MIC , total dose , mean daily dose , and ln ( mean Cmax / MIC ) correlated significantly ( P less than . 05 ) with cure .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: When examined individually , mean IF , MIC , total dose , mean daily dose , and ln ( mean Cmax / MIC ) correlated significantly ( P less than . 05 ) with cure .
Diseases: "	"Sentence: When examined individually , mean IF , MIC , total dose , mean daily dose , and ln ( mean Cmax / MIC ) correlated significantly ( P less than . 05 ) with cure .
Diseases:"
2971	In contrast , a simultaneous multivariable analysis identified IF , MIC , and total dose according to one model and ln ( mean Cmax / MIC ) according to a second statistical model of parameters selected to have the greatest prospective value .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast , a simultaneous multivariable analysis identified IF , MIC , and total dose according to one model and ln ( mean Cmax / MIC ) according to a second statistical model of parameters selected to have the greatest prospective value .
Diseases: "	"Sentence: In contrast , a simultaneous multivariable analysis identified IF , MIC , and total dose according to one model and ln ( mean Cmax / MIC ) according to a second statistical model of parameters selected to have the greatest prospective value .
Diseases:"
2972	Based on Bayes ' theorem and the first model , the predictive accuracy of identifying patients not cured increased from 0 . 19 to 0 . 83 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Based on Bayes ' theorem and the first model , the predictive accuracy of identifying patients not cured increased from 0 . 19 to 0 . 83 .
Diseases: "	"Sentence: Based on Bayes ' theorem and the first model , the predictive accuracy of identifying patients not cured increased from 0 . 19 to 0 . 83 .
Diseases:"
2973	For the second model , the predictive accuracy increased from 0 . 19 to 0 . 50 . ( ABSTRACT TRUNCATED AT 250 WORDS )	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: For the second model , the predictive accuracy increased from 0 . 19 to 0 . 50 . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases: "	"Sentence: For the second model , the predictive accuracy increased from 0 . 19 to 0 . 50 . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases:"
2974	Cardiac transplantation : improved quality of survival with a modified immunosuppressive protocol .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Cardiac transplantation : improved quality of survival with a modified immunosuppressive protocol .
Diseases: "	"Sentence: Cardiac transplantation : improved quality of survival with a modified immunosuppressive protocol .
Diseases:"
2975	The effects on renal function on two different immunosuppressive protocols were evaluated retrospectively in two subsequent groups of heart transplant recipients .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The effects on renal function on two different immunosuppressive protocols were evaluated retrospectively in two subsequent groups of heart transplant recipients .
Diseases: "	"Sentence: The effects on renal function on two different immunosuppressive protocols were evaluated retrospectively in two subsequent groups of heart transplant recipients .
Diseases:"
2976	In group I , cyclosporine was given before the procedure at a loading dose of 17 . 5 mg / kg and then continued after the procedure to keep a whole blood level about 1000 ng / ml .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In group I , cyclosporine was given before the procedure at a loading dose of 17 . 5 mg / kg and then continued after the procedure to keep a whole blood level about 1000 ng / ml .
Diseases: "	"Sentence: In group I , cyclosporine was given before the procedure at a loading dose of 17 . 5 mg / kg and then continued after the procedure to keep a whole blood level about 1000 ng / ml .
Diseases:"
2977	In group II , cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine , which was used for the first postoperative week .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: In group II , cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine , which was used for the first postoperative week .
Diseases: "	"Sentence: In group II , cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine , which was used for the first postoperative week .
Diseases:"
2978	Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B I I O O B O O	[]	0	0	"Sentence: Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels .
Diseases: "	"Sentence: Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels .
Diseases:"
2979	Group II also showed a significant decrease of chronic nephrotoxicity secondary to long - term therapy with cyclosporine .	O O O O O O O O O B O O O O O O O O O	O O O O O O O O O O O O O O O O O B O	['nephrotoxicity']	1	4	"Sentence: Group II also showed a significant decrease of chronic nephrotoxicity secondary to long - term therapy with cyclosporine .
Diseases: nephrotoxicity"	"Sentence: Group II also showed a significant decrease of chronic nephrotoxicity secondary to long - term therapy with cyclosporine .
Diseases:"
2980	Despite this improvement in late renal function , group II still shows a slow rise in serum creatinine .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: Despite this improvement in late renal function , group II still shows a slow rise in serum creatinine .
Diseases: "	"Sentence: Despite this improvement in late renal function , group II still shows a slow rise in serum creatinine .
Diseases:"
2981	We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect .
Diseases: nephrotoxicity"	"Sentence: We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect .
Diseases:"
2982	Reversible cholestasis with bile duct injury following azathioprine therapy .	O B O B I I O O O O	O O O O O O O B O O	['cholestasis', 'bile duct injury']	2	9	"Sentence: Reversible cholestasis with bile duct injury following azathioprine therapy .
Diseases: cholestasis, bile duct injury"	"Sentence: Reversible cholestasis with bile duct injury following azathioprine therapy .
Diseases:"
2983	A 67 - year - old patient , with primary polymyositis and without previous evidence of liver disease , developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy .	O O O O O O O O O O B O O O O O B I O O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['cholestasis', 'liver disease', 'polymyositis']	3	12	"Sentence: A 67 - year - old patient , with primary polymyositis and without previous evidence of liver disease , developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy .
Diseases: cholestasis, liver disease, polymyositis"	"Sentence: A 67 - year - old patient , with primary polymyositis and without previous evidence of liver disease , developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy .
Diseases:"
2984	Liver biopsy showed cholestasis with both cytological and architectural alterations of interlobular bile ducts .	O O O B O O O O O O O O O O O	O O O O O O O O O O O O O O O	['cholestasis']	1	4	"Sentence: Liver biopsy showed cholestasis with both cytological and architectural alterations of interlobular bile ducts .
Diseases: cholestasis"	"Sentence: Liver biopsy showed cholestasis with both cytological and architectural alterations of interlobular bile ducts .
Diseases:"
2985	Azathioprine withdrawal resulted after 7 weeks in the resolution of clinical and biochemical abnormalities .	O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O	[]	0	0	"Sentence: Azathioprine withdrawal resulted after 7 weeks in the resolution of clinical and biochemical abnormalities .
Diseases: "	"Sentence: Azathioprine withdrawal resulted after 7 weeks in the resolution of clinical and biochemical abnormalities .
Diseases:"
2986	It is believed that this is the first reported case of reversible azathioprine - induced cholestasis associated with histological evidence of bile duct injury .	O O O O O O O O O O O O O O O B O O O O O B I I O	O O O O O O O O O O O O B O O O O O O O O O O O O	['cholestasis', 'bile duct injury']	2	9	"Sentence: It is believed that this is the first reported case of reversible azathioprine - induced cholestasis associated with histological evidence of bile duct injury .
Diseases: cholestasis, bile duct injury"	"Sentence: It is believed that this is the first reported case of reversible azathioprine - induced cholestasis associated with histological evidence of bile duct injury .
Diseases:"
2987	Renal function and hemodynamics during prolonged isoflurane - induced hypotension in humans .	O O O O O O O O O B O O O	O O O O O O B O O O O O O	['hypotension']	1	3	"Sentence: Renal function and hemodynamics during prolonged isoflurane - induced hypotension in humans .
Diseases: hypotension"	"Sentence: Renal function and hemodynamics during prolonged isoflurane - induced hypotension in humans .
Diseases:"
2988	The effect of isoflurane - induced hypotension on glomerular function and renal blood flow was investigated in 20 human subjects .	O O O O O O B O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: The effect of isoflurane - induced hypotension on glomerular function and renal blood flow was investigated in 20 human subjects .
Diseases: hypotension"	"Sentence: The effect of isoflurane - induced hypotension on glomerular function and renal blood flow was investigated in 20 human subjects .
Diseases:"
2989	Glomerular filtration rate ( GFR ) and effective renal plasma flow ( ERPF ) were measured by inulin and para - aminohippurate ( PAH ) clearance , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O B I I O B O O O O O	[]	0	0	"Sentence: Glomerular filtration rate ( GFR ) and effective renal plasma flow ( ERPF ) were measured by inulin and para - aminohippurate ( PAH ) clearance , respectively .
Diseases: "	"Sentence: Glomerular filtration rate ( GFR ) and effective renal plasma flow ( ERPF ) were measured by inulin and para - aminohippurate ( PAH ) clearance , respectively .
Diseases:"
2990	Anesthesia was maintained with fentanyl , nitrous oxide , oxygen , and isoflurane .	O O O O O O O O O O O O O O	O O O O B O B I O B O O B O	[]	0	0	"Sentence: Anesthesia was maintained with fentanyl , nitrous oxide , oxygen , and isoflurane .
Diseases: "	"Sentence: Anesthesia was maintained with fentanyl , nitrous oxide , oxygen , and isoflurane .
Diseases:"
2991	Hypotension was induced for 236 . 9 + / - 15 . 1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59 . 8 + / - 0 . 4 mmHg .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: Hypotension was induced for 236 . 9 + / - 15 . 1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59 . 8 + / - 0 . 4 mmHg .
Diseases: hypotension"	"Sentence: Hypotension was induced for 236 . 9 + / - 15 . 1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59 . 8 + / - 0 . 4 mmHg .
Diseases:"
2992	GFR and ERPF decreased with the induction of anesthesia but not significantly more during hypotension .	O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: GFR and ERPF decreased with the induction of anesthesia but not significantly more during hypotension .
Diseases: hypotension"	"Sentence: GFR and ERPF decreased with the induction of anesthesia but not significantly more during hypotension .
Diseases:"
2993	Postoperatively , ERPF returned to preoperative values , whereas GFR was higher than preoperative values .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Postoperatively , ERPF returned to preoperative values , whereas GFR was higher than preoperative values .
Diseases: "	"Sentence: Postoperatively , ERPF returned to preoperative values , whereas GFR was higher than preoperative values .
Diseases:"
2994	Renal vascular resistance increased during anesthesia but decreased when hypotension was induced , allowing the maintenance of renal blood flow .	O O O O O O O O O B O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: Renal vascular resistance increased during anesthesia but decreased when hypotension was induced , allowing the maintenance of renal blood flow .
Diseases: hypotension"	"Sentence: Renal vascular resistance increased during anesthesia but decreased when hypotension was induced , allowing the maintenance of renal blood flow .
Diseases:"
2995	We conclude that renal compensatory mechanisms are preserved during isoflurane - induced hypotension and that renal function and hemodynamics quickly return to normal when normotension is resumed .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: We conclude that renal compensatory mechanisms are preserved during isoflurane - induced hypotension and that renal function and hemodynamics quickly return to normal when normotension is resumed .
Diseases: hypotension"	"Sentence: We conclude that renal compensatory mechanisms are preserved during isoflurane - induced hypotension and that renal function and hemodynamics quickly return to normal when normotension is resumed .
Diseases:"
2996	Debrisoquine phenotype and the pharmacokinetics and beta - 2 receptor pharmacodynamics of metoprolol and its enantiomers .	O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: Debrisoquine phenotype and the pharmacokinetics and beta - 2 receptor pharmacodynamics of metoprolol and its enantiomers .
Diseases: "	"Sentence: Debrisoquine phenotype and the pharmacokinetics and beta - 2 receptor pharmacodynamics of metoprolol and its enantiomers .
Diseases:"
2997	The metabolism of the cardioselective beta - blocker metoprolol is under genetic control of the debrisoquine / sparteine type .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O B O B O O	[]	0	0	"Sentence: The metabolism of the cardioselective beta - blocker metoprolol is under genetic control of the debrisoquine / sparteine type .
Diseases: "	"Sentence: The metabolism of the cardioselective beta - blocker metoprolol is under genetic control of the debrisoquine / sparteine type .
Diseases:"
2998	The two metabolic phenotypes , extensive ( EM ) and poor metabolizers ( PM ) , show different stereoselective metabolism , resulting in apparently higher beta - 1 adrenoceptor antagonistic potency of racemic metoprolol in EMs .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O	[]	0	0	"Sentence: The two metabolic phenotypes , extensive ( EM ) and poor metabolizers ( PM ) , show different stereoselective metabolism , resulting in apparently higher beta - 1 adrenoceptor antagonistic potency of racemic metoprolol in EMs .
Diseases: "	"Sentence: The two metabolic phenotypes , extensive ( EM ) and poor metabolizers ( PM ) , show different stereoselective metabolism , resulting in apparently higher beta - 1 adrenoceptor antagonistic potency of racemic metoprolol in EMs .
Diseases:"
2999	We investigated if the latter also applies to the beta - 2 adrenoceptor antagonism by metoprolol .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: We investigated if the latter also applies to the beta - 2 adrenoceptor antagonism by metoprolol .
Diseases: "	"Sentence: We investigated if the latter also applies to the beta - 2 adrenoceptor antagonism by metoprolol .
Diseases:"
3000	The drug effect studied was the antagonism by metoprolol of terbutaline - induced hypokalemia .	O O O O O O O O O O O O O B O	O O O O O O O O B O B O O O O	['hypokalemia']	1	4	"Sentence: The drug effect studied was the antagonism by metoprolol of terbutaline - induced hypokalemia .
Diseases: hypokalemia"	"Sentence: The drug effect studied was the antagonism by metoprolol of terbutaline - induced hypokalemia .
Diseases:"
3001	By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S - isomer , were quantitated in EMs and PMs in terms of IC50 values , representing metoprolol plasma concentrations resulting in half - maximum receptor occupancy .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S - isomer , were quantitated in EMs and PMs in terms of IC50 values , representing metoprolol plasma concentrations resulting in half - maximum receptor occupancy .
Diseases: "	"Sentence: By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S - isomer , were quantitated in EMs and PMs in terms of IC50 values , representing metoprolol plasma concentrations resulting in half - maximum receptor occupancy .
Diseases:"
3002	Six EMs received 0 . 5 mg of terbutaline s . c . on two different occasions : 1 ) 1 hr after administration of a placebo and 2 ) 1 hr after 150 mg of metoprolol p . o .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: Six EMs received 0 . 5 mg of terbutaline s . c . on two different occasions : 1 ) 1 hr after administration of a placebo and 2 ) 1 hr after 150 mg of metoprolol p . o .
Diseases: "	"Sentence: Six EMs received 0 . 5 mg of terbutaline s . c . on two different occasions : 1 ) 1 hr after administration of a placebo and 2 ) 1 hr after 150 mg of metoprolol p . o .
Diseases:"
3003	Five PMs were studied according to the same protocol , except for a higher terbutaline dose ( 0 . 75 mg ) on day 2 .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: Five PMs were studied according to the same protocol , except for a higher terbutaline dose ( 0 . 75 mg ) on day 2 .
Diseases: "	"Sentence: Five PMs were studied according to the same protocol , except for a higher terbutaline dose ( 0 . 75 mg ) on day 2 .
Diseases:"
3004	Blood samples for the analysis of plasma potassium , terbutaline , metoprolol ( racemic , R - and S - isomer ) , and alpha - hydroxymetoprolol concentrations were taken at regular time intervals , during 8 hr after metoprolol .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O B O B O O O O O O O O O O O O B I I O O O O O O O O O O O O B O	[]	0	0	"Sentence: Blood samples for the analysis of plasma potassium , terbutaline , metoprolol ( racemic , R - and S - isomer ) , and alpha - hydroxymetoprolol concentrations were taken at regular time intervals , during 8 hr after metoprolol .
Diseases: "	"Sentence: Blood samples for the analysis of plasma potassium , terbutaline , metoprolol ( racemic , R - and S - isomer ) , and alpha - hydroxymetoprolol concentrations were taken at regular time intervals , during 8 hr after metoprolol .
Diseases:"
3005	In PMs , metoprolol increased the terbutaline area under the plasma concentration vs . time curve ( + 67 % ) .	O O O O O O O O O O O O O O O O O O O O O O	O O O B O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In PMs , metoprolol increased the terbutaline area under the plasma concentration vs . time curve ( + 67 % ) .
Diseases: "	"Sentence: In PMs , metoprolol increased the terbutaline area under the plasma concentration vs . time curve ( + 67 % ) .
Diseases:"
3006	Higher metoprolol / alpha - hydroxymetoprolol ratios in PMs were predictive for higher R - / S - isomer ratios of unchanged drug .	O O O O O O O O O O O O O O O O O O O O O O O O	O B O B I I O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Higher metoprolol / alpha - hydroxymetoprolol ratios in PMs were predictive for higher R - / S - isomer ratios of unchanged drug .
Diseases: "	"Sentence: Higher metoprolol / alpha - hydroxymetoprolol ratios in PMs were predictive for higher R - / S - isomer ratios of unchanged drug .
Diseases:"
3007	There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs ( 72 + / - 7 ng . ml - 1 ) than EMs ( 42 + / - 8 ng . ml - 1 , P less than . 001 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs ( 72 + / - 7 ng . ml - 1 ) than EMs ( 42 + / - 8 ng . ml - 1 , P less than . 001 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases: "	"Sentence: There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs ( 72 + / - 7 ng . ml - 1 ) than EMs ( 42 + / - 8 ng . ml - 1 , P less than . 001 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases:"
3008	Cefotetan - induced immune hemolytic anemia .	O O O O B I O	B O O O O O O	['hemolytic anemia']	1	5	"Sentence: Cefotetan - induced immune hemolytic anemia .
Diseases: hemolytic anemia"	"Sentence: Cefotetan - induced immune hemolytic anemia .
Diseases:"
3009	Immune hemolytic anemia due to a drug - adsorption mechanism has been described primarily in patients receiving penicillins and first - generation cephalosporins .	O B I O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O B O	['hemolytic anemia']	1	5	"Sentence: Immune hemolytic anemia due to a drug - adsorption mechanism has been described primarily in patients receiving penicillins and first - generation cephalosporins .
Diseases: hemolytic anemia"	"Sentence: Immune hemolytic anemia due to a drug - adsorption mechanism has been described primarily in patients receiving penicillins and first - generation cephalosporins .
Diseases:"
3010	We describe a patient who developed anemia while receiving intravenous cefotetan .	O O O O O O B O O O O O	O O O O O O O O O O B O	['anemia']	1	2	"Sentence: We describe a patient who developed anemia while receiving intravenous cefotetan .
Diseases: anemia"	"Sentence: We describe a patient who developed anemia while receiving intravenous cefotetan .
Diseases:"
3011	Cefotetan - dependent antibodies were detected in the patient 's serum and in an eluate prepared from his red blood cells .	O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cefotetan - dependent antibodies were detected in the patient 's serum and in an eluate prepared from his red blood cells .
Diseases: "	"Sentence: Cefotetan - dependent antibodies were detected in the patient 's serum and in an eluate prepared from his red blood cells .
Diseases:"
3012	The eluate also reacted weakly with red blood cells in the absence of cefotetan , suggesting the concomitant formation of warm - reactive autoantibodies .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: The eluate also reacted weakly with red blood cells in the absence of cefotetan , suggesting the concomitant formation of warm - reactive autoantibodies .
Diseases: "	"Sentence: The eluate also reacted weakly with red blood cells in the absence of cefotetan , suggesting the concomitant formation of warm - reactive autoantibodies .
Diseases:"
3013	These observations , in conjunction with clinical and laboratory evidence of extravascular hemolysis , are consistent with drug - induced hemolytic anemia , possibly involving both drug - adsorption and autoantibody formation mechanisms .	O O O O O O O O O O O O B O O O O O O O B I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hemolysis', 'hemolytic anemia']	2	9	"Sentence: These observations , in conjunction with clinical and laboratory evidence of extravascular hemolysis , are consistent with drug - induced hemolytic anemia , possibly involving both drug - adsorption and autoantibody formation mechanisms .
Diseases: hemolysis, hemolytic anemia"	"Sentence: These observations , in conjunction with clinical and laboratory evidence of extravascular hemolysis , are consistent with drug - induced hemolytic anemia , possibly involving both drug - adsorption and autoantibody formation mechanisms .
Diseases:"
3014	This case emphasizes the need for increased awareness of hemolytic reactions to all cephalosporins .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O	[]	0	0	"Sentence: This case emphasizes the need for increased awareness of hemolytic reactions to all cephalosporins .
Diseases: "	"Sentence: This case emphasizes the need for increased awareness of hemolytic reactions to all cephalosporins .
Diseases:"
3015	Acute renal failure subsequent to the administration of rifampicin .	B I I O O O O O O O	O O O O O O O O B O	['acute renal failure']	1	4	"Sentence: Acute renal failure subsequent to the administration of rifampicin .
Diseases: acute renal failure"	"Sentence: Acute renal failure subsequent to the administration of rifampicin .
Diseases:"
3016	A follow - up study of cases reported earlier .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: A follow - up study of cases reported earlier .
Diseases: "	"Sentence: A follow - up study of cases reported earlier .
Diseases:"
3017	A clinical presentation is made of a 2 - 3 year follow - up of six cases of acute renal failure that have been reported earlier .	O O O O O O O O O O O O O O O O O O B I I O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['acute renal failure']	1	4	"Sentence: A clinical presentation is made of a 2 - 3 year follow - up of six cases of acute renal failure that have been reported earlier .
Diseases: acute renal failure"	"Sentence: A clinical presentation is made of a 2 - 3 year follow - up of six cases of acute renal failure that have been reported earlier .
Diseases:"
3018	The patients had developed transient renal failure after the intermittent administration of rifampicin .	O O O O O B I O O O O O O O	O O O O O O O O O O O O B O	['renal failure']	1	3	"Sentence: The patients had developed transient renal failure after the intermittent administration of rifampicin .
Diseases: renal failure"	"Sentence: The patients had developed transient renal failure after the intermittent administration of rifampicin .
Diseases:"
3019	The stage of olig - anuria lasted for 1 - 3 weeks , and five of the patients were treated by hemodialysis .	O O O O O B O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['anuria']	1	2	"Sentence: The stage of olig - anuria lasted for 1 - 3 weeks , and five of the patients were treated by hemodialysis .
Diseases: anuria"	"Sentence: The stage of olig - anuria lasted for 1 - 3 weeks , and five of the patients were treated by hemodialysis .
Diseases:"
3020	Two of the patients died due to unrelated causes during the follow - up period .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Two of the patients died due to unrelated causes during the follow - up period .
Diseases: "	"Sentence: Two of the patients died due to unrelated causes during the follow - up period .
Diseases:"
3021	The four patients re - examined were clinically cured .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: The four patients re - examined were clinically cured .
Diseases: "	"Sentence: The four patients re - examined were clinically cured .
Diseases:"
3022	Pathologic findings by light microscopy and immunofluorescence at biopsy were scarce .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: Pathologic findings by light microscopy and immunofluorescence at biopsy were scarce .
Diseases: "	"Sentence: Pathologic findings by light microscopy and immunofluorescence at biopsy were scarce .
Diseases:"
3023	Nothing abnormal was seen by electron microscopy in two of the cases studied .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Nothing abnormal was seen by electron microscopy in two of the cases studied .
Diseases: "	"Sentence: Nothing abnormal was seen by electron microscopy in two of the cases studied .
Diseases:"
3024	Renal function was normal .	O O O O O	O O O O O	[]	0	0	"Sentence: Renal function was normal .
Diseases: "	"Sentence: Renal function was normal .
Diseases:"
3025	In three cases the excretion at 131I - hippuran renography was slightly slowed .	O O O O O O O O O O O O O O	O O O O O O B I I O O O O O	[]	0	0	"Sentence: In three cases the excretion at 131I - hippuran renography was slightly slowed .
Diseases: "	"Sentence: In three cases the excretion at 131I - hippuran renography was slightly slowed .
Diseases:"
3026	Although in the acute stage the renal lesions histologically appeared toxic , evidence suggestive of an immunological mechanism can not be excluded .	O O O O O O B I O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['renal lesions']	1	3	"Sentence: Although in the acute stage the renal lesions histologically appeared toxic , evidence suggestive of an immunological mechanism can not be excluded .
Diseases: renal lesions"	"Sentence: Although in the acute stage the renal lesions histologically appeared toxic , evidence suggestive of an immunological mechanism can not be excluded .
Diseases:"
3027	Type B hepatitis after needle - stick exposure : prevention with hepatitis B immune globulin .	B I I O O O O O O O O B I O O O	O O O O O O O O O O O O O O I O	['type b hepatitis', 'hepatitis b']	2	6	"Sentence: Type B hepatitis after needle - stick exposure : prevention with hepatitis B immune globulin .
Diseases: type b hepatitis, hepatitis b"	"Sentence: Type B hepatitis after needle - stick exposure : prevention with hepatitis B immune globulin .
Diseases:"
3028	Final report of the Veterans Administration Cooperative Study .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Final report of the Veterans Administration Cooperative Study .
Diseases: "	"Sentence: Final report of the Veterans Administration Cooperative Study .
Diseases:"
3029	Hepatitis B immune globulin ( HBIG ) and immune serum globulin ( ISG ) were examined in a randomized , double - blind trial to assess their relative efficacies in preventing type B hepatitis after needle - stick exposure to hepatitis B surface antigen ( HBsAG ) - positive donors .	B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I O B O O O O O	['type b hepatitis', 'hepatitis b']	2	6	"Sentence: Hepatitis B immune globulin ( HBIG ) and immune serum globulin ( ISG ) were examined in a randomized , double - blind trial to assess their relative efficacies in preventing type B hepatitis after needle - stick exposure to hepatitis B surface antigen ( HBsAG ) - positive donors .
Diseases: type b hepatitis, hepatitis b"	"Sentence: Hepatitis B immune globulin ( HBIG ) and immune serum globulin ( ISG ) were examined in a randomized , double - blind trial to assess their relative efficacies in preventing type B hepatitis after needle - stick exposure to hepatitis B surface antigen ( HBsAG ) - positive donors .
Diseases:"
3030	Clinical hepatitis developed in 1 . 4 % of HBIG and in 5 . 9 % of ISG recipients ( P = 0 . 016 ) , and seroconversion ( anti - HBs ) occurred in 5 . 6 % and 20 . 7 % of them respectively ( P less than 0 . 001 ) .	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hepatitis']	1	3	"Sentence: Clinical hepatitis developed in 1 . 4 % of HBIG and in 5 . 9 % of ISG recipients ( P = 0 . 016 ) , and seroconversion ( anti - HBs ) occurred in 5 . 6 % and 20 . 7 % of them respectively ( P less than 0 . 001 ) .
Diseases: hepatitis"	"Sentence: Clinical hepatitis developed in 1 . 4 % of HBIG and in 5 . 9 % of ISG recipients ( P = 0 . 016 ) , and seroconversion ( anti - HBs ) occurred in 5 . 6 % and 20 . 7 % of them respectively ( P less than 0 . 001 ) .
Diseases:"
3031	Mild and transient side - effects were noted in 3 . 0 % of ISG and in 3 . 2 % of HBIG recipients .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O B O O	[]	0	0	"Sentence: Mild and transient side - effects were noted in 3 . 0 % of ISG and in 3 . 2 % of HBIG recipients .
Diseases: "	"Sentence: Mild and transient side - effects were noted in 3 . 0 % of ISG and in 3 . 2 % of HBIG recipients .
Diseases:"
3032	Available donor sera were examined for DNA polymerase ( DNAP ) and e antigen and antibody ( HBeAg ; anti - HBE ) .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O	[]	0	0	"Sentence: Available donor sera were examined for DNA polymerase ( DNAP ) and e antigen and antibody ( HBeAg ; anti - HBE ) .
Diseases: "	"Sentence: Available donor sera were examined for DNA polymerase ( DNAP ) and e antigen and antibody ( HBeAg ; anti - HBE ) .
Diseases:"
3033	Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg - positive donors .	O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O B O O O O	[]	0	0	"Sentence: Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg - positive donors .
Diseases: "	"Sentence: Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg - positive donors .
Diseases:"
3034	Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high - risk subgroups .	B I O O O O O O O O O B I I O O O O O O O O O O O O O O	B I I I O O O O B O O O O O O O O O O O O O O O O O O O	['type b hepatitis', 'hepatitis b']	2	6	"Sentence: Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high - risk subgroups .
Diseases: type b hepatitis, hepatitis b"	"Sentence: Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high - risk subgroups .
Diseases:"
3035	The efficacy of ISG in preventing type B hepatitis can not be ascertained because a true placebo group was not included .	O O O O O O B I I O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O	['type b hepatitis']	1	3	"Sentence: The efficacy of ISG in preventing type B hepatitis can not be ascertained because a true placebo group was not included .
Diseases: type b hepatitis"	"Sentence: The efficacy of ISG in preventing type B hepatitis can not be ascertained because a true placebo group was not included .
Diseases:"
3036	Serotonin syndrome from venlafaxine - tranylcypromine interaction .	B I O O O O O O	O O O B O B O O	['serotonin syndrome']	1	3	"Sentence: Serotonin syndrome from venlafaxine - tranylcypromine interaction .
Diseases: serotonin syndrome"	"Sentence: Serotonin syndrome from venlafaxine - tranylcypromine interaction .
Diseases:"
3037	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering , muscle rigidity , salivation , confusion , agitation and hyperthermia .	O O O O O O O O O O O O O O O O O B I O B O B O B O B O	O O O B O O O O O O B O O O O O O O O O O O O O O O O O	['muscle rigidity', 'confusion', 'hyperthermia', 'agitation', 'salivation']	5	15	"Sentence: Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering , muscle rigidity , salivation , confusion , agitation and hyperthermia .
Diseases: muscle rigidity, confusion, hyperthermia, agitation, salivation"	"Sentence: Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering , muscle rigidity , salivation , confusion , agitation and hyperthermia .
Diseases:"
3038	The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor ( MAOI ) and a specific serotonin reuptake inhibitor .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O B O O O	[]	0	0	"Sentence: The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor ( MAOI ) and a specific serotonin reuptake inhibitor .
Diseases: "	"Sentence: The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor ( MAOI ) and a specific serotonin reuptake inhibitor .
Diseases:"
3039	Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine .	O O O O O O O O O O O O O O O	B O O O B O O O O O O B O B O	[]	0	0	"Sentence: Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine .
Diseases: "	"Sentence: Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine .
Diseases:"
3040	We report a venlafaxine - MAOI interaction that resulted in the serotonin syndrome in a 23 - y - old male who was taking tranylcypromine for depression .	O O O O O O O O O O O B I O O O O O O O O O O O O O B O	O O O B O O O O O O O B O O O O O O O O O O O O B O O O	['serotonin syndrome', 'depression']	2	5	"Sentence: We report a venlafaxine - MAOI interaction that resulted in the serotonin syndrome in a 23 - y - old male who was taking tranylcypromine for depression .
Diseases: serotonin syndrome, depression"	"Sentence: We report a venlafaxine - MAOI interaction that resulted in the serotonin syndrome in a 23 - y - old male who was taking tranylcypromine for depression .
Diseases:"
3041	He had been well until the morning of presentation when he took 1 / 2 tab of venlafaxine .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: He had been well until the morning of presentation when he took 1 / 2 tab of venlafaxine .
Diseases: "	"Sentence: He had been well until the morning of presentation when he took 1 / 2 tab of venlafaxine .
Diseases:"
3042	Within 2 h he became confused with jerking movements of his extremities , tremors and rigidity .	O O O O O O O O O O O O O B O B O	O O O O O O O O O O O O O O O O O	['rigidity', 'tremors']	2	5	"Sentence: Within 2 h he became confused with jerking movements of his extremities , tremors and rigidity .
Diseases: rigidity, tremors"	"Sentence: Within 2 h he became confused with jerking movements of his extremities , tremors and rigidity .
Diseases:"
3043	He was brought directly to a hospital where he was found to be agitated and confused with shivering , myoclonic jerks , rigidity , salivation and diaphoresis .	O O O O O O O O O O O O O O O O O O O B I O B O B O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['rigidity', 'myoclonic jerks', 'salivation']	3	11	"Sentence: He was brought directly to a hospital where he was found to be agitated and confused with shivering , myoclonic jerks , rigidity , salivation and diaphoresis .
Diseases: rigidity, myoclonic jerks, salivation"	"Sentence: He was brought directly to a hospital where he was found to be agitated and confused with shivering , myoclonic jerks , rigidity , salivation and diaphoresis .
Diseases:"
3044	His pupils were 7 mm and sluggishly reactive to light .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: His pupils were 7 mm and sluggishly reactive to light .
Diseases: "	"Sentence: His pupils were 7 mm and sluggishly reactive to light .
Diseases:"
3045	Vital signs were : blood pressure 120 / 67	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Vital signs were : blood pressure 120 / 67
Diseases: "	"Sentence: Vital signs were : blood pressure 120 / 67
Diseases:"
3046	mm Hg , heart rate 127 / min , respiratory rate 28 / min , and temperature 97 F .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: mm Hg , heart rate 127 / min , respiratory rate 28 / min , and temperature 97 F .
Diseases: "	"Sentence: mm Hg , heart rate 127 / min , respiratory rate 28 / min , and temperature 97 F .
Diseases:"
3047	After 180 mg of diazepam i . v .	O O O O O O O O O	O O O O B O O O O	[]	0	0	"Sentence: After 180 mg of diazepam i . v .
Diseases: "	"Sentence: After 180 mg of diazepam i . v .
Diseases:"
3048	he remained tremulous with muscle rigidity and clenched jaws .	O O O O B I O O O O	O O O O O O O O O O	['muscle rigidity']	1	4	"Sentence: he remained tremulous with muscle rigidity and clenched jaws .
Diseases: muscle rigidity"	"Sentence: he remained tremulous with muscle rigidity and clenched jaws .
Diseases:"
3049	He was intubated for airway protection and because of hypoventilation , and was paralyzed to control muscle rigidity .	O O O O O O O O O B O O O B O O B I O	O O O O O O O O O O O O O O O O O O O	['muscle rigidity', 'hypoventilation', 'paralyzed']	3	11	"Sentence: He was intubated for airway protection and because of hypoventilation , and was paralyzed to control muscle rigidity .
Diseases: muscle rigidity, hypoventilation, paralyzed"	"Sentence: He was intubated for airway protection and because of hypoventilation , and was paralyzed to control muscle rigidity .
Diseases:"
3050	His subsequent course was remarkable for non - immune thrombocytopenia which resolved .	O O O O O O O O O B O O O	O O O O O O O O O O O O O	['thrombocytopenia']	1	7	"Sentence: His subsequent course was remarkable for non - immune thrombocytopenia which resolved .
Diseases: thrombocytopenia"	"Sentence: His subsequent course was remarkable for non - immune thrombocytopenia which resolved .
Diseases:"
3051	The patient 's maximal temperature was 101 . 2 F and his CPK remained < 500 units / L with no other evidence of rhabdomyolysis .	O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['rhabdomyolysis']	1	6	"Sentence: The patient 's maximal temperature was 101 . 2 F and his CPK remained < 500 units / L with no other evidence of rhabdomyolysis .
Diseases: rhabdomyolysis"	"Sentence: The patient 's maximal temperature was 101 . 2 F and his CPK remained < 500 units / L with no other evidence of rhabdomyolysis .
Diseases:"
3052	His mental status normalized and he was transferred to a psychiatry ward .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: His mental status normalized and he was transferred to a psychiatry ward .
Diseases: "	"Sentence: His mental status normalized and he was transferred to a psychiatry ward .
Diseases:"
3053	This patient survived without sequelae due to the aggressive sedation and neuromuscular paralysis .	O O O O O O O O O O O O B O	O O O O O O O O O O O O O O	['paralysis']	1	2	"Sentence: This patient survived without sequelae due to the aggressive sedation and neuromuscular paralysis .
Diseases: paralysis"	"Sentence: This patient survived without sequelae due to the aggressive sedation and neuromuscular paralysis .
Diseases:"
3054	Effect of nondopaminergic drugs on L - dopa - induced dyskinesias in MPTP - treated monkeys .	O O O O O O O O O O B O O O O O O	O O O O O B I I O O O O B O O O O	['dyskinesias']	1	5	"Sentence: Effect of nondopaminergic drugs on L - dopa - induced dyskinesias in MPTP - treated monkeys .
Diseases: dyskinesias"	"Sentence: Effect of nondopaminergic drugs on L - dopa - induced dyskinesias in MPTP - treated monkeys .
Diseases:"
3055	A group of four monkeys was rendered parkinsonian with the toxin MPTP .	O O O O O O O B O O O O O	O O O O O O O O O O O B O	['parkinsonian']	1	3	"Sentence: A group of four monkeys was rendered parkinsonian with the toxin MPTP .
Diseases: parkinsonian"	"Sentence: A group of four monkeys was rendered parkinsonian with the toxin MPTP .
Diseases:"
3056	They were then treated chronically with L - DOPA / benserazide 50 / 12 . 5 mg / kg given orally daily for 2 months .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B I I O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: They were then treated chronically with L - DOPA / benserazide 50 / 12 . 5 mg / kg given orally daily for 2 months .
Diseases: "	"Sentence: They were then treated chronically with L - DOPA / benserazide 50 / 12 . 5 mg / kg given orally daily for 2 months .
Diseases:"
3057	This dose produced a striking antiparkinsonian effect , but all animals manifested dyskinesia .	O O O O O O O O O O O O B O	O O O O O O O O O O O O O O	['dyskinesia']	1	5	"Sentence: This dose produced a striking antiparkinsonian effect , but all animals manifested dyskinesia .
Diseases: dyskinesia"	"Sentence: This dose produced a striking antiparkinsonian effect , but all animals manifested dyskinesia .
Diseases:"
3058	A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L - DOPA to see if the dyskinetic movements would be modified .	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	O O O O O O O O O O B O O O O O O B I I O O O O O O O O O O	['dyskinetic']	1	4	"Sentence: A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L - DOPA to see if the dyskinetic movements would be modified .
Diseases: dyskinetic"	"Sentence: A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L - DOPA to see if the dyskinetic movements would be modified .
Diseases:"
3059	Several drugs , including clonidine , physostigmine , methysergide , 5 - MDOT , propranolol , and MK - 801 , markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology .	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O B O O	O O O O B O B O B O B I I O B O O B I I O O O O O O O O O O O O O O O O O	['parkinsonian', 'dyskinetic']	2	7	"Sentence: Several drugs , including clonidine , physostigmine , methysergide , 5 - MDOT , propranolol , and MK - 801 , markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology .
Diseases: parkinsonian, dyskinetic"	"Sentence: Several drugs , including clonidine , physostigmine , methysergide , 5 - MDOT , propranolol , and MK - 801 , markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology .
Diseases:"
3060	However , yohimbine and meperidine reduced predominantly the dyskinetic movements .	O O O O O O O O B O O	O O B O B O O O O O O	['dyskinetic']	1	4	"Sentence: However , yohimbine and meperidine reduced predominantly the dyskinetic movements .
Diseases: dyskinetic"	"Sentence: However , yohimbine and meperidine reduced predominantly the dyskinetic movements .
Diseases:"
3061	Baclofen was also useful in one monkey against a more dystonic form of dyskinesia .	O O O O O O O O O O B O O B O	B O O O O O O O O O O O O O O	['dystonic', 'dyskinesia']	2	8	"Sentence: Baclofen was also useful in one monkey against a more dystonic form of dyskinesia .
Diseases: dystonic, dyskinesia"	"Sentence: Baclofen was also useful in one monkey against a more dystonic form of dyskinesia .
Diseases:"
3062	Atropine converted the dystonic movements into chorea .	O O O B O O B O	B O O O O O O O	['dystonic', 'chorea']	2	6	"Sentence: Atropine converted the dystonic movements into chorea .
Diseases: dystonic, chorea"	"Sentence: Atropine converted the dystonic movements into chorea .
Diseases:"
3063	CCNU ( lomustine ) toxicity in dogs : a retrospective study ( 2002 - 07 ) .	O O O O B O O O O O O O O O O O O	B O B O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: CCNU ( lomustine ) toxicity in dogs : a retrospective study ( 2002 - 07 ) .
Diseases: toxicity"	"Sentence: CCNU ( lomustine ) toxicity in dogs : a retrospective study ( 2002 - 07 ) .
Diseases:"
3064	To describe the incidence of haematological , renal , hepatic and gastrointestinal toxicities in tumour - bearing dogs receiving 1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea ( CCNU ) .	O O O O O B I I I I I I I O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B I I I I I I I I I I I I I I O B O O	['haematological , renal , hepatic and gastrointestinal toxicities']	1	13	"Sentence: To describe the incidence of haematological , renal , hepatic and gastrointestinal toxicities in tumour - bearing dogs receiving 1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea ( CCNU ) .
Diseases: haematological , renal , hepatic and gastrointestinal toxicities"	"Sentence: To describe the incidence of haematological , renal , hepatic and gastrointestinal toxicities in tumour - bearing dogs receiving 1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea ( CCNU ) .
Diseases:"
3065	The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated .
Diseases: "	"Sentence: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated .
Diseases:"
3066	RESULTS : Of the 206 dogs treated with CCNU , 185 met the inclusion criteria for at least one class of toxicity .	O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O B O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: RESULTS : Of the 206 dogs treated with CCNU , 185 met the inclusion criteria for at least one class of toxicity .
Diseases: toxicity"	"Sentence: RESULTS : Of the 206 dogs treated with CCNU , 185 met the inclusion criteria for at least one class of toxicity .
Diseases:"
3067	CCNU was used most commonly in the treatment of lymphoma , mast cell tumour , brain tumour , histiocytic tumours and epitheliotropic lymphoma .	O O O O O O O O O B O B I I O B I O B I O B I O	B O O O O O O O O O O O O O O O O O O O O O O O	['brain tumour', 'histiocytic tumours', 'epitheliotropic lymphoma', 'lymphoma', 'mast cell tumour']	5	26	"Sentence: CCNU was used most commonly in the treatment of lymphoma , mast cell tumour , brain tumour , histiocytic tumours and epitheliotropic lymphoma .
Diseases: brain tumour, histiocytic tumours, epitheliotropic lymphoma, lymphoma, mast cell tumour"	"Sentence: CCNU was used most commonly in the treatment of lymphoma , mast cell tumour , brain tumour , histiocytic tumours and epitheliotropic lymphoma .
Diseases:"
3068	Throughout treatment , 56 . 9 % of dogs experienced neutropenia , 34 . 2 % experienced anaemia and 14 . 2 % experienced thrombocytopenia .	O O O O O O O O O O B O O O O O O B O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['thrombocytopenia', 'neutropenia', 'anaemia']	3	16	"Sentence: Throughout treatment , 56 . 9 % of dogs experienced neutropenia , 34 . 2 % experienced anaemia and 14 . 2 % experienced thrombocytopenia .
Diseases: thrombocytopenia, neutropenia, anaemia"	"Sentence: Throughout treatment , 56 . 9 % of dogs experienced neutropenia , 34 . 2 % experienced anaemia and 14 . 2 % experienced thrombocytopenia .
Diseases:"
3069	Gastrointestinal toxicosis was detected in 37 . 8 % of dogs , the most common sign of which was vomiting ( 24 . 3 % ) .	B I O O O O O O O O O O O O O O O O O B O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['vomiting', 'gastrointestinal toxicosis']	2	7	"Sentence: Gastrointestinal toxicosis was detected in 37 . 8 % of dogs , the most common sign of which was vomiting ( 24 . 3 % ) .
Diseases: vomiting, gastrointestinal toxicosis"	"Sentence: Gastrointestinal toxicosis was detected in 37 . 8 % of dogs , the most common sign of which was vomiting ( 24 . 3 % ) .
Diseases:"
3070	Potential renal toxicity and elevated alanine transaminase ( ALT ) concentration were reported in 12 . 2 % and 48 . 8 % of dogs , respectively .	O O B O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: Potential renal toxicity and elevated alanine transaminase ( ALT ) concentration were reported in 12 . 2 % and 48 . 8 % of dogs , respectively .
Diseases: toxicity"	"Sentence: Potential renal toxicity and elevated alanine transaminase ( ALT ) concentration were reported in 12 . 2 % and 48 . 8 % of dogs , respectively .
Diseases:"
3071	The incidence of hepatic failure was 1 . 2 % .	O O O B I O O O O O O	O O O O O O O O O O O	['hepatic failure']	1	4	"Sentence: The incidence of hepatic failure was 1 . 2 % .
Diseases: hepatic failure"	"Sentence: The incidence of hepatic failure was 1 . 2 % .
Diseases:"
3072	CONCLUSIONS : CCNU - associated toxicity in dogs is common , but is usually not life threatening .	O O O O O B O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: CONCLUSIONS : CCNU - associated toxicity in dogs is common , but is usually not life threatening .
Diseases: toxicity"	"Sentence: CONCLUSIONS : CCNU - associated toxicity in dogs is common , but is usually not life threatening .
Diseases:"
3073	Neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice .	O O O O O O O O O O O O B O B I O O O	O B O O B O O B I O O O O O O O O O O	['status epilepticus', 'seizures']	2	6	"Sentence: Neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice .
Diseases: status epilepticus, seizures"	"Sentence: Neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice .
Diseases:"
3074	Several structurally related metabolites of progesterone ( 3 alpha - hydroxy pregnane - 20 - ones ) and deoxycorticosterone ( 3 alpha - hydroxy pregnane - 21 - diol - 20 - ones ) and their 3 beta - epimers were evaluated for protective activity against pilocarpine - , kainic acid -	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O B I I I I I I I I O O B O B I I I I I I I I I I I I O O O O O O O O O O O O O B O O B I O	[]	0	0	"Sentence: Several structurally related metabolites of progesterone ( 3 alpha - hydroxy pregnane - 20 - ones ) and deoxycorticosterone ( 3 alpha - hydroxy pregnane - 21 - diol - 20 - ones ) and their 3 beta - epimers were evaluated for protective activity against pilocarpine - , kainic acid -
Diseases: "	"Sentence: Several structurally related metabolites of progesterone ( 3 alpha - hydroxy pregnane - 20 - ones ) and deoxycorticosterone ( 3 alpha - hydroxy pregnane - 21 - diol - 20 - ones ) and their 3 beta - epimers were evaluated for protective activity against pilocarpine - , kainic acid -
Diseases:"
3075	and N - methyl - D - aspartate ( NMDA ) - induced seizures in mice .	O O O O O O O O O O O O O B O O O	O B I I I I I I O B O O O O O O O	['seizures']	1	3	"Sentence: and N - methyl - D - aspartate ( NMDA ) - induced seizures in mice .
Diseases: seizures"	"Sentence: and N - methyl - D - aspartate ( NMDA ) - induced seizures in mice .
Diseases:"
3076	Steroids with the 3 - hydroxy group in the alpha - position and 5 - H in the alpha - or beta - configurations were highly effective in protecting against pilocarpine ( 416 mg / kg , s . c . ) - induced limbic motor seizures and status epilepticus ( ED50 values , 7 . 0 - 18 . 7 mg / kg , i . p . ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B I O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['status epilepticus', 'seizures']	2	6	"Sentence: Steroids with the 3 - hydroxy group in the alpha - position and 5 - H in the alpha - or beta - configurations were highly effective in protecting against pilocarpine ( 416 mg / kg , s . c . ) - induced limbic motor seizures and status epilepticus ( ED50 values , 7 . 0 - 18 . 7 mg / kg , i . p . ) .
Diseases: status epilepticus, seizures"	"Sentence: Steroids with the 3 - hydroxy group in the alpha - position and 5 - H in the alpha - or beta - configurations were highly effective in protecting against pilocarpine ( 416 mg / kg , s . c . ) - induced limbic motor seizures and status epilepticus ( ED50 values , 7 . 0 - 18 . 7 mg / kg , i . p . ) .
Diseases:"
3077	The corresponding epimers with the 3 - hydroxy group in the beta - position were also effective but less potent ( ED50 values , 33 . 8 - 63 . 5 , i . p . ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The corresponding epimers with the 3 - hydroxy group in the beta - position were also effective but less potent ( ED50 values , 33 . 8 - 63 . 5 , i . p . ) .
Diseases: "	"Sentence: The corresponding epimers with the 3 - hydroxy group in the beta - position were also effective but less potent ( ED50 values , 33 . 8 - 63 . 5 , i . p . ) .
Diseases:"
3078	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O B O	O O O B O O O O O O O B O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O B O O O O O O	['seizures', 'seizure', 'toxicity']	3	7	"Sentence: Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .
Diseases: seizures, seizure, toxicity"	"Sentence: Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .
Diseases:"
3079	Steroids with the 5 alpha , 3 alpha - or 5 beta , 3 alpha - configurations also produced a dose - dependent delay in the onset of limbic seizures induced by kainic acid ( 32 mg / kg , s . c . ) , but did not completely protect against the seizures .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O B O	B O O O O O O O O O O O I O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O	['seizures']	1	3	"Sentence: Steroids with the 5 alpha , 3 alpha - or 5 beta , 3 alpha - configurations also produced a dose - dependent delay in the onset of limbic seizures induced by kainic acid ( 32 mg / kg , s . c . ) , but did not completely protect against the seizures .
Diseases: seizures"	"Sentence: Steroids with the 5 alpha , 3 alpha - or 5 beta , 3 alpha - configurations also produced a dose - dependent delay in the onset of limbic seizures induced by kainic acid ( 32 mg / kg , s . c . ) , but did not completely protect against the seizures .
Diseases:"
3080	However , when a second dose of the steroid was administered 1 hr after the first dose , complete protection from the kainic acid - induced limbic seizures and status epilepticus was obtained .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B I O O O	O O O O O O O O B O O O O O O O O O O O O O B I O O O O O O O O O O	['status epilepticus', 'seizures']	2	6	"Sentence: However , when a second dose of the steroid was administered 1 hr after the first dose , complete protection from the kainic acid - induced limbic seizures and status epilepticus was obtained .
Diseases: status epilepticus, seizures"	"Sentence: However , when a second dose of the steroid was administered 1 hr after the first dose , complete protection from the kainic acid - induced limbic seizures and status epilepticus was obtained .
Diseases:"
3081	The steroids also caused a dose - dependent delay in NMDA ( 257 mg / kg , s . c . ) - induced lethality , but did not completely protect against NMDA seizures or lethality .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O	O B O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O B O O O O	['seizures']	1	3	"Sentence: The steroids also caused a dose - dependent delay in NMDA ( 257 mg / kg , s . c . ) - induced lethality , but did not completely protect against NMDA seizures or lethality .
Diseases: seizures"	"Sentence: The steroids also caused a dose - dependent delay in NMDA ( 257 mg / kg , s . c . ) - induced lethality , but did not completely protect against NMDA seizures or lethality .
Diseases:"
3082	We conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice , and may be of utility in the treatment of some forms of status epilepticus in humans .	O O O O O O O O O O O O O O O O O O B O B I O O O O O O O O O O O O O O O B I O O O	O O O O B O O O O O O B O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O	['status epilepticus', 'seizures']	2	6	"Sentence: We conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice , and may be of utility in the treatment of some forms of status epilepticus in humans .
Diseases: status epilepticus, seizures"	"Sentence: We conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice , and may be of utility in the treatment of some forms of status epilepticus in humans .
Diseases:"
3083	The safety and efficacy of combination N - butyl - deoxynojirimycin ( SC - 48334 ) and zidovudine in patients with HIV - 1 infection and 200 - 500 CD4 cells / mm3 .	O O O O O O O O O O O O O O O O O O O O O B I I I O O O O O O O O O	O O O O O O B I I I I O B I I O O B O O O O O O O O O O O O O O O O	['hiv - 1 infection']	1	5	"Sentence: The safety and efficacy of combination N - butyl - deoxynojirimycin ( SC - 48334 ) and zidovudine in patients with HIV - 1 infection and 200 - 500 CD4 cells / mm3 .
Diseases: hiv - 1 infection"	"Sentence: The safety and efficacy of combination N - butyl - deoxynojirimycin ( SC - 48334 ) and zidovudine in patients with HIV - 1 infection and 200 - 500 CD4 cells / mm3 .
Diseases:"
3084	We conducted a double - blind , randomized phase II study to evaluate the safety and activity of combination therapy with N - butyl - deoxynojirimycin ( SC - 48334 ) ( an alpha - glucosidase I inhibitor ) and zidovudine versus zidovudine alone .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B I I I I O B I I O O O O O O O O O O B O B O O	[]	0	0	"Sentence: We conducted a double - blind , randomized phase II study to evaluate the safety and activity of combination therapy with N - butyl - deoxynojirimycin ( SC - 48334 ) ( an alpha - glucosidase I inhibitor ) and zidovudine versus zidovudine alone .
Diseases: "	"Sentence: We conducted a double - blind , randomized phase II study to evaluate the safety and activity of combination therapy with N - butyl - deoxynojirimycin ( SC - 48334 ) ( an alpha - glucosidase I inhibitor ) and zidovudine versus zidovudine alone .
Diseases:"
3085	Patients with 200 to 500 CD4 cells / mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC - 48334 ( 1000 mg every 8 h ) and zidovudine ( 100 mg every 8 h ) or zidovudine and placebo .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O B I I O O O O O O O O B O O O O O O O O B O O O	[]	0	0	"Sentence: Patients with 200 to 500 CD4 cells / mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC - 48334 ( 1000 mg every 8 h ) and zidovudine ( 100 mg every 8 h ) or zidovudine and placebo .
Diseases: "	"Sentence: Patients with 200 to 500 CD4 cells / mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC - 48334 ( 1000 mg every 8 h ) and zidovudine ( 100 mg every 8 h ) or zidovudine and placebo .
Diseases:"
3086	Sixty patients received combination therapy and 58 , zidovudine and placebo .	O O O O O O O O O O O O	O O O O O O O O B O O O	[]	0	0	"Sentence: Sixty patients received combination therapy and 58 , zidovudine and placebo .
Diseases: "	"Sentence: Sixty patients received combination therapy and 58 , zidovudine and placebo .
Diseases:"
3087	Twenty - three patients ( 38 % ) and 15 ( 26 % ) , in the combination and zidovudine groups , respectively , discontinued therapy ( p = 0 . 15 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: Twenty - three patients ( 38 % ) and 15 ( 26 % ) , in the combination and zidovudine groups , respectively , discontinued therapy ( p = 0 . 15 ) .
Diseases: "	"Sentence: Twenty - three patients ( 38 % ) and 15 ( 26 % ) , in the combination and zidovudine groups , respectively , discontinued therapy ( p = 0 . 15 ) .
Diseases:"
3088	The mean SC - 48334 steady - state trough level ( 4 . 04 + / - 0 . 99 micrograms / ml ) was below the in vitro inhibitory concentration for human immunodeficiency virus ( HIV ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['immunodeficiency']	1	5	"Sentence: The mean SC - 48334 steady - state trough level ( 4 . 04 + / - 0 . 99 micrograms / ml ) was below the in vitro inhibitory concentration for human immunodeficiency virus ( HIV ) .
Diseases: immunodeficiency"	"Sentence: The mean SC - 48334 steady - state trough level ( 4 . 04 + / - 0 . 99 micrograms / ml ) was below the in vitro inhibitory concentration for human immunodeficiency virus ( HIV ) .
Diseases:"
3089	The mean increase in CD4 cells at week 4 was 73 . 8 cells / mm3 and 52 . 4 cells / mm3 for the combination and zidovudine groups , respectively ( p > 0 . 36 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: The mean increase in CD4 cells at week 4 was 73 . 8 cells / mm3 and 52 . 4 cells / mm3 for the combination and zidovudine groups , respectively ( p > 0 . 36 ) .
Diseases: "	"Sentence: The mean increase in CD4 cells at week 4 was 73 . 8 cells / mm3 and 52 . 4 cells / mm3 for the combination and zidovudine groups , respectively ( p > 0 . 36 ) .
Diseases:"
3090	For patients with prior zidovudine therapy , the mean change in CD4 cells in the combination and zidovudine groups was 63 . 7 cells / mm3 and 4 . 9 cells / mm3 at week 8 and 6 . 8 cells / mm3 and - 45 . 1 cells / mm3 at week 16 , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: For patients with prior zidovudine therapy , the mean change in CD4 cells in the combination and zidovudine groups was 63 . 7 cells / mm3 and 4 . 9 cells / mm3 at week 8 and 6 . 8 cells / mm3 and - 45 . 1 cells / mm3 at week 16 , respectively .
Diseases: "	"Sentence: For patients with prior zidovudine therapy , the mean change in CD4 cells in the combination and zidovudine groups was 63 . 7 cells / mm3 and 4 . 9 cells / mm3 at week 8 and 6 . 8 cells / mm3 and - 45 . 1 cells / mm3 at week 16 , respectively .
Diseases:"
3091	The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six ( 40 % ) and two ( 11 % ) at week 4 ( p = 0 . 10 ) and five ( 45 % ) and two ( 14 % ) at week 24 ( p = 0 . 08 ) , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six ( 40 % ) and two ( 11 % ) at week 4 ( p = 0 . 10 ) and five ( 45 % ) and two ( 14 % ) at week 24 ( p = 0 . 08 ) , respectively .
Diseases: "	"Sentence: The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six ( 40 % ) and two ( 11 % ) at week 4 ( p = 0 . 10 ) and five ( 45 % ) and two ( 14 % ) at week 24 ( p = 0 . 08 ) , respectively .
Diseases:"
3092	Diarrhea , flatulence , abdominal pain , and weight loss were common for combination recipients . ( ABSTRACT TRUNCATED AT 250 WORDS )	B O B O B I O O B I O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['flatulence', 'abdominal pain', 'weight loss', 'diarrhea']	4	10	"Sentence: Diarrhea , flatulence , abdominal pain , and weight loss were common for combination recipients . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases: flatulence, abdominal pain, weight loss, diarrhea"	"Sentence: Diarrhea , flatulence , abdominal pain , and weight loss were common for combination recipients . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases:"
3093	Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10 - propargyl - 5 , 8 - dideazafolic acid ( CB 3717 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O B I I I I I I I I I O B I O O	[]	0	0	"Sentence: Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10 - propargyl - 5 , 8 - dideazafolic acid ( CB 3717 ) .
Diseases: "	"Sentence: Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10 - propargyl - 5 , 8 - dideazafolic acid ( CB 3717 ) .
Diseases:"
3094	CB 3717 , N10 - propargyl - 5 , 8 - dideazafolic acid , is a tight - binding inhibitor of thymidylate synthase ( TS ) whose cytotoxicity is mediated solely through the inhibition of this enzyme .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	B I O B I I I I I I I I I O O O O O O O O B O O O O O O O O O O O O O O O O	['cytotoxicity']	1	4	"Sentence: CB 3717 , N10 - propargyl - 5 , 8 - dideazafolic acid , is a tight - binding inhibitor of thymidylate synthase ( TS ) whose cytotoxicity is mediated solely through the inhibition of this enzyme .
Diseases: cytotoxicity"	"Sentence: CB 3717 , N10 - propargyl - 5 , 8 - dideazafolic acid , is a tight - binding inhibitor of thymidylate synthase ( TS ) whose cytotoxicity is mediated solely through the inhibition of this enzyme .
Diseases:"
3095	Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates .	O O O O O O O O O O O O O O	O O O O O O O O O O B I O O	[]	0	0	"Sentence: Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates .
Diseases: "	"Sentence: Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates .
Diseases:"
3096	Following a 12 - hour exposure of L1210 cells to 50 microM [ 3H ] CB 3717 , 30 % of the extractable radioactivity could be accounted for as CB 3717 tetra - and pentaglutamate , as determined by high - pressure liquid chromatography ( HPLC ) analyses .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B I I I I O O O O O O O O O O O O B I O I O I O O O O O O O O O O O O O O	[]	0	0	"Sentence: Following a 12 - hour exposure of L1210 cells to 50 microM [ 3H ] CB 3717 , 30 % of the extractable radioactivity could be accounted for as CB 3717 tetra - and pentaglutamate , as determined by high - pressure liquid chromatography ( HPLC ) analyses .
Diseases: "	"Sentence: Following a 12 - hour exposure of L1210 cells to 50 microM [ 3H ] CB 3717 , 30 % of the extractable radioactivity could be accounted for as CB 3717 tetra - and pentaglutamate , as determined by high - pressure liquid chromatography ( HPLC ) analyses .
Diseases:"
3097	As inhibitors of isolated L1210 TS , CB 3717 di - , tri - , tetra - and pentaglutamate are 26 - , 87 - , 119 - and 114 - fold more potent than CB 3717 , respectively , and their formation may , therefore , be an important determinant of CB 3717 cytotoxicity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O B I O O	['cytotoxicity']	1	4	"Sentence: As inhibitors of isolated L1210 TS , CB 3717 di - , tri - , tetra - and pentaglutamate are 26 - , 87 - , 119 - and 114 - fold more potent than CB 3717 , respectively , and their formation may , therefore , be an important determinant of CB 3717 cytotoxicity .
Diseases: cytotoxicity"	"Sentence: As inhibitors of isolated L1210 TS , CB 3717 di - , tri - , tetra - and pentaglutamate are 26 - , 87 - , 119 - and 114 - fold more potent than CB 3717 , respectively , and their formation may , therefore , be an important determinant of CB 3717 cytotoxicity .
Diseases:"
3098	In early clinical studies with CB 3717 , activity has been seen in breast cancer , ovarian cancer , hepatoma , and mesothelioma .	O O O O O O O O O O O O O B I O B I O B O O B O	O O O O O B I O O O O O O O O O O O O O O O O O	['ovarian cancer', 'hepatoma', 'breast cancer', 'mesothelioma']	4	15	"Sentence: In early clinical studies with CB 3717 , activity has been seen in breast cancer , ovarian cancer , hepatoma , and mesothelioma .
Diseases: ovarian cancer, hepatoma, breast cancer, mesothelioma"	"Sentence: In early clinical studies with CB 3717 , activity has been seen in breast cancer , ovarian cancer , hepatoma , and mesothelioma .
Diseases:"
3099	Toxicities included hepatotoxicity , malaise , and dose - limiting nephrotoxicity .	B O B O B O O O O O B O	O O O O O O O O O O O O	['hepatotoxicity', 'toxicities', 'nephrotoxicity', 'malaise']	4	16	"Sentence: Toxicities included hepatotoxicity , malaise , and dose - limiting nephrotoxicity .
Diseases: hepatotoxicity, toxicities, nephrotoxicity, malaise"	"Sentence: Toxicities included hepatotoxicity , malaise , and dose - limiting nephrotoxicity .
Diseases:"
3100	This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B I O O O O	[]	0	0	"Sentence: This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions .
Diseases: "	"Sentence: This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions .
Diseases:"
3101	In an attempt to overcome this problem , a clinical trial of CB 3717 administered with alkaline diuresis is under way .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B I O O O O O O O O	[]	0	0	"Sentence: In an attempt to overcome this problem , a clinical trial of CB 3717 administered with alkaline diuresis is under way .
Diseases: "	"Sentence: In an attempt to overcome this problem , a clinical trial of CB 3717 administered with alkaline diuresis is under way .
Diseases:"
3102	Preliminary results at 400 and 500 mg / m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients .	O O O O O O O O O O O O O O B O O O O O O O O O B I O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nephrotoxicity', 'renal toxicity']	2	7	"Sentence: Preliminary results at 400 and 500 mg / m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients .
Diseases: nephrotoxicity, renal toxicity"	"Sentence: Preliminary results at 400 and 500 mg / m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients .
Diseases:"
3103	Hepatotoxicity and malaise are again the most frequent side effects .	B O B O O O O O O O O	O O O O O O O O O O O	['hepatotoxicity', 'malaise']	2	8	"Sentence: Hepatotoxicity and malaise are again the most frequent side effects .
Diseases: hepatotoxicity, malaise"	"Sentence: Hepatotoxicity and malaise are again the most frequent side effects .
Diseases:"
3104	Evidence of antitumor activity has been seen in 3 patients .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: Evidence of antitumor activity has been seen in 3 patients .
Diseases: "	"Sentence: Evidence of antitumor activity has been seen in 3 patients .
Diseases:"
3105	Pharmacokinetic investigations have shown that alkaline diuresis does not alter CB 3717 plasma levels or urinary excretion and that satisfactory urinary alkalinization can be readily achieved .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B I O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Pharmacokinetic investigations have shown that alkaline diuresis does not alter CB 3717 plasma levels or urinary excretion and that satisfactory urinary alkalinization can be readily achieved .
Diseases: "	"Sentence: Pharmacokinetic investigations have shown that alkaline diuresis does not alter CB 3717 plasma levels or urinary excretion and that satisfactory urinary alkalinization can be readily achieved .
Diseases:"
3106	Ethopropazine and benztropine in neuroleptic - induced parkinsonism .	O O O O O O O B O	B O B O O O O O O	['parkinsonism']	1	3	"Sentence: Ethopropazine and benztropine in neuroleptic - induced parkinsonism .
Diseases: parkinsonism"	"Sentence: Ethopropazine and benztropine in neuroleptic - induced parkinsonism .
Diseases:"
3107	In a 12 - week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients .	O O O O O O O O O O O O O O O O B O O O O O O B O O	O O O O O O O B O O O B O O O O O O O B I O O O O O	['schizophrenic', 'parkinsonism']	2	7	"Sentence: In a 12 - week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients .
Diseases: schizophrenic, parkinsonism"	"Sentence: In a 12 - week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients .
Diseases:"
3108	Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine , their previous antiparkinsonian drug .	O O O O O O O O O O O B I O O O O O O O O O O O O	B O B O O O O O O O O O O O O O O O B O O O O O O	['parkinsonian symptoms']	1	4	"Sentence: Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine , their previous antiparkinsonian drug .
Diseases: parkinsonian symptoms"	"Sentence: Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine , their previous antiparkinsonian drug .
Diseases:"
3109	However , benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment , and significantly more anxiety and depression than ethopropazine treated patients .	O O O O O O O O O O B I O O O O O O O O O O O B O B O O O O O	O O B O O O O O O O O O O O O O O B O O O O O O O O O B O O O	['tardive dyskinesia', 'depression', 'anxiety']	3	11	"Sentence: However , benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment , and significantly more anxiety and depression than ethopropazine treated patients .
Diseases: tardive dyskinesia, depression, anxiety"	"Sentence: However , benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment , and significantly more anxiety and depression than ethopropazine treated patients .
Diseases:"
3110	This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic - induced parkinsonian symptoms , because of its more toxic central and peripheral atropinic effect .	O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['parkinsonian symptoms']	1	4	"Sentence: This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic - induced parkinsonian symptoms , because of its more toxic central and peripheral atropinic effect .
Diseases: parkinsonian symptoms"	"Sentence: This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic - induced parkinsonian symptoms , because of its more toxic central and peripheral atropinic effect .
Diseases:"
3111	Effect of alpha - tocopherol and deferoxamine on methamphetamine - induced neurotoxicity .	O O O O O O O O O O O B O	O O B I I O B O B O O O O	['neurotoxicity']	1	4	"Sentence: Effect of alpha - tocopherol and deferoxamine on methamphetamine - induced neurotoxicity .
Diseases: neurotoxicity"	"Sentence: Effect of alpha - tocopherol and deferoxamine on methamphetamine - induced neurotoxicity .
Diseases:"
3112	Methamphetamine ( MA ) - induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals .	O O O O O O O B O O O O O O O O O O O O O	B O B O O O O O O O O O O O O O O O O O O	['neurotoxicity']	1	4	"Sentence: Methamphetamine ( MA ) - induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals .
Diseases: neurotoxicity"	"Sentence: Methamphetamine ( MA ) - induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals .
Diseases:"
3113	This study examined the effect of alpha - tocopherol ( alpha - TC ) , a scavenger of reactive oxygen species , and deferoxamine ( DFO ) , an iron chelator , on the MA - induced neurotoxicity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O B I I O B I I O O O O O O B O O O B O B O O O B O O O O B O O O O	['neurotoxicity']	1	4	"Sentence: This study examined the effect of alpha - tocopherol ( alpha - TC ) , a scavenger of reactive oxygen species , and deferoxamine ( DFO ) , an iron chelator , on the MA - induced neurotoxicity .
Diseases: neurotoxicity"	"Sentence: This study examined the effect of alpha - tocopherol ( alpha - TC ) , a scavenger of reactive oxygen species , and deferoxamine ( DFO ) , an iron chelator , on the MA - induced neurotoxicity .
Diseases:"
3114	Male rats were treated with MA ( 10 mg / kg , every 2 h for four injections ) .	O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: Male rats were treated with MA ( 10 mg / kg , every 2 h for four injections ) .
Diseases: "	"Sentence: Male rats were treated with MA ( 10 mg / kg , every 2 h for four injections ) .
Diseases:"
3115	The rat received either alpha - TC ( 20 mg / kg ) intraperitoneally for 3 days and 30 min prior to MA administration or DFO ( 50 mg / kg ) subcutaneously 30 min before MA administration .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B I I O O O O O O O O O O O O O O O B O O B O O O O O O O O O O B O O	[]	0	0	"Sentence: The rat received either alpha - TC ( 20 mg / kg ) intraperitoneally for 3 days and 30 min prior to MA administration or DFO ( 50 mg / kg ) subcutaneously 30 min before MA administration .
Diseases: "	"Sentence: The rat received either alpha - TC ( 20 mg / kg ) intraperitoneally for 3 days and 30 min prior to MA administration or DFO ( 50 mg / kg ) subcutaneously 30 min before MA administration .
Diseases:"
3116	The concentrations of dopamine ( DA ) , serotonin and their metabolites decreased significantly after MA administration , which was inhibited by the alpha - TC and DFO pretreatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O B O O B O O O O O O B O O O O O O O B I I O B O O	[]	0	0	"Sentence: The concentrations of dopamine ( DA ) , serotonin and their metabolites decreased significantly after MA administration , which was inhibited by the alpha - TC and DFO pretreatment .
Diseases: "	"Sentence: The concentrations of dopamine ( DA ) , serotonin and their metabolites decreased significantly after MA administration , which was inhibited by the alpha - TC and DFO pretreatment .
Diseases:"
3117	alpha - TC and DFO attenuated the MA - induced hyperthermia as well as the alterations in the locomotor activity .	O O O O O O O O O O B O O O O O O O O O O	B I I O B O O B O O O O O O O O O O O O O	['hyperthermia']	1	3	"Sentence: alpha - TC and DFO attenuated the MA - induced hyperthermia as well as the alterations in the locomotor activity .
Diseases: hyperthermia"	"Sentence: alpha - TC and DFO attenuated the MA - induced hyperthermia as well as the alterations in the locomotor activity .
Diseases:"
3118	The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA - treated rats .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O B O O O O	[]	0	0	"Sentence: The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA - treated rats .
Diseases: "	"Sentence: The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA - treated rats .
Diseases:"
3119	These changes were significantly attenuated by alpha - TC and DFO .	O O O O O O O O O O O O	O O O O O O B I I O B O	[]	0	0	"Sentence: These changes were significantly attenuated by alpha - TC and DFO .
Diseases: "	"Sentence: These changes were significantly attenuated by alpha - TC and DFO .
Diseases:"
3120	This suggests that alpha - TC and DFO ameliorate the MA - induced neuronal damage by decreasing the level of oxidative stress .	O O O O O O O O O O O O O B I O O O O O O O O	O O O B I I O B O O B O O O O O O O O O O O O	['neuronal damage']	1	4	"Sentence: This suggests that alpha - TC and DFO ameliorate the MA - induced neuronal damage by decreasing the level of oxidative stress .
Diseases: neuronal damage"	"Sentence: This suggests that alpha - TC and DFO ameliorate the MA - induced neuronal damage by decreasing the level of oxidative stress .
Diseases:"
3121	Use of dexamethasone with mesna for the prevention of ifosfamide - induced hemorrhagic cystitis .	O O O O O O O O O O O O B I O	O O B O B O O O O B O O O O O	['hemorrhagic cystitis']	1	7	"Sentence: Use of dexamethasone with mesna for the prevention of ifosfamide - induced hemorrhagic cystitis .
Diseases: hemorrhagic cystitis"	"Sentence: Use of dexamethasone with mesna for the prevention of ifosfamide - induced hemorrhagic cystitis .
Diseases:"
3122	AIM : Hemorrhagic cystitis ( HC ) is a limiting side - effect of chemotherapy with ifosfamide ( IFS ) .	O O B I O B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O B O O	['hc', 'hemorrhagic cystitis']	2	8	"Sentence: AIM : Hemorrhagic cystitis ( HC ) is a limiting side - effect of chemotherapy with ifosfamide ( IFS ) .
Diseases: hc, hemorrhagic cystitis"	"Sentence: AIM : Hemorrhagic cystitis ( HC ) is a limiting side - effect of chemotherapy with ifosfamide ( IFS ) .
Diseases:"
3123	In the study presented here , we investigated the use of dexamethasone in combination with mesna for the prevention of IFS - induced HC .	O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O B O O O B O O O O O O O O O	['hc']	1	2	"Sentence: In the study presented here , we investigated the use of dexamethasone in combination with mesna for the prevention of IFS - induced HC .
Diseases: hc"	"Sentence: In the study presented here , we investigated the use of dexamethasone in combination with mesna for the prevention of IFS - induced HC .
Diseases:"
3124	Male Wistar rats ( 150 - 200 g ; 6 rats per group ) were treated with saline or mesna 5 min ( i . p . )	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: Male Wistar rats ( 150 - 200 g ; 6 rats per group ) were treated with saline or mesna 5 min ( i . p . )
Diseases: "	"Sentence: Male Wistar rats ( 150 - 200 g ; 6 rats per group ) were treated with saline or mesna 5 min ( i . p . )
Diseases:"
3125	before and 2 and 6 h after ( v . o . )	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: before and 2 and 6 h after ( v . o . )
Diseases: "	"Sentence: before and 2 and 6 h after ( v . o . )
Diseases:"
3126	administration of IFS .	O O O O	O O O O	[]	0	0	"Sentence: administration of IFS .
Diseases: "	"Sentence: administration of IFS .
Diseases:"
3127	One , two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna .	O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O B O O O B O B O	[]	0	0	"Sentence: One , two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna .
Diseases: "	"Sentence: One , two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna .
Diseases:"
3128	Cystitis was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis .	B O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	['cystitis']	1	3	"Sentence: Cystitis was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis .
Diseases: cystitis"	"Sentence: Cystitis was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis .
Diseases:"
3129	The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84 . 79 % and 89 . 13 % , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84 . 79 % and 89 . 13 % , respectively .
Diseases: "	"Sentence: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84 . 79 % and 89 . 13 % , respectively .
Diseases:"
3130	In addition , it almost abolished the macroscopic and microscopic alterations induced by IFS .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In addition , it almost abolished the macroscopic and microscopic alterations induced by IFS .
Diseases: "	"Sentence: In addition , it almost abolished the macroscopic and microscopic alterations induced by IFS .
Diseases:"
3131	Moreover , the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O B O O O O O O O B O O O O O	[]	0	0	"Sentence: Moreover , the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically .
Diseases: "	"Sentence: Moreover , the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically .
Diseases:"
3132	Dexamethasone in combination with mesna was efficient in blocking IFS - induced HC .	O O O O O O O O O O O O B O	B O O O B O O O O O O O O O	['hc']	1	2	"Sentence: Dexamethasone in combination with mesna was efficient in blocking IFS - induced HC .
Diseases: hc"	"Sentence: Dexamethasone in combination with mesna was efficient in blocking IFS - induced HC .
Diseases:"
3133	However , the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC .	O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O B O O O O O O B O O B O O O O O	['hc']	1	2	"Sentence: However , the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC .
Diseases: hc"	"Sentence: However , the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC .
Diseases:"
3134	Behavioral effects of MK - 801 on reserpine - treated mice .	O O O O O O O O O O O O	O O O B I I O B O O O O	[]	0	0	"Sentence: Behavioral effects of MK - 801 on reserpine - treated mice .
Diseases: "	"Sentence: Behavioral effects of MK - 801 on reserpine - treated mice .
Diseases:"
3135	The effects of dizocilpine ( MK - 801 ) , a noncompetitive N - methyl - D - aspartate ( NMDA ) receptor antagonist , were studied on dopamine - related behaviors induced by reserpine treatments .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O B I I O O O O B I I I I I I O B O O O O O O O B O O O O O B O O	[]	0	0	"Sentence: The effects of dizocilpine ( MK - 801 ) , a noncompetitive N - methyl - D - aspartate ( NMDA ) receptor antagonist , were studied on dopamine - related behaviors induced by reserpine treatments .
Diseases: "	"Sentence: The effects of dizocilpine ( MK - 801 ) , a noncompetitive N - methyl - D - aspartate ( NMDA ) receptor antagonist , were studied on dopamine - related behaviors induced by reserpine treatments .
Diseases:"
3136	This study focuses on behavioral syndromes that may used as models for Parkinson 's disease , or tardive dyskinesia , and its response after glutamatergic blockage .	O O O O O O O O O O O O B I I O O B I O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	"['tardive dyskinesia', ""parkinson 's disease""]"	2	13	"Sentence: This study focuses on behavioral syndromes that may used as models for Parkinson 's disease , or tardive dyskinesia , and its response after glutamatergic blockage .
Diseases: tardive dyskinesia, parkinson 's disease"	"Sentence: This study focuses on behavioral syndromes that may used as models for Parkinson 's disease , or tardive dyskinesia , and its response after glutamatergic blockage .
Diseases:"
3137	Reserpine ( 1 mg / kg ) , administered once every other day for 4 days , produced increases in orofacial dyskinesia , tongue protrusion and vacuous chewing in mice , which are signs indicative of tardive dyskinesia .	O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O B I O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['tardive dyskinesia', 'orofacial dyskinesia']	2	16	"Sentence: Reserpine ( 1 mg / kg ) , administered once every other day for 4 days , produced increases in orofacial dyskinesia , tongue protrusion and vacuous chewing in mice , which are signs indicative of tardive dyskinesia .
Diseases: tardive dyskinesia, orofacial dyskinesia"	"Sentence: Reserpine ( 1 mg / kg ) , administered once every other day for 4 days , produced increases in orofacial dyskinesia , tongue protrusion and vacuous chewing in mice , which are signs indicative of tardive dyskinesia .
Diseases:"
3138	Reserpine also produced tremor and catalepsy , which are signs suggestive of Parkinson 's disease .	O O O B O B O O O O O O B I I O	B O O O O O O O O O O O O O O O	"['tremor', 'catalepsy', ""parkinson 's disease""]"	3	14	"Sentence: Reserpine also produced tremor and catalepsy , which are signs suggestive of Parkinson 's disease .
Diseases: tremor, catalepsy, parkinson 's disease"	"Sentence: Reserpine also produced tremor and catalepsy , which are signs suggestive of Parkinson 's disease .
Diseases:"
3139	MK - 801 ( 0 . 1 mg / kg ) , administered 30 min before the observation test , prevented the vacuous chewing movements , tongue protrusions and catalepsy induced by reserpine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['catalepsy']	1	4	"Sentence: MK - 801 ( 0 . 1 mg / kg ) , administered 30 min before the observation test , prevented the vacuous chewing movements , tongue protrusions and catalepsy induced by reserpine .
Diseases: catalepsy"	"Sentence: MK - 801 ( 0 . 1 mg / kg ) , administered 30 min before the observation test , prevented the vacuous chewing movements , tongue protrusions and catalepsy induced by reserpine .
Diseases:"
3140	However , MK - 801 injection produced a significant increase of tremor in reserpine - treated mice .	O O O O O O O O O O O B O O O O O O	O O B I I O O O O O O O O B O O O O	['tremor']	1	3	"Sentence: However , MK - 801 injection produced a significant increase of tremor in reserpine - treated mice .
Diseases: tremor"	"Sentence: However , MK - 801 injection produced a significant increase of tremor in reserpine - treated mice .
Diseases:"
3141	Reserpine ( 1 mg / kg ) , administered 90 min before the test and followed by apomophine injection ( 0 . 1 mg / kg ) 5 min before the test , did not produce oral dyskinesia in mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O	B O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['oral dyskinesia']	1	5	"Sentence: Reserpine ( 1 mg / kg ) , administered 90 min before the test and followed by apomophine injection ( 0 . 1 mg / kg ) 5 min before the test , did not produce oral dyskinesia in mice .
Diseases: oral dyskinesia"	"Sentence: Reserpine ( 1 mg / kg ) , administered 90 min before the test and followed by apomophine injection ( 0 . 1 mg / kg ) 5 min before the test , did not produce oral dyskinesia in mice .
Diseases:"
3142	On the other hand , reserpine induced increases in tremor and catalepsy compared to control mice .	O O O O O O O O O B O B O O O O O	O O O O O B O O O O O O O O O O O	['tremor', 'catalepsy']	2	8	"Sentence: On the other hand , reserpine induced increases in tremor and catalepsy compared to control mice .
Diseases: tremor, catalepsy"	"Sentence: On the other hand , reserpine induced increases in tremor and catalepsy compared to control mice .
Diseases:"
3143	MK - 801 ( 0 . 1 mg / kg ) administration attenuated the catalepsy and tremor induced by reserpine .	O O O O O O O O O O O O O O B O B O O O O	B I I O O O O O O O O O O O O O O O O B O	['tremor', 'catalepsy']	2	8	"Sentence: MK - 801 ( 0 . 1 mg / kg ) administration attenuated the catalepsy and tremor induced by reserpine .
Diseases: tremor, catalepsy"	"Sentence: MK - 801 ( 0 . 1 mg / kg ) administration attenuated the catalepsy and tremor induced by reserpine .
Diseases:"
3144	Pretreatment with reserpine ( 1 mg / kg ) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion , as well as increases in tremor and catalepsy , whereas MK - 801 ( 0 . 1 mg / kg ) injection 90 min before the test reversed the effects of reserpine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O B O	['tremor', 'catalepsy']	2	8	"Sentence: Pretreatment with reserpine ( 1 mg / kg ) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion , as well as increases in tremor and catalepsy , whereas MK - 801 ( 0 . 1 mg / kg ) injection 90 min before the test reversed the effects of reserpine .
Diseases: tremor, catalepsy"	"Sentence: Pretreatment with reserpine ( 1 mg / kg ) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion , as well as increases in tremor and catalepsy , whereas MK - 801 ( 0 . 1 mg / kg ) injection 90 min before the test reversed the effects of reserpine .
Diseases:"
3145	These results show that reserpine produces different and abnormal movements , which are related to dose and schedule employed and can be considered as parkinsonian - like and tardive dsykinesia signs .	O O O O O O O O B I O O O O O O O O O O O O O O B O O O B I O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	['tardive dsykinesia', 'abnormal movements', 'parkinsonian']	3	15	"Sentence: These results show that reserpine produces different and abnormal movements , which are related to dose and schedule employed and can be considered as parkinsonian - like and tardive dsykinesia signs .
Diseases: tardive dsykinesia, abnormal movements, parkinsonian"	"Sentence: These results show that reserpine produces different and abnormal movements , which are related to dose and schedule employed and can be considered as parkinsonian - like and tardive dsykinesia signs .
Diseases:"
3146	The glutamatergic blockage produced by NMDA can restore these signs , such as vacuous chewing movements , tongue protrusions , catalepsy and tremor according to the employed model .	O O O O O O O O O O O O O O O O O O O O B O B O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['tremor', 'catalepsy']	2	8	"Sentence: The glutamatergic blockage produced by NMDA can restore these signs , such as vacuous chewing movements , tongue protrusions , catalepsy and tremor according to the employed model .
Diseases: tremor, catalepsy"	"Sentence: The glutamatergic blockage produced by NMDA can restore these signs , such as vacuous chewing movements , tongue protrusions , catalepsy and tremor according to the employed model .
Diseases:"
3147	Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine - morphine administration .	O O O O O O B I I I O O O O O O O	O O B I O O O O O O O O B O B O O	['sphincter of oddi spasm']	1	9	"Sentence: Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine - morphine administration .
Diseases: sphincter of oddi spasm"	"Sentence: Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine - morphine administration .
Diseases:"
3148	In this study the effect of glyceryl trinitrate on the prostigmine - morphine - induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia .	O O O O O O O O O O O O O O O B I I I O O O O O O O B I I I O	O O O O O O B I O O B O B O O O O O O O O O O O O O O O O O O	['sphincter of oddi dyskinesia', 'sphincter of oddi spasm']	2	21	"Sentence: In this study the effect of glyceryl trinitrate on the prostigmine - morphine - induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia .
Diseases: sphincter of oddi dyskinesia, sphincter of oddi spasm"	"Sentence: In this study the effect of glyceryl trinitrate on the prostigmine - morphine - induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia .
Diseases:"
3149	Sphincter of Oddi spasm was induced by prostigmine - morphine administration ( 0 . 5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously ) and visualized by quantitative hepatobiliary scintigraphy .	B I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O B O O O O O O B O O O O B O O O O O O O O O	['sphincter of oddi spasm']	1	9	"Sentence: Sphincter of Oddi spasm was induced by prostigmine - morphine administration ( 0 . 5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously ) and visualized by quantitative hepatobiliary scintigraphy .
Diseases: sphincter of oddi spasm"	"Sentence: Sphincter of Oddi spasm was induced by prostigmine - morphine administration ( 0 . 5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously ) and visualized by quantitative hepatobiliary scintigraphy .
Diseases:"
3150	The entire procedure was repeated during glyceryl trinitrate infusion ( Nitrolingual 1 microg / kg / min for 120 min ) .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B I O O B O O O O O O O O O O O	[]	0	0	"Sentence: The entire procedure was repeated during glyceryl trinitrate infusion ( Nitrolingual 1 microg / kg / min for 120 min ) .
Diseases: "	"Sentence: The entire procedure was repeated during glyceryl trinitrate infusion ( Nitrolingual 1 microg / kg / min for 120 min ) .
Diseases:"
3151	Prostigmine - morphine provocation caused significant increases in the time to peak activity ( Tmax ) over the hepatic hilum ( HH : 34 . 33 + / - 5 . 05 vs . 22 . 77 + / - 3 . 26 ) and the common bile duct ( CBD : 60 . 44 + / - 5 . 99 vs . 40 . 0 + / - 2 . 88 ) and in the half - time of excretion ( T1 / 2 ) over the liver parenchyma ( LP : 120 . 04 + / - 16 . 01 vs . 27 . 37 + / - 2 . 19 ) , HH ( 117 . 61 + / - 14 . 71 vs . 31 . 85 + / - 3 . 99 ) and CBD ( 158 . 11 + / - 9 . 18 vs . 40 . 1 + / - 6 . 24 ) , indicating a complete spasm at the level of the sphincter of Oddi .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['spasm']	1	2	"Sentence: Prostigmine - morphine provocation caused significant increases in the time to peak activity ( Tmax ) over the hepatic hilum ( HH : 34 . 33 + / - 5 . 05 vs . 22 . 77 + / - 3 . 26 ) and the common bile duct ( CBD : 60 . 44 + / - 5 . 99 vs . 40 . 0 + / - 2 . 88 ) and in the half - time of excretion ( T1 / 2 ) over the liver parenchyma ( LP : 120 . 04 + / - 16 . 01 vs . 27 . 37 + / - 2 . 19 ) , HH ( 117 . 61 + / - 14 . 71 vs . 31 . 85 + / - 3 . 99 ) and CBD ( 158 . 11 + / - 9 . 18 vs . 40 . 1 + / - 6 . 24 ) , indicating a complete spasm at the level of the sphincter of Oddi .
Diseases: spasm"	"Sentence: Prostigmine - morphine provocation caused significant increases in the time to peak activity ( Tmax ) over the hepatic hilum ( HH : 34 . 33 + / - 5 . 05 vs . 22 . 77 + / - 3 . 26 ) and the common bile duct ( CBD : 60 . 44 + / - 5 . 99 vs . 40 . 0 + / - 2 . 88 ) and in the half - time of excretion ( T1 / 2 ) over the liver parenchyma ( LP : 120 . 04 + / - 16 . 01 vs . 27 . 37 + / - 2 . 19 ) , HH ( 117 . 61 + / - 14 . 71 vs . 31 . 85 + / - 3 . 99 ) and CBD ( 158 . 11 + / - 9 . 18 vs . 40 . 1 + / - 6 . 24 ) , indicating a complete spasm at the level of the sphincter of Oddi .
Diseases:"
3152	Glyceryl trinitrate infusion completely normalized the prostigmine - morphine - induced alterations in these quantitative parameters ( TmaX over the LP : 11 . 33 + / - 1 . 13 ; over the HH : 18 . 88 + / - 1 . 48 ; and over the CBD : 36 . 22 + / - 1 . 92 ; and T1 / 2 over the LP : 28 . 21 + / - 1 . 83 ; over the HH : 33 . 42 + / - 3 . 10 ; and over the CBD : 41 . 66 + / - 6 . 33 ) , suggesting an effective sphincter - relaxing effect of glyceryl trinitrate .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B I O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	[]	0	0	"Sentence: Glyceryl trinitrate infusion completely normalized the prostigmine - morphine - induced alterations in these quantitative parameters ( TmaX over the LP : 11 . 33 + / - 1 . 13 ; over the HH : 18 . 88 + / - 1 . 48 ; and over the CBD : 36 . 22 + / - 1 . 92 ; and T1 / 2 over the LP : 28 . 21 + / - 1 . 83 ; over the HH : 33 . 42 + / - 3 . 10 ; and over the CBD : 41 . 66 + / - 6 . 33 ) , suggesting an effective sphincter - relaxing effect of glyceryl trinitrate .
Diseases: "	"Sentence: Glyceryl trinitrate infusion completely normalized the prostigmine - morphine - induced alterations in these quantitative parameters ( TmaX over the LP : 11 . 33 + / - 1 . 13 ; over the HH : 18 . 88 + / - 1 . 48 ; and over the CBD : 36 . 22 + / - 1 . 92 ; and T1 / 2 over the LP : 28 . 21 + / - 1 . 83 ; over the HH : 33 . 42 + / - 3 . 10 ; and over the CBD : 41 . 66 + / - 6 . 33 ) , suggesting an effective sphincter - relaxing effect of glyceryl trinitrate .
Diseases:"
3153	These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine - induced sphincter of Oddi spasm in humans .	O O O O O O O O O O O O O O O O O B I I I O O O	O O O O O O O O O O B I O O B O O O O O O O O O	['sphincter of oddi spasm']	1	9	"Sentence: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine - induced sphincter of Oddi spasm in humans .
Diseases: sphincter of oddi spasm"	"Sentence: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine - induced sphincter of Oddi spasm in humans .
Diseases:"
3154	Since glyceryl trinitrate is able to overcome even the drastic effect of morphine , it might be of relevance in the treatment of sphincter of Oddi dyskinesia .	O O O O O O O O O O O O O O O O O O O O O O O B I I I O	O B I O O O O O O O O O B O O O O O O O O O O O O O O O	['sphincter of oddi dyskinesia']	1	11	"Sentence: Since glyceryl trinitrate is able to overcome even the drastic effect of morphine , it might be of relevance in the treatment of sphincter of Oddi dyskinesia .
Diseases: sphincter of oddi dyskinesia"	"Sentence: Since glyceryl trinitrate is able to overcome even the drastic effect of morphine , it might be of relevance in the treatment of sphincter of Oddi dyskinesia .
Diseases:"
3155	Effects of acute steroid administration on ventilatory and peripheral muscles in rats .	O O O O O O O O O O O O O	O O O B O O O O O O O O O	[]	0	0	"Sentence: Effects of acute steroid administration on ventilatory and peripheral muscles in rats .
Diseases: "	"Sentence: Effects of acute steroid administration on ventilatory and peripheral muscles in rats .
Diseases:"
3156	Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids .	O O O O O O O B O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O	['myopathy']	1	2	"Sentence: Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids .
Diseases: myopathy"	"Sentence: Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids .
Diseases:"
3157	The mechanism of this myopathy is poorly understood .	O O O O B O O O O	O O O O O O O O O	['myopathy']	1	2	"Sentence: The mechanism of this myopathy is poorly understood .
Diseases: myopathy"	"Sentence: The mechanism of this myopathy is poorly understood .
Diseases:"
3158	Therefore , 60 male rats were randomly assigned to receive daily injection of saline ( C ) , methylprednisolone ( M ) , or triamcinolone ( T ) 80 mg / kg / d for 5 d . Nutritional intake , measured daily in 15 animals , showed a significant reduction of food intake in the steroid - treated groups ( - 50 and - 79 % in M and T , respectively ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	['reduction of food intake']	1	5	"Sentence: Therefore , 60 male rats were randomly assigned to receive daily injection of saline ( C ) , methylprednisolone ( M ) , or triamcinolone ( T ) 80 mg / kg / d for 5 d . Nutritional intake , measured daily in 15 animals , showed a significant reduction of food intake in the steroid - treated groups ( - 50 and - 79 % in M and T , respectively ) .
Diseases: reduction of food intake"	"Sentence: Therefore , 60 male rats were randomly assigned to receive daily injection of saline ( C ) , methylprednisolone ( M ) , or triamcinolone ( T ) 80 mg / kg / d for 5 d . Nutritional intake , measured daily in 15 animals , showed a significant reduction of food intake in the steroid - treated groups ( - 50 and - 79 % in M and T , respectively ) .
Diseases:"
3159	This was associated with a similar loss in body weight .	O O O O O O B I I I O	O O O O O O O O O O O	['loss in body weight']	1	4	"Sentence: This was associated with a similar loss in body weight .
Diseases: loss in body weight"	"Sentence: This was associated with a similar loss in body weight .
Diseases:"
3160	In the 45 remaining animals , diaphragm contractility and histopathologic features of several muscles were studied .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the 45 remaining animals , diaphragm contractility and histopathologic features of several muscles were studied .
Diseases: "	"Sentence: In the 45 remaining animals , diaphragm contractility and histopathologic features of several muscles were studied .
Diseases:"
3161	Weights of respiratory and peripheral muscles were similarly decreased after steroid treatment .	O O O O O O O O O O O O O	O O O O O O O O O O B O O	[]	0	0	"Sentence: Weights of respiratory and peripheral muscles were similarly decreased after steroid treatment .
Diseases: "	"Sentence: Weights of respiratory and peripheral muscles were similarly decreased after steroid treatment .
Diseases:"
3162	Maximal twitches of the diaphragm were lower in the C group ( 653 + / - 174 g / cm ( 2 ) ) than in the M group ( 837 + / - 171 g / cm ( 2 ) ; p < 0 . 05 ) and the T group ( 765 + / - 145 g / cm ( 2 ) , NS ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Maximal twitches of the diaphragm were lower in the C group ( 653 + / - 174 g / cm ( 2 ) ) than in the M group ( 837 + / - 171 g / cm ( 2 ) ; p < 0 . 05 ) and the T group ( 765 + / - 145 g / cm ( 2 ) , NS ) .
Diseases: "	"Sentence: Maximal twitches of the diaphragm were lower in the C group ( 653 + / - 174 g / cm ( 2 ) ) than in the M group ( 837 + / - 171 g / cm ( 2 ) ; p < 0 . 05 ) and the T group ( 765 + / - 145 g / cm ( 2 ) , NS ) .
Diseases:"
3163	Half - relaxation time was prolonged in both steroid groups , and time to peak tension was longer with M , whereas tetanic tensions were similar .	O O O O O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O O O B O O O O O O O O O O B O O O O O O O	['tetanic']	1	3	"Sentence: Half - relaxation time was prolonged in both steroid groups , and time to peak tension was longer with M , whereas tetanic tensions were similar .
Diseases: tetanic"	"Sentence: Half - relaxation time was prolonged in both steroid groups , and time to peak tension was longer with M , whereas tetanic tensions were similar .
Diseases:"
3164	Steroid treatment also induced a leftward shift of the force - frequency curve at 25 and 50 Hz when compared with saline treatment ( p < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Steroid treatment also induced a leftward shift of the force - frequency curve at 25 and 50 Hz when compared with saline treatment ( p < 0 . 05 ) .
Diseases: "	"Sentence: Steroid treatment also induced a leftward shift of the force - frequency curve at 25 and 50 Hz when compared with saline treatment ( p < 0 . 05 ) .
Diseases:"
3165	ATPase staining of the diaphragm , scalenus medius , and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T , whereas histologic examinations revealed a normal muscular pattern with absence of necrosis .	O O O O O O O O O O O O O O O B O O O O O O O O O B O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O B O O O O O O O O B O O O O O O O O O O O O O O	['necrosis', 'atrophy']	2	5	"Sentence: ATPase staining of the diaphragm , scalenus medius , and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T , whereas histologic examinations revealed a normal muscular pattern with absence of necrosis .
Diseases: necrosis, atrophy"	"Sentence: ATPase staining of the diaphragm , scalenus medius , and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T , whereas histologic examinations revealed a normal muscular pattern with absence of necrosis .
Diseases:"
3166	Finally , a pair - fed ( PF ) study , performed in 18 rats ( C , T , and PF ) , showed that muscle atrophy was considerably less pronounced in PF animals than in T - treated animals .	O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['muscle atrophy']	1	4	"Sentence: Finally , a pair - fed ( PF ) study , performed in 18 rats ( C , T , and PF ) , showed that muscle atrophy was considerably less pronounced in PF animals than in T - treated animals .
Diseases: muscle atrophy"	"Sentence: Finally , a pair - fed ( PF ) study , performed in 18 rats ( C , T , and PF ) , showed that muscle atrophy was considerably less pronounced in PF animals than in T - treated animals .
Diseases:"
3167	We conclude that ( 1 ) short - term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting ; ( 2 ) both types of steroids induced predominantly type IIb atrophy , resulting in the expected alterations in diaphragm contractile properties ; ( 3 ) neither steroid caused muscle necrosis ; ( 4 ) type IIb atrophy was not caused by acute nutritional deprivation alone .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O B O O O O O O B O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['necrosis', 'atrophy']	2	5	"Sentence: We conclude that ( 1 ) short - term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting ; ( 2 ) both types of steroids induced predominantly type IIb atrophy , resulting in the expected alterations in diaphragm contractile properties ; ( 3 ) neither steroid caused muscle necrosis ; ( 4 ) type IIb atrophy was not caused by acute nutritional deprivation alone .
Diseases: necrosis, atrophy"	"Sentence: We conclude that ( 1 ) short - term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting ; ( 2 ) both types of steroids induced predominantly type IIb atrophy , resulting in the expected alterations in diaphragm contractile properties ; ( 3 ) neither steroid caused muscle necrosis ; ( 4 ) type IIb atrophy was not caused by acute nutritional deprivation alone .
Diseases:"
3168	Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment .	O B I O O B I O O O O O O O	O O O O O O O O B O O B O O	['cardiogenic shock', 'heart block']	2	7	"Sentence: Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment .
Diseases: cardiogenic shock, heart block"	"Sentence: Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment .
Diseases:"
3169	A seventy - eight - year - old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained - release verapamil with concomitant use of metoprolol .	O O O O O O O O O O O O B I O O B O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O B O	['heart block', 'hypotension']	2	5	"Sentence: A seventy - eight - year - old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained - release verapamil with concomitant use of metoprolol .
Diseases: heart block, hypotension"	"Sentence: A seventy - eight - year - old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained - release verapamil with concomitant use of metoprolol .
Diseases:"
3170	The patient continued to remain hypotensive with complete heart block , even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine .	O O O O O B O O B I O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O O O O O B O B O	['heart block', 'hypotensive']	2	5	"Sentence: The patient continued to remain hypotensive with complete heart block , even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine .
Diseases: heart block, hypotensive"	"Sentence: The patient continued to remain hypotensive with complete heart block , even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine .
Diseases:"
3171	However , shortly after the use of intravenous calcium chloride , the refractory hypotension and complete heart block resolved .	O O O O O O O O O O O O O B O O B I O O	O O O O O O O O B I O O O O O O O O O O	['heart block', 'hypotension']	2	5	"Sentence: However , shortly after the use of intravenous calcium chloride , the refractory hypotension and complete heart block resolved .
Diseases: heart block, hypotension"	"Sentence: However , shortly after the use of intravenous calcium chloride , the refractory hypotension and complete heart block resolved .
Diseases:"
3172	A phase I clinical study of the antipurine antifolate lometrexol ( DDATHF ) given with oral folic acid .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O B O O O O B I O	[]	0	0	"Sentence: A phase I clinical study of the antipurine antifolate lometrexol ( DDATHF ) given with oral folic acid .
Diseases: "	"Sentence: A phase I clinical study of the antipurine antifolate lometrexol ( DDATHF ) given with oral folic acid .
Diseases:"
3173	Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase ( GARFT ) , an enzyme essential for de novo purine synthesis .	O O O O O O O O O O O O O O O O O O O O O O	B O O O O O B I O O O O O O O O O O O B O O	[]	0	0	"Sentence: Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase ( GARFT ) , an enzyme essential for de novo purine synthesis .
Diseases: "	"Sentence: Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase ( GARFT ) , an enzyme essential for de novo purine synthesis .
Diseases:"
3174	Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs , notably methotrexate .	O O O O O O O O O O O O O B O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O B O	['tumours']	1	3	"Sentence: Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs , notably methotrexate .
Diseases: tumours"	"Sentence: Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs , notably methotrexate .
Diseases:"
3175	However , the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities .	O O O O O O O O O O O O O O O O B O	O O O O O O O B O O O O O O O O O O	['toxicities']	1	3	"Sentence: However , the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities .
Diseases: toxicities"	"Sentence: However , the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities .
Diseases:"
3176	Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration , i . e . for 7 days prior to and 7 days following a single bolus dose .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O B I O O O O O O O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration , i . e . for 7 days prior to and 7 days following a single bolus dose .
Diseases: toxicity"	"Sentence: Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration , i . e . for 7 days prior to and 7 days following a single bolus dose .
Diseases:"
3177	This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation .	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	O O O O O O O O O B O O B I O O O O O O O O B O O O O O B I O O	['toxicity']	1	2	"Sentence: This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation .
Diseases: toxicity"	"Sentence: This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation .
Diseases:"
3178	Thrombocytopenia and mucositis were the major toxicities .	B O B O O O B O	O O O O O O O O	['mucositis', 'toxicities', 'thrombocytopenia']	3	15	"Sentence: Thrombocytopenia and mucositis were the major toxicities .
Diseases: mucositis, toxicities, thrombocytopenia"	"Sentence: Thrombocytopenia and mucositis were the major toxicities .
Diseases:"
3179	There was no clear relationship between clinical toxicity and the extent of plasma folate elevation .	O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O B O O	['toxicity']	1	2	"Sentence: There was no clear relationship between clinical toxicity and the extent of plasma folate elevation .
Diseases: toxicity"	"Sentence: There was no clear relationship between clinical toxicity and the extent of plasma folate elevation .
Diseases:"
3180	Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O	O O O O B O O O O O O B I O O O O O O O O O O O B O O O	['toxicity']	1	2	"Sentence: Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance .
Diseases: toxicity"	"Sentence: Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance .
Diseases:"
3181	The work described in this report has identified for the first time a clinically acceptable schedule for the administration of a GARFT inhibitor .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The work described in this report has identified for the first time a clinically acceptable schedule for the administration of a GARFT inhibitor .
Diseases: "	"Sentence: The work described in this report has identified for the first time a clinically acceptable schedule for the administration of a GARFT inhibitor .
Diseases:"
3182	This information will facilitate the future evaluation of this class of compounds in cancer therapy .	O O O O O O O O O O O O O B O O	O O O O O O O O O O O O O O O O	['cancer']	1	1	"Sentence: This information will facilitate the future evaluation of this class of compounds in cancer therapy .
Diseases: cancer"	"Sentence: This information will facilitate the future evaluation of this class of compounds in cancer therapy .
Diseases:"
3183	Involvement of the mu - opiate receptor in peripheral analgesia .	O O O O O O O O O B O	O O O O O O O O O O O	['analgesia']	1	4	"Sentence: Involvement of the mu - opiate receptor in peripheral analgesia .
Diseases: analgesia"	"Sentence: Involvement of the mu - opiate receptor in peripheral analgesia .
Diseases:"
3184	The intradermal injection of mu ( morphine , Tyr - D - Ala - Gly - NMe - Phe - Gly - ol and morphiceptin ) , kappa ( trans - 3 , 4 - dichloro - N - methyl - N [ 2 - ( 1 - pyrrolidinyl ) cyclohexyl ] benzeneactemide ) and delta ( [ D - Pen2 . 5 ] - enkephalin and [ D - Ser2 ] - [ Leu ] enkephalin - Thr ) selective opioid - agonists , by themselves , did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O B I I I I I I I I I I I I I I O B O O O O B I I I I I I I I I I I I I I I I I I I I I I I O O O O B I I I I I I I I O O O I I I I O I I I I I O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The intradermal injection of mu ( morphine , Tyr - D - Ala - Gly - NMe - Phe - Gly - ol and morphiceptin ) , kappa ( trans - 3 , 4 - dichloro - N - methyl - N [ 2 - ( 1 - pyrrolidinyl ) cyclohexyl ] benzeneactemide ) and delta ( [ D - Pen2 . 5 ] - enkephalin and [ D - Ser2 ] - [ Leu ] enkephalin - Thr ) selective opioid - agonists , by themselves , did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat .
Diseases: "	"Sentence: The intradermal injection of mu ( morphine , Tyr - D - Ala - Gly - NMe - Phe - Gly - ol and morphiceptin ) , kappa ( trans - 3 , 4 - dichloro - N - methyl - N [ 2 - ( 1 - pyrrolidinyl ) cyclohexyl ] benzeneactemide ) and delta ( [ D - Pen2 . 5 ] - enkephalin and [ D - Ser2 ] - [ Leu ] enkephalin - Thr ) selective opioid - agonists , by themselves , did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat .
Diseases:"
3185	Intradermal injection of mu , but not delta or kappa opioid - agonists , however , produced dose - dependent inhibition of prostaglandin E2 - induced hyperalgesia .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O B I O O O O	['hyperalgesia']	1	4	"Sentence: Intradermal injection of mu , but not delta or kappa opioid - agonists , however , produced dose - dependent inhibition of prostaglandin E2 - induced hyperalgesia .
Diseases: hyperalgesia"	"Sentence: Intradermal injection of mu , but not delta or kappa opioid - agonists , however , produced dose - dependent inhibition of prostaglandin E2 - induced hyperalgesia .
Diseases:"
3186	The analgesic effect of the mu - agonist morphine was dose - dependently antagonized by naloxone and prevented by co - injection of pertussis toxin .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: The analgesic effect of the mu - agonist morphine was dose - dependently antagonized by naloxone and prevented by co - injection of pertussis toxin .
Diseases: "	"Sentence: The analgesic effect of the mu - agonist morphine was dose - dependently antagonized by naloxone and prevented by co - injection of pertussis toxin .
Diseases:"
3187	Morphine did not , however , alter the hyperalgesia induced by 8 - bromo cyclic adenosine monophosphate .	O O O O O O O O B O O O O O O O O O	B O O O O O O O O O O B I I I I I O	['hyperalgesia']	1	4	"Sentence: Morphine did not , however , alter the hyperalgesia induced by 8 - bromo cyclic adenosine monophosphate .
Diseases: hyperalgesia"	"Sentence: Morphine did not , however , alter the hyperalgesia induced by 8 - bromo cyclic adenosine monophosphate .
Diseases:"
3188	We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu - opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O	[]	0	0	"Sentence: We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu - opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system .
Diseases: "	"Sentence: We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu - opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system .
Diseases:"
3189	Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C . BACKGROUND :	O O O O O O O O B O O O O O O O O B I I O O O	O O O B O O O O O O O O O B O B O O O O O O O	['hemolysis', 'chronic hepatitis c']	2	7	"Sentence: Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C . BACKGROUND :
Diseases: hemolysis, chronic hepatitis c"	"Sentence: Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C . BACKGROUND :
Diseases:"
3190	Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin .	B I O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O B O	['hemolytic anemia']	1	5	"Sentence: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin .
Diseases: hemolytic anemia"	"Sentence: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin .
Diseases:"
3191	Because of ribavirin - related hemolytic anemia , dose reduction is a common event in this therapy .	O O O O O B I O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O	['hemolytic anemia']	1	5	"Sentence: Because of ribavirin - related hemolytic anemia , dose reduction is a common event in this therapy .
Diseases: hemolytic anemia"	"Sentence: Because of ribavirin - related hemolytic anemia , dose reduction is a common event in this therapy .
Diseases:"
3192	In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy .	O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O O O O O O O O B O O O O O O O O O	['hemolysis']	1	3	"Sentence: In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy .
Diseases: hemolysis"	"Sentence: In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy .
Diseases:"
3193	Thirty - seven of 160 patients who had HCV - genotype 1b , had high virus load , and received 24 - week combination therapy developed anemia with hemoglobin level < 10 g / dl or anemia - related signs during therapy .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['anemia']	1	2	"Sentence: Thirty - seven of 160 patients who had HCV - genotype 1b , had high virus load , and received 24 - week combination therapy developed anemia with hemoglobin level < 10 g / dl or anemia - related signs during therapy .
Diseases: anemia"	"Sentence: Thirty - seven of 160 patients who had HCV - genotype 1b , had high virus load , and received 24 - week combination therapy developed anemia with hemoglobin level < 10 g / dl or anemia - related signs during therapy .
Diseases:"
3194	After that , these 37 patients were reduced one tablet of ribavirin ( 200 mg ) per day .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: After that , these 37 patients were reduced one tablet of ribavirin ( 200 mg ) per day .
Diseases: "	"Sentence: After that , these 37 patients were reduced one tablet of ribavirin ( 200 mg ) per day .
Diseases:"
3195	After reduction of ribavirin , 27 of 37 patients could continue combination therapy for a total of 24 weeks ( group A ) .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After reduction of ribavirin , 27 of 37 patients could continue combination therapy for a total of 24 weeks ( group A ) .
Diseases: "	"Sentence: After reduction of ribavirin , 27 of 37 patients could continue combination therapy for a total of 24 weeks ( group A ) .
Diseases:"
3196	However , 10 of 37 patients with reduction of ribavirin could not continue combination therapy because their < 8 . 5 g / dl hemoglobin values decreased to or anemia - related severe side effects occurred ( group B ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['anemia']	1	2	"Sentence: However , 10 of 37 patients with reduction of ribavirin could not continue combination therapy because their < 8 . 5 g / dl hemoglobin values decreased to or anemia - related severe side effects occurred ( group B ) .
Diseases: anemia"	"Sentence: However , 10 of 37 patients with reduction of ribavirin could not continue combination therapy because their < 8 . 5 g / dl hemoglobin values decreased to or anemia - related severe side effects occurred ( group B ) .
Diseases:"
3197	We assessed the final efficacy and safety after reduction of ribavirin in groups A and B . RESULTS :	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: We assessed the final efficacy and safety after reduction of ribavirin in groups A and B . RESULTS :
Diseases: "	"Sentence: We assessed the final efficacy and safety after reduction of ribavirin in groups A and B . RESULTS :
Diseases:"
3198	A sustained virological response ( SVR ) was 29 . 6 % ( 8 / 27 ) in group A and 10 % ( 1 / 10 ) in group B , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A sustained virological response ( SVR ) was 29 . 6 % ( 8 / 27 ) in group A and 10 % ( 1 / 10 ) in group B , respectively .
Diseases: "	"Sentence: A sustained virological response ( SVR ) was 29 . 6 % ( 8 / 27 ) in group A and 10 % ( 1 / 10 ) in group B , respectively .
Diseases:"
3199	A 34 . 4 % ( 12 / 27 ) of SVR + biological response in group A was higher than 10 % ( 1 / 10 ) in group B ( P = 0 . 051 ) , with slight significance .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A 34 . 4 % ( 12 / 27 ) of SVR + biological response in group A was higher than 10 % ( 1 / 10 ) in group B ( P = 0 . 051 ) , with slight significance .
Diseases: "	"Sentence: A 34 . 4 % ( 12 / 27 ) of SVR + biological response in group A was higher than 10 % ( 1 / 10 ) in group B ( P = 0 . 051 ) , with slight significance .
Diseases:"
3200	With respect to hemoglobin level at the time of ribavirin reduction , a rate of continuation of therapy in patients with > or = 10 g / dl hemoglobin was higher than that in patients with < 10 g / dl ( P = 0 . 036 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: With respect to hemoglobin level at the time of ribavirin reduction , a rate of continuation of therapy in patients with > or = 10 g / dl hemoglobin was higher than that in patients with < 10 g / dl ( P = 0 . 036 ) .
Diseases: "	"Sentence: With respect to hemoglobin level at the time of ribavirin reduction , a rate of continuation of therapy in patients with > or = 10 g / dl hemoglobin was higher than that in patients with < 10 g / dl ( P = 0 . 036 ) .
Diseases:"
3201	CONCLUSIONS : Reduction of ribavirin at hemoglobin level > or = 10 g / dl is suitable in terms of efficacy and side effects .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSIONS : Reduction of ribavirin at hemoglobin level > or = 10 g / dl is suitable in terms of efficacy and side effects .
Diseases: "	"Sentence: CONCLUSIONS : Reduction of ribavirin at hemoglobin level > or = 10 g / dl is suitable in terms of efficacy and side effects .
Diseases:"
3202	Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside - induced nephrotic syndrome in rats .	O O O O O O O O O O O O O O B I O O O	O O O O O O O O O O B I O O O O O O O	['nephrotic syndrome']	1	5	"Sentence: Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside - induced nephrotic syndrome in rats .
Diseases: nephrotic syndrome"	"Sentence: Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside - induced nephrotic syndrome in rats .
Diseases:"
3203	Nephrotic syndrome is often accompanied by sodium retention and generalized edema .	B I O O O O O O O O B O	O O O O O O B O O O O O	['nephrotic syndrome', 'edema']	2	8	"Sentence: Nephrotic syndrome is often accompanied by sodium retention and generalized edema .
Diseases: nephrotic syndrome, edema"	"Sentence: Nephrotic syndrome is often accompanied by sodium retention and generalized edema .
Diseases:"
3204	However , the molecular basis for the decreased renal sodium excretion remains undefined .	O O O O O O O O O O O O O O	O O O O O O O O O B O O O O	[]	0	0	"Sentence: However , the molecular basis for the decreased renal sodium excretion remains undefined .
Diseases: "	"Sentence: However , the molecular basis for the decreased renal sodium excretion remains undefined .
Diseases:"
3205	We hypothesized that epithelial Na channel ( ENaC ) subunit dysregulation may be responsible for the increased sodium retention .	O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O B O O	[]	0	0	"Sentence: We hypothesized that epithelial Na channel ( ENaC ) subunit dysregulation may be responsible for the increased sodium retention .
Diseases: "	"Sentence: We hypothesized that epithelial Na channel ( ENaC ) subunit dysregulation may be responsible for the increased sodium retention .
Diseases:"
3206	An experimental group of rats was treated with puromycin aminonucleoside ( PAN ; 180 mg / kg iv ) , whereas the control group received only vehicle .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B I O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: An experimental group of rats was treated with puromycin aminonucleoside ( PAN ; 180 mg / kg iv ) , whereas the control group received only vehicle .
Diseases: "	"Sentence: An experimental group of rats was treated with puromycin aminonucleoside ( PAN ; 180 mg / kg iv ) , whereas the control group received only vehicle .
Diseases:"
3207	After 7 days , PAN treatment induced significant proteinuria , hypoalbuminemia , decreased urinary sodium excretion , and extensive ascites .	O O O O O O O O B O B O O O O O O O O B O	O O O O B O O O O O O O O O B O O O O O O	['ascites', 'proteinuria', 'hypoalbuminemia']	3	11	"Sentence: After 7 days , PAN treatment induced significant proteinuria , hypoalbuminemia , decreased urinary sodium excretion , and extensive ascites .
Diseases: ascites, proteinuria, hypoalbuminemia"	"Sentence: After 7 days , PAN treatment induced significant proteinuria , hypoalbuminemia , decreased urinary sodium excretion , and extensive ascites .
Diseases:"
3208	The protein abundance of alpha - ENaC and beta - ENaC was increased in the inner stripe of the outer medulla ( ISOM ) and in the inner medulla ( IM ) but was not altered in the cortex .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The protein abundance of alpha - ENaC and beta - ENaC was increased in the inner stripe of the outer medulla ( ISOM ) and in the inner medulla ( IM ) but was not altered in the cortex .
Diseases: "	"Sentence: The protein abundance of alpha - ENaC and beta - ENaC was increased in the inner stripe of the outer medulla ( ISOM ) and in the inner medulla ( IM ) but was not altered in the cortex .
Diseases:"
3209	gamma - ENaC abundance was increased in the cortex , ISOM , and IM .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: gamma - ENaC abundance was increased in the cortex , ISOM , and IM .
Diseases: "	"Sentence: gamma - ENaC abundance was increased in the cortex , ISOM , and IM .
Diseases:"
3210	Immunoperoxidase brightfield - and laser - scanning confocal fluorescence microscopy demonstrated increased targeting of alpha - ENaC , beta - ENaC , and gamma - ENaC subunits to the apical plasma membrane in the distal convoluted tubule ( DCT2 ) , connecting tubule , and cortical and medullary collecting duct segments .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Immunoperoxidase brightfield - and laser - scanning confocal fluorescence microscopy demonstrated increased targeting of alpha - ENaC , beta - ENaC , and gamma - ENaC subunits to the apical plasma membrane in the distal convoluted tubule ( DCT2 ) , connecting tubule , and cortical and medullary collecting duct segments .
Diseases: "	"Sentence: Immunoperoxidase brightfield - and laser - scanning confocal fluorescence microscopy demonstrated increased targeting of alpha - ENaC , beta - ENaC , and gamma - ENaC subunits to the apical plasma membrane in the distal convoluted tubule ( DCT2 ) , connecting tubule , and cortical and medullary collecting duct segments .
Diseases:"
3211	Immunoelectron microscopy further revealed an increased labeling of alpha - ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN - treated rats , indicating enhanced apical targeting of alpha - ENaC subunits .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: Immunoelectron microscopy further revealed an increased labeling of alpha - ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN - treated rats , indicating enhanced apical targeting of alpha - ENaC subunits .
Diseases: "	"Sentence: Immunoelectron microscopy further revealed an increased labeling of alpha - ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN - treated rats , indicating enhanced apical targeting of alpha - ENaC subunits .
Diseases:"
3212	In contrast , the protein abundances of Na ( + ) / H ( + ) exchanger type 3 ( NHE3 ) , Na ( + ) - K ( + ) - 2Cl ( - ) cotransporter ( BSC - 1 ) , and thiazide - sensitive Na ( + ) - Cl ( - )	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O B O O O O O O O O O O B O O O O B O O O O O O O O O O O O O O O O B O O B O O O O B O O O	[]	0	0	"Sentence: In contrast , the protein abundances of Na ( + ) / H ( + ) exchanger type 3 ( NHE3 ) , Na ( + ) - K ( + ) - 2Cl ( - ) cotransporter ( BSC - 1 ) , and thiazide - sensitive Na ( + ) - Cl ( - )
Diseases: "	"Sentence: In contrast , the protein abundances of Na ( + ) / H ( + ) exchanger type 3 ( NHE3 ) , Na ( + ) - K ( + ) - 2Cl ( - ) cotransporter ( BSC - 1 ) , and thiazide - sensitive Na ( + ) - Cl ( - )
Diseases:"
3213	cotransporter ( TSC ) were decreased .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: cotransporter ( TSC ) were decreased .
Diseases: "	"Sentence: cotransporter ( TSC ) were decreased .
Diseases:"
3214	Moreover , the abundance of the alpha ( 1 ) - subunit of the Na - K - ATPase was decreased in the cortex and ISOM , but it remained unchanged in the IM .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Moreover , the abundance of the alpha ( 1 ) - subunit of the Na - K - ATPase was decreased in the cortex and ISOM , but it remained unchanged in the IM .
Diseases: "	"Sentence: Moreover , the abundance of the alpha ( 1 ) - subunit of the Na - K - ATPase was decreased in the cortex and ISOM , but it remained unchanged in the IM .
Diseases:"
3215	In conclusion , the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2 , connecting tubule , and collecting duct are likely to play a role in the sodium retention associated with PAN - induced nephrotic syndrome .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O B O O O O O	['nephrotic syndrome']	1	5	"Sentence: In conclusion , the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2 , connecting tubule , and collecting duct are likely to play a role in the sodium retention associated with PAN - induced nephrotic syndrome .
Diseases: nephrotic syndrome"	"Sentence: In conclusion , the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2 , connecting tubule , and collecting duct are likely to play a role in the sodium retention associated with PAN - induced nephrotic syndrome .
Diseases:"
3216	The decreased abundance of NHE3 , BSC - 1 , TSC , and Na - K - ATPase may play a compensatory role to promote sodium excretion .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O B O O O O O O O O O B O O	[]	0	0	"Sentence: The decreased abundance of NHE3 , BSC - 1 , TSC , and Na - K - ATPase may play a compensatory role to promote sodium excretion .
Diseases: "	"Sentence: The decreased abundance of NHE3 , BSC - 1 , TSC , and Na - K - ATPase may play a compensatory role to promote sodium excretion .
Diseases:"
3217	Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition ?	O O O O O O O B I O O B I I I I I O	O O O O O O O O O O O O O O O O O O	['detrimental effect on memory and cognition', 'breast cancer']	2	11	"Sentence: Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition ?
Diseases: detrimental effect on memory and cognition, breast cancer"	"Sentence: Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition ?
Diseases:"
3218	A pilot study .	O O O O	O O O O	[]	0	0	"Sentence: A pilot study .
Diseases: "	"Sentence: A pilot study .
Diseases:"
3219	This pilot study examines whether hormone therapy for breast cancer affects cognition .	O O O O O O O O B I O O O	O O O O O O O O O O O O O	['breast cancer']	1	3	"Sentence: This pilot study examines whether hormone therapy for breast cancer affects cognition .
Diseases: breast cancer"	"Sentence: This pilot study examines whether hormone therapy for breast cancer affects cognition .
Diseases:"
3220	Patients participating in a randomised trial of anastrozole , tamoxifen alone or combined ( ATAC ) ( n = 94 ) and a group of women without breast cancer ( n = 35 ) completed a battery of neuropsychological measures .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O	O O O O O O O B O B O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['breast cancer']	1	3	"Sentence: Patients participating in a randomised trial of anastrozole , tamoxifen alone or combined ( ATAC ) ( n = 94 ) and a group of women without breast cancer ( n = 35 ) completed a battery of neuropsychological measures .
Diseases: breast cancer"	"Sentence: Patients participating in a randomised trial of anastrozole , tamoxifen alone or combined ( ATAC ) ( n = 94 ) and a group of women without breast cancer ( n = 35 ) completed a battery of neuropsychological measures .
Diseases:"
3221	Compared with the control group , the patients were impaired on a processing speed task ( p = 0 . 032 ) and on a measure of immediate verbal memory ( p = 0 . 026 ) after controlling for the use of hormone replacement therapy in both groups .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Compared with the control group , the patients were impaired on a processing speed task ( p = 0 . 032 ) and on a measure of immediate verbal memory ( p = 0 . 026 ) after controlling for the use of hormone replacement therapy in both groups .
Diseases: "	"Sentence: Compared with the control group , the patients were impaired on a processing speed task ( p = 0 . 032 ) and on a measure of immediate verbal memory ( p = 0 . 026 ) after controlling for the use of hormone replacement therapy in both groups .
Diseases:"
3222	Patient group performance was not significantly related to length of treatment or measures of psychological morbidity .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patient group performance was not significantly related to length of treatment or measures of psychological morbidity .
Diseases: "	"Sentence: Patient group performance was not significantly related to length of treatment or measures of psychological morbidity .
Diseases:"
3223	The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer .	O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O	['breast cancer']	1	3	"Sentence: The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer .
Diseases: breast cancer"	"Sentence: The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer .
Diseases:"
3224	Verbal memory may be especially sensitive to changes in oestrogen levels , a finding commonly reported in studies of hormone replacement therapy in healthy women .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Verbal memory may be especially sensitive to changes in oestrogen levels , a finding commonly reported in studies of hormone replacement therapy in healthy women .
Diseases: "	"Sentence: Verbal memory may be especially sensitive to changes in oestrogen levels , a finding commonly reported in studies of hormone replacement therapy in healthy women .
Diseases:"
3225	In view of the increased use of hormone therapies in an adjuvant and preventative setting their impact on cognitive functioning should be investigated more thoroughly .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In view of the increased use of hormone therapies in an adjuvant and preventative setting their impact on cognitive functioning should be investigated more thoroughly .
Diseases: "	"Sentence: In view of the increased use of hormone therapies in an adjuvant and preventative setting their impact on cognitive functioning should be investigated more thoroughly .
Diseases:"
3226	Association of nitric oxide production and apoptosis in a model of experimental nephropathy .	O O O O O O O O O O O O B O	O O B I O O O O O O O O O O	['nephropathy']	1	4	"Sentence: Association of nitric oxide production and apoptosis in a model of experimental nephropathy .
Diseases: nephropathy"	"Sentence: Association of nitric oxide production and apoptosis in a model of experimental nephropathy .
Diseases:"
3227	In recent studies increased amounts of nitric oxide ( NO ) and apoptosis have been implicated in various pathological conditions in the kidney .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B I O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: In recent studies increased amounts of nitric oxide ( NO ) and apoptosis have been implicated in various pathological conditions in the kidney .
Diseases: "	"Sentence: In recent studies increased amounts of nitric oxide ( NO ) and apoptosis have been implicated in various pathological conditions in the kidney .
Diseases:"
3228	We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin ( ADR ) .	O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O B O B O O	['nephrotic syndrome']	1	5	"Sentence: We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin ( ADR ) .
Diseases: nephrotic syndrome"	"Sentence: We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin ( ADR ) .
Diseases:"
3229	The alteration in the NO pathway was assessed by measuring nitrite levels in serum / urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney ( IPRK ) system .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The alteration in the NO pathway was assessed by measuring nitrite levels in serum / urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney ( IPRK ) system .
Diseases: "	"Sentence: The alteration in the NO pathway was assessed by measuring nitrite levels in serum / urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney ( IPRK ) system .
Diseases:"
3230	Rats were stratified into control groups and ADR - induced nephropathy groups .	O O O O O O O O O O B O O	O O O O O O O B O O O O O	['nephropathy']	1	4	"Sentence: Rats were stratified into control groups and ADR - induced nephropathy groups .
Diseases: nephropathy"	"Sentence: Rats were stratified into control groups and ADR - induced nephropathy groups .
Diseases:"
3231	These two groups were then divided into : group 1 , animals receiving saline ; and group 2 , animals receiving aminoguanidine ( AG ) which is a specific inhibitor of inducible - NO synthase .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O B O O	[]	0	0	"Sentence: These two groups were then divided into : group 1 , animals receiving saline ; and group 2 , animals receiving aminoguanidine ( AG ) which is a specific inhibitor of inducible - NO synthase .
Diseases: "	"Sentence: These two groups were then divided into : group 1 , animals receiving saline ; and group 2 , animals receiving aminoguanidine ( AG ) which is a specific inhibitor of inducible - NO synthase .
Diseases:"
3232	On day 21 , rats were sacrificed after obtaining material for biochemical analysis .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: On day 21 , rats were sacrificed after obtaining material for biochemical analysis .
Diseases: "	"Sentence: On day 21 , rats were sacrificed after obtaining material for biochemical analysis .
Diseases:"
3233	Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation .	O O O O O O O O O O O O O O B I O O B I O	O O O O O O O O O B O O O O O O O O O O O	['mesangial proliferation', 'tubulointerstitial inflammation']	2	9	"Sentence: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation .
Diseases: mesangial proliferation, tubulointerstitial inflammation"	"Sentence: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation .
Diseases:"
3234	They also had significantly higher levels of proteinuria compared with control and treatment groups ( P < 0 . 05 ) .	O O O O O O O B O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: They also had significantly higher levels of proteinuria compared with control and treatment groups ( P < 0 . 05 ) .
Diseases: proteinuria"	"Sentence: They also had significantly higher levels of proteinuria compared with control and treatment groups ( P < 0 . 05 ) .
Diseases:"
3235	Urine nitrite levels were significantly increased in the ADR - nephropathy group ( P < 0 . 05 ) .	O O O O O O O O O O B O O O O O O O O O	O B O O O O O O B O O O O O O O O O O O	['nephropathy']	1	4	"Sentence: Urine nitrite levels were significantly increased in the ADR - nephropathy group ( P < 0 . 05 ) .
Diseases: nephropathy"	"Sentence: Urine nitrite levels were significantly increased in the ADR - nephropathy group ( P < 0 . 05 ) .
Diseases:"
3236	In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR - nephropathy group .	O O O O O O O O O O O O O O O B O O	O O O B O B O O O O O O O B O O O O	['nephropathy']	1	4	"Sentence: In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR - nephropathy group .
Diseases: nephropathy"	"Sentence: In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR - nephropathy group .
Diseases:"
3237	Apoptosis was not detected in controls .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: Apoptosis was not detected in controls .
Diseases: "	"Sentence: Apoptosis was not detected in controls .
Diseases:"
3238	However , in the ADR - nephropathy group , numerous apoptotic cells were identified in the tubulointerstitial areas .	O O O O O O B O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O	['nephropathy']	1	4	"Sentence: However , in the ADR - nephropathy group , numerous apoptotic cells were identified in the tubulointerstitial areas .
Diseases: nephropathy"	"Sentence: However , in the ADR - nephropathy group , numerous apoptotic cells were identified in the tubulointerstitial areas .
Diseases:"
3239	Double staining revealed numerous interstitial apoptotic cells to stain for ED1 , a marker for monocytes / macrophages .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Double staining revealed numerous interstitial apoptotic cells to stain for ED1 , a marker for monocytes / macrophages .
Diseases: "	"Sentence: Double staining revealed numerous interstitial apoptotic cells to stain for ED1 , a marker for monocytes / macrophages .
Diseases:"
3240	Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels .	O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels .
Diseases: "	"Sentence: Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels .
Diseases:"
3241	We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR - induced nephrosis .	O O O O O O O O O O O O O O O O O O B O	O O O O O B O O O O O O O O O B O O O O	['nephrosis']	1	3	"Sentence: We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR - induced nephrosis .
Diseases: nephrosis"	"Sentence: We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR - induced nephrosis .
Diseases:"
3242	The attenuating effect of carteolol hydrochloride , a beta - adrenoceptor antagonist , on neuroleptic - induced catalepsy in rats .	O O O O O O O O O O O O O O O O O B O O O	O O O O B I O O O O O O O O O O O O O O O	['catalepsy']	1	4	"Sentence: The attenuating effect of carteolol hydrochloride , a beta - adrenoceptor antagonist , on neuroleptic - induced catalepsy in rats .
Diseases: catalepsy"	"Sentence: The attenuating effect of carteolol hydrochloride , a beta - adrenoceptor antagonist , on neuroleptic - induced catalepsy in rats .
Diseases:"
3243	It is known that beta - adrenoceptor antagonists are effective in the treatment of akathisia , one of the extrapyramidal side effects that occur during neuroleptic treatment .	O O O O O O O O O O O O O O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['akathisia']	1	4	"Sentence: It is known that beta - adrenoceptor antagonists are effective in the treatment of akathisia , one of the extrapyramidal side effects that occur during neuroleptic treatment .
Diseases: akathisia"	"Sentence: It is known that beta - adrenoceptor antagonists are effective in the treatment of akathisia , one of the extrapyramidal side effects that occur during neuroleptic treatment .
Diseases:"
3244	Neuroleptic - induced catalepsy , a model of neuroleptic - induced extrapyramidal side effects , was considered suitable as a model for predicting neuroleptic - induced akathisia in humans , although neuroleptic - induced catalepsy was not considered a specific test for neuroleptic - induced akathisia .	O O O B O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O B O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['akathisia', 'catalepsy']	2	9	"Sentence: Neuroleptic - induced catalepsy , a model of neuroleptic - induced extrapyramidal side effects , was considered suitable as a model for predicting neuroleptic - induced akathisia in humans , although neuroleptic - induced catalepsy was not considered a specific test for neuroleptic - induced akathisia .
Diseases: akathisia, catalepsy"	"Sentence: Neuroleptic - induced catalepsy , a model of neuroleptic - induced extrapyramidal side effects , was considered suitable as a model for predicting neuroleptic - induced akathisia in humans , although neuroleptic - induced catalepsy was not considered a specific test for neuroleptic - induced akathisia .
Diseases:"
3245	Therefore , the effects of carteolol , a beta - adrenoceptor antagonist , on haloperidol - induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden , a muscarinic receptor antagonist .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O B O O O O O O O O O O O O O B O B O O O O O O	['catalepsy']	1	4	"Sentence: Therefore , the effects of carteolol , a beta - adrenoceptor antagonist , on haloperidol - induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden , a muscarinic receptor antagonist .
Diseases: catalepsy"	"Sentence: Therefore , the effects of carteolol , a beta - adrenoceptor antagonist , on haloperidol - induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden , a muscarinic receptor antagonist .
Diseases:"
3246	Carteolol , as well as propranolol and biperiden , inhibited the haloperidol - induced catalepsy .	O O O O O O O O O O O O O O B O	B O O O O B O B O O O B O O O O	['catalepsy']	1	4	"Sentence: Carteolol , as well as propranolol and biperiden , inhibited the haloperidol - induced catalepsy .
Diseases: catalepsy"	"Sentence: Carteolol , as well as propranolol and biperiden , inhibited the haloperidol - induced catalepsy .
Diseases:"
3247	The inhibitory effect of carteolol was almost comparable to that of propranolol , but was weaker than that of biperiden .	O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O B O O O O O O O B O	[]	0	0	"Sentence: The inhibitory effect of carteolol was almost comparable to that of propranolol , but was weaker than that of biperiden .
Diseases: "	"Sentence: The inhibitory effect of carteolol was almost comparable to that of propranolol , but was weaker than that of biperiden .
Diseases:"
3248	Carteolol did not evoke postsynaptic dopamine receptor - stimulating behavioral signs such as stereotypy and hyperlocomotion in rats .	O O O O O O O O O O O O O O O B O O O	B O O O O B O O O O O O O O O O O O O	['hyperlocomotion']	1	4	"Sentence: Carteolol did not evoke postsynaptic dopamine receptor - stimulating behavioral signs such as stereotypy and hyperlocomotion in rats .
Diseases: hyperlocomotion"	"Sentence: Carteolol did not evoke postsynaptic dopamine receptor - stimulating behavioral signs such as stereotypy and hyperlocomotion in rats .
Diseases:"
3249	Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine - induced stereotypy and locomotor activity in rats .	O O O O O O O O O O O O O O O O O O O O	B O O O O O O O B O B O O O O O O O O O	[]	0	0	"Sentence: Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine - induced stereotypy and locomotor activity in rats .
Diseases: "	"Sentence: Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine - induced stereotypy and locomotor activity in rats .
Diseases:"
3250	In addition , carteolol did not evoke 5 - HT1A receptor - stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5 - hydroxytryptophan - induced head twitch in rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O	[]	0	0	"Sentence: In addition , carteolol did not evoke 5 - HT1A receptor - stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5 - hydroxytryptophan - induced head twitch in rats .
Diseases: "	"Sentence: In addition , carteolol did not evoke 5 - HT1A receptor - stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5 - hydroxytryptophan - induced head twitch in rats .
Diseases:"
3251	Finally , carteolol did not inhibit physostigmine - induced lethality in rats .	O O O O O O O O O O O O O	O O B O O O B O O O O O O	[]	0	0	"Sentence: Finally , carteolol did not inhibit physostigmine - induced lethality in rats .
Diseases: "	"Sentence: Finally , carteolol did not inhibit physostigmine - induced lethality in rats .
Diseases:"
3252	These results strongly suggest that carteolol improves haloperidol - induced catalepsy via its beta - adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic - induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['akathisia', 'catalepsy']	2	9	"Sentence: These results strongly suggest that carteolol improves haloperidol - induced catalepsy via its beta - adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic - induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity .
Diseases: akathisia, catalepsy"	"Sentence: These results strongly suggest that carteolol improves haloperidol - induced catalepsy via its beta - adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic - induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity .
Diseases:"
3253	Penicillamine - induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis .	O O O O O B O O O O B I O	B O O O O O O O O O O O O	['rheumatoid arthritis', 'glomerulonephritis']	2	12	"Sentence: Penicillamine - induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis .
Diseases: rheumatoid arthritis, glomerulonephritis"	"Sentence: Penicillamine - induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis .
Diseases:"
3254	A 67 - year - old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis ( RPGN ) after 5 months of D - penicillamine ( 250 mg / day ) treatment .	O O O O O O O O B I O O O B O B O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O	['rheumatoid arthritis', 'rpgn', 'glomerulonephritis']	3	16	"Sentence: A 67 - year - old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis ( RPGN ) after 5 months of D - penicillamine ( 250 mg / day ) treatment .
Diseases: rheumatoid arthritis, rpgn, glomerulonephritis"	"Sentence: A 67 - year - old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis ( RPGN ) after 5 months of D - penicillamine ( 250 mg / day ) treatment .
Diseases:"
3255	Light microscopy study showed severe glomerulonephritis with crescent formation in 60 % of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole .	O O O O O B O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['glomerulonephritis']	1	5	"Sentence: Light microscopy study showed severe glomerulonephritis with crescent formation in 60 % of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole .
Diseases: glomerulonephritis"	"Sentence: Light microscopy study showed severe glomerulonephritis with crescent formation in 60 % of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole .
Diseases:"
3256	Immunofluorescence revealed scanty granular IgG , IgA and C3 deposits along the capillary walls and mesangium .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Immunofluorescence revealed scanty granular IgG , IgA and C3 deposits along the capillary walls and mesangium .
Diseases: "	"Sentence: Immunofluorescence revealed scanty granular IgG , IgA and C3 deposits along the capillary walls and mesangium .
Diseases:"
3257	The patient was treated with steroid pulse , plasmapheresis , cyclophosphamide and antiplatelet agents .	O O O O O O O O O O O O O O O	O O O O O B O O O O B O O O O	[]	0	0	"Sentence: The patient was treated with steroid pulse , plasmapheresis , cyclophosphamide and antiplatelet agents .
Diseases: "	"Sentence: The patient was treated with steroid pulse , plasmapheresis , cyclophosphamide and antiplatelet agents .
Diseases:"
3258	A complete recovery of renal function was achieved in a few weeks .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: A complete recovery of renal function was achieved in a few weeks .
Diseases: "	"Sentence: A complete recovery of renal function was achieved in a few weeks .
Diseases:"
3259	This new case of RPGN in the course of D - penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O	['rpgn', 'proteinuria']	2	6	"Sentence: This new case of RPGN in the course of D - penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients .
Diseases: rpgn, proteinuria"	"Sentence: This new case of RPGN in the course of D - penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients .
Diseases:"
3260	The prompt discontinuation of D - penicillamine and vigorous treatment measures could allow for a good prognosis as in this case .	O O O O O O O O O O O O O O O O O O O O O O	O O O O B I I O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The prompt discontinuation of D - penicillamine and vigorous treatment measures could allow for a good prognosis as in this case .
Diseases: "	"Sentence: The prompt discontinuation of D - penicillamine and vigorous treatment measures could allow for a good prognosis as in this case .
Diseases:"
3261	Nature , time course and dose dependence of zidovudine - related side effects : results from the Multicenter Canadian Azidothymidine Trial .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O B O O	[]	0	0	"Sentence: Nature , time course and dose dependence of zidovudine - related side effects : results from the Multicenter Canadian Azidothymidine Trial .
Diseases: "	"Sentence: Nature , time course and dose dependence of zidovudine - related side effects : results from the Multicenter Canadian Azidothymidine Trial .
Diseases:"
3262	To characterize the nature , time course and dose dependency of zidovudine - related side effects , we undertook a multicenter , prospective , dose - range finding study .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: To characterize the nature , time course and dose dependency of zidovudine - related side effects , we undertook a multicenter , prospective , dose - range finding study .
Diseases: "	"Sentence: To characterize the nature , time course and dose dependency of zidovudine - related side effects , we undertook a multicenter , prospective , dose - range finding study .
Diseases:"
3263	Our study group consisted of 74 HIV - positive homosexual men belonging to groups II B , III and IV C2 from the Centers for Disease Control ( CDC ) classification of HIV disease .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hiv disease']	1	3	"Sentence: Our study group consisted of 74 HIV - positive homosexual men belonging to groups II B , III and IV C2 from the Centers for Disease Control ( CDC ) classification of HIV disease .
Diseases: hiv disease"	"Sentence: Our study group consisted of 74 HIV - positive homosexual men belonging to groups II B , III and IV C2 from the Centers for Disease Control ( CDC ) classification of HIV disease .
Diseases:"
3264	Following a 3 - week observation period , volunteers were treated with zidovudine 600 mg / day for 18 weeks , 900 mg / day for 9 weeks and 1200 mg / day for 9 weeks , followed by a washout period of 6 weeks after which they were re - started on 1200 mg / day or the highest tolerated dose at 8 - hourly intervals .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Following a 3 - week observation period , volunteers were treated with zidovudine 600 mg / day for 18 weeks , 900 mg / day for 9 weeks and 1200 mg / day for 9 weeks , followed by a washout period of 6 weeks after which they were re - started on 1200 mg / day or the highest tolerated dose at 8 - hourly intervals .
Diseases: "	"Sentence: Following a 3 - week observation period , volunteers were treated with zidovudine 600 mg / day for 18 weeks , 900 mg / day for 9 weeks and 1200 mg / day for 9 weeks , followed by a washout period of 6 weeks after which they were re - started on 1200 mg / day or the highest tolerated dose at 8 - hourly intervals .
Diseases:"
3265	Subjects were randomly assigned to 4 - hourly or 8 - hourly regimens within CDC groups while taking 600 and 1200 mg / day .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Subjects were randomly assigned to 4 - hourly or 8 - hourly regimens within CDC groups while taking 600 and 1200 mg / day .
Diseases: "	"Sentence: Subjects were randomly assigned to 4 - hourly or 8 - hourly regimens within CDC groups while taking 600 and 1200 mg / day .
Diseases:"
3266	Clinical and laboratory evaluations were performed at 3 - week intervals .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: Clinical and laboratory evaluations were performed at 3 - week intervals .
Diseases: "	"Sentence: Clinical and laboratory evaluations were performed at 3 - week intervals .
Diseases:"
3267	Symptomatic adverse effects were present in 96 % of subjects , most commonly nausea ( 64 % ) , fatigue ( 55 % ) and headache ( 49 % ) .	O O O O O O O O O O O O O B O O O O O B O O O O O B O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nausea', 'headache', 'fatigue']	3	7	"Sentence: Symptomatic adverse effects were present in 96 % of subjects , most commonly nausea ( 64 % ) , fatigue ( 55 % ) and headache ( 49 % ) .
Diseases: nausea, headache, fatigue"	"Sentence: Symptomatic adverse effects were present in 96 % of subjects , most commonly nausea ( 64 % ) , fatigue ( 55 % ) and headache ( 49 % ) .
Diseases:"
3268	These were generally self - limited , reappearing briefly at each dose increment .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: These were generally self - limited , reappearing briefly at each dose increment .
Diseases: "	"Sentence: These were generally self - limited , reappearing briefly at each dose increment .
Diseases:"
3269	A decrease in hemoglobin occurred shortly after initiation of therapy .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: A decrease in hemoglobin occurred shortly after initiation of therapy .
Diseases: "	"Sentence: A decrease in hemoglobin occurred shortly after initiation of therapy .
Diseases:"
3270	This was not dose dependent and reversed rapidly upon discontinuation of treatment .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: This was not dose dependent and reversed rapidly upon discontinuation of treatment .
Diseases: "	"Sentence: This was not dose dependent and reversed rapidly upon discontinuation of treatment .
Diseases:"
3271	A red blood cell count decrease , a mean cell volume increase and a granulocyte count decrease developed early in a dose - independent fashion , reverting at least partially during the washout phase .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A red blood cell count decrease , a mean cell volume increase and a granulocyte count decrease developed early in a dose - independent fashion , reverting at least partially during the washout phase .
Diseases: "	"Sentence: A red blood cell count decrease , a mean cell volume increase and a granulocyte count decrease developed early in a dose - independent fashion , reverting at least partially during the washout phase .
Diseases:"
3272	The decrease in reticulocyte count was dose related between 600 and 900 mg / day with no further change when the dose was escalated to 1200 mg / day .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The decrease in reticulocyte count was dose related between 600 and 900 mg / day with no further change when the dose was escalated to 1200 mg / day .
Diseases: "	"Sentence: The decrease in reticulocyte count was dose related between 600 and 900 mg / day with no further change when the dose was escalated to 1200 mg / day .
Diseases:"
3273	Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95 % of 65 specimens at week 18 . ( ABSTRACT TRUNCATED AT 250 WORDS )	O O O O O O O O B O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['megaloblastosis']	1	5	"Sentence: Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95 % of 65 specimens at week 18 . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases: megaloblastosis"	"Sentence: Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95 % of 65 specimens at week 18 . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases:"
3274	Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment .	B I I O O O O O O O O	O O O O O O B O B O O	['bilateral optic neuropathy']	1	5	"Sentence: Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment .
Diseases: bilateral optic neuropathy"	"Sentence: Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment .
Diseases:"
3275	The case of a 40 - year - old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and isoniazid is reported .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B O B O O O	[]	0	0	"Sentence: The case of a 40 - year - old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and isoniazid is reported .
Diseases: "	"Sentence: The case of a 40 - year - old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and isoniazid is reported .
Diseases:"
3276	A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found .	O B I I O O O O O O B O O O	O O O O O O O O O O O O O O	['bilateral retrobulbar neuropathy', 'scotoma']	2	11	"Sentence: A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found .
Diseases: bilateral retrobulbar neuropathy, scotoma"	"Sentence: A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found .
Diseases:"
3277	Ethambutol was stopped and only small improvement of the visual acuity followed .	O O O O O O O O O O O O O	B O O O O O O O O O O O O	[]	0	0	"Sentence: Ethambutol was stopped and only small improvement of the visual acuity followed .
Diseases: "	"Sentence: Ethambutol was stopped and only small improvement of the visual acuity followed .
Diseases:"
3278	Isoniazid was discontinued later , followed by a dramatic improvement in the visual acuity .	O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O	[]	0	0	"Sentence: Isoniazid was discontinued later , followed by a dramatic improvement in the visual acuity .
Diseases: "	"Sentence: Isoniazid was discontinued later , followed by a dramatic improvement in the visual acuity .
Diseases:"
3279	The hazards of optic nerve toxicity due to ethambutol are known .	O O O O O B O O O O O O	O O O O O O O O B O O O	['toxicity']	1	2	"Sentence: The hazards of optic nerve toxicity due to ethambutol are known .
Diseases: toxicity"	"Sentence: The hazards of optic nerve toxicity due to ethambutol are known .
Diseases:"
3280	We emphasize the potential danger in the use of ethambutol and isoniazid .	O O O O O O O O O O O O O	O O O O O O O O O B O B O	[]	0	0	"Sentence: We emphasize the potential danger in the use of ethambutol and isoniazid .
Diseases: "	"Sentence: We emphasize the potential danger in the use of ethambutol and isoniazid .
Diseases:"
3281	Progestational agents and blood coagulation .	O O O B I O	B O O O O O	['blood coagulation']	1	4	"Sentence: Progestational agents and blood coagulation .
Diseases: blood coagulation"	"Sentence: Progestational agents and blood coagulation .
Diseases:"
3282	VII .	O O	O O	[]	0	0	"Sentence: VII .
Diseases: "	"Sentence: VII .
Diseases:"
3283	Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors : summary report of a ten - year study .	B O O O O O O O O O O O O O B I O O O O O O O O O O O	O O O O O B I O O O O O O O O O O O O O O O O O O O O	['thromboembolic', 'blood coagulation']	2	10	"Sentence: Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors : summary report of a ten - year study .
Diseases: thromboembolic, blood coagulation"	"Sentence: Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors : summary report of a ten - year study .
Diseases:"
3284	During a ten - year period , 348 women were studied for a total of 5 , 877 patient months in four separate studies relating oral contraceptives to changes in hematologic parameters .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O	[]	0	0	"Sentence: During a ten - year period , 348 women were studied for a total of 5 , 877 patient months in four separate studies relating oral contraceptives to changes in hematologic parameters .
Diseases: "	"Sentence: During a ten - year period , 348 women were studied for a total of 5 , 877 patient months in four separate studies relating oral contraceptives to changes in hematologic parameters .
Diseases:"
3285	Significant increases in certain factors of the blood coagulation and fibrinolysin systems ( factors I , II , VII , VIII , IX , and X and plasminogen ) were observed in the treated groups .	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['blood coagulation']	1	4	"Sentence: Significant increases in certain factors of the blood coagulation and fibrinolysin systems ( factors I , II , VII , VIII , IX , and X and plasminogen ) were observed in the treated groups .
Diseases: blood coagulation"	"Sentence: Significant increases in certain factors of the blood coagulation and fibrinolysin systems ( factors I , II , VII , VIII , IX , and X and plasminogen ) were observed in the treated groups .
Diseases:"
3286	Severe complications developed in four patients .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: Severe complications developed in four patients .
Diseases: "	"Sentence: Severe complications developed in four patients .
Diseases:"
3287	"All four had an abnormal blood coagulation profile , suggesting "" hypercoagulability "" before initiation of therapy ."	O O O O O B I O O O O B O O O O O O	O O O O O O O O O O O O O O O O O O	['blood coagulation', 'hypercoagulability']	2	10	"Sentence: All four had an abnormal blood coagulation profile , suggesting "" hypercoagulability "" before initiation of therapy .
Diseases: blood coagulation, hypercoagulability"	"Sentence: All four had an abnormal blood coagulation profile , suggesting "" hypercoagulability "" before initiation of therapy .
Diseases:"
3288	Some of these findings represented the most extreme abnormalities seen in the entire group of patients ; some increased further during therapy .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Some of these findings represented the most extreme abnormalities seen in the entire group of patients ; some increased further during therapy .
Diseases: "	"Sentence: Some of these findings represented the most extreme abnormalities seen in the entire group of patients ; some increased further during therapy .
Diseases:"
3289	One of these patients developed a myocardial infarction before receiving any medication , shortly after the base - line values were obtained .	O O O O O O B I O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['myocardial infarction']	1	6	"Sentence: One of these patients developed a myocardial infarction before receiving any medication , shortly after the base - line values were obtained .
Diseases: myocardial infarction"	"Sentence: One of these patients developed a myocardial infarction before receiving any medication , shortly after the base - line values were obtained .
Diseases:"
3290	One patient developed retinopathy 19 months after she began therapy , and another developed thrombophlebitis after 27 months of therapy .	O O O B O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O O O O O O O O O	['retinopathy', 'thrombophlebitis']	2	11	"Sentence: One patient developed retinopathy 19 months after she began therapy , and another developed thrombophlebitis after 27 months of therapy .
Diseases: retinopathy, thrombophlebitis"	"Sentence: One patient developed retinopathy 19 months after she began therapy , and another developed thrombophlebitis after 27 months of therapy .
Diseases:"
3291	The fourth patient developed thrombophlebitis 14 days after initiation of contraceptive therapy .	O O O O B O O O O O O O O	O O O O O O O O O O O O O	['thrombophlebitis']	1	7	"Sentence: The fourth patient developed thrombophlebitis 14 days after initiation of contraceptive therapy .
Diseases: thrombophlebitis"	"Sentence: The fourth patient developed thrombophlebitis 14 days after initiation of contraceptive therapy .
Diseases:"
3292	All four patients were of the A or AB blood group .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: All four patients were of the A or AB blood group .
Diseases: "	"Sentence: All four patients were of the A or AB blood group .
Diseases:"
3293	Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen .	O O O O O O O O O B I O O O O O O O	O O O O O O O O O O O O O O O O O O	['thromboembolic episodes']	1	6	"Sentence: Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen .
Diseases: thromboembolic episodes"	"Sentence: Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen .
Diseases:"
3294	It appears from these data that hematologic work - ups may be useful in women who are about to start long - term oral contraceptive therapy .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B I O O	[]	0	0	"Sentence: It appears from these data that hematologic work - ups may be useful in women who are about to start long - term oral contraceptive therapy .
Diseases: "	"Sentence: It appears from these data that hematologic work - ups may be useful in women who are about to start long - term oral contraceptive therapy .
Diseases:"
3295	Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine .	B I O O O O B I O O O O O O O O O	O O O O O O O O O B O O O O O B O	['cardiac arrest', 'cerebral palsy']	2	7	"Sentence: Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine .
Diseases: cardiac arrest, cerebral palsy"	"Sentence: Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine .
Diseases:"
3296	Clonidine is a frequently administered alpha2 - adrenergic agonist which can decrease heart rate and blood pressure .	O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Clonidine is a frequently administered alpha2 - adrenergic agonist which can decrease heart rate and blood pressure .
Diseases: "	"Sentence: Clonidine is a frequently administered alpha2 - adrenergic agonist which can decrease heart rate and blood pressure .
Diseases:"
3297	We present a case of a 5 - year - old child with cerebral palsy and seizure disorder , receiving clonidine for restlessness , who presented for placement of a baclofen pump .	O O O O O O O O O O O O O B I O B I O O O O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O B O O	['restlessness', 'cerebral palsy', 'seizure disorder']	3	9	"Sentence: We present a case of a 5 - year - old child with cerebral palsy and seizure disorder , receiving clonidine for restlessness , who presented for placement of a baclofen pump .
Diseases: restlessness, cerebral palsy, seizure disorder"	"Sentence: We present a case of a 5 - year - old child with cerebral palsy and seizure disorder , receiving clonidine for restlessness , who presented for placement of a baclofen pump .
Diseases:"
3298	Without the knowledge of the medical personnel , the patient 's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	['anxiety']	1	2	"Sentence: Without the knowledge of the medical personnel , the patient 's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety .
Diseases: anxiety"	"Sentence: Without the knowledge of the medical personnel , the patient 's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety .
Diseases:"
3299	During induction of anesthesia , the patient developed bradycardia and hypotension requiring cardiac resuscitation .	O O O O O O O O B O B O O O O	O O O O O O O O O O O O O O O	['bradycardia', 'hypotension']	2	7	"Sentence: During induction of anesthesia , the patient developed bradycardia and hypotension requiring cardiac resuscitation .
Diseases: bradycardia, hypotension"	"Sentence: During induction of anesthesia , the patient developed bradycardia and hypotension requiring cardiac resuscitation .
Diseases:"
3300	There are no previous reports of clonidine - associated cardiac arrest in a child undergoing induction of anesthesia .	O O O O O O O O O B I O O O O O O O O	O O O O O O B O O O O O O O O O O O O	['cardiac arrest']	1	3	"Sentence: There are no previous reports of clonidine - associated cardiac arrest in a child undergoing induction of anesthesia .
Diseases: cardiac arrest"	"Sentence: There are no previous reports of clonidine - associated cardiac arrest in a child undergoing induction of anesthesia .
Diseases:"
3301	Effects of UMB24 and ( + / - ) - SM 21 , putative sigma2 - preferring antagonists , on behavioral toxic and stimulant effects of cocaine in mice .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O B I O O O O O O O O O O O O O O B O O O	[]	0	0	"Sentence: Effects of UMB24 and ( + / - ) - SM 21 , putative sigma2 - preferring antagonists , on behavioral toxic and stimulant effects of cocaine in mice .
Diseases: "	"Sentence: Effects of UMB24 and ( + / - ) - SM 21 , putative sigma2 - preferring antagonists , on behavioral toxic and stimulant effects of cocaine in mice .
Diseases:"
3302	Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive , lethal , locomotor stimulatory and rewarding actions of cocaine in mice .	O O O O O O O O O O O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B O O O	['convulsive']	1	2	"Sentence: Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive , lethal , locomotor stimulatory and rewarding actions of cocaine in mice .
Diseases: convulsive"	"Sentence: Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive , lethal , locomotor stimulatory and rewarding actions of cocaine in mice .
Diseases:"
3303	In contrast , the contribution of sigma2 receptors is unclear because experimental tools to selectively target this subtype are unavailable .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast , the contribution of sigma2 receptors is unclear because experimental tools to selectively target this subtype are unavailable .
Diseases: "	"Sentence: In contrast , the contribution of sigma2 receptors is unclear because experimental tools to selectively target this subtype are unavailable .
Diseases:"
3304	To begin addressing this need , we characterized UMB24 ( 1 - ( 2 - phenethyl ) - 4 - ( 2 - pyridyl ) - piperazine ) and ( + / - ) - SM 21 ( 3alpha - tropanyl - 2 - ( 4 - chorophenoxy ) butyrate ) in receptor binding and behavioral studies .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O B I I I I I I I I I I I I I I I I O O O O O O O O B I O B I I I I I I I I I I I O O O O O O O O	[]	0	0	"Sentence: To begin addressing this need , we characterized UMB24 ( 1 - ( 2 - phenethyl ) - 4 - ( 2 - pyridyl ) - piperazine ) and ( + / - ) - SM 21 ( 3alpha - tropanyl - 2 - ( 4 - chorophenoxy ) butyrate ) in receptor binding and behavioral studies .
Diseases: "	"Sentence: To begin addressing this need , we characterized UMB24 ( 1 - ( 2 - phenethyl ) - 4 - ( 2 - pyridyl ) - piperazine ) and ( + / - ) - SM 21 ( 3alpha - tropanyl - 2 - ( 4 - chorophenoxy ) butyrate ) in receptor binding and behavioral studies .
Diseases:"
3305	Receptor binding studies confirmed that UMB24 and ( + / - ) - SM 21 display preferential affinity for sigma2 over sigma1 receptors .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O B I O O O O O O O O O	[]	0	0	"Sentence: Receptor binding studies confirmed that UMB24 and ( + / - ) - SM 21 display preferential affinity for sigma2 over sigma1 receptors .
Diseases: "	"Sentence: Receptor binding studies confirmed that UMB24 and ( + / - ) - SM 21 display preferential affinity for sigma2 over sigma1 receptors .
Diseases:"
3306	In behavioral studies , pretreatment of Swiss Webster mice with UMB24 or ( + / - ) - SM 21 significantly attenuated cocaine - induced convulsions and locomotor activity , but not lethality .	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	O O O O O O O O O O B O O O O O O O B I O O B O O O O O O O O O O O	['convulsions']	1	3	"Sentence: In behavioral studies , pretreatment of Swiss Webster mice with UMB24 or ( + / - ) - SM 21 significantly attenuated cocaine - induced convulsions and locomotor activity , but not lethality .
Diseases: convulsions"	"Sentence: In behavioral studies , pretreatment of Swiss Webster mice with UMB24 or ( + / - ) - SM 21 significantly attenuated cocaine - induced convulsions and locomotor activity , but not lethality .
Diseases:"
3307	When administered alone , ( + / - ) - SM 21 produced no significant effects compared to control injections of saline , but UMB24 had locomotor depressant actions .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B I O O O O O O O O O O O O B O O O O O	[]	0	0	"Sentence: When administered alone , ( + / - ) - SM 21 produced no significant effects compared to control injections of saline , but UMB24 had locomotor depressant actions .
Diseases: "	"Sentence: When administered alone , ( + / - ) - SM 21 produced no significant effects compared to control injections of saline , but UMB24 had locomotor depressant actions .
Diseases:"
3308	Together , the data suggest that sigma2 receptor antagonists have the potential to attenuate some of the behavioral effects of cocaine , and further development of more selective , high affinity ligands are warranted .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: Together , the data suggest that sigma2 receptor antagonists have the potential to attenuate some of the behavioral effects of cocaine , and further development of more selective , high affinity ligands are warranted .
Diseases: "	"Sentence: Together , the data suggest that sigma2 receptor antagonists have the potential to attenuate some of the behavioral effects of cocaine , and further development of more selective , high affinity ligands are warranted .
Diseases:"
3309	Methimazole - induced cholestatic jaundice .	O O O B I O	B O O O O O	['cholestatic jaundice']	1	7	"Sentence: Methimazole - induced cholestatic jaundice .
Diseases: cholestatic jaundice"	"Sentence: Methimazole - induced cholestatic jaundice .
Diseases:"
3310	Methimazole is a widely used and generally well - tolerated antithyroid agent .	O O O O O O O O O O O O O	B O O O O O O O O O O O O	[]	0	0	"Sentence: Methimazole is a widely used and generally well - tolerated antithyroid agent .
Diseases: "	"Sentence: Methimazole is a widely used and generally well - tolerated antithyroid agent .
Diseases:"
3311	A 43 - year - old woman had severe jaundice and itching 1 month after receiving methimazole ( 10 mg tid ) and propranolol ( 20 mg tid ) for treatment of hyperthyroidism .	O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O B O O O O O O B O O O O O O O O O O	['jaundice', 'itching', 'hyperthyroidism']	3	10	"Sentence: A 43 - year - old woman had severe jaundice and itching 1 month after receiving methimazole ( 10 mg tid ) and propranolol ( 20 mg tid ) for treatment of hyperthyroidism .
Diseases: jaundice, itching, hyperthyroidism"	"Sentence: A 43 - year - old woman had severe jaundice and itching 1 month after receiving methimazole ( 10 mg tid ) and propranolol ( 20 mg tid ) for treatment of hyperthyroidism .
Diseases:"
3312	The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications .	O O O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O O O O O O O	['jaundice']	1	3	"Sentence: The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications .
Diseases: jaundice"	"Sentence: The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications .
Diseases:"
3313	When seen at the emergency department 2 weeks later , she still had severe icterus , pruritus , and hyperbilirubinemia , formed mainly of the conjugated fraction .	O O O O O O O O O O O O O O B O B O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pruritus', 'icterus', 'hyperbilirubinemia']	3	14	"Sentence: When seen at the emergency department 2 weeks later , she still had severe icterus , pruritus , and hyperbilirubinemia , formed mainly of the conjugated fraction .
Diseases: pruritus, icterus, hyperbilirubinemia"	"Sentence: When seen at the emergency department 2 weeks later , she still had severe icterus , pruritus , and hyperbilirubinemia , formed mainly of the conjugated fraction .
Diseases:"
3314	Methimazole - induced cholestasis was diagnosed , and propranolol therapy was resumed .	O O O B O O O O O O O O O	B O O O O O O O B O O O O	['cholestasis']	1	4	"Sentence: Methimazole - induced cholestasis was diagnosed , and propranolol therapy was resumed .
Diseases: cholestasis"	"Sentence: Methimazole - induced cholestasis was diagnosed , and propranolol therapy was resumed .
Diseases:"
3315	Over the following 9 days , the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O B O	[]	0	0	"Sentence: Over the following 9 days , the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole .
Diseases: "	"Sentence: Over the following 9 days , the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole .
Diseases:"
3316	In rare cases within the first few weeks of therapy , this drug can cause severe and reversible cholestatic jaundice .	O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O	['cholestatic jaundice']	1	7	"Sentence: In rare cases within the first few weeks of therapy , this drug can cause severe and reversible cholestatic jaundice .
Diseases: cholestatic jaundice"	"Sentence: In rare cases within the first few weeks of therapy , this drug can cause severe and reversible cholestatic jaundice .
Diseases:"
3317	Physicians and patients should be aware of this adverse effect so that , upon occurrence , they can discontinue methimazole therapy and avoid unnecessary invasive procedures .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: Physicians and patients should be aware of this adverse effect so that , upon occurrence , they can discontinue methimazole therapy and avoid unnecessary invasive procedures .
Diseases: "	"Sentence: Physicians and patients should be aware of this adverse effect so that , upon occurrence , they can discontinue methimazole therapy and avoid unnecessary invasive procedures .
Diseases:"
3318	Ciprofloxacin - induced acute interstitial nephritis and autoimmune hemolytic anemia .	O O O O B I O B I I O	B O O O O O O O O O O	['autoimmune hemolytic anemia', 'interstitial nephritis']	2	13	"Sentence: Ciprofloxacin - induced acute interstitial nephritis and autoimmune hemolytic anemia .
Diseases: autoimmune hemolytic anemia, interstitial nephritis"	"Sentence: Ciprofloxacin - induced acute interstitial nephritis and autoimmune hemolytic anemia .
Diseases:"
3319	Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia .	O O O O O O O O O B I O B I O	B O O O O O O O O O O O O O O	['interstitial nephritis', 'hemolytic anemia']	2	10	"Sentence: Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia .
Diseases: interstitial nephritis, hemolytic anemia"	"Sentence: Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia .
Diseases:"
3320	The combination of both side effects is extremely rare .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: The combination of both side effects is extremely rare .
Diseases: "	"Sentence: The combination of both side effects is extremely rare .
Diseases:"
3321	In this report , we describe a case of ciprofloxacin - induced interstitial nephritis and autoimmune hemolytic anemia .	O O O O O O O O O O O O B I O B I I O	O O O O O O O O O B O O O O O O O O O	['autoimmune hemolytic anemia', 'interstitial nephritis']	2	13	"Sentence: In this report , we describe a case of ciprofloxacin - induced interstitial nephritis and autoimmune hemolytic anemia .
Diseases: autoimmune hemolytic anemia, interstitial nephritis"	"Sentence: In this report , we describe a case of ciprofloxacin - induced interstitial nephritis and autoimmune hemolytic anemia .
Diseases:"
3322	Hemolytic anemia improved after stopping the drug and initiation of steroid therapy .	B I O O O O O O O O O O O	O O O O O O O O O O B O O	['hemolytic anemia']	1	5	"Sentence: Hemolytic anemia improved after stopping the drug and initiation of steroid therapy .
Diseases: hemolytic anemia"	"Sentence: Hemolytic anemia improved after stopping the drug and initiation of steroid therapy .
Diseases:"
3323	Unfortunately , acute interstitial nephritis was irreversible and the patient developed end - stage renal disease .	O O O B I O O O O O O B I I I I O	O O O O O O O O O O O O O O O O O	['end - stage renal disease', 'interstitial nephritis']	2	11	"Sentence: Unfortunately , acute interstitial nephritis was irreversible and the patient developed end - stage renal disease .
Diseases: end - stage renal disease, interstitial nephritis"	"Sentence: Unfortunately , acute interstitial nephritis was irreversible and the patient developed end - stage renal disease .
Diseases:"
3324	Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone .	O O O O O O B I I I I I I O	O O B I O O O O O O O O O O	['syndrome of inappropriate secretion of antidiuretic hormone']	1	12	"Sentence: Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone .
Diseases: syndrome of inappropriate secretion of antidiuretic hormone"	"Sentence: Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone .
Diseases:"
3325	We report the case of a 62 - year - old man who was administered sodium valproate ( VPA ) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) .	O O O O O O O O O O O O O O O O O O O O O O O O O B I I I I I I O B O O	O O O O O O O O O O O O O O O B I O B O O O O O O O O O O O O O O O O O	['syndrome of inappropriate secretion of antidiuretic hormone', 'siadh']	2	15	"Sentence: We report the case of a 62 - year - old man who was administered sodium valproate ( VPA ) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) .
Diseases: syndrome of inappropriate secretion of antidiuretic hormone, siadh"	"Sentence: We report the case of a 62 - year - old man who was administered sodium valproate ( VPA ) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) .
Diseases:"
3326	He had been taking VPA for treatment of idiopathic generalized tonic - clonic convulsions since he was 56 years old .	O O O O O O O O O O B I I I O O O O O O O	O O O O B O O O O O O O O O O O O O O O O	['tonic - clonic convulsions']	1	8	"Sentence: He had been taking VPA for treatment of idiopathic generalized tonic - clonic convulsions since he was 56 years old .
Diseases: tonic - clonic convulsions"	"Sentence: He had been taking VPA for treatment of idiopathic generalized tonic - clonic convulsions since he was 56 years old .
Diseases:"
3327	After substituting VPA with zonisamide , the serum sodium level returned to normal .	O O O O O O O O O O O O O O	O O B O B O O O B O O O O O	[]	0	0	"Sentence: After substituting VPA with zonisamide , the serum sodium level returned to normal .
Diseases: "	"Sentence: After substituting VPA with zonisamide , the serum sodium level returned to normal .
Diseases:"
3328	We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long - term administration of VPA .	O O O O O B O O O O O O O O O O O B I I I I I O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['weakness of the central nervous system', 'siadh']	2	10	"Sentence: We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long - term administration of VPA .
Diseases: weakness of the central nervous system, siadh"	"Sentence: We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long - term administration of VPA .
Diseases:"
3329	Vasopressin in the treatment of milrinone - induced hypotension in severe heart failure .	O O O O O O O O B O O B I O	B O O O O B O O O O O O O O	['heart failure', 'hypotension']	2	5	"Sentence: Vasopressin in the treatment of milrinone - induced hypotension in severe heart failure .
Diseases: heart failure, hypotension"	"Sentence: Vasopressin in the treatment of milrinone - induced hypotension in severe heart failure .
Diseases:"
3330	The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension .	O O O O O O O O O O O O O B I O O O O O O O O B O	O O O O O O O B O O O O O O O O O O O O O O O O O	['heart failure', 'hypotension']	2	5	"Sentence: The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension .
Diseases: heart failure, hypotension"	"Sentence: The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension .
Diseases:"
3331	In patients with decompensated heart failure with hypotension after treatment with milrinone , low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone .	O O O O B I O B O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O B O O O O O O O O O B O	['heart failure', 'hypotension']	2	5	"Sentence: In patients with decompensated heart failure with hypotension after treatment with milrinone , low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone .
Diseases: heart failure, hypotension"	"Sentence: In patients with decompensated heart failure with hypotension after treatment with milrinone , low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone .
Diseases:"
3332	Halogenated anesthetics form liver adducts and antigens that cross - react with halothane - induced antibodies .	O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: Halogenated anesthetics form liver adducts and antigens that cross - react with halothane - induced antibodies .
Diseases: "	"Sentence: Halogenated anesthetics form liver adducts and antigens that cross - react with halothane - induced antibodies .
Diseases:"
3333	Two halogenated anesthetics , enflurane and isoflurane , have been associated with an allergic - type hepatic injury both alone and following previous exposure to halothane .	O O O O O O O O O O O O O O O O B I O O O O O O O O O	O O O O B O B O O O O O O O O O O O O O O O O O O B O	['hepatic injury']	1	4	"Sentence: Two halogenated anesthetics , enflurane and isoflurane , have been associated with an allergic - type hepatic injury both alone and following previous exposure to halothane .
Diseases: hepatic injury"	"Sentence: Two halogenated anesthetics , enflurane and isoflurane , have been associated with an allergic - type hepatic injury both alone and following previous exposure to halothane .
Diseases:"
3334	Halothane hepatitis appears to involve an aberrant immune response .	O B O O O O O O O O	B O O O O O O O O O	['hepatitis']	1	3	"Sentence: Halothane hepatitis appears to involve an aberrant immune response .
Diseases: hepatitis"	"Sentence: Halothane hepatitis appears to involve an aberrant immune response .
Diseases:"
3335	An antibody response to a protein - bound biotransformation product ( trifluoroacetyl adduct ) has been detected on halothane hepatitis patients .	O O O O O O O O O O O O O O O O O O O B O O	O O O O O O O O O O O B I O O O O O B O O O	['hepatitis']	1	3	"Sentence: An antibody response to a protein - bound biotransformation product ( trifluoroacetyl adduct ) has been detected on halothane hepatitis patients .
Diseases: hepatitis"	"Sentence: An antibody response to a protein - bound biotransformation product ( trifluoroacetyl adduct ) has been detected on halothane hepatitis patients .
Diseases:"
3336	This study was performed to determine cross - reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane .	O O O O O O O O O O O O O O O B O O O O	O O O O O O O O O O B O B O O O O O B O	['hypersensitivity']	1	3	"Sentence: This study was performed to determine cross - reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane .
Diseases: hypersensitivity"	"Sentence: This study was performed to determine cross - reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane .
Diseases:"
3337	The subcellular and lobular production of hepatic neoantigens recognized by halothane - induced antibodies following enflurane and isoflurane , and the biochemical nature of these neoantigens was investigated in two animal models .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O B O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The subcellular and lobular production of hepatic neoantigens recognized by halothane - induced antibodies following enflurane and isoflurane , and the biochemical nature of these neoantigens was investigated in two animal models .
Diseases: "	"Sentence: The subcellular and lobular production of hepatic neoantigens recognized by halothane - induced antibodies following enflurane and isoflurane , and the biochemical nature of these neoantigens was investigated in two animal models .
Diseases:"
3338	Enflurane administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver .	O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Enflurane administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver .
Diseases: "	"Sentence: Enflurane administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver .
Diseases:"
3339	In the same liver , biochemical analysis detected fluorinated liver adducts that were up to 20 - fold greater in guinea pigs than in rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the same liver , biochemical analysis detected fluorinated liver adducts that were up to 20 - fold greater in guinea pigs than in rats .
Diseases: "	"Sentence: In the same liver , biochemical analysis detected fluorinated liver adducts that were up to 20 - fold greater in guinea pigs than in rats .
Diseases:"
3340	This supports and extends previous evidence for a mechanism by which enflurane and / or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration .	O O O O O O O O O O O O O O O O O O O B O O O O O O B O O O O O O O O	O O O O O O O O O O O B O O O B O O O O O O O O O B O O O O O O B O O	['hypersensitivity', 'hepatitis']	2	5	"Sentence: This supports and extends previous evidence for a mechanism by which enflurane and / or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration .
Diseases: hypersensitivity, hepatitis"	"Sentence: This supports and extends previous evidence for a mechanism by which enflurane and / or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration .
Diseases:"
3341	The guinea pig would appear to be a useful model for further investigations of the immunological response to these antigens .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The guinea pig would appear to be a useful model for further investigations of the immunological response to these antigens .
Diseases: "	"Sentence: The guinea pig would appear to be a useful model for further investigations of the immunological response to these antigens .
Diseases:"
3342	Induction by paracetamol of bladder and liver tumours in the rat .	O O O O B I I I O O O O	O O B O O O O O O O O O	['bladder and liver tumours']	1	6	"Sentence: Induction by paracetamol of bladder and liver tumours in the rat .
Diseases: bladder and liver tumours"	"Sentence: Induction by paracetamol of bladder and liver tumours in the rat .
Diseases:"
3343	Effects on hepatocyte fine structure .	O O O O O O	O O O O O O	[]	0	0	"Sentence: Effects on hepatocyte fine structure .
Diseases: "	"Sentence: Effects on hepatocyte fine structure .
Diseases:"
3344	Groups of male and female inbred Leeds strain rats were fed diets containing either 0 . 5 % or 1 . 0 % paracetamol by weight for up to 18 months .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: Groups of male and female inbred Leeds strain rats were fed diets containing either 0 . 5 % or 1 . 0 % paracetamol by weight for up to 18 months .
Diseases: "	"Sentence: Groups of male and female inbred Leeds strain rats were fed diets containing either 0 . 5 % or 1 . 0 % paracetamol by weight for up to 18 months .
Diseases:"
3345	At the 1 . 0 % dosage level , 20 % of rats of both sexes developed neoplastic nodules of the liver , a statistically significant incidence .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At the 1 . 0 % dosage level , 20 % of rats of both sexes developed neoplastic nodules of the liver , a statistically significant incidence .
Diseases: "	"Sentence: At the 1 . 0 % dosage level , 20 % of rats of both sexes developed neoplastic nodules of the liver , a statistically significant incidence .
Diseases:"
3346	These rats also showed gross enlargement of their livers and an increase in foci of cellular alteration , the latter also being observed in the low dosage male rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These rats also showed gross enlargement of their livers and an increase in foci of cellular alteration , the latter also being observed in the low dosage male rats .
Diseases: "	"Sentence: These rats also showed gross enlargement of their livers and an increase in foci of cellular alteration , the latter also being observed in the low dosage male rats .
Diseases:"
3347	Papillomas of the transitional epithelium of the bladder developed in all paracetamol - treated groups , and three rats bore bladder carcinomas .	B O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O B O O O O O O O O O O O	['bladder carcinomas', 'papillomas']	2	8	"Sentence: Papillomas of the transitional epithelium of the bladder developed in all paracetamol - treated groups , and three rats bore bladder carcinomas .
Diseases: bladder carcinomas, papillomas"	"Sentence: Papillomas of the transitional epithelium of the bladder developed in all paracetamol - treated groups , and three rats bore bladder carcinomas .
Diseases:"
3348	However , significant yields of bladder tumours were only obtained from low dosage females and high dosage males .	O O O O O B I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	['bladder tumours']	1	4	"Sentence: However , significant yields of bladder tumours were only obtained from low dosage females and high dosage males .
Diseases: bladder tumours"	"Sentence: However , significant yields of bladder tumours were only obtained from low dosage females and high dosage males .
Diseases:"
3349	Additionally , 20 to 25 % of paracetamol - treated rats developed hyperplasia of the bladder epithelium , which was not coincident with the presence of bladder calculi .	O O O O O O O O O O O O B O O O O O O O O O O O O O B I O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	['hyperplasia', 'bladder calculi']	2	7	"Sentence: Additionally , 20 to 25 % of paracetamol - treated rats developed hyperplasia of the bladder epithelium , which was not coincident with the presence of bladder calculi .
Diseases: hyperplasia, bladder calculi"	"Sentence: Additionally , 20 to 25 % of paracetamol - treated rats developed hyperplasia of the bladder epithelium , which was not coincident with the presence of bladder calculi .
Diseases:"
3350	A low yield of tumours at various other sites also arose following paracetamol feeding .	O O O O B O O O O O O O O O O	O O O O O O O O O O O O B O O	['tumours']	1	3	"Sentence: A low yield of tumours at various other sites also arose following paracetamol feeding .
Diseases: tumours"	"Sentence: A low yield of tumours at various other sites also arose following paracetamol feeding .
Diseases:"
3351	An electron microscope study of the livers of paracetamol - treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known hepatocarcinogens .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['hepatocarcinogens']	1	6	"Sentence: An electron microscope study of the livers of paracetamol - treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known hepatocarcinogens .
Diseases: hepatocarcinogens"	"Sentence: An electron microscope study of the livers of paracetamol - treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known hepatocarcinogens .
Diseases:"
3352	Rat extraocular muscle regeneration .	O O O O O	O O O O O	[]	0	0	"Sentence: Rat extraocular muscle regeneration .
Diseases: "	"Sentence: Rat extraocular muscle regeneration .
Diseases:"
3353	Repair of local anesthetic - induced damage .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: Repair of local anesthetic - induced damage .
Diseases: "	"Sentence: Repair of local anesthetic - induced damage .
Diseases:"
3354	Local anesthetics that are commonly used in ophthalmic surgery ( 0 . 75 % bupivacaine hydrochloride , 2 . 0 % mepivacaine hydrochloride , and 2 . 0 % lidocaine hydrochloride plus 1 : 100 , 000 epinephrine ) were injected into the retrobulbar area of rat eyes .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B I O O O O O B I O O O O O O B I O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: Local anesthetics that are commonly used in ophthalmic surgery ( 0 . 75 % bupivacaine hydrochloride , 2 . 0 % mepivacaine hydrochloride , and 2 . 0 % lidocaine hydrochloride plus 1 : 100 , 000 epinephrine ) were injected into the retrobulbar area of rat eyes .
Diseases: "	"Sentence: Local anesthetics that are commonly used in ophthalmic surgery ( 0 . 75 % bupivacaine hydrochloride , 2 . 0 % mepivacaine hydrochloride , and 2 . 0 % lidocaine hydrochloride plus 1 : 100 , 000 epinephrine ) were injected into the retrobulbar area of rat eyes .
Diseases:"
3355	Controls were injected with physiological saline .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: Controls were injected with physiological saline .
Diseases: "	"Sentence: Controls were injected with physiological saline .
Diseases:"
3356	All three anesthetics produced massive degeneration of the extraocular muscles .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: All three anesthetics produced massive degeneration of the extraocular muscles .
Diseases: "	"Sentence: All three anesthetics produced massive degeneration of the extraocular muscles .
Diseases:"
3357	Muscle degeneration is followed by regeneration of the damaged muscle fibers .	B I O O O O O O O O O O	O O O O O O O O O O O O	['muscle degeneration']	1	4	"Sentence: Muscle degeneration is followed by regeneration of the damaged muscle fibers .
Diseases: muscle degeneration"	"Sentence: Muscle degeneration is followed by regeneration of the damaged muscle fibers .
Diseases:"
3358	In addition to muscle damage , severe damage was also seen in harderian glands , especially after exposure to mepivacaine and lidocaine plus epinephrine .	O O O B I O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O B O B O	['muscle damage']	1	3	"Sentence: In addition to muscle damage , severe damage was also seen in harderian glands , especially after exposure to mepivacaine and lidocaine plus epinephrine .
Diseases: muscle damage"	"Sentence: In addition to muscle damage , severe damage was also seen in harderian glands , especially after exposure to mepivacaine and lidocaine plus epinephrine .
Diseases:"
3359	With these findings in rats , it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic - induced damage to the extraocular muscles .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['diplopia']	1	3	"Sentence: With these findings in rats , it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic - induced damage to the extraocular muscles .
Diseases: diplopia"	"Sentence: With these findings in rats , it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic - induced damage to the extraocular muscles .
Diseases:"
3360	Reversal of neuroleptic - induced catalepsy by novel aryl - piperazine anxiolytic drugs .	O O O O O B O O O O O O O O	O O O O O O O O B I I O O O	['catalepsy']	1	4	"Sentence: Reversal of neuroleptic - induced catalepsy by novel aryl - piperazine anxiolytic drugs .
Diseases: catalepsy"	"Sentence: Reversal of neuroleptic - induced catalepsy by novel aryl - piperazine anxiolytic drugs .
Diseases:"
3361	The novel anxiolytic drug , buspirone , reverses catalepsy induced by haloperidol .	O O O O O O O O B O O O O	O O O O O B O O O O O B O	['catalepsy']	1	4	"Sentence: The novel anxiolytic drug , buspirone , reverses catalepsy induced by haloperidol .
Diseases: catalepsy"	"Sentence: The novel anxiolytic drug , buspirone , reverses catalepsy induced by haloperidol .
Diseases:"
3362	A series of aryl - piperazine analogues of buspirone and other 5 - hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy .	O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O B I I O O B O O B I I O O O O O O O O B O O O	['catalepsy']	1	4	"Sentence: A series of aryl - piperazine analogues of buspirone and other 5 - hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy .
Diseases: catalepsy"	"Sentence: A series of aryl - piperazine analogues of buspirone and other 5 - hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy .
Diseases:"
3363	Those drugs with strong affinity for 5 - hydroxytryptamine1a receptors were able to reverse catalepsy .	O O O O O O O O O O O O O O B O	O O O O O O B I I O O O O O O O	['catalepsy']	1	4	"Sentence: Those drugs with strong affinity for 5 - hydroxytryptamine1a receptors were able to reverse catalepsy .
Diseases: catalepsy"	"Sentence: Those drugs with strong affinity for 5 - hydroxytryptamine1a receptors were able to reverse catalepsy .
Diseases:"
3364	Drugs with affinity for other 5 - HT receptors or weak affinity were ineffective .	O O O O O O O O O O O O O O O	O O O O O B I I O O O O O O O	[]	0	0	"Sentence: Drugs with affinity for other 5 - HT receptors or weak affinity were ineffective .
Diseases: "	"Sentence: Drugs with affinity for other 5 - HT receptors or weak affinity were ineffective .
Diseases:"
3365	However , inhibition of postsynaptic 5 - HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect .	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O	['catalepsy']	1	4	"Sentence: However , inhibition of postsynaptic 5 - HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect .
Diseases: catalepsy"	"Sentence: However , inhibition of postsynaptic 5 - HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect .
Diseases:"
3366	Diazepam facilitates reflex bradycardia in conscious rats .	O O O B O O O O	B O O O O O O O	['bradycardia']	1	4	"Sentence: Diazepam facilitates reflex bradycardia in conscious rats .
Diseases: bradycardia"	"Sentence: Diazepam facilitates reflex bradycardia in conscious rats .
Diseases:"
3367	The effects of diazepam on cardiovascular function were assessed in conscious rats .	O O O O O O O O O O O O O	O O O B O O O O O O O O O	[]	0	0	"Sentence: The effects of diazepam on cardiovascular function were assessed in conscious rats .
Diseases: "	"Sentence: The effects of diazepam on cardiovascular function were assessed in conscious rats .
Diseases:"
3368	Intravenous administration of diazepam ( 1 - 30 mg kg - 1 ) produced a dose - dependent decrease in both the mean arterial pressure and the heart rate .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Intravenous administration of diazepam ( 1 - 30 mg kg - 1 ) produced a dose - dependent decrease in both the mean arterial pressure and the heart rate .
Diseases: "	"Sentence: Intravenous administration of diazepam ( 1 - 30 mg kg - 1 ) produced a dose - dependent decrease in both the mean arterial pressure and the heart rate .
Diseases:"
3369	Also , reflex bradycardia was produced in rats by intravenous infusion of adrenaline ( 1 . 25 - 2 . 5 micrograms kg - 1 ) .	O O O B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O O O	['bradycardia']	1	4	"Sentence: Also , reflex bradycardia was produced in rats by intravenous infusion of adrenaline ( 1 . 25 - 2 . 5 micrograms kg - 1 ) .
Diseases: bradycardia"	"Sentence: Also , reflex bradycardia was produced in rats by intravenous infusion of adrenaline ( 1 . 25 - 2 . 5 micrograms kg - 1 ) .
Diseases:"
3370	Intravenous pretreatment of the rats with diazepam , although causing no change in the adrenaline - induced pressor effect , did enhance the adrenaline - induced reflex bradycardia .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O B O O O O O O O B O O O O O O O O B O O O O O	['bradycardia']	1	4	"Sentence: Intravenous pretreatment of the rats with diazepam , although causing no change in the adrenaline - induced pressor effect , did enhance the adrenaline - induced reflex bradycardia .
Diseases: bradycardia"	"Sentence: Intravenous pretreatment of the rats with diazepam , although causing no change in the adrenaline - induced pressor effect , did enhance the adrenaline - induced reflex bradycardia .
Diseases:"
3371	However , the diazepam enhancement of adrenaline - induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin ( an agent blocks chloride channels by binding to sites associated with the benzodiazepine - GABA - chloride channel macromolecular complex ) .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O B O O O O O O O O O O O O O O O B O O O O O O O O O O O O O B O B O B O O O O O	['bradycardia']	1	4	"Sentence: However , the diazepam enhancement of adrenaline - induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin ( an agent blocks chloride channels by binding to sites associated with the benzodiazepine - GABA - chloride channel macromolecular complex ) .
Diseases: bradycardia"	"Sentence: However , the diazepam enhancement of adrenaline - induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin ( an agent blocks chloride channels by binding to sites associated with the benzodiazepine - GABA - chloride channel macromolecular complex ) .
Diseases:"
3372	The data indicate that diazepam acts through the benzodiazepine - GABA - chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure .	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	O O O O B O O O B O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['bradycardia']	1	4	"Sentence: The data indicate that diazepam acts through the benzodiazepine - GABA - chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure .
Diseases: bradycardia"	"Sentence: The data indicate that diazepam acts through the benzodiazepine - GABA - chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure .
Diseases:"
3373	Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine .	O O O O O O O O B O O O O O O	O B O O O O O O O O O B O B O	['seizures']	1	3	"Sentence: Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine .
Diseases: seizures"	"Sentence: Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine .
Diseases:"
3374	The effects of carbamazepine ( CBZ ) treatment on local anesthetic - kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O B O O	['seizures']	1	3	"Sentence: The effects of carbamazepine ( CBZ ) treatment on local anesthetic - kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration .
Diseases: seizures"	"Sentence: The effects of carbamazepine ( CBZ ) treatment on local anesthetic - kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration .
Diseases:"
3375	Chronic oral CBZ inhibited the development of both lidocaine - and cocaine - induced seizures , but had little effect on the fully developed local anesthetic seizures .	O O O O O O O O O O O O O O B O O O O O O O O O O O B O	O O B O O O O O B O O B O O O O O O O O O O O O O O O O	['seizures']	1	3	"Sentence: Chronic oral CBZ inhibited the development of both lidocaine - and cocaine - induced seizures , but had little effect on the fully developed local anesthetic seizures .
Diseases: seizures"	"Sentence: Chronic oral CBZ inhibited the development of both lidocaine - and cocaine - induced seizures , but had little effect on the fully developed local anesthetic seizures .
Diseases:"
3376	Chronic CBZ also decreased the incidence of seizure - related mortality in the cocaine - injected rats .	O O O O O O O B O O O O O O O O O O	O B O O O O O O O O O O O B O O O O	['seizure']	1	3	"Sentence: Chronic CBZ also decreased the incidence of seizure - related mortality in the cocaine - injected rats .
Diseases: seizure"	"Sentence: Chronic CBZ also decreased the incidence of seizure - related mortality in the cocaine - injected rats .
Diseases:"
3377	Acute CBZ over a range of doses ( 15 - 50 mg / kg ) had no effect on completed lidocaine - kindled or acute cocaine - induced seizures .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O B O O O O O O O O O O O O O O O O O O B O O O O B O O O O	['seizures']	1	3	"Sentence: Acute CBZ over a range of doses ( 15 - 50 mg / kg ) had no effect on completed lidocaine - kindled or acute cocaine - induced seizures .
Diseases: seizures"	"Sentence: Acute CBZ over a range of doses ( 15 - 50 mg / kg ) had no effect on completed lidocaine - kindled or acute cocaine - induced seizures .
Diseases:"
3378	Repeated i . p . injection of CBZ ( 15 mg / kg ) also was without effect on the development of lidocaine - or cocaine - kindled seizures .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O B O O O O O O O O O O O O O O B O O B O O O O	['seizures']	1	3	"Sentence: Repeated i . p . injection of CBZ ( 15 mg / kg ) also was without effect on the development of lidocaine - or cocaine - kindled seizures .
Diseases: seizures"	"Sentence: Repeated i . p . injection of CBZ ( 15 mg / kg ) also was without effect on the development of lidocaine - or cocaine - kindled seizures .
Diseases:"
3379	The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic - kindled seizures .	O O O O O O O O O B O O O O O O O O O O O O O O O B O	O O O O B O O O O O O O O O O O O O O O O O O O O O O	['seizures', 'seizure']	2	5	"Sentence: The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic - kindled seizures .
Diseases: seizures, seizure"	"Sentence: The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic - kindled seizures .
Diseases:"
3380	The effectiveness of chronic but not repeated , intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: The effectiveness of chronic but not repeated , intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens .
Diseases: "	"Sentence: The effectiveness of chronic but not repeated , intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens .
Diseases:"
3381	The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data , but remains to be directly evaluated .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data , but remains to be directly evaluated .
Diseases: "	"Sentence: The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data , but remains to be directly evaluated .
Diseases:"
3382	D - penicillamine in the treatment of localized scleroderma .	O O O O O O O B I O	B I I O O O O O O O	['localized scleroderma']	1	6	"Sentence: D - penicillamine in the treatment of localized scleroderma .
Diseases: localized scleroderma"	"Sentence: D - penicillamine in the treatment of localized scleroderma .
Diseases:"
3383	Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children .	B I O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	['localized scleroderma']	1	6	"Sentence: Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children .
Diseases: localized scleroderma"	"Sentence: Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children .
Diseases:"
3384	There is no accepted or proven treatment for localized scleroderma .	O O O O O O O O B I O	O O O O O O O O O O O	['localized scleroderma']	1	6	"Sentence: There is no accepted or proven treatment for localized scleroderma .
Diseases: localized scleroderma"	"Sentence: There is no accepted or proven treatment for localized scleroderma .
Diseases:"
3385	Case reports of 11 patients with severe , extensive localized scleroderma who were treated with D - penicillamine are summarized in this article .	O O O O O O O O O B I O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B I I O O O O O O	['localized scleroderma']	1	6	"Sentence: Case reports of 11 patients with severe , extensive localized scleroderma who were treated with D - penicillamine are summarized in this article .
Diseases: localized scleroderma"	"Sentence: Case reports of 11 patients with severe , extensive localized scleroderma who were treated with D - penicillamine are summarized in this article .
Diseases:"
3386	This drug was judged to have a favorable effect on the disease course in 7 ( 64 % ) of 11 patients .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This drug was judged to have a favorable effect on the disease course in 7 ( 64 % ) of 11 patients .
Diseases: "	"Sentence: This drug was judged to have a favorable effect on the disease course in 7 ( 64 % ) of 11 patients .
Diseases:"
3387	Improvement began within 3 to 6 months and consisted of cessation of active cutaneous lesions in all 7 patients , skin softening in 5 , and more normal growth of the affected limb in 2 of 3 children .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Improvement began within 3 to 6 months and consisted of cessation of active cutaneous lesions in all 7 patients , skin softening in 5 , and more normal growth of the affected limb in 2 of 3 children .
Diseases: "	"Sentence: Improvement began within 3 to 6 months and consisted of cessation of active cutaneous lesions in all 7 patients , skin softening in 5 , and more normal growth of the affected limb in 2 of 3 children .
Diseases:"
3388	Joint stiffness and contractures also improved .	O O O B O O O	O O O O O O O	['contractures']	1	2	"Sentence: Joint stiffness and contractures also improved .
Diseases: contractures"	"Sentence: Joint stiffness and contractures also improved .
Diseases:"
3389	The dose of D - penicillamine associated with a favorable response was as low as 2 to 5 mg / kg per day given over a period ranging from 15 to 53 months .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The dose of D - penicillamine associated with a favorable response was as low as 2 to 5 mg / kg per day given over a period ranging from 15 to 53 months .
Diseases: "	"Sentence: The dose of D - penicillamine associated with a favorable response was as low as 2 to 5 mg / kg per day given over a period ranging from 15 to 53 months .
Diseases:"
3390	D - Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients ; none developed renal insufficiency .	O O O O B I O O O O O O B O O O O O O O B I O	B I I O O O O O O O O O O O O O O O O O O O O	['renal insufficiency', 'nephrotic syndrome', 'proteinuria']	3	14	"Sentence: D - Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients ; none developed renal insufficiency .
Diseases: renal insufficiency, nephrotic syndrome, proteinuria"	"Sentence: D - Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients ; none developed renal insufficiency .
Diseases:"
3391	These data suggest that D - penicillamine may be effective in severe cases of localized scleroderma .	O O O O O O O O O O O O O O B I O	O O O O B I I O O O O O O O O O O	['localized scleroderma']	1	6	"Sentence: These data suggest that D - penicillamine may be effective in severe cases of localized scleroderma .
Diseases: localized scleroderma"	"Sentence: These data suggest that D - penicillamine may be effective in severe cases of localized scleroderma .
Diseases:"
3392	Preservation of renal blood flow during hypotension induced with fenoldopam in dogs .	O O O O O O B O O O O O O	O O O O O O O O O B O O O	['hypotension']	1	3	"Sentence: Preservation of renal blood flow during hypotension induced with fenoldopam in dogs .
Diseases: hypotension"	"Sentence: Preservation of renal blood flow during hypotension induced with fenoldopam in dogs .
Diseases:"
3393	The introduction of drugs that could induce hypotension with different pharmacological actions would be advantageous because side effects unique to a specific drug could be minimized by selecting appropriate therapy .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: The introduction of drugs that could induce hypotension with different pharmacological actions would be advantageous because side effects unique to a specific drug could be minimized by selecting appropriate therapy .
Diseases: hypotension"	"Sentence: The introduction of drugs that could induce hypotension with different pharmacological actions would be advantageous because side effects unique to a specific drug could be minimized by selecting appropriate therapy .
Diseases:"
3394	Specific dopamine - 1 , ( DA1 ) and dopamine - 2 ( DA2 ) receptor agonists are now under clinical investigation .	O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: Specific dopamine - 1 , ( DA1 ) and dopamine - 2 ( DA2 ) receptor agonists are now under clinical investigation .
Diseases: "	"Sentence: Specific dopamine - 1 , ( DA1 ) and dopamine - 2 ( DA2 ) receptor agonists are now under clinical investigation .
Diseases:"
3395	Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation .	O O O O O O O O O O O O O O O	B I O O O O O O O O O O O O O	[]	0	0	"Sentence: Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation .
Diseases: "	"Sentence: Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation .
Diseases:"
3396	The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested .	O O O O O O O O O B O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested .
Diseases: hypotension"	"Sentence: The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested .
Diseases:"
3397	Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively , in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B I O O O O B O O O	[]	0	0	"Sentence: Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively , in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia .
Diseases: "	"Sentence: Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively , in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia .
Diseases:"
3398	Mean arterial pressure was decreased 30 + / - 8 per cent from control with infusion of fenoldopam ( 3 . 4 + / - 2 . 0 micrograms . kg - 1 . min - 1 ) and 34 + / - 4 per cent with infusion of sodium nitroprusside ( 5 . 9 micrograms . kg - 1 . min - 1 )	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O	[]	0	0	"Sentence: Mean arterial pressure was decreased 30 + / - 8 per cent from control with infusion of fenoldopam ( 3 . 4 + / - 2 . 0 micrograms . kg - 1 . min - 1 ) and 34 + / - 4 per cent with infusion of sodium nitroprusside ( 5 . 9 micrograms . kg - 1 . min - 1 )
Diseases: "	"Sentence: Mean arterial pressure was decreased 30 + / - 8 per cent from control with infusion of fenoldopam ( 3 . 4 + / - 2 . 0 micrograms . kg - 1 . min - 1 ) and 34 + / - 4 per cent with infusion of sodium nitroprusside ( 5 . 9 micrograms . kg - 1 . min - 1 )
Diseases:"
3399	( NS ) .	O O O O	O O O O	[]	0	0	"Sentence: ( NS ) .
Diseases: "	"Sentence: ( NS ) .
Diseases:"
3400	Renal blood flow ( RBF ) increased during fenoldopam - induced hypotension 11 + / - 7 per cent and decreased 21 + / - 8 per cent during sodium nitroprusside - induced hypotension ( P less than 0 . 01 ) .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: Renal blood flow ( RBF ) increased during fenoldopam - induced hypotension 11 + / - 7 per cent and decreased 21 + / - 8 per cent during sodium nitroprusside - induced hypotension ( P less than 0 . 01 ) .
Diseases: hypotension"	"Sentence: Renal blood flow ( RBF ) increased during fenoldopam - induced hypotension 11 + / - 7 per cent and decreased 21 + / - 8 per cent during sodium nitroprusside - induced hypotension ( P less than 0 . 01 ) .
Diseases:"
3401	Sodium nitroprusside is a non - selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension .	O O O O O O O O O O O O O O O O O O O O O O O O B O	B I O O O O O O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: Sodium nitroprusside is a non - selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension .
Diseases: hypotension"	"Sentence: Sodium nitroprusside is a non - selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension .
Diseases:"
3402	Fenoldopam is a selective dopamine - 1 ( DA1 ) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	B O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: Fenoldopam is a selective dopamine - 1 ( DA1 ) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension .
Diseases: hypotension"	"Sentence: Fenoldopam is a selective dopamine - 1 ( DA1 ) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension .
Diseases:"
3403	Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias .	O O O O O O O O O B I O	O O O O O O B O O O O O	['ventricular arrhythmias']	1	6	"Sentence: Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias .
Diseases: ventricular arrhythmias"	"Sentence: Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias .
Diseases:"
3404	Antiarrhythmic effects of ( + ) - cibenzoline and ( - ) - cibenzoline were examined using two canine ventricular arrhythmia models .	O O O O O O O O O O O O O O O O O O O B I O O	O O O O O O O B O O O O O B O O O O O O O O O	['ventricular arrhythmia']	1	6	"Sentence: Antiarrhythmic effects of ( + ) - cibenzoline and ( - ) - cibenzoline were examined using two canine ventricular arrhythmia models .
Diseases: ventricular arrhythmia"	"Sentence: Antiarrhythmic effects of ( + ) - cibenzoline and ( - ) - cibenzoline were examined using two canine ventricular arrhythmia models .
Diseases:"
3405	Digitalis arrhythmia , which is suppressed by Na channel blockers , was induced by intermittent intravenous ( i . v . )	O B O O O O O O O O O O O O O O O O O O O O	B O O O O O O B O O O O O O O O O O O O O O	['arrhythmia']	1	4	"Sentence: Digitalis arrhythmia , which is suppressed by Na channel blockers , was induced by intermittent intravenous ( i . v . )
Diseases: arrhythmia"	"Sentence: Digitalis arrhythmia , which is suppressed by Na channel blockers , was induced by intermittent intravenous ( i . v . )
Diseases:"
3406	injection of ouabain in pentobarbital - anesthetized dogs .	O O O O O O O O O	O O B O B O O O O	[]	0	0	"Sentence: injection of ouabain in pentobarbital - anesthetized dogs .
Diseases: "	"Sentence: injection of ouabain in pentobarbital - anesthetized dogs .
Diseases:"
3407	Adrenaline arrhythmia , which is suppressed by Ca channel blockers , was induced by adrenaline infusion in halothane - anesthetized dogs .	B I O O O O O O O O O O O O O O O O O O O O	B O O O O O O B O O O O O O B O O B O O O O	['adrenaline arrhythmia']	1	7	"Sentence: Adrenaline arrhythmia , which is suppressed by Ca channel blockers , was induced by adrenaline infusion in halothane - anesthetized dogs .
Diseases: adrenaline arrhythmia"	"Sentence: Adrenaline arrhythmia , which is suppressed by Ca channel blockers , was induced by adrenaline infusion in halothane - anesthetized dogs .
Diseases:"
3408	Ten and 5 mg / kg i . v .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Ten and 5 mg / kg i . v .
Diseases: "	"Sentence: Ten and 5 mg / kg i . v .
Diseases:"
3409	( + ) - cibenzoline suppressed digitalis - and adrenaline - induced arrhythmias , respectively .	O O O O O O O O O O O O B O O O	O O O O B O B O O B O O O O O O	['arrhythmias']	1	4	"Sentence: ( + ) - cibenzoline suppressed digitalis - and adrenaline - induced arrhythmias , respectively .
Diseases: arrhythmias"	"Sentence: ( + ) - cibenzoline suppressed digitalis - and adrenaline - induced arrhythmias , respectively .
Diseases:"
3410	The minimum effective plasma concentrations of ( + ) - cibenzoline for digitalis - and adrenaline - induced arrhythmias were 1 . 4 + / - 0 . 4 and 2 . 0 + / - 0 . 6 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O B O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['arrhythmias']	1	4	"Sentence: The minimum effective plasma concentrations of ( + ) - cibenzoline for digitalis - and adrenaline - induced arrhythmias were 1 . 4 + / - 0 . 4 and 2 . 0 + / - 0 . 6 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .
Diseases: arrhythmias"	"Sentence: The minimum effective plasma concentrations of ( + ) - cibenzoline for digitalis - and adrenaline - induced arrhythmias were 1 . 4 + / - 0 . 4 and 2 . 0 + / - 0 . 6 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .
Diseases:"
3411	A lower dose of 1 mg / kg i . v .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: A lower dose of 1 mg / kg i . v .
Diseases: "	"Sentence: A lower dose of 1 mg / kg i . v .
Diseases:"
3412	of ( - ) - cibenzoline suppressed the digitalis - induced arrhythmia , whereas 5 mg / kg i . v . was needed to suppress adrenaline - induced arrhythmias .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O B O	O O O O O B O O B O O O O O O O O O O O O O O O O O B O O O O	['arrhythmias', 'arrhythmia']	2	9	"Sentence: of ( - ) - cibenzoline suppressed the digitalis - induced arrhythmia , whereas 5 mg / kg i . v . was needed to suppress adrenaline - induced arrhythmias .
Diseases: arrhythmias, arrhythmia"	"Sentence: of ( - ) - cibenzoline suppressed the digitalis - induced arrhythmia , whereas 5 mg / kg i . v . was needed to suppress adrenaline - induced arrhythmias .
Diseases:"
3413	The minimum effective plasma concentrations of ( - ) - cibenzoline for digitalis - and adrenaline - induced arrhythmia were 0 . 06 + / - 0 . 04 and 0 . 7 + / - 0 . 1 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O B O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['arrhythmia']	1	4	"Sentence: The minimum effective plasma concentrations of ( - ) - cibenzoline for digitalis - and adrenaline - induced arrhythmia were 0 . 06 + / - 0 . 04 and 0 . 7 + / - 0 . 1 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .
Diseases: arrhythmia"	"Sentence: The minimum effective plasma concentrations of ( - ) - cibenzoline for digitalis - and adrenaline - induced arrhythmia were 0 . 06 + / - 0 . 04 and 0 . 7 + / - 0 . 1 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .
Diseases:"
3414	The stronger antiarrhythmic effect of ( - ) - cibenzoline indicates that ( - ) - isomer may have an effect nearly 5 - 20 times stronger in suppressing Na channels , but effects of both drugs on Ca channels may be almost equipotent .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O I O O O O O O O O O O O O O O O O O O O B O O O O O O O O B O O O O O O	[]	0	0	"Sentence: The stronger antiarrhythmic effect of ( - ) - cibenzoline indicates that ( - ) - isomer may have an effect nearly 5 - 20 times stronger in suppressing Na channels , but effects of both drugs on Ca channels may be almost equipotent .
Diseases: "	"Sentence: The stronger antiarrhythmic effect of ( - ) - cibenzoline indicates that ( - ) - isomer may have an effect nearly 5 - 20 times stronger in suppressing Na channels , but effects of both drugs on Ca channels may be almost equipotent .
Diseases:"
3415	Effect of Hibiscus rosa sinensis on reserpine - induced neurobehavioral and biochemical alterations in rats .	O O O O O O O O O O O O O O O O	O O O I O O B O O O O O O O O O	[]	0	0	"Sentence: Effect of Hibiscus rosa sinensis on reserpine - induced neurobehavioral and biochemical alterations in rats .
Diseases: "	"Sentence: Effect of Hibiscus rosa sinensis on reserpine - induced neurobehavioral and biochemical alterations in rats .
Diseases:"
3416	Effect of methanolic extract of Hibiscus rosa sinensis ( 100 - 300 mg / kg ) was studied on reserpine - induced orofacial dyskinesia and neurochemical alterations .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O I O O O O O O O O O O O O B O O O O O O O O	['dyskinesia']	1	5	"Sentence: Effect of methanolic extract of Hibiscus rosa sinensis ( 100 - 300 mg / kg ) was studied on reserpine - induced orofacial dyskinesia and neurochemical alterations .
Diseases: dyskinesia"	"Sentence: Effect of methanolic extract of Hibiscus rosa sinensis ( 100 - 300 mg / kg ) was studied on reserpine - induced orofacial dyskinesia and neurochemical alterations .
Diseases:"
3417	The rats were treated with intraperitoneal reserpine ( 1 mg / kg , ip ) for 3 days every other day .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The rats were treated with intraperitoneal reserpine ( 1 mg / kg , ip ) for 3 days every other day .
Diseases: "	"Sentence: The rats were treated with intraperitoneal reserpine ( 1 mg / kg , ip ) for 3 days every other day .
Diseases:"
3418	On day 5 , vacuous chewing movements and tongue protrusions were counted for 5 min .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: On day 5 , vacuous chewing movements and tongue protrusions were counted for 5 min .
Diseases: "	"Sentence: On day 5 , vacuous chewing movements and tongue protrusions were counted for 5 min .
Diseases:"
3419	Reserpine treated rats significantly developed vacuous chewing movements and tongue protrusions however , coadministration of Hibiscus rosa sinensis roots extract ( 100 , 200 and 300 mg / kg , per orally ) attenuated the effects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O B I I I I O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Reserpine treated rats significantly developed vacuous chewing movements and tongue protrusions however , coadministration of Hibiscus rosa sinensis roots extract ( 100 , 200 and 300 mg / kg , per orally ) attenuated the effects .
Diseases: "	"Sentence: Reserpine treated rats significantly developed vacuous chewing movements and tongue protrusions however , coadministration of Hibiscus rosa sinensis roots extract ( 100 , 200 and 300 mg / kg , per orally ) attenuated the effects .
Diseases:"
3420	Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase ( SOD ) , catalase ( CAT ) and glutathione reductase ( GSH ) , an index of oxidative stress process .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O B O O O O O O O O O O B O O B O O O O O O O O O	[]	0	0	"Sentence: Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase ( SOD ) , catalase ( CAT ) and glutathione reductase ( GSH ) , an index of oxidative stress process .
Diseases: "	"Sentence: Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase ( SOD ) , catalase ( CAT ) and glutathione reductase ( GSH ) , an index of oxidative stress process .
Diseases:"
3421	Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD , CAT and GSH levels .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD , CAT and GSH levels .
Diseases: "	"Sentence: Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD , CAT and GSH levels .
Diseases:"
3422	The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine - induced orofacial dyskinesia and oxidative stress .	O O O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O O O O O O O O O O O B O O O O O O O O	['dyskinesia']	1	5	"Sentence: The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine - induced orofacial dyskinesia and oxidative stress .
Diseases: dyskinesia"	"Sentence: The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine - induced orofacial dyskinesia and oxidative stress .
Diseases:"
3423	Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24 - hour heart rate response in patients on treatment for glaucoma .	O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O B O O O O O O O O O O O O O O O O O	['glaucoma']	1	4	"Sentence: Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24 - hour heart rate response in patients on treatment for glaucoma .
Diseases: glaucoma"	"Sentence: Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24 - hour heart rate response in patients on treatment for glaucoma .
Diseases:"
3424	Topical beta - blocker treatment is routine therapy in the management of patients with glaucoma .	O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O	['glaucoma']	1	4	"Sentence: Topical beta - blocker treatment is routine therapy in the management of patients with glaucoma .
Diseases: glaucoma"	"Sentence: Topical beta - blocker treatment is routine therapy in the management of patients with glaucoma .
Diseases:"
3425	Therapy results in systemic absorption , however , the degree of reduction of resting and peak heart rate has not been quantified .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Therapy results in systemic absorption , however , the degree of reduction of resting and peak heart rate has not been quantified .
Diseases: "	"Sentence: Therapy results in systemic absorption , however , the degree of reduction of resting and peak heart rate has not been quantified .
Diseases:"
3426	DESIGN : This trial evaluated the effect of placebo , 0 . 5 % aqueous timolol ( timolol solution ) and a 0 . 5 % timolol suspension that forms a gel on application to the conjunctiva ( timolol gellan ) on the 24 - hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	O O O O O O O O O O O O O O O B O B O O O O O O O O B O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['glaucoma']	1	4	"Sentence: DESIGN : This trial evaluated the effect of placebo , 0 . 5 % aqueous timolol ( timolol solution ) and a 0 . 5 % timolol suspension that forms a gel on application to the conjunctiva ( timolol gellan ) on the 24 - hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate .
Diseases: glaucoma"	"Sentence: DESIGN : This trial evaluated the effect of placebo , 0 . 5 % aqueous timolol ( timolol solution ) and a 0 . 5 % timolol suspension that forms a gel on application to the conjunctiva ( timolol gellan ) on the 24 - hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate .
Diseases:"
3427	METHODS : Forty - three Caucasian patients with primary open - angle glaucoma or ocular hypertension with a mean ( + / - SD ) age of 63 ( + / - 8 ) years were randomized and crossed over in a double - masked manner to 14 days of treatment with placebo ( morning and evening in both eyes ) , timolol solution ( morning and evening in both eyes ) , or timolol gellan ( morning in both eyes with placebo in the evening ) .	O O O O O O O O O B I I I O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O B I O O O O O O O O O O O O	['open - angle glaucoma', 'ocular hypertension']	2	11	"Sentence: METHODS : Forty - three Caucasian patients with primary open - angle glaucoma or ocular hypertension with a mean ( + / - SD ) age of 63 ( + / - 8 ) years were randomized and crossed over in a double - masked manner to 14 days of treatment with placebo ( morning and evening in both eyes ) , timolol solution ( morning and evening in both eyes ) , or timolol gellan ( morning in both eyes with placebo in the evening ) .
Diseases: open - angle glaucoma, ocular hypertension"	"Sentence: METHODS : Forty - three Caucasian patients with primary open - angle glaucoma or ocular hypertension with a mean ( + / - SD ) age of 63 ( + / - 8 ) years were randomized and crossed over in a double - masked manner to 14 days of treatment with placebo ( morning and evening in both eyes ) , timolol solution ( morning and evening in both eyes ) , or timolol gellan ( morning in both eyes with placebo in the evening ) .
Diseases:"
3428	On the 13th day of each period , heart rate was recorded continuously during a typical , ambulant 24 - hour period .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: On the 13th day of each period , heart rate was recorded continuously during a typical , ambulant 24 - hour period .
Diseases: "	"Sentence: On the 13th day of each period , heart rate was recorded continuously during a typical , ambulant 24 - hour period .
Diseases:"
3429	RESULTS : Both timolol solution and timolol gellan reduced the mean 24 - hour heart rate compared with placebo ( P < or = . 001 ) , and this reduction was most pronounced during the daytime ( - 7 . 5 % change in mean heart rate , - 5 . 7 beats / min ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: RESULTS : Both timolol solution and timolol gellan reduced the mean 24 - hour heart rate compared with placebo ( P < or = . 001 ) , and this reduction was most pronounced during the daytime ( - 7 . 5 % change in mean heart rate , - 5 . 7 beats / min ) .
Diseases: "	"Sentence: RESULTS : Both timolol solution and timolol gellan reduced the mean 24 - hour heart rate compared with placebo ( P < or = . 001 ) , and this reduction was most pronounced during the daytime ( - 7 . 5 % change in mean heart rate , - 5 . 7 beats / min ) .
Diseases:"
3430	Timolol gellan showed a numerically but not significantly smaller reduction in 24 - hour heart rate , compared with timolol solution .	O O O O O O O O O O O O O O O O O O O O O O	B I O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Timolol gellan showed a numerically but not significantly smaller reduction in 24 - hour heart rate , compared with timolol solution .
Diseases: "	"Sentence: Timolol gellan showed a numerically but not significantly smaller reduction in 24 - hour heart rate , compared with timolol solution .
Diseases:"
3431	During the night , the mean 12 - hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution ; the difference between solution and gellan treatments was statistically significant ( P = . 01 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O B O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: During the night , the mean 12 - hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution ; the difference between solution and gellan treatments was statistically significant ( P = . 01 ) .
Diseases: "	"Sentence: During the night , the mean 12 - hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution ; the difference between solution and gellan treatments was statistically significant ( P = . 01 ) .
Diseases:"
3432	CONCLUSIONS : Both timolol solution and timolol gellan decrease the mean 24 - hour heart rate compared with placebo .	O O O O O O O O O O O O O O O O O O O O	O O O B O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSIONS : Both timolol solution and timolol gellan decrease the mean 24 - hour heart rate compared with placebo .
Diseases: "	"Sentence: CONCLUSIONS : Both timolol solution and timolol gellan decrease the mean 24 - hour heart rate compared with placebo .
Diseases:"
3433	This response was most pronounced during the active daytime period .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: This response was most pronounced during the active daytime period .
Diseases: "	"Sentence: This response was most pronounced during the active daytime period .
Diseases:"
3434	These data quantify the modest bradycardia associated with ophthalmic beta - blocker therapy in a typical patient population on therapy for glaucoma .	O O O O O B O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O	['glaucoma', 'bradycardia']	2	9	"Sentence: These data quantify the modest bradycardia associated with ophthalmic beta - blocker therapy in a typical patient population on therapy for glaucoma .
Diseases: glaucoma, bradycardia"	"Sentence: These data quantify the modest bradycardia associated with ophthalmic beta - blocker therapy in a typical patient population on therapy for glaucoma .
Diseases:"
3435	Although exercise performance was not assessed in this trial , reductions of this magnitude should not have substantial clinical consequences .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Although exercise performance was not assessed in this trial , reductions of this magnitude should not have substantial clinical consequences .
Diseases: "	"Sentence: Although exercise performance was not assessed in this trial , reductions of this magnitude should not have substantial clinical consequences .
Diseases:"
3436	5 flourouracil - induced apical ballooning syndrome : a case report .	O O O O B I I O O O O O	B I O O O O O O O O O O	['apical ballooning syndrome']	1	5	"Sentence: 5 flourouracil - induced apical ballooning syndrome : a case report .
Diseases: apical ballooning syndrome"	"Sentence: 5 flourouracil - induced apical ballooning syndrome : a case report .
Diseases:"
3437	The apical ballooning syndrome ( ABS ) is a recently described stress - mediated acute cardiac syndrome characterized by transient wall - motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular ( LV ) segments without obstructive epicardial coronary disease .	O B I I O B O O O O O O O O B I I O O O O O O O O O O O O O B O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['abs', 'epicardial coronary disease', 'acute cardiac syndrome', 'apical ballooning syndrome', 'hyperkinesis']	5	22	"Sentence: The apical ballooning syndrome ( ABS ) is a recently described stress - mediated acute cardiac syndrome characterized by transient wall - motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular ( LV ) segments without obstructive epicardial coronary disease .
Diseases: abs, epicardial coronary disease, acute cardiac syndrome, apical ballooning syndrome, hyperkinesis"	"Sentence: The apical ballooning syndrome ( ABS ) is a recently described stress - mediated acute cardiac syndrome characterized by transient wall - motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular ( LV ) segments without obstructive epicardial coronary disease .
Diseases:"
3438	Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents .	B O O O O O O O O O O	O O O O O O O O O O O	['cardiotoxicity']	1	3	"Sentence: Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents .
Diseases: cardiotoxicity"	"Sentence: Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents .
Diseases:"
3439	However , there are no reports of ABS secondary to chemotherapeutic agents .	O O O O O O O B O O O O O	O O O O O O O O O O O O O	['abs']	1	1	"Sentence: However , there are no reports of ABS secondary to chemotherapeutic agents .
Diseases: abs"	"Sentence: However , there are no reports of ABS secondary to chemotherapeutic agents .
Diseases:"
3440	We describe the case of a woman who developed the syndrome after chemotherapy for metastatic cancer .	O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O	['cancer']	1	1	"Sentence: We describe the case of a woman who developed the syndrome after chemotherapy for metastatic cancer .
Diseases: cancer"	"Sentence: We describe the case of a woman who developed the syndrome after chemotherapy for metastatic cancer .
Diseases:"
3441	A 79 - year - old woman presented with typical ischemic chest pain , elevated cardiac enzymes with significant ST - segment abnormalities on her electrocardiogram .	O O O O O O O O O O B B I O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['chest pain', 'ischemic']	2	6	"Sentence: A 79 - year - old woman presented with typical ischemic chest pain , elevated cardiac enzymes with significant ST - segment abnormalities on her electrocardiogram .
Diseases: chest pain, ischemic"	"Sentence: A 79 - year - old woman presented with typical ischemic chest pain , elevated cardiac enzymes with significant ST - segment abnormalities on her electrocardiogram .
Diseases:"
3442	She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer .	O O O O O O O O B I O	O O O O O B O O O O O	['colorectal cancer']	1	5	"Sentence: She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer .
Diseases: colorectal cancer"	"Sentence: She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer .
Diseases:"
3443	Echocardiography revealed a wall - motion abnormality involving the apical and periapical segments which appeared akinetic .	O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O	['akinetic']	1	2	"Sentence: Echocardiography revealed a wall - motion abnormality involving the apical and periapical segments which appeared akinetic .
Diseases: akinetic"	"Sentence: Echocardiography revealed a wall - motion abnormality involving the apical and periapical segments which appeared akinetic .
Diseases:"
3444	Coronary angiography revealed no obstructive coronary lesions .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: Coronary angiography revealed no obstructive coronary lesions .
Diseases: "	"Sentence: Coronary angiography revealed no obstructive coronary lesions .
Diseases:"
3445	The patient was stabilized with medical therapy .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: The patient was stabilized with medical therapy .
Diseases: "	"Sentence: The patient was stabilized with medical therapy .
Diseases:"
3446	Four weeks later she remained completely asymptomatic .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: Four weeks later she remained completely asymptomatic .
Diseases: "	"Sentence: Four weeks later she remained completely asymptomatic .
Diseases:"
3447	Echocardiogram revealed a normal ejection fraction and a resolution of the apical akinesis .	O O O O O O O O O O O O B O	O O O O O O O O O O O O O O	['akinesis']	1	3	"Sentence: Echocardiogram revealed a normal ejection fraction and a resolution of the apical akinesis .
Diseases: akinesis"	"Sentence: Echocardiogram revealed a normal ejection fraction and a resolution of the apical akinesis .
Diseases:"
3448	Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm , endothelial damage and consequent thrombus formation .	O O O B I O B O O O O B I O O O O O B O O	O O O O O O O O O O O O O O O O O O O O O	['cardiac complications', 'thrombus', 'cancer', 'coronary vasospasm']	4	14	"Sentence: Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm , endothelial damage and consequent thrombus formation .
Diseases: cardiac complications, thrombus, cancer, coronary vasospasm"	"Sentence: Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm , endothelial damage and consequent thrombus formation .
Diseases:"
3449	In our patient , both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O B O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['abs', 'cancer']	2	3	"Sentence: In our patient , both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS .
Diseases: abs, cancer"	"Sentence: In our patient , both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS .
Diseases:"
3450	Reduction of pain during induction with target - controlled propofol and remifentanil .	O O B O O O O O O O O O O	O O O O O O O O O B O B O	['pain']	1	1	"Sentence: Reduction of pain during induction with target - controlled propofol and remifentanil .
Diseases: pain"	"Sentence: Reduction of pain during induction with target - controlled propofol and remifentanil .
Diseases:"
3451	Pain on injection of propofol is unpleasant .	B O O O O O O O	O O O O B O O O	['pain']	1	1	"Sentence: Pain on injection of propofol is unpleasant .
Diseases: pain"	"Sentence: Pain on injection of propofol is unpleasant .
Diseases:"
3452	We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target - controlled infusions ( TCI ) of both drugs were used .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O B O O O B O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target - controlled infusions ( TCI ) of both drugs were used .
Diseases: pain"	"Sentence: We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target - controlled infusions ( TCI ) of both drugs were used .
Diseases:"
3453	A prospective , randomized , double - blind , placebo - controlled trial was performed to determine the effect - site concentration ( Ce ) of remifentanil to prevent the pain without producing complications .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['pain']	1	1	"Sentence: A prospective , randomized , double - blind , placebo - controlled trial was performed to determine the effect - site concentration ( Ce ) of remifentanil to prevent the pain without producing complications .
Diseases: pain"	"Sentence: A prospective , randomized , double - blind , placebo - controlled trial was performed to determine the effect - site concentration ( Ce ) of remifentanil to prevent the pain without producing complications .
Diseases:"
3454	A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline ( control ) or remifentanil to a target Ce of 2 ng ml ( - 1 ) ( R2 ) , 4 ng ml ( - 1 ) ( R4 ) , or 6 ng ml ( - 1 ) ( R6 ) administered via TCI .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline ( control ) or remifentanil to a target Ce of 2 ng ml ( - 1 ) ( R2 ) , 4 ng ml ( - 1 ) ( R4 ) , or 6 ng ml ( - 1 ) ( R6 ) administered via TCI .
Diseases: "	"Sentence: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline ( control ) or remifentanil to a target Ce of 2 ng ml ( - 1 ) ( R2 ) , 4 ng ml ( - 1 ) ( R4 ) , or 6 ng ml ( - 1 ) ( R6 ) administered via TCI .
Diseases:"
3455	After the target Ce was achieved , the infusion of propofol was started .	O O O O O O O O O O O O O O	O O O O O O O O O O B O O O	[]	0	0	"Sentence: After the target Ce was achieved , the infusion of propofol was started .
Diseases: "	"Sentence: After the target Ce was achieved , the infusion of propofol was started .
Diseases:"
3456	Remifentanil - related complications were assessed during the remifentanil infusion , and pain caused by propofol was evaluated using a four - point scale during the propofol infusion .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	B O O O O O O O B O O O O O O B O O O O O O O O O O B O O	['pain']	1	1	"Sentence: Remifentanil - related complications were assessed during the remifentanil infusion , and pain caused by propofol was evaluated using a four - point scale during the propofol infusion .
Diseases: pain"	"Sentence: Remifentanil - related complications were assessed during the remifentanil infusion , and pain caused by propofol was evaluated using a four - point scale during the propofol infusion .
Diseases:"
3457	The incidence of pain was significantly lower in Groups R4 and R6 than in the control and R2 groups ( 12 / 32 and 6 / 31 vs 26 / 31 and 25 / 32 , respectively , P < 0 . 001 ) .	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: The incidence of pain was significantly lower in Groups R4 and R6 than in the control and R2 groups ( 12 / 32 and 6 / 31 vs 26 / 31 and 25 / 32 , respectively , P < 0 . 001 ) .
Diseases: pain"	"Sentence: The incidence of pain was significantly lower in Groups R4 and R6 than in the control and R2 groups ( 12 / 32 and 6 / 31 vs 26 / 31 and 25 / 32 , respectively , P < 0 . 001 ) .
Diseases:"
3458	Pain was less severe in Groups R4 and R6 than in the control and R2 groups ( P < 0 . 001 ) .	B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: Pain was less severe in Groups R4 and R6 than in the control and R2 groups ( P < 0 . 001 ) .
Diseases: pain"	"Sentence: Pain was less severe in Groups R4 and R6 than in the control and R2 groups ( P < 0 . 001 ) .
Diseases:"
3459	However , both incidence and severity of pain were not different between Groups R4 and R6 .	O O O O O O O B O O O O O O O O O	O O O O O O O O O O O O O O O O O	['pain']	1	1	"Sentence: However , both incidence and severity of pain were not different between Groups R4 and R6 .
Diseases: pain"	"Sentence: However , both incidence and severity of pain were not different between Groups R4 and R6 .
Diseases:"
3460	No significant complications were observed during the study .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: No significant complications were observed during the study .
Diseases: "	"Sentence: No significant complications were observed during the study .
Diseases:"
3461	During induction of anaesthesia with TCI of propofol and remifentanil , a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml ( - 1 ) .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O B O O O O O B O O O O O O O O O O O B O O O O O O O O O O O O O	['pain']	1	1	"Sentence: During induction of anaesthesia with TCI of propofol and remifentanil , a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml ( - 1 ) .
Diseases: pain"	"Sentence: During induction of anaesthesia with TCI of propofol and remifentanil , a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml ( - 1 ) .
Diseases:"
3462	Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat .	O O O O O B I I O O O O	O O O B O O O O O O O O	['fetal pulmonary hypertension']	1	4	"Sentence: Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat .
Diseases: fetal pulmonary hypertension"	"Sentence: Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat .
Diseases:"
3463	RATIONALE :	O O	O O	[]	0	0	"Sentence: RATIONALE :
Diseases: "	"Sentence: RATIONALE :
Diseases:"
3464	Fluoxetine is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women .	O O O O O O O O O O O O O O	B O O B B I I B O O O O O O	[]	0	0	"Sentence: Fluoxetine is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women .
Diseases: "	"Sentence: Fluoxetine is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women .
Diseases:"
3465	Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn .	O O O O O O O O O O O O B I I O O O O	O O O O B O O O O O O O O O O O O O O	['pulmonary hypertension syndrome']	1	5	"Sentence: Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn .
Diseases: pulmonary hypertension syndrome"	"Sentence: Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn .
Diseases:"
3466	The mechanism responsible for this effect is unclear and paradoxical , considering the current evidence of a pulmonary hypertension protective fluoxetine effect in adult rodents .	O O O O O O O O O O O O O O O O O B I O O O O O O O	O O O O O O O O O O O O O O O O O O O O B O O O O O	['pulmonary hypertension']	1	4	"Sentence: The mechanism responsible for this effect is unclear and paradoxical , considering the current evidence of a pulmonary hypertension protective fluoxetine effect in adult rodents .
Diseases: pulmonary hypertension"	"Sentence: The mechanism responsible for this effect is unclear and paradoxical , considering the current evidence of a pulmonary hypertension protective fluoxetine effect in adult rodents .
Diseases:"
3467	To evaluate the fluoxetine effect on fetal rat pulmonary vascular smooth muscle mechanical properties and cell proliferation rate .	O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: To evaluate the fluoxetine effect on fetal rat pulmonary vascular smooth muscle mechanical properties and cell proliferation rate .
Diseases: "	"Sentence: To evaluate the fluoxetine effect on fetal rat pulmonary vascular smooth muscle mechanical properties and cell proliferation rate .
Diseases:"
3468	Pregnant rats were treated with fluoxetine ( 10 mg / kg ) from Day 11 through Day 21 of gestation .	O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Pregnant rats were treated with fluoxetine ( 10 mg / kg ) from Day 11 through Day 21 of gestation .
Diseases: "	"Sentence: Pregnant rats were treated with fluoxetine ( 10 mg / kg ) from Day 11 through Day 21 of gestation .
Diseases:"
3469	MEASUREMENTS AND MAIN RESULTS :	O O O O O	O O O O O	[]	0	0	"Sentence: MEASUREMENTS AND MAIN RESULTS :
Diseases: "	"Sentence: MEASUREMENTS AND MAIN RESULTS :
Diseases:"
3470	Fetuses were delivered by cesarean section .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: Fetuses were delivered by cesarean section .
Diseases: "	"Sentence: Fetuses were delivered by cesarean section .
Diseases:"
3471	As compared with controls , fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum ( P = 0 . 02 ) and by an increase in pulmonary arterial medial thickness ( P < 0 . 01 ) .	O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['fetal pulmonary hypertension']	1	4	"Sentence: As compared with controls , fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum ( P = 0 . 02 ) and by an increase in pulmonary arterial medial thickness ( P < 0 . 01 ) .
Diseases: fetal pulmonary hypertension"	"Sentence: As compared with controls , fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum ( P = 0 . 02 ) and by an increase in pulmonary arterial medial thickness ( P < 0 . 01 ) .
Diseases:"
3472	Postnatal mortality was increased among experimental animals , and arterial oxygen saturation was 96 + / - 1 % in 1 - day - old control animals and significantly lower ( P < 0 . 01 ) in fluoxetine - exposed pups ( 79 + / - 2 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: Postnatal mortality was increased among experimental animals , and arterial oxygen saturation was 96 + / - 1 % in 1 - day - old control animals and significantly lower ( P < 0 . 01 ) in fluoxetine - exposed pups ( 79 + / - 2 % ) .
Diseases: "	"Sentence: Postnatal mortality was increased among experimental animals , and arterial oxygen saturation was 96 + / - 1 % in 1 - day - old control animals and significantly lower ( P < 0 . 01 ) in fluoxetine - exposed pups ( 79 + / - 2 % ) .
Diseases:"
3473	In vitro , fluoxetine induced pulmonary arterial muscle contraction in fetal , but not adult , animals ( P < 0 . 01 ) and reduced serotonin - induced contraction at both ages ( P < 0 . 01 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: In vitro , fluoxetine induced pulmonary arterial muscle contraction in fetal , but not adult , animals ( P < 0 . 01 ) and reduced serotonin - induced contraction at both ages ( P < 0 . 01 ) .
Diseases: "	"Sentence: In vitro , fluoxetine induced pulmonary arterial muscle contraction in fetal , but not adult , animals ( P < 0 . 01 ) and reduced serotonin - induced contraction at both ages ( P < 0 . 01 ) .
Diseases:"
3474	After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal , but not adult , cells ( P < 0 . 01 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal , but not adult , cells ( P < 0 . 01 ) .
Diseases: "	"Sentence: After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal , but not adult , cells ( P < 0 . 01 ) .
Diseases:"
3475	In contrast to the adult , fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation .	O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['pulmonary hypertension']	1	4	"Sentence: In contrast to the adult , fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation .
Diseases: pulmonary hypertension"	"Sentence: In contrast to the adult , fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation .
Diseases:"
3476	Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen .	B O B I O O O O O O O O O O O O O O	O O O O O O O O B O B O O O O O O O	['qt prolongation', 'syncope']	2	6	"Sentence: Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen .
Diseases: qt prolongation, syncope"	"Sentence: Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen .
Diseases:"
3477	Methadone is prescribed to heroin addicts to decrease illicit opioid use .	O O O O O O O O O O O O	B O O O O O O O O O O O	[]	0	0	"Sentence: Methadone is prescribed to heroin addicts to decrease illicit opioid use .
Diseases: "	"Sentence: Methadone is prescribed to heroin addicts to decrease illicit opioid use .
Diseases:"
3478	Prolongation of the QT interval in the ECG of patients with torsade de pointes ( TdP ) has been reported in methadone users .	O O O O O O O O O O O B I I O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B O O	['torsade de pointes', 'tdp']	2	9	"Sentence: Prolongation of the QT interval in the ECG of patients with torsade de pointes ( TdP ) has been reported in methadone users .
Diseases: torsade de pointes, tdp"	"Sentence: Prolongation of the QT interval in the ECG of patients with torsade de pointes ( TdP ) has been reported in methadone users .
Diseases:"
3479	As heroin addicts sometimes faint while using illicit drugs , doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population , and the high mortality in this population may , in part , be caused by the proarrhythmic effect of methadone .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['syncope', 'tdp']	2	5	"Sentence: As heroin addicts sometimes faint while using illicit drugs , doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population , and the high mortality in this population may , in part , be caused by the proarrhythmic effect of methadone .
Diseases: syncope, tdp"	"Sentence: As heroin addicts sometimes faint while using illicit drugs , doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population , and the high mortality in this population may , in part , be caused by the proarrhythmic effect of methadone .
Diseases:"
3480	In this cross - sectional study interview , ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O	[]	0	0	"Sentence: In this cross - sectional study interview , ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis .
Diseases: "	"Sentence: In this cross - sectional study interview , ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis .
Diseases:"
3481	Of the patients at the Drug Addiction Service in the municipal of Copenhagen , 450 ( approximately 52 % ) were included .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Of the patients at the Drug Addiction Service in the municipal of Copenhagen , 450 ( approximately 52 % ) were included .
Diseases: "	"Sentence: Of the patients at the Drug Addiction Service in the municipal of Copenhagen , 450 ( approximately 52 % ) were included .
Diseases:"
3482	The QT interval was estimated from 12 lead ECGs .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: The QT interval was estimated from 12 lead ECGs .
Diseases: "	"Sentence: The QT interval was estimated from 12 lead ECGs .
Diseases:"
3483	All participants were interviewed about any experience of syncope .	O O O O O O O O B O	O O O O O O O O O O	['syncope']	1	2	"Sentence: All participants were interviewed about any experience of syncope .
Diseases: syncope"	"Sentence: All participants were interviewed about any experience of syncope .
Diseases:"
3484	The association between opioid dose and QT , and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression , respectively .	O O O O O O O O O O O O O O B O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O	['syncope']	1	2	"Sentence: The association between opioid dose and QT , and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression , respectively .
Diseases: syncope"	"Sentence: The association between opioid dose and QT , and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression , respectively .
Diseases:"
3485	Methadone dose was associated with longer QT interval of 0 . 140 ms / mg ( p = 0 . 002 ) .	O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Methadone dose was associated with longer QT interval of 0 . 140 ms / mg ( p = 0 . 002 ) .
Diseases: "	"Sentence: Methadone dose was associated with longer QT interval of 0 . 140 ms / mg ( p = 0 . 002 ) .
Diseases:"
3486	No association between buprenorphine and QTc was found .	O O O O O O O O O	O O O B O O O O O	[]	0	0	"Sentence: No association between buprenorphine and QTc was found .
Diseases: "	"Sentence: No association between buprenorphine and QTc was found .
Diseases:"
3487	Among the subjects treated with methadone , 28 % men and 32 % women had prolonged QTc interval .	O O O O O O O O O O O O O O O B I I O	O O O O O B O O O O O O O O O O O O O	['prolonged qtc interval']	1	6	"Sentence: Among the subjects treated with methadone , 28 % men and 32 % women had prolonged QTc interval .
Diseases: prolonged qtc interval"	"Sentence: Among the subjects treated with methadone , 28 % men and 32 % women had prolonged QTc interval .
Diseases:"
3488	None of the subjects treated with buprenorphine had QTc interval > 0 . 440 s ( ( 1 / 2 ) ) .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: None of the subjects treated with buprenorphine had QTc interval > 0 . 440 s ( ( 1 / 2 ) ) .
Diseases: "	"Sentence: None of the subjects treated with buprenorphine had QTc interval > 0 . 440 s ( ( 1 / 2 ) ) .
Diseases:"
3489	A 50 mg higher methadone dose was associated with a 1 . 2 ( 95 % CI 1 . 1 to 1 . 4 ) times higher odds for syncope .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['syncope']	1	2	"Sentence: A 50 mg higher methadone dose was associated with a 1 . 2 ( 95 % CI 1 . 1 to 1 . 4 ) times higher odds for syncope .
Diseases: syncope"	"Sentence: A 50 mg higher methadone dose was associated with a 1 . 2 ( 95 % CI 1 . 1 to 1 . 4 ) times higher odds for syncope .
Diseases:"
3490	CONCLUSIONS : Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts .	O O O O O O B I O O O O B O O O O O O O	O O B O O O O O O O O O O O O O O O O O	['qt prolongation', 'syncope']	2	6	"Sentence: CONCLUSIONS : Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts .
Diseases: qt prolongation, syncope"	"Sentence: CONCLUSIONS : Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts .
Diseases:"
3491	Peripheral neuropathy caused by high - dose cytosine arabinoside treatment in a patient with acute myeloid leukemia .	B I O O O O O O O O O O O O B I I O	O O O O O O O B I O O O O O O O O O	['peripheral neuropathy', 'acute myeloid leukemia']	2	11	"Sentence: Peripheral neuropathy caused by high - dose cytosine arabinoside treatment in a patient with acute myeloid leukemia .
Diseases: peripheral neuropathy, acute myeloid leukemia"	"Sentence: Peripheral neuropathy caused by high - dose cytosine arabinoside treatment in a patient with acute myeloid leukemia .
Diseases:"
3492	The central nervous system toxicity of high - dose cytosine arabinoside is well recognized , but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported .	O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O O	O O O O O O O O O B I O O O O O O O O B I O O O O O O O O O O	['toxicity']	1	2	"Sentence: The central nervous system toxicity of high - dose cytosine arabinoside is well recognized , but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported .
Diseases: toxicity"	"Sentence: The central nervous system toxicity of high - dose cytosine arabinoside is well recognized , but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported .
Diseases:"
3493	A 49 - year - old Japanese man was diagnosed with acute myeloid leukemia .	O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O O	['acute myeloid leukemia']	1	6	"Sentence: A 49 - year - old Japanese man was diagnosed with acute myeloid leukemia .
Diseases: acute myeloid leukemia"	"Sentence: A 49 - year - old Japanese man was diagnosed with acute myeloid leukemia .
Diseases:"
3494	After he achieved complete remission , he received high - dose cytosine arabinoside treatment ( 2 g / m2 twice a day for 5 days ; total , 20 g / m2 ) as consolidation therapy .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After he achieved complete remission , he received high - dose cytosine arabinoside treatment ( 2 g / m2 twice a day for 5 days ; total , 20 g / m2 ) as consolidation therapy .
Diseases: "	"Sentence: After he achieved complete remission , he received high - dose cytosine arabinoside treatment ( 2 g / m2 twice a day for 5 days ; total , 20 g / m2 ) as consolidation therapy .
Diseases:"
3495	The first course of high - dose cytosine arabinoside resulted in no unusual symptoms , but on day 21 of the second course of treatment , the patient complained of numbness in his right foot .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O	['numbness']	1	3	"Sentence: The first course of high - dose cytosine arabinoside resulted in no unusual symptoms , but on day 21 of the second course of treatment , the patient complained of numbness in his right foot .
Diseases: numbness"	"Sentence: The first course of high - dose cytosine arabinoside resulted in no unusual symptoms , but on day 21 of the second course of treatment , the patient complained of numbness in his right foot .
Diseases:"
3496	Electromyogram and nerve - conduction studies showed peripheral neuropathy in both peroneal nerves .	O O O O O O O B I O O O O O	O O O O O O O O O O O O O O	['peripheral neuropathy']	1	5	"Sentence: Electromyogram and nerve - conduction studies showed peripheral neuropathy in both peroneal nerves .
Diseases: peripheral neuropathy"	"Sentence: Electromyogram and nerve - conduction studies showed peripheral neuropathy in both peroneal nerves .
Diseases:"
3497	This neuropathy was gradually resolving ; however , after the patient received allogeneic bone marrow transplantation , the symptoms worsened , with the development of graft - versus - host disease , and the symptoms subsequently responded to methylprednisolone .	O B O O O O O O O O O O O O O O O O O O O O O O O B I I I I I O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['neuropathy', 'graft - versus - host disease']	2	10	"Sentence: This neuropathy was gradually resolving ; however , after the patient received allogeneic bone marrow transplantation , the symptoms worsened , with the development of graft - versus - host disease , and the symptoms subsequently responded to methylprednisolone .
Diseases: neuropathy, graft - versus - host disease"	"Sentence: This neuropathy was gradually resolving ; however , after the patient received allogeneic bone marrow transplantation , the symptoms worsened , with the development of graft - versus - host disease , and the symptoms subsequently responded to methylprednisolone .
Diseases:"
3498	Although the mechanisms of peripheral neuropathy are still unclear , high - dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system , and auto / alloimmunity may play an important role in these mechanisms .	O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O	['peripheral neuropathy']	1	5	"Sentence: Although the mechanisms of peripheral neuropathy are still unclear , high - dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system , and auto / alloimmunity may play an important role in these mechanisms .
Diseases: peripheral neuropathy"	"Sentence: Although the mechanisms of peripheral neuropathy are still unclear , high - dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system , and auto / alloimmunity may play an important role in these mechanisms .
Diseases:"
3499	Atorvastatin prevented and reversed dexamethasone - induced hypertension in the rat .	O O O O O O O B O O O O	B O O O B O O O O O O O	['hypertension']	1	3	"Sentence: Atorvastatin prevented and reversed dexamethasone - induced hypertension in the rat .
Diseases: hypertension"	"Sentence: Atorvastatin prevented and reversed dexamethasone - induced hypertension in the rat .
Diseases:"
3500	To assess the antioxidant effects of atorvastatin ( atorva ) on dexamethasone ( dex ) - induced hypertension , 60 male Sprague - Dawley rats were treated with atorva 30 mg / kg / day or tap water for 15 days .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O B O O B O B O O O O O O O O O O O O O O B O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: To assess the antioxidant effects of atorvastatin ( atorva ) on dexamethasone ( dex ) - induced hypertension , 60 male Sprague - Dawley rats were treated with atorva 30 mg / kg / day or tap water for 15 days .
Diseases: hypertension"	"Sentence: To assess the antioxidant effects of atorvastatin ( atorva ) on dexamethasone ( dex ) - induced hypertension , 60 male Sprague - Dawley rats were treated with atorva 30 mg / kg / day or tap water for 15 days .
Diseases:"
3501	Dex increased systolic blood pressure ( SBP ) from 109 + / - 1 . 8 to 135 + / - 0 . 6 mmHg and plasma superoxide ( 5711 + / - 284 . 9 saline , 7931 + / -	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: Dex increased systolic blood pressure ( SBP ) from 109 + / - 1 . 8 to 135 + / - 0 . 6 mmHg and plasma superoxide ( 5711 + / - 284 . 9 saline , 7931 + / -
Diseases: "	"Sentence: Dex increased systolic blood pressure ( SBP ) from 109 + / - 1 . 8 to 135 + / - 0 . 6 mmHg and plasma superoxide ( 5711 + / - 284 . 9 saline , 7931 + / -
Diseases:"
3502	392 . 8 U / ml dex , P < 0 . 001 ) .	O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O	[]	0	0	"Sentence: 392 . 8 U / ml dex , P < 0 . 001 ) .
Diseases: "	"Sentence: 392 . 8 U / ml dex , P < 0 . 001 ) .
Diseases:"
3503	In this prevention study , SBP in the atorva + dex group was increased from 115 + / - 0 . 4 to 124 + / - 1 . 5 mmHg , but this was significantly lower than in the dex - only group ( P ' < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: In this prevention study , SBP in the atorva + dex group was increased from 115 + / - 0 . 4 to 124 + / - 1 . 5 mmHg , but this was significantly lower than in the dex - only group ( P ' < 0 . 05 ) .
Diseases: "	"Sentence: In this prevention study , SBP in the atorva + dex group was increased from 115 + / - 0 . 4 to 124 + / - 1 . 5 mmHg , but this was significantly lower than in the dex - only group ( P ' < 0 . 05 ) .
Diseases:"
3504	Atorva reversed dex - induced hypertension ( 129 + / - 0 . 6 mmHg , vs . 135 + / - 0 . 6 mmHg P ' < 0 . 05 ) and decreased plasma superoxide ( 7931 + / - 392 . 8 dex , 1187 + / -	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O B O O O O O	['hypertension']	1	3	"Sentence: Atorva reversed dex - induced hypertension ( 129 + / - 0 . 6 mmHg , vs . 135 + / - 0 . 6 mmHg P ' < 0 . 05 ) and decreased plasma superoxide ( 7931 + / - 392 . 8 dex , 1187 + / -
Diseases: hypertension"	"Sentence: Atorva reversed dex - induced hypertension ( 129 + / - 0 . 6 mmHg , vs . 135 + / - 0 . 6 mmHg P ' < 0 . 05 ) and decreased plasma superoxide ( 7931 + / - 392 . 8 dex , 1187 + / -
Diseases:"
3505	441 . 2 atorva + dex , P < 0 . 0001 ) .	O O O O O O O O O O O O O O	O O O B O B O O O O O O O O	[]	0	0	"Sentence: 441 . 2 atorva + dex , P < 0 . 0001 ) .
Diseases: "	"Sentence: 441 . 2 atorva + dex , P < 0 . 0001 ) .
Diseases:"
3506	Plasma nitrate / nitrite ( NOx ) was decreased in dex - treated rats compared to saline - treated rats ( 11 . 2 + / -	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O B O B O O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Plasma nitrate / nitrite ( NOx ) was decreased in dex - treated rats compared to saline - treated rats ( 11 . 2 + / -
Diseases: "	"Sentence: Plasma nitrate / nitrite ( NOx ) was decreased in dex - treated rats compared to saline - treated rats ( 11 . 2 + / -
Diseases:"
3507	1 . 08 microm , 15 . 3 + / -	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: 1 . 08 microm , 15 . 3 + / -
Diseases: "	"Sentence: 1 . 08 microm , 15 . 3 + / -
Diseases:"
3508	1 . 17 microm , respectively , P < 0 . 05 ) .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: 1 . 17 microm , respectively , P < 0 . 05 ) .
Diseases: "	"Sentence: 1 . 17 microm , respectively , P < 0 . 05 ) .
Diseases:"
3509	Atorva affected neither plasma NOx nor thymus weight .	O O O O O O O O O	B O O O B O O O O	[]	0	0	"Sentence: Atorva affected neither plasma NOx nor thymus weight .
Diseases: "	"Sentence: Atorva affected neither plasma NOx nor thymus weight .
Diseases:"
3510	Thus , atorvastatin prevented and reversed dexamethasone - induced hypertension in the rat .	O O O O O O O O O B O O O O	O O B O O O B O O O O O O O	['hypertension']	1	3	"Sentence: Thus , atorvastatin prevented and reversed dexamethasone - induced hypertension in the rat .
Diseases: hypertension"	"Sentence: Thus , atorvastatin prevented and reversed dexamethasone - induced hypertension in the rat .
Diseases:"
3511	Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain .	O O O O O O O O O O O O O O O O B O	O O O O O O O B O O O O O O O O O O	['pain']	1	1	"Sentence: Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain .
Diseases: pain"	"Sentence: Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain .
Diseases:"
3512	Amino acids 5 and 7 , two potent and selective competitive GluR5 KA receptor antagonists , exhibited high GluR5 receptor affinity over other glutamate receptors .	O O O O O O O O O O O O O O O O O O O O O O O O O O	B I O O O O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Amino acids 5 and 7 , two potent and selective competitive GluR5 KA receptor antagonists , exhibited high GluR5 receptor affinity over other glutamate receptors .
Diseases: "	"Sentence: Amino acids 5 and 7 , two potent and selective competitive GluR5 KA receptor antagonists , exhibited high GluR5 receptor affinity over other glutamate receptors .
Diseases:"
3513	Their ester prodrugs 6 and 8 were orally active in three models of pain : reversal of formalin - induced paw licking , carrageenan - induced thermal hyperalgesia , and capsaicin - induced mechanical hyperalgesia .	O O O O O O O O O O O O O B O O O O O O O O O O O O B I O O O O O B I O	O O O O O O O O O O O O O O O O O B O O O O O B O O O O O O B O O O O O	['mechanical hyperalgesia', 'pain', 'thermal hyperalgesia']	3	15	"Sentence: Their ester prodrugs 6 and 8 were orally active in three models of pain : reversal of formalin - induced paw licking , carrageenan - induced thermal hyperalgesia , and capsaicin - induced mechanical hyperalgesia .
Diseases: mechanical hyperalgesia, pain, thermal hyperalgesia"	"Sentence: Their ester prodrugs 6 and 8 were orally active in three models of pain : reversal of formalin - induced paw licking , carrageenan - induced thermal hyperalgesia , and capsaicin - induced mechanical hyperalgesia .
Diseases:"
3514	Sirolimus and mycophenolate mofetil for calcineurin - free immunosuppression in renal transplant recipients .	O O O O O O O O O O O O O O	B O B I O O O O O O O O O O	[]	0	0	"Sentence: Sirolimus and mycophenolate mofetil for calcineurin - free immunosuppression in renal transplant recipients .
Diseases: "	"Sentence: Sirolimus and mycophenolate mofetil for calcineurin - free immunosuppression in renal transplant recipients .
Diseases:"
3515	Calcineurin inhibitors , such as cyclosporine and tacrolimus , have been available for almost 20 years .	O O O O O O O O O O O O O O O O O	O O O O O B O B O O O O O O O O O	[]	0	0	"Sentence: Calcineurin inhibitors , such as cyclosporine and tacrolimus , have been available for almost 20 years .
Diseases: "	"Sentence: Calcineurin inhibitors , such as cyclosporine and tacrolimus , have been available for almost 20 years .
Diseases:"
3516	Although these drugs are highly effective and represent the mainstay of transplant immunosuppression , they are associated with acute and chronic nephrotoxicity .	O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: Although these drugs are highly effective and represent the mainstay of transplant immunosuppression , they are associated with acute and chronic nephrotoxicity .
Diseases: nephrotoxicity"	"Sentence: Although these drugs are highly effective and represent the mainstay of transplant immunosuppression , they are associated with acute and chronic nephrotoxicity .
Diseases:"
3517	Acute nephrotoxicity , which occurs in the early period after transplantation , leads to a higher rate of dialysis , and chronic nephrotoxicity may eventually result in graft loss .	O B O O O O O O O O O O O O O O O O O O O O B O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: Acute nephrotoxicity , which occurs in the early period after transplantation , leads to a higher rate of dialysis , and chronic nephrotoxicity may eventually result in graft loss .
Diseases: nephrotoxicity"	"Sentence: Acute nephrotoxicity , which occurs in the early period after transplantation , leads to a higher rate of dialysis , and chronic nephrotoxicity may eventually result in graft loss .
Diseases:"
3518	Acute and chronic nephrotoxicity is becoming more common as the use of marginal kidneys for transplantation increases .	O O O B O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	['nephrotoxicity']	1	4	"Sentence: Acute and chronic nephrotoxicity is becoming more common as the use of marginal kidneys for transplantation increases .
Diseases: nephrotoxicity"	"Sentence: Acute and chronic nephrotoxicity is becoming more common as the use of marginal kidneys for transplantation increases .
Diseases:"
3519	Two recently available immunosuppressive agents , mycophenolate mofetil and sirolimus ( rapamycin ) , have no nephrotoxicity .	O O O O O O O O O O O O O O O O B O	O O O O O O B I O B O B O O O O O O	['nephrotoxicity']	1	4	"Sentence: Two recently available immunosuppressive agents , mycophenolate mofetil and sirolimus ( rapamycin ) , have no nephrotoxicity .
Diseases: nephrotoxicity"	"Sentence: Two recently available immunosuppressive agents , mycophenolate mofetil and sirolimus ( rapamycin ) , have no nephrotoxicity .
Diseases:"
3520	The use of these drugs in combination with other agents has led to the development of new paradigms of immunosuppressive therapy .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The use of these drugs in combination with other agents has led to the development of new paradigms of immunosuppressive therapy .
Diseases: "	"Sentence: The use of these drugs in combination with other agents has led to the development of new paradigms of immunosuppressive therapy .
Diseases:"
3521	This paper reviews the results of clinical trials that have investigated these new approaches to immunosuppression in renal transplant recipients .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This paper reviews the results of clinical trials that have investigated these new approaches to immunosuppression in renal transplant recipients .
Diseases: "	"Sentence: This paper reviews the results of clinical trials that have investigated these new approaches to immunosuppression in renal transplant recipients .
Diseases:"
3522	Erythropoietin restores the anemia - induced reduction in cyclophosphamide cytotoxicity in rat tumors .	O O O B O O O O O B O O B O	O O O O O O O O B O O O O O	['cytotoxicity', 'anemia', 'tumors']	3	9	"Sentence: Erythropoietin restores the anemia - induced reduction in cyclophosphamide cytotoxicity in rat tumors .
Diseases: cytotoxicity, anemia, tumors"	"Sentence: Erythropoietin restores the anemia - induced reduction in cyclophosphamide cytotoxicity in rat tumors .
Diseases:"
3523	The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin ( rHuEPO ) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors .	O O O O O O O O O O O B O O O O O O O O O O O B O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	['cytotoxicity', 'anemia', 'tumors']	3	9	"Sentence: The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin ( rHuEPO ) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors .
Diseases: cytotoxicity, anemia, tumors"	"Sentence: The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin ( rHuEPO ) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors .
Diseases:"
3524	Anemia was induced using a single dose of carboplatin ( 50 mg / kg i . v . ) resulting in a long - lasting reduction ( 30 % ) of the hemoglobin concentration .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['anemia']	1	2	"Sentence: Anemia was induced using a single dose of carboplatin ( 50 mg / kg i . v . ) resulting in a long - lasting reduction ( 30 % ) of the hemoglobin concentration .
Diseases: anemia"	"Sentence: Anemia was induced using a single dose of carboplatin ( 50 mg / kg i . v . ) resulting in a long - lasting reduction ( 30 % ) of the hemoglobin concentration .
Diseases:"
3525	In a second group , the development of anemia was prevented by rHuEPO ( 1000 IU / kg ) administered s . c .	O O O O O O O O B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	['anemia']	1	2	"Sentence: In a second group , the development of anemia was prevented by rHuEPO ( 1000 IU / kg ) administered s . c .
Diseases: anemia"	"Sentence: In a second group , the development of anemia was prevented by rHuEPO ( 1000 IU / kg ) administered s . c .
Diseases:"
3526	three times / week starting 7 days before carboplatin application .	O O O O O O O O O O O	O O O O O O O O B O O	[]	0	0	"Sentence: three times / week starting 7 days before carboplatin application .
Diseases: "	"Sentence: three times / week starting 7 days before carboplatin application .
Diseases:"
3527	Four days after carboplatin treatment , tumors ( DS - sarcoma of the rat ) were implanted s . c .	O O O O O O B O O O B O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O	['sarcoma', 'tumors']	2	6	"Sentence: Four days after carboplatin treatment , tumors ( DS - sarcoma of the rat ) were implanted s . c .
Diseases: sarcoma, tumors"	"Sentence: Four days after carboplatin treatment , tumors ( DS - sarcoma of the rat ) were implanted s . c .
Diseases:"
3528	onto the hind food dorsum .	O O O O O O	O O O O O O	[]	0	0	"Sentence: onto the hind food dorsum .
Diseases: "	"Sentence: onto the hind food dorsum .
Diseases:"
3529	Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se .	O O O O O O B O O O O O	O B O O O O O O O O O O	['tumor']	1	3	"Sentence: Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se .
Diseases: tumor"	"Sentence: Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se .
Diseases:"
3530	When tumors were treated with a single dose of cyclophosphamide ( 60 mg / kg i . p . ) 5 days after implantation , a growth delay with a subsequent regrowth of the tumors was observed .	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['tumors']	1	3	"Sentence: When tumors were treated with a single dose of cyclophosphamide ( 60 mg / kg i . p . ) 5 days after implantation , a growth delay with a subsequent regrowth of the tumors was observed .
Diseases: tumors"	"Sentence: When tumors were treated with a single dose of cyclophosphamide ( 60 mg / kg i . p . ) 5 days after implantation , a growth delay with a subsequent regrowth of the tumors was observed .
Diseases:"
3531	In the anemia group , the growth delay was significantly shorter compared with nonanemic controls ( 13 . 3 days versus 8 . 6 days ) .	O O B O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['anemia']	1	2	"Sentence: In the anemia group , the growth delay was significantly shorter compared with nonanemic controls ( 13 . 3 days versus 8 . 6 days ) .
Diseases: anemia"	"Sentence: In the anemia group , the growth delay was significantly shorter compared with nonanemic controls ( 13 . 3 days versus 8 . 6 days ) .
Diseases:"
3532	In the group where anemia was prevented by rHuEPO treatment , growth delay was comparable with that of nonanemic controls ( 13 . 3 days ) .	O O O O B O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['anemia']	1	2	"Sentence: In the group where anemia was prevented by rHuEPO treatment , growth delay was comparable with that of nonanemic controls ( 13 . 3 days ) .
Diseases: anemia"	"Sentence: In the group where anemia was prevented by rHuEPO treatment , growth delay was comparable with that of nonanemic controls ( 13 . 3 days ) .
Diseases:"
3533	These results suggest that chemotherapy - induced anemia reduces cytotoxicity of cyclophosphamide in tumors , whereas correction of anemia by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved oxygen supply to tumor tissue .	O O O O O O O B O B O O O B O O O O B O O O O O O O O O O O O O O O O O O O O O B O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	['tumor', 'cytotoxicity', 'anemia', 'tumors']	4	12	"Sentence: These results suggest that chemotherapy - induced anemia reduces cytotoxicity of cyclophosphamide in tumors , whereas correction of anemia by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved oxygen supply to tumor tissue .
Diseases: tumor, cytotoxicity, anemia, tumors"	"Sentence: These results suggest that chemotherapy - induced anemia reduces cytotoxicity of cyclophosphamide in tumors , whereas correction of anemia by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved oxygen supply to tumor tissue .
Diseases:"
3534	The role of nitrergic system in lidocaine - induced convulsion in the mouse .	O O O O O O O O O B O O O O	O O O O O O B O O O O O O O	['convulsion']	1	2	"Sentence: The role of nitrergic system in lidocaine - induced convulsion in the mouse .
Diseases: convulsion"	"Sentence: The role of nitrergic system in lidocaine - induced convulsion in the mouse .
Diseases:"
3535	The effects of N - nitro - L - arginine - methyl ester ( L - NAME ) a nitric oxide ( NO ) synthase inhibitor and L - arginine , a NO precursor , were investigated on lidocaine - induced convulsions .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O B I I I I I I I I I O B I I O O B I O B O O O O B I I O O B O O O O O B O O O O	['convulsions']	1	3	"Sentence: The effects of N - nitro - L - arginine - methyl ester ( L - NAME ) a nitric oxide ( NO ) synthase inhibitor and L - arginine , a NO precursor , were investigated on lidocaine - induced convulsions .
Diseases: convulsions"	"Sentence: The effects of N - nitro - L - arginine - methyl ester ( L - NAME ) a nitric oxide ( NO ) synthase inhibitor and L - arginine , a NO precursor , were investigated on lidocaine - induced convulsions .
Diseases:"
3536	In the first experiment , four groups of mice received physiological saline ( 0 . 9 % ) , L - arginine ( 300 mg / kg , i . p . ) , L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O B I I O O O O O O O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: In the first experiment , four groups of mice received physiological saline ( 0 . 9 % ) , L - arginine ( 300 mg / kg , i . p . ) , L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) , respectively .
Diseases: "	"Sentence: In the first experiment , four groups of mice received physiological saline ( 0 . 9 % ) , L - arginine ( 300 mg / kg , i . p . ) , L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) , respectively .
Diseases:"
3537	Thirty minutes after these injections , all mice received lidocaine ( 50 mg / kg , i . p . ) .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: Thirty minutes after these injections , all mice received lidocaine ( 50 mg / kg , i . p . ) .
Diseases: "	"Sentence: Thirty minutes after these injections , all mice received lidocaine ( 50 mg / kg , i . p . ) .
Diseases:"
3538	In the second experiment , four groups of mice received similar treatment in the first experiment , and 30 min after these injections , all mice received a higher dose of lidocaine ( 80 mg / kg ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: In the second experiment , four groups of mice received similar treatment in the first experiment , and 30 min after these injections , all mice received a higher dose of lidocaine ( 80 mg / kg ) .
Diseases: "	"Sentence: In the second experiment , four groups of mice received similar treatment in the first experiment , and 30 min after these injections , all mice received a higher dose of lidocaine ( 80 mg / kg ) .
Diseases:"
3539	L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) significantly decreased the incidence of lidocaine ( 50 mg / kg ) - induced convulsions .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	B I I O O O O O O O O O O O O B O O O O O O O O O O O B O O O O O O O O O O	['convulsions']	1	3	"Sentence: L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) significantly decreased the incidence of lidocaine ( 50 mg / kg ) - induced convulsions .
Diseases: convulsions"	"Sentence: L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) significantly decreased the incidence of lidocaine ( 50 mg / kg ) - induced convulsions .
Diseases:"
3540	In contrast , the L - arginine treatment increased the incidence of lidocaine ( 80 mg / kg , i . p . ) - induced convulsions significantly .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	O O O O B I I O O O O O B O O O O O O O O O O O O O O O O	['convulsions']	1	3	"Sentence: In contrast , the L - arginine treatment increased the incidence of lidocaine ( 80 mg / kg , i . p . ) - induced convulsions significantly .
Diseases: convulsions"	"Sentence: In contrast , the L - arginine treatment increased the incidence of lidocaine ( 80 mg / kg , i . p . ) - induced convulsions significantly .
Diseases:"
3541	These results may suggest that NO is a proconvulsant mediator in lidocaine - induced convulsions .	O O O O O O O O O O O O O O B O	O O O O O B O O O O O B O O O O	['convulsions']	1	3	"Sentence: These results may suggest that NO is a proconvulsant mediator in lidocaine - induced convulsions .
Diseases: convulsions"	"Sentence: These results may suggest that NO is a proconvulsant mediator in lidocaine - induced convulsions .
Diseases:"
3542	Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine - induced myocardial ischemia .	O O O O O O O O O O O O O B I O	O O O B O O B O B O B O O O O O	['myocardial ischemia']	1	6	"Sentence: Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine - induced myocardial ischemia .
Diseases: myocardial ischemia"	"Sentence: Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine - induced myocardial ischemia .
Diseases:"
3543	To determine the effect of metoprolol on dobutamine stress testing with technetium - 99 m sestamibi single - photon emission computed tomography imaging and ST - segment monitoring , and to assess the impact of intravenous glucagon on metoprolol 's effects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O B O O O B I I I I O O O O O O O O O O O O O O O O O O O O B O B O O O	[]	0	0	"Sentence: To determine the effect of metoprolol on dobutamine stress testing with technetium - 99 m sestamibi single - photon emission computed tomography imaging and ST - segment monitoring , and to assess the impact of intravenous glucagon on metoprolol 's effects .
Diseases: "	"Sentence: To determine the effect of metoprolol on dobutamine stress testing with technetium - 99 m sestamibi single - photon emission computed tomography imaging and ST - segment monitoring , and to assess the impact of intravenous glucagon on metoprolol 's effects .
Diseases:"
3544	DESIGN : Randomized , double - blind , placebo - controlled trial .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: DESIGN : Randomized , double - blind , placebo - controlled trial .
Diseases: "	"Sentence: DESIGN : Randomized , double - blind , placebo - controlled trial .
Diseases:"
3545	SETTING : Community hospital .	O O O O O	O O O O O	[]	0	0	"Sentence: SETTING : Community hospital .
Diseases: "	"Sentence: SETTING : Community hospital .
Diseases:"
3546	Twenty - two patients with known reversible perfusion defects .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Twenty - two patients with known reversible perfusion defects .
Diseases: "	"Sentence: Twenty - two patients with known reversible perfusion defects .
Diseases:"
3547	INTERVENTION :	O O	O O	[]	0	0	"Sentence: INTERVENTION :
Diseases: "	"Sentence: INTERVENTION :
Diseases:"
3548	Patients underwent dobutamine stress tests per standard protocol .	O O O O O O O O O	O O B O O O O O O	[]	0	0	"Sentence: Patients underwent dobutamine stress tests per standard protocol .
Diseases: "	"Sentence: Patients underwent dobutamine stress tests per standard protocol .
Diseases:"
3549	Before dobutamine was begun , no therapy was given during the first visit , and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O O O O O B O B O B O O O	[]	0	0	"Sentence: Before dobutamine was begun , no therapy was given during the first visit , and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg .
Diseases: "	"Sentence: Before dobutamine was begun , no therapy was given during the first visit , and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg .
Diseases:"
3550	Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats / minute or a total intravenous dose of 20 mg .	O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats / minute or a total intravenous dose of 20 mg .
Diseases: "	"Sentence: Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats / minute or a total intravenous dose of 20 mg .
Diseases:"
3551	Metoprolol reduced maximum heart rate 31 % , summed stress scores 29 % , and summed difference scores 43 % versus control .	O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Metoprolol reduced maximum heart rate 31 % , summed stress scores 29 % , and summed difference scores 43 % versus control .
Diseases: "	"Sentence: Metoprolol reduced maximum heart rate 31 % , summed stress scores 29 % , and summed difference scores 43 % versus control .
Diseases:"
3552	Metoprolol plus glucagon also reduced the maximum heart rate 29 % versus control .	O O O O O O O O O O O O O O	B O B O O O O O O O O O O O	[]	0	0	"Sentence: Metoprolol plus glucagon also reduced the maximum heart rate 29 % versus control .
Diseases: "	"Sentence: Metoprolol plus glucagon also reduced the maximum heart rate 29 % versus control .
Diseases:"
3553	Summed stress and summed difference scores were not significantly reduced , although they were 18 % and 30 % lower , respectively , than control .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Summed stress and summed difference scores were not significantly reduced , although they were 18 % and 30 % lower , respectively , than control .
Diseases: "	"Sentence: Summed stress and summed difference scores were not significantly reduced , although they were 18 % and 30 % lower , respectively , than control .
Diseases:"
3554	No significant differences were found in any parameter between metoprolol and metoprolol - glucagon .	O O O O O O O O O O O O O O O	O O O O O O O O O B O B O B O	[]	0	0	"Sentence: No significant differences were found in any parameter between metoprolol and metoprolol - glucagon .
Diseases: "	"Sentence: No significant differences were found in any parameter between metoprolol and metoprolol - glucagon .
Diseases:"
3555	During dobutamine stress testing , metoprolol attenuates or eliminates evidence of myocardial ischemia .	O O O O O O O O O O O B I O	O B O O O B O O O O O O O O	['myocardial ischemia']	1	6	"Sentence: During dobutamine stress testing , metoprolol attenuates or eliminates evidence of myocardial ischemia .
Diseases: myocardial ischemia"	"Sentence: During dobutamine stress testing , metoprolol attenuates or eliminates evidence of myocardial ischemia .
Diseases:"
3556	Glucagon 1 mg , although somewhat effective , does not correct this effect to the extent that it can be administered clinically .	O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Glucagon 1 mg , although somewhat effective , does not correct this effect to the extent that it can be administered clinically .
Diseases: "	"Sentence: Glucagon 1 mg , although somewhat effective , does not correct this effect to the extent that it can be administered clinically .
Diseases:"
3557	Prednisolone - induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression .	O O O B I O O O O B O O O O O O O	B O O O O O O O O O O O O B O O O	['atrophy', 'muscle dysfunction']	2	6	"Sentence: Prednisolone - induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression .
Diseases: atrophy, muscle dysfunction"	"Sentence: Prednisolone - induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression .
Diseases:"
3558	Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood .	O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood .
Diseases: "	"Sentence: Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood .
Diseases:"
3559	We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology , and their relationship to changes in muscle size and acetylcholine receptor ( AChR ) expression .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O O B O O O O O O	[]	0	0	"Sentence: We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology , and their relationship to changes in muscle size and acetylcholine receptor ( AChR ) expression .
Diseases: "	"Sentence: We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology , and their relationship to changes in muscle size and acetylcholine receptor ( AChR ) expression .
Diseases:"
3560	With institutional approval , 35 Sprague - Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg / kg prednisolone ( P10 group ) , 100 mg / kg prednisolone ( P100 group ) , or an equal volume of saline ( S group ) for 7 days .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: With institutional approval , 35 Sprague - Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg / kg prednisolone ( P10 group ) , 100 mg / kg prednisolone ( P100 group ) , or an equal volume of saline ( S group ) for 7 days .
Diseases: "	"Sentence: With institutional approval , 35 Sprague - Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg / kg prednisolone ( P10 group ) , 100 mg / kg prednisolone ( P100 group ) , or an equal volume of saline ( S group ) for 7 days .
Diseases:"
3561	A fourth group of rats was pair fed ( food restricted ) with the P100 rats for 7 days ( FR group ) .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A fourth group of rats was pair fed ( food restricted ) with the P100 rats for 7 days ( FR group ) .
Diseases: "	"Sentence: A fourth group of rats was pair fed ( food restricted ) with the P100 rats for 7 days ( FR group ) .
Diseases:"
3562	On Day 8 , the nerve - evoked peak twitch tensions , tetanic tensions , and fatigability , and the dose - response curves of d - tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs .	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O	['tetanic']	1	3	"Sentence: On Day 8 , the nerve - evoked peak twitch tensions , tetanic tensions , and fatigability , and the dose - response curves of d - tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs .
Diseases: tetanic"	"Sentence: On Day 8 , the nerve - evoked peak twitch tensions , tetanic tensions , and fatigability , and the dose - response curves of d - tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs .
Diseases:"
3563	Rate of body weight gain was depressed in the P100 , FR , and P10 groups compared with the S group .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Rate of body weight gain was depressed in the P100 , FR , and P10 groups compared with the S group .
Diseases: "	"Sentence: Rate of body weight gain was depressed in the P100 , FR , and P10 groups compared with the S group .
Diseases:"
3564	Tibialis muscle mass was smaller in the P100 group than in the P10 or S groups .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Tibialis muscle mass was smaller in the P100 group than in the P10 or S groups .
Diseases: "	"Sentence: Tibialis muscle mass was smaller in the P100 group than in the P10 or S groups .
Diseases:"
3565	The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups , however , tension per milligram of muscle mass was greater in the P100 group than in the S group .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['tetanic']	1	3	"Sentence: The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups , however , tension per milligram of muscle mass was greater in the P100 group than in the S group .
Diseases: tetanic"	"Sentence: The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups , however , tension per milligram of muscle mass was greater in the P100 group than in the S group .
Diseases:"
3566	The 50 % effective dose of d - tubocurarine ( microg / kg ) in the tibialis muscle was smaller in the P10 ( 33 . 6 + / - 5 . 4 ) than in the S ( 61 . 9 + / - 5 . 0 ) or the P100 ( 71 . 3 + / - 9 . 6 ) groups .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The 50 % effective dose of d - tubocurarine ( microg / kg ) in the tibialis muscle was smaller in the P10 ( 33 . 6 + / - 5 . 4 ) than in the S ( 61 . 9 + / - 5 . 0 ) or the P100 ( 71 . 3 + / - 9 . 6 ) groups .
Diseases: "	"Sentence: The 50 % effective dose of d - tubocurarine ( microg / kg ) in the tibialis muscle was smaller in the P10 ( 33 . 6 + / - 5 . 4 ) than in the S ( 61 . 9 + / - 5 . 0 ) or the P100 ( 71 . 3 + / - 9 . 6 ) groups .
Diseases:"
3567	AChR expression was less in the P10 group than in the S group .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: AChR expression was less in the P10 group than in the S group .
Diseases: "	"Sentence: AChR expression was less in the P10 group than in the S group .
Diseases:"
3568	The evoked tensions correlated with muscle mass ( r ( 2 ) = 0 . 32 , P < 0 . 001 ) , however , not with expression of AChR .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The evoked tensions correlated with muscle mass ( r ( 2 ) = 0 . 32 , P < 0 . 001 ) , however , not with expression of AChR .
Diseases: "	"Sentence: The evoked tensions correlated with muscle mass ( r ( 2 ) = 0 . 32 , P < 0 . 001 ) , however , not with expression of AChR .
Diseases:"
3569	The 50 % effective dose of d - tubocurarine did not correlate with muscle mass or AChR expression .	O O O O O O O O O O O O O O O O O O O	O O O O O O B I I O O O O O O O O O O	[]	0	0	"Sentence: The 50 % effective dose of d - tubocurarine did not correlate with muscle mass or AChR expression .
Diseases: "	"Sentence: The 50 % effective dose of d - tubocurarine did not correlate with muscle mass or AChR expression .
Diseases:"
3570	Our results suggest that the neuromuscular dysfunction after prednisolone is dose - dependent , and derives primarily from muscle atrophy and derives less so from changes in AChR expression .	O O O O O B I O O O O O O O O O O O B I O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	['muscle atrophy', 'neuromuscular dysfunction']	2	10	"Sentence: Our results suggest that the neuromuscular dysfunction after prednisolone is dose - dependent , and derives primarily from muscle atrophy and derives less so from changes in AChR expression .
Diseases: muscle atrophy, neuromuscular dysfunction"	"Sentence: Our results suggest that the neuromuscular dysfunction after prednisolone is dose - dependent , and derives primarily from muscle atrophy and derives less so from changes in AChR expression .
Diseases:"
3571	IMPLICATIONS :	O O	O O	[]	0	0	"Sentence: IMPLICATIONS :
Diseases: "	"Sentence: IMPLICATIONS :
Diseases:"
3572	The mechanisms by which chronic glucocorticoid therapy alters neuromuscular physiology and pharmacology are unclear .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mechanisms by which chronic glucocorticoid therapy alters neuromuscular physiology and pharmacology are unclear .
Diseases: "	"Sentence: The mechanisms by which chronic glucocorticoid therapy alters neuromuscular physiology and pharmacology are unclear .
Diseases:"
3573	We suggest that the observed effects are dose - dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression .	O O O O O O O O O O O O O O B I O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O B O O O	['muscle atrophy']	1	4	"Sentence: We suggest that the observed effects are dose - dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression .
Diseases: muscle atrophy"	"Sentence: We suggest that the observed effects are dose - dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression .
Diseases:"
3574	Rapid reversal of life - threatening diltiazem - induced tetany with calcium chloride .	O O O O O O O O O B O O O O	O O O O O O B O O O O B I O	['tetany']	1	3	"Sentence: Rapid reversal of life - threatening diltiazem - induced tetany with calcium chloride .
Diseases: tetany"	"Sentence: Rapid reversal of life - threatening diltiazem - induced tetany with calcium chloride .
Diseases:"
3575	We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem .	O O O O O O B O O B I O O O O O O O	O O O O O O O O O O O O O O O O B O	['respiratory arrest', 'tetany']	2	7	"Sentence: We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem .
Diseases: respiratory arrest, tetany"	"Sentence: We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem .
Diseases:"
3576	The administration of calcium chloride rapidly resolved the patient 's tetany with prompt recovery of respiratory function , averting the need for more aggressive airway management and ventilatory support .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O	['tetany']	1	3	"Sentence: The administration of calcium chloride rapidly resolved the patient 's tetany with prompt recovery of respiratory function , averting the need for more aggressive airway management and ventilatory support .
Diseases: tetany"	"Sentence: The administration of calcium chloride rapidly resolved the patient 's tetany with prompt recovery of respiratory function , averting the need for more aggressive airway management and ventilatory support .
Diseases:"
3577	The emergency physician should be aware that life - threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O B I O O O O O O O O	['tetany']	1	3	"Sentence: The emergency physician should be aware that life - threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy .
Diseases: tetany"	"Sentence: The emergency physician should be aware that life - threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy .
Diseases:"
3578	Effects of nonsteroidal anti - inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage .	O O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O O O	['aneurysmal subarachnoid hemorrhage']	1	11	"Sentence: Effects of nonsteroidal anti - inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage .
Diseases: aneurysmal subarachnoid hemorrhage"	"Sentence: Effects of nonsteroidal anti - inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage .
Diseases:"
3579	Platelet function is impaired by nonsteroidal anti - inflammatory drugs ( NSAIDs ) with prominent anti - inflammatory properties .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Platelet function is impaired by nonsteroidal anti - inflammatory drugs ( NSAIDs ) with prominent anti - inflammatory properties .
Diseases: "	"Sentence: Platelet function is impaired by nonsteroidal anti - inflammatory drugs ( NSAIDs ) with prominent anti - inflammatory properties .
Diseases:"
3580	Their safety in patients undergoing intracranial surgery is under debate .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: Their safety in patients undergoing intracranial surgery is under debate .
Diseases: "	"Sentence: Their safety in patients undergoing intracranial surgery is under debate .
Diseases:"
3581	Patients with aneurysmal subarachnoid hemorrhage ( SAH ) were randomized to receive either ketoprofen , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of aneurysmal SAH .	O O B I I O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B B O	O O O O O O O O O O O O O B O O O O O O O O O B O O O O O O O O O O O B O O O O O O O O O B O O O O O O O O O O O O O O O	['aneurysmal', 'sah', 'aneurysmal subarachnoid hemorrhage']	3	19	"Sentence: Patients with aneurysmal subarachnoid hemorrhage ( SAH ) were randomized to receive either ketoprofen , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of aneurysmal SAH .
Diseases: aneurysmal, sah, aneurysmal subarachnoid hemorrhage"	"Sentence: Patients with aneurysmal subarachnoid hemorrhage ( SAH ) were randomized to receive either ketoprofen , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of aneurysmal SAH .
Diseases:"
3582	Treatment was continued for 3 days postoperatively .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: Treatment was continued for 3 days postoperatively .
Diseases: "	"Sentence: Treatment was continued for 3 days postoperatively .
Diseases:"
3583	Test blood samples were taken before treatment and surgery as well as on the first , third , and fifth postoperative mornings .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Test blood samples were taken before treatment and surgery as well as on the first , third , and fifth postoperative mornings .
Diseases: "	"Sentence: Test blood samples were taken before treatment and surgery as well as on the first , third , and fifth postoperative mornings .
Diseases:"
3584	Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen .	O B I O O O O O O O O O O O O O	O O O O O O O O B I O O O O B O	['platelet aggregation']	1	3	"Sentence: Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen .
Diseases: platelet aggregation"	"Sentence: Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen .
Diseases:"
3585	Aggregation was lower ( P < . 05 ) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: Aggregation was lower ( P < . 05 ) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day .
Diseases: "	"Sentence: Aggregation was lower ( P < . 05 ) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day .
Diseases:"
3586	In contrast , maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results ( P < . 05 ) .	O O O O B I O O O O O O O O O O O O O O O B I O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	['platelet aggregation']	1	3	"Sentence: In contrast , maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results ( P < . 05 ) .
Diseases: platelet aggregation"	"Sentence: In contrast , maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results ( P < . 05 ) .
Diseases:"
3587	One patient in the ketoprofen group developed a postoperative intracranial hematoma .	O O O O O O O O O O B O	O O O O B O O O O O O O	['hematoma']	1	2	"Sentence: One patient in the ketoprofen group developed a postoperative intracranial hematoma .
Diseases: hematoma"	"Sentence: One patient in the ketoprofen group developed a postoperative intracranial hematoma .
Diseases:"
3588	Coagulation ( prothrombin time [ PT ] , activated partial thromboplastin time [ APPT ] , fibrinogen concentration , and antithrombin III	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Coagulation ( prothrombin time [ PT ] , activated partial thromboplastin time [ APPT ] , fibrinogen concentration , and antithrombin III
Diseases: "	"Sentence: Coagulation ( prothrombin time [ PT ] , activated partial thromboplastin time [ APPT ] , fibrinogen concentration , and antithrombin III
Diseases:"
3589	[ AT III ] ) was comparable between the two groups .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: [ AT III ] ) was comparable between the two groups .
Diseases: "	"Sentence: [ AT III ] ) was comparable between the two groups .
Diseases:"
3590	Ketoprofen but not acetaminophen impaired platelet function in patients with SAH .	O O O O O O O O O O B O	B O O B O O O O O O O O	['sah']	1	2	"Sentence: Ketoprofen but not acetaminophen impaired platelet function in patients with SAH .
Diseases: sah"	"Sentence: Ketoprofen but not acetaminophen impaired platelet function in patients with SAH .
Diseases:"
3591	If ketoprofen is used before surgery on cerebral artery aneurysms , it may pose an additional risk factor for hemorrhage .	O O O O O O O O B I O O O O O O O O O B O	O B O O O O O O O O O O O O O O O O O O O	['artery aneurysms', 'hemorrhage']	2	9	"Sentence: If ketoprofen is used before surgery on cerebral artery aneurysms , it may pose an additional risk factor for hemorrhage .
Diseases: artery aneurysms, hemorrhage"	"Sentence: If ketoprofen is used before surgery on cerebral artery aneurysms , it may pose an additional risk factor for hemorrhage .
Diseases:"
3592	Value of methylprednisolone in prevention of the arthralgia - myalgia syndrome associated with the total dose infusion of iron dextran : a double blind randomized trial .	O O O O O O O B O B O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O B I O O O O O O O	['myalgia', 'arthralgia']	2	8	"Sentence: Value of methylprednisolone in prevention of the arthralgia - myalgia syndrome associated with the total dose infusion of iron dextran : a double blind randomized trial .
Diseases: myalgia, arthralgia"	"Sentence: Value of methylprednisolone in prevention of the arthralgia - myalgia syndrome associated with the total dose infusion of iron dextran : a double blind randomized trial .
Diseases:"
3593	The safety and efficacy of total dose infusion ( TDI ) of iron dextran has been well documented .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B I O O O O O	[]	0	0	"Sentence: The safety and efficacy of total dose infusion ( TDI ) of iron dextran has been well documented .
Diseases: "	"Sentence: The safety and efficacy of total dose infusion ( TDI ) of iron dextran has been well documented .
Diseases:"
3594	In 40 % of treated patients , an arthralgia - myalgia syndrome develops .	O O O O O O O O B O B O O O	O O O O O O O O O O O O O O	['myalgia', 'arthralgia']	2	8	"Sentence: In 40 % of treated patients , an arthralgia - myalgia syndrome develops .
Diseases: myalgia, arthralgia"	"Sentence: In 40 % of treated patients , an arthralgia - myalgia syndrome develops .
Diseases:"
3595	The purpose of this randomized , double - blind , prospective study was to investigate whether intravenous ( i . v . )	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The purpose of this randomized , double - blind , prospective study was to investigate whether intravenous ( i . v . )
Diseases: "	"Sentence: The purpose of this randomized , double - blind , prospective study was to investigate whether intravenous ( i . v . )
Diseases:"
3596	administration of methylprednisolone ( MP ) prevents this complication .	O O O O O O O O O O	O O B O B O O O O O	[]	0	0	"Sentence: administration of methylprednisolone ( MP ) prevents this complication .
Diseases: "	"Sentence: administration of methylprednisolone ( MP ) prevents this complication .
Diseases:"
3597	Sixty - five patients , 34 women and 31 men , ages 36 to 80 years , received either normal saline before and after TDI ( group 1 ) , 125 mg i . v .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: Sixty - five patients , 34 women and 31 men , ages 36 to 80 years , received either normal saline before and after TDI ( group 1 ) , 125 mg i . v .
Diseases: "	"Sentence: Sixty - five patients , 34 women and 31 men , ages 36 to 80 years , received either normal saline before and after TDI ( group 1 ) , 125 mg i . v .
Diseases:"
3598	MP before and saline after TDI ( group 2 ) , or 125 mg i . v .	O O O O O O O O O O O O O O O O O O	B O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: MP before and saline after TDI ( group 2 ) , or 125 mg i . v .
Diseases: "	"Sentence: MP before and saline after TDI ( group 2 ) , or 125 mg i . v .
Diseases:"
3599	MP before and after TDI ( group 3 ) .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: MP before and after TDI ( group 3 ) .
Diseases: "	"Sentence: MP before and after TDI ( group 3 ) .
Diseases:"
3600	Patients were observed for 72 hours and reactions were recorded and graded according to severity .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients were observed for 72 hours and reactions were recorded and graded according to severity .
Diseases: "	"Sentence: Patients were observed for 72 hours and reactions were recorded and graded according to severity .
Diseases:"
3601	Fifty - eight percent of group 1 patients , 33 % of group 2 , and 26 % of group 3 had reactions to TDI .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: Fifty - eight percent of group 1 patients , 33 % of group 2 , and 26 % of group 3 had reactions to TDI .
Diseases: "	"Sentence: Fifty - eight percent of group 1 patients , 33 % of group 2 , and 26 % of group 3 had reactions to TDI .
Diseases:"
3602	The severity of reactions ( minimal , mild , and moderate , respectively ) was as follows : group 1 - - 6 , 6 , and 2 ; group 2 - - 1 , 5 , and 0 ; group 3 - - 5 , 1 , and 0 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The severity of reactions ( minimal , mild , and moderate , respectively ) was as follows : group 1 - - 6 , 6 , and 2 ; group 2 - - 1 , 5 , and 0 ; group 3 - - 5 , 1 , and 0 .
Diseases: "	"Sentence: The severity of reactions ( minimal , mild , and moderate , respectively ) was as follows : group 1 - - 6 , 6 , and 2 ; group 2 - - 1 , 5 , and 0 ; group 3 - - 5 , 1 , and 0 .
Diseases:"
3603	Data were analyzed by the two - sided Fisher 's exact test using 95 % confidence intervals with the approximation of Woolf .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Data were analyzed by the two - sided Fisher 's exact test using 95 % confidence intervals with the approximation of Woolf .
Diseases: "	"Sentence: Data were analyzed by the two - sided Fisher 's exact test using 95 % confidence intervals with the approximation of Woolf .
Diseases:"
3604	These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia - myalgia syndrome .	O O O O O O O O O O O O O O O O O O B O B O O	O O O O O O B O O O B O O O O O O O O O O O O	['myalgia', 'arthralgia']	2	8	"Sentence: These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia - myalgia syndrome .
Diseases: myalgia, arthralgia"	"Sentence: These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia - myalgia syndrome .
Diseases:"
3605	We conclude that 125 mg i . v .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: We conclude that 125 mg i . v .
Diseases: "	"Sentence: We conclude that 125 mg i . v .
Diseases:"
3606	MP should be given routinely before and after TDI of iron dextran .	O O O O O O O O O O O O O	B O O O O O O O O O B I O	[]	0	0	"Sentence: MP should be given routinely before and after TDI of iron dextran .
Diseases: "	"Sentence: MP should be given routinely before and after TDI of iron dextran .
Diseases:"
3607	Long - term effects of vincristine on the peripheral nervous system .	O O O O O O O O O O O O	O O O O O B O O O O O O	[]	0	0	"Sentence: Long - term effects of vincristine on the peripheral nervous system .
Diseases: "	"Sentence: Long - term effects of vincristine on the peripheral nervous system .
Diseases:"
3608	Forty patients with Non - Hodgkin 's Lymphoma treated with vincristine between 1984 and 1990 ( cumulative dose 12 mg in 18 - 24 weeks ) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system .	O O O B I I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O	"[""non - hodgkin 's lymphoma""]"	1	10	"Sentence: Forty patients with Non - Hodgkin 's Lymphoma treated with vincristine between 1984 and 1990 ( cumulative dose 12 mg in 18 - 24 weeks ) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system .
Diseases: non - hodgkin 's lymphoma"	"Sentence: Forty patients with Non - Hodgkin 's Lymphoma treated with vincristine between 1984 and 1990 ( cumulative dose 12 mg in 18 - 24 weeks ) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system .
Diseases:"
3609	The patients were interviewed with emphasis on neuropathic symptoms .	O O O O O O O B I O	O O O O O O O O O O	['neuropathic symptoms']	1	4	"Sentence: The patients were interviewed with emphasis on neuropathic symptoms .
Diseases: neuropathic symptoms"	"Sentence: The patients were interviewed with emphasis on neuropathic symptoms .
Diseases:"
3610	Physical and quantitative sensory examination with determination of vibratory perception and thermal discrimination thresholds were performed , four to 77 months ( median 34 months ) after vincristine treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Physical and quantitative sensory examination with determination of vibratory perception and thermal discrimination thresholds were performed , four to 77 months ( median 34 months ) after vincristine treatment .
Diseases: "	"Sentence: Physical and quantitative sensory examination with determination of vibratory perception and thermal discrimination thresholds were performed , four to 77 months ( median 34 months ) after vincristine treatment .
Diseases:"
3611	Twenty - seven patients reported neuropathic symptoms .	O O O O O B I O	O O O O O O O O	['neuropathic symptoms']	1	4	"Sentence: Twenty - seven patients reported neuropathic symptoms .
Diseases: neuropathic symptoms"	"Sentence: Twenty - seven patients reported neuropathic symptoms .
Diseases:"
3612	In 13 of these 27 patients symptoms were still present at the time of examination .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In 13 of these 27 patients symptoms were still present at the time of examination .
Diseases: "	"Sentence: In 13 of these 27 patients symptoms were still present at the time of examination .
Diseases:"
3613	In these patients sensory signs and symptoms predominated .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: In these patients sensory signs and symptoms predominated .
Diseases: "	"Sentence: In these patients sensory signs and symptoms predominated .
Diseases:"
3614	In the other 14 patients symptoms had been present in the past .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: In the other 14 patients symptoms had been present in the past .
Diseases: "	"Sentence: In the other 14 patients symptoms had been present in the past .
Diseases:"
3615	Symptoms persisted maximally 40 months since cessation of therapy .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Symptoms persisted maximally 40 months since cessation of therapy .
Diseases: "	"Sentence: Symptoms persisted maximally 40 months since cessation of therapy .
Diseases:"
3616	There was no age difference between patients with and without complaints at the time of examination .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There was no age difference between patients with and without complaints at the time of examination .
Diseases: "	"Sentence: There was no age difference between patients with and without complaints at the time of examination .
Diseases:"
3617	Normal reflexes were found in two third of patients .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Normal reflexes were found in two third of patients .
Diseases: "	"Sentence: Normal reflexes were found in two third of patients .
Diseases:"
3618	Neuropathic complaints were not very troublesome on the long term .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: Neuropathic complaints were not very troublesome on the long term .
Diseases: "	"Sentence: Neuropathic complaints were not very troublesome on the long term .
Diseases:"
3619	It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	O O O O O O O O B O O O O O O B O O O O O O O O O O O O O	['neuropathy']	1	3	"Sentence: It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good .
Diseases: neuropathy"	"Sentence: It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good .
Diseases:"
3620	A case of polymyositis in a patient with primary biliary cirrhosis treated with D - penicillamine .	O O O B O O O O B I I O O O O O O	O O O O O O O O O O O O O B I I O	['primary biliary cirrhosis', 'polymyositis']	2	11	"Sentence: A case of polymyositis in a patient with primary biliary cirrhosis treated with D - penicillamine .
Diseases: primary biliary cirrhosis, polymyositis"	"Sentence: A case of polymyositis in a patient with primary biliary cirrhosis treated with D - penicillamine .
Diseases:"
3621	Although D - penicillamine has been used for many rheumatologic diseases , toxicity limits its usefulness in many patients .	O O O O O O O O O B I O B O O O O O O O	O B I I O O O O O O O O O O O O O O O O	['toxicity', 'rheumatologic diseases']	2	7	"Sentence: Although D - penicillamine has been used for many rheumatologic diseases , toxicity limits its usefulness in many patients .
Diseases: toxicity, rheumatologic diseases"	"Sentence: Although D - penicillamine has been used for many rheumatologic diseases , toxicity limits its usefulness in many patients .
Diseases:"
3622	Polymyositis / dermatomyositis can develop as one of the autoimmune complications of D - penicillamine treatment , but its exact pathogenesis remains unclear .	B O B O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B I I O O O O O O O O O	['dermatomyositis', 'polymyositis']	2	10	"Sentence: Polymyositis / dermatomyositis can develop as one of the autoimmune complications of D - penicillamine treatment , but its exact pathogenesis remains unclear .
Diseases: dermatomyositis, polymyositis"	"Sentence: Polymyositis / dermatomyositis can develop as one of the autoimmune complications of D - penicillamine treatment , but its exact pathogenesis remains unclear .
Diseases:"
3623	We report a patient with primary biliary cirrhosis , who developed polymyositis while receiving D - penicillamine therapy .	O O O O O B I I O O O B O O O O O O O	O O O O O O O O O O O O O O B I I O O	['primary biliary cirrhosis', 'polymyositis']	2	11	"Sentence: We report a patient with primary biliary cirrhosis , who developed polymyositis while receiving D - penicillamine therapy .
Diseases: primary biliary cirrhosis, polymyositis"	"Sentence: We report a patient with primary biliary cirrhosis , who developed polymyositis while receiving D - penicillamine therapy .
Diseases:"
3624	We described the special clinical course of the patient .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: We described the special clinical course of the patient .
Diseases: "	"Sentence: We described the special clinical course of the patient .
Diseases:"
3625	Patients receiving D - penicillamine therapy should be followed carefully for the development of autoimmune complications like polymyositis / dermatomyositis .	O O O O O O O O O O O O O O O O O B O B O	O O B I I O O O O O O O O O O O O O O O O	['dermatomyositis', 'polymyositis']	2	10	"Sentence: Patients receiving D - penicillamine therapy should be followed carefully for the development of autoimmune complications like polymyositis / dermatomyositis .
Diseases: dermatomyositis, polymyositis"	"Sentence: Patients receiving D - penicillamine therapy should be followed carefully for the development of autoimmune complications like polymyositis / dermatomyositis .
Diseases:"
3626	Photodistributed nifedipine - induced facial telangiectasia .	O O O O O B O	O B O O O O O	['telangiectasia']	1	5	"Sentence: Photodistributed nifedipine - induced facial telangiectasia .
Diseases: telangiectasia"	"Sentence: Photodistributed nifedipine - induced facial telangiectasia .
Diseases:"
3627	Five months after starting nifedipine ( Adalat ) , two patients developed photodistributed facial telangiectasia , which became more noticeable with time .	O O O O O O O O O O O O O O B O O O O O O O O	O O O O B O B O O O O O O O O O O O O O O O O	['telangiectasia']	1	5	"Sentence: Five months after starting nifedipine ( Adalat ) , two patients developed photodistributed facial telangiectasia , which became more noticeable with time .
Diseases: telangiectasia"	"Sentence: Five months after starting nifedipine ( Adalat ) , two patients developed photodistributed facial telangiectasia , which became more noticeable with time .
Diseases:"
3628	Neither patient complained of photosensitivity or flushing .	O O O O O O B O	O O O O O O O O	['flushing']	1	2	"Sentence: Neither patient complained of photosensitivity or flushing .
Diseases: flushing"	"Sentence: Neither patient complained of photosensitivity or flushing .
Diseases:"
3629	Both patients reported a significant cosmetic improvement after discontinuing the drug .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: Both patients reported a significant cosmetic improvement after discontinuing the drug .
Diseases: "	"Sentence: Both patients reported a significant cosmetic improvement after discontinuing the drug .
Diseases:"
3630	One commenced the closely related drug amlodipine 3 years later , with recurrence of telangiectasia .	O O O O O O O O O O O O O O B O	O O O O O O B O O O O O O O O O	['telangiectasia']	1	5	"Sentence: One commenced the closely related drug amlodipine 3 years later , with recurrence of telangiectasia .
Diseases: telangiectasia"	"Sentence: One commenced the closely related drug amlodipine 3 years later , with recurrence of telangiectasia .
Diseases:"
3631	The photodistribution of the telangiectasia suggests a significant drug / light interaction .	O O O O B O O O O O O O O	O O O O O O O O O O O O O	['telangiectasia']	1	5	"Sentence: The photodistribution of the telangiectasia suggests a significant drug / light interaction .
Diseases: telangiectasia"	"Sentence: The photodistribution of the telangiectasia suggests a significant drug / light interaction .
Diseases:"
3632	Nephrotoxicity of cyclosporin A and FK506 : inhibition of calcineurin phosphatase .	B O O O O O O O O O O O	O O B I O B O O O O O O	['nephrotoxicity']	1	4	"Sentence: Nephrotoxicity of cyclosporin A and FK506 : inhibition of calcineurin phosphatase .
Diseases: nephrotoxicity"	"Sentence: Nephrotoxicity of cyclosporin A and FK506 : inhibition of calcineurin phosphatase .
Diseases:"
3633	Cyclosporin A ( CsA ; 50 mg / kg ) and Fujimycine ( FK506 ; 5 mg / kg ) , but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ) , caused a reduction of glomerular filtration rate , degenerative changes of proximal tubular epithelium , and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	B I O B O O O O O O O B O B O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertrophy']	1	4	"Sentence: Cyclosporin A ( CsA ; 50 mg / kg ) and Fujimycine ( FK506 ; 5 mg / kg ) , but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ) , caused a reduction of glomerular filtration rate , degenerative changes of proximal tubular epithelium , and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days .
Diseases: hypertrophy"	"Sentence: Cyclosporin A ( CsA ; 50 mg / kg ) and Fujimycine ( FK506 ; 5 mg / kg ) , but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ) , caused a reduction of glomerular filtration rate , degenerative changes of proximal tubular epithelium , and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days .
Diseases:"
3634	The molecular mechanisms of CsA and FK506 toxicity were investigated .	O O O O O O O B O O O	O O O O B O B O O O O	['toxicity']	1	2	"Sentence: The molecular mechanisms of CsA and FK506 toxicity were investigated .
Diseases: toxicity"	"Sentence: The molecular mechanisms of CsA and FK506 toxicity were investigated .
Diseases:"
3635	Cyclophilin A and FK506 - binding protein , the main intracytoplasmic receptors for CsA and FK506 , respectively , were each detected in renal tissue extract .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O B O B O O O O O O O O O O O	[]	0	0	"Sentence: Cyclophilin A and FK506 - binding protein , the main intracytoplasmic receptors for CsA and FK506 , respectively , were each detected in renal tissue extract .
Diseases: "	"Sentence: Cyclophilin A and FK506 - binding protein , the main intracytoplasmic receptors for CsA and FK506 , respectively , were each detected in renal tissue extract .
Diseases:"
3636	In the kidney , high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506 , but not by rapamycin .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O B O B O O O O B O	[]	0	0	"Sentence: In the kidney , high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506 , but not by rapamycin .
Diseases: "	"Sentence: In the kidney , high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506 , but not by rapamycin .
Diseases:"
3637	Finally , specific immunophilin - drug - calcineurin complexes formed only in the presence of CsA and FK506 , but not rapamycin .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O B O O O B O	[]	0	0	"Sentence: Finally , specific immunophilin - drug - calcineurin complexes formed only in the presence of CsA and FK506 , but not rapamycin .
Diseases: "	"Sentence: Finally , specific immunophilin - drug - calcineurin complexes formed only in the presence of CsA and FK506 , but not rapamycin .
Diseases:"
3638	These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase .	O O O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O B O B O O O O O O O O O O O O O	['nephrotoxic']	1	4	"Sentence: These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase .
Diseases: nephrotoxic"	"Sentence: These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase .
Diseases:"
3639	Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose : possible role of cranial decompression .	O B I O O O B I O O B O O O O O O O	O O O O O O O O O B O O O O O O O O	['hepatic failure', 'overdose', 'cerebral edema']	3	10	"Sentence: Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose : possible role of cranial decompression .
Diseases: hepatic failure, overdose, cerebral edema"	"Sentence: Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose : possible role of cranial decompression .
Diseases:"
3640	Cerebral edema may complicate the course of fulminant hepatic failure .	B I O O O O O B I I O	O O O O O O O O O O O	['cerebral edema', 'fulminant hepatic failure']	2	12	"Sentence: Cerebral edema may complicate the course of fulminant hepatic failure .
Diseases: cerebral edema, fulminant hepatic failure"	"Sentence: Cerebral edema may complicate the course of fulminant hepatic failure .
Diseases:"
3641	Response to conventional therapy has been disappointing .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: Response to conventional therapy has been disappointing .
Diseases: "	"Sentence: Response to conventional therapy has been disappointing .
Diseases:"
3642	We present a patient with fatal acetaminophen - induced fulminant hepatic failure , with signs and symptoms of cerebral edema , unresponsive to conventional medical therapy .	O O O O O O O O O B I I O O O O O O B I O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O O	['cerebral edema', 'fulminant hepatic failure']	2	12	"Sentence: We present a patient with fatal acetaminophen - induced fulminant hepatic failure , with signs and symptoms of cerebral edema , unresponsive to conventional medical therapy .
Diseases: cerebral edema, fulminant hepatic failure"	"Sentence: We present a patient with fatal acetaminophen - induced fulminant hepatic failure , with signs and symptoms of cerebral edema , unresponsive to conventional medical therapy .
Diseases:"
3643	Cranial decompression was carried out .	O O O O O O	O O O O O O	[]	0	0	"Sentence: Cranial decompression was carried out .
Diseases: "	"Sentence: Cranial decompression was carried out .
Diseases:"
3644	A justification of the need for further evaluation of cranial decompression in such patients is presented .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A justification of the need for further evaluation of cranial decompression in such patients is presented .
Diseases: "	"Sentence: A justification of the need for further evaluation of cranial decompression in such patients is presented .
Diseases:"
3645	Gentamicin nephropathy in a neonate .	O B O O O O	B O O O O O	['nephropathy']	1	4	"Sentence: Gentamicin nephropathy in a neonate .
Diseases: nephropathy"	"Sentence: Gentamicin nephropathy in a neonate .
Diseases:"
3646	The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin ( 5 mg / kg / day ) and penicillin are presented .	O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O O O B O O O	['acute renal failure']	1	4	"Sentence: The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin ( 5 mg / kg / day ) and penicillin are presented .
Diseases: acute renal failure"	"Sentence: The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin ( 5 mg / kg / day ) and penicillin are presented .
Diseases:"
3647	The serum gentamicin concentration had reached toxic levels when anuria developed .	O O O O O O O O O B O O	O O B O O O O O O O O O	['anuria']	1	2	"Sentence: The serum gentamicin concentration had reached toxic levels when anuria developed .
Diseases: anuria"	"Sentence: The serum gentamicin concentration had reached toxic levels when anuria developed .
Diseases:"
3648	Numerous periodic acid Schiff ( PAS ) positive , diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Numerous periodic acid Schiff ( PAS ) positive , diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules .
Diseases: "	"Sentence: Numerous periodic acid Schiff ( PAS ) positive , diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules .
Diseases:"
3649	The pathological changes induced by gentamicin in the human neonatal kidneys have not been previously reported .	O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: The pathological changes induced by gentamicin in the human neonatal kidneys have not been previously reported .
Diseases: "	"Sentence: The pathological changes induced by gentamicin in the human neonatal kidneys have not been previously reported .
Diseases:"
3650	Anti - carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat .	O O B O O O O O O O O O O O	O O O O O B O O O B O O O O	['carcinogenic']	1	4	"Sentence: Anti - carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat .
Diseases: carcinogenic"	"Sentence: Anti - carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat .
Diseases:"
3651	The present work has been planned in order to elucidate the effect of phenobarbital ( PB : 15 mg per rat of ingested dose ) on carcinogenesis when it is administered simultaneously with diethylnitrosamine ( DEN : 10 mg / kg / day ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O B O B O O O O O O O O O	['carcinogenesis']	1	4	"Sentence: The present work has been planned in order to elucidate the effect of phenobarbital ( PB : 15 mg per rat of ingested dose ) on carcinogenesis when it is administered simultaneously with diethylnitrosamine ( DEN : 10 mg / kg / day ) .
Diseases: carcinogenesis"	"Sentence: The present work has been planned in order to elucidate the effect of phenobarbital ( PB : 15 mg per rat of ingested dose ) on carcinogenesis when it is administered simultaneously with diethylnitrosamine ( DEN : 10 mg / kg / day ) .
Diseases:"
3652	Wistar rats ( 180 g ) were treated by DEN alone or by DEN + PB during 2 , 4 and 6 weeks according to our schedule for hepatocarcinogenesis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O B O O O B O B O O O O O O O O O O O O O O	['hepatocarcinogenesis']	1	6	"Sentence: Wistar rats ( 180 g ) were treated by DEN alone or by DEN + PB during 2 , 4 and 6 weeks according to our schedule for hepatocarcinogenesis .
Diseases: hepatocarcinogenesis"	"Sentence: Wistar rats ( 180 g ) were treated by DEN alone or by DEN + PB during 2 , 4 and 6 weeks according to our schedule for hepatocarcinogenesis .
Diseases:"
3653	After the end of the treatment , the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks .	O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O B O O O O B O O O O O O	['preneoplastic foci']	1	6	"Sentence: After the end of the treatment , the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks .
Diseases: preneoplastic foci"	"Sentence: After the end of the treatment , the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks .
Diseases:"
3654	The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O B O B O O O	[]	0	0	"Sentence: The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats .
Diseases: "	"Sentence: The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats .
Diseases:"
3655	When the treatment last only 2 weeks , the presence of PB did not change significantly the last parameters .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: When the treatment last only 2 weeks , the presence of PB did not change significantly the last parameters .
Diseases: "	"Sentence: When the treatment last only 2 weeks , the presence of PB did not change significantly the last parameters .
Diseases:"
3656	In DEN + PB treated rats , the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone .	O O O O O O O O O O O O O B O O O O O O O O O O O O	O B O B O O O O O O O O O O O O O O O O O O O B O O	['tumor']	1	3	"Sentence: In DEN + PB treated rats , the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone .
Diseases: tumor"	"Sentence: In DEN + PB treated rats , the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone .
Diseases:"
3657	It is concluded that PB , which promotes carcinogenesis when administered after the DEN treatment , reduces the carcinogen effect when given simultaneously with DEN .	O O O O O O O O B O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O B O O O O O O O O O O B O	['carcinogenesis']	1	4	"Sentence: It is concluded that PB , which promotes carcinogenesis when administered after the DEN treatment , reduces the carcinogen effect when given simultaneously with DEN .
Diseases: carcinogenesis"	"Sentence: It is concluded that PB , which promotes carcinogenesis when administered after the DEN treatment , reduces the carcinogen effect when given simultaneously with DEN .
Diseases:"
3658	This ' anti - carcinogen ' effect acts on the initiation as well as on the promotion of the precancerous lesions .	O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O	['precancerous lesions']	1	4	"Sentence: This ' anti - carcinogen ' effect acts on the initiation as well as on the promotion of the precancerous lesions .
Diseases: precancerous lesions"	"Sentence: This ' anti - carcinogen ' effect acts on the initiation as well as on the promotion of the precancerous lesions .
Diseases:"
3659	Biochemical investigations are in progress to obtain more information about this ' paradoxical ' PB effect .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Biochemical investigations are in progress to obtain more information about this ' paradoxical ' PB effect .
Diseases: "	"Sentence: Biochemical investigations are in progress to obtain more information about this ' paradoxical ' PB effect .
Diseases:"
3660	Post - operative rigidity after fentanyl administration .	O O O B O O O O	O O O O O B O O	['rigidity']	1	2	"Sentence: Post - operative rigidity after fentanyl administration .
Diseases: rigidity"	"Sentence: Post - operative rigidity after fentanyl administration .
Diseases:"
3661	A case of thoraco - abdominal rigidity leading to respiratory failure is described in the post - operative period in an elderly patient who received a moderate dose of fentanyl .	O O O O O O B O O B I O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['rigidity', 'respiratory failure']	2	5	"Sentence: A case of thoraco - abdominal rigidity leading to respiratory failure is described in the post - operative period in an elderly patient who received a moderate dose of fentanyl .
Diseases: rigidity, respiratory failure"	"Sentence: A case of thoraco - abdominal rigidity leading to respiratory failure is described in the post - operative period in an elderly patient who received a moderate dose of fentanyl .
Diseases:"
3662	This was successfully reversed by naloxone .	O O O O O O O	O O O O O B O	[]	0	0	"Sentence: This was successfully reversed by naloxone .
Diseases: "	"Sentence: This was successfully reversed by naloxone .
Diseases:"
3663	The mechanisms possibly implicated in this accident are discussed .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: The mechanisms possibly implicated in this accident are discussed .
Diseases: "	"Sentence: The mechanisms possibly implicated in this accident are discussed .
Diseases:"
3664	Postpartum psychosis induced by bromocriptine .	O B O O O O	O O O O B O	['psychosis']	1	2	"Sentence: Postpartum psychosis induced by bromocriptine .
Diseases: psychosis"	"Sentence: Postpartum psychosis induced by bromocriptine .
Diseases:"
3665	Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis , having received bromocriptine for inhibition of lactation .	O O O O O O B O O O O O B O O O O O B I I O	O O O O O O O O O O O O O O O O B O O O O O	['psychosis', 'inhibition of lactation', 'psychiatric']	3	9	"Sentence: Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis , having received bromocriptine for inhibition of lactation .
Diseases: psychosis, inhibition of lactation, psychiatric"	"Sentence: Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis , having received bromocriptine for inhibition of lactation .
Diseases:"
3666	Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson 's disease .	O O O O O O O O O B O O O O O O B I I O	B O O O O O O O O O O O O O O O O O O O	"['psychosis', ""parkinson 's disease""]"	2	8	"Sentence: Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson 's disease .
Diseases: psychosis, parkinson 's disease"	"Sentence: Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson 's disease .
Diseases:"
3667	These cases demonstrate that bromocriptine may cause psychosis even when given in low doses .	O O O O O O O B O O O O O O O	O O O O B O O O O O O O O O O	['psychosis']	1	2	"Sentence: These cases demonstrate that bromocriptine may cause psychosis even when given in low doses .
Diseases: psychosis"	"Sentence: These cases demonstrate that bromocriptine may cause psychosis even when given in low doses .
Diseases:"
3668	A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C .	O O O O O O O O B O O O O O	O O O O O O O O O O O B I O	['cardiotoxicity']	1	3	"Sentence: A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C .
Diseases: cardiotoxicity"	"Sentence: A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C .
Diseases:"
3669	Since 1975 mitomycin C ( MMC ) has been suggested to be cardiotoxic , especially when combined with or given following doxorubicin .	O O O O O O O O O O O O B O O O O O O O O O O	O O B I O B O O O O O O O O O O O O O O O B O	['cardiotoxic']	1	3	"Sentence: Since 1975 mitomycin C ( MMC ) has been suggested to be cardiotoxic , especially when combined with or given following doxorubicin .
Diseases: cardiotoxic"	"Sentence: Since 1975 mitomycin C ( MMC ) has been suggested to be cardiotoxic , especially when combined with or given following doxorubicin .
Diseases:"
3670	Data on dose dependency or incidence concerning this side effect were not known .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Data on dose dependency or incidence concerning this side effect were not known .
Diseases: "	"Sentence: Data on dose dependency or incidence concerning this side effect were not known .
Diseases:"
3671	We have initiated a prospective study to obtain some more data on these subjects .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We have initiated a prospective study to obtain some more data on these subjects .
Diseases: "	"Sentence: We have initiated a prospective study to obtain some more data on these subjects .
Diseases:"
3672	Forty - four MMC - treated patients were studied , 37 of them could be evaluated .	O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: Forty - four MMC - treated patients were studied , 37 of them could be evaluated .
Diseases: "	"Sentence: Forty - four MMC - treated patients were studied , 37 of them could be evaluated .
Diseases:"
3673	All patients were studied by repeated physical examinations , chest X - rays , electro - and echocardiography and radionuclide left ventricular ejection fraction ( EF ) determinations .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: All patients were studied by repeated physical examinations , chest X - rays , electro - and echocardiography and radionuclide left ventricular ejection fraction ( EF ) determinations .
Diseases: "	"Sentence: All patients were studied by repeated physical examinations , chest X - rays , electro - and echocardiography and radionuclide left ventricular ejection fraction ( EF ) determinations .
Diseases:"
3674	The results were evaluated per cumulative dose level .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: The results were evaluated per cumulative dose level .
Diseases: "	"Sentence: The results were evaluated per cumulative dose level .
Diseases:"
3675	One of the patients developed cardiac failure after 30 mg m - 2 MMC and only 150 mg m - 2 doxorubicin .	O O O O O B I O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O B O	['cardiac failure']	1	3	"Sentence: One of the patients developed cardiac failure after 30 mg m - 2 MMC and only 150 mg m - 2 doxorubicin .
Diseases: cardiac failure"	"Sentence: One of the patients developed cardiac failure after 30 mg m - 2 MMC and only 150 mg m - 2 doxorubicin .
Diseases:"
3676	The cardiac failure was predicted by a drop in EF determined during a cold pressor test .	O B I O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	['cardiac failure']	1	3	"Sentence: The cardiac failure was predicted by a drop in EF determined during a cold pressor test .
Diseases: cardiac failure"	"Sentence: The cardiac failure was predicted by a drop in EF determined during a cold pressor test .
Diseases:"
3677	None of the other patients developed clinical cardiotoxicity , nor did the studied parameters change .	O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O	['cardiotoxicity']	1	3	"Sentence: None of the other patients developed clinical cardiotoxicity , nor did the studied parameters change .
Diseases: cardiotoxicity"	"Sentence: None of the other patients developed clinical cardiotoxicity , nor did the studied parameters change .
Diseases:"
3678	The literature on this subject was also reviewed .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: The literature on this subject was also reviewed .
Diseases: "	"Sentence: The literature on this subject was also reviewed .
Diseases:"
3679	Based on the combined data from the present study and the literature , we suggest that MMC - related cardiotoxicity is dose dependent , occurring at cumulative dose levels of 30 mg m - 2 or more , mainly in patients also ( previously or simultaneously ) treated with doxorubicin .	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['cardiotoxicity']	1	3	"Sentence: Based on the combined data from the present study and the literature , we suggest that MMC - related cardiotoxicity is dose dependent , occurring at cumulative dose levels of 30 mg m - 2 or more , mainly in patients also ( previously or simultaneously ) treated with doxorubicin .
Diseases: cardiotoxicity"	"Sentence: Based on the combined data from the present study and the literature , we suggest that MMC - related cardiotoxicity is dose dependent , occurring at cumulative dose levels of 30 mg m - 2 or more , mainly in patients also ( previously or simultaneously ) treated with doxorubicin .
Diseases:"
3680	The incidence is likely to be less than 10 % even for this risk group .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The incidence is likely to be less than 10 % even for this risk group .
Diseases: "	"Sentence: The incidence is likely to be less than 10 % even for this risk group .
Diseases:"
3681	Phlorizin - induced glycosuria does not prevent gentamicin nephrotoxicity in rats .	O O O B O O O O B O O O	B O O O O O O B O O O O	['nephrotoxicity', 'glycosuria']	2	8	"Sentence: Phlorizin - induced glycosuria does not prevent gentamicin nephrotoxicity in rats .
Diseases: nephrotoxicity, glycosuria"	"Sentence: Phlorizin - induced glycosuria does not prevent gentamicin nephrotoxicity in rats .
Diseases:"
3682	Because rats with streptozotocin - induced diabetes mellitus ( DM ) have a high solute diuresis ( glycosuria of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to gentamicin - induced acute renal failure ( ARF ) .	O O O O O O B I O B O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O B O O	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	['diabetes mellitus', 'arf', 'glycosuria', 'dm', 'acute renal failure']	5	18	"Sentence: Because rats with streptozotocin - induced diabetes mellitus ( DM ) have a high solute diuresis ( glycosuria of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to gentamicin - induced acute renal failure ( ARF ) .
Diseases: diabetes mellitus, arf, glycosuria, dm, acute renal failure"	"Sentence: Because rats with streptozotocin - induced diabetes mellitus ( DM ) have a high solute diuresis ( glycosuria of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to gentamicin - induced acute renal failure ( ARF ) .
Diseases:"
3683	The protection from gentamicin nephrotoxicity was studied in non - diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin ( P ) .	O O O O B O O O O O B O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O B O O B O B O O	['nephrotoxicity', 'diabetic']	2	6	"Sentence: The protection from gentamicin nephrotoxicity was studied in non - diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin ( P ) .
Diseases: nephrotoxicity, diabetic"	"Sentence: The protection from gentamicin nephrotoxicity was studied in non - diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin ( P ) .
Diseases:"
3684	DM rats with mild glycosuria ( similar in degree to that of the P treated animals ) were also studied .	B O O O B O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O	['glycosuria', 'dm']	2	6	"Sentence: DM rats with mild glycosuria ( similar in degree to that of the P treated animals ) were also studied .
Diseases: glycosuria, dm"	"Sentence: DM rats with mild glycosuria ( similar in degree to that of the P treated animals ) were also studied .
Diseases:"
3685	Unanesthetized adult female , Sprague - Dawley rats were divided in four groups and studied for 15 days .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Unanesthetized adult female , Sprague - Dawley rats were divided in four groups and studied for 15 days .
Diseases: "	"Sentence: Unanesthetized adult female , Sprague - Dawley rats were divided in four groups and studied for 15 days .
Diseases:"
3686	Group 1 ( P alone ) received P , 360 mg / day , for 15 days ; Group II ( P + gentamicin ) ; Group III ( gentamicin alone ) and Group IV ( mild DM + gentamicin ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	O O O B O O O B O O O O O O O O O O O O O B O B O O O O O B O O O O O O O B O B O O	['dm']	1	1	"Sentence: Group 1 ( P alone ) received P , 360 mg / day , for 15 days ; Group II ( P + gentamicin ) ; Group III ( gentamicin alone ) and Group IV ( mild DM + gentamicin ) .
Diseases: dm"	"Sentence: Group 1 ( P alone ) received P , 360 mg / day , for 15 days ; Group II ( P + gentamicin ) ; Group III ( gentamicin alone ) and Group IV ( mild DM + gentamicin ) .
Diseases:"
3687	Nephrotoxic doses ( 40 mg / kg body wt / day ) of gentamicin were injected during the last nine days of study to the animals of groups II to IV .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	['nephrotoxic']	1	4	"Sentence: Nephrotoxic doses ( 40 mg / kg body wt / day ) of gentamicin were injected during the last nine days of study to the animals of groups II to IV .
Diseases: nephrotoxic"	"Sentence: Nephrotoxic doses ( 40 mg / kg body wt / day ) of gentamicin were injected during the last nine days of study to the animals of groups II to IV .
Diseases:"
3688	In Group I , P induced a moderate and stable glycosuria ( 3 . 9 + / -	O O O O O O O O O O B O O O O O O O	O O O O B O O O O O O O O O O O O O	['glycosuria']	1	3	"Sentence: In Group I , P induced a moderate and stable glycosuria ( 3 . 9 + / -
Diseases: glycosuria"	"Sentence: In Group I , P induced a moderate and stable glycosuria ( 3 . 9 + / -
Diseases:"
3689	0 . 1	O O O	O O O	[]	0	0	"Sentence: 0 . 1
Diseases: "	"Sentence: 0 . 1
Diseases:"
3690	g / day , SE ) , and no functional or morphologic evidence of renal dysfunction ( baseline CCr 2 . 1 + / - 0 . 1 ml / min , undetectable lysozymuria ) or damage ( tubular necrosis score [ maximum 4 ] , zero ) .	O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['tubular necrosis', 'renal dysfunction']	2	8	"Sentence: g / day , SE ) , and no functional or morphologic evidence of renal dysfunction ( baseline CCr 2 . 1 + / - 0 . 1 ml / min , undetectable lysozymuria ) or damage ( tubular necrosis score [ maximum 4 ] , zero ) .
Diseases: tubular necrosis, renal dysfunction"	"Sentence: g / day , SE ) , and no functional or morphologic evidence of renal dysfunction ( baseline CCr 2 . 1 + / - 0 . 1 ml / min , undetectable lysozymuria ) or damage ( tubular necrosis score [ maximum 4 ] , zero ) .
Diseases:"
3691	In Group II , P did not prevent gentamicin - ARF ( maximal decrease in CCr at day 9 . 89 % , P less than 0 . 001 ; peak lysozymuria , 1863 + / -	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['arf']	1	1	"Sentence: In Group II , P did not prevent gentamicin - ARF ( maximal decrease in CCr at day 9 . 89 % , P less than 0 . 001 ; peak lysozymuria , 1863 + / -
Diseases: arf"	"Sentence: In Group II , P did not prevent gentamicin - ARF ( maximal decrease in CCr at day 9 . 89 % , P less than 0 . 001 ; peak lysozymuria , 1863 + / -
Diseases:"
3692	321 micrograms / day ; and tubular necrosis score , 3 . 9 + / - 0 . 1 ) .	O O O O O O B I O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	['tubular necrosis']	1	4	"Sentence: 321 micrograms / day ; and tubular necrosis score , 3 . 9 + / - 0 . 1 ) .
Diseases: tubular necrosis"	"Sentence: 321 micrograms / day ; and tubular necrosis score , 3 . 9 + / - 0 . 1 ) .
Diseases:"
3693	These values were not different from those of Group III : maximal decrease in CCr 73 % ( P less than 0 . 001 ) ; lysozymuria , 2147 + / -	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These values were not different from those of Group III : maximal decrease in CCr 73 % ( P less than 0 . 001 ) ; lysozymuria , 2147 + / -
Diseases: "	"Sentence: These values were not different from those of Group III : maximal decrease in CCr 73 % ( P less than 0 . 001 ) ; lysozymuria , 2147 + / -
Diseases:"
3694	701 micrograms / day ; tubular necrosis score , 3 . 8 + / - 0 . 1 . ( ABSTRACT TRUNCATED AT 250 WORDS )	O O O O O B I O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['tubular necrosis']	1	4	"Sentence: 701 micrograms / day ; tubular necrosis score , 3 . 8 + / - 0 . 1 . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases: tubular necrosis"	"Sentence: 701 micrograms / day ; tubular necrosis score , 3 . 8 + / - 0 . 1 . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases:"
3695	Tiapride in levodopa - induced involuntary movements .	O O O O O B I O	B O B O O O O O	['involuntary movements']	1	4	"Sentence: Tiapride in levodopa - induced involuntary movements .
Diseases: involuntary movements"	"Sentence: Tiapride in levodopa - induced involuntary movements .
Diseases:"
3696	Tiapride , a substituted benzamide derivative closely related to metoclopramide , reduced levodopa - induced peak dose involuntary movements in 16 patients with idiopathic Parkinson 's disease .	O O O O O O O O O O O O O O O O O B I O O O O B I I I O	B O O O I O O O O B O O B O O O O O O O O O O O O O O O	"[""idiopathic parkinson 's disease"", 'involuntary movements']"	2	12	"Sentence: Tiapride , a substituted benzamide derivative closely related to metoclopramide , reduced levodopa - induced peak dose involuntary movements in 16 patients with idiopathic Parkinson 's disease .
Diseases: idiopathic parkinson 's disease, involuntary movements"	"Sentence: Tiapride , a substituted benzamide derivative closely related to metoclopramide , reduced levodopa - induced peak dose involuntary movements in 16 patients with idiopathic Parkinson 's disease .
Diseases:"
3697	However , an unacceptable increase in disability from Parkinsonism with aggravation of end - of - dose akinesia led to its cessation in 14 patients .	O O O O O O O O B O O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['parkinsonism', 'akinesia']	2	7	"Sentence: However , an unacceptable increase in disability from Parkinsonism with aggravation of end - of - dose akinesia led to its cessation in 14 patients .
Diseases: parkinsonism, akinesia"	"Sentence: However , an unacceptable increase in disability from Parkinsonism with aggravation of end - of - dose akinesia led to its cessation in 14 patients .
Diseases:"
3698	"Tiapride had no effect on levodopa - induced early morning of "" off - period "" segmental dystonia ."	O O O O O O O O O O O O O O O O O B O	B O O O O B O O O O O O O O O O O O O	['dystonia']	1	3	"Sentence: Tiapride had no effect on levodopa - induced early morning of "" off - period "" segmental dystonia .
Diseases: dystonia"	"Sentence: Tiapride had no effect on levodopa - induced early morning of "" off - period "" segmental dystonia .
Diseases:"
3699	These results fail to support the notion that levodopa - induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors .	O O O O O O O O O O O B O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O B O O	['dyskinesias']	1	5	"Sentence: These results fail to support the notion that levodopa - induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors .
Diseases: dyskinesias"	"Sentence: These results fail to support the notion that levodopa - induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors .
Diseases:"
3700	Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in penicillin - induced epilepsy model in rats .	O O O O O O O O O B O O O O O B O O O O	O O O O O O O O O O O O B O O O O O O O	['epileptic', 'epilepsy']	2	5	"Sentence: Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in penicillin - induced epilepsy model in rats .
Diseases: epileptic, epilepsy"	"Sentence: Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in penicillin - induced epilepsy model in rats .
Diseases:"
3701	AIM : Experimental and clinical studies have revealed that hippocampal DBS can control epileptic activity , but the mechanism of action is obscure and optimal stimulation parameters are not clearly defined .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['epileptic']	1	3	"Sentence: AIM : Experimental and clinical studies have revealed that hippocampal DBS can control epileptic activity , but the mechanism of action is obscure and optimal stimulation parameters are not clearly defined .
Diseases: epileptic"	"Sentence: AIM : Experimental and clinical studies have revealed that hippocampal DBS can control epileptic activity , but the mechanism of action is obscure and optimal stimulation parameters are not clearly defined .
Diseases:"
3702	The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in penicillin - induced epilepsy model .	O O O O O O O O O O O O O O B O O O O O B O O	O O O O O O O O O O O O O O O O O B O O O O O	['epileptic', 'epilepsy']	2	5	"Sentence: The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in penicillin - induced epilepsy model .
Diseases: epileptic, epilepsy"	"Sentence: The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in penicillin - induced epilepsy model .
Diseases:"
3703	MATERIAL AND METHODS : Twenty - five Sprague - Dawley rats were implanted DBS electrodes .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: MATERIAL AND METHODS : Twenty - five Sprague - Dawley rats were implanted DBS electrodes .
Diseases: "	"Sentence: MATERIAL AND METHODS : Twenty - five Sprague - Dawley rats were implanted DBS electrodes .
Diseases:"
3704	In group - 1 ( n = 10 ) hippocampal DBS was off and in the group - 2 ( n = 10 ) hippocampal DBS was on ( 185 Hz , 0 . 5V , 1V , 2V , and 5V for 60 sec ) following penicillin G injection intracortically .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O	[]	0	0	"Sentence: In group - 1 ( n = 10 ) hippocampal DBS was off and in the group - 2 ( n = 10 ) hippocampal DBS was on ( 185 Hz , 0 . 5V , 1V , 2V , and 5V for 60 sec ) following penicillin G injection intracortically .
Diseases: "	"Sentence: In group - 1 ( n = 10 ) hippocampal DBS was off and in the group - 2 ( n = 10 ) hippocampal DBS was on ( 185 Hz , 0 . 5V , 1V , 2V , and 5V for 60 sec ) following penicillin G injection intracortically .
Diseases:"
3705	In the control group hippocampal DBS was on following 8 l saline injection intracortically .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the control group hippocampal DBS was on following 8 l saline injection intracortically .
Diseases: "	"Sentence: In the control group hippocampal DBS was on following 8 l saline injection intracortically .
Diseases:"
3706	EEG recordings were obtained before and 15 minutes following penicillin - G injection , and at 10th minutes following each stimulus for analysis in terms of frequency , amplitude , and power spectrum .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: EEG recordings were obtained before and 15 minutes following penicillin - G injection , and at 10th minutes following each stimulus for analysis in terms of frequency , amplitude , and power spectrum .
Diseases: "	"Sentence: EEG recordings were obtained before and 15 minutes following penicillin - G injection , and at 10th minutes following each stimulus for analysis in terms of frequency , amplitude , and power spectrum .
Diseases:"
3707	High frequency hippocampal DBS suppressed the acute penicillin - induced cortical epileptic activity independent from stimulus intensity .	O O O O O O O O O O O B O O O O O O	O O O O O O O B O O O O O O O O O O	['epileptic']	1	3	"Sentence: High frequency hippocampal DBS suppressed the acute penicillin - induced cortical epileptic activity independent from stimulus intensity .
Diseases: epileptic"	"Sentence: High frequency hippocampal DBS suppressed the acute penicillin - induced cortical epileptic activity independent from stimulus intensity .
Diseases:"
3708	In the control group , hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the control group , hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation .
Diseases: "	"Sentence: In the control group , hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation .
Diseases:"
3709	Our results revealed that continuous high frequency stimulation of the hippocampus suppressed acute cortical epileptic activity effectively without causing secondary epileptic discharges .	O O O O O O O O O O O O O O B O O O O O B O O	O O O O O O O O O O O O O O O O O O O O O O O	['epileptic']	1	3	"Sentence: Our results revealed that continuous high frequency stimulation of the hippocampus suppressed acute cortical epileptic activity effectively without causing secondary epileptic discharges .
Diseases: epileptic"	"Sentence: Our results revealed that continuous high frequency stimulation of the hippocampus suppressed acute cortical epileptic activity effectively without causing secondary epileptic discharges .
Diseases:"
3710	These results are important in terms of defining the optimal parameters of hippocampal DBS in patients with epilepsy .	O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O	['epilepsy']	1	3	"Sentence: These results are important in terms of defining the optimal parameters of hippocampal DBS in patients with epilepsy .
Diseases: epilepsy"	"Sentence: These results are important in terms of defining the optimal parameters of hippocampal DBS in patients with epilepsy .
Diseases:"
3711	Neural correlates of S - ketamine induced psychosis during overt continuous verbal fluency .	O O O O O O O B O O O O O O	O O O B I I O O O O O O O O	['psychosis']	1	2	"Sentence: Neural correlates of S - ketamine induced psychosis during overt continuous verbal fluency .
Diseases: psychosis"	"Sentence: Neural correlates of S - ketamine induced psychosis during overt continuous verbal fluency .
Diseases:"
3712	The glutamatergic N - methyl - D - aspartate ( NMDA ) receptor has been implicated in the pathophysiology of schizophrenia .	O O O O O O O O O O O O O O O O O O O O B O	O O B I I I I I I O B O O O O O O O O O O O	['schizophrenia']	1	3	"Sentence: The glutamatergic N - methyl - D - aspartate ( NMDA ) receptor has been implicated in the pathophysiology of schizophrenia .
Diseases: schizophrenia"	"Sentence: The glutamatergic N - methyl - D - aspartate ( NMDA ) receptor has been implicated in the pathophysiology of schizophrenia .
Diseases:"
3713	Administered to healthy volunteers , a subanesthetic dose of the non - competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O B O O B O O O O O O O O O O O	['schizophrenia']	1	3	"Sentence: Administered to healthy volunteers , a subanesthetic dose of the non - competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia .
Diseases: schizophrenia"	"Sentence: Administered to healthy volunteers , a subanesthetic dose of the non - competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia .
Diseases:"
3714	In patients with schizophrenia , ketamine exacerbates the core symptoms of illness , supporting the hypothesis of a glutamatergic dysfunction .	O O O B O O O O O O O O O O O O O O B I O	O O O O O B O O O O O O O O O O O O O O O	['schizophrenia', 'glutamatergic dysfunction']	2	10	"Sentence: In patients with schizophrenia , ketamine exacerbates the core symptoms of illness , supporting the hypothesis of a glutamatergic dysfunction .
Diseases: schizophrenia, glutamatergic dysfunction"	"Sentence: In patients with schizophrenia , ketamine exacerbates the core symptoms of illness , supporting the hypothesis of a glutamatergic dysfunction .
Diseases:"
3715	In a counterbalanced , placebo - controlled , double - blind study design , healthy subjects were administered a continuous subanesthetic S - ketamine infusion while differences in BOLD responses measured with fMRI were detected .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O	[]	0	0	"Sentence: In a counterbalanced , placebo - controlled , double - blind study design , healthy subjects were administered a continuous subanesthetic S - ketamine infusion while differences in BOLD responses measured with fMRI were detected .
Diseases: "	"Sentence: In a counterbalanced , placebo - controlled , double - blind study design , healthy subjects were administered a continuous subanesthetic S - ketamine infusion while differences in BOLD responses measured with fMRI were detected .
Diseases:"
3716	During the scanning period , subjects performed continuous overt verbal fluency tasks ( phonological , lexical and semantic ) .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: During the scanning period , subjects performed continuous overt verbal fluency tasks ( phonological , lexical and semantic ) .
Diseases: "	"Sentence: During the scanning period , subjects performed continuous overt verbal fluency tasks ( phonological , lexical and semantic ) .
Diseases:"
3717	Ketamine - induced psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale ( PANSS ) .	O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ketamine - induced psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale ( PANSS ) .
Diseases: "	"Sentence: Ketamine - induced psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale ( PANSS ) .
Diseases:"
3718	Ketamine elicited psychosis like psychopathology .	O O B O O O	B O O O O O	['psychosis']	1	2	"Sentence: Ketamine elicited psychosis like psychopathology .
Diseases: psychosis"	"Sentence: Ketamine elicited psychosis like psychopathology .
Diseases:"
3719	Post - hoc t - tests revealed significant differences between placebo and ketamine for the amounts of words generated during lexical and semantic verbal fluency , while the phonological domain remained unaffected .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Post - hoc t - tests revealed significant differences between placebo and ketamine for the amounts of words generated during lexical and semantic verbal fluency , while the phonological domain remained unaffected .
Diseases: "	"Sentence: Post - hoc t - tests revealed significant differences between placebo and ketamine for the amounts of words generated during lexical and semantic verbal fluency , while the phonological domain remained unaffected .
Diseases:"
3720	Ketamine led to enhanced cortical activations in supramarginal and frontal brain regions for phonological and lexical verbal fluency , but not for semantic verbal fluency .	O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ketamine led to enhanced cortical activations in supramarginal and frontal brain regions for phonological and lexical verbal fluency , but not for semantic verbal fluency .
Diseases: "	"Sentence: Ketamine led to enhanced cortical activations in supramarginal and frontal brain regions for phonological and lexical verbal fluency , but not for semantic verbal fluency .
Diseases:"
3721	Ketamine induces activation changes in healthy subjects similar to those observed in patients with schizophrenia , particularly in frontal and temporal brain regions .	O O O O O O O O O O O O O O B O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O	['schizophrenia']	1	3	"Sentence: Ketamine induces activation changes in healthy subjects similar to those observed in patients with schizophrenia , particularly in frontal and temporal brain regions .
Diseases: schizophrenia"	"Sentence: Ketamine induces activation changes in healthy subjects similar to those observed in patients with schizophrenia , particularly in frontal and temporal brain regions .
Diseases:"
3722	Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia .	O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O B O O O O O O O O	['schizophrenia']	1	3	"Sentence: Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia .
Diseases: schizophrenia"	"Sentence: Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia .
Diseases:"
3723	Dopamine is not essential for the development of methamphetamine - induced neurotoxicity .	O O O O O O O O O O O B O	B O O O O O O O B O O O O	['neurotoxicity']	1	4	"Sentence: Dopamine is not essential for the development of methamphetamine - induced neurotoxicity .
Diseases: neurotoxicity"	"Sentence: Dopamine is not essential for the development of methamphetamine - induced neurotoxicity .
Diseases:"
3724	It is widely believed that dopamine ( DA ) mediates methamphetamine ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance toxicity .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O B O O O O O O O O B O	O O O O O B O B O O B O B O O O O O O O O O O O O O O B O O O O O O O O B O O O O	['toxicity']	1	2	"Sentence: It is widely believed that dopamine ( DA ) mediates methamphetamine ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance toxicity .
Diseases: toxicity"	"Sentence: It is widely believed that dopamine ( DA ) mediates methamphetamine ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance toxicity .
Diseases:"
3725	However , temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: However , temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data .
Diseases: "	"Sentence: However , temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data .
Diseases:"
3726	Here we show that the recently reported ability of L - dihydroxyphenylalanine to reverse the protective effect of alpha - methyl - para - tyrosine on METH - induced DA neurotoxicity is also confounded by drug effects on body temperature .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	O O O O O O O O O B I I O O O O O O B I I I I I I O B O O B O O O O O O O O O O O	['neurotoxicity']	1	4	"Sentence: Here we show that the recently reported ability of L - dihydroxyphenylalanine to reverse the protective effect of alpha - methyl - para - tyrosine on METH - induced DA neurotoxicity is also confounded by drug effects on body temperature .
Diseases: neurotoxicity"	"Sentence: Here we show that the recently reported ability of L - dihydroxyphenylalanine to reverse the protective effect of alpha - methyl - para - tyrosine on METH - induced DA neurotoxicity is also confounded by drug effects on body temperature .
Diseases:"
3727	Further , we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity , as long as the thermic effects of METH are preserved .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	O O O O O O O O O O O O O B O B O O O O O O O O O B O O O	['neurotoxicity']	1	4	"Sentence: Further , we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity , as long as the thermic effects of METH are preserved .
Diseases: neurotoxicity"	"Sentence: Further , we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity , as long as the thermic effects of METH are preserved .
Diseases:"
3728	In addition , we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH - induced dopaminergic deficits that are of comparable magnitude on both sides of the brain .	O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O	O O O O O O O O O O O O O B O O B O O O O O O O O O O O O O O O O	['dopaminergic deficits']	1	5	"Sentence: In addition , we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH - induced dopaminergic deficits that are of comparable magnitude on both sides of the brain .
Diseases: dopaminergic deficits"	"Sentence: In addition , we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH - induced dopaminergic deficits that are of comparable magnitude on both sides of the brain .
Diseases:"
3729	Taken together , these findings demonstrate that DA is not essential for the development of METH - induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation .	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	O O O O O O O B O O O O O O O B O O O O O O O O O O B O O O O O	['neurotoxicity']	1	4	"Sentence: Taken together , these findings demonstrate that DA is not essential for the development of METH - induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation .
Diseases: neurotoxicity"	"Sentence: Taken together , these findings demonstrate that DA is not essential for the development of METH - induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation .
Diseases:"
3730	Brainstem dysgenesis in an infant prenatally exposed to cocaine .	B I O O O O O O O O	O O O O O O O O B O	['brainstem dysgenesis']	1	5	"Sentence: Brainstem dysgenesis in an infant prenatally exposed to cocaine .
Diseases: brainstem dysgenesis"	"Sentence: Brainstem dysgenesis in an infant prenatally exposed to cocaine .
Diseases:"
3731	Many authors described the effects on the fetus of maternal cocaine abuse during pregnancy .	O O O O O O O O O O B I O O O	O O O O O O O O O O B O O O O	['cocaine abuse']	1	4	"Sentence: Many authors described the effects on the fetus of maternal cocaine abuse during pregnancy .
Diseases: cocaine abuse"	"Sentence: Many authors described the effects on the fetus of maternal cocaine abuse during pregnancy .
Diseases:"
3732	Vasoconstriction appears to be the common mechanism of action leading to a wide range of fetal anomalies .	O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O	['fetal anomalies']	1	3	"Sentence: Vasoconstriction appears to be the common mechanism of action leading to a wide range of fetal anomalies .
Diseases: fetal anomalies"	"Sentence: Vasoconstriction appears to be the common mechanism of action leading to a wide range of fetal anomalies .
Diseases:"
3733	We report on an infant with multiple cranial - nerve involvement attributable to brainstem dysgenesis , born to a cocaine - addicted mother .	O O O O O O B I I I I O O B I O O O O B I I O O	O O O O O O O O O O O O O O O O O O O B O O O O	['multiple cranial - nerve involvement', 'cocaine - addicted', 'brainstem dysgenesis']	3	16	"Sentence: We report on an infant with multiple cranial - nerve involvement attributable to brainstem dysgenesis , born to a cocaine - addicted mother .
Diseases: multiple cranial - nerve involvement, cocaine - addicted, brainstem dysgenesis"	"Sentence: We report on an infant with multiple cranial - nerve involvement attributable to brainstem dysgenesis , born to a cocaine - addicted mother .
Diseases:"
3734	The protective role of Nrf2 in streptozotocin - induced diabetic nephropathy .	O O O O O O O O O B I O	O O O O O O B O O O O O	['diabetic nephropathy']	1	6	"Sentence: The protective role of Nrf2 in streptozotocin - induced diabetic nephropathy .
Diseases: diabetic nephropathy"	"Sentence: The protective role of Nrf2 in streptozotocin - induced diabetic nephropathy .
Diseases:"
3735	Diabetic nephropathy is one of the major causes of renal failure , which is accompanied by the production of reactive oxygen species ( ROS ) .	B I O O O O O O O B I O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O B O O O O O	['diabetic nephropathy', 'renal failure']	2	9	"Sentence: Diabetic nephropathy is one of the major causes of renal failure , which is accompanied by the production of reactive oxygen species ( ROS ) .
Diseases: diabetic nephropathy, renal failure"	"Sentence: Diabetic nephropathy is one of the major causes of renal failure , which is accompanied by the production of reactive oxygen species ( ROS ) .
Diseases:"
3736	Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis .
Diseases: "	"Sentence: Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis .
Diseases:"
3737	Here , we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy .	O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O	['diabetic nephropathy']	1	6	"Sentence: Here , we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy .
Diseases: diabetic nephropathy"	"Sentence: Here , we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy .
Diseases:"
3738	RESEARCH DESIGN AND METHODS : We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients , a streptozotocin - induced diabetic nephropathy model in Nrf2 ( - / - ) mice , and cultured human mesangial cells .	O O O O O O O O O O O O O B I O O O O O O B I O O O O O O B I O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['diabetic nephropathy']	1	6	"Sentence: RESEARCH DESIGN AND METHODS : We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients , a streptozotocin - induced diabetic nephropathy model in Nrf2 ( - / - ) mice , and cultured human mesangial cells .
Diseases: diabetic nephropathy"	"Sentence: RESEARCH DESIGN AND METHODS : We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients , a streptozotocin - induced diabetic nephropathy model in Nrf2 ( - / - ) mice , and cultured human mesangial cells .
Diseases:"
3739	The glomeruli of human diabetic nephropathy patients were under oxidative stress and had elevated Nrf2 levels .	O O O O B I O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	['diabetic nephropathy']	1	6	"Sentence: The glomeruli of human diabetic nephropathy patients were under oxidative stress and had elevated Nrf2 levels .
Diseases: diabetic nephropathy"	"Sentence: The glomeruli of human diabetic nephropathy patients were under oxidative stress and had elevated Nrf2 levels .
Diseases:"
3740	In the animal study , Nrf2 was demonstrated to be crucial in ameliorating streptozotocin - induced renal damage .	O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O B O O O O O	['renal damage']	1	3	"Sentence: In the animal study , Nrf2 was demonstrated to be crucial in ameliorating streptozotocin - induced renal damage .
Diseases: renal damage"	"Sentence: In the animal study , Nrf2 was demonstrated to be crucial in ameliorating streptozotocin - induced renal damage .
Diseases:"
3741	This is evident by Nrf2 ( - / - )	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: This is evident by Nrf2 ( - / - )
Diseases: "	"Sentence: This is evident by Nrf2 ( - / - )
Diseases:"
3742	mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2 ( + / + ) mice .	O O O O O O O O O O O O O B I O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['renal injury']	1	3	"Sentence: mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2 ( + / + ) mice .
Diseases: renal injury"	"Sentence: mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2 ( + / + ) mice .
Diseases:"
3743	Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2 - mediated protection against diabetic nephropathy is , at least , partially through inhibition of transforming growth factor - beta1 ( TGF - beta1 ) and reduction of extracellular matrix production .	O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['diabetic nephropathy']	1	6	"Sentence: Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2 - mediated protection against diabetic nephropathy is , at least , partially through inhibition of transforming growth factor - beta1 ( TGF - beta1 ) and reduction of extracellular matrix production .
Diseases: diabetic nephropathy"	"Sentence: Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2 - mediated protection against diabetic nephropathy is , at least , partially through inhibition of transforming growth factor - beta1 ( TGF - beta1 ) and reduction of extracellular matrix production .
Diseases:"
3744	In human renal mesangial cells , high glucose induced ROS production and activated expression of Nrf2 and its downstream genes .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O B O O O O O O O O O O O	[]	0	0	"Sentence: In human renal mesangial cells , high glucose induced ROS production and activated expression of Nrf2 and its downstream genes .
Diseases: "	"Sentence: In human renal mesangial cells , high glucose induced ROS production and activated expression of Nrf2 and its downstream genes .
Diseases:"
3745	Furthermore , activation or overexpression of Nrf2 inhibited the promoter activity of TGF - beta1 in a dose - dependent manner , whereas knockdown of Nrf2 by siRNA enhanced TGF - beta1 transcription and fibronectin production .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Furthermore , activation or overexpression of Nrf2 inhibited the promoter activity of TGF - beta1 in a dose - dependent manner , whereas knockdown of Nrf2 by siRNA enhanced TGF - beta1 transcription and fibronectin production .
Diseases: "	"Sentence: Furthermore , activation or overexpression of Nrf2 inhibited the promoter activity of TGF - beta1 in a dose - dependent manner , whereas knockdown of Nrf2 by siRNA enhanced TGF - beta1 transcription and fibronectin production .
Diseases:"
3746	This work clearly indicates a protective role of Nrf2 in diabetic nephropathy , suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy .	O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['diabetic nephropathy']	1	6	"Sentence: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy , suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy .
Diseases: diabetic nephropathy"	"Sentence: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy , suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy .
Diseases:"
3747	High - dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients .	O O O O O O O O O O B O O O O O	O O O B I O O O O O O O O O O O	['seizures']	1	3	"Sentence: High - dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients .
Diseases: seizures"	"Sentence: High - dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients .
Diseases:"
3748	In 2 separate centers , we observed a notable increase in the incidence of postoperative convulsive seizures from 1 . 3 % to 3 . 8 % in patients having undergone major cardiac surgical procedures .	O O O O O O O O O O O O O O O B B O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['convulsive', 'seizures']	2	4	"Sentence: In 2 separate centers , we observed a notable increase in the incidence of postoperative convulsive seizures from 1 . 3 % to 3 . 8 % in patients having undergone major cardiac surgical procedures .
Diseases: convulsive, seizures"	"Sentence: In 2 separate centers , we observed a notable increase in the incidence of postoperative convulsive seizures from 1 . 3 % to 3 . 8 % in patients having undergone major cardiac surgical procedures .
Diseases:"
3749	These events were temporally coincident with the initial use of high - dose tranexamic acid ( TXA ) therapy after withdrawal of aprotinin from general clinical usage .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B I O B O O O O O O O O O O O	[]	0	0	"Sentence: These events were temporally coincident with the initial use of high - dose tranexamic acid ( TXA ) therapy after withdrawal of aprotinin from general clinical usage .
Diseases: "	"Sentence: These events were temporally coincident with the initial use of high - dose tranexamic acid ( TXA ) therapy after withdrawal of aprotinin from general clinical usage .
Diseases:"
3750	The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery .	O O O O O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O	['seizures']	1	3	"Sentence: The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery .
Diseases: seizures"	"Sentence: The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery .
Diseases:"
3751	METHODS : An in - depth chart review was undertaken in all 24 patients who developed perioperative seizures .	O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O	['seizures']	1	3	"Sentence: METHODS : An in - depth chart review was undertaken in all 24 patients who developed perioperative seizures .
Diseases: seizures"	"Sentence: METHODS : An in - depth chart review was undertaken in all 24 patients who developed perioperative seizures .
Diseases:"
3752	Electroencephalographic activity was recorded in 11 of these patients , and all patients had a formal neurological evaluation and brain imaging studies .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Electroencephalographic activity was recorded in 11 of these patients , and all patients had a formal neurological evaluation and brain imaging studies .
Diseases: "	"Sentence: Electroencephalographic activity was recorded in 11 of these patients , and all patients had a formal neurological evaluation and brain imaging studies .
Diseases:"
3753	Twenty - one of the 24 patients did not have evidence of new cerebral ischemic injury , but seizures were likely due to ischemic brain injury in 3 patients .	O O O O O O O O O O O O O B I I O O B O O O O B I I O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cerebral ischemic injury', 'seizures', 'ischemic brain injury']	3	15	"Sentence: Twenty - one of the 24 patients did not have evidence of new cerebral ischemic injury , but seizures were likely due to ischemic brain injury in 3 patients .
Diseases: cerebral ischemic injury, seizures, ischemic brain injury"	"Sentence: Twenty - one of the 24 patients did not have evidence of new cerebral ischemic injury , but seizures were likely due to ischemic brain injury in 3 patients .
Diseases:"
3754	All patients with seizures did not have permanent neurological abnormalities .	O O O B O O O O B I O	O O O O O O O O O O O	['neurological abnormalities', 'seizures']	2	7	"Sentence: All patients with seizures did not have permanent neurological abnormalities .
Diseases: neurological abnormalities, seizures"	"Sentence: All patients with seizures did not have permanent neurological abnormalities .
Diseases:"
3755	All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg / kg , had a mean age of 69 . 9 years , and 21 of 24 had undergone open chamber rather than coronary bypass procedures .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['seizures']	1	3	"Sentence: All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg / kg , had a mean age of 69 . 9 years , and 21 of 24 had undergone open chamber rather than coronary bypass procedures .
Diseases: seizures"	"Sentence: All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg / kg , had a mean age of 69 . 9 years , and 21 of 24 had undergone open chamber rather than coronary bypass procedures .
Diseases:"
3756	All but one patient were managed using cardiopulmonary bypass .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: All but one patient were managed using cardiopulmonary bypass .
Diseases: "	"Sentence: All but one patient were managed using cardiopulmonary bypass .
Diseases:"
3757	No evidence of brain ischemic , metabolic , or hyperthermia - induced causes for their seizures was apparent .	O O O B I O O O O B O O O O O B O O O	O O O O O O O O O O O O O O O O O O O	['hyperthermia', 'brain ischemic', 'seizures']	3	10	"Sentence: No evidence of brain ischemic , metabolic , or hyperthermia - induced causes for their seizures was apparent .
Diseases: hyperthermia, brain ischemic, seizures"	"Sentence: No evidence of brain ischemic , metabolic , or hyperthermia - induced causes for their seizures was apparent .
Diseases:"
3758	Our results suggest that use of high - dose TXA in older patients in conjunction with cardiopulmonary bypass and open - chamber cardiac surgery is associated with clinical seizures in susceptible patients .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['seizures']	1	3	"Sentence: Our results suggest that use of high - dose TXA in older patients in conjunction with cardiopulmonary bypass and open - chamber cardiac surgery is associated with clinical seizures in susceptible patients .
Diseases: seizures"	"Sentence: Our results suggest that use of high - dose TXA in older patients in conjunction with cardiopulmonary bypass and open - chamber cardiac surgery is associated with clinical seizures in susceptible patients .
Diseases:"
3759	Recurrent dysosmia induced by pyrazinamide .	O B O O O O	O O O O B O	['dysosmia']	1	4	"Sentence: Recurrent dysosmia induced by pyrazinamide .
Diseases: dysosmia"	"Sentence: Recurrent dysosmia induced by pyrazinamide .
Diseases:"
3760	Pyrazinamide can have adverse effects such as hepatic toxicity , hyperuricemia or digestive disorders .	O O O O O O O B I O B O O O O	B O O O O O O O O O O O O O O	['hyperuricemia', 'hepatic toxicity']	2	8	"Sentence: Pyrazinamide can have adverse effects such as hepatic toxicity , hyperuricemia or digestive disorders .
Diseases: hyperuricemia, hepatic toxicity"	"Sentence: Pyrazinamide can have adverse effects such as hepatic toxicity , hyperuricemia or digestive disorders .
Diseases:"
3761	In rare cases , alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O	[]	0	0	"Sentence: In rare cases , alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs .
Diseases: "	"Sentence: In rare cases , alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs .
Diseases:"
3762	We report a case of reversible olfactory disorder related to pyrazinamide in a woman , with a positive rechallenge .	O O O O O O B I O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O	['olfactory disorder']	1	3	"Sentence: We report a case of reversible olfactory disorder related to pyrazinamide in a woman , with a positive rechallenge .
Diseases: olfactory disorder"	"Sentence: We report a case of reversible olfactory disorder related to pyrazinamide in a woman , with a positive rechallenge .
Diseases:"
3763	The patient presented every day a sensation of smelling something burning 15 min after drug intake .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The patient presented every day a sensation of smelling something burning 15 min after drug intake .
Diseases: "	"Sentence: The patient presented every day a sensation of smelling something burning 15 min after drug intake .
Diseases:"
3764	Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge .	B O O O O O O O O O O O	O O O O B O O O O O O O	['dysosmia']	1	4	"Sentence: Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge .
Diseases: dysosmia"	"Sentence: Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge .
Diseases:"
3765	The case was reported to the Tunisian Centre of Pharmacovigilance .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: The case was reported to the Tunisian Centre of Pharmacovigilance .
Diseases: "	"Sentence: The case was reported to the Tunisian Centre of Pharmacovigilance .
Diseases:"
3766	Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas .	O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O B O B O O O O O O O	['colorectal adenomas']	1	7	"Sentence: Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas .
Diseases: colorectal adenomas"	"Sentence: Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas .
Diseases:"
3767	A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine ( DFMO ) plus sulindac or matched placebos .	O O O O O O O O O B I O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O B O O B O O O O	['adenomatous polyps']	1	6	"Sentence: A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine ( DFMO ) plus sulindac or matched placebos .
Diseases: adenomatous polyps"	"Sentence: A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine ( DFMO ) plus sulindac or matched placebos .
Diseases:"
3768	Temporary hearing loss is a known toxicity of treatment with DFMO , thus a comprehensive approach was developed to analyze serial air conduction audiograms .	O B I O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O	['hearing loss', 'toxicity']	2	5	"Sentence: Temporary hearing loss is a known toxicity of treatment with DFMO , thus a comprehensive approach was developed to analyze serial air conduction audiograms .
Diseases: hearing loss, toxicity"	"Sentence: Temporary hearing loss is a known toxicity of treatment with DFMO , thus a comprehensive approach was developed to analyze serial air conduction audiograms .
Diseases:"
3769	The generalized estimating equation method estimated the mean difference between treatment arms with regard to change in air conduction pure tone thresholds while accounting for within - subject correlation due to repeated measurements at frequencies .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The generalized estimating equation method estimated the mean difference between treatment arms with regard to change in air conduction pure tone thresholds while accounting for within - subject correlation due to repeated measurements at frequencies .
Diseases: "	"Sentence: The generalized estimating equation method estimated the mean difference between treatment arms with regard to change in air conduction pure tone thresholds while accounting for within - subject correlation due to repeated measurements at frequencies .
Diseases:"
3770	Based on 290 subjects , there was an average difference of 0 . 50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo ( 95 % confidence interval , - 0 . 64 to 1 . 63 dB ; P = 0 . 39 ) , adjusted for baseline values , age , and frequencies .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Based on 290 subjects , there was an average difference of 0 . 50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo ( 95 % confidence interval , - 0 . 64 to 1 . 63 dB ; P = 0 . 39 ) , adjusted for baseline values , age , and frequencies .
Diseases: "	"Sentence: Based on 290 subjects , there was an average difference of 0 . 50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo ( 95 % confidence interval , - 0 . 64 to 1 . 63 dB ; P = 0 . 39 ) , adjusted for baseline values , age , and frequencies .
Diseases:"
3771	In the normal speech range of 500 to 3 , 000 Hz , an estimated difference of 0 . 99 dB ( - 0 . 17 to 2 . 14 dB ; P = 0 . 09 ) was detected .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the normal speech range of 500 to 3 , 000 Hz , an estimated difference of 0 . 99 dB ( - 0 . 17 to 2 . 14 dB ; P = 0 . 09 ) was detected .
Diseases: "	"Sentence: In the normal speech range of 500 to 3 , 000 Hz , an estimated difference of 0 . 99 dB ( - 0 . 17 to 2 . 14 dB ; P = 0 . 09 ) was detected .
Diseases:"
3772	Dose intensity did not add information to models .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Dose intensity did not add information to models .
Diseases: "	"Sentence: Dose intensity did not add information to models .
Diseases:"
3773	There were 14 of 151 ( 9 . 3 % ) in the DFMO plus sulindac group and 4 of 139 ( 2 . 9 % ) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested ( P = 0 . 02 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: There were 14 of 151 ( 9 . 3 % ) in the DFMO plus sulindac group and 4 of 139 ( 2 . 9 % ) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested ( P = 0 . 02 ) .
Diseases: "	"Sentence: There were 14 of 151 ( 9 . 3 % ) in the DFMO plus sulindac group and 4 of 139 ( 2 . 9 % ) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested ( P = 0 . 02 ) .
Diseases:"
3774	Follow - up air conduction done at least 6 months after end of treatment showed an adjusted mean difference in hearing thresholds of 1 . 08 dB ( - 0 . 81 to 2 . 96 dB ; P = 0 . 26 ) between treatment arms .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Follow - up air conduction done at least 6 months after end of treatment showed an adjusted mean difference in hearing thresholds of 1 . 08 dB ( - 0 . 81 to 2 . 96 dB ; P = 0 . 26 ) between treatment arms .
Diseases: "	"Sentence: Follow - up air conduction done at least 6 months after end of treatment showed an adjusted mean difference in hearing thresholds of 1 . 08 dB ( - 0 . 81 to 2 . 96 dB ; P = 0 . 26 ) between treatment arms .
Diseases:"
3775	There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group .	O O O O O O O O O O O O O O O O O O O O B I O O O O O O	O O O O O O O O O O O O B O B O O O O O O O O O O O O O	['hearing loss']	1	3	"Sentence: There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group .
Diseases: hearing loss"	"Sentence: There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group .
Diseases:"
3776	The estimated attributable risk of ototoxicity from exposure to the drug is 8 . 4 % ( 95 % confidence interval , - 2 . 0 % to 18 . 8 % ; P = 0 . 12 ) .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ototoxicity']	1	3	"Sentence: The estimated attributable risk of ototoxicity from exposure to the drug is 8 . 4 % ( 95 % confidence interval , - 2 . 0 % to 18 . 8 % ; P = 0 . 12 ) .
Diseases: ototoxicity"	"Sentence: The estimated attributable risk of ototoxicity from exposure to the drug is 8 . 4 % ( 95 % confidence interval , - 2 . 0 % to 18 . 8 % ; P = 0 . 12 ) .
Diseases:"
3777	There is a < 2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O B O O O O O O O	[]	0	0	"Sentence: There is a < 2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo .
Diseases: "	"Sentence: There is a < 2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo .
Diseases:"
3778	Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly .	O B I O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O	['mental slowing']	1	2	"Sentence: Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly .
Diseases: mental slowing"	"Sentence: Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly .
Diseases:"
3779	The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl - induced subjective effects and objective memory performance .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O	['confusion']	1	2	"Sentence: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl - induced subjective effects and objective memory performance .
Diseases: confusion"	"Sentence: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl - induced subjective effects and objective memory performance .
Diseases:"
3780	This study comprised 24 cognitively intact , health elderly adults ( 12 APOE epsilon4 carriers ) at an outpatient geriatric psychiatry research clinic .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This study comprised 24 cognitively intact , health elderly adults ( 12 APOE epsilon4 carriers ) at an outpatient geriatric psychiatry research clinic .
Diseases: "	"Sentence: This study comprised 24 cognitively intact , health elderly adults ( 12 APOE epsilon4 carriers ) at an outpatient geriatric psychiatry research clinic .
Diseases:"
3781	This was a randomized , double blind , placebo - controlled , three - way , crossover experimental design .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This was a randomized , double blind , placebo - controlled , three - way , crossover experimental design .
Diseases: "	"Sentence: This was a randomized , double blind , placebo - controlled , three - way , crossover experimental design .
Diseases:"
3782	All participants received 1 . 0 mg or 2 . 0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: All participants received 1 . 0 mg or 2 . 0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks .
Diseases: "	"Sentence: All participants received 1 . 0 mg or 2 . 0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks .
Diseases:"
3783	Bond and Lader 's visual analog scales and alternate versions of the Buschke Selective Reminding Test were administered in a repeated measures design at baseline , 1 , 2 . 5 , and 5 hours postdrug administration .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Bond and Lader 's visual analog scales and alternate versions of the Buschke Selective Reminding Test were administered in a repeated measures design at baseline , 1 , 2 . 5 , and 5 hours postdrug administration .
Diseases: "	"Sentence: Bond and Lader 's visual analog scales and alternate versions of the Buschke Selective Reminding Test were administered in a repeated measures design at baseline , 1 , 2 . 5 , and 5 hours postdrug administration .
Diseases:"
3784	A 2 . 0 - mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only .	O O O O O O O O O O O O O O O O B I O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O	['mental slowness']	1	4	"Sentence: A 2 . 0 - mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only .
Diseases: mental slowness"	"Sentence: A 2 . 0 - mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only .
Diseases:"
3785	Drug effects as determined by difference scores between 2 . 0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only .	O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['mental slowness']	1	4	"Sentence: Drug effects as determined by difference scores between 2 . 0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only .
Diseases: mental slowness"	"Sentence: Drug effects as determined by difference scores between 2 . 0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only .
Diseases:"
3786	However , no significant effects were found with other visual analog scales reflecting subjective sedation and clear - headedness .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , no significant effects were found with other visual analog scales reflecting subjective sedation and clear - headedness .
Diseases: "	"Sentence: However , no significant effects were found with other visual analog scales reflecting subjective sedation and clear - headedness .
Diseases:"
3787	The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge .	O O O O O O O O O O O B I O O O O O	O O O O O O O O O O O O O O B O O O	['mental slowing']	1	2	"Sentence: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge .
Diseases: mental slowing"	"Sentence: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge .
Diseases:"
3788	Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin .	O O O O O O O O O O O O O O O	O O O O B I I O O O O O O B O	[]	0	0	"Sentence: Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin .
Diseases: "	"Sentence: Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin .
Diseases:"
3789	The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid ( AAS ) exposure and brain serotonin ( 5 - hydroxytryptamine , 5 - HT ) depletion on behavior of pubertal male rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B I I O B O O O O B O B I I O B I I O O O O O O O O O	[]	0	0	"Sentence: The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid ( AAS ) exposure and brain serotonin ( 5 - hydroxytryptamine , 5 - HT ) depletion on behavior of pubertal male rats .
Diseases: "	"Sentence: The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid ( AAS ) exposure and brain serotonin ( 5 - hydroxytryptamine , 5 - HT ) depletion on behavior of pubertal male rats .
Diseases:"
3790	Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine ( PCPA 100 mg / kg , every other day ) ; controls received saline .	O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O B O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine ( PCPA 100 mg / kg , every other day ) ; controls received saline .
Diseases: "	"Sentence: Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine ( PCPA 100 mg / kg , every other day ) ; controls received saline .
Diseases:"
3791	At puberty ( P40 ) , half the PCPA - treated rats and half the saline - treated rats began treatment with testosterone ( T , 5 mg / kg , 5 days / week ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O B O B O O O O O O O O O O O O	[]	0	0	"Sentence: At puberty ( P40 ) , half the PCPA - treated rats and half the saline - treated rats began treatment with testosterone ( T , 5 mg / kg , 5 days / week ) .
Diseases: "	"Sentence: At puberty ( P40 ) , half the PCPA - treated rats and half the saline - treated rats began treatment with testosterone ( T , 5 mg / kg , 5 days / week ) .
Diseases:"
3792	Behavioral measures included locomotion , irritability , copulation , partner preference , and aggression .	O O O O O B O O O O O O O B O	O O O O O O O O O O O O O O O	['aggression', 'irritability']	2	5	"Sentence: Behavioral measures included locomotion , irritability , copulation , partner preference , and aggression .
Diseases: aggression, irritability"	"Sentence: Behavioral measures included locomotion , irritability , copulation , partner preference , and aggression .
Diseases:"
3793	Animals were tested for aggression in their home cage , both with and without physical provocation ( mild tail pinch ) .	O O O O B O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	['aggression']	1	2	"Sentence: Animals were tested for aggression in their home cage , both with and without physical provocation ( mild tail pinch ) .
Diseases: aggression"	"Sentence: Animals were tested for aggression in their home cage , both with and without physical provocation ( mild tail pinch ) .
Diseases:"
3794	Brain levels of 5 - HT and its metabolite , 5 - hydroxyindoleacetic acid ( 5 - HIAA ) , were determined using HPLC .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B I I O O O O B I I I O B I I O O O O O O O	[]	0	0	"Sentence: Brain levels of 5 - HT and its metabolite , 5 - hydroxyindoleacetic acid ( 5 - HIAA ) , were determined using HPLC .
Diseases: "	"Sentence: Brain levels of 5 - HT and its metabolite , 5 - hydroxyindoleacetic acid ( 5 - HIAA ) , were determined using HPLC .
Diseases:"
3795	PCPA significantly and substantially depleted 5 - HT and 5 - HIAA in all brain regions examined .	O O O O O O O O O O O O O O O O O O	B O O O O B I I O B I I O O O O O O	[]	0	0	"Sentence: PCPA significantly and substantially depleted 5 - HT and 5 - HIAA in all brain regions examined .
Diseases: "	"Sentence: PCPA significantly and substantially depleted 5 - HT and 5 - HIAA in all brain regions examined .
Diseases:"
3796	Chronic T treatment significantly decreased 5 - HT and 5 - HIAA in certain brain areas , but to a much lesser extent than PCPA .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O O O B I I O B I I O O O O O O O O O O O O B O	[]	0	0	"Sentence: Chronic T treatment significantly decreased 5 - HT and 5 - HIAA in certain brain areas , but to a much lesser extent than PCPA .
Diseases: "	"Sentence: Chronic T treatment significantly decreased 5 - HT and 5 - HIAA in certain brain areas , but to a much lesser extent than PCPA .
Diseases:"
3797	Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior , partner preference , or aggression .	O O O O O O O O O O O B O O O O O O O O O O O O B O	O O O B O O O O O O O O O O O O O O O O O O O O O O	['aggression', 'irritability']	2	5	"Sentence: Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior , partner preference , or aggression .
Diseases: aggression, irritability"	"Sentence: Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior , partner preference , or aggression .
Diseases:"
3798	T alone had no effect on locomotion , irritability , or sexual behavior but increased partner preference and aggression .	O O O O O O O O B O O O O O O O O O B O	B O O O O O O O O O O O O O O O O O O O	['aggression', 'irritability']	2	5	"Sentence: T alone had no effect on locomotion , irritability , or sexual behavior but increased partner preference and aggression .
Diseases: aggression, irritability"	"Sentence: T alone had no effect on locomotion , irritability , or sexual behavior but increased partner preference and aggression .
Diseases:"
3799	The most striking effect of combining T + PCPA was a significant increase in attack frequency as well as a significant decrease in the latency to attack , particularly following physical provocation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The most striking effect of combining T + PCPA was a significant increase in attack frequency as well as a significant decrease in the latency to attack , particularly following physical provocation .
Diseases: "	"Sentence: The most striking effect of combining T + PCPA was a significant increase in attack frequency as well as a significant decrease in the latency to attack , particularly following physical provocation .
Diseases:"
3800	Based on these data , it can be speculated that pubertal AAS users with low central 5 - HT may be especially prone to exhibit aggressive behavior .	O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O B O O O O B I I O O O O O O O O O	['aggressive behavior']	1	2	"Sentence: Based on these data , it can be speculated that pubertal AAS users with low central 5 - HT may be especially prone to exhibit aggressive behavior .
Diseases: aggressive behavior"	"Sentence: Based on these data , it can be speculated that pubertal AAS users with low central 5 - HT may be especially prone to exhibit aggressive behavior .
Diseases:"
3801	Intracavitary chemotherapy ( paclitaxel / carboplatin liquid crystalline cubic phases ) for recurrent glioblastoma - - clinical observations .	O O O O O O O O O O O O O B O O O O O	O O O B O B O O O O O O O O O O O O O	['glioblastoma']	1	5	"Sentence: Intracavitary chemotherapy ( paclitaxel / carboplatin liquid crystalline cubic phases ) for recurrent glioblastoma - - clinical observations .
Diseases: glioblastoma"	"Sentence: Intracavitary chemotherapy ( paclitaxel / carboplatin liquid crystalline cubic phases ) for recurrent glioblastoma - - clinical observations .
Diseases:"
3802	Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy .	O O B I O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	['brain tumors']	1	2	"Sentence: Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy .
Diseases: brain tumors"	"Sentence: Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy .
Diseases:"
3803	Cubic phases consist of curved biocontinuous lipid bilayers , separating two congruent networks of water channels .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cubic phases consist of curved biocontinuous lipid bilayers , separating two congruent networks of water channels .
Diseases: "	"Sentence: Cubic phases consist of curved biocontinuous lipid bilayers , separating two congruent networks of water channels .
Diseases:"
3804	Used as a host for cytotoxic drugs , the gel - like matrix can easily be applied to the walls of a surgical resection cavity .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Used as a host for cytotoxic drugs , the gel - like matrix can easily be applied to the walls of a surgical resection cavity .
Diseases: "	"Sentence: Used as a host for cytotoxic drugs , the gel - like matrix can easily be applied to the walls of a surgical resection cavity .
Diseases:"
3805	For human glioblastoma recurrences , the feasibility , safety , and short - term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study .	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O	['glioblastoma']	1	5	"Sentence: For human glioblastoma recurrences , the feasibility , safety , and short - term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study .
Diseases: glioblastoma"	"Sentence: For human glioblastoma recurrences , the feasibility , safety , and short - term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study .
Diseases:"
3806	A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re - resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages .	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O	['glioblastoma']	1	5	"Sentence: A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re - resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages .
Diseases: glioblastoma"	"Sentence: A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re - resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages .
Diseases:"
3807	Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema , while the remaining patients received only a total of 15 mg paclitaxel .	O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O B O	['brain edema']	1	3	"Sentence: Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema , while the remaining patients received only a total of 15 mg paclitaxel .
Diseases: brain edema"	"Sentence: Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema , while the remaining patients received only a total of 15 mg paclitaxel .
Diseases:"
3808	In the latter group , brain edema was markedly reduced and dealt medically .	O O O O O B I O O O O O O O	O O O O O O O O O O O O O O	['brain edema']	1	3	"Sentence: In the latter group , brain edema was markedly reduced and dealt medically .
Diseases: brain edema"	"Sentence: In the latter group , brain edema was markedly reduced and dealt medically .
Diseases:"
3809	Intracavitary chemotherapy in recurrent glioblastoma using cubic phases is feasible and safe , yet the clinical benefit remains to be examined in a clinical phase II study .	O O O O B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['glioblastoma']	1	5	"Sentence: Intracavitary chemotherapy in recurrent glioblastoma using cubic phases is feasible and safe , yet the clinical benefit remains to be examined in a clinical phase II study .
Diseases: glioblastoma"	"Sentence: Intracavitary chemotherapy in recurrent glioblastoma using cubic phases is feasible and safe , yet the clinical benefit remains to be examined in a clinical phase II study .
Diseases:"
3810	Methylphenidate - induced obsessive - compulsive symptoms in an elderly man .	O O O B I I I O O O O O	B O O O O O O O O O O O	['obsessive - compulsive symptoms']	1	7	"Sentence: Methylphenidate - induced obsessive - compulsive symptoms in an elderly man .
Diseases: obsessive - compulsive symptoms"	"Sentence: Methylphenidate - induced obsessive - compulsive symptoms in an elderly man .
Diseases:"
3811	An 82 - year - old man with treatment - resistant depression and early Alzheimer 's disease was started on methylphenidate .	O O O O O O O O B I I I O O B I I O O O O O	O O O O O O O O O O O O O O O O O O O O B O	"['treatment - resistant depression', ""alzheimer 's disease""]"	2	11	"Sentence: An 82 - year - old man with treatment - resistant depression and early Alzheimer 's disease was started on methylphenidate .
Diseases: treatment - resistant depression, alzheimer 's disease"	"Sentence: An 82 - year - old man with treatment - resistant depression and early Alzheimer 's disease was started on methylphenidate .
Diseases:"
3812	Significant obsessive - compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine .	O B I I I O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O B O	['obsessive - compulsive behavior']	1	7	"Sentence: Significant obsessive - compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine .
Diseases: obsessive - compulsive behavior"	"Sentence: Significant obsessive - compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine .
Diseases:"
3813	The patient had no prior psychiatric history , but he had a sister with obsessive - compulsive disorder .	O O O O O B O O O O O O O O B I I I O	O O O O O O O O O O O O O O O O O O O	['obsessive - compulsive disorder', 'psychiatric']	2	9	"Sentence: The patient had no prior psychiatric history , but he had a sister with obsessive - compulsive disorder .
Diseases: obsessive - compulsive disorder, psychiatric"	"Sentence: The patient had no prior psychiatric history , but he had a sister with obsessive - compulsive disorder .
Diseases:"
3814	It appears that methylphenidate precipitated the patient 's pathological behavior .	O O O O O O O O O O O	O O O B O O O O O O O	[]	0	0	"Sentence: It appears that methylphenidate precipitated the patient 's pathological behavior .
Diseases: "	"Sentence: It appears that methylphenidate precipitated the patient 's pathological behavior .
Diseases:"
3815	Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest .	B I O O O O O O O O O O O O O O O O B I O	O O O O B O O O O O O O O B O O O O O O O	['cardiac arrest']	1	3	"Sentence: Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest .
Diseases: cardiac arrest"	"Sentence: Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest .
Diseases:"
3816	We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly .	O O O O O O O O O O O O O B O O	O O O O O O O O B O O O O O O O	['asystole']	1	3	"Sentence: We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly .
Diseases: asystole"	"Sentence: We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly .
Diseases:"
3817	The patient received metoclopramide 10 mg i . v .	O O O O O O O O O O	O O O B O O O O O O	[]	0	0	"Sentence: The patient received metoclopramide 10 mg i . v .
Diseases: "	"Sentence: The patient received metoclopramide 10 mg i . v .
Diseases:"
3818	five times during 48 h . After interviewing the attending nurses and reviewing the written documentation , it is clear that every administration of metoclopramide was immediately ( within s ) followed by asystole .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	['asystole']	1	3	"Sentence: five times during 48 h . After interviewing the attending nurses and reviewing the written documentation , it is clear that every administration of metoclopramide was immediately ( within s ) followed by asystole .
Diseases: asystole"	"Sentence: five times during 48 h . After interviewing the attending nurses and reviewing the written documentation , it is clear that every administration of metoclopramide was immediately ( within s ) followed by asystole .
Diseases:"
3819	The asystole lasted 15 - 30 s on four occasions , on one occasion it lasted 2 min .	O B O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	['asystole']	1	3	"Sentence: The asystole lasted 15 - 30 s on four occasions , on one occasion it lasted 2 min .
Diseases: asystole"	"Sentence: The asystole lasted 15 - 30 s on four occasions , on one occasion it lasted 2 min .
Diseases:"
3820	The patient received atropine 0 . 5 - 1 mg and chest compressions , before sinus rhythm again took over .	O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The patient received atropine 0 . 5 - 1 mg and chest compressions , before sinus rhythm again took over .
Diseases: "	"Sentence: The patient received atropine 0 . 5 - 1 mg and chest compressions , before sinus rhythm again took over .
Diseases:"
3821	We interpret this as episodes of cardiac arrest caused by metoclopramide .	O O O O O O B I O O O O	O O O O O O O O O O B O	['cardiac arrest']	1	3	"Sentence: We interpret this as episodes of cardiac arrest caused by metoclopramide .
Diseases: cardiac arrest"	"Sentence: We interpret this as episodes of cardiac arrest caused by metoclopramide .
Diseases:"
3822	The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction .
Diseases: "	"Sentence: The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction .
Diseases:"
3823	Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures .	O O B I O O O O O O O O O O O O	O O O O O O O O O B O O O O O O	['hemolytic anemia']	1	5	"Sentence: Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures .
Diseases: hemolytic anemia"	"Sentence: Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures .
Diseases:"
3824	Second - and third - generation cephalosporins , especially cefotetan , are increasingly associated with severe , sometimes fatal immune hemolytic anemia .	O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O B O O B O O O O O O O O O O O O O	['hemolytic anemia']	1	5	"Sentence: Second - and third - generation cephalosporins , especially cefotetan , are increasingly associated with severe , sometimes fatal immune hemolytic anemia .
Diseases: hemolytic anemia"	"Sentence: Second - and third - generation cephalosporins , especially cefotetan , are increasingly associated with severe , sometimes fatal immune hemolytic anemia .
Diseases:"
3825	We noticed that 10 of our 35 cases of cefotetan - induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures .	O O O O O O O O O O O O B I O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O B O O O O O O O	['hemolytic anemias']	1	6	"Sentence: We noticed that 10 of our 35 cases of cefotetan - induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures .
Diseases: hemolytic anemias"	"Sentence: We noticed that 10 of our 35 cases of cefotetan - induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures .
Diseases:"
3826	Eight of these cases of severe immune hemolytic anemia are described .	O O O O O O O B I O O O	O O O O O O O O O O O O	['hemolytic anemia']	1	5	"Sentence: Eight of these cases of severe immune hemolytic anemia are described .
Diseases: hemolytic anemia"	"Sentence: Eight of these cases of severe immune hemolytic anemia are described .
Diseases:"
3827	Cauda equina syndrome after spinal anaesthesia with hyperbaric 5 % lignocaine : a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993 - 1997 .	B I I O O O O O O O O O O O O O O O B I I O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	['cauda equina syndrome']	1	6	"Sentence: Cauda equina syndrome after spinal anaesthesia with hyperbaric 5 % lignocaine : a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993 - 1997 .
Diseases: cauda equina syndrome"	"Sentence: Cauda equina syndrome after spinal anaesthesia with hyperbaric 5 % lignocaine : a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993 - 1997 .
Diseases:"
3828	Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993 - 1997 .	O O O B I I O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['cauda equina syndrome']	1	6	"Sentence: Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993 - 1997 .
Diseases: cauda equina syndrome"	"Sentence: Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993 - 1997 .
Diseases:"
3829	All were associated with spinal anaesthesia using hyperbaric 5 % lignocaine .	O O O O O O O O O O O O	O O O O O O O O O O B O	[]	0	0	"Sentence: All were associated with spinal anaesthesia using hyperbaric 5 % lignocaine .
Diseases: "	"Sentence: All were associated with spinal anaesthesia using hyperbaric 5 % lignocaine .
Diseases:"
3830	Five cases had single - shot spinal anaesthesia and one had a repeat spinal anaesthetic due to inadequate block .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Five cases had single - shot spinal anaesthesia and one had a repeat spinal anaesthetic due to inadequate block .
Diseases: "	"Sentence: Five cases had single - shot spinal anaesthesia and one had a repeat spinal anaesthetic due to inadequate block .
Diseases:"
3831	The dose of hyperbaric 5 % lignocaine administered ranged from 60 to 120 mg .	O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O	[]	0	0	"Sentence: The dose of hyperbaric 5 % lignocaine administered ranged from 60 to 120 mg .
Diseases: "	"Sentence: The dose of hyperbaric 5 % lignocaine administered ranged from 60 to 120 mg .
Diseases:"
3832	Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5 % lignocaine .	O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O O O B O	['neurotoxicity']	1	4	"Sentence: Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5 % lignocaine .
Diseases: neurotoxicity"	"Sentence: Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5 % lignocaine .
Diseases:"
3833	In the other 3 cases , direct neurotoxicity was also probable , but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology .	O O O O O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['neurotoxicity']	1	4	"Sentence: In the other 3 cases , direct neurotoxicity was also probable , but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology .
Diseases: neurotoxicity"	"Sentence: In the other 3 cases , direct neurotoxicity was also probable , but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology .
Diseases:"
3834	All cases sustained permanent neurological deficits .	O O O O B I O	O O O O O O O	['neurological deficits']	1	5	"Sentence: All cases sustained permanent neurological deficits .
Diseases: neurological deficits"	"Sentence: All cases sustained permanent neurological deficits .
Diseases:"
3835	We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2 % and at a total dose preferably not exceeding 60 mg .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2 % and at a total dose preferably not exceeding 60 mg .
Diseases: "	"Sentence: We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2 % and at a total dose preferably not exceeding 60 mg .
Diseases:"
3836	Cortical motor overactivation in parkinsonian patients with L - dopa - induced peak - dose dyskinesia .	O O O O B O O O O O O O O O O B O	O O O O O O O B I I O O O O O O O	['parkinsonian', 'dyskinesia']	2	8	"Sentence: Cortical motor overactivation in parkinsonian patients with L - dopa - induced peak - dose dyskinesia .
Diseases: parkinsonian, dyskinesia"	"Sentence: Cortical motor overactivation in parkinsonian patients with L - dopa - induced peak - dose dyskinesia .
Diseases:"
3837	We have studied the regional cerebral blood flow ( rCBF ) changes induced by the execution of a finger - to - thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L - dopa medication , the first one without L - dopa induced dyskinesia ( n = 23 ) and the other with moderate peak - dose dyskinesia ( n = 15 ) , and of a group of 14 normal subjects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O B O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['parkinsonian', 'dyskinesia']	2	8	"Sentence: We have studied the regional cerebral blood flow ( rCBF ) changes induced by the execution of a finger - to - thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L - dopa medication , the first one without L - dopa induced dyskinesia ( n = 23 ) and the other with moderate peak - dose dyskinesia ( n = 15 ) , and of a group of 14 normal subjects .
Diseases: parkinsonian, dyskinesia"	"Sentence: We have studied the regional cerebral blood flow ( rCBF ) changes induced by the execution of a finger - to - thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L - dopa medication , the first one without L - dopa induced dyskinesia ( n = 23 ) and the other with moderate peak - dose dyskinesia ( n = 15 ) , and of a group of 14 normal subjects .
Diseases:"
3838	Single photon emission tomography with i . v .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Single photon emission tomography with i . v .
Diseases: "	"Sentence: Single photon emission tomography with i . v .
Diseases:"
3839	133Xe was used to measure the rCBF changes .	O O O O O O O O O	B O O O O O O O O	[]	0	0	"Sentence: 133Xe was used to measure the rCBF changes .
Diseases: "	"Sentence: 133Xe was used to measure the rCBF changes .
Diseases:"
3840	The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non - dyskinetic parkinsonian patients , with a significant overactivation in the supplementary motor area and the ipsi - and contralateral primary motor areas .	O B B O O O O O O O O O O O O O O O O O O O B B O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['parkinsonian', 'dyskinetic']	2	7	"Sentence: The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non - dyskinetic parkinsonian patients , with a significant overactivation in the supplementary motor area and the ipsi - and contralateral primary motor areas .
Diseases: parkinsonian, dyskinetic"	"Sentence: The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non - dyskinetic parkinsonian patients , with a significant overactivation in the supplementary motor area and the ipsi - and contralateral primary motor areas .
Diseases:"
3841	These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement , like L - dopa - induced peak dose dyskinesia , is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop .	O O O O O O O O O B B I I O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['dyskinesia', 'abnormal involuntary movement', 'hyperkinetic']	3	13	"Sentence: These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement , like L - dopa - induced peak dose dyskinesia , is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop .
Diseases: dyskinesia, abnormal involuntary movement, hyperkinetic"	"Sentence: These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement , like L - dopa - induced peak dose dyskinesia , is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop .
Diseases:"
3842	Dexamethasone - induced ocular hypertension in perfusion - cultured human eyes .	O O O B I O O O O O O O	B O O O O O O O O O O O	['ocular hypertension']	1	2	"Sentence: Dexamethasone - induced ocular hypertension in perfusion - cultured human eyes .
Diseases: ocular hypertension"	"Sentence: Dexamethasone - induced ocular hypertension in perfusion - cultured human eyes .
Diseases:"
3843	Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility .	O O O O O O O O B I O B I O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ocular hypertension', 'corticosteroid glaucoma']	2	11	"Sentence: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility .
Diseases: ocular hypertension, corticosteroid glaucoma"	"Sentence: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility .
Diseases:"
3844	The purpose of this study was to determine whether glucocorticoid treatment can directly affect the outflow facility of isolated , perfusion - cultured human eyes .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The purpose of this study was to determine whether glucocorticoid treatment can directly affect the outflow facility of isolated , perfusion - cultured human eyes .
Diseases: "	"Sentence: The purpose of this study was to determine whether glucocorticoid treatment can directly affect the outflow facility of isolated , perfusion - cultured human eyes .
Diseases:"
3845	The anterior segments of human donor eyes from regional eye banks were placed in a constant flow , variable pressure perfusion culture system .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The anterior segments of human donor eyes from regional eye banks were placed in a constant flow , variable pressure perfusion culture system .
Diseases: "	"Sentence: The anterior segments of human donor eyes from regional eye banks were placed in a constant flow , variable pressure perfusion culture system .
Diseases:"
3846	Paired eyes were perfused in serum - free media with or without 10 ( - 7 )	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Paired eyes were perfused in serum - free media with or without 10 ( - 7 )
Diseases: "	"Sentence: Paired eyes were perfused in serum - free media with or without 10 ( - 7 )
Diseases:"
3847	M dexamethasone for 12 days .	O O O O O O	O B O O O O	[]	0	0	"Sentence: M dexamethasone for 12 days .
Diseases: "	"Sentence: M dexamethasone for 12 days .
Diseases:"
3848	Intraocular pressure was monitored daily .	O O O O O O	O O O O O O	[]	0	0	"Sentence: Intraocular pressure was monitored daily .
Diseases: "	"Sentence: Intraocular pressure was monitored daily .
Diseases:"
3849	After incubation , the eyes were morphologically characterized by light microscopy , transmission and scanning electron microscopy , and scanning laser confocal microscopy .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: After incubation , the eyes were morphologically characterized by light microscopy , transmission and scanning electron microscopy , and scanning laser confocal microscopy .
Diseases: "	"Sentence: After incubation , the eyes were morphologically characterized by light microscopy , transmission and scanning electron microscopy , and scanning laser confocal microscopy .
Diseases:"
3850	A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17 . 5 + / - 3 . 8 mm	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17 . 5 + / - 3 . 8 mm
Diseases: "	"Sentence: A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17 . 5 + / - 3 . 8 mm
Diseases:"
3851	Hg after 12 days of dexamethasone exposure .	O O O O O O O O	O O O O O B O O	[]	0	0	"Sentence: Hg after 12 days of dexamethasone exposure .
Diseases: "	"Sentence: Hg after 12 days of dexamethasone exposure .
Diseases:"
3852	The contralateral control eyes , which did not receive dexamethasone , maintained a stable intraocular pressure during the same period .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: The contralateral control eyes , which did not receive dexamethasone , maintained a stable intraocular pressure during the same period .
Diseases: "	"Sentence: The contralateral control eyes , which did not receive dexamethasone , maintained a stable intraocular pressure during the same period .
Diseases:"
3853	The outflow pathway of the untreated eyes appeared morphologically normal .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: The outflow pathway of the untreated eyes appeared morphologically normal .
Diseases: "	"Sentence: The outflow pathway of the untreated eyes appeared morphologically normal .
Diseases:"
3854	In contrast , the dexamethasone - treated hypertensive eyes had thickened trabecular beams , decreased intertrabecular spaces , thickened juxtacanalicular tissue , activated trabecular meshwork cells , and increased amounts of amorphogranular extracellular material , especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm .	O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertensive eyes']	1	4	"Sentence: In contrast , the dexamethasone - treated hypertensive eyes had thickened trabecular beams , decreased intertrabecular spaces , thickened juxtacanalicular tissue , activated trabecular meshwork cells , and increased amounts of amorphogranular extracellular material , especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm .
Diseases: hypertensive eyes"	"Sentence: In contrast , the dexamethasone - treated hypertensive eyes had thickened trabecular beams , decreased intertrabecular spaces , thickened juxtacanalicular tissue , activated trabecular meshwork cells , and increased amounts of amorphogranular extracellular material , especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm .
Diseases:"
3855	The dexamethasone - treated nonresponder eyes appeared to be morphologically similar to the untreated eyes , although several subtle dexamethasone - induced morphologic changes were evident .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: The dexamethasone - treated nonresponder eyes appeared to be morphologically similar to the untreated eyes , although several subtle dexamethasone - induced morphologic changes were evident .
Diseases: "	"Sentence: The dexamethasone - treated nonresponder eyes appeared to be morphologically similar to the untreated eyes , although several subtle dexamethasone - induced morphologic changes were evident .
Diseases:"
3856	Dexamethasone treatment of isolated , perfusion - cultured human eyes led to the generation of ocular hypertension in approximately 30 % of the dexamethasone - treated eyes .	O O O O O O O O O O O O O O O B I O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O B O O O O	['ocular hypertension']	1	2	"Sentence: Dexamethasone treatment of isolated , perfusion - cultured human eyes led to the generation of ocular hypertension in approximately 30 % of the dexamethasone - treated eyes .
Diseases: ocular hypertension"	"Sentence: Dexamethasone treatment of isolated , perfusion - cultured human eyes led to the generation of ocular hypertension in approximately 30 % of the dexamethasone - treated eyes .
Diseases:"
3857	Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma .	O O O O O O O O O O O O O O O B I O B I I O	B O O O O O O O O O O O O O O B O O O O O O	['open angle glaucoma', 'corticosteroid glaucoma']	2	15	"Sentence: Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma .
Diseases: open angle glaucoma, corticosteroid glaucoma"	"Sentence: Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma .
Diseases:"
3858	This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma .	O O O O O O O O O O O O O O O O B I O B I I I O	O O O O O O O O O O O O O O O O B O O O O O O O	['primary open angle glaucoma', 'steroid glaucoma']	2	13	"Sentence: This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma .
Diseases: primary open angle glaucoma, steroid glaucoma"	"Sentence: This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma .
Diseases:"
3859	Cognitive deterioration from long - term abuse of dextromethorphan : a case report .	B I O O O O O O O O O O O O	O O O O O O O O B O O O O O	['cognitive deterioration']	1	3	"Sentence: Cognitive deterioration from long - term abuse of dextromethorphan : a case report .
Diseases: cognitive deterioration"	"Sentence: Cognitive deterioration from long - term abuse of dextromethorphan : a case report .
Diseases:"
3860	Dextromethorphan ( DM ) , the dextrorotatory isomer of 3 - hydroxy - N - methylmorphinan , is the main ingredient in a number of widely available , over - the - counter antitussives .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O B O O O O O O B I I I I I I O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Dextromethorphan ( DM ) , the dextrorotatory isomer of 3 - hydroxy - N - methylmorphinan , is the main ingredient in a number of widely available , over - the - counter antitussives .
Diseases: "	"Sentence: Dextromethorphan ( DM ) , the dextrorotatory isomer of 3 - hydroxy - N - methylmorphinan , is the main ingredient in a number of widely available , over - the - counter antitussives .
Diseases:"
3861	Initial studies ( Bornstein 1968 ) showed that it possessed no respiratory suppressant effects and no addiction liability .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Initial studies ( Bornstein 1968 ) showed that it possessed no respiratory suppressant effects and no addiction liability .
Diseases: "	"Sentence: Initial studies ( Bornstein 1968 ) showed that it possessed no respiratory suppressant effects and no addiction liability .
Diseases:"
3862	Subsequently , however , several articles reporting abuse of this drug have appeared in the literature .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Subsequently , however , several articles reporting abuse of this drug have appeared in the literature .
Diseases: "	"Sentence: Subsequently , however , several articles reporting abuse of this drug have appeared in the literature .
Diseases:"
3863	The drug is known to cause a variety of acute toxic effects , ranging from nausea , restlessness , insomnia , ataxia , slurred speech and nystagmus to mood changes , perceptual alterations , inattention , disorientation and aggressive behavior ( Rammer et al 1988 ; Katona and Watson 1986 ; Isbell and Fraser 1953 ; Devlin et al 1985 ; McCarthy 1971 ; Dodds and Revai 1967 ; Degkwitz 1964 ; Hildebrand et al 1989 ) .	O O O O O O O O O O O O O O O B O B O B O B O O O O B O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ataxia', 'aggressive behavior', 'insomnia', 'nausea', 'restlessness', 'nystagmus']	6	19	"Sentence: The drug is known to cause a variety of acute toxic effects , ranging from nausea , restlessness , insomnia , ataxia , slurred speech and nystagmus to mood changes , perceptual alterations , inattention , disorientation and aggressive behavior ( Rammer et al 1988 ; Katona and Watson 1986 ; Isbell and Fraser 1953 ; Devlin et al 1985 ; McCarthy 1971 ; Dodds and Revai 1967 ; Degkwitz 1964 ; Hildebrand et al 1989 ) .
Diseases: ataxia, aggressive behavior, insomnia, nausea, restlessness, nystagmus"	"Sentence: The drug is known to cause a variety of acute toxic effects , ranging from nausea , restlessness , insomnia , ataxia , slurred speech and nystagmus to mood changes , perceptual alterations , inattention , disorientation and aggressive behavior ( Rammer et al 1988 ; Katona and Watson 1986 ; Isbell and Fraser 1953 ; Devlin et al 1985 ; McCarthy 1971 ; Dodds and Revai 1967 ; Degkwitz 1964 ; Hildebrand et al 1989 ) .
Diseases:"
3864	There have also been two reported fatalities from DM overdoses ( Fleming 1986 ) .	O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O	[]	0	0	"Sentence: There have also been two reported fatalities from DM overdoses ( Fleming 1986 ) .
Diseases: "	"Sentence: There have also been two reported fatalities from DM overdoses ( Fleming 1986 ) .
Diseases:"
3865	However , there are no reports describing the effects of chronic abuse .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: However , there are no reports describing the effects of chronic abuse .
Diseases: "	"Sentence: However , there are no reports describing the effects of chronic abuse .
Diseases:"
3866	This report describes a case of cognitive deterioration resulting from prolonged use of DM .	O O O O O O B I O O O O O O O	O O O O O O O O O O O O O B O	['cognitive deterioration']	1	3	"Sentence: This report describes a case of cognitive deterioration resulting from prolonged use of DM .
Diseases: cognitive deterioration"	"Sentence: This report describes a case of cognitive deterioration resulting from prolonged use of DM .
Diseases:"
3867	Long - term lithium treatment and the kidney .	O O O O O O O O O	O O O B O O O O O	[]	0	0	"Sentence: Long - term lithium treatment and the kidney .
Diseases: "	"Sentence: Long - term lithium treatment and the kidney .
Diseases:"
3868	Interim report on fifty patients .	O O O O O O	O O O O O O	[]	0	0	"Sentence: Interim report on fifty patients .
Diseases: "	"Sentence: Interim report on fifty patients .
Diseases:"
3869	This is a report on the first part of our study of the effects of long - term lithium treatment on the kidney .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O	[]	0	0	"Sentence: This is a report on the first part of our study of the effects of long - term lithium treatment on the kidney .
Diseases: "	"Sentence: This is a report on the first part of our study of the effects of long - term lithium treatment on the kidney .
Diseases:"
3870	Creatinine clearance , maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long - term lithium for more than one year .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O	[]	0	0	"Sentence: Creatinine clearance , maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long - term lithium for more than one year .
Diseases: "	"Sentence: Creatinine clearance , maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long - term lithium for more than one year .
Diseases:"
3871	These findings have been compared with norms and with values of the same tests from screening prior to lithium , available for most of our patients .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: These findings have been compared with norms and with values of the same tests from screening prior to lithium , available for most of our patients .
Diseases: "	"Sentence: These findings have been compared with norms and with values of the same tests from screening prior to lithium , available for most of our patients .
Diseases:"
3872	No evidence was found for any reduction of glomerular filtration during lithium treatment .	O O O O O O O O O O O O O O	O O O O O O O O O O O B O O	[]	0	0	"Sentence: No evidence was found for any reduction of glomerular filtration during lithium treatment .
Diseases: "	"Sentence: No evidence was found for any reduction of glomerular filtration during lithium treatment .
Diseases:"
3873	Low clearance values found in several patients could be accounted for by their age and their pre - lithium values .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Low clearance values found in several patients could be accounted for by their age and their pre - lithium values .
Diseases: "	"Sentence: Low clearance values found in several patients could be accounted for by their age and their pre - lithium values .
Diseases:"
3874	Urinary concentration defect appeared frequent but the extent of the impairment is difficult to assess because of the uncertainty about the norms applicable to this group of patients .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Urinary concentration defect appeared frequent but the extent of the impairment is difficult to assess because of the uncertainty about the norms applicable to this group of patients .
Diseases: "	"Sentence: Urinary concentration defect appeared frequent but the extent of the impairment is difficult to assess because of the uncertainty about the norms applicable to this group of patients .
Diseases:"
3875	The concentration defect appeared reversible , at least in part .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: The concentration defect appeared reversible , at least in part .
Diseases: "	"Sentence: The concentration defect appeared reversible , at least in part .
Diseases:"
3876	Polyuria above 3 litres / 24 hours was found in 10 % of patients .	B O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	['polyuria']	1	2	"Sentence: Polyuria above 3 litres / 24 hours was found in 10 % of patients .
Diseases: polyuria"	"Sentence: Polyuria above 3 litres / 24 hours was found in 10 % of patients .
Diseases:"
3877	An attempt is made to draw practical conclusions from the preliminary findings .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: An attempt is made to draw practical conclusions from the preliminary findings .
Diseases: "	"Sentence: An attempt is made to draw practical conclusions from the preliminary findings .
Diseases:"
3878	Complete heart block following a single dose of trazodone .	O B I O O O O O O O	O O O O O O O O B O	['heart block']	1	2	"Sentence: Complete heart block following a single dose of trazodone .
Diseases: heart block"	"Sentence: Complete heart block following a single dose of trazodone .
Diseases:"
3879	Forty minutes after receiving a single starting dose of trazodone , a patient developed complete heart block .	O O O O O O O O O O O O O O O B I O	O O O O O O O O O B O O O O O O O O	['heart block']	1	2	"Sentence: Forty minutes after receiving a single starting dose of trazodone , a patient developed complete heart block .
Diseases: heart block"	"Sentence: Forty minutes after receiving a single starting dose of trazodone , a patient developed complete heart block .
Diseases:"
3880	The case illustrates that , despite the results of earlier studies , trazodone 's effect on cardiac conduction may be severe in individuals at risk for conduction delay .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The case illustrates that , despite the results of earlier studies , trazodone 's effect on cardiac conduction may be severe in individuals at risk for conduction delay .
Diseases: "	"Sentence: The case illustrates that , despite the results of earlier studies , trazodone 's effect on cardiac conduction may be severe in individuals at risk for conduction delay .
Diseases:"
3881	Quinidine phenylethylbarbiturate - induced fulminant hepatitis in a pregnant woman .	O O O O O B O O O O O	B I O O O O O O O O O	['hepatitis']	1	3	"Sentence: Quinidine phenylethylbarbiturate - induced fulminant hepatitis in a pregnant woman .
Diseases: hepatitis"	"Sentence: Quinidine phenylethylbarbiturate - induced fulminant hepatitis in a pregnant woman .
Diseases:"
3882	We report the case of a 19 - year - old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1 - month administration of quinidine phenylethylbarbiturate .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	['hepatitis']	1	3	"Sentence: We report the case of a 19 - year - old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1 - month administration of quinidine phenylethylbarbiturate .
Diseases: hepatitis"	"Sentence: We report the case of a 19 - year - old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1 - month administration of quinidine phenylethylbarbiturate .
Diseases:"
3883	After delivery , the patient underwent orthotopic liver transplantation .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: After delivery , the patient underwent orthotopic liver transplantation .
Diseases: "	"Sentence: After delivery , the patient underwent orthotopic liver transplantation .
Diseases:"
3884	The patient was in good condition 16 months after liver transplantation .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: The patient was in good condition 16 months after liver transplantation .
Diseases: "	"Sentence: The patient was in good condition 16 months after liver transplantation .
Diseases:"
3885	Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient .	O O O O O O O O O B O O O O	B O O B O O O O O O O O O O	['hepatitis']	1	3	"Sentence: Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient .
Diseases: hepatitis"	"Sentence: Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient .
Diseases:"
3886	The epidemiology of the acute flank pain syndrome from suprofen .	O O O O O B I O O O O	O O O O O O O O O B O	['flank pain']	1	3	"Sentence: The epidemiology of the acute flank pain syndrome from suprofen .
Diseases: flank pain"	"Sentence: The epidemiology of the acute flank pain syndrome from suprofen .
Diseases:"
3887	Suprofen , a new nonsteroidal anti - inflammatory drug , was marketed in early 1986 as an analgesic agent .	O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Suprofen , a new nonsteroidal anti - inflammatory drug , was marketed in early 1986 as an analgesic agent .
Diseases: "	"Sentence: Suprofen , a new nonsteroidal anti - inflammatory drug , was marketed in early 1986 as an analgesic agent .
Diseases:"
3888	Until physicians began reporting an unusual acute flank pain syndrome to the spontaneous reporting system , 700 , 000 persons used the drug in the United States .	O O O O O O O B I O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['flank pain']	1	3	"Sentence: Until physicians began reporting an unusual acute flank pain syndrome to the spontaneous reporting system , 700 , 000 persons used the drug in the United States .
Diseases: flank pain"	"Sentence: Until physicians began reporting an unusual acute flank pain syndrome to the spontaneous reporting system , 700 , 000 persons used the drug in the United States .
Diseases:"
3889	Through August 1986 , a total of 163 cases of this syndrome were reported .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Through August 1986 , a total of 163 cases of this syndrome were reported .
Diseases: "	"Sentence: Through August 1986 , a total of 163 cases of this syndrome were reported .
Diseases:"
3890	To elucidate the epidemiology of the syndrome , a case - control study was performed , comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 suprofen - exposed control subjects who did not have the syndrome .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: To elucidate the epidemiology of the syndrome , a case - control study was performed , comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 suprofen - exposed control subjects who did not have the syndrome .
Diseases: "	"Sentence: To elucidate the epidemiology of the syndrome , a case - control study was performed , comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 suprofen - exposed control subjects who did not have the syndrome .
Diseases:"
3891	Case patients were more likely to be men ( odds ratio , 3 . 8 ; 95 % confidence interval , 1 . 2 - 12 . 1 ) , suffer from hay fever and asthma ( odds ratio , 3 . 4 ; 95 % confidence interval , 1 . 0 - 11 . 9 ) ; to participate in regular exercise ( odds ratio , 5 . 9 ; 95 % confidence interval , 1 . 1 - 30 . 7 ) , especially in the use of Nautilus equipment ( p = 0 . 02 ) ; and to use alcohol ( odds ratio , 4 . 4 ; 95 % confidence interval , 1 . 1 - 17 . 5 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	['asthma', 'hay fever']	2	6	"Sentence: Case patients were more likely to be men ( odds ratio , 3 . 8 ; 95 % confidence interval , 1 . 2 - 12 . 1 ) , suffer from hay fever and asthma ( odds ratio , 3 . 4 ; 95 % confidence interval , 1 . 0 - 11 . 9 ) ; to participate in regular exercise ( odds ratio , 5 . 9 ; 95 % confidence interval , 1 . 1 - 30 . 7 ) , especially in the use of Nautilus equipment ( p = 0 . 02 ) ; and to use alcohol ( odds ratio , 4 . 4 ; 95 % confidence interval , 1 . 1 - 17 . 5 ) .
Diseases: asthma, hay fever"	"Sentence: Case patients were more likely to be men ( odds ratio , 3 . 8 ; 95 % confidence interval , 1 . 2 - 12 . 1 ) , suffer from hay fever and asthma ( odds ratio , 3 . 4 ; 95 % confidence interval , 1 . 0 - 11 . 9 ) ; to participate in regular exercise ( odds ratio , 5 . 9 ; 95 % confidence interval , 1 . 1 - 30 . 7 ) , especially in the use of Nautilus equipment ( p = 0 . 02 ) ; and to use alcohol ( odds ratio , 4 . 4 ; 95 % confidence interval , 1 . 1 - 17 . 5 ) .
Diseases:"
3892	Possible risk factors included young age , concurrent use of other analgesic agents ( especially ibuprofen ) , preexisting renal disease , a history of kidney stones , a history of gout , a recent increase in activity , a recent increase in sun exposure , and residence in the Sunbelt .	O O O O O O O O O O O O O O O O O O O B I O O O O B I O O O O B O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['renal disease', 'kidney stones', 'gout']	3	9	"Sentence: Possible risk factors included young age , concurrent use of other analgesic agents ( especially ibuprofen ) , preexisting renal disease , a history of kidney stones , a history of gout , a recent increase in activity , a recent increase in sun exposure , and residence in the Sunbelt .
Diseases: renal disease, kidney stones, gout"	"Sentence: Possible risk factors included young age , concurrent use of other analgesic agents ( especially ibuprofen ) , preexisting renal disease , a history of kidney stones , a history of gout , a recent increase in activity , a recent increase in sun exposure , and residence in the Sunbelt .
Diseases:"
3893	These were findings that were suggestive but did not reach conventional statistical significance .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: These were findings that were suggestive but did not reach conventional statistical significance .
Diseases: "	"Sentence: These were findings that were suggestive but did not reach conventional statistical significance .
Diseases:"
3894	These findings are consistent with the postulated mechanism for this unusual syndrome : acute diffuse crystallization of uric acid in renal tubules .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B I O O O O	[]	0	0	"Sentence: These findings are consistent with the postulated mechanism for this unusual syndrome : acute diffuse crystallization of uric acid in renal tubules .
Diseases: "	"Sentence: These findings are consistent with the postulated mechanism for this unusual syndrome : acute diffuse crystallization of uric acid in renal tubules .
Diseases:"
3895	Hemolytic - uremic syndrome associated with ingestion of quinine .	B I I I O O O O O O	O O O O O O O O B O	['hemolytic - uremic syndrome']	1	8	"Sentence: Hemolytic - uremic syndrome associated with ingestion of quinine .
Diseases: hemolytic - uremic syndrome"	"Sentence: Hemolytic - uremic syndrome associated with ingestion of quinine .
Diseases:"
3896	Hemolytic - uremic syndrome following quinine ingestion is a newly described phenomenon , with just two previous descriptions of 4 cases in the literature .	B I I I O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O	['hemolytic - uremic syndrome']	1	8	"Sentence: Hemolytic - uremic syndrome following quinine ingestion is a newly described phenomenon , with just two previous descriptions of 4 cases in the literature .
Diseases: hemolytic - uremic syndrome"	"Sentence: Hemolytic - uremic syndrome following quinine ingestion is a newly described phenomenon , with just two previous descriptions of 4 cases in the literature .
Diseases:"
3897	We describe a 5th case .	O O O O O O	O O O O O O	[]	0	0	"Sentence: We describe a 5th case .
Diseases: "	"Sentence: We describe a 5th case .
Diseases:"
3898	The reaction may be mediated by the presence of antibodies reactive against platelets in the presence of quinine .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: The reaction may be mediated by the presence of antibodies reactive against platelets in the presence of quinine .
Diseases: "	"Sentence: The reaction may be mediated by the presence of antibodies reactive against platelets in the presence of quinine .
Diseases:"
3899	Treatment has included use of plasma exchange , prednisone , aspirin , and dipyridamole .	O O O O O O O O O O O O O O O	O O O O O O O O B O B O O B O	[]	0	0	"Sentence: Treatment has included use of plasma exchange , prednisone , aspirin , and dipyridamole .
Diseases: "	"Sentence: Treatment has included use of plasma exchange , prednisone , aspirin , and dipyridamole .
Diseases:"
3900	The patients have all regained some degree of renal function .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: The patients have all regained some degree of renal function .
Diseases: "	"Sentence: The patients have all regained some degree of renal function .
Diseases:"
3901	However , it is unclear whether pharmacological treatment or spontaneous resolution is responsible for the improvement .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , it is unclear whether pharmacological treatment or spontaneous resolution is responsible for the improvement .
Diseases: "	"Sentence: However , it is unclear whether pharmacological treatment or spontaneous resolution is responsible for the improvement .
Diseases:"
3902	Quinine - associated hemolytic - uremic syndrome probably occurs more often than is recognized .	O O O B I I I O O O O O O O O	B O O O O O O O O O O O O O O	['hemolytic - uremic syndrome']	1	8	"Sentence: Quinine - associated hemolytic - uremic syndrome probably occurs more often than is recognized .
Diseases: hemolytic - uremic syndrome"	"Sentence: Quinine - associated hemolytic - uremic syndrome probably occurs more often than is recognized .
Diseases:"
3903	It is important to recognize this reaction when it occurs and to avoid further quinine exposure , since the reaction seems to be recurrent .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: It is important to recognize this reaction when it occurs and to avoid further quinine exposure , since the reaction seems to be recurrent .
Diseases: "	"Sentence: It is important to recognize this reaction when it occurs and to avoid further quinine exposure , since the reaction seems to be recurrent .
Diseases:"
3904	Pyeloureteral filling defects associated with systemic anticoagulation : a case report .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: Pyeloureteral filling defects associated with systemic anticoagulation : a case report .
Diseases: "	"Sentence: Pyeloureteral filling defects associated with systemic anticoagulation : a case report .
Diseases:"
3905	The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation .	O O O B I O O O O O O B O B O	O O O O O O O O O O O O O O O	['pyeloureteritis cystica', 'inflammation', 'infection']	3	13	"Sentence: The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation .
Diseases: pyeloureteritis cystica, inflammation, infection"	"Sentence: The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation .
Diseases:"
3906	A case is presented that is unique in that the acute onset and the rapid resolution of pyeloureteral filling defects in this patient were documented by radiography .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A case is presented that is unique in that the acute onset and the rapid resolution of pyeloureteral filling defects in this patient were documented by radiography .
Diseases: "	"Sentence: A case is presented that is unique in that the acute onset and the rapid resolution of pyeloureteral filling defects in this patient were documented by radiography .
Diseases:"
3907	There is no evidence of antecedent or concurrent infection in this patient .	O O O O O O O O B O O O O	O O O O O O O O O O O O O	['infection']	1	2	"Sentence: There is no evidence of antecedent or concurrent infection in this patient .
Diseases: infection"	"Sentence: There is no evidence of antecedent or concurrent infection in this patient .
Diseases:"
3908	The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation .	O O O O O O O O O O O O O B O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O	['thrombophlebitis']	1	7	"Sentence: The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation .
Diseases: thrombophlebitis"	"Sentence: The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation .
Diseases:"
3909	The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage .	O O O O O O O O O O O O O O O B I O B I O	O O O O O O O O O O O O O O O O O O O O O	['pyeloureteritis cystica', 'submucosal hemorrhage']	2	16	"Sentence: The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage .
Diseases: pyeloureteritis cystica, submucosal hemorrhage"	"Sentence: The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage .
Diseases:"
3910	Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha - benzene hexachloride .	O O O O O O O B O O O O O O O O O	O O O O O O O O O O O O B I I I O	['hepatoma']	1	3	"Sentence: Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha - benzene hexachloride .
Diseases: hepatoma"	"Sentence: Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha - benzene hexachloride .
Diseases:"
3911	Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha - benzene hexachloride were examined histochemically and electron microscopically .	O O B O O O B I O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B I I I O O O O O O O	['hepatomas', 'liver lesions']	2	6	"Sentence: Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha - benzene hexachloride were examined histochemically and electron microscopically .
Diseases: hepatomas, liver lesions"	"Sentence: Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha - benzene hexachloride were examined histochemically and electron microscopically .
Diseases:"
3912	Although most of the hepatomas were well - differentiated tumors and contained a considerable number of peroxisomes , the tumor cells did not respond to ethyl - alpha - p - chlorophenoxyisobutyrate with proliferation of peroxisomes .	O O O O B O O O O B O O O O O O O O O B O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O B I I I I I I O O O O O	['tumor', 'hepatomas', 'tumors']	3	8	"Sentence: Although most of the hepatomas were well - differentiated tumors and contained a considerable number of peroxisomes , the tumor cells did not respond to ethyl - alpha - p - chlorophenoxyisobutyrate with proliferation of peroxisomes .
Diseases: tumor, hepatomas, tumors"	"Sentence: Although most of the hepatomas were well - differentiated tumors and contained a considerable number of peroxisomes , the tumor cells did not respond to ethyl - alpha - p - chlorophenoxyisobutyrate with proliferation of peroxisomes .
Diseases:"
3913	At the 16th week of carcinogen feeding , hyperplastic nodules appeared and advanced to further stages .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At the 16th week of carcinogen feeding , hyperplastic nodules appeared and advanced to further stages .
Diseases: "	"Sentence: At the 16th week of carcinogen feeding , hyperplastic nodules appeared and advanced to further stages .
Diseases:"
3914	A majority of the nodules showed a considerable number of peroxisomes and the inductive proliferation of peroxisomes .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A majority of the nodules showed a considerable number of peroxisomes and the inductive proliferation of peroxisomes .
Diseases: "	"Sentence: A majority of the nodules showed a considerable number of peroxisomes and the inductive proliferation of peroxisomes .
Diseases:"
3915	Within the nodules , foci of proliferation of the cells that showed no inducibility of proliferation of peroxisomes appeared .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Within the nodules , foci of proliferation of the cells that showed no inducibility of proliferation of peroxisomes appeared .
Diseases: "	"Sentence: Within the nodules , foci of proliferation of the cells that showed no inducibility of proliferation of peroxisomes appeared .
Diseases:"
3916	These cells proliferated further , replacing the most part of the nodules , and with this process hepatomas appeared to have been formed .	O O O O O O O O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	['hepatomas']	1	3	"Sentence: These cells proliferated further , replacing the most part of the nodules , and with this process hepatomas appeared to have been formed .
Diseases: hepatomas"	"Sentence: These cells proliferated further , replacing the most part of the nodules , and with this process hepatomas appeared to have been formed .
Diseases:"
3917	No abnormal matrical inclusions of peroxisomes were formed in the cells of hyperplastic nodules by ethyl - alpha - p - chlorophenoxyisobutyrate unlike in the case of rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B I I I I I I O O O O O O O	[]	0	0	"Sentence: No abnormal matrical inclusions of peroxisomes were formed in the cells of hyperplastic nodules by ethyl - alpha - p - chlorophenoxyisobutyrate unlike in the case of rats .
Diseases: "	"Sentence: No abnormal matrical inclusions of peroxisomes were formed in the cells of hyperplastic nodules by ethyl - alpha - p - chlorophenoxyisobutyrate unlike in the case of rats .
Diseases:"
3918	Quinidine hepatitis .	O B O	B O O	['hepatitis']	1	3	"Sentence: Quinidine hepatitis .
Diseases: hepatitis"	"Sentence: Quinidine hepatitis .
Diseases:"
3919	Long - term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT , lactic acid dehydrogenase , and alkaline phosphatase .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: Long - term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT , lactic acid dehydrogenase , and alkaline phosphatase .
Diseases: "	"Sentence: Long - term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT , lactic acid dehydrogenase , and alkaline phosphatase .
Diseases:"
3920	Liver biopsy showed active hepatitis .	O O O O B O	O O O O O O	['hepatitis']	1	3	"Sentence: Liver biopsy showed active hepatitis .
Diseases: hepatitis"	"Sentence: Liver biopsy showed active hepatitis .
Diseases:"
3921	Discontinuance of quinidine therapy led to normalization of liver function tests .	O O O O O O O O O O O O	O O B O O O O O O O O O	[]	0	0	"Sentence: Discontinuance of quinidine therapy led to normalization of liver function tests .
Diseases: "	"Sentence: Discontinuance of quinidine therapy led to normalization of liver function tests .
Diseases:"
3922	A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT , alkaline phosphatase , and lactic acid dehydrogenase values .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT , alkaline phosphatase , and lactic acid dehydrogenase values .
Diseases: "	"Sentence: A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT , alkaline phosphatase , and lactic acid dehydrogenase values .
Diseases:"
3923	We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation .	O O O O O O O B O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O	['hepatotoxicity']	1	4	"Sentence: We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation .
Diseases: hepatotoxicity"	"Sentence: We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation .
Diseases:"
3924	This report also suggests that , even after long - term administration , the hepatic toxicity is reversible .	O O O O O O O O O O O O O O B I O O O	O O O O O O O O O O O O O O O O O O O	['hepatic toxicity']	1	4	"Sentence: This report also suggests that , even after long - term administration , the hepatic toxicity is reversible .
Diseases: hepatic toxicity"	"Sentence: This report also suggests that , even after long - term administration , the hepatic toxicity is reversible .
Diseases:"
3925	Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen , adriamycin , carbon tetrachloride , chloroform and galactosamine .	O O O O O O O O O O O O O O O O O O O O O	B I O O O O O O O O B O B O B I O B O B O	[]	0	0	"Sentence: Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen , adriamycin , carbon tetrachloride , chloroform and galactosamine .
Diseases: "	"Sentence: Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen , adriamycin , carbon tetrachloride , chloroform and galactosamine .
Diseases:"
3926	In addition to its use as a stabilizer / rigidifier of membranes , cholesteryl hemisuccinate , tris salt ( CS ) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride ( CCl4 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O B I O I I O B O O O O O O O O O O O O O O B I O B O O	['hepatotoxic']	1	4	"Sentence: In addition to its use as a stabilizer / rigidifier of membranes , cholesteryl hemisuccinate , tris salt ( CS ) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride ( CCl4 ) .
Diseases: hepatotoxic"	"Sentence: In addition to its use as a stabilizer / rigidifier of membranes , cholesteryl hemisuccinate , tris salt ( CS ) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride ( CCl4 ) .
Diseases:"
3927	To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , tris salt ( CSE ) against acetaminophen - , adriamycin - , carbon tetrachloride - , chloroform - and galactosamine - induced toxicity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O B O O O O O O O O O O O O B O O O O O O O O B O B I I I O O O O B O O B O O B O O B I O O B O O B O O O O	['toxicity']	1	2	"Sentence: To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , tris salt ( CSE ) against acetaminophen - , adriamycin - , carbon tetrachloride - , chloroform - and galactosamine - induced toxicity .
Diseases: toxicity"	"Sentence: To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , tris salt ( CSE ) against acetaminophen - , adriamycin - , carbon tetrachloride - , chloroform - and galactosamine - induced toxicity .
Diseases:"
3928	The results of these studies demonstrated that CS - mediated protection is not selective for a particular species , organ system or toxic chemical .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results of these studies demonstrated that CS - mediated protection is not selective for a particular species , organ system or toxic chemical .
Diseases: "	"Sentence: The results of these studies demonstrated that CS - mediated protection is not selective for a particular species , organ system or toxic chemical .
Diseases:"
3929	A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the hepatotoxic effects of CCl4 , CHCl3 , acetaminophen and galactosamine and against the lethal ( and presumably cardiotoxic ) effect of adriamycin administration .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O B O B O B O B O O O O O O O O O O O B O O	['hepatotoxic', 'cardiotoxic']	2	8	"Sentence: A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the hepatotoxic effects of CCl4 , CHCl3 , acetaminophen and galactosamine and against the lethal ( and presumably cardiotoxic ) effect of adriamycin administration .
Diseases: hepatotoxic, cardiotoxic"	"Sentence: A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the hepatotoxic effects of CCl4 , CHCl3 , acetaminophen and galactosamine and against the lethal ( and presumably cardiotoxic ) effect of adriamycin administration .
Diseases:"
3930	Maximal CS - mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult .	O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Maximal CS - mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult .
Diseases: "	"Sentence: Maximal CS - mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult .
Diseases:"
3931	These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death .	O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death .
Diseases: "	"Sentence: These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death .
Diseases:"
3932	The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate ( in light of the protection observed against galactosamine hepatotoxicity ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O	['hepatotoxicity']	1	4	"Sentence: The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate ( in light of the protection observed against galactosamine hepatotoxicity ) .
Diseases: hepatotoxicity"	"Sentence: The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate ( in light of the protection observed against galactosamine hepatotoxicity ) .
Diseases:"
3933	However , based on the data presented , we can not exclude the possibility that CS administration inhibits chemical bioactivation .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O O O	[]	0	0	"Sentence: However , based on the data presented , we can not exclude the possibility that CS administration inhibits chemical bioactivation .
Diseases: "	"Sentence: However , based on the data presented , we can not exclude the possibility that CS administration inhibits chemical bioactivation .
Diseases:"
3934	Our findings do suggest that CS - mediated protection is dependent on the action of the intact anionic CS molecule ( non - hydrolyzable CSE was as protective as CS ) , whose mechanism has yet to be defined .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O B O O O O O B O O O O B O O O O O O O O O O	[]	0	0	"Sentence: Our findings do suggest that CS - mediated protection is dependent on the action of the intact anionic CS molecule ( non - hydrolyzable CSE was as protective as CS ) , whose mechanism has yet to be defined .
Diseases: "	"Sentence: Our findings do suggest that CS - mediated protection is dependent on the action of the intact anionic CS molecule ( non - hydrolyzable CSE was as protective as CS ) , whose mechanism has yet to be defined .
Diseases:"
3935	DSMM XI study : dose definition for intravenous cyclophosphamide in combination with bortezomib / dexamethasone for remission induction in patients with newly diagnosed myeloma .	O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O B O O O B O B O O O O O O O O O O	['myeloma']	1	3	"Sentence: DSMM XI study : dose definition for intravenous cyclophosphamide in combination with bortezomib / dexamethasone for remission induction in patients with newly diagnosed myeloma .
Diseases: myeloma"	"Sentence: DSMM XI study : dose definition for intravenous cyclophosphamide in combination with bortezomib / dexamethasone for remission induction in patients with newly diagnosed myeloma .
Diseases:"
3936	A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma ( MM ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O B O O	O O O O O O O O O O O B O O O B O B O O O O O O O O O O O O O O O O O O O	['mm', 'multiple myeloma']	2	6	"Sentence: A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma ( MM ) .
Diseases: mm, multiple myeloma"	"Sentence: A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma ( MM ) .
Diseases:"
3937	Thirty patients were treated with three 21 - day cycles of bortezomib 1 . 3 mg / m ( 2 ) on days 1 , 4 , 8 , and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900 , 1 , 200 , or 1 , 500 mg / m ( 2 ) on day 1 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O B O O O O O O B O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thirty patients were treated with three 21 - day cycles of bortezomib 1 . 3 mg / m ( 2 ) on days 1 , 4 , 8 , and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900 , 1 , 200 , or 1 , 500 mg / m ( 2 ) on day 1 .
Diseases: "	"Sentence: Thirty patients were treated with three 21 - day cycles of bortezomib 1 . 3 mg / m ( 2 ) on days 1 , 4 , 8 , and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900 , 1 , 200 , or 1 , 500 mg / m ( 2 ) on day 1 .
Diseases:"
3938	The maximum tolerated dose of cyclophosphamide was defined as 900 mg / m ( 2 ) .	O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: The maximum tolerated dose of cyclophosphamide was defined as 900 mg / m ( 2 ) .
Diseases: "	"Sentence: The maximum tolerated dose of cyclophosphamide was defined as 900 mg / m ( 2 ) .
Diseases:"
3939	At this dose level , 92 % of patients achieved at least a partial response .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At this dose level , 92 % of patients achieved at least a partial response .
Diseases: "	"Sentence: At this dose level , 92 % of patients achieved at least a partial response .
Diseases:"
3940	The overall response rate [ complete response ( CR ) plus partial response ( PR ) ] across all dose levels was 77 % , with a 10 % CR rate .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The overall response rate [ complete response ( CR ) plus partial response ( PR ) ] across all dose levels was 77 % , with a 10 % CR rate .
Diseases: "	"Sentence: The overall response rate [ complete response ( CR ) plus partial response ( PR ) ] across all dose levels was 77 % , with a 10 % CR rate .
Diseases:"
3941	No patient experienced progressive disease .	O O O O O O	O O O O O O	[]	0	0	"Sentence: No patient experienced progressive disease .
Diseases: "	"Sentence: No patient experienced progressive disease .
Diseases:"
3942	The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy .	O O O O O O B I I I O O O B O	O O O O O O O O O O O O O O O	['hematological and gastrointestinal toxicities', 'neuropathy']	2	9	"Sentence: The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy .
Diseases: hematological and gastrointestinal toxicities, neuropathy"	"Sentence: The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy .
Diseases:"
3943	The results suggest that bortezomib in combination with cyclophosphamide at 900 mg / m ( 2 ) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	O O O O B O O O B O O O O O O O O O B O O O O O O O O O O O O O O O O	['mm']	1	1	"Sentence: The results suggest that bortezomib in combination with cyclophosphamide at 900 mg / m ( 2 ) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation .
Diseases: mm"	"Sentence: The results suggest that bortezomib in combination with cyclophosphamide at 900 mg / m ( 2 ) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation .
Diseases:"
3944	Results of a comparative , phase III , 12 - week , multicenter , prospective , randomized , double - blind assessment of the efficacy and tolerability of a fixed - dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O B O O O O O O O O O	['hypertension']	1	3	"Sentence: Results of a comparative , phase III , 12 - week , multicenter , prospective , randomized , double - blind assessment of the efficacy and tolerability of a fixed - dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension .
Diseases: hypertension"	"Sentence: Results of a comparative , phase III , 12 - week , multicenter , prospective , randomized , double - blind assessment of the efficacy and tolerability of a fixed - dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension .
Diseases:"
3945	The aim of this study was to evaluate the efficacy and tolerability of a new fixed - dose combination ( FDC ) of telmisartan 40 mg + amlodipine 5 mg ( T + A ) compared with amlodipine 5 - mg monotherapy ( A ) in adult Indian patients with stage II hypertension .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O B O O O B O O O O O O O O O B O O O O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: The aim of this study was to evaluate the efficacy and tolerability of a new fixed - dose combination ( FDC ) of telmisartan 40 mg + amlodipine 5 mg ( T + A ) compared with amlodipine 5 - mg monotherapy ( A ) in adult Indian patients with stage II hypertension .
Diseases: hypertension"	"Sentence: The aim of this study was to evaluate the efficacy and tolerability of a new fixed - dose combination ( FDC ) of telmisartan 40 mg + amlodipine 5 mg ( T + A ) compared with amlodipine 5 - mg monotherapy ( A ) in adult Indian patients with stage II hypertension .
Diseases:"
3946	This comparative , Phase III , 12 - week , multicenter , prospective , randomized , double - blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: This comparative , Phase III , 12 - week , multicenter , prospective , randomized , double - blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension .
Diseases: hypertension"	"Sentence: This comparative , Phase III , 12 - week , multicenter , prospective , randomized , double - blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension .
Diseases:"
3947	Patients were treated with oral FDC of T + A or A QD before breakfast for 12 weeks ; blood pressure ( BP ) and heart rate were measured in the sitting position .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O I O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Patients were treated with oral FDC of T + A or A QD before breakfast for 12 weeks ; blood pressure ( BP ) and heart rate were measured in the sitting position .
Diseases: "	"Sentence: Patients were treated with oral FDC of T + A or A QD before breakfast for 12 weeks ; blood pressure ( BP ) and heart rate were measured in the sitting position .
Diseases:"
3948	Primary efficacy end points were reduction in clinical systolic BP ( SBP ) / diastolic BP ( DBP ) from baseline to study end and number of responders ( ie , patients who achieved target SBP / DBP < 130 / < 80 mm	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Primary efficacy end points were reduction in clinical systolic BP ( SBP ) / diastolic BP ( DBP ) from baseline to study end and number of responders ( ie , patients who achieved target SBP / DBP < 130 / < 80 mm
Diseases: "	"Sentence: Primary efficacy end points were reduction in clinical systolic BP ( SBP ) / diastolic BP ( DBP ) from baseline to study end and number of responders ( ie , patients who achieved target SBP / DBP < 130 / < 80 mm
Diseases:"
3949	Hg ) at end of study .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: Hg ) at end of study .
Diseases: "	"Sentence: Hg ) at end of study .
Diseases:"
3950	Tolerability was assessed by treatment - emergent adverse events , identified using physical examination , laboratory analysis , and electrocardiography .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Tolerability was assessed by treatment - emergent adverse events , identified using physical examination , laboratory analysis , and electrocardiography .
Diseases: "	"Sentence: Tolerability was assessed by treatment - emergent adverse events , identified using physical examination , laboratory analysis , and electrocardiography .
Diseases:"
3951	A total of 210 patients were enrolled in the study ; 203 patients ( 143 men , 60 women ) completed the study while 7 were lost to follow - up ( 4 patients in the T + A group and 3 in the A group ) and considered with - drawn .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A total of 210 patients were enrolled in the study ; 203 patients ( 143 men , 60 women ) completed the study while 7 were lost to follow - up ( 4 patients in the T + A group and 3 in the A group ) and considered with - drawn .
Diseases: "	"Sentence: A total of 210 patients were enrolled in the study ; 203 patients ( 143 men , 60 women ) completed the study while 7 were lost to follow - up ( 4 patients in the T + A group and 3 in the A group ) and considered with - drawn .
Diseases:"
3952	At study end , statistically significant percentage reductions from baseline within groups and between groups were observed in SBP ( T + A	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At study end , statistically significant percentage reductions from baseline within groups and between groups were observed in SBP ( T + A
Diseases: "	"Sentence: At study end , statistically significant percentage reductions from baseline within groups and between groups were observed in SBP ( T + A
Diseases:"
3953	[ - 27 . 4 % ] ; A [ - 16 . 6 % ] ) and DBP ( T + A	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: [ - 27 . 4 % ] ; A [ - 16 . 6 % ] ) and DBP ( T + A
Diseases: "	"Sentence: [ - 27 . 4 % ] ; A [ - 16 . 6 % ] ) and DBP ( T + A
Diseases:"
3954	[ - 20 . 1 % ] ; A [ - 13 . 3 % ] )	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: [ - 20 . 1 % ] ; A [ - 13 . 3 % ] )
Diseases: "	"Sentence: [ - 20 . 1 % ] ; A [ - 13 . 3 % ] )
Diseases:"
3955	( all , P < 0 . 05 ) .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: ( all , P < 0 . 05 ) .
Diseases: "	"Sentence: ( all , P < 0 . 05 ) .
Diseases:"
3956	Response rates were 87 . 3 % ( 89 / 102 ) in the T + A group and 69 . 3 % ( 70 / 101 ) in the A group ( P < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Response rates were 87 . 3 % ( 89 / 102 ) in the T + A group and 69 . 3 % ( 70 / 101 ) in the A group ( P < 0 . 05 ) .
Diseases: "	"Sentence: Response rates were 87 . 3 % ( 89 / 102 ) in the T + A group and 69 . 3 % ( 70 / 101 ) in the A group ( P < 0 . 05 ) .
Diseases:"
3957	The prevalences of adverse events were not significantly different between the 2 treatment groups ( T + A , 16 . 0 % [ 17 / 106 ] ; A , 15 . 4 % [ 16 / 104 ] ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The prevalences of adverse events were not significantly different between the 2 treatment groups ( T + A , 16 . 0 % [ 17 / 106 ] ; A , 15 . 4 % [ 16 / 104 ] ) .
Diseases: "	"Sentence: The prevalences of adverse events were not significantly different between the 2 treatment groups ( T + A , 16 . 0 % [ 17 / 106 ] ; A , 15 . 4 % [ 16 / 104 ] ) .
Diseases:"
3958	Peripheral edema was reported in 8 . 5 % patients ( 9 / 106 ) in the T + A group compared with 13 . 5 % ( 14 / 104 ) in the A group , and cough was reported in 3 . 8 % patients ( 4 / 106 ) in the T + A group and 1 . 0 % ( 1 / 104 ) patients in the A group ; these differences did not reach statistical significance .	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['edema', 'cough']	2	4	"Sentence: Peripheral edema was reported in 8 . 5 % patients ( 9 / 106 ) in the T + A group compared with 13 . 5 % ( 14 / 104 ) in the A group , and cough was reported in 3 . 8 % patients ( 4 / 106 ) in the T + A group and 1 . 0 % ( 1 / 104 ) patients in the A group ; these differences did not reach statistical significance .
Diseases: edema, cough"	"Sentence: Peripheral edema was reported in 8 . 5 % patients ( 9 / 106 ) in the T + A group compared with 13 . 5 % ( 14 / 104 ) in the A group , and cough was reported in 3 . 8 % patients ( 4 / 106 ) in the T + A group and 1 . 0 % ( 1 / 104 ) patients in the A group ; these differences did not reach statistical significance .
Diseases:"
3959	The incidences of headache , dizziness , and diarrhea were similar between the 2 groups .	O O O B O B O O B O O O O O O O	O O O O O O O O O O O O O O O O	['headache', 'dizziness', 'diarrhea']	3	7	"Sentence: The incidences of headache , dizziness , and diarrhea were similar between the 2 groups .
Diseases: headache, dizziness, diarrhea"	"Sentence: The incidences of headache , dizziness , and diarrhea were similar between the 2 groups .
Diseases:"
3960	Among these Indian patients with stage II hypertension , the FDC of T + A was found to be significantly more effective , with regard to BP reductions , than A , and both treatments were well tolerated .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: Among these Indian patients with stage II hypertension , the FDC of T + A was found to be significantly more effective , with regard to BP reductions , than A , and both treatments were well tolerated .
Diseases: hypertension"	"Sentence: Among these Indian patients with stage II hypertension , the FDC of T + A was found to be significantly more effective , with regard to BP reductions , than A , and both treatments were well tolerated .
Diseases:"
3961	Cutaneous leucocytoclastic vasculitis associated with oxacillin .	B I I O O O O	O O O O O B O	['cutaneous leucocytoclastic vasculitis']	1	11	"Sentence: Cutaneous leucocytoclastic vasculitis associated with oxacillin .
Diseases: cutaneous leucocytoclastic vasculitis"	"Sentence: Cutaneous leucocytoclastic vasculitis associated with oxacillin .
Diseases:"
3962	A 67 - year - old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia , developed renal failure and diffuse , symmetric , palpable purpuric lesions on his feet .	O O O O O O O O O O O O O O O O O B I I O O B I O O O O O O B I O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	['purpuric lesions', 'renal failure', 'staphylococcus aureus bacteremia']	3	20	"Sentence: A 67 - year - old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia , developed renal failure and diffuse , symmetric , palpable purpuric lesions on his feet .
Diseases: purpuric lesions, renal failure, staphylococcus aureus bacteremia"	"Sentence: A 67 - year - old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia , developed renal failure and diffuse , symmetric , palpable purpuric lesions on his feet .
Diseases:"
3963	Necrotic blisters were noted on his fingers .	B I O O O O O O	O O O O O O O O	['necrotic blisters']	1	5	"Sentence: Necrotic blisters were noted on his fingers .
Diseases: necrotic blisters"	"Sentence: Necrotic blisters were noted on his fingers .
Diseases:"
3964	Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis .	O O O O O O B I O	O O O O O O O O O	['leucocytoclastic vasculitis']	1	9	"Sentence: Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis .
Diseases: leucocytoclastic vasculitis"	"Sentence: Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis .
Diseases:"
3965	Oxacillin was discontinued and patient was treated with corticosteroids .	O O O O O O O O O O	B O O O O O O O O O	[]	0	0	"Sentence: Oxacillin was discontinued and patient was treated with corticosteroids .
Diseases: "	"Sentence: Oxacillin was discontinued and patient was treated with corticosteroids .
Diseases:"
3966	The rash disappeared after three weeks and renal function returned to normal .	O B O O O O O O O O O O O	O O O O O O O O O O O O O	['rash']	1	2	"Sentence: The rash disappeared after three weeks and renal function returned to normal .
Diseases: rash"	"Sentence: The rash disappeared after three weeks and renal function returned to normal .
Diseases:"
3967	Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain , arthralgia , and renal involvement .	B I O O O B O O O O O O O B I O B O O B I O	O O O O O O O O O O O O O O O O O O O O O O	['abdominal pain', 'purpura', 'renal involvement', 'arthralgia', 'leucocytoclastic vasculitis']	5	27	"Sentence: Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain , arthralgia , and renal involvement .
Diseases: abdominal pain, purpura, renal involvement, arthralgia, leucocytoclastic vasculitis"	"Sentence: Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain , arthralgia , and renal involvement .
Diseases:"
3968	Etiologic factors or associated disorders include infections , medications , collagen vascular disease and neoplasia .	O O O O O O B O O O B I I O B O	O O O O O O O O O O O O O O O O	['neoplasia', 'infections', 'collagen vascular disease']	3	9	"Sentence: Etiologic factors or associated disorders include infections , medications , collagen vascular disease and neoplasia .
Diseases: neoplasia, infections, collagen vascular disease"	"Sentence: Etiologic factors or associated disorders include infections , medications , collagen vascular disease and neoplasia .
Diseases:"
3969	However , in half of the cases no etiologic factor is identified .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: However , in half of the cases no etiologic factor is identified .
Diseases: "	"Sentence: However , in half of the cases no etiologic factor is identified .
Diseases:"
3970	Usually it is a self - limited disorder , but corticosteroid therapy may be needed in life - threatening cases since early treatment with corticosteroids in severe cases can prevent complications .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: Usually it is a self - limited disorder , but corticosteroid therapy may be needed in life - threatening cases since early treatment with corticosteroids in severe cases can prevent complications .
Diseases: "	"Sentence: Usually it is a self - limited disorder , but corticosteroid therapy may be needed in life - threatening cases since early treatment with corticosteroids in severe cases can prevent complications .
Diseases:"
3971	Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis .	O O O O O O O O O O B I O	B O O O O O O O O O O O O	['leucocytoclastic vasculitis']	1	9	"Sentence: Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis .
Diseases: leucocytoclastic vasculitis"	"Sentence: Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis .
Diseases:"
3972	Naloxazone pretreatment modifies cardiorespiratory , temperature , and behavioral effects of morphine .	O O O O O O O O O O O O O	B O O O O O O O O O O B O	[]	0	0	"Sentence: Naloxazone pretreatment modifies cardiorespiratory , temperature , and behavioral effects of morphine .
Diseases: "	"Sentence: Naloxazone pretreatment modifies cardiorespiratory , temperature , and behavioral effects of morphine .
Diseases:"
3973	Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone , an antagonist of high - affinity mu 1 opioid receptors .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone , an antagonist of high - affinity mu 1 opioid receptors .
Diseases: "	"Sentence: Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone , an antagonist of high - affinity mu 1 opioid receptors .
Diseases:"
3974	Pretreatment with naloxazone significantly blocked morphine analgesia , catalepsy and hypothermia at a dose which completely eliminated high - affinity binding in brain membranes .	O O O O O O B O B O B O O O O O O O O O O O O O O	O O B O O B O O O O O O O O O O O O O O O O O O O	['catalepsy', 'hypothermia', 'analgesia']	3	11	"Sentence: Pretreatment with naloxazone significantly blocked morphine analgesia , catalepsy and hypothermia at a dose which completely eliminated high - affinity binding in brain membranes .
Diseases: catalepsy, hypothermia, analgesia"	"Sentence: Pretreatment with naloxazone significantly blocked morphine analgesia , catalepsy and hypothermia at a dose which completely eliminated high - affinity binding in brain membranes .
Diseases:"
3975	Moreover , naloxazone significantly attenuated the morphine - induced hypotension and respiratory depression , whereas morphine - induced bradycardia was less affected .	O O O O O O O O O B O B I O O O O O B O O O O	O O B O O O B O O O O O O O O B O O O O O O O	['bradycardia', 'respiratory depression', 'hypotension']	3	12	"Sentence: Moreover , naloxazone significantly attenuated the morphine - induced hypotension and respiratory depression , whereas morphine - induced bradycardia was less affected .
Diseases: bradycardia, respiratory depression, hypotension"	"Sentence: Moreover , naloxazone significantly attenuated the morphine - induced hypotension and respiratory depression , whereas morphine - induced bradycardia was less affected .
Diseases:"
3976	Results indicate that subpopulations of mu receptors may mediate selective behavioral and cardiorespiratory responses to morphine .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: Results indicate that subpopulations of mu receptors may mediate selective behavioral and cardiorespiratory responses to morphine .
Diseases: "	"Sentence: Results indicate that subpopulations of mu receptors may mediate selective behavioral and cardiorespiratory responses to morphine .
Diseases:"
3977	Dexrazoxane protects against myelosuppression from the DNA cleavage - enhancing drugs etoposide and daunorubicin but not doxorubicin .	O O O B O O O O O O O O O O O O O O	B O O O O O O O O O O B O B O O B O	['myelosuppression']	1	5	"Sentence: Dexrazoxane protects against myelosuppression from the DNA cleavage - enhancing drugs etoposide and daunorubicin but not doxorubicin .
Diseases: myelosuppression"	"Sentence: Dexrazoxane protects against myelosuppression from the DNA cleavage - enhancing drugs etoposide and daunorubicin but not doxorubicin .
Diseases:"
3978	The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , myelosuppression and cardiac toxicity limit their use .	O O O O O O O O O O O O O O O O O O O O O O O O O O B O B I O O O O	O B B O B O O B B O O O O O O O O O O O O O O O O O O O O O O O O O	['myelosuppression', 'cardiac toxicity']	2	8	"Sentence: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , myelosuppression and cardiac toxicity limit their use .
Diseases: myelosuppression, cardiac toxicity"	"Sentence: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , myelosuppression and cardiac toxicity limit their use .
Diseases:"
3979	Dexrazoxane ( ICRF - 187 ) is recommended for protection against anthracycline - induced cardiotoxicity .	O O O O O O O O O O O O O O B O	B O B I I O O O O O O B O O O O	['cardiotoxicity']	1	3	"Sentence: Dexrazoxane ( ICRF - 187 ) is recommended for protection against anthracycline - induced cardiotoxicity .
Diseases: cardiotoxicity"	"Sentence: Dexrazoxane ( ICRF - 187 ) is recommended for protection against anthracycline - induced cardiotoxicity .
Diseases:"
3980	EXPERIMENTAL DESIGN : Because of their widespread use , the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated :	O O O O O O O O O O B I O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O O O O O O O O O	['hematologic toxicity']	1	3	"Sentence: EXPERIMENTAL DESIGN : Because of their widespread use , the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated :
Diseases: hematologic toxicity"	"Sentence: EXPERIMENTAL DESIGN : Because of their widespread use , the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated :
Diseases:"
3981	Sensitivity of human and murine blood progenitor cells to etoposide , daunorubicin , and doxorubicin + / - dexrazoxane was determined in granulocyte - macrophage colony forming assays .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O B O O B O O O B O O O O O O O O O O	[]	0	0	"Sentence: Sensitivity of human and murine blood progenitor cells to etoposide , daunorubicin , and doxorubicin + / - dexrazoxane was determined in granulocyte - macrophage colony forming assays .
Diseases: "	"Sentence: Sensitivity of human and murine blood progenitor cells to etoposide , daunorubicin , and doxorubicin + / - dexrazoxane was determined in granulocyte - macrophage colony forming assays .
Diseases:"
3982	Likewise , in vivo , B6D2F1 mice were treated with etoposide , daunorubicin , and doxorubicin , with or without dexrazoxane over a wide range of doses : posttreatment , a full hematologic evaluation was done .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O B O O B O O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Likewise , in vivo , B6D2F1 mice were treated with etoposide , daunorubicin , and doxorubicin , with or without dexrazoxane over a wide range of doses : posttreatment , a full hematologic evaluation was done .
Diseases: "	"Sentence: Likewise , in vivo , B6D2F1 mice were treated with etoposide , daunorubicin , and doxorubicin , with or without dexrazoxane over a wide range of doses : posttreatment , a full hematologic evaluation was done .
Diseases:"
3983	Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro cytotoxicity from doxorubicin .	O O O O O B O B I O O O O O O O O O O O O O O O O O O O O O B O B I O O O O O B O O O	O O O B O O O O O O B O B O O O O O O O O O O O O O O B O O O O O O O O O O O O O B O	['myelosuppression', 'cytotoxicity', 'weight loss']	3	12	"Sentence: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro cytotoxicity from doxorubicin .
Diseases: myelosuppression, cytotoxicity, weight loss"	"Sentence: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro cytotoxicity from doxorubicin .
Diseases:"
3984	Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically , the potent antagonism of daunorubicin activity raises concern ; a possible interference with anticancer efficacy certainly would call for renewed attention .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O B O O O O O O B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically , the potent antagonism of daunorubicin activity raises concern ; a possible interference with anticancer efficacy certainly would call for renewed attention .
Diseases: "	"Sentence: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically , the potent antagonism of daunorubicin activity raises concern ; a possible interference with anticancer efficacy certainly would call for renewed attention .
Diseases:"
3985	Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane .	O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O B O	[]	0	0	"Sentence: Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane .
Diseases: "	"Sentence: Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane .
Diseases:"
3986	Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity .	O O O O O O B O O O O O O O O O O O O O O O O O B I O	O O O O O O O O B O O O O B O O O O O O O O O O O O O	['hematologic toxicity', 'metastases']	2	6	"Sentence: Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity .
Diseases: hematologic toxicity, metastases"	"Sentence: Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity .
Diseases:"
3987	If successful , this represents an exciting mechanism for pharmacologic regulation of side effects from cytotoxic chemotherapy .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: If successful , this represents an exciting mechanism for pharmacologic regulation of side effects from cytotoxic chemotherapy .
Diseases: "	"Sentence: If successful , this represents an exciting mechanism for pharmacologic regulation of side effects from cytotoxic chemotherapy .
Diseases:"
3988	Effects of the novel compound aniracetam ( Ro 13 - 5057 ) upon impaired learning and memory in rodents .	O O O O O O O O O O O O O B I I I O O O	O O O O O B O B I I I O O O O O O O O O	['impaired learning and memory']	1	6	"Sentence: Effects of the novel compound aniracetam ( Ro 13 - 5057 ) upon impaired learning and memory in rodents .
Diseases: impaired learning and memory"	"Sentence: Effects of the novel compound aniracetam ( Ro 13 - 5057 ) upon impaired learning and memory in rodents .
Diseases:"
3989	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .	O O O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	O O O B O B I I I O B I I I I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	['hypercapnia', 'impaired cognitive functions', 'amnesia']	3	10	"Sentence: The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
Diseases: hypercapnia, impaired cognitive functions, amnesia"	"Sentence: The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
Diseases:"
3990	These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10 - 100 mg / kg .	O O O O O B I I O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O	['impaired cognitive functions']	1	5	"Sentence: These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10 - 100 mg / kg .
Diseases: impaired cognitive functions"	"Sentence: These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10 - 100 mg / kg .
Diseases:"
3991	Generally , the dose - response curves were bell - shaped .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: Generally , the dose - response curves were bell - shaped .
Diseases: "	"Sentence: Generally , the dose - response curves were bell - shaped .
Diseases:"
3992	The mechanisms underlying the activity of aniracetam and its ' therapeutic window ' are unknown .	O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: The mechanisms underlying the activity of aniracetam and its ' therapeutic window ' are unknown .
Diseases: "	"Sentence: The mechanisms underlying the activity of aniracetam and its ' therapeutic window ' are unknown .
Diseases:"
3993	Piracetam , another pyrrolidinone derivative was used for comparison .	O O O O O O O O O O	B O O B O O O O O O	[]	0	0	"Sentence: Piracetam , another pyrrolidinone derivative was used for comparison .
Diseases: "	"Sentence: Piracetam , another pyrrolidinone derivative was used for comparison .
Diseases:"
3994	It was active only in six of nine tests and had about one - tenth the potency of aniracetam .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: It was active only in six of nine tests and had about one - tenth the potency of aniracetam .
Diseases: "	"Sentence: It was active only in six of nine tests and had about one - tenth the potency of aniracetam .
Diseases:"
3995	The results indicate that aniracetam improves cognitive functions which are impaired by different procedure and in different phases of the learning and memory process .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The results indicate that aniracetam improves cognitive functions which are impaired by different procedure and in different phases of the learning and memory process .
Diseases: "	"Sentence: The results indicate that aniracetam improves cognitive functions which are impaired by different procedure and in different phases of the learning and memory process .
Diseases:"
3996	Nicotine potentiation of morphine - induced catalepsy in mice .	O O O O O O B O O O	B O O B O O O O O O	['catalepsy']	1	4	"Sentence: Nicotine potentiation of morphine - induced catalepsy in mice .
Diseases: catalepsy"	"Sentence: Nicotine potentiation of morphine - induced catalepsy in mice .
Diseases:"
3997	In the present study , effects of nicotine on catalepsy induced by morphine in mice have been investigated .	O O O O O O O O O B O O O O O O O O O	O O O O O O O B O O O O B O O O O O O	['catalepsy']	1	4	"Sentence: In the present study , effects of nicotine on catalepsy induced by morphine in mice have been investigated .
Diseases: catalepsy"	"Sentence: In the present study , effects of nicotine on catalepsy induced by morphine in mice have been investigated .
Diseases:"
3998	Morphine but not nicotine induced a dose - dependent catalepsy .	O O O O O O O O O B O	B O O B O O O O O O O	['catalepsy']	1	4	"Sentence: Morphine but not nicotine induced a dose - dependent catalepsy .
Diseases: catalepsy"	"Sentence: Morphine but not nicotine induced a dose - dependent catalepsy .
Diseases:"
3999	The response of morphine was potentiated by nicotine .	O O O O O O O O O	O O O B O O O B O	[]	0	0	"Sentence: The response of morphine was potentiated by nicotine .
Diseases: "	"Sentence: The response of morphine was potentiated by nicotine .
Diseases:"
4000	Intraperitoneal administration of atropine , naloxone , mecamylamine , and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine .	O O O O O O O O O O O O O O B O O O O O O O O O	O O O B O B O B O O B O O O O O O O O O B O B O	['catalepsy']	1	4	"Sentence: Intraperitoneal administration of atropine , naloxone , mecamylamine , and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine .
Diseases: catalepsy"	"Sentence: Intraperitoneal administration of atropine , naloxone , mecamylamine , and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine .
Diseases:"
4001	Intracerebroventricular injection of atropine , hexamethonium , and naloxone also decreased catalepsy induced by morphine plus nicotine .	O O O O O O O O O O O B O O O O O O	O O O B O B O O B O O O O O B O B O	['catalepsy']	1	4	"Sentence: Intracerebroventricular injection of atropine , hexamethonium , and naloxone also decreased catalepsy induced by morphine plus nicotine .
Diseases: catalepsy"	"Sentence: Intracerebroventricular injection of atropine , hexamethonium , and naloxone also decreased catalepsy induced by morphine plus nicotine .
Diseases:"
4002	Intraperitoneal administration of atropine , but not intraperitoneal or intracerebroventricular injection of hexamethonium , decreased the effect of a single dose of morphine .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O B O O O O O O O O O B O	[]	0	0	"Sentence: Intraperitoneal administration of atropine , but not intraperitoneal or intracerebroventricular injection of hexamethonium , decreased the effect of a single dose of morphine .
Diseases: "	"Sentence: Intraperitoneal administration of atropine , but not intraperitoneal or intracerebroventricular injection of hexamethonium , decreased the effect of a single dose of morphine .
Diseases:"
4003	It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors , and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms .	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O B O O B O O O O O O O O O	['catalepsy']	1	4	"Sentence: It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors , and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms .
Diseases: catalepsy"	"Sentence: It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors , and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms .
Diseases:"
4004	Reduced cardiotoxicity and preserved antitumor efficacy of liposome - encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized , multicenter trial of metastatic breast cancer .	O B O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O B O B O O O B O B O O O O O O O O O O O	['cardiotoxicity', 'breast cancer']	2	6	"Sentence: Reduced cardiotoxicity and preserved antitumor efficacy of liposome - encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized , multicenter trial of metastatic breast cancer .
Diseases: cardiotoxicity, breast cancer"	"Sentence: Reduced cardiotoxicity and preserved antitumor efficacy of liposome - encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized , multicenter trial of metastatic breast cancer .
Diseases:"
4005	To determine whether Myocet ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first - line treatment of metastatic breast cancer ( MBC ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O B I O B O O	O O O B O O O O B O O O O O O O O O O O O O O O B O O B O O O O O O O O O O O O O O O O O O O	['cardiotoxicity', 'mbc', 'breast cancer']	3	9	"Sentence: To determine whether Myocet ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first - line treatment of metastatic breast cancer ( MBC ) .
Diseases: cardiotoxicity, mbc, breast cancer"	"Sentence: To determine whether Myocet ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first - line treatment of metastatic breast cancer ( MBC ) .
Diseases:"
4006	PATIENTS AND METHODS : Two hundred ninety - seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg / m ( 2 ) of Myocet ( M ) or conventional doxorubicin ( A ) , in combination with 600 mg / m ( 2 ) of cyclophosphamide ( C ) , every 3 weeks until disease progression or unacceptable toxicity .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O B O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	['mbc', 'toxicity']	2	4	"Sentence: PATIENTS AND METHODS : Two hundred ninety - seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg / m ( 2 ) of Myocet ( M ) or conventional doxorubicin ( A ) , in combination with 600 mg / m ( 2 ) of cyclophosphamide ( C ) , every 3 weeks until disease progression or unacceptable toxicity .
Diseases: mbc, toxicity"	"Sentence: PATIENTS AND METHODS : Two hundred ninety - seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg / m ( 2 ) of Myocet ( M ) or conventional doxorubicin ( A ) , in combination with 600 mg / m ( 2 ) of cyclophosphamide ( C ) , every 3 weeks until disease progression or unacceptable toxicity .
Diseases:"
4007	Cardiotoxicity was defined by reductions in left - ventricular ejection fraction , assessed by serial multigated radionuclide angiography scans , or congestive heart failure ( CHF ) .	B O O O O O O O O O O O O O O O O O O O O B I I O B O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cardiotoxicity', 'chf', 'congestive heart failure']	3	11	"Sentence: Cardiotoxicity was defined by reductions in left - ventricular ejection fraction , assessed by serial multigated radionuclide angiography scans , or congestive heart failure ( CHF ) .
Diseases: cardiotoxicity, chf, congestive heart failure"	"Sentence: Cardiotoxicity was defined by reductions in left - ventricular ejection fraction , assessed by serial multigated radionuclide angiography scans , or congestive heart failure ( CHF ) .
Diseases:"
4008	Antitumor efficacy was assessed by objective tumor response rates ( World Health Organization criteria ) , time to progression , and survival .	O O O O O O B O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['tumor']	1	3	"Sentence: Antitumor efficacy was assessed by objective tumor response rates ( World Health Organization criteria ) , time to progression , and survival .
Diseases: tumor"	"Sentence: Antitumor efficacy was assessed by objective tumor response rates ( World Health Organization criteria ) , time to progression , and survival .
Diseases:"
4009	Six percent of MC patients versus 21 % ( including five cases of CHF ) of AC patients developed cardiotoxicity ( P = . 0002 ) .	O O O O O O O O O O O O O B O O O O O B O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O O O O O	['cardiotoxicity', 'chf']	2	6	"Sentence: Six percent of MC patients versus 21 % ( including five cases of CHF ) of AC patients developed cardiotoxicity ( P = . 0002 ) .
Diseases: cardiotoxicity, chf"	"Sentence: Six percent of MC patients versus 21 % ( including five cases of CHF ) of AC patients developed cardiotoxicity ( P = . 0002 ) .
Diseases:"
4010	Median cumulative doxorubicin dose at onset was more than 2 , 220 mg / m ( 2 ) for MC versus 480 mg / m ( 2 ) for AC ( P = . 0001 , hazard ratio , 5 . 04 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O B O O O O O O O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: Median cumulative doxorubicin dose at onset was more than 2 , 220 mg / m ( 2 ) for MC versus 480 mg / m ( 2 ) for AC ( P = . 0001 , hazard ratio , 5 . 04 ) .
Diseases: "	"Sentence: Median cumulative doxorubicin dose at onset was more than 2 , 220 mg / m ( 2 ) for MC versus 480 mg / m ( 2 ) for AC ( P = . 0001 , hazard ratio , 5 . 04 ) .
Diseases:"
4011	MC patients also experienced less grade 4 neutropenia .	O O O O O O O B O	O O O O O O O O O	['neutropenia']	1	5	"Sentence: MC patients also experienced less grade 4 neutropenia .
Diseases: neutropenia"	"Sentence: MC patients also experienced less grade 4 neutropenia .
Diseases:"
4012	Antitumor efficacy of MC versus AC was comparable : objective response rates , 43 % versus 43 % ; median time to progression , 5 . 1 % versus 5 . 5 months ; median time to treatment failure , 4 . 6 versus 4 . 4 months ; and median survival , 19 versus 16 months .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Antitumor efficacy of MC versus AC was comparable : objective response rates , 43 % versus 43 % ; median time to progression , 5 . 1 % versus 5 . 5 months ; median time to treatment failure , 4 . 6 versus 4 . 4 months ; and median survival , 19 versus 16 months .
Diseases: "	"Sentence: Antitumor efficacy of MC versus AC was comparable : objective response rates , 43 % versus 43 % ; median time to progression , 5 . 1 % versus 5 . 5 months ; median time to treatment failure , 4 . 6 versus 4 . 4 months ; and median survival , 19 versus 16 months .
Diseases:"
4013	CONCLUSION : Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy , when used in combination with cyclophosphamide as first - line therapy for MBC .	O O O O O O O O O O O O B O O O B O O O O O O O O O O O O O O O O O O B O	O O B O O O O O B O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['cardiotoxicity', 'neutropenia', 'mbc']	3	11	"Sentence: CONCLUSION : Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy , when used in combination with cyclophosphamide as first - line therapy for MBC .
Diseases: cardiotoxicity, neutropenia, mbc"	"Sentence: CONCLUSION : Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy , when used in combination with cyclophosphamide as first - line therapy for MBC .
Diseases:"
4014	Protective effect of a specific platelet - activating factor antagonist , BN 52021 , on bupivacaine - induced cardiovascular impairments in rats .	O O O O O O O O O O O O O O O O O O B I O O O	O O O O O O O O O O O B I O O B O O O O O O O	['cardiovascular impairments']	1	4	"Sentence: Protective effect of a specific platelet - activating factor antagonist , BN 52021 , on bupivacaine - induced cardiovascular impairments in rats .
Diseases: cardiovascular impairments"	"Sentence: Protective effect of a specific platelet - activating factor antagonist , BN 52021 , on bupivacaine - induced cardiovascular impairments in rats .
Diseases:"
4015	Administration of the local anaesthetic bupivacaine ( 1 . 5 or 2 mg / kg , i . v . ) to rats elicited a marked decrease of mean arterial blood pressure ( MBP ) and heart rate ( HR ) leading to death ( in 67 % or 90 % of animals respectively ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I I I I I I I I I I I I O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['decrease of mean arterial blood pressure ( mbp ) and heart rate ( hr )']	1	19	"Sentence: Administration of the local anaesthetic bupivacaine ( 1 . 5 or 2 mg / kg , i . v . ) to rats elicited a marked decrease of mean arterial blood pressure ( MBP ) and heart rate ( HR ) leading to death ( in 67 % or 90 % of animals respectively ) .
Diseases: decrease of mean arterial blood pressure ( mbp ) and heart rate ( hr )"	"Sentence: Administration of the local anaesthetic bupivacaine ( 1 . 5 or 2 mg / kg , i . v . ) to rats elicited a marked decrease of mean arterial blood pressure ( MBP ) and heart rate ( HR ) leading to death ( in 67 % or 90 % of animals respectively ) .
Diseases:"
4016	Intravenous injection of the specific platelet - activating factor ( PAF ) antagonist BN 52021 ( 10 mg / kg ) , 30 min before bupivacaine administration ( 2 mg / kg i . v . )	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B I O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: Intravenous injection of the specific platelet - activating factor ( PAF ) antagonist BN 52021 ( 10 mg / kg ) , 30 min before bupivacaine administration ( 2 mg / kg i . v . )
Diseases: "	"Sentence: Intravenous injection of the specific platelet - activating factor ( PAF ) antagonist BN 52021 ( 10 mg / kg ) , 30 min before bupivacaine administration ( 2 mg / kg i . v . )
Diseases:"
4017	suppressed both the decrease of MBP and HR .	O O O B I I I I O	O O O O O O O O O	['decrease of mbp and hr']	1	8	"Sentence: suppressed both the decrease of MBP and HR .
Diseases: decrease of mbp and hr"	"Sentence: suppressed both the decrease of MBP and HR .
Diseases:"
4018	In contrast , doses of 1 mg / kg BN 52021 given 30 min before or 10 mg / kg administered 5 min before i . v . injection of bupivacaine were ineffective .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O B O O O	[]	0	0	"Sentence: In contrast , doses of 1 mg / kg BN 52021 given 30 min before or 10 mg / kg administered 5 min before i . v . injection of bupivacaine were ineffective .
Diseases: "	"Sentence: In contrast , doses of 1 mg / kg BN 52021 given 30 min before or 10 mg / kg administered 5 min before i . v . injection of bupivacaine were ineffective .
Diseases:"
4019	When BN 52021 ( 20 mg / kg i . v . ) was injected immediately after bupivacaine ( 2 mg / kg ) , a partial reversion of the decrease of MBP and HR was observed , whereas the dose of 10 mg / kg was ineffective .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I I O O O O O O O O O O O O O O	O B I O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['decrease of mbp and hr']	1	8	"Sentence: When BN 52021 ( 20 mg / kg i . v . ) was injected immediately after bupivacaine ( 2 mg / kg ) , a partial reversion of the decrease of MBP and HR was observed , whereas the dose of 10 mg / kg was ineffective .
Diseases: decrease of mbp and hr"	"Sentence: When BN 52021 ( 20 mg / kg i . v . ) was injected immediately after bupivacaine ( 2 mg / kg ) , a partial reversion of the decrease of MBP and HR was observed , whereas the dose of 10 mg / kg was ineffective .
Diseases:"
4020	A partial recovery of bupivacaine - induced ECG alterations was observed after pretreatment of the rats with BN 52021 .	O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O B I O	[]	0	0	"Sentence: A partial recovery of bupivacaine - induced ECG alterations was observed after pretreatment of the rats with BN 52021 .
Diseases: "	"Sentence: A partial recovery of bupivacaine - induced ECG alterations was observed after pretreatment of the rats with BN 52021 .
Diseases:"
4021	Since the administration of BN 52021 , at all doses studied , did not alter MBP and HR at the doses used , the bulk of these results clearly demonstrate a protective action of BN 52021 , a specific antagonist of PAF , against bupivacaine - induced cardiovascular toxicity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O B O O B O O O O O	['cardiovascular toxicity']	1	3	"Sentence: Since the administration of BN 52021 , at all doses studied , did not alter MBP and HR at the doses used , the bulk of these results clearly demonstrate a protective action of BN 52021 , a specific antagonist of PAF , against bupivacaine - induced cardiovascular toxicity .
Diseases: cardiovascular toxicity"	"Sentence: Since the administration of BN 52021 , at all doses studied , did not alter MBP and HR at the doses used , the bulk of these results clearly demonstrate a protective action of BN 52021 , a specific antagonist of PAF , against bupivacaine - induced cardiovascular toxicity .
Diseases:"
4022	Thus , consistent with its direct effect on heart , PAF appears to be implicated in bupivacaine - induced cardiovascular alterations .	O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O B O O O O O B O O O O O	['cardiovascular alterations']	1	3	"Sentence: Thus , consistent with its direct effect on heart , PAF appears to be implicated in bupivacaine - induced cardiovascular alterations .
Diseases: cardiovascular alterations"	"Sentence: Thus , consistent with its direct effect on heart , PAF appears to be implicated in bupivacaine - induced cardiovascular alterations .
Diseases:"
4023	Benzylacyclouridine reverses azidothymidine - induced marrow suppression without impairment of anti - human immunodeficiency virus activity .	O O O O O B I O O O O O O B O O O	B O B O O O O O O O O O O O O O O	['immunodeficiency', 'marrow suppression']	2	8	"Sentence: Benzylacyclouridine reverses azidothymidine - induced marrow suppression without impairment of anti - human immunodeficiency virus activity .
Diseases: immunodeficiency, marrow suppression"	"Sentence: Benzylacyclouridine reverses azidothymidine - induced marrow suppression without impairment of anti - human immunodeficiency virus activity .
Diseases:"
4024	Increased extracellular concentrations of uridine ( Urd ) have been reported to reduce , in vitro , azidothymidine ( AZT ) - induced inhibition of human granulocyte - macrophage progenitor cells without impairment of its antihuman immunodeficiency virus ( HIV ) activity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O	O O O O B O B O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O	['immunodeficiency']	1	5	"Sentence: Increased extracellular concentrations of uridine ( Urd ) have been reported to reduce , in vitro , azidothymidine ( AZT ) - induced inhibition of human granulocyte - macrophage progenitor cells without impairment of its antihuman immunodeficiency virus ( HIV ) activity .
Diseases: immunodeficiency"	"Sentence: Increased extracellular concentrations of uridine ( Urd ) have been reported to reduce , in vitro , azidothymidine ( AZT ) - induced inhibition of human granulocyte - macrophage progenitor cells without impairment of its antihuman immunodeficiency virus ( HIV ) activity .
Diseases:"
4025	Because of the clinical toxicities associated with chronic Urd administration , the ability of benzylacyclouridine ( BAU ) to effect , in vivo , AZT - induced anemia and leukopenia was assessed .	O O O O B O O O O O O O O O O O O O O O O O O O O O O B O B O O O	O O O O O O O O B O O O O O B O B O O O O O O O B O O O O O O O O	['toxicities', 'leukopenia', 'anemia']	3	11	"Sentence: Because of the clinical toxicities associated with chronic Urd administration , the ability of benzylacyclouridine ( BAU ) to effect , in vivo , AZT - induced anemia and leukopenia was assessed .
Diseases: toxicities, leukopenia, anemia"	"Sentence: Because of the clinical toxicities associated with chronic Urd administration , the ability of benzylacyclouridine ( BAU ) to effect , in vivo , AZT - induced anemia and leukopenia was assessed .
Diseases:"
4026	This agent inhibits Urd catabolism and , in vivo , increases the plasma concentration of Urd in a dose - dependent manner , without Urd - related toxicity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O B O O O O O O O O O O O B O O O O O O O O B O O O O	['toxicity']	1	2	"Sentence: This agent inhibits Urd catabolism and , in vivo , increases the plasma concentration of Urd in a dose - dependent manner , without Urd - related toxicity .
Diseases: toxicity"	"Sentence: This agent inhibits Urd catabolism and , in vivo , increases the plasma concentration of Urd in a dose - dependent manner , without Urd - related toxicity .
Diseases:"
4027	In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .	O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O B O O B O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['leukopenic', 'anemic', 'megaloblastosis', 'anemia', 'leukopenia']	5	21	"Sentence: In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
Diseases: leukopenic, anemic, megaloblastosis, anemia, leukopenia"	"Sentence: In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
Diseases:"
4028	When coadministered with AZT from the onset of drug administration , BAU reduced AZT - induced marrow toxicity .	O O O O O O O O O O O O O O O O B I O	O O O B O O O O O O O B O B O O O O O	['marrow toxicity']	1	3	"Sentence: When coadministered with AZT from the onset of drug administration , BAU reduced AZT - induced marrow toxicity .
Diseases: marrow toxicity"	"Sentence: When coadministered with AZT from the onset of drug administration , BAU reduced AZT - induced marrow toxicity .
Diseases:"
4029	In vitro , at a concentration of 100 mumol / L , BAU possesses minimal anti - HIV activity and has no effect on the ability of AZT to reverse the HIV - induced cytopathic effect in MT4 cells .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: In vitro , at a concentration of 100 mumol / L , BAU possesses minimal anti - HIV activity and has no effect on the ability of AZT to reverse the HIV - induced cytopathic effect in MT4 cells .
Diseases: "	"Sentence: In vitro , at a concentration of 100 mumol / L , BAU possesses minimal anti - HIV activity and has no effect on the ability of AZT to reverse the HIV - induced cytopathic effect in MT4 cells .
Diseases:"
4030	The clinical and biochemical implications of these findings are discussed .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: The clinical and biochemical implications of these findings are discussed .
Diseases: "	"Sentence: The clinical and biochemical implications of these findings are discussed .
Diseases:"
4031	Cyclophosphamide - induced cystitis in freely - moving conscious rats : behavioral approach to a new model of visceral pain .	O O O B O O O O O O O O O O O O O O B I O	B O O O O O O O O O O O O O O O O O O O O	['cystitis', 'visceral pain']	2	6	"Sentence: Cyclophosphamide - induced cystitis in freely - moving conscious rats : behavioral approach to a new model of visceral pain .
Diseases: cystitis, visceral pain"	"Sentence: Cyclophosphamide - induced cystitis in freely - moving conscious rats : behavioral approach to a new model of visceral pain .
Diseases:"
4032	To develop a model of visceral pain in rats using a behavioral approach .	O O O O O B I O O O O O O O	O O O O O O O O O O O O O O	['visceral pain']	1	4	"Sentence: To develop a model of visceral pain in rats using a behavioral approach .
Diseases: visceral pain"	"Sentence: To develop a model of visceral pain in rats using a behavioral approach .
Diseases:"
4033	Cyclophosphamide ( CP ) , an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein , was used to induce cystitis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	B O B O O O O O O O O O O O O O O O O O O O B O O O O O O O	['cystitis']	1	3	"Sentence: Cyclophosphamide ( CP ) , an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein , was used to induce cystitis .
Diseases: cystitis"	"Sentence: Cyclophosphamide ( CP ) , an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein , was used to induce cystitis .
Diseases:"
4034	MATERIALS AND METHODS : CP was administered at doses of 50 , 100 and 200 mg . / kg .	O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: MATERIALS AND METHODS : CP was administered at doses of 50 , 100 and 200 mg . / kg .
Diseases: "	"Sentence: MATERIALS AND METHODS : CP was administered at doses of 50 , 100 and 200 mg . / kg .
Diseases:"
4035	i . p .	O O O O	O O O O	[]	0	0	"Sentence: i . p .
Diseases: "	"Sentence: i . p .
Diseases:"
4036	to male rats , and their behavior observed and scored .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: to male rats , and their behavior observed and scored .
Diseases: "	"Sentence: to male rats , and their behavior observed and scored .
Diseases:"
4037	The effects of morphine ( 0 . 5 to 4 mg . / kg .	O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O	[]	0	0	"Sentence: The effects of morphine ( 0 . 5 to 4 mg . / kg .
Diseases: "	"Sentence: The effects of morphine ( 0 . 5 to 4 mg . / kg .
Diseases:"
4038	i . v . )	O O O O O	O O O O O	[]	0	0	"Sentence: i . v . )
Diseases: "	"Sentence: i . v . )
Diseases:"
4039	on CP - induced behavioral modifications were tested administered alone and after naloxone ( 1 mg . / kg .	O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: on CP - induced behavioral modifications were tested administered alone and after naloxone ( 1 mg . / kg .
Diseases: "	"Sentence: on CP - induced behavioral modifications were tested administered alone and after naloxone ( 1 mg . / kg .
Diseases:"
4040	s . c . ) .	O O O O O O	O O O O O O	[]	0	0	"Sentence: s . c . ) .
Diseases: "	"Sentence: s . c . ) .
Diseases:"
4041	In addition , 90 minutes after CP injection , that is , at the time of administration of morphine , the bladder was removed in some rats for histological examination .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: In addition , 90 minutes after CP injection , that is , at the time of administration of morphine , the bladder was removed in some rats for histological examination .
Diseases: "	"Sentence: In addition , 90 minutes after CP injection , that is , at the time of administration of morphine , the bladder was removed in some rats for histological examination .
Diseases:"
4042	Finally , to show that the bladder is essential for the CP - induced behavioral modifications , female rats also received CP at doses of 200 mg . / kg .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: Finally , to show that the bladder is essential for the CP - induced behavioral modifications , female rats also received CP at doses of 200 mg . / kg .
Diseases: "	"Sentence: Finally , to show that the bladder is essential for the CP - induced behavioral modifications , female rats also received CP at doses of 200 mg . / kg .
Diseases:"
4043	and of 20 mg .	O O O O O	O O O O O	[]	0	0	"Sentence: and of 20 mg .
Diseases: "	"Sentence: and of 20 mg .
Diseases:"
4044	by the intravesical route , and acrolein at doses of 0 . 5 mg .	O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O	[]	0	0	"Sentence: by the intravesical route , and acrolein at doses of 0 . 5 mg .
Diseases: "	"Sentence: by the intravesical route , and acrolein at doses of 0 . 5 mg .
Diseases:"
4045	by the intravesical route and of 5 mg . / kg .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: by the intravesical route and of 5 mg . / kg .
Diseases: "	"Sentence: by the intravesical route and of 5 mg . / kg .
Diseases:"
4046	i . v .	O O O O	O O O O	[]	0	0	"Sentence: i . v .
Diseases: "	"Sentence: i . v .
Diseases:"
4047	CP dose - relatedly induced marked behavioral modifications in male rats : breathing rate decrease , closing of the eyes and occurrence of specific postures .	O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: CP dose - relatedly induced marked behavioral modifications in male rats : breathing rate decrease , closing of the eyes and occurrence of specific postures .
Diseases: "	"Sentence: CP dose - relatedly induced marked behavioral modifications in male rats : breathing rate decrease , closing of the eyes and occurrence of specific postures .
Diseases:"
4048	Morphine dose - dependently reversed these behavioral disorders .	O O O O O O B I O	B O O O O O O O O	['behavioral disorders']	1	3	"Sentence: Morphine dose - dependently reversed these behavioral disorders .
Diseases: behavioral disorders"	"Sentence: Morphine dose - dependently reversed these behavioral disorders .
Diseases:"
4049	A dose of 0 . 5 mg . / kg . produced a reduction of almost 50 % of the behavioral score induced by CP 200 mg . / kg .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O	[]	0	0	"Sentence: A dose of 0 . 5 mg . / kg . produced a reduction of almost 50 % of the behavioral score induced by CP 200 mg . / kg .
Diseases: "	"Sentence: A dose of 0 . 5 mg . / kg . produced a reduction of almost 50 % of the behavioral score induced by CP 200 mg . / kg .
Diseases:"
4050	This effect was completely prevented by pretreatment with naloxone .	O O O O O O O O O O	O O O O O O O O B O	[]	0	0	"Sentence: This effect was completely prevented by pretreatment with naloxone .
Diseases: "	"Sentence: This effect was completely prevented by pretreatment with naloxone .
Diseases:"
4051	At the time of administration of morphine , histological modifications of the bladder wall , such as chorionic and muscle layer edema , were observed .	O O O O O O O O O O O O O O O O O O O O O B O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O	['edema']	1	2	"Sentence: At the time of administration of morphine , histological modifications of the bladder wall , such as chorionic and muscle layer edema , were observed .
Diseases: edema"	"Sentence: At the time of administration of morphine , histological modifications of the bladder wall , such as chorionic and muscle layer edema , were observed .
Diseases:"
4052	In female rats , CP 200 mg . / kg .	O O O O O O O O O O O	O O O O B O O O O O O	[]	0	0	"Sentence: In female rats , CP 200 mg . / kg .
Diseases: "	"Sentence: In female rats , CP 200 mg . / kg .
Diseases:"
4053	i . p . produced the same marked behavioral modifications as those observed in male rats .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: i . p . produced the same marked behavioral modifications as those observed in male rats .
Diseases: "	"Sentence: i . p . produced the same marked behavioral modifications as those observed in male rats .
Diseases:"
4054	Administered at the dose of 20 mg .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: Administered at the dose of 20 mg .
Diseases: "	"Sentence: Administered at the dose of 20 mg .
Diseases:"
4055	intravesically , CP did not produce any behavioral effects , whereas acrolein at 0 . 5 mg .	O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O B O O O O O O	[]	0	0	"Sentence: intravesically , CP did not produce any behavioral effects , whereas acrolein at 0 . 5 mg .
Diseases: "	"Sentence: intravesically , CP did not produce any behavioral effects , whereas acrolein at 0 . 5 mg .
Diseases:"
4056	intravesically induced behavioral modifications identical to those under CP 200 mg . / kg .	O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O	[]	0	0	"Sentence: intravesically induced behavioral modifications identical to those under CP 200 mg . / kg .
Diseases: "	"Sentence: intravesically induced behavioral modifications identical to those under CP 200 mg . / kg .
Diseases:"
4057	, with the same maximal levels .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: , with the same maximal levels .
Diseases: "	"Sentence: , with the same maximal levels .
Diseases:"
4058	Conversely , acrolein 5 mg . / kg .	O O O O O O O O O	O O B O O O O O O	[]	0	0	"Sentence: Conversely , acrolein 5 mg . / kg .
Diseases: "	"Sentence: Conversely , acrolein 5 mg . / kg .
Diseases:"
4059	did not produce any behavioral effects at all .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: did not produce any behavioral effects at all .
Diseases: "	"Sentence: did not produce any behavioral effects at all .
Diseases:"
4060	Overall , these results indicate that this experimental model of CP - induced cystitis may be an interesting new behavioral model of inflammatory visceral pain , allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them .	O O O O O O O O O O O O O B O O O O O O O O O B I O O O O O O O B I O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['painful syndromes', 'cystitis', 'visceral pain']	3	12	"Sentence: Overall , these results indicate that this experimental model of CP - induced cystitis may be an interesting new behavioral model of inflammatory visceral pain , allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them .
Diseases: painful syndromes, cystitis, visceral pain"	"Sentence: Overall , these results indicate that this experimental model of CP - induced cystitis may be an interesting new behavioral model of inflammatory visceral pain , allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them .
Diseases:"
4061	Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine .	B O B O O B O O O O O O O	O O O O O O O O O O O B O	['cancer', 'myoclonus', 'hyperalgesia']	3	11	"Sentence: Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine .
Diseases: cancer, myoclonus, hyperalgesia"	"Sentence: Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine .
Diseases:"
4062	Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia .	O B O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O B O O O	['cancer', 'hyperalgesia']	2	6	"Sentence: Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia .
Diseases: cancer, hyperalgesia"	"Sentence: Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia .
Diseases:"
4063	All cases were retrospectively sampled from three different hospitals in Copenhagen .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: All cases were retrospectively sampled from three different hospitals in Copenhagen .
Diseases: "	"Sentence: All cases were retrospectively sampled from three different hospitals in Copenhagen .
Diseases:"
4064	Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus .	O O O O B O B O O O O O O O B O	O O O O O O O O O O O O O O O O	['hyperesthesia', 'myoclonus', 'hyperalgesia']	3	14	"Sentence: Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus .
Diseases: hyperesthesia, myoclonus, hyperalgesia"	"Sentence: Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus .
Diseases:"
4065	In 3 patients a pre - existing neuralgia increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously .	O O O O O O O B O O O O O O O O O O B O O O	O O O O O O O O O O O O O O O O O O O O O O	['myoclonus', 'neuralgia']	2	9	"Sentence: In 3 patients a pre - existing neuralgia increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously .
Diseases: myoclonus, neuralgia"	"Sentence: In 3 patients a pre - existing neuralgia increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously .
Diseases:"
4066	Although only few clinical descriptions of the relationship between hyperalgesia / myoclonus and high doses of morphine are available , experimental support from animal studies indicates that morphine , or its metabolites , plays a causative role for the observed behavioural syndrome .	O O O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O O O O O B O O O O O O O O O O O O O O O	['myoclonus', 'hyperalgesia']	2	9	"Sentence: Although only few clinical descriptions of the relationship between hyperalgesia / myoclonus and high doses of morphine are available , experimental support from animal studies indicates that morphine , or its metabolites , plays a causative role for the observed behavioural syndrome .
Diseases: myoclonus, hyperalgesia"	"Sentence: Although only few clinical descriptions of the relationship between hyperalgesia / myoclonus and high doses of morphine are available , experimental support from animal studies indicates that morphine , or its metabolites , plays a causative role for the observed behavioural syndrome .
Diseases:"
4067	The possible mechanisms are discussed and treatment proposals given suggesting the use of more efficacious opioids with less excitatory potency in these situations .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The possible mechanisms are discussed and treatment proposals given suggesting the use of more efficacious opioids with less excitatory potency in these situations .
Diseases: "	"Sentence: The possible mechanisms are discussed and treatment proposals given suggesting the use of more efficacious opioids with less excitatory potency in these situations .
Diseases:"
4068	A prospective study of adverse reactions associated with vancomycin therapy .	O O O O O O O O O O O	O O O O O O O O B O O	[]	0	0	"Sentence: A prospective study of adverse reactions associated with vancomycin therapy .
Diseases: "	"Sentence: A prospective study of adverse reactions associated with vancomycin therapy .
Diseases:"
4069	A prospective evaluation of the efficacy and safety of vancomycin was conducted in 54 consecutive patients over a 16 - month period .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: A prospective evaluation of the efficacy and safety of vancomycin was conducted in 54 consecutive patients over a 16 - month period .
Diseases: "	"Sentence: A prospective evaluation of the efficacy and safety of vancomycin was conducted in 54 consecutive patients over a 16 - month period .
Diseases:"
4070	Vancomycin was curative in 95 % of 43 patients with proven infection .	O O O O O O O O O O O B O	B O O O O O O O O O O O O	['infection']	1	2	"Sentence: Vancomycin was curative in 95 % of 43 patients with proven infection .
Diseases: infection"	"Sentence: Vancomycin was curative in 95 % of 43 patients with proven infection .
Diseases:"
4071	Drugs were ceased in six patients because of adverse reactions ; in three of these vancomycin was considered the likely cause .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O O O O	[]	0	0	"Sentence: Drugs were ceased in six patients because of adverse reactions ; in three of these vancomycin was considered the likely cause .
Diseases: "	"Sentence: Drugs were ceased in six patients because of adverse reactions ; in three of these vancomycin was considered the likely cause .
Diseases:"
4072	Reactions included thrombophlebitis ( 20 of 54 patients ) , rash ( 4 of 54 ) , nephrotoxicity ( 4 of 50 ) , proteinuria ( 1 of 50 ) and ototoxicity ( 1 of 11 patients tested by audiometry ) .	O O B O O O O O O O B O O O O O O B O O O O O O B O O O O O O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['proteinuria', 'nephrotoxicity', 'rash', 'thrombophlebitis', 'ototoxicity']	5	21	"Sentence: Reactions included thrombophlebitis ( 20 of 54 patients ) , rash ( 4 of 54 ) , nephrotoxicity ( 4 of 50 ) , proteinuria ( 1 of 50 ) and ototoxicity ( 1 of 11 patients tested by audiometry ) .
Diseases: proteinuria, nephrotoxicity, rash, thrombophlebitis, ototoxicity"	"Sentence: Reactions included thrombophlebitis ( 20 of 54 patients ) , rash ( 4 of 54 ) , nephrotoxicity ( 4 of 50 ) , proteinuria ( 1 of 50 ) and ototoxicity ( 1 of 11 patients tested by audiometry ) .
Diseases:"
4073	Thrombophlebitis occurred only with infusion through peripheral cannulae ; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin .	B O O O O O O O O B O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O B O	['nephrotoxicity', 'thrombophlebitis', 'ototoxicity']	3	16	"Sentence: Thrombophlebitis occurred only with infusion through peripheral cannulae ; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin .
Diseases: nephrotoxicity, thrombophlebitis, ototoxicity"	"Sentence: Thrombophlebitis occurred only with infusion through peripheral cannulae ; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin .
Diseases:"
4074	We conclude that vancomycin , administered appropriately , constitutes safe , effective therapy for infections caused by susceptible bacteria .	O O O O O O O O O O O O O O B O O O O O	O O O B O O O O O O O O O O O O O O O O	['infections']	1	2	"Sentence: We conclude that vancomycin , administered appropriately , constitutes safe , effective therapy for infections caused by susceptible bacteria .
Diseases: infections"	"Sentence: We conclude that vancomycin , administered appropriately , constitutes safe , effective therapy for infections caused by susceptible bacteria .
Diseases:"
4075	Blockade of both D - 1 and D - 2 dopamine receptors may induce catalepsy in mice .	O O O O O O O O O O O O O O B O O O	O O O O O O O O O O B O O O O O O O	['catalepsy']	1	4	"Sentence: Blockade of both D - 1 and D - 2 dopamine receptors may induce catalepsy in mice .
Diseases: catalepsy"	"Sentence: Blockade of both D - 1 and D - 2 dopamine receptors may induce catalepsy in mice .
Diseases:"
4076	The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined .	O B O O O O O O O O O O O O O O B O O O	O O O O B O O O O O O O B O O O O O O O	['catalepsy']	1	4	"Sentence: The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined .
Diseases: catalepsy"	"Sentence: The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined .
Diseases:"
4077	Dopamine antagonist fluphenazine , D - 1 antagonist SCH 23390 or D - 2 antagonist sulpiride induced catalepsy .	O O O O O O O O O O O O O O O O O B O	B O B O O O O O B I O O O O O B O O O	['catalepsy']	1	4	"Sentence: Dopamine antagonist fluphenazine , D - 1 antagonist SCH 23390 or D - 2 antagonist sulpiride induced catalepsy .
Diseases: catalepsy"	"Sentence: Dopamine antagonist fluphenazine , D - 1 antagonist SCH 23390 or D - 2 antagonist sulpiride induced catalepsy .
Diseases:"
4078	The effect of fluphenazine and sulpiride was dose - dependent .	O O O O O O O O O O O	O O O B O B O O O O O	[]	0	0	"Sentence: The effect of fluphenazine and sulpiride was dose - dependent .
Diseases: "	"Sentence: The effect of fluphenazine and sulpiride was dose - dependent .
Diseases:"
4079	Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation .	O O O O O O O O O B O O	O O B I O B O O O O O O	['catalepsy']	1	4	"Sentence: Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation .
Diseases: catalepsy"	"Sentence: Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation .
Diseases:"
4080	3 . D - 1 agonist SKF 38393 or D - 2 agonist quinpirole decreased the catalepsy induced by fluphenazine , SCH 23390 or sulpiride .	O O O O O O O O O O O O O O O O B O O O O O O O O O	O O O O O O B I O O O O O B O O O O O B O B I O B O	['catalepsy']	1	4	"Sentence: 3 . D - 1 agonist SKF 38393 or D - 2 agonist quinpirole decreased the catalepsy induced by fluphenazine , SCH 23390 or sulpiride .
Diseases: catalepsy"	"Sentence: 3 . D - 1 agonist SKF 38393 or D - 2 agonist quinpirole decreased the catalepsy induced by fluphenazine , SCH 23390 or sulpiride .
Diseases:"
4081	Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists .	O O O O O O O O O O O O O B O O O O O	O O B I O B O O O O O O O O O O B O O	['catalepsy']	1	4	"Sentence: Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists .
Diseases: catalepsy"	"Sentence: Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists .
Diseases:"
4082	5 .	O O	O O	[]	0	0	"Sentence: 5 .
Diseases: "	"Sentence: 5 .
Diseases:"
4083	The data may indicate that although D - 2 receptor blockade is involved in catalepsy , the D - 1 receptor may plan a role .	O O O O O O O O O O O O O O B O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['catalepsy']	1	4	"Sentence: The data may indicate that although D - 2 receptor blockade is involved in catalepsy , the D - 1 receptor may plan a role .
Diseases: catalepsy"	"Sentence: The data may indicate that although D - 2 receptor blockade is involved in catalepsy , the D - 1 receptor may plan a role .
Diseases:"
4084	Dextran - etodolac conjugates : synthesis , in vitro and in vivo evaluation .	O O O O O O O O O O O O O O	B O B O O O O O O O O O O O	[]	0	0	"Sentence: Dextran - etodolac conjugates : synthesis , in vitro and in vivo evaluation .
Diseases: "	"Sentence: Dextran - etodolac conjugates : synthesis , in vitro and in vivo evaluation .
Diseases:"
4085	Etodolac ( E ) , is a non - narcotic analgesic and antiinflammatory drug .	O O O O O O O O O O O O O O O	B O B O O O O O O O O O O O O	[]	0	0	"Sentence: Etodolac ( E ) , is a non - narcotic analgesic and antiinflammatory drug .
Diseases: "	"Sentence: Etodolac ( E ) , is a non - narcotic analgesic and antiinflammatory drug .
Diseases:"
4086	A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac - dextran conjugates ( ED ) to improve its aqueous solubility and reduce gastrointestinal side effects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O B O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac - dextran conjugates ( ED ) to improve its aqueous solubility and reduce gastrointestinal side effects .
Diseases: "	"Sentence: A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac - dextran conjugates ( ED ) to improve its aqueous solubility and reduce gastrointestinal side effects .
Diseases:"
4087	An activated moiety , i . e . N - acylimidazole derivative of etodolac ( EAI ) , was condensed with the polysaccharide polymer dextran of different molecular weights ( 40000 , 60000 , 110000 and 200000 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B I I O O B O B O O O O O O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: An activated moiety , i . e . N - acylimidazole derivative of etodolac ( EAI ) , was condensed with the polysaccharide polymer dextran of different molecular weights ( 40000 , 60000 , 110000 and 200000 ) .
Diseases: "	"Sentence: An activated moiety , i . e . N - acylimidazole derivative of etodolac ( EAI ) , was condensed with the polysaccharide polymer dextran of different molecular weights ( 40000 , 60000 , 110000 and 200000 ) .
Diseases:"
4088	IR spectral data confirmed formation of ester bonding in the conjugates .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: IR spectral data confirmed formation of ester bonding in the conjugates .
Diseases: "	"Sentence: IR spectral data confirmed formation of ester bonding in the conjugates .
Diseases:"
4089	Etodolac contents were evaluated by UV - spectrophotometric analysis .	O O O O O O O O O O	B O O O O O O O O O	[]	0	0	"Sentence: Etodolac contents were evaluated by UV - spectrophotometric analysis .
Diseases: "	"Sentence: Etodolac contents were evaluated by UV - spectrophotometric analysis .
Diseases:"
4090	The molecular weights were determined by measuring viscosity using the Mark - Howink - Sakurada equation .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The molecular weights were determined by measuring viscosity using the Mark - Howink - Sakurada equation .
Diseases: "	"Sentence: The molecular weights were determined by measuring viscosity using the Mark - Howink - Sakurada equation .
Diseases:"
4091	In vitro hydrolysis of ED was done in aqueous buffers ( pH 1 . 2 , 7 . 4 , 9 ) and in 80 % ( v / v ) human plasma ( pH 7 . 4 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In vitro hydrolysis of ED was done in aqueous buffers ( pH 1 . 2 , 7 . 4 , 9 ) and in 80 % ( v / v ) human plasma ( pH 7 . 4 ) .
Diseases: "	"Sentence: In vitro hydrolysis of ED was done in aqueous buffers ( pH 1 . 2 , 7 . 4 , 9 ) and in 80 % ( v / v ) human plasma ( pH 7 . 4 ) .
Diseases:"
4092	At pH 9 , a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7 . 4 and 80 % human plasma ( pH 7 . 4 ) , following first - order kinetics .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: At pH 9 , a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7 . 4 and 80 % human plasma ( pH 7 . 4 ) , following first - order kinetics .
Diseases: "	"Sentence: At pH 9 , a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7 . 4 and 80 % human plasma ( pH 7 . 4 ) , following first - order kinetics .
Diseases:"
4093	In vivo investigations were performed in animals .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: In vivo investigations were performed in animals .
Diseases: "	"Sentence: In vivo investigations were performed in animals .
Diseases:"
4094	Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model ( mice ) and carrageenan - induced rat paw edema model , respectively .	O O O O O O O O O O O B O O O O O O O O O O B O O O O	O O O O O O O O B I O O O O O O O B O O O O O O O O O	['writhing', 'edema']	2	5	"Sentence: Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model ( mice ) and carrageenan - induced rat paw edema model , respectively .
Diseases: writhing, edema"	"Sentence: Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model ( mice ) and carrageenan - induced rat paw edema model , respectively .
Diseases:"
4095	In comparison to control , E and ED1 - ED4 showed highly significant analgesic and antiinflammatory activities ( p < 0 . 001 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In comparison to control , E and ED1 - ED4 showed highly significant analgesic and antiinflammatory activities ( p < 0 . 001 ) .
Diseases: "	"Sentence: In comparison to control , E and ED1 - ED4 showed highly significant analgesic and antiinflammatory activities ( p < 0 . 001 ) .
Diseases:"
4096	Biological evaluation suggested that conjugates ( ED1 - ED4 ) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug - - etodolac .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: Biological evaluation suggested that conjugates ( ED1 - ED4 ) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug - - etodolac .
Diseases: "	"Sentence: Biological evaluation suggested that conjugates ( ED1 - ED4 ) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug - - etodolac .
Diseases:"
4097	Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart .	B B O B I O O	O O O O O O O	['hypersensitivity', 'hypertrophic cardiomyopathy', 'myocarditis']	3	14	"Sentence: Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart .
Diseases: hypersensitivity, hypertrophic cardiomyopathy, myocarditis"	"Sentence: Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart .
Diseases:"
4098	The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy .	O O O O O O O B I O B I O	O O O O O O O O O O O O O	['hypertrophic cardiomyopathy', 'eosinophilic myocarditis']	2	16	"Sentence: The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy .
Diseases: hypertrophic cardiomyopathy, eosinophilic myocarditis"	"Sentence: The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy .
Diseases:"
4099	The 47 - year - old female patient , known to have hypertrophic cardiomyopathy , was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation .	O O O O O O O O O O O O B I O O O O B I O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O	['hypertrophic cardiomyopathy', 'biventricular failure']	2	13	"Sentence: The 47 - year - old female patient , known to have hypertrophic cardiomyopathy , was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation .
Diseases: hypertrophic cardiomyopathy, biventricular failure"	"Sentence: The 47 - year - old female patient , known to have hypertrophic cardiomyopathy , was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation .
Diseases:"
4100	On transthoracic echocardiogram , she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation .	O O O O O O O B I I O O O O O B I O	O O O O O O O O O O O O O O O O O O	['left ventricular dysfunction', 'mitral regurgitation']	2	10	"Sentence: On transthoracic echocardiogram , she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation .
Diseases: left ventricular dysfunction, mitral regurgitation"	"Sentence: On transthoracic echocardiogram , she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation .
Diseases:"
4101	The recipient 's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils .	O O O O O O O O O B I O B O O O O	O O O O O O O O O O O O O O O O O	['hypertrophic cardiomyopathy', 'myocarditis']	2	11	"Sentence: The recipient 's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils .
Diseases: hypertrophic cardiomyopathy, myocarditis"	"Sentence: The recipient 's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils .
Diseases:"
4102	Myocarditis is rare and eosinophilic myocarditis is rarer .	B O O O B I O O O	O O O O O O O O O	['eosinophilic myocarditis', 'myocarditis']	2	12	"Sentence: Myocarditis is rare and eosinophilic myocarditis is rarer .
Diseases: eosinophilic myocarditis, myocarditis"	"Sentence: Myocarditis is rare and eosinophilic myocarditis is rarer .
Diseases:"
4103	It is likely that the hypersensitivity ( eosinophilic ) myocarditis was related to dobutamine infusion therapy .	O O O O O B O B O B O O O O O O O	O O O O O O O O O O O O O B O O O	['hypersensitivity', 'eosinophilic', 'myocarditis']	3	13	"Sentence: It is likely that the hypersensitivity ( eosinophilic ) myocarditis was related to dobutamine infusion therapy .
Diseases: hypersensitivity, eosinophilic, myocarditis"	"Sentence: It is likely that the hypersensitivity ( eosinophilic ) myocarditis was related to dobutamine infusion therapy .
Diseases:"
4104	Eosinophilic myocarditis has been reported with an incidence of 2 . 4 % to 7 . 2 % in explanted hearts and may be related to multidrug therapy .	B I O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['eosinophilic myocarditis']	1	8	"Sentence: Eosinophilic myocarditis has been reported with an incidence of 2 . 4 % to 7 . 2 % in explanted hearts and may be related to multidrug therapy .
Diseases: eosinophilic myocarditis"	"Sentence: Eosinophilic myocarditis has been reported with an incidence of 2 . 4 % to 7 . 2 % in explanted hearts and may be related to multidrug therapy .
Diseases:"
4105	All - trans - retinoic acid - induced erythema nodosum in patients with acute promyelocytic leukemia .	O O O O O O O O B I O O O B I I O	B I I I I I O O O O O O O O O O O	['erythema nodosum', 'acute promyelocytic leukemia']	2	14	"Sentence: All - trans - retinoic acid - induced erythema nodosum in patients with acute promyelocytic leukemia .
Diseases: erythema nodosum, acute promyelocytic leukemia"	"Sentence: All - trans - retinoic acid - induced erythema nodosum in patients with acute promyelocytic leukemia .
Diseases:"
4106	Erythema nodosum associated with all - trans - retinoic acid ( ATRA ) for acute promyelocytic leukemia ( APL ) is very rare .	B I O O O O O O O O O O O O B I I O B O O O O O	O O O O B I I I I I O B O O O O O O O O O O O O	['erythema nodosum', 'acute promyelocytic leukemia', 'apl']	3	17	"Sentence: Erythema nodosum associated with all - trans - retinoic acid ( ATRA ) for acute promyelocytic leukemia ( APL ) is very rare .
Diseases: erythema nodosum, acute promyelocytic leukemia, apl"	"Sentence: Erythema nodosum associated with all - trans - retinoic acid ( ATRA ) for acute promyelocytic leukemia ( APL ) is very rare .
Diseases:"
4107	We describe four patients with classic APL who developed erythema nodosum during ATRA therapy .	O O O O O O B O O B I O O O O	O O O O O O O O O O O O B O O	['erythema nodosum', 'apl']	2	9	"Sentence: We describe four patients with classic APL who developed erythema nodosum during ATRA therapy .
Diseases: erythema nodosum, apl"	"Sentence: We describe four patients with classic APL who developed erythema nodosum during ATRA therapy .
Diseases:"
4108	Fever and subsequent multiple painful erythematous nodules over extremities developed on D11 , D16 , D17 , and D19 , respectively , after ATRA therapy .	B O O O B B I O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O B O O	['erythematous nodules', 'fever', 'painful']	3	10	"Sentence: Fever and subsequent multiple painful erythematous nodules over extremities developed on D11 , D16 , D17 , and D19 , respectively , after ATRA therapy .
Diseases: erythematous nodules, fever, painful"	"Sentence: Fever and subsequent multiple painful erythematous nodules over extremities developed on D11 , D16 , D17 , and D19 , respectively , after ATRA therapy .
Diseases:"
4109	The skin biopsy taken from each patient was consistent with erythema nodosum .	O O O O O O O O O O B I O	O O O O O O O O O O O O O	['erythema nodosum']	1	6	"Sentence: The skin biopsy taken from each patient was consistent with erythema nodosum .
Diseases: erythema nodosum"	"Sentence: The skin biopsy taken from each patient was consistent with erythema nodosum .
Diseases:"
4110	All patients received short course of steroids .	O O O O O O O O	O O O O O O B O	[]	0	0	"Sentence: All patients received short course of steroids .
Diseases: "	"Sentence: All patients received short course of steroids .
Diseases:"
4111	Fever subsided rapidly and the skin lesions regressed completely .	B O O O O O O O O O	O O O O O O O O O O	['fever']	1	2	"Sentence: Fever subsided rapidly and the skin lesions regressed completely .
Diseases: fever"	"Sentence: Fever subsided rapidly and the skin lesions regressed completely .
Diseases:"
4112	All patients achieved complete remission without withdrawal of ATRA .	O O O O O O O O O O	O O O O O O O O B O	[]	0	0	"Sentence: All patients achieved complete remission without withdrawal of ATRA .
Diseases: "	"Sentence: All patients achieved complete remission without withdrawal of ATRA .
Diseases:"
4113	ATRA seemed to be the most possible etiology of erythema nodosum in our patients .	O O O O O O O O O B I O O O O	B O O O O O O O O O O O O O O	['erythema nodosum']	1	6	"Sentence: ATRA seemed to be the most possible etiology of erythema nodosum in our patients .
Diseases: erythema nodosum"	"Sentence: ATRA seemed to be the most possible etiology of erythema nodosum in our patients .
Diseases:"
4114	Short - term use of steroid is very effective in ATRA - induced erythema nodosum .	O O O O O O O O O O O O O B I O	O O O O O B O O O O B O O O O O	['erythema nodosum']	1	6	"Sentence: Short - term use of steroid is very effective in ATRA - induced erythema nodosum .
Diseases: erythema nodosum"	"Sentence: Short - term use of steroid is very effective in ATRA - induced erythema nodosum .
Diseases:"
4115	Delayed - onset heparin - induced thrombocytopenia .	O O O O O O B O	O O O B O O O O	['thrombocytopenia']	1	7	"Sentence: Delayed - onset heparin - induced thrombocytopenia .
Diseases: thrombocytopenia"	"Sentence: Delayed - onset heparin - induced thrombocytopenia .
Diseases:"
4116	Heparin - induced thrombocytopenia presents 5 to 12 days after heparin exposure , with or without arterial or venous thromboemboli .	O O O B O O O O O O O O O O O O B I I I O	B O O O O O O O O O B O O O O O O O O O O	['arterial or venous thromboemboli', 'thrombocytopenia']	2	18	"Sentence: Heparin - induced thrombocytopenia presents 5 to 12 days after heparin exposure , with or without arterial or venous thromboemboli .
Diseases: arterial or venous thromboemboli, thrombocytopenia"	"Sentence: Heparin - induced thrombocytopenia presents 5 to 12 days after heparin exposure , with or without arterial or venous thromboemboli .
Diseases:"
4117	Delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes .	O O O O O O O O B O O O O O O	O O O O O B O O O O O O O O O	['thrombocytopenia']	1	7	"Sentence: Delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes .
Diseases: thrombocytopenia"	"Sentence: Delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes .
Diseases:"
4118	To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin - induced thrombocytopenia are delayed .	O O O O O O O O O O O O O O O O O O O B O O O	O O O O O O O O O O O O O O O O B O O O O O O	['thrombocytopenia']	1	7	"Sentence: To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin - induced thrombocytopenia are delayed .
Diseases: thrombocytopenia"	"Sentence: To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin - induced thrombocytopenia are delayed .
Diseases:"
4119	Retrospective case series .	O O O O	O O O O	[]	0	0	"Sentence: Retrospective case series .
Diseases: "	"Sentence: Retrospective case series .
Diseases:"
4120	SETTING : Three large urban hospitals ( with active cardiovascular surgery programs ) .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: SETTING : Three large urban hospitals ( with active cardiovascular surgery programs ) .
Diseases: "	"Sentence: SETTING : Three large urban hospitals ( with active cardiovascular surgery programs ) .
Diseases:"
4121	PATIENTS : 14 patients seen over a 3 - year period in whom heparin - induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications .	O O O O O O O O O O O O O O O O B O O O O O O B O O	O O O O O O O O O O O O O B O O O O O O O O O O O O	['thromboembolic', 'thrombocytopenia']	2	13	"Sentence: PATIENTS : 14 patients seen over a 3 - year period in whom heparin - induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications .
Diseases: thromboembolic, thrombocytopenia"	"Sentence: PATIENTS : 14 patients seen over a 3 - year period in whom heparin - induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications .
Diseases:"
4122	MEASUREMENTS : Platelet counts , onset of objectively determined thromboembolism , results of heparin - induced platelet factor 4 antibody tests , and outcomes .	O O O O O O O O O B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O	['thromboembolism']	1	6	"Sentence: MEASUREMENTS : Platelet counts , onset of objectively determined thromboembolism , results of heparin - induced platelet factor 4 antibody tests , and outcomes .
Diseases: thromboembolism"	"Sentence: MEASUREMENTS : Platelet counts , onset of objectively determined thromboembolism , results of heparin - induced platelet factor 4 antibody tests , and outcomes .
Diseases:"
4123	Patients went home after hospitalizations that had included heparin exposure - - in most cases , with no thrombocytopenia recognized - - only to return to the hospital ( median , day 14 ) with thromboembolic complications .	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O B O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['thromboembolic', 'thrombocytopenia']	2	13	"Sentence: Patients went home after hospitalizations that had included heparin exposure - - in most cases , with no thrombocytopenia recognized - - only to return to the hospital ( median , day 14 ) with thromboembolic complications .
Diseases: thromboembolic, thrombocytopenia"	"Sentence: Patients went home after hospitalizations that had included heparin exposure - - in most cases , with no thrombocytopenia recognized - - only to return to the hospital ( median , day 14 ) with thromboembolic complications .
Diseases:"
4124	Thromboemboli were venous ( 12 patients , 7 with pulmonary emboli ) or arterial ( 4 patients ) or both .	B O O O O O O O O B I O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	['thromboemboli', 'pulmonary emboli']	2	9	"Sentence: Thromboemboli were venous ( 12 patients , 7 with pulmonary emboli ) or arterial ( 4 patients ) or both .
Diseases: thromboemboli, pulmonary emboli"	"Sentence: Thromboemboli were venous ( 12 patients , 7 with pulmonary emboli ) or arterial ( 4 patients ) or both .
Diseases:"
4125	Platelet counts were mildly decreased in all but 2 patients on second presentation .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Platelet counts were mildly decreased in all but 2 patients on second presentation .
Diseases: "	"Sentence: Platelet counts were mildly decreased in all but 2 patients on second presentation .
Diseases:"
4126	On readmission , 11 patients received therapeutic heparin , which worsened the patients ' clinical condition and , in all 11 cases , decreased the platelet count ( mean at readmission , 143 x 10 ( 9 ) cells / L ; mean nadir after heparin re - exposure , 39 x 10 ( 9 ) cells / L ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: On readmission , 11 patients received therapeutic heparin , which worsened the patients ' clinical condition and , in all 11 cases , decreased the platelet count ( mean at readmission , 143 x 10 ( 9 ) cells / L ; mean nadir after heparin re - exposure , 39 x 10 ( 9 ) cells / L ) .
Diseases: "	"Sentence: On readmission , 11 patients received therapeutic heparin , which worsened the patients ' clinical condition and , in all 11 cases , decreased the platelet count ( mean at readmission , 143 x 10 ( 9 ) cells / L ; mean nadir after heparin re - exposure , 39 x 10 ( 9 ) cells / L ) .
Diseases:"
4127	Results of serologic tests for heparin - induced antibodies were positive in all patients .	O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O	[]	0	0	"Sentence: Results of serologic tests for heparin - induced antibodies were positive in all patients .
Diseases: "	"Sentence: Results of serologic tests for heparin - induced antibodies were positive in all patients .
Diseases:"
4128	Subsequent treatments included alternative anticoagulants ( 11 patients ) , thrombolytic drugs ( 3 patients ) , inferior vena cava filters ( 3 patients ) and , eventually , warfarin ( 11 patients ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	[]	0	0	"Sentence: Subsequent treatments included alternative anticoagulants ( 11 patients ) , thrombolytic drugs ( 3 patients ) , inferior vena cava filters ( 3 patients ) and , eventually , warfarin ( 11 patients ) .
Diseases: "	"Sentence: Subsequent treatments included alternative anticoagulants ( 11 patients ) , thrombolytic drugs ( 3 patients ) , inferior vena cava filters ( 3 patients ) and , eventually , warfarin ( 11 patients ) .
Diseases:"
4129	Three patients died .	O O O O	O O O O	[]	0	0	"Sentence: Three patients died .
Diseases: "	"Sentence: Three patients died .
Diseases:"
4130	CONCLUSIONS : Delayed - onset heparin - induced thrombocytopenia is increasingly being recognized .	O O O O O O O O B O O O O O	O O O O O B O O O O O O O O	['thrombocytopenia']	1	7	"Sentence: CONCLUSIONS : Delayed - onset heparin - induced thrombocytopenia is increasingly being recognized .
Diseases: thrombocytopenia"	"Sentence: CONCLUSIONS : Delayed - onset heparin - induced thrombocytopenia is increasingly being recognized .
Diseases:"
4131	To avoid disastrous outcomes , physicians must consider heparin - induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism ; therapy with alternative anticoagulants , not heparin , should be initiated .	O O O O O O O O O O O B O O O O O O O B O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O B O O O O O	['thromboembolism', 'thrombocytopenia']	2	14	"Sentence: To avoid disastrous outcomes , physicians must consider heparin - induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism ; therapy with alternative anticoagulants , not heparin , should be initiated .
Diseases: thromboembolism, thrombocytopenia"	"Sentence: To avoid disastrous outcomes , physicians must consider heparin - induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism ; therapy with alternative anticoagulants , not heparin , should be initiated .
Diseases:"
4132	Valsartan , a new angiotensin II antagonist for the treatment of essential hypertension : a comparative study of the efficacy and safety against amlodipine .	O O O O O O O O O O O O B O O O O O O O O O O O O	B O O O B I O O O O O O O O O O O O O O O O O B O	['hypertension']	1	3	"Sentence: Valsartan , a new angiotensin II antagonist for the treatment of essential hypertension : a comparative study of the efficacy and safety against amlodipine .
Diseases: hypertension"	"Sentence: Valsartan , a new angiotensin II antagonist for the treatment of essential hypertension : a comparative study of the efficacy and safety against amlodipine .
Diseases:"
4133	To compare the antihypertensive efficacy of a new angiotensin II antagonist , valsartan , with a reference therapy , amlodipine .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B I O O B O O O O O O B O	[]	0	0	"Sentence: To compare the antihypertensive efficacy of a new angiotensin II antagonist , valsartan , with a reference therapy , amlodipine .
Diseases: "	"Sentence: To compare the antihypertensive efficacy of a new angiotensin II antagonist , valsartan , with a reference therapy , amlodipine .
Diseases:"
4134	METHODS : One hundred sixty - eight adult outpatients with mild to moderate hypertension	O O O O O O O O O O O O O B	O O O O O O O O O O O O O O	['hypertension']	1	3	"Sentence: METHODS : One hundred sixty - eight adult outpatients with mild to moderate hypertension
Diseases: hypertension"	"Sentence: METHODS : One hundred sixty - eight adult outpatients with mild to moderate hypertension
Diseases:"
4135	were randomly allocated in double - blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O B O O O O	[]	0	0	"Sentence: were randomly allocated in double - blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks .
Diseases: "	"Sentence: were randomly allocated in double - blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks .
Diseases:"
4136	After 8 weeks of therapy , in patients whose blood pressure remained uncontrolled , 5 mg amlodipine was added to the initial therapy .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O O	[]	0	0	"Sentence: After 8 weeks of therapy , in patients whose blood pressure remained uncontrolled , 5 mg amlodipine was added to the initial therapy .
Diseases: "	"Sentence: After 8 weeks of therapy , in patients whose blood pressure remained uncontrolled , 5 mg amlodipine was added to the initial therapy .
Diseases:"
4137	Patients were assessed at 4 , 8 , and 12 weeks .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: Patients were assessed at 4 , 8 , and 12 weeks .
Diseases: "	"Sentence: Patients were assessed at 4 , 8 , and 12 weeks .
Diseases:"
4138	The primary efficacy variable was change from baseline in mean sitting diastolic blood pressure at 8 weeks .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The primary efficacy variable was change from baseline in mean sitting diastolic blood pressure at 8 weeks .
Diseases: "	"Sentence: The primary efficacy variable was change from baseline in mean sitting diastolic blood pressure at 8 weeks .
Diseases:"
4139	Secondary variables included change in sitting systolic blood pressure and responder rates .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Secondary variables included change in sitting systolic blood pressure and responder rates .
Diseases: "	"Sentence: Secondary variables included change in sitting systolic blood pressure and responder rates .
Diseases:"
4140	RESULTS : Both valsartan and amlodipine were effective at lowering blood pressure at 4 , 8 , and 12 weeks .	O O O O O O O O O O O O O O O O O O O O O	O O O B O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: RESULTS : Both valsartan and amlodipine were effective at lowering blood pressure at 4 , 8 , and 12 weeks .
Diseases: "	"Sentence: RESULTS : Both valsartan and amlodipine were effective at lowering blood pressure at 4 , 8 , and 12 weeks .
Diseases:"
4141	Similar decreases were observed in both groups , with no statistically significant differences between the groups for any variable analyzed .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Similar decreases were observed in both groups , with no statistically significant differences between the groups for any variable analyzed .
Diseases: "	"Sentence: Similar decreases were observed in both groups , with no statistically significant differences between the groups for any variable analyzed .
Diseases:"
4142	For the primary variable the difference was 0 . 5 mm	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: For the primary variable the difference was 0 . 5 mm
Diseases: "	"Sentence: For the primary variable the difference was 0 . 5 mm
Diseases:"
4143	Hg in favor of valsartan ( p = 0 . 68 ; 95 % confidence interval , - 2 . 7 to 1 . 7 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Hg in favor of valsartan ( p = 0 . 68 ; 95 % confidence interval , - 2 . 7 to 1 . 7 ) .
Diseases: "	"Sentence: Hg in favor of valsartan ( p = 0 . 68 ; 95 % confidence interval , - 2 . 7 to 1 . 7 ) .
Diseases:"
4144	Responder rates at 8 weeks were 66 . 7 % for valsartan and 60 . 2 % for amlodipine ( p = 0 . 39 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O B O O O O O O O O	[]	0	0	"Sentence: Responder rates at 8 weeks were 66 . 7 % for valsartan and 60 . 2 % for amlodipine ( p = 0 . 39 ) .
Diseases: "	"Sentence: Responder rates at 8 weeks were 66 . 7 % for valsartan and 60 . 2 % for amlodipine ( p = 0 . 39 ) .
Diseases:"
4145	Both treatments were well tolerated .	O O O O O O	O O O O O O	[]	0	0	"Sentence: Both treatments were well tolerated .
Diseases: "	"Sentence: Both treatments were well tolerated .
Diseases:"
4146	The incidence of drug - related dependent edema was somewhat higher in the amlodipine group , particularly at a dose of 10 mg per day ( 2 . 4 % for 80 mg valsartan ; 3 . 6 % for 5 mg amlodipine ; 0 % for valsartan plus 5 mg amlodipine ; 14 . 3 % for 10 mg amlodipine ) .	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O B O O O O O O O O B O O O O B O O O B O O O O O O O O B O O	['edema']	1	2	"Sentence: The incidence of drug - related dependent edema was somewhat higher in the amlodipine group , particularly at a dose of 10 mg per day ( 2 . 4 % for 80 mg valsartan ; 3 . 6 % for 5 mg amlodipine ; 0 % for valsartan plus 5 mg amlodipine ; 14 . 3 % for 10 mg amlodipine ) .
Diseases: edema"	"Sentence: The incidence of drug - related dependent edema was somewhat higher in the amlodipine group , particularly at a dose of 10 mg per day ( 2 . 4 % for 80 mg valsartan ; 3 . 6 % for 5 mg amlodipine ; 0 % for valsartan plus 5 mg amlodipine ; 14 . 3 % for 10 mg amlodipine ) .
Diseases:"
4147	CONCLUSIONS : The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension .	O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O B O O O O O O B O O O O O O O O O	['hypertension']	1	3	"Sentence: CONCLUSIONS : The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension .
Diseases: hypertension"	"Sentence: CONCLUSIONS : The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension .
Diseases:"
4148	The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class , dihydropyridine calcium antagonists .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O B B O O	[]	0	0	"Sentence: The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class , dihydropyridine calcium antagonists .
Diseases: "	"Sentence: The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class , dihydropyridine calcium antagonists .
Diseases:"
4149	KF17837 : a novel selective adenosine A2A receptor antagonist with anticataleptic activity .	O O O O O O O O O O O O O	B O O O O B O O O O O O O	[]	0	0	"Sentence: KF17837 : a novel selective adenosine A2A receptor antagonist with anticataleptic activity .
Diseases: "	"Sentence: KF17837 : a novel selective adenosine A2A receptor antagonist with anticataleptic activity .
Diseases:"
4150	KF17837 is a novel selective adenosine A2A receptor antagonist .	O O O O O O O O O O	B O O O O B O O O O	[]	0	0	"Sentence: KF17837 is a novel selective adenosine A2A receptor antagonist .
Diseases: "	"Sentence: KF17837 is a novel selective adenosine A2A receptor antagonist .
Diseases:"
4151	Oral administration of KF17837 ( 2 . 5 , 10 . 0 and 30 . 0 mg / kg ) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist , CGS 21680 ( 10 micrograms ) , in a dose - dependent manner . KF17837 also reduced the catalepsy induced by haloperidol ( 1 mg / kg i . p . ) and by reserpine ( 5 mg / kg i . p . ) .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O B I O O O O O O O O O O O O B O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O	['catalepsy', 'cataleptic']	2	8	"Sentence: Oral administration of KF17837 ( 2 . 5 , 10 . 0 and 30 . 0 mg / kg ) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist , CGS 21680 ( 10 micrograms ) , in a dose - dependent manner . KF17837 also reduced the catalepsy induced by haloperidol ( 1 mg / kg i . p . ) and by reserpine ( 5 mg / kg i . p . ) .
Diseases: catalepsy, cataleptic"	"Sentence: Oral administration of KF17837 ( 2 . 5 , 10 . 0 and 30 . 0 mg / kg ) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist , CGS 21680 ( 10 micrograms ) , in a dose - dependent manner . KF17837 also reduced the catalepsy induced by haloperidol ( 1 mg / kg i . p . ) and by reserpine ( 5 mg / kg i . p . ) .
Diseases:"
4152	These anticataleptic effects were exhibited dose dependently at doses from 0 . 625 and 2 . 5 mg / kg	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These anticataleptic effects were exhibited dose dependently at doses from 0 . 625 and 2 . 5 mg / kg
Diseases: "	"Sentence: These anticataleptic effects were exhibited dose dependently at doses from 0 . 625 and 2 . 5 mg / kg
Diseases:"
4153	p . o . , respectively .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: p . o . , respectively .
Diseases: "	"Sentence: p . o . , respectively .
Diseases:"
4154	Moreover , KF17837 ( 0 . 625 mg / kg p . o . ) potentiated the anticataleptic effects of a subthreshold dose of L - 3 , 4 - dihydroxyphenylalanine ( L - DOPA ; 25 mg / kg i . p . ) plus benserazide ( 6 . 25 mg / kg i . p . ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O B I I I I I I O B I I O O O O O O O O O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: Moreover , KF17837 ( 0 . 625 mg / kg p . o . ) potentiated the anticataleptic effects of a subthreshold dose of L - 3 , 4 - dihydroxyphenylalanine ( L - DOPA ; 25 mg / kg i . p . ) plus benserazide ( 6 . 25 mg / kg i . p . ) .
Diseases: "	"Sentence: Moreover , KF17837 ( 0 . 625 mg / kg p . o . ) potentiated the anticataleptic effects of a subthreshold dose of L - 3 , 4 - dihydroxyphenylalanine ( L - DOPA ; 25 mg / kg i . p . ) plus benserazide ( 6 . 25 mg / kg i . p . ) .
Diseases:"
4155	These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O B O O O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists .
Diseases: "	"Sentence: These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists .
Diseases:"
4156	Furthermore , KF17837 may be a useful drug in the treatment of parkinsonism .	O O O O O O O O O O O O B O	O O B O O O O O O O O O O O	['parkinsonism']	1	3	"Sentence: Furthermore , KF17837 may be a useful drug in the treatment of parkinsonism .
Diseases: parkinsonism"	"Sentence: Furthermore , KF17837 may be a useful drug in the treatment of parkinsonism .
Diseases:"
4157	Some central effects of repeated treatment with fluvoxamine .	O O O O O O O O O	O O O O O O O B O	[]	0	0	"Sentence: Some central effects of repeated treatment with fluvoxamine .
Diseases: "	"Sentence: Some central effects of repeated treatment with fluvoxamine .
Diseases:"
4158	"We investigated the effect of repeated treatment with fluvoxamine , a selective serotonin uptake inhibitor , on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the "" behavioral despair "" test ."	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O B O O O O O O O B O B O O O O O O O O O O O O O	[]	0	0	"Sentence: We investigated the effect of repeated treatment with fluvoxamine , a selective serotonin uptake inhibitor , on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the "" behavioral despair "" test .
Diseases: "	"Sentence: We investigated the effect of repeated treatment with fluvoxamine , a selective serotonin uptake inhibitor , on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the "" behavioral despair "" test .
Diseases:"
4159	A repeated treatment with fluvoxamine ( twice daily for 14 days ) potentiated in mice and in rats ( weaker ) the amphetamine - induced hyperactivity .	O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O B O O O O O O O O O O O O O O O O O B O O O O	['hyperactivity']	1	2	"Sentence: A repeated treatment with fluvoxamine ( twice daily for 14 days ) potentiated in mice and in rats ( weaker ) the amphetamine - induced hyperactivity .
Diseases: hyperactivity"	"Sentence: A repeated treatment with fluvoxamine ( twice daily for 14 days ) potentiated in mice and in rats ( weaker ) the amphetamine - induced hyperactivity .
Diseases:"
4160	The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine .	O B O O O O O O O O O O	O O O O B O O O O O B O	['hyperactivity']	1	2	"Sentence: The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine .
Diseases: hyperactivity"	"Sentence: The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine .
Diseases:"
4161	The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine .	O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O B O	[]	0	0	"Sentence: The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine .
Diseases: "	"Sentence: The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine .
Diseases:"
4162	"Given three times fluvoxamine had no effect on the immobilization time in the "" behavioral despair "" test in rats ."	O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Given three times fluvoxamine had no effect on the immobilization time in the "" behavioral despair "" test in rats .
Diseases: "	"Sentence: Given three times fluvoxamine had no effect on the immobilization time in the "" behavioral despair "" test in rats .
Diseases:"
4163	The results indicate that fluvoxamine given repeatedly acts differently than citalopram , another selective serotonin uptake inhibitor , and differs also from other antidepressant drugs .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O B O O O B O O O O O O O O B O O	[]	0	0	"Sentence: The results indicate that fluvoxamine given repeatedly acts differently than citalopram , another selective serotonin uptake inhibitor , and differs also from other antidepressant drugs .
Diseases: "	"Sentence: The results indicate that fluvoxamine given repeatedly acts differently than citalopram , another selective serotonin uptake inhibitor , and differs also from other antidepressant drugs .
Diseases:"
4164	Severe congestive heart failure patient on amiodarone presenting with myxedemic coma : a case report .	O B I I O O O O O B I O O O O O	O O O O O O B O O O O O O O O O	['congestive heart failure', 'myxedemic coma']	2	11	"Sentence: Severe congestive heart failure patient on amiodarone presenting with myxedemic coma : a case report .
Diseases: congestive heart failure, myxedemic coma"	"Sentence: Severe congestive heart failure patient on amiodarone presenting with myxedemic coma : a case report .
Diseases:"
4165	This is a case report of myxedema coma secondary to amiodarone - induced hypothyroidism in a patient with severe congestive heart failure ( CHF ) .	O O O O O O B I O O O O O B O O O O O B I I O B O O	O O O O O O O O O O B O O O O O O O O O O O O O O O	['chf', 'congestive heart failure', 'myxedema coma', 'hypothyroidism']	4	18	"Sentence: This is a case report of myxedema coma secondary to amiodarone - induced hypothyroidism in a patient with severe congestive heart failure ( CHF ) .
Diseases: chf, congestive heart failure, myxedema coma, hypothyroidism"	"Sentence: This is a case report of myxedema coma secondary to amiodarone - induced hypothyroidism in a patient with severe congestive heart failure ( CHF ) .
Diseases:"
4166	To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term amiodarone therapy .	O O O O O O O O O O O O O O B I O O O O O O	O O O O O O O O O O O O O O O O O O O B O O	['myxedema coma']	1	5	"Sentence: To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term amiodarone therapy .
Diseases: myxedema coma"	"Sentence: To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term amiodarone therapy .
Diseases:"
4167	Myxedema coma is a life threatening condition that carries a mortality reaching as high as 20 % with treatment .	B I O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	['myxedema coma']	1	5	"Sentence: Myxedema coma is a life threatening condition that carries a mortality reaching as high as 20 % with treatment .
Diseases: myxedema coma"	"Sentence: Myxedema coma is a life threatening condition that carries a mortality reaching as high as 20 % with treatment .
Diseases:"
4168	The condition is treated with intravenous thyroxine ( T4 ) or intravenous tri - iodo - thyronine ( T3 ) .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O B O O O B I I I I O B O O	[]	0	0	"Sentence: The condition is treated with intravenous thyroxine ( T4 ) or intravenous tri - iodo - thyronine ( T3 ) .
Diseases: "	"Sentence: The condition is treated with intravenous thyroxine ( T4 ) or intravenous tri - iodo - thyronine ( T3 ) .
Diseases:"
4169	Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism , and thus may deserve closer follow up for thyroid stimulating hormone ( TSH ) levels .	O O B O O O O O O O O O B O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['chf', 'hypothyroidism']	2	7	"Sentence: Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism , and thus may deserve closer follow up for thyroid stimulating hormone ( TSH ) levels .
Diseases: chf, hypothyroidism"	"Sentence: Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism , and thus may deserve closer follow up for thyroid stimulating hormone ( TSH ) levels .
Diseases:"
4170	This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients .	O O O O O O O O O O O O O O O B O O	O O O O O O O O O O O O O B O O O O	['chf']	1	2	"Sentence: This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients .
Diseases: chf"	"Sentence: This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients .
Diseases:"
4171	The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension , weakness or other unexplained symptoms .	O O O O O B I O O O O O O O O O O O O O O O B O O O B O B O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['chf', 'myxedema coma', 'hypotension', 'weakness']	4	13	"Sentence: The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension , weakness or other unexplained symptoms .
Diseases: chf, myxedema coma, hypotension, weakness"	"Sentence: The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension , weakness or other unexplained symptoms .
Diseases:"
4172	Fear - potentiated startle , but not light - enhanced startle , is enhanced by anxiogenic drugs .	O O O B O O O O O O B O O O O O O O	O O O O O O O O O O O O O O O O O O	['startle']	1	2	"Sentence: Fear - potentiated startle , but not light - enhanced startle , is enhanced by anxiogenic drugs .
Diseases: startle"	"Sentence: Fear - potentiated startle , but not light - enhanced startle , is enhanced by anxiogenic drugs .
Diseases:"
4173	RATIONALE AND OBJECTIVES :	O O O O	O O O O	[]	0	0	"Sentence: RATIONALE AND OBJECTIVES :
Diseases: "	"Sentence: RATIONALE AND OBJECTIVES :
Diseases:"
4174	The light - enhanced startle paradigm ( LES ) is suggested to model anxiety , because of the non - specific cue and the long - term effect .	O O O O B O O O O O O O O B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['startle', 'anxiety']	2	4	"Sentence: The light - enhanced startle paradigm ( LES ) is suggested to model anxiety , because of the non - specific cue and the long - term effect .
Diseases: startle, anxiety"	"Sentence: The light - enhanced startle paradigm ( LES ) is suggested to model anxiety , because of the non - specific cue and the long - term effect .
Diseases:"
4175	In contrast , the fear - potentiated startle ( FPS ) is suggested to model conditioned fear .	O O O O O O O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	['startle']	1	2	"Sentence: In contrast , the fear - potentiated startle ( FPS ) is suggested to model conditioned fear .
Diseases: startle"	"Sentence: In contrast , the fear - potentiated startle ( FPS ) is suggested to model conditioned fear .
Diseases:"
4176	However , the pharmacological profiles of these two paradigms are very similar .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: However , the pharmacological profiles of these two paradigms are very similar .
Diseases: "	"Sentence: However , the pharmacological profiles of these two paradigms are very similar .
Diseases:"
4177	The present study investigated the effects of putative anxiogenic drugs on LES and FPS and aimed at determining the sensitivity of LES for anxiogenic drugs and to potentially showing a pharmacological differentiation between these two paradigms .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The present study investigated the effects of putative anxiogenic drugs on LES and FPS and aimed at determining the sensitivity of LES for anxiogenic drugs and to potentially showing a pharmacological differentiation between these two paradigms .
Diseases: "	"Sentence: The present study investigated the effects of putative anxiogenic drugs on LES and FPS and aimed at determining the sensitivity of LES for anxiogenic drugs and to potentially showing a pharmacological differentiation between these two paradigms .
Diseases:"
4178	Male Wistar rats received each dose of the alpha ( 2 ) - adrenoceptor antagonist yohimbine ( 0 . 25 - 1 . 0mg / kg ) , the 5 - HT ( 2C ) receptor agonist m - chlorophenylpiperazine ( mCPP , 0 . 5 - 2 . 0mg / kg ) or the GABA ( A ) inverse receptor agonist pentylenetetrazole ( PTZ , 3 - 30mg / kg ) and were subsequently tested in either LES or FPS .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O B I I O O O O O B I I O B O O O O O O O O O O O O O B O O O O O O B O B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Male Wistar rats received each dose of the alpha ( 2 ) - adrenoceptor antagonist yohimbine ( 0 . 25 - 1 . 0mg / kg ) , the 5 - HT ( 2C ) receptor agonist m - chlorophenylpiperazine ( mCPP , 0 . 5 - 2 . 0mg / kg ) or the GABA ( A ) inverse receptor agonist pentylenetetrazole ( PTZ , 3 - 30mg / kg ) and were subsequently tested in either LES or FPS .
Diseases: "	"Sentence: Male Wistar rats received each dose of the alpha ( 2 ) - adrenoceptor antagonist yohimbine ( 0 . 25 - 1 . 0mg / kg ) , the 5 - HT ( 2C ) receptor agonist m - chlorophenylpiperazine ( mCPP , 0 . 5 - 2 . 0mg / kg ) or the GABA ( A ) inverse receptor agonist pentylenetetrazole ( PTZ , 3 - 30mg / kg ) and were subsequently tested in either LES or FPS .
Diseases:"
4179	None of the drugs enhanced LES , whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O B O O O O O	[]	0	0	"Sentence: None of the drugs enhanced LES , whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values .
Diseases: "	"Sentence: None of the drugs enhanced LES , whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values .
Diseases:"
4180	Furthermore , yohimbine increased baseline startle amplitude in the LES , while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS .	O O O O O B O O O O O O O O O B O O O O O O O O O O B O O O O	O O B O O O O O O O O O B O O O O O O O O O O B O O O O O O O	['startle']	1	2	"Sentence: Furthermore , yohimbine increased baseline startle amplitude in the LES , while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS .
Diseases: startle"	"Sentence: Furthermore , yohimbine increased baseline startle amplitude in the LES , while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS .
Diseases:"
4181	In contrast to findings in the FPS paradigm , none of the drugs were able to exacerbate the LES response .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In contrast to findings in the FPS paradigm , none of the drugs were able to exacerbate the LES response .
Diseases: "	"Sentence: In contrast to findings in the FPS paradigm , none of the drugs were able to exacerbate the LES response .
Diseases:"
4182	Thus , a clear pharmacological differentiation was found between LES and FPS .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Thus , a clear pharmacological differentiation was found between LES and FPS .
Diseases: "	"Sentence: Thus , a clear pharmacological differentiation was found between LES and FPS .
Diseases:"
4183	Proteinase 3 - antineutrophil cytoplasmic antibody - ( PR3 - ANCA ) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment .	O O O O O O O O O O O O O O B O O O O O	O O O O O O O O O O O O O O O O O B O O	['glomerulonephritis']	1	5	"Sentence: Proteinase 3 - antineutrophil cytoplasmic antibody - ( PR3 - ANCA ) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment .
Diseases: glomerulonephritis"	"Sentence: Proteinase 3 - antineutrophil cytoplasmic antibody - ( PR3 - ANCA ) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment .
Diseases:"
4184	A 59 - year - old woman with ulcerative colitis developed red eyes , pleural effusion , eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment .	O O O O O O O O B I O B I O B I O B O B I O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B O O	['pleural effusion', 'urinary abnormalities', 'ulcerative colitis', 'eosinophilia', 'red eyes']	5	22	"Sentence: A 59 - year - old woman with ulcerative colitis developed red eyes , pleural effusion , eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment .
Diseases: pleural effusion, urinary abnormalities, ulcerative colitis, eosinophilia, red eyes"	"Sentence: A 59 - year - old woman with ulcerative colitis developed red eyes , pleural effusion , eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment .
Diseases:"
4185	Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement .	O O O O O O O B I I O O O O O O O	O O O O O O O O O O O O O O O O O	['segmental necrotizing glomerulonephritis']	1	12	"Sentence: Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement .
Diseases: segmental necrotizing glomerulonephritis"	"Sentence: Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement .
Diseases:"
4186	Proteinase 3 - antineutrophil cytoplasmic antibody ( PR3 - ANCA ) titer was elevated at 183 ELISA units ( EU ) in sera ( normal range less than 10 EU ) , myeloperoxidase - ANCA was negative .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Proteinase 3 - antineutrophil cytoplasmic antibody ( PR3 - ANCA ) titer was elevated at 183 ELISA units ( EU ) in sera ( normal range less than 10 EU ) , myeloperoxidase - ANCA was negative .
Diseases: "	"Sentence: Proteinase 3 - antineutrophil cytoplasmic antibody ( PR3 - ANCA ) titer was elevated at 183 ELISA units ( EU ) in sera ( normal range less than 10 EU ) , myeloperoxidase - ANCA was negative .
Diseases:"
4187	PR3 - ANCA titer was 250 and 1 , 070 EU in pleural effusions on right and left side , respectively .	O O O O O O O O O O O O B I O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	['pleural effusions']	1	4	"Sentence: PR3 - ANCA titer was 250 and 1 , 070 EU in pleural effusions on right and left side , respectively .
Diseases: pleural effusions"	"Sentence: PR3 - ANCA titer was 250 and 1 , 070 EU in pleural effusions on right and left side , respectively .
Diseases:"
4188	Although cessation of sulphasalazine treatment resulted in improvements in fever , red eyes , chest pain , titer of C - reactive protein and volume of the pleural effusions , we initiated steroid therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the pleural effusion remained .	O O O O O O O O O B O B I O B I O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pleural effusion', 'chest pain', 'fever', 'red eyes', 'pleural effusions']	5	17	"Sentence: Although cessation of sulphasalazine treatment resulted in improvements in fever , red eyes , chest pain , titer of C - reactive protein and volume of the pleural effusions , we initiated steroid therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the pleural effusion remained .
Diseases: pleural effusion, chest pain, fever, red eyes, pleural effusions"	"Sentence: Although cessation of sulphasalazine treatment resulted in improvements in fever , red eyes , chest pain , titer of C - reactive protein and volume of the pleural effusions , we initiated steroid therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the pleural effusion remained .
Diseases:"
4189	One month after steroid therapy , the pleural effusion disappeared , and PR3 - ANCA titer normalized 3 months later .	O O O O O O O B I O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O	['pleural effusion']	1	4	"Sentence: One month after steroid therapy , the pleural effusion disappeared , and PR3 - ANCA titer normalized 3 months later .
Diseases: pleural effusion"	"Sentence: One month after steroid therapy , the pleural effusion disappeared , and PR3 - ANCA titer normalized 3 months later .
Diseases:"
4190	This case suggests that sulphasalazine can induce PR3 - ANCA - positive necrotizing glomerulonephritis .	O O O O O O O O O O O O O B O	O O O O B O O O O O O O O O O	['glomerulonephritis']	1	5	"Sentence: This case suggests that sulphasalazine can induce PR3 - ANCA - positive necrotizing glomerulonephritis .
Diseases: glomerulonephritis"	"Sentence: This case suggests that sulphasalazine can induce PR3 - ANCA - positive necrotizing glomerulonephritis .
Diseases:"
4191	Is phenytoin administration safe in a hypothermic child ?	O O O O O O B O O	O B O O O O O O O	['hypothermic']	1	3	"Sentence: Is phenytoin administration safe in a hypothermic child ?
Diseases: hypothermic"	"Sentence: Is phenytoin administration safe in a hypothermic child ?
Diseases:"
4192	A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele .	O O O O O B I O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	['chiari malformation']	1	4	"Sentence: A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele .
Diseases: chiari malformation"	"Sentence: A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele .
Diseases:"
4193	During anaesthesia and surgery , he inadvertently became moderately hypothermic .	O O O O O O O O O B O	O O O O O O O O O O O	['hypothermic']	1	3	"Sentence: During anaesthesia and surgery , he inadvertently became moderately hypothermic .
Diseases: hypothermic"	"Sentence: During anaesthesia and surgery , he inadvertently became moderately hypothermic .
Diseases:"
4194	Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis .	O O O O O O O O O O O O B O O	O B O O O O O O O O O O O O O	['seizure']	1	3	"Sentence: Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis .
Diseases: seizure"	"Sentence: Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis .
Diseases:"
4195	Following phenytoin administration , the patient developed acute severe bradycardia , refractory to atropine and adrenaline .	O O O O O O O O O B O O O O O O O	O B O O O O O O O O O O O B O B O	['bradycardia']	1	4	"Sentence: Following phenytoin administration , the patient developed acute severe bradycardia , refractory to atropine and adrenaline .
Diseases: bradycardia"	"Sentence: Following phenytoin administration , the patient developed acute severe bradycardia , refractory to atropine and adrenaline .
Diseases:"
4196	The cardiac depressant actions of phenytoin and hypothermia can be additive .	O O O O O O O B O O O O	O O O O O B O O O O O O	['hypothermia']	1	3	"Sentence: The cardiac depressant actions of phenytoin and hypothermia can be additive .
Diseases: hypothermia"	"Sentence: The cardiac depressant actions of phenytoin and hypothermia can be additive .
Diseases:"
4197	Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children .	O O O O O O O B O O O O O O O O O O	O O B O O O O O O O O O O O O O O O	['hypothermia']	1	3	"Sentence: Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children .
Diseases: hypothermia"	"Sentence: Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children .
Diseases:"
4198	As phenytoin is a commonly used drug , clinicians need to be aware of this interaction .	O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: As phenytoin is a commonly used drug , clinicians need to be aware of this interaction .
Diseases: "	"Sentence: As phenytoin is a commonly used drug , clinicians need to be aware of this interaction .
Diseases:"
4199	Amisulpride related tic - like symptoms in an adolescent schizophrenic .	O O B I I I O O O B O	B O O O O O O O O O O	['schizophrenic', 'tic - like symptoms']	2	9	"Sentence: Amisulpride related tic - like symptoms in an adolescent schizophrenic .
Diseases: schizophrenic, tic - like symptoms"	"Sentence: Amisulpride related tic - like symptoms in an adolescent schizophrenic .
Diseases:"
4200	Tic disorders can be effectively treated by atypical antipsychotics such as risperidone , olanzapine and ziprasidone .	B I O O O O O O O O O O O O O O O	O O O O O O O O O O O B O B O B O	['tic disorders']	1	2	"Sentence: Tic disorders can be effectively treated by atypical antipsychotics such as risperidone , olanzapine and ziprasidone .
Diseases: tic disorders"	"Sentence: Tic disorders can be effectively treated by atypical antipsychotics such as risperidone , olanzapine and ziprasidone .
Diseases:"
4201	However , there are two case reports that show tic - like symptoms , including motor and phonic variants , occurring during treatment with quetiapine or clozapine .	O O O O O O O O O B I I I O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B O B O	['tic - like symptoms']	1	4	"Sentence: However , there are two case reports that show tic - like symptoms , including motor and phonic variants , occurring during treatment with quetiapine or clozapine .
Diseases: tic - like symptoms"	"Sentence: However , there are two case reports that show tic - like symptoms , including motor and phonic variants , occurring during treatment with quetiapine or clozapine .
Diseases:"
4202	We present a 15 - year - old girl schizophrenic who developed frequent involuntary eye - blinking movements after 5 months of amisulpride treatment ( 1000 mg per day ) .	O O O O O O O O O B O O O B I I I I O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['schizophrenic', 'involuntary eye - blinking movements']	2	9	"Sentence: We present a 15 - year - old girl schizophrenic who developed frequent involuntary eye - blinking movements after 5 months of amisulpride treatment ( 1000 mg per day ) .
Diseases: schizophrenic, involuntary eye - blinking movements"	"Sentence: We present a 15 - year - old girl schizophrenic who developed frequent involuntary eye - blinking movements after 5 months of amisulpride treatment ( 1000 mg per day ) .
Diseases:"
4203	The tic - like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day .	O B I I I O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O	['tic - like symptoms']	1	4	"Sentence: The tic - like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day .
Diseases: tic - like symptoms"	"Sentence: The tic - like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day .
Diseases:"
4204	However , her psychosis recurred after the dose reduction .	O O O B O O O O O O	O O O O O O O O O O	['psychosis']	1	2	"Sentence: However , her psychosis recurred after the dose reduction .
Diseases: psychosis"	"Sentence: However , her psychosis recurred after the dose reduction .
Diseases:"
4205	We then placed her on an additional 100 mg per day of quetiapine .	O O O O O O O O O O O O O O	O O O O O O O O O O O O B O	[]	0	0	"Sentence: We then placed her on an additional 100 mg per day of quetiapine .
Diseases: "	"Sentence: We then placed her on an additional 100 mg per day of quetiapine .
Diseases:"
4206	She has been in complete remission under the combined medications for more than one year and maintains a fair role function .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: She has been in complete remission under the combined medications for more than one year and maintains a fair role function .
Diseases: "	"Sentence: She has been in complete remission under the combined medications for more than one year and maintains a fair role function .
Diseases:"
4207	No more tic - like symptoms or other side effects have been reported .	O O B I I I O O O O O O O O	O O O O O O O O O O O O O O	['tic - like symptoms']	1	4	"Sentence: No more tic - like symptoms or other side effects have been reported .
Diseases: tic - like symptoms"	"Sentence: No more tic - like symptoms or other side effects have been reported .
Diseases:"
4208	Together with previously reported cases , our patient suggests that tic - like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine , clozapine , or amisulpride .	O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O B O	['tic - like symptoms']	1	4	"Sentence: Together with previously reported cases , our patient suggests that tic - like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine , clozapine , or amisulpride .
Diseases: tic - like symptoms"	"Sentence: Together with previously reported cases , our patient suggests that tic - like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine , clozapine , or amisulpride .
Diseases:"
4209	Comparison of developmental toxicology of aspirin ( acetylsalicylic acid ) in rats using selected dosing paradigms .	O O O O O O O O O O O O O O O O O	O O O O O B O B I O O O O O O O O	[]	0	0	"Sentence: Comparison of developmental toxicology of aspirin ( acetylsalicylic acid ) in rats using selected dosing paradigms .
Diseases: "	"Sentence: Comparison of developmental toxicology of aspirin ( acetylsalicylic acid ) in rats using selected dosing paradigms .
Diseases:"
4210	Analysis of the literature for nonsteroidal anti - inflammatory drugs ( NSAIDs ) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis .	O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O	O O O O O O I O O O O O O O O O O O O O O O O O O O O O O O O O	['developmental anomalies']	1	3	"Sentence: Analysis of the literature for nonsteroidal anti - inflammatory drugs ( NSAIDs ) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis .
Diseases: developmental anomalies"	"Sentence: Analysis of the literature for nonsteroidal anti - inflammatory drugs ( NSAIDs ) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis .
Diseases:"
4211	Aspirin ( acetylsalicylic acid [ ASA ] ) , an irreversible cyclooxygenase 1 and 2 inhibitor , induces developmental anomalies when administered to Wistar rats on gestational day ( GD ) 9 , 10 , or 11 ( Kimmel CA , Wilson JG , Schumacher HJ .	O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O B I O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['developmental anomalies']	1	3	"Sentence: Aspirin ( acetylsalicylic acid [ ASA ] ) , an irreversible cyclooxygenase 1 and 2 inhibitor , induces developmental anomalies when administered to Wistar rats on gestational day ( GD ) 9 , 10 , or 11 ( Kimmel CA , Wilson JG , Schumacher HJ .
Diseases: developmental anomalies"	"Sentence: Aspirin ( acetylsalicylic acid [ ASA ] ) , an irreversible cyclooxygenase 1 and 2 inhibitor , induces developmental anomalies when administered to Wistar rats on gestational day ( GD ) 9 , 10 , or 11 ( Kimmel CA , Wilson JG , Schumacher HJ .
Diseases:"
4212	Teratology 4 : 15 - 24 , 1971 ) .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Teratology 4 : 15 - 24 , 1971 ) .
Diseases: "	"Sentence: Teratology 4 : 15 - 24 , 1971 ) .
Diseases:"
4213	There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17 .	O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O B O O O O	[]	0	0	"Sentence: There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17 .
Diseases: "	"Sentence: There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17 .
Diseases:"
4214	Objectives of the current study were to compare results between Sprague - Dawley ( SD ) and Wistar strains when ASA is administered on GD 9 , 10 , or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['malformations', 'gastrointestinal toxicity']	2	6	"Sentence: Objectives of the current study were to compare results between Sprague - Dawley ( SD ) and Wistar strains when ASA is administered on GD 9 , 10 , or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used .
Diseases: malformations, gastrointestinal toxicity"	"Sentence: Objectives of the current study were to compare results between Sprague - Dawley ( SD ) and Wistar strains when ASA is administered on GD 9 , 10 , or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used .
Diseases:"
4215	METHODS : ASA was administered as a single dose on GD 9 ( 0 , 250 , 500 , or 625 mg / kg ) , 10 ( 0 , 500 , 625 , or 750 mg / kg ) , or 11 ( 0 , 500 , 750 , or 1000 mg / kg ) and from GD 6 to GD 17 ( 0 , 50 , 125 , or 250 mg / kg a day ) in the multiple dose study to SD rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: METHODS : ASA was administered as a single dose on GD 9 ( 0 , 250 , 500 , or 625 mg / kg ) , 10 ( 0 , 500 , 625 , or 750 mg / kg ) , or 11 ( 0 , 500 , 750 , or 1000 mg / kg ) and from GD 6 to GD 17 ( 0 , 50 , 125 , or 250 mg / kg a day ) in the multiple dose study to SD rats .
Diseases: "	"Sentence: METHODS : ASA was administered as a single dose on GD 9 ( 0 , 250 , 500 , or 625 mg / kg ) , 10 ( 0 , 500 , 625 , or 750 mg / kg ) , or 11 ( 0 , 500 , 750 , or 1000 mg / kg ) and from GD 6 to GD 17 ( 0 , 50 , 125 , or 250 mg / kg a day ) in the multiple dose study to SD rats .
Diseases:"
4216	Animals were killed on GD 21 , and fetuses were examined viscerally .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Animals were killed on GD 21 , and fetuses were examined viscerally .
Diseases: "	"Sentence: Animals were killed on GD 21 , and fetuses were examined viscerally .
Diseases:"
4217	The literature evaluation suggested that NSAIDs induce ventricular septal defects ( VSDs ) and midline defects ( MDs ) in rats and diaphragmatic hernia ( DH ) , MDs , and VSDs in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these malformations , even though ASA induces several other low - incidence malformations .	O O O O O O O B I I O B O O B I O B O O O O B I O B O O B O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O B O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	['vsds', 'diaphragmatic hernia', 'mds', 'malformations', 'dh', 'midline defects', 'ventricular septal defects']	7	29	"Sentence: The literature evaluation suggested that NSAIDs induce ventricular septal defects ( VSDs ) and midline defects ( MDs ) in rats and diaphragmatic hernia ( DH ) , MDs , and VSDs in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these malformations , even though ASA induces several other low - incidence malformations .
Diseases: vsds, diaphragmatic hernia, mds, malformations, dh, midline defects, ventricular septal defects"	"Sentence: The literature evaluation suggested that NSAIDs induce ventricular septal defects ( VSDs ) and midline defects ( MDs ) in rats and diaphragmatic hernia ( DH ) , MDs , and VSDs in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these malformations , even though ASA induces several other low - incidence malformations .
Diseases:"
4218	In single dose studies , DH , MD , and VSD were induced on GDs 9 and 10 .	O O O O O B O B O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O	['md', 'vsd', 'dh']	3	6	"Sentence: In single dose studies , DH , MD , and VSD were induced on GDs 9 and 10 .
Diseases: md, vsd, dh"	"Sentence: In single dose studies , DH , MD , and VSD were induced on GDs 9 and 10 .
Diseases:"
4219	VSD also was noted following treatment on GD 11 .	B O O O O O O O O O	O O O O O O O O O O	['vsd']	1	2	"Sentence: VSD also was noted following treatment on GD 11 .
Diseases: vsd"	"Sentence: VSD also was noted following treatment on GD 11 .
Diseases:"
4220	In contrast , DH and MD were noted in the multiple dose study design only in the high - dose group , and VSD was noted across all dose groups .	O O O B O B O O O O O O O O O O O O O O O O O B O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['md', 'vsd', 'dh']	3	6	"Sentence: In contrast , DH and MD were noted in the multiple dose study design only in the high - dose group , and VSD was noted across all dose groups .
Diseases: md, vsd, dh"	"Sentence: In contrast , DH and MD were noted in the multiple dose study design only in the high - dose group , and VSD was noted across all dose groups .
Diseases:"
4221	CONCLUSIONS : High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats .	O O O O O O B I O O O O O O O O O O O B O O O O O B O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['developmental anomalies', 'vsd', 'hydrocephalus']	3	10	"Sentence: CONCLUSIONS : High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats .
Diseases: developmental anomalies, vsd, hydrocephalus"	"Sentence: CONCLUSIONS : High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats .
Diseases:"
4222	Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis ( GDs 6 to 17 ) .	O O B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O	['malformations']	1	3	"Sentence: Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis ( GDs 6 to 17 ) .
Diseases: malformations"	"Sentence: Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis ( GDs 6 to 17 ) .
Diseases:"
4223	It was also evident that , by titrating the dose to achieve a maximum tolerated dose , malformations that normally occur at low incidence , as reported from previous single dose studies , could also be induced with ASA given at multiple doses .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	['malformations']	1	3	"Sentence: It was also evident that , by titrating the dose to achieve a maximum tolerated dose , malformations that normally occur at low incidence , as reported from previous single dose studies , could also be induced with ASA given at multiple doses .
Diseases: malformations"	"Sentence: It was also evident that , by titrating the dose to achieve a maximum tolerated dose , malformations that normally occur at low incidence , as reported from previous single dose studies , could also be induced with ASA given at multiple doses .
Diseases:"
4224	Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block .	B I I O O O O O O O O O O B I I I O	O O O O O B O O O O O O O O O O O O	['torsade de pointes', 'left bundle branch block']	2	11	"Sentence: Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block .
Diseases: torsade de pointes, left bundle branch block"	"Sentence: Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block .
Diseases:"
4225	There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes .	O O O O O O O O O O B I I O B I I O	O O O O O O O O O O O O O O O O O O	['torsade de pointes', 'long qt syndrome']	2	11	"Sentence: There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes .
Diseases: torsade de pointes, long qt syndrome"	"Sentence: There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes .
Diseases:"
4226	However , the torsadogenic potential of metoclopramide , a commonly used antiemetic and prokinetic drug , has not been reported in the literature , despite its chemical similarity to procainamide .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: However , the torsadogenic potential of metoclopramide , a commonly used antiemetic and prokinetic drug , has not been reported in the literature , despite its chemical similarity to procainamide .
Diseases: "	"Sentence: However , the torsadogenic potential of metoclopramide , a commonly used antiemetic and prokinetic drug , has not been reported in the literature , despite its chemical similarity to procainamide .
Diseases:"
4227	We report on a 92 - year - old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide .	O O O O O O O O O O O O O B I I I O O B I I O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['torsade de pointes', 'left bundle branch block']	2	11	"Sentence: We report on a 92 - year - old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide .
Diseases: torsade de pointes, left bundle branch block"	"Sentence: We report on a 92 - year - old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide .
Diseases:"
4228	This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously .	O O O O B I I O O O O O O O O	O O O O O O O O B O B O O O O	['torsade de pointes']	1	6	"Sentence: This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously .
Diseases: torsade de pointes"	"Sentence: This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously .
Diseases:"
4229	These two episodes were suppressed successfully after discontinuing the offending drugs and administering class IB drugs .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These two episodes were suppressed successfully after discontinuing the offending drugs and administering class IB drugs .
Diseases: "	"Sentence: These two episodes were suppressed successfully after discontinuing the offending drugs and administering class IB drugs .
Diseases:"
4230	This is the first documentation that metoclopramide provokes torsade de pointes clinically .	O O O O O O O O B I I O O	O O O O O O B O O O O O O	['torsade de pointes']	1	6	"Sentence: This is the first documentation that metoclopramide provokes torsade de pointes clinically .
Diseases: torsade de pointes"	"Sentence: This is the first documentation that metoclopramide provokes torsade de pointes clinically .
Diseases:"
4231	Metoclopramide should be used cautiously in patients with a risk of torsade de pointes .	O O O O O O O O O O O B I I O	B O O O O O O O O O O O O O O	['torsade de pointes']	1	6	"Sentence: Metoclopramide should be used cautiously in patients with a risk of torsade de pointes .
Diseases: torsade de pointes"	"Sentence: Metoclopramide should be used cautiously in patients with a risk of torsade de pointes .
Diseases:"
4232	Apomorphine : an underutilized therapy for Parkinson 's disease .	O O O O O O B I I O	B O O O O O O O O O	"[""parkinson 's disease""]"	1	5	"Sentence: Apomorphine : an underutilized therapy for Parkinson 's disease .
Diseases: parkinson 's disease"	"Sentence: Apomorphine : an underutilized therapy for Parkinson 's disease .
Diseases:"
4233	Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson 's disease .	O O O O O O O O O O O O B I I O	B O O O O O O O O O O O O O O O	"[""parkinson 's disease""]"	1	5	"Sentence: Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson 's disease .
Diseases: parkinson 's disease"	"Sentence: Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson 's disease .
Diseases:"
4234	While powerful antiparkinsonian effects had been observed as early as 1951 , the potential of treating fluctuating Parkinson 's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study .	O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	"[""parkinson 's disease""]"	1	5	"Sentence: While powerful antiparkinsonian effects had been observed as early as 1951 , the potential of treating fluctuating Parkinson 's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study .
Diseases: parkinson 's disease"	"Sentence: While powerful antiparkinsonian effects had been observed as early as 1951 , the potential of treating fluctuating Parkinson 's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study .
Diseases:"
4235	A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off - periods even in patients with complex on - off motor swings .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O B O O B O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off - periods even in patients with complex on - off motor swings .
Diseases: "	"Sentence: A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off - periods even in patients with complex on - off motor swings .
Diseases:"
4236	Continuous subcutaneous apomorphine infusions can reduce daily off - time by more than 50 % in this group of patients , which appears to be a stronger effect than that generally seen with add - on therapy with oral dopamine agonists or COMT inhibitors .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	[]	0	0	"Sentence: Continuous subcutaneous apomorphine infusions can reduce daily off - time by more than 50 % in this group of patients , which appears to be a stronger effect than that generally seen with add - on therapy with oral dopamine agonists or COMT inhibitors .
Diseases: "	"Sentence: Continuous subcutaneous apomorphine infusions can reduce daily off - time by more than 50 % in this group of patients , which appears to be a stronger effect than that generally seen with add - on therapy with oral dopamine agonists or COMT inhibitors .
Diseases:"
4237	Extended follow - up studies of up to 8 years have demonstrated long - term persistence of apomorphine efficacy .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Extended follow - up studies of up to 8 years have demonstrated long - term persistence of apomorphine efficacy .
Diseases: "	"Sentence: Extended follow - up studies of up to 8 years have demonstrated long - term persistence of apomorphine efficacy .
Diseases:"
4238	In addition , there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa - induced dyskinesias .	O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O B O O O O O O O O B O O O O	['dyskinesias']	1	5	"Sentence: In addition , there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa - induced dyskinesias .
Diseases: dyskinesias"	"Sentence: In addition , there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa - induced dyskinesias .
Diseases:"
4239	The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems , whereas sedation and psychiatric complications play a lesser role .	O O O O O O O O O O O O O O O O O O B O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O	['psychiatric']	1	2	"Sentence: The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems , whereas sedation and psychiatric complications play a lesser role .
Diseases: psychiatric"	"Sentence: The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems , whereas sedation and psychiatric complications play a lesser role .
Diseases:"
4240	Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson 's disease , this approach seems to deserve more widespread clinical use .	O O O O O O O O O O O O B I I O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O	"[""parkinson 's disease""]"	1	5	"Sentence: Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson 's disease , this approach seems to deserve more widespread clinical use .
Diseases: parkinson 's disease"	"Sentence: Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson 's disease , this approach seems to deserve more widespread clinical use .
Diseases:"
4241	Fatal excited delirium following cocaine use : epidemiologic findings provide new evidence for mechanisms of cocaine toxicity .	O O B O O O O O O O O O O O O O B O	O O O O B O O O O O O O O O O B O O	['delirium', 'toxicity']	2	5	"Sentence: Fatal excited delirium following cocaine use : epidemiologic findings provide new evidence for mechanisms of cocaine toxicity .
Diseases: delirium, toxicity"	"Sentence: Fatal excited delirium following cocaine use : epidemiologic findings provide new evidence for mechanisms of cocaine toxicity .
Diseases:"
4242	We describe an outbreak of deaths from cocaine - induced excited delirium ( EDDs ) in Dade County , Florida between 1979 and 1990 .	O O O O O O O O O O O B O B O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O	['delirium', 'edds']	2	6	"Sentence: We describe an outbreak of deaths from cocaine - induced excited delirium ( EDDs ) in Dade County , Florida between 1979 and 1990 .
Diseases: delirium, edds"	"Sentence: We describe an outbreak of deaths from cocaine - induced excited delirium ( EDDs ) in Dade County , Florida between 1979 and 1990 .
Diseases:"
4243	From a registry of all cocaine - related deaths in Dade County , Florida , from 1969 - 1990 , 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium .	O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O B O O B O	O O O O O B O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	['delirium', 'overdose', 'edds']	3	8	"Sentence: From a registry of all cocaine - related deaths in Dade County , Florida , from 1969 - 1990 , 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium .
Diseases: delirium, overdose, edds"	"Sentence: From a registry of all cocaine - related deaths in Dade County , Florida , from 1969 - 1990 , 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium .
Diseases:"
4244	Compared with controls , EDDs were more frequently black , male , and younger .	O O O O B O O O O O O O O O O	O O O O O O O O O O O O O O O	['edds']	1	2	"Sentence: Compared with controls , EDDs were more frequently black , male , and younger .
Diseases: edds"	"Sentence: Compared with controls , EDDs were more frequently black , male , and younger .
Diseases:"
4245	They were less likely to have a low body mass index , and more likely to have died in police custody , to have received medical treatment immediately before death , to have survived for a longer period , to have developed hyperthermia , and to have died in summer months .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hyperthermia']	1	3	"Sentence: They were less likely to have a low body mass index , and more likely to have died in police custody , to have received medical treatment immediately before death , to have survived for a longer period , to have developed hyperthermia , and to have died in summer months .
Diseases: hyperthermia"	"Sentence: They were less likely to have a low body mass index , and more likely to have died in police custody , to have received medical treatment immediately before death , to have survived for a longer period , to have developed hyperthermia , and to have died in summer months .
Diseases:"
4246	EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls .	B O O O O O O O O O O O O O O O O O	O O O O B O B O O O O O O O O O O O	['edds']	1	2	"Sentence: EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls .
Diseases: edds"	"Sentence: EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls .
Diseases:"
4247	The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and , when coupled with recent cocaine use , may precipitate agitation , delirium , aberrant thermoregulation , rhabdomyolysis , and sudden death .	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O B O O O O B O O B I O	O O O O O O O O O O O B O O O O O O O O O O B O O O O O O O O O O O O O O O O O	['agitation', 'delirium', 'rhabdomyolysis', 'sudden death']	4	16	"Sentence: The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and , when coupled with recent cocaine use , may precipitate agitation , delirium , aberrant thermoregulation , rhabdomyolysis , and sudden death .
Diseases: agitation, delirium, rhabdomyolysis, sudden death"	"Sentence: The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and , when coupled with recent cocaine use , may precipitate agitation , delirium , aberrant thermoregulation , rhabdomyolysis , and sudden death .
Diseases:"
4248	Heparin - induced thrombocytopenia , thrombosis , and hemorrhage .	O O O B O B O O B O	B O O O O O O O O O	['hemorrhage', 'thrombocytopenia', 'thrombosis']	3	17	"Sentence: Heparin - induced thrombocytopenia , thrombosis , and hemorrhage .
Diseases: hemorrhage, thrombocytopenia, thrombosis"	"Sentence: Heparin - induced thrombocytopenia , thrombosis , and hemorrhage .
Diseases:"
4249	Sixty - two patients with a heparin - induced thrombocytopenia are reported .	O O O O O O O O O B O O O	O O O O O O B O O O O O O	['thrombocytopenia']	1	7	"Sentence: Sixty - two patients with a heparin - induced thrombocytopenia are reported .
Diseases: thrombocytopenia"	"Sentence: Sixty - two patients with a heparin - induced thrombocytopenia are reported .
Diseases:"
4250	Clinical manifestations of this disorder include hemorrhage or , more frequently , thromboembolic events in patients receiving heparin .	O O O O O O B O O O O O B O O O O O O	O O O O O O O O O O O O O O O O O B O	['thromboembolic', 'hemorrhage']	2	8	"Sentence: Clinical manifestations of this disorder include hemorrhage or , more frequently , thromboembolic events in patients receiving heparin .
Diseases: thromboembolic, hemorrhage"	"Sentence: Clinical manifestations of this disorder include hemorrhage or , more frequently , thromboembolic events in patients receiving heparin .
Diseases:"
4251	Laboratory testing has revealed a falling platelet count , increased resistance to heparin , and aggregation of platelets by the patient 's plasma when heparin is added .	O O O O B I I I O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O B O O O	['a falling platelet count']	1	5	"Sentence: Laboratory testing has revealed a falling platelet count , increased resistance to heparin , and aggregation of platelets by the patient 's plasma when heparin is added .
Diseases: a falling platelet count"	"Sentence: Laboratory testing has revealed a falling platelet count , increased resistance to heparin , and aggregation of platelets by the patient 's plasma when heparin is added .
Diseases:"
4252	Immunologic testing has demonstrated the presence of a heparin - dependent platelet membrane antibody .	O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O	[]	0	0	"Sentence: Immunologic testing has demonstrated the presence of a heparin - dependent platelet membrane antibody .
Diseases: "	"Sentence: Immunologic testing has demonstrated the presence of a heparin - dependent platelet membrane antibody .
Diseases:"
4253	The 20 deaths , 52 hemorrhagic and thromboembolic complications , and 21 surgical procedures to manage the complications confirm the seriousness of the disorder .	O O O O O B I I I O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	['hemorrhagic and thromboembolic complications']	1	11	"Sentence: The 20 deaths , 52 hemorrhagic and thromboembolic complications , and 21 surgical procedures to manage the complications confirm the seriousness of the disorder .
Diseases: hemorrhagic and thromboembolic complications"	"Sentence: The 20 deaths , 52 hemorrhagic and thromboembolic complications , and 21 surgical procedures to manage the complications confirm the seriousness of the disorder .
Diseases:"
4254	Specific risk factors have not been identified ; therefore , all patients receiving heparin should be monitored .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: Specific risk factors have not been identified ; therefore , all patients receiving heparin should be monitored .
Diseases: "	"Sentence: Specific risk factors have not been identified ; therefore , all patients receiving heparin should be monitored .
Diseases:"
4255	If the platelet count falls to less than 100 , 000 / mm3 , while the patient is receiving heparin , platelet aggregation testing , using the patient 's plasma , is indicated .	O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	['platelet aggregation']	1	3	"Sentence: If the platelet count falls to less than 100 , 000 / mm3 , while the patient is receiving heparin , platelet aggregation testing , using the patient 's plasma , is indicated .
Diseases: platelet aggregation"	"Sentence: If the platelet count falls to less than 100 , 000 / mm3 , while the patient is receiving heparin , platelet aggregation testing , using the patient 's plasma , is indicated .
Diseases:"
4256	Management consists of cessation of heparin , platelet anti - aggregating agents , and alternate forms of anticoagulation when indicated .	O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Management consists of cessation of heparin , platelet anti - aggregating agents , and alternate forms of anticoagulation when indicated .
Diseases: "	"Sentence: Management consists of cessation of heparin , platelet anti - aggregating agents , and alternate forms of anticoagulation when indicated .
Diseases:"
4257	Cardiac toxicity of 5 - fluorouracil .	B I O O O O O	O O O B I I O	['cardiac toxicity']	1	3	"Sentence: Cardiac toxicity of 5 - fluorouracil .
Diseases: cardiac toxicity"	"Sentence: Cardiac toxicity of 5 - fluorouracil .
Diseases:"
4258	Report of a case of spontaneous angina .	O O O O O O B O	O O O O O O O O	['angina']	1	2	"Sentence: Report of a case of spontaneous angina .
Diseases: angina"	"Sentence: Report of a case of spontaneous angina .
Diseases:"
4259	We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5 - fluorouracil ( 5 - FU ) administration .	O O O O O O O O B I O O B O O B I O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B I I O B I I O O O	['metastasis', 'colon carcinoma', 'chest pain']	3	10	"Sentence: We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5 - fluorouracil ( 5 - FU ) administration .
Diseases: metastasis, colon carcinoma, chest pain"	"Sentence: We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5 - fluorouracil ( 5 - FU ) administration .
Diseases:"
4260	Clinical electrocardiographic evolution was similar to that observed in Prinzmetal 's angina , and chest pain promptly resolved with nifedipine .	O O O O O O O O O B I I O O B I O O O O O	O O O O O O O O O O O O O O O O O O O B O	"[""prinzmetal 's angina"", 'chest pain']"	2	11	"Sentence: Clinical electrocardiographic evolution was similar to that observed in Prinzmetal 's angina , and chest pain promptly resolved with nifedipine .
Diseases: prinzmetal 's angina, chest pain"	"Sentence: Clinical electrocardiographic evolution was similar to that observed in Prinzmetal 's angina , and chest pain promptly resolved with nifedipine .
Diseases:"
4261	These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5 - FU , and that calcium antagonists may probably be used in the prevention or treatment of 5 - FU cardiotoxicity .	O O O O B I O O O O O B O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O B I I O O O B O O O O O O O O O O O B I I O O	['coronary spasm', 'cardiotoxicity']	2	9	"Sentence: These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5 - FU , and that calcium antagonists may probably be used in the prevention or treatment of 5 - FU cardiotoxicity .
Diseases: coronary spasm, cardiotoxicity"	"Sentence: These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5 - FU , and that calcium antagonists may probably be used in the prevention or treatment of 5 - FU cardiotoxicity .
Diseases:"
4262	Toxicity due to remission inducing drugs in rheumatoid arthritis .	B O O O O O O B I O	O O O O O O O O O O	['rheumatoid arthritis', 'toxicity']	2	7	"Sentence: Toxicity due to remission inducing drugs in rheumatoid arthritis .
Diseases: rheumatoid arthritis, toxicity"	"Sentence: Toxicity due to remission inducing drugs in rheumatoid arthritis .
Diseases:"
4263	Association with HLA - B35 and Cw4 antigens .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Association with HLA - B35 and Cw4 antigens .
Diseases: "	"Sentence: Association with HLA - B35 and Cw4 antigens .
Diseases:"
4264	Twenty - five patients with rheumatoid arthritis ( RA ) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens .	O O O O O B I O B O O O B O O O O O O O O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ra', 'rheumatoid arthritis', 'toxicity']	3	9	"Sentence: Twenty - five patients with rheumatoid arthritis ( RA ) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens .
Diseases: ra, rheumatoid arthritis, toxicity"	"Sentence: Twenty - five patients with rheumatoid arthritis ( RA ) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens .
Diseases:"
4265	A strong association has been found between nephritis and dermatitis due to Tiopronin ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between dermatitis due to gold thiosulphate and B35 .	O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	O O O O O O O O O O O O B O O B I I O O O O O O O O O O O O O O O O B I O O O	['nephritis', 'dermatitis']	2	6	"Sentence: A strong association has been found between nephritis and dermatitis due to Tiopronin ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between dermatitis due to gold thiosulphate and B35 .
Diseases: nephritis, dermatitis"	"Sentence: A strong association has been found between nephritis and dermatitis due to Tiopronin ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between dermatitis due to gold thiosulphate and B35 .
Diseases:"
4266	Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group .	O O O O O O O O O O O O O B O O O O O B O O	O O O O O O O O O O O O O O O O O B O O O O	['ra', 'nephritis']	2	5	"Sentence: Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group .
Diseases: ra, nephritis"	"Sentence: Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group .
Diseases:"
4267	Transient hemiparesis : a rare manifestation of diphenylhydantoin toxicity .	O B O O O O O O B O	O O O O O O O B O O	['hemiparesis', 'toxicity']	2	6	"Sentence: Transient hemiparesis : a rare manifestation of diphenylhydantoin toxicity .
Diseases: hemiparesis, toxicity"	"Sentence: Transient hemiparesis : a rare manifestation of diphenylhydantoin toxicity .
Diseases:"
4268	Report of two cases .	O O O O O	O O O O O	[]	0	0	"Sentence: Report of two cases .
Diseases: "	"Sentence: Report of two cases .
Diseases:"
4269	Among the common side effects of diphenylhydantoin ( DPH ) overdose , the most frequently encountered neurological signs are those of cerebellar dysfunction .	O O O O O O O O O O B O O O O O O O O O O B I O	O O O O O O B O B O O O O O O O O O O O O O O O	['overdose', 'cerebellar dysfunction']	2	7	"Sentence: Among the common side effects of diphenylhydantoin ( DPH ) overdose , the most frequently encountered neurological signs are those of cerebellar dysfunction .
Diseases: overdose, cerebellar dysfunction"	"Sentence: Among the common side effects of diphenylhydantoin ( DPH ) overdose , the most frequently encountered neurological signs are those of cerebellar dysfunction .
Diseases:"
4270	Very rarely , the toxic neurological manifestations of this drug are of cerebral origin .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Very rarely , the toxic neurological manifestations of this drug are of cerebral origin .
Diseases: "	"Sentence: Very rarely , the toxic neurological manifestations of this drug are of cerebral origin .
Diseases:"
4271	Two patients are presented who suffered progressive hemiparesis due to DPH overdose .	O O O O O O O B O O O B O	O O O O O O O O O O B O O	['overdose', 'hemiparesis']	2	7	"Sentence: Two patients are presented who suffered progressive hemiparesis due to DPH overdose .
Diseases: overdose, hemiparesis"	"Sentence: Two patients are presented who suffered progressive hemiparesis due to DPH overdose .
Diseases:"
4272	Both had brain surgery before DPH treatment .	O O O O O O O O	O O O O O B O O	[]	0	0	"Sentence: Both had brain surgery before DPH treatment .
Diseases: "	"Sentence: Both had brain surgery before DPH treatment .
Diseases:"
4273	It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs .	O O O O O O O B I O O O O O B O O O O O	O O O O O O O O O O O O O B O O O O O O	['toxicity', 'cerebral damage']	2	6	"Sentence: It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs .
Diseases: toxicity, cerebral damage"	"Sentence: It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs .
Diseases:"
4274	Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder .	O O O O O O O O O O O O B I O	O O O O B O O O O O O O O O O	['overactive bladder']	1	3	"Sentence: Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder .
Diseases: overactive bladder"	"Sentence: Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder .
Diseases:"
4275	NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine .	O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine .
Diseases: "	"Sentence: NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine .
Diseases:"
4276	We investigated changes in urinary NGF and PGs in women with OAB .	O O O O O O O O O O O B O	O O O O O O O O O O O O O	['oab']	1	2	"Sentence: We investigated changes in urinary NGF and PGs in women with OAB .
Diseases: oab"	"Sentence: We investigated changes in urinary NGF and PGs in women with OAB .
Diseases:"
4277	The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls .	O O O O O O O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	['oab']	1	2	"Sentence: The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls .
Diseases: oab"	"Sentence: The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls .
Diseases:"
4278	Evaluation included patient history , urinalysis , a voiding diary and urodynamic studies .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: Evaluation included patient history , urinalysis , a voiding diary and urodynamic studies .
Diseases: "	"Sentence: Evaluation included patient history , urinalysis , a voiding diary and urodynamic studies .
Diseases:"
4279	Urine samples were collected .	O O O O O	O O O O O	[]	0	0	"Sentence: Urine samples were collected .
Diseases: "	"Sentence: Urine samples were collected .
Diseases:"
4280	NGF , PGE2 , PGF2alpha and PGI2 were measured using enzyme - linked immunosorbent assay and compared between the groups .	O O O O O O O O O O O O O O O O O O O O O	O O B O B O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: NGF , PGE2 , PGF2alpha and PGI2 were measured using enzyme - linked immunosorbent assay and compared between the groups .
Diseases: "	"Sentence: NGF , PGE2 , PGF2alpha and PGI2 were measured using enzyme - linked immunosorbent assay and compared between the groups .
Diseases:"
4281	In addition , correlations between urinary NGF and PG , and urodynamic parameters in patients with OAB were examined .	O O O O O O O O O O O O O O O O B O O O	O O O O O O O O O O O O O O O O O O O O	['oab']	1	2	"Sentence: In addition , correlations between urinary NGF and PG , and urodynamic parameters in patients with OAB were examined .
Diseases: oab"	"Sentence: In addition , correlations between urinary NGF and PG , and urodynamic parameters in patients with OAB were examined .
Diseases:"
4282	Urinary NGF , PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls ( p < 0 . 05 ) .	O O O O O O O O O O O O B O O O O O O O O O O O	O O O B O B O O O O O O O O O O O O O O O O O O	['oab']	1	2	"Sentence: Urinary NGF , PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls ( p < 0 . 05 ) .
Diseases: oab"	"Sentence: Urinary NGF , PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls ( p < 0 . 05 ) .
Diseases:"
4283	However , urinary PGI2 was not different between controls and patients with OAB .	O O O O O O O O O O O O B O	O O O B O O O O O O O O O O	['oab']	1	2	"Sentence: However , urinary PGI2 was not different between controls and patients with OAB .
Diseases: oab"	"Sentence: However , urinary PGI2 was not different between controls and patients with OAB .
Diseases:"
4284	In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity ( p < 0 . 05 ) .	O O O B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O	['oab']	1	2	"Sentence: In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity ( p < 0 . 05 ) .
Diseases: oab"	"Sentence: In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity ( p < 0 . 05 ) .
Diseases:"
4285	Urinary NGF , PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB .	O O O O O O O O O O O O O O O B O	O O O B O B O O O O O O O O O O O	['oab']	1	2	"Sentence: Urinary NGF , PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB .
Diseases: oab"	"Sentence: Urinary NGF , PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB .
Diseases:"
4286	CONCLUSIONS : NGF and PGs have important roles in the development of OAB symptoms in female patients .	O O O O O O O O O O O O B O O O O O	O O O O O O O O O O O O O O O O O O	['oab']	1	2	"Sentence: CONCLUSIONS : NGF and PGs have important roles in the development of OAB symptoms in female patients .
Diseases: oab"	"Sentence: CONCLUSIONS : NGF and PGs have important roles in the development of OAB symptoms in female patients .
Diseases:"
4287	Urinary levels of these factors may be used as markers to evaluate OAB symptoms .	O O O O O O O O O O O O B O O	O O O O O O O O O O O O O O O	['oab']	1	2	"Sentence: Urinary levels of these factors may be used as markers to evaluate OAB symptoms .
Diseases: oab"	"Sentence: Urinary levels of these factors may be used as markers to evaluate OAB symptoms .
Diseases:"
4288	Acute low back pain during intravenous administration of amiodarone : a report of two cases .	O B I I O O O O O O O O O O O O	O O O O O O O O B O O O O O O O	['low back pain']	1	3	"Sentence: Acute low back pain during intravenous administration of amiodarone : a report of two cases .
Diseases: low back pain"	"Sentence: Acute low back pain during intravenous administration of amiodarone : a report of two cases .
Diseases:"
4289	Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent - onset atrial fibrillation ( AF ) and maintenance of sinus rhythm .	O O O O O O O O O O O O B I O B O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O	['af', 'atrial fibrillation']	2	7	"Sentence: Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent - onset atrial fibrillation ( AF ) and maintenance of sinus rhythm .
Diseases: af, atrial fibrillation"	"Sentence: Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent - onset atrial fibrillation ( AF ) and maintenance of sinus rhythm .
Diseases:"
4290	We briefly describe two patients suffering from recent - onset atrial fibrillation , who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading .	O O O O O O O O O O B I O O O O O O B I I O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['atrial fibrillation', 'low back pain']	2	9	"Sentence: We briefly describe two patients suffering from recent - onset atrial fibrillation , who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading .
Diseases: atrial fibrillation, low back pain"	"Sentence: We briefly describe two patients suffering from recent - onset atrial fibrillation , who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading .
Diseases:"
4291	Notably , this side effect has not been ever reported in the medical literature .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Notably , this side effect has not been ever reported in the medical literature .
Diseases: "	"Sentence: Notably , this side effect has not been ever reported in the medical literature .
Diseases:"
4292	Clinicians should be aware of this reaction since prompt termination of parenteral administration leads to complete resolution .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Clinicians should be aware of this reaction since prompt termination of parenteral administration leads to complete resolution .
Diseases: "	"Sentence: Clinicians should be aware of this reaction since prompt termination of parenteral administration leads to complete resolution .
Diseases:"
4293	Postoperative myalgia after succinylcholine : no evidence for an inflammatory origin .	B I O O O O O O O O O O	O O O B O O O O O O O O	['postoperative myalgia']	1	4	"Sentence: Postoperative myalgia after succinylcholine : no evidence for an inflammatory origin .
Diseases: postoperative myalgia"	"Sentence: Postoperative myalgia after succinylcholine : no evidence for an inflammatory origin .
Diseases:"
4294	A common side effect associated with succinylcholine is postoperative myalgia .	O O O O O O O O B I O	O O O O O O B O O O O	['postoperative myalgia']	1	4	"Sentence: A common side effect associated with succinylcholine is postoperative myalgia .
Diseases: postoperative myalgia"	"Sentence: A common side effect associated with succinylcholine is postoperative myalgia .
Diseases:"
4295	The pathogenesis of this myalgia is still unclear ; inflammation has been suggested but without convincing evidence .	O O O O B O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O	['inflammation', 'myalgia']	2	4	"Sentence: The pathogenesis of this myalgia is still unclear ; inflammation has been suggested but without convincing evidence .
Diseases: inflammation, myalgia"	"Sentence: The pathogenesis of this myalgia is still unclear ; inflammation has been suggested but without convincing evidence .
Diseases:"
4296	We designed the present study to investigate whether an inflammatory reaction contributes to this myalgia .	O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O	['myalgia']	1	2	"Sentence: We designed the present study to investigate whether an inflammatory reaction contributes to this myalgia .
Diseases: myalgia"	"Sentence: We designed the present study to investigate whether an inflammatory reaction contributes to this myalgia .
Diseases:"
4297	The incidence and severity of succinylcholine - associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine ( n = 32 for each ) .	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O B O B O O O O O O O O	['myalgia']	1	2	"Sentence: The incidence and severity of succinylcholine - associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine ( n = 32 for each ) .
Diseases: myalgia"	"Sentence: The incidence and severity of succinylcholine - associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine ( n = 32 for each ) .
Diseases:"
4298	Incidence and severity of myalgia did not differ significantly between the two groups : 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group , and severe myalgia was reported by five patients and three patients , respectively ( not significant ) .	O O O O B O O O O O O O O O O O O O O O O O B O O O O O O O O O O O B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['myalgia']	1	2	"Sentence: Incidence and severity of myalgia did not differ significantly between the two groups : 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group , and severe myalgia was reported by five patients and three patients , respectively ( not significant ) .
Diseases: myalgia"	"Sentence: Incidence and severity of myalgia did not differ significantly between the two groups : 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group , and severe myalgia was reported by five patients and three patients , respectively ( not significant ) .
Diseases:"
4299	At 48 h after surgery , 12 patients in both groups still suffered from myalgia ( not significant ) .	O O O O O O O O O O O O O O B O O O O O	O O O O O O O O O O O O O O O O O O O O	['myalgia']	1	2	"Sentence: At 48 h after surgery , 12 patients in both groups still suffered from myalgia ( not significant ) .
Diseases: myalgia"	"Sentence: At 48 h after surgery , 12 patients in both groups still suffered from myalgia ( not significant ) .
Diseases:"
4300	In addition , interleukin - 6 ( IL - 6 ) as an early marker of inflammation was assessed in a subgroup of 10 patients pretreated with saline .	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['inflammation']	1	2	"Sentence: In addition , interleukin - 6 ( IL - 6 ) as an early marker of inflammation was assessed in a subgroup of 10 patients pretreated with saline .
Diseases: inflammation"	"Sentence: In addition , interleukin - 6 ( IL - 6 ) as an early marker of inflammation was assessed in a subgroup of 10 patients pretreated with saline .
Diseases:"
4301	We found an increase of IL - 6 for only three patients , but only one patient reported myalgia ; no relationship between myalgia and the increase of IL - 6 was found .	O O O O O O O O O O O O O O O O O O B O O O O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['myalgia']	1	2	"Sentence: We found an increase of IL - 6 for only three patients , but only one patient reported myalgia ; no relationship between myalgia and the increase of IL - 6 was found .
Diseases: myalgia"	"Sentence: We found an increase of IL - 6 for only three patients , but only one patient reported myalgia ; no relationship between myalgia and the increase of IL - 6 was found .
Diseases:"
4302	In conclusion , there is no evidence for an inflammatory origin of succinylcholine - associated myalgia .	O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O B O O O O	['myalgia']	1	2	"Sentence: In conclusion , there is no evidence for an inflammatory origin of succinylcholine - associated myalgia .
Diseases: myalgia"	"Sentence: In conclusion , there is no evidence for an inflammatory origin of succinylcholine - associated myalgia .
Diseases:"
4303	IMPLICATIONS : Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine - induced postoperative myalgia .	O O O O O O O O O O O O O O O O O O O O O B I O	O O O O B O B O O O O O O O O O O O B O O O O O	['postoperative myalgia']	1	4	"Sentence: IMPLICATIONS : Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine - induced postoperative myalgia .
Diseases: postoperative myalgia"	"Sentence: IMPLICATIONS : Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine - induced postoperative myalgia .
Diseases:"
4304	Furthermore , there was no significant relationship between postoperative myalgia and time course of interleukin - 6 concentrations , a marker of inflammation .	O O O O O O O O B I O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O	['inflammation', 'postoperative myalgia']	2	7	"Sentence: Furthermore , there was no significant relationship between postoperative myalgia and time course of interleukin - 6 concentrations , a marker of inflammation .
Diseases: inflammation, postoperative myalgia"	"Sentence: Furthermore , there was no significant relationship between postoperative myalgia and time course of interleukin - 6 concentrations , a marker of inflammation .
Diseases:"
4305	Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine .	O O O O O O O O B I O O O	O O B O O O O O O O O B O	['postoperative myalgia']	1	4	"Sentence: Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine .
Diseases: postoperative myalgia"	"Sentence: Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine .
Diseases:"
4306	Levodopa - induced oromandibular dystonia in progressive supranuclear palsy .	O O O O B O B I I O	B O O O O O O O O O	['progressive supranuclear palsy', 'dystonia']	2	12	"Sentence: Levodopa - induced oromandibular dystonia in progressive supranuclear palsy .
Diseases: progressive supranuclear palsy, dystonia"	"Sentence: Levodopa - induced oromandibular dystonia in progressive supranuclear palsy .
Diseases:"
4307	Levodopa - induced dyskinesias have been reported in Parkinson 's disease and multiple system atrophy .	O O O B O O O O B I I O B I I O	B O O O O O O O O O O O O O O O	"['dyskinesias', 'multiple system atrophy', ""parkinson 's disease""]"	3	16	"Sentence: Levodopa - induced dyskinesias have been reported in Parkinson 's disease and multiple system atrophy .
Diseases: dyskinesias, multiple system atrophy, parkinson 's disease"	"Sentence: Levodopa - induced dyskinesias have been reported in Parkinson 's disease and multiple system atrophy .
Diseases:"
4308	Cranial dystonias are rare in patients with progressive supranuclear palsy ( PSP ) .	O B O O O O O B I I O B O O	O O O O O O O O O O O O O O	['psp', 'progressive supranuclear palsy', 'dystonias']	3	14	"Sentence: Cranial dystonias are rare in patients with progressive supranuclear palsy ( PSP ) .
Diseases: psp, progressive supranuclear palsy, dystonias"	"Sentence: Cranial dystonias are rare in patients with progressive supranuclear palsy ( PSP ) .
Diseases:"
4309	In this report we describe an unusual case of reversible levodopa - induced Oromandibular dystonia ( OMD ) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP , and discuss the possible underlying pathophysiology .	O O O O O O O O O O O O O B I O B O O O B O O O O O O O O O O O O O O O B O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['psp', 'omd', 'oromandibular dystonia']	3	14	"Sentence: In this report we describe an unusual case of reversible levodopa - induced Oromandibular dystonia ( OMD ) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP , and discuss the possible underlying pathophysiology .
Diseases: psp, omd, oromandibular dystonia"	"Sentence: In this report we describe an unusual case of reversible levodopa - induced Oromandibular dystonia ( OMD ) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP , and discuss the possible underlying pathophysiology .
Diseases:"
4310	Protective effect of edaravone against streptomycin - induced vestibulotoxicity in the guinea pig .	O O O O O O O O B O O O O O	O O O B O B O O O O O O O O	['vestibulotoxicity']	1	5	"Sentence: Protective effect of edaravone against streptomycin - induced vestibulotoxicity in the guinea pig .
Diseases: vestibulotoxicity"	"Sentence: Protective effect of edaravone against streptomycin - induced vestibulotoxicity in the guinea pig .
Diseases:"
4311	This study investigated alleviation of streptomycin - induced vestibulotoxicity by edaravone in guinea pigs .	O O O O O O O O B O O O O O O	O O O O O B O O O O B O O O O	['vestibulotoxicity']	1	5	"Sentence: This study investigated alleviation of streptomycin - induced vestibulotoxicity by edaravone in guinea pigs .
Diseases: vestibulotoxicity"	"Sentence: This study investigated alleviation of streptomycin - induced vestibulotoxicity by edaravone in guinea pigs .
Diseases:"
4312	Edaravone , a free radical scavenger , has potent free radical quenching action and is used in clinical practice to treat cerebral infarction .	O O O O O O O O O O O O O O O O O O O O O B I O	B O O O O O O O O O O O O O O O O O O O O O O O	['cerebral infarction']	1	6	"Sentence: Edaravone , a free radical scavenger , has potent free radical quenching action and is used in clinical practice to treat cerebral infarction .
Diseases: cerebral infarction"	"Sentence: Edaravone , a free radical scavenger , has potent free radical quenching action and is used in clinical practice to treat cerebral infarction .
Diseases:"
4313	Streptomycin was administered to the inner ear by osmotic pump for 24 h , and edaravone ( n = 8 ) or saline ( n = 6 ) was intraperitoneally injected once a day for 7 days .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Streptomycin was administered to the inner ear by osmotic pump for 24 h , and edaravone ( n = 8 ) or saline ( n = 6 ) was intraperitoneally injected once a day for 7 days .
Diseases: "	"Sentence: Streptomycin was administered to the inner ear by osmotic pump for 24 h , and edaravone ( n = 8 ) or saline ( n = 6 ) was intraperitoneally injected once a day for 7 days .
Diseases:"
4314	We observed horizontal vestibulo - ocular reflex as a marker of postoperative vestibular function .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: We observed horizontal vestibulo - ocular reflex as a marker of postoperative vestibular function .
Diseases: "	"Sentence: We observed horizontal vestibulo - ocular reflex as a marker of postoperative vestibular function .
Diseases:"
4315	Animals injected with saline showed statistically smaller gains than those injected with edaravone .	O O O O O O O O O O O O O O	O O O O O O O O O O O O B O	[]	0	0	"Sentence: Animals injected with saline showed statistically smaller gains than those injected with edaravone .
Diseases: "	"Sentence: Animals injected with saline showed statistically smaller gains than those injected with edaravone .
Diseases:"
4316	These results suggest that edaravone suppresses streptomycin - induced vestibulotoxicity .	O O O O O O O O O B O	O O O O B O B O O O O	['vestibulotoxicity']	1	5	"Sentence: These results suggest that edaravone suppresses streptomycin - induced vestibulotoxicity .
Diseases: vestibulotoxicity"	"Sentence: These results suggest that edaravone suppresses streptomycin - induced vestibulotoxicity .
Diseases:"
4317	Ketamine in war / tropical surgery ( a final tribute to the racemic mixture ) .	O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Ketamine in war / tropical surgery ( a final tribute to the racemic mixture ) .
Diseases: "	"Sentence: Ketamine in war / tropical surgery ( a final tribute to the racemic mixture ) .
Diseases:"
4318	A technique of continuous intravenous anaesthesia with ketamine was used successfully during the Somalia civil war in 1994 and in north Uganda in 1999 for 64 operations in 62 patients , aged from 6 weeks to 70 years , undergoing limb and abdominal surgery including caesarian sections and interventions in neonates .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A technique of continuous intravenous anaesthesia with ketamine was used successfully during the Somalia civil war in 1994 and in north Uganda in 1999 for 64 operations in 62 patients , aged from 6 weeks to 70 years , undergoing limb and abdominal surgery including caesarian sections and interventions in neonates .
Diseases: "	"Sentence: A technique of continuous intravenous anaesthesia with ketamine was used successfully during the Somalia civil war in 1994 and in north Uganda in 1999 for 64 operations in 62 patients , aged from 6 weeks to 70 years , undergoing limb and abdominal surgery including caesarian sections and interventions in neonates .
Diseases:"
4319	Operations lasting up to 2h could be performed in the absence of sophisticated equipment such as pulse oximeters or ventilators in patients on spontaneous ventilation breathing air / oxygen only .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Operations lasting up to 2h could be performed in the absence of sophisticated equipment such as pulse oximeters or ventilators in patients on spontaneous ventilation breathing air / oxygen only .
Diseases: "	"Sentence: Operations lasting up to 2h could be performed in the absence of sophisticated equipment such as pulse oximeters or ventilators in patients on spontaneous ventilation breathing air / oxygen only .
Diseases:"
4320	After premedication with diazepam , glycopyrrolate and local anaesthesia , and induction with standard doses of ketamine , a maintenance dose of 10 - 20 microg / kg / min of ketamine proved safe and effective .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O B O O O O O O O O O O B O O O O O O O O O O O O O O B O O O O O	[]	0	0	"Sentence: After premedication with diazepam , glycopyrrolate and local anaesthesia , and induction with standard doses of ketamine , a maintenance dose of 10 - 20 microg / kg / min of ketamine proved safe and effective .
Diseases: "	"Sentence: After premedication with diazepam , glycopyrrolate and local anaesthesia , and induction with standard doses of ketamine , a maintenance dose of 10 - 20 microg / kg / min of ketamine proved safe and effective .
Diseases:"
4321	Emphasis was placed on bedside clinical monitoring , relying heavily on the heart rate .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Emphasis was placed on bedside clinical monitoring , relying heavily on the heart rate .
Diseases: "	"Sentence: Emphasis was placed on bedside clinical monitoring , relying heavily on the heart rate .
Diseases:"
4322	Diazepam , unless contraindicated or risky , remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	B O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	['hallucinations']	1	3	"Sentence: Diazepam , unless contraindicated or risky , remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations .
Diseases: hallucinations"	"Sentence: Diazepam , unless contraindicated or risky , remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations .
Diseases:"
4323	Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia .	O O O O O O O O O O O B O	O O O O O O O O O O O O O	['analgesia']	1	4	"Sentence: Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia .
Diseases: analgesia"	"Sentence: Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia .
Diseases:"
4324	An antisialogue was usually unnecessary in operations lasting up to 2 h , glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects , especially in a hot climate .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: An antisialogue was usually unnecessary in operations lasting up to 2 h , glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects , especially in a hot climate .
Diseases: "	"Sentence: An antisialogue was usually unnecessary in operations lasting up to 2 h , glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects , especially in a hot climate .
Diseases:"
4325	Experience in war / tropical settings suggests this technique could be useful in civilian contexts such as outdoor life - saving emergency surgery or in mass casualties where , e . g . amputation and rapid extrication were required .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Experience in war / tropical settings suggests this technique could be useful in civilian contexts such as outdoor life - saving emergency surgery or in mass casualties where , e . g . amputation and rapid extrication were required .
Diseases: "	"Sentence: Experience in war / tropical settings suggests this technique could be useful in civilian contexts such as outdoor life - saving emergency surgery or in mass casualties where , e . g . amputation and rapid extrication were required .
Diseases:"
4326	Steroid structure and pharmacological properties determine the anti - amnesic effects of pregnenolone sulphate in the passive avoidance task in rats .	O O O O O O O O O B O O O O O O O O O O O O	B O O O O O O O O O O O B I O O O O O O O O	['amnesic']	1	3	"Sentence: Steroid structure and pharmacological properties determine the anti - amnesic effects of pregnenolone sulphate in the passive avoidance task in rats .
Diseases: amnesic"	"Sentence: Steroid structure and pharmacological properties determine the anti - amnesic effects of pregnenolone sulphate in the passive avoidance task in rats .
Diseases:"
4327	Pregnenolone sulphate ( PREGS ) has generated interest as one of the most potent memory - enhancing neurosteroids to be examined in rodent learning studies , with particular importance in the ageing process .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B I O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Pregnenolone sulphate ( PREGS ) has generated interest as one of the most potent memory - enhancing neurosteroids to be examined in rodent learning studies , with particular importance in the ageing process .
Diseases: "	"Sentence: Pregnenolone sulphate ( PREGS ) has generated interest as one of the most potent memory - enhancing neurosteroids to be examined in rodent learning studies , with particular importance in the ageing process .
Diseases:"
4328	The mechanism by which this endogenous steroid enhances memory formation is hypothesized to involve actions on glutamatergic and GABAergic systems .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: The mechanism by which this endogenous steroid enhances memory formation is hypothesized to involve actions on glutamatergic and GABAergic systems .
Diseases: "	"Sentence: The mechanism by which this endogenous steroid enhances memory formation is hypothesized to involve actions on glutamatergic and GABAergic systems .
Diseases:"
4329	This hypothesis stems from findings that PREGS is a potent positive modulator of N - methyl - d - aspartate receptors ( NMDARs ) and a negative modulator of gamma - aminobutyric acid ( A ) receptors ( GABA ( A ) Rs ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O B I I I I I I O O O O O O O O O B I I I O O O O O B O O O O O O	[]	0	0	"Sentence: This hypothesis stems from findings that PREGS is a potent positive modulator of N - methyl - d - aspartate receptors ( NMDARs ) and a negative modulator of gamma - aminobutyric acid ( A ) receptors ( GABA ( A ) Rs ) .
Diseases: "	"Sentence: This hypothesis stems from findings that PREGS is a potent positive modulator of N - methyl - d - aspartate receptors ( NMDARs ) and a negative modulator of gamma - aminobutyric acid ( A ) receptors ( GABA ( A ) Rs ) .
Diseases:"
4330	Moreover , PREGS is able to reverse the amnesic - like effects of NMDAR and GABA ( A ) R ligands .	O O O O O O O O B O O O O O O O O O O O O O	O O B O O O O O O O O O O O O B O O O O O O	['amnesic']	1	3	"Sentence: Moreover , PREGS is able to reverse the amnesic - like effects of NMDAR and GABA ( A ) R ligands .
Diseases: amnesic"	"Sentence: Moreover , PREGS is able to reverse the amnesic - like effects of NMDAR and GABA ( A ) R ligands .
Diseases:"
4331	To investigate this hypothesis , the present study in rats examined the memory - altering abilities of structural analogs of PREGS , which differ in their modulation of NMDAR and / or GABA ( A ) R function .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O B O O O O O O	[]	0	0	"Sentence: To investigate this hypothesis , the present study in rats examined the memory - altering abilities of structural analogs of PREGS , which differ in their modulation of NMDAR and / or GABA ( A ) R function .
Diseases: "	"Sentence: To investigate this hypothesis , the present study in rats examined the memory - altering abilities of structural analogs of PREGS , which differ in their modulation of NMDAR and / or GABA ( A ) R function .
Diseases:"
4332	The analogs tested were : 11 - ketopregnenolone sulphate ( an agent that is inactive at GABA ( A ) Rs and NMDARs ) , epipregnanolone ( [ 3beta - hydroxy - 5beta - pregnan - 20 - one ] sulphate , an inhibitor of both GABA ( A ) Rs and NMDARs ) , and a newly synthesized ( - ) PREGS enantiomer ( which is identical to PREGS in effects on GABA ( A ) Rs and NMDARs ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B I I I O O O O O O O B O O O O O O O O B O B B I I I I I I I I I I I I O O O O O B O O O O O O O O O O O O O O O B O O O O O O B O O O B O O O O O O O O	[]	0	0	"Sentence: The analogs tested were : 11 - ketopregnenolone sulphate ( an agent that is inactive at GABA ( A ) Rs and NMDARs ) , epipregnanolone ( [ 3beta - hydroxy - 5beta - pregnan - 20 - one ] sulphate , an inhibitor of both GABA ( A ) Rs and NMDARs ) , and a newly synthesized ( - ) PREGS enantiomer ( which is identical to PREGS in effects on GABA ( A ) Rs and NMDARs ) .
Diseases: "	"Sentence: The analogs tested were : 11 - ketopregnenolone sulphate ( an agent that is inactive at GABA ( A ) Rs and NMDARs ) , epipregnanolone ( [ 3beta - hydroxy - 5beta - pregnan - 20 - one ] sulphate , an inhibitor of both GABA ( A ) Rs and NMDARs ) , and a newly synthesized ( - ) PREGS enantiomer ( which is identical to PREGS in effects on GABA ( A ) Rs and NMDARs ) .
Diseases:"
4333	The memory - enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine - induced amnesia .	O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O B O O O O O O O O O O O O O O B O O O O	['amnesia']	1	2	"Sentence: The memory - enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine - induced amnesia .
Diseases: amnesia"	"Sentence: The memory - enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine - induced amnesia .
Diseases:"
4334	Both PREGS and its ( - ) enantiomer blocked the effects of scopolamine .	O O O O O O O O O O O O O O	O B O O O O O O O O O O B O	[]	0	0	"Sentence: Both PREGS and its ( - ) enantiomer blocked the effects of scopolamine .
Diseases: "	"Sentence: Both PREGS and its ( - ) enantiomer blocked the effects of scopolamine .
Diseases:"
4335	The results show that , unlike PREGS , 11 - ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine , suggesting that altering the modulation of NMDA receptors diminishes the memory - enhancing effects of PREGS .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O B I I I O B I O O O O O O B O O O O O O O B O O O O O O O O B O	[]	0	0	"Sentence: The results show that , unlike PREGS , 11 - ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine , suggesting that altering the modulation of NMDA receptors diminishes the memory - enhancing effects of PREGS .
Diseases: "	"Sentence: The results show that , unlike PREGS , 11 - ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine , suggesting that altering the modulation of NMDA receptors diminishes the memory - enhancing effects of PREGS .
Diseases:"
4336	Moreover , enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine - induced amnesia .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O B O O O O O O O O O O O O O O B O O O O	['amnesia']	1	2	"Sentence: Moreover , enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine - induced amnesia .
Diseases: amnesia"	"Sentence: Moreover , enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine - induced amnesia .
Diseases:"
4337	These results identify a novel neuropharmacological site for the modulation of memory processes by neuroactive steroids .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: These results identify a novel neuropharmacological site for the modulation of memory processes by neuroactive steroids .
Diseases: "	"Sentence: These results identify a novel neuropharmacological site for the modulation of memory processes by neuroactive steroids .
Diseases:"
4338	Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans .	O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O	[]	0	0	"Sentence: Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans .
Diseases: "	"Sentence: Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans .
Diseases:"
4339	Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans , and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation .	O O O O O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	['hypersensitivity', 'acute and chronic pain']	2	8	"Sentence: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans , and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation .
Diseases: hypersensitivity, acute and chronic pain"	"Sentence: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans , and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation .
Diseases:"
4340	The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US , using both acute noxious stimulation and capsaicin - evoked mechanical hypersensitivity .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O B O O O O O O O O O O O B O O O O O	['hypersensitivity']	1	3	"Sentence: The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US , using both acute noxious stimulation and capsaicin - evoked mechanical hypersensitivity .
Diseases: hypersensitivity"	"Sentence: The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US , using both acute noxious stimulation and capsaicin - evoked mechanical hypersensitivity .
Diseases:"
4341	METHODS : Following Food and Drug Administration and institutional review board approval and written informed consent , 65 volunteers were studied in two trials : an open - label , dose - escalating trial with intrathecal adenosine doses of 0 . 25 - 2 . 0 mg and a double - blind , placebo - controlled trial of adenosine , 2 mg .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: METHODS : Following Food and Drug Administration and institutional review board approval and written informed consent , 65 volunteers were studied in two trials : an open - label , dose - escalating trial with intrathecal adenosine doses of 0 . 25 - 2 . 0 mg and a double - blind , placebo - controlled trial of adenosine , 2 mg .
Diseases: "	"Sentence: METHODS : Following Food and Drug Administration and institutional review board approval and written informed consent , 65 volunteers were studied in two trials : an open - label , dose - escalating trial with intrathecal adenosine doses of 0 . 25 - 2 . 0 mg and a double - blind , placebo - controlled trial of adenosine , 2 mg .
Diseases:"
4342	Cerebrospinal fluid was obtained for pharmacokinetic analysis , and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined .	O O O O O O O O O B O O O O O O O O O O B I O B O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['mechanical hyperalgesia', 'pain', 'allodynia']	3	13	"Sentence: Cerebrospinal fluid was obtained for pharmacokinetic analysis , and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined .
Diseases: mechanical hyperalgesia, pain, allodynia"	"Sentence: Cerebrospinal fluid was obtained for pharmacokinetic analysis , and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined .
Diseases:"
4343	Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h .	O O O O O B O O O O O O O O O O B I O B O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	['mechanical hyperalgesia', 'pain', 'allodynia']	3	13	"Sentence: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h .
Diseases: mechanical hyperalgesia, pain, allodynia"	"Sentence: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h .
Diseases:"
4344	In contrast , residence time of adenosine in cerebrospinal fluid was short ( < 4 h ) .	O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: In contrast , residence time of adenosine in cerebrospinal fluid was short ( < 4 h ) .
Diseases: "	"Sentence: In contrast , residence time of adenosine in cerebrospinal fluid was short ( < 4 h ) .
Diseases:"
4345	CONCLUSIONS : These results show selective inhibition by intrathecal adenosine of hypersensitivity , presumed to reflect central sensitization in humans after peripheral capsaicin injection .	O O O O O O O O O O O B O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O B O O	['hypersensitivity']	1	3	"Sentence: CONCLUSIONS : These results show selective inhibition by intrathecal adenosine of hypersensitivity , presumed to reflect central sensitization in humans after peripheral capsaicin injection .
Diseases: hypersensitivity"	"Sentence: CONCLUSIONS : These results show selective inhibition by intrathecal adenosine of hypersensitivity , presumed to reflect central sensitization in humans after peripheral capsaicin injection .
Diseases:"
4346	The long - lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid .	O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['neuropathic pain']	1	4	"Sentence: The long - lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid .
Diseases: neuropathic pain"	"Sentence: The long - lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid .
Diseases:"
4347	Effect of lithium maintenance therapy on thyroid and parathyroid function .	O O O O O O O O O O O	O O B O O O O O O O O	[]	0	0	"Sentence: Effect of lithium maintenance therapy on thyroid and parathyroid function .
Diseases: "	"Sentence: Effect of lithium maintenance therapy on thyroid and parathyroid function .
Diseases:"
4348	To assess changes induced by lithium maintenance therapy on the incidence of thyroid , parathyroid and ion alterations .	O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: To assess changes induced by lithium maintenance therapy on the incidence of thyroid , parathyroid and ion alterations .
Diseases: "	"Sentence: To assess changes induced by lithium maintenance therapy on the incidence of thyroid , parathyroid and ion alterations .
Diseases:"
4349	These were evaluated with respect to the duration of lithium therapy , age , sex , and family history ( whether or not the patient had a first - degree relative with thyroid disease ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['thyroid disease']	1	3	"Sentence: These were evaluated with respect to the duration of lithium therapy , age , sex , and family history ( whether or not the patient had a first - degree relative with thyroid disease ) .
Diseases: thyroid disease"	"Sentence: These were evaluated with respect to the duration of lithium therapy , age , sex , and family history ( whether or not the patient had a first - degree relative with thyroid disease ) .
Diseases:"
4350	DESIGN : Prospective study .	O O O O O	O O O O O	[]	0	0	"Sentence: DESIGN : Prospective study .
Diseases: "	"Sentence: DESIGN : Prospective study .
Diseases:"
4351	SETTING : Affective Disorders Clinic at St . Mary 's Hospital , Montreal .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: SETTING : Affective Disorders Clinic at St . Mary 's Hospital , Montreal .
Diseases: "	"Sentence: SETTING : Affective Disorders Clinic at St . Mary 's Hospital , Montreal .
Diseases:"
4352	PATIENTS : One hundred and one patients ( 28 men and 73 women ) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year 's to 32 years ' duration .	O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O	['bipolar disorder']	1	3	"Sentence: PATIENTS : One hundred and one patients ( 28 men and 73 women ) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year 's to 32 years ' duration .
Diseases: bipolar disorder"	"Sentence: PATIENTS : One hundred and one patients ( 28 men and 73 women ) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year 's to 32 years ' duration .
Diseases:"
4353	The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital 's out - patient clinics .	O O O O O O O O O B O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	['psychiatric']	1	2	"Sentence: The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital 's out - patient clinics .
Diseases: psychiatric"	"Sentence: The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital 's out - patient clinics .
Diseases:"
4354	OUTCOME MEASURES : Laboratory analyses of calcium , magnesium and thyroid - stimulating hormone levels performed before beginning lithium therapy and at biannual follow - up .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O B O O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: OUTCOME MEASURES : Laboratory analyses of calcium , magnesium and thyroid - stimulating hormone levels performed before beginning lithium therapy and at biannual follow - up .
Diseases: "	"Sentence: OUTCOME MEASURES : Laboratory analyses of calcium , magnesium and thyroid - stimulating hormone levels performed before beginning lithium therapy and at biannual follow - up .
Diseases:"
4355	RESULTS : Hypothyroidism developed in 40 patients , excluding 8 patients who were hypothyroid at baseline .	O O B O O O O O O O O O O B O O O	O O O O O O O O O O O O O O O O O	['hypothyroid', 'hypothyroidism']	2	8	"Sentence: RESULTS : Hypothyroidism developed in 40 patients , excluding 8 patients who were hypothyroid at baseline .
Diseases: hypothyroid, hypothyroidism"	"Sentence: RESULTS : Hypothyroidism developed in 40 patients , excluding 8 patients who were hypothyroid at baseline .
Diseases:"
4356	All patients having first - degree relatives affected by thyroid illness had accelerated onset of hypothyroidism ( 3 . 7 years after onset of lithium therapy ) compared with patients without a family history ( 8 . 6 years after onset of lithium therapy ) .	O O O O O O O O O B I O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O B O O O	['thyroid illness', 'hypothyroidism']	2	8	"Sentence: All patients having first - degree relatives affected by thyroid illness had accelerated onset of hypothyroidism ( 3 . 7 years after onset of lithium therapy ) compared with patients without a family history ( 8 . 6 years after onset of lithium therapy ) .
Diseases: thyroid illness, hypothyroidism"	"Sentence: All patients having first - degree relatives affected by thyroid illness had accelerated onset of hypothyroidism ( 3 . 7 years after onset of lithium therapy ) compared with patients without a family history ( 8 . 6 years after onset of lithium therapy ) .
Diseases:"
4357	Women over 60 years of age were more often affected by hypothyroidism than women under 60 years of age ( 34 . 6 % versus 31 . 9 % ) .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypothyroidism']	1	4	"Sentence: Women over 60 years of age were more often affected by hypothyroidism than women under 60 years of age ( 34 . 6 % versus 31 . 9 % ) .
Diseases: hypothyroidism"	"Sentence: Women over 60 years of age were more often affected by hypothyroidism than women under 60 years of age ( 34 . 6 % versus 31 . 9 % ) .
Diseases:"
4358	Magnesium levels in patients on lithium treatment were unchanged from baseline levels .	O O O O O O O O O O O O O	B O O O O B O O O O O O O	[]	0	0	"Sentence: Magnesium levels in patients on lithium treatment were unchanged from baseline levels .
Diseases: "	"Sentence: Magnesium levels in patients on lithium treatment were unchanged from baseline levels .
Diseases:"
4359	After lithium treatment , calcium levels were higher than either baseline levels or control levels .	O O O O O O O O O O O O O O O O	O B O O B O O O O O O O O O O O	[]	0	0	"Sentence: After lithium treatment , calcium levels were higher than either baseline levels or control levels .
Diseases: "	"Sentence: After lithium treatment , calcium levels were higher than either baseline levels or control levels .
Diseases:"
4360	Thus , lithium treatment counteracted the decrease in plasma calcium levels associated with aging .	O O O O O O O O O O O O O O O	O O B O O O O O O B O O O O O	[]	0	0	"Sentence: Thus , lithium treatment counteracted the decrease in plasma calcium levels associated with aging .
Diseases: "	"Sentence: Thus , lithium treatment counteracted the decrease in plasma calcium levels associated with aging .
Diseases:"
4361	Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy .	O B I O O O O O B O B O O O O	O O O O O O O O O O O O B O O	['thyroid illness', 'hypothyroidism', 'hypercalcemia']	3	13	"Sentence: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy .
Diseases: thyroid illness, hypothyroidism, hypercalcemia"	"Sentence: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy .
Diseases:"
4362	Systemic toxicity following administration of sirolimus ( formerly rapamycin ) for psoriasis : association of capillary leak syndrome with apoptosis of lesional lymphocytes .	O B O O O O O O O O O B O O O B I I O O O O O O	O O O O O B O O B O O O O O O O O O O O O O O O	['psoriasis', 'capillary leak syndrome', 'toxicity']	3	11	"Sentence: Systemic toxicity following administration of sirolimus ( formerly rapamycin ) for psoriasis : association of capillary leak syndrome with apoptosis of lesional lymphocytes .
Diseases: psoriasis, capillary leak syndrome, toxicity"	"Sentence: Systemic toxicity following administration of sirolimus ( formerly rapamycin ) for psoriasis : association of capillary leak syndrome with apoptosis of lesional lymphocytes .
Diseases:"
4363	BACKGROUND : Sirolimus ( formerly rapamycin ) is an immunosuppressive agent that interferes with T - cell activation .	O O O O O O O O O O O O O O O O O O O	O O B O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: BACKGROUND : Sirolimus ( formerly rapamycin ) is an immunosuppressive agent that interferes with T - cell activation .
Diseases: "	"Sentence: BACKGROUND : Sirolimus ( formerly rapamycin ) is an immunosuppressive agent that interferes with T - cell activation .
Diseases:"
4364	After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis .	O O O O B O O B I I O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	['capillary leak syndrome', 'psoriasis']	2	8	"Sentence: After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis .
Diseases: capillary leak syndrome, psoriasis"	"Sentence: After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis .
Diseases:"
4365	OBSERVATIONS :	O O	O O	[]	0	0	"Sentence: OBSERVATIONS :
Diseases: "	"Sentence: OBSERVATIONS :
Diseases:"
4366	A keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2 . 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ) .	O O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	['psoriasis', 'capillary leak syndrome']	2	8	"Sentence: A keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2 . 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ) .
Diseases: psoriasis, capillary leak syndrome"	"Sentence: A keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2 . 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ) .
Diseases:"
4367	Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone - induced apoptosis than did normal T cells , particularly in the presence of sirolimus .	O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O B O	['psoriasis']	1	3	"Sentence: Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone - induced apoptosis than did normal T cells , particularly in the presence of sirolimus .
Diseases: psoriasis"	"Sentence: Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone - induced apoptosis than did normal T cells , particularly in the presence of sirolimus .
Diseases:"
4368	CONCLUSIONS : Severe adverse effects of sirolimus include fever , anemia , and capillary leak syndrome .	O O O O O O O O B O B O O B I I O	O O O O O O B O O O O O O O O O O	['anemia', 'fever', 'capillary leak syndrome']	3	9	"Sentence: CONCLUSIONS : Severe adverse effects of sirolimus include fever , anemia , and capillary leak syndrome .
Diseases: anemia, fever, capillary leak syndrome"	"Sentence: CONCLUSIONS : Severe adverse effects of sirolimus include fever , anemia , and capillary leak syndrome .
Diseases:"
4369	These symptoms may be the result of drug - induced apoptosis of lesional leukocytes , especially activated T lymphocytes , and possibly release of inflammatory mediators .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: These symptoms may be the result of drug - induced apoptosis of lesional leukocytes , especially activated T lymphocytes , and possibly release of inflammatory mediators .
Diseases: "	"Sentence: These symptoms may be the result of drug - induced apoptosis of lesional leukocytes , especially activated T lymphocytes , and possibly release of inflammatory mediators .
Diseases:"
4370	Because patients with severe psoriasis may develop capillary leak from various systemic therapies , clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators .	O O O O B O O B I O O O O O O O O O O O O B I O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['inflammatory diseases', 'capillary leak', 'psoriasis']	3	10	"Sentence: Because patients with severe psoriasis may develop capillary leak from various systemic therapies , clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators .
Diseases: inflammatory diseases, capillary leak, psoriasis"	"Sentence: Because patients with severe psoriasis may develop capillary leak from various systemic therapies , clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators .
Diseases:"
4371	Contribution of the glycine site of NMDA receptors in rostral and intermediate - caudal parts of the striatum to the regulation of muscle tone in rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Contribution of the glycine site of NMDA receptors in rostral and intermediate - caudal parts of the striatum to the regulation of muscle tone in rats .
Diseases: "	"Sentence: Contribution of the glycine site of NMDA receptors in rostral and intermediate - caudal parts of the striatum to the regulation of muscle tone in rats .
Diseases:"
4372	The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O B O O O O O O O O O O O	[]	0	0	"Sentence: The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone .
Diseases: "	"Sentence: The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone .
Diseases:"
4373	Muscle tone was examined using a combined mechanoand electromyographic method , which measured simultaneously the muscle resistance ( MMG ) of the rat 's hind foot to passive extension and flexion in the ankle joint and the electromyographic activity ( EMG ) of the antagonistic muscles of that joint : gastrocnemius and tibialis anterior .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Muscle tone was examined using a combined mechanoand electromyographic method , which measured simultaneously the muscle resistance ( MMG ) of the rat 's hind foot to passive extension and flexion in the ankle joint and the electromyographic activity ( EMG ) of the antagonistic muscles of that joint : gastrocnemius and tibialis anterior .
Diseases: "	"Sentence: Muscle tone was examined using a combined mechanoand electromyographic method , which measured simultaneously the muscle resistance ( MMG ) of the rat 's hind foot to passive extension and flexion in the ankle joint and the electromyographic activity ( EMG ) of the antagonistic muscles of that joint : gastrocnemius and tibialis anterior .
Diseases:"
4374	Muscle rigidity was induced by haloperidol ( 2 . 5 mg / kg i . p . ) .	B I O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O	['muscle rigidity']	1	4	"Sentence: Muscle rigidity was induced by haloperidol ( 2 . 5 mg / kg i . p . ) .
Diseases: muscle rigidity"	"Sentence: Muscle rigidity was induced by haloperidol ( 2 . 5 mg / kg i . p . ) .
Diseases:"
4375	5 , 7 - dichlorokynurenic acid ( 5 , 7 - DCKA ) , a selective glycine site antagonist , injected in doses of 2 . 5 and 4 . 5 microg / 0 . 5 microl bilaterally , into the rostral region of the striatum , decreased both the haloperidol - induced muscle rigidity ( MMG ) and the enhanced electromyographic activity ( EMG ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O	B I I I I I O B I I I I O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O	['muscle rigidity']	1	4	"Sentence: 5 , 7 - dichlorokynurenic acid ( 5 , 7 - DCKA ) , a selective glycine site antagonist , injected in doses of 2 . 5 and 4 . 5 microg / 0 . 5 microl bilaterally , into the rostral region of the striatum , decreased both the haloperidol - induced muscle rigidity ( MMG ) and the enhanced electromyographic activity ( EMG ) .
Diseases: muscle rigidity"	"Sentence: 5 , 7 - dichlorokynurenic acid ( 5 , 7 - DCKA ) , a selective glycine site antagonist , injected in doses of 2 . 5 and 4 . 5 microg / 0 . 5 microl bilaterally , into the rostral region of the striatum , decreased both the haloperidol - induced muscle rigidity ( MMG ) and the enhanced electromyographic activity ( EMG ) .
Diseases:"
4376	5 , 7 - DCKA injected bilaterally in a dose of 4 . 5 microg / 0 . 5 microl into the intermediate - caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B I I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: 5 , 7 - DCKA injected bilaterally in a dose of 4 . 5 microg / 0 . 5 microl into the intermediate - caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone .
Diseases: "	"Sentence: 5 , 7 - DCKA injected bilaterally in a dose of 4 . 5 microg / 0 . 5 microl into the intermediate - caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone .
Diseases:"
4377	The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug .
Diseases: "	"Sentence: The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug .
Diseases:"
4378	Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia .	O O O O O O O O O O B O	O O O O B O O O O O O O	['hypercholesterolemia']	1	5	"Sentence: Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia .
Diseases: hypercholesterolemia"	"Sentence: Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia .
Diseases:"
4379	To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia .	O O O O O O O O O O O O B O	O O O O O O O B O O O O O O	['hypercholesterolemia']	1	5	"Sentence: To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia .
Diseases: hypercholesterolemia"	"Sentence: To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia .
Diseases:"
4380	DESIGN : The Expanded Clinical Evaluation of Lovastatin ( EXCEL ) Study , a multicenter , double - blind , diet - and placebo - controlled trial , in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily , or 20 or 40 mg twice daily for 48 weeks .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: DESIGN : The Expanded Clinical Evaluation of Lovastatin ( EXCEL ) Study , a multicenter , double - blind , diet - and placebo - controlled trial , in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily , or 20 or 40 mg twice daily for 48 weeks .
Diseases: "	"Sentence: DESIGN : The Expanded Clinical Evaluation of Lovastatin ( EXCEL ) Study , a multicenter , double - blind , diet - and placebo - controlled trial , in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily , or 20 or 40 mg twice daily for 48 weeks .
Diseases:"
4381	SETTING : Ambulatory patients recruited by 362 participating centers throughout the United States .	O O O O O O O O O O O O O O	O O O O O O O O O O O O O O	[]	0	0	"Sentence: SETTING : Ambulatory patients recruited by 362 participating centers throughout the United States .
Diseases: "	"Sentence: SETTING : Ambulatory patients recruited by 362 participating centers throughout the United States .
Diseases:"
4382	PATIENTS : Women ( n = 3390 ) from the total cohort of 8245 volunteers .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: PATIENTS : Women ( n = 3390 ) from the total cohort of 8245 volunteers .
Diseases: "	"Sentence: PATIENTS : Women ( n = 3390 ) from the total cohort of 8245 volunteers .
Diseases:"
4383	MEASUREMENTS :	O O	O O	[]	0	0	"Sentence: MEASUREMENTS :
Diseases: "	"Sentence: MEASUREMENTS :
Diseases:"
4384	Plasma total , low - density lipoprotein ( LDL ) , and high - density lipoprotein ( HDL ) cholesterol , and triglycerides ; and laboratory and clinical evidence of adverse events monitored periodically throughout the study .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Plasma total , low - density lipoprotein ( LDL ) , and high - density lipoprotein ( HDL ) cholesterol , and triglycerides ; and laboratory and clinical evidence of adverse events monitored periodically throughout the study .
Diseases: "	"Sentence: Plasma total , low - density lipoprotein ( LDL ) , and high - density lipoprotein ( HDL ) cholesterol , and triglycerides ; and laboratory and clinical evidence of adverse events monitored periodically throughout the study .
Diseases:"
4385	Among women , lovastatin ( 20 to 80 mg / d ) produced sustained ( 12 - to 48 - week ) , dose - related changes ( P < 0 . 001 ) : decreases in LDL cholesterol ( 24 % to 40 % ) and triglycerides ( 9 % to 18 % ) , and increases in HDL cholesterol ( 6 . 7 % to 8 . 6 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: Among women , lovastatin ( 20 to 80 mg / d ) produced sustained ( 12 - to 48 - week ) , dose - related changes ( P < 0 . 001 ) : decreases in LDL cholesterol ( 24 % to 40 % ) and triglycerides ( 9 % to 18 % ) , and increases in HDL cholesterol ( 6 . 7 % to 8 . 6 % ) .
Diseases: "	"Sentence: Among women , lovastatin ( 20 to 80 mg / d ) produced sustained ( 12 - to 48 - week ) , dose - related changes ( P < 0 . 001 ) : decreases in LDL cholesterol ( 24 % to 40 % ) and triglycerides ( 9 % to 18 % ) , and increases in HDL cholesterol ( 6 . 7 % to 8 . 6 % ) .
Diseases:"
4386	Depending on the dose , from 82 % to 95 % of lovastatin - treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4 . 14 mmol / L ( 160 mg / dL ) , and 40 % to 87 % achieved the goal of 3 . 36 mmol / L ( 130 mg / dL ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O B O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Depending on the dose , from 82 % to 95 % of lovastatin - treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4 . 14 mmol / L ( 160 mg / dL ) , and 40 % to 87 % achieved the goal of 3 . 36 mmol / L ( 130 mg / dL ) .
Diseases: "	"Sentence: Depending on the dose , from 82 % to 95 % of lovastatin - treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4 . 14 mmol / L ( 160 mg / dL ) , and 40 % to 87 % achieved the goal of 3 . 36 mmol / L ( 130 mg / dL ) .
Diseases:"
4387	Successive transaminase elevations greater than three times the upper limit of normal occurred in 0 . 1 % of women and were dose dependent above the 20 - mg dose .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Successive transaminase elevations greater than three times the upper limit of normal occurred in 0 . 1 % of women and were dose dependent above the 20 - mg dose .
Diseases: "	"Sentence: Successive transaminase elevations greater than three times the upper limit of normal occurred in 0 . 1 % of women and were dose dependent above the 20 - mg dose .
Diseases:"
4388	Myopathy , defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal , was rare and associated with the highest recommended daily dose of lovastatin ( 80 mg ) .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	['myopathy']	1	2	"Sentence: Myopathy , defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal , was rare and associated with the highest recommended daily dose of lovastatin ( 80 mg ) .
Diseases: myopathy"	"Sentence: Myopathy , defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal , was rare and associated with the highest recommended daily dose of lovastatin ( 80 mg ) .
Diseases:"
4389	Estrogen - replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin .	O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: Estrogen - replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin .
Diseases: "	"Sentence: Estrogen - replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin .
Diseases:"
4390	Lovastatin is highly effective and generally well tolerated as therapy for primary hypercholesterolemia in women .	O O O O O O O O O O O O B O O O	B O O O O O O O O O O O O O O O	['hypercholesterolemia']	1	5	"Sentence: Lovastatin is highly effective and generally well tolerated as therapy for primary hypercholesterolemia in women .
Diseases: hypercholesterolemia"	"Sentence: Lovastatin is highly effective and generally well tolerated as therapy for primary hypercholesterolemia in women .
Diseases:"
4391	REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats .	B I I O O O O O O O O O O O O	O O O O O O O O O O O O O O O	['rem sleep deprivation']	1	3	"Sentence: REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats .
Diseases: rem sleep deprivation"	"Sentence: REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats .
Diseases:"
4392	The effects of REM sleep deprivation ( REMD ) on apomorphine - induced aggressiveness and quipazine - induced head twitches in rats were determined .	O O O B I I O B O O O O O B O O O O B I O O O O O	O O O O O O O O O O B O O O O B O O O O O O O O O	['remd', 'aggressiveness', 'head twitches', 'rem sleep deprivation']	4	13	"Sentence: The effects of REM sleep deprivation ( REMD ) on apomorphine - induced aggressiveness and quipazine - induced head twitches in rats were determined .
Diseases: remd, aggressiveness, head twitches, rem sleep deprivation"	"Sentence: The effects of REM sleep deprivation ( REMD ) on apomorphine - induced aggressiveness and quipazine - induced head twitches in rats were determined .
Diseases:"
4393	Forty - eight hr of REMD increased apomorphine - induced aggressiveness , and reduced ( immediately after completing of REMD ) or increased ( 96 hr after completing of REMD ) quipazine - induced head twitches .	O O O O O B O O O O B O O O O O O O O B O O O O O O O O O B O O O O B I O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	['remd', 'aggressiveness', 'head twitches']	3	9	"Sentence: Forty - eight hr of REMD increased apomorphine - induced aggressiveness , and reduced ( immediately after completing of REMD ) or increased ( 96 hr after completing of REMD ) quipazine - induced head twitches .
Diseases: remd, aggressiveness, head twitches"	"Sentence: Forty - eight hr of REMD increased apomorphine - induced aggressiveness , and reduced ( immediately after completing of REMD ) or increased ( 96 hr after completing of REMD ) quipazine - induced head twitches .
Diseases:"
4394	Results are discussed in terms of similarity to pharmacological effects of other antidepressive treatments .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Results are discussed in terms of similarity to pharmacological effects of other antidepressive treatments .
Diseases: "	"Sentence: Results are discussed in terms of similarity to pharmacological effects of other antidepressive treatments .
Diseases:"
4395	Extrapyramidal side effects and oral haloperidol : an analysis of explanatory patient and treatment characteristics .	O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: Extrapyramidal side effects and oral haloperidol : an analysis of explanatory patient and treatment characteristics .
Diseases: "	"Sentence: Extrapyramidal side effects and oral haloperidol : an analysis of explanatory patient and treatment characteristics .
Diseases:"
4396	The incidence of extrapyramidal side effects ( EPS ) was evaluated in 98 patients treated with haloperidol .	O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: The incidence of extrapyramidal side effects ( EPS ) was evaluated in 98 patients treated with haloperidol .
Diseases: "	"Sentence: The incidence of extrapyramidal side effects ( EPS ) was evaluated in 98 patients treated with haloperidol .
Diseases:"
4397	The incidence of parkinsonism was higher at higher doses of haloperidol and in younger patients .	O O O B O O O O O O O O O O O O	O O O O O O O O O O B O O O O O	['parkinsonism']	1	3	"Sentence: The incidence of parkinsonism was higher at higher doses of haloperidol and in younger patients .
Diseases: parkinsonism"	"Sentence: The incidence of parkinsonism was higher at higher doses of haloperidol and in younger patients .
Diseases:"
4398	Prophylactic antiparkinsonian medication was effective in younger but not in older patients .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Prophylactic antiparkinsonian medication was effective in younger but not in older patients .
Diseases: "	"Sentence: Prophylactic antiparkinsonian medication was effective in younger but not in older patients .
Diseases:"
4399	However , these medications were more effective in both young and old patients when given after parkinsonism developed .	O O O O O O O O O O O O O O O O B O O	O O O O O O O O O O O O O O O O O O O	['parkinsonism']	1	3	"Sentence: However , these medications were more effective in both young and old patients when given after parkinsonism developed .
Diseases: parkinsonism"	"Sentence: However , these medications were more effective in both young and old patients when given after parkinsonism developed .
Diseases:"
4400	Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients , while prophylactic antiparkinsonians were ineffective .	B O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O	['akathisia']	1	4	"Sentence: Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients , while prophylactic antiparkinsonians were ineffective .
Diseases: akathisia"	"Sentence: Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients , while prophylactic antiparkinsonians were ineffective .
Diseases:"
4401	The present study points to patient characteristics that may be of significance in the development of EPS due to haloperidol .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: The present study points to patient characteristics that may be of significance in the development of EPS due to haloperidol .
Diseases: "	"Sentence: The present study points to patient characteristics that may be of significance in the development of EPS due to haloperidol .
Diseases:"
4402	Hepatic veno - occlusive disease caused by 6 - thioguanine .	B I I I I O O O O O O	O O O O O O O B I I O	['hepatic veno - occlusive disease']	1	10	"Sentence: Hepatic veno - occlusive disease caused by 6 - thioguanine .
Diseases: hepatic veno - occlusive disease"	"Sentence: Hepatic veno - occlusive disease caused by 6 - thioguanine .
Diseases:"
4403	Clinically reversible veno - occlusive disease of the liver developed in a 23 - year - old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6 - thioguanine .	O O B I I I I I I O O O O O O O O O O B I I O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O	['veno - occlusive disease of the liver', 'acute lymphocytic leukemia']	2	16	"Sentence: Clinically reversible veno - occlusive disease of the liver developed in a 23 - year - old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6 - thioguanine .
Diseases: veno - occlusive disease of the liver, acute lymphocytic leukemia"	"Sentence: Clinically reversible veno - occlusive disease of the liver developed in a 23 - year - old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6 - thioguanine .
Diseases:"
4404	Serial liver biopsies showed the development and resolution of intense sinusoidal engorgement .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Serial liver biopsies showed the development and resolution of intense sinusoidal engorgement .
Diseases: "	"Sentence: Serial liver biopsies showed the development and resolution of intense sinusoidal engorgement .
Diseases:"
4405	Although this disease was clinically reversible , some subintimal fibrosis about the terminal hepatic veins persisted .	O O O O O O O O O B O O O O O O O	O O O O O O O O O O O O O O O O O	['fibrosis']	1	3	"Sentence: Although this disease was clinically reversible , some subintimal fibrosis about the terminal hepatic veins persisted .
Diseases: fibrosis"	"Sentence: Although this disease was clinically reversible , some subintimal fibrosis about the terminal hepatic veins persisted .
Diseases:"
4406	This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno - occlusive disease over time , and may be the first case of veno - occlusive related solely to 6 - thioguanine .	O O O O O O O O O O O O O O B I I I I O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O	['hepatic veno - occlusive disease']	1	10	"Sentence: This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno - occlusive disease over time , and may be the first case of veno - occlusive related solely to 6 - thioguanine .
Diseases: hepatic veno - occlusive disease"	"Sentence: This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno - occlusive disease over time , and may be the first case of veno - occlusive related solely to 6 - thioguanine .
Diseases:"
4407	Treatment of ifosfamide - induced urothelial toxicity by oral administration of sodium 2 - mercaptoethane sulphonate ( MESNA ) to patients with inoperable lung cancer .	O O O O O B I O O O O O O O O O O O O O O O O B I O	O O B O O O O O O O O B I I I I O B O O O O O O O O	['urothelial toxicity', 'lung cancer']	2	7	"Sentence: Treatment of ifosfamide - induced urothelial toxicity by oral administration of sodium 2 - mercaptoethane sulphonate ( MESNA ) to patients with inoperable lung cancer .
Diseases: urothelial toxicity, lung cancer"	"Sentence: Treatment of ifosfamide - induced urothelial toxicity by oral administration of sodium 2 - mercaptoethane sulphonate ( MESNA ) to patients with inoperable lung cancer .
Diseases:"
4408	The protective effect of oral administration of the thiol compound sodium 2 - mercaptoethane sulphonate ( MESNA ) against urothelial toxicity induced by ifosfamide ( IF ) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .	O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B I I I I O B O O O O O O B O B O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	['urothelial toxicity', 'lung cancer']	2	7	"Sentence: The protective effect of oral administration of the thiol compound sodium 2 - mercaptoethane sulphonate ( MESNA ) against urothelial toxicity induced by ifosfamide ( IF ) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .
Diseases: urothelial toxicity, lung cancer"	"Sentence: The protective effect of oral administration of the thiol compound sodium 2 - mercaptoethane sulphonate ( MESNA ) against urothelial toxicity induced by ifosfamide ( IF ) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .
Diseases:"
4409	MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg / m2 , each administered at 0	O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg / m2 , each administered at 0
Diseases: "	"Sentence: MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg / m2 , each administered at 0
Diseases:"
4410	hr	O	O	[]	0	0	"Sentence: hr
Diseases: "	"Sentence: hr
Diseases:"
4411	( = injection of IF ) , 4 hr and 8 hr p . i .	O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: ( = injection of IF ) , 4 hr and 8 hr p . i .
Diseases: "	"Sentence: ( = injection of IF ) , 4 hr and 8 hr p . i .
Diseases:"
4412	Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria .	O O O O O O O O O O O O O O O O O B O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O	['haematuria']	1	4	"Sentence: Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria .
Diseases: haematuria"	"Sentence: Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria .
Diseases:"
4413	In this group of 45 patients under protection with MESNA there were 5 complete remissions and 9 partial remissions ( total 31 % ) .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In this group of 45 patients under protection with MESNA there were 5 complete remissions and 9 partial remissions ( total 31 % ) .
Diseases: "	"Sentence: In this group of 45 patients under protection with MESNA there were 5 complete remissions and 9 partial remissions ( total 31 % ) .
Diseases:"
4414	A further group of 25 patients under polychemotherapy with IF were treated by conventional prophylactic measures ( raised fluid intake and forced diuresis ) .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: A further group of 25 patients under polychemotherapy with IF were treated by conventional prophylactic measures ( raised fluid intake and forced diuresis ) .
Diseases: "	"Sentence: A further group of 25 patients under polychemotherapy with IF were treated by conventional prophylactic measures ( raised fluid intake and forced diuresis ) .
Diseases:"
4415	In this group there were 1 complete and 5 partial remissions ( total 24 % ) , but nearly all patients developed either gross haematuria and / or symptoms of bladder irritation ( cystitis and pollakisuria ) .	O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O B I O B O B O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pollakisuria', 'cystitis', 'bladder irritation', 'haematuria']	4	15	"Sentence: In this group there were 1 complete and 5 partial remissions ( total 24 % ) , but nearly all patients developed either gross haematuria and / or symptoms of bladder irritation ( cystitis and pollakisuria ) .
Diseases: pollakisuria, cystitis, bladder irritation, haematuria"	"Sentence: In this group there were 1 complete and 5 partial remissions ( total 24 % ) , but nearly all patients developed either gross haematuria and / or symptoms of bladder irritation ( cystitis and pollakisuria ) .
Diseases:"
4416	There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment .	O O O O O O O O O O O O O O O O O O O O O B O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O	['toxicity']	1	2	"Sentence: There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment .
Diseases: toxicity"	"Sentence: There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment .
Diseases:"
4417	Our results support the view that MESNA , given orally in conjunction with combined cytostatic regimens which include IF , simplifies the treatment and provides optimum protection for the urinary epithelium .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Our results support the view that MESNA , given orally in conjunction with combined cytostatic regimens which include IF , simplifies the treatment and provides optimum protection for the urinary epithelium .
Diseases: "	"Sentence: Our results support the view that MESNA , given orally in conjunction with combined cytostatic regimens which include IF , simplifies the treatment and provides optimum protection for the urinary epithelium .
Diseases:"
4418	Protection with oral MESNA is particularly suitable for outpatients .	O O O O O O O O O O	O O O B O O O O O O	[]	0	0	"Sentence: Protection with oral MESNA is particularly suitable for outpatients .
Diseases: "	"Sentence: Protection with oral MESNA is particularly suitable for outpatients .
Diseases:"
4419	Time course alterations of QTC interval due to hypaque 76 .	O O O O O O O O O O O	O O O O O O O O B I O	[]	0	0	"Sentence: Time course alterations of QTC interval due to hypaque 76 .
Diseases: "	"Sentence: Time course alterations of QTC interval due to hypaque 76 .
Diseases:"
4420	Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one , three , five and ten minutes after injection of hypaque 76 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O B I O	[]	0	0	"Sentence: Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one , three , five and ten minutes after injection of hypaque 76 .
Diseases: "	"Sentence: Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one , three , five and ten minutes after injection of hypaque 76 .
Diseases:"
4421	The subjects were ten patients found to have normal left ventricles and coronary arteries .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The subjects were ten patients found to have normal left ventricles and coronary arteries .
Diseases: "	"Sentence: The subjects were ten patients found to have normal left ventricles and coronary arteries .
Diseases:"
4422	Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output .	O B I O O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O O O O O O O O O	['qtc prolongation', 'hypotension']	2	7	"Sentence: Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output .
Diseases: qtc prolongation, hypotension"	"Sentence: Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output .
Diseases:"
4423	Production of autochthonous prostate cancer in Lobund - Wistar rats by treatments with N - nitroso - N - methylurea and testosterone .	O O O B I O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B I I I I I I O B O	['prostate cancer']	1	3	"Sentence: Production of autochthonous prostate cancer in Lobund - Wistar rats by treatments with N - nitroso - N - methylurea and testosterone .
Diseases: prostate cancer"	"Sentence: Production of autochthonous prostate cancer in Lobund - Wistar rats by treatments with N - nitroso - N - methylurea and testosterone .
Diseases:"
4424	More than 50 % of Lobund - Wistar ( L - W ) strain rats developed large , palpable prostate adenocarcinomas ( PAs ) following treatments with N - nitroso - N - methylurea ( CAS : 684 - 93 - 5 ) and testosterone propionate [ ( TP ) CAS : 57 - 85 - 2 ] , and most of the tumor - bearing rats manifested metastatic lesions .	O O O O O O O O O O O O O O O O O O O B I O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I I I I O O O O O O O O O O B I O O B O O O O O O O O O O O O O O O O O O O O O O	['tumor', 'pas', 'prostate adenocarcinomas']	3	13	"Sentence: More than 50 % of Lobund - Wistar ( L - W ) strain rats developed large , palpable prostate adenocarcinomas ( PAs ) following treatments with N - nitroso - N - methylurea ( CAS : 684 - 93 - 5 ) and testosterone propionate [ ( TP ) CAS : 57 - 85 - 2 ] , and most of the tumor - bearing rats manifested metastatic lesions .
Diseases: tumor, pas, prostate adenocarcinomas"	"Sentence: More than 50 % of Lobund - Wistar ( L - W ) strain rats developed large , palpable prostate adenocarcinomas ( PAs ) following treatments with N - nitroso - N - methylurea ( CAS : 684 - 93 - 5 ) and testosterone propionate [ ( TP ) CAS : 57 - 85 - 2 ] , and most of the tumor - bearing rats manifested metastatic lesions .
Diseases:"
4425	The incubation periods averaged 10 . 6 months .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: The incubation periods averaged 10 . 6 months .
Diseases: "	"Sentence: The incubation periods averaged 10 . 6 months .
Diseases:"
4426	Within the same timeframe , no L - W rat developed a similar palpable PA when treated only with TP .	O O O O O O O O O O O O O O B O O O O O O	O O O O O O O O O O O O O O O O O O O B O	['pa']	1	1	"Sentence: Within the same timeframe , no L - W rat developed a similar palpable PA when treated only with TP .
Diseases: pa"	"Sentence: Within the same timeframe , no L - W rat developed a similar palpable PA when treated only with TP .
Diseases:"
4427	In L - W rats , TP acted as a tumor enhancement agent , with primary emphasis on the development of prostate cancer .	O O O O O O O O O O B O O O O O O O O O O B I O	O O O O O O B O O O O O O O O O O O O O O O O O	['tumor', 'prostate cancer']	2	6	"Sentence: In L - W rats , TP acted as a tumor enhancement agent , with primary emphasis on the development of prostate cancer .
Diseases: tumor, prostate cancer"	"Sentence: In L - W rats , TP acted as a tumor enhancement agent , with primary emphasis on the development of prostate cancer .
Diseases:"
4428	A dystonia - like syndrome after neuropeptide ( MSH / ACTH ) stimulation of the rat locus ceruleus .	O B O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O	['dystonia']	1	3	"Sentence: A dystonia - like syndrome after neuropeptide ( MSH / ACTH ) stimulation of the rat locus ceruleus .
Diseases: dystonia"	"Sentence: A dystonia - like syndrome after neuropeptide ( MSH / ACTH ) stimulation of the rat locus ceruleus .
Diseases:"
4429	The movement disorder investigated in these studies has some features in common with human idiopathic dystonia , and information obtained in these studies may be of potential clinical benefit .	O B I O O O O O O O O O O O O B O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['movement disorder', 'dystonia']	2	7	"Sentence: The movement disorder investigated in these studies has some features in common with human idiopathic dystonia , and information obtained in these studies may be of potential clinical benefit .
Diseases: movement disorder, dystonia"	"Sentence: The movement disorder investigated in these studies has some features in common with human idiopathic dystonia , and information obtained in these studies may be of potential clinical benefit .
Diseases:"
4430	The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE - mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo - cerebellar pathway .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE - mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo - cerebellar pathway .
Diseases: "	"Sentence: The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE - mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo - cerebellar pathway .
Diseases:"
4431	However , it is not certain as to the following : ( a ) what receptors were stimulated by the ACTH N - terminal fragments at the LC that resulted in this disorder ; ( b ) whether NE , released onto Purkinje cell synapses located at terminals of the ceruleo - cerebellar pathway , did indeed cause the long - term depression at Purkinje cell synapses ( previously described by others ) that resulted in the long duration of the movement disorder ; ( c ) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei , the output targets of the Purkinje cell axons , that may have been an important contributing factor to this disorder .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['depression', 'movement disorder']	2	5	"Sentence: However , it is not certain as to the following : ( a ) what receptors were stimulated by the ACTH N - terminal fragments at the LC that resulted in this disorder ; ( b ) whether NE , released onto Purkinje cell synapses located at terminals of the ceruleo - cerebellar pathway , did indeed cause the long - term depression at Purkinje cell synapses ( previously described by others ) that resulted in the long duration of the movement disorder ; ( c ) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei , the output targets of the Purkinje cell axons , that may have been an important contributing factor to this disorder .
Diseases: depression, movement disorder"	"Sentence: However , it is not certain as to the following : ( a ) what receptors were stimulated by the ACTH N - terminal fragments at the LC that resulted in this disorder ; ( b ) whether NE , released onto Purkinje cell synapses located at terminals of the ceruleo - cerebellar pathway , did indeed cause the long - term depression at Purkinje cell synapses ( previously described by others ) that resulted in the long duration of the movement disorder ; ( c ) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei , the output targets of the Purkinje cell axons , that may have been an important contributing factor to this disorder .
Diseases:"
4432	These questions are currently being investigated .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: These questions are currently being investigated .
Diseases: "	"Sentence: These questions are currently being investigated .
Diseases:"
4433	Dexmedetomidine , acting through central alpha - 2 adrenoceptors , prevents opiate - induced muscle rigidity in the rat .	O O O O O O O O O O O O O O B I O O O O	B O O O O O O O O O O O O O O O O O O O	['muscle rigidity']	1	4	"Sentence: Dexmedetomidine , acting through central alpha - 2 adrenoceptors , prevents opiate - induced muscle rigidity in the rat .
Diseases: muscle rigidity"	"Sentence: Dexmedetomidine , acting through central alpha - 2 adrenoceptors , prevents opiate - induced muscle rigidity in the rat .
Diseases:"
4434	The highly - selective alpha - 2 adrenergic agonist dexmedetomidine ( D - MED ) is capable of inducing muscle flaccidity and anesthesia in rats and dogs .	O O O O O O O O O O O O O O O O O O O B I O O O O O O O	O O O O O O O O O B O B I I O O O O O O O O O O O O O O	['muscle flaccidity']	1	5	"Sentence: The highly - selective alpha - 2 adrenergic agonist dexmedetomidine ( D - MED ) is capable of inducing muscle flaccidity and anesthesia in rats and dogs .
Diseases: muscle flaccidity"	"Sentence: The highly - selective alpha - 2 adrenergic agonist dexmedetomidine ( D - MED ) is capable of inducing muscle flaccidity and anesthesia in rats and dogs .
Diseases:"
4435	Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists .	O O B I O O O O O O O O O O	O O O O O O O O O O O O O O	['muscle rigidity']	1	4	"Sentence: Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists .
Diseases: muscle rigidity"	"Sentence: Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists .
Diseases:"
4436	Although the neurochemistry of opiate - induced rigidity has yet to be fully elucidated , recent work suggests a role for a central adrenergic mechanism .	O O O O O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['rigidity']	1	2	"Sentence: Although the neurochemistry of opiate - induced rigidity has yet to be fully elucidated , recent work suggests a role for a central adrenergic mechanism .
Diseases: rigidity"	"Sentence: Although the neurochemistry of opiate - induced rigidity has yet to be fully elucidated , recent work suggests a role for a central adrenergic mechanism .
Diseases:"
4437	In the present study , the authors determined if treatment with D - MED prevents the muscle rigidity caused by high - dose alfentanil anesthesia in the rat .	O O O O O O O O O O O O O O O O B I O O O O O O O O O O O	O O O O O O O O O O O B I I O O O O O O O O O B O O O O O	['muscle rigidity']	1	4	"Sentence: In the present study , the authors determined if treatment with D - MED prevents the muscle rigidity caused by high - dose alfentanil anesthesia in the rat .
Diseases: muscle rigidity"	"Sentence: In the present study , the authors determined if treatment with D - MED prevents the muscle rigidity caused by high - dose alfentanil anesthesia in the rat .
Diseases:"
4438	Animals ( n = 42 ) were treated intraperitoneally with one of the following six regimens : 1 ) L - MED ( the inactive L - isomer of medetomidine ) , 30 micrograms / kg ; 2 ) D - MED , 10 micrograms / kg ; 3 ) D - MED , 30 micrograms / kg ; 4 ) D - MED	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O I O O O O O O O B O O O O O O O O O O O B O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: Animals ( n = 42 ) were treated intraperitoneally with one of the following six regimens : 1 ) L - MED ( the inactive L - isomer of medetomidine ) , 30 micrograms / kg ; 2 ) D - MED , 10 micrograms / kg ; 3 ) D - MED , 30 micrograms / kg ; 4 ) D - MED
Diseases: "	"Sentence: Animals ( n = 42 ) were treated intraperitoneally with one of the following six regimens : 1 ) L - MED ( the inactive L - isomer of medetomidine ) , 30 micrograms / kg ; 2 ) D - MED , 10 micrograms / kg ; 3 ) D - MED , 30 micrograms / kg ; 4 ) D - MED
Diseases:"
4439	[ 30 micrograms / kg ] and the central - acting alpha - 2 antagonist , idazoxan [ 10 mg / kg ] ; 5 )	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O O O O	[]	0	0	"Sentence: [ 30 micrograms / kg ] and the central - acting alpha - 2 antagonist , idazoxan [ 10 mg / kg ] ; 5 )
Diseases: "	"Sentence: [ 30 micrograms / kg ] and the central - acting alpha - 2 antagonist , idazoxan [ 10 mg / kg ] ; 5 )
Diseases:"
4440	D - MED [ 30 micrograms / kg ] and the peripheral - acting alpha - 2 antagonist DG - 5128	O O O O O O O O O O O O O O O O O O O O O	B I I O O O O O O O O O O O O O O O B I I	[]	0	0	"Sentence: D - MED [ 30 micrograms / kg ] and the peripheral - acting alpha - 2 antagonist DG - 5128
Diseases: "	"Sentence: D - MED [ 30 micrograms / kg ] and the peripheral - acting alpha - 2 antagonist DG - 5128
Diseases:"
4441	[ 10 mg / kg ] , or ; 6 ) saline .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: [ 10 mg / kg ] , or ; 6 ) saline .
Diseases: "	"Sentence: [ 10 mg / kg ] , or ; 6 ) saline .
Diseases:"
4442	Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment .
Diseases: "	"Sentence: Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment .
Diseases:"
4443	Each rat was then injected with alfentanil ( ALF , 0 . 5 mg / kg sc ) .	O O O O O O O O O O O O O O O O O O O	O O O O O O B O B O O O O O O O O O O	[]	0	0	"Sentence: Each rat was then injected with alfentanil ( ALF , 0 . 5 mg / kg sc ) .
Diseases: "	"Sentence: Each rat was then injected with alfentanil ( ALF , 0 . 5 mg / kg sc ) .
Diseases:"
4444	ALF injection resulted in a marked increase in hindlimb EMG activity in the L - MED treatment group which was indistinguishable from that seen in animals treated with saline .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O B I I O O O O O O O O O O O O O O	[]	0	0	"Sentence: ALF injection resulted in a marked increase in hindlimb EMG activity in the L - MED treatment group which was indistinguishable from that seen in animals treated with saline .
Diseases: "	"Sentence: ALF injection resulted in a marked increase in hindlimb EMG activity in the L - MED treatment group which was indistinguishable from that seen in animals treated with saline .
Diseases:"
4445	In contrast , D - MED prevented alfentanil - induced muscle rigidity in a dose - dependent fashion .	O O O O O O O O O O B I O O O O O O O	O O O B I I O B O O O O O O O O O O O	['muscle rigidity']	1	4	"Sentence: In contrast , D - MED prevented alfentanil - induced muscle rigidity in a dose - dependent fashion .
Diseases: muscle rigidity"	"Sentence: In contrast , D - MED prevented alfentanil - induced muscle rigidity in a dose - dependent fashion .
Diseases:"
4446	The small EMG values obtained in the high - dose D - MED group were comparable with those recorded in earlier studies from control animals not given any opiate .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B I I O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The small EMG values obtained in the high - dose D - MED group were comparable with those recorded in earlier studies from control animals not given any opiate .
Diseases: "	"Sentence: The small EMG values obtained in the high - dose D - MED group were comparable with those recorded in earlier studies from control animals not given any opiate .
Diseases:"
4447	The high - dose D - MED animals were flaccid , akinetic , and lacked a startle response during the entire experimental period . ( ABSTRACT TRUNCATED AT 250 WORDS )	O O O O O O O O O O O B O O O O B O O O O O O O O O O O O O O	O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O	['akinetic', 'startle']	2	5	"Sentence: The high - dose D - MED animals were flaccid , akinetic , and lacked a startle response during the entire experimental period . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases: akinetic, startle"	"Sentence: The high - dose D - MED animals were flaccid , akinetic , and lacked a startle response during the entire experimental period . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases:"
4448	Seizure activity with imipenem therapy : incidence and risk factors .	B O O O O O O O O O O	O O O B O O O O O O O	['seizure']	1	3	"Sentence: Seizure activity with imipenem therapy : incidence and risk factors .
Diseases: seizure"	"Sentence: Seizure activity with imipenem therapy : incidence and risk factors .
Diseases:"
4449	Two elderly patients with a history of either cerebral vascular accident ( CVA ) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem / cilastatin .	O O O O O O O O B I I O B O O B I O O O O B I O B O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O	['cerebral vascular accident', 'renal disease', 'head trauma', 'seizures', 'cva']	5	16	"Sentence: Two elderly patients with a history of either cerebral vascular accident ( CVA ) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem / cilastatin .
Diseases: cerebral vascular accident, renal disease, head trauma, seizures, cva"	"Sentence: Two elderly patients with a history of either cerebral vascular accident ( CVA ) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem / cilastatin .
Diseases:"
4450	Neither patient had reported previous seizures or seizure - like activity nor was receiving anticonvulsant agents .	O O O O O B O B O O O O O O O O O	O O O O O O O O O O O O O O O O O	['seizures', 'seizure']	2	5	"Sentence: Neither patient had reported previous seizures or seizure - like activity nor was receiving anticonvulsant agents .
Diseases: seizures, seizure"	"Sentence: Neither patient had reported previous seizures or seizure - like activity nor was receiving anticonvulsant agents .
Diseases:"
4451	All seizures were controlled with therapeutic doses of phenytoin .	O B O O O O O O O O	O O O O O O O O B O	['seizures']	1	3	"Sentence: All seizures were controlled with therapeutic doses of phenytoin .
Diseases: seizures"	"Sentence: All seizures were controlled with therapeutic doses of phenytoin .
Diseases:"
4452	Both patients had received maximum doses of other beta - lactam antibiotics without evidence of seizure activity .	O O O O O O O O O O O O O O O B O O	O O O O O O O O B I I O O O O O O O	['seizure']	1	3	"Sentence: Both patients had received maximum doses of other beta - lactam antibiotics without evidence of seizure activity .
Diseases: seizure"	"Sentence: Both patients had received maximum doses of other beta - lactam antibiotics without evidence of seizure activity .
Diseases:"
4453	The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin - induced diabetes mellitus .	O O O O O O O O O O O O O O O O O O O O B I O	O O O B O O O O O O O O O O O O O B O O O O O	['diabetes mellitus']	1	4	"Sentence: The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin - induced diabetes mellitus .
Diseases: diabetes mellitus"	"Sentence: The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin - induced diabetes mellitus .
Diseases:"
4454	The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin - diabetic rats were investigated .	O O O O O O O O O O O O O O O O O B O O O O	O O O B O O O O O O O O O O O B O O O O O O	['diabetic']	1	2	"Sentence: The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin - diabetic rats were investigated .
Diseases: diabetic"	"Sentence: The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin - diabetic rats were investigated .
Diseases:"
4455	Diabetes of 2 months duration resulted in decreases in body weight and increases in fluid consumption , urine volume , frequency of micturition , and average volume per micturition ; effects which were prevented by insulin treatment .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['diabetes']	1	2	"Sentence: Diabetes of 2 months duration resulted in decreases in body weight and increases in fluid consumption , urine volume , frequency of micturition , and average volume per micturition ; effects which were prevented by insulin treatment .
Diseases: diabetes"	"Sentence: Diabetes of 2 months duration resulted in decreases in body weight and increases in fluid consumption , urine volume , frequency of micturition , and average volume per micturition ; effects which were prevented by insulin treatment .
Diseases:"
4456	Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation , ATP , and bethanechol .	O O O O O O O O O O O O O O B O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O B O O B O	['diabetic']	1	2	"Sentence: Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation , ATP , and bethanechol .
Diseases: diabetic"	"Sentence: Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation , ATP , and bethanechol .
Diseases:"
4457	Diabetes of 4 months duration also resulted in decreases in body weight , and increases in fluid consumption , urine volume , frequency of micturition , and average volume per micturition , effects which were reversed by insulin treatment for the final 2 months of the study .	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['diabetes']	1	2	"Sentence: Diabetes of 4 months duration also resulted in decreases in body weight , and increases in fluid consumption , urine volume , frequency of micturition , and average volume per micturition , effects which were reversed by insulin treatment for the final 2 months of the study .
Diseases: diabetes"	"Sentence: Diabetes of 4 months duration also resulted in decreases in body weight , and increases in fluid consumption , urine volume , frequency of micturition , and average volume per micturition , effects which were reversed by insulin treatment for the final 2 months of the study .
Diseases:"
4458	Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation , ATP , and bethanechol .	O O O O O O O O O O O O O B O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O B O O B O	['diabetic']	1	2	"Sentence: Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation , ATP , and bethanechol .
Diseases: diabetic"	"Sentence: Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation , ATP , and bethanechol .
Diseases:"
4459	6 .	O O	O O	[]	0	0	"Sentence: 6 .
Diseases: "	"Sentence: 6 .
Diseases:"
4460	The data indicate that the effects of streptozotocin - induced diabetes on urinary bladder function are both prevented and reversed by insulin treatment .	O O O O O O O O O O B O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O B O O	['diabetes']	1	2	"Sentence: The data indicate that the effects of streptozotocin - induced diabetes on urinary bladder function are both prevented and reversed by insulin treatment .
Diseases: diabetes"	"Sentence: The data indicate that the effects of streptozotocin - induced diabetes on urinary bladder function are both prevented and reversed by insulin treatment .
Diseases:"
4461	Delayed institution of hypertension during focal cerebral ischemia : effect on brain edema .	O O O B O O B I O O O B I O	O O O O O O O O O O O O O O	['brain edema', 'cerebral ischemia', 'hypertension']	3	10	"Sentence: Delayed institution of hypertension during focal cerebral ischemia : effect on brain edema .
Diseases: brain edema, cerebral ischemia, hypertension"	"Sentence: Delayed institution of hypertension during focal cerebral ischemia : effect on brain edema .
Diseases:"
4462	The effect of induced hypertension instituted after a 2 - h delay following middle cerebral artery occlusion ( MCAO ) on brain edema formation and histochemical injury was studied .	O O O O B O O O O O O O O B I I I O B O O B I O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['middle cerebral artery occlusion', 'brain edema', 'mcao', 'hypertension']	4	15	"Sentence: The effect of induced hypertension instituted after a 2 - h delay following middle cerebral artery occlusion ( MCAO ) on brain edema formation and histochemical injury was studied .
Diseases: middle cerebral artery occlusion, brain edema, mcao, hypertension"	"Sentence: The effect of induced hypertension instituted after a 2 - h delay following middle cerebral artery occlusion ( MCAO ) on brain edema formation and histochemical injury was studied .
Diseases:"
4463	Under isoflurane anesthesia , the MCA of 14 spontaneously hypertensive rats was occluded .	O O O O O O O O O B O O O O	O B O O O O O O O O O O O O	['hypertensive']	1	3	"Sentence: Under isoflurane anesthesia , the MCA of 14 spontaneously hypertensive rats was occluded .
Diseases: hypertensive"	"Sentence: Under isoflurane anesthesia , the MCA of 14 spontaneously hypertensive rats was occluded .
Diseases:"
4464	In the control group ( n = 7 ) , the mean arterial pressure ( MAP ) was not manipulated .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In the control group ( n = 7 ) , the mean arterial pressure ( MAP ) was not manipulated .
Diseases: "	"Sentence: In the control group ( n = 7 ) , the mean arterial pressure ( MAP ) was not manipulated .
Diseases:"
4465	In the hypertensive group ( n = 7 ) , the MAP was elevated by 25 - 30 mm Hg beginning 2 h after MCAO .	O O B O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertensive', 'mcao']	2	6	"Sentence: In the hypertensive group ( n = 7 ) , the MAP was elevated by 25 - 30 mm Hg beginning 2 h after MCAO .
Diseases: hypertensive, mcao"	"Sentence: In the hypertensive group ( n = 7 ) , the MAP was elevated by 25 - 30 mm Hg beginning 2 h after MCAO .
Diseases:"
4466	Four hours after MCAO , the rats were killed and the brains harvested .	O O O B O O O O O O O O O O	O O O O O O O O O O O O O O	['mcao']	1	2	"Sentence: Four hours after MCAO , the rats were killed and the brains harvested .
Diseases: mcao"	"Sentence: Four hours after MCAO , the rats were killed and the brains harvested .
Diseases:"
4467	The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO .	O O O O O O O O O O O B O O B O	O O O O O O O O O O O O O O O O	['mcao', 'ischemia']	2	6	"Sentence: The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO .
Diseases: mcao, ischemia"	"Sentence: The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO .
Diseases:"
4468	Specific gravity ( SG ) was determined in the subcortex and in two sites in the cortex ( core and periphery of the ischemic territory ) .	O O O O O O O O O O O O O O O O O O O O O O O B O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ischemic']	1	3	"Sentence: Specific gravity ( SG ) was determined in the subcortex and in two sites in the cortex ( core and periphery of the ischemic territory ) .
Diseases: ischemic"	"Sentence: Specific gravity ( SG ) was determined in the subcortex and in two sites in the cortex ( core and periphery of the ischemic territory ) .
Diseases:"
4469	The extent of neuronal injury was determined by 2 , 3 , 5 - triphenyltetrazolium staining .	O O O B I O O O O O O O O O O O O	O O O O O O O O B I I I I I I O O	['neuronal injury']	1	4	"Sentence: The extent of neuronal injury was determined by 2 , 3 , 5 - triphenyltetrazolium staining .
Diseases: neuronal injury"	"Sentence: The extent of neuronal injury was determined by 2 , 3 , 5 - triphenyltetrazolium staining .
Diseases:"
4470	In the ischemic core , there was no difference in SG in the subcortex and cortex in the two groups .	O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	['ischemic']	1	3	"Sentence: In the ischemic core , there was no difference in SG in the subcortex and cortex in the two groups .
Diseases: ischemic"	"Sentence: In the ischemic core , there was no difference in SG in the subcortex and cortex in the two groups .
Diseases:"
4471	In the periphery of the ischemic territory , SG in the cortex was greater ( less edema accumulation ) in the hypertensive group ( 1 . 041 + / -	O O O O O B O O O O O O O O O O B O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertensive', 'edema', 'ischemic']	3	10	"Sentence: In the periphery of the ischemic territory , SG in the cortex was greater ( less edema accumulation ) in the hypertensive group ( 1 . 041 + / -
Diseases: hypertensive, edema, ischemic"	"Sentence: In the periphery of the ischemic territory , SG in the cortex was greater ( less edema accumulation ) in the hypertensive group ( 1 . 041 + / -
Diseases:"
4472	0 . 001 vs 1 . 039 + / -	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: 0 . 001 vs 1 . 039 + / -
Diseases: "	"Sentence: 0 . 001 vs 1 . 039 + / -
Diseases:"
4473	0 . 001 , P less than 0 . 05 ) .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: 0 . 001 , P less than 0 . 05 ) .
Diseases: "	"Sentence: 0 . 001 , P less than 0 . 05 ) .
Diseases:"
4474	The area of histochemical injury ( as a percent of the cross - sectional area of the hemisphere ) was less in the hypertensive group ( 33 + / - 3 % vs 21 + / - 2 % , P less than 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypertensive']	1	3	"Sentence: The area of histochemical injury ( as a percent of the cross - sectional area of the hemisphere ) was less in the hypertensive group ( 33 + / - 3 % vs 21 + / - 2 % , P less than 0 . 05 ) .
Diseases: hypertensive"	"Sentence: The area of histochemical injury ( as a percent of the cross - sectional area of the hemisphere ) was less in the hypertensive group ( 33 + / - 3 % vs 21 + / - 2 % , P less than 0 . 05 ) .
Diseases:"
4475	The data indicate that phenylephrine - induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core , that it improves edema in the periphery of the ischemic territory , and that it reduces the area of histochemical neuronal dysfunction .	O O O O O O O B O O O O B O O O B O O B O O O O O B O O O O O B O O O O O O O O O O B I O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['neuronal dysfunction', 'edema', 'hypertension', 'mcao', 'ischemic']	5	16	"Sentence: The data indicate that phenylephrine - induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core , that it improves edema in the periphery of the ischemic territory , and that it reduces the area of histochemical neuronal dysfunction .
Diseases: neuronal dysfunction, edema, hypertension, mcao, ischemic"	"Sentence: The data indicate that phenylephrine - induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core , that it improves edema in the periphery of the ischemic territory , and that it reduces the area of histochemical neuronal dysfunction .
Diseases:"
4476	Amiodarone pulmonary toxicity .	O B I O	B O O O	['pulmonary toxicity']	1	4	"Sentence: Amiodarone pulmonary toxicity .
Diseases: pulmonary toxicity"	"Sentence: Amiodarone pulmonary toxicity .
Diseases:"
4477	Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side - effects , the most problematic being pneumonitis .	O O O O O O O O O O O O O O O O O O O O B O	B O O O O O O O O O O O O O O O O O O O O O	['pneumonitis']	1	4	"Sentence: Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side - effects , the most problematic being pneumonitis .
Diseases: pneumonitis"	"Sentence: Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side - effects , the most problematic being pneumonitis .
Diseases:"
4478	The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell - mediated hypersensitivity pneumonitis .	O B I O O O O O O O O O O O O O O O O O O O O O B I O	O O O O B O O O O O O O O O O O O O B O O O O O O O O	['pulmonary toxicity', 'hypersensitivity pneumonitis']	2	10	"Sentence: The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell - mediated hypersensitivity pneumonitis .
Diseases: pulmonary toxicity, hypersensitivity pneumonitis"	"Sentence: The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell - mediated hypersensitivity pneumonitis .
Diseases:"
4479	The clinical and radiographic features of amiodarone - induced pulmonary toxicity are characteristic but nonspecific .	O O O O O O O O O B I O O O O O	O O O O O O B O O O O O O O O O	['pulmonary toxicity']	1	4	"Sentence: The clinical and radiographic features of amiodarone - induced pulmonary toxicity are characteristic but nonspecific .
Diseases: pulmonary toxicity"	"Sentence: The clinical and radiographic features of amiodarone - induced pulmonary toxicity are characteristic but nonspecific .
Diseases:"
4480	The diagnosis depends on exclusion of other entities , such as heart failure , infection , and malignancy .	O O O O O O O O O O O B I O B O O B O	O O O O O O O O O O O O O O O O O O O	['heart failure', 'malignancy', 'infection']	3	8	"Sentence: The diagnosis depends on exclusion of other entities , such as heart failure , infection , and malignancy .
Diseases: heart failure, malignancy, infection"	"Sentence: The diagnosis depends on exclusion of other entities , such as heart failure , infection , and malignancy .
Diseases:"
4481	While withdrawal of amiodarone leads to clinical improvement in majority of cases , this is not always possible or advisable .	O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: While withdrawal of amiodarone leads to clinical improvement in majority of cases , this is not always possible or advisable .
Diseases: "	"Sentence: While withdrawal of amiodarone leads to clinical improvement in majority of cases , this is not always possible or advisable .
Diseases:"
4482	Dose reduction or concomitant steroid therapy may have a role in selected patients .	O O O O O O O O O O O O O O	O O O O B O O O O O O O O O	[]	0	0	"Sentence: Dose reduction or concomitant steroid therapy may have a role in selected patients .
Diseases: "	"Sentence: Dose reduction or concomitant steroid therapy may have a role in selected patients .
Diseases:"
4483	Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis .	O O B O O O O O O O O O B O	O O O O O O O O B O O O O O	['tuberculosis', 'proteinuria']	2	6	"Sentence: Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis .
Diseases: tuberculosis, proteinuria"	"Sentence: Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis .
Diseases:"
4484	Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin .	O O B O O O O O O B O O O O O	O O O O O O O O O O O O O B O	['tuberculosis', 'proteinuria']	2	6	"Sentence: Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin .
Diseases: tuberculosis, proteinuria"	"Sentence: Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin .
Diseases:"
4485	Concomitant assay of cellular mediated immunity in these patients using skin test antigen and a lymphokine in vitro test provided results that were different .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Concomitant assay of cellular mediated immunity in these patients using skin test antigen and a lymphokine in vitro test provided results that were different .
Diseases: "	"Sentence: Concomitant assay of cellular mediated immunity in these patients using skin test antigen and a lymphokine in vitro test provided results that were different .
Diseases:"
4486	Response to Varidase skin test antigen was negative for all eight tuberculosis patients tested , but there occurred a hyper - responsiveness of the lymphocytes of these eight patients to phytomitogen ( PHA - P ) .	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['tuberculosis']	1	3	"Sentence: Response to Varidase skin test antigen was negative for all eight tuberculosis patients tested , but there occurred a hyper - responsiveness of the lymphocytes of these eight patients to phytomitogen ( PHA - P ) .
Diseases: tuberculosis"	"Sentence: Response to Varidase skin test antigen was negative for all eight tuberculosis patients tested , but there occurred a hyper - responsiveness of the lymphocytes of these eight patients to phytomitogen ( PHA - P ) .
Diseases:"
4487	as well as of those of seven other tuberculous patients .	O O O O O O O O B O O	O O O O O O O O O O O	['tuberculous']	1	4	"Sentence: as well as of those of seven other tuberculous patients .
Diseases: tuberculous"	"Sentence: as well as of those of seven other tuberculous patients .
Diseases:"
4488	This last finding may be related to time of testing and / or endogenous serum binding of rifampin which could have inhibited mitogen activity for the lymphocyte .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: This last finding may be related to time of testing and / or endogenous serum binding of rifampin which could have inhibited mitogen activity for the lymphocyte .
Diseases: "	"Sentence: This last finding may be related to time of testing and / or endogenous serum binding of rifampin which could have inhibited mitogen activity for the lymphocyte .
Diseases:"
4489	Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension : the influence of dietary sodium restriction .	O O O O B O O O O O O O B O O O O O O O O	O B O O O O B O O O O O O O O O O O B O O	['hypokalaemia', 'hypertension']	2	6	"Sentence: Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension : the influence of dietary sodium restriction .
Diseases: hypokalaemia, hypertension"	"Sentence: Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension : the influence of dietary sodium restriction .
Diseases:"
4490	To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic , metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment .	O O O O O O O O O B O O O O O O O O O O O O O O O O O O B O O O B O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypokalaemia', 'hypertension']	2	6	"Sentence: To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic , metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment .
Diseases: hypokalaemia, hypertension"	"Sentence: To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic , metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment .
Diseases:"
4491	Chlorthalidone ( 50 mg daily ) was given for 14 days .	O O O O O O O O O O O O	B O O O O O O O O O O O	[]	0	0	"Sentence: Chlorthalidone ( 50 mg daily ) was given for 14 days .
Diseases: "	"Sentence: Chlorthalidone ( 50 mg daily ) was given for 14 days .
Diseases:"
4492	Six patients received a normal - sodium diet and four a low - sodium ( 17 mmol / day ) diet .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O B O O O O O O O O	[]	0	0	"Sentence: Six patients received a normal - sodium diet and four a low - sodium ( 17 mmol / day ) diet .
Diseases: "	"Sentence: Six patients received a normal - sodium diet and four a low - sodium ( 17 mmol / day ) diet .
Diseases:"
4493	All patients had a normal initial total body potassium ( 40 K ) .	O O O O O O O O O O O O O O	O O O O O O O O B O O B O O	[]	0	0	"Sentence: All patients had a normal initial total body potassium ( 40 K ) .
Diseases: "	"Sentence: All patients had a normal initial total body potassium ( 40 K ) .
Diseases:"
4494	The electrolyte balances , weight , bromide space , plasma renin activity , and aldosterone secretion rate were measured .	O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O B O O O O O	[]	0	0	"Sentence: The electrolyte balances , weight , bromide space , plasma renin activity , and aldosterone secretion rate were measured .
Diseases: "	"Sentence: The electrolyte balances , weight , bromide space , plasma renin activity , and aldosterone secretion rate were measured .
Diseases:"
4495	In both groups a potassium deficit developed , with proportionally larger losses from the extracellular than from the intracellular compartment .	O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In both groups a potassium deficit developed , with proportionally larger losses from the extracellular than from the intracellular compartment .
Diseases: "	"Sentence: In both groups a potassium deficit developed , with proportionally larger losses from the extracellular than from the intracellular compartment .
Diseases:"
4496	In the normal - sodium group the highest mean potassium deficit was 176 mmol on day 9 , after which some potassium was regained ; in the low - sodium group the highest deficit was 276 mmol on day 13 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O B O O O O O O O O O O O B O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: In the normal - sodium group the highest mean potassium deficit was 176 mmol on day 9 , after which some potassium was regained ; in the low - sodium group the highest deficit was 276 mmol on day 13 .
Diseases: "	"Sentence: In the normal - sodium group the highest mean potassium deficit was 176 mmol on day 9 , after which some potassium was regained ; in the low - sodium group the highest deficit was 276 mmol on day 13 .
Diseases:"
4497	The normal - sodium group showed an immediate but temporary rise of the renin and aldosterone levels ; in the low - sodium group renin and aldosterone increased more slowly but remained elevated .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O B O O O O O O B O O O B O O O O O O O	[]	0	0	"Sentence: The normal - sodium group showed an immediate but temporary rise of the renin and aldosterone levels ; in the low - sodium group renin and aldosterone increased more slowly but remained elevated .
Diseases: "	"Sentence: The normal - sodium group showed an immediate but temporary rise of the renin and aldosterone levels ; in the low - sodium group renin and aldosterone increased more slowly but remained elevated .
Diseases:"
4498	It is concluded that dietary sodium restriction increases diuretic - induced potassium loss , presumably by an increased activity of the renin - angiotensin - aldosterone system , while sodium delivery to the distal renal tubules remains sufficiently high to allow increased potassium secretion .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O B O O O O O O O O O O O B O B O O O B O O O O O O O O O O O O B O O	[]	0	0	"Sentence: It is concluded that dietary sodium restriction increases diuretic - induced potassium loss , presumably by an increased activity of the renin - angiotensin - aldosterone system , while sodium delivery to the distal renal tubules remains sufficiently high to allow increased potassium secretion .
Diseases: "	"Sentence: It is concluded that dietary sodium restriction increases diuretic - induced potassium loss , presumably by an increased activity of the renin - angiotensin - aldosterone system , while sodium delivery to the distal renal tubules remains sufficiently high to allow increased potassium secretion .
Diseases:"
4499	Dynamic response of blood vessel in acute renal failure .	O O O O O O B I I O	O O O O O O O O O O	['acute renal failure']	1	4	"Sentence: Dynamic response of blood vessel in acute renal failure .
Diseases: acute renal failure"	"Sentence: Dynamic response of blood vessel in acute renal failure .
Diseases:"
4500	In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected , and that antioxidants can prevent the changes in dynamic responses of blood vessels .	O O O O O O O B I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['acute renal failure']	1	4	"Sentence: In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected , and that antioxidants can prevent the changes in dynamic responses of blood vessels .
Diseases: acute renal failure"	"Sentence: In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected , and that antioxidants can prevent the changes in dynamic responses of blood vessels .
Diseases:"
4501	The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered , but also dynamics of this response , was used in this paper .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered , but also dynamics of this response , was used in this paper .
Diseases: "	"Sentence: The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered , but also dynamics of this response , was used in this paper .
Diseases:"
4502	Our results confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin - treated animals .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: Our results confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin - treated animals .
Diseases: "	"Sentence: Our results confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin - treated animals .
Diseases:"
4503	The beneficial effects of vitamin C administration to gentamicin - treated animals are also confirmed through : lower level of blood urea and creatinine and higher level of potassium .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B I O O B O O O O O O O O O O O O B O B O O O O B O	[]	0	0	"Sentence: The beneficial effects of vitamin C administration to gentamicin - treated animals are also confirmed through : lower level of blood urea and creatinine and higher level of potassium .
Diseases: "	"Sentence: The beneficial effects of vitamin C administration to gentamicin - treated animals are also confirmed through : lower level of blood urea and creatinine and higher level of potassium .
Diseases:"
4504	The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin - treated animals ( 8 . 07 + / - 1 . 7 s vs . 5 . 64 + / -	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin - treated animals ( 8 . 07 + / - 1 . 7 s vs . 5 . 64 + / -
Diseases: "	"Sentence: The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin - treated animals ( 8 . 07 + / - 1 . 7 s vs . 5 . 64 + / -
Diseases:"
4505	0 . 18 s ) .	O O O O O O	O O O O O O	[]	0	0	"Sentence: 0 . 18 s ) .
Diseases: "	"Sentence: 0 . 18 s ) .
Diseases:"
4506	Vitamin C administration induced slowdown of pressure change back to the control values .	O O O O O O O O O O O O O O	B I O O O O O O O O O O O O	[]	0	0	"Sentence: Vitamin C administration induced slowdown of pressure change back to the control values .
Diseases: "	"Sentence: Vitamin C administration induced slowdown of pressure change back to the control values .
Diseases:"
4507	The pressure dynamic properties , quantitatively defined by comparative pressure dynamic and total pressure dynamic , confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin - treated animals and beneficial effects of vitamin C administration .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O B I O O	[]	0	0	"Sentence: The pressure dynamic properties , quantitatively defined by comparative pressure dynamic and total pressure dynamic , confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin - treated animals and beneficial effects of vitamin C administration .
Diseases: "	"Sentence: The pressure dynamic properties , quantitatively defined by comparative pressure dynamic and total pressure dynamic , confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin - treated animals and beneficial effects of vitamin C administration .
Diseases:"
4508	The hemodynamics of oxytocin and other vasoactive agents during neuraxial anesthesia for cesarean delivery : findings in six cases .	O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The hemodynamics of oxytocin and other vasoactive agents during neuraxial anesthesia for cesarean delivery : findings in six cases .
Diseases: "	"Sentence: The hemodynamics of oxytocin and other vasoactive agents during neuraxial anesthesia for cesarean delivery : findings in six cases .
Diseases:"
4509	Oxytocin is a commonly used uterotonic that can cause significant and even fatal hypotension , particularly when given as a bolus .	O O O O O O O O O O O O O B O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: Oxytocin is a commonly used uterotonic that can cause significant and even fatal hypotension , particularly when given as a bolus .
Diseases: hypotension"	"Sentence: Oxytocin is a commonly used uterotonic that can cause significant and even fatal hypotension , particularly when given as a bolus .
Diseases:"
4510	The resulting hypotension can be produced by a decrease in systemic vascular resistance or cardiac output through a decrease in venous return .	O O B O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: The resulting hypotension can be produced by a decrease in systemic vascular resistance or cardiac output through a decrease in venous return .
Diseases: hypotension"	"Sentence: The resulting hypotension can be produced by a decrease in systemic vascular resistance or cardiac output through a decrease in venous return .
Diseases:"
4511	Parturients with normal volume status , heart valves and pulmonary vasculature most often respond to this hypotension with a compensatory increase in heart rate and stroke volume .	O O O O O O O O O O O O O O O O B O O O O O O O O B O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['stroke', 'hypotension']	2	4	"Sentence: Parturients with normal volume status , heart valves and pulmonary vasculature most often respond to this hypotension with a compensatory increase in heart rate and stroke volume .
Diseases: stroke, hypotension"	"Sentence: Parturients with normal volume status , heart valves and pulmonary vasculature most often respond to this hypotension with a compensatory increase in heart rate and stroke volume .
Diseases:"
4512	Oxytocin - induced hypotension at cesarean delivery may be incorrectly attributed to blood loss .	O O O B O O O O O O O O B I O	B O O O O O O O O O O O O O O	['hypotension', 'blood loss']	2	6	"Sentence: Oxytocin - induced hypotension at cesarean delivery may be incorrectly attributed to blood loss .
Diseases: hypotension, blood loss"	"Sentence: Oxytocin - induced hypotension at cesarean delivery may be incorrectly attributed to blood loss .
Diseases:"
4513	"Pulse power analysis ( also called "" pulse contour analysis "" ) of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time , thereby elucidating the causative factors behind changes in blood pressure ."	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Pulse power analysis ( also called "" pulse contour analysis "" ) of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time , thereby elucidating the causative factors behind changes in blood pressure .
Diseases: "	"Sentence: Pulse power analysis ( also called "" pulse contour analysis "" ) of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time , thereby elucidating the causative factors behind changes in blood pressure .
Diseases:"
4514	Pulse power analysis was conducted in six cases of cesarean delivery performed under neuraxial anesthesia .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Pulse power analysis was conducted in six cases of cesarean delivery performed under neuraxial anesthesia .
Diseases: "	"Sentence: Pulse power analysis was conducted in six cases of cesarean delivery performed under neuraxial anesthesia .
Diseases:"
4515	Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume , heart rate and cardiac output .	B O O O O O O O O O O O O O O O O O O B O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O	['stroke', 'hypotension']	2	4	"Sentence: Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume , heart rate and cardiac output .
Diseases: stroke, hypotension"	"Sentence: Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume , heart rate and cardiac output .
Diseases:"
4516	Pulse power analysis may be helpful in determining the etiology of and treating hypotension during cesarean delivery under neuraxial anesthesia .	O O O O O O O O O O O O O B O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	['hypotension']	1	3	"Sentence: Pulse power analysis may be helpful in determining the etiology of and treating hypotension during cesarean delivery under neuraxial anesthesia .
Diseases: hypotension"	"Sentence: Pulse power analysis may be helpful in determining the etiology of and treating hypotension during cesarean delivery under neuraxial anesthesia .
Diseases:"
4517	Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout ( VIP - / - ) mice with cyclophosphamide ( CYP ) - induced cystitis .	O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O B O B O O O O O	['cystitis']	1	3	"Sentence: Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout ( VIP - / - ) mice with cyclophosphamide ( CYP ) - induced cystitis .
Diseases: cystitis"	"Sentence: Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout ( VIP - / - ) mice with cyclophosphamide ( CYP ) - induced cystitis .
Diseases:"
4518	Vasoactive intestinal polypeptide ( VIP ) is an immunomodulatory neuropeptide distributed in micturition pathways .	O O O O O O O O O O O O O O O	O I I O B O O O O O O O O O O	[]	0	0	"Sentence: Vasoactive intestinal polypeptide ( VIP ) is an immunomodulatory neuropeptide distributed in micturition pathways .
Diseases: "	"Sentence: Vasoactive intestinal polypeptide ( VIP ) is an immunomodulatory neuropeptide distributed in micturition pathways .
Diseases:"
4519	VIP ( - / - ) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide ( CYP ) - induced cystitis .	O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O B O B O O O O O	['cystitis']	1	3	"Sentence: VIP ( - / - ) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide ( CYP ) - induced cystitis .
Diseases: cystitis"	"Sentence: VIP ( - / - ) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide ( CYP ) - induced cystitis .
Diseases:"
4520	Given VIP 's role as an anti - inflammatory mediator , we hypothesized that VIP ( - / - ) mice would exhibit enhanced inflammatory mediator expression after cystitis .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['cystitis']	1	3	"Sentence: Given VIP 's role as an anti - inflammatory mediator , we hypothesized that VIP ( - / - ) mice would exhibit enhanced inflammatory mediator expression after cystitis .
Diseases: cystitis"	"Sentence: Given VIP 's role as an anti - inflammatory mediator , we hypothesized that VIP ( - / - ) mice would exhibit enhanced inflammatory mediator expression after cystitis .
Diseases:"
4521	A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type ( WT ) and VIP ( - / - ) mice with or without CYP - induced cystitis ( 150 mg / kg ; i . p . ; 48 h ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	['cystitis']	1	3	"Sentence: A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type ( WT ) and VIP ( - / - ) mice with or without CYP - induced cystitis ( 150 mg / kg ; i . p . ; 48 h ) .
Diseases: cystitis"	"Sentence: A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type ( WT ) and VIP ( - / - ) mice with or without CYP - induced cystitis ( 150 mg / kg ; i . p . ; 48 h ) .
Diseases:"
4522	Four binary comparisons were made : WT control versus CYP treatment ( 48 h ) , VIP ( - / - ) control versus CYP treatment ( 48 h ) , WT control versus VIP ( - / - ) control , and WT with CYP treatment ( 48 h ) versus VIP ( - / - ) with CYP treatment ( 48 h ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O B O O O O O O	[]	0	0	"Sentence: Four binary comparisons were made : WT control versus CYP treatment ( 48 h ) , VIP ( - / - ) control versus CYP treatment ( 48 h ) , WT control versus VIP ( - / - ) control , and WT with CYP treatment ( 48 h ) versus VIP ( - / - ) with CYP treatment ( 48 h ) .
Diseases: "	"Sentence: Four binary comparisons were made : WT control versus CYP treatment ( 48 h ) , VIP ( - / - ) control versus CYP treatment ( 48 h ) , WT control versus VIP ( - / - ) control , and WT with CYP treatment ( 48 h ) versus VIP ( - / - ) with CYP treatment ( 48 h ) .
Diseases:"
4523	The genes presented represent ( 1 ) greater than 1 . 5 - fold change in either direction and ( 2 ) the p value is less than 0 . 05 for the comparison being made .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The genes presented represent ( 1 ) greater than 1 . 5 - fold change in either direction and ( 2 ) the p value is less than 0 . 05 for the comparison being made .
Diseases: "	"Sentence: The genes presented represent ( 1 ) greater than 1 . 5 - fold change in either direction and ( 2 ) the p value is less than 0 . 05 for the comparison being made .
Diseases:"
4524	Several regulated genes were validated using enzyme - linked immunoassays including IL - 1beta and CXCL1 .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Several regulated genes were validated using enzyme - linked immunoassays including IL - 1beta and CXCL1 .
Diseases: "	"Sentence: Several regulated genes were validated using enzyme - linked immunoassays including IL - 1beta and CXCL1 .
Diseases:"
4525	CYP treatment significantly ( p < or = 0 . 001 ) increased expression of CXCL1 and IL - 1beta in the urinary bladder of WT and VIP ( - / - ) mice , but expression in VIP ( - / - ) mice with CYP treatment was significantly ( p < or = 0 . 001 )	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: CYP treatment significantly ( p < or = 0 . 001 ) increased expression of CXCL1 and IL - 1beta in the urinary bladder of WT and VIP ( - / - ) mice , but expression in VIP ( - / - ) mice with CYP treatment was significantly ( p < or = 0 . 001 )
Diseases: "	"Sentence: CYP treatment significantly ( p < or = 0 . 001 ) increased expression of CXCL1 and IL - 1beta in the urinary bladder of WT and VIP ( - / - ) mice , but expression in VIP ( - / - ) mice with CYP treatment was significantly ( p < or = 0 . 001 )
Diseases:"
4526	greater ( 4 . 2 - to 13 - fold increase ) than that observed in WT urinary bladder ( 3 . 6 - to 5 - fold increase ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: greater ( 4 . 2 - to 13 - fold increase ) than that observed in WT urinary bladder ( 3 . 6 - to 5 - fold increase ) .
Diseases: "	"Sentence: greater ( 4 . 2 - to 13 - fold increase ) than that observed in WT urinary bladder ( 3 . 6 - to 5 - fold increase ) .
Diseases:"
4527	The data suggest that in VIP ( - / - ) mice with bladder inflammation , inflammatory mediators are increased above that observed in WT with CYP .	O O O O O O O O O O O O O B I O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['bladder inflammation']	1	3	"Sentence: The data suggest that in VIP ( - / - ) mice with bladder inflammation , inflammatory mediators are increased above that observed in WT with CYP .
Diseases: bladder inflammation"	"Sentence: The data suggest that in VIP ( - / - ) mice with bladder inflammation , inflammatory mediators are increased above that observed in WT with CYP .
Diseases:"
4528	This shift in balance may contribute to increased bladder dysfunction in VIP ( - / - ) mice with bladder inflammation and altered neurochemical expression in micturition pathways .	O O O O O O O O B I O O O O O O O O O B I O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['bladder inflammation', 'bladder dysfunction']	2	6	"Sentence: This shift in balance may contribute to increased bladder dysfunction in VIP ( - / - ) mice with bladder inflammation and altered neurochemical expression in micturition pathways .
Diseases: bladder inflammation, bladder dysfunction"	"Sentence: This shift in balance may contribute to increased bladder dysfunction in VIP ( - / - ) mice with bladder inflammation and altered neurochemical expression in micturition pathways .
Diseases:"
4529	Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants .	O O O O O B O O O O O O	O O O O O O O O B I O O	['uveitis']	1	2	"Sentence: Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants .
Diseases: uveitis"	"Sentence: Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants .
Diseases:"
4530	To report the incidence and management of elevated intraocular pressure ( IOP ) in patients with uveitis treated with the fluocinolone acetonide ( FA ) intravitreal implant .	O O O O O O O B I I O O O O O O B O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O B I O B O O O O	['uveitis', 'elevated intraocular pressure']	2	7	"Sentence: To report the incidence and management of elevated intraocular pressure ( IOP ) in patients with uveitis treated with the fluocinolone acetonide ( FA ) intravitreal implant .
Diseases: uveitis, elevated intraocular pressure"	"Sentence: To report the incidence and management of elevated intraocular pressure ( IOP ) in patients with uveitis treated with the fluocinolone acetonide ( FA ) intravitreal implant .
Diseases:"
4531	DESIGN : Pooled data from 3 multicenter , double - masked , randomized , controlled , phase 2b / 3 clinical trials evaluating the safety and efficacy of the 0 . 59 - mg or 2 . 1 - mg FA intravitreal implant or standard therapy were analyzed .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: DESIGN : Pooled data from 3 multicenter , double - masked , randomized , controlled , phase 2b / 3 clinical trials evaluating the safety and efficacy of the 0 . 59 - mg or 2 . 1 - mg FA intravitreal implant or standard therapy were analyzed .
Diseases: "	"Sentence: DESIGN : Pooled data from 3 multicenter , double - masked , randomized , controlled , phase 2b / 3 clinical trials evaluating the safety and efficacy of the 0 . 59 - mg or 2 . 1 - mg FA intravitreal implant or standard therapy were analyzed .
Diseases:"
4532	During the 3 - year follow - up , 71 . 0 % of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55 . 1 % , 24 . 7 % , and 6 . 2 % of eyes reached an IOP of 30 mm Hg or more , 40 mm Hg or more , and 50 mm Hg or more , respectively .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: During the 3 - year follow - up , 71 . 0 % of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55 . 1 % , 24 . 7 % , and 6 . 2 % of eyes reached an IOP of 30 mm Hg or more , 40 mm Hg or more , and 50 mm Hg or more , respectively .
Diseases: "	"Sentence: During the 3 - year follow - up , 71 . 0 % of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55 . 1 % , 24 . 7 % , and 6 . 2 % of eyes reached an IOP of 30 mm Hg or more , 40 mm Hg or more , and 50 mm Hg or more , respectively .
Diseases:"
4533	Topical IOP - lowering medication was administered in 74 . 8 % of implanted eyes , and IOP - lowering surgeries , most of which were trabeculectomies ( 76 . 2 % ) , were performed on 36 . 6 % of implanted eyes .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Topical IOP - lowering medication was administered in 74 . 8 % of implanted eyes , and IOP - lowering surgeries , most of which were trabeculectomies ( 76 . 2 % ) , were performed on 36 . 6 % of implanted eyes .
Diseases: "	"Sentence: Topical IOP - lowering medication was administered in 74 . 8 % of implanted eyes , and IOP - lowering surgeries , most of which were trabeculectomies ( 76 . 2 % ) , were performed on 36 . 6 % of implanted eyes .
Diseases:"
4534	Intraocular pressure - lowering surgeries were considered a success ( postoperative IOP of 6 - 21 mm Hg with or without additional IOP - lowering medication ) in 85 . 1 % of eyes at 1 year .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Intraocular pressure - lowering surgeries were considered a success ( postoperative IOP of 6 - 21 mm Hg with or without additional IOP - lowering medication ) in 85 . 1 % of eyes at 1 year .
Diseases: "	"Sentence: Intraocular pressure - lowering surgeries were considered a success ( postoperative IOP of 6 - 21 mm Hg with or without additional IOP - lowering medication ) in 85 . 1 % of eyes at 1 year .
Diseases:"
4535	The rate of hypotony ( IOP < / = 5 mm Hg ) following IOP - lowering surgery ( 42 . 5 % ) was not different from that of implanted eyes not subjected to surgery ( 35 . 4 % )	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hypotony']	1	3	"Sentence: The rate of hypotony ( IOP < / = 5 mm Hg ) following IOP - lowering surgery ( 42 . 5 % ) was not different from that of implanted eyes not subjected to surgery ( 35 . 4 % )
Diseases: hypotony"	"Sentence: The rate of hypotony ( IOP < / = 5 mm Hg ) following IOP - lowering surgery ( 42 . 5 % ) was not different from that of implanted eyes not subjected to surgery ( 35 . 4 % )
Diseases:"
4536	( P = . 09 ) .	O O O O O O O	O O O O O O O	[]	0	0	"Sentence: ( P = . 09 ) .
Diseases: "	"Sentence: ( P = . 09 ) .
Diseases:"
4537	CONCLUSION : Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: CONCLUSION : Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery .
Diseases: "	"Sentence: CONCLUSION : Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery .
Diseases:"
4538	Pallidal stimulation : an alternative to pallidotomy ?	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: Pallidal stimulation : an alternative to pallidotomy ?
Diseases: "	"Sentence: Pallidal stimulation : an alternative to pallidotomy ?
Diseases:"
4539	A resurgence of interest in the surgical treatment of Parkinson 's disease ( PD ) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985 .	O O O O O O O O O B I I O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O	"['pd', ""parkinson 's disease""]"	2	7	"Sentence: A resurgence of interest in the surgical treatment of Parkinson 's disease ( PD ) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985 .
Diseases: pd, parkinson 's disease"	"Sentence: A resurgence of interest in the surgical treatment of Parkinson 's disease ( PD ) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985 .
Diseases:"
4540	Laitinen 's procedure improved most symptoms in drug - resistant PD , which engendered wide interest in the neurosurgical community .	O O O O O O O O O O B O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	['pd']	1	1	"Sentence: Laitinen 's procedure improved most symptoms in drug - resistant PD , which engendered wide interest in the neurosurgical community .
Diseases: pd"	"Sentence: Laitinen 's procedure improved most symptoms in drug - resistant PD , which engendered wide interest in the neurosurgical community .
Diseases:"
4541	Another lesioning procedure , ventrolateral thalamotomy , has become a powerful alternative to stimulate the nucleus ventralis intermedius , producing high long - term success rates and low morbidity rates .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Another lesioning procedure , ventrolateral thalamotomy , has become a powerful alternative to stimulate the nucleus ventralis intermedius , producing high long - term success rates and low morbidity rates .
Diseases: "	"Sentence: Another lesioning procedure , ventrolateral thalamotomy , has become a powerful alternative to stimulate the nucleus ventralis intermedius , producing high long - term success rates and low morbidity rates .
Diseases:"
4542	Pallidal stimulation has not met with the same success .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: Pallidal stimulation has not met with the same success .
Diseases: "	"Sentence: Pallidal stimulation has not met with the same success .
Diseases:"
4543	"According to the literature pallidotomy improves the "" on "" symptoms of PD , such as dyskinesias , as well as the "" off "" symptoms , such as rigidity , bradykinesia , and on - off fluctuations ."	O O O O O O O O O O O O B O O O B O O O O O O O O O O O O B O B O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['pd', 'bradykinesia', 'dyskinesias', 'rigidity']	4	15	"Sentence: According to the literature pallidotomy improves the "" on "" symptoms of PD , such as dyskinesias , as well as the "" off "" symptoms , such as rigidity , bradykinesia , and on - off fluctuations .
Diseases: pd, bradykinesia, dyskinesias, rigidity"	"Sentence: According to the literature pallidotomy improves the "" on "" symptoms of PD , such as dyskinesias , as well as the "" off "" symptoms , such as rigidity , bradykinesia , and on - off fluctuations .
Diseases:"
4544	Pallidal stimulation improves bradykinesia and rigidity to a minor extent ; however , its strength seems to be in improving levodopa - induced dyskinesias .	O O O B O B O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O B O O O O	['rigidity', 'bradykinesia', 'dyskinesias']	3	13	"Sentence: Pallidal stimulation improves bradykinesia and rigidity to a minor extent ; however , its strength seems to be in improving levodopa - induced dyskinesias .
Diseases: rigidity, bradykinesia, dyskinesias"	"Sentence: Pallidal stimulation improves bradykinesia and rigidity to a minor extent ; however , its strength seems to be in improving levodopa - induced dyskinesias .
Diseases:"
4545	"Stimulation often produces an improvement in the hyper - or dyskinetic upper limbs , but increases the "" freezing "" phenomenon in the lower limbs at the same time ."	O O O O O O O B I I I O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['hyper - or dyskinetic']	1	6	"Sentence: Stimulation often produces an improvement in the hyper - or dyskinetic upper limbs , but increases the "" freezing "" phenomenon in the lower limbs at the same time .
Diseases: hyper - or dyskinetic"	"Sentence: Stimulation often produces an improvement in the hyper - or dyskinetic upper limbs , but increases the "" freezing "" phenomenon in the lower limbs at the same time .
Diseases:"
4546	Considering the small increase in the patient 's independence , the high costs of bilateral implants , and the difficulty most patients experience in handling the devices , the question arises as to whether bilateral pallidal stimulation is a real alternative to pallidotomy .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Considering the small increase in the patient 's independence , the high costs of bilateral implants , and the difficulty most patients experience in handling the devices , the question arises as to whether bilateral pallidal stimulation is a real alternative to pallidotomy .
Diseases: "	"Sentence: Considering the small increase in the patient 's independence , the high costs of bilateral implants , and the difficulty most patients experience in handling the devices , the question arises as to whether bilateral pallidal stimulation is a real alternative to pallidotomy .
Diseases:"
4547	Case report : Dexatrim ( Phenylpropanolamine ) as a cause of myocardial infarction .	O O O O O O O O O O O B I O	O O O B O B O O O O O O O O	['myocardial infarction']	1	6	"Sentence: Case report : Dexatrim ( Phenylpropanolamine ) as a cause of myocardial infarction .
Diseases: myocardial infarction"	"Sentence: Case report : Dexatrim ( Phenylpropanolamine ) as a cause of myocardial infarction .
Diseases:"
4548	Phenylpropanolamine ( PPA ) is a sympathetic amine used in over - the - counter cold remedies and weight - control preparations worldwide .	O O O O O O O O O O O O O O O O O O O O O O O O	B O B O O O B I O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Phenylpropanolamine ( PPA ) is a sympathetic amine used in over - the - counter cold remedies and weight - control preparations worldwide .
Diseases: "	"Sentence: Phenylpropanolamine ( PPA ) is a sympathetic amine used in over - the - counter cold remedies and weight - control preparations worldwide .
Diseases:"
4549	Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women .	O O O O O O B O O B I O O O O	O O O O O O O O O O O O O O O	['hypertensive', 'hemorrhagic strokes']	2	7	"Sentence: Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women .
Diseases: hypertensive, hemorrhagic strokes"	"Sentence: Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women .
Diseases:"
4550	Several reports have linked the abuse of PPA with myocardial injury , especially when overdose is involved .	O O O O O O O O O B I O O O B O O O	O O O O O O O B O O O O O O O O O O	['overdose', 'myocardial injury']	2	7	"Sentence: Several reports have linked the abuse of PPA with myocardial injury , especially when overdose is involved .
Diseases: overdose, myocardial injury"	"Sentence: Several reports have linked the abuse of PPA with myocardial injury , especially when overdose is involved .
Diseases:"
4551	We report here the first case of Dexatrim ( PPA ) - induced myocardial injury in a young woman who was using it at recommended doses for weight control .	O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O	O O O O O O O B O B O O O O O O O O O O O O O O O O O O O O	['myocardial injury']	1	4	"Sentence: We report here the first case of Dexatrim ( PPA ) - induced myocardial injury in a young woman who was using it at recommended doses for weight control .
Diseases: myocardial injury"	"Sentence: We report here the first case of Dexatrim ( PPA ) - induced myocardial injury in a young woman who was using it at recommended doses for weight control .
Diseases:"
4552	In addition , we review the 7 other cases of PPA related myocardial injury that have been reported so far .	O O O O O O O O O O O O B I O O O O O O O	O O O O O O O O O O B O O O O O O O O O O	['myocardial injury']	1	4	"Sentence: In addition , we review the 7 other cases of PPA related myocardial injury that have been reported so far .
Diseases: myocardial injury"	"Sentence: In addition , we review the 7 other cases of PPA related myocardial injury that have been reported so far .
Diseases:"
4553	Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA , even at doses generally considered to be safe .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA , even at doses generally considered to be safe .
Diseases: "	"Sentence: Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA , even at doses generally considered to be safe .
Diseases:"
4554	Risperidone - associated , benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse .	O O O O O O B I O B O O O O O O O O O	B O O O O O O O O O O O O O O O B O O	['schizophrenic', 'visual disturbances']	2	6	"Sentence: Risperidone - associated , benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse .
Diseases: schizophrenic, visual disturbances"	"Sentence: Risperidone - associated , benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse .
Diseases:"
4555	Two schizophrenic patients , who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics , were successfully treated with risperidone .	O B O O O O O O O O O O O O O O O B O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O O B O	['schizophrenic', 'eps']	2	6	"Sentence: Two schizophrenic patients , who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics , were successfully treated with risperidone .
Diseases: schizophrenic, eps"	"Sentence: Two schizophrenic patients , who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics , were successfully treated with risperidone .
Diseases:"
4556	They both reported short episodes of transient visual disturbances , which appeared immediately after starting treatment with risperidone .	O O O O O O O B I O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O	['visual disturbances']	1	2	"Sentence: They both reported short episodes of transient visual disturbances , which appeared immediately after starting treatment with risperidone .
Diseases: visual disturbances"	"Sentence: They both reported short episodes of transient visual disturbances , which appeared immediately after starting treatment with risperidone .
Diseases:"
4557	"This imagery resembled visual disturbances previously experienced as "" flashbacks "" related to prior LSD consumption ."	O O O B I O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O	['visual disturbances']	1	2	"Sentence: This imagery resembled visual disturbances previously experienced as "" flashbacks "" related to prior LSD consumption .
Diseases: visual disturbances"	"Sentence: This imagery resembled visual disturbances previously experienced as "" flashbacks "" related to prior LSD consumption .
Diseases:"
4558	Risperidone administration was continued and the visual disturbances gradually wore off .	O O O O O O B I O O O O	B O O O O O O O O O O O	['visual disturbances']	1	2	"Sentence: Risperidone administration was continued and the visual disturbances gradually wore off .
Diseases: visual disturbances"	"Sentence: Risperidone administration was continued and the visual disturbances gradually wore off .
Diseases:"
4559	During a six - month follow - up period , there was no recurrence of visual disturbances .	O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O	['visual disturbances']	1	2	"Sentence: During a six - month follow - up period , there was no recurrence of visual disturbances .
Diseases: visual disturbances"	"Sentence: During a six - month follow - up period , there was no recurrence of visual disturbances .
Diseases:"
4560	This phenomenon may be interpreted as a benign , short - term and self - limiting side effect which does not contraindicate the use of risperidone or interfere with treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O	[]	0	0	"Sentence: This phenomenon may be interpreted as a benign , short - term and self - limiting side effect which does not contraindicate the use of risperidone or interfere with treatment .
Diseases: "	"Sentence: This phenomenon may be interpreted as a benign , short - term and self - limiting side effect which does not contraindicate the use of risperidone or interfere with treatment .
Diseases:"
4561	Conclusions based on two case reports should be taken with appropriate caution .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Conclusions based on two case reports should be taken with appropriate caution .
Diseases: "	"Sentence: Conclusions based on two case reports should be taken with appropriate caution .
Diseases:"
4562	Activation of poly ( ADP - ribose ) polymerase contributes to development of doxorubicin - induced heart failure .	O O O O O O O O O O O O O O O O B I O	O O B I I I I O O O O O O B O O O O O	['heart failure']	1	2	"Sentence: Activation of poly ( ADP - ribose ) polymerase contributes to development of doxorubicin - induced heart failure .
Diseases: heart failure"	"Sentence: Activation of poly ( ADP - ribose ) polymerase contributes to development of doxorubicin - induced heart failure .
Diseases:"
4563	Activation of the nuclear enzyme poly ( ADP - ribose ) polymerase ( PARP ) by oxidant - mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B I I I I O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Activation of the nuclear enzyme poly ( ADP - ribose ) polymerase ( PARP ) by oxidant - mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress .
Diseases: "	"Sentence: Activation of the nuclear enzyme poly ( ADP - ribose ) polymerase ( PARP ) by oxidant - mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress .
Diseases:"
4564	Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin ( DOX ) , a widely used antitumor anthracycline antibiotic .	O O O O O O O O O O B O O O O O O O O O O O O O	O O O O O O O O O O O O B O B O O O O O O B O O	['cardiotoxicity']	1	3	"Sentence: Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin ( DOX ) , a widely used antitumor anthracycline antibiotic .
Diseases: cardiotoxicity"	"Sentence: Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin ( DOX ) , a widely used antitumor anthracycline antibiotic .
Diseases:"
4565	Thus , we hypothesized that the activation of PARP may contribute to the DOX - induced cardiotoxicity .	O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O B O O O O	['cardiotoxicity']	1	3	"Sentence: Thus , we hypothesized that the activation of PARP may contribute to the DOX - induced cardiotoxicity .
Diseases: cardiotoxicity"	"Sentence: Thus , we hypothesized that the activation of PARP may contribute to the DOX - induced cardiotoxicity .
Diseases:"
4566	Using a dual approach of PARP - 1 suppression , by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34 , we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I O O O O	O O O O O O O O O O O O O O O O O O B O O B O O O O O O O O O O O O O O O O B O	['cardiac dysfunction']	1	3	"Sentence: Using a dual approach of PARP - 1 suppression , by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34 , we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX .
Diseases: cardiac dysfunction"	"Sentence: Using a dual approach of PARP - 1 suppression , by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34 , we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX .
Diseases:"
4567	PARP - 1 + / + and PARP - 1 - / - mice received a single injection of DOX ( 25 mg / kg i . p ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O	[]	0	0	"Sentence: PARP - 1 + / + and PARP - 1 - / - mice received a single injection of DOX ( 25 mg / kg i . p ) .
Diseases: "	"Sentence: PARP - 1 + / + and PARP - 1 - / - mice received a single injection of DOX ( 25 mg / kg i . p ) .
Diseases:"
4568	Five days after DOX administration , left ventricular performance was significantly depressed in PARP - 1 + / + mice , but only to a smaller extent in PARP - 1 - / - ones .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Five days after DOX administration , left ventricular performance was significantly depressed in PARP - 1 + / + mice , but only to a smaller extent in PARP - 1 - / - ones .
Diseases: "	"Sentence: Five days after DOX administration , left ventricular performance was significantly depressed in PARP - 1 + / + mice , but only to a smaller extent in PARP - 1 - / - ones .
Diseases:"
4569	Similar experiments were conducted in BALB / c mice treated with PJ34 or vehicle .	O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O	[]	0	0	"Sentence: Similar experiments were conducted in BALB / c mice treated with PJ34 or vehicle .
Diseases: "	"Sentence: Similar experiments were conducted in BALB / c mice treated with PJ34 or vehicle .
Diseases:"
4570	Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals .	O O O O O O B I O O O O O O O O	O O O B O O O O O O O O O O O O	['cardiac dysfunction']	1	3	"Sentence: Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals .
Diseases: cardiac dysfunction"	"Sentence: Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals .
Diseases:"
4571	In addition PJ34 significantly reduced the DOX - induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O B O O O O O O B O O B O O O O O O O O O O	[]	0	0	"Sentence: In addition PJ34 significantly reduced the DOX - induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart .
Diseases: "	"Sentence: In addition PJ34 significantly reduced the DOX - induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart .
Diseases:"
4572	Thus , PARP activation contributes to the cardiotoxicity of DOX .	O O O O O O O B O O O	O O O O O O O O O B O	['cardiotoxicity']	1	3	"Sentence: Thus , PARP activation contributes to the cardiotoxicity of DOX .
Diseases: cardiotoxicity"	"Sentence: Thus , PARP activation contributes to the cardiotoxicity of DOX .
Diseases:"
4573	PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment .	O O O O O O O O O O O B I O O O O O O	O O O O O O O O O O O O O O O O B O O	['cardiac complications']	1	3	"Sentence: PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment .
Diseases: cardiac complications"	"Sentence: PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment .
Diseases:"
4574	Fluconazole - induced torsade de pointes .	O O O B I I O	B O O O O O O	['torsade de pointes']	1	6	"Sentence: Fluconazole - induced torsade de pointes .
Diseases: torsade de pointes"	"Sentence: Fluconazole - induced torsade de pointes .
Diseases:"
4575	To present a case of fluconazole - associated torsade de pointes ( TDP ) and discuss fluconazole 's role in causing TDP .	O O O O O O O O B I I O B O O O O O O O O B O	O O O O O B O O O O O O O O O O B O O O O O O	['torsade de pointes', 'tdp']	2	9	"Sentence: To present a case of fluconazole - associated torsade de pointes ( TDP ) and discuss fluconazole 's role in causing TDP .
Diseases: torsade de pointes, tdp"	"Sentence: To present a case of fluconazole - associated torsade de pointes ( TDP ) and discuss fluconazole 's role in causing TDP .
Diseases:"
4576	A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP , including coronary artery disease , cardiomyopathy , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP .	O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O B O O B I I O B O B I I O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O	['congestive heart failure', 'cardiomyopathy', 'coronary artery disease', 'tdp']	4	18	"Sentence: A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP , including coronary artery disease , cardiomyopathy , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP .
Diseases: congestive heart failure, cardiomyopathy, coronary artery disease, tdp"	"Sentence: A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP , including coronary artery disease , cardiomyopathy , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP .
Diseases:"
4577	The TDP resolved when fluconazole was discontinued ; however , the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia ( NSVT ) until six days after drug cessation DISCUSSION :	O B O O O O O O O O O O O O O B I I O O B I O B O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['nsvt', 'ventricular tachycardia', 'tdp', 'premature ventricular contractions']	4	18	"Sentence: The TDP resolved when fluconazole was discontinued ; however , the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia ( NSVT ) until six days after drug cessation DISCUSSION :
Diseases: nsvt, ventricular tachycardia, tdp, premature ventricular contractions"	"Sentence: The TDP resolved when fluconazole was discontinued ; however , the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia ( NSVT ) until six days after drug cessation DISCUSSION :
Diseases:"
4578	Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP .	O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O B O O O O O O	['tdp']	1	2	"Sentence: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP .
Diseases: tdp"	"Sentence: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP .
Diseases:"
4579	The possible mechanism is depression of rapidly activating delayed rectifier potassium currents .	O O O O B O O O O O O O O	O O O O O O O O O O B O O	['depression']	1	2	"Sentence: The possible mechanism is depression of rapidly activating delayed rectifier potassium currents .
Diseases: depression"	"Sentence: The possible mechanism is depression of rapidly activating delayed rectifier potassium currents .
Diseases:"
4580	In our patient , there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology .	O O O O O O O O O O O O O B I O B O O O O B O B I I O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	['nsvt', 'qt prolongation', 'tdp', 'premature ventricular contractions']	4	16	"Sentence: In our patient , there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology .
Diseases: nsvt, qt prolongation, tdp, premature ventricular contractions"	"Sentence: In our patient , there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology .
Diseases:"
4581	CONCLUSIONS : Clinicians should be aware that fluconazole , even at low doses , may cause prolongation of the QT interval , leading to TDP .	O O O O O O O O O O O O O O O O B I I I I O O O B O	O O O O O O O B O O O O O O O O O O O O O O O O O O	['prolongation of the qt interval', 'tdp']	2	11	"Sentence: CONCLUSIONS : Clinicians should be aware that fluconazole , even at low doses , may cause prolongation of the QT interval , leading to TDP .
Diseases: prolongation of the qt interval, tdp"	"Sentence: CONCLUSIONS : Clinicians should be aware that fluconazole , even at low doses , may cause prolongation of the QT interval , leading to TDP .
Diseases:"
4582	Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias .	O O O O O O O O O O O O O O O O O B I O	O O O O O O O B O O O O O O O O O O O O	['ventricular arrhythmias']	1	6	"Sentence: Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias .
Diseases: ventricular arrhythmias"	"Sentence: Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias .
Diseases:"
4583	High - dose methylprednisolone may do more harm for spinal cord injury .	O O O O O O O O O B I I O	O O O B O O O O O O O O O	['spinal cord injury']	1	4	"Sentence: High - dose methylprednisolone may do more harm for spinal cord injury .
Diseases: spinal cord injury"	"Sentence: High - dose methylprednisolone may do more harm for spinal cord injury .
Diseases:"
4584	Because of the National Acute Spinal Cord Injury Studies ( NASCIS ) , high - dose methylprednisolone became the standard of care for the acute spinal cord injury .	O O O O O B I I O O O O O O O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O	['spinal cord injury']	1	4	"Sentence: Because of the National Acute Spinal Cord Injury Studies ( NASCIS ) , high - dose methylprednisolone became the standard of care for the acute spinal cord injury .
Diseases: spinal cord injury"	"Sentence: Because of the National Acute Spinal Cord Injury Studies ( NASCIS ) , high - dose methylprednisolone became the standard of care for the acute spinal cord injury .
Diseases:"
4585	In the NASCIS , there was no mention regarding the possibility of acute corticosteroid myopathy that high - dose methylprednisolone may cause .	O O O O O O O O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O B O O O O O B O O O	['myopathy']	1	2	"Sentence: In the NASCIS , there was no mention regarding the possibility of acute corticosteroid myopathy that high - dose methylprednisolone may cause .
Diseases: myopathy"	"Sentence: In the NASCIS , there was no mention regarding the possibility of acute corticosteroid myopathy that high - dose methylprednisolone may cause .
Diseases:"
4586	The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2 - day period for any clinical condition .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2 - day period for any clinical condition .
Diseases: "	"Sentence: The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2 - day period for any clinical condition .
Diseases:"
4587	We hypothesize that it may cause some damage to the muscle of spinal cord injury patients .	O O O O O O O B I I I O B I I O O	O O O O O O O O O O O O O O O O O	['spinal cord injury', 'damage to the muscle']	2	9	"Sentence: We hypothesize that it may cause some damage to the muscle of spinal cord injury patients .
Diseases: spinal cord injury, damage to the muscle"	"Sentence: We hypothesize that it may cause some damage to the muscle of spinal cord injury patients .
Diseases:"
4588	Further , steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy , instead of any protection that methylprednisolone offers to the spinal cord injury .	O O O B O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O B I I O	O O B O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O B O O O O O O O	['myopathy', 'spinal cord injury']	2	6	"Sentence: Further , steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy , instead of any protection that methylprednisolone offers to the spinal cord injury .
Diseases: myopathy, spinal cord injury"	"Sentence: Further , steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy , instead of any protection that methylprednisolone offers to the spinal cord injury .
Diseases:"
4589	To our knowledge , this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy .	O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O B O O O O O O B O O	['myopathy']	1	2	"Sentence: To our knowledge , this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy .
Diseases: myopathy"	"Sentence: To our knowledge , this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy .
Diseases:"
4590	Probing peripheral and central cholinergic system responses .	O O O O O O O O	O O O O O O O O	[]	0	0	"Sentence: Probing peripheral and central cholinergic system responses .
Diseases: "	"Sentence: Probing peripheral and central cholinergic system responses .
Diseases:"
4591	The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer 's disease , yet correlations between central and peripheral responses have not been properly studied .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	"[""alzheimer 's disease""]"	1	6	"Sentence: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer 's disease , yet correlations between central and peripheral responses have not been properly studied .
Diseases: alzheimer 's disease"	"Sentence: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer 's disease , yet correlations between central and peripheral responses have not been properly studied .
Diseases:"
4592	This study assessed the effect of normal aging on ( 1 ) the tropicamide - induced increase in pupil diameter , and ( 2 ) the reversal of this effect with pilocarpine .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O B O	[]	0	0	"Sentence: This study assessed the effect of normal aging on ( 1 ) the tropicamide - induced increase in pupil diameter , and ( 2 ) the reversal of this effect with pilocarpine .
Diseases: "	"Sentence: This study assessed the effect of normal aging on ( 1 ) the tropicamide - induced increase in pupil diameter , and ( 2 ) the reversal of this effect with pilocarpine .
Diseases:"
4593	Scopolamine was used as a positive control to detect age - dependent changes in central cholinergic functioning in the elderly .	O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Scopolamine was used as a positive control to detect age - dependent changes in central cholinergic functioning in the elderly .
Diseases: "	"Sentence: Scopolamine was used as a positive control to detect age - dependent changes in central cholinergic functioning in the elderly .
Diseases:"
4594	DESIGN : Randomized double - blind controlled trial .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: DESIGN : Randomized double - blind controlled trial .
Diseases: "	"Sentence: DESIGN : Randomized double - blind controlled trial .
Diseases:"
4595	PARTICIPANTS : Ten healthy elderly ( mean age 70 ) and 9 young ( mean age 33 ) volunteers .	O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: PARTICIPANTS : Ten healthy elderly ( mean age 70 ) and 9 young ( mean age 33 ) volunteers .
Diseases: "	"Sentence: PARTICIPANTS : Ten healthy elderly ( mean age 70 ) and 9 young ( mean age 33 ) volunteers .
Diseases:"
4596	INTERVENTIONS :	O O	O O	[]	0	0	"Sentence: INTERVENTIONS :
Diseases: "	"Sentence: INTERVENTIONS :
Diseases:"
4597	Pupil diameter was monitored using a computerized infrared pupillometer over 4 hours .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: Pupil diameter was monitored using a computerized infrared pupillometer over 4 hours .
Diseases: "	"Sentence: Pupil diameter was monitored using a computerized infrared pupillometer over 4 hours .
Diseases:"
4598	The study involved 4 sessions .	O O O O O O	O O O O O O	[]	0	0	"Sentence: The study involved 4 sessions .
Diseases: "	"Sentence: The study involved 4 sessions .
Diseases:"
4599	In 1 session , tropicamide ( 20 microL , 0 . 01 % ) was administered to one eye and placebo to the other .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In 1 session , tropicamide ( 20 microL , 0 . 01 % ) was administered to one eye and placebo to the other .
Diseases: "	"Sentence: In 1 session , tropicamide ( 20 microL , 0 . 01 % ) was administered to one eye and placebo to the other .
Diseases:"
4600	In another session , tropicamide ( 20 microL , 0 . 01 % ) was administered to both eyes , followed 23 minutes later by the application of pilocarpine ( 20 microL , 0 . 1 % ) to one eye and placebo to the other .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In another session , tropicamide ( 20 microL , 0 . 01 % ) was administered to both eyes , followed 23 minutes later by the application of pilocarpine ( 20 microL , 0 . 1 % ) to one eye and placebo to the other .
Diseases: "	"Sentence: In another session , tropicamide ( 20 microL , 0 . 01 % ) was administered to both eyes , followed 23 minutes later by the application of pilocarpine ( 20 microL , 0 . 1 % ) to one eye and placebo to the other .
Diseases:"
4601	All eye drops were given in a randomized order .	O O O O O O O O O O	O O O O O O O O O O	[]	0	0	"Sentence: All eye drops were given in a randomized order .
Diseases: "	"Sentence: All eye drops were given in a randomized order .
Diseases:"
4602	In 2 separate sessions , a single dose of scopolamine ( 0 . 5 mg , intravenously ) or placebo was administered , and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: In 2 separate sessions , a single dose of scopolamine ( 0 . 5 mg , intravenously ) or placebo was administered , and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours .
Diseases: "	"Sentence: In 2 separate sessions , a single dose of scopolamine ( 0 . 5 mg , intravenously ) or placebo was administered , and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours .
Diseases:"
4603	OUTCOME MEASURES :	O O O	O O O	[]	0	0	"Sentence: OUTCOME MEASURES :
Diseases: "	"Sentence: OUTCOME MEASURES :
Diseases:"
4604	Pupil size at time points after administration of tropicamide and pilocarpine ; scopolamine - induced impairment in word recall .	O O O O O O O O O O O O O O O B I I I O	O O O O O O O O B O B O B O O O O O O O	['impairment in word recall']	1	6	"Sentence: Pupil size at time points after administration of tropicamide and pilocarpine ; scopolamine - induced impairment in word recall .
Diseases: impairment in word recall"	"Sentence: Pupil size at time points after administration of tropicamide and pilocarpine ; scopolamine - induced impairment in word recall .
Diseases:"
4605	There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point ( p > 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O O O O O O O O O O O O	[]	0	0	"Sentence: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point ( p > 0 . 05 ) .
Diseases: "	"Sentence: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point ( p > 0 . 05 ) .
Diseases:"
4606	The elderly group had a significantly greater pilocarpine - induced net decrease in pupil size 85 , 125 , 165 and 215 minutes after administration , compared with the young group ( p < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The elderly group had a significantly greater pilocarpine - induced net decrease in pupil size 85 , 125 , 165 and 215 minutes after administration , compared with the young group ( p < 0 . 05 ) .
Diseases: "	"Sentence: The elderly group had a significantly greater pilocarpine - induced net decrease in pupil size 85 , 125 , 165 and 215 minutes after administration , compared with the young group ( p < 0 . 05 ) .
Diseases:"
4607	Compared with the young group , the elderly group had greater scopolamine - induced impairment in word recall 60 , 90 and 120 minutes after administration ( p < 0 . 05 ) .	O O O O O O O O O O O O O O B I I I O O O O O O O O O O O O O O O O	O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O	['impairment in word recall']	1	6	"Sentence: Compared with the young group , the elderly group had greater scopolamine - induced impairment in word recall 60 , 90 and 120 minutes after administration ( p < 0 . 05 ) .
Diseases: impairment in word recall"	"Sentence: Compared with the young group , the elderly group had greater scopolamine - induced impairment in word recall 60 , 90 and 120 minutes after administration ( p < 0 . 05 ) .
Diseases:"
4608	There is an age - related pupillary response to pilocarpine that is not found with tropicamide .	O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O B O	[]	0	0	"Sentence: There is an age - related pupillary response to pilocarpine that is not found with tropicamide .
Diseases: "	"Sentence: There is an age - related pupillary response to pilocarpine that is not found with tropicamide .
Diseases:"
4609	Thus , pilocarpine may be useful to assess variations in central cholinergic function in elderly patients .	O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: Thus , pilocarpine may be useful to assess variations in central cholinergic function in elderly patients .
Diseases: "	"Sentence: Thus , pilocarpine may be useful to assess variations in central cholinergic function in elderly patients .
Diseases:"
4610	Acetazolamide - induced Gerstmann syndrome .	O O O B I O	B O O O O O	['gerstmann syndrome']	1	4	"Sentence: Acetazolamide - induced Gerstmann syndrome .
Diseases: gerstmann syndrome"	"Sentence: Acetazolamide - induced Gerstmann syndrome .
Diseases:"
4611	Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment .	O B O O O O O O O O O O O O O B I O	O O O O B O O O O O O O O O O O O O	['confusion', 'renal impairment']	2	5	"Sentence: Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment .
Diseases: confusion, renal impairment"	"Sentence: Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment .
Diseases:"
4612	We report a case of acetazolamide - induced Gerstmann syndrome in a patient with normal renal function , to highlight predisposing factors that are frequently overlooked .	O O O O O O O O B I O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O O	['gerstmann syndrome']	1	4	"Sentence: We report a case of acetazolamide - induced Gerstmann syndrome in a patient with normal renal function , to highlight predisposing factors that are frequently overlooked .
Diseases: gerstmann syndrome"	"Sentence: We report a case of acetazolamide - induced Gerstmann syndrome in a patient with normal renal function , to highlight predisposing factors that are frequently overlooked .
Diseases:"
4613	Hypomania - like syndrome induced by olanzapine .	B O O O O O O O	O O O O O O B O	['hypomania']	1	3	"Sentence: Hypomania - like syndrome induced by olanzapine .
Diseases: hypomania"	"Sentence: Hypomania - like syndrome induced by olanzapine .
Diseases:"
4614	We report a female patient with a diagnosis of a not otherwise specified psychotic disorder ( DSM - IV ) who developed hypomania shortly after the introduction of olanzapine treatment .	O O O O O O O O O O O O O B I O O O O O O O B O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O	['psychotic disorder', 'hypomania']	2	7	"Sentence: We report a female patient with a diagnosis of a not otherwise specified psychotic disorder ( DSM - IV ) who developed hypomania shortly after the introduction of olanzapine treatment .
Diseases: psychotic disorder, hypomania"	"Sentence: We report a female patient with a diagnosis of a not otherwise specified psychotic disorder ( DSM - IV ) who developed hypomania shortly after the introduction of olanzapine treatment .
Diseases:"
4615	Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure .	O O O O O O O O O B I I O	O B O B I O O O O O O O O	['acute liver failure']	1	4	"Sentence: Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure .
Diseases: acute liver failure"	"Sentence: Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure .
Diseases:"
4616	Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure ( ALF ) .	O O O O O O O O O O O O O O O B I O O O B I I O B O O	O O B O B I O O O O O O O O O O O O O O O O O O O O O	['acute liver failure', 'bacterial infections', 'alf']	3	10	"Sentence: Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure ( ALF ) .
Diseases: acute liver failure, bacterial infections, alf"	"Sentence: Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure ( ALF ) .
Diseases:"
4617	In the present study , oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers .	O O O O O O O O O O O B O O O B O O O O O O O O	O O O O O B O O O O O O O O B O O O O O O O O O	['overdose', 'alf']	2	5	"Sentence: In the present study , oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers .
Diseases: overdose, alf"	"Sentence: In the present study , oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers .
Diseases:"
4618	Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum .	O O O B O O O O O O O O O O O B O O O O	O O O O O O O O O O O O O O O O O O O O	['alf']	1	1	"Sentence: Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum .
Diseases: alf"	"Sentence: Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum .
Diseases:"
4619	Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects ( P < 0 . 01 ) .	O O O O O O B O O O O O O B O O O O O O O O O O O O O O O O O	B O B I O O O O O O O O O O O O O O O O O O O O O O O O O O O	['alf']	1	1	"Sentence: Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects ( P < 0 . 01 ) .
Diseases: alf"	"Sentence: Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects ( P < 0 . 01 ) .
Diseases:"
4620	This defect persisted when zymosan opsonized by control serum was used ( P < 0 . 05 ) .	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This defect persisted when zymosan opsonized by control serum was used ( P < 0 . 05 ) .
Diseases: "	"Sentence: This defect persisted when zymosan opsonized by control serum was used ( P < 0 . 05 ) .
Diseases:"
4621	Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl - methionyl - leucyl - phenylalanine ( fMLP ) from a further 18 ALF patients was unaffected compared with control neutrophils .	O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O	B O B I O O O O O B I I I I I I O B O O O O O O O O O O O O O O	['alf']	1	1	"Sentence: Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl - methionyl - leucyl - phenylalanine ( fMLP ) from a further 18 ALF patients was unaffected compared with control neutrophils .
Diseases: alf"	"Sentence: Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl - methionyl - leucyl - phenylalanine ( fMLP ) from a further 18 ALF patients was unaffected compared with control neutrophils .
Diseases:"
4622	Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects ( P < 0 . 0005 ) .	O O O O O O O O B O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O	['alf']	1	1	"Sentence: Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects ( P < 0 . 0005 ) .
Diseases: alf"	"Sentence: Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects ( P < 0 . 0005 ) .
Diseases:"
4623	These results demonstrate a neutrophil defect in ALF due to paracetamol overdose , that is complement dependent but independent of serum complement , possibly connected to the complement receptor .	O O O O O O O B O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O	['overdose', 'alf']	2	5	"Sentence: These results demonstrate a neutrophil defect in ALF due to paracetamol overdose , that is complement dependent but independent of serum complement , possibly connected to the complement receptor .
Diseases: overdose, alf"	"Sentence: These results demonstrate a neutrophil defect in ALF due to paracetamol overdose , that is complement dependent but independent of serum complement , possibly connected to the complement receptor .
Diseases:"
4624	Absence of effect of sertraline on time - based sensitization of cognitive impairment with haloperidol .	O O O O O O O O O O O B I O O O	O O O O B O O O O O O O O O B O	['cognitive impairment']	1	3	"Sentence: Absence of effect of sertraline on time - based sensitization of cognitive impairment with haloperidol .
Diseases: cognitive impairment"	"Sentence: Absence of effect of sertraline on time - based sensitization of cognitive impairment with haloperidol .
Diseases:"
4625	This double - blind , randomized , placebo - controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O B O O B O B O O O O O O O O O O O	[]	0	0	"Sentence: This double - blind , randomized , placebo - controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects .
Diseases: "	"Sentence: This double - blind , randomized , placebo - controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects .
Diseases:"
4626	All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25 .	O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O	[]	0	0	"Sentence: All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25 .
Diseases: "	"Sentence: All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25 .
Diseases:"
4627	From Days 9 to 25 , subjects were randomly assigned to either sertraline ( 12 subjects ) or placebo ( 12 subjects ) ; the sertraline dose was titrated from 50 to 200 mg / day from Days 9 to 16 , and remained at 200 mg / day for the final 10 days of the drug administration period .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O B O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: From Days 9 to 25 , subjects were randomly assigned to either sertraline ( 12 subjects ) or placebo ( 12 subjects ) ; the sertraline dose was titrated from 50 to 200 mg / day from Days 9 to 16 , and remained at 200 mg / day for the final 10 days of the drug administration period .
Diseases: "	"Sentence: From Days 9 to 25 , subjects were randomly assigned to either sertraline ( 12 subjects ) or placebo ( 12 subjects ) ; the sertraline dose was titrated from 50 to 200 mg / day from Days 9 to 16 , and remained at 200 mg / day for the final 10 days of the drug administration period .
Diseases:"
4628	Cognitive function testing was performed before dosing and over a 24 - hour period after dosing on Days 1 , 2 , and 25 .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Cognitive function testing was performed before dosing and over a 24 - hour period after dosing on Days 1 , 2 , and 25 .
Diseases: "	"Sentence: Cognitive function testing was performed before dosing and over a 24 - hour period after dosing on Days 1 , 2 , and 25 .
Diseases:"
4629	Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing .	B I I I O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O	['impairment of cognitive function']	1	6	"Sentence: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing .
Diseases: impairment of cognitive function"	"Sentence: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing .
Diseases:"
4630	When single - dose haloperidol was given again 25 days later , greater impairment with earlier onset was noted in several tests in both treatment groups , suggesting enhancement of this effect .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: When single - dose haloperidol was given again 25 days later , greater impairment with earlier onset was noted in several tests in both treatment groups , suggesting enhancement of this effect .
Diseases: "	"Sentence: When single - dose haloperidol was given again 25 days later , greater impairment with earlier onset was noted in several tests in both treatment groups , suggesting enhancement of this effect .
Diseases:"
4631	There was no indication that sertraline exacerbated the impairment produced by haloperidol since an equivalent effect also occurred in the placebo group .	O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O B O O O O O O O O O O O	[]	0	0	"Sentence: There was no indication that sertraline exacerbated the impairment produced by haloperidol since an equivalent effect also occurred in the placebo group .
Diseases: "	"Sentence: There was no indication that sertraline exacerbated the impairment produced by haloperidol since an equivalent effect also occurred in the placebo group .
Diseases:"
4632	Three subjects ( 2 on sertraline and 1 on placebo ) withdrew from the study because of side effects .	O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: Three subjects ( 2 on sertraline and 1 on placebo ) withdrew from the study because of side effects .
Diseases: "	"Sentence: Three subjects ( 2 on sertraline and 1 on placebo ) withdrew from the study because of side effects .
Diseases:"
4633	Ten subjects in each group reported side effects related to treatment .	O O O O O O O O O O O O	O O O O O O O O O O O O	[]	0	0	"Sentence: Ten subjects in each group reported side effects related to treatment .
Diseases: "	"Sentence: Ten subjects in each group reported side effects related to treatment .
Diseases:"
4634	The side effect profiles of sertraline and of placebo were similar .	O O O O O O O O O O O O	O O O O O B O O O O O O	[]	0	0	"Sentence: The side effect profiles of sertraline and of placebo were similar .
Diseases: "	"Sentence: The side effect profiles of sertraline and of placebo were similar .
Diseases:"
4635	Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration .	O O O O O O B I O O O O O O O O O	B O O O O O O O O O O O O O B O O	['cognitive impairment']	1	3	"Sentence: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration .
Diseases: cognitive impairment"	"Sentence: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration .
Diseases:"
4636	Ciprofloxacin - induced nephrotoxicity in patients with cancer .	O O O B O O O B O	B O O O O O O O O	['nephrotoxicity', 'cancer']	2	6	"Sentence: Ciprofloxacin - induced nephrotoxicity in patients with cancer .
Diseases: nephrotoxicity, cancer"	"Sentence: Ciprofloxacin - induced nephrotoxicity in patients with cancer .
Diseases:"
4637	Nephrotoxicity associated with ciprofloxacin is uncommon .	B O O O O O O	O O O B O O O	['nephrotoxicity']	1	4	"Sentence: Nephrotoxicity associated with ciprofloxacin is uncommon .
Diseases: nephrotoxicity"	"Sentence: Nephrotoxicity associated with ciprofloxacin is uncommon .
Diseases:"
4638	Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed .	O O O B O O B I I O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O B O O O O O O O O O O O O O O	['acute renal failure', 'cancer']	2	6	"Sentence: Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed .
Diseases: acute renal failure, cancer"	"Sentence: Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed .
Diseases:"
4639	Other than elevation of serum creatinine levels , characteristic clinical manifestations and abnormal laboratory findings are not frequently present .	O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: Other than elevation of serum creatinine levels , characteristic clinical manifestations and abnormal laboratory findings are not frequently present .
Diseases: "	"Sentence: Other than elevation of serum creatinine levels , characteristic clinical manifestations and abnormal laboratory findings are not frequently present .
Diseases:"
4640	Allergic interstitial nephritis is believed to be the underlying pathological - process .	O B I O O O O O O O O O O	O O O O O O O O O O O O O	['interstitial nephritis']	1	4	"Sentence: Allergic interstitial nephritis is believed to be the underlying pathological - process .
Diseases: interstitial nephritis"	"Sentence: Allergic interstitial nephritis is believed to be the underlying pathological - process .
Diseases:"
4641	Definitive diagnosis requires performance of renal biopsy , although this is not always feasible .	O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Definitive diagnosis requires performance of renal biopsy , although this is not always feasible .
Diseases: "	"Sentence: Definitive diagnosis requires performance of renal biopsy , although this is not always feasible .
Diseases:"
4642	An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin - induced acute renal failure .	O O O O O O O O O O O O O O O O O O O O O B I I O	O O O O O O O O O O O O O O O O O O B O O O O O O	['acute renal failure']	1	4	"Sentence: An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin - induced acute renal failure .
Diseases: acute renal failure"	"Sentence: An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin - induced acute renal failure .
Diseases:"
4643	Case report : pentamidine and polymorphic ventricular tachycardia revisited .	O O O O O O B I O O	O O O B O O O O O O	['ventricular tachycardia']	1	6	"Sentence: Case report : pentamidine and polymorphic ventricular tachycardia revisited .
Diseases: ventricular tachycardia"	"Sentence: Case report : pentamidine and polymorphic ventricular tachycardia revisited .
Diseases:"
4644	Pentamidine isethionate has been associated with ventricular tachyarrhythmias , including torsade de pointes .	O O O O O O B I O O B I I O	B I O O O O O O O O O O O O	['torsade de pointes', 'ventricular tachyarrhythmias']	2	15	"Sentence: Pentamidine isethionate has been associated with ventricular tachyarrhythmias , including torsade de pointes .
Diseases: torsade de pointes, ventricular tachyarrhythmias"	"Sentence: Pentamidine isethionate has been associated with ventricular tachyarrhythmias , including torsade de pointes .
Diseases:"
4645	This article reports two cases of this complication and reviews all reported cases to date .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This article reports two cases of this complication and reviews all reported cases to date .
Diseases: "	"Sentence: This article reports two cases of this complication and reviews all reported cases to date .
Diseases:"
4646	Pentamidine - induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade .	O O O B I I O O O O O O O O B O O O O O	B O O O O O O O O O O B O O O O O O O O	['hypomagnesemia', 'torsade de pointes']	2	12	"Sentence: Pentamidine - induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade .
Diseases: hypomagnesemia, torsade de pointes"	"Sentence: Pentamidine - induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade .
Diseases:"
4647	Torsade de pointes occurred after an average of 10 days of treatment with pentamidine .	B I I O O O O O O O O O O O O	O O O O O O O O O O O O O B O	['torsade de pointes']	1	6	"Sentence: Torsade de pointes occurred after an average of 10 days of treatment with pentamidine .
Diseases: torsade de pointes"	"Sentence: Torsade de pointes occurred after an average of 10 days of treatment with pentamidine .
Diseases:"
4648	In these patients , no other acute side effects of pentamidine were observed .	O O O O O O O O O O O O O O	O O O O O O O O O O B O O O	[]	0	0	"Sentence: In these patients , no other acute side effects of pentamidine were observed .
Diseases: "	"Sentence: In these patients , no other acute side effects of pentamidine were observed .
Diseases:"
4649	Torsade de pointes can be treated when recognized early , possibly without discontinuation of pentamidine .	B I I O O O O O O O O O O O O O	O O O O O O O O O O O O O O B O	['torsade de pointes']	1	6	"Sentence: Torsade de pointes can be treated when recognized early , possibly without discontinuation of pentamidine .
Diseases: torsade de pointes"	"Sentence: Torsade de pointes can be treated when recognized early , possibly without discontinuation of pentamidine .
Diseases:"
4650	When QTc interval prolongation is observed , early magnesium supplementation is advocated .	O B I I O O O O O O O O O	O O O O O O O O B O O O O	['qtc interval prolongation']	1	5	"Sentence: When QTc interval prolongation is observed , early magnesium supplementation is advocated .
Diseases: qtc interval prolongation"	"Sentence: When QTc interval prolongation is observed , early magnesium supplementation is advocated .
Diseases:"
4651	Time dependence of plasma malondialdehyde , oxypurines , and nucleosides during incomplete cerebral ischemia in the rat .	O O O O O O O O O O O O B I O O O O	O O O O B O B O O B O O O O O O O O	['cerebral ischemia']	1	6	"Sentence: Time dependence of plasma malondialdehyde , oxypurines , and nucleosides during incomplete cerebral ischemia in the rat .
Diseases: cerebral ischemia"	"Sentence: Time dependence of plasma malondialdehyde , oxypurines , and nucleosides during incomplete cerebral ischemia in the rat .
Diseases:"
4652	Incomplete cerebral ischemia ( 30 min ) was induced in the rat by bilaterally clamping the common carotid arteries .	O B I O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O	['cerebral ischemia']	1	6	"Sentence: Incomplete cerebral ischemia ( 30 min ) was induced in the rat by bilaterally clamping the common carotid arteries .
Diseases: cerebral ischemia"	"Sentence: Incomplete cerebral ischemia ( 30 min ) was induced in the rat by bilaterally clamping the common carotid arteries .
Diseases:"
4653	Peripheral venous blood samples were withdrawn from the femoral vein four times ( once every 5 min ) before ischemia ( 0 time ) and 5 , 15 , and 30 min after ischemia .	O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ischemia']	1	3	"Sentence: Peripheral venous blood samples were withdrawn from the femoral vein four times ( once every 5 min ) before ischemia ( 0 time ) and 5 , 15 , and 30 min after ischemia .
Diseases: ischemia"	"Sentence: Peripheral venous blood samples were withdrawn from the femoral vein four times ( once every 5 min ) before ischemia ( 0 time ) and 5 , 15 , and 30 min after ischemia .
Diseases:"
4654	Plasma extracts were analyzed by a highly sensitive high - performance liquid chromatographic method for the direct determination of malondialdehyde , oxypurines , and nucleosides .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O B O B O O B O	[]	0	0	"Sentence: Plasma extracts were analyzed by a highly sensitive high - performance liquid chromatographic method for the direct determination of malondialdehyde , oxypurines , and nucleosides .
Diseases: "	"Sentence: Plasma extracts were analyzed by a highly sensitive high - performance liquid chromatographic method for the direct determination of malondialdehyde , oxypurines , and nucleosides .
Diseases:"
4655	During ischemia , a time - dependent increase of plasma oxypurines and nucleosides was observed .	O B O O O O O O O O O O O O O O	O O O O O O O O O O B O B O O O	['ischemia']	1	3	"Sentence: During ischemia , a time - dependent increase of plasma oxypurines and nucleosides was observed .
Diseases: ischemia"	"Sentence: During ischemia , a time - dependent increase of plasma oxypurines and nucleosides was observed .
Diseases:"
4656	Plasma malondialdehyde , which was present in minimal amount at zero time ( 0 . 058 mumol / liter plasma ; SD 0 . 015 ) , increased after 5 min of ischemia , resulting in a fivefold increase after 30 min of carotid occlusion ( 0 . 298 mumol / liter plasma ; SD 0 . 078 ) .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['ischemia']	1	3	"Sentence: Plasma malondialdehyde , which was present in minimal amount at zero time ( 0 . 058 mumol / liter plasma ; SD 0 . 015 ) , increased after 5 min of ischemia , resulting in a fivefold increase after 30 min of carotid occlusion ( 0 . 298 mumol / liter plasma ; SD 0 . 078 ) .
Diseases: ischemia"	"Sentence: Plasma malondialdehyde , which was present in minimal amount at zero time ( 0 . 058 mumol / liter plasma ; SD 0 . 015 ) , increased after 5 min of ischemia , resulting in a fivefold increase after 30 min of carotid occlusion ( 0 . 298 mumol / liter plasma ; SD 0 . 078 ) .
Diseases:"
4657	Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model , one receiving 20 mg / kg b . w .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model , one receiving 20 mg / kg b . w .
Diseases: "	"Sentence: Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model , one receiving 20 mg / kg b . w .
Diseases:"
4658	of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia , the other receiving 650 micrograms / kg b . w .	O O O O O O O O B O O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O	['ischemia']	1	3	"Sentence: of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia , the other receiving 650 micrograms / kg b . w .
Diseases: ischemia"	"Sentence: of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia , the other receiving 650 micrograms / kg b . w .
Diseases:"
4659	of the hypotensive drug nitroprusside at a flow rate of 103 microliters / min intravenously during ischemia , although in this latter group malondialdehyde was significantly higher .	O O B O O O O O O O O O O O O O B O O O O O O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O B O O O O	['hypotensive', 'ischemia']	2	7	"Sentence: of the hypotensive drug nitroprusside at a flow rate of 103 microliters / min intravenously during ischemia , although in this latter group malondialdehyde was significantly higher .
Diseases: hypotensive, ischemia"	"Sentence: of the hypotensive drug nitroprusside at a flow rate of 103 microliters / min intravenously during ischemia , although in this latter group malondialdehyde was significantly higher .
Diseases:"
4660	The present data indicate that the determination of malondialdehyde , oxypurines , and nucleosides in peripheral blood , may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena . ( ABSTRACT TRUNCATED AT 250 WORDS )	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O O O O O O	O O O O O O O O B O B O O B O O O O O O O O O O O O O O O O O O O O O O O O O O	['ischemic']	1	3	"Sentence: The present data indicate that the determination of malondialdehyde , oxypurines , and nucleosides in peripheral blood , may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases: ischemic"	"Sentence: The present data indicate that the determination of malondialdehyde , oxypurines , and nucleosides in peripheral blood , may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena . ( ABSTRACT TRUNCATED AT 250 WORDS )
Diseases:"
4661	Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops .	O B O O O O O O O O O O	O O O O O O O B I O O O	['toxicity']	1	2	"Sentence: Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops .
Diseases: toxicity"	"Sentence: Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops .
Diseases:"
4662	A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops , presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis .	O O O O O O O O O O O O O O O O O O O B I O O O O O O O B I O	O O O O O O O O O O O B I O O O O O O O O O O O O O O O O O O	['muscle weakness', 'myasthenia gravis']	2	10	"Sentence: A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops , presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis .
Diseases: muscle weakness, myasthenia gravis"	"Sentence: A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops , presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis .
Diseases:"
4663	Red blood cell and serum cholinesterase levels were severely depressed and symptoms resolved spontaneously following discontinuation of the eye drops .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Red blood cell and serum cholinesterase levels were severely depressed and symptoms resolved spontaneously following discontinuation of the eye drops .
Diseases: "	"Sentence: Red blood cell and serum cholinesterase levels were severely depressed and symptoms resolved spontaneously following discontinuation of the eye drops .
Diseases:"
4664	Acute renal failure in high dose carboplatin chemotherapy .	B I I O O O O O O	O O O O O O B O O	['acute renal failure']	1	4	"Sentence: Acute renal failure in high dose carboplatin chemotherapy .
Diseases: acute renal failure"	"Sentence: Acute renal failure in high dose carboplatin chemotherapy .
Diseases:"
4665	Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients .	O O O O O O B I I O O O O O O O O O	B O O O O O O O O O O O O O O O O O	['acute renal failure']	1	4	"Sentence: Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients .
Diseases: acute renal failure"	"Sentence: Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients .
Diseases:"
4666	We report a 4 1 / 2 - year - old girl who was treated with high - dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma .	O O O O O O O O O O O O O O O O O O O O O O O B I O	O O O O O O O O O O O O O O O O O O O B O O O O O O	['embryonal rhabdomyosarcoma']	1	11	"Sentence: We report a 4 1 / 2 - year - old girl who was treated with high - dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma .
Diseases: embryonal rhabdomyosarcoma"	"Sentence: We report a 4 1 / 2 - year - old girl who was treated with high - dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma .
Diseases:"
4667	Acute renal failure developed followed by a slow partial recovery of renal function .	B I I O O O O O O O O O O O	O O O O O O O O O O O O O O	['acute renal failure']	1	4	"Sentence: Acute renal failure developed followed by a slow partial recovery of renal function .
Diseases: acute renal failure"	"Sentence: Acute renal failure developed followed by a slow partial recovery of renal function .
Diseases:"
4668	Possible contributing factors are discussed .	O O O O O O	O O O O O O	[]	0	0	"Sentence: Possible contributing factors are discussed .
Diseases: "	"Sentence: Possible contributing factors are discussed .
Diseases:"
4669	Endometrial carcinoma after Hodgkin disease in childhood .	B I O B I O O O	O O O O O O O O	['endometrial carcinoma', 'hodgkin disease']	2	11	"Sentence: Endometrial carcinoma after Hodgkin disease in childhood .
Diseases: endometrial carcinoma, hodgkin disease"	"Sentence: Endometrial carcinoma after Hodgkin disease in childhood .
Diseases:"
4670	A 34 - year - old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood .	O O O O O O O O O B I O B I O O O	O O O O O O O O O O O O O O O O O	['endometrial carcinoma', 'hodgkin disease']	2	11	"Sentence: A 34 - year - old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood .
Diseases: endometrial carcinoma, hodgkin disease"	"Sentence: A 34 - year - old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood .
Diseases:"
4671	She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease , and received exogenous estrogens , a treatment implicated in the development of endometrial cancer in menopausal women .	O O B I O O O O O O B I O O O O O O O O O O O O O B I O O O O	O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O	['ovarian failure', 'endometrial cancer', 'hodgkin disease']	3	14	"Sentence: She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease , and received exogenous estrogens , a treatment implicated in the development of endometrial cancer in menopausal women .
Diseases: ovarian failure, endometrial cancer, hodgkin disease"	"Sentence: She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease , and received exogenous estrogens , a treatment implicated in the development of endometrial cancer in menopausal women .
Diseases:"
4672	Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically .	O O O O O O B I O B O O O O O O O B I O O O O O O	O O O O B O O O O O O O O O O O O O O O O O O O O	['ovarian failure', 'endometrial carcinoma', 'cancer']	3	11	"Sentence: Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically .
Diseases: ovarian failure, endometrial carcinoma, cancer"	"Sentence: Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically .
Diseases:"
4673	Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration .	O O O B I I I O O O O O O O O	O O O O O O O O O O O O O O O	['obstructive sleep apnea syndrome']	1	7	"Sentence: Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration .
Diseases: obstructive sleep apnea syndrome"	"Sentence: Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration .
Diseases:"
4674	We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54 - yr - old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B I I I I O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O	['syndrome of obstructive sleep apnea']	1	9	"Sentence: We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54 - yr - old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens .
Diseases: syndrome of obstructive sleep apnea"	"Sentence: We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54 - yr - old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens .
Diseases:"
4675	When the androgens were withdrawn , the patient 's physical changes , symptoms , sleep study , and supraglottic resistance all returned to normal .	O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: When the androgens were withdrawn , the patient 's physical changes , symptoms , sleep study , and supraglottic resistance all returned to normal .
Diseases: "	"Sentence: When the androgens were withdrawn , the patient 's physical changes , symptoms , sleep study , and supraglottic resistance all returned to normal .
Diseases:"
4676	A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone .	O O O O O O O B I I O O O O O O O O	O O O B O O O O O O O O O O O O O O	['obstructive sleep apnea']	1	6	"Sentence: A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone .
Diseases: obstructive sleep apnea"	"Sentence: A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone .
Diseases:"
4677	Previous reports have favored a role of androgens in the pathogenesis of sleep apnea .	O O O O O O O O O O O O B I O	O O O O O O O B O O O O O O O	['sleep apnea']	1	3	"Sentence: Previous reports have favored a role of androgens in the pathogenesis of sleep apnea .
Diseases: sleep apnea"	"Sentence: Previous reports have favored a role of androgens in the pathogenesis of sleep apnea .
Diseases:"
4678	Our report provides direct evidence for this role .	O O O O O O O O O	O O O O O O O O O	[]	0	0	"Sentence: Our report provides direct evidence for this role .
Diseases: "	"Sentence: Our report provides direct evidence for this role .
Diseases:"
4679	Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep .	O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep .
Diseases: "	"Sentence: Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep .
Diseases:"
4680	Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy .	O O O B I I I O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	['obstructive sleep apnea syndrome']	1	7	"Sentence: Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy .
Diseases: obstructive sleep apnea syndrome"	"Sentence: Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy .
Diseases:"
4681	Effect of captopril on pre - existing and aminonucleoside - induced proteinuria in spontaneously hypertensive rats .	O O O O O O O O O O O B O O B O O	O O B O O O O O B O O O O O O O O	['hypertensive', 'proteinuria']	2	6	"Sentence: Effect of captopril on pre - existing and aminonucleoside - induced proteinuria in spontaneously hypertensive rats .
Diseases: hypertensive, proteinuria"	"Sentence: Effect of captopril on pre - existing and aminonucleoside - induced proteinuria in spontaneously hypertensive rats .
Diseases:"
4682	Proteinuria is a side effect of captopril treatment in hypertensive patients .	B O O O O O O O O B O O	O O O O O O B O O O O O	['hypertensive', 'proteinuria']	2	6	"Sentence: Proteinuria is a side effect of captopril treatment in hypertensive patients .
Diseases: hypertensive, proteinuria"	"Sentence: Proteinuria is a side effect of captopril treatment in hypertensive patients .
Diseases:"
4683	The possibility of reproducing the same renal abnormality with captopril was examined in SHR .	O O O O O O B I O O O O O O O	O O O O O O O O O B O O O O O	['renal abnormality']	1	4	"Sentence: The possibility of reproducing the same renal abnormality with captopril was examined in SHR .
Diseases: renal abnormality"	"Sentence: The possibility of reproducing the same renal abnormality with captopril was examined in SHR .
Diseases:"
4684	Oral administration of captopril at 100 mg / kg for 14 days failed to aggravate proteinuria pre - existing in SHR .	O O O O O O O O O O O O O O O B O O O O O O	O O O B O O O O O O O O O O O O O O O O O O	['proteinuria']	1	2	"Sentence: Oral administration of captopril at 100 mg / kg for 14 days failed to aggravate proteinuria pre - existing in SHR .
Diseases: proteinuria"	"Sentence: Oral administration of captopril at 100 mg / kg for 14 days failed to aggravate proteinuria pre - existing in SHR .
Diseases:"
4685	Also , captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR .	O O O O O O O O O O O O B O O O O O O O	O O B O O O O O O O O O O O O B I O O O	['proteinuria']	1	2	"Sentence: Also , captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR .
Diseases: proteinuria"	"Sentence: Also , captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR .
Diseases:"
4686	Captopril had little or no demonstrable effects on serum electrolyte concentrations , excretion of urine , sodium and potassium , endogenous creatinine clearance , body weight , and food and water consumption .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O B O B O O B O O O O O O O O O O O	[]	0	0	"Sentence: Captopril had little or no demonstrable effects on serum electrolyte concentrations , excretion of urine , sodium and potassium , endogenous creatinine clearance , body weight , and food and water consumption .
Diseases: "	"Sentence: Captopril had little or no demonstrable effects on serum electrolyte concentrations , excretion of urine , sodium and potassium , endogenous creatinine clearance , body weight , and food and water consumption .
Diseases:"
4687	However , ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR .	O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O B O O O	[]	0	0	"Sentence: However , ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR .
Diseases: "	"Sentence: However , ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR .
Diseases:"
4688	Epileptogenic properties of enflurane and their clinical interpretation .	O O O O O O O O O	O O O B O O O O O	[]	0	0	"Sentence: Epileptogenic properties of enflurane and their clinical interpretation .
Diseases: "	"Sentence: Epileptogenic properties of enflurane and their clinical interpretation .
Diseases:"
4689	Three cases of EEG changes induced by single exposure to enflurane anesthesia are reported .	O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O	[]	0	0	"Sentence: Three cases of EEG changes induced by single exposure to enflurane anesthesia are reported .
Diseases: "	"Sentence: Three cases of EEG changes induced by single exposure to enflurane anesthesia are reported .
Diseases:"
4690	In one patient , enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures .	O O O O O O O O O O O O O O O B O	O O O O B O O O O O O O O O O O O	['seizures']	1	3	"Sentence: In one patient , enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures .
Diseases: seizures"	"Sentence: In one patient , enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures .
Diseases:"
4691	Until the cause of the seizures was correctly identified , the patient was inappropriately treated with anticonvulsants .	O O O O O B O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O	['seizures']	1	3	"Sentence: Until the cause of the seizures was correctly identified , the patient was inappropriately treated with anticonvulsants .
Diseases: seizures"	"Sentence: Until the cause of the seizures was correctly identified , the patient was inappropriately treated with anticonvulsants .
Diseases:"
4692	Two other patients suffered from partial , complex and generalized seizures uncontrolled by medication .	O O O O O O O O O O B O O O O	O O O O O O O O O O O O O O O	['seizures']	1	3	"Sentence: Two other patients suffered from partial , complex and generalized seizures uncontrolled by medication .
Diseases: seizures"	"Sentence: Two other patients suffered from partial , complex and generalized seizures uncontrolled by medication .
Diseases:"
4693	Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure - free .	B O O O O O O O O O O O O O O B O O O	O O O O O O B O O O O O O O O O O O O	['epileptic', 'seizure']	2	5	"Sentence: Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure - free .
Diseases: epileptic, seizure"	"Sentence: Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure - free .
Diseases:"
4694	Previous exposures to enflurane have to be disclosed to avoid mistakes in clinical interpretation of the EEG .	O O O O O O O O O O O O O O O O O O	O O O B O O O O O O O O O O O O O O	[]	0	0	"Sentence: Previous exposures to enflurane have to be disclosed to avoid mistakes in clinical interpretation of the EEG .
Diseases: "	"Sentence: Previous exposures to enflurane have to be disclosed to avoid mistakes in clinical interpretation of the EEG .
Diseases:"
4695	On the other hand , enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings .	O O O O O O O O O O O O O O O O B O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O O O O	['epileptic']	1	3	"Sentence: On the other hand , enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings .
Diseases: epileptic"	"Sentence: On the other hand , enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings .
Diseases:"
4696	Reversible cerebral lesions associated with tiazofurin usage : MR demonstration .	O B I O O O O O O O O	O O O O O B O O O O O	['cerebral lesions']	1	4	"Sentence: Reversible cerebral lesions associated with tiazofurin usage : MR demonstration .
Diseases: cerebral lesions"	"Sentence: Reversible cerebral lesions associated with tiazofurin usage : MR demonstration .
Diseases:"
4697	Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation .	O O O O O O O O O O O	B O O O O O O O O O O	[]	0	0	"Sentence: Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation .
Diseases: "	"Sentence: Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation .
Diseases:"
4698	We report our results with magnetic resonance ( MR ) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug .	O O O O O O O O O O O O O B I O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['cerebral abnormalities']	1	4	"Sentence: We report our results with magnetic resonance ( MR ) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug .
Diseases: cerebral abnormalities"	"Sentence: We report our results with magnetic resonance ( MR ) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug .
Diseases:"
4699	The abnormalities on MR were correlated with findings on CT as well as with cerebral angiography .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The abnormalities on MR were correlated with findings on CT as well as with cerebral angiography .
Diseases: "	"Sentence: The abnormalities on MR were correlated with findings on CT as well as with cerebral angiography .
Diseases:"
4700	The utility of MR in the evaluation of patients receiving this new agent is illustrated .	O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The utility of MR in the evaluation of patients receiving this new agent is illustrated .
Diseases: "	"Sentence: The utility of MR in the evaluation of patients receiving this new agent is illustrated .
Diseases:"
4701	Antagonism of diazepam - induced sedative effects by Ro15 - 1788 in patients after surgery under lumbar epidural block .	O O O O O O O O O O O O O O O O O O O O	O O B O O O O O B I I O O O O O O O O O	[]	0	0	"Sentence: Antagonism of diazepam - induced sedative effects by Ro15 - 1788 in patients after surgery under lumbar epidural block .
Diseases: "	"Sentence: Antagonism of diazepam - induced sedative effects by Ro15 - 1788 in patients after surgery under lumbar epidural block .
Diseases:"
4702	A double - blind placebo - controlled investigation of efficacy and safety .	O O O O O O O O O O O O O	O O O O O O O O O O O O O	[]	0	0	"Sentence: A double - blind placebo - controlled investigation of efficacy and safety .
Diseases: "	"Sentence: A double - blind placebo - controlled investigation of efficacy and safety .
Diseases:"
4703	The aim of this study was to assess the efficacy of Ro15 - 1788 and a placebo in reversing diazepam - induced effects after surgery under epidural block , and to evaluate the local tolerance and general safety of Ro15 - 1788 .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O B I I O O O O O B O O O O O O O O O O O O O O O O O O O B I I O	[]	0	0	"Sentence: The aim of this study was to assess the efficacy of Ro15 - 1788 and a placebo in reversing diazepam - induced effects after surgery under epidural block , and to evaluate the local tolerance and general safety of Ro15 - 1788 .
Diseases: "	"Sentence: The aim of this study was to assess the efficacy of Ro15 - 1788 and a placebo in reversing diazepam - induced effects after surgery under epidural block , and to evaluate the local tolerance and general safety of Ro15 - 1788 .
Diseases:"
4704	Fifty - seven patients were sedated with diazepam for surgery under epidural anaesthesia .	O O O O O O O O O O O O O O	O O O O O O O B O O O O O O	[]	0	0	"Sentence: Fifty - seven patients were sedated with diazepam for surgery under epidural anaesthesia .
Diseases: "	"Sentence: Fifty - seven patients were sedated with diazepam for surgery under epidural anaesthesia .
Diseases:"
4705	Antagonism of diazepam - induced effects by Ro15 - 1788 was investigated postoperatively in a double - blind placebo - controlled trial .	O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O B I I O O O O O O O O O O O O O	[]	0	0	"Sentence: Antagonism of diazepam - induced effects by Ro15 - 1788 was investigated postoperatively in a double - blind placebo - controlled trial .
Diseases: "	"Sentence: Antagonism of diazepam - induced effects by Ro15 - 1788 was investigated postoperatively in a double - blind placebo - controlled trial .
Diseases:"
4706	The patient 's subjective assessment of mood rating , an objective test of performance , a test for amnesia , and vital signs were recorded for up to 300 min after administration of the trial drug .	O O O O O O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['amnesia']	1	2	"Sentence: The patient 's subjective assessment of mood rating , an objective test of performance , a test for amnesia , and vital signs were recorded for up to 300 min after administration of the trial drug .
Diseases: amnesia"	"Sentence: The patient 's subjective assessment of mood rating , an objective test of performance , a test for amnesia , and vital signs were recorded for up to 300 min after administration of the trial drug .
Diseases:"
4707	No significant differences between the two groups were observed for mood rating , amnesia , or vital signs .	O O O O O O O O O O O O O B O O O O O	O O O O O O O O O O O O O O O O O O O	['amnesia']	1	2	"Sentence: No significant differences between the two groups were observed for mood rating , amnesia , or vital signs .
Diseases: amnesia"	"Sentence: No significant differences between the two groups were observed for mood rating , amnesia , or vital signs .
Diseases:"
4708	The Ro15 - 1788 group showed a significant improvement in the performance test up to 120 min after administration of the drug .	O O O O O O O O O O O O O O O O O O O O O O O	O B I I O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: The Ro15 - 1788 group showed a significant improvement in the performance test up to 120 min after administration of the drug .
Diseases: "	"Sentence: The Ro15 - 1788 group showed a significant improvement in the performance test up to 120 min after administration of the drug .
Diseases:"
4709	There was no evidence of reaction at the injection site .	O O O O O O O O O O O	O O O O O O O O O O O	[]	0	0	"Sentence: There was no evidence of reaction at the injection site .
Diseases: "	"Sentence: There was no evidence of reaction at the injection site .
Diseases:"
4710	Enhanced stimulus - induced neurotransmitter overflow in epinephrine - induced hypertensive rats is not mediated by prejunctional beta - adrenoceptor activation .	O O O O O O O O O O B O O O O O O O O O O O	O O O O O O O B O O O O O O O O O O O O O O	['hypertensive']	1	3	"Sentence: Enhanced stimulus - induced neurotransmitter overflow in epinephrine - induced hypertensive rats is not mediated by prejunctional beta - adrenoceptor activation .
Diseases: hypertensive"	"Sentence: Enhanced stimulus - induced neurotransmitter overflow in epinephrine - induced hypertensive rats is not mediated by prejunctional beta - adrenoceptor activation .
Diseases:"
4711	The present study examines the effect of 6 - day epinephrine treatment ( 100 micrograms / kg per h , s . c . ) on stimulus - induced ( 1 Hz ) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle - and epinephrine - treated rats .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: The present study examines the effect of 6 - day epinephrine treatment ( 100 micrograms / kg per h , s . c . ) on stimulus - induced ( 1 Hz ) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle - and epinephrine - treated rats .
Diseases: "	"Sentence: The present study examines the effect of 6 - day epinephrine treatment ( 100 micrograms / kg per h , s . c . ) on stimulus - induced ( 1 Hz ) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle - and epinephrine - treated rats .
Diseases:"
4712	Renal catecholamine stores and stimulus - induced overflow in the vehicle - treated group consisted of norepinephrine only .	O O O O O O O O O O O O O O O O O O O	O B O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Renal catecholamine stores and stimulus - induced overflow in the vehicle - treated group consisted of norepinephrine only .
Diseases: "	"Sentence: Renal catecholamine stores and stimulus - induced overflow in the vehicle - treated group consisted of norepinephrine only .
Diseases:"
4713	However , epinephrine treatment resulted in the incorporation of epinephrine into renal catecholamine stores such that approximately 40 % of the catecholamine present was epinephrine while the norepinephrine content was reduced by a similar degree .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O B O O O O O O B O O B O O O O O O O O B O O B O O B O O O O O O O O	[]	0	0	"Sentence: However , epinephrine treatment resulted in the incorporation of epinephrine into renal catecholamine stores such that approximately 40 % of the catecholamine present was epinephrine while the norepinephrine content was reduced by a similar degree .
Diseases: "	"Sentence: However , epinephrine treatment resulted in the incorporation of epinephrine into renal catecholamine stores such that approximately 40 % of the catecholamine present was epinephrine while the norepinephrine content was reduced by a similar degree .
Diseases:"
4714	Total tissue catecholamine content of the kidney on a molar basis was unchanged .	O O O O O O O O O O O O O O	O O B O O O O O O O O O O O	[]	0	0	"Sentence: Total tissue catecholamine content of the kidney on a molar basis was unchanged .
Diseases: "	"Sentence: Total tissue catecholamine content of the kidney on a molar basis was unchanged .
Diseases:"
4715	Stimulus - induced fractional overflow of neurotransmitter from the epinephrine - treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O B O B O O O O O O O O O O	[]	0	0	"Sentence: Stimulus - induced fractional overflow of neurotransmitter from the epinephrine - treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney .
Diseases: "	"Sentence: Stimulus - induced fractional overflow of neurotransmitter from the epinephrine - treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney .
Diseases:"
4716	This difference in fractional overflow between groups was not affected by neuronal and extraneuronal uptake blockade .	O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: This difference in fractional overflow between groups was not affected by neuronal and extraneuronal uptake blockade .
Diseases: "	"Sentence: This difference in fractional overflow between groups was not affected by neuronal and extraneuronal uptake blockade .
Diseases:"
4717	Propranolol had no effect on stimulus - induced overflow in either group .	O O O O O O O O O O O O O	B O O O O O O O O O O O O	[]	0	0	"Sentence: Propranolol had no effect on stimulus - induced overflow in either group .
Diseases: "	"Sentence: Propranolol had no effect on stimulus - induced overflow in either group .
Diseases:"
4718	Phentolamine increased stimulus - induced overflow in both groups although the increment in overflow was greater in the epinephrine - treated group .	O O O O O O O O O O O O O O O O O O O O O O O	B O O O O O O O O O O O O O O O O O B O O O O	[]	0	0	"Sentence: Phentolamine increased stimulus - induced overflow in both groups although the increment in overflow was greater in the epinephrine - treated group .
Diseases: "	"Sentence: Phentolamine increased stimulus - induced overflow in both groups although the increment in overflow was greater in the epinephrine - treated group .
Diseases:"
4719	In conclusion , chronic epinephrine treatment results in enhanced fractional neurotransmitter overflow .	O O O O O O O O O O O O O	O O O O B O O O O O O O O	[]	0	0	"Sentence: In conclusion , chronic epinephrine treatment results in enhanced fractional neurotransmitter overflow .
Diseases: "	"Sentence: In conclusion , chronic epinephrine treatment results in enhanced fractional neurotransmitter overflow .
Diseases:"
4720	However , neither alterations in prejunctional beta - adrenoceptor influences nor alterations in neuronal and extraneuronal uptake mechanisms appear to be responsible for this alteration .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: However , neither alterations in prejunctional beta - adrenoceptor influences nor alterations in neuronal and extraneuronal uptake mechanisms appear to be responsible for this alteration .
Diseases: "	"Sentence: However , neither alterations in prejunctional beta - adrenoceptor influences nor alterations in neuronal and extraneuronal uptake mechanisms appear to be responsible for this alteration .
Diseases:"
4721	Furthermore , data obtained with phentolamine alone do not suggest alpha - adrenoceptor desensitization as the cause of the enhanced neurotransmitter overflow after epinephrine treatment .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O B O O O O O O O O O O O O O O O O O B O O	[]	0	0	"Sentence: Furthermore , data obtained with phentolamine alone do not suggest alpha - adrenoceptor desensitization as the cause of the enhanced neurotransmitter overflow after epinephrine treatment .
Diseases: "	"Sentence: Furthermore , data obtained with phentolamine alone do not suggest alpha - adrenoceptor desensitization as the cause of the enhanced neurotransmitter overflow after epinephrine treatment .
Diseases:"
4722	Ocular manifestations of juvenile rheumatoid arthritis .	O O O B I I O	O O O O O O O	['juvenile rheumatoid arthritis']	1	7	"Sentence: Ocular manifestations of juvenile rheumatoid arthritis .
Diseases: juvenile rheumatoid arthritis"	"Sentence: Ocular manifestations of juvenile rheumatoid arthritis .
Diseases:"
4723	We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years .	O O O O O B I I O O O O O	O O O O O O O O O O O O O	['juvenile rheumatoid arthritis']	1	7	"Sentence: We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years .
Diseases: juvenile rheumatoid arthritis"	"Sentence: We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years .
Diseases:"
4724	Thirty - six of the 210 patients ( 17 . 2 % ) developed iridocyclitis .	O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O	['iridocyclitis']	1	5	"Sentence: Thirty - six of the 210 patients ( 17 . 2 % ) developed iridocyclitis .
Diseases: iridocyclitis"	"Sentence: Thirty - six of the 210 patients ( 17 . 2 % ) developed iridocyclitis .
Diseases:"
4725	Iridocyclitis was seen most frequently in young female patients ( 0 to 4 years ) with the monoarticular or pauciatricular form of the arthritis .	B O O O O O O O O O O O O O O O O O O O O O O B O	O O O O O O O O O O O O O O O O O O O O O O O O O	['iridocyclitis', 'arthritis']	2	7	"Sentence: Iridocyclitis was seen most frequently in young female patients ( 0 to 4 years ) with the monoarticular or pauciatricular form of the arthritis .
Diseases: iridocyclitis, arthritis"	"Sentence: Iridocyclitis was seen most frequently in young female patients ( 0 to 4 years ) with the monoarticular or pauciatricular form of the arthritis .
Diseases:"
4726	However , 30 % of the patients developed uveitis after 16 years of age .	O O O O O O O O B O O O O O O	O O O O O O O O O O O O O O O	['uveitis']	1	2	"Sentence: However , 30 % of the patients developed uveitis after 16 years of age .
Diseases: uveitis"	"Sentence: However , 30 % of the patients developed uveitis after 16 years of age .
Diseases:"
4727	Although 61 % of patients had a noncontributory ocular history on entry , 42 % had active uveitis on entry .	O O O O O O O O O O O O O O O O O B O O O	O O O O O O O O O O O O O O O O O O O O O	['uveitis']	1	2	"Sentence: Although 61 % of patients had a noncontributory ocular history on entry , 42 % had active uveitis on entry .
Diseases: uveitis"	"Sentence: Although 61 % of patients had a noncontributory ocular history on entry , 42 % had active uveitis on entry .
Diseases:"
4728	Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases .	O O O O O O B O O O O O O B O O O O	O O O O O O O O O O O O O O O O O O	['uveitis']	1	2	"Sentence: Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases .
Diseases: uveitis"	"Sentence: Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases .
Diseases:"
4729	Forty - four percent of patients with uveitis had one or more identifiable signs or symptoms , such as red eye , ocular pain , decreased visual acuity , or photophobia , in order of decreasing frequency .	O O O O O O O B O O O O O O O O O O O O O O B I O B I I O O B O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['decreased visual acuity', 'uveitis', 'photophobia', 'ocular pain']	4	17	"Sentence: Forty - four percent of patients with uveitis had one or more identifiable signs or symptoms , such as red eye , ocular pain , decreased visual acuity , or photophobia , in order of decreasing frequency .
Diseases: decreased visual acuity, uveitis, photophobia, ocular pain"	"Sentence: Forty - four percent of patients with uveitis had one or more identifiable signs or symptoms , such as red eye , ocular pain , decreased visual acuity , or photophobia , in order of decreasing frequency .
Diseases:"
4730	Even after early detection and prompt treatment , 41 % of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics .	O O O O O O O O O O O O O B O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['uveitis']	1	2	"Sentence: Even after early detection and prompt treatment , 41 % of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics .
Diseases: uveitis"	"Sentence: Even after early detection and prompt treatment , 41 % of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics .
Diseases:"
4731	Despite this , there was a dramatic decrease in the 50 % incidence of blinding complications of uveitis cited in earlier studies .	O O O O O O O O O O O O O O O O O B O O O O O	O O O O O O O O O O O O O O O O O O O O O O O	['uveitis']	1	2	"Sentence: Despite this , there was a dramatic decrease in the 50 % incidence of blinding complications of uveitis cited in earlier studies .
Diseases: uveitis"	"Sentence: Despite this , there was a dramatic decrease in the 50 % incidence of blinding complications of uveitis cited in earlier studies .
Diseases:"
4732	Cataract and band keratopathy occurred in only 22 and 13 % of our group , respectively .	B O B I O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O	['cataract', 'band keratopathy']	2	8	"Sentence: Cataract and band keratopathy occurred in only 22 and 13 % of our group , respectively .
Diseases: cataract, band keratopathy"	"Sentence: Cataract and band keratopathy occurred in only 22 and 13 % of our group , respectively .
Diseases:"
4733	We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs .	O O O O O O O O O O O O O O O O B O O O O O	O O B O B O O O O O O O O O O O O O O O O O	['chorioretinopathy']	1	5	"Sentence: We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs .
Diseases: chorioretinopathy"	"Sentence: We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs .
Diseases:"
4734	Systemically administered corticosteroids were used in 75 of 210 cases ; a significant number of posterior subcapsular cataracts was found .	O O O O O O O O O O O O O O O O O B O O O	O O B O O O O O O O O O O O O O O O O O O	['cataracts']	1	3	"Sentence: Systemically administered corticosteroids were used in 75 of 210 cases ; a significant number of posterior subcapsular cataracts was found .
Diseases: cataracts"	"Sentence: Systemically administered corticosteroids were used in 75 of 210 cases ; a significant number of posterior subcapsular cataracts was found .
Diseases:"
4735	Typical keratoconjunctivitis sicca developed in three of the uveitis cases .	O B O O O O O O B O O	O O O O O O O O O O O	['uveitis', 'keratoconjunctivitis']	2	10	"Sentence: Typical keratoconjunctivitis sicca developed in three of the uveitis cases .
Diseases: uveitis, keratoconjunctivitis"	"Sentence: Typical keratoconjunctivitis sicca developed in three of the uveitis cases .
Diseases:"
4736	This association with uveitis and JRA was not noted previously .	O O O B O O O O O O O	O O O O O O O O O O O	['uveitis']	1	2	"Sentence: This association with uveitis and JRA was not noted previously .
Diseases: uveitis"	"Sentence: This association with uveitis and JRA was not noted previously .
Diseases:"
4737	Surgical treatment of cataracts , band keratopathy , and glaucoma achieved uniformly discouraging results .	O O O B O B I O O B O O O O O	O O O O O O O O O O O O O O O	['cataracts', 'glaucoma', 'band keratopathy']	3	13	"Sentence: Surgical treatment of cataracts , band keratopathy , and glaucoma achieved uniformly discouraging results .
Diseases: cataracts, glaucoma, band keratopathy"	"Sentence: Surgical treatment of cataracts , band keratopathy , and glaucoma achieved uniformly discouraging results .
Diseases:"
4738	Water intoxication associated with oxytocin administration during saline - induced abortion .	B I O O O O O O O O B O	O O O O B O O O O O O O	['water intoxication', 'abortion']	2	4	"Sentence: Water intoxication associated with oxytocin administration during saline - induced abortion .
Diseases: water intoxication, abortion"	"Sentence: Water intoxication associated with oxytocin administration during saline - induced abortion .
Diseases:"
4739	Four cases of water intoxication in connection with oxytocin administration during saline - induced abortions are described .	O O O B I O O O O O O O O O B O O O	O O O O O O O O B O O O O O O O O O	['water intoxication', 'abortions']	2	4	"Sentence: Four cases of water intoxication in connection with oxytocin administration during saline - induced abortions are described .
Diseases: water intoxication, abortions"	"Sentence: Four cases of water intoxication in connection with oxytocin administration during saline - induced abortions are described .
Diseases:"
4740	The mechanism of water intoxication is discussed in regard to these cases .	O O O B I O O O O O O O O	O O O O O O O O O O O O O	['water intoxication']	1	2	"Sentence: The mechanism of water intoxication is discussed in regard to these cases .
Diseases: water intoxication"	"Sentence: The mechanism of water intoxication is discussed in regard to these cases .
Diseases:"
4741	Oxytocin administration during midtrimester - induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff , aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia , muscular irritability , or headaches .	O O O O O O B O O O O O O O O O O O O O O O O O O O O O O O B I O O O O O O O O O O O O O O O B O O B O O B O	B O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	['irritability', 'abortions', 'water intoxication', 'asthenia', 'headaches']	5	14	"Sentence: Oxytocin administration during midtrimester - induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff , aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia , muscular irritability , or headaches .
Diseases: irritability, abortions, water intoxication, asthenia, headaches"	"Sentence: Oxytocin administration during midtrimester - induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff , aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia , muscular irritability , or headaches .
Diseases:"
4742	The oxytocin should be given only in Ringers lactate or , alternately , in Ringers lactate and a 5 per cent dextrose and water solutions .	O O O O O O O O O O O O O O O O O O O O O O O O O O	O B O O O O O O I O O O O O O I O O O O O B O O O O	[]	0	0	"Sentence: The oxytocin should be given only in Ringers lactate or , alternately , in Ringers lactate and a 5 per cent dextrose and water solutions .
Diseases: "	"Sentence: The oxytocin should be given only in Ringers lactate or , alternately , in Ringers lactate and a 5 per cent dextrose and water solutions .
Diseases:"
4743	The urinary output should be monitored and the oxytocin administration discontinued and the serum electrolytes checked if the urinary output decreases .	O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O B O O O O O O O O O O O O O	[]	0	0	"Sentence: The urinary output should be monitored and the oxytocin administration discontinued and the serum electrolytes checked if the urinary output decreases .
Diseases: "	"Sentence: The urinary output should be monitored and the oxytocin administration discontinued and the serum electrolytes checked if the urinary output decreases .
Diseases:"
4744	The oxytocin should not be administered in excess of 36 hours .	O O O O O O O O O O O O	O B O O O O O O O O O O	[]	0	0	"Sentence: The oxytocin should not be administered in excess of 36 hours .
Diseases: "	"Sentence: The oxytocin should not be administered in excess of 36 hours .
Diseases:"
4745	If the patient has not aborted by then the oxytocin should be discontinued for 10 to 12 hours in order to perform electrolyte determinations and correct any electrolyte imbalance .	O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O	O O O O O O O O O B O O O O O O O O O O O O O O O O O O O O	[]	0	0	"Sentence: If the patient has not aborted by then the oxytocin should be discontinued for 10 to 12 hours in order to perform electrolyte determinations and correct any electrolyte imbalance .
Diseases: "	"Sentence: If the patient has not aborted by then the oxytocin should be discontinued for 10 to 12 hours in order to perform electrolyte determinations and correct any electrolyte imbalance .
Diseases:"
